<SEC-DOCUMENT>0001193125-20-267263.txt : 20201009
<SEC-HEADER>0001193125-20-267263.hdr.sgml : 20201009
<ACCEPTANCE-DATETIME>20201009164233
ACCESSION NUMBER:		0001193125-20-267263
CONFORMED SUBMISSION TYPE:	F-1/A
PUBLIC DOCUMENT COUNT:		44
FILED AS OF DATE:		20201009
DATE AS OF CHANGE:		20201009

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Opthea Ltd
		CENTRAL INDEX KEY:			0001815620
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			C3
		FISCAL YEAR END:			0630

	FILING VALUES:
		FORM TYPE:		F-1/A
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-249020
		FILM NUMBER:		201233682

	BUSINESS ADDRESS:	
		STREET 1:		LEVEL 4
		STREET 2:		650 CHAPEL STREET
		CITY:			SOUTH YARRA, VICTORIA
		STATE:			C3
		ZIP:			3141
		BUSINESS PHONE:		61 3 9826 0399

	MAIL ADDRESS:	
		STREET 1:		LEVEL 4
		STREET 2:		650 CHAPEL STREET
		CITY:			SOUTH YARRA, VICTORIA
		STATE:			C3
		ZIP:			3141
</SEC-HEADER>
<DOCUMENT>
<TYPE>F-1/A
<SEQUENCE>1
<FILENAME>d947560df1a.htm
<DESCRIPTION>F-1/A
<TEXT>
<HTML><HEAD>
<TITLE>F-1/A</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>As filed with the United States Securities and Exchange Commission October 9,
2020. </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Registration No.&nbsp;333-249020 </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="line-height:0px;margin-top:0px;margin-bottom:0px;border-bottom:0.5pt solid #000000">&nbsp;</P>
<P STYLE="line-height:3px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000">&nbsp;</P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="5"><B>UNITED STATES </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="5"><B>SECURITIES AND EXCHANGE COMMISSION </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="3"><B>Washington, D.C. 20549 </B></FONT></P><center>
<P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000;width:16%">&nbsp;</P></center>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="5"><B>AMENDMENT NO. 1 </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="5"><B>TO </B></FONT></P>  <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="5"><B><FONT STYLE="white-space:nowrap">FORM&nbsp;F-1</FONT>
</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="5"><B>REGISTRATION STATEMENT </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="3"><B><I>UNDER </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="3"><B><I>THE SECURITIES ACT OF&nbsp;1933
</I></B></FONT></P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000;width:16%">&nbsp;</P></center> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="6"><B>Opthea Limited </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(Exact name of registrant as specified in its charter)
</B></FONT></P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000;width:16%">&nbsp;</P></center>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>

<TD WIDTH="34%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>


<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Australia</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>2836</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Not Applicable</B></FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(State or other jurisdiction of</B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>incorporation or organization)</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(Primary Standard Industrial</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="1"><B>Classification Code Number)</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(I.R.S.&nbsp;Employer</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="1"><B>Identification&nbsp;Number)</B></FONT></P></TD></TR>
</TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Opthea Limited
</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Level&nbsp;4 </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>650 Chapel Street </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>South Yarra, Victoria 3141 </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Australia </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>+ 61 3 9826 0399 </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="1"><B>(Address, including zip code, and telephone number, including area code, of registrant&#146;s principal executive offices) </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000;width:16%">&nbsp;</P></center>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Corporation Service Company </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>1180 Avenue of the Americas, Suite 210 </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>New York, New York 10036 </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(Name, address, including zip code, and
telephone number, including area code, of agent for service) </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P><center>
<P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000;width:16%">&nbsp;</P></center> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Copies to: </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>

<TD WIDTH="23%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="19%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="20%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="16%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="16%"></TD></TR>


<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Ferish Patel</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>John McKenna</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Milson Yu</B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Cooley LLP</B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Ocean Financial Centre</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>10 Collyer Quay</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Raffles Place</B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Singapore 049315</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>+65 6962 7500</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Divakar Gupta</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>Brent Siler</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Cooley LLP</B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>55 Hudson Yards</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>New York, NY&nbsp;10001</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(212)
<FONT STYLE="white-space:nowrap">479-6000</FONT></B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Craig Semple</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>Gilbert + Tobin</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Level&nbsp;22, 101 Collins Street</B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Melbourne, Victoria 3000</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>Australia</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>+61 3 8656 3300</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Edwin&nbsp;O&#146;Connor</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>Seo Salimi</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Goodwin&nbsp;Procter&nbsp;LLP</B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>620 8th Avenue</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>New York, NY&nbsp;10018</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(212)
<FONT STYLE="white-space:nowrap">813-8800</FONT></B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Michael&nbsp;Ziegelaar</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>Herbert&nbsp;Smith&nbsp;Freehills</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Level&nbsp;42, 101 Collins
Street</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Melbourne, Victoria 3000</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>Australia</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>+61 3 9288 1234</B></FONT></P></TD></TR>
</TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000;width:16%">&nbsp;</P></center>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Approximate date of commencement of proposed sale to the
public</B>: As soon as practicable after this Registration Statement becomes effective. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">If any of the securities being
registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act, check the following box:&nbsp;&nbsp;&#9744; </FONT></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">If this Form is filed to register additional securities for an offering pursuant to
Rule 462(b) under the Securities Act, please check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering.&nbsp;&nbsp;&#9744; </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">If this Form is a post-effective amendment filed pursuant to
Rule 462(c) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering.&nbsp;&nbsp;&#9744; </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">If this Form is a post-effective amendment filed pursuant to
Rule 462(d) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering.&nbsp;&nbsp;&#9744; </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Indicate by check mark whether the registrant is an emerging
growth company as defined in Rule 405 of the Securities Act. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Emerging growth company&nbsp;&nbsp;&#9746; </FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">If an emerging growth company that prepares its financial statements in accordance with U.S. GAAP, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards&#134; provided pursuant to Section&nbsp;7(a)(2)(B) of the Securities Act.&nbsp;&nbsp;&#9746; </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000;width:16%">&nbsp;</P></center>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Calculation of Registration Fee </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>

<TD WIDTH="68%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="15%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="15%"></TD></TR>


<TR STYLE="font-size:1px">
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-TOP:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Title of Each Class&nbsp;of <BR>Securities to be Registered<SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(1) </SUP></B></FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Proposed</B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Maximum<BR>Aggregate<BR>Offering&nbsp;Price<SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(2)(3)
</SUP></B></FONT></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Amount of<BR>Registration&nbsp;Fee<SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(3)
</SUP></B></FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Ordinary shares, no par value</FONT></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">$184,595,700</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">$20,140</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD></TR>
<TR STYLE="font-size:1px">
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD></TR>
</TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(1)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">All ordinary shares in the offering will be in the form of American Depositary Shares, or ADSs, with each ADS representing eight ordinary shares. ADSs issuable upon
deposit of the ordinary shares registered hereby are being registered pursuant to a separate registration statement on <FONT STYLE="white-space:nowrap">Form&nbsp;F-6</FONT> (File No. 333-249327). </FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(2)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Includes additional ordinary shares represented by ADSs that the underwriters have an option to purchase. </FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(3)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Estimated solely for the purpose of computing the amount of the registration fee pursuant to Rule 457(o) under the Securities Act of 1933, as amended based on the
proposed maximum aggregate offering price. The registrant previously paid a registration fee of $19,470. </FONT></TD></TR></TABLE>  <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P><center>
<P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000;width:16%">&nbsp;</P></center> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>The Registrant hereby amends this Registration Statement on such date or dates as may be necessary to delay its effective date until
the Registrant shall file a further amendment which specifically states that this Registration Statement shall thereafter become effective in accordance with Section&nbsp;8(a) of the Securities Act of 1933, as amended, or until the Registration
Statement shall become effective on such date as the Securities and Exchange Commission, acting pursuant to said Section&nbsp;8(a), may determine. </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P><center>
<P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000;width:16%">&nbsp;</P></center> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#134;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">The term &#147;new or revised financial accounting standard&#148; refers to any update issued by the Financial Accounting Standards Board to its Accounting Standards
Codification after April&nbsp;5, 2012. </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="line-height:0px;margin-top:0px;margin-bottom:0px;border-bottom:0.5pt solid #000000">&nbsp;</P>
<P STYLE="line-height:3px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000">&nbsp;</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2" COLOR="#cc062a"><B>The information in this preliminary prospectus is not complete and may be changed. We may not
sell these securities until the registration statement filed with the Securities and Exchange Commission is effective. This preliminary prospectus is not an offer to sell these securities and we are not soliciting an offer to buy these securities in
any jurisdiction where the offer or sale is not permitted. </B></FONT></P> <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>  <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2" COLOR="#cc062a"><B>SUBJECT TO COMPLETION, DATED OCTOBER&nbsp;9, 2020 </B></FONT></P>  <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>PRELIMINARY PROSPECTUS </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center">


<IMG SRC="g947560g04e62.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>  <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="5"><B>9,300,000 American
Depositary Shares </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="5"><B>representing 74,400,000 Ordinary Shares </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="3"><B>$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per American Depositary Share
</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000;width:16%">&nbsp;</P></center>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>  <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">This is the initial public offering of 9,300,000 American
depositary shares, or ADSs, in the United States, representing 74,400,000 ordinary shares of Opthea Limited. Each ADS represents eight ordinary shares, no par value, deposited with The Bank of New York Mellon, as depositary. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We have granted the underwriters an option to purchase up to
an additional 1,395,000 ADSs to cover over-allotments, if any. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Prior to this offering, there has been no public market for the ADSs. We have applied to list the ADSs on the Nasdaq Global Select Market under the symbol &#147;OPT.&#148; </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our ordinary shares are listed on the Australian Securities
Exchange under the symbol &#147;OPT.&#148; On October&nbsp;8, 2020, the last reported sale price of our ordinary shares on the Australian Securities Exchange was A$3.02 per ordinary share, equivalent to a price of US$17.26 per ADS, after giving
effect to the Australian dollar/U.S. dollar exchange rate of A$1.3996 to US$1.00 as of October&nbsp;8, 2020, and an <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">ADS-to-ordinary</FONT></FONT> share ratio of 1-to-8. </FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The final offering price per ADS in U.S. dollars will be
determined through negotiations between us and the representatives of the underwriters and will be based, in part, on prevailing market prices of our ordinary shares on the Australian Securities Exchange, after taking into account market conditions
and other factors. For a discussion of the other factors considered in determining the final offering price per ADS, see &#147;Underwriting.&#148; </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P><center>
<P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000;width:16%">&nbsp;</P></center> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="3"><B>Investing in the ADSs involves a high degree of risk. See &#147;<A HREF="#cov947560_100">Risk Factors</A>&#148; beginning on
page&nbsp;12 of this prospectus. </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We are an
&#147;emerging growth company&#148; as that term is used in the Jumpstart Our Business Startups Act of 2012 and, as such, have elected to comply with certain reduced public company reporting requirements. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="3"><B>Neither the U.S. Securities and Exchange Commission nor
any U.S. state securities commission has approved or disapproved of these securities or determined if this prospectus is truthful or complete. Any representation to the contrary is a criminal offense. </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000;width:16%">&nbsp;</P></center>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>

<TD WIDTH="76%"></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Per&nbsp;ADS</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Total</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Public offering price</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">US$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">US$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Underwriting discounts and commissions</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">US$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">US$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Proceeds, before expenses, to Opthea Limited</FONT><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(1)</SUP></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">US$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">US$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
</TABLE> <P STYLE="line-height:8px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(1)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">We have agreed to reimburse the underwriters for certain expenses. See &#147;Underwriting.&#148; </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The underwriters expect to deliver the ADSs to purchasers on or
about&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2020 through the book-entry facilities of The Depository Trust Company. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000;width:16%">&nbsp;</P></center>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Joint Book-Running Managers </I></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE">


<TR>

<TD WIDTH="50%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="49%"></TD></TR>


<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="5"><B>Citigroup</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="5"><B>SVB Leerink</B></FONT></TD></TR>
</TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Lead Managers
</I></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE">


<TR>

<TD WIDTH="49%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="49%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD></TR>


<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="4"><B>Oppenheimer &amp; Co.</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" NOWRAP ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="4"><B>Truist Securities</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD></TR>
</TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000;width:16%">&nbsp;</P></center>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2020. </FONT></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="toc"></A>TABLE OF CONTENTS </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>

<TD WIDTH="95%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Page</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#rom947560_1">Prospectus Summary</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#rom947560_2">The Offering</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">8</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#rom947560_3">Summary Consolidated Financial Data</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">10</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#rom947560_4">Risk Factors</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">12</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#rom947560_5">Special Note Regarding Forward-Looking Statements</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">71</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#rom947560_6">Industry and Market Data</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">73</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#rom947560_7">Use of Proceeds</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">74</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#rom947560_8">Dividend Policy</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">76</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#rom947560_9">Capitalization</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">77</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#rom947560_10">Dilution</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">79</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#rom947560_11">Selected Consolidated Financial Data</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">82</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#rom947560_12">Management&#146;s Discussion and Analysis of Financial Condition and Results of
Operations</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">84</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#rom947560_13">Business</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">100</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#rom947560_14">Management</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">154</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#rom947560_15">Certain Relationships and Related Party Transactions</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">165</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#rom947560_16">Principal Shareholders</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">167</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#rom947560_17">Description of Share Capital</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">170</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#rom947560_18">Description of American Depositary Shares</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">177</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#rom947560_19">Shares and American Depositary Shares Eligible for Future Sale</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">185</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#rom947560_20">Material United States Federal Income and Australian Tax Considerations</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">187</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#rom947560_21">Enforcement of Civil Liabilities</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">197</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#rom947560_22">Underwriting</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">198</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#rom947560_23">Expenses Relating to the Offering</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">206</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#rom947560_24">Legal Matters</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">206</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#rom947560_25">Experts</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">206</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#rom947560_26">Where You Can Find More Information</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">206</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#rom947560_27">Index to Consolidated Financial Statements</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="white-space:nowrap">F-1</FONT></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
</TABLE>  <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000;width:16%">&nbsp;</P></center>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>We are responsible for the information contained in this
prospectus and any free writing prospectus we prepare or authorize. We and the underwriters have not authorized anyone to provide you with different information. We and the underwriters take no responsibility for, and can provide no assurance as to
the reliability of, any other information others may give you. We are not, and the underwriters are not, making an offer to sell these securities in any jurisdiction where the offer or sale is not permitted. You should not assume that the
information contained in this prospectus is accurate as of any date other than its date. </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>For investors outside the United States: neither we nor any of the underwriters have done anything that would permit this offering or possession or distribution of this prospectus or any free writing
prospectus in any jurisdiction where action for that purpose is required, other than in the United States. Persons outside the United States who come into possession of this prospectus or any free writing prospectus must inform themselves about, and
observe any restrictions relating to, the offering of the ADSs and the distribution of this prospectus and any free writing prospectus outside the United States. </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We are incorporated under the laws of Australia, and a
majority of our outstanding ordinary shares are owned <FONT STYLE="white-space:nowrap">by&nbsp;non-U.S.&nbsp;residents.</FONT> Under the rules of the U.S. Securities and Exchange Commission, or the SEC, we are eligible for treatment as a
&#147;foreign private issuer.&#148; As a foreign private issuer, we will not be required to file periodic reports and financial statements with the SEC as frequently or as promptly as domestic registrants whose securities are registered under
the&nbsp;Securities Exchange Act of 1934, as amended, or the Exchange Act. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">i </FONT></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our reporting and functional currency is the Australian dollar, and our financial
statements included elsewhere in this prospectus are presented in Australian dollars. The consolidated financial statements and related notes included elsewhere in this prospectus have been prepared under the International Financial Reporting
Standards, or IFRS, as issued by the International Accounting Standards Board, or IASB, which differs in certain significant respects from U.S. Generally Accepted Accounting Principles, or GAAP. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>  <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">All references in this prospectus to &#147;US$,&#148;
&#147;U.S. dollars,&#148; and &#147;dollars&#148; mean U.S. dollars and all references to &#147;A$&#148; mean Australian dollars, unless otherwise noted. Throughout this prospectus, all references to &#147;ADSs&#148; mean American depositary shares,
each of which represents eight of our ordinary shares, no par value, and all references to &#147;ADRs&#148; mean the American depositary receipts that evidence the ADSs. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">This prospectus contains translations of some Australian
dollar amounts into U.S. dollars. Except as otherwise stated in this prospectus, all translations from Australian dollars to U.S. dollars are based on the rate published by the Reserve Bank of Australia as of October&nbsp;8, 2020. No representation
is made that the Australian dollar amounts referred to in this prospectus could have been or could be converted into U.S. dollars at such rate. </FONT></P>  <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%;padding-bottom:0px; "><FONT STYLE="font-family:Times New Roman" SIZE="2">&#147;Opthea,&#148; the Opthea logo and other trademarks or service marks of Opthea appearing in this prospectus are
the property of Opthea or its subsidiary. Solely for convenience, the trademarks, service marks and trade names referred to in this prospectus are listed without the <FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> and <FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&#153;</SUP></FONT> symbols, but such
references should not be construed as any indicator that their respective owners will not assert, to the fullest extent under applicable law, their right thereto. All other trademarks, trade names and service marks appearing in this prospectus are
the property of their respective owners. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">ii </FONT></P>


</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1pt solid #000000;BORDER-LEFT:1pt solid #000000;BORDER-RIGHT:1pt solid #000000;BORDER-TOP:1pt solid #000000; MARGIN-LEFT:0px; MARGIN-RIGHT:0px; max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="rom947560_1"></A>PROSPECTUS SUMMARY </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>This summary highlights selected information contained
elsewhere in this prospectus. This summary does not contain all of the information you should consider before investing in the ADSs. You should read this entire prospectus, and the registration statement of which this prospectus is a part, including
&#147;Risk Factors,&#148; &#147;Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations,&#148; and our consolidated financial statements and the related notes included elsewhere in this prospectus, before making an
investment decision. Unless otherwise indicated or the context otherwise requires, &#147;Opthea,&#148; the &#147;Company,&#148; &#147;our company,&#148; &#147;we,&#148; &#147;us&#148; and &#147;our&#148; refer to Opthea Limited and its consolidated
subsidiary, taken as a whole. </I></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Overview
</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We are a clinical stage biopharmaceutical
company developing a novel therapy for the treatment of highly prevalent and progressive retinal diseases. We are developing our Phase <FONT STYLE="white-space:nowrap">3-ready</FONT> product candidate,
<FONT STYLE="white-space:nowrap">OPT-302,</FONT> a biologic designed to inhibit <FONT STYLE="white-space:nowrap">VEGF-C</FONT> and <FONT STYLE="white-space:nowrap">VEGF-D,</FONT> to complement <FONT STYLE="white-space:nowrap">VEGF-A</FONT>
inhibitors for the treatment of ophthalmic diseases. <FONT STYLE="white-space:nowrap">Anti-VEGF-A</FONT> therapies represent the standard of care for wet <FONT STYLE="white-space:nowrap">age-related</FONT> macular degeneration, or AMD, and other
retinal diseases; however, there remains a significant unmet medical need as many patients do not adequately respond to these treatments. As the only biologic inhibitor of <FONT STYLE="white-space:nowrap">VEGF-C</FONT> and <FONT
STYLE="white-space:nowrap">VEGF-D</FONT> in clinical development, <FONT STYLE="white-space:nowrap">OPT-302</FONT> differs from standard of care therapies and when administered in combination with a <FONT STYLE="white-space:nowrap">VEGF-A</FONT>
inhibitor, is designed to achieve broader inhibition of the vascular endothelial growth factor, or VEGF, family and target a mechanism of clinical resistance to improve visual acuity. Our lead indication for
<FONT STYLE="white-space:nowrap">OPT-302</FONT> combination therapy is wet AMD, a chronic, progressive disease and the leading cause of vision loss for individuals over the age of 50. In a 366-patient Phase 2b clinical trial for the treatment of wet
AMD, 2.0 mg <FONT STYLE="white-space:nowrap">OPT-302,</FONT> in combination with a standard of care <FONT STYLE="white-space:nowrap">anti-VEGF-A</FONT> therapy, ranibizumab (Lucentis), met the primary endpoint of a statistically significant superior
mean gain in visual acuity over ranibizumab monotherapy at week 24. We intend to initiate two pivotal Phase 3 clinical trials in treatment-naive patients with wet AMD to evaluate the efficacy and safety of
<FONT STYLE="white-space:nowrap">OPT-302</FONT> in combination with <FONT STYLE="white-space:nowrap">anti-VEGF-A</FONT> therapies compared to <FONT STYLE="white-space:nowrap">anti-VEGF-A</FONT> monotherapy in the first half of 2021. We expect to
report topline data from these Phase 3 clinical trials in 2023. In addition to our clinical trials in wet AMD, we have observed evidence of improved clinical outcomes in a Phase 1b/2a clinical trial of <FONT STYLE="white-space:nowrap">OPT-302</FONT>
in combination with another standard of care <FONT STYLE="white-space:nowrap">anti-VEGF-A</FONT> therapy, aflibercept (Eylea), in patients with treatment-refractory diabetic macular edema, or DME. We retain worldwide rights to develop and
commercialize <FONT STYLE="white-space:nowrap">OPT-302</FONT> for the treatment of wet AMD and DME and believe that the novel treatment mechanism of <FONT STYLE="white-space:nowrap">OPT-302</FONT> has the potential to provide therapeutic benefit for
other progressive eye diseases. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Wet AMD is a
rapidly progressing disease with loss of central vision developing over a period of weeks to months in which abnormal new blood vessels form in the back of the eye in a process called choroidal neovascularization. These newly formed vessels are
highly permeable, leaking exudate leading to fluid accumulation and retinal lesion formation. This, in turn, adversely affects sensory cells in the retina and if left untreated, results in rapid loss of visual acuity. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Wet AMD affects approximately one million people in the
United States and 2.5&nbsp;million people in Europe. The standard of care for wet AMD and other ocular neovascular diseases is the administration of monotherapies that primarily inhibit <FONT STYLE="white-space:nowrap">VEGF-A.</FONT> These
therapeutic agents, which include ranibizumab and aflibercept, prevent <FONT STYLE="white-space:nowrap">VEGF-A</FONT> molecules from binding to, and activating, VEGF receptors and thereby inhibit the formation and permeability of blood vessels. As
the risk of developing wet AMD increases with age, it is predicted that the overall aging of the population will result in a significant increase in the number of wet AMD cases, both in the United States and worldwide. Many wet AMD patients also
experience suboptimal clinical responses despite </FONT></P>
</div></div>

 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">1 </FONT></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1pt solid #000000;BORDER-LEFT:1pt solid #000000;BORDER-RIGHT:1pt solid #000000;BORDER-TOP:1pt solid #000000; MARGIN-LEFT:0px; MARGIN-RIGHT:0px; max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
receiving one or both of the leading standard of care treatments, ranibizumab and aflibercept, which had combined annual worldwide sales of over US$11.9&nbsp;billion in 2019. In addition, nearly
half of wet AMD patients are treated with off-label bevacizumab as a lower cost alternative anti-VEGF-A therapy. As a result, we believe there is a significant and expanding market opportunity for novel therapies that can improve vision in patients
with wet AMD, which has the potential to lead to sales greater than the combined annual sales of ranibizumab and aflibercept. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="white-space:nowrap">OPT-302</FONT> is designed to address a deficiency in the treatment paradigm for wet AMD and other
retinal diseases, such as DME, by targeting alternate members of the VEGF family, namely <FONT STYLE="white-space:nowrap">VEGF-C</FONT> and <FONT STYLE="white-space:nowrap">VEGF-D,</FONT> which are not targeted by current standard of care therapies.
<FONT STYLE="white-space:nowrap">VEGF-C</FONT> and <FONT STYLE="white-space:nowrap">VEGF-D</FONT> function in parallel with <FONT STYLE="white-space:nowrap">VEGF-A</FONT> to drive neovascularization and vascular leakage, which are key hallmarks of
both wet AMD and DME. In addition, treatment with <FONT STYLE="white-space:nowrap">VEGF-A</FONT> inhibitors leads to upregulation of <FONT STYLE="white-space:nowrap">VEGF-C</FONT> and <FONT STYLE="white-space:nowrap">VEGF-D</FONT> to compensate for <FONT
STYLE="white-space:nowrap">VEGF-A</FONT> inhibition, which may represent an important mechanism of clinical resistance to <FONT STYLE="white-space:nowrap">anti-VEGF-A</FONT> monotherapy. We are developing
<FONT STYLE="white-space:nowrap">OPT-302</FONT> to be used in combination with standard of care <FONT STYLE="white-space:nowrap">anti-VEGF-A</FONT> monotherapies to achieve broader inhibition of the VEGF family, with the goal of improving overall
efficacy and demonstrating superior vision gains over that which can be achieved by inhibiting <FONT STYLE="white-space:nowrap">VEGF-A</FONT> alone. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In our completed Phase 2b wet AMD clinical trial, 2.0 mg <FONT STYLE="white-space:nowrap">OPT-302</FONT> in combination with ranibizumab
met the primary endpoint of a statistically significant superior mean gain in visual acuity at week 24 compared to patients treated with ranibizumab with a sham injection, which we refer to as ranibizumab monotherapy. The trial was an international,
multi-center, double-masked trial in 366 treatment-naive patients with wet AMD. Patients were randomized into three groups and received intravitreal injections every four weeks of either 0.5&nbsp;mg or 2.0&nbsp;mg
<FONT STYLE="white-space:nowrap">OPT-302</FONT> in combination with 0.5&nbsp;mg ranibizumab or 0.5&nbsp;mg ranibizumab monotherapy. Secondary endpoints in the trial included changes in retinal thickness and change in intraretinal and subretinal
fluid. Results from such measures were generally consistent with the visual acuity gains observed in the trial. Our clinical experience to date, which includes administration of over 1,800 doses of <FONT STYLE="white-space:nowrap">OPT-302</FONT> to
399 patients with retinal disease for treatment periods of up to 24 weeks, indicates that OPT-302 intravitreal injections are well tolerated, with the incidence of treatment-emergent adverse events, or TEAEs, comparable to <FONT
STYLE="white-space:nowrap">anti-VEGF-A</FONT> monotherapy in our clinical trials. In the Phase&nbsp;2b wet AMD clinical trial, <FONT STYLE="white-space:nowrap">OPT-302</FONT> was well tolerated with a very low incidence of ocular inflammation and no
safety issues identified with addition of OPT-302 to ranibizumab intravitreal therapy. The incidence of ocular TEAEs was similar in OPT-302 combination groups compared to the ranibizumab monotherapy group. Three patients treated with OPT-302
combination therapy had potentially treatment-related serious adverse events, or SAEs: one case each of vitritis, endophthalmitis and myocardial infarction. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We are planning to initiate two concurrent pivotal Phase&nbsp;3 clinical trials for the treatment of wet AMD. These double-masked,
sham-controlled Phase&nbsp;3 clinical trials will enroll treatment-naive patients and assess the efficacy and safety of 2.0&nbsp;mg of <FONT STYLE="white-space:nowrap">OPT-302</FONT> in combination with ranibizumab (Lucentis) (referred to as the
ShORe trial) or aflibercept (Eylea) (referred to as the COAST trial), compared to ranibizumab or aflibercept monotherapy in each respective trial. In addition, to understand the durability of <FONT STYLE="white-space:nowrap">OPT-302</FONT> treatment
effect with less frequent dosing, each trial will compare the clinical efficacy of <FONT STYLE="white-space:nowrap">OPT-302</FONT> administered in combination with the applicable <FONT STYLE="white-space:nowrap">VEGF-A</FONT> inhibitor on an every
four-week and every eight-week dosing regimen. For consistency, the ShORe and COAST Phase&nbsp;3 trials build upon and maintain key features of our Phase&nbsp;2b clinical trial of <FONT STYLE="white-space:nowrap">OPT-302</FONT> combination therapy
for the treatment of wet AMD, while evaluating the administration of <FONT STYLE="white-space:nowrap">OPT-302</FONT> combination therapy over a longer treatment period and in a greater number of patients. We expect to initiate the trials in the
first half of 2021 and to report topline data in 2023. If the results at the completion of the primary efficacy phase at week 52 of the Phase&nbsp;3 clinical trials are favorable, we intend to file for marketing approval for <FONT
STYLE="white-space:nowrap">OPT-302</FONT> for the treatment of wet AMD in the United States, European Union and other territories. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In addition to our planned pivotal Phase 3 clinical trials, we plan to develop a <FONT STYLE="white-space:nowrap">co-formulation</FONT> of
<FONT STYLE="white-space:nowrap">OPT-302</FONT> with an approved and/or biosimilar <FONT STYLE="white-space:nowrap">anti-VEGF-A</FONT> therapy designed to achieve <FONT STYLE="white-space:nowrap">VEGF-A,</FONT>
<FONT STYLE="white-space:nowrap">VEGF-C</FONT> and <FONT STYLE="white-space:nowrap">VEGF-D</FONT> inhibition following the administration of a single intravitreal injection of the <FONT STYLE="white-space:nowrap">co-formulated</FONT> product. <FONT
STYLE="white-space:nowrap">OPT-302</FONT> is </FONT></P>
</div></div>

 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">2 </FONT></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1pt solid #000000;BORDER-LEFT:1pt solid #000000;BORDER-RIGHT:1pt solid #000000;BORDER-TOP:1pt solid #000000; MARGIN-LEFT:0px; MARGIN-RIGHT:0px; max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
currently administered as a combination therapy consisting of a sequential injection of <FONT STYLE="white-space:nowrap">OPT-302</FONT> following intravitreal administration of a <FONT
STYLE="white-space:nowrap">VEGF-A</FONT> inhibitor. We believe that a <FONT STYLE="white-space:nowrap">co-formulated</FONT> <FONT STYLE="white-space:nowrap">OPT-302</FONT> and <FONT STYLE="white-space:nowrap">VEGF-A</FONT> inhibitor product could
provide flexibility of treatment options for physicians and reduce the frequency and number of injections for patients. We expect to file an investigative new drug application, or IND, for the <FONT STYLE="white-space:nowrap">co-formulated</FONT>
product in the second half of 2021 and subsequently investigate the <FONT STYLE="white-space:nowrap">co-formulated</FONT> product in a Phase 1 clinical trial for the treatment of wet AMD. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
SIZE="1">&nbsp;</FONT></P>  <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We are also investigating the therapeutic potential of <FONT STYLE="white-space:nowrap">OPT-302</FONT> for
DME. DME is a progressive eye disease and a complication of diabetic retinopathy, or DR, a condition caused by chronically elevated glucose levels in diabetics that damages the retina. DME can cause blurred vision, severe vision loss and blindness.
Wet AMD and DME share a similar underlying pathophysiology, including retinal neovascularization and increased vascular permeability, and as a result, <FONT STYLE="white-space:nowrap">VEGF-A</FONT> inhibitors are also considered the standard of care
treatment for DME. Based on its mechanism of action and clinical results to date, we believe that <FONT STYLE="white-space:nowrap">OPT-302</FONT> also has the potential to deliver therapeutic benefit in DME patients. In our Phase 1b/2a clinical
trial of <FONT STYLE="white-space:nowrap">OPT-302</FONT> in combination with aflibercept in patients with treatment-refractory DME, we observed evidence of improved clinical outcomes following <FONT STYLE="white-space:nowrap">OPT-302</FONT>
combination therapy in this indication, as OPT-302 combination therapy met the primary efficacy endpoint based on the proportion of patients achieving a <FONT STYLE="FONT-FAMILY:SYMBOL">&#179;</FONT>5 letter gain in visual acuity at week 12 compared
to baseline. OPT-302 combination therapy was also well tolerated in this trial. The most common TEAEs were mainly related to the intravitreal injection procedure, and TEAEs did not lead to discontinuation of the trial for any patient. There was only
one potentially treatment-related SAE of cerebrovascular accident, or stroke, resulting in one patient discontinuing treatment and withdrawing from the trial. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We also believe that our novel treatment mechanism has the
potential to provide therapeutic benefit for other progressive retinal diseases beyond wet AMD and DME. We may further investigate the efficacy of <FONT STYLE="white-space:nowrap">OPT-302</FONT> to improve clinical outcomes in patients with
polypoidal choroidal vasculopathy, a form of wet AMD that is highly prevalent in Asian populations and less responsive to <FONT STYLE="white-space:nowrap">anti-VEGF-A</FONT> therapy than other wet AMD subtypes. Beyond wet AMD and DME, we may explore
applications of <FONT STYLE="white-space:nowrap">OPT-302</FONT> in other retinal diseases in which a <FONT STYLE="white-space:nowrap">VEGF-C</FONT> or <FONT STYLE="white-space:nowrap">VEGF-D</FONT> inhibitor could have therapeutic potential, such as
retinal vein occlusion. </FONT></P>
</div></div>

 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">3 </FONT></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1pt solid #000000;BORDER-LEFT:1pt solid #000000;BORDER-RIGHT:1pt solid #000000;BORDER-TOP:1pt solid #000000; MARGIN-LEFT:0px; MARGIN-RIGHT:0px; max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Our Pipeline </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The following table summarizes the stage of clinical
development and status of our product candidate, <FONT STYLE="white-space:nowrap">OPT-302.</FONT> </FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center">


<IMG SRC="g947560g91o61.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Our Strategy
</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our goal is to become a leader in developing
and commercializing therapeutics for the treatment of retinal diseases. The key elements of our strategy are to: </FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Advance <FONT STYLE="white-space:nowrap">OPT-302</FONT> through two concurrent Phase 3 trials for the treatment of wet AMD.
</FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Optimize <FONT STYLE="white-space:nowrap">OPT-302</FONT> administration and develop a co-formulation to reduce injection burden for patients and
provide treatment flexibility. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Expand clinical development of <FONT STYLE="white-space:nowrap">OPT-302</FONT> in wet AMD, DME and other retinal diseases.
</FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Maximize the commercial potential <FONT STYLE="white-space:nowrap">of&nbsp;OPT-302</FONT> through commercialization independently and opportunistic
collaborations with third parties. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>  <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>Certain Preliminary Financial Information </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">As of September 30, 2020, we had estimated cash and cash equivalents of approximately A$54.1 million (or approximately US$38.5 million, based on the Australian dollar/U.S. dollar exchange rate of A$1.4068
to US$1.00 as of September&nbsp;30, 2020). This estimate of our cash and cash equivalents is preliminary and subject to completion, including the completion of customary financial statement closing and review procedures for the three months ended
September&nbsp;30, 2020. As a result, the unaudited preliminary cash and cash equivalents set forth above reflects our preliminary estimate with respect to such information, based on information currently available to management, and may vary from
our actual financial position as of September&nbsp;30, 2020. Further, this </FONT></P>
</div></div>

 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">4 </FONT></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1pt solid #000000;BORDER-LEFT:1pt solid #000000;BORDER-RIGHT:1pt solid #000000;BORDER-TOP:1pt solid #000000; MARGIN-LEFT:0px; MARGIN-RIGHT:0px; max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

  <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
preliminary estimate is not a comprehensive statement or estimate of our financial results or financial condition as of and for the three months ended September&nbsp;30, 2020. The unaudited
preliminary cash and cash equivalents included herein has been prepared by, and is the responsibility of, management. Deloitte Touche Tohmatsu, our independent registered public accounting firm, has not audited, reviewed, compiled or performed any
procedures with respect to the unaudited preliminary cash and cash equivalents set forth above. Accordingly, Deloitte Touche Tohmatsu does not express an opinion or any other form of assurance with respect thereto and assumes no responsibility for,
and disclaims any association with, the unaudited preliminary cash and cash equivalents set forth above. This estimate should not be viewed as a substitute for financial statements prepared in accordance with IFRS and is not necessarily indicative
of the results to be achieved in any future period. Accordingly, you should not place undue reliance on this preliminary estimate. </FONT></P>  <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Risks Associated with Our Business </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our business is subject to numerous risks and uncertainties, including those described in &#147;Risk Factors&#148; and elsewhere in this
prospectus. You should carefully consider these risks before making an investment. These risks include, among others, the following: </FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">We are a clinical stage biopharmaceutical company with no products approved for commercial sale. We have incurred net losses since our inception, we
expect to incur significant losses and increasing operating losses for the foreseeable future, and we may never be profitable. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">We currently have no source of product revenue and may never become profitable. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">We will require substantial additional capital to finance our operations, which may not be available to us on acceptable terms, or at all. As a result,
we may not complete the development and commercialization of <FONT STYLE="white-space:nowrap">OPT-302</FONT> or develop new product candidates. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our business substantially depends on the success of <FONT STYLE="white-space:nowrap">OPT-302,</FONT> our only product candidate under clinical
development, which has not completed a pivotal Phase 3 clinical trial. If we are unable to obtain regulatory approval for and successfully commercialize <FONT STYLE="white-space:nowrap">OPT-302</FONT> or any future product candidates, or we
experience significant delays in doing so, our business will be harmed. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Clinical drug development involves a lengthy and expensive process with uncertain timelines and uncertain outcomes. Our clinical trials may fail to
adequately demonstrate the safety and efficacy of <FONT STYLE="white-space:nowrap">OPT-302</FONT> or any future product candidates. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">If we experience delays in clinical testing, our commercial prospects will be harmed, our costs may increase and our business may be harmed.
</FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">If we encounter difficulties in enrolling patients in our clinical trials, our clinical development activities could be delayed or otherwise negatively
affected. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="white-space:nowrap">OPT-302</FONT> and any future product candidates may cause undesirable side effects or have other properties that
could delay or prevent their regulatory approval or limit the commercial profile of an approved label. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Even if we complete the necessary Phase 3 pivotal clinical trials, the marketing approval process is expensive, time-consuming and uncertain and may
prevent us or any future collaboration partners from obtaining approvals for the commercialization of <FONT STYLE="white-space:nowrap">OPT-302</FONT> for the treatment of wet AMD or any other indication as well as for any other product candidate we
develop. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="white-space:nowrap">OPT-302</FONT> and any future product candidates may not achieve adequate market acceptance among physicians,
patients, healthcare payors and others in the medical community necessary for commercial success. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Lack of efficacy, adverse events or undesirable side effects may emerge in clinical trials conducted by third parties with product candidates for wet
AMD or DME, which could negatively affect our stock price, our ability to attract additional capital and our development program. </FONT></P></TD></TR></TABLE>
</div></div>

 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">5 </FONT></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1pt solid #000000;BORDER-LEFT:1pt solid #000000;BORDER-RIGHT:1pt solid #000000;BORDER-TOP:1pt solid #000000; MARGIN-LEFT:0px; MARGIN-RIGHT:0px; max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">The results of completed clinical trials may not be predictive of future results. Data from our clinical trials to date may not be indicative of
results obtained when these trials are completed or in later stage trials. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Interim, topline and preliminary data from our clinical trials that we announce or publish from time to time may change as more patient data become
available and are subject to audit and verification procedures that could result in material changes in the final data. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">We may face substantial competition, which may result in others discovering, developing or commercializing competing products before or more
successfully than us. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our business could be negatively affected by the effects of health epidemics, including the evolving effects of the
<FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic, in regions where we or third parties on which we rely have significant manufacturing facilities, concentrations of clinical trial sites or other business operations.
</FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">We have relied on, and expect to continue to rely on, third-party manufacturers to produce <FONT STYLE="white-space:nowrap">OPT-302</FONT> or any
future product candidates. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our success depends upon our ability to obtain and maintain intellectual property protection for our products and technologies.
</FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">There has been no prior market for the ADSs and an active and liquid market for our securities may fail to develop, which could harm the market price
of the ADSs. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">If we fail to implement and maintain an effective system of internal controls to remediate our material weaknesses over financial reporting, we may be
unable to accurately report our results of operations, meet our reporting obligations or prevent fraud, and investor confidence in our company and the market price of the ADSs may be negatively impacted. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">If we are unable to adequately address these and other risks
we face, our business may be harmed. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Corporate
Information </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We were incorporated under the
laws of Australia in 1984 under the name Circadian Technologies Limited. In 1985, we completed an initial public offering of our ordinary shares and the listing of our ordinary shares on the Australian Securities Exchange, or the ASX. In December
2015, we changed the name of our company to Opthea Limited. Our headquarters and registered offices are located at Suite 0403, Level&nbsp;4, 650 Chapel Street, South Yarra, VIC 3141, Australia. Our telephone number is +61 3 9826 0399. Our agent for
service of process in the United States is Corporation Service Company, located at 1180 Avenue of the Americas, Suite 210, New York, NY 10036. Our website address is www.opthea.com. The reference to our website is an inactive textual reference only
and information contained in, or that can be assessed through, our website is not part of this prospectus. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Implications of Being an Emerging Growth Company </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">As a company with less than $1.07&nbsp;billion in revenue
during our last fiscal year, we qualify as an &#147;emerging growth company&#148; as defined in the JOBS Act. As an emerging growth company, we may take advantage of specified reduced disclosure and other requirements that are otherwise applicable
generally to public companies. These provisions include: </FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">exemption from the auditor attestation requirement of Section&nbsp;404 of the Sarbanes-Oxley Act of 2002, or the Sarbanes-Oxley Act, in the assessment
of our internal controls over financial reporting; and </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">to the extent that we no longer qualify as a foreign private issuer, (i)&nbsp;reduced disclosure obligations regarding executive compensation in our
periodic reports and proxy statements and (ii)&nbsp;exemptions from </FONT></P></TD></TR></TABLE>
</div></div>

 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">6 </FONT></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1pt solid #000000;BORDER-LEFT:1pt solid #000000;BORDER-RIGHT:1pt solid #000000;BORDER-TOP:1pt solid #000000; MARGIN-LEFT:0px; MARGIN-RIGHT:0px; max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"> <P><FONT STYLE="font-family:Times New Roman" SIZE="2">
the requirements of holding <FONT STYLE="white-space:nowrap">a&nbsp;non-binding&nbsp;advisory</FONT> vote on executive compensation, including golden parachute compensation.
</FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We may take advantage of these
exemptions until such time that we are no longer an emerging growth company. Accordingly, the information that we provide shareholders and holders of the ADSs may be different than you might obtain from other public companies. We will cease to be an
emerging growth company upon the earliest to occur of (i)&nbsp;the last day of the fiscal year in which we have more than $1.07&nbsp;billion in annual revenue; (ii)&nbsp;the last day of the fiscal year in which we qualify as a &#147;large
accelerated filer&#148;; (iii)&nbsp;the date on which we have, during the previous three-year period, issued more than $1.0&nbsp;billion <FONT STYLE="white-space:nowrap">in&nbsp;non-convertible&nbsp;debt</FONT> securities;&nbsp;and (iv)&nbsp;the
last day of the fiscal year in which the fifth anniversary of this offering occurs. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">In addition, Section&nbsp;107 of the JOBS Act provides that an emerging growth company can use the extended transition period provided in Section&nbsp;7(a)(2)(B) of the Securities Act for complying with
new or revised accounting standards. Given that we currently report and expect to continue to report under IFRS, as issued by the IASB, we have irrevocably elected not to avail ourselves of this extended transition period and, as a result, we will
adopt new or revised accounting standards on the relevant dates on which adoption of such standards is required by the IASB. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Implications of Being a Foreign Private Issuer </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We are also considered a &#147;foreign private issuer&#148;
under U.S. securities laws. In our capacity as a foreign private issuer, we are exempt from certain rules under the Exchange Act that impose certain disclosure obligations and procedural requirements for proxy solicitations under Section&nbsp;14 of
the Exchange Act. In addition, our senior management, the members of our board of directors and our principal shareholders are exempt from the reporting and &#147;short-swing&#148; profit recovery provisions of Section&nbsp;16 of the Exchange Act
and the rules under the Exchange Act with respect to their purchases and sales of our securities. Moreover, we are not required to file periodic reports and financial statements with the SEC as frequently or as promptly as U.S. companies whose
securities are registered under the Exchange Act. In addition, we are not required to comply with Regulation FD, which restricts the selective disclosure of material information. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We may take advantage of these exemptions until such time as
we are no longer a foreign private issuer. We will remain a foreign private issuer until such time that 50% or more of our outstanding voting securities are held by U.S. residents and any of the following three circumstances applies: (i)&nbsp;the
majority of the members of board of directors or our senior management are U.S. citizens or residents; (ii)&nbsp;more than 50% of our assets are located in the United States; or (iii)&nbsp;our business is administered principally in the United
States. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We have taken advantage of certain
reduced reporting and other requirements in this prospectus. Accordingly, the information contained herein may be different from the information you receive from other public companies. </FONT></P>
</div></div>

 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">7 </FONT></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1pt solid #000000;BORDER-LEFT:1pt solid #000000;BORDER-RIGHT:1pt solid #000000;BORDER-TOP:1pt solid #000000; MARGIN-LEFT:0px; MARGIN-RIGHT:0px; max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="rom947560_2"></A>THE OFFERING </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE="margin-top:0px;margin-bottom:1px; margin-left:2%; text-indent:-2%"><FONT STYLE="font-family:Times New Roman" SIZE="2">ADSs offered by us </FONT></P></TD>
<TD><FONT STYLE="font-family:Times New Roman" SIZE="2">9,300,000 ADSs. </FONT></TD></TR></TABLE>  <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE="margin-top:0px;margin-bottom:1px; margin-left:2%; text-indent:-2%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Option to purchase additional ADSs </FONT></P></TD>
<TD><FONT STYLE="font-family:Times New Roman" SIZE="2">The underwriters have an option for a period of 30 days from the date of this prospectus to purchase up to 1,395,000 additional ADSs. </FONT></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE="margin-top:0px;margin-bottom:1px; margin-left:2%; text-indent:-2%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Ordinary shares to be outstanding after this offering, including shares underlying ADSs </FONT></P></TD>

<TD><FONT STYLE="font-family:Times New Roman" SIZE="2">343,557,769 shares (or 354,717,769 shares if the underwriters exercise their option to purchase 1,395,000 additional ADSs in full). </FONT></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE="margin-top:0px;margin-bottom:1px; margin-left:2%; text-indent:-2%"><FONT STYLE="font-family:Times New Roman" SIZE="2">American depositary shares </FONT></P></TD>
<TD><FONT STYLE="font-family:Times New Roman" SIZE="2">Each ADS represents eight ordinary shares, no par value. The ADSs are issued by the depositary. You will have the rights of an ADS holder as provided in the deposit agreement among us, the
depositary and all owners and holders of ADSs issued thereunder. The depositary, through its custodian, will be the holder of the ordinary shares underlying the ADSs. </FONT></TD></TR></TABLE>  <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="38%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">You may surrender your ADSs to the depositary for cancellation to receive the ordinary shares underlying your ADSs. The depositary will charge you a fee for such a
cancellation. </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="38%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">We may amend or terminate the deposit agreement for any reason without your consent. Any amendment that imposes or increases fees or charges or which materially
prejudices any substantial existing right you have as an ADS holder will not become effective as to outstanding ADSs until 30 days after notice of the amendment is given to ADS holders. If an amendment becomes effective, you will be bound by the
deposit agreement as amended if you continue to hold your ADSs. </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="38%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">To better understand the terms of the ADSs, you should carefully read the section titled &#147;Description of American Depositary Shares.&#148; We also encourage you to
read the deposit agreement, which is filed as an exhibit to the registration statement of which this prospectus forms a part. </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE="margin-top:0px;margin-bottom:1px; margin-left:2%; text-indent:-2%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Depositary </FONT></P></TD>
<TD><FONT STYLE="font-family:Times New Roman" SIZE="2">The Bank of New York Mellon. </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE="margin-top:0px;margin-bottom:1px; margin-left:2%; text-indent:-2%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Use of proceeds </FONT></P></TD>
<TD><FONT STYLE="font-family:Times New Roman" SIZE="2">We estimate that the net proceeds from the sale of the ADSs that we are selling in this offering will be approximately US$146.4&nbsp;million (or approximately US$168.8&nbsp;million if the
underwriters&#146; option to purchase additional ADSs is exercised in full), based upon an assumed initial public offering price of US$17.26 per ADS, the U.S. dollar equivalent of the last reported sale price of our ordinary shares on the ASX on
October&nbsp;8, 2020, after giving effect to the Australian dollar/U.S. dollar exchange rate of A$1.3996 to US$1.00 as of October&nbsp;8, 2020, and an <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">ADS-to-ordinary</FONT></FONT>
share ratio of 1-to-8, after deducting underwriting discounts and commissions and estimated offering expenses payable by us. </FONT></TD></TR></TABLE>
</div></div>

 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">8 </FONT></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1pt solid #000000;BORDER-LEFT:1pt solid #000000;BORDER-RIGHT:1pt solid #000000;BORDER-TOP:1pt solid #000000; MARGIN-LEFT:0px; MARGIN-RIGHT:0px; max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="38%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">We intend to use the net proceeds from this offering, together with our existing cash and cash equivalents, to advance the clinical development of <FONT
STYLE="white-space:nowrap">OPT-302</FONT> for the treatment of wet AMD, including the initiation of and reporting of top line data from two pivotal Phase&nbsp;3 clinical trials, to advance the development of, and non-clinical studies for, a
co-formulation of <FONT STYLE="white-space:nowrap">OPT-302</FONT> with an approved and/or biosimilar <FONT STYLE="white-space:nowrap">anti-VEGF-A</FONT> therapy, and to fund other research and development activities for <FONT
STYLE="white-space:nowrap">OPT-302</FONT> in potential additional indications, including DME, and for working capital and other general corporate purposes. See &#147;Use of Proceeds&#148; for additional information. </FONT></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE="margin-top:0px;margin-bottom:1px; margin-left:2%; text-indent:-2%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Risk factors </FONT></P></TD>
<TD><FONT STYLE="font-family:Times New Roman" SIZE="2">See &#147;Risk Factors&#148; and the other information included in this prospectus for a discussion of the risks you should carefully consider before investing in the ADSs.
</FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE="margin-top:0px;margin-bottom:1px; margin-left:2%; text-indent:-2%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Proposed Nasdaq Global Select Market&nbsp;symbol for the ADSs </FONT></P></TD>
<TD><FONT STYLE="font-family:Times New Roman" SIZE="2">&#147;OPT&#148; </FONT></TD></TR></TABLE>  <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE="margin-top:0px;margin-bottom:1px; margin-left:2%; text-indent:-2%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Australian Securities Exchange symbol for our ordinary shares </FONT></P></TD>
<TD><FONT STYLE="font-family:Times New Roman" SIZE="2">&#147;OPT&#148; </FONT></TD></TR></TABLE>  <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">The number of ordinary shares (including ordinary shares underlying ADSs) that will be outstanding after this offering is based on 269,157,769&nbsp;ordinary shares outstanding as of June&nbsp;30, 2020,
and excludes: </FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">18,044,000 ordinary shares issuable upon the exercise of outstanding options as of June&nbsp;30, 2020 with a weighted-average exercise price of A$0.68
per ordinary share under our equity incentive plans; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">7,000,000 ordinary shares issuable upon the exercise of options that will be granted under our non-executive director share and option plan to certain
of our non-employee directors upon approval of such options by our shareholders, of which (i)&nbsp;options to purchase 4,000,000 shares are subject to approval at our annual general meeting of shareholders for 2020 on October&nbsp;12, 2020, at which
time an exercise price per ordinary share will be determined for such options, and (ii)&nbsp;an option to purchase 3,000,000 shares will be subject to approval at a future meeting of shareholders following the completion of this offering (see
&#147;Management&#151;Remuneration of Non-Employee Directors&#148;); and </FONT></P></TD></TR></TABLE>  <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">12,446,777&nbsp;ordinary shares reserved for future issuance under our Long Term Incentive Plan. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>  <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In addition, unless we specifically state otherwise, all
information in this prospectus assumes (i)&nbsp;no exercise by the underwriters of their option to purchase up to 1,395,000 additional ADSs and (ii)&nbsp;no exercise of outstanding options to purchase ordinary shares. </FONT></P>
</div></div>

 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">9 </FONT></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1pt solid #000000;BORDER-LEFT:1pt solid #000000;BORDER-RIGHT:1pt solid #000000;BORDER-TOP:1pt solid #000000; MARGIN-LEFT:0px; MARGIN-RIGHT:0px; max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="rom947560_3"></A>SUMMARY CONSOLIDATED FINANCIAL DATA </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The following tables summarize our consolidated financial and
other data. The summary consolidated statement of profit or loss and other comprehensive income data for the years ended June&nbsp;30, 2019 and 2020 have been derived from our audited consolidated financial statements included elsewhere in this
prospectus. Our audited consolidated financial statements have been prepared in accordance with IFRS, as issued by the IASB, as of and for the years ended June&nbsp;30, 2019 and 2020. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">You should read the consolidated financial and other data set forth below in conjunction with our consolidated
financial statements and the accompanying notes, the information in &#147;Selected Consolidated Financial and Other Data&#148; and the information in &#147;Management&#146;s Discussion and Analysis of Financial Condition and Results of
Operations&#148; contained elsewhere in this prospectus. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Consolidated Statement of Profit or Loss and Other Comprehensive Income Data </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>

<TD WIDTH="80%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Year Ended June&nbsp;30,</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2019</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2020</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(in&nbsp;thousands,&nbsp;except<BR>per&nbsp;share&nbsp;data)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Revenue</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">A$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">159</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">A$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">87</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Other income</FONT><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(1)</SUP></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">837</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">784</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Research and development expenses</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(31,348</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(17,954</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Patent expenses</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(161</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(429</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Intellectual property costs</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(113</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(114</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Administrative expenses</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(5,175</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(7,001</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Occupancy expenses</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(109</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(34</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Net foreign exchange gain (loss)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">363</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(401</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Loss before income tax</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(35,547</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(25,062</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Income tax benefit</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">14,637</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">8,533</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Loss for the year</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(20,910</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(16,529</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Other comprehensive income:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Items that will not be reclassified subsequently to profit or loss:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Fair value gains on investments in financial assets</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">260</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">59</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Other comprehensive income for the period, net of tax</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">260</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">59</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total comprehensive loss for the year</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">A$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(20,650</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">A$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(16,470</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total comprehensive loss for the year is attributable to:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Owners of the Company</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(20,650</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(16,470</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">A$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(20,650</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">A$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(16,470</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Loss per share attributable to Owners of the Company &#150; basic and diluted (in cents)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">A$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(8.98</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">A$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(6.34</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
</TABLE> <P STYLE="line-height:8px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(1)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Other income primarily comprises finance income from interest on bank deposits, funding under a <FONT STYLE="white-space:nowrap">one-time</FONT> Australian government
grant from the Commonwealth Scientific and Industrial Research Organization during the year ended June 30, 2019, and funding under a one-time government grant from the Australian Tax Office during the year ended June 30, 2020.
</FONT></TD></TR></TABLE>
</div></div>

 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">10 </FONT></P>


</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1pt solid #000000;BORDER-LEFT:1pt solid #000000;BORDER-RIGHT:1pt solid #000000;BORDER-TOP:1pt solid #000000; MARGIN-LEFT:0px; MARGIN-RIGHT:0px; max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Consolidated Statement of Financial Position Data </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>

<TD WIDTH="77%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>As of June&nbsp;30, 2020</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Actual</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>As<BR>Adjusted<SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(1)(2)</SUP></B></FONT></TD>

<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(in thousands)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Cash and cash equivalents</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">A$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">62,020</FONT></TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">A$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">266,896</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Working capital</FONT><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(3)</SUP></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">64,398</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">269,274</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total assets</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">71,887</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">276,763</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total liabilities</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">7,079</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">7,079</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Accumulated losses</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(102,589</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(102,589</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total equity</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">64,808</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">269,684</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
</TABLE>  <P STYLE="line-height:8px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(1)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">The as adjusted statement of financial position data give effect to our receipt of net proceeds from the issuance and sale of 9,300,000 ADSs at the assumed initial
offering price of US$17.26&nbsp;per ADS, the U.S. dollar equivalent of the last reported sale price of our ordinary shares on the ASX on October 8, 2020, after giving effect to the Australian dollar/U.S. dollar exchange rate of A$1.3996 to US$1.00
as of October 8, 2020, and an <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">ADS-to-ordinary</FONT></FONT> share ratio of 1-to-8, after deducting underwriting commissions and estimated offering expenses payable by us.
</FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(2)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Each $1.00 increase (decrease) in the assumed initial public offering price of US$17.26&nbsp;per ADS, the U.S. dollar equivalent of the last reported sale price of our
ordinary shares on the ASX on October&nbsp;8, 2020, after giving effect to the Australian dollar/U.S. dollar exchange rate of A$1.3996 to US$1.00 as of October&nbsp;8, 2020, and an
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">ADS-to-ordinary</FONT></FONT> share ratio of 1-to-8, would increase (decrease) the amount of cash and cash equivalents, working capital, total assets and total equity by
A$12.1&nbsp;million (or US$8.6&nbsp;million), assuming the number of ADSs offered by us, as set forth on the cover page of this prospectus, remains the same and after deducting underwriting discounts and commissions and estimated offering expenses
payable by us. We may also increase or decrease the number of ADSs we are offering. An increase (decrease) of 1,000,000 in the number of ADSs we are offering would increase (decrease) the amount of cash and cash equivalents, working capital, total
assets and total equity by A$22.5&nbsp;million (or US$16.1&nbsp;million), assuming the assumed initial public offering price per ADS remains the same and after deducting underwriting discounts and commissions. The as adjusted information is
illustrative only and will be adjusted based on the actual initial public offering price and other terms of this offering determined at pricing. </FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(3)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Working capital is defined as current assets less current liabilities. </FONT></TD></TR></TABLE>
</div></div>

 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">11 </FONT></P>


</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="rom947560_4"></A><A NAME="cov947560_100"></A>RISK FACTORS </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Investing in the ADSs involves a high degree of risk. You
should consider and read carefully all of the risks and uncertainties described below, as well as other information included in this prospectus, including our consolidated financial statements and related notes included elsewhere in this prospectus,
before making an investment decision. If any of the following risks actually occur, it could harm our business, prospects, results of operations and financial condition. In such event, the trading price of the ADSs could decline and you might lose
all or part of your investment. </I></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Risks Related to Our
Financial Position and Need for Capital </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>We are a clinical stage biopharmaceutical company with no products approved for commercial sale. We have incurred net losses since
our inception, we expect to incur significant losses and increasing operating losses for the foreseeable future, and we may never be profitable. </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We are a clinical stage biopharmaceutical company with no products approved for commercial sale. To date, our operations have been limited
to organizing and staffing our company, business planning, raising capital, developing our product candidate, <FONT STYLE="white-space:nowrap">OPT-302,</FONT> and licensing certain related technology, conducting research and development activities,
including preclinical studies and clinical trials, and providing general and administrative support for these operations. Investment in biopharmaceutical product development is highly speculative because it entails substantial upfront capital
expenditures and significant risk that any potential product candidate will fail to demonstrate adequate effect and/or an acceptable safety profile, gain regulatory approval and become commercially viable. We have not generated any revenue from
product sales to date, and we continue to incur significant research and development and other expenses related to our ongoing operations. We are not profitable and have incurred net losses since our inception. Our total comprehensive losses were
$20.7&nbsp;million and $16.5 million for the years ended June&nbsp;30, 2019 and 2020. As of June&nbsp;30, 2020, we had an accumulated loss of $102.6 million. We have spent, and expect to continue to spend, significant resources to fund research and
development of, and seek regulatory approvals for, <FONT STYLE="white-space:nowrap">OPT-302</FONT> and any future product candidates. We expect to incur substantial and increasing operating losses over the next several years as our research,
development, manufacturing and clinical trial activities increase. Additionally, if <FONT STYLE="white-space:nowrap">OPT-302</FONT> is approved for commercial sale, our commercialization expenses will increase significantly as we establish sales,
marketing, distribution, manufacturing, supply chain and other commercial infrastructure. As a result, our accumulated losses will also increase significantly. We may encounter unforeseen expenses, difficulties, complications, delays and other
unknown factors that may negatively affect our business. The size of our future net losses will depend, in part, on the rate of future growth of our expenses and our ability to generate revenue. Our prior losses and expected future losses have had
and will continue to have a negative impact on our total (deficit) equity and working capital. The net losses we incur may fluctuate significantly from
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">quarter-to-quarter</FONT></FONT> such that a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">period-to-period</FONT></FONT> comparison of our results of operations
may not be a good indication of our future performance. Even if we eventually generate product revenue, we may never be profitable and, if we do achieve profitability, we may not be able to sustain or increase profitability on a quarterly or annual
basis. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>We currently have no source of
product revenue and may never become profitable. </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="white-space:nowrap">OPT-302</FONT> has not been approved for commercial sale, and we expect it to be several years before <FONT STYLE="white-space:nowrap">OPT-302</FONT> is approved, if ever,
and we are able to commence sales of <FONT STYLE="white-space:nowrap">OPT-302.</FONT> To date, we have not generated any revenue from the licensing or commercialization of <FONT STYLE="white-space:nowrap">OPT-302</FONT> and do not expect to receive
revenue from it for a number of years, if ever. We will not be able to generate product revenue unless and until <FONT STYLE="white-space:nowrap">OPT-302</FONT> or any future product candidate, alone or with future partners, successfully completes
clinical trials, receives regulatory approval and is successfully commercialized. Although we may seek to obtain revenue from collaboration or licensing agreements with third parties, we currently have no such agreements that could provide us with
material, ongoing future revenue and we may never enter into any such agreements. Our ability to generate future product revenue </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">12 </FONT></P>


</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
from <FONT STYLE="white-space:nowrap">OPT-302</FONT> or any future product candidates also depends on a number of additional factors, including our or our future partners&#146; ability to:
</FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">successfully complete research and clinical development of <FONT STYLE="white-space:nowrap">OPT-302</FONT> and any future product candidates and obtain
regulatory approvals for commercialization; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">maintain supply and manufacturing relationships with third parties, and ensure adequate and legally compliant manufacturing of bulk drug substances and
drug products to maintain that supply, including any scale up of manufacturing processes for <FONT STYLE="white-space:nowrap">OPT-302</FONT> to support our planned Phase 3 clinical program of <FONT STYLE="white-space:nowrap">OPT-302</FONT> in
combination with anti-vascular endothelial growth factor-A, or <FONT STYLE="white-space:nowrap">anti-VEGF-A,</FONT> therapy for the treatment of wet <FONT STYLE="white-space:nowrap">age-related</FONT> macular degeneration, or AMD;
</FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">launch and commercialize future product candidates for which we obtain marketing approval, if any, and, if launched independently, successfully
establish a sales force, marketing and distribution infrastructure; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">demonstrate the necessary safety data post-approval to ensure continued regulatory approval; </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">obtain coverage and adequate product reimbursement from third-party payors, including government payors; </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">achieve market acceptance for our or our future partners&#146; products, if any; </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">establish, maintain, protect and enforce our intellectual property rights; and </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">attract, hire and retain qualified personnel. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In addition, because of the numerous risks and uncertainties
associated with biologic product development, including that <FONT STYLE="white-space:nowrap">OPT-302</FONT> may not advance through development, achieve the endpoints of applicable clinical trials or receive approval for use in combination with one
or more approved therapies, we are unable to predict the timing or amount of increased expenses, or if or when we will achieve or maintain profitability. In addition, our expenses could increase beyond expectations if we decide, or are required by
the U.S. Food and Drug Administration, or the FDA, or comparable <FONT STYLE="white-space:nowrap">non-U.S.</FONT> regulatory authorities, including the European Medicines Agency, or the EMA, to perform studies or trials in addition to those that we
currently anticipate. Even if we complete the development and regulatory processes described above, we anticipate incurring significant costs associated with launching and commercializing these products. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Even if we generate revenue from the sale of any of our
product candidates that may be approved, we may not become profitable and may need to obtain additional funding to continue operations. If we fail to become profitable or do not sustain profitability on a continuing basis, then we may be unable to
continue our operations at planned levels and be forced to reduce our operations. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B><I>We will require substantial additional capital to finance our operations, which may not be available to us on acceptable terms, or at all. As a result, we may not complete the development and
commercialization of <FONT STYLE="white-space:nowrap">OPT-302</FONT> or develop new product candidates. </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">As a clinical-stage biopharmaceutical company, our operations have consumed significant amounts of cash since our inception. We expect our
research and development expenses to increase substantially in connection with our ongoing activities, particularly as we prepare to initiate our planned Phase 3 clinical trials of <FONT STYLE="white-space:nowrap">OPT-302</FONT> in combination with <FONT
STYLE="white-space:nowrap">anti-VEGF-A</FONT> therapy for the treatment of wet AMD and continue clinical development of <FONT STYLE="white-space:nowrap">OPT-302</FONT> in combination with aflibercept for the treatment of persistent diabetic macular
edema, or DME, and other retinal diseases. Even if we are able to obtain regulatory approval for <FONT STYLE="white-space:nowrap">OPT-302</FONT> and any future product candidates that we may develop, we will require substantial additional capital to
commercialize such product candidates. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>  <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We
believe that the net proceeds from this offering, together with our existing cash and cash equivalents, will fund our projected operating requirements until the third calendar quarter of 2023. Our forecast of the period
</FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">13 </FONT></P>


</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
of time through which our financial resources will adequately support our operations is a forward-looking statement and involves risks and uncertainties, and actual results could vary as a result
of a number of factors, including the factors discussed elsewhere in this &#147;Risk Factors&#148; section. We have based this estimate on assumptions that may prove to be wrong, and we could utilize our available capital resources sooner than we
currently expect. Our future funding requirements, both short and long-term, will depend on many factors, including: </FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the initiation, progress, timing, costs and results of clinical trials for <FONT STYLE="white-space:nowrap">OPT-302</FONT> and any future product
candidates we may develop, including whether the FDA or comparable <FONT STYLE="white-space:nowrap">non-U.S.</FONT> regulatory authorities require additional clinical trials beyond our proposed Phase 3 clinical trials of <FONT
STYLE="white-space:nowrap">OPT-302</FONT> in combination with <FONT STYLE="white-space:nowrap">anti-VEGF-A</FONT> therapy for the treatment of wet AMD to support an approved label of <FONT STYLE="white-space:nowrap">OPT-302</FONT> in combination
with multiple existing <FONT STYLE="white-space:nowrap">anti-VEGF-A</FONT> therapies; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the initiation, progress, timing, costs and results of additional clinical trials and studies to evaluate the potential for <FONT
STYLE="white-space:nowrap">co-formulation</FONT> of <FONT STYLE="white-space:nowrap">OPT-302</FONT> with approved and/or biosimilar forms of <FONT STYLE="white-space:nowrap">VEGF-A</FONT> inhibitors to provide flexibility of treatment options for
physicians and to reduce the frequency and number of injections for patients; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the outcome, timing and cost of seeking and obtaining regulatory approvals from the FDA and comparable <FONT STYLE="white-space:nowrap">non-U.S.</FONT>
regulatory authorities; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">if approved, the costs of commercialization activities for <FONT STYLE="white-space:nowrap">OPT-302,</FONT> or any other product candidate that
receives regulatory approval; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the cost to establish, maintain, expand, enforce and defend the scope of our intellectual property portfolio, including the amount and timing of any
payments we may be required to make, or that we may receive, in connection with licensing, preparing, filing, prosecuting, defending and enforcing of any patents or other intellectual property rights; </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">our headcount growth and associated costs as we expand our research and development capabilities and establish a commercial infrastructure;
</FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">market acceptance of any approved product candidates, including product pricing and adequate reimbursement by third-party payors;
</FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the cost of acquiring, licensing or investing in additional businesses, products, product candidates and technologies; </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the cost of establishing sales, marketing and distribution capabilities for <FONT STYLE="white-space:nowrap">OPT-302</FONT> and any future product
candidates for which we may receive regulatory approval and that we determine to commercialize ourselves or in collaboration with our future partners; and </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the costs of operating as a public company with securities listed in both Australia and the United States. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We will require additional capital to develop, obtain
regulatory approval for and commercialize <FONT STYLE="white-space:nowrap">OPT-302</FONT> and any future product candidates. In particular, we will require additional capital to progress our ongoing and future planned clinical trials without delays,
including payments in connection with the achievement of certain regulatory milestones. We do not have any committed external source of funds. We expect to finance future cash needs through public or private equity or debt offerings or
collaborations. We also intend to continue to apply for tax incentives under the Research and Development Tax Incentive scheme provided by the Australian government. See &#147;&#151;Risks Related to Development and Commercialization of Our Product
Candidates&#151;We have received tax credits under the Research and Development Tax Incentive scheme in Australia that may become repayable if we did not or do not comply with the rules of the scheme, or we may become ineligible for tax credits in
our current or future tax years, which could harm our business, financial condition and results of operations.&#148; Additional capital may not be available in sufficient amounts or on reasonable terms, if at all. If we are not able to raise
additional capital, we may not be able to expand our operations or otherwise capitalize on our business opportunities, and our business and financial condition will be negatively impacted. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">14 </FONT></P>


</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Raising additional capital may cause dilution to holders purchasing ADSs in this
offering, restrict our operations or require us to relinquish rights to our technologies or product candidates. </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Holders purchasing ADSs in this offering could suffer dilution or be negatively affected by fixed payment obligations we may incur if we
raise additional funds through the issuance of additional equity securities or debt. Further, these securities may have rights senior to those of our ordinary shares and could contain covenants or protective rights that would restrict our operations
and potentially impair our competitiveness, such as limitations on our ability to incur additional debt, limitations on our ability to acquire, sell or license intellectual property rights and other operating restrictions that could negatively
impact our ability to conduct our business. If we need to secure additional financing, such additional fundraising efforts may divert our management and research efforts from our
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">day-to-day</FONT></FONT> activities, which may negatively affect our ability to develop and commercialize <FONT STYLE="white-space:nowrap">OPT-302</FONT> and any future product
candidates. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">To the extent we obtain additional
funding through product collaborations, these arrangements would generally require us to relinquish rights to some of our technologies, product candidates or products, and we may not be able to enter into such agreements, on acceptable terms, if at
all. If we are unable to obtain additional funding on a timely basis, we may be required to curtail or terminate some or all of our development programs or product candidates. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Risks Related to Development and Commercialization of Our Product
Candidates </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Our business substantially
depends on the success of <FONT STYLE="white-space:nowrap">OPT-302,</FONT> our only product candidate under clinical development, which has not completed a pivotal Phase 3 clinical trial. If we are unable to obtain regulatory approval for and
successfully commercialize <FONT STYLE="white-space:nowrap">OPT-302</FONT> or any future product candidates, or we experience significant delays in doing so, our business will be harmed. </I></B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">To date, the primary focus of our product development has
been <FONT STYLE="white-space:nowrap">OPT-302</FONT> in combination with <FONT STYLE="white-space:nowrap">anti-VEGF-A</FONT> therapy for the treatment of patients with wet AMD and DME. Currently, <FONT STYLE="white-space:nowrap">OPT-302</FONT> is
our only product candidate under clinical development. This may make an investment in our company riskier than similar companies that have multiple product candidates in active development and that therefore may be able to better sustain a failure
of a lead candidate. Successful continued development and ultimate regulatory approval of <FONT STYLE="white-space:nowrap">OPT-302</FONT> combination therapy for the treatment of wet AMD, DME or other indications is critical to the future success of
our business. We have invested, and will continue to invest, a significant portion of our time and financial resources in the clinical development of <FONT STYLE="white-space:nowrap">OPT-302.</FONT> If we cannot successfully develop, obtain
regulatory approval for and commercialize <FONT STYLE="white-space:nowrap">OPT-302,</FONT> we may not be able to continue our operations. The future regulatory and commercial success of <FONT STYLE="white-space:nowrap">OPT-302</FONT> is subject to a
number of risks, including the following: </FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">we may not have sufficient financial and other resources to complete the necessary clinical trials for <FONT STYLE="white-space:nowrap">OPT-302,</FONT>
including, but not limited to, the pivotal clinical trials needed to obtain drug approval; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">we may not be able to obtain adequate evidence from clinical trials of efficacy and safety for <FONT STYLE="white-space:nowrap">OPT-302</FONT>
combination therapy for the treatment of wet AMD, DME or other indications; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">in our clinical trials for <FONT STYLE="white-space:nowrap">OPT-302,</FONT> we may need to adjust our clinical trial procedures and may need additional
clinical trial sites, which could delay our clinical trial progress; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the results of our clinical trials may not meet the level of statistical or clinical significance required by the FDA or comparable <FONT
STYLE="white-space:nowrap">non-U.S.</FONT> regulatory authorities for marketing approval; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the standards implemented by clinical or regulatory agencies may change at any time and we cannot be certain what regulatory agencies may require in
pivotal clinical trials for the approval of <FONT STYLE="white-space:nowrap">OPT-302;</FONT> </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the results of later stage clinical trials may not be as favorable as the results we have observed to date in our preclinical studies and early
clinical trials; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">we cannot be certain of the number and type of clinical trials and <FONT STYLE="white-space:nowrap">non-clinical</FONT> studies that the FDA or
comparable <FONT STYLE="white-space:nowrap">non-U.S.</FONT> regulatory agencies will require in order to approve <FONT STYLE="white-space:nowrap">OPT-302</FONT> combination therapy
</FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">15 </FONT></P>


</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"> <P><FONT STYLE="font-family:Times New Roman" SIZE="2">
for the treatment of wet AMD, DME or any other indication, including an approved label for use of <FONT STYLE="white-space:nowrap">OPT-302</FONT> in combination with multiple <FONT
STYLE="white-space:nowrap">anti-VEGF-A</FONT> therapies for the treatment of wet AMD; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">establishing sales, marketing and distribution capabilities and launching commercial sales of our products, if and when approved, whether alone or in
collaboration with others; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">acceptance of our products, if and when approved, by patients, the medical community and third-party payors; </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">obtaining and maintaining third-party coverage and adequate reimbursement; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT
SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">maintaining a continued acceptable safety profile of our products following approval, including when used in combination with existing therapies;
</FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">effectively competing with other therapies; and </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">enforcing and defending intellectual property rights and claims. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Many of these risks are beyond our control, including the
risks related to clinical development, the regulatory submission process, potential threats to our intellectual property rights and the manufacturing, marketing and sales efforts of any future collaborator. Of the large number of drugs in
development in the pharmaceutical industry, only a small percentage result in the submission of a new drug application or a biologics license application, or BLA, to the FDA and even fewer are approved for commercialization. Furthermore, even if we
do receive regulatory approval to market <FONT STYLE="white-space:nowrap">OPT-302,</FONT> any such approval may be subject to limitations on the indicated uses or patient populations for which we may market the products. Accordingly, even if we are
able to obtain the requisite financing to continue to fund our development programs, we may be unable to successfully develop or commercialize <FONT STYLE="white-space:nowrap">OPT-302.</FONT> If we or any of our future development collaborators are
unable to develop, or obtain regulatory approval for, or, if approved, successfully commercialize <FONT STYLE="white-space:nowrap">OPT-302,</FONT> we may not be able to generate sufficient revenue to continue our business. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Clinical drug development involves a lengthy and
expensive process with uncertain timelines and uncertain outcomes. Our clinical trials may fail to adequately demonstrate the safety and efficacy of <FONT STYLE="white-space:nowrap">OPT-302</FONT> or any future product candidates.
</I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="white-space:nowrap">OPT-302</FONT> and any future product candidates will be subject to rigorous and extensive clinical
trials and extensive regulatory approval processes implemented by the FDA and comparable <FONT STYLE="white-space:nowrap">non-U.S.</FONT> regulatory authorities before obtaining marketing approval from these regulatory authorities. The drug
development and approval process is lengthy and expensive, and approval is never certain. Investigational new drugs, such as <FONT STYLE="white-space:nowrap">OPT-302,</FONT> may not prove to be safe and effective in clinical trials. We have no
direct experience as a company in conducting pivotal stage clinical trials required to obtain regulatory approval. We may be unable to conduct clinical trials at preferred sites, enlist clinical investigators, enroll sufficient numbers of
participants or begin or successfully complete clinical trials in a timely fashion, if at all. In addition, the design of a clinical trial can determine whether its results will support approval of a product, and flaws in the design of a clinical
trial may not become apparent until the clinical trial is well advanced. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">The protocols for our planned Phase&nbsp;3 clinical trials for <FONT STYLE="white-space:nowrap">OPT-302</FONT> in combination with <FONT STYLE="white-space:nowrap">anti-VEGF-A</FONT> therapy are subject
to review by the FDA and comparable <FONT STYLE="white-space:nowrap">non-U.S.</FONT> regulatory authorities. The FDA is not obligated to comment on our protocols within any specified time period or at all or to affirmatively clear or approve our
Phase&nbsp;3 clinical program. We have submitted summaries of the protocols for our Phase&nbsp;3 clinical trials to the FDA and comparable <FONT STYLE="white-space:nowrap">non-U.S.</FONT> regulatory authorities, including the EMA. The FDA or other
regulatory authorities may request additional information, require us to conduct additional <FONT STYLE="white-space:nowrap">non-clinical</FONT> trials or require us to modify our proposed Phase&nbsp;3 clinical program, including its endpoints,
patient enrollment criteria or selection of <FONT STYLE="white-space:nowrap">anti-VEGF-A</FONT> therapies, to receive clearance to initiate such program or to continue such program once initiated. In addition, the FDA or other regulatory authorities
may disagree with all or a portion of our proposed trial protocols, including whether our Phase 3 clinical trial protocol is sufficient for approval of <FONT STYLE="white-space:nowrap">OPT-302</FONT> in
</FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">16 </FONT></P>


</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
combination with two or more approved <FONT STYLE="white-space:nowrap">anti-VEGF-A</FONT> therapies for the treatment of wet AMD. Any such limitations could reduce the market acceptance of <FONT
STYLE="white-space:nowrap">OPT-302</FONT> and harm our business, financial condition and results of operations. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>If we experience delays in clinical testing, our commercial prospects will be harmed, our costs may increase and our business may be
harmed. </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Conducting clinical studies for
any product candidates in the United States requires filing an investigational new drug application, or IND, and reaching agreement with the FDA on clinical protocols, finding appropriate clinical sites and clinical investigators, securing approvals
for such studies from the institutional review board at each such site, manufacturing clinical quantities of product candidates and supplying drug product to clinical sites. Currently, we have an active IND with the FDA in the United States for <FONT
STYLE="white-space:nowrap">OPT-302.</FONT> If any such future IND is not approved by the FDA, our clinical development timeline may be negatively impacted and any future clinical programs may be delayed or terminated. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We cannot guarantee that we will be able to successfully
accomplish required regulatory activities or all of the other activities necessary to initiate and complete clinical trials. As a result, our clinical trials may be extended, delayed or terminated, and we may be unable to obtain regulatory approvals
or successfully commercialize our products. We do not know whether any other clinical trials will begin as planned, will need to be restructured or will be completed on schedule, or at all. Our product development costs will increase if we
experience delays in clinical testing. Significant clinical trial delays also could shorten any periods during which we may have the exclusive right to commercialize <FONT STYLE="white-space:nowrap">OPT-302</FONT> and any future product candidates
or allow our competitors to bring products to market before we do, which would impair our ability to successfully commercialize <FONT STYLE="white-space:nowrap">OPT-302</FONT> or any future product candidates and may harm our business, results of
operations and prospects. Events that may result in a delay or unsuccessful completion of clinical development include: </FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the unavailability of financial resources to commence and completed planned trials; </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">delays in reaching agreement on acceptable terms with prospective contract research organizations, or CROs, and clinical trial sites;
</FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">revisions to labeling, including adding limitations on approved uses or the additions of additional warnings, contraindications or other safety
information including boxed warnings; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">ongoing discussions with the FDA or comparable <FONT STYLE="white-space:nowrap">non-U.S.</FONT> regulatory authorities regarding the scope or design of
our clinical trials, including our planned pivotal Phase 3 clinical trials of <FONT STYLE="white-space:nowrap">OPT-302</FONT> in combination with <FONT STYLE="white-space:nowrap">anti-VEGF-A</FONT> therapy for the treatment of wet AMD;
</FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">deviations from the trial protocol by clinical trial sites and investigators, or failures to conduct the trial in accordance with regulatory
requirements; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the need to repeat clinical trials as a result of inconclusive or negative results or poorly executed testing or changes in required endpoints by the
FDA or comparable <FONT STYLE="white-space:nowrap">non-U.S.</FONT> authorities; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">unfavorable FDA inspection and review of a clinical trial site or records of any clinical or preclinical investigation; </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the placement of a clinical hold on a clinical trial by the FDA or comparable <FONT STYLE="white-space:nowrap">non-U.S.</FONT> authorities;
</FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">delays in obtaining, or the inability to obtain, required approvals from institutional review boards or other governing entities at clinical sites
selected for participation in our clinical trials; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">failure of third parties, such as CROs, to satisfy their contractual duties to us or meet expected deadlines; </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">delays in the testing, validation, manufacturing and delivery of the product candidates to the clinical sites; </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">insufficient supply or deficient quality of product candidate materials or other materials necessary to conduct our clinical trials, including of drugs
to be used in the proposed combination therapy with our product candidates; </FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">17 </FONT></P>


</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">delays in enrolling participants into our clinical trials; </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">delays in patients completing a trial or returning for post-treatment <FONT STYLE="white-space:nowrap">follow-up;</FONT> </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">delays caused by patients dropping out of a trial due to side effects, disease progression or otherwise; </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">serious and unexpected drug-related adverse effects experienced by participants in our clinical trials; </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">implementation of new, or changes to, guidance or interpretations from the FDA or comparable <FONT STYLE="white-space:nowrap">non-U.S.</FONT>
authorities with respect to approval pathways for any product candidates we are pursuing; and </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">changes in government regulations or administrative actions or lack of adequate funding to continue the clinical trials. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our or our future collaborators&#146; inability to timely
complete clinical trials could result in additional costs to us as well as impair our ability to generate product revenue, continue development, commercialize <FONT STYLE="white-space:nowrap">OPT-302</FONT> and any future product candidates and
receive royalties on product sales. In addition, if we make changes to a product candidate, we may need to conduct additional nonclinical studies or clinical trials to bridge or demonstrate the comparability of our modified product candidate to
earlier versions, which could delay our clinical development plan or marketing approval for our current product candidate and any future product candidates. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>If we encounter difficulties in enrolling patients in our clinical trials, our clinical development activities could be delayed or
otherwise negatively affected. </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The
timely completion of clinical trials largely depends on patient enrollment. We may encounter delays in enrolling, or be unable to enroll, a sufficient number of patients to complete any of our clinical trials, and even once enrolled, we may be
unable to retain a sufficient number of patients to complete any of our trials. Many factors affect patient enrollment, including: </FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the size and nature of the patient population, which may be limited due to eligibility requirements; </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the number and location of clinical sites; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">competition with other companies for clinical sites or patients; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT
SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the availability and amount of any patient stipend; </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the eligibility and exclusion criteria for the trial; </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the design of the clinical trial; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">our ability to recruit clinical trial investigators with the appropriate competencies and experience; </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">inability to obtain and maintain patient consents; </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">significant adverse events or other side effects observed, if any; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT
SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">risk that enrolled participants will drop out before completion; and </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT
SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">competing clinical trials and clinicians&#146; and patients&#146; perceptions as to the potential advantages of the drug being studied in relation to
other available therapies. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In
addition, other companies are conducting clinical trials for the same indications and seek to enroll patients in their trials that may otherwise be eligible for our clinical studies or trials, which could lead to slow recruitment and delays in our
clinical programs. Further, since the number of qualified clinical investigators is limited, we expect to conduct some of our clinical trials at the same clinical trial sites that some of our competitors use, which could further reduce the number of
patients who are available for our clinical trials in these sites. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Our inability to enroll a sufficient number of patients for our clinical trials would result in significant delays or may require us to abandon one or more clinical trials altogether. If we are unable to
enroll a sufficient number </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">18 </FONT></P>


</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
of patients that will complete clinical testing, we will be unable to seek or gain marketing approval for <FONT STYLE="white-space:nowrap">OPT-302</FONT> and any future product candidates and our
business will be harmed. Even if we are able to enroll a sufficient number of patients in our clinical studies or trials, delays in patient enrollment may result in increased costs or may affect the timing or outcome of our clinical trials, which
could prevent completion of these trials and negatively affect our ability to advance the development of <FONT STYLE="white-space:nowrap">OPT-302</FONT> and any future product candidates. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I><FONT STYLE="white-space:nowrap">OPT-302</FONT> and any future product candidates may cause undesirable
side effects or have other properties that could delay or prevent their regulatory approval or limit the commercial profile of an approved label. </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Undesirable side effects caused by <FONT STYLE="white-space:nowrap">OPT-302</FONT> combination therapy or any future product candidates
could cause us or regulatory authorities to interrupt, delay or halt clinical trials and could result in a more restrictive label or the delay or denial of regulatory approval by the FDA or other comparable
<FONT STYLE="white-space:nowrap">non-U.S.</FONT> regulatory authorities. Additional clinical studies may be required to evaluate the safety profile of <FONT STYLE="white-space:nowrap">OPT-302</FONT> combination therapy or any future product
candidates. We have no clinical safety data on patient exposure to <FONT STYLE="white-space:nowrap">OPT-302</FONT> administered in combination with an <FONT STYLE="white-space:nowrap">anti-VEGF-A</FONT> therapy for longer than 24 weeks. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Future results of our trials could reveal a high and
unacceptable severity and prevalence of side effects or unexpected characteristics, including, for example, immunogenicity. In such an event, we could suspend or terminate our trials or the FDA or comparable
<FONT STYLE="white-space:nowrap">non-U.S.</FONT> regulatory authorities could order us to cease clinical trials or deny approval of <FONT STYLE="white-space:nowrap">OPT-302</FONT> in combination with
<FONT STYLE="white-space:nowrap">anti-VEGF-A</FONT> therapy or any future product candidates for any or all targeted indications. Drug-related side effects could affect patient recruitment or the ability of enrolled subjects to complete the trial or
result in potential product liability claims. Any of these occurrences could materially and negatively affect our business, financial condition, results of operations and prospects. While <FONT STYLE="white-space:nowrap">OPT-302</FONT> has been well
tolerated in our completed clinical trials, dosed patients have experienced certain adverse events, including potentially treatment-related serious adverse events, or SAEs, of myocardial infarction, endophthalmitis and vitritis in our Phase 2b
clinical trial of <FONT STYLE="white-space:nowrap">OPT-302</FONT> combination therapy for the treatment of wet AMD, and a potentially treatment-related SAE of stroke for one patient in our Phase 1b/2a clinical trial of
<FONT STYLE="white-space:nowrap">OPT-302</FONT> combination therapy for the treatment of DME. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">It may be difficult to discern whether certain events or symptoms observed during our clinical trials or by patients using our approved products are related to
<FONT STYLE="white-space:nowrap">OPT-302</FONT> or any future product candidates or approved products, including <FONT STYLE="white-space:nowrap">anti-VEGF-A</FONT> therapies used in combination with <FONT STYLE="white-space:nowrap">OPT-302,</FONT>
or some other factor. As a result, we and our development programs may be negatively affected even if such events or symptoms are ultimately determined to be unlikely related to <FONT STYLE="white-space:nowrap">OPT-302</FONT> or any future product
candidates or approved products. We are developing <FONT STYLE="white-space:nowrap">OPT-302</FONT> to complement existing <FONT STYLE="white-space:nowrap">VEGF-A</FONT> inhibitors, including ranibizumab and aflibercept. There are some potential side
effects associated with intravitreal <FONT STYLE="white-space:nowrap">anti-VEGF-A</FONT> therapies such as intraocular hemorrhage, intraocular pressure elevation, retinal detachment, inflammation, vasculitis, artery occlusion or infection inside the
eye and over-inhibition of VEGF, as well as the potential for potential systemic side effects such as heart attack, stroke, wound healing problems and high blood pressure.&nbsp;Further, <FONT STYLE="white-space:nowrap">OPT-302</FONT> in combination
with <FONT STYLE="white-space:nowrap">anti-VEGF-A</FONT> therapies for the treatment of wet AMD is administered as sequential intravitreal injections over several weeks. There are risks inherent in the intravitreal injection procedure of drugs such
as existing <FONT STYLE="white-space:nowrap">anti-VEGF-A</FONT> therapies in combination with <FONT STYLE="white-space:nowrap">OPT-302</FONT> which can cause injury to the eye and other complications including conjunctival hemorrhage, punctate
keratitis, eye pain, conjunctival hyperemia, which results in a discharge, intra-ocular inflammation and inflammation of the interior of the eye. For example, in our completed clinical trials, patients dosed with
<FONT STYLE="white-space:nowrap">OPT-302</FONT> have experienced potentially treatment-related ocular adverse events such as eye pain, vitreous floaters, eye irritation and raised intraocular pressure. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We cannot assure you that additional or more severe adverse
side effects than those observed to date related to <FONT STYLE="white-space:nowrap">OPT-302</FONT> combination therapy or any future product candidates will not be observed in our clinical trials or in the commercial setting. If observed, such
adverse side effects could delay or preclude regulatory approval of <FONT STYLE="white-space:nowrap">OPT-302</FONT> combination therapy or any future product candidates, limit commercial use or result in the withdrawal
</FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">19 </FONT></P>


</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
of previously granted marketing approvals. If we or others identify undesirable or unacceptable side effects caused by <FONT STYLE="white-space:nowrap">OPT-302</FONT> combination therapy or any
future product candidates or products: </FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">we may be required to modify, suspend or terminate our clinical trials; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT
SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">we may be required to modify or include additional dosage and administration instructions, warnings and precautions, contraindications, boxed warnings,
limitations, restrictions or other statements in the product label for our approved products, or issue field alerts to physicians and pharmacies; </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">we, or any future collaborators, may be required to create a risk evaluation and mitigation strategy, or REMS, which could include a medication guide
outlining the risks of such side effects for distribution to patients, a communication plan for healthcare providers, and/or other elements to assure safe use; </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">we may be required to conduct costly additional clinical trials; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT
SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">we may be subject to limitations on how we may promote our approved products; </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">sales of our approved products may decrease significantly; </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">regulatory authorities may require us to take our approved products off the market; </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">we may be subject to regulatory investigations, government enforcement actions, litigation or product liability claims; and
</FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">our products may become less competitive or our reputation may suffer. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Any of these results could decrease or prevent any sales of our approved product or substantially increase the
costs and expenses of commercializing and marketing our product. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B><I>Even if we complete the necessary Phase 3 pivotal clinical trials, the marketing approval process is expensive, time-consuming and uncertain and may prevent us or any future collaboration partners
from obtaining approvals for the commercialization of <FONT STYLE="white-space:nowrap">OPT-302</FONT> for the treatment of wet AMD or any other indication as well as for any other product candidate we develop. </I></B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Any product candidate we may develop and the activities
associated with their development and commercialization, including their design, testing, manufacture, safety, efficacy, recordkeeping, labeling, storage, approval, advertising, promotion, sale and distribution, are subject to comprehensive
regulation by the FDA and other regulatory authorities in the United States and by comparable <FONT STYLE="white-space:nowrap">non-U.S.</FONT> regulatory authorities. Failure to obtain marketing approval for a product candidate will prevent us from
commercializing the product candidate in a given jurisdiction. We have not received approval to market any product candidates from regulatory authorities in any jurisdiction and it is possible that none of the product candidates we may seek to
develop in the future will ever obtain regulatory approval. While we expect to expand our internal regulatory function to support the marketing approval process for <FONT STYLE="white-space:nowrap">OPT-302,</FONT> we have no prior experience in
filing and supporting the applications necessary to gain marketing approvals and expect to rely in part on third-party CROs or regulatory consultants to assist us in this process. Securing regulatory approval requires the submission of extensive
preclinical and clinical data and supporting information to the various regulatory authorities for each therapeutic indication to establish the biologic product candidate&#146;s safety, purity, efficacy and potency. Securing regulatory approval also
requires the submission of information about the product manufacturing process to, and inspection of manufacturing facilities by, the relevant regulatory authority. Any product candidates we develop may not be effective, may be only moderately
effective or may prove to have undesirable or unintended side effects, toxicities or other characteristics that may preclude our obtaining marketing approval or prevent or limit commercial use. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The process of obtaining marketing approvals, both in the
United States and in other jurisdictions, is expensive, may take many years if additional clinical trials are required, if approval is obtained at all, and can vary substantially based upon a variety of factors, including the type, complexity and
novelty of the product </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">20 </FONT></P>


</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
candidates involved. Changes in marketing approval policies during the development period, changes in or the enactment of additional statutes or regulations, or changes in regulatory review for
each submitted product application, may cause delays in the approval or rejection of an application. The FDA and comparable authorities in other countries have substantial discretion in the approval process and may refuse to accept any application
or may decide that our data are insufficient for approval and require additional preclinical, clinical or other studies. In addition, varying interpretations of the data obtained from preclinical and clinical testing could delay, limit, or prevent
marketing approval of a product candidate. Any marketing approval we ultimately obtain may be limited or subject to restrictions or post-approval commitments that render the approved product not commercially viable. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">If we experience delays in obtaining approval or if we fail
to obtain approval of any product candidates we may develop, the commercial prospects for those product candidates, including for <FONT STYLE="white-space:nowrap">OPT-302</FONT> in other indications, may be harmed, and our ability to generate
revenues will be materially impaired. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Lack
of efficacy, adverse events or undesirable side effects may emerge in clinical trials conducted by third parties with product candidates for wet AMD or DME, which could negatively affect our stock price, our ability to attract additional capital and
our development program. </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Lack of
efficacy, adverse events or undesirable side effects may emerge in clinical trials conducted by third parties developing product candidates for wet AMD or DME. In addition, other companies have developed products for wet AMD and DME, including
product candidates administered in combination with <FONT STYLE="white-space:nowrap">anti-VEGF-A</FONT> therapies, and have suffered setbacks and clinical trial failures in the past, including failures of primary endpoints in Phase 3 pivotal
clinical trials following positive data from Phase 1 and 2 trials. Lack of efficacy, adverse events or undesirable side effects experienced by subjects in third party clinical trials currently being conducted or previously conducted could negatively
affect our stock price, our ability to attract additional capital and our development of <FONT STYLE="white-space:nowrap">OPT-302</FONT> or even the viability of <FONT STYLE="white-space:nowrap">OPT-302</FONT> as a product candidate. In addition,
any such adverse events or undesirable side effects may lead to increased regulatory requirements for, or additional regulatory review of, <FONT STYLE="white-space:nowrap">OPT-302,</FONT> which may result in delays in development and
commercialization of <FONT STYLE="white-space:nowrap">OPT-302</FONT> and harm our business, financial condition and results of operations. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>The results of completed clinical trials may not be predictive of future results. Data from our clinical trials to date may not be
indicative of results obtained when these trials are completed or in later stage trials. </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">There is a high failure rate for drugs and biologic products proceeding through clinical trials. Failure can occur at any time during the clinical trial process. The results of completed clinical trials
of <FONT STYLE="white-space:nowrap">OPT-302</FONT> or any future product candidate may not be predictive of the results of later-stage clinical trials, including our planned Phase 3 trials of <FONT STYLE="white-space:nowrap">OPT-302</FONT> in
combination with <FONT STYLE="white-space:nowrap">anti-VEGF-A</FONT> therapy for the treatment of wet AMD, and the results of trials in certain patients may not be predictive of those obtained in another. In fact, many companies in the
pharmaceutical and biotechnology industries have suffered significant setbacks in late stage clinical trials even after achieving promising results in earlier stage clinical trials. In addition, data obtained from clinical activities is subject to
varying interpretations, which may delay, limit or prevent regulatory approval. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">The results of our Phase 2b clinical trial of <FONT STYLE="white-space:nowrap">OPT-302</FONT> combination therapy may not be predictive of the results of our Phase 3 clinical program due, in part, to the
fact that we have no clinical data on <FONT STYLE="white-space:nowrap">OPT-302</FONT> in combination with <FONT STYLE="white-space:nowrap">anti-VEGF-A</FONT> therapy in any clinical trial longer than 24 weeks and that we plan to conduct our Phase 3
clinical trials at many clinical centers that were not included in our Phase 2b clinical trial. The number of patients exposed to product candidates and the average exposure time in prior clinical trials may be inadequate to detect rare adverse
events or findings that may only be detected once a product candidate is administered to more patients and for greater periods of time. Any approved label for OPT-302 combination therapy may also be limited if our Phase 3 clinical trial results do
not show long-term clinically significant efficacy results, including for over 12 months or in combination with either of the approved anti-VEGF-A therapies. In addition, if a combination of <FONT STYLE="white-space:nowrap">OPT-302</FONT> with an <FONT
STYLE="white-space:nowrap">anti-VEGF-A</FONT> therapy in our Phase 3 clinical program for the treatment of wet </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">21 </FONT></P>


</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
AMD does not achieve clinically significant superiority over <FONT STYLE="white-space:nowrap">anti-VEGF-A</FONT> monotherapy with statistical significance on the primary endpoints of our Phase 3
clinical trials, or the FDA or a comparable <FONT STYLE="white-space:nowrap">non-U.S.</FONT> regulatory authority requires additional clinical trials beyond our Phase 3 clinical program to support an approved label of
<FONT STYLE="white-space:nowrap">OPT-302</FONT> used in combination with multiple <FONT STYLE="white-space:nowrap">anti-VEGF-A</FONT> therapies, our ability to successfully commercialize <FONT STYLE="white-space:nowrap">OPT-302</FONT> in combination
with <FONT STYLE="white-space:nowrap">anti-VEGF-A</FONT> therapy for the treatment of wet AMD would be harmed. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Interim, topline and preliminary data from our clinical trials that we announce or publish from time to time may change as more
patient data become available and are subject to audit and verification procedures that could result in material changes in the final data. </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">From time to time, we may publicly disclose preliminary or topline data from our clinical trials, which are based on a preliminary
analysis of then-available data, and the results and related findings and conclusions are subject to change following a more comprehensive review of the data related to the particular study or trial. We also make assumptions, estimations,
calculations and conclusions as part of our analyses of data, and we may not have received or had the opportunity to fully and carefully evaluate all data. As a result, the topline results that we report may differ from future results of the same
studies or different conclusions or considerations may qualify such results, once additional data have been received and fully evaluated. Topline data also remain subject to audit and verification procedures that may result in the final data being
materially different from the preliminary data we previously published. As a result, topline data should be viewed with caution until the final data are available. From time to time, we may also disclose interim data from our clinical trials. In
addition, we may report interim analyses of only certain endpoints rather than all endpoints. Interim data from clinical trials that we may complete are subject to the risk that one or more of the clinical outcomes may materially change as patient
enrollment continues and more patient data become available. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">In addition, adverse changes between interim data and final data could significantly harm our business and prospects. Additional disclosure of interim data by us or by our competitors in the future could
also result in volatility in the price of the ADSs and our ordinary shares after this offering. Further, others, including regulatory agencies, may not accept or agree with our assumptions, estimates, calculations, conclusions or analyses or may
interpret or weigh the importance of data differently, which could impact the value of the particular program, the approvability or commercialization of the particular product candidate or product and our company in general. In addition, the
information we choose to publicly disclose regarding a particular study or clinical trial is based on what is typically extensive information, and you or others may not agree with what we determine is the material or otherwise appropriate
information to include in our disclosure, and any information we determine not to disclose may ultimately be deemed significant with respect to future decisions, conclusions, views, activities or otherwise regarding a particular product candidate or
our business. If the topline data that we report differ from actual results, or if others, including regulatory authorities, disagree with the conclusions reached, our ability to obtain approval for, and commercialize,
<FONT STYLE="white-space:nowrap">OPT-302</FONT> or any future product candidates may be harmed, which could harm our business, financial condition, results of operations and prospects. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>We may face substantial competition, which may result in others discovering, developing or
commercializing competing products before or more successfully than us. </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">The biopharmaceutical industry is intensely competitive and subject to rapid innovation and significant technological advancements. We believe the key competitive factors that will affect the development
and commercial success of <FONT STYLE="white-space:nowrap">OPT-302</FONT> and any future product candidates are efficacy, safety and tolerability profile, reliability, convenience of dosing, price, the level of generic competition and reimbursement.
Our competitors include multinational pharmaceutical companies, specialized biotechnology companies, universities and other research institutions. A number of biotechnology and pharmaceutical companies are pursuing the development or marketing of
pharmaceuticals that target the same diseases that we are targeting. Smaller or earlier-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large, established companies. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">22 </FONT></P>


</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">There are a number of large pharmaceutical and biotechnology companies that are
currently pursuing the development of products for the treatment of wet AMD and DME, or have commercially approved products for the treatment of wet AMD or DME, including Roche,&nbsp;Regeneron&nbsp;and Novartis. The current standard of care for wet
AMD is monotherapy administration of <FONT STYLE="white-space:nowrap">anti-VEGF-A</FONT> therapies, including ranibizumab and aflibercept, as well as <FONT STYLE="white-space:nowrap">off-label</FONT> use of bevacizumab. These drugs are well
established therapies and are widely accepted by physicians, patients and third-party payors, which may make it difficult to convince these parties to switch to <FONT STYLE="white-space:nowrap">OPT-302</FONT> combination therapy. In addition to
competition from other companies directly targeting wet AMD or DME, any products we may develop may also face competition from other types of therapies or patient and physician preferences. In addition, many companies are developing new
therapeutics, and we cannot predict what the standard of care will be as <FONT STYLE="white-space:nowrap">OPT-302</FONT> or any future product candidates progress through clinical development. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">If our competitors market products that are more effective, safer or cheaper than our products, that are more
durable or have reduced injection burden compared to our products (including <FONT STYLE="white-space:nowrap">OPT-302),</FONT> or that reach the market sooner than our products, we may not achieve commercial success. In addition, the
biopharmaceutical industry is characterized by rapid technological change. If we fail to stay at the forefront of technological change, we may be unable to compete effectively. Technological advances or products developed by our competitors may
render our technologies, products or product candidates obsolete, less competitive or not economical. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Many of our competitors have substantially greater financial, technical, human and other resources than we do and may be better equipped
to develop, manufacture and market technologically superior products. In addition, many of these competitors have significantly longer operating histories and greater experience than we have in undertaking nonclinical studies and human clinical
trials of new pharmaceutical products and in obtaining regulatory approvals of human therapeutic products. Clinical trials for the treatment of wet AMD and DME may be relatively costly and time consuming. The requirements for approval by the FDA and
comparable <FONT STYLE="white-space:nowrap">non-U.S.</FONT> regulatory authorities may change over time and this may require changes to ongoing or future clinical trial designs that could impact timelines and cost. Further, many of our competitors
have established distribution channels for the commercialization of their products, whereas we have no such channel or capabilities. In addition, many competitors have greater name recognition and more extensive collaborative relationships.
</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">As a result, our competitors may obtain
regulatory approval of their products more rapidly than we do or may obtain patent protection or other intellectual property rights that limit our ability to develop or commercialize our product candidate or any future product candidates. Our
competitors may also develop and succeed in obtaining approval for drugs that are more effective, more convenient, more widely used and less costly or have a better safety profile than our products and these competitors may also be more successful
than we are in manufacturing and marketing their products. If we are unable to compete effectively against these companies, then we may not be able to commercialize our product candidate or any future product candidates or achieve a competitive
position in the market. This would negatively affect our ability to generate revenue. Our competitors also compete with us in recruiting and retaining qualified scientific, management and commercial personnel, establishing clinical trial sites and
enrolling patients for clinical trials, as well as in acquiring technologies complementary to, or necessary for, our programs. Our inability to compete effectively in any of these aspects of our business could harm our business, financial condition,
results of operations and prospects. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>We may
encounter difficulties in managing our growth, which could negatively impact our operations. </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">As we advance our clinical development programs for product candidates, seek regulatory approval in the United States and elsewhere and
increase the number of ongoing product development programs, we anticipate that we will need to increase our product development, scientific and administrative headcount. In particular, as we progress our Phase 3 clinical trials for <FONT
STYLE="white-space:nowrap">OPT-302</FONT> in combination with <FONT STYLE="white-space:nowrap">anti-VEGF-A</FONT> therapy for the treatment of wet AMD, we will require additional key staff for clinical development operations as well as additional
key financial and administrative personnel. We will also need to establish commercial capabilities in order to commercialize any product candidates that may be approved. Such an evolution may impact our strategic focus and our deployment and
allocation of resources. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">23 </FONT></P>


</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our ability to manage our operations and growth effectively depends upon the continual
improvement of our procedures, reporting systems and operational, financial and management controls. We may not be able to implement administrative and operational improvements in an efficient or timely manner and may discover deficiencies in
existing systems and controls. If we do not meet these challenges, we may be unable to execute our business strategies and may be forced to expend more resources than anticipated addressing these issues. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We may acquire additional technology and complementary
businesses in the future. Acquisitions involve many risks, any of which could materially harm our business, including the diversion of management&#146;s attention from core business concerns, failure to effectively exploit acquired technologies,
failure to successfully integrate the acquired business or realize expected synergies or the loss of key employees from either our business or the acquired businesses. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In addition, in order to continue to meet our obligations as
a public listed company in both Australia and the United States and to support our anticipated long-term growth, we will need to increase our general and administrative capabilities. Our management, personnel and systems may not be adequate to
support this future growth. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">If we are unable to
successfully manage our growth and the increased complexity of our operations, our business, financial position, results of operations and prospects may be harmed. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>A fast track designation by the FDA, even if granted
for <FONT STYLE="white-space:nowrap">OPT-302</FONT> or any other future product candidates, may not lead to a faster development or regulatory review or approval process and does not increase the likelihood that our product candidates will receive
marketing approval. </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">If a drug or
biologic is intended for the treatment of a serious or life-threatening condition and the product demonstrates the potential to address unmet medical needs for this condition, the sponsor may apply for FDA fast track designation for a particular
indication. We may seek fast track designation for certain of our current or future product candidates, including <FONT STYLE="white-space:nowrap">OPT-302,</FONT> but there is no assurance that the FDA will grant this status to any of our proposed
product candidates. If granted, fast track designation makes a product eligible for more frequent interactions with FDA to discuss the development plan and clinical trial design, as well as rolling review of the application, which means that the
company can submit completed sections of its marketing application for review prior to completion of the entire submission. Marketing applications of products candidates with fast track designation may qualify for priority review under the policies
and procedures offered by the FDA, but the fast track designation does not assure any such qualification or ultimate marketing approval by the FDA. The FDA has broad discretion whether or not to grant fast track designation, so even if we believe a
particular product candidate is eligible for this designation, there can be no assurance that the FDA would decide to grant it. Even if we do receive fast track designation, we may not experience a faster development process, review or approval
compared to conventional FDA procedures, and receiving a fast track designation does not provide any assurance of ultimate FDA approval. In addition, the FDA may withdraw fast track designation if it believes that the designation is no longer
supported by data from our clinical development program. In addition, the FDA may withdraw any fast track designation at any time. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I><FONT STYLE="white-space:nowrap">OPT-302</FONT> and any future product candidates may not achieve adequate market acceptance among
physicians, patients, healthcare payors and others in the medical community necessary for commercial success. </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Even if our product candidates receive regulatory approval, they may not gain adequate market acceptance among physicians, patients,
healthcare payors and others in the medical community. Given the number of drugs in development or currently approved for the treatment of wet AMD and DME, if we are unsuccessful in achieving a differentiated profile with <FONT
STYLE="white-space:nowrap">OPT-302,</FONT> including in combination with existing therapies, based on efficacy, safety and tolerability, dosing and administration, market acceptance will be limited. For example, current treatments for wet AMD,
including ranibizumab, aflibercept and low cost, <FONT STYLE="white-space:nowrap">off-label</FONT> use of bevacizumab, </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">24 </FONT></P>


</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
are well established in the medical community and perceived as demonstrating meaningful clinical response in many cases. As a result, doctors may continue to rely on these treatments without <FONT
STYLE="white-space:nowrap">OPT-302</FONT> or may continue to use such existing treatments as first-line therapies. The medical community may also resist adopting a combination therapy over monotherapy for any of our targeted indications. In
particular, recent clinical development has focused on maintaining vision gains with a <FONT STYLE="white-space:nowrap">VEGF-A</FONT> inhibitor while reducing the number of injections. While we plan to evaluate the potential for <FONT
STYLE="white-space:nowrap">co-formulation</FONT> of <FONT STYLE="white-space:nowrap">OPT-302</FONT> with approved and/or biosimilar forms of <FONT STYLE="white-space:nowrap">VEGF-A</FONT> inhibitors to provide flexibility of treatment options for
physicians and to reduce the frequency and number of injections for patients, there can be no assurance that we will be successful or that any <FONT STYLE="white-space:nowrap">co-formulated</FONT> product will have a favorable safety profile. If we
are unable to reduce the injection burden of <FONT STYLE="white-space:nowrap">OPT-302</FONT> combination therapy or demonstrate sufficient efficacy improvements with a comparatively higher frequency and number of injections over standard of care
anti-VEGF-A therapies, develop a <FONT STYLE="white-space:nowrap">co-formulation</FONT> of <FONT STYLE="white-space:nowrap">OPT-302</FONT> for patients or otherwise increase the duration of efficacy of <FONT STYLE="white-space:nowrap">OPT-302</FONT>
doses, or if physicians determine that a more frequent regimen is necessary, the market acceptance of <FONT STYLE="white-space:nowrap">OPT-302</FONT> may be limited which would harm our business, financial condition and results of operations.
</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In addition, the potential market opportunity for
<FONT STYLE="white-space:nowrap">OPT-302</FONT> is difficult to estimate precisely. If <FONT STYLE="white-space:nowrap">OPT-302</FONT> receives marketing approval for the treatment of wet AMD, it will be approved solely for use in combination with
one or more <FONT STYLE="white-space:nowrap">anti-VEGF-A</FONT> therapies, and may be limited to use with only one <FONT STYLE="white-space:nowrap">anti-VEGF-A</FONT> therapy for the treatment of wet AMD depending on the protocol for our planned
Phase 3 clinical trials or whether the results from each of our Phase 3 clinical trials support an approved label for use of <FONT STYLE="white-space:nowrap">OPT-302</FONT> in combination with more than one
<FONT STYLE="white-space:nowrap">anti-VEGF-A</FONT> therapy. The market opportunity for <FONT STYLE="white-space:nowrap">OPT-302</FONT> will be dependent upon the continued use of <FONT STYLE="white-space:nowrap">anti-VEGF-A</FONT> therapies in the
treatment of wet AMD and the market share of such <FONT STYLE="white-space:nowrap">anti-VEGF-A</FONT> therapies for which <FONT STYLE="white-space:nowrap">OPT-302</FONT> is approved as a combination therapy. The degree of market acceptance of any of
our approved product candidates will depend on a number of factors, including: </FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the efficacy, safety and dosing profile of the product candidate as demonstrated in clinical trials; </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the timing of market introduction of the product candidate as well as competitive products; </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the clinical indications for which the product candidate is approved; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT
SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the imposition of a REMS which may include distribution or use restrictions; </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">any restrictions on the use of our products to a subgroup of patients; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT
SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">acceptance of the product candidate as a safe and effective treatment by physicians and patients; </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the potential and perceived advantages of the product candidate over alternative treatments, including any similar generic treatments;
</FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the cost of treatment in relation to alternative treatments; </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the availability of coverage and adequate reimbursement and pricing by third parties and government authorities; </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">patients&#146; willingness to pay <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> in the absence of
coverage and/or adequate reimbursement from third-party payors; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the relative convenience and ease of administration; </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the frequency and severity of adverse events; </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the effectiveness of sales and marketing efforts; and </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">unfavorable publicity relating to the product candidate. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Sales of medical products also depend on the willingness of
physicians to prescribe the treatment, which is likely to be based on a determination by these physicians that the products are safe, therapeutically effective and cost effective. In addition, the inclusion or exclusion of products from treatment
guidelines established by various physician groups and the viewpoints of influential physicians can affect the willingness of other </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">25 </FONT></P>


</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
physicians to prescribe the treatment. We cannot predict whether physicians, physicians&#146; organizations, hospitals, other healthcare providers, government agencies or private insurers will
determine that our products are safe, therapeutically effective and cost effective as compared with competing treatments. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Efforts to educate the medical community and third-party payors on the benefits of <FONT STYLE="white-space:nowrap">OPT-302</FONT>
combination therapy may require significant resources and may not be successful. Demonstrating the safety and efficacy of our product candidates and obtaining regulatory approvals will not guarantee future revenue. Our commercial success also
depends on coverage and adequate reimbursement of our product candidates by third-party payors, including government payors, which may be difficult or time-consuming to obtain, may be limited in scope and may not be obtained in all jurisdictions in
which we may seek to market our products. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>If the market opportunities for any product that we or our strategic collaborators develop are smaller than we believe they are, our
revenue may be negatively affected and our business may suffer. </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">We intend to focus our product candidate development on therapies for the treatment of wet AMD and additional retinal disease indications such as DME or retinal vein occlusion, or RVO. Our projections of
addressable patient populations that have the potential to benefit from treatment with our product candidate are based on estimates. These estimates have been derived from a variety of sources, including the scientific literature, surveys of
clinics, patient foundations or market research, and may prove to be incorrect. Further, new studies may change the estimated incidence or prevalence of these diseases. The number of patients may turn out to be lower than expected. Additionally, the
potentially addressable patient population for our product candidates may not ultimately be amenable to treatment with our product candidates. Our market opportunity may also be limited by future competitor treatments that enter the market. If any
of our estimates are inaccurate, the market opportunities for any of our product candidates could be significantly diminished and have an adverse impact on our business. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>If <FONT STYLE="white-space:nowrap">OPT-302</FONT> is
approved by the FDA as a combination therapy for the treatment of wet AMD, the approval will be limited to this specific indication and, unless we seek regulatory approval for additional indications, we will be prohibited from marketing <FONT
STYLE="white-space:nowrap">OPT-302</FONT> for other indications. We may be subject to fines, penalties or injunctions if we are determined to have promoted or be promoting the use of <FONT STYLE="white-space:nowrap">OPT-302</FONT> for unapproved or <FONT
STYLE="white-space:nowrap">&#147;off-label&#148;</FONT> uses, resulting in damage to our reputation and business. </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">If <FONT STYLE="white-space:nowrap">OPT-302</FONT> receives marketing approval for the treatment of wet AMD, it will be approved solely
for use in combination with one or more <FONT STYLE="white-space:nowrap">anti-VEGF-A</FONT> therapies, and may be limited to only one <FONT STYLE="white-space:nowrap">anti-VEGF-A</FONT> therapy for the treatment of wet AMD depending on the protocols
for our planned pivotal Phase 3 clinical trials. Although we are also developing <FONT STYLE="white-space:nowrap">OPT-302</FONT> for other retinal diseases, any regulatory approval of <FONT STYLE="white-space:nowrap">OPT-302</FONT> for wet AMD would
not be cover the treatment of any other indication. As a result, we would be prohibited from promoting <FONT STYLE="white-space:nowrap">OPT-302</FONT> for the treatment of DME unless we are granted FDA approval for such indication. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The FDA strictly regulates the promotional claims that may be
made about prescription products. While physicians may choose to prescribe products for uses that are not described in the product&#146;s labeling and for uses that differ from those tested in clinical trials and approved by the regulatory
authorities, we are prohibited from marketing and promoting the products for indications that are not specifically approved by the FDA or comparable <FONT STYLE="white-space:nowrap">non-U.S.</FONT> regulatory authorities. These <FONT
STYLE="white-space:nowrap">&#147;off-label&#148;</FONT> uses are common across medical specialties and may constitute an appropriate treatment for some patients in varied circumstances. Regulatory authorities in the United States generally do not
restrict or regulate the behavior of physicians in their choice of treatment within the practice of medicine. Regulatory authorities do, however, restrict communications by biotechnology or pharmaceutical companies on
<FONT STYLE="white-space:nowrap">off-label</FONT> use. If the FDA determines that our promotional activities constitute promotion of an <FONT STYLE="white-space:nowrap">off-label</FONT> use, it could request that we modify our promotional materials
and subject us to FDA regulatory or enforcement actions as well as actions by other agencies, including issuance of warning letters or untitled letters, suspension or withdrawal of an approved product from the market, mandatory or voluntary recalls,
civil fines, disgorgement of money, operating restrictions, additional reporting requirements and/or </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">26 </FONT></P>


</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
oversight if we become subject to a corporate integrity agreement or similar agreement, injunctions or criminal prosecution, any of which could significantly harm our business. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I><FONT STYLE="white-space:nowrap">OPT-302</FONT> is
being developed to be used as a combination therapy for use with <FONT STYLE="white-space:nowrap">anti-VEGF-A</FONT> therapies, which exposes us to additional risks. </I></B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We are developing
<FONT STYLE="white-space:nowrap">OPT-302</FONT> to be used in combination with currently approved <FONT STYLE="white-space:nowrap">VEGF-A</FONT> inhibitors. Even if <FONT STYLE="white-space:nowrap">OPT-302</FONT> were to receive marketing approval
or be commercialized, we would continue to be subject to the risks that the FDA or similar regulatory authorities could revoke approval of some or all approved <FONT STYLE="white-space:nowrap">anti-VEGF-A</FONT> therapies for safety, efficacy,
manufacturing or supply issues. This could result in <FONT STYLE="white-space:nowrap">OPT-302</FONT> being restricted from commercialization or being less commercially successful. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We may also evaluate
<FONT STYLE="white-space:nowrap">OPT-302</FONT> or any other future product candidates in combination with one or more other product candidates that have not yet been approved for marketing by the FDA or similar foreign regulatory authorities. We
will not be able to market and sell <FONT STYLE="white-space:nowrap">OPT-302</FONT> or any product candidate we develop in combination with any such unapproved therapies that do not ultimately obtain marketing approval. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">If the FDA or similar foreign regulatory authorities do not
approve these other product candidates or revoke their approval of, or if safety, efficacy, manufacturing, or supply issues arise with, the drugs we choose to evaluate in combination with <FONT STYLE="white-space:nowrap">OPT-302</FONT> or any
product candidate we develop, we may be unable to obtain approval of or market <FONT STYLE="white-space:nowrap">OPT-302</FONT> or any product candidate we develop. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>If we fail to develop and commercialize additional
product candidates, we may be unable to grow our business. </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Although the development and commercialization of <FONT STYLE="white-space:nowrap">OPT-302</FONT> is currently our primary focus, as part of our longer-term growth strategy, we plan to evaluate the
development and commercialization of other therapies related to retinal diseases. The success of this strategy depends primarily upon our ability to identify and validate new therapeutic candidates, and to identify, develop and commercialize new
drugs and biologics. Our research efforts may initially show promise in discovering potential new drugs and biologics, yet fail to yield product candidates for clinical development for a number of reasons, including: </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">we may need to rely on third parties to generate molecules for some of our product candidate programs; </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">we may encounter product manufacturing difficulties that limit yield or produce undesirable characteristics that increase the cost of manufacturing our
product candidates, cause delays or make our product candidates unmarketable; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">product candidates may cause adverse effects in patients or subjects, even after successful initial toxicology studies, which may make the product
candidates unmarketable; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">product candidates may not demonstrate a meaningful benefit to patients or subjects; and </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">our future collaboration partners may change their development profiles or plans for potential product candidates or abandon a therapeutic area or the
development of a partnered product. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">If any of these events occur, we may be forced to abandon our development efforts for one or more programs, which could harm our business, operating results and prospects and could potentially cause us to
cease operations. Future research programs to identify new product candidates may require substantial technical, financial and human resources. We may focus our efforts and resources on potential programs or product candidates that ultimately prove
to be unsuccessful. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Product candidates may
require additional, time-consuming development efforts prior to commercial sale, including preclinical studies, clinical trials and approval by the FDA and/or comparable <FONT STYLE="white-space:nowrap">non-U.S.</FONT> regulatory
</FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">27 </FONT></P>


</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
authorities. All product candidates are prone to the risks of failure that are inherent in pharmaceutical product development, including the possibility that the product candidate will not be
shown to be sufficiently safe and effective for approval by regulatory authorities. In addition, we cannot assure you that any such products that are approved will be manufactured or produced economically, be successfully commercialized, be widely
accepted in the marketplace or be more effective than other commercially available alternatives. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B><I>We may expend our limited resources to pursue one or more particular indications and fail to capitalize on indications that may be more profitable or for which there is a greater likelihood of
success. </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We have limited financial and
management resources. As a result, we may forego or delay pursuit of opportunities with other indications that later prove to have greater commercial potential. Our resource allocation decisions may cause us to fail to capitalize on viable
commercial products or profitable market opportunities. Our spending on current and future development programs for specific indications may not yield any commercially viable products. Any such failures would negatively affect our business and
results of operations. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>We must attract and
retain highly skilled employees in order to succeed. If we are not able to retain our current senior management team and our scientific advisors or continue to attract and retain qualified scientific, technical and business personnel, our business
will suffer. </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We may not be able to
attract or retain qualified personnel and consultants due to the intense competition for such individuals among in the biotechnology and pharmaceutical industries. If we are not able to attract and retain necessary personnel and consultants to
accomplish our business objectives, we may experience constraints that will significantly impede the achievement of our development and commercial objectives, our ability to raise additional capital and our ability to implement our business
strategy. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our industry has experienced a high
rate of turnover of management personnel in recent years. We are highly dependent on the development, regulatory, commercialization and business development expertise of the members of our executive team, as well as other key employees and
consultants. If we lose one or more of our executive officers or other key employees or consultants, our ability to implement our business strategy successfully could be seriously harmed. Any of our executive officers or other key employees or
consultants may terminate their employment at any time with three months&#146; notice, subject to certain exceptions, and replacing such individuals may be difficult and time-consuming because of the limited number of individuals in our industry
with the necessary breadth of skills and experience. Competition to hire and retain employees and consultants from this limited pool is intense, and we may be unable to hire, train, retain or motivate such individuals. Additionally, we do not
currently maintain &#147;key person&#148; life insurance on the lives of our executives or any of our employees. This lack of insurance means that we may not receive adequate compensation for the loss of the services of these individuals. If we are
unable to continue to attract and retain high-quality personnel, the rate and success with which we can discover and develop product candidates and our business will be limited. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>As we evolve from a company that is primarily involved
in clinical development to a company that is also involved in preparing for commercialization, we may encounter difficulties in expanding our operations successfully. </I></B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">As we advance our product candidates through clinical
trials, we will need to expand our development, regulatory, manufacturing and marketing and sales capabilities and may need to further contract with third parties to provide these capabilities, such as collaborators, distributors, marketers and
additional suppliers. We currently have no experience as a company in or infrastructure for sales, marketing and distribution, and our operations are currently limited to clinical development activities and as our operations expand, we likely will
need to manage additional relationships with such third parties. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">If <FONT STYLE="white-space:nowrap">OPT-302</FONT> or any future product candidate is approved, we intend either to establish a sales and organization with technical expertise and supporting distribution
capabilities to commercialize <FONT STYLE="white-space:nowrap">OPT-302</FONT> or any </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">28 </FONT></P>


</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
future product candidate or to outsource such functions to one or more third parties. Either of these options would be expensive and time-consuming. Some or all of these costs may be incurred in
advance of any approval of <FONT STYLE="white-space:nowrap">OPT-302</FONT> or any future product candidate. In addition, we may not be able to hire a sales force that is sufficient in size or has adequate expertise in the medical markets that we
intend to target. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Factors that may inhibit our
efforts to commercialize our products on our own include: </FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">our inability to recruit, train and retain adequate numbers of effective sales and marketing personnel; </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the inability of sales personnel to obtain access to physicians or attain adequate numbers of physicians to prescribe any drugs;
</FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the inability to obtain sufficient access and reimbursement for our product candidate, if approved; and </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">unforeseen costs and expenses associated with creating a sales and marketing organization. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Any failure or delay in the development of our internal
sales, marketing and distribution capabilities would negatively affect the commercialization of <FONT STYLE="white-space:nowrap">OPT-302</FONT> and other future product candidates. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Maintaining third-party relationships for these purposes will
impose significant added responsibilities on members of our management and other personnel. We must be able to effectively manage our development efforts, recruit and train sales and marketing personnel, effectively manage our participation in the
clinical trials in which our product candidates are involved and improve our managerial, development, operational and finance systems, all of which may impose a strain on our administrative and operational infrastructure. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">If we enter into arrangements with third parties to perform
sales, marketing or distribution services, any product revenues that we receive, or the profitability of these product revenues to us, are likely to be lower than if we were to market and sell any products that we develop without the involvement of
these third parties. In addition, we may not be successful in entering into arrangements with third parties to sell and market our products and can provide no assurance that the terms of any such arrangements will remain favorable for us over time.
We likely will have little control over such third parties, and any of them may fail to devote the necessary resources and attention to sell and market our products effectively. If we do not establish sales and marketing capabilities successfully,
either on our own or in collaboration with third parties, we will not be successful in commercializing our products. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Our business could be negatively affected by the effects of health epidemics, including the evolving effects of the COVID-19
pandemic, in regions where we or third parties on which we rely have significant manufacturing facilities, concentrations of clinical trial sites or other business operations. </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT
SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Health epidemics in regions where we have concentrations of clinical trial sites or other business operations
could negatively affect our business, including by causing significant disruption in the operations of third-party manufacturers and CROs upon whom we rely. For example, the novel coronavirus disease 2019, or
<FONT STYLE="white-space:nowrap">COVID-19,</FONT> pandemic has presented a substantial public health and economic challenge around the world and is affecting employees, patients, communities and business operations, as well as the U.S. economy and
financial markets. Based on guidance issued by Australian federal and state governments, we transitioned to a remote work environment for all of our employees. In connection with these measures, we may be subject to claims based upon, arising out
of, or related to <FONT STYLE="white-space:nowrap">COVID-19</FONT> and our actions and responses thereto, including any determinations that we may make to continue to operate or to <FONT STYLE="white-space:nowrap">re-open</FONT> our facilities.
Further, the effects of the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">shelter-in-place</FONT></FONT> orders in Australia and across the world and our work-from-home policies may negatively impact productivity, disrupt our
business and delay our clinical programs and timelines, the magnitude of which will depend, in part, on the length and severity of the restrictions and other limitations on our ability to conduct our business in the ordinary course. These and
similar, and perhaps more severe, disruptions in our operations could negatively impact our business, financial condition, results of operations and growth prospects. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">29 </FONT></P>


</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">As the pandemic continues, we may experience a negative impact on our ability to
initiate clinical trial sites, maintain patient enrollment and enroll new patients which may impact timelines in the future. Our ability to attract additional clinical trial sites and principal investigators to conduct our clinical trials and to
conduct the necessary clinical trial site initiation procedures may be impacted by quarantines, <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">shelter-in-place</FONT></FONT> and similar restrictions imposed by federal, state and
local governments. These restrictions may also prohibit patients from enrolling in, or continuing to participate in, our clinical trials. Principal investigators and clinical trial site staff, as healthcare providers, may have heightened exposure to
COVID-19 and if their health is impacted by <FONT STYLE="white-space:nowrap">COVID-19</FONT> it could negatively impact the conduct of our clinical trials at their sites. Similarly, potential participants in our clinical trials, many of whom are
medically vulnerable, may be unwilling to enroll in, and enrolled patients may be unwilling to continue to participate in, our clinical trials due to an unwillingness to travel to sites for required screening and clinical trial visits and
procedures. Enrolled patients may be unable to comply with clinical trial protocols if quarantines, <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">shelter-in-place</FONT></FONT> and similar restrictions continue to impede patient
movement or interrupt healthcare services. In addition, we may be required to develop and implement additional clinical study policies and procedures designed to help protect patients from the <FONT STYLE="white-space:nowrap">COVID-19</FONT>
disease, which may include using telemedicine visits, remote monitoring of patients and clinical trial sites, and measures designed to ensure that data from clinical trials that may be disrupted as result of the pandemic are collected pursuant to
the study protocol and consistent with cGCPs, with any significant protocol deviation reviewed and approved by the clinical trial site institutional review board, or IRB, all or any of which could materially and negatively affect our clinical
development timelines and our ability to obtain regulatory approvals of our product candidates, and could significantly increase our costs. We could also see an impact on our ability to report clinical trial results, or interact with regulators,
ethics committees or other important agencies due to limitations in regulatory authority employee resources or otherwise. In addition, the FDA or comparable <FONT STYLE="white-space:nowrap">non-U.S.</FONT> regulatory authorities may refuse to accept
data from clinical trials conducted in geographies experiencing heightened impact from <FONT STYLE="white-space:nowrap">COVID-19.</FONT> </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Moreover, we rely on third-party CROs and other third parties to assist us with clinical development activities, and we cannot guarantee
that they will continue to perform their contractual duties in a timely and satisfactory manner as a result of the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic. In addition, quarantines, <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">shelter-in-place</FONT></FONT> and similar government orders could impact personnel at third-party manufacturing facilities in the United States and other countries, or the availability or cost of materials, which would
disrupt our supply chain. In particular, some of our suppliers of certain materials used in the production of our drug products are located in Europe. In any event, if the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic continues and
persists for an extended period of time or more acutely impacts geographies with particular impact on our business, we could experience significant disruptions to our clinical development timelines, which would harm our business, financial
condition, results of operations and growth prospects. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">In addition, while the potential economic impact brought by, and the duration of, the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic may be difficult to assess or predict, the pandemic could
result in significant and prolonged disruption of global financial markets, reducing our ability to access capital, which could in the future negatively affect our liquidity. In addition, a recession or market correction resulting from the spread of
<FONT STYLE="white-space:nowrap">COVID-19</FONT> could harm our business and the value of our ordinary shares and ADSs offered hereby following this offering. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Disruptions at the FDA and other government agencies caused by funding shortages or global health concerns could hinder their
ability to hire and retain key leadership and other personnel, otherwise prevent new products from being developed, approved or commercialized in a timely manner or at all, or otherwise prevent those agencies from performing normal business
functions on which the operation of our business may rely, which could negatively impact our business. </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The ability of the FDA to review and approve new products can be affected by a variety of factors, including government budget and funding
levels, ability to hire and retain key personnel and accept the payment of user fees, statutory, regulatory and policy changes, and other events that may otherwise affect the FDA&#146;s ability to perform routine functions. Average review times at
the agency have fluctuated in recent years as a </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">30 </FONT></P>


</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
result. In addition, government funding of other government agencies on which our operations may rely, including those that fund research and development activities, is subject to the political
process, which is inherently fluid and unpredictable. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Disruptions at the FDA and other agencies may also slow the time necessary for new drugs to be reviewed and/or approved by necessary government agencies, which would adversely affect our business. For
example, in recent years, including in 2018 and 2019, the U.S. government shut down several times and certain regulatory agencies, such as the FDA, had to furlough critical employees and stop critical activities. Separately, in response to the <FONT
STYLE="white-space:nowrap">COVID-19</FONT> pandemic, in March 2020, the FDA announced its intention to postpone most inspections of foreign manufacturing facilities and products through April 2020. Also in March 2020, the FDA announced its intention
to temporarily postpone routine surveillance inspections of domestic manufacturing facilities. Regulatory authorities outside the United States may adopt similar restrictions or other policy measures in response to the
<FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic or issue guidance materially affecting the conduct of clinical trials. If a prolonged government shutdown occurs, or if global health concerns continue to prevent the FDA or other regulatory
authorities from conducting their regular inspections, reviews or other regulatory activities, it could significantly impact the ability of the FDA to timely review and process our regulatory submissions, which could have a material adverse effect
on our business. Further, upon completion of this offering and in our operations as a public company, future government shutdowns or delays could impact our ability to access the public markets and obtain necessary capital in order to properly
capitalize and continue our operations. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Even if we commercialize <FONT STYLE="white-space:nowrap">OPT-302</FONT> or any future product candidate, we may face challenges to
achieving profitability such as our products becoming subject to unfavorable pricing regulations, third-party reimbursement practices or healthcare reform initiatives, which could harm our business. </I></B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In the United States and in other countries, patients who
are prescribed treatment for their conditions generally rely on third-party payors to reimburse all or part of the costs associated with their treatment. The availability of coverage and adequacy of reimbursement for our products by third-party
payors, including government health care programs (e.g., Medicare, Medicaid, TRICARE), managed care providers, private health insurers, health maintenance organizations and other organizations is essential for most patients to be able to afford
medical services and pharmaceutical products such as <FONT STYLE="white-space:nowrap">OPT-302</FONT> or any our product candidates. Third-party payors decide which medications they will pay for and establish reimbursement levels. The availability of
coverage and extent of reimbursement by governmental and other third-party payors is essential for most patients to be able to afford treatments such as <FONT STYLE="white-space:nowrap">OPT-302.</FONT> </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In the United States, the principal decisions about
reimbursement for new medicines are typically made by the Centers for Medicare&nbsp;&amp; Medicaid Services, or CMS, an agency within the U.S. Department of Health and Human Services, or HHS. CMS decides whether and to what extent our products will
be covered and reimbursed under Medicare and private payors tend to follow CMS to a substantial degree. Factors payors consider in determining reimbursement are based on whether the product is: </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">a covered benefit under its health plan; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">safe, effective and medically necessary; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">appropriate for the specific patient; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">cost-effective; and </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">neither experimental nor investigational. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our ability to commercialize any products successfully will depend in part on the extent to which coverage and adequate reimbursement for
these products and related treatments will be available from third-party payors, including government health care programs and private health insurers. Moreover, a payor&#146;s decision to provide coverage for a drug product does not imply that an
adequate reimbursement rate will be approved. If coverage </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">31 </FONT></P>


</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
and adequate reimbursement is not available, or is available only to limited levels, we may not be able to successfully commercialize our product candidates. Even if coverage is provided, the
approved reimbursement amount may not be high enough to allow us to establish or maintain pricing sufficient to realize a sufficient return on our investment. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In the United States, no uniform policy for coverage and reimbursement for products exists among third-party payors. Therefore, coverage
and reimbursement for our products can differ significantly from payor to payor. The process for determining whether a payor will provide coverage for a product may be separate from the process for setting the reimbursement rate that the payor will
pay for the product. One payor&#146;s determination to provide coverage for a product does not assure that other payors will also provide coverage and reimbursement for the product. Third-party payors may also limit coverage to specific products on
an approved list, or formulary, which might not include all of the <FONT STYLE="white-space:nowrap">FDA-approved</FONT> products for a particular indication. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Government authorities and other third-party payors in the United States and abroad have attempted to control costs by limiting
coverage and the amount of reimbursement for particular medications and for newly approved products, and as a result, they may not cover or provide adequate reimbursement for <FONT STYLE="white-space:nowrap">OPT-302</FONT> and future product
candidates. Increasingly, certain third-party payors are requiring that drug companies provide them with predetermined discounts from list prices and are challenging the prices charged for medical products. We cannot be sure that coverage and
reimbursement will be available for any product that we or our future collaborators commercialize and, if reimbursement is available, what the level of reimbursement will be. Coverage and reimbursement may impact the demand for, or the price of, any
product candidate for which we or our future collaborators obtain marketing approval. If coverage and reimbursement are not available or reimbursement is available only to limited levels, we and our future collaborators may not be able to
successfully commercialize any product candidate for which marketing approval is obtained. A decision by a third-party payor not to cover or not to separately reimburse for our medical products or therapies using our products could reduce physician
utilization of our products once approved. Assuming there is coverage for our product candidates, or therapies using our product candidates by a third-party payor, the resulting reimbursement payment rates may not be adequate or may require <FONT
STYLE="white-space:nowrap">co-payments</FONT> that patients find unacceptably high. We cannot be sure that coverage and reimbursement in the United States will be available for <FONT STYLE="white-space:nowrap">OPT-302</FONT> and any future product
candidates and any reimbursement that may become available may not be adequate or may be decreased or eliminated in the future. </FONT></P>  <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">There may be significant delays in obtaining coverage and reimbursement for newly approved drugs, and coverage may be more limited than
the purposes for which the drug is approved by the FDA or comparable <FONT STYLE="white-space:nowrap">non-U.S.</FONT> regulatory authorities. Moreover, eligibility for coverage and reimbursement does not imply that a drug will be paid for in all
cases or at a rate that covers our costs, including research, development, manufacture, sale and distribution. Interim reimbursement levels for new drugs, if applicable, may also not be sufficient to cover our costs and may only be temporary.
Reimbursement rates may vary according to the use of the drug and the clinical setting in which it is used, may be based on reimbursement levels already set for lower cost drugs and may be incorporated into existing payments for other services. Net
prices for drugs may be reduced by mandatory discounts or rebates required by government healthcare programs or private payors and by any future relaxation of laws that presently restrict imports of drugs from countries where they may be sold at
lower prices than in the United States. Our inability to promptly obtain coverage and profitable reimbursement rates from both government-funded and private payors for any approved products that we develop could harm our operating results, our
ability to raise capital needed to commercialize products and our overall financial condition. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">The regulations that govern marketing approvals, pricing and reimbursement for new drug products vary widely from country to country. Current and future legislation may significantly change the approval
requirements in ways that could involve additional costs and cause delays in obtaining approvals. Some countries require approval of the sale price of a drug before it can be marketed. In many countries, the pricing review period begins after
marketing or product licensing approval is granted. In some <FONT STYLE="white-space:nowrap">non-U.S.</FONT> markets, prescription pharmaceutical pricing remains subject to continuing governmental control even after initial approval is granted. As a
result, we might obtain marketing approval for a product in a particular country, but then be subject to price </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">32 </FONT></P>


</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
regulations that delay or limit our commercial launch of the product, possibly for lengthy time periods, which could negatively impact the revenue we generate from the sale of the product in that
particular country. Adverse pricing limitations may hinder our ability to recoup our investment in one or more product candidates, even if our product candidates obtain marketing approval. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">To become and remain profitable, we or any potential future collaborator must develop and eventually
commercialize <FONT STYLE="white-space:nowrap">OPT-302</FONT> or any future product candidates with significant market potential at an adequate profit margin after cost of goods sold and other expenses. Commercialization of <FONT
STYLE="white-space:nowrap">OPT-302</FONT> or any future product candidates may entail a substantial cost of goods sold and there can be no assurance that we will be able to achieve a suitable gross margin with respect to sales of <FONT
STYLE="white-space:nowrap">OPT-302</FONT> or any future product candidates. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B><I>Changes in U.S. healthcare law and implementing regulations, as well as changes in healthcare policy, may impact our business in ways that we cannot currently predict and may harm our business and
results of operations. </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">There have been,
and likely will continue to be, several executive, legislative and regulatory changes and proposed changes regarding the healthcare system that could prevent or delay marketing approval of product candidates, restrict or regulate post-approval
activities and affect our ability to profitably sell any product candidates for which we obtain marketing approval. Among policy makers and payors in the United States there is significant interest in promoting changes in healthcare systems with the
stated goals of containing healthcare costs, improving quality and/or expanding access and the pharmaceutical industry has been a particular focus of these efforts and has been significantly affected by major legislative initiatives. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Patient Protection and Affordable Care Act, as amended by
the Health Care and Education Reconciliation Act of 2010, collectively referred to as the Affordable Care Act, substantially changed the way healthcare is financed by both the government and private insurers, and significantly impacts the U.S.
pharmaceutical industry. The Affordable Care Act, among other things: (1)&nbsp;introduced a new average manufacturer price definition for drugs and biologics that are inhaled, infused, instilled, implanted or injected and not generally dispensed
through retail community pharmacies; (2)&nbsp;increased the minimum Medicaid rebates owed by manufacturers under the Medicaid Drug Rebate Program and expanded rebate liability from
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">fee-for-service</FONT></FONT> Medicaid utilization to include the utilization of Medicaid managed care organizations as well; (3)&nbsp;established a branded prescription drug fee that
pharmaceutical manufacturers of branded prescription drugs must pay to the federal government; (4)&nbsp;expanded the list of covered entities eligible to participate in the 340B drug pricing program by adding new entities eligible for the program;
(5)&nbsp;established a new Medicare Part D coverage gap discount program, in which manufacturers must agree to offer 50% (increased to 70% pursuant to the Bipartisan Budget Act of 2018, or BBA, effective as of January 2019) <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">point-of-sale</FONT></FONT> discounts off negotiated prices of applicable branded drugs to eligible beneficiaries during their coverage gap period, as a condition for the
manufacturer&#146;s outpatient drugs to be covered under Medicare Part D; (6)&nbsp;extended manufacturers&#146; Medicaid rebate liability to covered drugs dispensed to individuals who are enrolled in Medicaid managed care organizations;
(7)&nbsp;expanded eligibility criteria for Medicaid programs by, among other things, allowing states to offer Medicaid coverage to additional individuals, including individuals with income at or below 133% of the federal poverty level, thereby
potentially increasing manufacturers&#146; Medicaid rebate liability; (8)&nbsp;created a licensure framework for <FONT STYLE="white-space:nowrap">follow-on</FONT> biologic products; and (9)&nbsp;established a Center for Medicare and Medicaid
Innovation at the CMS to test innovative payment and service delivery models to lower Medicare and Medicaid spending. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">There remain judicial and Congressional challenges to certain aspects of the Affordable Care Act, as well as efforts by the Trump
administration to repeal or replace certain aspects of the Affordable Care Act. For example, the Tax Cuts and Jobs Act of 2017, or the TCJA, was enacted, which included a provision that repealed, effective January&nbsp;1, 2019, the <FONT
STYLE="white-space:nowrap">tax-based</FONT> shared responsibility payment imposed by the Affordable Care Act on certain individuals who fail to maintain qualifying health coverage for all or part of a year that is commonly referred to as the
&#147;individual mandate.&#148; On December&nbsp;14, 2018, a U.S. District Court Judge in the Northern District of Texas ruled that the individual mandate is a critical and inseverable feature of the Affordable Care Act, and
</FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">33 </FONT></P>


</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
therefore, because it was repealed as part of the TCJA, the remaining provisions of the Affordable Care Act are invalid as well. On December&nbsp;18, 2019, the U.S. Court of Appeals for the 5th
Circuit ruled that the individual mandate was unconstitutional but remanded the case back to the District Court to determine whether the remaining provisions of the Affordable Care Act are invalid as well. On March&nbsp;2, 2020, the U.S. Supreme
Court granted the petitions for writs of certiorari to review the case, although it is unclear when a decision will be made or how the Supreme Court will rule. In addition, there may be other efforts to challenge, repeal or replace the Affordable
Care Act. We are continuing to monitor any changes to the Affordable Care Act that, in turn, may potentially impact our business in the future. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Other legislative changes have been proposed and adopted since the Affordable Care Act was enacted. These changes include aggregate
reductions to Medicare payments to providers of 2% per fiscal year pursuant to the Budget Control Act of 2011 and subsequent laws, which began in 2013 and will remain in effect through 2030, unless additional Congressional action is taken. These
Medicare sequester reductions will be suspended from May&nbsp;1, 2020 through December&nbsp;31, 2020 due to the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic. In January 2013, the American Taxpayer Relief Act of 2012 was signed into law,
which, among other things, further reduced Medicare payments to several types of providers, including hospitals, imaging centers and cancer treatment centers, and increased the statute of limitations period for the government to recover overpayments
to providers from three to five years. New laws may result in additional reductions in Medicare and other healthcare funding, which may materially negatively affect customer demand and affordability for our products and, accordingly, the results of
our financial operations. Also, there has been heightened governmental scrutiny recently over the manner in which pharmaceutical companies set prices for their marketed products, which have resulted in several Congressional inquiries and proposed
federal legislation, as well as state efforts, designed to, among other things, bring more transparency to product pricing, reduce the cost of prescription drugs under Medicare, review the relationship between pricing and manufacturer patient
programs, and reform government program reimbursement methodologies for drug products. For example, at the federal level, the Trump administration&#146;s budget proposal for fiscal year 2021 includes a $135&nbsp;billion allowance to support
legislative proposals seeking to reduce drug prices, increase competition, lower <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> drug costs for patients, and increase patient access to lower-cost generic
and biosimilar drugs. On March&nbsp;10, 2020, the Trump administration sent &#147;principles&#148; for drug pricing to Congress, calling for legislation that would, among other things, cap Medicare Part D beneficiary
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> pharmacy expenses, provide an option to cap Medicare Part D beneficiary monthly
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> expenses, and place limits on pharmaceutical price increases. Further, the Trump administration previously released a &#147;Blueprint,&#148; or plan, to
lower drug prices and reduce out of pocket costs of drugs that contained proposals to increase drug manufacturer competition, increase the negotiating power of certain federal healthcare programs, incentivize manufacturers to lower the list price of
their products, and reduce the out of pocket costs of drug products paid by consumers. HHS has solicited feedback on some of these measures and has implemented others under its existing authority. For example, in May 2019, CMS issued a final rule to
allow Medicare Advantage plans the option to use step therapy for Part B drugs beginning January&nbsp;1, 2020. This final rule codified CMS&#146;s policy change that was effective January&nbsp;1, 2019. While some of these and other measures may
require additional authorization to become effective, Congress and the Trump administration have each indicated that it will continue to seek new legislative and/or administrative measures to control drug costs. At the state level, individual states
in the United States are increasingly active in passing legislation and implementing regulations designed to control pharmaceutical and biological product pricing, including price or patient reimbursement constraints, discounts, restrictions on
certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing. Legally mandated price controls on payment amounts by third-party payors
or other restrictions on coverage or access could harm our business, results of operations, financial condition and prospects. In addition, regional healthcare authorities and individual hospitals are increasingly using bidding procedures to
determine what pharmaceutical products and which suppliers will be included in their prescription drug and other healthcare programs. This could reduce the ultimate demand for our product candidates that we successfully commercialize or put pressure
on our product pricing. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">34 </FONT></P>


</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We expect that these and other healthcare reform measures that may be adopted in
the future, may result in more rigorous coverage criteria and lower reimbursement, and put additional downward pressure on the price that we receive for any approved product. It is possible that additional governmental action is taken in response to
the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic. For example, on August&nbsp;6, 2020, the Trump administration issued another executive order that instructs the federal government to develop a list of &#147;essential&#148; medicines
and then buy them and other medical supplies from U.S. manufacturers instead of from companies around the world, including China. The order is meant to reduce regulatory barriers to domestic pharmaceutical manufacturing and catalyze manufacturing
technologies needed to keep drug prices low and the production of drug products in the United States. Any reduction in reimbursement from Medicare or other government-funded programs may result in a similar reduction in payments from private payors.
The implementation of cost containment measures or other healthcare reforms may prevent us from being able to generate revenue, attain profitability or commercialize our drugs, once marketing approval is obtained. We cannot predict the likelihood,
nature or extent of government regulation that may arise from future legislation or administrative action in the United States. If we or any third parties we may engage are slow or unable to adapt to changes in existing requirements or the adoption
of new requirements or policies, or if we or such third parties are not able to maintain regulatory compliance, our product candidates may lose any regulatory approval that may have been obtained and we may not achieve or sustain profitability
</FONT></P>  <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>As a company primarily based outside
of the United States, our business is subject to economic, political, regulatory and other risks associated with international operations. </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">As a company with substantial operations in Australia and an international clinical trial program, our business is subject to risks
associated with conducting business outside the United States. Many of our suppliers and clinical trial relationships are located outside the United States. Accordingly, our future results could be harmed by a variety of factors, including:
</FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">economic weakness, including inflation, or political instability in particular <FONT STYLE="white-space:nowrap">non-U.S.</FONT> economies and markets;
</FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">differing and changing regulatory requirements for product approvals; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT
SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">differing jurisdictions could present different issues for securing, maintaining or obtaining freedom to operate in such jurisdictions;
</FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">potentially reduced protection for intellectual property rights; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT
SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">difficulties in compliance with different, complex and changing laws, regulations and court systems of multiple jurisdictions and compliance with a
wide variety of foreign laws, treaties and regulations; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">changes in <FONT STYLE="white-space:nowrap">non-U.S.</FONT> regulations and customs, tariffs and trade barriers; </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">changes in <FONT STYLE="white-space:nowrap">non-U.S.</FONT> currency exchange rates, Australian dollar, U.S. dollar, euro and currency controls;
</FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">changes in a specific country&#146;s or region&#146;s political or economic environment; </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">trade protection measures, import or export licensing requirements or other restrictive actions by governments; </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">differing reimbursement regimes and price controls in certain <FONT STYLE="white-space:nowrap">non-U.S.</FONT> markets; </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">negative consequences from changes in tax laws; </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">workforce uncertainty in countries where labor unrest is more common than in the United States; </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">litigation or administrative actions resulting from claims against us by current or former employees or consultants individually or as part of class
actions, including claims of wrongful terminations, discrimination, misclassification or other violations of labor law or other alleged conduct; </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">difficulties associated with staffing and managing international operations, including differing labor relations; </FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">35 </FONT></P>


</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">production shortages resulting from any events affecting raw material supply or manufacturing capabilities abroad; and </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">business interruptions resulting from <FONT STYLE="white-space:nowrap">geo-political</FONT> actions, including war and terrorism, health epidemics, or
natural disasters including earthquakes, typhoons, floods and fires. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B><I>If we fail to comply with <FONT STYLE="white-space:nowrap">non-U.S.</FONT> regulatory requirements governing human clinical trials and marketing approval for drugs, we could be prevented from
selling our product candidates in <FONT STYLE="white-space:nowrap">non-U.S.</FONT> markets, which may negatively affect our operating results and financial condition. </I></B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The requirements governing the conduct of clinical trials,
product licensing, pricing and reimbursement for marketing our product candidates outside the United States vary greatly from country to country and may require additional testing. We expect that our future clinical development of our product
candidates will involve a number of clinical trials in <FONT STYLE="white-space:nowrap">non-U.S.</FONT> jurisdictions. We have no direct experience as a company in obtaining <FONT STYLE="white-space:nowrap">non-U.S.</FONT> regulatory approvals. The
time required to obtain approvals outside the United States may differ from that required to obtain FDA approval. We may not obtain <FONT STYLE="white-space:nowrap">non-U.S.</FONT> regulatory approvals on a timely basis, if at all. Approval by the
FDA does not guarantee approval by comparable <FONT STYLE="white-space:nowrap">non-U.S.</FONT> regulatory authorities, and approval by one <FONT STYLE="white-space:nowrap">non-U.S.</FONT> regulatory authority does not ensure approval by regulatory
authorities in other countries or by the FDA. Failure to comply with these regulatory requirements or obtain required approvals could impair our ability to develop <FONT STYLE="white-space:nowrap">non-U.S.</FONT> markets for our product candidates
and may harm our results of operations and financial condition. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B><I>Price controls may be imposed in <FONT STYLE="white-space:nowrap">non-U.S.</FONT> markets, which may negatively affect our future profitability. </I></B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In some countries, particularly EU member states, Japan,
Australia and Canada, the pricing of prescription drugs is subject to governmental control. In these countries, pricing negotiations with governmental authorities can take considerable time after receipt of marketing approval for a product. In
addition, there can be considerable pressure by governments and other stakeholders on prices and reimbursement levels, including as part of cost containment measures. Political, economic and regulatory developments may further complicate pricing
negotiations, and pricing negotiations may continue after reimbursement has been obtained. Reference pricing used by various EU member states and parallel distribution, or arbitrage between <FONT STYLE="white-space:nowrap">low-priced</FONT> and
high-priced member states, can further reduce prices. In some countries, we or our collaborators may be required to conduct a clinical trial or other studies that compare the cost-effectiveness of our product candidates to other available therapies
in order to obtain or maintain reimbursement or pricing approval. Publication of discounts by third-party payors or authorities may lead to further pressure on the prices or reimbursement levels within the country of publication and other countries.
If reimbursement of our products is unavailable or limited in scope or amount, or if pricing is set at unsatisfactory levels, our business, revenues or profitability could be harmed. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>We have received tax incentives under the Research and Development Tax Incentive scheme in Australia that
may become repayable if we did not or do not comply with the rules of the scheme, or we may become ineligible for tax incentives in our current or future tax years, which could harm our business, financial condition and results of operations.
</I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We have received cash incentives in the
past under the Research and Development Tax Incentive scheme, or the R&amp;D Scheme, to offset the costs of our clinical trials and other qualifying expenses incurred both in Australia and other jurisdictions. Certain research and development costs
that we incur in the future may be ineligible for cash incentives under the R&amp;D Scheme. For example, costs incurred outside Australia in connection with our future clinical trials are generally not eligible for cash incentives under the R&amp;D
Scheme. In addition, the federal government of Australia and the Australian Taxation Office, or ATO, could change the rules of the regulatory regime or amend past tax returns and, as a result, amounts paid to us may become repayable to the ATO
including the amount of tax incentives in respect of our fiscal year ended June&nbsp;30, 2020 included as current receivables in our consolidated financial statements. We have received an aggregate of A$35.1&nbsp;million in cash tax incentives
during the five fiscal years ended June&nbsp;30, 2020 under the R&amp;D Scheme. As at June&nbsp;30, 2020, our </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">36 </FONT></P>


</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
current tax receivable under the R&amp;D Scheme was A$14.6 million. This receivable amount as at June&nbsp;30, 2020 is based on Australian legislation as enacted as at June&nbsp;30, 2020. Any
proposed changes to the legislation, such as the currently proposed rate change from 43.5% to 41%, may have a retrospective impact on our current tax receivable under the R&amp;D Scheme. Any rule changes made to reduce the amount we are able to
claim under the R&amp;D Scheme currently or in the future and any retrospective changes made to the R&amp;D Scheme that reduce the incentives that we have claimed in past tax years could harm our business, financial condition and results of
operations. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Legal, political and economic
uncertainty surrounding the planned exit of the U.K. from the EU are a source of instability and uncertainty. </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">On June&nbsp;23, 2016, the U.K. held a referendum in which a majority of the eligible members of the electorate voted for the U.K. to
leave the EU. The U.K&#146;s withdrawal from the EU is commonly referred to as &#147;Brexit.&#148; The U.K. and the EU have agreed to a withdrawal agreement, or the Withdrawal Agreement, which was approved by the U.K. Parliament on January&nbsp;24,
2020. Under the Withdrawal Agreement, the U.K. is subject to a transition period until December&nbsp;31, 2020, or the Transition Period, during which EU rules will continue to apply. Negotiations between the U.K. and the EU are expected to continue
in relation to the customs and trading relationship between the U.K. and the EU following the expiration of the Transition Period. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The uncertainty concerning the U.K&#146;s legal, political and economic relationship with the EU after the Transition Period may be a
source of instability in the international markets, create significant currency fluctuations, and/or otherwise negatively affect trading agreements or similar cross-border cooperation arrangements (whether economic, tax, fiscal, legal, regulatory or
otherwise). These developments, or the perception that any of them could occur, have had, and may continue to have, a significant negative impact on global economic conditions and the stability of global financial markets, and could significantly
reduce global market liquidity and limit the ability of key market participants to operate in certain financial markets. In particular, it could also lead to a period of considerable uncertainty in relation to the regulatory process in Europe.
</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Brexit has created political and economic
uncertainty, particularly in the U.K. and the EU, and this uncertainty may persist for years. A withdrawal could, among other outcomes, disrupt the free movement of goods, services and people between the U.K. and the EU, and result in increased
legal and regulatory complexities, as well as potentially higher costs of conducting business in Europe. The U.K.&#146;s vote to exit the EU could also result in similar referendums or votes in other European countries in which we do business. Given
the lack of comparable precedent, it is unclear what financial, trade and legal implications the withdrawal of the U.K. from the EU would have and how such withdrawal would affect us. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Any new regulations could add time and expense to the conduct of our business, as well as the process by which
our product candidate receives regulatory approval in the U.K., the EU and elsewhere. In addition, the announcement of Brexit and the withdrawal of the U.K. from the EU have had and may continue to negatively affect global economic conditions and
the stability of global financial markets, and may significantly reduce global market liquidity and restrict the ability of key market participants to operate in certain financial markets. Any of these effects of Brexit, among others, could harm our
business, our results of operations, liquidity and financial condition. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B><I>Product liability lawsuits against us could cause us to incur substantial liabilities and to limit commercialization of any products that we may develop. </I></B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We face an inherent risk of product liability exposure
related to the testing of our product candidates in human clinical trials and will face an even greater risk if we commercialize any resulting products. Product liability claims may be brought against us by subjects enrolled in our clinical trials,
patients, or others using our products. If we cannot successfully defend ourselves against claims that our product candidates or products that </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">37 </FONT></P>


</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
we may develop caused injuries, we could incur substantial liabilities. Regardless of merit or eventual outcome, liability claims may result in: </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">decreased demand for any product candidates or products that we may develop; </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">product recalls or a change in the indications for which products may be used; </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">termination of clinical trial sites or entire trial programs; </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">injury to our reputation and significant negative media attention; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT
SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">withdrawal of clinical trial participants; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">significant costs to defend the related litigation; </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">substantial monetary awards to trial subjects or patients; </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">loss of revenue; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">diversion of management and scientific resources from our business operations; and </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the inability to commercialize any products that we may develop. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our clinical trial liability insurance coverage may not
adequately cover all liabilities that we may incur. We may not be able to maintain insurance coverage at a reasonable cost or in an amount adequate to satisfy any liability that may arise. Our inability to obtain product liability insurance at an
acceptable cost or to otherwise protect against potential product liability claims could prevent or delay the commercialization of any products or product candidates that we develop. We intend to expand our insurance coverage for products to include
the sale of commercial products if we obtain marketing approval for our product candidates in development, but we may be unable to obtain commercially reasonable product liability insurance for any products approved for marketing. Large judgments
have been awarded in class action lawsuits based on drugs that had unanticipated side effects. If we are sued for any injury caused by our products, product candidates or processes, our liability could exceed our product liability insurance coverage
and our total assets. Claims against us, regardless of their merit or potential outcome, may also generate negative publicity or harm our ability to obtain physician endorsement of our products or expand our business. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Our employees, contractors, vendors, principal
investigators, consultants and future partners may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements and insider trading. </I></B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We are exposed to the risk of fraud or other misconduct by
our employees, contractors, vendors, principal investigators, consultants or future partners. Misconduct by these parties could include failures to comply with FDA or comparable <FONT STYLE="white-space:nowrap">non-U.S.</FONT> authority regulations,
to provide accurate information to the FDA or comparable <FONT STYLE="white-space:nowrap">non-U.S.</FONT> regulators, to comply with U.S. federal and state and <FONT STYLE="white-space:nowrap">non-U.S.</FONT> healthcare fraud and abuse laws and
regulations, to report financial information or data timely, completely or accurately, or to disclose unauthorized activities to us. In particular, sales, marketing and business arrangements in the healthcare industry are subject to extensive laws
and regulations intended to prevent fraud, misconduct, kickbacks, self-dealing and other abusive practices. These laws and regulations may restrict or prohibit a wide range of pricing, discounting, marketing and promotion, sales commission, customer
incentive programs and other business arrangements. Third-party misconduct could also involve the improper use of information obtained in the course of clinical trials, which could result in regulatory sanctions and serious harm to our reputation.
Although we have adopted a Code of Conduct, it is not always possible to identify and deter misconduct, and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in
protecting us from governmental investigations or other actions or lawsuits stemming from a failure to comply with these laws or regulations. If any such actions are instituted against us resulting from this misconduct and we are not successful in
defending ourselves or asserting our rights, those actions could have a significant impact on our business, including the imposition of significant fines or other sanctions. If we or our future partners market products in a manner that violates
fraud and abuse and other healthcare laws, or if we or our future partners </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">38 </FONT></P>


</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
violate government price reporting laws, we or our future partners may be subject to administrative civil and/or criminal penalties, among other sanctions. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Most states also have statutes or regulations similar to
these federal laws, which may apply to items such as pharmaceutical products and services reimbursed by private insurers. We and/or our future partners may be subject to administrative, civil and criminal sanctions for violations of any of these
federal and state laws. Pharmaceutical and other healthcare companies have been prosecuted under these laws for a variety of promotional and marketing activities, such as: providing free trips, free goods, sham consulting fees and grants and other
monetary benefits to prescribers; reporting to pricing services inflated average wholesale prices that were then used by federal programs to set reimbursement rates; engaging in <FONT STYLE="white-space:nowrap">off-label</FONT> promotion; and
submitting inflated best price information to the Medicaid Rebate Program to reduce liability for Medicaid rebates. Ensuring that our internal operations and future business arrangements with third parties comply with applicable healthcare laws and
regulations will involve substantial costs. It is possible that governmental authorities will conclude that our business practices do not comply with current or future statutes, regulations, agency guidance or case law involving applicable fraud and
abuse or other healthcare laws and regulations. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Our business operations and relationships with investigators, healthcare professionals, consultants, third-party payors, patient
organizations and customers are subject to broadly applicable healthcare laws and regulations, which could expose us civil to penalties, criminal sanctions, contractual damages, reputational harm and diminished profits and future earnings.
</I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Healthcare providers, physicians and
third-party payors will play a primary role in the recommendation and prescription of any product candidate for which we obtain regulatory approval. Our current and future arrangements may expose us to broadly applicable fraud and abuse and other
healthcare laws that may constrain the business or financial arrangements and relationships through which we would market, sell and distribute our products. In particular, the research of our product candidates, as well as the promotion, sales and
marketing of healthcare items and services, as well as certain business arrangements in the healthcare industry, are subject to extensive laws designed to prevent fraud, kickbacks, self-dealing and other abusive practices. These laws and regulations
may restrict or prohibit a wide range of pricing, discounting, marketing and promotion, structuring and commission(s), certain customer incentive programs and other business or financial arrangements. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Such laws include, but are not limited to, the following:
</FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the federal Anti-Kickback Statute, which prohibits, among other things, persons and entities from knowingly and willfully soliciting, offering,
receiving or providing remuneration (including any kickback, bribe or rebate), directly or indirectly, in cash or in kind, to induce or reward, or in return for, either the referral of an individual for, or the purchase, lease, order or
recommendation of, any good, facility, item or service, for which payment may be made, in whole or in part, under a federal healthcare program such as Medicare and Medicaid. The term &#147;remuneration&#148; has been broadly interpreted to include
anything of value. Although there are a number of statutory exceptions and regulatory safe harbors protecting some common activities from prosecution, the exceptions and safe harbors are drawn narrowly. Practices that involve remuneration that may
be alleged to be intended to induce prescribing, purchases or recommendations may be subject to scrutiny if they do not qualify for an exception or safe harbor. A person or entity does not need to have actual knowledge of the federal Anti-Kickback
Statute or specific intent to violate it to have committed a violation. The Anti-Kickback Statute has been interpreted to apply to arrangements between biopharmaceutical manufacturers, on the one hand, and prescribers, purchasers and formulary
managers, among others, on the other. In addition, the government may assert that a claim including items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the False
Claims Act; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the federal criminal and civil false claims laws, including the False Claims Act, which imposes criminal and civil penalties, including through civil
whistleblower or qui tam actions, against individuals or entities for knowingly presenting, or causing to be presented, to the federal government, claims for payment that </FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">39 </FONT></P>


</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"> <P><FONT STYLE="font-family:Times New Roman" SIZE="2">
are false or fraudulent, knowingly making, using or causing to be made or used, a false record or statement material to a false or fraudulent claim, or knowingly making or causing to be made, a
false statement to avoid, decrease or conceal an obligation to pay money to the federal government. Manufacturers can be held liable under the False Claims Act even when they do not submit claims directly to government payors if they are deemed to
&#147;cause&#148; the submission of false or fraudulent claims. When an entity is determined to have violated the False Claims Act, the government may impose civil fines and penalties for each false claim, plus treble damages, and exclude the entity
from participation in Medicare, Medicaid and other federal healthcare programs; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the federal Health Insurance Portability and Accountability Act of 1996, or HIPAA, which imposes criminal and civil liability for, among other things,
knowingly and willfully executing, or attempting to execute, a scheme to defraud any healthcare benefit program or making false or fraudulent statements relating to healthcare matters; similar to the federal Anti-Kickback Statute, a person or entity
does not need to have actual knowledge of the statute or specific intent to violate it to have committed a violation; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act, or HITECH, and their implementing regulations, which also
impose obligations, including mandatory contractual terms, with respect to safeguarding the privacy, security, and transmission of individually identifiable health information on health plans, health care clearing houses, and certain healthcare
providers and their business associates, defined as independent contractors or agents of covered entities that create, receive or obtain protected health information in connection with providing a service for or on behalf of a covered entity, as
well as their subcontractors. HITECH also created new tiers of civil monetary penalties, amended HIPAA to make civil and criminal penalties directly applicable to business associates, and gave state attorneys general new authority to file civil
actions for damages or injunctions in federal courts to enforce the federal HIPAA laws and seek attorneys&#146; fees and costs associated with pursuing federal civil actions. In addition, there may be additional federal, state and <FONT
STYLE="white-space:nowrap">non-U.S.</FONT> laws which govern the privacy and security of health and other personally identifiable information, or personal information or personal data, in certain circumstances, many of which differ from each other
in significant ways and may not have the same effect, thus complicating compliance efforts; </FONT></P></TD></TR></TABLE>  <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the federal Physician Payments Sunshine Act, which requires certain manufacturers of drugs, devices, biologics and medical supplies for which payment
is available under Medicare, Medicaid or the Children&#146;s Health Insurance Program (with certain exceptions) to report annually to the government information related to payments or other &#147;transfers of value&#148; made to physicians, as
defined by law, and teaching hospitals, and requires applicable manufacturers and group purchasing organizations to report annually to the ownership and investment interests held by such physicians and their immediate family members and payments or
other &#147;transfers of value&#148; to such physician owners (covered manufacturers are required to submit reports to CMS by the 90th day of each calendar year). Effective January&nbsp;1, 2022, these reporting obligations will extend to include
transfers of value made in the previous year to certain <FONT STYLE="white-space:nowrap">non-physician</FONT> providers such as physician assistants and nurse practitioners; and </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">analogous state and <FONT STYLE="white-space:nowrap">non-U.S.</FONT> laws and regulations, such as state anti-kickback and false claims laws, which may
apply to our business practices, including but not limited to, research, distribution, sales and marketing arrangements and claims involving healthcare items or services reimbursed by <FONT STYLE="white-space:nowrap">non-governmental</FONT>
third-party payors, including private insurers, or otherwise restrict payments that may be made to healthcare providers and other potential referral sources; and state laws that require pharmaceutical companies to comply with the pharmaceutical
industry&#146;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government, and state laws that require drug manufacturers to report information related to payments and other transfers of value to
physicians and other healthcare providers, marketing expenditures or drug pricing; and state and local laws that require the registration of pharmaceutical sales representatives; and state and <FONT STYLE="white-space:nowrap">non-U.S.</FONT> laws
governing the privacy and security of health information in some circumstances, many of which differ from each other in significant ways and often are not preempted by HIPAA, thus complicating compliance efforts. </FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">40 </FONT></P>


</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Pharmaceutical and other healthcare companies have been prosecuted under these laws
for a variety of promotional and marketing activities, such as: providing free trips, free or discounted goods, improper consulting fees and grants and other monetary benefits to prescribers; reporting to pricing services inflated average wholesale
prices that were then used by federal programs to set reimbursement rates; engaging in <FONT STYLE="white-space:nowrap">off-label</FONT> promotion; and submitting inflated best price information to the Medicaid Rebate Program to reduce liability for
Medicaid rebates. Ensuring that our internal operations and future business arrangements with third parties comply with applicable healthcare laws and regulations will involve substantial costs. It is possible that governmental authorities will
conclude that our business practices do not comply with current or future statutes, regulations, agency guidance or case law involving applicable fraud and abuse or other healthcare laws and regulations. If any actions are instituted against us for
violation of these laws or regulations, and we are not successful in defending ourselves, those actions could have a significant impact on our business, including the imposition of significant civil, criminal and administrative sanctions, damages,
disgorgement, monetary fines, possible exclusion from participation in Medicare, Medicaid and other federal healthcare programs, imprisonment, integrity oversight and reporting obligations, contractual damages, reputational harm, diminished profits
and future earnings, and curtailment or restructuring of our operations, any of which could harm our ability to operate our business and our results of operations. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The global data protection landscape is rapidly evolving, and
we may be affected by or subject to new, amended or existing laws and regulations in the future, including as our operations continue to expand or if we operate in <FONT STYLE="white-space:nowrap">non-U.S.</FONT> jurisdictions. Several <FONT
STYLE="white-space:nowrap">non-U.S.</FONT> jurisdictions, including the European Union, or EU, its member states, the United Kingdom, Japan and Australia, among others, have adopted legislation and regulations that increase or change the
requirements governing the collection, use, disclosure and transfer of the personal information of individuals in these jurisdictions. Additionally, certain countries have passed or are considering passing laws that require local data residency
and/or restrict the international transfer of data and/or impose data localization requirements with respect to certain personal information. These laws have the potential to increase costs of compliance, risks of noncompliance and penalties for
noncompliance. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Efforts to ensure that our
business arrangements with third parties will comply with applicable healthcare laws and regulations will involve substantial costs. If our operations are found to be in violation of any of these laws or any other governmental regulations that may
apply to us, we may be subject to significant civil, criminal and administrative penalties, damages, disgorgement, fines, imprisonment, exclusion from government funded healthcare programs, such as Medicare and Medicaid, additional oversight and
reporting obligations, contractual damages, reputational harm, diminished profits and future earnings, and the curtailment or restructuring of our operations. If any of the physicians or other healthcare providers or entities with whom we expect to
do business is found not to be in compliance with applicable laws, that person or entity may be subject to significant criminal, civil or administrative sanctions, including exclusions from government funded healthcare programs. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>We depend on our information technology systems and
those of our third-party collaborators, service providers, contractors or consultants. Our internal computer systems, or those of our third-party collaborators, service providers, contractors or consultants, may fail or suffer security breaches,
disruptions, or incidents, which could result in a material disruption of our development programs or loss of data or compromise the privacy, security, integrity or confidentiality of sensitive information related to our business and could harm our
reputation, business, financial condition or results of operations. </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">In the ordinary course of our business, we collect, store and transmit large amounts of confidential information, including intellectual property, proprietary business information and personal
information. Our internal technology systems and infrastructure, and those of our current or future third-party collaborators, service providers, contractors and consultants are vulnerable to damage from computer viruses, unauthorized access or use
resulting from malware, natural disasters, terrorism, war and telecommunication and electrical failures, <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">denial-of-service</FONT></FONT> attacks, cyber-attacks or cyber-intrusions
over the Internet, hacking, phishing and other social engineering attacks, persons inside our organizations (including employees or contractors), loss or theft, or persons with access to systems inside our organization. Attacks on information
technology systems are </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">41 </FONT></P>


</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
increasing in their frequency, levels of persistence, sophistication and intensity, and they are being conducted by increasingly sophisticated and organized
<FONT STYLE="white-space:nowrap">non-U.S.</FONT> governments, groups and individuals with a wide range of motives and expertise. For example, in June 2020, a coordinated cyber security attack targeted Australian government entities and companies. In
addition to extracting or accessing sensitive information, such attacks could include the deployment of harmful malware, ransomware, <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">denial-of-service</FONT></FONT> attacks, social
engineering and other means to affect service reliability and threaten the security, confidentiality, integrity and availability of information. The prevalent use of mobile devices that access sensitive information also increases the risk of data
security incidents which could lead to such sensitive information (which may include confidential information, other intellectual property or personal information) being subject to unauthorized access or otherwise compromised. While to our knowledge
we have not experienced any material system failure, accident or security breach to date, if such an event were to occur and cause interruptions in our operations or the operations of third-party collaborators, service providers, contractors and
consultants, it could result in a material disruption of our development programs and significant reputational, financial, legal, regulatory, business or operational harm. The costs to us to mitigate, investigate and respond to potential security
incidents, breaches, disruptions, network security problems, bugs, viruses, worms, malicious software programs and security vulnerabilities could be significant, and while we have implemented security measures to protect our data security and
information technology systems, our efforts to address these problems may not be successful, and these problems could result in unexpected interruptions, delays, cessation of service and other harm to our business and our competitive position.
</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">For example, the loss of clinical trial data from
completed, ongoing or planned clinical trials for our product candidates could result in delays in our regulatory approval efforts and significantly increase our costs to recover or reproduce the data. To the extent that any real or perceived
security breach affects our systems (or those of our third-party collaborators, service providers, contractors or consultants), or results in the loss of or accidental, unlawful or unauthorized access to, use of, release of, or other processing of
personal information or damage to our data or applications or other data or applications relating to our technology or product candidates, or inappropriate disclosure of confidential or proprietary information, we could incur liabilities and the
further development of our product candidates could be delayed. Such a breach may require notification to governmental agencies, the media or individuals pursuant to various <FONT STYLE="white-space:nowrap">non-U.S.</FONT> domestic (federal and
state) privacy and security laws, if applicable, including HIPAA, as amended by HITECH, and its implementing rules and regulations, as well as regulations promulgated by the Federal Trade Commission and state breach notification laws. In addition,
our liability insurance may not be sufficient in type or amount to cover us against all losses and claims related to security breaches, cyberattacks and other related incidents. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Any failure or perceived failure by us or any third-party
collaborators, service providers, contractors or consultants to comply with our privacy, confidentiality, data security or similar obligations, or any data security incidents or other security breaches that result in the accidental, unlawful or
unauthorized access to, use of, release of, processing of, or transfer of sensitive information, including personal information, may result in negative publicity, harm to our reputation, governmental investigations, enforcement actions, regulatory
fines, litigation or public statements against us, could cause third parties to lose trust in us or could result in claims by third parties, including those that assert that we have breached our privacy, confidentiality, data security or similar
obligations, any of which could harm our reputation, business, financial condition or results of operations. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">To the extent we maintain individually identifiable health information, we could be subject to fines and penalties (including civil and
criminal) under HIPAA for any failure by us or our business associates to comply with HIPAA&#146;s requirements. Moreover, data security incidents and other security breaches can be difficult to detect, and any delay in identifying them may lead to
increased harm. While we have implemented data security measures intended to protect our information, data, information technology systems, applications and infrastructure, there can be no assurance that such measures will successfully prevent
service interruptions or data security incidents. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">42 </FONT></P>


</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>European data collection is governed by restrictive regulations governing the
collection, use, processing and cross-border transfer of personal information. </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">We may collect, process, use or transfer personal information from individuals located in the European Economic Area in connection with our business, including in connection with conducting clinical
trials in the European Economic Area, or the EEA. Additionally, if any of our product candidates are approved, we may seek to commercialize those products in the European Economic Area. The collection and use of personal health data in the European
Economic Area is governed by the provisions of the General Data Protection Regulation ((EU) 2016/679), or the GDPR, along with other European Union and country-specific laws and regulations. The United Kingdom and Switzerland have also adopted data
protection laws and regulations. These legislative acts (together with regulations and guidelines) impose requirements relating to having legal bases for processing personal data relating to identifiable individuals and transferring such data
outside of the European Economic Area, including to the United States, providing details to those individuals regarding the processing of their personal data, keeping personal data secure, having data processing agreements with third parties who
process personal data, responding to individuals&#146; requests to exercise their rights in respect of their personal data, reporting security breaches involving personal data to the competent national data protection authority and affected
individuals, appointing data protection officers or corporate representatives, conducting data protection impact assessments and record-keeping. The GDPR imposes additional responsibilities and liabilities in relation to personal data that we
process and we may be required to put in place additional mechanisms ensuring compliance with the new data protection rules. Failure to comply with the requirements of the GDPR and related national data protection laws of the member states of the
European Economic Area and other states in the European Economic Area may result in substantial penalties, including potential fines of up to &#128;20&nbsp;million or 4% of annual global revenues, whichever is greater, other administrative penalties
and civil claims being brought against us, which could harm our business, financial condition and results of operations. European data protection authorities may interpret the GDPR and national laws differently and may impose additional
requirements, which adds to the complexity of processing personal data in or from the EEA or United Kingdom. Guidance on implementation and compliance practices are often updated or otherwise revised. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Our insurance policies are expensive and only protect
us from some business risks, leaving us exposed to significant uninsured liabilities. </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">We do not carry insurance for all categories of risk that our business may encounter. We believe that we maintain insurance customary for businesses of our size and type, including clinical trial
liability insurance. However, there are types of losses we may incur that cannot be insured against or that we believe are not economically reasonable to insure. Moreover, any loss incurred could exceed policy limits and policy payments made to us
may not be made on a timely basis. Such losses could negatively affect our business prospects, results of operations, cash flows and financial condition. We do not know if our current levels of coverage are adequate or if we will be able to obtain
insurance with adequate levels of coverage in the future, if at all. Any significant uninsured liability may require us to pay substantial amounts, which could negatively impact our financial position and results of operations. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Disputes under key agreements or conflicts of interest
with our scientific advisors or clinical investigators could delay or prevent development or commercialization of our product candidates. </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Any agreements we have or may enter into with third parties, such as collaboration, license, formulation supplier, manufacturing, clinical
research organization or clinical trial agreements, may give rise to disputes regarding the rights and obligations of the parties. Disagreements could develop over contract interpretation, rights to ownership or use of intellectual property, the
scope and direction of research and development, the approach for regulatory approvals or commercialization strategy. We intend to conduct research programs in a range of therapeutic areas, but our pursuit of these opportunities could result in
conflicts with the other parties to these agreements that may be developing or selling pharmaceuticals or conducting other activities in these same therapeutic areas. Any disputes or commercial conflicts could lead to the termination of our
agreements, delay </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">43 </FONT></P>


</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
progress of our product development programs, compromise our ability to renew agreements or obtain future agreements, lead to the loss of intellectual property rights, result in increased
financial obligations for us or result in costly litigation. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">We work with outside scientific advisors and collaborators at academic and other institutions that assist us in our research and development efforts. Our scientific advisors are not our employees and may
have other commitments that limit their availability to us. If a conflict of interest between their work for us and their work for another entity arises, we may lose their services. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Unstable market and economic conditions may have serious adverse consequences on our business and
financial condition. </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Global credit and
financial markets have experienced extreme disruptions at various points over the last few decades, characterized by diminished liquidity and credit availability, declines in consumer confidence, declines in economic growth, increases in
unemployment rates and uncertainty about economic stability. If another such disruption in credit and financial markets and deterioration of confidence in economic conditions occurs, our business may be harmed. If the equity and credit markets were
to deteriorate significantly in the future, it may make any necessary debt or equity financing more difficult to complete, more costly and more dilutive. Failure to secure any necessary financing in a timely manner and on favorable terms could harm
our growth strategy, financial performance and share price and could require us to delay or abandon development or commercialization plans. In addition, there is a risk that one or more of our service providers, manufacturers or other partners would
not survive or be able to meet their commitments to us under such circumstances, which could directly affect our ability to attain our operating goals on schedule and on budget. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>If we fail to implement and maintain an effective
system of internal controls to remediate our material weaknesses over financial reporting, we may be unable to accurately report our results of operations, meet our reporting obligations or prevent fraud, and investor confidence in our company and
the market price of the ADSs may be negatively impacted. </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;404(a) of the&nbsp;Sarbanes-Oxley Act of 2002, or the Sarbanes-Oxley Act, requires that our management assess and report annually on the effectiveness of our internal controls over financial
reporting and identify any material weaknesses in our internal controls over financial reporting. During the audit of our consolidated financial statements for the fiscal year ended June&nbsp;30, 2019, material weaknesses were identified in our
internal control over financial reporting. Under standards established by the PCAOB, a &#147;material weakness&#148; is a deficiency, or combination of deficiencies in internal control over financial reporting, such that there is a reasonable
possibility that a material misstatement of the annual or interim financial statements will not be prevented or detected on a timely basis. The material weaknesses that have been identified relate to our lack of (i)&nbsp;sufficient accounting and
financial reporting personnel with requisite knowledge of and experience in application of SEC rules and regulations and (ii)&nbsp;adequate controls to address segregation of duties. We and our independent registered public accounting firm were not
required to perform an evaluation of our internal control over financial reporting as of June&nbsp;30, 2019 and 2020 in accordance with the provisions of the Sarbanes-Oxley Act. Accordingly, we cannot assure you that we have identified all, or that
we will not in the future have additional, material weaknesses. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">We are in the process of implementing a number of measures to address the material weaknesses that have been identified including: (i)&nbsp;hiring additional accounting and financial reporting personnel
with SEC reporting experience, (ii)&nbsp;expanding the capabilities of existing accounting and financial reporting personnel through continuous training and education in the accounting and reporting requirements under International Financial
Reporting Standards, or IFRS, and SEC rules and regulations, (iii)&nbsp;establishing effective monitoring and oversight controls for <FONT STYLE="white-space:nowrap">non-recurring</FONT> and complex transactions to ensure the accuracy and
completeness of our company&#146;s consolidated financial statements and related disclosures and (iv)&nbsp;implementing formal processes and controls to identify, monitor and mitigate segregation of duties conflicts. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">44 </FONT></P>


</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The presence of material weaknesses could result in financial statement errors which,
in turn, could lead to errors in our financial reports or delays in our financial reporting, which could require us to restate our operating results or result in our auditors issuing a qualified audit report. In order to establish and maintain
effective disclosure controls and procedures and internal controls over financial reporting, we will need to expend significant resources and provide significant management oversight. Developing, implementing and testing changes to our internal
controls may require specific compliance training of our directors and employees, entail substantial costs in order to modify our existing accounting systems, take a significant period of time to complete and divert management&#146;s attention from
other business concerns. These changes may not, however, be effective in establishing and maintaining adequate internal controls. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">If either we are unable to conclude that we have effective internal controls over financial reporting or our independent auditors are
unwilling or unable to provide us with an unqualified report on the effectiveness of our internal controls over financial reporting as required by Section&nbsp;404(b) of the Sarbanes-Oxley Act, investors may lose confidence in our operating results,
the price of the ADSs could decline and we may be subject to litigation or regulatory enforcement actions. In addition, if we are unable to meet the requirements of Section&nbsp;404 of the Sarbanes-Oxley Act, we may not be able to remain listed on
The Nasdaq Global Select Market, or Nasdaq. </FONT></P>  <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Risks Related
to Regulatory Approvals </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>If we are not
able to obtain required regulatory approvals, we will not be able to commercialize <FONT STYLE="white-space:nowrap">OPT-302</FONT> or any future product candidate, and our ability to generate product revenue will be impaired. </I></B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="white-space:nowrap">OPT-302</FONT> and any
future product candidate that we may develop, as well as the activities associated with their development and commercialization, including their design, research, testing, manufacture, safety, efficacy, recordkeeping, labeling, packaging, storage,
approval, advertising, promotion, sale and distribution are subject to comprehensive regulation by the FDA and other regulatory agencies in the United States and by similar regulatory authorities outside the United States. Failure to obtain
marketing approval for, and thus commercialize any product candidate, could negatively impact our ability to generate any revenue from product sales. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We have not received approval from regulatory authorities to market any product candidate in any jurisdiction, and it is possible that our
product candidate will never obtain the appropriate regulatory approvals necessary for us to commence product sales. Neither we nor any collaborator is permitted to market our product candidate in the United States or any other jurisdiction until we
receive regulatory approval of a BLA from the FDA or similar application from regulatory authorities outside of the United States. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The time required to obtain approval of a BLA by the FDA or similar application from regulatory authorities outside of the United States
is unpredictable but typically takes many years following the commencement of clinical trials and depends upon numerous factors, including the substantial discretion of the regulatory authority. Prior to submitting a BLA to the FDA or any comparable
application to any other <FONT STYLE="white-space:nowrap">non-U.S.</FONT> regulatory authorities for approval of any product candidate, we will need to complete pivotal Phase 3 clinical trials and demonstrate favorable results with respect to
safety, tolerability and efficacy. In addition, approval policies, regulations or the type and amount of clinical data necessary to gain approval may change during the course of a product candidate&#146;s clinical development and may vary among
jurisdictions. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Securing marketing approvals
requires the submission of extensive nonclinical and clinical data and supporting information to regulatory authorities for each therapeutic indication to establish the safety and efficacy of our product candidate for the specified indications. We
expect to rely on third-party CROs, consultants and our collaborators to assist us in filing and supporting the applications necessary to gain marketing approvals. Securing marketing approval also requires the submission of information about the
product manufacturing process to, and inspection of manufacturing facilities by, regulatory authorities. Errors in the submission of applications for marketing approval or issues, including those related to gathering the appropriate data and the
inspection process, may ultimately delay or affect our ability to obtain regulatory approval, commercialize our product candidate and generate product revenue. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">45 </FONT></P>


</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Our failure to obtain regulatory approval in international jurisdictions would
prevent us from marketing our product candidates outside the United States. </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">If we succeed in developing any products, we intend to market them in <FONT STYLE="white-space:nowrap">non-U.S.</FONT> jurisdictions in addition to the United States. In order to market and sell our
products in other jurisdictions, we must obtain separate marketing approvals and comply with numerous and varying regulatory requirements. We may not obtain <FONT STYLE="white-space:nowrap">non-U.S.</FONT> regulatory approvals on a timely basis, if
at all. Approval by the FDA does not ensure approval by regulatory authorities in other countries or jurisdictions. Approval by one regulatory authority outside the United States does not ensure approval by regulatory authorities in other countries
or jurisdictions or by the FDA. If we fail to obtain approval of any of our product candidates by regulatory authorities in another country we will be unable to commercialize our product in that country, and the commercial prospects of that product
candidate and our business prospects could decline. The approval procedure varies among countries and can involve additional testing. The time required to obtain approval may differ substantially from that required to obtain FDA approval. The
regulatory approval process outside the United States generally includes all of the risks associated with obtaining FDA approval. In addition, in many countries outside the United States, we must secure product reimbursement approvals before
regulatory authorities will approve the product for sale in that country. Obtaining <FONT STYLE="white-space:nowrap">non-U.S.</FONT> regulatory approvals and compliance with <FONT STYLE="white-space:nowrap">non-U.S.</FONT> regulatory requirements
could result in significant delays, difficulties and costs for us and could delay or prevent the introduction of our products in certain countries. Further, clinical trials conducted in one country may not be accepted by regulatory authorities in
other countries and regulatory approval in one country does not ensure approval in any other country, while a failure or delay in obtaining regulatory approval in one country may have a negative effect on the regulatory approval process in others.
Also, regulatory approval for any of our product candidates may be withdrawn if we fail to comply with regulatory requirements, if problems occur after the product candidate reaches the market or for other reasons. If we fail to comply with the
regulatory requirements in international markets and fail to receive applicable marketing approvals, our target market will be reduced and our ability to realize the full market potential of our product candidates will be harmed and our business
will be negatively affected. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Even if <FONT
STYLE="white-space:nowrap">OPT-302</FONT> combination therapy or any future product candidate receives regulatory approval, it may still face future development and regulatory difficulties. </I></B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Even if we obtained regulatory approval for a product
candidate, it would be subject to ongoing requirements by the FDA and comparable <FONT STYLE="white-space:nowrap">non-U.S.</FONT> regulatory authorities governing the manufacture, quality control, further development, labeling, packaging, storage,
distribution, safety surveillance, import, export, advertising, promotion, recordkeeping and reporting of safety and other post-market information. The FDA and comparable <FONT STYLE="white-space:nowrap">non-U.S.</FONT> regulatory authorities will
continue to closely monitor the safety profile of any product even after approval. If the FDA, or comparable <FONT STYLE="white-space:nowrap">non-U.S.</FONT> regulatory authorities, become aware of new safety information after approval of any of our
product candidates, it may require labeling changes or establishment of a risk evaluation and mitigation strategy or similar strategy, impose significant restrictions on a product&#146;s indicated uses or marketing or impose ongoing requirements for
potentially costly post-approval studies or post-market surveillance. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">In addition, manufacturers of drug products and their facilities are subject to continual review and periodic inspections by the FDA and other regulatory authorities for compliance with current good
manufacturing practices, or cGMP, regulations and standards. If we or a regulatory agency discover previously unknown problems with a product, such as adverse events of unanticipated severity or frequency, or problems with the facility where the
product is manufactured, a regulatory agency may impose restrictions on that product, the manufacturing facility or us, including requiring recall or withdrawal of the product from the market or suspension of manufacturing. If we, our product
candidates or the manufacturing facilities for our product candidates fail to comply with applicable regulatory requirements, or undesirable side effects caused by such products are identified, a regulatory agency may: </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">issue safety alerts, Dear Healthcare Provider letters, press releases or other communications containing warnings about such product;
</FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">46 </FONT></P>


</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">mandate modifications to promotional materials or require us to provide corrective information to healthcare practitioners;
</FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">revise labeling, including adding limitations on approved uses or the additions of additional warnings, contraindications or other safety information
including boxed warnings; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">impose a REMS which may include distribution on or use restrictions; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT
SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">require that we conduct post-marketing studies; </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">require us to enter into a consent decree, which can include imposition of various fines, reimbursements for inspection costs, required due dates for
specific actions and penalties for noncompliance; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">seek an injunction or impose civil or criminal penalties or monetary fines; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT
SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">suspend marketing of, withdraw regulatory approval of or recall such product; </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">suspend any ongoing clinical studies; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">refuse to approve pending applications or supplements to applications filed by us; </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">suspend or impose restrictions on operations, including costly new manufacturing requirements; or </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">seize or detain products, refuse to permit the import or export of products or require us to initiate a product recall. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The occurrence of any event or penalty described above may
inhibit our ability to commercialize our products and generate product revenue. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Advertising and promotion of any product candidate that obtains approval in the United States will be heavily scrutinized by the FDA, the Department of Justice, the Department of Health and Human
Services&#146; Office of Inspector General, state attorneys general, members of Congress and the public. Violations, including promotion of our products for unapproved (or <FONT STYLE="white-space:nowrap">off-label)</FONT> uses, are subject to
enforcement letters, inquiries and investigations and significant civil and criminal sanctions by the government. In the United States, engaging in the impermissible promotion of our products for <FONT STYLE="white-space:nowrap">off-label</FONT>
uses can also subject us to false claims litigation under federal and state statutes, which can lead to significant civil and criminal penalties. Additionally, comparable <FONT STYLE="white-space:nowrap">non-U.S.</FONT> regulatory authorities will
heavily scrutinize advertising and promotion of any product candidate that obtains approval outside of the United States. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The FDA&#146;s policies may change and additional government regulations may be enacted that could prevent, limit or delay regulatory
approval of our product candidates. If we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we are not able to maintain regulatory compliance, we may lose any marketing approval
that we may have obtained, which would negatively affect our business, prospects and ability to achieve or sustain profitability. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Risks Related to Our Reliance on Third Parties </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>We have relied on, and expect to continue to rely on, third-party manufacturers to produce
<FONT STYLE="white-space:nowrap">OPT-302</FONT> or any future product candidates. Any failure by a third-party manufacturer to produce acceptable product candidates for us pursuant to our specifications and regulatory standards may delay or impair
our ability to initiate or complete our clinical trials, obtain and maintain regulatory approvals or commercialize approved products. </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The manufacturing of biologic drugs such as <FONT STYLE="white-space:nowrap">OPT-302</FONT> is complex and the process of identifying the
qualifying suppliers takes a significant investment of time and money. We do not own or operate manufacturing facilities for the production of clinical or commercial quantities of our product candidates, and we lack the resources and the
capabilities to do so. As a result, we currently rely, and expect to rely for the foreseeable future, on third-party manufacturers to supply us with <FONT STYLE="white-space:nowrap">OPT-302</FONT> and any future product candidates. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">47 </FONT></P>


</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We currently have a sole source relationship with Patheon N.V., a division of Thermo
Fisher Scientific Inc., pursuant to which they supply us with <FONT STYLE="white-space:nowrap">OPT-302</FONT> drug substance and drug product. If there should be any disruption in our supply arrangement with Patheon, including any adverse events
affecting Patheon or Thermo Fisher Scientific, it could have a negative effect on the clinical development of <FONT STYLE="white-space:nowrap">OPT-302</FONT> and other operations while we work to identify and qualify an alternate supply source. In
addition, we do not have a long-term supply arrangement to purchase <FONT STYLE="white-space:nowrap">anti-VEGF-A</FONT> therapy for use in combination with <FONT STYLE="white-space:nowrap">OPT-302</FONT> in our clinical trials and acquire such drug
product on a purchase order basis. Any complications with our existing suppliers of <FONT STYLE="white-space:nowrap">anti-VEGF-A</FONT> therapies could considerably delay our clinical trials for <FONT STYLE="white-space:nowrap">OPT-302,</FONT>
including our Phase 3 pivotal clinical program of <FONT STYLE="white-space:nowrap">OPT-302</FONT> for the treatment of wet AMD, or the regulatory approvals of <FONT STYLE="white-space:nowrap">OPT-302.</FONT> </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Reliance on third-party suppliers and manufacturers entails
risks to which we would not be subject if we manufacture product candidates or products ourselves. For example, if we do not maintain our key manufacturing relationships, including with Patheon, we may fail to find replacement manufacturers or
develop our own manufacturing capabilities in a timely manner or at all, which could delay or impair our ability to obtain regulatory approval for our products and substantially increase our costs or deplete profit margins, if any. If we do find
replacement manufacturers, we may not be able to enter into agreements with them on terms and conditions favorable to us in a timely manner, if at all, and there could be a substantial delay before new facilities could be qualified and registered
with or licensed by the FDA and other comparable <FONT STYLE="white-space:nowrap">non-U.S.</FONT> regulatory authorities. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Even if we are able to establish agreements with third-party manufacturers, reliance on third-party manufacturers entails additional
risks, including: </FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">failure of the third party to manufacture product candidates according to our schedule, or at all, including if our third-party contractors give
greater priority to the supply of other products over our product candidates or otherwise do not satisfactorily perform according to the terms of the agreements between us and them; </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">breach of the manufacturing agreement by the third party because of factors beyond our control (including a failure to manufacture product candidates
in accordance with our product specifications); </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the failure of the third-party manufacturer to comply with applicable regulatory requirements and reliance on third-parties for manufacturing process
development, regulatory compliance and quality assurance; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">mislabeling of clinical supplies, potentially resulting in the wrong dose amounts being supplied or active drug or placebo not being properly
identified; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">clinical supplies not being delivered to clinical sites on time, leading to clinical trial interruptions, or of drug supplies not being distributed to
commercial vendors in a timely manner, resulting in lost sales; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">misappropriation of our proprietary information, including our trade secrets and <FONT STYLE="white-space:nowrap">know-how;</FONT>
</FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">termination or nonrenewal of the agreement by the third party at a time that is costly or inconvenient for us; and </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">reliance on the third party for regulatory compliance, quality assurance and safety and pharmacovigilance reporting. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The FDA and other comparable
<FONT STYLE="white-space:nowrap">non-U.S.</FONT> regulatory authorities require manufacturers to register manufacturing facilities. The FDA and other comparable <FONT STYLE="white-space:nowrap">non-U.S.</FONT> regulatory authorities also inspect
these facilities to confirm compliance with cGMP. Contract manufacturers may face manufacturing or quality control problems causing drug substance production and shipment delays or a situation where the contractor may not be able to maintain
compliance with the applicable cGMP requirements. We may have little to no control regarding the occurrence of third-party manufacturer incidents. Failure by our third-party manufacturers and suppliers to pass such inspections and otherwise
satisfactorily complete the FDA approval regimen with respect to our product candidate may result in regulatory actions such as the issuance of FDA Form 483 notices of </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">48 </FONT></P>


</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
observations, warning letters or injunctions or the loss of operating licenses. In addition, our third-party manufacturers and suppliers are subject to numerous environmental, health and safety
laws and regulations, including those governing the handling, use, storage, treatment and disposal of waste products, and failure to comply with such laws and regulations could result in significant costs associated with civil or criminal fines and
penalties for such third parties. Any failure to comply with cGMP requirements or other FDA or comparable <FONT STYLE="white-space:nowrap">non-U.S.</FONT> regulatory requirements could negatively impact our clinical research activities and our
ability to develop <FONT STYLE="white-space:nowrap">OPT-302</FONT> or any future product candidates and market our products following approval. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">If <FONT STYLE="white-space:nowrap">OPT-302</FONT> or any future product candidates are approved by the FDA or other comparable <FONT
STYLE="white-space:nowrap">non-U.S.</FONT> regulatory authorities for commercial sale, we may need to manufacture such product candidate in larger quantities. We intend to use third-party manufacturers for commercial quantities of <FONT
STYLE="white-space:nowrap">OPT-302</FONT> to the extent we advance this product candidate and other product candidates. Our manufacturers may not be able to successfully increase the manufacturing capacity for any of our product candidates in a
timely or efficient manner, or at all. If we are unable to successfully increase the manufacturing capacity for a product candidate, the regulatory approval or commercial launch of that product candidate may be delayed or there may be a shortage in
the supply of the product candidate. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In addition,
the operations of our third-party manufacturers may be subject to earthquakes, power shortages, telecommunications failures, failures or breaches of information technology systems, water shortages, floods, hurricanes, typhoons, fires, extreme
weather conditions, medical epidemics, such as the recent <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic, and other natural or <FONT STYLE="white-space:nowrap">man-made</FONT> disasters or business interruptions. Damage or extended
periods of interruption to our facilities due to fire, natural disaster, power loss, communications failure, unauthorized entry or other events could cause us to cease or delay development of some or all of our product candidates. Our ability to
obtain clinical supplies of our product candidates could be disrupted if the operations of these suppliers are affected by a <FONT STYLE="white-space:nowrap">man-made</FONT> or natural disaster or other business interruption. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our current and anticipated future dependence upon others for
the manufacture of our product candidates may negatively affect our future profit margins and our ability to develop our product candidates and commercialize any products that receive regulatory approval on a timely basis. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In some cases, the technical skills or technology required to
manufacture our product candidates may be unique or proprietary to the original manufacturer, we may have difficulty transferring such skills or technology to another third party and a feasible alternative many not exist. These factors would
increase our reliance on such manufacturer or require us to obtain a license from such manufacturer in order to have another third party manufacture our product candidates. If we are required to change manufacturers for any reason, we will be
required to verify that the new manufacturer maintains facilities and procedures that comply with quality standards and with all applicable regulations and guidelines and the manufacturer may be required to obtain applicable licenses or approvals.
The delays associated with the verification of a new manufacturer, if we are able to identify an alternative source, could negatively affect our ability to develop product candidates in a timely manner or within budget. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>The manufacture of biologic products is complex and we
are subject to many manufacturing risks, any of which could substantially increase our costs and limit supply of our products. </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The manufacture of biologic products is complex and requires significant expertise and capital investment, including the development of
advanced manufacturing techniques and process controls. Manufacturers of biologic products often encounter difficulties in production, particularly in scaling up and validating initial production and ensuring the avoidance of contamination. These
problems include difficulties with production costs and yields, quality control, including stability of the product, quality assurance testing, operator error and shortages of qualified personnel, as well as compliance with strictly enforced
federal, state and <FONT STYLE="white-space:nowrap">non-U.S.</FONT> regulations. We cannot assure you that any stability or other issues relating to the manufacture of <FONT STYLE="white-space:nowrap">OPT-302</FONT> will not occur in the future.
</FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">49 </FONT></P>


</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The process of manufacturing <FONT STYLE="white-space:nowrap">OPT-302</FONT> is
complex, highly regulated and subject to several risks, including: </FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the process of manufacturing biologics is susceptible to product loss due to contamination, equipment failure, improper installation or operation of
equipment, vendor or operator error and improper storage conditions. Even minor deviations from normal manufacturing processes could result in reduced production yields, product defects and other supply disruptions. If microbial, viral or other
contaminations are discovered in our product candidates or in the manufacturing facilities in which our product candidates are made, the manufacturing facilities may need to be closed for an extended period of time to investigate and eliminate the
contamination; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the manufacturing facilities in which our products are made could be negatively affected by equipment failures, labor and raw material shortages,
financial difficulties of our contract manufacturers, natural disasters, power failures, local political unrest and numerous other factors; and </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">any adverse developments affecting manufacturing operations for our product candidates may result in shipment delays, inventory shortages, lot
failures, and for any approved products, product withdrawals, or recalls or other interruptions in the supply of our products. We may also have to record inventory write-offs and incur other charges and expenses for products that fail to meet
specifications, undertake costly remediation efforts or seek costlier manufacturing alternatives. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">To date, <FONT STYLE="white-space:nowrap">OPT-302</FONT> has been manufactured by a single third-party manufacturer, Patheon, solely for
preclinical studies and Phase 1 and 2 trials. This manufacturer may not be able to scale production to the larger quantities required for large clinical trials, including our planned Phase 3 clinical trials of
<FONT STYLE="white-space:nowrap">OPT-302</FONT> in combination with <FONT STYLE="white-space:nowrap">anti-VEGF-A</FONT> therapy for the treatment of wet AMD, and to commercialize <FONT STYLE="white-space:nowrap">OPT-302,</FONT> on a timely basis or
at all. Any such failure will require us to seek alternative manufacturing sources, which may result in considerable additional expense and delays in our planned clinical trials. We have limited process development capabilities and have access only
to external manufacturing capabilities. We do not have and we do not currently plan to acquire or develop the facilities or capabilities to manufacture bulk drug substance or filled drug product for use in human clinical trials or commercialization.
Any delay or interruption in the supply of clinical trial materials, including as a result of breach by us or Patheon of our agreement with Patheon, or our inability to agree to the terms of supply or related services in any statement of work, could
delay the completion of clinical trials, increase the costs associated with maintaining clinical trial programs and, depending upon the period of delay, require us to commence new clinical trials at additional expense or terminate clinical trials
completely. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Changes in methods of product
candidate manufacturing or formulation may result in additional costs or delay. </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">As product candidates proceed through nonclinical studies to late-stage clinical trials towards potential approval and commercialization, it is common that various aspects of the development program, such
as manufacturing methods and formulation, are altered along the way in an effort to optimize processes and results. Such changes carry the risk that they will not achieve these intended objectives. Any of these changes could cause <FONT
STYLE="white-space:nowrap">OPT-302</FONT> or any future product candidate to perform differently and affect the results of planned clinical trials or other future clinical trials conducted with the altered materials. Such changes may also require
additional testing, FDA notification or FDA approval. This could delay completion of clinical trials, require the conduct of bridging clinical trials or the repetition of one or more clinical trials, increase clinical trial costs, delay approval of <FONT
STYLE="white-space:nowrap">OPT-302</FONT> or any future product candidate or jeopardize our ability to commence sales and generate revenue. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>We rely on third parties to conduct our clinical trials and some aspects of our research and development activities, and those third
parties may not perform satisfactorily, including failing to meet deadlines for the completion of such trials, research or testing. </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We currently rely on, and expect to continue to rely on, third parties, such as CROs, clinical data management organizations, medical
institutions, consultants and clinical investigators, to conduct our clinical </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">50 </FONT></P>


</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
trials and certain aspects of our research and development activities. Any of these third parties may terminate their engagements with us at any time. If we need to enter into alternative
arrangements, it would delay our product development activities and such alternative arrangements may not be available on terms acceptable to us. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our reliance on these third parties for research and development activities will reduce our control over these activities, but will not
relieve us of our responsibilities. For example, we will remain responsible for ensuring that each of our clinical trials is conducted in accordance with the general investigational plan and clinical trial protocols. Moreover, the FDA requires us to
comply with standards, commonly referred to as current Good Clinical Practices, for conducting, recording and reporting the results of clinical trials to assure that data and reported results are credible and accurate and that the rights, integrity
and confidentiality of trial participants are protected. We are also required to register ongoing clinical trials and post the results of completed clinical trials on a government-sponsored database within certain timeframes. Failure to do so can
result in fines, adverse publicity and civil and criminal sanctions. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Furthermore, these third parties may also have relationships with other entities, some of which may be our competitors. If these third parties do not successfully carry out their contractual duties, meet
expected deadlines or conduct our clinical trials in accordance with regulatory requirements, standard operating procedures or clinical trial protocols, we will not be able to obtain, or may be delayed in obtaining, marketing approvals for <FONT
STYLE="white-space:nowrap">OPT-302</FONT> or any future product candidates and will not be able to, or may be delayed in our efforts to, successfully commercialize our product candidates. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We also expect to rely on other third parties to store and distribute drug supplies for our clinical trials.
Any performance failure on the part of our distributors could delay clinical development, marketing approval and/or commercialization of <FONT STYLE="white-space:nowrap">OPT-302</FONT> or any future product candidates, producing additional losses
and depriving us of potential revenue. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>We
may seek to establish commercial collaborations for our product candidates, and, if we are not able to establish them on commercially reasonable terms, we may have to alter our development and commercialization plans. </I></B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our drug development programs and the potential
commercialization of our product candidates will require substantial additional cash to fund expenses. We may decide to collaborate with other pharmaceutical and biotechnology companies for the development and potential commercialization of our
product candidates. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We face significant
competition in seeking appropriate collaborators. Whether we reach a definitive agreement for a collaboration will depend, among other things, upon our assessment of the collaborator&#146;s resources and expertise, the terms and conditions of the
proposed collaboration and the proposed collaborator&#146;s evaluation of a number of factors. Those factors may include the design or results of clinical trials, the likelihood of approval by the FDA or comparable
<FONT STYLE="white-space:nowrap">non-U.S.</FONT> regulatory authorities, the potential market for the product candidate, the costs and complexities of manufacturing and delivering such product candidate to patients, the potential of competing
products and the existence of uncertainty with respect to our ownership of technology, which can exist if there is a challenge to such ownership without regard to the merits of the challenge and industry and market conditions generally. The
collaborators may also consider alternative product candidates or technologies for similar indications that may be available to collaborate on and whether such a collaboration could be more attractive than the one with us for our product candidate.
</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Collaborations are complex and time-consuming to
negotiate and document. In addition, there have been a significant number of business combinations among large pharmaceutical companies that have resulted in a reduced number of potential future collaborators. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We may not be able to negotiate collaborations on a timely
basis, on acceptable terms, or at all. If we are unable to do so, we may have to curtail the development of the product candidate for which we are seeking to </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">51 </FONT></P>


</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
collaborate, reduce or delay its development program or one or more of our other development programs, delay its potential commercialization or reduce the scope of any sales or marketing
activities or increase our expenditures and undertake development or commercialization activities at our own expense. If we elect to increase our expenditures to fund development or commercialization activities on our own, we may need to obtain
additional capital, which may not be available to us on acceptable terms, or at all. If we do not have sufficient funds, we may not be able to further develop our product candidates or bring them to market and generate product revenue. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Risks Relating to Intellectual Property </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Our success depends upon our ability to obtain and
maintain intellectual property protection for our products and technologies. </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Our success will depend in significant part on our current or future licensors&#146;, licensees&#146; or collaborators&#146; ability to establish and maintain adequate protection of our owned and licensed
intellectual property covering the product candidates we plan to develop, and the ability to develop these product candidates and commercialize the products resulting therefrom, without infringing the intellectual property rights of others. In
addition to taking other steps to protect our intellectual property, we hold issued patents, we have applied for patents, and we intend to continue to apply for, patents with claims covering our technologies, processes and product candidates when
and where we deem it appropriate to do so. We have filed patent applications both in the United States and in certain <FONT STYLE="white-space:nowrap">non-U.S.</FONT> jurisdictions to obtain patent rights to inventions we have developed, with claims
directed to compositions of matter, methods of use and other technologies relating to our programs. There can be no assurance that any of these patent applications will issue as patents or, for those applications that do mature into patents, that
the claims of the patents will exclude others from making, using or selling our product candidates or products that compete with or are similar to our product candidates. In countries where we have not sought and do not seek patent protection, third
parties may be able to manufacture and sell our product candidates without our permission, and we may not be able to stop them from doing so. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">With respect to patent rights, we do not know whether any of the pending patent applications for any of our product candidates will result
in the issuance of patents that effectively protect our technologies, processes and product candidates, or if any of our issued patents or our current or future licensors&#146;, licensees&#146; or collaborators&#146; issued patents will effectively
prevent others from commercializing competitive technologies, processes and products. Publications of discoveries in the scientific literature often lag behind the actual discoveries, and patent applications in the United States and other
jurisdictions are typically not published until 18 months after filing or in some cases not at all, until they are issued as a patent. Therefore, we cannot be certain that we or our current or future licensors, licensees or collaborators were the
first to make the inventions claimed in our owned or licensed patents or pending patent applications, or that we or our current or future licensors, licensees or collaborators were the first to file for patent protection of such inventions. For a
description of our patent portfolio, see &#147;Business&#151;Intellectual Property.&#148; </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Any changes we make to <FONT STYLE="white-space:nowrap">OPT-302</FONT> or any future product candidates to cause them to have what we view as more advantageous properties may not be covered by our
existing patents and patent applications, and we may be required to file new applications and/or seek other forms of protection for any such altered product candidates. The patent landscape surrounding the technology underlying our product
candidates is potentially crowded, and there can be no assurance that we would be able to secure patent protection that would adequately cover an alternative to <FONT STYLE="white-space:nowrap">OPT-302</FONT> or any future product candidates.
</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The patent prosecution process is expensive and
time-consuming, and we and our current or future licensors, licensees or collaborators may not be able to prepare, file and prosecute all necessary or desirable patent applications at a reasonable cost or in a timely manner. It is also possible that
we or our current or future licensors, licensees or collaborators will fail to identify patentable aspects of inventions made in the course of development and commercialization activities before it is too late to obtain patent protection for them.
Moreover, </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">52 </FONT></P>


</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
in some circumstances, we may not have the right to control the preparation, filing and prosecution of patent applications, or to maintain or enforce the patents, covering technology that we
license from or license to third parties and may be reliant on our current or future licensors, licensees or collaborators to perform these activities, which means that these patent applications may not be prosecuted, and these patents enforced, in
a manner consistent with the best interests of our business. If our current or future licensors, licensees or collaborators fail to establish, maintain, protect or enforce such patents and other intellectual property rights, such rights may be
reduced or eliminated. If our current or future licensors, licensees or collaborators are not fully cooperative or disagree with us as to the prosecution, maintenance or enforcement of any patent rights, such patent rights could be compromised.
</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Similar to the patent rights of other
biotechnology companies, the scope, validity and enforceability of our owned and licensed patent rights generally are highly uncertain and involve complex legal and factual questions. The issuance of a patent is not conclusive as to its
inventorship, scope, validity or enforceability, and our patents may be challenged in the courts or patent offices in the United States and abroad. In recent years, these areas have been the subject of much litigation in the industry. As a result,
the issuance, scope, validity, enforceability and commercial value of our and our current or future licensors&#146;, licensees&#146; or collaborators&#146; patent rights are highly uncertain. Our and our current or future licensors&#146;,
licensees&#146; or collaborators&#146; pending and future patent applications may not result in patents being issued that protect our technology or product candidates, or products resulting therefrom, in whole or in part, or that effectively prevent
others from commercializing competitive technologies and products. The patent examination process may require us or our current or future licensors, licensees or collaborators to narrow the scope of the claims of pending and future patent
applications, which would limit the scope of patent protection that is obtained, if any. Our and our current or future licensors&#146;, licensees&#146; or collaborators&#146; patent applications cannot be enforced against third parties practicing
the technology that is currently claimed in such applications unless and until a patent issues from such applications, and then only to the extent the claims that issue are broad enough to cover the technology being practiced by those third parties.
</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Furthermore, given the amount of time required
for the development, testing and regulatory review of new product candidates, patents protecting such candidates might expire before or shortly after the resulting products are commercialized. As a result, our owned and <FONT
STYLE="white-space:nowrap">in-licensed</FONT> patents may not provide us with sufficient rights to exclude others from commercializing products similar or identical to ours. We expect to seek extensions of patent terms for our issued patents, where
available. This includes in the United States under the Hatch-Waxman Act, which permits a patent term extension of up to five years beyond the original expiration date of the patent as compensation for regulatory delays. However, such a patent term
extension cannot lengthen the remaining term of a patent beyond a total of 14 years from the product&#146;s approval date. Only one patent applicable to each regulatory review period may be extended and only those claims covering the approved drug,
a method for using it, or a method for manufacturing it may be extended, with extended rights limited to the approved product, its approved uses and/or its manufacture. During the period of patent term extension, the claims of a patent are not
enforceable for their full scope, but are instead limited to the scope of the approved product. In addition, the applicable authorities, including the FDA in the United States, and any comparable <FONT STYLE="white-space:nowrap">non-U.S.</FONT>
regulatory authorities, may not agree with our assessment of whether such extensions are available, and may refuse to grant extensions to our patents, or may grant more limited extensions than we request. In addition, we may not be granted an
extension because of, for example, failing to apply within applicable deadlines, failing to apply prior to the expiration of relevant patents or otherwise failing to satisfy applicable requirements. If this occurs, any period during which we have
the right to exclusively market our product will be shorter than we would otherwise expect, and our competitors may obtain approval of and launch products earlier than might otherwise be the case. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>We may not be able to protect our intellectual property
rights throughout the world. </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The legal
protection afforded to inventors and owners of intellectual property in countries outside of the United States may not be as protective or effective as that in the United States and we may, therefore, be unable to acquire and enforce intellectual
property rights outside the United States to the same extent as in the United </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">53 </FONT></P>


</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
States. Whether filed in the United States or abroad, our patent applications may be challenged or may fail to result in issued patents. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In addition, our existing patents and any future patents we obtain may not be sufficiently broad to prevent
others from practicing our technologies or from developing or commercializing competing products. Furthermore, others may independently develop or commercialize similar or alternative technologies or drugs, or design around our patents. Our patents
may be challenged, invalidated, circumvented or narrowed, or fail to provide us with any competitive advantages. In many <FONT STYLE="white-space:nowrap">non-U.S.</FONT> countries, patent applications and/or issued patents, or parts thereof, must be
translated into the native language. If our patent applications or issued patents are translated incorrectly, they may not adequately cover our technologies; in some countries, it may not be possible to rectify an incorrect translation, which may
result in patent protection that does not adequately cover our technologies in those countries. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Filing, prosecuting, enforcing and defending patents on product candidates in all countries throughout the world would be prohibitively expensive, and our intellectual property rights in some countries
outside the United States may be less extensive than those in the United States. In addition, the laws of some <FONT STYLE="white-space:nowrap">non-U.S.</FONT> countries do not protect intellectual property rights to the same extent as federal and
certain state laws in the United States. Consequently, we may not be able to prevent third parties from practicing our inventions in all countries outside the United States, or from selling or importing products made using our inventions in and into
the United States or other jurisdictions. Competitors may use technologies in jurisdictions where we have not obtained patent protection to develop their own products and, further, may export otherwise infringing products to territories where we
have patent protection, but enforcement is not as strong as that in the United States. These products may compete with <FONT STYLE="white-space:nowrap">OPT-302</FONT> or any future product candidates and our patents or other intellectual property
rights may not be effective or sufficient to prevent them from competing. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Many companies have encountered significant problems in protecting and defending intellectual property rights in <FONT STYLE="white-space:nowrap">non-U.S.</FONT> jurisdictions. The legal systems of
certain countries, particularly certain developing countries, do not favor the enforcement of patents and other intellectual property protection, particularly those relating to biopharmaceuticals. This could make it difficult for us to stop the
infringement of our patents or the marketing of competing products in violation of our proprietary rights, generally. Proceedings to enforce our patent rights in <FONT STYLE="white-space:nowrap">non-U.S.</FONT> jurisdictions could result in
substantial costs and divert our efforts and attention from other aspects of our business, could put our patents at risk of being invalidated or interpreted narrowly, could place our patent applications at risk of not issuing and could provoke third
parties to assert claims against us or our collaborator. We may not prevail in any lawsuits that we initiate and the damages or other remedies awarded, if any, may not be commercially meaningful. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The requirements for patentability differ and certain
countries have heightened requirements for patentability, requiring more disclosure in the patent application. In addition, certain countries have compulsory licensing laws under which a patent owner may be compelled to grant licenses to third
parties. In those countries, we may have limited remedies if patents are infringed or if we are compelled to grant a license to a third party, which could materially diminish the value of those patents. This could limit our potential revenue
opportunities. In addition, many countries limit the enforceability of patents against government agencies or government contractors. In these countries, the patent owner may have limited remedies, which could materially diminish the value of such
patent. Accordingly, our efforts to enforce intellectual property rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual property that we own or license. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Changes in patent law could diminish the value of
patents in general, thereby impairing our ability to protect <FONT STYLE="white-space:nowrap">OPT-302</FONT> and any future product candidates. </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">As is the case with other biotechnology and pharmaceutical companies, our success is heavily dependent on intellectual property rights,
particularly patents. Obtaining and enforcing patents in the biopharmaceutical industry involves technological and legal complexity, and obtaining and enforcing biopharmaceutical patents is </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">54 </FONT></P>


</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
costly, time-consuming and inherently uncertain. The U.S. Supreme Court in recent years has issued rulings either narrowing the scope of patent protection available in certain circumstances or
weakening the rights of patent owners in certain situations or ruling that certain subject matter is not eligible for patent protection. In addition to increasing uncertainty with regard to our ability to obtain patents in the future, this
combination of events has created uncertainty with respect to the value of patents, once obtained. Depending on decisions by Congress, the federal courts, the USPTO and equivalent bodies in <FONT STYLE="white-space:nowrap">non-U.S.</FONT>
jurisdictions, the laws and regulations governing patents could change in unpredictable ways that would weaken our ability to obtain new patents or to enforce existing patents and patents we may obtain in the future. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Patent reform laws, such as the Leahy-Smith America Invents
Act, or the Leahy-Smith Act, as well as changes in how patent laws are interpreted, could increase the uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of our issued patents. The
Leahy-Smith Act made a number of significant changes to U.S. patent law. These include provisions that affect the filing and prosecution strategies associated with patent applications, including a change from a <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">&#147;first-to-invent&#148;</FONT></FONT> to a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">&#147;first-inventor-to-file&#148;</FONT></FONT> patent system, and a change allowing third-party submission
of prior art to the USPTO during patent prosecution and additional procedures to attack the validity of a patent by USPTO-administered post-grant proceedings, including post-grant review, <I>inter partes </I>review and derivation proceedings. The
USPTO has developed regulations and procedures to govern administration of the Leahy-Smith Act, and many of the substantive changes to patent law associated with the Leahy-Smith Act and, in particular, the <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">&#147;first-inventor-to-file&#148;</FONT></FONT> provisions, became effective in 2013. The Leahy-Smith Act and its implementation may increase the uncertainties and costs surrounding the prosecution of our patent
applications and the enforcement or defense of our issued patents, all of which could have harm our business, financial condition and results of operations. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>We may be unable to obtain intellectual property rights or technology necessary to develop and commercialize <FONT
STYLE="white-space:nowrap">OPT-302</FONT> and any future product candidates. </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">The patent landscape around our programs is complex, and there may be one or more third-party patents and patent applications containing subject matter that might be relevant to <FONT
STYLE="white-space:nowrap">OPT-302.</FONT> Depending on what claims may ultimately issue from these patent applications, and how courts construe the issued patent claims, as well as depending on the ultimate formulation and method of use of <FONT
STYLE="white-space:nowrap">OPT-302</FONT> or any future product candidates, we may need to obtain a license to practice the technology claimed in such patents. There can be no assurance that such licenses will be available on commercially reasonable
terms, or at all. If a third party does not offer us a necessary license or offers a license only on terms that are unattractive or unacceptable to us, we might be unable to develop and commercialize one or more of our product candidates, which
would harm our business, financial condition and results of operations. Moreover, even if we obtain licenses to such intellectual property, but subsequently fail to meet our obligations under the relevant license agreements, or such license
agreements are terminated for any other reasons, we may lose our rights to the technologies licensed under those agreements. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The licensing or acquisition of third-party intellectual property rights is an area in which many companies operate that have interests
that are in conflict with ours, and several more established companies may pursue strategies to license or acquire third-party intellectual property rights that we may consider attractive or necessary. These established companies may have a
competitive advantage over us due to their size, capital resources and greater clinical development and commercialization capabilities. In addition, companies that perceive us to be a competitor may be unwilling to assign or license rights to us. We
also may be unable to license or acquire third-party intellectual property rights on terms that would allow us to make an appropriate return on our investment, or at all. If we are unable to successfully obtain rights to required third-party
intellectual property rights or maintain the existing intellectual property rights we have, we may have to abandon development of the relevant program or product candidate, which could harm our business, financial condition, results of operations
and prospects. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">55 </FONT></P>


</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>We may become involved in lawsuits or other proceedings to protect or enforce our
intellectual property, which could be expensive, time-consuming and unsuccessful and have a negative effect on the success of our business. </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Third parties may infringe our patents or misappropriate or otherwise violate our intellectual property rights. In the future, we may
initiate legal proceedings to enforce or defend our intellectual property rights, to protect our trade secrets or to determine the validity or scope of intellectual property rights we own or control. Also, third parties may initiate legal
proceedings against us to challenge the validity or scope of intellectual property rights we own, control or to which we have rights. For example, generic or biosimilar drug manufacturers or other competitors or third parties may challenge the
scope, validity or enforceability of our patents, requiring us to engage in complex, lengthy and costly litigation or other proceedings. These proceedings can be expensive and time-consuming and many of our adversaries in these proceedings may have
the ability to dedicate substantially greater resources to prosecuting these legal actions than we can. Accordingly, despite our efforts, we may not be able to prevent third parties from infringing upon or misappropriating intellectual property
rights we own, control or have rights to, particularly in countries where the laws may not protect those rights as fully as in the United States. Litigation could result in substantial costs and diversion of management resources, which could harm
our business and financial results. In addition, if we initiated legal proceedings against a third party to enforce a patent covering a product candidate, the defendant could counterclaim that such patent is invalid or unenforceable. In patent
litigation in the United States, defendants usually assert counterclaims alleging invalidity or unenforceability. Grounds for a validity challenge could be an alleged failure to meet any of several statutory requirements, including lack of novelty,
obviousness or <FONT STYLE="white-space:nowrap">non-enablement.</FONT> Grounds for an unenforceability assertion could be an allegation that someone connected with prosecution of the patent withheld relevant information from the USPTO, or made a
misleading statement, during prosecution. In an infringement or declaratory judgment proceeding, a court may decide that a patent owned by or licensed to us is invalid or unenforceable, or may refuse to stop the other party from using the subject
matter alleged to be infringing on the grounds that our patents do not cover that subject matter. An adverse result in any litigation proceeding could put one or more of our patents at risk of being invalidated, narrowed, held unenforceable or
interpreted in such a manner that would not preclude third parties from entering the market with competing products. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Third-party <FONT STYLE="white-space:nowrap">pre-issuance</FONT> submission of prior art to the USPTO, or opposition, derivation,
revocation, reexamination, <I>inter partes </I>review or interference proceedings, or other <FONT STYLE="white-space:nowrap">pre-issuance</FONT> or post-grant proceedings or other patent office proceedings or litigation in the United States or other
jurisdictions provoked by third parties or brought by us, may be necessary to determine the inventorship, priority, patentability or validity of inventions with respect to our patents or patent applications. An unfavorable outcome could leave our
technology or product candidates without patent protection, allow third parties to commercialize our technology or product candidates and compete directly with us, without payment to us, or could require us to obtain license rights from the
prevailing party in order to be able to manufacture or commercialize our product candidates without infringing third-party patent rights. Our business could be harmed if the prevailing party in such a case does not offer us a license on commercially
reasonable terms, or at all. Even if we obtain a license, it may be <FONT STYLE="white-space:nowrap">non-exclusive,</FONT> thereby giving our competitors access to the same technologies licensed to us. In addition, if the breadth or strength of
protection provided by our patents and patent applications is threatened, it could dissuade companies from collaborating with us to license, develop or commercialize current or future product candidates. Even if we successfully defend such
litigation or proceeding, we may incur substantial costs and our defense may distract our management and other employees. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk
that some of our confidential information could be compromised by disclosure during this type of litigation. In addition, many <FONT STYLE="white-space:nowrap">non-U.S.</FONT> jurisdictions have rules of discovery that are different than those in
the United States and that may make defending or enforcing our patents extremely difficult. There could also be public announcements of the results of hearings, motions or other interim proceedings or developments. If securities analysts or
investors perceive these results to be negative, it could negatively affect the price of the ADSs and our ordinary shares. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">56 </FONT></P>


</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Third parties may initiate legal proceedings against us alleging that we infringe
their intellectual property rights or we may initiate legal proceedings against third parties to challenge the validity or scope of intellectual property rights controlled by third parties, the outcome of which would be uncertain and could harm our
business. </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our commercial success depends
upon our ability to develop, manufacture, market and sell <FONT STYLE="white-space:nowrap">OPT-302</FONT> and any future product candidates that we may develop and use our proprietary technologies without infringing, misappropriating or otherwise
violating the intellectual property and proprietary rights of third parties. The biotechnology and pharmaceutical industries are characterized by extensive litigation regarding patents and other intellectual property rights. Third parties may
initiate legal proceedings against us alleging that we infringe their intellectual property rights or we may initiate legal proceedings against third parties to challenge the validity or scope of intellectual property rights controlled by third
parties, including in oppositions, interferences, revocations, reexaminations, <I>inter partes </I>review or derivation proceedings before the USPTO or its counterparts in other jurisdictions. These proceedings can be expensive and time-consuming
and many of our adversaries in these proceedings may have the ability to dedicate substantially greater resources to prosecuting these legal actions than we can. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We could be found liable for monetary damages, including
treble damages and attorneys&#146; fees, if we are found to have willfully infringed a patent of a third party. A finding of infringement could prevent us from commercializing <FONT STYLE="white-space:nowrap">OPT-302</FONT> or any future product
candidates or force us to cease some of our business operations, which could materially harm our business. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We may not be aware of all third-party intellectual property rights potentially relating to
<FONT STYLE="white-space:nowrap">OPT-302</FONT> or any future product candidates and technologies. We are not aware of any facts that would lead us to conclude that the valid and enforceable claims of any third-party patents would reasonably be
interpreted to cover our product candidates. As to pending third-party applications, we cannot predict with any certainty which claims will issue, if any, or the scope of such issued claims. Even if we believe third-party intellectual property
claims are without merit, there is no assurance that a court would find in our favor on questions of infringement, validity, enforceability or priority. A court of competent jurisdiction could hold that these third-party patents are valid,
enforceable and infringed, which could materially and negatively affect our ability to commercialize any product candidates we may develop and any other product candidates or technologies covered by the asserted third-party patents. In order to
successfully challenge the validity of any such U.S. patent in federal court, we would need to overcome a presumption of validity. As this burden is a high one requiring us to present clear and convincing evidence as to the invalidity of any such
U.S. patent claim, there is no assurance that a court of competent jurisdiction would invalidate the claims of any such U.S. patent. If any such third-party patents (including those that may issue from such applications) were successfully asserted
against us or other commercialization partners and we were unable to successfully challenge the validity or enforceability of any such asserted patents, then we and other commercialization partners may be prevented from commercializing our product
candidates, or may be required to pay significant damages, including treble damages and attorneys&#146; fees if we are found to willfully infringe the asserted patents, or obtain a license to such patents, which may not be available on commercially
reasonable terms, or at all. Even if we were able to obtain a license, it could be <FONT STYLE="white-space:nowrap">non-exclusive,</FONT> thereby giving our competitors and other third parties access to the same technologies licensed to us, and it
could require us to make substantial licensing and royalty payments. Any of the foregoing would harm our business, financial condition and operating results. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Although we have reviewed certain third-party patents and patent filings that we believe may be relevant to our therapeutic candidates or
products, we have not conducted a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">freedom-to-operate</FONT></FONT> search or analysis for any of our therapeutic candidates or products, and we may not be aware of patents or pending
or future patent applications that, if issued, would block us from commercializing our therapeutic candidates or products. Thus, we cannot guarantee that our therapeutic candidates or products, or our commercialization thereof, do not and will not
infringe any third party&#146;s intellectual property. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">57 </FONT></P>


</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>We may be subject to claims by third parties asserting misappropriation of
intellectual property, or claiming ownership of what we regard as our own intellectual property. </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Although we seek to ensure that our employees do not use the proprietary information or <FONT STYLE="white-space:nowrap">know-how</FONT>
of others in their work for us, we may be subject to claims that we or these employees have used or disclosed confidential information or intellectual property, including trade secrets or other proprietary information, of any such employee&#146;s
former employer, or that third parties have an interest in our patents as an inventor or <FONT STYLE="white-space:nowrap">co-inventor.</FONT> Litigation may be necessary to defend against these claims. If we fail in prosecuting or defending any such
claims, in addition to paying monetary damages, we may lose valuable intellectual property rights or the services of personnel or sustain other damages. Such intellectual property rights could be awarded to a third party, and we could be required to
obtain a license from such third party to commercialize our technology or products. Such a license may not be available on commercially reasonable terms, or at all. Even if we successfully prosecute or defend against such claims, litigation could
result in substantial costs and distract management. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">In addition, while it is our policy to require our employees and contractors who may be involved in the conception or development of intellectual property to execute agreements assigning such intellectual
property to us, we may be unsuccessful in executing such an agreement with each party who, in fact, conceives or develops intellectual property that we regard as our own. The assignment of intellectual property rights may not be self-executing, or
the assignment agreements may be breached, and we may be forced to bring claims against third parties, or defend claims that they may bring against us, to determine the ownership of what we regard as our intellectual property. Such claims could harm
our business, financial condition, results of operations and prospects. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B><I>Our inability to protect our confidential information and trade secrets would harm our business and competitive position. </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT
SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In addition to seeking patents for some of our technology and product candidates, we also rely substantially on
trade secrets, including unpatented <FONT STYLE="white-space:nowrap">know-how,</FONT> technology and other proprietary materials and information, to maintain our competitive position. We seek to protect these trade secrets, in part, by entering into
<FONT STYLE="white-space:nowrap">non-disclosure</FONT> and confidentiality agreements with parties who have access to them, such as our employees, corporate collaborators, outside scientific collaborators, contract manufacturers, consultants,
advisors and other third parties. We also enter into confidentiality and invention or patent assignment agreements with our employees and consultants. However, these steps may be inadequate, we may fail to enter into agreements with all such parties
or any of these parties may breach the agreements and disclose our trade secrets and there may be no adequate remedy available for such breach of an agreement. We cannot assure you that our trade secrets will not be disclosed or that we can
meaningfully protect our trade secrets. Enforcing a claim that a party illegally disclosed or misappropriated a trade secret is difficult, expensive and time consuming, and the outcome is unpredictable. In addition, some courts both within and
outside the United States may be less willing, or unwilling, to protect trade secrets. If a competitor lawfully obtained or independently developed any technology or information that we protect as trade secret, we would have no right to prevent such
competitor from using that technology or information to compete with us, which could harm our competitive position. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Intellectual property rights do not necessarily address all potential threats. </I></B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The degree of future protection afforded by our intellectual
property rights is uncertain because intellectual property rights have limitations and may not adequately protect our business or permit us to maintain our competitive advantage. For example: </FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT
SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">others may be able to make products that are similar to <FONT STYLE="white-space:nowrap">OPT-302</FONT> and any future product candidates we may
develop or utilize similar technology but that are not covered by the claims of the patents that we exclusively license or may own in the future; </FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">58 </FONT></P>


</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">we, our licensors or our future collaborators, might not have been the first to make the inventions covered by the issued patents and pending patent
applications that we exclusively license or may own in the future; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">we, our licensors or our future collaborators, might not have been the first to file patent applications covering certain of our or their inventions;
</FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">others may independently develop similar or alternative technologies or duplicate any of our technologies without infringing our owned or exclusively
licensed intellectual property rights; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">it is possible that our pending patent applications or those that we may file in the future, including those that we have licensed, will not result in
issued patents; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">issued patents to which we hold rights may be held invalid or unenforceable, including as a result of legal challenges by our competitors;
</FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">our competitors might conduct research and development activities in countries where we do not have patent rights and then use the information learned
from such activities to develop competitive products for sale in major commercial markets in which we do not have sufficient patent rights to stop such sales; </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">we may not develop additional proprietary technologies that are patentable; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT
SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the patents of others may be asserted against our product candidates and technologies in a manner that harms our business; and
</FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">we may choose not to file a patent application in order to maintain certain trade secrets or <FONT STYLE="white-space:nowrap">know-how,</FONT> and a
third party may subsequently file a patent covering such trade secrets or <FONT STYLE="white-space:nowrap">know-how.</FONT> </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Should any of these events occur, they could harm our business, financial condition, results of operations and prospects. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>If our trademarks and trade names are not maintained
and adequately protected, we may not be able to build name recognition in our markets of interest, and our business may be negatively affected. </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Failure to obtain trademark registrations in the future, could limit our ability to protect and enforce our trademarks and impede our
marketing efforts in the countries in which we operate. We may not be able to protect our rights to trademarks and trade names which we may need to build name recognition with potential partners or customers in our markets of interest. As a means to
enforce any future trademark rights and prevent infringement, we may be required to file trademark claims against third parties or initiate trademark opposition proceedings. This can be expensive and time consuming and can strain the financial
resources of a company of our size, and we may not be successful in enforcing our trademark rights. In addition, our registered or unregistered trademarks or trade names may be challenged, infringed, circumvented, declared generic or determined to
be infringing on other marks. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Future trademark
applications in the United States and in other <FONT STYLE="white-space:nowrap">non-U.S.</FONT> jurisdictions where we may file may not be allowed or may subsequently be opposed. Even if these applications result in registration of trademarks, third
parties may challenge our use or registration of these trademarks in the future. Over the long term, if we are unable to establish name recognition based on our trademarks and trade names, then we may not be able to compete effectively and our
business may be negatively affected. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Our
product candidates may face competition sooner than anticipated from biosimilar products. </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Even if we are successful in achieving regulatory approval to commercialize a product candidate faster than our competitors, our product candidates may face competition from biosimilar products. In the
United States, our product candidates are regulated by the FDA. The Biologics Price Competition and Innovation Act of 2009, or BPCIA, created an abbreviated pathway for the approval of biosimilar and interchangeable biologic products. The
abbreviated regulatory pathway establishes legal authority for the FDA to review and approve biosimilar </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">59 </FONT></P>


</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
biologics, including the possible designation of a biosimilar as &#147;interchangeable&#148; based on its similarity to an existing brand product. Under the BPCIA, an application for a biosimilar
product cannot be approved by the FDA until 12 years after the original branded product was approved under a BLA. The law is complex and is still being interpreted and implemented by the FDA. As a result, its ultimate impact, implementation, and
meaning are subject to uncertainty. While it is uncertain when such processes intended to implement BPCIA may be fully adopted by the FDA, any such processes could have a material adverse effect on the future commercial prospects for our product
candidates. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">There is a risk that any exclusivity
we may be afforded if any of our product candidates are approved as a biologic product under a BLA could be shortened due to congressional action or otherwise, or that the FDA will not consider our product candidates to be reference products for
competing products, potentially creating the opportunity for generic or biosimilar competition sooner than anticipated. Moreover, the extent to which a biosimilar product, once approved, will be substituted for any one of our reference products in a
way that is similar to traditional generic substitution for <FONT STYLE="white-space:nowrap">non-biologic</FONT> products is not yet clear, and will depend on a number of marketplace and regulatory factors that are still developing. In addition, a
competitor could decide to forego the biosimilar approval path and submit a full BLA after completing its own preclinical studies and clinical trials. In such cases, any exclusivity to which we may be eligible under the BPCIA would not prevent the
competitor from marketing its product as soon as it is approved. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">In Europe, the European Commission has granted marketing authorizations for several biosimilar products pursuant to a set of general and product class-specific guidelines for biosimilar approvals issued
over the past few years. In Europe, a competitor may reference data supporting approval of an innovative biological product, but will not be able to market it until 10 years after the time of approval of the innovative product. This <FONT
STYLE="white-space:nowrap">10-year</FONT> marketing exclusivity period may be extended to 11 years if, during the first eight of those 10 years, the marketing authorization holder obtains an approval for one or more new therapeutic indications that
bring significant clinical benefits compared with existing therapies. In addition, companies may be developing biosimilar products in other countries that could compete with our products, if approved. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">If competitors are able to obtain marketing approval for
biosimilars referencing our product candidates, if approved, such products may become subject to competition from such biosimilars, with the attendant competitive pressure and potential adverse consequences. Such competitive products may be able to
immediately compete with us in each indication for which our product candidates may have received approval. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>Risks Related to Ownership of the ADSs and this Offering </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>There has been no prior market for the ADSs and an active and liquid market for our securities may fail to develop, which could harm
the market price of the ADSs. </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>  <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">While
our ordinary shares have been listed on the Australian Securities Exchange, or ASX, since 1985, and certain ADSs have been traded on the over-the-counter market in the United States since June 2011 through our existing sponsored Level&nbsp;I ADR
facility with The Bank of New York Mellon, as depositary, prior to this offering, there has been no public market on a U.S. national securities exchange for our ordinary shares or ADSs. Although we anticipate that the ADSs will be approved for
listing on Nasdaq, an active trading market for the ADSs may never develop or be sustained following this offering. The initial offering price of the ADSs will be determined through negotiations between us and the underwriters and will be based, in
part, on prevailing market prices of our ordinary shares on the ASX, after taking into account market conditions and other factors. This offering price may not be indicative of the market price of the ADSs after this offering. In the absence of an
active trading market for the ADSs, investors may not be able to sell their ADSs at or above the offering price or at the time that they would like to sell. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">60 </FONT></P>


</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>The trading price and volume of the ADSs may be volatile, and purchasers of the
ADSs could incur substantial losses. </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The
price and trading volumes of our ordinary shares and ADSs may be significantly affected by events such as announcements regarding scientific and clinical results concerning product candidates currently being developed by us, our collaboration
partners or our main competitors, changes in market conditions related to our sector of activity, announcements of new contracts, technological innovations and collaborations by us or our main competitors, developments concerning intellectual
property rights, as well as the development, regulatory approval and commercialization of new products by us or our main competitors and changes in our financial results. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In addition, equity markets may be subject to considerable
price and trading volume fluctuations, and often, these movements do not reflect the operational and financial performance of the listed companies concerned. In particular, biotechnology companies&#146; share prices have been highly volatile in the
past and may continue to be highly volatile in the future. As we operate in a single industry, we are especially vulnerable to these factors to the extent that they affect our industry. Fluctuations in the stock market as well as the macroeconomic
environment could significantly affect the price of the ADSs. As a result of this volatility, investors may not be able to sell their ADSs at or above the price originally paid for the security. The market price and trading volume for the ADSs may
be influenced by many factors, including: </FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">actual or anticipated fluctuations in our financial condition and operating results; </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">actual or anticipated changes in our growth rate relative to our competitors; </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">competition from existing products or new products that may emerge; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT
SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">announcements by us or our competitors of significant acquisitions, divestitures, spin-offs, strategic partnerships, joint ventures, collaborations,
capital commitments or changes in business strategy; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">adverse results of delays in our or any of our competitors&#146; preclinical studies or clinical trials; </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">adverse regulatory decisions, including failure to receive regulatory approval for any of our product candidates; </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the termination of a strategic alliance or the inability to establish additional strategic alliances; </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">failure to meet or exceed financial estimates and projections of the investment community or that we provide to the public;
</FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">issuance of new or updated research or reports by securities analysts; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT
SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">fluctuations in the valuation of companies perceived by investors to be comparable to us; </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">ADS price and volume fluctuations attributable to inconsistent trading volume levels of the ADSs; </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">price and volume fluctuations in trading of our ordinary shares on the ASX; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT
SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">short selling or other market manipulation activities; </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">fluctuations of exchange rates between the U.S. dollar and the Australian dollar; </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">additions or departures of key management or scientific personnel; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT
SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">disruptions in our supply or manufacturing arrangements; </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">disputes or other developments related to proprietary rights, including patents, litigation matters and our ability to obtain patent and other
intellectual property protection for our technologies; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">changes to coverage policies or reimbursement levels by commercial third-party payors and government payors and any announcements relating to coverage
policies or reimbursement levels; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">litigation involving our company; </FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">61 </FONT></P>


</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">announcement or expectation of additional debt or equity financing efforts; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT
SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">natural disasters or other calamities or disease outbreaks, such as the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic;
</FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">sales of the ADSs by us, our affiliates or our other shareholders; and </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT
SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">general economic and market conditions. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">These and other market and industry factors may cause the market price and demand for the ADSs to fluctuate, regardless of our actual
operating performance, which may limit or prevent investors from readily selling their ADSs and may otherwise negatively affect the liquidity of the trading market for the ADSs. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>If securities or industry analysts do not publish
research or publish inaccurate or unfavorable research about our business, the price of the ADSs and their trading volume could decline. </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The trading market for the ADSs depends in part on the research and reports that securities or industry analysts publish about us or our
business. As a public listed company in Australia since 1985, our equity securities are currently subject to coverage by a number of analysts. If fewer securities or industry analysts cover our company, the trading price for the ADSs could be
negatively impacted. If one or more of the analysts who covers us downgrades our equity securities or publishes incorrect or unfavorable research about our business, the price of the ADSs would likely decline. If one or more of these analysts ceases
coverage of our company or fails to publish reports on us regularly, or downgrades our securities, demand for the ADSs could decrease, which could cause the price of the ADSs or their trading volume to decline. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>We do not currently intend to pay dividends on our
securities and, consequently, your ability to achieve a return on your investment will depend on appreciation in the price of the ADSs. </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We have not declared or paid any cash dividends on our ordinary shares since February 2005 and do not currently intend to do so for the
foreseeable future. We currently intend to invest our future earnings, if any, to fund our operations and growth. Therefore, you are not likely to receive any dividends on your ADSs for the foreseeable future and the success of an investment in the
ADSs will depend upon any future appreciation in its value. Consequently, investors may need to sell all or part of their holdings of the ADSs after price appreciation, which may never occur, as the only way to realize any future gains on their
investment. There is no guarantee that the ADSs will appreciate in value or even maintain the price at which our shareholders have purchased them. Investors seeking cash dividends should consider not purchasing the ADSs. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">While we do not anticipate paying any cash dividends on our
ordinary shares in the foreseeable future, if such a dividend is declared, the depositary for the ADSs has agreed to pay to you the cash dividends or other distributions it or the custodian receives on our ordinary shares or other deposited
securities after deducting its fees and expenses. You will receive these distributions in proportion to the number of our ordinary shares your ADSs represent. However, in accordance with the limitations set forth in the deposit agreement, it may be
unlawful or impractical to make a distribution available to holders of ADSs. We have no obligation to take any other action to permit the distribution of the ADSs, ordinary shares, rights or anything else to holders of the ADSs. This means that you
may not receive the distributions we make on our ordinary shares or any value from them if it is unlawful or impractical to make them available to you. These restrictions may negatively impact the value of your ADSs. In addition, exchange rate
fluctuations may affect the amount of Australian dollars that we are able to distribute, and the amount in U.S. dollars that our shareholders receive upon the payment of cash dividends or other distributions we declare and pay in Australian dollars,
if any. These factors could harm the value of the ADSs, and, in turn, the U.S. dollar proceeds that holders receive from the sale of the ADSs. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>You will experience immediate and substantial dilution in the net tangible book value of the ADSs you purchase in this offering.
</I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The assumed initial public offering
price of the ADSs is substantially higher than the net tangible book value per ADS or per ordinary share immediately after this offering. If you purchase ADSs in this offering, you </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">62 </FONT></P>


</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
will suffer immediate dilution of US$12.82&nbsp;per ADS (or US$1.60&nbsp;per ordinary share), or US$12.45&nbsp;per ADS (or US$1.56&nbsp;per ordinary share) if the underwriters exercise their
option to purchase additional shares in full, representing the difference between our as adjusted net tangible book value per ADS or per ordinary share after giving effect to the sale of ADSs in this offering and the assumed initial public offering
price of US$17.26&nbsp;per ADS, the U.S. dollar equivalent of the last reported sale of price of our ordinary shares on the ASX on October&nbsp;8,&nbsp;2020, after giving effect to the Australian dollar/U.S. dollar exchange rate of A$1.3996 to
US$1.00 as of October&nbsp;8, 2020, and an <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">ADS-to-ordinary</FONT></FONT> share ratio of 1-to-8. See &#147;Dilution.&#148; If outstanding options are exercised in the future, you will
experience additional dilution. </FONT></P>  <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>We
have broad discretion in the use of the net proceeds from this offering and may not use them effectively. </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We will have broad discretion in the application of the net proceeds that we receive from this offering as well as of our existing cash
and cash equivalents and <FONT STYLE="white-space:nowrap">non-current</FONT> financial assets, and we may spend or invest these funds in a way with which our shareholders or holders of the ADSs disagree. Our failure to apply these funds effectively
could harm our business and financial condition. Pending their use, we may invest the net proceeds from the offering in a manner that does not produce income or that loses value. These investments may not yield a favorable return to our investors.
</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Future sales of ordinary shares or ADSs by
existing holders could depress the market price of the ordinary shares or ADSs. </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>  <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Based on 269,157,769&nbsp;ordinary shares outstanding as of June&nbsp;30, 2020, upon the closing of this offering, we will have outstanding a total of 343,557,769&nbsp;ordinary shares (including ordinary
shares represented by ADSs), assuming no exercise of the underwriters&#146; option to purchase additional ADSs and no exercise of outstanding options. Each member of our senior management and board of directors and their affiliates are subject <FONT
STYLE="white-space:nowrap">to&nbsp;lock-up&nbsp;agreements</FONT> with the underwriters that restrict their ability to transfer ordinary shares, options and other securities convertible into, exchangeable for, or exercisable for ordinary shares
during the period ending on, and including, the 90th day after the date of this prospectus, subject to specified exceptions. Citigroup Global Markets Inc.&nbsp;and SVB Leerink LLC&nbsp;may, in their discretion, permit our shareholders who are
subject to <FONT STYLE="white-space:nowrap">these&nbsp;lock-up&nbsp;agreements</FONT> to sell securities prior to the expiration of <FONT STYLE="white-space:nowrap">the&nbsp;lock-up&nbsp;agreements.</FONT> As of the date of this prospectus, the
exercise of all outstanding options exercisable for ordinary shares would enable the subscription of new ordinary shares representing approximately 7.6% of the diluted share capital. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">After <FONT STYLE="white-space:nowrap">the&nbsp;lock-up&nbsp;agreements</FONT> pertaining to this offering
expire, 2,408,861 additional ordinary shares will be eligible for sale in the public market, all of which ordinary shares are held by members of our senior management and board of directors and will be subject to volume limitations under Rule 144
under the Securities Act of 1933, as amended, or the Securities Act. In addition, the ordinary shares subject to subscription under outstanding options exercisable for ordinary shares will become eligible for sale in the public market in the future,
subject to certain legal and contractual limitations. Sales of a large number of the ordinary shares in the public market could depress the market price of the ADSs. See &#147;Shares and American Depository Shares Eligible for Future Sale&#148; for
a more detailed description of sales that may occur in the future. If these additional ordinary shares are sold, or if it is perceived that they will be sold, in the public market, the trading price of the ordinary shares and ADSs could decline
substantially, which could impair our ability to raise additional capital through the issuance of ordinary shares, ADSs or other securities in the future. </FONT></P>  <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>The dual listing of our ordinary shares and the ADSs following this offering may negatively impact the liquidity and value of the
ADSs. </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Following this offering and after
the ADSs are listed on Nasdaq, our ordinary shares will continue to be listed on the ASX. We cannot predict the effect of this dual listing on the value of our ordinary shares and ADSs. However, the dual listing of our ordinary shares and ADSs may
dilute the liquidity of these securities in one or both markets and may negatively impact the development of an active trading market for the ADSs in the United States. The price of the ADSs could also be negatively impacted by trading in our
ordinary shares on the ASX. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">63 </FONT></P>


</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>We are subject to risks associated with currency fluctuations, and changes in
foreign currency exchange rates could impact our results of operations. </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Our ordinary shares are quoted in Australian dollars on the ASX and the ADSs will be quoted in U.S. dollars. In the past year, the Australian dollar has generally weakened against the U.S. dollar;
however, this trend may not continue and may be reversed. As such, any significant change in the value of the Australian dollar may have a negative effect on the value of the ADSs in U.S. dollars. In addition, if the Australian dollar weakens
against the U.S. dollar, then, if we decide to convert our Australian dollars into U.S. dollars for any business purpose, appreciation of the U.S. dollar against the Australian dollar would have a negative effect on the U.S. dollar amount available
to us. While we engage in limited hedging transactions to manage our foreign exchange risk, these activities may not be effective in limiting or eliminating foreign exchange losses. To the extent that we need to convert U.S. dollars we receive from
this offering into Australian dollars for our operations, appreciation of the Australian dollar against the U.S. dollar would have a negative effect on the Australian dollar amount we would receive from the conversion. Consequently, appreciation or
depreciation in the value of the Australian dollar relative to the U.S. dollar would affect our financial results reported in U.S. dollar terms without giving effect to any underlying change in our business or results of operations. As a result of
such foreign currency fluctuations, it could be more difficult to detect underlying trends in our business and results of operations. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>We will incur significant increased costs as a result of operating as a company with ADSs that are publicly traded in the United
States, and our management will be required to devote substantial time to new compliance initiatives. </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">As a company whose ADSs will be publicly traded in the United States, we will incur significant legal, accounting, insurance and other
expenses that we did not previously incur. In addition, the Sarbanes-Oxley Act, Dodd-Frank Wall Street Reform and Consumer Protection Act and related rules implemented by the SEC and Nasdaq have imposed various requirements on public companies
listed in the United States including requiring establishment and maintenance of effective disclosure and financial controls. Our management and other personnel will need to devote a substantial amount of time to these compliance initiatives, and we
will need to add additional personnel and build our internal compliance infrastructure. Moreover, these rules and regulations will increase our legal and financial compliance costs and will make some activities more time-consuming and costly. These
laws and regulations could also make it more difficult and expensive for us to attract and retain qualified persons to serve on our board of directors, our board committees or as our senior management. Furthermore, if we are unable to satisfy our
obligations as a public company listed in the United States, we could be subject to delisting of the ADSs, fines, sanctions and other regulatory action and potentially civil litigation. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>U.S. investors may have difficulty enforcing civil liabilities against our company, our directors or
members of senior management and the experts named in this prospectus. </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Certain members of our senior management and board of directors named in this prospectus are <FONT STYLE="white-space:nowrap">non-residents</FONT> of the United States, and a substantial portion of the
assets of such persons are located outside the United States. As a result, it may be impracticable to serve process on such persons in the United States or to enforce judgments obtained in U.S. courts against them based on civil liability provisions
of the securities laws of the United States. Even if you are successful in bringing such an action, there is doubt as to whether Australian courts would enforce certain civil liabilities under U.S. securities laws in original actions or judgments of
U.S. courts based upon these civil liability provisions. In addition, awards of punitive damages in actions brought in the United States or elsewhere may be unenforceable in Australia or elsewhere outside the United States. An award for monetary
damages under U.S. securities laws would be considered punitive if it does not seek to compensate the claimant for loss or damage suffered and is intended to punish the defendant. The enforceability of any judgment in Australia will depend on the
particular facts of the case as well as the laws and treaties in effect at the time. The United States and Australia do not currently have a treaty or statute providing for recognition and enforcement of the judgments of the other country (other
than arbitration awards) in civil and commercial matters. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">64 </FONT></P>


</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">As a result, our public shareholders may have more difficulty in protecting their
interests through actions against us, our management or our directors than would shareholders of a corporation incorporated in a jurisdiction in the United States. In addition, as a company incorporated in Australia, the provisions of the
Corporations Act 2001 (Cth), or the Corporations Act, regulate the circumstances in which shareholder derivative actions may be commenced which may be different, and in many ways less permissive, than for companies incorporated in the United States.
</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Australian takeover laws may discourage
takeover offers being made for us or may discourage the acquisition of a significant position in our ordinary shares or ADSs. </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We are incorporated in Australia and are subject to the takeover laws of Australia. Among other things, we are subject to the Corporations
Act. Subject to a range of exceptions, the Corporations Act prohibits the acquisition of a direct or indirect interest in our issued voting shares if the acquisition of that interest will lead to a person&#146;s voting power in us increasing to more
than 20%, or increasing from a starting point that is above 20% and below 90%. Australian takeover laws may discourage takeover offers being made for us or may discourage the acquisition of a significant position in our ordinary shares. This may
have the ancillary effect of entrenching our board of directors and may deprive or limit our shareholders&#146; opportunity to sell their ordinary shares and may further restrict the ability of our shareholders to obtain a premium from such
transactions. See &#147;Description of Share Capital&#151;Change of Control.&#148; </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B><I>Our Constitution and Australian laws and regulations applicable to us may adversely affect our ability to take actions that could be beneficial to our shareholders. </I></B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">As an Australian company we are subject to different
corporate requirements than a corporation organized under the laws of the United States. Our Constitution, as well as the Corporations Act, sets forth various rights and obligations that apply to us as an Australian company and which may not apply
to a U.S. corporation. These requirements may operate differently than those of many U.S. companies. You should carefully review the summary of these matters set forth under &#147;Description of Share Capital&#148; as well as our Constitution, which
is included as an exhibit to the registration statement of which this prospectus forms a part, prior to investing in the ADSs. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Purchasers of ADSs in this offering will not be directly holding our ordinary shares. </I></B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">A holder of ADSs will not be treated as one of our
shareholders and will not have direct shareholder rights. Our Constitution and Australian law govern our shareholder rights. The depositary, through the custodian or the custodian&#146;s nominee, will be the holder of the ordinary shares underlying
ADSs held by purchasers of ADSs in this offering. Purchasers of ADSs in this offering will have ADS holder rights. The deposit agreement among us, the depositary and purchasers of ADSs in this offering, as an ADS holder, and all other persons
directly and indirectly holding ADSs, sets out ADS holder rights, as well as the rights and obligations of us and the depositary. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Your right as a holder of ADSs to participate in any future preferential subscription rights offering or to elect to receive
dividends in ordinary shares may be limited, which may cause dilution to your holdings. </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">The deposit agreement provides<B><I></I></B>&nbsp;that the depositary will not make rights available to you unless the distribution to ADS holders of both the<B><I></I></B>&nbsp;rights and any related
securities are either registered under the Securities Act or exempted from registration<B><I></I></B>&nbsp;under the Securities Act. If we offer holders of our ordinary shares the option to receive&nbsp;dividends in either cash or shares, under the
deposit agreement the depositary may require satisfactory<B><I></I></B>&nbsp;assurances from us that extending the offer to holders of ADSs does not require registration of any<B><I></I></B>&nbsp;securities under the Securities Act before making the
option available to holders of ADSs. We are under<B><I></I></B>&nbsp;no obligation to file a registration statement with respect to any such rights or securities or to endeavor to<B><I></I></B>&nbsp;cause such a registration statement to be declared
effective. Moreover, we may not be able to establish an<B><I></I></B>&nbsp;exemption from registration under the Securities Act. Accordingly, ADS holders may be unable to<B><I></I></B>&nbsp;participate in our rights
</FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">65 </FONT></P>


</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
offerings or to elect to receive dividends in shares and may experience dilution in<B><I></I></B>&nbsp;their holdings. In addition, if the depositary is unable to sell rights that are not
exercised or not distributed<B><I></I></B>&nbsp;or if the sale is not lawful or reasonably practicable, it will allow the rights to lapse, in which case you<B><I></I></B>&nbsp;will receive no value for these rights. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>You may not be able to exercise your right to vote the
ordinary shares underlying your ADSs. </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Holders of ADSs may exercise voting rights with respect to the ordinary shares represented by the ADSs only in accordance with the
provisions of the deposit agreement. The deposit agreement provides that, upon receipt of notice of any meeting of holders of our ordinary shares, the depositary will fix a record date for the determination of ADS holders who shall be entitled to
give instructions for the exercise of voting rights. Upon timely receipt of notice from us, if we so request, the depositary shall distribute to the holders as of the record date (i)&nbsp;the notice of the meeting or solicitation of consent or proxy
sent by us and (ii)&nbsp;a statement as to the manner in which instructions may be given by the holders. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">You may instruct the depositary to vote the ordinary shares underlying your ADSs. Otherwise, you will not be able to exercise your right
to vote, unless you withdraw the ordinary shares underlying the ADSs you hold. However, you may not know about the meeting far enough in advance to withdraw those ordinary shares. If we ask for your instructions, the depositary, upon timely notice
from us, will notify you of the upcoming vote and arrange to deliver our voting materials to you and will try to vote ordinary shares as you instruct. We cannot guarantee you that you will receive the voting materials in time to ensure that you can
instruct the depositary to vote your ordinary shares or to withdraw your ordinary shares so that you can vote them yourself. If we do not ask for your instructions, you can still send voting instructions to the depository and the depository may try
to carry out those instructions, but it is not required to do so. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Under our Constitution, any resolution to be considered at a meeting of the shareholders shall be decided on a show of hands unless a poll is demanded in accordance with the terms of our Constitution. A
poll may be demanded before a vote is taken, or, in the case of a vote taken on a show of hands, immediately before or immediately after, the declaration of the result of the show of hands. Under voting by a show of hands, multiple &#147;yes&#148;
votes by ADS holders will only count as one &#147;yes&#148; vote and will be negated by a single &#147;no&#148; vote, unless a poll is demanded. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>You may be subject to limitations on the transfer of your ADSs and the withdrawal of the underlying ordinary shares.
</I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Your ADSs are transferable on the books
of the depositary. However, the depositary may close its books at any time or from time to time when it deems expedient in connection with the performance of its duties. The depositary may refuse to deliver, transfer or register transfers of your
ADSs generally when our books or the books of the depositary are closed, or at any time if we or the depositary think it is advisable to do so because of any requirement of law, government or governmental body, or under any provision of the deposit
agreement, or for any other reason subject to your right to surrender your ADSs and receive the underlying ordinary shares. Temporary delays in the surrendering of your ADSs and receipt of the underlying ordinary shares may arise because the
depositary has closed its transfer books or we have closed our transfer books, the transfer of ordinary shares is blocked to permit voting at a shareholders&#146; meeting or we are paying a dividend on our ordinary shares. In addition, you may not
be able to surrender your ADSs and receive the underlying ordinary shares when you owe money for fees, taxes and similar charges and when it is necessary to prohibit withdrawals in order to comply with any laws or governmental regulations that apply
to ADSs or to the withdrawal of ordinary shares or other deposited securities. See &#147;Description of American Depositary Shares.&#148; </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Holders of ADSs are not treated as holders of our ordinary shares. </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT
SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">By participating in this offering you will become a holder of ADSs with underlying ordinary shares in an
Australian public listed company. Holders of ADSs are not treated as holders of our ordinary shares, unless they surrender the ADSs to receive the ordinary shares underlying their ADSs in accordance with the deposit
</FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">66 </FONT></P>


</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
agreement and applicable laws and regulations. The depositary is the holder of the ordinary shares underlying the ADSs. Holders of ADSs therefore do not have any rights as holders of our ordinary
shares, other than the rights that they have pursuant to the deposit agreement. See &#147;Description of American Depositary Shares.&#148; </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>ADS holders may not be entitled to a jury trial with respect to claims arising under the deposit agreement, which could result in
less favorable outcomes to the plaintiff(s) in any such action. </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">The deposit agreement governing the ADSs provides that holders and beneficial owners of ADSs, including those holders and owners who acquired ADSs in secondary transactions, irrevocably waive the right to
a trial by jury in any legal proceeding arising out of or relating to the deposit agreement or the ADSs, including in respect of claims under federal securities laws, against us or the depositary to the fullest extent permitted by applicable law. If
this jury trial waiver provision is prohibited by applicable law, an action could nevertheless proceed under the terms of the deposit agreement with a jury trial. To our knowledge, the enforceability of a jury trial waiver under the federal
securities laws has not been finally adjudicated by a federal court. However, we believe that a jury trial waiver provision is generally enforceable under the laws of the State of New York, which govern the deposit agreement, by a court of the State
of New York or a federal court, which have non-exclusive jurisdiction over matters arising under the deposit agreement, applying such law. In determining whether to enforce a jury trial waiver provision, New York courts and federal courts will
consider whether the visibility of the jury trial waiver provision within the agreement is sufficiently prominent such that a party has knowingly waived any right to trial by jury. We believe that this is the case with respect to the deposit
agreement and the ADSs. In addition, New York courts will not enforce a jury trial waiver provision in order to bar a viable setoff or counterclaim sounding in fraud or one which is based upon a creditor&#146;s negligence in failing to liquidate
collateral upon a guarantor&#146;s demand, or in the case of an intentional tort claim (as opposed to a contract dispute), none of which we believe are applicable in the case of the deposit agreement or the ADSs. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">No condition, stipulation or provision of the deposit
agreement or ADSs serves as a waiver by any holder or beneficial owner of ADSs or by us or the depositary of compliance with any provision of the federal securities laws. If you or any other holder or beneficial owner of ADSs brings a claim against
us or the depositary in connection with such matters, you or such other holder or beneficial owner may not be entitled to a jury trial with respect to such claims, which may have the effect of limiting and discouraging lawsuits against us and/or the
depositary. If a lawsuit is brought against us and/or the depositary under the deposit agreement, it may be heard only by a judge or justice of the applicable trial court, which would be conducted according to different civil procedures and may
result in different outcomes than a trial by jury would have had, including results that could be less favorable to the plaintiff(s) in any such action, depending on, among other things, the nature of the claims, the judge or justice hearing such
claims, and the venue of the hearing. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">As the jury
trial waiver relates to claims arising out of or relating to the ADSs or the deposit agreement, we believe that the waiver would likely continue to apply to ADS holders or beneficial owners who withdraw the ordinary shares from the ADS facility with
respect to claims arising before the cancellation of the ADSs and the withdrawal of the ordinary shares, and the waiver would likely not apply to ADS holders or beneficial owners who subsequently withdraw the ordinary shares represented by ADSs from
the ADS facility with respect to claims arising after the withdrawal. However, to our knowledge, there has been no case law on the applicability of the jury trial waiver to ADS holders or beneficial owners who withdraw the ordinary shares
represented by the ADSs from the ADS facility. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>We currently report our financial results under IFRS, which differs in certain significant respect from U.S. generally accepted
accounting principles, or U.S. GAAP. </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Currently we report our financial statements under IFRS. There have been and there may in the future be certain significant differences
between IFRS and U.S. GAAP, including differences related to revenue recognition, intangible assets, share-based compensation expense, income tax and earnings per share. As a result, our financial information and reported earnings for historical or
future periods could be significantly different if they were prepared in accordance with U.S. GAAP. In addition, we do not intend to provide a reconciliation </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">67 </FONT></P>


</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
between IFRS and U.S. GAAP unless it is required under applicable law. As a result, you may not be able to meaningfully compare our financial statements under IFRS with those companies that
prepare financial statements under U.S. GAAP. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>As a foreign private issuer, we are exempt from a number of rules under the U.S. securities laws and are permitted to file less
information with the SEC than a U.S. company. </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">We are a foreign private issuer, as defined in the SEC&#146;s rules and regulations and, consequently, we are not subject to all of the disclosure requirements applicable to public companies organized
within the United States. For example, we are exempt from certain rules under the Exchange Act that regulate disclosure obligations and procedural requirements related to the solicitation of proxies, consents or authorizations applicable to a
security registered under the Exchange Act, including the U.S. proxy rules under Section&nbsp;14 of the Exchange Act. In addition, our senior management and directors are exempt from the reporting and &#147;short-swing&#148; profit recovery
provisions of Section&nbsp;16 of the Exchange Act and related rules with respect to their purchases and sales of our securities. Moreover, while we currently make annual and semi-annual filings with respect to our listing on the ASX and expect to
file financial reports on an annual and semi-annual basis, we will not be required to file periodic reports and financial statements with the SEC as frequently or as promptly as U.S. public companies and will not be required to file quarterly
reports on <FONT STYLE="white-space:nowrap">Form&nbsp;10-Q&nbsp;or</FONT> current reports on <FONT STYLE="white-space:nowrap">Form&nbsp;8-K&nbsp;under</FONT> the Exchange Act. In addition, foreign private issuers are not required to file their
annual report <FONT STYLE="white-space:nowrap">on&nbsp;Form&nbsp;20-F&nbsp;until</FONT> four months after the end of each fiscal year. Accordingly, there may be less publicly available information concerning our company than there would be if we
were not a foreign private issuer. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>As a
foreign private issuer, we are permitted to adopt certain home country practices in relation to corporate governance matters that differ significantly from Nasdaq corporate governance listing standards and these practices may afford less protection
to shareholders than they would enjoy if we complied fully with Nasdaq&nbsp;corporate governance listing standards. </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">As a foreign private issuer listed on Nasdaq, we will be subject to their corporate governance listing standards. However, Nasdaq rules
permit foreign private issuers to follow the corporate governance practices of its home country. Some corporate governance practices in Australia may differ from Nasdaq&nbsp;corporate governance listing standards. For example, we could <FONT
STYLE="white-space:nowrap">include&nbsp;non-independent&nbsp;directors</FONT> as members of our Remuneration and Nomination committees, and our independent directors may not necessarily hold regularly scheduled meetings at which only independent
members of the board of directors are present. Currently, we intend to follow home country practice to the maximum extent possible. Therefore, our shareholders may be afforded less protection than they otherwise would have under corporate governance
listing standards applicable to U.S. domestic issuers. For an overview of our corporate governance practices, see &#147;Management.&#148; </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>We may lose our foreign private issuer status in the future, which could result in significant additional cost and expense.
</I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">While we currently qualify as a foreign
private issuer, the determination of foreign private issuer status is made annually on the last business day of an issuer&#146;s most recently completed second fiscal quarter and, accordingly, our next determination will be made on June&nbsp;30,
2021. In the future, we would lose our foreign private issuer status if we to fail to meet the requirements necessary to maintain our foreign private issuer status as of the relevant determination date. For example, if 50% or more of our securities
are held by U.S. residents and more than 50% of our senior management or directors are residents or citizens of the United States, we could lose our foreign private issuer status. Immediately following the closing of this offering, approximately
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;% of our outstanding ordinary shares (including ordinary shares in the form of ADSs) will likely be held by U.S. residents (assuming that all purchasers
in this offering are residents of the United States). </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">The regulatory and compliance costs to us under U.S. securities laws as a U.S. domestic issuer may be significantly more than costs we incur as a foreign private issuer. If we are not a foreign private
issuer, we will be required to file periodic reports and registration statements on U.S. domestic issuer forms with the SEC, which </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">68 </FONT></P>


</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
are more detailed and extensive in certain respects than the forms available to a foreign private issuer. We would be required under current SEC rules to prepare our financial statements in
accordance with U.S. GAAP rather than IFRS, and modify certain of our policies to comply with corporate governance practices required of U.S. domestic issuers. Such conversion of our financial statements to U.S. GAAP would involve significant time
and cost. In addition, we may lose our ability to rely upon exemptions from certain corporate governance requirements on U.S. stock exchanges that are available to foreign private issuers such as the ones described above and exemptions from
procedural requirements related to the solicitation of proxies. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B><I>We are an &#147;emerging growth company&#148; under the JOBS Act and will be able to avail ourselves of reduced disclosure requirements applicable to emerging growth companies, which could make our
ordinary shares ADSs less attractive to investors. </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">We are an &#147;emerging growth company,&#148; as defined in the JOBS Act, and we intend to take advantage of certain exemptions from various reporting requirements that are applicable to other public
companies that are not &#147;emerging growth companies,&#148; including not being required to comply with the auditor attestation requirements of Section&nbsp;404(b) of the Sarbanes-Oxley Act, and exemptions from the requirements of holding a
nonbinding advisory vote on executive compensation and shareholder approval of any golden parachute payments not previously approved. In addition, Section&nbsp;107 of the JOBS Act also provides that an emerging growth company can take advantage of
the extended transition period provided in Section&nbsp;7(a)(2)(B) of the Securities Act, for complying with new or revised accounting standards. We will not take advantage of the extended transition period provided under Section&nbsp;7(a)(2)(B) of
the Securities Act for complying with new or revised accounting standards. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">We cannot predict if investors will find the ordinary shares or ADSs less attractive because we may rely on these exemptions. If some investors find the ordinary shares or ADSs less attractive as a
result, there may be a less active trading market for the ordinary shares or ADSs and the price of the ordinary shares or ADSs may be more volatile. We may take advantage of these exemptions until such time that we are no longer an emerging growth
company. We would cease to be an emerging growth company upon the earliest to occur of (i)&nbsp;the last day of the fiscal year in which we have more than $1.07&nbsp;billion in annual revenue; (ii)&nbsp;the last day of the fiscal year in which we
qualify as a &#147;large accelerated filer&#148;; (iii)&nbsp;the date on which we have, during the previous three-year period, issued more than $1.0&nbsp;billion <FONT STYLE="white-space:nowrap">in&nbsp;non-convertible&nbsp;debt</FONT>
securities;&nbsp;and (iv)&nbsp;the last day of the fiscal year in which the fifth anniversary of this offering occurs. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>If we are a passive foreign investment company, there could be adverse U.S. federal income tax consequences to U.S. holders.
</I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Based on the nature and composition of
our income, assets, activities and market capitalization for our taxable year ended June&nbsp;30, 2019, we believe that we were not classified as a passive foreign investment company, or PFIC, for the taxable year ended June&nbsp;30, 2019. Based on
the nature and composition of our income, assets, activities and market capitalization for our taxable year ended June&nbsp;30, 2020, we believe that we would not be classified as a PFIC for the taxable year ended June&nbsp;30, 2020. However, there
can be no assurance that we will not be considered a PFIC in any past, current or future taxable year. A separate determination must be made after the close of each taxable year as to whether we are a PFIC for that year. As a result, our PFIC status
may change from year to year. Our status as a PFIC will depend on the composition of our income (including whether we receive certain grants or subsidies and whether such amounts will constitute gross income for purposes of the PFIC income test) and
the composition and value of our assets, which may be determined in large part by reference to the market value of the ADSs and our ordinary shares, which may be volatile, from time to time. Our status may also depend, in part, on how quickly we
utilize the cash proceeds from this offering in our business. Our U.S. counsel expresses no opinion regarding our conclusions or our expectations regarding our PFIC status. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Under the Code,
<FONT STYLE="white-space:nowrap">a&nbsp;non-U.S.&nbsp;company</FONT> will be considered a PFIC for any taxable year in which (1) 75% or more of its gross income consists of passive income or (2) 50% or more of the average quarterly value of its
assets consists of assets that produce, or are held for the production of, passive income. For purposes of these tests, passive income includes dividends, interest, gains from the sale or exchange of investment property and
</FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">69 </FONT></P>


</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
certain rents and royalties. In addition, for purposes of the above calculations, <FONT STYLE="white-space:nowrap">a&nbsp;non-U.S.&nbsp;corporation</FONT> that directly or indirectly owns at
least 25% by value of the shares of another corporation is treated as if it held its proportionate share of the assets and received directly its proportionate share of the income of such other corporation. If we are a PFIC for any taxable year
during which a U.S. holder (as defined in the section titled &#147;Material United States Federal Income Tax and Australian Tax Considerations&#151;Material United States Federal Income Tax Considerations&#148;) holds our ordinary shares or ADSs, we
will continue to be treated as a PFIC with respect to such U.S. holder in all succeeding years during which the U.S. holder owns the ordinary shares or ADSs, regardless of whether we continue to meet the PFIC test described above, unless the U.S.
holder is eligible to make and makes a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">mark-to-market</FONT></FONT> election or makes a specified election once we cease to be a PFIC. If we are classified as a PFIC for any taxable
year during which a U.S. holder holds our ordinary shares or ADSs, the U.S. holder may be subject to adverse tax consequences regardless of whether we continue to qualify as a PFIC, including ineligibility for any preferred tax rates on capital
gains or on actual or deemed dividends, interest charges on certain taxes treated as deferred, and additional reporting requirements. For further discussion of the PFIC rules and the adverse U.S. federal income tax consequences in the event we are
classified as a PFIC, see &#147;Material United States Federal Income Tax and Australian Tax Considerations&#151;Material United States Federal Income Tax Considerations.&#148; </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>If a United States person is treated as owning at least
10% of our ordinary shares, such holder may be subject to adverse U.S. federal income tax consequences. </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">If a U.S. holder is treated as owning, directly, indirectly or constructively, at least 10% of the value or voting power of our ordinary
shares or ADSs, such U.S. holder may be treated as a &#147;United States shareholder&#148; with respect to each &#147;controlled foreign corporation&#148; in our group, if any. While our group does not currently include any U.S. subsidiaries, if we
form or acquire any U.S. subsidiaries in the future any of our <FONT STYLE="white-space:nowrap">current&nbsp;non-U.S.&nbsp;subsidiaries</FONT> and any future newly formed or
<FONT STYLE="white-space:nowrap">acquired&nbsp;non-U.S.&nbsp;subsidiaries</FONT> will be treated as controlled foreign corporations, regardless of whether we are treated as a controlled foreign corporation. A United States shareholder of a
controlled foreign corporation may be required to annually report and include in its U.S. taxable income its pro rata share of &#147;Subpart F income,&#148; &#147;global
<FONT STYLE="white-space:nowrap">intangible&nbsp;low-taxed&nbsp;income&#148;</FONT> and investments in U.S. property by controlled foreign corporations, regardless of whether we make any distributions. An individual that is a United States
shareholder with respect to a controlled foreign corporation generally would not be allowed certain tax deductions or foreign tax credits that would be allowed to a United States shareholder that is a U.S. corporation. Failure to comply with
controlled foreign corporation reporting obligations may subject a United States shareholder to significant monetary penalties. We cannot provide any assurances that we will furnish to any United States shareholder information that may be necessary
to comply with the reporting and tax paying obligations applicable under the controlled foreign corporation rules of the Code. U.S. holders should consult their tax advisors regarding the potential application of these rules to their investment in
our ordinary shares or ADSs. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Future changes
to tax laws could materially adversely affect our company and reduce net returns to our shareholders. </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our tax treatment is subject to the enactment of, or changes in, tax laws, regulations and treaties, or the interpretation thereof, tax
policy initiatives and reforms under consideration and the practices of tax authorities in jurisdictions in which we operate, including those related to the Organization for Economic <FONT STYLE="white-space:nowrap">Co-Operation</FONT> and
Development&#146;s Base Erosion and Profit Shifting Project, the European Commission&#146;s state aid investigations and other initiatives. Such changes may include (but are not limited to) the taxation of operating income, investment income,
dividends received or (in the specific context of withholding tax) dividends paid. We are unable to predict what tax reform may be proposed or enacted in the future or what effect such changes would have on our business, but such changes, to the
extent they are brought into tax legislation, regulations, policies or practices, could affect our financial position and overall or effective tax rates in the future in countries where we have operations, reduce
<FONT STYLE="white-space:nowrap">post-tax</FONT> returns to our shareholders, and increase the complexity, burden and cost of tax compliance. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">70 </FONT></P>


</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="rom947560_5"></A>SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS
</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">This prospectus contains forward-looking
statements about us and our industry that involve substantial risks and uncertainties. All statements other than statements of historical facts contained in this prospectus, including statements regarding our future results of operations, financial
condition, business strategy and plans and objectives of management for future operations, are forward-looking statements. In some cases, you can identify forward-looking statements because they contain words such as &#147;anticipate,&#148;
&#147;believe,&#148; &#147;contemplate,&#148; &#147;continue,&#148; &#147;could,&#148; &#147;estimate,&#148; &#147;expect,&#148; &#147;intend,&#148; &#147;may,&#148; &#147;plan,&#148; &#147;potential,&#148; &#147;predict,&#148; &#147;project,&#148;
&#147;should,&#148; &#147;target,&#148; &#147;will,&#148; or &#147;would,&#148; or the negative of these words or other similar terms or expressions. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We have based these forward-looking statements largely on our current expectations and projections about future events and trends that we
believe may affect our financial condition, results of operations, business strategy and financial needs. These forward-looking statements are subject to a number of known and unknown risks, uncertainties, other factors and assumptions, including
the risks described in &#147;Risk Factors&#148; and elsewhere in this prospectus, regarding, among other things: </FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the success, cost and timing of our product development activities and clinical trials; </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">our expectations about the timing or likelihood of achieving regulatory approval and the cost of our development programs;
</FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">our reliance on the success of <FONT STYLE="white-space:nowrap">OPT-302</FONT> as our only product candidate; </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">our ability to obtain funding for our operations, including funding necessary to complete further development and commercialization of our product
candidates; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the commercialization of our product candidates, if approved; </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">our plans to research, develop and commercialize our product candidates; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT
SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">our ability to maintain, expand, protect and enforce our intellectual property portfolio; </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">our ability to operate our business without infringing, misappropriating or otherwise violating the intellectual property rights of third parties;
</FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">our ability to attract collaborators with development, regulatory and commercialization expertise; </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">business disruptions affecting the initiation, patient enrollment, development and operation of our clinical trials, including as a result of a public
health emergency, such as the global outbreak of the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">our expectations regarding our ability to obtain and maintain intellectual property protection for our product candidate; </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">future agreements with third parties in connection with the commercialization of our product candidates; </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the size and growth potential of the markets for our product candidates, and our ability to serve those markets; </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the rate and degree of market acceptance of our product candidates; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT
SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">regulatory developments in the United States, Australia and other jurisdictions; </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">our ability to contract with third-party suppliers and manufacturers and their ability to perform adequately; </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the success of competing therapies that are or may become available; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT
SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">our ability to attract and retain key scientific or management personnel; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT
SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the accuracy of our estimates regarding expenses, future revenue, capital requirements and needs for additional financing;
</FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">71 </FONT></P>


</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">our expectations regarding the period during which we qualify as an emerging growth company under the JOBS Act; </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">our use of the proceeds from this offering; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the future trading price of the ADSs and impact of securities analysts&#146; reports on these prices; and </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">other risks and uncertainties, including those listed under &#147;Risk Factors.&#148; </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">These risks are not exhaustive. Other sections of this
prospectus may include additional factors that could harm our business and financial performance. New risk factors may emerge from time to time and it is not possible for our management to predict all risk factors, nor can we assess the impact of
all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in, or implied by, any forward-looking statements. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">You should not rely on forward-looking statements as
predictions of future events. We have based the forward-looking statements contained in this prospectus primarily on our current expectations and projections about future events and trends that we believe may affect our business, financial condition
and operating results. We undertake no obligation to update any forward-looking statements made in this prospectus to reflect events or circumstances after the date of this prospectus or to reflect new information or the occurrence of unanticipated
events, except as required by law. We may not actually achieve the plans, intentions or expectations disclosed in our forward-looking statements, and you should not place undue reliance on our forward-looking statements. Our forward-looking
statements do not reflect the potential impact of any future acquisitions, mergers, dispositions, joint ventures or investments. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In addition, statements that &#147;we believe&#148; and similar statements reflect our beliefs and opinions on the relevant subject. These
statements are based on information available to us as of the date of this prospectus. While we believe that information provides a reasonable basis for these statements, that information may be limited or incomplete. Our statements should not be
read to indicate that we have conducted an exhaustive inquiry into, or review of, all relevant information. These statements are inherently uncertain, and investors are cautioned not to unduly rely on these statements. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">You should read this prospectus and the documents that we
reference in this prospectus and have filed as exhibits to the registration statement of which this prospectus is a part with the understanding that our actual future results, levels of activity, performance and achievements may be different from
what we expect. We qualify all of our forward-looking statements by these cautionary statements. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">72 </FONT></P>


</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="rom947560_6"></A>INDUSTRY AND MARKET DATA </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">This prospectus contains estimates and information
concerning our industry and our business, including estimated market size and projected growth rates of the markets for our product candidates. Unless otherwise expressly stated, we obtained this industry, business, market, medical and other
information from reports, research surveys, studies and similar data prepared by third parties, industry, medical and general publications, government data and similar sources. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">This information involves a number of assumptions and
limitations. Although we are responsible for all of the disclosure contained in this prospectus and we believe the third-party market position, market opportunity and market size data included in this prospectus are reliable, we have not
independently verified the accuracy or completeness of this third-party data. In addition, projections, assumptions and estimates of our future performance and the future performance of the industry in which we operate are necessarily subject to a
high degree of uncertainty and risk due to a variety of factors, including those described in &#147;Risk Factors.&#148; These and other factors could cause results to differ materially from those expressed in these publications and reports.
</FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">73 </FONT></P>


</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="rom947560_7"></A>USE OF PROCEEDS </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>  <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We estimate that the net proceeds to us from the sale of
9,300,000&nbsp;ADSs in this offering will be approximately US$146.4&nbsp;million (or approximately US$168.8&nbsp;million if the underwriters exercise their option to purchase 1,395,000 additional ADSs in full), based on the assumed initial public
offering price of US$17.26 per ADS, the U.S. dollar equivalent of the last reported sale price of our ordinary shares on the ASX on October&nbsp;8, 2020, after giving effect to the Australian dollar/U.S. dollar exchange rate of A$1.3996 to US$1.00
as of October&nbsp;8, 2020, and an <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">ADS-to-ordinary</FONT></FONT> share ratio of 1-to-8, after deducting underwriting discounts and commissions and estimated offering expenses payable
by us. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Each US$1.00 increase (decrease) in the
assumed initial offering price of US$17.26&nbsp;per ADS, the U.S. dollar equivalent of the last reported sale price of our ordinary shares on the ASX on October&nbsp;8, 2020, after giving effect to the Australian dollar/U.S. dollar exchange rate of
A$1.3996 to US$1.00 as of October&nbsp;8, 2020, and an <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">ADS-to-ordinary</FONT></FONT> share ratio of 1-to-8, would increase (decrease) the net proceeds to us from this offering by
approximately US$8.6&nbsp;million, assuming the number of ADSs offered by us, as set forth on the cover page of this prospectus, remains the same and after deducting underwriting discounts and commissions and estimated offering expenses payable by
us. Similarly, an increase (decrease) of 1,000,000 ADSs offered by us would increase (decrease) the net proceeds to us by US$16.1&nbsp;million, assuming the assumed initial public offering price of US$17.26&nbsp;per ADS, the U.S. dollar equivalent
of the last reported sale price of our ordinary shares on the ASX on October&nbsp;8, 2020, after giving effect to the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">ADS-to-ordinary</FONT></FONT> share ratio of 1-to-8, remains the
same and after deducting underwriting discounts and commissions. </FONT></P>  <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">We expect to use the net proceeds from this offering, together with our existing cash and cash equivalents, as follows: </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">approximately US$130&nbsp;million to US$135&nbsp;million to advance the clinical development of <FONT STYLE="white-space:nowrap">OPT-302</FONT> for the
treatment of wet AMD, including the initiation of and reporting of topline data from two pivotal Phase 3 clinical trials; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">approximately US$5&nbsp;million to US$7&nbsp;million to advance the development of, and non-clinical studies for, a co-formulation of OPT-302 with an
approved and/or biosimilar anti-VEGF-A therapy; and </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the remaining proceeds for other research and development activities for <FONT STYLE="white-space:nowrap">OPT-302</FONT> in potential additional
indications, including DME, and for working capital and general corporate purposes. </FONT></P></TD></TR></TABLE>  <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">However, due to the uncertainties inherent in the product development process, it is difficult to estimate with certainty the exact
amounts of the net proceeds from this offering that may be used for the above purposes. Our management will have broad discretion over the use of the net proceeds from this offering. The amounts and timing of our expenditures will depend upon
numerous factors including the results of our research and development efforts, the timing and success of preclinical studies and any ongoing clinical trials or clinical trials we may commence in the future, the timing of regulatory submissions and
the amount of cash obtained through future collaborations, if any. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">We believe opportunities may exist from time to time to expand our current business through acquisitions or <FONT STYLE="white-space:nowrap">in-licensing</FONT> of complementary companies, medicines or
technologies. While we have no current agreements, commitments or understandings for any specific acquisitions or <FONT STYLE="white-space:nowrap">in-licensing</FONT> at this time, we may use a portion of the net proceeds for these purposes.
</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>  <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">As of June&nbsp;30, 2020, we had cash and
cash equivalents of A$62 million (or US$42.6&nbsp;million). We believe our cash and cash equivalents, together with the net proceeds of this offering, will be sufficient to fund our operations through the third calendar quarter of 2023. In
particular, we estimate that such funds, together with such existing cash and cash equivalents, will be sufficient to enable us to (i) advance the clinical development of OPT-302 for the treatment of wet AMD through the reporting of topline data
from two pivotal Phase 3 clinical trials in 2023 and (ii) advance the development of a co-formulation of OPT-302 with an approved and/or </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">74 </FONT></P>


</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
biosimilar anti-VEGF-A therapy through the completion of manufacturing activities and IND-enabling safety toxicology studies to support an IND filing in the second half of 2021. In the event the
net proceeds are insufficient for each of the uses set forth above, we intend to prioritize the allocation of the use of proceeds to the clinical development of OPT-302 for the treatment of wet AMD. We have based these estimates on assumptions that
may prove to be wrong, and we could use our available capital resources sooner than we currently expect. Following this offering, we will require additional funding to complete clinical development and commercialize OPT-302 in any indication,
including wet AMD. </FONT></P>  <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Pending our use of the
net proceeds from this offering, we intend to invest the net proceeds in a variety of capital preservation investments, including short-term, investment-grade, interest-bearing instruments. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">75 </FONT></P>


</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="rom947560_8"></A>DIVIDEND POLICY </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>  <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We have not declared or paid any dividends on our
ordinary shares since February 2005. We intend to retain any earnings for use in our business and do not currently intend to pay cash dividends on our ordinary shares. Dividends, if any, on our outstanding ordinary shares will be declared by and
subject to the discretion of our board of directors, and subject to Australian law. </FONT></P>  <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Any dividend we declare will be paid to the holders of ADSs, subject to the terms of the deposit agreement, to the same extent as holders of our ordinary shares, to the extent permitted by applicable law
and regulations, less the fees and expenses payable under the deposit agreement. Any dividend we declare will be distributed by the depositary bank to the holders of the ADSs, subject to the terms of the deposit agreement. See &#147;Description of
American Depositary Shares&#151;Dividends and Distributions.&#148; </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">76 </FONT></P>


</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="rom947560_9"></A>CAPITALIZATION </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The following table sets forth our cash and our
capitalization as of June&nbsp;30, 2020, on: </FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">an actual basis; and </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">an as adjusted basis to give effect to the issuance and sale of 9,300,000&nbsp;ADSs in this offering at the assumed initial public offering price of
US$17.26&nbsp;per ADS, the U.S. dollar equivalent of the last reported sale price of our ordinary shares on the ASX on October&nbsp;8, 2020, after giving effect to the Australian dollar/U.S. dollar exchange rate of A$1.3996 to US$1.00 as of
October&nbsp;8, 2020, and an <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">ADS-to-ordinary</FONT></FONT> share ratio of 1-to-8, after deducting underwriting discounts and commissions and estimated offering expenses payable by us.
</FONT></P></TD></TR></TABLE>  <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">You should read this
information in conjunction with our consolidated financial statements and the related notes included elsewhere in this prospectus, the information set forth in &#147;Management&#146;s Discussion and Analysis of Financial Condition and Results of
Operations&#148; and other financial information contained elsewhere in this prospectus. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>

<TD WIDTH="44%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>As of June&nbsp;30, 2020</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Actual<SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(1)</SUP></B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>As&nbsp;
Adjusted<SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(1)(2)</SUP></B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(in&nbsp;thousands,&nbsp;except&nbsp;share&nbsp;data)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total cash and cash equivalents</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">A$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">62,020</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">US$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">42,565</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">A$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">266,896</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">US$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">188,946</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Contributed equity: 269,157,769&nbsp;ordinary shares, no par value, outstanding, actual; 343,557,769&nbsp;ordinary shares, no par
value, outstanding, as adjusted</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">A$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">162,102</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">US$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">111,251</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">A$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">366,978</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">US$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">257,633</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Accumulated losses</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(102,589</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(70,407</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(102,589</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(70,407</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Reserves</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">5,295</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3,634</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">5,295</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3,634</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total equity</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">64,808</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">44,478</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">269,684</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">190,860</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total capitalization</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">A$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">64,808</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">US$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">44,478</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">A$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">269,684</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">US$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">190,860</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>  <P STYLE="line-height:8px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(1)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Amounts have been translated from Australian dollars to U.S. dollars at an assumed exchange rate of A$1.4571&nbsp;per US1.00, which was the official exchange rate
published by the Reserve Bank of Australia on June&nbsp;30, 2020. </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(2)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Each US$1.00 increase (decrease) in the assumed initial public offering price of US$17.26&nbsp;per ADS, the U.S. dollar equivalent of the last reported sale price of
our ordinary shares on the ASX on October 8, 2020, after giving effect to the Australian dollar/U.S. dollar exchange rate of A$1.3996 to US$1.00 as of October&nbsp;8, 2020, and an
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">ADS-to-ordinary</FONT></FONT> share ratio of 1-to-8, would increase (decrease) each of cash and cash equivalents, contributed equity, total equity and total capitalization by
A$12.1&nbsp;million (or US$8.6&nbsp;million), assuming the number of ADSs offered by us, as set forth on the cover page of this prospectus, remains the same, and after deducting underwriting discounts and commissions and estimated offering expenses
payable by us. Similarly, an increase (decrease) of 1,000,000 ADSs offered by us would increase (decrease) each of cash and cash equivalents, contributed equity, total equity and total capitalization by A$22.5&nbsp;million (or US$16.1&nbsp;million),
assuming the assumed initial public offering price of US$17.26&nbsp;per ADS, the U.S. dollar equivalent of the last reported sale price of our ordinary shares on the ASX on October 8, 2020, after giving effect to the
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">ADS-to-ordinary</FONT></FONT> share ratio of <FONT STYLE="white-space:nowrap">1-to-8,</FONT> remains the same, and after deducting underwriting discounts and commissions. The as
adjusted information is illustrative only and will depend on the actual initial public offering price, number of ADSs offered and other terms of this offering determined at pricing. </FONT></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">77 </FONT></P>


</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The outstanding ordinary share information in the table above is based on
269,157,769&nbsp;ordinary shares outstanding as of June&nbsp;30, 2020, and excludes: </FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">18,044,000 ordinary shares issuable upon the exercise of outstanding options as of June&nbsp;30, 2020 with a weighted-average exercise price of A$0.68
per ordinary share under our equity incentive plans; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">7,000,000 ordinary shares issuable upon the exercise of options that will be granted under our non-executive director share and option plan to certain
of our non-employee directors upon approval of such options by our shareholders, of which (i)&nbsp;options to purchase 4,000,000 shares are subject to approval at our annual general meeting of shareholders for 2020 on October&nbsp;12, 2020, at which
time an exercise price per ordinary share will be determined for such options, and (ii)&nbsp;an option to purchase 3,000,000 shares will be subject to approval at a future meeting of shareholders following the completion of this offering (see
&#147;Management&#151;Remuneration of Non-Employee Directors&#148;); and </FONT></P></TD></TR></TABLE>  <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">12,446,777&nbsp;ordinary shares reserved for future issuance under our Long Term Incentive Plan. </FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">78 </FONT></P>


</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="rom947560_10"></A>DILUTION </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">If you invest in the ADSs in this offering, your ownership
interest will be immediately diluted to the extent of the difference between the initial public offering price per ADS and the as adjusted net tangible book value per ordinary share or ADS immediately after this offering. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>  <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">As of June&nbsp;30, 2020, our historical net tangible
book value was A$64.8 million (or US$44.5 million), or A$1.93 (or US$1.32) per ADS. Historical net tangible book value per ADS represents our total tangible assets less total liabilities, divided by the number of ordinary shares outstanding as of
June&nbsp;30, 2020, converted to ADSs at an <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">ADS-to-ordinary</FONT></FONT> share ratio of 1-to-8. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">After giving effect to the receipt of the net proceeds from
our sale of 9,300,000 ADSs in this offering at an assumed initial public offering price of US$17.26&nbsp;per ADS, the U.S. dollar equivalent of the last reported sale price of our ordinary shares on the ASX on October&nbsp;8, 2020, after giving
effect to the Australian dollar/U.S. dollar exchange rate of A$1.3996 to US$1.00 as of October&nbsp;8, 2020, and an <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">ADS-to-ordinary</FONT></FONT> share ratio of <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">1-to-8,</FONT></FONT> after deducting underwriting discounts and commissions and estimated offering expenses payable by us, our as adjusted net tangible book value as of June&nbsp;30, 2020
was A$269.7&nbsp;million (or US$190.9&nbsp;million), or A$6.28 (or US$4.44)&nbsp;per ADS, equivalent to A$0.78 (or US$0.56) per ordinary share, in each case based on an
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">ADS-to-ordinary</FONT></FONT> share ratio of 1-to-8. This represents an immediate increase in net tangible book value of A$4.35 (or US$3.12)&nbsp;per ADS, equivalent to A$0.54 or
(US$0.39) per ordinary share, to our existing shareholders and immediate dilution of A$17.88 (or US$12.82)&nbsp;per ADS, equivalent to A$2.24 (US$1.60)&nbsp;per ordinary share, to investors purchasing ADSs in this offering, in each case based on an <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">ADS-to-ordinary</FONT></FONT> share ratio of 1-to-8. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The following table illustrates this dilution on a per ADS basis, assuming all ordinary shares outstanding as of June&nbsp;30, 2020
converted to ADSs at an <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">ADS-to-ordinary</FONT></FONT> share ratio of 1-to-8: </FONT></P>  <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>

<TD WIDTH="77%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Assumed initial public offering price per ADS</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">US$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">17.26</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Historical net tangible book value per ADS as of June&nbsp;30, 2020</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">US$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.32</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Increase in net tangible book value per ADS attributed to investors purchasing ADSs in this offering</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3.12</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">As adjusted net tangible book value per ADS after this offering</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">4.44</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Dilution in net tangible book value per ADS to investors in this offering</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">US$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">12.82</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>  <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>  <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Each US$1.00
increase (decrease) in the assumed initial public offering price of US$17.26 per ADS, the U.S. dollar equivalent of the last reported sale price of our ordinary shares on the ASX on October&nbsp;8, 2020, after giving effect to the Australian
dollar/U.S. dollar exchange rate of A$1.3996 to US$1.00 as of October&nbsp;8, 2020, and an <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">ADS-to-ordinary</FONT></FONT> share ratio of 1-to-8, would increase (decrease) the as
adjusted net tangible book value per ADS after this offering by US$0.20 per ADS and dilution to investors in this offering by US$0.80&nbsp;per ADS, assuming that the number of ADSs offered by us, as set forth on the cover page of this prospectus,
remains the same and after deducting underwriting discounts and commissions. An increase of 1,000,000 ADSs offered by us would increase the as adjusted net tangible book value by US$0.26&nbsp;per ADS and the dilution to investors in this offering
would decrease by US$0.26 per ADS, assuming the assumed initial public offering price remains the same and after deducting underwriting discounts and commissions. A decrease of 1,000,000 ADSs offered by us would decrease the as adjusted net tangible
book value by US$0.28&nbsp;per ADS and the dilution to investors in this offering would increase by US$0.28&nbsp;per ADS, assuming the assumed initial public offering price remains the same and after deducting underwriting discounts and commissions.
</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">If the underwriters exercise their option to
purchase 1,395,000 additional ADSs in full, the as adjusted net tangible book value after the offering would be US$4.81 per ADS, the increase in net tangible book value per ADS to existing shareholders would be US$3.49&nbsp;per ADS and the dilution
per ADS to new investors in </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">79 </FONT></P>


</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
this offering would be US$12.45 per ADS, in each case assuming an initial public offering price of US$17.26&nbsp;per ADS, the U.S. dollar equivalent of the last reported sale price of our
ordinary shares on the ASX on October&nbsp;8, 2020, after giving effect to the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">ADS-to-ordinary</FONT></FONT> share ratio of 1-to-8. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The dilution information above is for illustration purposes
only. Our as adjusted net tangible book value following the closing of this offering will depend on the actual initial public offering price and other terms of this offering determined at pricing. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The following table summarizes, as of June&nbsp;30, 2020:
</FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the total number of ordinary shares purchased from us by existing shareholders and the equivalent number of ordinary shares underlying ADSs purchased
by investors in this offering; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the total consideration paid to us by our existing shareholders and by investors purchasing ADSs in this offering, assuming an initial public offering
price of US$17.26&nbsp;per ADS, the U.S. dollar equivalent of the last reported sale price of our ordinary shares on the ASX on October&nbsp;8, 2020, after giving effect to the
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">ADS-to-ordinary</FONT></FONT> share ratio of 1-to-8, before deducting underwriting discounts and commissions and estimated offering expenses payable by us in connection with this
offering; and </FONT></P></TD></TR></TABLE>  <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the average price per ordinary share paid by existing shareholders and the average price per ADS or equivalent number of ordinary shares.
</FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>

<TD WIDTH="50%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Ordinary Shares<BR>(Directly or in the Form<BR>of ADSs)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Total&nbsp;Consideration</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ROWSPAN="2"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Average<BR>Price<BR>Per&nbsp;Share</B></FONT></TD>
<TD VALIGN="bottom" ROWSPAN="2"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ROWSPAN="2"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Average<BR>Price&nbsp;per<BR>ADS</B></FONT></TD>
<TD VALIGN="bottom" ROWSPAN="2"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Number</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Percent</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Amount</B></FONT><br><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(in&nbsp;
millions)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Percent</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Existing shareholders</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">269,157,769</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">78</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">US$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">131.8</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">45</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">US$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.49</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">US$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3.92</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Purchasers of ADSs</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">74,400,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">22</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">160.5</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">55</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">US$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2.16</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">US$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">17.26</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">343,557,769</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">100</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">US$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">292.3</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">100</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE>  <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>  <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">If the underwriters
exercise their option to purchase 1,395,000 additional ADSs in full, our existing shareholders would own 76% and investors in this offering would own 24% of the total number of ordinary shares outstanding (including shares underlying ADSs) upon the
closing of this offering. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Each US$1.00 increase
(decrease) in the assumed initial public offering price of US$17.26 per ADS, the U.S. dollar equivalent of the last reported sale price of our ordinary shares on the ASX on October&nbsp;8, 2020, after giving effect to the <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">ADS-to-ordinary</FONT></FONT> share ratio of 1-to-8, would increase (decrease) the total consideration paid by investors in this offering by US$9,300,000&nbsp;million and increase
(decrease) the total consideration paid by investors in this offering by 5.8%, assuming that the number of ADSs offered by us, as set forth on the cover page of this prospectus, remains the same and before deducting underwriting discounts and
commissions. </FONT></P>  <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The outstanding ordinary share
information in the tables above is based on 269,157,769&nbsp;ordinary shares as of June&nbsp;30, 2020, and excludes: </FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">18,044,000 ordinary shares issuable upon the exercise of outstanding options as of June&nbsp;30, 2020, with a weighted-average exercise price of A$0.68
per ordinary share under our equity incentive plans; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">7,000,000 ordinary shares issuable upon the exercise of options that will be granted under our non-executive director share and option plan to certain
of our non-employee directors upon approval of such options by our shareholders, of which (i)&nbsp;options to purchase 4,000,000 shares are subject to approval at our annual general meeting of shareholders for 2020 on October&nbsp;12, 2020, at which
time an exercise price per ordinary share will be determined for such options, and (ii)&nbsp;an option to purchase 3,000,000 shares will be subject to approval at a future meeting of shareholders following the completion of this offering (see
&#147;Management&#151;Remuneration of Non-Employee Directors&#148;); and </FONT></P></TD></TR></TABLE>  <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">12,446,777 ordinary shares reserved for future issuance under our Long Term Incentive Plan. </FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">80 </FONT></P>


</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">To the extent any outstanding options are exercised, there will be further dilution to
investors purchasing in this offering. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">81 </FONT></P>


</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="rom947560_11"></A>SELECTED CONSOLIDATED FINANCIAL DATA </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The following tables summarize our consolidated financial
and other data. The summary consolidated statement of profit or loss and other comprehensive income data for the years ended June&nbsp;30, 2019 and 2020 have been derived from our audited consolidated financial statements included elsewhere in this
prospectus. Our audited consolidated financial statements have been prepared in accordance with IFRS, as issued by the IASB, as of and for the years ended June&nbsp;30, 2019 and 2020. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">You should read the consolidated financial and other data set forth below in conjunction with our consolidated
financial statements and the accompanying notes and the information in &#147;Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations&#148; contained elsewhere in this prospectus. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Consolidated Statement of Profit or Loss and Other Comprehensive Income
Data </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>

<TD WIDTH="72%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Year Ended June&nbsp;30,</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2019</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2020</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(in&nbsp;thousands,&nbsp;except&nbsp;per&nbsp;share&nbsp;data)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Revenue</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">A$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">159</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">A$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">87</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Other income</FONT><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(1)</SUP></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">837</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">784</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Research and development expenses</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(31,348</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(17,954</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Patent expenses</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(161</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(429</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Intellectual property costs</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(113</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(114</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Administrative expenses</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(5,175</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(7,001</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Occupancy expenses</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(109</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(34</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Net foreign exchange gain (loss)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">363</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(401</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Loss before income tax</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(35,547</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(25,062</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Income tax benefit</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">14,637</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">8,533</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Loss for the year</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(20,910</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(16,529</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Other comprehensive income:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Items that will not be reclassified subsequently to profit or loss:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Fair value gains on investments in financial assets</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">260</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">59</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Other comprehensive income for the period, net of tax</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">260</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">59</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total comprehensive loss for the year</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">A$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(20,650</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">A$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(16,470</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total comprehensive loss for the year is attributable to:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Owners of the Company</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(20,650</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(16,470</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">A$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(20,650</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">A$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(16,470</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Loss per share attributable to Owners of the Company&#151;basic and diluted (in&nbsp;cents)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">A$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(8.98</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">A$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(6.34</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
</TABLE> <P STYLE="line-height:8px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(1)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Other income primarily comprises finance income from interest on bank deposits, funding under a <FONT STYLE="white-space:nowrap">one-time</FONT> Australian government
grant from the Commonwealth Scientific and Industrial Research Organization during the year ended June 30, 2019, and funding under a one-time government grant from the ATO during the year ended June 30, 2020. </FONT></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">82 </FONT></P>


</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Consolidated Statement of Financial Position Data </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>

<TD WIDTH="78%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>As of June&nbsp;30,</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2019</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2020</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(in&nbsp;thousands)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Cash and cash equivalents</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">A$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">21,535</FONT></TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">A$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">62,020</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Working capital</FONT><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(1)</SUP></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">30,376</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">64,398</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total assets</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">37,660</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">71,887</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total liabilities</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">6,541</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">7,079</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Accumulated losses</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(86,060</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(102,589</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total equity</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">31,120</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">64,808</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
</TABLE> <P STYLE="line-height:8px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(1)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Working capital is defined as current assets less current liabilities. </FONT></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">83 </FONT></P>


</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="rom947560_12"></A>MANAGEMENT&#146;S DISCUSSION AND ANALYSIS OF
</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>FINANCIAL CONDITION AND RESULTS OF OPERATIONS </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>The following &#147;Management&#146;s Discussion and
Analysis of Financial Condition and Results of Operations&#148; should be read together the section titled &#147;Selected Consolidated Financial Data&#148; and our consolidated financial statements and the accompanying notes included elsewhere in
this prospectus. This discussion includes both historical information and forward-looking information based upon current expectations that involve risk, uncertainties and assumptions. Our actual results may differ materially from management&#146;s
expectations as a result of various factors, including, but not limited to, those discussed in &#147;Risk Factors&#148; and elsewhere in this prospectus</I>. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Overview </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We are a clinical stage biopharmaceutical company developing a novel therapy for the treatment of highly prevalent and progressive retinal
diseases. We are developing our Phase <FONT STYLE="white-space:nowrap">3-ready</FONT> product candidate, <FONT STYLE="white-space:nowrap">OPT-302,</FONT> a biologic designed to inhibit <FONT STYLE="white-space:nowrap">VEGF-C</FONT> and <FONT
STYLE="white-space:nowrap">VEGF-D,</FONT> to complement <FONT STYLE="white-space:nowrap">VEGF-A</FONT> inhibitors for the treatment of ophthalmic diseases. <FONT STYLE="white-space:nowrap">Anti-VEGF-A</FONT> therapies represent the standard of care
for wet <FONT STYLE="white-space:nowrap">age-related</FONT> macular degeneration, or AMD, and other retinal diseases; however, there remains a significant unmet medical need as many patients do not adequately respond to these treatments. As the only
biologic inhibitor of <FONT STYLE="white-space:nowrap">VEGF-C</FONT> and <FONT STYLE="white-space:nowrap">VEGF-D</FONT> in clinical development, <FONT STYLE="white-space:nowrap">OPT-302</FONT> differs from standard of care therapies and when
administered in combination with a <FONT STYLE="white-space:nowrap">VEGF-A</FONT> inhibitor, is designed to achieve broader inhibition of the vascular endothelial growth factor, or VEGF, family and target a mechanism of clinical resistance to
improve visual acuity. Our lead indication for <FONT STYLE="white-space:nowrap">OPT-302</FONT> combination therapy is wet AMD, a chronic, progressive disease and the leading cause of vision loss for individuals over the age of 50. In a <FONT
STYLE="white-space:nowrap">366-patient</FONT> Phase 2b clinical trial for the treatment of wet AMD, 2.0 mg <FONT STYLE="white-space:nowrap">OPT-302,</FONT> in combination with a standard of care <FONT STYLE="white-space:nowrap">anti-VEGF-A</FONT>
therapy, ranibizumab (Lucentis), met the primary endpoint of a statistically significant superior mean gain in visual acuity over ranibizumab monotherapy at week 24. We intend to initiate two pivotal Phase 3 clinical trials in treatment-naive
patients with wet AMD to evaluate the efficacy and safety of <FONT STYLE="white-space:nowrap">OPT-302</FONT> in combination with <FONT STYLE="white-space:nowrap">anti-VEGF-A</FONT> therapies compared to
<FONT STYLE="white-space:nowrap">anti-VEGF-A</FONT> monotherapy in the first half of 2021. We expect to report topline data from these Phase 3 clinical trials in 2023. In addition to our clinical trials in wet AMD, we have observed evidence of
improved clinical outcomes in a Phase 1b/2a clinical trial of <FONT STYLE="white-space:nowrap">OPT-302</FONT> in combination with another standard of care <FONT STYLE="white-space:nowrap">anti-VEGF-A</FONT> therapy, aflibercept (Eylea), in patients
with treatment-refractory diabetic macular edema, or DME. We retain worldwide rights to develop and commercialize <FONT STYLE="white-space:nowrap">OPT-302</FONT> for the treatment of wet AMD and DME and believe that the novel treatment mechanism of <FONT
STYLE="white-space:nowrap">OPT-302</FONT> has the potential to provide therapeutic benefit for other progressive eye diseases. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We were founded in 1984 and completed our initial public offering and listing of ordinary shares on the Australian Securities Exchange in
1985. In April 2007, we acquired intellectual property relating to VEGF receptor 3 and subsequently developed the intellectual property for our lead product candidate, <FONT STYLE="white-space:nowrap">OPT-302.</FONT> Our development focus on the
treatment of retinal diseases began in 2013. Since then, we have devoted substantially all of our efforts to organizing and staffing our company, business planning, raising capital, developing and manufacturing our lead product candidate, <FONT
STYLE="white-space:nowrap">OPT-302,</FONT> conducting research and development activities, including preclinical studies and clinical trials, and providing general and administrative support for these operations. Our operations relating to the
development of <FONT STYLE="white-space:nowrap">OPT-302</FONT> have been financed primarily through the issuance and sale of new ordinary shares totaling A$112.7&nbsp;million through June&nbsp;30, 2020. We have also received an aggregate of
A$35.1&nbsp;million in cash tax incentives for the five fiscal years ended June&nbsp;30, 2020 under the Research and Development, or R&amp;D, Tax Incentive Scheme for the funding of the development of and clinical trials for <FONT
STYLE="white-space:nowrap">OPT-302.</FONT> </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We
have incurred operating losses since 2013. Our ability to generate product revenue sufficient to achieve profitability will be dependent on the successful development and eventual commercialization of <FONT STYLE="white-space:nowrap">OPT-302</FONT>
and any future product candidates. Our total comprehensive loss was A$20.7&nbsp;million and A$16.5&nbsp;million for the years </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">84 </FONT></P>


</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
ended June&nbsp;30, 2019 and 2020, respectively. As of June&nbsp;30, 2020, we had an accumulated loss of A$102.6&nbsp;million. We expect to continue to incur significant expenses for at least the
next several years as we advance <FONT STYLE="white-space:nowrap">OPT-302</FONT> through late-stage clinical development, including our planned pivotal Phase 3 trials of <FONT STYLE="white-space:nowrap">OPT-302</FONT> in combination with <FONT
STYLE="white-space:nowrap">anti-VEGF-A</FONT> therapy for the treatment of wet AMD, and, if these results are favorable, seek regulatory approval for <FONT STYLE="white-space:nowrap">OPT-302.</FONT> In addition, we may also pursue development of <FONT
STYLE="white-space:nowrap">OPT-302</FONT> for the treatment of additional indications, including DME, retinal vein occlusion and other indications in which <FONT STYLE="white-space:nowrap">OPT-302</FONT> has the potential to provide therapeutic
benefit. In addition, if we obtain marketing approval for <FONT STYLE="white-space:nowrap">OPT-302,</FONT> we expect to incur significant commercialization expenses related to product manufacturing, marketing, sales and distribution. Upon the
completion of this offering, we expect to incur additional costs associated with operating as a public company in the United States, including significant additional legal, accounting, investor relations, compliance and other expenses. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">As a result, we will need substantial additional funding to
support our continuing operations and pursue our growth strategy. Until such time as we can generate significant revenue from product sales, if ever, we expect to finance our operations through the sale of equity, debt financings, or other capital
sources, which may include collaborations with other companies or other strategic transactions as well as Australian research and development tax incentives. We may be unable to raise additional funds or enter into such other agreements or
arrangements when needed on favorable terms, or at all. If we fail to raise capital or enter into such agreements as and when needed, we may have to significantly delay, scale back or discontinue the development and commercialization of <FONT
STYLE="white-space:nowrap">OPT-302.</FONT> </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Because of the numerous risks and uncertainties associated with the development of biopharmaceutical product candidates, we are unable to
predict the timing or amount of increased expenses or when or if we will be able to achieve or maintain profitability. Even if we are able to generate product sales, we may never become profitable. If we fail to become profitable or are unable to
sustain profitability on a continuing basis, then we may be unable to continue our operations at planned levels and be forced to scale back or discontinue our operations. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>  <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">As of June&nbsp;30, 2020, we had cash and cash
equivalents of A$62.0&nbsp;million. We believe that the anticipated net proceeds from this offering, together with our existing cash and cash equivalents as of June&nbsp;30, 2020, will enable us to fund our operating and research and development
expenses through the third calendar quarter of 2023. We have based this estimate on assumptions that may prove to be wrong, and we could exhaust our available capital resources sooner than we expect. See &#147;&#151;Liquidity and Capital
Resources.&#148; </FONT></P>  <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Impact of
<FONT STYLE="white-space:nowrap">COVID-19</FONT> </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">We are closely monitoring how the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic is affecting our employees, business, preclinical studies and clinical trials. In response to the <FONT
STYLE="white-space:nowrap">COVID-19</FONT> pandemic, all of our employees have transitioned to working remotely and travel has been restricted. Although operations to date have not been materially affected by the
<FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic, at this time, there is significant uncertainty relating to the trajectory of the pandemic. The impact of related responses and disruptions caused by the
<FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic may result in difficulties or delays in initiating, enrolling, conducting or completing our planned clinical trials and the incurrence of unforeseen costs as a result of disruptions in
clinical supply or clinical trial delays. The impact of <FONT STYLE="white-space:nowrap">COVID-19</FONT> on our future results will largely depend on future developments, which are highly uncertain and cannot be predicted with confidence, such as
the ultimate geographic spread of the disease, the duration of the pandemic, travel restrictions and social distancing in Australia, the United States and other countries, business closures or business disruptions, the ultimate impact on financial
markets and the global economy and the effectiveness of actions taken in Australia, the United States and other countries to contain and treat the disease. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Components of Our Results of Operations </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Revenue </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Revenue consists of sales-based royalties in connection with the <FONT STYLE="white-space:nowrap">out-licensing</FONT> of certain
intellectual property assets that are unrelated to our core business and the development of <FONT STYLE="white-space:nowrap">OPT-302</FONT> and are not currently </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">85 </FONT></P>


</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
under development. These licenses are primarily used by third-party licensees for research purposes, and we expect revenue from these <FONT STYLE="white-space:nowrap">out-licensing</FONT>
arrangements to be nominal in future periods. These are variable consideration amounts and are recognized when the sales by our license partners to third parties occur, as the performance obligation to transfer the intellectual property to the
license partner is already satisfied. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">To date, we
have not generated any revenue from sales of approved products. Because of the numerous risks and uncertainties associated with product development and regulatory approval, we are unable to predict the amount, timing or whether we will be able to
obtain revenue from sales of approved products, and we may never succeed in obtaining regulatory approval for <FONT STYLE="white-space:nowrap">OPT-302</FONT> or any other product candidate. If our development efforts for <FONT
STYLE="white-space:nowrap">OPT-302</FONT> are successful and result in an approved and marketed product, or if we enter into additional collaboration or license agreements with third parties, we may generate revenue in the future from a combination
of product sales or payments from such collaboration or license agreements. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B><I>Other Income </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Other income primarily comprises finance income from interest on bank deposits and funding under a <FONT STYLE="white-space:nowrap">one-time</FONT> Australian government grant from the Commonwealth
Scientific and Industrial Research Organization, or the CSIRO, and the Australian Tax Office. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B><I>Operating Expenses </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><I>Research and Development Expenses</I>.&nbsp;&nbsp;&nbsp;&nbsp;Research and development expenses comprise the research project costs related to the development programs, including clinical trials, for <FONT
STYLE="white-space:nowrap">OPT-302</FONT> for the treatment of wet AMD and DME. R&amp;D expenses also include: </FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">expenses incurred in connection with the clinical development of our product candidates, including under agreements with third parties, such as
consultants and contract research organizations, or CROs; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the cost of manufacturing and purchasing drug products for use in our clinical trials, including under agreements with third parties, such as
consultants and contract manufacturing organizations, or CMOs; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">facilities, depreciation and other expenses, which include direct or allocated expenses for rent, maintenance of facilities and insurance;
</FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">costs related to compliance with regulatory requirements; and </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">clinical trial insurance. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We expense R&amp;D costs as incurred and have not capitalized any amounts of R&amp;D costs as of June&nbsp;30, 2020. For the years ended
June&nbsp;30, 2019 and 2020, we did not make any advance payments for goods or services to be received in future periods for use in R&amp;D activities. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our direct R&amp;D expenses are tracked on a
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">program-by-program</FONT></FONT> basis for our product candidate and consist primarily of external costs, such as fees paid to CROs, CMOs, research laboratories and outside
consultants in connection with our process development, manufacturing and clinical development activities. We do not allocate employee costs associated with our research efforts, laboratory supplies and facilities, including depreciation and other
indirect costs, to specific programs because these costs are deployed across multiple development activities and indications for <FONT STYLE="white-space:nowrap">OPT-302</FONT> and, as such, are not separately classified. We use internal resources
primarily to conduct our research activities as well as for managing our process development, manufacturing and clinical development activities. These employees work across multiple development programs and, therefore, we do not track these costs by
program. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">R&amp;D expenses in fiscal years after
June&nbsp;30, 2020 are expected to comprise costs of a similar nature to that recorded to date. Product candidates in later stages of clinical development, such as <FONT STYLE="white-space:nowrap">OPT-302,</FONT> generally have
</FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">86 </FONT></P>


</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
higher development costs than those in earlier stages of clinical development, primarily due to the increased size and duration of later-stage clinical trials. We expect that our R&amp;D expenses
will increase in connection with our planned clinical development, manufacturing and regulatory approval activities in the near term and in the future, including as we initiate our planned pivotal Phase 3 clinical trials of <FONT
STYLE="white-space:nowrap">OPT-302</FONT> in combination with <FONT STYLE="white-space:nowrap">anti-VEGF-A</FONT> therapy for the treatment of wet AMD. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">At this time, we cannot accurately estimate or know the nature, timing and costs of the efforts that will be necessary to complete the
clinical development of <FONT STYLE="white-space:nowrap">OPT-302</FONT> and any future product candidates. We may never succeed in achieving regulatory approval for any of our product candidates. The duration, costs and timing of clinical trials and
development of our product candidates will depend on a variety of factors, including: </FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the scope, rate of progress and expense of our planned clinical trials as well as other R&amp;D activities; </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">clinical trial results; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the terms and timing of regulatory approvals; </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the expense of filing, maintaining, prosecuting, defending and enforcing patent claims and other intellectual property rights;
</FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the ability to raise necessary additional funds; </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the ability to obtain and maintain third-party insurance coverage and adequate reimbursement; </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the ability to market, commercialize and achieve market acceptance for any products that receive regulatory approval; </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">a continued acceptable safety profile of <FONT STYLE="white-space:nowrap">OPT-302</FONT> combination therapy following approval in any indication; and
</FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">establishing and maintaining agreements with third-party suppliers and manufacturers for clinical supply and commercial manufacturing of <FONT
STYLE="white-space:nowrap">OPT-302,</FONT> or any other product candidate, if approved. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">A change in the outcome of any of these factors with respect to the development of <FONT STYLE="white-space:nowrap">OPT-302</FONT> could
significantly change the duration, costs and timing associated with clinical trials and development of <FONT STYLE="white-space:nowrap">OPT-302.</FONT> </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Patent Expenses</I>.&nbsp;&nbsp;&nbsp;&nbsp;Patent expenses comprise the cost of outside patent attorneys to manage and prosecute our
patent portfolio. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Intellectual Property
Costs</I>.&nbsp;&nbsp;&nbsp;&nbsp;Intellectual property costs relate to the license and patent assignment costs in respect of our <FONT STYLE="white-space:nowrap">in-license</FONT> agreements for certain technologies not currently under development
and unrelated to our <FONT STYLE="white-space:nowrap">out-licensing</FONT> arrangements under which we receive sales-based royalties. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Administrative Expenses</I>.&nbsp;&nbsp;&nbsp;&nbsp;Administrative expenses comprise employee benefit expenses, including share-based
payment expenses; investor relations expenses; insurance costs; audit, accountancy and legal fees; other personnel-related expenses; and depreciation expense. We anticipate that our administrative expenses will increase in the future as we increase
our headcount to support development of <FONT STYLE="white-space:nowrap">OPT-302</FONT> and our continued research activities. We also anticipate that we will incur increased accounting, audit, legal, regulatory, compliance and director and officer
insurance costs as well as investor and public relations expenses associated with being a public company in the United States. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Occupancy Expenses</I>.&nbsp;&nbsp;&nbsp;&nbsp;Occupancy expenses represent the costs relating to our headquarters in Melbourne,
Australia, including lease maintenance and incidental costs. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B><I>Net Foreign Exchange Gain (Loss) </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Net foreign exchange gain (loss) represents the impact of the variance in exchange rates between the Australian dollar and the U.S. dollar, Euro, British Pound and Canadian dollar on our cash and cash
equivalents, financial assets, financial liabilities and foreign currency denominated transactions. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">87 </FONT></P>


</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Income Tax Benefit </I></B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Income tax benefit represents the cash incentive amount
receivable under the R&amp;D Tax Incentive Scheme, an Australian Federal Government program under which eligible companies with annual aggregated revenue of less than A$20.0&nbsp;million can receive cash amounts equal to 43.5% of eligible R&amp;D
expenditures from the Australian Taxation Office, or the ATO. The ATO may reduce this rate to 41% for the year ended June 30, 2020 if the Australian Federal Government enacts changes to the legislation that governs the scheme in October 2020. The
ATO may also make other changes to the eligibility of R&amp;D expenditures, including placing a cap on the amount of non-clinical trial R&amp;D expenses claimed under the scheme. If the rate were to reduce to 41%, the current tax receivable recorded
in our consolidated statement of financial position as at June 30, 2020 would be reduced by A$490 thousand, with no change as at June 30, 2019. In addition, if a cap on non-clinical trial R&amp;D expenses were introduced, any effect on our amount
claimed under the scheme in respect of the fiscal years ended June 30, 2019 and 2020 would be de minimis. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The R&amp;D Tax Incentive Scheme incentive relates to eligible expenditures incurred in Australia and, under certain circumstances, in
other countries in connection with the development of <FONT STYLE="white-space:nowrap">OPT-302.</FONT> The R&amp;D tax incentive is applied annually to eligible expenditures incurred during the fiscal year following an annual application and
subsequent filing of our income tax return subsequent to fiscal year end. We estimate the amount of R&amp;D tax incentive after the completion of a fiscal year based on eligible Australia and overseas expenditures incurred during that year. We
expect to continue applying for the R&amp;D tax incentive as we further develop <FONT STYLE="white-space:nowrap">OPT-302.</FONT> In particular, we intend to apply for the costs expected to be incurred in Australia related to our planned pivotal
Phase 3 clinical trials of <FONT STYLE="white-space:nowrap">OPT-302</FONT> in combination with <FONT STYLE="white-space:nowrap">anti-VEGF-A</FONT> therapy for the treatment of wet AMD to be eligible for the R&amp;D tax incentive for future fiscal
years once incurred. However, there can be no assurance that the ATO will allow these costs to be eligible for the tax incentive. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Results of Operations for the Fiscal Years Ended June&nbsp;30, 2019 and 2020 </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The following table sets forth a summary of our consolidated
statement of profit or loss and other comprehensive income for the periods presented. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>

<TD WIDTH="80%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Year Ended June&nbsp;30,</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2019<SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(1)</SUP></B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2020<SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(2)</SUP></B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(in thousands)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Revenue</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">A$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">159</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">A$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">87</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Other income</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">837</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">784</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Research and development expenses</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(31,348</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(17,954</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Patent expenses</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(161</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(429</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Intellectual property costs</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(113</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(114</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Administrative expenses</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(5,175</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(7,001</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Occupancy expenses</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(109</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(34</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Net foreign exchange gain (loss)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">363</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(401</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Loss before income tax</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(35,547</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(25,062</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Income tax benefit</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">14,637</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">8,533</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Loss for the year</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(20,910</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(16,529</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Other comprehensive income:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Items that will not be reclassified subsequently to profit or loss:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Fair value gains on investments in financial assets</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">260</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">59</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Other comprehensive income for the period, net of tax</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">260</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">59</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total comprehensive loss for the year</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">A$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(20,650</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">A$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(16,470</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(1)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">The consolidated statement of profit or loss and other comprehensive income for the year ended June&nbsp;30, 2019 reflects the impact of the adoption
of IFRS 15 &#147;Revenue from Contracts with Customers&#148; and IFRS 9 </FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">88 </FONT></P>


</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P><FONT STYLE="font-family:Times New Roman" SIZE="2">
&#147;Financial Instruments,&#148; which became applicable on January&nbsp;1, 2018. The impact of the adoption of IFRS 15 and IFRS 9 was not material to the consolidated statement of profit or
loss and other comprehensive income. </FONT></P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(2)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">The consolidated statement of profit or loss and other comprehensive income for the year ended June&nbsp;30, 2020 reflects the impact of the adoption of IFRS 16
&#147;Leases&#148; which became applicable on January&nbsp;1, 2019. The details on the impact of the transition are presented in note 5 to our consolidated financial statements appearing elsewhere in this prospectus. </FONT></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Revenue </I></B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Revenue was A$159&nbsp;thousand for the year ended
June&nbsp;30, 2019, compared to A$87&nbsp;thousand for the year ended June&nbsp;30, 2020. This decrease was due to lower sales-based royalties received under our <FONT STYLE="white-space:nowrap">out-licensing</FONT> arrangements. Revenue for the
years ended June&nbsp;30, 2019 and 2020 consisted of sales-based royalties in connection with the <FONT STYLE="white-space:nowrap">out-licensing</FONT> of certain intellectual property assets that are unrelated to our core business and the
development of <FONT STYLE="white-space:nowrap">OPT-302</FONT> and are not currently under development. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Other Income </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Other income was A$837&nbsp;thousand for the year ended June&nbsp;30, 2019, compared to A$784&nbsp;thousand for the year ended
June&nbsp;30, 2020. This decrease was primarily due to lower finance income from interest on bank deposits and receipt of a A$78&nbsp;thousand <FONT STYLE="white-space:nowrap">one-time</FONT> Australian government grant from the CSIRO during the
year ended June&nbsp;30, 2019, partially offset by receipt of a A$63&nbsp;thousand <FONT STYLE="white-space:nowrap">one-time</FONT> ATO grant during the year ended June&nbsp;20, 2020. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Research and Development Expenses </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT
SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Research and development expenses were A$31.3&nbsp;million for the year ended June&nbsp;30, 2019, compared to
A$18.0&nbsp;million for the year ended June&nbsp;30, 2020. This decrease was primarily due to costs related to our Phase 2b clinical trial of <FONT STYLE="white-space:nowrap">OPT-302</FONT> in wet AMD completed during the year ended June&nbsp;30,
2019, partially offset by increased chemistry manufacturing and controls costs incurred during the year ended June&nbsp;30, 2020 related to manufacturing activities in preparation for our planned Phase 3 clinical trials of <FONT
STYLE="white-space:nowrap">OPT-302</FONT> in combination with <FONT STYLE="white-space:nowrap">anti-VEGF-A</FONT> therapy for the treatment of wet AMD. Our research and development expenses are broken down as set forth in the table below:
</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>

<TD WIDTH="80%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Year Ended June&nbsp;30,</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2019</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2020</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(in thousands)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Costs related to the Phase 2b clinical trial of <FONT STYLE="white-space:nowrap">OPT-302</FONT> in wet AMD</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">A$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">20,718</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">A$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3,197</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Costs related to the Phase 1b/2a clinical trial of <FONT STYLE="white-space:nowrap">OPT-302</FONT> in DME</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">9,646</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">8,022</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Chemistry manufacturing and controls</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">675</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">5,890</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Other direct <FONT STYLE="white-space:nowrap">non-clinical</FONT> expenses</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">309</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">845</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total research and development expenses</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">A$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">31,348</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">A$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">17,954</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Patent Expenses
</I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Patent expenses were A$161&nbsp;thousand
for the year ended June&nbsp;30, 2019, compared to A$429&nbsp;thousand for the year ended June&nbsp;30, 2020. This increase was primarily due to validation work carried out on our European patent application across multiple jurisdictions.
</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Intellectual Property Costs
</I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Intellectual property costs were
A$113&nbsp;thousand for the year ended June&nbsp;30, 2019, compared to A$114&nbsp;thousand for the year ended June&nbsp;30, 2020. This increase was due to fluctuations in exchange rates. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">89 </FONT></P>


</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
Intellectual property costs for the years ended June&nbsp;30, 2019 and 2020 consisted of the license and patent assignment costs in respect of our
<FONT STYLE="white-space:nowrap">in-license</FONT> agreements for certain technologies not currently under development and unrelated to our <FONT STYLE="white-space:nowrap">out-licensing</FONT> arrangements under which we receive sales-based
royalties. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Administrative Expenses
</I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Administrative expenses were
A$5.2&nbsp;million for the year ended June&nbsp;30, 2019, compared to A$7.0&nbsp;million for the year ended June&nbsp;30, 2020. This increase was primarily due to a A$0.1&nbsp;million increase in share-based payments, a A$1.3&nbsp;million increase
in professional fees and expenses and a A$0.2&nbsp;million increase in personnel-related expenses, each resulting from expansion of supporting administrative functions to aid continued research and development and capital raising activities in the
year ended June&nbsp;30, 2020, as well as a A$0.1&nbsp;million increase in depreciation expense and a A$0.1&nbsp;million increase in insurance costs. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Occupancy Expenses </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Occupancy expenses were A$109&nbsp;thousand for the year ended June&nbsp;30, 2019, compared to A$34&nbsp;thousand for the year ended
June&nbsp;30, 2020. This decrease was primarily due to a reduction in lease rental costs under the lease for our headquarters in Melbourne, Australia of A$77&nbsp;thousand resulting from the reclassification of lease rental expenses into
depreciation of <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">right-of-use</FONT></FONT> assets. This reclassification followed our adoption of accounting treatments required by IFRS 16 &#147;Leases&#148; during the fiscal year
ended June&nbsp;30, 2020. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Net Foreign
Exchange Gain (Loss) </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Net foreign
exchange differences were a gain of A$363&nbsp;thousand for the year ended June&nbsp;30, 2019, compared to a loss of A$401&nbsp;thousand for the year ended June&nbsp;30, 2020, primarily as a result of net variances of the exchange rate between the
Australian dollar and U.S. dollar on U.S. dollar-denominated cash and cash equivalents, financial assets, financial liabilities and foreign currency denominated transactions. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Income Tax Benefit </I></B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Income tax benefit was A$14.6&nbsp;million for the year
ended June&nbsp;30, 2019, compared to A$8.5&nbsp;million for the years ended June&nbsp;30, 2020. This decrease was due to lower R&amp;D tax incentive receivable recognized during the year ended June&nbsp;30, 2020. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Liquidity and Capital Resources </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The liquidity and capital resources discussion that follows
contains certain estimates as of the date of this prospectus of our estimated future sources and uses of liquidity (including estimated future capital resources and capital expenditures) and future financial and operating results. These estimates
reflect numerous assumptions made by us with respect to industry performance, general business, economic, regulatory, market and financial conditions and other future events, and matters specific to our businesses, all of which are difficult or
impossible to predict and many of which are beyond our control. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B><I>Sources and Uses of Liquidity </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Our operations relating to the development of <FONT STYLE="white-space:nowrap">OPT-302</FONT> have been financed primarily through the issuance and sale of new ordinary shares totaling
A$112.7&nbsp;million through June&nbsp;30, 2020. We have also received an aggregate of A$35.1&nbsp;million in the five fiscal years ended June&nbsp;30, 2020 under the R&amp;D Tax Incentive Scheme for the funding of the development and clinical
trials of <FONT STYLE="white-space:nowrap">OPT-302.</FONT> </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">As of June&nbsp;30, 2020, we had cash and cash equivalents of A$62.0&nbsp;million to fund the manufacturing of sufficient clinical grade <FONT STYLE="white-space:nowrap">OPT-302</FONT> drug product and
complete the regulatory and clinical preparation activities to initiate our planned pivotal Phase 3 clinical trials of <FONT STYLE="white-space:nowrap">OPT-302</FONT> in combination with <FONT STYLE="white-space:nowrap">anti-VEGF-A</FONT> therapy
for the treatment of wet AMD. As of June&nbsp;30, 2020, we had an accumulated loss of A$102.6&nbsp;million. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">90 </FONT></P>


</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Funding Requirements </I></B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>  <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We believe that the net proceeds from this offering,
together with our existing cash and cash equivalents, will enable us to fund our operating and research and development expenses through the third calendar quarter of 2023. We have based this estimate on assumptions that may prove to be wrong, and
we could use our capital resources sooner than we currently expect. </FONT></P>  <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">We expect our expenses to increase in connection with our ongoing activities, particularly as we continue the research and development of, continue or initiate clinical trials of, and seek marketing
approval for, <FONT STYLE="white-space:nowrap">OPT-302</FONT> and any future product candidates. In addition, if we obtain marketing approval for <FONT STYLE="white-space:nowrap">OPT-302</FONT> or any future product candidates, we expect to incur
significant commercialization expenses related to sales, marketing, manufacturing and distribution to the extent that such sales, marketing and distribution are not the responsibility of any future collaborators. Further, following the completion of
this offering, we expect to incur additional costs associated with operating as a public company in the United States. Accordingly, we will need to obtain substantial additional funding in connection with our continuing operations. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Until we can generate a sufficient amount of revenue from the
sale of approved products, if ever, we expect to finance our operating activities through our existing liquidity, the net proceeds from this offering and future financing activities, including a combination of equity offerings, debt financings,
collaborations, strategic alliances and licensing arrangements. To the extent that we raise additional capital through the sale of equity or convertible debt securities, your ownership interest will be diluted, and the terms of these securities may
include liquidation or other preferences that adversely affect your rights as a holder of ADSs. Debt financing, if available, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as
incurring additional debt, making capital expenditures or declaring dividends. If we raise funds through collaborations, strategic alliances or licensing arrangements with third parties, we may have to relinquish valuable rights to our technologies,
intellectual property, future revenue streams or product candidates. If we are unable to raise additional funds through equity or debt financings when needed, we may be required to delay, limit, reduce or terminate our product development or future
commercialization efforts or grant rights to develop and market product candidates that we would otherwise prefer to develop and market ourselves. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our present and future funding requirements will depend on many factors, including, among other things: </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the initiation, progress, timing, costs and results of our clinical trials for <FONT STYLE="white-space:nowrap">OPT-302,</FONT> including our planned
pivotal Phase 3 clinical trials of <FONT STYLE="white-space:nowrap">OPT-302</FONT> in combination with <FONT STYLE="white-space:nowrap">anti-VEGF-A</FONT> therapies for the treatment of wet AMD, and any future product candidates we may develop;
</FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">costs associated with expanding our organization, including our management infrastructure; </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the costs involved in filing patent applications and maintaining and enforcing patents or defending against claims of infringement raised by third
parties; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the time and costs involved in obtaining regulatory approval for our product candidates and any delays we may encounter as a result of evolving
regulatory requirements or adverse results with respect to any of these product candidates; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">selling and marketing activities undertaken in connection with the commercialization of <FONT STYLE="white-space:nowrap">OPT-302,</FONT> together with
the costs involved in the creation of a sales and marketing organization; and </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the costs of operating as a public listed company in both Australia and the United States. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Conducting clinical trials is a time-consuming, expensive and
uncertain process that takes many years to complete, and we may never generate the necessary data or results required to obtain marketing approval and achieve product sales. In addition, <FONT STYLE="white-space:nowrap">OPT-302</FONT> or any future
product candidate, if approved, may not achieve commercial success. Our commercial revenues, if any, will be derived from sales of <FONT STYLE="white-space:nowrap">OPT-302</FONT> and any future product candidate that we do not expect to be
commercially available for many years, if at all. Accordingly, we </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">91 </FONT></P>


</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
will need to continue to rely on additional financing to achieve our business objectives. Adequate additional financing may not be available to us on acceptable terms, or at all. For more
information as to the risks associated with our future funding needs, see &#147;Risk Factors&#151;Risks Related to Our Financial Position and Need for Capital.&#148; </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Cash Flows </I></B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The following table summarizes our cash flows for the
periods presented: </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>

<TD WIDTH="80%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Year Ended June&nbsp;30,</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2019</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2020</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(in thousands)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Net cash used in operating activities</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">A$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(24,185</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">A$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(8,782</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Net cash provided by investing activities</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">321</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">476</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Net cash provided by financing activities</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">12,630</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">48,980</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Net (decrease)/increase in cash and cash equivalents</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">A$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(11,234</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">A$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">40,674</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Operating Activities
</I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">For the year ended June&nbsp;30, 2019,
net cash used in operating activities was A$24.2&nbsp;million, attributable to a net loss of A$20.9&nbsp;million adjusted for A$13.9&nbsp;million in <FONT STYLE="white-space:nowrap">non-cash</FONT> items as well as a net cash outflow from changes in
operating assets and liabilities of A$1.4&nbsp;million, partially offset by a R&amp;D tax incentive of A$12.0&nbsp;million. <FONT STYLE="white-space:nowrap">Non-cash</FONT> adjustments of A$13.9&nbsp;million consisted of A$14.6&nbsp;million in
income tax benefit recognized in profit or loss and A$259&nbsp;thousand in net exchange differences, partially offset by A$967&nbsp;thousand in share-based payments and A$33&nbsp;thousand in depreciation expense. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">For the year ended June&nbsp;30, 2020, net cash used in
operating activities was A$8.8&nbsp;million, attributable to a net loss of A$16.5&nbsp;million adjusted for A$6.9&nbsp;million in <FONT STYLE="white-space:nowrap">non-cash</FONT> items as well as a net cash flow from changes in operating assets and
liabilities of A$18&nbsp;thousand, partially offset by a R&amp;D tax incentive of A$14.6&nbsp;million. <FONT STYLE="white-space:nowrap">Non-cash</FONT> adjustments of A$6.9&nbsp;million consisted of A$8.5&nbsp;million in income tax benefit
recognized in profit or loss and A$401&nbsp;thousand in net exchange differences, partially offset by A$1.1&nbsp;million in share-based payments and A$144&nbsp;thousand in depreciation expense. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Investing Activities </I></B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">For the years ended June&nbsp;30, 2019 and 2020, net cash
provided by investing activities was A$321&nbsp;thousand and A$476&nbsp;thousand, respectively, attributable to A$339&nbsp;thousand and A$482&nbsp;thousand, respectively, in cash received on disposal of our financial asset of shares and options in
Antisense Therapeutics Ltd., an <FONT STYLE="white-space:nowrap">ASX-listed</FONT> company, offset by cash payments of A$18&nbsp;thousand and A$7&nbsp;thousand, respectively, for the purchase of computer equipment. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Financing Activities </I></B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">For the year ended June&nbsp;30, 2019, net cash provided by
financing activities was A$12.6&nbsp;million from the issuance of new ordinary shares on the exercise of options previously issued in connection with a capital raise. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">For the year ended June&nbsp;30, 2020, net cash provided by
financing activities was A$49.0&nbsp;million, attributable to A$420&nbsp;thousand received on the exercise of options granted to employees and A$48.7&nbsp;million from the issuance of new ordinary shares in a private placement to institutional
investors in Australia and the United Kingdom. Net cash provided by financing activities also included A$100&nbsp;thousand in respect of the payment of lease liabilities. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">92 </FONT></P>


</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Contractual Obligations </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The following table summarizes our contractual obligations
as of June&nbsp;30, 2020: </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>

<TD WIDTH="58%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="18" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Payments Due By Period</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Total</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Less&nbsp;than&nbsp;1<BR>Year</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B><FONT STYLE="white-space:nowrap">1-3&nbsp;Years</FONT></B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B><FONT STYLE="white-space:nowrap">3-5&nbsp;Years</FONT></B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>More&nbsp;than<BR>5 Years</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="18" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(in thousands)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>June&nbsp;30, 2020</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Operating lease commitments</FONT><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(1)</SUP></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">24</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">7</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">17</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Purchase obligations</FONT><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(2)</SUP></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">8,625</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">8,285</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">340</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">License agreements</FONT><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(3)</SUP></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">218</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">22</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">87</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">109</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">A$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">8,867</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">A$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">8,314</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">A$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">444</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">A$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">A$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">109</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(1)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Amounts represent payments due for low value leases of office equipment not included in our consolidated financial statements appearing elsewhere in this prospectus.
</FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(2)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Amounts consist of purchase obligations of <FONT STYLE="white-space:nowrap">OPT-302</FONT> drug product under our manufacturing services agreement with Patheon
Biologics Company Australia Pty Ltd. and Patheon Biologics Company B.V. </FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(3)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Amounts represent payments due under <FONT STYLE="white-space:nowrap">in-license</FONT> agreements with the Schepens Eye Research Institute and the University of Siena
for technologies not currently under development and unrelated to our <FONT STYLE="white-space:nowrap">out-licensing</FONT> arrangements under which we receive sales-based royalties. </FONT></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The commitment amounts in the table above are associated with
contracts that are enforceable and legally binding and that specify all significant terms, including fixed or minimum services to be used, fixed, minimum or variable price provisions, and the approximate timing of the actions under the contracts.
The table does not include obligations under agreements that we can cancel without a significant penalty. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We enter into agreements in the normal course of business with contract research organizations for clinical trials and with vendors for
other services and products for operating purposes which are cancelable at any time by us. These payments are not included in this table of contractual obligations. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Commercial License Agreement with Selexis SA
</I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In October 2013, we entered into a
commercial license agreement, or the Selexis Agreement, with Selexis SA, or Selexis, under which Selexis granted us a <FONT STYLE="white-space:nowrap">non-exclusive,</FONT> worldwide, sublicensable license under certain patents, <FONT
STYLE="white-space:nowrap">know-how</FONT> and other intellectual property controlled by Selexis to use certain cell lines, deliverables and materials provided by Selexis to manufacture <FONT STYLE="white-space:nowrap">OPT-302</FONT> and related
products and to use, sell and otherwise exploit such products. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">We paid Selexis a nominal upfront payment upon entering into the Selexis Agreement. We are also required to make certain payments under the Selexis Agreement totaling approximately US$1.3&nbsp;million
upon the achievement of certain development and commercial milestones. We are also obligated to pay a low single-digit running royalty on worldwide net sales of the licensed products. Our royalty obligations will continue, on a <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">product-by-product</FONT></FONT> and <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">country-by-country</FONT></FONT> basis, until the expiration of the relevant patents,
but will not extend beyond October 2024 in any event. After the expiration of the royalty term, our license will continue and become full paid, perpetual and irrevocable. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Selexis Agreement will expire on the date of expiration
of the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">last-to-expire</FONT></FONT> of the license patents. Either party may terminate the Selexis Agreement for the other party&#146;s uncured material breach or bankruptcy. We may
also terminate the Selexis Agreement at any time upon prior notice to Selexis. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B><FONT STYLE="white-space:nowrap">Off-Balance</FONT> Sheet Arrangements </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">During the periods presented, we did not, and we do not currently, engage in <FONT STYLE="white-space:nowrap">off-balance</FONT> sheet
financing arrangements as defined under SEC rules, such as relationships with other entities or financial partnerships, </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">93 </FONT></P>


</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
which are often referred to as structured finance or special purpose entities, established for the purpose of facilitating financing transactions that are not required to be reflected on our
consolidated statement of financial position. In addition, we do not engage in trading activities involving <FONT STYLE="white-space:nowrap">non-exchange</FONT> traded contracts. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Critical Accounting Policies and Estimates </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We believe that the following accounting policies involve a
high degree of judgment and complexity. Accordingly, these are the policies we believe are the most critical to aid in fully understanding and evaluating our consolidated financial condition and results of our operations. See note 3 to our
consolidated financial statements appearing elsewhere in this prospectus for a description of our other significant accounting policies. The preparation of our consolidated financial statements in conformity with IFRS requires us to make estimates
and judgments that affect the amounts reported in those financial statements and accompanying notes. Although we believe that the estimates we use are reasonable, due to the inherent uncertainty involved in making those estimates, actual results
reported in future periods could differ from those estimates. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B><I>Research and Development Costs </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">The majority of our expenditures is incurred as a result of our clinical trials for <FONT STYLE="white-space:nowrap">OPT-302.</FONT> During the years ended June&nbsp;30, 2019 and 2020, we completed a
Phase 2b clinical trial of <FONT STYLE="white-space:nowrap">OPT-302</FONT> combination therapy for the treatment of wet AMD. During the years ended June&nbsp;30, 2019 and 2020, we progressed a Phase 1b/2a clinical trial of <FONT
STYLE="white-space:nowrap">OPT-302</FONT> combination therapy for the treatment of DME. A key measure of our performance is the level of expenditures incurred on the research and development of <FONT STYLE="white-space:nowrap">OPT-302.</FONT>
</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Judgement is required in relation to: </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the classification of expenses in the income statement between research and development costs and operating expenses; and </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">whether costs relate to research or development, and consequently if they meet the capitalization criteria under International Accounting Standards, or
IAS, 38 &#147;Intangible Assets.&#148; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">We have determined that we are still in a research phase, and accordingly, no development costs have been capitalized as of June&nbsp;30, 2019 or June&nbsp;30, 2020. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Share-based Payment Transactions </I></B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We provide benefits to our directors and employees
(including key management personnel) in the form of share-based payments, whereby employees render services in exchange for ordinary shares or rights over ordinary shares (equity-settled transactions). The cost of these equity-settled transactions
with employees is measured by reference to the fair value at the date at which they are granted. Binomial models are used to value the options issued, with key assumptions being the listed price per ordinary share on the grant date, the option
exercise price, expected volatility of the underlying ordinary shares based on the historical share price volatility and the risk-free interest rate. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The cost of the equity-settled transactions is recognized, together with a corresponding increase in equity, over the period in which the
performance conditions are fulfilled (the vesting period), ending on the date on which the relevant employees become fully entitled to the award (the vesting date). The charge to profit or loss for the period is the cumulative amount less the
amounts already charged in previous periods. There is a corresponding credit to equity. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Until an award has vested, any amounts recorded are contingent and will be adjusted if more or fewer awards vest than were originally anticipated to do so. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">94 </FONT></P>


</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Income Tax&#151;Research and Development Tax Incentive </I></B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The R&amp;D Tax Incentive Scheme is an Australian Federal
Government program under which eligible companies with annual aggregated revenue of less than A$20&nbsp;million can receive cash amounts equal to 43.5% of eligible research and development expenditures from the ATO. The R&amp;D Tax Incentive Scheme
incentive relates to eligible expenditures incurred in Australia and, under certain circumstances, overseas on the development of our lead candidate <FONT STYLE="white-space:nowrap">OPT-302.</FONT> The R&amp;D tax incentive is applied annually to
eligible expenditures incurred during our financial year following an annual application and subsequent filing of our income tax return after the financial year end. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We estimate the amount of R&amp;D tax incentive after the
completion of the financial year based on eligible Australia and overseas expenditures incurred during that year. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We have presented incentives in respect of the R&amp;D Tax Incentive Scheme within income tax benefit in the Statement of Profit or Loss
and Other Comprehensive Income by analogizing with IAS 12 &#147;Income Taxes.&#148; </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Judgment is required as to the eligibility for the R&amp;D tax incentive in respect of: </FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">our ability to make claims and its continued compliance under the scheme; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT
SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">research and development and other supporting costs previously approved by Australian tax authorities; </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">estimated amounts, timing and geographical location of future costs related to the projects for which applications have been approved to date; and
</FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">assessment of whether expenditure on projects for which approval has been given by Australian tax authorities relate to Australian or overseas
expenditure. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">For the years
ended June&nbsp;30, 2019 and 2020, we have recognized an R&amp;D tax incentive receivable of A$14.6&nbsp;million and $8.5&nbsp;million, respectively within our consolidated statement of financial position with a corresponding amount recognized
within income tax benefit within the consolidated statement of profit or loss and other comprehensive income. The R&amp;D tax incentive receivable as at June 30, 2020 is based on the legislation as currently enacted as at June 30, 2020. Any proposed
changes to the legislation, such as rate changes to the eligibility requirements, may have a retrospective impact if the legislation is passed in its currently proposed form. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Investment tax credits such as the R&amp;D tax incentive are
outside of the scope of IAS 12 &#147;Income Taxes&#148; and IAS 20 &#147;Accounting for Government Grants and Disclosure of Government Assistance.&#148; Based on the guidance in IAS 8 &#147;Accounting Policies, Changes in Accounting Estimates and
Errors,&#148; companies need to make an accounting policy choice on how to present these incentives, which in practice is done by either analogizing with IAS 12 or with IAS 20. We have determined that the R&amp;D tax incentive should be presented by
analogizing to IAS 12 because the nature of the incentive is considered to be more closely aligned to income taxes, based on the following considerations: </FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">The R&amp;D tax incentive is considered an income tax offset which will be offset against our tax obligation if and when we return to a net tax payable
position. In addition, while we are currently eligible to receive cash payments under the Scheme since our consolidated revenue is currently below A$20&nbsp;million, if and when we generate revenue in excess of A$20&nbsp;million, the R&amp;D tax
incentive will become <FONT STYLE="white-space:nowrap">non-refundable</FONT> and can only be offset against any future income tax payable by us. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">The ATO, which is the tax authority in Australia, manages the annual claims process as the R&amp;D tax incentive is included in our annual income tax
return. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">The ATO is also responsible for making the R&amp;D tax incentive cash payment if a company is eligible for a cash refund under the program, oversees
compliance with the requirements of the R&amp;D tax incentive scheme and performs <FONT STYLE="white-space:nowrap">pre-issuance</FONT> reviews. </FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">95 </FONT></P>


</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Recently Adopted Accounting Pronouncements </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Amendments to Accounting Standards that are
Mandatorily Effective for the Current Year </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We have adopted all of the new and revised Standards and Interpretations issued by the IASB that are relevant to our operations and
effective for the current year. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">New and revised
Standards and amendments thereof and Interpretations effective for the current year that are relevant to us include: </FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">IFRS 16 &#147;Leases&#148;; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Annual Improvements to IFRS Standards 2015&#150;2017 Cycle Amendments to IFRS 3 &#147;Business Combinations&#148;, IFRS 11 &#147;Joint
Arrangements&#148;, IAS 12 &#147;Income Taxes&#148; and IAS 23 &#147;Borrowing Costs&#148;; and </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">IFRIC 23 &#147;Uncertainty over Income Tax Treatments&#148;. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>IFRS 16 Leases </I></B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In the current year, we applied IFRS 16 Leases, which is
effective for annual periods that begin on or after January&nbsp;1, 2019. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">IFRS 16 introduces new or amended requirements with respect to lease accounting. It introduces significant changes to lessee accounting by removing the distinction between operating and finance leases and
requiring the recognition of a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">right-of-use</FONT></FONT> asset and a lease liability at commencement for all leases, except for short-term leases and leases of low value assets.
Details of these new requirements are described in note 3 to our consolidated financial statements appearing elsewhere in this prospectus. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The date of initial application of IFRS 16 for us is July&nbsp;1, 2019. We have applied IFRS 16 using the cumulative catch-up approach
which: </FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">requires us to recognize the cumulative effect of initially applying IFRS 16 as an adjustment to the opening balance of retained earnings at the date
of initial application; and </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">does not permit restatement of comparatives, which continue to be presented under IAS 17 &#147;Leases&#148; and IFRIC 4 &#147;Determining whether an
Arrangement Contains a Lease.&#148; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">We have made use of the practical expedient available on transition to IFRS 16 to not reassess whether a contract is or contains a lease. Accordingly, the definition of a lease in accordance with IAS 17
and IFRIC 4 will continue to be applied to those leases entered or changed before July 1, 2019. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">The change in definition of a lease mainly relates to the concept of control. IFRS 16 determines whether a contract contains a lease on the basis of whether the customer has the right to control the use
of an identified asset for a period of time in exchange for consideration. This is in contrast to the focus on &#147;risks and rewards&#148; in IAS 17 and IFRIC 4. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Impact on Lease Accounting </I></B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Former Operating Leases </I></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">IFRS 16 changes how we account for leases previously
classified as operating leases under IAS 17, which operating lease payments were recognized as an expense in profit or loss on a straight-line basis over the lease term. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">96 </FONT></P>


</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Applying IFRS 16, for all leases (except as noted below), we have: </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Recognize <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">right-of-use</FONT></FONT> assets and lease liabilities in the consolidated
statement of financial position, initially measured at the present value of the future lease payments; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Recognize depreciation of <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">right-of-use</FONT></FONT> assets and interest on lease
liabilities in profit or loss; and </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Separate the total amount of cash paid into a principal portion (presented within financing activities) and interest (presented within operating
activities) in the consolidated statement of cash flows. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Lease incentives (e.g. rent-free period) are recognized as part of the measurement of the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">right-of-use</FONT></FONT> assets and lease
liabilities whereas under IAS 17 they resulted in the recognition of a lease incentive, amortized as a reduction of rental expenses generally on a straight-line basis. Under IFRS 16,
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">right-of-use</FONT></FONT> assets are tested for impairment in accordance with IAS 36 &#147;Impairment of Assets&#148;. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">For short-term leases (lease term of 12 months or less) and leases of
<FONT STYLE="white-space:nowrap">low-value</FONT> assets (such as photo copiers and telephones), we have opted to recognize a lease expense on a straight-line basis as permitted by IFRS 16. This expense is presented within &#147;administrative
expenses&#148; in profit or loss. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Financial
Impact of the Initial Application of IFRS 16 </I></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The previous lease for our headquarters expired on July&nbsp;14, 2019. The adoption of IFRS 16 did not have a material impact on our
results on the date of transition. Following the renewal of the leased office premises on July&nbsp;15, 2019, we recognized a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">right-of-use</FONT></FONT> asset of A$365,264 and a
corresponding lease liability of $365,264 in respect of this lease. The impact on profit or loss during the fiscal year ended June&nbsp;30, 2020 was to decrease occupancy expenses by A$110,800; increase depreciation by A$121,754; and increase
finance interest expense by A$7,680. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Under IAS
17, all lease payments on operating leases are presented as part of cash flows from operating activities. During the year ended June&nbsp;30, 2020, the impact of the changes under IFRS 16 reduced the cash used in operating activities by A$100,189
and decreased net cash generated from financing activities by the same amount. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B><I>Other Pronouncements Adopted for the First Time in the Year Ended June&nbsp;30, 2020 </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">During the fiscal year ended June&nbsp;30, 2020, we applied a number of amendments to IFRS and Interpretations issued by the IASB that are
effective for an annual period that begins on or after January&nbsp;1, 2019. Their adoption has not had any material impact on the disclosures or on the amounts reported in our consolidated financial statements. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>New and Revised International Financial Reporting
Standards and Interpretations on Issue But not Yet Effective </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">The new and revised International Financial Reporting Standards, Interpretations and amendments that have been issued but are not yet effective, are not expected to have a material impact on the amounts
recognized or disclosures included in our consolidated financial statements. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>Qualitative and Quantitative Disclosures about Market Risk </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We are exposed to market risks in the ordinary course of our business. Market risk represents the risk of loss that may impact our
financial position due to adverse changes in financial market prices and rates. Our market risk exposure is primarily the result of fluctuations in interest rates and foreign currency exchange rate risk. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Interest Rate Risk </I></B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">As of June&nbsp;30, 2020, we had cash and cash equivalents
of A$62.0&nbsp;million. We have limited exposure to interest rate risk. Our exposure to market interest rates relates primarily to the short-term deposits. The deposits </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">97 </FONT></P>


</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
are held with two of Australia&#146;s largest banks. Our cash and cash equivalents are not locked into long-term deposits at fixed rates so as to mitigate the risk of earning interest below the
current floating rate. We do not have any credit facilities bearing variable interest rates. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B><I>Foreign Currency Exchange Rate Risk </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">As a result of services provided by <FONT STYLE="white-space:nowrap">non-related</FONT> entities in the United States, Canada, United Kingdom and Europe, part of our financial assets and liabilities and
foreign currency denominated transactions are affected by movements in the applicable exchange rate. We do not enter into any hedging transactions. We enter into forward rate foreign exchange rate contracts in respect of the settlement of supplier
invoices denominated in U.S. dollars to mitigate the risk of movements in the U.S. dollar and Australian dollar exchange rates. We are primarily exposed to foreign exchange risk inherent in U.S. dollar-denominated contracts related to our clinical
development activities. As of June&nbsp;30, 2019 and June&nbsp;30, 2020, we had A$4.5&nbsp;million and A$5.0&nbsp;million, respectively, in net exposure to the U.S. dollar, primarily in payables. An increase or decrease of the Australian dollar to
U.S. dollar exchange rate by 10% would increase our after tax loss by A$319&nbsp;thousand (2019: A$285 thousand) or decrease our after tax loss by A$390&nbsp;thousand (2019: A$349 thousand), respectively. As we continue our clinical development
activities, we expect to face continued exposure to exchange rate risk from the U.S. dollar. There was minimal or insignificant exposure to the British Pound, Euro and Canadian dollar during the years ended June&nbsp;30, 2019 and 2020. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Emerging Growth Company Status </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">As a company with less than $1.07&nbsp;billion in revenue
during our last fiscal year, we qualify as an &#147;emerging growth company&#148; as defined in the JOBS Act. As an emerging growth company, we may take advantage of specified reduced disclosure and other requirements that are otherwise applicable
generally to public companies. These provisions include: </FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">exemption from the auditor attestation requirement of Section&nbsp;404 of the Sarbanes-Oxley Act of 2002, or the Sarbanes-Oxley Act, in the assessment
of our internal controls over financial reporting; and </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">to the extent that we no longer qualify as a foreign private issuer, (i)&nbsp;reduced disclosure obligations regarding executive compensation in our
periodic reports and proxy statements and (ii)&nbsp;exemptions from the requirements of holding a <FONT STYLE="white-space:nowrap">non-binding</FONT> advisory vote on executive compensation, including golden parachute compensation.
</FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We may take advantage of these
exemptions until such time that we are no longer an emerging growth company. Accordingly, the information that we provide shareholders and holders of the ADSs may be different than you might obtain from other public companies. We will cease to be an
emerging growth company upon the earliest to occur of (i)&nbsp;the last day of the fiscal year in which we have more than $1.07&nbsp;billion in annual revenue; (ii)&nbsp;the last day of the fiscal year in which we qualify as a &#147;large
accelerated filer&#148;; (iii)&nbsp;the date on which we have, during the previous three-year period, issued more than $1.0&nbsp;billion in <FONT STYLE="white-space:nowrap">non-convertible</FONT> debt securities; and (iv)&nbsp;the last day of the
fiscal year in which the fifth anniversary of this offering occurs. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">In addition, Section&nbsp;107 of the JOBS Act provides that an emerging growth company can use the extended transition period provided in Section&nbsp;7(a)(2)(B) of the Securities Act for complying with
new or revised accounting standards. Given that we currently report and expect to continue to report under IFRS, as issued by the IASB, we have irrevocably elected not to avail ourselves of this extended transition period and, as a result, we will
adopt new or revised accounting standards on the relevant dates on which adoption of such standards is required by the IASB. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Foreign Private Issuer Status </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We are also considered a &#147;foreign private issuer&#148; under U.S. securities laws. In our capacity as a foreign private issuer, we
are exempt from certain rules under the Securities Exchange Act of 1934, as amended, that </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">98 </FONT></P>


</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
impose certain disclosure obligations and procedural requirements for proxy solicitations under Section&nbsp;14 of the Exchange Act. In addition, our senior management, the members of our board
of directors and our principal shareholders are exempt from the reporting and &#147;short-swing&#148; profit recovery provisions of Section&nbsp;16 of the Exchange Act and the rules under the Exchange Act with respect to their purchases and sales of
our securities. Moreover, we are not required to file periodic reports and financial statements with the SEC as frequently or as promptly as U.S. companies whose securities are registered under the Exchange Act. In addition, we are not required to
comply with Regulation FD, which restricts the selective disclosure of material information. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">We may take advantage of these exemptions until such time as we are no longer a foreign private issuer. We will remain a foreign private issuer until such time that 50% or more of our outstanding voting
securities are held by U.S. residents and any of the following three circumstances applies: (i)&nbsp;the majority of the members of board of directors or our senior management are U.S. citizens or residents; (ii)&nbsp;more than 50% of our assets are
located in the United States; or (iii)&nbsp;our business is administered principally in the United States. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We have taken advantage of certain reduced reporting and other requirements in this prospectus. Accordingly, the information contained
herein may be different from the information you receive from other public companies. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">99 </FONT></P>


</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="rom947560_13"></A>BUSINESS </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Overview </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT
SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We are a clinical stage biopharmaceutical company developing a novel therapy for the treatment of highly
prevalent and progressive retinal diseases. We are developing our Phase <FONT STYLE="white-space:nowrap">3-ready</FONT> product candidate, <FONT STYLE="white-space:nowrap">OPT-302,</FONT> a biologic designed to inhibit
<FONT STYLE="white-space:nowrap">VEGF-C</FONT> and <FONT STYLE="white-space:nowrap">VEGF-D,</FONT> to complement <FONT STYLE="white-space:nowrap">VEGF-A</FONT> inhibitors for the treatment of ophthalmic diseases.
<FONT STYLE="white-space:nowrap">Anti-VEGF-A</FONT> therapies represent the standard of care for wet <FONT STYLE="white-space:nowrap">age-related</FONT> macular degeneration, or AMD, and other retinal diseases; however, there remains a significant
unmet medical need as many patients do not adequately respond to these treatments. As the only biologic inhibitor of <FONT STYLE="white-space:nowrap">VEGF-C</FONT> and <FONT STYLE="white-space:nowrap">VEGF-D</FONT> in clinical development, <FONT
STYLE="white-space:nowrap">OPT-302</FONT> differs from standard of care therapies and when administered in combination with a <FONT STYLE="white-space:nowrap">VEGF-A</FONT> inhibitor, is designed to achieve broader inhibition of the vascular
endothelial growth factor, or VEGF, family and target a mechanism of clinical resistance to improve visual acuity. Our lead indication for <FONT STYLE="white-space:nowrap">OPT-302</FONT> combination therapy is wet AMD, a chronic, progressive disease
and the leading cause of vision loss for individuals over the age of 50. In a <FONT STYLE="white-space:nowrap">366-patient</FONT> Phase 2b clinical trial for the treatment of wet AMD, 2.0 mg <FONT STYLE="white-space:nowrap">OPT-302,</FONT> in
combination with a standard of care <FONT STYLE="white-space:nowrap">anti-VEGF-A</FONT> therapy, ranibizumab (Lucentis), met the primary endpoint of a statistically significant superior mean gain in visual acuity over ranibizumab monotherapy at week
24. We intend to initiate two pivotal Phase 3 clinical trials in treatment-naive patients with wet AMD to evaluate the efficacy and safety of <FONT STYLE="white-space:nowrap">OPT-302</FONT> in combination with
<FONT STYLE="white-space:nowrap">anti-VEGF-A</FONT> therapies compared to <FONT STYLE="white-space:nowrap">anti-VEGF-A</FONT> monotherapy in the first half of 2021. We expect to report topline data from these Phase 3 clinical trials in 2023. In
addition to our clinical trials in wet AMD, we have observed evidence of improved clinical outcomes in a Phase 1b/2a clinical trial of <FONT STYLE="white-space:nowrap">OPT-302</FONT> in combination with another standard of care <FONT
STYLE="white-space:nowrap">anti-VEGF-A</FONT> therapy, aflibercept (Eylea), in patients with treatment-refractory diabetic macular edema, or DME. We retain worldwide rights to develop and commercialize <FONT STYLE="white-space:nowrap">OPT-302</FONT>
for the treatment of wet AMD and DME and believe that the novel treatment mechanism of <FONT STYLE="white-space:nowrap">OPT-302</FONT> has the potential to provide therapeutic benefit for other progressive eye diseases. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Wet AMD is a rapidly progressing disease with loss of central
vision developing over a period of weeks to months in which abnormal new blood vessels form in the back of the eye in a process called choroidal neovascularization, or CNV. These newly formed vessels are highly permeable, leaking exudate leading to
fluid accumulation and retinal lesion formation. This, in turn, adversely affects sensory cells in the retina and if left untreated, results in rapid loss of visual acuity. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Wet AMD affects approximately one million people in the
United States and 2.5&nbsp;million people in Europe. The standard of care for wet AMD and other ocular neovascular diseases is the administration of monotherapies that primarily inhibit <FONT STYLE="white-space:nowrap">VEGF-A.</FONT> These
therapeutic agents, which include ranibizumab and aflibercept, prevent <FONT STYLE="white-space:nowrap">VEGF-A</FONT> molecules from binding to, and activating, VEGF receptors and thereby inhibit the formation and permeability of blood vessels. As
the risk of developing wet AMD increases with age, it is predicted that the overall aging of the population will result in a significant increase in the number of wet AMD cases, both in the United States and worldwide. Many wet AMD patients also
experience suboptimal clinical responses despite receiving one or both of the leading standard of care treatments ranibizumab and aflibercept, which had combined annual worldwide sales of over US$11.9 billion in 2019. In addition, nearly half of wet
AMD patients are treated with off-label bevacizumab as a lower cost alternative anti-VEGF-A therapy. As a result, we believe there is a significant and expanding market opportunity for novel therapies that can improve vision in patients with wet
AMD, which has the potential to lead to sales greater than the combined annual sales of ranibizumab and aflibercept. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Despite the widespread use and commercial success of <FONT STYLE="white-space:nowrap">VEGF-A</FONT> inhibitors, at least 45% of wet AMD
patients treated with a <FONT STYLE="white-space:nowrap">VEGF-A</FONT> inhibitor experience some degree of suboptimal clinical response, with a majority of patients failing to achieve 20/40 vision after 12 months of treatment, providing further
opportunity for visual acuity improvement. Furthermore, many patients have persistent retinal fluid and insufficient gains in visual acuity to resume routine daily activities such as driving and reading following regular treatment with a
</FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">100
</FONT></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
<FONT STYLE="white-space:nowrap">VEGF-A</FONT> inhibitor. In addition, improvements in visual acuity following regular administration of <FONT STYLE="white-space:nowrap">VEGF-A</FONT> monotherapy
are often not sustained with long-term use. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT
STYLE="white-space:nowrap">OPT-302</FONT> is designed to address a deficiency in the treatment paradigm for wet AMD and other retinal diseases, such as DME, by targeting alternate members of the VEGF family, namely
<FONT STYLE="white-space:nowrap">VEGF-C</FONT> and <FONT STYLE="white-space:nowrap">VEGF-D,</FONT> which are not targeted by current standard of care therapies. <FONT STYLE="white-space:nowrap">VEGF-C</FONT> and
<FONT STYLE="white-space:nowrap">VEGF-D</FONT> function in parallel with <FONT STYLE="white-space:nowrap">VEGF-A</FONT> to drive neovascularization and vascular leakage, which are key hallmarks of both wet AMD and DME. In addition, treatment with <FONT
STYLE="white-space:nowrap">VEGF-A</FONT> inhibitors leads to upregulation of <FONT STYLE="white-space:nowrap">VEGF-C</FONT> and <FONT STYLE="white-space:nowrap">VEGF-D</FONT> to compensate for <FONT STYLE="white-space:nowrap">VEGF-A</FONT>
inhibition, which may represent an important mechanism of clinical resistance to <FONT STYLE="white-space:nowrap">anti-VEGF-A</FONT> monotherapy. We are developing <FONT STYLE="white-space:nowrap">OPT-302</FONT> to be used in combination with
standard of care <FONT STYLE="white-space:nowrap">anti-VEGF-A</FONT> monotherapies to achieve broader inhibition of the VEGF family, with the goal of improving overall efficacy and demonstrating superior vision gains over that which can be achieved
by inhibiting <FONT STYLE="white-space:nowrap">VEGF-A</FONT> alone. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">In our completed Phase 2b wet AMD clinical trial, 2.0 mg <FONT STYLE="white-space:nowrap">OPT-302</FONT> in combination with ranibizumab demonstrated a statistically significant superior mean gain in
visual acuity at week 24 compared to patients treated with ranibizumab with a sham injection, which we refer to as ranibizumab monotherapy. The trial was an international, multi-center, double-masked trial in 366 treatment-naive patients with wet
AMD. Patients were randomized into three groups and received intravitreal injections every four weeks of either 0.5 mg or 2.0 mg <FONT STYLE="white-space:nowrap">OPT-302</FONT> in combination with 0.5 mg ranibizumab or 0.5 mg ranibizumab
monotherapy. Treatments were administered by intravitreal injections once every four weeks for 20 weeks (six treatments in total). The primary endpoint was the mean change at week 24 in best corrected visual acuity, or BCVA, from baseline on the
Early Treatment of Diabetic Retinopathy Study, or ETDRS, standardized eye chart, which we refer to as visual acuity. Patients treated with 2.0 mg <FONT STYLE="white-space:nowrap">OPT-302</FONT> combination therapy demonstrated a statistically
significant improvement in visual acuity compared to patients treated with ranibizumab monotherapy. In the patients that received 2.0 mg <FONT STYLE="white-space:nowrap">OPT-302</FONT> combination therapy, visual acuity improved at week 24 from
baseline by a mean of +14.2 letters compared to +10.8 letters for those treated with ranibizumab monotherapy, a statistically significant benefit of +3.4 letters. Patients that received 2.0 mg <FONT STYLE="white-space:nowrap">OPT-302</FONT>
combination therapy also demonstrated improvements in retinal anatomy which were consistent with the visual acuity gains observed in the trial, including reductions in retinal fluid and lesion size by week 24. In a
<FONT STYLE="white-space:nowrap">pre-specified</FONT> subgroup analysis, greater activity of <FONT STYLE="white-space:nowrap">OPT-302</FONT> was observed in lesion types that are considered more difficult to treat with
<FONT STYLE="white-space:nowrap">anti-VEGF-A</FONT> therapy. Our clinical experience to date, which includes administration of over 1,800 doses of <FONT STYLE="white-space:nowrap">OPT-302</FONT> to 399 patients with retinal disease, indicates that <FONT
STYLE="white-space:nowrap">OPT-302</FONT> intravitreal injections are well tolerated, with the incidence of treatment-emergent adverse events, or TEAEs, comparable to <FONT STYLE="white-space:nowrap">anti-VEGF-A</FONT> monotherapy in our clinical
trials. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We are planning to initiate two
concurrent pivotal Phase 3 clinical trials for the treatment of wet AMD. These double-masked, sham-controlled Phase 3 clinical trials will enroll treatment-naive patients and assess the efficacy and safety of 2.0 mg of
<FONT STYLE="white-space:nowrap">OPT-302</FONT> in combination with ranibizumab (Lucentis) (referred to as the ShORe trial) or aflibercept (Eylea) (referred to as the COAST trial), compared to ranibizumab or aflibercept monotherapy in each
respective trial. In addition, to understand the durability of OPT-302 treatment effect with less frequent dosing, each trial will compare the clinical efficacy of OPT-302 administered in combination with the applicable VEGF-A inhibitor on an every
four-week and every eight-week dosing regimen. For consistency, the ShORe and COAST Phase&nbsp;3 trials build upon and maintain key features of our Phase 2b clinical trial of OPT-302 combination therapy for the treatment of wet AMD, while evaluating
the administration of OPT-302 combination therapy over a longer treatment period and in a greater number of patients. The primary endpoint of both trials will be the mean change in visual acuity from baseline at week 52. Patients will continue to be
dosed until week 96 to further assess long-term safety at week 100. We expect to initiate the trials in the first half of 2021 and to report topline data in 2023. If the results at the completion of the primary efficacy phase at week 52 of the
Phase&nbsp;3 clinical trials are favorable, we intend to file for marketing approval for <FONT STYLE="white-space:nowrap">OPT-302</FONT> for the treatment of wet AMD in the United States, European Union and other territories. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In addition to our planned pivotal Phase 3 clinical trials,
we plan to develop a co-formulation of OPT-302 with an approved and/or biosimilar anti-VEGF-A therapy designed to achieve VEGF-A, VEGF-C and VEGF-D inhibition following the administration of a single intravitreal injection of the co-formulated
product. OPT-302 is </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">101
</FONT></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
currently administered as a combination therapy consisting of a sequential injection of OPT-302 following intravitreal administration of a VEGF-A inhibitor. We believe that a co-formulated
OPT-302 and VEGF-A inhibitor product could provide flexibility of treatment options for physicians and reduce the frequency and number of injections for patients. We expect to file an investigative new drug application, or IND, for the co-formulated
product in the second half of 2021 and subsequently investigate the co-formulated product in a Phase 1 clinical trial for the treatment of wet AMD. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We are also investigating the therapeutic potential of <FONT STYLE="white-space:nowrap">OPT-302</FONT> for DME. DME is a progressive eye
disease and a complication of diabetic retinopathy, or DR, a condition caused by chronically elevated glucose levels in diabetics that damages the retina. DME can cause blurred vision, severe vision loss and blindness. Wet AMD and DME share a
similar underlying pathophysiology, including retinal neovascularization and increased vascular permeability, and as a result, <FONT STYLE="white-space:nowrap">VEGF-A</FONT> inhibitors are also considered the standard of care treatment for DME.
Based on its mechanism of action and clinical results to date, we believe that <FONT STYLE="white-space:nowrap">OPT-302</FONT> also has the potential to deliver therapeutic benefit in DME patients. In our Phase 1b/2a clinical trial of <FONT
STYLE="white-space:nowrap">OPT-302</FONT> in combination with aflibercept in patients with treatment-refractory DME, we observed evidence of improved clinical outcomes following <FONT STYLE="white-space:nowrap">OPT-302</FONT> combination therapy in
this indication. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We also believe that our novel
treatment mechanism has the potential to provide therapeutic benefit for other progressive retinal diseases beyond wet AMD and DME. We may further investigate the efficacy of <FONT STYLE="white-space:nowrap">OPT-302</FONT> to improve clinical
outcomes in patients with polypoidal choroidal vasculopathy, or PCV, a form of wet AMD that is highly prevalent in Asian populations and less responsive to <FONT STYLE="white-space:nowrap">anti-VEGF-A</FONT> therapy than other wet AMD subtypes.
Beyond wet AMD and DME, we may explore applications of <FONT STYLE="white-space:nowrap">OPT-302</FONT> in other retinal diseases in which a <FONT STYLE="white-space:nowrap">VEGF-C</FONT> or <FONT STYLE="white-space:nowrap">VEGF-D</FONT> inhibitor
could have therapeutic potential, such as retinal vein occlusion, or RVO. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>Our Company </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">We are a public company listed on the Australian Securities Exchange. We have assembled a team of experts with deep scientific, clinical and business expertise in biotechnology and specifically in
neovascular disease. Megan Baldwin, Ph.D., our Chief Executive Officer and Managing Director, has over 20 years of research and development and biopharmaceutical industry experience on neovascularization and therapeutic strategies in ophthalmic
indications and cancer. Prior to joining our company, she was a postdoctoral research fellow and an associate market planning manager at Genentech, where she conducted angiogenesis research before joining the anti-angiogenic therapy commercial
group. Mike Tonroe, our Chief Financial Officer and Company Secretary, was previously Chief Financial Officer of the Australian Synchrotron in Melbourne and has over 20 years of experience in financial management, including as Chief Financial
Officer to other companies as well as board-level positions for private and listed companies in Australia, United Kingdom, the United States and Canada. We believe that the breadth of experience and successful track record of our senior management,
combined with our established relationships with leaders in the industry and medical community, provide us with unique insights into biologic drug development for the treatment of neovascular disease. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Our Strategy </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT
SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our goal is to become a leader in developing and commercializing therapeutics for the treatment of retinal
diseases. The key elements of our strategy are to: </FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Advance <FONT STYLE="white-space:nowrap">OPT-302</FONT> through two concurrent Phase 3 trials for the treatment of wet
AMD.&nbsp;&nbsp;&nbsp;&nbsp;</B>Based on the positive results of our Phase 2b trial in wet AMD, we plan to initiate two concurrent pivotal Phase 3 clinical trials in treatment-naive patients with wet AMD to evaluate the efficacy and safety of <FONT
STYLE="white-space:nowrap">OPT-302</FONT> in combination with <FONT STYLE="white-space:nowrap">anti-VEGF-A</FONT> therapy. We expect to initiate these trials in the first half of 2021 with <FONT STYLE="white-space:nowrap">top-line</FONT> results in
2023. If these results are favorable, we plan to file for marketing approval for <FONT STYLE="white-space:nowrap">OPT-302</FONT> for the treatment of wet AMD in the United States, European Union and other territories. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Optimize <FONT STYLE="white-space:nowrap">OPT-302</FONT> administration and develop a co-formulation to reduce injection burden for patients and
provide treatment flexibility.</B>&nbsp;&nbsp;&nbsp;&nbsp;Currently, <FONT STYLE="white-space:nowrap">OPT-302</FONT> is administered as an injection </FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">102
</FONT></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"> <P><FONT STYLE="font-family:Times New Roman" SIZE="2">
following intravitreal administration of a <FONT STYLE="white-space:nowrap">VEGF-A</FONT> inhibitor. We plan to investigate the efficacy and durability of less frequent administration of <FONT
STYLE="white-space:nowrap">OPT-302</FONT> in clinical trials based on <FONT STYLE="white-space:nowrap">OPT-302&#146;s</FONT> pharmacokinetic profile, structural similarity to aflibercept and potential for improved and prolonged clinical efficacy
over time. In addition, we plan to develop a <FONT STYLE="white-space:nowrap">co-formulation</FONT> of <FONT STYLE="white-space:nowrap">OPT-302</FONT> with an approved and/or biosimilar <FONT STYLE="white-space:nowrap">anti-VEGF-A</FONT> therapy to
provide flexibility of treatment options for physicians and to reduce the frequency and number of injections for patients. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Expand clinical development of <FONT STYLE="white-space:nowrap">OPT-302</FONT> in wet AMD, DME and other retinal
diseases</B>.&nbsp;&nbsp;&nbsp;&nbsp;Due to similarities in the underlying pathophysiology, we anticipate that <FONT STYLE="white-space:nowrap">OPT-302</FONT> in combination with <FONT STYLE="white-space:nowrap">VEGF-A</FONT> inhibitors may provide
therapeutic benefit to patients with other neovascular ophthalmic diseases, such as DME. We reported positive data from a Phase 1b/2a trial of <FONT STYLE="white-space:nowrap">OPT-302</FONT> in combination with aflibercept for the treatment of DME,
and we plan to continue further development in this indication. We also continue to explore the potential benefit of <FONT STYLE="white-space:nowrap">OPT-302</FONT> in PCV and other ocular diseases, such as RVO and DR, in which there is a strong
scientific and clinical rationale. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Maximize the commercial potential of</B><B></B><B><FONT STYLE="white-space:nowrap">&nbsp;OPT-302.&nbsp;&nbsp;&nbsp;&nbsp;</FONT></B>We retain
worldwide rights for the development and commercialization of <FONT STYLE="white-space:nowrap">OPT-302.</FONT> If <FONT STYLE="white-space:nowrap">OPT-302</FONT> receives marketing approval in the United States and European Union for wet AMD or any
other retinal indications we are pursuing, we intend to establish our own commercial organization in these key territories. We may also enter into collaborations where we believe there is an opportunity to accelerate the development and
commercialization of <FONT STYLE="white-space:nowrap">OPT-302</FONT> in select territories. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>Our Pipeline </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">The following table summarizes the stage of clinical development and status of our product candidate, <FONT STYLE="white-space:nowrap">OPT-302.</FONT> </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center">


<IMG SRC="g947560g91o61.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>VEGFs in Ocular Diseases
</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Multiple ophthalmic diseases and conditions,
including wet AMD and DME, involve aberrant blood vessel formation and growth, as well as vascular permeability and resulting leakage that contributes to disease </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">103
</FONT></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
progression. In wet AMD, lesions consist of newly formed blood vessels that are typically fragile and leak, leading to the accumulation of fluid in the retinal tissue at the back of the eye. As
shown in the figure below, if left untreated, this fluid can cause retinal swelling that disrupts the local architecture and function of sensory cells and neurons in the eye, resulting in vision loss. In patients with DME, high blood glucose levels
drive physiological changes resulting in vascular permeability that also result in fluid accumulation, or edema, in the macula, the central region of the retina, and loss of visual acuity. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Neovascularization and Vascular Permeability are Key Hallmarks of a Number of Retinal Diseases, Leading to
Lesion Formation, Edema and Distortion of the Retina Photoreceptor Layer Causing Loss of Vision </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center">


<IMG SRC="g947560g20b36.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Neovascularization and
vascular permeability associated with retinal disease progression are driven by a family of related growth factors known as VEGFs. Members of the VEGF family, including <FONT STYLE="white-space:nowrap">VEGF-A,</FONT>
<FONT STYLE="white-space:nowrap">VEGF-C</FONT> and <FONT STYLE="white-space:nowrap">VEGF-D,</FONT> exert their activity by binding and activating VEGF receptors referred to as <FONT STYLE="white-space:nowrap">VEGFR-1,</FONT> <FONT
STYLE="white-space:nowrap">VEGFR-2,</FONT> and <FONT STYLE="white-space:nowrap">VEGFR-3.</FONT> Receptor activation triggers signaling pathways that lead to the development of new blood vessels, a process known as angiogenesis, as well as vascular
permeability. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">104
</FONT></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Members of the VEGF Family of Growth Factors Have Overlapping but Distinct
Specificities for VEGFRs </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center">


<IMG SRC="g947560g01v78.jpg" ALT="LOGO">
 </P> <P STYLE="line-height:8px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="1">*</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="1">Lymphangiogenesis refers to the proliferation of lymphatic vessels from <FONT STYLE="white-space:nowrap">pre-existing</FONT> lymphatic vessels.
</FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I><FONT STYLE="white-space:nowrap">VEGF-A</FONT> </I></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="white-space:nowrap">VEGF-A</FONT> is the most
well-characterized member of the VEGF family of growth factors and was the first to be targeted for therapeutic intervention. <FONT STYLE="white-space:nowrap">VEGF-A</FONT> is a potent growth factor and its relevance in ophthalmic neovascularization
has been well-established. Overexpression of <FONT STYLE="white-space:nowrap">VEGF-A</FONT> in animal models has shown <FONT STYLE="white-space:nowrap">VEGF-A</FONT> to be a causal factor in the development of neovascularization and vascular
permeability, which are key hallmarks in the progression of wet AMD. In wet AMD patients, <FONT STYLE="white-space:nowrap">VEGF-A</FONT> levels are shown to be elevated in the aqueous humor fluid of the eye.
<FONT STYLE="white-space:nowrap">VEGF-A</FONT> binds to <FONT STYLE="white-space:nowrap">VEGFR-1,</FONT> which acts to regulate <FONT STYLE="white-space:nowrap">VEGF-A</FONT> activity, and <FONT STYLE="white-space:nowrap">VEGFR-2,</FONT> which is a
key driver of neovascularization and vascular permeability. Several inhibitors of <FONT STYLE="white-space:nowrap">VEGF-A</FONT> have been approved to treat a number of neovascular ocular diseases. The two leading ocular <FONT
STYLE="white-space:nowrap">VEGF-A</FONT> inhibitors by revenue, ranibizumab and aflibercept, had combined annual worldwide sales of over US$11.9&nbsp;billion in 2019. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I><FONT STYLE="white-space:nowrap">VEGF-C</FONT> and <FONT
STYLE="white-space:nowrap">VEGF-D</FONT> </I></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT
STYLE="white-space:nowrap">VEGF-C</FONT> and <FONT STYLE="white-space:nowrap">VEGF-D</FONT> contribute to the development and persistence of neovascular diseases, as evidenced by their elevated levels in multiple pathological conditions. Both <FONT
STYLE="white-space:nowrap">VEGF-C</FONT> and <FONT STYLE="white-space:nowrap">VEGF-D</FONT> can stimulate neovascularization and <FONT STYLE="white-space:nowrap">VEGF-C</FONT> can induce permeability by binding to
<FONT STYLE="white-space:nowrap">VEGFR-2,</FONT> independent of <FONT STYLE="white-space:nowrap">VEGF-A</FONT> activity. Additionally, <FONT STYLE="white-space:nowrap">VEGF-C</FONT> and <FONT STYLE="white-space:nowrap">VEGF-D</FONT> bind to <FONT
STYLE="white-space:nowrap">VEGFR-3,</FONT> a receptor that is not activated by <FONT STYLE="white-space:nowrap">VEGF-A,</FONT> which confers biological activities to both <FONT STYLE="white-space:nowrap">VEGF-C</FONT> and <FONT
STYLE="white-space:nowrap">VEGF-D</FONT> that are distinct from those of <FONT STYLE="white-space:nowrap">VEGF-A.</FONT> Activation of <FONT STYLE="white-space:nowrap">VEGFR-3</FONT> can stimulate vascular proliferation and modulate vascular
permeability, vascular leakage and edema formation. The receptor binding profiles and the distinct biological activities of <FONT STYLE="white-space:nowrap">VEGF-C</FONT> and <FONT STYLE="white-space:nowrap">VEGF-D</FONT> suggest that inhibiting <FONT
STYLE="white-space:nowrap">VEGF-C</FONT> and <FONT STYLE="white-space:nowrap">VEGF-D</FONT> may have therapeutic potential in ocular diseases by acting independently of, and in tandem with, the activity of
<FONT STYLE="white-space:nowrap">VEGF-A</FONT> inhibitors. There are currently no other therapies either approved or in clinical development that are designed to specifically target <FONT STYLE="white-space:nowrap">VEGF-C</FONT> or <FONT
STYLE="white-space:nowrap">VEGF-D.</FONT> </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">105
</FONT></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Resistance to <FONT STYLE="white-space:nowrap">VEGF-A</FONT> Therapies May be Driven
by <FONT STYLE="white-space:nowrap">VEGF-C</FONT> and <FONT STYLE="white-space:nowrap">VEGF-D</FONT> </I></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Standard of care treatments for wet AMD and DME inhibit <FONT STYLE="white-space:nowrap">VEGF-A</FONT> activation of its receptors that
are typically expressed on vascular endothelium. This can lead to inhibition of blood vessel growth and leakage which can stabilize disease and improve clinical outcomes, including visual acuity, in patients with retinal eye conditions. However, not
all patients fully respond to <FONT STYLE="white-space:nowrap">VEGF-A</FONT> inhibition. A substantial proportion of patients with wet AMD and DME have further opportunity for visual acuity gain and/or a need for resolution of persistent retinal
fluid following <FONT STYLE="white-space:nowrap">anti-VEGF-A</FONT> treatment. Furthermore, gains in visual acuity are often not sustained over the long term, even when <FONT STYLE="white-space:nowrap">anti-VEGF-A</FONT> therapies are administered
regularly. This resistance may occur as <FONT STYLE="white-space:nowrap">anti-VEGF-A</FONT> monotherapies do not fully address the multifactorial pathogenesis of wet AMD and DME, including having no activity to block
<FONT STYLE="white-space:nowrap">VEGF-C</FONT> and <FONT STYLE="white-space:nowrap">VEGF-D.</FONT> </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="white-space:nowrap">VEGF-C</FONT> and <FONT STYLE="white-space:nowrap">VEGF-D</FONT> are implicated in the development of resistance to clinical use of
<FONT STYLE="white-space:nowrap">anti-VEGF-A</FONT> therapies. Levels of <FONT STYLE="white-space:nowrap">VEGF-C</FONT> and/or <FONT STYLE="white-space:nowrap">VEGF-D</FONT> have been observed to be upregulated in response to <FONT
STYLE="white-space:nowrap">anti-VEGF-A</FONT> therapies, most notably in patients with wet AMD. In a study conducted by third-party researchers in wet AMD patients, a 66% increase in the level of <FONT STYLE="white-space:nowrap">VEGF-C</FONT> in the
aqueous humor fluid in eyes was observed following two monthly doses of the <FONT STYLE="white-space:nowrap">VEGF-A</FONT> inhibitor, bevacizumab (Avastin). This is illustrated in the figure below. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><FONT STYLE="white-space:nowrap">VEGF-C</FONT> Levels are
Increased in Aqueous Fluid of the Eye in Wet AMD Patients Treated with Monthly Intravitreal Bevacizumab </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center">


<IMG SRC="g947560g02v46.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1">Study conducted by Cabral
et al. (2018) </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Upregulation of <FONT
STYLE="white-space:nowrap">VEGF-C</FONT> and <FONT STYLE="white-space:nowrap">VEGF-D</FONT> can continue to drive signaling through <FONT STYLE="white-space:nowrap">VEGFR-2,</FONT> even in the presence of a
<FONT STYLE="white-space:nowrap">VEGF-A</FONT> inhibitor, as well as signal through <FONT STYLE="white-space:nowrap">VEGFR-3,</FONT> both of which may contribute to ongoing angiogenesis and vascular permeability associated with persistent wet AMD. <FONT
STYLE="white-space:nowrap">VEGF-C</FONT> and <FONT STYLE="white-space:nowrap">VEGF-D</FONT> mediated activation of <FONT STYLE="white-space:nowrap">VEGFR-2</FONT> and <FONT STYLE="white-space:nowrap">VEGFR-3,</FONT> as well as their compensatory
elevation following <FONT STYLE="white-space:nowrap">VEGF-A</FONT> inhibition, may contribute to <FONT STYLE="white-space:nowrap">sub-optimal</FONT> clinical response to <FONT STYLE="white-space:nowrap">anti-VEGF-A</FONT> monotherapy. We believe <FONT
STYLE="white-space:nowrap">OPT-302</FONT> in combination with a <FONT STYLE="white-space:nowrap">VEGF-A</FONT> inhibitor can address a key mechanism of clinical <FONT STYLE="white-space:nowrap">sub-responsiveness</FONT> to standard of care
treatments for serious retinal eye diseases by broad blockade of the VEGF family of growth factors which is not achieved by <FONT STYLE="white-space:nowrap">anti-VEGF-A</FONT> monotherapies. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><FONT STYLE="white-space:nowrap">OPT-302</FONT> </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We are developing our Phase
<FONT STYLE="white-space:nowrap">3-ready</FONT> product candidate, <FONT STYLE="white-space:nowrap">OPT-302,</FONT> a biologic designed to inhibit <FONT STYLE="white-space:nowrap">VEGF-C</FONT> and <FONT STYLE="white-space:nowrap">VEGF-D,</FONT> to
complement existing <FONT STYLE="white-space:nowrap">VEGF-A</FONT> inhibitors, for the treatment of ophthalmic diseases, including wet AMD and DME. <FONT STYLE="white-space:nowrap">Anti-VEGF-A</FONT> therapies represent the standard of care for wet
AMD and other retinal </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">106
</FONT></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
diseases. However, there remains a significant unmet need as many patients do not adequately respond to these treatments. As the only biologic inhibitor of
<FONT STYLE="white-space:nowrap">VEGF-C</FONT> and <FONT STYLE="white-space:nowrap">VEGF-D</FONT> in clinical development, <FONT STYLE="white-space:nowrap">OPT-302</FONT> differs from standard of care <FONT STYLE="white-space:nowrap">VEGF-A</FONT>
inhibitors, and in combination with a <FONT STYLE="white-space:nowrap">VEGF-A</FONT> inhibitor, is designed to address the <FONT STYLE="white-space:nowrap">sub-optimal</FONT> clinical responses of <FONT STYLE="white-space:nowrap">anti-VEGF-A</FONT>
monotherapies by achieving broader inhibition of the VEGF family to improve visual acuity over standard of care <FONT STYLE="white-space:nowrap">anti-VEGF-A</FONT> monotherapies. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In 2019, we completed a
<FONT STYLE="white-space:nowrap">366-patient</FONT> Phase 2b clinical trial of <FONT STYLE="white-space:nowrap">OPT-302</FONT> in combination with ranibizumab for the treatment of wet AMD, which met the primary endpoint of a statistically
significant superior mean gain in visual acuity over ranibizumab monotherapy at week 24. We intend to initiate two pivotal Phase 3 clinical trials in treatment-naive patients with wet AMD to evaluate the efficacy and safety of <FONT
STYLE="white-space:nowrap">OPT-302</FONT> in combination with <FONT STYLE="white-space:nowrap">anti-VEGF-A</FONT> therapy compared to a standard of care monotherapy. We intend to initiate two pivotal Phase 3 clinical trials in treatment-naive
patients with wet AMD to evaluate the efficacy and safety of OPT-302 in combination with anti-VEGF-A therapy compared to anti-VEGF-A monotherapy in the first half of 2021. We expect to report topline data from these Phase 3 clinical trials in 2023.
In addition, in our Phase 1b/2a clinical trial of <FONT STYLE="white-space:nowrap">OPT-302</FONT> in combination with aflibercept for the treatment of persistent DME, we observed evidence of clinical activity and improvements in visual acuity
outcomes compared to aflibercept monotherapy. <FONT STYLE="white-space:nowrap">OPT-302</FONT> was observed to be well tolerated across Phase 1 and Phase 2 clinical studies in two disease indications following intravitreal administration of over
1,800 doses of <FONT STYLE="white-space:nowrap">OPT-302</FONT> to 399 patients either as monotherapy or in combination with standard of care <FONT STYLE="white-space:nowrap">VEGF-A</FONT> inhibitors. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I><FONT STYLE="white-space:nowrap">OPT-302</FONT>
Mechanism of Action </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%;padding-bottom:0px; "><FONT STYLE="font-family:Times New Roman" SIZE="2">We have designed <FONT STYLE="white-space:nowrap">OPT-302</FONT> to function as a ligand trap, capable of binding and
sequestering <FONT STYLE="white-space:nowrap">VEGF-C</FONT> and <FONT STYLE="white-space:nowrap">VEGF-D,</FONT> thereby preventing these growth factors from activating <FONT STYLE="white-space:nowrap">VEGFR-2</FONT> and <FONT
STYLE="white-space:nowrap">VEGFR-3.</FONT> <FONT STYLE="white-space:nowrap">OPT-302</FONT> is comprised of the first three extracellular domains of human <FONT STYLE="white-space:nowrap">VEGFR-3,</FONT> fused to the Fc domain, or the constant
fragment of human immunoglobulin G</FONT><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUB STYLE="vertical-align:baseline; position:relative; top:.4ex">1</SUB></FONT><FONT STYLE="font-family:Times New Roman" SIZE="2">, or IgG</FONT><FONT
STYLE="font-family:Times New Roman" SIZE="1"><SUB STYLE="vertical-align:baseline; position:relative; top:.4ex">1</SUB></FONT><FONT STYLE="font-family:Times New Roman" SIZE="2">, as illustrated in the figure below.
<FONT STYLE="white-space:nowrap">VEGF-C</FONT> and <FONT STYLE="white-space:nowrap">VEGF-D</FONT> function independent of, but in parallel with, <FONT STYLE="white-space:nowrap">VEGF-A</FONT> to drive neovascularization and vascular leakage, key
hallmarks of both wet AMD and DME. In addition, treatment with <FONT STYLE="white-space:nowrap">VEGF-A</FONT> inhibitors leads to upregulation of <FONT STYLE="white-space:nowrap">VEGF-C</FONT> and <FONT STYLE="white-space:nowrap">VEGF-D</FONT> to
compensate for <FONT STYLE="white-space:nowrap">VEGF-A</FONT> inhibition, which may represent an important mechanism of clinical resistance to <FONT STYLE="white-space:nowrap">VEGF-A</FONT> monotherapy. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Structure of
<FONT STYLE="white-space:nowrap">OPT-302</FONT> </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center">


<IMG SRC="g947560g03q94.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Ligand trap therapeutics
that include the receptor-binding domains for other ligands have been approved for a number of indications. One such agent is aflibercept, marketed as Eylea, a ligand trap consisting of extracellular domains of
<FONT STYLE="white-space:nowrap">VEGFR-1</FONT> and <FONT STYLE="white-space:nowrap">VEGFR-2,</FONT> which primarily mediates its activity by binding and inhibiting <FONT STYLE="white-space:nowrap">VEGF-A.</FONT> Aflibercept has marketing approval
for the treatment of wet AMD, DME, macular edema </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">107
</FONT></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
secondary to RVO and DR. In rabbits, OPT-302 has been shown to have a comparable ocular biodistribution and intravitreal pharmacokinetic profile as aflibercept, with low systemic exposure.
</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Wet AMD </I></B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">AMD is a chronic, progressive disease of the macula, a part
of the retina containing the greatest concentration of light-sensing cells responsible for detailed, high visual acuity and central vision. The development of AMD is strongly associated with age, affecting up to 40% of individuals over the age of
75. There are two forms of AMD, dry AMD and wet AMD. Dry AMD is the most common form, representing approximately 85% to 90% of all AMD cases. However, dry AMD can develop into wet AMD, and wet AMD accounts for 90% of the severe vision loss
associated with the disease. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Wet AMD is a rapidly
progressing disease with loss of central vision developing over a period of weeks to months, and is the leading cause of vision loss for individuals over the age of 50. The most common symptoms of wet AMD are loss of central vision, distortion of
objects or blurred vision. Peripheral vision usually remains intact. The disease typically affects patients initially in one eye, with a high likelihood of it occurring in the second eye over time. If left untreated, wet AMD can lead to rapid loss
of visual acuity and blindness, adversely impacting the patient&#146;s ability to conduct daily activities, such as driving and reading. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Wet AMD occurs when new blood vessels in the choroid, or the vascular layer in the eye just under the retina, intrude into the retinal
layers and leak fluid. The formation of these new blood vessels is referred to as CNV. These newly formed vessels are highly permeable, which can lead to fluid accumulation and adversely affect sensory cells in the retina. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Wet AMD can be classified as occult or classic, based on the
neovascular pattern within lesions. In occult lesions, all of the blood vessels are below the retinal pigment epithelium, or RPE, and the areas on angiograms have a stippled appearance. Classic lesions, by contrast, appear as well-demarcated areas
on angiograms due to neovascular blood vessels being located above the RPE. Classic lesions are further subdivided into predominantly classic if 50% or more of the blood vessels are above the RPE, and minimally classic, if greater than 0% and less
than 50% of the blood vessels are above the RPE. Classic-containing lesions tend to be the most responsive to <FONT STYLE="white-space:nowrap">anti-VEGF-A</FONT> therapies. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Classifications of Wet AMD Based on Neovascular Lesion
Pattern </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center">


<IMG SRC="g947560g37q51.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">There is a further <FONT
STYLE="white-space:nowrap">sub-type</FONT> of wet AMD lesion referred to as retinal angiomatous proliferation, or RAP. RAP lesions are a type of CNV in which neovascularization in the retina protrudes into the
<FONT STYLE="white-space:nowrap">sub-retinal</FONT> space and connects to the choroidal circulation. Between 10% and 21% of wet AMD patients have RAP lesions which are more commonly found in older Caucasian patients. Although there are no therapies
specifically approved to treat RAP lesions, patients are typically treated with <FONT STYLE="white-space:nowrap">VEGF-A</FONT> inhibitors. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">108
</FONT></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">PCV is a further <FONT STYLE="white-space:nowrap">sub-type</FONT> of wet AMD. PCV is an
abnormality of inner choroidal vessels that causes dilations in the blood vessels in the retina that resemble polyps, known as polypoidal protrusions. PCV typically does not respond well to <FONT STYLE="white-space:nowrap">VEGF-A</FONT> inhibitor
therapies and many patients are diagnosed with PCV only after they fail to respond to these therapies. There is a high prevalence of PCV in Asian countries, with between 23% and 54% of patients with presumed cases of wet AMD in Japan having PCV.
Prevalence rates of between 4% and 10% have been reported in Caucasian patients with presumed cases of wet AMD. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Current Treatments for Wet AMD and Their Limitations </I></B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">There are four
<FONT STYLE="white-space:nowrap">VEGF-A</FONT> inhibitors approved by the Food and Drug Administration, or FDA, for the treatment of wet AMD, all of which are administered by regular intravitreal injections as monotherapy. These <FONT
STYLE="white-space:nowrap">VEGF-A</FONT> inhibitors include: the <FONT STYLE="white-space:nowrap">VEGF-A</FONT> specific antibody ranibizumab, the antibody fragment brolucizumab (Beovu) and the VEGFR-based ligand trap aflibercept. The <FONT
STYLE="white-space:nowrap">VEGF-A</FONT> antibody, bevacizumab, an FDA approved therapy for colorectal and other cancers, is also used <FONT STYLE="white-space:nowrap">off-label</FONT> by many physicians to treat wet AMD, comprising approximately
46% of anti-VEGF-A injections administered globally. In addition, pegaptanib sodium (Macugen) is an aptamer or antibody-like RNA construct that inhibits <FONT STYLE="white-space:nowrap">VEGF-A</FONT> but is now infrequently administered following
the approval of biologic <FONT STYLE="white-space:nowrap">VEGF-A</FONT> inhibitors. Recent clinical development has focused on maintaining vision gains with a <FONT STYLE="white-space:nowrap">VEGF-A</FONT> inhibitor whilst reducing the number of
injections. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="white-space:nowrap">VEGF-A</FONT> inhibitors stabilize loss vision in over 90% of wet AMD patients. However, the
effectiveness of these therapies in many patients is limited. Improvements of <FONT STYLE="FONT-FAMILY:SYMBOL">&#179;</FONT>15 letters of visual acuity typically occur in less than 40% of treated patients. In addition, despite regular treatment with
a <FONT STYLE="white-space:nowrap">VEGF-A</FONT> inhibitor, many patients have insufficient gains in visual acuity to resume routine daily activities such as driving and reading. Chronic vision loss can also occur despite ongoing treatment with an <FONT
STYLE="white-space:nowrap">anti-VEGF-A</FONT> inhibitor. Retrospective and prospective analyses of patients treated with <FONT STYLE="white-space:nowrap">VEGF-A</FONT> inhibitor therapies for five years have found that, after initial gains in visual
function following one year of treatment, many patients then had a gradual decline in visual acuity in subsequent years, resulting in the eventual reversal of the majority of gains. In addition, in clinical settings, up to two-thirds of patients
treated with VEGF-A inhibitor therapies continue to have retinal fluid following treatment and approximately 25% experience further vision loss 12&nbsp;months following treatment. Treatment options are limited for patients who do not respond
adequately or experience visual decline despite ongoing therapy with standard of care <FONT STYLE="white-space:nowrap">VEGF-A</FONT> inhibitors, and typically involve switching treatment from one <FONT STYLE="white-space:nowrap">anti-VEGF-A</FONT>
monotherapy to another with minimal additional visual benefit achieved. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B><I>Market Opportunity for the Treatment of Wet AMD </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Wet AMD affects approximately 1&nbsp;million people in the United States and 2.5&nbsp;million in Europe. As the risk of developing wet AMD
increases with age, it is predicted that the overall aging of the population will result in a significant increase in the number of wet AMD cases, both in the United States and worldwide. Many wet AMD patients also experience suboptimal clinical
responses despite receiving one or both of the leading standard of care treatments ranibizumab and aflibercept, which had combined annual worldwide sales of over US$11.9&nbsp;billion in 2019. In addition, nearly half of wet AMD patients are treated
with off-label bevacizumab as a lower cost alternative anti-VEGF-A therapy. As a result, we believe there is a significant and expanding market opportunity for novel therapies that can improve vision in patients with wet AMD, which has the potential
to lead to sales greater than the combined annual sales of ranibizumab and aflibercept. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">We believe that <FONT STYLE="white-space:nowrap">OPT-302,</FONT> used in combination with standard of care <FONT STYLE="white-space:nowrap">VEGF-A</FONT> inhibitors, can address the significant unmet need
for wet AMD patients by providing improved outcomes over that which can be achieved by inhibiting <FONT STYLE="white-space:nowrap">VEGF-A</FONT> alone. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Phase 1/2a Clinical Trial Results in Wet AMD </I></B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In 2017, we completed a Phase 1/2a clinical trial of <FONT
STYLE="white-space:nowrap">OPT-302</FONT> in wet AMD patients under an investigational new drug, or IND, application accepted by the FDA in 2015. The trial was divided into two parts. Part 1 was a Phase&nbsp;1 <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">first-in-human</FONT></FONT> <FONT STYLE="white-space:nowrap">20-patient</FONT> dose-escalation study in which <FONT STYLE="white-space:nowrap">OPT-302</FONT> was administered at three escalating
</FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">109
</FONT></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
doses (0.3&nbsp;mg, 1.0 mg or 2.0 mg), either in combination with 0.5 mg ranibizumab or alone as a 2.0&nbsp;mg monotherapy, once every four weeks for a total of three doses, with a <FONT
STYLE="white-space:nowrap">follow-up</FONT> visit at week&nbsp;12. Part&nbsp;2 was a Phase 2a <FONT STYLE="white-space:nowrap">31-patient</FONT> dose-expansion trial in which 2.0 mg <FONT STYLE="white-space:nowrap">OPT-302</FONT> was administered in
combination with ranibizumab or as a monotherapy once every four weeks for a total of three doses, with a <FONT STYLE="white-space:nowrap">follow-up</FONT> visit at week 12. Of the 51 patients dosed, 49% were treatment naive and 51% were previously
treated with <FONT STYLE="white-space:nowrap">anti-VEGF-A</FONT> therapy. The previously-treated patients had received an average of 17 prior treatments, equating to prior treatment over an average of 1.3 years, of an intravitreal <FONT
STYLE="white-space:nowrap">VEGF-A</FONT> inhibitor prior to enrolling in the trial. The Phase 1/2a trial was conducted at 14 trial sites in the United States. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="white-space:nowrap">OPT-302</FONT> was well tolerated up to the highest dose tested both in combination with ranibizumab and
as a monotherapy. No dose-limiting toxicities, or DLTs, were observed and the maximum tolerated dose, or MTD, was not reached. There were no treatment-related serious adverse events, or SAEs. The most common TEAEs were conjunctival hemorrhage, eye
pain and corneal inflammation mainly related to the intravitreal injection procedure. TEAEs did not lead to permanent discontinuation of the study for any patient. The pharmacokinetic profile of <FONT STYLE="white-space:nowrap">OPT-302</FONT> was
similar in the absence or presence of ranibizumab, and there was no evidence of <FONT STYLE="white-space:nowrap">OPT-302</FONT> immunogenicity in this clinical trial. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Although the focus of this trial was safety, we also observed
preliminary signals of clinical benefit. Improvements in visual acuity were observed in treatment-naive patients as well as patients previously treated with <FONT STYLE="white-space:nowrap">anti-VEGF-A</FONT> therapy, as measured by the number of
letters that could be read on a standard eye chart following <FONT STYLE="white-space:nowrap">OPT-302</FONT> monotherapy and <FONT STYLE="white-space:nowrap">OPT-302</FONT> combination therapy. As illustrated in the figure below, after
12&nbsp;weeks, in patients across all dose groups, the mean change in visual acuity from baseline increased by +10.8 letters in treatment-naive patients and +4.9 letters in previously treated patients who received
<FONT STYLE="white-space:nowrap">OPT-302</FONT> combination therapy. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>Mean Change in Visual Acuity from Baseline to Week 12 in Treatment-Naive and Previously-Treated Wet AMD Patients Administered <FONT STYLE="white-space:nowrap">OPT-302</FONT> in Combination with
Ranibizumab </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center">


<IMG SRC="g947560g02f26.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In addition, improvements
in visual acuity following treatment with <FONT STYLE="white-space:nowrap">OPT-302</FONT> combination therapy were consistent with anatomical outcomes, such as reductions in intraretinal and subretinal fluid. Retinal thickness, which is assessed by
spectral domain optical coherence tomography, or <FONT STYLE="white-space:nowrap">SD-OCT,</FONT> using a standard criterion called central subfield thickness, or CST, was also reduced following <FONT STYLE="white-space:nowrap">OPT-302</FONT>
combination therapy. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">110
</FONT></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Phase 2b Clinical Trial Results in Wet AMD </I></B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Based on the positive results of the Phase 1/2a trial, we
completed an international, multi-center, double-masked Phase 2b clinical trial of <FONT STYLE="white-space:nowrap">OPT-302</FONT> in combination with ranibizumab in a total of 366 treatment-naive patients in August 2019. As illustrated in the
figure below, patients were randomized into three groups to receive either 0.5 mg or 2.0 mg <FONT STYLE="white-space:nowrap">OPT-302</FONT> with 0.5 mg ranibizumab or ranibizumab monotherapy, which included a sham injection. A sham intravitreal
injection involves pressing a syringe hub against the surface of the eye to mimic an intravitreal injection so that the patient remains masked to the treatment group to which they have been randomized. Administration was by intravitreal injection
once every four weeks for 20 weeks (six treatments in total). The primary endpoint of the clinical trial was the mean change in BCVA from baseline on the ETDRS standardized eye chart at week 24. Secondary outcome measures included the proportion of
patients gaining <FONT STYLE="FONT-FAMILY:SYMBOL">&#179;</FONT>15 letters in BCVA, changes in retinal thickness, change in intraretinal and subretinal fluid and proportion of patients losing <FONT STYLE="FONT-FAMILY:SYMBOL">&#179;</FONT>15 letters
in BCVA. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Design of the Phase 2b Clinical Trial
of <FONT STYLE="white-space:nowrap">OPT-302</FONT> with Ranibizumab in Wet AMD </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center">


<IMG SRC="g947560g58w10.jpg" ALT="LOGO">
 </P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">111
</FONT></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">As illustrated in the figure below, 366 treatment-naive patients were randomized 1:1:1
to each of the three treatment groups. We used data from the 362 patients who had a baseline assessment of their visual acuity and completed at least one post-dose visit as the modified intent to treat population, or mITT, in all analyses. Key
inclusion criteria for patients in the trial included CNV classified as either occult, minimally classic or predominantly classic, and BCVA on the ETDRS standardized eye chart of <FONT STYLE="FONT-FAMILY:SYMBOL">&#179;</FONT>25 and <FONT
STYLE="FONT-FAMILY:SYMBOL">&#163;</FONT>60 letters. The Phase 2b trial was conducted at 109 trial sites in the United States, Europe, Israel and the United Kingdom. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Patient Distribution in the Phase 2b Clinical Trial in Wet
AMD </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center">


<IMG SRC="g947560g59e21.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1">Q4W refers to
administration every four weeks. IVT refers to administration by intravitreal injection. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">In presentations of statistical results in this prospectus, a p-value is a measure of statistical significance of the observed results, or the probability that the observed results were achieved purely by
chance. By convention, a p-value of 0.05 or lower is commonly considered statistically significant. The FDA and comparable non-U.S. regulatory authorities utilize the reported statistical measures when evaluating the results of a clinical trial,
including statistical significance as measured by p-value, to evaluate the reported evidence of a drug product&#146;s safety and efficacy. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Improvements in Visual Acuity </I></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Phase 2b clinical trial met the primary endpoint, demonstrating a statistically significant superior mean gain in visual acuity at
week 24 compared to baseline in the 2.0 mg <FONT STYLE="white-space:nowrap">OPT-302</FONT> combination therapy group compared to the ranibizumab monotherapy group. The figure below illustrates patients in the 2.0 mg
<FONT STYLE="white-space:nowrap">OPT-302</FONT> combination therapy group had a mean visual acuity improvement of +14.22 letters relative to baseline, compared to +10.84 letters for those treated with ranibizumab monotherapy at week 24 (p=0.0107).
This represents a statistically significant benefit of +3.4 letters and a greater than 30% relative improvement in vision outcomes in the <FONT STYLE="white-space:nowrap">OPT-302</FONT> combination group compared to ranibizumab monotherapy. Evidence
of improved visual acuity was observed beginning as early as week 8 and continued throughout the course of the trial to week&nbsp;24. Mean visual acuity in the lower dose 0.5 mg <FONT STYLE="white-space:nowrap">OPT-302</FONT> combination therapy
group was not significantly </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">112
</FONT></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
different from the ranibizumab monotherapy group. However, evidence of a dose response was observed between the 2.0 mg and 0.5 mg <FONT STYLE="white-space:nowrap">OPT-302</FONT> combination
therapy groups on several anatomical outcomes, such as retinal thickness and the proportion of patients with intraretinal and subretinal fluid at week 24. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Mean Change in Visual Acuity from Baseline to Week 24 in Treatment-Naive Wet AMD Patients Administered Ranibizumab Monotherapy or <FONT
STYLE="white-space:nowrap">OPT-302</FONT> Combination Therapy </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center">


<IMG SRC="g947560g60r81.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1">Error bars shown in all
figures represent the SEM, or the standard error of the mean. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">113
</FONT></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Secondary outcome measurements from the trial were also supportive of the primary
endpoint. As illustrated in the figure below, we observed a greater proportion of patients gaining <FONT STYLE="FONT-FAMILY:SYMBOL">&#179;</FONT>15, <FONT STYLE="FONT-FAMILY:SYMBOL">&#179;</FONT>10 and <FONT STYLE="FONT-FAMILY:SYMBOL">&#179;</FONT>5
letters in the 2.0 mg <FONT STYLE="white-space:nowrap">OPT-302</FONT> combination therapy group compared to the ranibizumab monotherapy group. In addition, the proportion of patients losing <FONT STYLE="FONT-FAMILY:SYMBOL">&#179;</FONT>15, <FONT
STYLE="FONT-FAMILY:SYMBOL">&#179;</FONT>10 and <FONT STYLE="FONT-FAMILY:SYMBOL">&#179;</FONT>5 letters was lower in the 2.0 mg <FONT STYLE="white-space:nowrap">OPT-302</FONT> combination therapy group compared to the ranibizumab monotherapy group.
The Phase 2b trial was not designed for statistical significance on secondary and exploratory endpoints and was not powered to detect statistically significant differences in secondary outcome measurements. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Greater Proportion of Patients Gaining, and Fewer Patients
Losing, </B><FONT STYLE="FONT-FAMILY:SYMBOL">&#179;</FONT><B></B><B>15, </B><FONT STYLE="FONT-FAMILY:SYMBOL">&#179;</FONT><B></B><B>10 and </B><FONT STYLE="FONT-FAMILY:SYMBOL">&#179;</FONT><B></B><B>5 Letters with
<FONT STYLE="white-space:nowrap">OPT-302</FONT> Combination Therapy Compared to Ranibizumab Monotherapy </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center">


<IMG SRC="g947560g61k18.jpg" ALT="LOGO">
 </P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">114
</FONT></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Reductions in Retinal Thickness and Fluid </I></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In addition to the statistically significant improvement in
visual acuity, treatment with <FONT STYLE="white-space:nowrap">OPT-302</FONT> combination therapy led to greater reductions in retinal thickness. The reductions in retinal thickness in patients is consistent with less fluid accumulation in the
retina and reduced disease severity as increased fluid accumulation in the retina is associated with the loss of visual acuity in wet AMD patients. The figure below depicts the greater mean reduction in retinal thickness in the <FONT
STYLE="white-space:nowrap">OPT-302</FONT> combination therapy group compared to the ranibizumab monotherapy group at week 24. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Greater Reduction in Retinal Thickness from Baseline to Week 24 following <FONT STYLE="white-space:nowrap">OPT-302</FONT> Combination
Therapy Compared to Ranibizumab Monotherapy </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center">


<IMG SRC="g947560g12r10.jpg" ALT="LOGO">
 </P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">115
</FONT></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Fewer patients in the <FONT STYLE="white-space:nowrap">OPT-302</FONT> combination
therapy group had subretinal fluid and intraretinal fluid present compared to the ranibizumab monotherapy group. The presence of subretinal fluid is a hallmark of wet AMD and its resolution is referred to as &#147;drying&#148; of the retina while
intraretinal fluid is a prognostic biomarker for poor visual acuity and <FONT STYLE="white-space:nowrap">sub-optimal</FONT> response to <FONT STYLE="white-space:nowrap">anti-VEGF-A</FONT> therapies. As illustrated in the figure below, there were
approximately 10% fewer patients with subretinal fluid and 5% fewer patients with intraretinal fluid following administration of <FONT STYLE="white-space:nowrap">OPT-302</FONT> combination therapy compared to ranibizumab monotherapy. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Fewer Patients with Subretinal and Intraretinal Fluid
Present at Week 24 Following <FONT STYLE="white-space:nowrap">OPT-302</FONT> Combination Therapy Compared to Ranibizumab Monotherapy </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px">&nbsp;</P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center">


<IMG SRC="g947560g12q20.jpg" ALT="LOGO">
 </P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">116
</FONT></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Greater improvements in anatomical indicators of disease severity, including on
exploratory endpoints of mean reduction in total lesion area and CNV area, were observed in the <FONT STYLE="white-space:nowrap">OPT-302</FONT> combination therapy group compared to ranibizumab monotherapy. As illustrated in the figure below, the
patients treated with <FONT STYLE="white-space:nowrap">OPT-302</FONT> combination therapy had an approximately 39% further reduction in both total lesion area and CNV area compared to ranibizumab monotherapy. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Greater Reduction in Total Lesion Area and CNV Area from
Baseline to Week 24 following <FONT STYLE="white-space:nowrap">OPT-302</FONT> Combination Therapy Compared to Ranibizumab Monotherapy </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px">&nbsp;</P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center">


<IMG SRC="g947560g17z07.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Improved Therapeutic
Outcomes in Wet AMD Lesion Subtypes </I></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">A number
of <FONT STYLE="white-space:nowrap">pre-specified</FONT> subgroup and exploratory analyses were incorporated into the Phase 2b trial design in order to identify those wet AMD patients who may respond best to
<FONT STYLE="white-space:nowrap">OPT-302.</FONT> The Phase 2b trial randomized patients with a broad range of lesion morphologies including occult, minimally classic and predominantly classic lesions. In addition, the Phase 2b trial investigated
efficacy in post-hoc analyses in other wet AMD subtypes, including PCV and RAP. This trial was not designed for statistical significance on these subgroup and exploratory analyses and was not powered to detect statistically significant differences
in related measurements. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">117
</FONT></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Patients enrolled in our Phase 2b trial consisted of 44% occult, 43% minimally classic
and 13% predominantly classic lesion types, which is similar to the distribution reported in treatment-naive wet AMD patients. Predominantly classic patients typically respond well to <FONT STYLE="white-space:nowrap">VEGF-A</FONT> inhibitor therapy
and an additive benefit of <FONT STYLE="white-space:nowrap">OPT-302</FONT> combination therapy could not be discerned in this small patient group of only 15 patients per treatment arm. The majority of patients randomized in the Phase 2b trial had
occult or minimally classic lesions. These patients did not respond as well to ranibizumab monotherapy as those with predominantly classic lesions. Patients with occult and minimally classic lesions treated with
<FONT STYLE="white-space:nowrap">OPT-302</FONT> combination therapy experienced improvement in visual acuity beginning at week 8 and persisting through week 24 compared to ranibizumab monotherapy. The figure below illustrates the mean change in
visual acuity over 24 weeks in each of the lesion classifications treated with <FONT STYLE="white-space:nowrap">OPT-302</FONT> combination therapy compared to ranibizumab monotherapy. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Mean Change in Visual Acuity from Baseline to Week 24 in Wet AMD Lesion Types Following <FONT
STYLE="white-space:nowrap">OPT-302</FONT> Combination Therapy Compared to Ranibizumab Monotherapy </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center">


<IMG SRC="g947560g38g34.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In a post-hoc analysis, in
the occult lesion subgroup, the mean visual acuity gain from baseline to week 24 in the <FONT STYLE="white-space:nowrap">OPT-302</FONT> combination therapy group was +16.2 letters (n=53), compared to +10.2 letters in the ranibizumab monotherapy
group (n=51), a benefit of +6.0 letters. In addition, in the minimally classic subgroup, the mean visual acuity gain from baseline to week 24 in the <FONT STYLE="white-space:nowrap">OPT-302</FONT> combination therapy group was +13.7 letters (n=53),
compared to +11.1 letters in the ranibizumab monotherapy group (n=53), a benefit of +2.7 letters. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">118
</FONT></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Gains in Visual Acuity from Baseline to Week 24 in Patients with Occult and Minimally
Classic Lesions Following <FONT STYLE="white-space:nowrap">OPT-302</FONT> Combination Therapy Compared to Ranibizumab Monotherapy </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px">&nbsp;</P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center">


<IMG SRC="g947560g60u79.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In particular, in the
occult lesion subgroup, we observed a greater proportion of patients gaining <FONT STYLE="FONT-FAMILY:SYMBOL">&#179;</FONT>15 and </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT
STYLE="FONT-FAMILY:SYMBOL">&#179;</FONT>10 letters in the OPT-302 combination therapy group compared to the ranibizumab monotherapy group </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">(approximately 22% and 19% over ranibizumab monotherapy, respectively). In the minimally classic subgroup, </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">we observed a greater proportion of patients (approximately 10% over ranibizumab monotherapy) gaining <FONT STYLE="FONT-FAMILY:SYMBOL">&#179;</FONT>10
letters in the OPT-302 combination therapy group compared to the ranibizumab monotherapy group. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">In patients with occult lesions, treatment with <FONT STYLE="white-space:nowrap">OPT-302</FONT> combination therapy also led to a greater mean reduction in retinal thickness of <FONT
STYLE="white-space:nowrap">-134.6</FONT> &micro;m from baseline compared to <FONT STYLE="white-space:nowrap">-103.5</FONT> &micro;m for ranibizumab monotherapy. <FONT STYLE="white-space:nowrap">OPT-302</FONT> combination therapy did not have greater
clinical benefit in the reduction of retinal thickness in minimally classic lesions, compared to the ranibizumab monotherapy group. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In patients with occult lesions, approximately 13% and 12% fewer patients in the OPT-302 combination group had subretinal fluid and
intraretinal fluid, respectively, as compared to ranibizumab monotherapy at week 24. In patients with minimally classic lesions, approximately 2% fewer patients treated with <FONT STYLE="white-space:nowrap">OPT-302</FONT> combination therapy had
subretinal fluid and intraretinal fluid compared to patients treated with ranibizumab monotherapy at week 24. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">119
</FONT></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">As shown in the figures below, by week 24, patients with occult and minimally classic
lesions also had greater reductions in both wet AMD total lesion area and CNV area following <FONT STYLE="white-space:nowrap">OPT-302</FONT> combination therapy compared to patients receiving ranibizumab monotherapy. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Greater Reduction in Total Lesion Area from Baseline to
Week 24 in Patients with Occult and Minimally Classic Lesions Following <FONT STYLE="white-space:nowrap">OPT-302</FONT> Combination Therapy Compared to Ranibizumab Monotherapy </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px">&nbsp;</P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center">


<IMG SRC="g947560g70z93.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Greater Reduction in CNV
Area from Baseline to Week 24 in Patients with Occult and Minimally Classic Lesions Following <FONT STYLE="white-space:nowrap">OPT-302</FONT> Combination Therapy Compared to Ranibizumab Monotherapy </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center">


<IMG SRC="g947560g29f80.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">OPT-302 combination
therapy improved visual acuity to the greatest extent in occult lesions compared to minimally classic or predominantly classic lesions, in each case compared to ranibizumab monotherapy. While these results were generated in treatment-naive wet AMD
patients, classification of lesions following treatment with either OPT-302 combination therapy or ranibizumab monotherapy suggests that virtually all lesions shifted </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">120
</FONT></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
toward an occult morphology. This suggests that OPT-302 combination therapy also has the potential to provide benefit to patients who have been previously treated with anti-VEGF-A monotherapy,
given the predominantly occult morphology of their lesions following treatment. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><I>RAP and PCV Lesion Subtypes </I></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">In our Phase 2b clinical trial, over 85% of patients enrolled did not have RAP lesions detected at randomization and these patients responded better to <FONT STYLE="white-space:nowrap">OPT-302</FONT> than
patients with RAP lesions. In patients without RAP lesions, the mean visual acuity gain from baseline to week 24 was +15.0 letters (n=103) with <FONT STYLE="white-space:nowrap">OPT-302</FONT> combination therapy, compared to +10.6 letters for those
treated with ranibizumab monotherapy (n=102), a benefit of +4.4 letters. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>Mean Change in Visual Acuity from Baseline to Week 24 in Patients Without RAP Lesions Following <FONT STYLE="white-space:nowrap">OPT-302</FONT> Combination Therapy Compared to Ranibizumab Monotherapy
</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center">


<IMG SRC="g947560g02q76.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In patients without RAP
lesions who had occult or minimally classic lesions, representing the majority of wet AMD patients, the mean visual acuity gain from baseline to week 24 was +16.1 letters with <FONT STYLE="white-space:nowrap">OPT-302</FONT> combination therapy
(n=88) compared to +10.3 letters for those treated with ranibizumab monotherapy (n=87), a benefit of +5.7 letters. This represents the patient population for which the primary analysis of the primary endpoint of the planned Phase 3 trials of OPT-302
combination therapy for the treatment of wet AMD will be first conducted, followed by analysis of the total patient population and the every-eight week dosing groups. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">121
</FONT></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Mean Change in Visual Acuity from Baseline to Week 24 in the combined group of RAP
Absent Occult and Minimally Classic Lesions Following OPT-302 Combination Therapy Compared to Ranibizumab Monotherapy </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center">


<IMG SRC="g947560g25k68.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Patients with RAP absent
occult lesions demonstrated a mean visual acuity gain at week 24 of +16.8 letters with <FONT STYLE="white-space:nowrap">OPT-302</FONT> combination therapy (n=49) compared to +10.2 letters for those treated with ranibizumab monotherapy (n=47), a gain
of +6.5 letters. Patients with RAP absent minimally classic lesions demonstrated a mean visual acuity gain at week 24 of +14.9 letters with <FONT STYLE="white-space:nowrap">OPT-302</FONT> combination therapy (n=39) compared to +10.0 letters for
those treated with ranibizumab monotherapy (n=40), a gain of +4.7 letters. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>Mean Change in Visual Acuity from Baseline to Week 24 in RAP Absent Occult and Minimally Classic Lesions Following OPT-302 Combination Therapy Compared to Ranibizumab Monotherapy </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center">


<IMG SRC="g947560g14j65.jpg" ALT="LOGO">
 </P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">122
</FONT></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Improved Therapeutic Outcomes of <FONT STYLE="white-space:nowrap">OPT-302</FONT> in
PCV Lesions </I></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In patients with PCV lesions,
the mean visual acuity gain from baseline to week 24 in the <FONT STYLE="white-space:nowrap">OPT-302</FONT> combination therapy group was +13.5 letters (n=22), compared to +6.9 letters in the ranibizumab monotherapy group (n=20). This equates to a
benefit of +6.7 letters and is almost a <FONT STYLE="white-space:nowrap">two-fold</FONT> improvement in visual acuity gain observed from baseline following <FONT STYLE="white-space:nowrap">OPT-302</FONT> combination therapy. Ranibizumab monotherapy
was not observed to be as effective in patients with PCV compared to other wet AMD subtypes. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><I>Safety and Tolerability </I></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="white-space:nowrap">OPT-302</FONT> was well tolerated in this Phase 2b trial with a very low incidence of ocular inflammation and no safety issues identified with addition of <FONT
STYLE="white-space:nowrap">OPT-302</FONT> to ranibizumab intravitreal therapy. The incidence of ocular TEAEs was similar in <FONT STYLE="white-space:nowrap">OPT-302</FONT> combination groups compared to the ranibizumab monotherapy group. TEAEs were
considered potentially treatment related in approximately 15% of patients. The most common treatment-related TEAEs were eye pain, vitreous floaters, eye irritation and raised intraocular pressure. One patient discontinued from the trial due to a
TEAE, which was not considered treatment related. Three patients treated with <FONT STYLE="white-space:nowrap">OPT-302</FONT> combination therapy had potentially treatment-related SAEs: one case each of vitritis, endophthalmitis and myocardial
infarction. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Planned Pivotal Phase 3
Clinical Trials in Wet AMD </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We are
planning to initiate two concurrent pivotal Phase 3 clinical trials for the treatment of wet AMD. These double-masked, sham-controlled Phase 3 clinical trials will enroll treatment-naive patients and assess the efficacy and safety of 2.0 mg of <FONT
STYLE="white-space:nowrap">OPT-302</FONT> in combination with <FONT STYLE="white-space:nowrap">anti-VEGF-A</FONT> therapy for treatment-naive patients with wet AMD compared to a standard of care <FONT STYLE="white-space:nowrap">anti-VEGF-A</FONT>
monotherapy. In addition, to understand the durability of OPT-302 treatment effect with less frequent dosing, each trial will compare the clinical efficacy of OPT-302 administered in combination with the applicable VEGF-A inhibitor on an every
4-week and every 8-week dosing regimen. The primary endpoint of both trials will be the mean change in visual acuity from baseline at week 52. Patients will continue to be dosed until week 96 to further assess long-term safety at week 100. We expect
to initiate the trials in the first half of 2021 and to report topline data in 2023. If the results at the completion of the primary efficacy phase at week 52 of the Phase 3 clinical trials are favorable, we intend to file for marketing approval for
OPT-302 for the treatment of wet AMD in the United States, European Union and certain other territories. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">123
</FONT></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Study of OPT-302 in Combination with Ranibizumab (ShORe) Phase 3 Trial </I></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In the Study of OPT-302 in combination with Ranibizumab, or
ShORe, Phase 3 trial, treatment-naive patients with wet AMD will be randomized to one of three treatment groups. Patients randomized to the standard dosing arm will receive standard of care 0.5 mg ranibizumab every four weeks in combination with 2.0
mg OPT-302 on a standard every four weeks dosing regimen. In the extended dosing arm, 0.5 mg ranibizumab will be administered every four weeks to week 52, in combination with 2.0 mg OPT-302 administered every four weeks for three total doses over 12
weeks, followed by OPT-302 dosing every eight weeks to week 52, with a sham injection administered at visits where OPT-302 is not administered. Patients randomized to the control arm will receive 0.5 mg ranibizumab administered in combination with
sham intravitreal injections administered every four weeks to week&nbsp;52. The primary and secondary efficacy outcomes will be determined at the end of the efficacy phase at week&nbsp;52. Each patient will then continue to be treated for an
additional year in the safety phase to reach week 100 to evaluate safety and tolerability over a total two-year period. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px">&nbsp;</P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center">


<IMG SRC="g947560g01f75.jpg" ALT="LOGO">
 </P>  <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Combination of OPT-302 with
Aflibercept STudy (COAST) Phase 3 Trial </I></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In
the Combination OPT-302 with Aflibercept STudy, or COAST, Phase 3 trial, treatment-naive wet AMD patients will be randomized to one of three treatment groups. Patients randomized to the standard dosing arm will receive 2.0 mg aflibercept
administered every four weeks for three total doses over 12 weeks, followed by aflibercept dosing every eight weeks to week 52, in combination with 2.0 mg OPT-302 administered every four weeks to week 52. In the extended dosing arm, 2.0 mg
aflibercept in combination with 2.0 mg OPT-302 will be administered every four weeks for three total doses over 12 weeks, followed by dosing every eight weeks to week 52, with a sham injection administered at visits where OPT-302 and aflibercept are
not administered. Patients randomized to the control arm, will receive 2.0 mg aflibercept administered every four weeks for three total doses over 12 weeks, followed by dosing every eight weeks to week 52, in combination with sham intravitreal
injections administered every four weeks to week 52. Similar to the ShORe trial, the primary and secondary efficacy outcomes of the COAST trial will be assessed at the end of the efficacy phase at week 52. Each patient will then continue to be
treated for an additional year in the safety phase to reach week&nbsp;100 to evaluate the safety and tolerability over a total two-year period. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px">&nbsp;</P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center">


<IMG SRC="g947560g02g78.jpg" ALT="LOGO">
 </P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">124
</FONT></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">For consistency, the ShORe and COAST Phase 3 trials build upon and maintain key
features of our Phase&nbsp;2b clinical trial of OPT-302 combination therapy for the treatment of wet AMD, while evaluating the administration of OPT-302 combination therapy over a longer treatment period and in a greater number of patients. In
addition, the results of our Phase 2b clinical trial has informed the design of the Phase 3 trials. Analysis of the Phase 2b trial demonstrated that OPT-302 combination therapy increased visual acuity by a further +5.7 letters over ranibizumab
monotherapy in wet AMD patients with minimally classic and occult lesions, representing the majority of wet AMD patients. Based on these positive data, primary analysis of the primary endpoint of the Phase 3 trials will be first conducted in
patients with minimally classic and occult lesions administered OPT-302 every four weeks, followed by analysis on the total patient population and the every-eight week dosing groups. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Development of Co-Formulation </I></B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">OPT-302 is currently administered as a combination therapy
consisting of a sequential injection of OPT-302 following intravitreal administration of a VEGF-A inhibitor. We plan to develop a co-formulation of OPT-302 with an approved and/or biosimilar anti-VEGF-A therapy to achieve VEGF-A, VEGF-C and VEGF-D
inhibition following the administration of a single intravitreal injection of the co-formulated product. We believe that a co-formulated OPT-302 and VEGF-A inhibitor product could provide flexibility of treatment options for physicians and reduce
the frequency and number of injections for patients. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">We are currently assessing opportunities with multiple third parties to in-license and/or generate a biosimilar anti-VEGF-A therapy, which we intend to co-formulate with OPT-302 and advance through
non-clinical studies, including IND-enabling safety and tolerability studies. We expect to file an IND for the co-formulated product in the second half of 2021 and subsequently investigate the co-formulated product in a Phase 1 clinical trial for
the treatment of wet AMD. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Diabetic Macular Edema
</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Diabetic macular edema is a complication of
DR, a disease affecting the blood vessels of the retina in diabetics. Chronically elevated blood glucose levels, or hyperglycemia, causes damage to the small blood vessels or capillaries in the retina in patients with diabetes. The consequent
chronic decrease in oxygen supply to retinal cells results in tissue damage that is referred to as DR. Approximately <FONT STYLE="white-space:nowrap">one-third</FONT> of patients with DR or up to 10% of diabetics develop DME, which is characterized
by accumulation of fluid and retinal thickening within the macula and is responsible for most of the central visual loss experienced in the diabetic population. Central-involved DME is diagnosed when swelling or edema occurs from fluid leaking into
the central fovea region of the macula. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Current Treatments for DME and Their Limitations </I></B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="white-space:nowrap">VEGF-A</FONT> inhibitor
therapy is the first-line standard of care therapy for DME. Both ranibizumab and aflibercept are approved for the treatment of DME, and similarly to wet AMD, many patients receive bevacizumab as an <FONT STYLE="white-space:nowrap">off-label,</FONT>
lower cost alternative <FONT STYLE="white-space:nowrap">VEGF-A</FONT> inhibitor therapy. Many patients with central-involved DME require near-monthly administration of intravitreal <FONT STYLE="white-space:nowrap">VEGF-A</FONT> inhibitors during the
first 12 months of treatment, with fewer injections needed in subsequent years to maintain clinical benefit. <FONT STYLE="white-space:nowrap">VEGF-A</FONT> inhibitors have largely replaced the use of laser photocoagulation as a treatment for DME.
</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The anti-inflammatory corticosteroid therapies
dexamethasone (Ozurdex) and fluocinolone acetonide (Illuvian) are also approved for use in central-involved DME. These agents however, are rarely used as first-line therapy due to inferior visual acuity outcomes compared to <FONT
STYLE="white-space:nowrap">anti-VEGF-A</FONT> therapy. Patients with persistent DME and who are insufficiently responsive to <FONT STYLE="white-space:nowrap">anti-VEGF-A</FONT> therapy have shown some treatment benefit with intravitreal
corticosteroids. However, as intravitreal corticosteroids are associated with high rates of ocular adverse events including cataract progression and intraocular pressure elevation, switching to corticosteroids from an
<FONT STYLE="white-space:nowrap">anti-VEGF-A</FONT> therapy with a <FONT STYLE="white-space:nowrap">sub-optimal</FONT> response needs to be carefully considered. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">125
</FONT></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Despite the widespread use of treatments targeting
<FONT STYLE="white-space:nowrap">VEGF-A</FONT> in the management of DME, there is still a significant unmet need as many patients demonstrate a <FONT STYLE="white-space:nowrap">sub-optimal</FONT> response, remain treatment refractory or require
frequent injections for persistent leakage in the macula. Up to two-thirds of patients with central-involved DME treated with <FONT STYLE="white-space:nowrap">VEGF-A</FONT> inhibitors do not show reductions in the fluid or clinically meaningful
improvement in visual acuity. In addition, approximately 25% of DME patients treated with VEGF-A inhibitors continue to have macula thickening and swelling following treatment. This resistance may occur as treatment selective <FONT
STYLE="white-space:nowrap">anti-VEGF-A</FONT> monotherapies do not fully address all of the factors involved in the pathogenesis of DME. As such, combination therapies targeting alternative factors and pathways have the potential for improved
clinical outcomes in DME patients. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Market
Opportunity for the Treatment of DME </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">It
is estimated that between 1.3&nbsp;million and 2.0&nbsp;million people worldwide, including 14% of Type 1 diabetics and 6% of Type 2 diabetics, have DME . The risk of developing DME increases with time. According to the Wisconsin Epidemiologic Study
of Diabetic Retinopathy, after 10 years of <FONT STYLE="white-space:nowrap">follow-up,</FONT> 20% of patients with Type 1 diabetes and 25% of those with Type 2 diabetes will have developed DME. Ranibizumab and aflibercept, two <FONT
STYLE="white-space:nowrap">VEGF-A</FONT> inhibitors approved for the treatment of DME, generated combined annual worldwide sales of over $11.9&nbsp;billion in 2019. Approximately 22% of these sales are attributable to the treatment of DME.
</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Potential for <FONT
STYLE="white-space:nowrap">OPT-302</FONT> in DME </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">We believe that as a potent inhibitor of <FONT STYLE="white-space:nowrap">VEGF-C</FONT> and <FONT STYLE="white-space:nowrap">VEGF-D,</FONT> <FONT STYLE="white-space:nowrap">OPT-302</FONT> has the
potential to provide significant therapeutic benefit to patients affected by DME. Although the underlying causes of wet AMD and DME differ, members of the VEGF family play a role in the progression of both diseases.
<FONT STYLE="white-space:nowrap">VEGF-C</FONT> and <FONT STYLE="white-space:nowrap">VEGF-D</FONT> and their receptors are specifically implicated in the progression of diabetes. For example, patients with diabetes have higher levels of <FONT
STYLE="white-space:nowrap">VEGF-C</FONT> and <FONT STYLE="white-space:nowrap">VEGF-A</FONT> and increased expression of both <FONT STYLE="white-space:nowrap">VEGFR-2</FONT> and <FONT STYLE="white-space:nowrap">VEGFR-3</FONT> in the retina compared
to <FONT STYLE="white-space:nowrap">non-diabetics.</FONT> The <FONT STYLE="white-space:nowrap">VEGF-A</FONT> inhibitors ranibizumab and aflibercept, originally approved for treatment of wet AMD patients, have also been approved for treatment of DME
patients. Similar to wet AMD, bevacizumab is also frequently used <FONT STYLE="white-space:nowrap">off-label</FONT> as a treatment for DME. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In our completed Phase 1b dose escalation clinical trial in patients with persistent DME, we observed promising evidence of a dose
response of <FONT STYLE="white-space:nowrap">OPT-302</FONT> in combination with aflibercept, including further improvements in visual acuity despite patients&#146; having been previously treated with
<FONT STYLE="white-space:nowrap">anti-VEGF-A</FONT> therapy. In our completed Phase 2a clinical trial, we observed improved visual acuity outcomes and evidence of a reduction in retinal thickness in treatment-refractory DME patients following <FONT
STYLE="white-space:nowrap">OPT-302</FONT> combination therapy. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B><I>Phase 1b Clinical Trial of <FONT STYLE="white-space:nowrap">OPT-302</FONT> in DME </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In 2018, we completed a Phase 1b dose-escalation clinical trial of <FONT STYLE="white-space:nowrap">OPT-302</FONT> in combination with
aflibercept in nine patients with persistent DME that were previously treated with <FONT STYLE="white-space:nowrap">anti-VEGF-A</FONT> therapies. Patients were administered three escalating doses (0.3 mg, 1.0 mg or 2.0 mg) of <FONT
STYLE="white-space:nowrap">OPT-302</FONT> in combination with 2.0 mg aflibercept by intravitreal injections once every four weeks for a total of three doses. The primary analysis was conducted at week 12, four weeks after the final dose. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Across all nine patients in the Phase 1b trial, a mean gain
in visual acuity of +7.7 letters from baseline to week 12 was observed across all dose groups, with a clear dose response of improved visual acuity with increasing doses of <FONT STYLE="white-space:nowrap">OPT-302.</FONT> There was a corresponding
mean decrease in retinal thickness at week 12 of <FONT STYLE="white-space:nowrap">-71&nbsp;&micro;m</FONT> from baseline and six of nine (67%) patients had a <FONT STYLE="FONT-FAMILY:SYMBOL">&#179;</FONT>50% reduction in excess foveal thickness.
</FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">126
</FONT></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Dose-dependent Increases in Visual Acuity and Reduction in Retinal Thickness at Week
12 Following Treatment with <FONT STYLE="white-space:nowrap">OPT-302</FONT> in Combination with Aflibercept </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center">


<IMG SRC="g947560g95s99.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Five of the nine patients
in the Phase 1b trial had bilateral, persistent treatment-refractory DME. In these patients, study eyes received <FONT STYLE="white-space:nowrap">OPT-302</FONT> in combination with aflibercept, and fellow eyes received standard of care <FONT
STYLE="white-space:nowrap">anti-VEGF-A</FONT> monotherapy. In these bilateral disease patients, the mean change in visual acuity from baseline to week 12 was +10.0 letters in the study eye and +2.6 letters in the fellow eye. The corresponding
reduction in retinal thickness from baseline to week 12 was <FONT STYLE="white-space:nowrap">-80</FONT> &micro;m for <FONT STYLE="white-space:nowrap">OPT-302</FONT> combination treated study eyes, compared to
<FONT STYLE="white-space:nowrap">-6</FONT> &micro;m in fellow eyes that received <FONT STYLE="white-space:nowrap">anti-VEGF-A</FONT> monotherapy. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">127
</FONT></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>In Patients with Bilateral DME, <FONT STYLE="white-space:nowrap">OPT-302</FONT>
Combination Therapy Improved Visual Acuity and Reduced Retinal Thickness Compared to Fellow Eyes Treated with <FONT STYLE="white-space:nowrap">Anti-VEGF-A</FONT> Monotherapy </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px">&nbsp;</P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center">


<IMG SRC="g947560g29k54.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1">* Patients with bilateral disease and persistent DME in the fellow eye receiving anti-VEGF-A
(ranibizumab or aflibercept) monotherapy. Prior anti-VEGF-A therapy in Fellow Eyes BL to Week 12 (5 patients): 3x Aflibercept, 3x Ranibizumab, 1x Ranibizumab, 4x Ranibizumab, 3x Aflibercept. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="white-space:nowrap">OPT-302</FONT> in combination with aflibercept was well tolerated at all dose
levels, with no DLTs and the MTD was not reached. There were no treatment-related clinically significant changes in intraocular pressure, electrocardiograms or vital signs. The most common AEs were related to the intravitreal injection procedure.
</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Phase 2a Clinical Trial of <FONT
STYLE="white-space:nowrap">OPT-302</FONT> in DME </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Based on the positive results of our Phase 1b trial, we reported outcomes from a Phase 2a trial in persistent DME patients refractory to <FONT STYLE="white-space:nowrap">anti-VEGF-A</FONT> therapy in June
2020. Similar to the Phase 1b trial, this <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">proof-of-concept</FONT></FONT> trial was designed to investigate the ability of <FONT STYLE="white-space:nowrap">OPT-302</FONT> to improve
outcomes in persistent DME patients. The primary endpoints were clinical response rate in visual acuity as well as safety and tolerability. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Clinical Trial Design </I></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">This Phase 2a trial was a randomized, double-masked, dose expansion trial that enrolled patients diagnosed with persistent center-involved
DME despite regular administration of prior <FONT STYLE="white-space:nowrap">anti-VEGF-A</FONT> monotherapy. These patients are considered to be a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">difficult-to-treat</FONT></FONT>
patient population since they have received prior <FONT STYLE="white-space:nowrap">anti-VEGF-A</FONT> therapy and experienced a suboptimal clinical response. In our trial, these patients were defined as having visual acuity between 20/40 and 20/320
Snellen equivalent, or <FONT STYLE="FONT-FAMILY:SYMBOL">&#163;</FONT>73 and <FONT STYLE="FONT-FAMILY:SYMBOL">&#179;</FONT>24 BCVA letters on the ETDRS standardized eye chart, and retinal thickness of <FONT STYLE="FONT-FAMILY:SYMBOL">&#179;</FONT>320
&micro;m on <FONT STYLE="white-space:nowrap">SD-OCT.</FONT> In this Phase 2a trial, the mean number of prior intravitreal <FONT STYLE="white-space:nowrap">anti-VEGF-A</FONT> injections was eight in each of the treatment groups, reflecting that the
patients recruited into this trial were heavily <FONT STYLE="white-space:nowrap">pre-treated,</FONT> with a mean of 39 days since the immediate prior injection to the start of the trial. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Phase 2a trial was conducted at 53 trial sites in the United States, Israel, Australia and Latvia. Of the
144 patients randomized in the trial, 115 patients conformed sufficiently with the trial protocol and were included in our analyses of clinical efficacy. Patients were randomized 2:1 to receive either 2.0 mg
<FONT STYLE="white-space:nowrap">OPT-302</FONT> in </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">128
</FONT></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
combination with 2.0 mg aflibercept or a sham injection and 2.0 mg aflibercept. Patients received intravitreal injections once every four weeks for a total of three doses. The primary analysis
was conducted at week 12, four weeks after the final dose. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>Design of the Phase 2a Clinical Trial of <FONT STYLE="white-space:nowrap">OPT-302</FONT> in Combination with Aflibercept in Persistent Diabetic Macular Edema </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center">


<IMG SRC="g947560g44c18.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1">PRN refers to <I>pro re
nata</I>, or treatment on an as needed basis. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Improvements in Visual Acuity </I></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The primary efficacy endpoint of the trial was the clinical response rate, defined as the proportion of patients receiving <FONT
STYLE="white-space:nowrap">OPT-302</FONT> combination therapy that achieved a <FONT STYLE="FONT-FAMILY:SYMBOL">&#179;</FONT>5 letter gain in visual acuity at week 12 compared to baseline. Our predefined measure of success was a response rate of
greater than or equal to 38%, based on historical observations that show limited ability to achieve a <FONT STYLE="FONT-FAMILY:SYMBOL">&#179;</FONT>5 letter improvement in DME patients on long-term <FONT STYLE="white-space:nowrap">anti-VEGF-A</FONT>
monotherapy. As an exploratory trial, this Phase 2a was not powered to detect statistical significance of <FONT STYLE="white-space:nowrap">OPT-302</FONT> combination therapy compared to aflibercept monotherapy. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We observed that 52.8% of patients treated with <FONT
STYLE="white-space:nowrap">OPT-302</FONT> combination therapy achieved a <FONT STYLE="FONT-FAMILY:SYMBOL">&#179;</FONT>5 letter improvement in visual acuity at week 12 compared to baseline, meeting the
<FONT STYLE="white-space:nowrap">pre-specified</FONT> primary efficacy endpoint for this trial. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">The mean change in visual acuity at week 12 compared to baseline was +5.9 letters in patients receiving <FONT STYLE="white-space:nowrap">OPT-302</FONT> combination therapy and +6.1 letters in the
aflibercept monotherapy group. In the <FONT STYLE="white-space:nowrap">OPT-302</FONT> combination therapy group, the percentage of patients with visual acuity gains of <FONT STYLE="FONT-FAMILY:SYMBOL">&#179;</FONT>10 and <FONT
STYLE="FONT-FAMILY:SYMBOL">&#179;</FONT>15 letters was higher, and the percentage of patients who lost <FONT STYLE="FONT-FAMILY:SYMBOL">&#179;</FONT>5 letters was lower than that in the aflibercept monotherapy group. These measures of visual
function are shown in the figure below. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Measures of Visual Acuity at Week 12 Following <FONT STYLE="white-space:nowrap">OPT-302</FONT> Combination Therapy and Aflibercept
Monotherapy </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center">


<IMG SRC="g947560g42m12.jpg" ALT="LOGO">
 </P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">129
</FONT></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Patients treated with <FONT STYLE="white-space:nowrap">OPT-302</FONT> combination
therapy also had decreased retinal thickness compared to aflibercept monotherapy, as shown in the figure below. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Greater Reduction in Retinal Thickness from Baseline to Week 12 following <FONT STYLE="white-space:nowrap">OPT-302</FONT> Combination
Therapy Compared to Aflibercept Monotherapy </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center">


<IMG SRC="g947560g42j16.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Prior Treatment History
in Persistent DME Patients </I></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Prior studies
have shown that DME patients with mild visual acuity loss of 20/40 or better at baseline, show similar outcomes to any of the <FONT STYLE="white-space:nowrap">VEGF-A</FONT> therapies: ranibizumab, aflibercept and bevacizumab. However, in patients
with poorer baseline vision of 20/50 or worse, aflibercept has better outcomes compared to ranibizumab and bevacizumab over the first 12 months of treatment. It has also been shown that DME patients who experience inadequate responses to ranibizumab
have achieved further anatomical and functional improvements upon switching to aflibercept. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Due to the challenge of enrolling a large group of patients with identical prior treatment histories, we designed our Phase&nbsp;2a trial to accelerate enrollment by randomizing patients with variable
prior treatment histories. This strategy allowed us to more broadly understand the prior treatment history in persistent DME patients, which will inform the design of our future trials in DME. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In order to explore the importance of differences in prior treatment history, we collected detailed <FONT
STYLE="white-space:nowrap">anti-VEGF-A</FONT> treatment histories for patients enrolled in our Phase&nbsp;2a DME trial. Patients randomized into our Phase&nbsp;2a trial had variable prior treatment histories which included infrequent or irregular
dosing and/or therapy with aflibercept, ranibizumab and bevacizumab. Approximately one third of patients had a prior treatment history of having received only aflibercept, or aflibercept for their three anti-VEGF-A treatments immediately before
trial enrollment. Approximately 11% of patients had a prior treatment history of having received only ranibizumab, or ranibizumab for their three anti-VEGF-A treatments immediately before trial enrolment, whereas approximately 44% of patients had
received only bevacizumab prior to trial enrollment. Patients with a prior treatment history of bevacizumab were required to receive at least one injection of either aflibercept or ranibizumab immediately prior to randomization in to the trial.
Post-hoc analyses of the results from our Phase&nbsp;2a trial suggest that some patients may have benefitted from the increased efficacy of aflibercept and/or from the switch to aflibercept therapy as administered in our trial on an every four-week
dosing cycle. In the subset of </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">130
</FONT></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
patients who had only received aflibercept, or received aflibercept for their three <FONT STYLE="white-space:nowrap">anti-VEGF-A</FONT> treatments immediately before trial enrollment, referred to
as treatment history of prior aflibercept, the mean improvement in visual acuity observed for the aflibercept monotherapy group was +3.4 letters (n=13), compared to a mean improvement of +7.4 letters for those patients with more variable prior
treatment history who received aflibercept monotherapy (n=27) following randomization into the trial. This suggests that the majority of patients enrolled in the trial had not achieved a maximal response to all
<FONT STYLE="white-space:nowrap">anti-VEGF-A</FONT> therapies prior to enrolling in the trial. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Due to the observed increase in treatment benefit for patients with a variable treatment history who then received aflibercept every four weeks in the trial, the subset of patients with a treatment
history of prior aflibercept may represent the most stringent and least variable patient population in which to test the ability of <FONT STYLE="white-space:nowrap">OPT-302</FONT> to provide additional benefit. In this more homogeneous patient
population, as shown in the figure below, patients administered <FONT STYLE="white-space:nowrap">OPT-302</FONT> combination therapy demonstrated a mean improvement in visual acuity of +6.6 letters (n=22) from baseline to week 12, compared to +3.4
letters (n=13) in the aflibercept monotherapy group. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Greater Gains in Visual Acuity following <FONT STYLE="white-space:nowrap">OPT-302</FONT> Combination Therapy in Patients with a
Treatment History of Prior Aflibercept </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center">


<IMG SRC="g947560g01q44.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In addition, 27.3% of
patients gained <FONT STYLE="FONT-FAMILY:SYMBOL">&#179;</FONT>10 letters and 9.1% gained <FONT STYLE="FONT-FAMILY:SYMBOL">&#179;</FONT>15 letters of visual acuity from baseline to week 12 following <FONT STYLE="white-space:nowrap">OPT-302</FONT>
combination therapy. There were no patients with a treatment history of prior aflibercept that gained <FONT STYLE="FONT-FAMILY:SYMBOL">&#179;</FONT>10 letters of visual acuity in the aflibercept monotherapy group. Furthermore, the proportion of
patients who lost <FONT STYLE="FONT-FAMILY:SYMBOL">&#179;</FONT>1 letters was 9.1% in the <FONT STYLE="white-space:nowrap">OPT-302</FONT> combination therapy group and 23.1% in the aflibercept monotherapy group. We believe that these results, as
shown in the figures below, strongly support the potential of <FONT STYLE="white-space:nowrap">OPT-302</FONT> to improve the visual acuity in patients with persistent DME despite prior treatment with
<FONT STYLE="white-space:nowrap">anti-VEGF-A</FONT> monotherapy. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">131
</FONT></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Proportion of Patients with a Treatment History of Prior Aflibercept Who Gained and
Lost Visual Acuity from Baseline to Week 12 </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center">


<IMG SRC="g947560g54a02.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In this subgroup of
patients with a treatment history of prior aflibercept, anatomical changes were consistent with functional visual acuity outcomes. As shown in the figure below, a greater mean reduction in retinal thickness was observed in the <FONT
STYLE="white-space:nowrap">OPT-302</FONT> combination therapy group compared to the aflibercept monotherapy group at week&nbsp;12. In particular, 22.7% of patients in the OPT-302 combination therapy group experienced at least a 300&nbsp;&micro;m
reduction in retinal thickness at week&nbsp;12, compared to 7.7% of patients in the aflibercept monotherapy group. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Greater Mean Reduction in Retinal Thickness following <FONT STYLE="white-space:nowrap">OPT-302</FONT> Combination Therapy in Patients
with a Treatment History of Prior Aflibercept </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center">


<IMG SRC="g947560g02a85.jpg" ALT="LOGO">
 </P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">132
</FONT></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Safety and Tolerability </I></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>  <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="white-space:nowrap">OPT-302</FONT>
combination therapy was well tolerated. There was one potentially treatment-related SAE of cerebrovascular accident, or stroke, resulting in one patient discontinuing treatment and withdrawing from the trial. The most common TEAEs were conjunctival
hemorrhage and increased intraocular pressure and were mainly related to the intravitreal injection procedure. TEAEs did not lead to discontinuation of the trial for any patient. The incidence of intra-ocular inflammation was low, occurring in one
patient for each treatment group, and the observed events were manageable and able to be resolved. </FONT></P>  <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We now have extensive global clinical dosing experience demonstrating a favorable tolerability profile following repeated intravitreal
administration of <FONT STYLE="white-space:nowrap">OPT-302</FONT> in 399 patients, with over 1,800 doses of <FONT STYLE="white-space:nowrap">OPT-302</FONT> administered across three international clinical studies in two disease indications and in
combination with the two leading standard of care <FONT STYLE="white-space:nowrap">anti-VEGF-A</FONT> therapies, ranibizumab and aflibercept. In particular, across our clinical trials, the incidence of intra-ocular inflammation was similar across
all treatment groups. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Retinal Vein
Occlusion </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Based on the positive clinical
data from our clinical trials of <FONT STYLE="white-space:nowrap">OPT-302</FONT> in wet AMD and DME, we intend to prioritize future development in these two indications while exploring potential opportunities to develop <FONT
STYLE="white-space:nowrap">OPT-302</FONT> in other ophthalmic indications such as RVO, DR and other diseases involving aberrant CNV. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">RVO is a sight-threatening visual disorder resulting from blockage of one of the veins carrying blood out of the retina. This blocked vein
can leak blood and fluid resulting in swelling that can cause macular edema. Persistent, inadequately-treated macular edema associated with RVO can blur vision, cause significant loss in visual acuity and eventually lead to blindness. Macular edema
is the most common cause of vision loss in people who suffer from RVO. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Similar to wet AMD and DME, the first-line standard of care to treat macular edema associated with RVO is intravitreal <FONT STYLE="white-space:nowrap">anti-VEGF-A</FONT> monotherapy. <FONT
STYLE="white-space:nowrap">VEGF-A</FONT> inhibitors however, are only effective in significantly improving vision in approximately 30% to 40% of patients with macular edema associated with RVO above sham control. The prevalence of RVO in people over
the age of 50 has been reported to be 0.7%, or approximately 1.8&nbsp;million people in the United States and Europe. Over 500,000 individuals in the United States and Europe have macular edema associated with RVO. We believe that <FONT
STYLE="white-space:nowrap">OPT-302</FONT> has the potential to bring therapeutic benefit to patients suffering from macular edema secondary to RVO. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Competition </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The biotechnology and pharmaceutical industries, and the ophthalmic disease subsector, are characterized by rapidly advancing
technologies, evolving understanding of disease etiology, intense competition and a strong emphasis on intellectual property. While we believe that <FONT STYLE="white-space:nowrap">OPT-302</FONT> and our knowledge and experience provide us with
certain competitive advantages, we face substantial potential competition from many different sources, including large and specialty pharmaceutical and biotechnology companies, academic research institutions and governmental agencies and public and
private research institutions. Many of our current or potential competitors, either alone or with their collaboration partners, have significantly greater financial resources and expertise in research and development, manufacturing, <FONT
STYLE="white-space:nowrap">pre-clinical</FONT> studies, conducting clinical trials and marketing approved products than we do. Mergers and acquisitions in the pharmaceutical and biotechnology industries may result in even more resources being
concentrated among a smaller number of our competitors. Smaller or early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies. These competitors also
compete with us in recruiting and retaining qualified scientific and management personnel and establishing clinical trial sites and patient registration for clinical trials, as well as in acquiring technologies complementary to, or necessary for,
our programs. Accordingly, our competitors may be more successful than we may be in developing, commercializing and achieving widespread </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">133
</FONT></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
market acceptance. In addition, our competitors&#146; products may be more effective or more effectively marketed and sold than any treatment we or our development partners may commercialize and
may render our product candidates obsolete or noncompetitive before we can recover the expenses related to developing and commercializing our product candidates. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We are developing
<FONT STYLE="white-space:nowrap">OPT-302</FONT> for the treatment of wet AMD and additional retinal disease indications, such as DME and RVO, together with certain combination agents. Companies that have products that may compete with <FONT
STYLE="white-space:nowrap">OPT-302</FONT> include Roche Group, Regeneron Pharmaceuticals, Inc. and Novartis AG, which have marketed <FONT STYLE="white-space:nowrap">anti-VEGF-A</FONT> therapies including ranibizumab (Lucentis) and aflibercept
(Eylea), each a standard of care treatment for wet AMD, and brolucizumab (Beovu), as well as Ocugen, Inc., Kodiak Sciences Inc. and Graybug Vision, Inc., which have product candidates in development for the treatment of wet AMD and DME. We are also
aware of other companies that are working on therapies for the whole eye, including Santen, Inc. and Ocular Therapeutix, Inc. In addition, bevacizumab (Avastin), marketed by Genentech, Inc., is used <FONT STYLE="white-space:nowrap">off-label</FONT>
to treat wet AMD. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">It is possible that our
competitors will succeed in developing technologies that are more effective than our product candidates or that would render our technology obsolete or noncompetitive, or will succeed in developing biosimilar or interchangeable products for our
product candidates. We anticipate that we will continue to face increasing competition in the future as new companies enter our market and scientific developments surrounding biosimilars and other retinal therapies continue to accelerate,
particularly once ranibizumab and aflibercept approach loss of exclusivity. We cannot predict to what extent the entry of biosimilars or other competing products will impact potential future sales of our products or our product candidates.
</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">With respect to our current and potential future
product candidates, we believe that our ability to compete effectively and develop products that can be manufactured cost-effectively and marketed successfully will depend on our ability to: </FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT
SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">advance the development of <FONT STYLE="white-space:nowrap">OPT-302</FONT> and any other product candidates; </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">license additional technology; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">complete clinical trials which position our products for regulatory and commercial success; </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">maintain a proprietary position in our products; </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">obtain required government and other public and private approvals on a timely basis; </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">attract and retain key personnel; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">commercialize effectively; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">obtain reimbursement for our products in approved indications; </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">establish efficient manufacturing processes and supply chain; </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">comply with applicable laws, regulations and regulatory requirements and restrictions with respect to our business, including the commercialization of
our products, including with respect to any changed or increased regulatory restrictions; and </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">enter into additional collaborations to advance the development and commercialization of our product candidates. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Our Commercial License Arrangement with Selexis SA </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In October 2013, we entered into a commercial license
agreement, or the Selexis Agreement, with Selexis SA, or Selexis, under which Selexis granted us a <FONT STYLE="white-space:nowrap">non-exclusive,</FONT> worldwide, sublicensable license under certain patents,
<FONT STYLE="white-space:nowrap">know-how</FONT> and other intellectual property controlled by Selexis to use certain cell lines, deliverables and </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">134
</FONT></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
materials provide by Selexis to manufacture <FONT STYLE="white-space:nowrap">OPT-302</FONT> and related products and to use, sale and otherwise exploit such products. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We paid Selexis a nominal upfront payment upon entering into
the Selexis Agreement. We are also required to make certain payments under the Selexis Agreement totaling approximately US$1.3&nbsp;million upon the achievement of certain development and commercial milestones. We are also obligated to pay a low
single-digit running royalty on worldwide net sales of the licensed products. Our royalty obligations will continue, on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">product-by-product</FONT></FONT> and <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">country-by-country</FONT></FONT> basis, until the expiration of the relevant patents, but will not extend beyond October 2024 in any event. After the expiration of the royalty term, our
license will continue and become full paid, perpetual and irrevocable. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">The Selexis Agreement will expire on the date of expiration of the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">last-to-expire</FONT></FONT> of the license patents. Either party may
terminate the Selexis Agreement for the other party&#146;s uncured material breach or bankruptcy. We may also terminate the Selexis Agreement at any time upon prior notice to Selexis. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Intellectual Property </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">As of June&nbsp;30, 2020, we have rights to over 22 issued U.S. patents, over four U.S. patent applications, over 75 issued <FONT
STYLE="white-space:nowrap">non-U.S.</FONT> patents and over eight pending <FONT STYLE="white-space:nowrap">non-U.S.</FONT> applications. All of our current issued patents and patent applications are projected to expire between August 2021 and
November 2034. </FONT></P>  <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">With respect to soluble forms
of VEGFR-3, we own and have licensed rights to patent families including issued patents in the United States, Europe, Canada and Australia, which are expected to expire between 2022 and 2031. These patents cover composition of matter and/or method
of use claims, including claims directed at the treatment of eye diseases associated with abnormal blood vessel growth, such as wet AMD. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">With respect to <FONT STYLE="white-space:nowrap">OPT-302,</FONT> we own a patent family with two issued U.S. patents, an issued European
patent validated in 38 countries and over eight issued non-U.S. patents granted in jurisdictions such as Japan, Australia, South Africa, Mexico, Malaysia, New Zealand, Colombia, Singapore and Russia. Patent applications are pending in the United
States and in over eight other non-U.S. jurisdictions, including Europe, China, Brazil, South Korea and India. The two issued U.S. patents have claims covering the composition of matter of <FONT STYLE="white-space:nowrap">OPT-302</FONT> and its use
and/or nucleic acids, vectors, and host cells for producing it. These issued patents and pending patent applications, if issued, are expected to expire in 2034, without taking into account any patent term extension. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The actual protection afforded by a patent, which can vary
from country to country, depends on the type of patent, the scope of its coverage as determined by the patent office or courts in the country, and the availability of legal remedies in the country. The information in the above list is based on our
current assessment of patents that we own or control or have exclusively licensed. The information is subject to revision, for example, in the event of changes in the law or legal rulings affecting our patents or if we become aware of new
information. Significant legal issues remain unresolved as to the extent and scope of available patent protection for biotechnology products and processes in the United States and other important markets outside the United States. We expect that
litigation will likely be necessary to determine the term, validity, enforceability and/or scope of certain of our patents and other proprietary rights. An adverse decision or ruling with respect to one or more of our patents could result in the
loss of patent protection for a product and, in turn, the introduction of competitor products or <FONT STYLE="white-space:nowrap">follow-on</FONT> biologics to the market earlier than anticipated. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Patents expire, on a country by country basis, at various
times depending on various factors, including the filing date of the corresponding patent application(s), the availability of patent term adjustment, patent term extension and supplemental protection certificates and requirements for terminal
disclaimers. In most countries, including the United States, the patent term is 20 years from the earliest claimed filing date of a non-provisional </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">135
</FONT></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
patent application or its foreign equivalent in the applicable country. In the United States, a patent&#146;s term may, in certain cases, be lengthened by patent term adjustment, which
compensates a patentee for administrative delays by the USPTO in examining and granting a patent, or may be shortened if a patent is terminally disclaimed over a commonly owned patent or a patent naming a common inventor and having an earlier
expiration date. In the United States, a patent may also be eligible for limited patent term extension under the Drug Price Competition and Patent Term Restoration Act of 1984, or Hatch-Waxman Amendments. The Hatch-Waxman Amendments permit a patent
extension term of up to five years as compensation for patent term lost during the FDA regulatory review process. A patent term extension cannot extend the remaining term of a patent beyond a total of 14 years from the date of product approval, only
one patent applicable to each regulatory review period may be extended and only those claims covering the approved drug, a method for using it, or a method for manufacturing it may be extended, with extended rights limited to the approved product,
its approved uses, and/or its manufacture. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Although we believe our owned and licensed patents and patent applications provide us with a competitive advantage, the patent positions
of biotechnology and pharmaceutical companies can be uncertain and involve complex legal and factual questions. We may not be able to develop patentable products or processes or obtain patents from pending patent applications. In the event of patent
issuance, the patents may not be sufficient to protect the proprietary technology owned by or licensed to us or our partners. Our current patents, or patents that issue on pending applications, may be challenged, invalidated, infringed or
circumvented. In addition, changes to patent laws in the United States or in other countries may limit our ability to defend or enforce our patents, or may apply retroactively to affect the term and/or scope of our patents. Our patents have been and
may in the future be challenged by third parties in post-issuance administrative proceedings or in litigation as invalid, not infringed or unenforceable under U.S. or foreign laws, or they may be infringed by third parties. As a result, we are or
may be from time to time involved in the defense and enforcement of our patent or other intellectual property rights in a court of law and administrative tribunals, such as in USPTO <I>inter partes</I> review or reexamination proceedings, foreign
opposition proceedings or related legal and administrative proceedings in the United States and elsewhere. The costs of defending our patents or enforcing our proprietary rights in post-issuance administrative proceedings or litigation may be
substantial and the outcome can be uncertain. An adverse outcome may allow third parties to use our proprietary technologies without a license from us. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Furthermore, we rely upon trade secrets and <FONT STYLE="white-space:nowrap">know-how</FONT> and continuing technological innovation to
develop and maintain our competitive position. We seek to protect our proprietary information, in part, by using confidentiality and invention assignment agreements with its commercial partners, collaborators, employees and consultants. These
agreements are designed to protect our proprietary information and, in the case of the invention assignment agreements, to grant it ownership of technologies that are developed through a relationship with a third party. These agreements may be
breached, and we may not have adequate remedies for any breach. In addition, our trade secrets may otherwise become known or be independently discovered by competitors. To the extent that our commercial partners, collaborators, employees and
consultants use intellectual property owned by others in their work for us, disputes may arise as to the rights in related or resulting <FONT STYLE="white-space:nowrap">know-how</FONT> and inventions. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our commercial success will also depend in part on not
infringing upon the proprietary rights of third parties. It is uncertain whether the issuance of any third-party patent would require us to alter its development or commercial strategies for our product candidates or processes, or to obtain licenses
or cease certain activities. Our breach of any license agreements or failure to obtain a license to proprietary rights that it may require to develop or commercialize its future products may have an adverse impact on us. If third parties prepare and
file patent applications in the United States that also claim technology to which we have rights, we may have to participate in interference or derivation proceedings in the USPTO to determine priority of invention. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">As of June&nbsp;30, 2020, we or our subsidiary have
registered and own &#147;Opthea&#148; as a trademark in nine jurisdictions, including the United States and Europe. Other than the registered trademark listed above, we currently rely on our unregistered trademarks, trade names and service marks, as
well as our domain names and logos, as appropriate, to market our brands and to build and maintain brand recognition. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">136
</FONT></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Government Regulation </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The FDA and other regulatory authorities at federal, state,
and local levels, as well as in <FONT STYLE="white-space:nowrap">non-U.S.</FONT> countries, extensively regulate, among other things, the research, development, testing, manufacture, quality control, import, export, safety, effectiveness, labeling,
packaging, storage, distribution, record keeping, approval, advertising, promotion, marketing, post-approval monitoring, and post-approval reporting of biologics such as those we are developing. We, along with third-party contractors, will be
required to navigate the various nonclinical, clinical and commercial approval requirements of the governing regulatory agencies of the countries in which we wish to conduct studies or seek approval or licensure of
<FONT STYLE="white-space:nowrap">OPT-302</FONT> or any future product candidate. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B><I>U.S. Biological Product Development </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">In the United States, the FDA regulates biologics under both the Federal Food, Drug and Cosmetic Act and the Public Health Services Act and their implementing regulations. Both drugs and biologics also
are subject to other federal, state and local statutes and regulations. The process of obtaining regulatory approvals and the subsequent compliance with appropriate federal, state and local statutes and regulations requires the expenditure of
substantial time and financial resources. Failure to comply with the applicable U.S. requirements at any time during the product development process, approval process or post-market may subject an applicant to administrative or judicial sanctions.
These sanctions could include, among other actions, the FDA&#146;s refusal to approve pending applications, withdrawal of an approval, license revocation, a clinical hold, untitled or warning letters, product recalls or market withdrawals, product
seizures, total or partial suspension of production or distribution, injunctions, fines, refusals of government contracts, restitution, disgorgement and civil or criminal penalties. Any agency or judicial enforcement action could have a material
adverse effect on us. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our product candidates and
any future biological product candidates we develop must be approved by the FDA through a biologics license application, or BLA, process before they may be legally marketed in the United States. The BLA is a request for approval to market the
biologic for one or more specified indications and must contain proof of safety, purity and potency. The FDA review and approval process generally involves the following: </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">completion of preclinical laboratory tests and animal studies performed in accordance with the FDA&#146;s current Good Laboratory Practices
regulations; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">submission to the FDA of an IND, which must become effective before clinical trials may begin and must be updated annually or when significant changes
are made; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">approval by an institutional review board, or IRB, or ethics committee at each clinical site before the trial is commenced;
</FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">performance of adequate and well-controlled human clinical trials to establish the safety, purity and potency of the proposed biologic product
candidate for its intended purpose; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">preparation of and submission to the FDA of a BLA after completion of all pivotal clinical trials that includes substantial evidence of safety, purity
and potency from results of nonclinical testing and clinical trials; satisfactory completion of an FDA advisory committee review, if applicable; </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">a determination by the FDA within 60 days of its receipt of a BLA to file the application for review; </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">satisfactory completion of an FDA <FONT STYLE="white-space:nowrap">pre-approval</FONT> inspection of the manufacturing facility or facilities at which
the proposed product is produced to assess compliance with current good manufacturing practices, or cGMP, and to assure that the facilities, methods and controls are adequate to preserve the biological product&#146;s continued safety, purity and
potency, and of selected clinical investigation sites to assess compliance with GCP; and </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">FDA review and approval, or licensure, of the BLA to permit commercial marketing of the product for particular indications for use in the United
States. </FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">137
</FONT></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Nonclinical Studies and IND </I></B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Preclinical studies include laboratory evaluation of product
chemistry and formulation, as well as in vitro and animal studies to assess the potential for adverse events and in some cases to establish a rationale for therapeutic use. The conduct of preclinical studies is subject to federal regulations and
requirements, including GLP regulations for safety/toxicology studies. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Prior to beginning the first clinical trial with a product candidate in the United States, we must submit an IND to the FDA. An IND is a request for authorization from the FDA to administer an
investigational new drug product to humans. The central focus of an IND submission is on the general investigational plan and the protocol(s) for clinical studies. The IND also includes results of animal and in vitro studies assessing the
toxicology, PK, pharmacology, and PD characteristics of the product candidate; chemistry, manufacturing, and controls information; and any available human data or literature to support the use of the investigational product. An IND must become
effective before human clinical trials may begin. The IND automatically becomes effective 30 days after receipt by the FDA, unless the FDA, within the <FONT STYLE="white-space:nowrap">30-day</FONT> time period, raises safety concerns or questions
about the proposed clinical trial. In such a case, the IND may be placed on clinical hold until the IND sponsor and the FDA resolve the outstanding concerns or questions. Submission of an IND therefore may or may not result in FDA authorization to
begin a clinical trial. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Clinical Trials
</I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Clinical trials involve the
administration of the investigational product to human subjects under the supervision of qualified investigators in accordance with GCPs, which include the requirement that all research subjects provide their informed consent for their participation
in any clinical study. Clinical trials are conducted under protocols detailing, among other things, the objectives of the study, the parameters to be used in monitoring safety and the effectiveness criteria to be evaluated. A separate submission to
the existing IND must be made for each successive clinical trial conducted during product development and for any subsequent protocol amendments. For new indications, a separate new IND may be required. Furthermore, an independent IRB for each site
proposing to conduct the clinical trial must review and approve the plan for any clinical trial and its informed consent form before the clinical trial begins at that site, and must monitor the study until completed. Regulatory authorities, the IRB
or the sponsor may suspend a clinical trial at any time on various grounds, including a finding that the subjects are being exposed to an unacceptable health risk or that the trial is unlikely to meet its stated objectives. Some studies also include
oversight by an independent group of qualified experts organized by the clinical study sponsor, known as a data safety monitoring board, which provides authorization for whether or not a study may move forward at designated check points based on
access to certain data from the study and may halt the clinical trial if it determines that there is an unacceptable safety risk for subjects or other grounds, such as no demonstration of efficacy. There are also requirements governing the reporting
of ongoing clinical studies and clinical study results to public registries. For purposes of BLA approval, human clinical trials are typically conducted in three sequential phases that may overlap. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">A sponsor who wishes to conduct a clinical trial outside of
the United States may, but need not, obtain FDA authorization to conduct the clinical trial under an IND. If a foreign clinical trial is not conducted under an IND, the sponsor may submit data from the clinical trial to the FDA in support of a BLA.
The FDA will accept a well-designed and well-conducted foreign clinical study not conducted under an IND if the study was conducted in accordance with GCP requirements, and the FDA is able to validate the data through an onsite inspection if deemed
necessary. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Phase 1 &#151; The investigational product is initially introduced into healthy human subjects or patients with the target disease or condition. These
studies are designed to test the safety, dosage tolerance, absorption, metabolism, distribution and elimination of the investigational product in humans, the side effects associated with increasing doses, and, if possible, to gain early evidence on
effectiveness. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Phase 2 &#151; The investigational product is administered to a limited patient population with a specified disease or condition to evaluate the
preliminary efficacy, optimal dosages and dosing schedule and to </FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">138
</FONT></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"> <P><FONT STYLE="font-family:Times New Roman" SIZE="2">
identify possible adverse side effects and safety risks. Multiple Phase 2 clinical trials may be conducted to obtain information prior to beginning larger and more expensive Phase 3 clinical
trials. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Phase 3 &#151; The investigational product is administered to an expanded patient population to further evaluate dosage, to provide statistically
significant evidence of clinical efficacy and to further test for safety, generally at multiple geographically dispersed clinical trial sites. These clinical trials are intended to establish the overall risk/benefit ratio of the investigational
product and to provide an adequate basis for product approval and product labeling. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In some cases, the FDA may require, or companies may voluntarily pursue, additional clinical trials after a product is approved to gain
more information about the product. These <FONT STYLE="white-space:nowrap">so-called</FONT> Phase 4 studies may be made a condition to approval of the BLA. Concurrent with clinical trials, companies may complete additional animal studies and develop
additional information about the biological characteristics of the product candidate, and must finalize a process for manufacturing the product in commercial quantities in accordance with cGMP requirements. The manufacturing process must be capable
of consistently producing quality batches of the product candidate and, among other things, must develop methods for testing the identity, strength, quality and purity of the final product, or for biologics, the safety, purity and potency.
Additionally, appropriate packaging must be selected and tested and stability studies must be conducted to demonstrate that the product candidate does not undergo unacceptable deterioration over its shelf life. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>BLA Submission, Review and Approval </I></B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Assuming successful completion of the clinical trials, the
results of product development, nonclinical studies and clinical trials are submitted to the FDA as part of a BLA requesting approval to market the product for one or more indications. The BLA must include all relevant data available from pertinent
preclinical and clinical studies, including negative or ambiguous results as well as positive findings, together with detailed information relating to the product&#146;s chemistry, manufacturing, controls, and proposed labeling, among other things.
The submission of a BLA requires payment of a substantial application user fee to FDA, unless a waiver or exemption applies. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Once a BLA has been submitted, the FDA&#146;s goal is to review standard applications within ten months after it accepts the application
for filing (a <FONT STYLE="white-space:nowrap">60-day</FONT> process), or, if the application qualifies for priority review, six months after the FDA accepts the application for filing. In both standard and priority reviews, the review process can
be significantly extended by FDA requests for additional information or clarification. The FDA reviews a BLA to determine, among other things, whether a product is safe, pure and potent and the facility in which it is manufactured, processed,
packed, or held meets standards designed to assure the product&#146;s continued safety, purity and potency. The FDA may convene an advisory committee to provide clinical insight on application review questions. Before approving a BLA, the FDA will
typically inspect the facility or facilities where the product is manufactured. The FDA will not approve an application unless it determines that the manufacturing processes and facilities are in compliance with cGMP requirements and adequate to
assure consistent production of the product within required specifications. Additionally, before approving a BLA, the FDA will typically inspect one or more clinical sites to assure compliance with GCP. If the FDA determines that the application,
manufacturing process or manufacturing facilities are not acceptable, it will outline the deficiencies in the submission and often will request additional testing or information. Notwithstanding the submission of any requested additional
information, the FDA ultimately may decide that the application does not satisfy the regulatory criteria for approval. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">After the FDA evaluates a BLA and conducts inspections of manufacturing facilities where the investigational product and/or its drug
substance will be produced, the FDA may issue an approval letter or a Complete Response letter. An approval letter authorizes commercial marketing of the product with specific prescribing information for specific indications. A Complete Response
letter will describe all of the deficiencies that the FDA has identified in the BLA, except that where the FDA determines that the data supporting the </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">139
</FONT></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
application are inadequate to support approval, the FDA may issue the Complete Response letter without first conducting required inspections, testing submitted product lots, and/or reviewing
proposed labeling. In issuing the Complete Response letter, the FDA may recommend actions that the applicant might take to place the BLA in condition for approval, including requests for additional information or clarification. The FDA may delay or
refuse approval of a BLA if applicable regulatory criteria are not satisfied, require additional testing or information and/or require post-marketing testing and surveillance to monitor safety or efficacy of a product. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">If regulatory approval of a product is granted, such approval
will be granted for particular indications and may entail limitations on the indicated uses for which such product may be marketed. For example, the FDA may approve the BLA with a Risk Evaluation and Mitigation Strategy, or REMS, to ensure the
benefits of the product outweigh its risks. A REMS is a safety strategy to manage a known or potential serious risk associated with a product and to enable patients to have continued access to such medicines by managing their safe use, and could
include medication guides, physician communication plans, or elements to assure safe use, such as restricted distribution methods, patient registries and other risk minimization tools. The FDA also may condition approval on, among other things,
changes to proposed labeling or the development of adequate controls and specifications. Once approved, the FDA may withdraw the product approval if compliance with <FONT STYLE="white-space:nowrap">pre-</FONT> and post-marketing requirements is not
maintained or if problems occur after the product reaches the marketplace. The FDA may require one or more Phase 4 post-market studies and surveillance to further assess and monitor the product&#146;s safety and effectiveness after
commercialization, and may limit further marketing of the product based on the results of these post-marketing studies. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Expedited Development and Review Programs </I></B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Any marketing application for a biologic submitted to the
FDA for approval may be eligible for FDA programs intended to expedite the FDA review and approval process, such as priority review, fast track designation, breakthrough therapy and accelerated approval. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">A product is eligible for priority review if it has the
potential to provide safe and effective therapy where no satisfactory alternative therapy exists or to provide a significant improvement in the treatment, diagnosis or prevention of a serious disease or condition compared to marketed products. For
products containing new molecular entities, priority review designation means the FDA&#146;s goal is to take action on the marketing application within six months of the <FONT STYLE="white-space:nowrap">60-day</FONT> filing date (compared with ten
months under standard review). </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">To be eligible for
a fast track designation, the FDA must determine, based on the request of a sponsor, that a product is intended to treat a serious or life-threatening disease or condition and demonstrates the potential to address an unmet medical need by providing
a therapy where none exists or a therapy that may be potentially superior to existing therapy based on efficacy or safety factors. Fast track designation provides opportunities for frequent interactions with the FDA review team to expedite
development and review of the product. The FDA may also review sections of the BLA for a fast track product on a rolling basis before the complete application is submitted, if the sponsor and FDA agree on a schedule for the submission of the
application sections, and the sponsor pays any required user fees upon submission of the first section of the BLA. The review clock does not begin until the final section of the BLA is submitted. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In addition, a sponsor can request designation of a product
candidate as a &#147;breakthrough therapy.&#148; A breakthrough therapy is defined as a drug or biologic that is intended, alone or in combination with one or more other drugs or biologics, to treat a serious or life-threatening disease or
condition, and preliminary clinical evidence indicates that the drug or biologic may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in
clinical development. Drugs or biologics designated as breakthrough therapies are also eligible for accelerated approval. The FDA must take certain actions, such as holding timely meetings and providing advice, intended to expedite the development
and review of an application for approval of a breakthrough therapy. The benefits of breakthrough therapy designation include the same benefits as fast track designation, plus intensive guidance from the FDA to ensure an efficient drug development
program. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">140
</FONT></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Additionally, products studied for their safety and effectiveness in treating serious
or life-threatening diseases or conditions may receive accelerated approval upon a determination that the product has an effect on a surrogate endpoint that is reasonably likely to predict clinical benefit, or on a clinical endpoint that can be
measured earlier than irreversible morbidity or mortality, that is reasonably likely to predict an effect on irreversible morbidity or mortality or other clinical benefit, taking into account the severity, rarity, or prevalence of the condition and
the availability or lack of alternative treatments. As a condition of accelerated approval, the FDA will generally require the sponsor to perform adequate and well-controlled post-marketing clinical studies to verify and describe the anticipated
effect on irreversible morbidity or mortality or other clinical benefit. In addition, the FDA currently requires as a condition for accelerated approval <FONT STYLE="white-space:nowrap">pre-approval</FONT> of promotional materials, which could
adversely impact the timing of the commercial launch of the product. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Even if a product qualifies for one or more of these programs, the FDA may later decide that the product no longer meets the conditions for qualification or decide that the time period for FDA review and
approval will not be shortened. Furthermore, priority review, fast track designation, breakthrough therapy designation, and accelerated approval do not change the standards for approval but may expedite the development or approval process.
</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Orphan Drug Designation </I></B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Under the Orphan Drug Act, the FDA may grant orphan
designation to a drug or biologic intended to treat a rare disease or condition, which is a disease or condition that affects fewer than 200,000 individuals in the United States, or 200,000 or more individuals in the United States for which there is
no reasonable expectation that the cost of developing and making available in the United States a drug or biologic for this type of disease or condition will be recovered from sales in the United States for that drug or biologic. Orphan designation
must be requested before submitting a BLA. After the FDA grants orphan designation, the generic identity of the therapeutic agent and its potential orphan use are disclosed publicly by the FDA. The orphan drug designation does not convey any
advantage in, or automatically shorten the duration of, the regulatory review or approval process. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">If a product that has orphan designation subsequently receives the first FDA approval for the disease for which it has such designation, the product is entitled to orphan exclusivity, which means that the
FDA may not approve any other applications, including a full BLA, to market the same product for the same indication for seven years, except in limited circumstances, such as a showing of clinical superiority to the product with orphan drug
exclusivity. Orphan exclusivity does not prevent FDA from approving a different drug or biologic for the same disease or condition, or the same drug or biologic for a different disease or condition. Among the other benefits of orphan drug
designation are tax credits for certain research and a waiver of the BLA application fee. A designated orphan product may not receive orphan exclusivity if it is approved for a use that is broader than the indication for which it received orphan
designation. In addition, exclusive marketing rights in the United States may be lost if the FDA later determines that the request for designation was materially defective or if the manufacturer is unable to assure sufficient quantities of the
product to meet the needs of patients with the rare disease or condition. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B><I>Post-Approval Requirements </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Any products manufactured or distributed by us pursuant to FDA approvals are subject to pervasive and continuing regulation by the FDA, including, among other things, requirements relating to quality
control and quality assurance, record-keeping, reporting of adverse experiences, periodic reporting, product sampling and distribution, and advertising and promotion of the product. After approval, most changes to the approved product, such as
adding new indications or other labeling claims, are subject to prior FDA review and approval. There also are continuing user fee requirements, under which FDA assesses an annual program fee for each product identified in an approved BLA. Biologic
manufacturers and their subcontractors are required to register their establishments with the FDA and certain state agencies, and are subject to periodic unannounced inspections by </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">141
</FONT></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
the FDA and certain state agencies for compliance with cGMP, which impose certain procedural and documentation requirements upon us and our third-party manufacturers. Changes to the manufacturing
process are strictly regulated, and, depending on the significance of the change, may require prior FDA approval before being implemented. FDA regulations also require investigation and correction of any deviations from cGMP and impose reporting
requirements upon us and any third-party manufacturers that we may decide to use. Accordingly, manufacturers must continue to expend time, money and effort in the area of production and quality control to maintain compliance with cGMP and other
aspects of regulatory compliance. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The FDA may
withdraw approval if compliance with regulatory requirements and standards is not maintained or if problems occur after the product reaches the market. Later discovery of previously unknown problems with a product, including AEs of unanticipated
severity or frequency, or with manufacturing processes, or failure to comply with regulatory requirements, may result in revisions to the approved labeling to add new safety information; imposition of post-market studies or clinical studies to
assess new safety risks; or imposition of distribution restrictions or other restrictions under a REMS program. Other potential consequences include, among other things: </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">restrictions on the marketing or manufacturing of a product, mandated modification of promotional materials or issuance of corrective information,
issuance by FDA or other regulatory authorities of safety alerts, Dear Healthcare Provider letters, press releases or other communications containing warnings or other safety information about the product, or complete withdrawal of the product from
the market or product recalls; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">fines, warning or untitled letters or holds on post-approval clinical studies; </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">refusal of the FDA to approve pending applications or supplements to approved applications, or suspension or revocation of existing product approvals;
</FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">product seizure or detention, or refusal of the FDA to permit the import or export of products; or </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">injunctions, consent decrees or the imposition of civil or criminal penalties. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The FDA closely regulates the marketing, labeling,
advertising and promotion of biologics. A company can make only those claims relating to safety and efficacy, purity and potency that are approved by the FDA and in accordance with the provisions of the approved label. The FDA and other agencies
actively enforce the laws and regulations prohibiting the promotion of <FONT STYLE="white-space:nowrap">off-label</FONT> uses. Failure to comply with these requirements can result in, among other things, adverse publicity, warning letters,
corrective advertising and potential civil and criminal penalties. Physicians may prescribe legally available products for uses that are not described in the product&#146;s labeling and that differ from those tested by us and approved by the FDA.
The FDA does not regulate the behavior of physicians in their choice of treatments. The FDA does, however, restrict manufacturer&#146;s communications on the subject of <FONT STYLE="white-space:nowrap">off-label</FONT> use of their products.
</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Biosimilars and Reference Product
Exclusivity </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Affordable Care Act
signed into law in 2010, includes a subtitle called the Biologics Price Competition and Innovation Act of 2009, which created an abbreviated approval pathway for biological products that are biosimilar to or interchangeable with an <FONT
STYLE="white-space:nowrap">FDA-approved</FONT> reference biological product. To date, a number of biosimilars have been licensed under the BPCIA, and numerous biosimilars have been approved in Europe. The FDA has issued several guidance documents
outlining its approach to the review and approval of biosimilars. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Biosimilarity, which requires that there be no clinically meaningful differences between the biological product and the reference product in terms of safety, purity, and potency, can be shown through
analytical studies, animal studies, and a clinical study or studies. Interchangeability requires that a product is biosimilar to the reference product and the product must demonstrate that it can be expected to produce the same clinical results as
the reference product in any given patient and, for products that are administered multiple times to an </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">142
</FONT></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
individual, the biologic and the reference biologic may be alternated or switched after one has been previously administered without increasing safety risks or risks of diminished efficacy
relative to exclusive use of the reference biologic. Complexities associated with the larger, and often more complex, structures of biological products, as well as the processes by which such products are manufactured, pose significant hurdles to
implementation of the abbreviated approval pathway that are still being worked out by the FDA. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Under the BPCIA, an application for a biosimilar product may not be submitted to the FDA until four years following the date that the reference product was first licensed by the FDA. In addition, the
approval of a biosimilar product may not be made effective by the FDA until 12 years from the date on which the reference product was first licensed. During this <FONT STYLE="white-space:nowrap">12-year</FONT> period of exclusivity, another company
may still market a competing version of the reference product if the FDA approves a full BLA for the competing product containing that applicant&#146;s own preclinical data and data from adequate and well-controlled clinical trials to demonstrate
the safety, purity and potency of its product. The BPCIA also created certain exclusivity periods for biosimilars approved as interchangeable products. At this juncture, it is unclear whether products deemed &#147;interchangeable&#148; by the FDA
will, in fact, be readily substituted by pharmacies, which are governed by state pharmacy law. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">The BPCIA is complex and continues to be interpreted and implemented by the FDA. In addition, government proposals have sought to reduce the <FONT STYLE="white-space:nowrap">12-year</FONT> reference
product exclusivity period. Other aspects of the BPCIA, some of which may impact the BPCIA exclusivity provisions, have also been the subject of recent litigation. As a result, the ultimate impact, implementation, and impact of the BPCIA is subject
to significant uncertainty. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Other U.S.
Healthcare Laws and Compliance Requirements </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>  <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">In the United States, our current and future operations are subject to regulation by various federal, state and local authorities in addition to the FDA, including but not limited to, CMS other divisions
of the U.S. Department of Health and Human Services, or HHS (such as the Office of Inspector General, Office for Civil Rights and the Health Resources and Service Administration), the U.S. Department of Justice, or DOJ, and individual U.S. Attorney
offices within the DOJ, and state and local governments. For example, our clinical research, sales, marketing and scientific/educational grant programs may have to comply with the anti-fraud and abuse provisions of the Social Security Act, the false
claims laws, transparency and price reporting laws, the privacy and security provisions of HIPAA and similar state laws, each as amended, as applicable. Our business operations and current and future arrangements with investigators, healthcare
professionals, consultants, third-party payors and customers may be subject to healthcare laws, regulations and enforcement by the federal government and by authorities in the states and foreign jurisdictions in which we conduct our business. Such
laws include, without limitation, state and federal anti-kickback, fraud and abuse, false claims, privacy and security, price reporting, and transparency laws. Some of our <FONT STYLE="white-space:nowrap">pre-commercial</FONT> activities are subject
to some of these laws. </FONT></P>  <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The federal
Anti-Kickback Statute prohibits, among other things, any person or entity, from knowingly and willfully offering, paying, soliciting or receiving any remuneration, directly or indirectly, overtly or covertly, in cash or in kind, to induce or in
return for purchasing, leasing, ordering or arranging for the purchase, lease or order of any item or service reimbursable, in whole or in part, under Medicare, Medicaid or other federal healthcare programs. The term remuneration has been
interpreted broadly to include anything of value. The Anti-Kickback Statute has been interpreted to apply to arrangements between therapeutic product manufacturers on one hand and prescribers, purchasers, and formulary managers on the other. There
are a number of statutory exceptions and regulatory safe harbors protecting some common activities from prosecution. The exceptions and safe harbors are drawn narrowly and practices that involve remuneration that may be alleged to be intended to
induce prescribing, purchasing or recommending may be subject to scrutiny if they do not qualify for an exception or safe harbor. Failure to meet all of the requirements of a particular applicable statutory exception or regulatory safe harbor does
not make the conduct per se illegal under the Anti-Kickback Statute. Instead, the legality of the arrangement will be evaluated on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">case-by-case</FONT></FONT> basis based on a
cumulative review of all of its facts and circumstances. Our practices may not in all cases meet all of the criteria for protection under a statutory exception or regulatory safe harbor. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">143
</FONT></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Additionally, the intent standard under the Anti-Kickback Statute was amended by the
Affordable Care Act to a stricter standard such that a person or entity no longer needs to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation. Further, courts have found that if &#147;one
purpose&#148; of remuneration is to induce referrals, the federal Anti-Kickback statute is violated. Violations of the Anti-Kickback Statute can result in significant civil and criminal fines and penalties for each violation, imprisonment, and
exclusion from federal healthcare programs. In addition, the Affordable Care Act codified case law that a claim including items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for
purposes of the federal False Claims Act, or the FCA, as discussed below. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">The federal false claims laws, including the FCA, which can be enforced by private citizens through civil qui tam actions, and civil monetary penalty laws, prohibit any person or entity from, among other
things, knowingly presenting, or causing to be presented, a false or fraudulent claim for payment to, or approval by, the federal government, including federal healthcare programs, such as Medicare and Medicaid, knowingly making, using, or causing
to be made or used a false record or statement material to a false or fraudulent claim to the federal government, or knowingly making a false statement to improperly avoid, decrease or conceal an obligation to pay money to the federal government. A
claim includes &#147;any request or demand&#148; for money or property presented to the U.S. government. Pharmaceutical and other healthcare companies have been, and continue to be, prosecuted under these laws, among other things, for allegedly
providing free product to customers with the expectation that the customers would bill federal programs for the product and for causing false claims to be submitted because of the companies&#146; marketing of the product for unapproved, <FONT
STYLE="white-space:nowrap">off-label,</FONT> and thus generally <FONT STYLE="white-space:nowrap">non-reimbursable,</FONT> uses. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">HIPAA created additional federal criminal statutes that prohibit, among other things, knowingly and willfully executing, or attempting to
execute, a scheme to defraud or to obtain, by means of false or fraudulent pretenses, representations or promises, any money or property owned by, or under the control or custody of, any healthcare benefit program, including private third-party
payors, willfully obstructing a criminal investigation of a healthcare offense, and knowingly and willfully falsifying, concealing or covering up by trick, scheme or device, a material fact or making any materially false, fictitious or fraudulent
statement in connection with the delivery of or payment for healthcare benefits, items or services. Like the Anti-Kickback Statute, the Affordable Care Act amended the intent standard for certain healthcare fraud statutes under HIPAA such that a
person or entity no longer needs to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation. When an entity is determined to have violated the FCA, the government may impose civil fines and
penalties for each false claim, plus treble damages, and exclude the entity from participation in Medicare, Medicaid and other federal healthcare programs. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We may be subject to data privacy and security regulations by both the federal government and the states in which we conduct our business.
HIPAA, as amended by HITECH, and its implementing regulations, imposes requirements on certain covered healthcare providers, health plans, and healthcare clearinghouses as well as their respective business associates and their subcontractors
relating to the privacy, security and transmission of individually identifiable health information. Among other things, HITECH makes HIPAA&#146;s privacy and security standards directly applicable to business associates, which are independent
contractors or agents of covered entities that create, maintain, transmit, receive or obtain protected health information in connection with providing a service on behalf of a covered entity. HITECH also created four new tiers of civil monetary
penalties, amended HIPAA to make civil and criminal penalties directly applicable to business associates, and gave state attorneys general new authority to file civil actions for damages or injunctions in federal courts to enforce HIPAA and seek
attorneys&#146; fees and costs associated with pursuing federal civil actions. In addition, many state laws govern the privacy and security of health information in specified circumstances, many of which differ from each other in significant ways,
are often not <FONT STYLE="white-space:nowrap">pre-empted</FONT> by HIPAA, and may have a more prohibitive effect than HIPAA, thus complicating compliance efforts. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">144
</FONT></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Additionally, the federal Physician Payments Sunshine Act, or the Sunshine Act, within
the Affordable Care Act, and its implementing regulations, require that certain manufacturers of drugs, devices, biological and medical supplies for which payment is available under Medicare, Medicaid or the Children&#146;s Health Insurance Program
(with certain exceptions) report annually to CMS information related to certain payments or other transfers of value made or distributed to physicians, as defined by such law, and teaching hospitals, or to entities or individuals at the request of,
or designated on behalf of, the physicians and teaching hospitals and to report annually certain ownership and investment interests held by physicians and their immediate family members. Failure to report accurately could result in penalties.
Effective January&nbsp;1, 2022, these reporting obligations will extend to include transfers of value made in the previous year to certain <FONT STYLE="white-space:nowrap">non-physician</FONT> providers such as physician assistants and nurse
practitioners. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>  <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Many states have similar
statutes or regulations to the above federal laws that may be broader in scope and may apply regardless of payor. We may also be subject to state laws that require pharmaceutical companies to comply with the pharmaceutical industry&#146;s voluntary
compliance guidelines and the relevant compliance guidance promulgated by the federal government, and/or state laws that require drug manufacturers to report information related to payments and other transfers of value to physicians and other
healthcare providers, drug pricing or marketing expenditures. Certain state and local laws also require the registration of pharmaceutical sales representatives. We may be subject to state and foreign laws governing the privacy and security of
health information, some of which may be more stringent than those in the United States (such as the GDPR, which was adopted by the EU and subsequently became effective in May 2018). These laws may differ from each other in significant ways and may
not have the same effect, further complicating compliance efforts. </FONT></P>  <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">In order to distribute products commercially, we must comply with state laws that require the registration of manufacturers and wholesale distributors of drug and biological products in a state,
including, in certain states, manufacturers and distributors who ship products into the state even if such manufacturers or distributors have no place of business within the state. Some states also impose requirements on manufacturers and
distributors to establish the pedigree of product in the chain of distribution, including some states that require manufacturers and others to adopt new technology capable of tracking and tracing product as it moves through the distribution chain.
Several states have enacted legislation requiring pharmaceutical and biotechnology companies to establish marketing compliance programs, file periodic reports with the state, make periodic public disclosures on sales, marketing, pricing, clinical
trials and other activities, and/or register their sales representatives, as well as to prohibit pharmacies and other healthcare entities from providing certain physician prescribing data to pharmaceutical and biotechnology companies for use in
sales and marketing, and to prohibit certain other sales and marketing practices. All of our activities are potentially subject to federal and state consumer protection and unfair competition laws. Additionally, to the extent that we have business
operations in foreign countries or sell any of our products in foreign countries and jurisdictions, including Canada or the EU, we may be subject to additional regulation. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Ensuring business arrangements with third parties comply with
applicable healthcare laws and regulations is a costly endeavor. If our operations are found to be in violation of any of the federal and state healthcare laws described above or any other current or future governmental regulations that apply to us,
we may be subject to penalties, including without limitation, significant civil, criminal and/or administrative penalties, damages, fines, disgorgement, imprisonment, exclusion from participation in government programs, such as Medicare and
Medicaid, injunctions, private &#147;qui tam&#148; actions brought by individual whistleblowers in the name of the government, or refusal to allow us to enter into government contracts, contractual damages, reputational harm, administrative burdens,
diminished profits and future earnings, additional reporting obligations and oversight if we become subject to a corporate integrity agreement or other agreement to resolve allegations of <FONT STYLE="white-space:nowrap">non-compliance</FONT> with
these laws, and the curtailment or restructuring of our operations, any of which could adversely affect its ability to operate our business and results of operations. Any action against us for violation of these laws, even if we successfully defend
against it, could cause us to incur significant legal expenses and divert our management&#146;s attention from the operation of our business. The shifting compliance environment and the need to build and maintain robust and expandable systems to
comply with multiple jurisdictions with different compliance or reporting requirements increases the possibility that a healthcare company may run afoul of one or more of the requirements. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">145
</FONT></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Coverage, Pricing and Reimbursement </I></B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Significant uncertainty exists as to the coverage and
reimbursement status of any product candidates for which we may obtain regulatory approval. In the United States and in foreign markets, sales of any products for which we receive regulatory approval for commercial sale will depend, in part, on the
extent to which third-party payors provide coverage and establish adequate reimbursement levels for such products. In the United States, third-party payors include federal and state healthcare programs, private managed care providers, health
insurers and other organizations. Third-party payors decide which medications they will pay for and establish reimbursement levels. Adequate coverage and reimbursement from governmental healthcare programs, such as Medicare and Medicaid in the
United States, and commercial payors are critical to new product acceptance. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>  <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Our ability to commercialize any products successfully also will depend in part on the extent to which coverage and reimbursement for these products and related treatments will be available from
third-party payors, which decide which therapeutics they will pay for and establish reimbursement levels. In the United States, the principal decisions about reimbursement for new medicines are typically made by CMS, an agency within HHS. CMS
decides whether and to what extent our products will be covered and reimbursed under Medicare and private payors tend to follow CMS to a substantial degree. Coverage and reimbursement by a third-party payor may depend upon a number of factors,
including the third-party payor&#146;s determination that use of a therapeutic is: </FONT></P>  <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">a covered benefit under its health plan; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">safe, effective and medically necessary; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">appropriate for the specific patient; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">cost-effective; and </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">neither experimental nor investigational. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We cannot be sure that coverage or reimbursement will be available for any product that we commercialize and, if coverage and
reimbursement are available, what the level of reimbursement will be. Coverage may also be more limited than the purposes for which the product is approved by the FDA or comparable foreign regulatory authorities. Reimbursement may impact the demand
for, or the price of, any product for which we obtain regulatory approval. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">We may develop products that, once approved, may be administered by a physician. For products administered under the supervision of a physician, obtaining coverage and adequate reimbursement may be
particularly difficult because of the higher prices often associated with such drugs. Additionally, separate reimbursement for the product itself or the treatment or procedure in which the product is used may not be available, which may impact
physician utilization. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Third-party payors are
increasingly challenging the price, examining the medical necessity, and reviewing the cost-effectiveness of medical products, therapies and services, in addition to questioning their safety and efficacy. Obtaining reimbursement for our products may
be particularly difficult because of the higher prices often associated with branded drugs and drugs administered under the supervision of a physician. We may need to conduct expensive pharmacoeconomic studies in order to demonstrate the medical
necessity and cost-effectiveness of our products, in addition to the costs required to obtain FDA approvals. Our product candidates may not be considered medically necessary or cost-effective. Obtaining coverage and reimbursement approval of a
product from a government or other third-party payor is a time-consuming and costly process that could require us to provide to each payor supporting scientific, clinical and cost-effectiveness data for the use of our product on a <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">payor-by-payor</FONT></FONT> basis, with no assurance that coverage and adequate reimbursement will be obtained. A payor&#146;s decision to provide coverage for a product does not imply
that an adequate reimbursement rate will be approved. Further, one payor&#146;s determination to provide coverage for a product does not assure that other payors will also provide coverage for the product. Adequate third-party reimbursement may not
be available to enable us to </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">146
</FONT></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
maintain price levels sufficient to realize an appropriate return on its investment in product development. If reimbursement is not available or is available only at limited levels, we may not be
able to successfully commercialize any product candidate that we successfully develops. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Different pricing and reimbursement schemes exist in other countries. In the EU, governments influence the price of biopharmaceutical products through their pricing and reimbursement rules and control of
national health care systems that fund a large part of the cost of those products to consumers. Some jurisdictions operate positive and negative list systems under which products may only be marketed once a reimbursement price has been agreed. To
obtain reimbursement or pricing approval, some of these countries may require the completion of clinical trials that compare the cost effectiveness of a particular product candidate to currently available therapies. Other member states allow
companies to establish their own prices for medicines, but monitor and control company profits. The downward pressure on health care costs has become intense. As a result, increasingly high barriers are being erected to the entry of new products. In
addition, in some countries, cross-border imports from <FONT STYLE="white-space:nowrap">low-priced</FONT> markets exert a commercial pressure on pricing within a country. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The marketability of any product candidates for which we
receive regulatory approval for commercial sale may suffer if the government and third-party payors fail to provide adequate coverage and reimbursement. In addition, emphasis on managed care, the increasing influence of health maintenance
organizations, and additional legislative changes in the United States has increased, and we expect will continue to increase, the pressure on healthcare pricing. The downward pressure on the rise in healthcare costs in general, particularly
prescription medicines, medical devices and surgical procedures and other treatments, has become very intense. Coverage policies and third-party reimbursement rates may change at any time. Even if favorable coverage and reimbursement status is
attained for one or more products for which we receive regulatory approval, less favorable coverage policies and reimbursement rates may be implemented in the future. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Healthcare Reform </I></B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In the United States and some foreign jurisdictions, there
have been, and continue to be, several legislative and regulatory changes and proposed changes regarding the healthcare system that could prevent or delay marketing approval of product candidates, restrict or regulate post-approval activities, and
affect the ability to profitably sell product candidates for which marketing approval is obtained. Among policy makers and payors in the United States and elsewhere, there is significant interest in promoting changes in healthcare systems with the
stated goals of containing healthcare costs, improving quality and/or expanding access. In the United States, the pharmaceutical industry has been a particular focus of these efforts and has been significantly affected by major legislative
initiatives. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">For example, the Affordable Care Act
has substantially changed healthcare financing and delivery by both governmental and private insurers. Among the Affordable Care Act provisions of importance to the pharmaceutical and biotechnology industries, in addition to those otherwise
described above, are the following: </FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">an annual, nondeductible fee on any entity that manufactures or imports certain specified branded prescription drugs and biologic agents apportioned
among these entities according to their market share in some government healthcare programs; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">an increase in the statutory minimum rebates a manufacturer must pay under the Medicaid Drug Rebate Program to 23% and 13% of the average manufacturer
price for most branded and generic drugs, respectively, and capped the total rebate amount for innovator drugs at 100% of the Average Manufacturer Price; </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">a new Medicare Part D coverage gap discount program, in which manufacturers must agree to offer 50% (increased to 70% pursuant to the Bipartisan Budget
Act of 2018, or BBA, effective as of January 2019) <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">point-of-sale</FONT></FONT> discounts off negotiated prices of applicable branded drugs to eligible beneficiaries during their
coverage gap period, as a condition for the manufacturers&#146; outpatient drugs to be covered under Medicare Part D; </FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">147
</FONT></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">extension of manufacturers&#146; Medicaid rebate liability to covered drugs dispensed to individuals who are enrolled in Medicaid managed care
organizations; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">expansion of eligibility criteria for Medicaid programs by, among other things, allowing states to offer Medicaid coverage to additional individuals
and by adding new mandatory eligibility categories for individuals with income at or below 133% of the federal poverty level, thereby potentially increasing manufacturers&#146; Medicaid rebate liability; </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">expansion of the entities eligible for discounts under the 340B Drug Discount Program; </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">a new Patient-Centered Outcomes Research Institute to oversee, identify priorities in, and conduct comparative clinical effectiveness research, along
with funding for such research; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">expansion of healthcare fraud and abuse laws, including the FCA and the Anti-Kickback Statute, new government investigative powers, and enhanced
penalties for noncompliance; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">a new methodology by which rebates owed by manufacturers under the Medicaid Drug Rebate Program are calculated for drugs that are inhaled, infused,
instilled, implanted, or injected; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">requirements to report certain financial arrangements with certain healthcare providers and teaching hospitals; </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">a requirement to annually report certain information regarding drug samples that manufacturers and distributors provide to physicians;
</FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">establishment of a Center for Medicare and Medicaid Innovation at CMS to test innovative payment and service delivery models to lower Medicare and
Medicaid spending; and </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">a licensure framework for follow on biologic products. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>  <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Since its enactment, there have been executive, legal and
political challenges to certain aspects of the Affordable Care Act. By way of example, the TCJA included a provision that repealed, effective January&nbsp;1, 2019, the <FONT STYLE="white-space:nowrap">tax-based</FONT> shared responsibility payment
imposed by the Affordable Care Act on certain individuals who fail to maintain qualifying health coverage for all or part of a year that is commonly referred to as the &#147;individual mandate.&#148; On December&nbsp;14, 2018, a U.S. District Court
Judge in the Northern District of Texas ruled that the individual mandate is a critical and inseverable feature of the Affordable Care Act, and therefore, because it was repealed as part of the TCJA, the remaining provisions of the Affordable Care
Act are invalid as well. On December&nbsp;18, 2019, the U.S. Court of Appeals for the 5th Circuit ruled that the individual mandate was unconstitutional but remanded the case back to the District Court to determine whether the remaining provisions
of the Affordable Care Act are invalid as well. On March&nbsp;2, 2020, the U.S. Supreme Court granted the petitions for writs of certiorari to review the case, although it is unclear when a decision will be made or how the Supreme Court will rule.
In addition, there may be other efforts to challenge, repeal or replace the Affordable Care Act. </FONT></P>  <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Further legislation or regulation could be passed that could harm our business, financial condition and results of operations. Other
legislative changes have been proposed and adopted since the Affordable Care Act was enacted. For example, in August 2011, President Obama signed into law the Budget Control Act of 2011, which, among other things, included aggregate reductions to
Medicare payments to providers of 2% per fiscal year, which went into effect beginning on April&nbsp;1, 2013 and will stay in effect through 2030 unless additional Congressional action is taken. These Medicare sequester reductions have been
suspended from May&nbsp;1, 2020 through December&nbsp;31, 2020 due to the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic. In January 2013, the American Taxpayer Relief Act of 2012 was signed into law, which, among other things, further
reduced Medicare payments to several types of providers, including hospitals, imaging centers and cancer treatment centers, and increased the statute of limitations period for the government to recover overpayments to providers from three to five
years. In addition, the BBA amended the Affordable Care Act, effective January&nbsp;1, 2019, by increasing the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">point-of-sale</FONT></FONT> discount that is owed by pharmaceutical
manufacturers who participate in Medicare Part D and closing the coverage gap in most Medicare drug plans, commonly referred to as the &#147;donut hole.&#148; </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">148
</FONT></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Additionally, there has been increasing legislative and enforcement interest in the
United States with respect to specialty drug pricing practices. Specifically, there have been several recent U.S. Congressional inquiries and proposed federal legislation designed to, among other things, bring more transparency to drug pricing,
reduce the cost of prescription drugs under Medicare, review the relationship between pricing and manufacturer patient programs, and reform government program reimbursement methodologies for drugs. At the federal level, the Trump
administration&#146;s budget proposal for fiscal year 2021 includes a $135&nbsp;billion allowance to support legislative proposals seeking to reduce drug prices, increase competition, lower <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> drug costs for patients, and increase patient access to lower-cost generic and biosimilar drugs. On March&nbsp;10, 2020, the Trump administration sent &#147;principles&#148; for drug pricing to
Congress, calling for legislation that would, among other things, cap Medicare Part D beneficiary <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> pharmacy expenses, provide an option to cap Medicare Part
D beneficiary monthly <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> expenses, and place limits on pharmaceutical price increases. Further, the Trump administration previously released a
&#147;Blueprint,&#148; or plan, to lower drug prices and reduce out of pocket costs of drugs that contained proposals to increase drug manufacturer competition, increase the negotiating power of certain federal healthcare programs, incentivize
manufacturers to lower the list price of their products, and reduce the out of pocket costs of drug products paid by consumers. HHS has solicited feedback on some of these measures and has implemented others under its existing authority. For
example, in May 2019, CMS issued a final rule to allow Medicare Advantage Plans the option of using step therapy for Part B drugs beginning January&nbsp;1, 2020. This final rule codified CMS&#146;s policy change that was effective January&nbsp;1,
2019. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">While some of these and other measures may
require additional authorization to become effective, Congress and the Trump administration have each indicated that it will continue to seek new legislative or administrative measures to control drug costs. Individual states in the United States
have also become increasingly active in passing legislation and implementing regulations designed to control biopharmaceutical product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access
and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing. Legally mandated price controls on payment amounts by third-party payors or other restrictions
on coverage or access could harm our business, results of operations, financial condition and prospects. In addition, regional healthcare authorities and individual hospitals are increasingly using bidding procedures to determine what pharmaceutical
products and which suppliers will be included in their prescription drug and other healthcare programs. This could reduce the ultimate demand for our product candidates that we successfully commercialize or put pressure on our product pricing.
</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>  <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We expect that these and other healthcare
reform measures that may be adopted in the future, may result in more rigorous coverage criteria and lower reimbursement, and in additional downward pressure on the price that we receive for any approved product. It is possible that additional
governmental action is taken in response to the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic. For example, on August&nbsp;6, 2020, the Trump administration issued another executive order that instructs the federal government to develop
a list of &#147;essential&#148; medicines and then buy them and other medical supplies from U.S. manufacturers instead of from companies around the world, including China. The order is meant to reduce regulatory barriers to domestic pharmaceutical
manufacturing and catalyze manufacturing technologies needed to keep drug prices low and the production of drug products in the United States. Any reduction in reimbursement from Medicare and other government programs may result in a similar
reduction in payments from private payors. The implementation of cost containment measures or other healthcare reforms may prevent us from being able to generate revenue, attain profitability, or commercialize our products. Such reforms could have
an adverse effect on anticipated revenue from product candidates that we may successfully develop and for which we may obtain regulatory approval and may affect our overall financial condition and ability to develop product candidates. </FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>European Union Regulation </I></B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In the European Union, a clinical trial application must be
submitted to each country&#146;s national regulatory authority in which the clinical trial is to take place, together with an independent ethics committee, much like the FDA and IRB, respectively. It is expected, however, that the Clinical Trials
Regulation 536/2014 shall start to </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">149
</FONT></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
apply during the course of 2020. This new Regulation takes direct effect in each European Union Member State and seeks to simplify and streamline the approval of clinical trials in the European
Union, for example, by allowing the clinical trial sponsor to submit a single application for approval of a clinical trial across the EU via a new EU Portal. The new Regulation also aims to streamline and simplify the rules on safety reporting, and
introduces enhanced transparency requirements such as mandatory submission of a summary of the clinical trial results to a new EU Database. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Medicinal products can only be commercialized in the European Economic Area after a marketing authorization, or MA, has been obtained.
There are two types of marketing authorizations: </FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">The centralized MA, which is issued by the European Commission through the Centralised Procedure, based on the opinion of the Committee for Medicinal
Products for Human Use of the European Medicines Agency, or EMA, and which is valid throughout the entirety of the EEA. The Centralised Procedure is mandatory for certain types of products, such as biotechnology medicinal products, orphan medicinal
products, and medicinal products indicated for the treatment of AIDS, cancer, neurodegenerative disorders, diabetes, auto immune and viral diseases. The Centralised Procedure is optional for products containing an active substance not authorized in
the EEA before 20&nbsp;May 2004, for products that constitute a significant therapeutic, scientific or technical innovation or for which a centralized authorization would be in the interest of patients. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">National MAs, which are issued by the competent authorities of the Member States of the EEA and only cover their respective territory, are available
for products not falling within the mandatory scope of the Centralised Procedure. Where a product has already been authorized for marketing in a Member State of the EEA, this National MA can be recognized in another Member State through the Mutual
Recognition Procedure. If the product has not received a National MA in any Member State at the time of application, it can be approved simultaneously in various Member States through the Decentralized Procedure. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Under the above described procedures, before granting the MA,
the EMA or the competent authorities of the Member States of the EEA make an assessment of the risk benefit balance of the product on the basis of scientific criteria concerning its quality, safety and efficacy. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The European Union also provides opportunities for market
exclusivity. For example, in the European Union, upon receiving marketing authorization, innovative medicinal products generally receive eight years of data exclusivity and an additional two years of market exclusivity. If granted, data exclusivity
prevents regulatory authorities in the European Union from referencing the innovator&#146;s data to assess a generic or biosimilar application. During the additional <FONT STYLE="white-space:nowrap">two-year</FONT> period of market exclusivity, a
generic or biosimilar marketing authorization can be submitted, and the innovator&#146;s data may be referenced, but no generic or biosimilar product can be marketed until the expiration of the market exclusivity. Products receiving orphan
designation, can receive ten years of market exclusivity, during which time no similar medicinal product for the same indication may be placed on the market. An orphan product&#146;s market exclusivity may be reduced to six years if, at the end of
the fifth year, it is established that the criteria for orphan drug designation are no longer met, in other words, when it is shown on the basis of available evidence that the product is sufficiently profitable not to justify maintenance of market
exclusivity. Additionally, marketing authorization may be granted to a similar product for the same indication at any time if: </FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the second applicant can establish that its product, although similar, is safer, more effective or otherwise clinically superior;
</FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the applicant consents to a second orphan medicinal product application; or </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT
SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the applicant cannot supply sufficient quantities of the orphan medicinal product. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In the EU, companies developing a new medicinal product must
agree to a Paediatric Investigation Plan, or a PIP, with the EMA and must conduct pediatric clinical trials in accordance with that PIP, unless a deferral or </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">150
</FONT></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
waiver applies (for example, because the relevant disease or condition occurs only in adults). The MA application for the product must include the results of pediatric clinical trials conducted
in accordance with the PIP, unless a waiver applies, or a deferral has been granted, in which case the pediatric clinical trials must be completed at a later date. Products that are granted a marketing authorization on the basis of the pediatric
clinical trials conducted in accordance with the PIP are eligible for a six month extension of the protection under a supplementary protection certificate (if any is in effect at the time of approval) or, in the case of orphan medicinal products, a
two year extension of the orphan market exclusivity. This pediatric reward is subject to specific conditions and is not automatically available when data in compliance with the PIP are developed and submitted. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Coverage, Pricing and Reimbursement </I></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In the European Union, pricing and reimbursement schemes
vary widely from country to country. Some countries provide that drug products may be marketed only after a reimbursement price has been agreed. Some countries may require the completion of additional studies that compare the cost effectiveness of a
particular drug candidate to currently available therapies. For example, the European Union provides options for its member states to restrict the range of drug products for which their national health insurance systems provide reimbursement and to
control the prices of medicinal products for human use. European Union member states may approve a specific price for a drug product or it may instead adopt a system of direct or indirect controls on the profitability of the company placing the drug
product on the market. Other member states allow companies to fix their own prices for drug products, but monitor and control company profits. The downward pressure on health care costs in general, particularly prescription drugs, has become
intense. As a result, increasingly high barriers are being erected to the entry of new products. In addition, in some countries, cross border imports from low priced markets exert competitive pressure that may reduce pricing within a country. Any
country that has price controls or reimbursement limitations for drug products may not allow favorable reimbursement and pricing arrangements. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Advertising Regulation </I></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">All advertising and promotional activities for the product must be consistent with the approved summary of product characteristics, and
therefore all <FONT STYLE="white-space:nowrap">off-label</FONT> promotion is prohibited. <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Direct-to-consumer</FONT></FONT> advertising of prescription medicines is also prohibited in
the European Union. Although general requirements for advertising and promotion of medicinal products are established under European Union directives, the details are governed by regulations in each European Union Member State and can differ from
one country to another. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">If we fail to comply with
applicable foreign regulatory requirements, we may be subject to, among other things, fines, suspension or withdrawal of regulatory approvals, product recalls, seizure of products, operating restrictions and criminal prosecution. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Pharmacovigilance System </I></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The holder of a European MA must establish and maintain a
pharmacovigilance system and appoint an individual qualified person for pharmacovigilance, or QPPV, who is responsible for oversight of that system. Key obligations include expedited reporting of suspected serious adverse reactions and submission of
periodic safety update reports, or PSURs. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">All new
European MA applications must include a risk management plan, or RMP, describing the risk management system that the company will put in place and documenting measures to prevent or minimize the risks associated with the product. The regulatory
authorities may also impose specific obligations as a condition of the MA. Such risk-minimization measures or post-authorization obligations may include additional safety monitoring, more frequent submission of PSURs, or the conduct of additional
clinical trials or post-authorization safety studies. RMPs and PSURs are routinely available to third parties requesting access, subject to limited redactions. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">151
</FONT></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Rest of the World Regulation </I></B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">For other countries outside of the EU and the United States,
such as countries in Eastern Europe, Latin America or Asia, the requirements governing the conduct of clinical trials, product licensing, pricing and reimbursement vary from country to country. Additionally, the clinical trials must be conducted in
accordance with GCP requirements and the applicable regulatory requirements and the ethical principles that have their origin in the Declaration of Helsinki. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">If we fail to comply with applicable foreign regulatory requirements, we may be subject to, among other things, fines, suspension or
withdrawal of regulatory approvals, product recalls, seizure of products, operating restrictions and criminal prosecution. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Brexit and the Regulatory Framework in the United Kingdom </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT
SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">On June&nbsp;23, 2016, the electorate in the United Kingdom, or UK, voted in favor of leaving the EU, commonly
referred to as &#147;Brexit&#148; and the United Kingdom officially withdrew from the EU on January&nbsp;31, 2020. The United Kingdom and the EU are currently in a transition period during which the United Kingdom and the EU are negotiating
additional arrangements, including their future trading arrangement. The United Kingdom has stated that it wants the transition period to expire, and the future trading terms to be agreed, by December&nbsp;31, 2020. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Since the regulatory framework for pharmaceutical products in
the United Kingdom covering quality, safety and efficacy of pharmaceutical products, clinical trials, marketing authorization, commercial sales and distribution of pharmaceutical products is derived from EU directives and regulations, immediately
following Brexit, it is expected that the United Kingdom&#146;s regulatory regime will remain aligned with EU regulations. It remains to be seen how, if at all, Brexit will impact regulatory requirements for product candidates and products in the
United Kingdom. In the longer term, Brexit could materially impact the future regulatory regime which applies to products and the approval of product candidates in the United Kingdom. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>The Foreign Corrupt Practices Act </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT
SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The FCPA prohibits any U.S. individual or business from paying, offering, or authorizing payment or offering of
anything of value, directly or indirectly, to any foreign official, political party or candidate for the purpose of influencing any act or decision of the foreign entity in order to assist the individual or business in obtaining or retaining
business. The FCPA also obligates companies whose securities are listed in the United States to comply with accounting provisions requiring us to maintain books and records that accurately and fairly reflect all transactions of the corporation,
including international subsidiaries, and to devise and maintain an adequate system of internal accounting controls for international operations. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Additional Regulation </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In addition to the foregoing, state and federal laws regarding environmental protection and hazardous substances, including the
Occupational Safety and Health Act, the Resource Conservancy and Recovery Act and the Toxic Substances Control Act, affect our business. These and other laws govern our use, handling and disposal of various biological, chemical and radioactive
substances used in, and wastes generated by, our operations. If our operations result in contamination of the environment or expose individuals to hazardous substances, we could be liable for damages and governmental fines. We believe that we are in
material compliance with applicable environmental laws and that continued compliance therewith will not have a material adverse effect on our business. We cannot predict, however, how changes in these laws may affect our future operations.
</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Other Regulations </I></B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We are also subject to numerous federal, state and local
laws relating to such matters as safe working conditions, manufacturing practices, environmental protection, fire hazard control, and disposal of hazardous or potentially hazardous substances. We may incur significant costs to comply with such laws
and regulations now or in the future. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">152
</FONT></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In addition to regulation in the United States and Europe, a variety of foreign
regulations govern clinical trials, commercial sales and distribution of drugs. Pharmaceutical firms who wish to market their medicinal drugs outside the European Union and the United States must submit marketing authorization application to the
national authorities of the concerned countries, such as the Pharmaceutical and Medical Device Agency, or PMDA in Japan. The approval process varies from jurisdiction to jurisdiction and the time to approval may be longer or shorter than that
required by the FDA or European Commission. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Manufacturing and
Supply </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We are dependent on specialized third
parties, who are subject to cGMP requirements and regulations, for the supply and manufacture of <FONT STYLE="white-space:nowrap">OPT-302</FONT> drug substance and drug product. We do not have any internal manufacturing and control capabilities. We
source the drug substance for <FONT STYLE="white-space:nowrap">OPT-302</FONT> and our clinical trials on a purchase order basis. However, we believe that competitive pricing is achieved because there are a number of potential long-term replacements
for our suppliers of drug substance. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In October
2013, we entered into a biopharmaceutical manufacturing agreement, or the Patheon Agreement, with Patheon Biologics Company, Austria Pty Ltd. and Patheon Biologics Company B.V., or collectively Patheon. The Patheon Agreement establishes the general
terms and conditions pursuant to which Patheon or its affiliates will manufacture <FONT STYLE="white-space:nowrap">OPT-302</FONT> drug product for us in accordance with cGMP requirements. Under the Patheon Agreement, Patheon granted us a perpetual,
royalty-free, fully <FONT STYLE="white-space:nowrap">paid-up,</FONT> <FONT STYLE="white-space:nowrap">non-exclusive,</FONT> worldwide, transferable and sublicensable license, under all of Patheon&#146;s intellectual property rights embedded in the
development and manufacture process to the extent necessary for developing, making, using and selling <FONT STYLE="white-space:nowrap">OPT-302.</FONT> </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Patheon Agreement will expire on the date that all of the manufacturing services to be performed by Patheon are completed. We may
terminate the Patheon Agreement for any reason upon prior written notice. Patheon may terminate the Patheon Agreement upon prior written notice if Patheon has not performed any activities under the Patheon Agreement for certain period of time or if,
despite Patheon&#146;s commercially reasonably best efforts, Patheon determines that the services cannot be completed according to specifications approved by us or within a reasonable time after the originally planned timeframe. Either party may
terminate the Patheon Agreement for the other party&#146;s uncured material breach or bankruptcy. In addition, the Patheon Agreement will terminate if the parties are unable to reach agreement regarding necessary changes to the services based on the
results of individual stage of development work. Upon termination of the Patheon Agreement, we are required to pay Patheon for services properly performed, including <FONT STYLE="white-space:nowrap">non-cancelable</FONT> costs. Based upon the timing
of the termination, we may also be required to pay Patheon certain close out cost for canceled services </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>Employees </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">As of June&nbsp;30, 2020, we had eight full-time employees, four of whom had an M.D. or Ph.D. degree. None of our employees are represented by collective bargaining agreements. We believe that our
management maintains good relations with our employees. As of June&nbsp;30, 2020, all of our employees were based in Australia, with four employees in our research and development department and four employees in our general and administrative
department. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Facilities </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We occupy approximately 591 square feet of office space in
South Yarra, Victoria, Australia under a lease that expires in July 2022. We believe that our existing facilities are adequate to meet our current needs and that suitable additional alternative facilities will be available in the future on
commercially reasonable terms to meet our future needs. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Legal
Proceedings </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">From time to time, we may become
involved in legal proceedings arising in the ordinary course of our business. We are currently not a party to any material legal proceedings. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">153
</FONT></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="rom947560_14"></A>MANAGEMENT </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Directors and Senior Management </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>  <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The following table sets forth information relating to
our directors, director nominee, senior management and key employees as of September&nbsp;30, 2020. </FONT></P>  <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>

<TD WIDTH="35%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="61%"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1px solid #000000 ; display:table-cell;"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Name</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Age</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1px solid #000000"> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Position</B></FONT></P></TD></TR>


<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Senior Management and Key Employees</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Megan Baldwin, Ph.D.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">46</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Chief Executive Officer and Managing Director</FONT></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Michael Tonroe</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">54</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Chief Financial Officer and Company Secretary</FONT></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Richard Chadwick, Ph.D.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">54</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Head of Intellectual Property</FONT></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Michael Gerometta, Ph.D.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">56</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Head of Chemistry, Manufacturing and Controls Development</FONT></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Clare Price</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">52</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Director of Clinical Development</FONT></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Annette Leahy</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">45</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Director of Clinical Research</FONT></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Ian Leitch, Ph.D.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">57</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Director of Clinical Research</FONT></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><FONT STYLE="white-space:nowrap">Non-Employee</FONT> Directors</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Geoffrey Kempler</FONT><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(1)</SUP></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">65</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Chairperson</FONT></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Lawrence Gozlan</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">41</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Director</FONT></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Michael Sistenich</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">45</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Director</FONT></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Daniel Spiegelman</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">62</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Director</FONT></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Jeremy Levin, D.Phil, MB BChir</FONT><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(2)</SUP></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">67</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Director Nominee</FONT></P></TD></TR>
</TABLE>  <P STYLE="line-height:8px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(1)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Mr. Kempler will retire from our board of directors effective as of October 12, 2020. </FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(2)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Dr. Levin will join our board of directors as Chairperson effective as of October 12, 2020. </FONT></TD></TR></TABLE>  <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The business addresses for our senior management and board of directors is Opthea Limited, Suite 0403,
Level&nbsp;4, 650 Chapel Street, South Yarra, VIC 3141, Australia. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B><I>Senior Management and Key Employees </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><I>Megan Baldwin, Ph.D., </I>has served as our Chief Executive Officer and Managing Director since February 2014. Since joining our company in 2008, Dr.&nbsp;Baldwin has held various positions, including
Head of Preclinical R&amp;D from February 2009 to November 2012 and Chief Executive Officer of Opthea Pty Ltd., previously a wholly-owned subsidiary, from November 2012 to December 2015. Dr.&nbsp;Baldwin has over 20 years of experience focusing on
angiogenesis and therapeutic strategies for ophthalmic and cancer indications. Prior to joining our company, Dr.&nbsp;Baldwin was employed at Genentech, Inc. (now a subsidiary of the Roche Group), a leader in the field of angiogenesis-based
therapies for cancer and other diseases. Dr.&nbsp;Baldwin earned a Bachelor of Science Honours and Ph.D. in Medicine from the University of Melbourne. We believe that Dr.&nbsp;Baldwin&#146;s business expertise and her daily insight into corporate
matters as our Chief Executive Officer qualify her to serve on our board of directors. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><I>Michael Tonroe</I> has served as our Chief Financial Officer and Company Secretary since May 2014. From March 2011 to April 2014, Mr.&nbsp;Tonroe served as the Chief Financial Officer and Company
Secretary of the Australian Synchrotron Co. Ltd. in Melbourne. Mr.&nbsp;Tonroe has over 20 years of experience in financial </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">154
</FONT></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
management serving in board-level positions for private and listed companies in Australia, the United Kingdom, the United States and Canada. Mr.&nbsp;Tonroe is a fellow of the Institute of
Chartered Accountants in England and Wales and earned a Bachelor of Science in Business Studies from Buckingham University. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Richard Chadwick, Ph.D.,</I> has served as our Head of Intellectual Property since February 2008. From April 2003 to December 2007,
Dr.&nbsp;Chadwick was a patent attorney at FB Rice&nbsp;&amp; Co., a private law firm. Prior to FB Rice&nbsp;&amp; Co., Dr.&nbsp;Chadwick was a patent attorney at Wynne-Jones, Laine&nbsp;&amp; James, a private law firm, and also worked as an <FONT
STYLE="white-space:nowrap">in-house</FONT> attorney at Dow Corning Limited, a materials science company, and Unilever plc, a consumer goods company. Dr.&nbsp;Chadwick earned a Bachelor of Science in Biochemistry with Microbiology from the University
of St. Andrews and a Ph.D. in Biochemistry and Molecular Biology from the University of Manchester. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><I>Michael Gerometta, Ph.D.,</I> has served as our Head of Chemistry, Manufacturing and Controls Development since December 2008. Dr.&nbsp;Gerometta has over 30 years of experience in the Australian
biotechnology industry, working with numerous contract manufacturing organizations overseas and locally in all facets of translational CMC from concept through to Phase&nbsp;2 studies. Dr.&nbsp;Gerometta earned a Bachelor of Science in Chemistry
from the University of Technology, Sydney, and a Ph.D. in Biotechnology from the Queensland University of Technology. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Clare Price</I> has served as our Director of Clinical Development since July 2016. From February 2016 to July 2016, Ms.&nbsp;Price
served as the Director of Clinical Development at Commercial Eyes Pty Ltd., a pharmaceutical consulting firm. From January 2007 to January 2016, Ms.&nbsp;Price served in various roles, most recently as the Clinical Programme Director, at Starpharma
Holdings Ltd, an Australian biotechnology company. Ms.&nbsp;Price earned a Bachelor of Pharmacy from Bath Spa University. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Annette Leahy </I>has served as one of our Directors of Clinical Research since August 2017. From May 2016 to August 2017, she was the
Clinical Trials Manager at Swisse Wellness Pty Ltd., an Australian wellness company. From September 2014 to May 2016, she served in various roles, most recently as Senior Manager, Learning and Development, at Novotech (Australia) Pty Ltd., an
Australian clinical research organization. Ms Leahy earned a Bachelor of Health Information Management from La Trobe University.<I> </I></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Ian Leitch, Ph.D.,</I> has served as one of our Directors of Clinical Research since September 2011. From September 2006 to September
2011, Dr.&nbsp;Leitch was a member of the Medical Sciences group at Amgen Inc., a biopharmaceutical company, and had responsibility for the design and management of clinical studies in oncology. From 1998 to 2006, Dr.&nbsp;Leitch was Senior Program
Manager for Cardiovascular Research and Clinical Study Director for Ophthalmology at Miravant Medical Technologies Inc., a biopharmaceutical company. He earned a Bachelor of Science with Honours and a Ph.D. from the Department of Pharmacology,
Faculty of Medicine, at Monash University and completed part of the doctoral studies at the University of California, Santa Barbara. </FONT></P>  <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I><FONT STYLE="white-space:nowrap">Non-Employee</FONT> Directors </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT
SIZE="1">&nbsp;</FONT></P>  <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Geoffrey Kempler </I>has served as the Chairperson of our board of directors since November 2015.
Mr.&nbsp;Kempler has also served as the Chairman of the board of directors since 1997 and as Chief Executive Officer since June 2005 of Alterity Therapeutics Ltd., a pharmaceutical development company listed on both the Nasdaq Capital Market and the
Australian Securities Exchange. Mr.&nbsp;Kempler earned a Bachelor of Science from Monash University and a Graduate Diploma in Applied Social Psychology from Swinburne University of Technology. We believe Mr.&nbsp;Kempler&#146;s extensive experience
in investment and business development have qualified him to serve on our board of directors. Mr. Kempler will retire from our board of directors effective as of October&nbsp;12, 2020. </FONT></P>  <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Lawrence Gozlan</I>&nbsp;has served as a member of our board of directors since July 2020. Since 2007,
Mr.&nbsp;Gozlan has served as the Life Sciences Investment Manager of Jagen Pty Ltd., an international investment organization. Mr.&nbsp;Gozlan has also served as a member of the board of directors of Alterity Therapeutics Ltd., a drug
</FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">155
</FONT></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
development company, since 2011. Mr.&nbsp;Gozlan earned a Bachelor of Science in Microbiology and Immunology from the University of Melbourne. We believe Mr.&nbsp;Gozlan&#146;s extensive
investment experience in biotechnology and life sciences companies qualify him to serve on our board of directors. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Jeremy Levin, D.Phil., MB BChir</I> will join our board of directors and serve as Chairperson effective as of October 12, 2020
following the retirement of Mr.&nbsp;Kempler from our board of directors on the same date. Since March 2015, Dr. Levin has served as the Chief Executive Officer, and since April 2014, as the chairperson of the board of directors, of Ovid
Therapeutics Inc., a biopharmaceutical company. From May 2012 to October 2013, Dr. Levin served as the President and Chief Executive Officer of Teva Pharmaceutical Industries Ltd., a publicly held pharmaceutical company. From September 2007 to
December 2012, Dr. Levin held several roles at Bristol-Myers Squibb Company, a publicly held pharmaceutical company, ultimately serving as the Senior Vice President of Strategy, Alliances and Transactions. Dr. Levin also served as a member of the
executive committee at Bristol-Myers Squibb Company. Dr. Levin earned a Bachelor of Arts in Zoology, Master of Arts in Cell Biology and D.Phil. in Chromatin Structure, all from University of Oxford, and a Bachelor of Medicine, Bachelor of Surgery
from the University of Cambridge. We believe Dr. Levin&#146;s extensive experience in the global biotechnology and pharmaceutical industry qualify him to serve on our board of directors. </FONT></P>  <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Michael Sistenich </I>has served as a member of our board of directors since November 2015. Since May 2017,
Mr.&nbsp;Sistenich has served as a <FONT STYLE="white-space:nowrap">co-founder</FONT> and partner of Aurenda Partners Pty Ltd., an investment firm. From August 2016 to February 2017, Mr.&nbsp;Sistenich served as the interim Chief Executive Officer
of Nohla Therapeutics, Inc., a cellular therapy company, and has also served as a member of the board of directors of Nohla Therapeutics, Inc. from March 2017 to June 2019. Mr.&nbsp;Sistenich has advised a wide range of global institutions, high net
worth individuals and companies on healthcare investments over the past 20 years. He is a healthcare specialist in international investment management and investment banking. Mr.&nbsp;Sistenich earned a Master of Science in Biochemistry from the
University of Oxford. We believe Mr.&nbsp;Sistenich&#146;s financial experience and his service on the boards of directors of several biotechnology companies qualify him to serve on our board of directors. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>  <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Daniel Spiegelman </I>has served as a member of our
board of directors since September 2020. Since July 2020, Mr.&nbsp;Spiegelman has served as interim President of Recardia Therapeutics Inc., a pharmaceutical development company. From May 2012 to January 2020, Mr. Spiegelman served as Executive Vice
President, Chief Financial Officer and a member of the board of directors of BioMarin Pharmaceutical Inc., a biotechnology company. From October 2008 to March 2018, Mr.&nbsp;Spiegelman served as a member of the board of directors of Cascadian
Therapeutics, Inc., a publicly held biotechnology company that was acquired by Seattle Genetics, Inc. in 2018. From October 2008 to March 2018, Mr. Spiegelman served as a member of the board of directors of Cascadian Therapeutics, Inc., a publicly
held biotechnology company that was acquired by Seattle Genetics, Inc. in 2018. From May 2009 to May 2012, Mr. Spiegelman served as a consultant to provide strategic financial management support to a portfolio of public and private life science
companies. Mr. Spiegelman has also served as a member of the board of directors of Myriad Genetics, a molecular diagnostic company, since May 2020. Mr.&nbsp;Spiegelman earned a Bachelor of Arts from Stanford University and a Master of Business
Administration from the Stanford Graduate School of Business. We believe Mr. Spiegelman&#146;s extensive leadership experience in biotechnology and pharmaceutical companies qualify him to serve on our board of directors. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Board of Directors </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>  <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our board of directors currently consists of five
members, including Dr.&nbsp;Baldwin, our Chief Executive Officer and Managing Director. Upon the completion of this offering, our board of directors will remain at five members following the retirement of Mr.&nbsp;Kempler and the addition of
Dr.&nbsp;Levin, each effective as of October&nbsp;12, 2020. Directors are elected at our annual general meeting of shareholders. Under our Constitution, at the close of each annual general meeting <FONT STYLE="white-space:nowrap">one-third</FONT> of
the directors, other than the Managing Director, or if their number is not a multiple of three, then the number nearest to but not more than <FONT STYLE="white-space:nowrap">one-third</FONT> of the directors must retire. In addition, a director,
other than the managing director, must retire from office at the conclusion of the third annual </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">156
</FONT></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
general meeting of shareholders after the director was last elected, even if his or her retirement results in more than <FONT STYLE="white-space:nowrap">one-third</FONT> of all directors retiring
from office. A retiring director remains in office until the end of such shareholder meeting and will be eligible for re-election at that meeting. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The membership of our board of directors is directed by the following requirements as set forth in our Constitution and our Board Charter,
as applicable: </FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">there will be a minimum of three directors and a maximum of 10, and our board of directors may determine the number of directors within those limits;
</FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the majority of our board of directors should be independent; </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">our board of directors has the power to appoint any person to be a director, either to fill a vacancy or as an additional director (provided that the
total number of directors does not exceed the maximum number of directors permitted), and any director so appointed will hold office until the end of the next annual general meeting when he or she may be
<FONT STYLE="white-space:nowrap">re-elected;</FONT> and </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">our board of directors should, collectively, have the appropriate level of personal qualities, skills, experience and time commitment to properly
fulfill its responsibilities. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our board of directors has delegated responsibility for the management of our businesses to the Chief Executive Officer and Managing
Director but remains responsible for overseeing the performance of management. The principal roles and responsibilities of our board of directors include the following: </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">review, evaluate, provide input into and approve our business plan; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT
SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">monitor senior management&#146;s performance and implementation of strategy, and ensure appropriate resources are available;
</FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">review, evaluate and approve and monitor major resource allocations and capital investments, and acquisitions and divestitures;
</FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">review, evaluate, approve and monitor major resource allocations and capital investments, and acquisitions and divestitures;
</FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">review and monitor our financial and operating results; </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">review, evaluate and approve the overall corporate organizational structure, the assignment of senior management responsibilities and plans for senior
management development and succession; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">review, evaluate and approve compensation strategy as it relates to our senior management; and </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">review and ratify systems of risk management and internal compliance and control, codes of conduct and legal compliance. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our board of directors has established delegated limits of
authority, which define the matters that are delegated to management and those that require board of director approval. Under the Corporations Act, at least two of our directors must be resident Australians. None of our <FONT
STYLE="white-space:nowrap">non-employee</FONT> directors have any service contracts with us that provide for benefits upon termination of employment. Under our Board Charter, the board of directors is required to meet at least six times per year.
</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Board Committees </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">To assist with the effective discharge of its duties, the
board of directors has established an Audit and Risk Committee, a Remuneration Committee and a Nomination Committee. Each committee operates under a charter approved by our board of directors, which sets forth the purposes and responsibilities of
the committees as well as qualifications for committee membership, committee structure and operations and committee reporting to the board of directors. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">157
</FONT></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Audit and Risk Committee </I></B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The members of our Audit and Risk Committee are Messrs.
Lawrence Gozlan, Michael Sistenich and Daniel Spiegelman. Our board of directors has determined that each of Messrs. Gozlan, Sistenich and Spiegelman satisfies the independence requirements under Nasdaq listing standards and Rule <FONT
STYLE="white-space:nowrap">10A-3(b)(1)</FONT> of the Exchange Act. The chairperson of our Audit and Risk Committee is Mr.&nbsp;Spiegelman. Our board of directors has determined that Mr.&nbsp;Spiegelman is an &#147;audit committee financial
expert&#148; within the meaning of SEC regulations. Each member of our Audit and Risk Committee can read and understand fundamental financial statements in accordance with applicable requirements. In arriving at these determinations, our board of
directors has examined each member&#146;s scope of experience and the nature of his or her employment. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The charter for our Audit and Risk Committee requires the committee to consist of at least three directors, each of whom must be <FONT
STYLE="white-space:nowrap">non-employee</FONT> directors and a majority of which must be independent directors. The chairperson of our Audit and Risk Committee must be an independent director and cannot be the chairperson of our board of directors.
The Audit and Risk Committee is required to hold at least one regular meeting per fiscal quarter and must review its charter at least annually. </FONT></P>  <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The role of the Audit and Risk Committee is to advise our board of directors in discharging responsibilities of our board of directors
with respect to our financial reporting including accounting standards, internal control integrity and compliance, external audit activities including auditor appointment, independence, terms of engagement and fees and business risk management.
Specific responsibilities of our Audit and Risk Committee include: </FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">reviewing accounting standards and quarterly and annual financial statements prior to referral to the board of directors; </FONT></P></TD></TR></TABLE>
 <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">monitor developments likely to affect financial reporting including legislative pronouncements or disclosure requirements, as they affect both current
and future years; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">review any unusual transactions, pending litigation, outstanding claims or contingencies which the management, auditors or legal counsel believe may
have a material effect on the financial position or operations and the manner in which these matters are disclosed in financial statements; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">evaluating internal control policies and procedures; </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">making recommendations to the board of directors on the appointment, reappointment or replacement of external auditors; </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">evaluating the independence and effectiveness of external auditors and preapprove all audit and material
<FONT STYLE="white-space:nowrap">non-audit</FONT> services provided by external auditors; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">reviewing the results of the external audit and assess remedial action taken or proposed in audit reports; </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">reviewing all representation letters signed by management to ensure that the information presented is complete and appropriate;
</FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">monitoring risks and establish risk management policies; </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">making recommendations to the board of directors regarding proposed changes to our risk management framework; and </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">reviewing the schedule of insurance annually. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Remuneration Committee </I></B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The members of our Remuneration Committee are Messrs.
Gozlan, Sistenich and Spiegelman. The chairperson of our Remuneration Committee is Mr.&nbsp;Sistenich. The objectives of the Remuneration Committee are to link remuneration to the creation of shareholder value, to offer competitive and appropriate
remuneration for </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">158
</FONT></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
the business performance delivered and to put into place a remuneration framework that reflects the responsibilities of senior management while being sufficiently competitive to attract and
retain high caliber performers. The charter of our Remuneration Committee requires the committee to consist of at least three directors, a majority of whom must be independent. The chairperson of our Remuneration Committee must be an independent
director. The Remuneration Committee is required to hold at least one regular meeting each year. Specific responsibilities of our Remuneration Committee include: </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">overseeing our remuneration strategy; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">ensuring remuneration policies and practices enable us to attract, motivate and retain a diverse mix of directors and senior management;
</FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">fairly and responsibly remunerating directors and senior management; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT
SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">at least annually, reviewing and reporting on diversity of our employee base; and </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">seeking information it considers necessary to fulfill its duties, including external advice. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Nomination Committee </I></B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The members of our Nomination Committee are Messrs. Gozlan,
Sistenich and Spiegelman. The chairperson of our Nomination Committee is Mr.&nbsp;Gozlan. The role of the Nomination Committee is to assist our board of directors by identifying, reviewing and evaluating individuals qualified to become members of
our board of directors, reviewing and recommending the nomination of directors and assisting the board of directors with other related tasks. The charter of our Nomination Committee requires the committee to consist of at least three directors, the
majority of whom must meet the independence recommendations of the ASX Corporate Governance Council (as well as all applicable laws and regulations) and each of whom must be free of any relationship that, in the opinion of the board of directors,
would interfere with his or her exercise of independent judgment. The members of the Nomination Committee will be appointed annually by the board of directors. The Nomination Committee is required to hold at least one regular meeting each year.
Specific responsibilities of our Nomination Committee include: </FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">assisting in identifying, interviewing and recruiting candidates for the board of directors; </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">reviewing potential director qualifications; </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">preparing a description of the role and capabilities required for a particular role; </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">at least annually, presenting to the board of directors a list of individuals recommended for nomination for election to the board of directors at the
annual meeting of shareholders; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">planning succession of our directors; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">inducting and coordinating professional development programs for our directors; </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">developing and implementing a process for evaluating the performance of the board of directors and its committees; </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">managing the succession of our senior management; </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">reviewing and making recommendations about changes to the charter of the Nomination Committee as required in the Committee&#146;s opinion; and
</FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">annually review its own performance. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Foreign Private Issuer Exemption </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We qualify as a &#147;foreign private issuer&#148; as defined in Section&nbsp;405 of the Securities Act of 1933, as amended. As a foreign
private issuer, we are exempt from certain rules under the Exchange Act that impose disclosure </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">159
</FONT></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
requirements as well as procedural requirements for proxy solicitations under Section&nbsp;14 of the Exchange Act. In addition, the members of our board of directors and senior management are not
subject to short-swing profit and insider trading reporting obligations under Section&nbsp;16 of the Exchange Act. They will, however, be subject to the obligations to report changes in share ownership under Section&nbsp;13 of the Exchange Act and
related SEC rules, to the extent applicable. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The
foreign private issuer exemption will also permit us to follow home country corporate governance practices or requirements instead of certain Nasdaq listing requirements, including the following: </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">We expect to rely on an exemption from the requirement that our independent directors meet regularly in executive sessions under Nasdaq listing rules.
The ASX Listing Rules and the Corporations Act do not require the independent directors of an Australian company to have such executive sessions. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">We expect to rely on an exemption from the quorum requirements applicable to meetings of shareholders under Nasdaq listing rules. In compliance with
Australian law, our Constitution provides that three shareholders present, in person or by proxy, attorney or a representative, shall constitute a quorum for a general meeting. Nasdaq listing rules require that an issuer provide for a quorum as
specified in its by-laws for any meeting of the holders of ordinary shares, which quorum may not be less than 33&nbsp;1/3% of the outstanding voting ordinary shares. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT
SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">We expect to follow applicable Australian law and the ASX Listing Rules regarding prior shareholder approval in lieu of the requirement prescribed by
Nasdaq listing rules that issuers obtain shareholder approval prior to the issuance of securities in connection with certain acquisitions, private placements of securities, or the establishment or amendment of certain stock option, purchase or other
compensation plans. Applicable Australian law and the ASX Listing Rules differ from Nasdaq requirements, with the ASX Listing Rules requiring prior shareholder approval for issuance of equity securities in a number of circumstances, including
(i)&nbsp;issuance of equity securities exceeding 15% of our issued share capital in any 12-month period (but, in determining the 15% limit, securities issued under certain exceptions to the rule or with shareholder approval are not counted),
(ii)&nbsp;subject to certain exceptions, issuance of equity securities to related parties (as defined in the ASX Listing Rules) and (iii)&nbsp;issuances of securities to directors or their associates under an employee incentive plan.
</FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">We expect to rely on an exemption from the requirement to disclose third-party director and director nominee compensation under Nasdaq listing rules.
The ASX Listing Rules and the Corporations Act do not have a similar requirement. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">These exemptions do not modify the independence requirements for our Audit and Risk Committee, and we intend to comply with the requirements of the Sarbanes-Oxley Act and the Nasdaq listing rules, which
require that our Audit and Risk Committee be composed of at least three independent members. <FONT STYLE="white-space:nowrap">Rule&nbsp;10A-3&nbsp;under</FONT> the Exchange Act provides that the Audit and Risk Committee must have direct
responsibility for the nomination, compensation and choice of our auditors, as well as control over the performance of their duties, management of complaints made, and selection of consultants. Under
<FONT STYLE="white-space:nowrap">Rule&nbsp;10A-3,&nbsp;if</FONT> the laws of a foreign private issuer&#146;s home country require that any such matter be approved by the board of directors or the shareholders of the Company, the Audit and Risk
Committee&#146;s responsibilities or powers with respect to such matter may instead be advisory. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">We intend to take all actions necessary for us to maintain compliance as a foreign private issuer under the applicable corporate governance requirements of the Sarbanes-Oxley Act, the rules adopted by the
SEC and the listing rules of Nasdaq. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Code of Conduct
</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We have adopted a Code of Conduct applicable
to all of our directors, officers and employees. Our Code of Conduct is available on our website at www.opthea.com. We post on our website all disclosures that are required by law or the listing standards of Nasdaq concerning any amendments to, or
waivers from, any provision of the Code </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">160
</FONT></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
of Conduct. The reference to our website address does not constitute incorporation by reference of the information contained at or available through our website, and you should not consider it to
be a part of, this prospectus. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Family Relationships
</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">There are no family relationships among any
of the members of our board of directors and our senior management. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Remuneration </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Overview </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our remuneration policy is to align director and senior management objectives with shareholder and business objectives by providing a
fixed remuneration component and typically offering long-term incentives based on key performance areas. Our board of directors believes the remuneration policy to be appropriate and effective in its ability to attract and retain the best executives
and directors to run and manage the consolidated entity, as well as create goal congruence between directors, executives and shareholders. Our board of directors and the Remuneration Committee are responsible for determining the appropriate
remuneration package for our senior management, including our Chief Executive Officer. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Australian executives and directors receive a superannuation guarantee contribution required under Australian law and do not receive any other retirement benefits. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Remuneration of Senior Management </I></B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">For the fiscal year ended June&nbsp;30, 2020, the aggregate
cash remuneration paid to our senior management was A$942,855. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Our senior management receive fixed compensation and performance-linked remuneration. The level of fixed remuneration is set to provide a base level of compensation which is both appropriate to the
applicable position and is competitive in the marketplace. The Remuneration Committee accesses external advice independent of senior management if required. Fixed compensation is comprised of base salary and superannuation contribution and is
reviewed every 12 months by the Remuneration Committee. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Performance-linked remuneration consists of short-term and long-term incentives. The objective of short-term incentives is to link the achievement of our operational targets with the remuneration received
by our senior management charged with meeting those targets. Total potential short-term incentives are set at a level that we believe provides sufficient incentive to our senior management to achieve the operational targets at a cost to us that is
reasonable under the circumstances. Short-term incentives may include cash bonuses based on the extent to which specific targets set at the beginning of each fiscal year are met. The targets consist of a number of key performance indicators covering
corporate objectives and individual measures of performance. Individual performance indicators are linked to our development plans. Our Remuneration Committee determines, on an annual basis and after consideration of performance against the key
performance indicators, the amount, if any, of short-term incentives payable to our senior management. Payments of short-term incentive bonuses are made in the following reporting period. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We also provide long-term incentives through option grants under our Long Term Incentive Plan. The objective of
the Long Term Incentive Plan is to reward our management and key employees in a manner that aligns this element of compensation with the creation of shareholder wealth. Long Term Incentive Plan grants are made to senior management and employees who
are able to influence the generation of shareholder wealth and have a direct impact on our performance and development. Option vesting conditions are based on continued service to us. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">161
</FONT></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In making remuneration determinations for our senior management, the Remuneration
Committee considers operational contributions by our senior management as well as the following performance indicators: revenue, loss before tax, tax benefit, loss after tax, basic loss per ordinary share, net tangible assets per share and changes
in prevailing trading prices of our ordinary shares on the ASX. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B><I>Remuneration of <FONT STYLE="white-space:nowrap">Non-Employee</FONT> Directors </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our <FONT STYLE="white-space:nowrap">non-employee</FONT> directors receive a fixed fee annually, which is reviewed by our board of
directors on an annual basis. Mr.&nbsp;Kempler, who will retire from our board of directors effective October 12, 2020, is entitled to an annual fixed fee of A$99,000 (inclusive of superannuation contributions and fees for his service as chairperson
of the board of directors). Messrs.&nbsp;Sistenich and Gozlan are each entitled to an annual fixed fee of A$65,700 (inclusive of superannuation contributions). Mr.&nbsp;Spiegelman is entitled to an annual fixed fee of US$70,000 (inclusive of
superannuation contributions and fees for his service as chairperson of the audit and risk committee), plus an annual fixed fee of US$10,000 for service as Chair of any other committees and US$5,000 for service on any other committee in a non-Chair
role. Upon joining the board of directors, Dr.&nbsp;Levin will be entitled to an annual fixed fee of US$75,000 (inclusive of superannuation contributions and fees for his service as chairperson of the board of directors), plus an annual fixed fee of
US$5,000 for service on any committee of the board of directors. Unless otherwise noted, the fixed fees cover both service on the board of directors and committees of the board of directors. The remuneration of our
<FONT STYLE="white-space:nowrap">non-employee</FONT> directors is reviewed by our board of directors on an annual basis. <FONT STYLE="white-space:nowrap">Non-employee</FONT> directors are not provided with retirement benefits apart from statutory
superannuation, which is only applicable to Australian resident directors. <FONT STYLE="white-space:nowrap">Non-employee</FONT> directors are reimbursed for costs directly related to conducting business related to their service on our board of
directors. </FONT></P>  <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We implemented a <FONT
STYLE="white-space:nowrap">non-executive</FONT> director share and option plan, or the NED Plan, in 2014. Under the NED Plan, present and future <FONT STYLE="white-space:nowrap">non-executive</FONT> directors may: </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">elect to receive ordinary shares or options to purchase ordinary shares in lieu of receiving some or all of their annual fixed fee;
</FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">be awarded ordinary shares or options to purchase ordinary shares in lieu of additional cash remuneration in respect of services provided to the
Company which in the opinion of the board of directors are outside the scope of the ordinary duties of the relevant director; and </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">otherwise be awarded ordinary shares or options to purchase ordinary shares as part of the directors&#146; remuneration in addition to any existing
cash remuneration paid to directors (if any). </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">The NED Plan is designed to assist us in preserving our cash for use toward advancing the clinical development of our product candidate and provide our <FONT STYLE="white-space:nowrap">non-employee</FONT>
directors an opportunity to demonstrate their commitment and support for us through sacrificing some or all of their cash fees for ordinary shares or options. The NED Plan also provides us with further flexibility in the design of the
directors&#146; remuneration packages and in turn assists us with retaining existing directors and attracting new additional directors with the relevant experience and expertise. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>  <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We expect to grant an option to purchase 2,000,000
ordinary shares to each of Messrs. Gozlan and Spiegelman under the NED Plan upon approval of such grants by our shareholders at our annual general meeting of shareholders for 2020 on October 12, 2020, at which time an exercise price per ordinary
share will be determined for such options. The exercise price per ordinary share for such options will be (1)&nbsp;150% of the five-day volume-weighted average trading price of our ordinary shares as of the grant date, for Mr.&nbsp;Gozlan&#146;s
option, and (2)&nbsp;100% of such price, for Mr.&nbsp;Spiegelman&#146;s option. In addition, our board of directors has approved an option to purchase 3,000,000 ordinary shares for Dr. Levin, which we expect to grant under the NED Plan following
approval of such grant by our shareholders at an extraordinary general meeting of shareholders to be convened following the completion of this offering. The exercise price per ordinary share for Dr.&nbsp;Levin&#146;s option will be the five-day
volume-weighted average trading price of our ordinary shares as of October&nbsp;12, 2020. For </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">162
</FONT></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
each of the options described above, 25% of the ordinary shares underlying such option will vest immediately on the applicable grant date, and 25% of the ordinary shares will vest annually
thereafter over the following three years. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In
addition, if a change in control of our company (as defined in the NED Plan) occurs prior to the grant of Dr. Levin&#146;s option upon receipt of shareholder approval, we have agreed to pay Dr. Levin a cash amount equal to the value Dr. Levin would
have received had his option been granted prior to the change in control and accelerated in full in connection with the change in control. </FONT></P>  <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">For the fiscal year ended June&nbsp;30, 2020, the aggregate cash remuneration paid to our
<FONT STYLE="white-space:nowrap">non-employee</FONT> directors was A$167,441, including A$2,747&nbsp;in cash reimbursements. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Employment Agreements with Senior Management </I></B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The key provisions of the employment agreements are set out
below for each member of our senior management. None of these employment agreements have termination dates. The base salary under the employment agreements may be increased by the board of directors from time to time, including by 3% for the fiscal
year ending June 30, 2021. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>

<TD WIDTH="22%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="10%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="28%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="28%"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1px solid #000000 ; display:table-cell;"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Officer</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Date of<BR>Agreement</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1px solid #000000"> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Base Salary</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1px solid #000000"> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Termination without Cause</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1px solid #000000"> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Benefits upon Termination
without<BR>Cause</B></FONT></P></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Megan Baldwin, Ph.D.<BR><I>Chief Executive Officer and Managing Director</I></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">April&nbsp;23,<BR>2014</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">A$440,000 per&nbsp;year</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Not less than three months&#146; notice (if by employee)</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Not less than three months&#146; notice or payment in lieu of notice period
(if by us)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Upon notice of termination by us, any options that have vested or will vest during the notice period will be released; all other options will lapse at the discretion of our board of
directors.</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Michael Tonroe<BR><I>Chief Financial Officer and Company Secretary</I></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">May&nbsp;8,<BR>2014</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">A$256,844 per&nbsp;year</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Not less than three months&#146; notice (if by employee)</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Not less than three months&#146; notice or payment in lieu of notice period
(if by us)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Not applicable.</FONT></TD></TR>
</TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Upon termination of
employment, our senior management are entitled to receive their statutory entitlements of accrued annual and long service leave, together with any superannuation benefits. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>  <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Remuneration of Our Non-Employee Directors and
Senior Management During the Fiscal Year Ended June 30, 2020 </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Details of the remuneration of our <FONT STYLE="white-space:nowrap">non-employee</FONT> directors and senior management for the fiscal year ended June&nbsp;30, 2020 are set forth below. During the fiscal
year ended June&nbsp;30, 2020, no options to purchase ordinary shares were granted to any of our <FONT STYLE="white-space:nowrap">non-employee</FONT> directors or senior management. </FONT></P>  <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
SIZE="1">&nbsp;</FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>

<TD WIDTH="55%"></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD COLSPAN="2" VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Short-Term<BR>Incentive</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B><FONT STYLE="white-space:nowrap">Post-Employment</FONT></B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD COLSPAN="2" VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Salary/Fees<SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(1)</SUP></B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Cash&nbsp;
Bonus<SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(2)</SUP></B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Superannuation</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Total</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><FONT STYLE="white-space:nowrap">Non-Employee</FONT> Directors<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(3)</SUP></FONT></B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Geoffrey Kempler</FONT><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(4)</SUP></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">A$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">90,405</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">A$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">A$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">8,589</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">A$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">98,994</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Michael Sistenich</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">60,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">5,700</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">65,700</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Senior Management</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD COLSPAN="5" VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Megan Baldwin, Ph.D.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">440,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">100,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">51,300</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">591,300</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Michael Tonroe</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">256,844</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">64,211</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">30,500</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">351,555</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
</TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">163
</FONT></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="line-height:8px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(1)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">For our <FONT STYLE="white-space:nowrap">non-employee</FONT> directors, amounts set forth in this column include our reimbursement of expenses incurred in connection
with performance of services relating to board service. </FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(2)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Bonuses are paid in the fiscal year following the year in which they were earned. </FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(3)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Messrs. Gozlan and Spiegelman joined our board of directors in July 2020 and September 2020, respectively, and are not presented in the table. Dr. Levin will join our
board of directors effective as of October&nbsp;12, 2020 and is not presented in the table. See &#147;&#151;Remuneration of Non-Employee Directors&#148; for information regarding options expected to be granted to each of Messrs. Gozlan and
Spiegelman and Dr. Levin. </FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(4)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Mr. Kempler will retire from our board of directors effective as of October 12, 2020. </FONT></TD></TR></TABLE>  <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Details of options held by our <FONT STYLE="white-space:nowrap">non-employee</FONT> directors and senior
management as of June&nbsp;30, 2020 are set forth below. None of our <FONT STYLE="white-space:nowrap">non-employee</FONT> directors or senior management exercised any options to purchase ordinary shares during the fiscal year ended June&nbsp;30,
2020. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>

<TD WIDTH="44%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="8%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="9%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="8%"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Number&nbsp;of<BR>Options</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Grant&nbsp;Date</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Exercise<BR>Price</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1px solid #000000"> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Percentage<BR>Vested<SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(1)</SUP></B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1px solid #000000"> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Last&nbsp;Vesting<BR>Date</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1px solid #000000"> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Expiration<BR>Date</B></FONT></P></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><FONT STYLE="white-space:nowrap">Non-Employee</FONT> Directors<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(2)</SUP></FONT></B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Geoffrey Kempler</FONT><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(3)</SUP></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">2,000,000</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">3/7/16</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">A$0.480</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">100%</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">3/7/18</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">3/7/21</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,500,000</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">11/29/18</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.855</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">100</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">11/29/19</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">11/29/22</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Michael Sistenich</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,000,000</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">3/7/16</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.480</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">100</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">3/7/18</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">3/7/21</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,500,000</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">11/29/18</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.855</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">100</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">11/29/19</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">11/29/22</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Senior Management</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Megan Baldwin, Ph.D.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">4,000,000</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">3/7/16</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.480</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">100</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">3/7/18</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">3/7/21</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">3,000,000</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">11/29/18</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.855</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">100</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">11/29/19</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">11/29/22</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Michael Tonroe</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">800,000</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">3/7/16</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.480</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">100</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">1/1/19</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">1/1/22</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">600,000</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">4/3/19</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.855</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">100</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">4/3/20</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">4/3/23</FONT></TD></TR>
</TABLE>  <P STYLE="line-height:8px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(1)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">No options lapsed or were forfeited during the fiscal year ended June&nbsp;30, 2020. </FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(2)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Messrs. Gozlan and Spiegelman joined our board of directors in July 2020 and September 2020, respectively, and are not presented in the table. Dr. Levin will join our
board of directors effective as of October&nbsp;12, 2020 and is not presented in the table. </FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(3)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Mr. Kempler will retire from our board of directors effective as of October 12, 2020. </FONT></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">164
</FONT></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="rom947560_15"></A>CERTAIN RELATIONSHIPS AND RELATED PARTY TRANSACTIONS
</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Other than compensation arrangements which
are described under &#147;Management&#151;Remuneration&#148; or as disclosed below, from July&nbsp;1, 2017 through the date of this prospectus, we did not enter into any transactions or loans with any: (i)&nbsp;enterprises that directly or
indirectly, through one or more intermediaries, control, are controlled by or are under common control with us; (ii)&nbsp;associates; (iii)&nbsp;individuals owning, directly or indirectly, an interest in our voting power that gives them significant
influence over us, and close members of any such individual&#146;s family; (iv)&nbsp;key management personnel and close members of such individuals&#146; families; or (v)&nbsp;enterprises in which a substantial interest in our voting power is owned,
directly or indirectly, by any person described in (iii)&nbsp;or (iv)&nbsp;or over which such person is able to exercise significant influence. </I></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Ordinary Share Private Financing </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In December 2019, we issued and sold to certain institutional investors, including Regal Funds Management Pty Ltd., approximately
18.9&nbsp;million ordinary shares at a purchase price of A$2.65 per share for an aggregate purchase price of A$50.0&nbsp;million. Regal Funds Management Pty Ltd., a holder of over 10% of our outstanding ordinary shares as of June&nbsp;30, 2020,
purchased approximately 2.8&nbsp;million shares for A$7.5&nbsp;million. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B><I>Director and Senior Management Compensation </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">See &#147;Management&#151;Remuneration&#148; for information regarding compensation of our senior management and directors. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Indemnification Agreements </I></B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our Constitution provides that, except to the extent
prohibited by law including under the Corporations Act and, to the extent that an officer is not otherwise indemnified by us pursuant to an indemnity, we will indemnify every person who is or has been an officer of the company against any liability
(other than legal costs that are unreasonable) incurred by that person as an officer. This includes any liability incurred by that person in their capacity as an officer of our subsidiary where we requested that person to accept that appointment.
</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>  <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We have entered into Deeds of Indemnity,
Insurance and Access, or Indemnity Deeds, with Megan Baldwin, Ph.D., Michael Tonroe, Lawrence Gozlan, Geoffrey Kempler, Jeremy Levin, Michael Sistenich and Daniel Spiegelman, each a <FONT STYLE="white-space:nowrap">non-employee</FONT> director,
director nominee, or executive officer. Under the Indemnity Deeds, we have agreed to indemnify (to the maximum extent permitted under Australian law and our Constitution, subject to certain specified exceptions) each director and executive officer
against all liabilities incurred in their capacity as our or our subsidiaries&#146; director or officer and any and all costs and expenses relating to such a claim or to any notified event incurred by such director or executive officer, including
costs and expenses reasonably and necessarily incurred to mitigate any liability for such a claim or any claim which may arise from such a notified event. The Indemnity Deeds provide that the indemnities are unlimited as to amount, continuous and
irrevocable. </FONT></P>  <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Separately, we have obtained
insurance for our directors and executive officers, as required by the Indemnity Deeds. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers or persons controlling us pursuant to the foregoing provisions, we have been informed
that in the opinion of the SEC such indemnification is against public policy as expressed in the Securities Act and is therefore unenforceable. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Related Person Transaction Policy </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We comply with Australian law and the rules and regulations of the ASX regarding approval of transactions with related parties. Prior to
the closing of this offering, we intend to adopt a related person transaction policy </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">165
</FONT></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
that sets forth our procedures for the identification, review, consideration and approval or ratification of related person transactions. The policy will become effective upon the execution of
the underwriting agreement for this offering. For purposes of our policy, a related person transaction is a transaction, arrangement or similar contractual relationship, or any series of similar transactions, arrangements or relationships, in which
we and any related person are, were or will be participants and the amount involved in the transaction exceeds $120,000, with the exception of usual transactions concluded under normal conditions. A related person is any member of our board of
directors, our senior management or any beneficial owner of more than 5% of any class of our ordinary shares, including any of their immediate family members and any entity owned or controlled by such persons. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Under the policy, if a transaction has been identified as a
related person transaction, including any transaction that was not a related person transaction when originally consummated or any transaction that was not initially identified as a related person transaction prior to consummation, our senior
management must present information regarding the related person transaction to the board of directors for review, consideration and approval or ratification. The presentation must include a description of, among other things, the material facts,
the interests, direct and indirect, of the related persons, the benefits to us of the transaction and whether the transaction is on terms that are comparable to the terms available to or from, as the case may be, an unrelated third party or to or
from employees generally. Under the policy, we will collect information that we deem reasonably necessary from each member of our board of directors and, to the extent feasible, significant shareholder to enable us to identify any existing or
potential related-person transactions and to effectuate the terms of the policy. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">All of the transactions described above were entered into prior to the adoption of the written policy, but our board of directors evaluated and approved all transactions that were considered to be related
party transactions under Australian law and the rules and regulations of the ASX at the time at which they were consummated. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">166
</FONT></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="rom947560_16"></A>PRINCIPAL SHAREHOLDERS </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>  <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The following table sets forth information with respect
to the beneficial ownership of our ordinary shares as of September&nbsp;30, 2020, for: </FONT></P>  <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">each person or group of affiliated persons known by us to beneficially own more than 5% of our ordinary shares; </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">each member of our senior management; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">each of our directors and director nominees; and </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">all of our directors and senior management as a group. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>  <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">To our knowledge, as of September&nbsp;30, 2020,
approximately 371,334 ordinary shares, or 0.14% of our ordinary shares, were held of record by five residents of the United States. </FONT></P>  <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We have determined beneficial ownership in accordance with the rules and regulations of the SEC, and the information is not necessarily
indicative of beneficial ownership for any other purpose. Except as indicated by the footnotes below, we believe, based on information furnished to us, that the persons and entities named in the table below have sole voting and sole investment power
with respect to all shares that they beneficially own. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>  <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Applicable percentage ownership before the offering is based on 269,157,769 ordinary shares outstanding as of September&nbsp;30, 2020. Applicable percentage ownership after the offering is based on
ordinary shares outstanding immediately after the closing of this offering (after giving effect to the sale and issuance of 9,300,000 ADSs representing 74,400,000 ordinary shares at an ADS-to-ordinary share ratio of 1-to-8), assuming no exercise by
the underwriters of their option to purchase additional ADSs. In computing the number of shares beneficially owned by a person or entity and the percentage ownership of such person or entity, we deemed to be outstanding all shares subject to options
held by the person or entity that are currently exercisable, or exercisable within 60 days of September&nbsp;30, 2020. However, except as described above, we did not deem such shares outstanding for the purpose of computing the percentage ownership
of any other person or entity. The information contained in the following table is not necessarily indicative of beneficial ownership for any other purpose, and the inclusion of any shares in the table does not constitute an admission of beneficial
ownership of those shares. Each of our shareholders is entitled to one vote per ordinary share. None of the holders of our shares will have different voting rights from other holders of shares after the closing of this offering. We are not aware of
any arrangement that may, at a subsequent date, result in a change of control of our company. For further information regarding options to purchase ordinary shares held by our directors and senior management, see
&#147;Management&#151;Remuneration.&#148; </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">167
</FONT></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Unless otherwise indicated, the address of each beneficial owner listed below is c/o
Opthea Limited, Suite 0403, Level&nbsp;4, 650 Chapel Street, South Yarra, VIC 3141, Australia. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>

<TD WIDTH="55%"></TD>

<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD COLSPAN="2" VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Percentage&nbsp;of&nbsp;Shares&nbsp;Beneficially&nbsp;Owned</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1px solid #000000 ; display:table-cell;"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Name of Beneficial Owner</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Number of<BR>Ordinary&nbsp;Shares<BR>Beneficially<BR>Owned</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Before Offering</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>After Offering</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Principal Shareholders</I></B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Funds affiliated with Regal Funds Management Pty Ltd.</FONT><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(1)</SUP></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">28,726,324</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">10.7</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">8.4</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Baker Brothers Advisors L.P.</FONT><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(2)</SUP></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">26,526,759</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">9.9</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">7.7</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Entities affiliated with the Liberman Family</FONT><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(3)</SUP></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">19,228,128</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">7.1</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">5.6</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">KiFin Ltd.</FONT><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(4)</SUP></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">16,275,227</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">6.0</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">4.7</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Directors, Director Nominees and Senior Management</I></B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Megan Baldwin, Ph.D.</FONT><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(5)</SUP></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">7,987,723</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2.9</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2.3</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Michael Tonroe</FONT><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(6)</SUP></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,400,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">*</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">*</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Geoffrey Kempler</FONT><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(7)</SUP></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">4,400,960</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.6</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.3</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Lawrence Gozlan</FONT><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(8)</SUP></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">500,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">*</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">*</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Jeremy Levin, DPhil, MB BChir</FONT><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(9)</SUP></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">*</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">*</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Michael Sistenich</FONT><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(10)</SUP></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3,020,178</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.1</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">*</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Daniel Spiegelman</FONT><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(11)</SUP></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">500,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">*</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">*</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">All directors, director nominees and senior management as a group (seven persons)</FONT><FONT
STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(12)</SUP></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">17,808,861</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">6.3</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">5.0</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD></TR>
</TABLE>  <P STYLE="line-height:8px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">*</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Represents beneficial ownership of less than 1%. </FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(1)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Consists of 28,726,324 ordinary shares held by funds affiliated with Regal Funds Management Pty Ltd., referred to together as the Regal Funds. Regal Funds Management
Pty Ltd. is the investment manager for each of such funds holding our ordinary shares. Philip King and Craig Collie are the Chief Investment Officer and portfolio manager, respectively, of Regal Funds Management Pty Ltd. and, as such, they may be
deemed to have voting and dispositive power with respect to the ordinary shares held by the affiliated funds. Philip King and Craig Collie disclaim beneficial ownership of the ordinary shares held by the Regal Funds except to the extent of their
pecuniary interest. The address for Regal Funds Management Pty Ltd. is Level&nbsp;47, Gateway, 1 Macquarie Place, Sydney, NSW 2000, Australia. </FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(2)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Consists of (i) 2,166,666 ordinary shares held by 667, L.P. and (ii) 24,360,093 ordinary shares held by Baker Brothers Life Sciences, L.P. We refer to 667, L.P. and
Baker Brothers Life Sciences, L.P. together as the Baker Entities. Baker Bros. Advisors LP is the investment advisor of the Baker Entities and has sole voting and dispositive power with respect to the ordinary shares held by the Baker Entities.
Baker Bros. Advisors (GP) LLC is the sole general partner of Baker Bros. Advisors LP. The managing members of Baker Bros. Advisors (GP) LLC are Julian C. Baker and Felix J. Baker and, as such, they may be deemed to have voting and dispositive power
with respect to the ordinary shares held by the Baker Entities. Julian C. Baker and Felix J. Baker disclaim beneficial ownership of the ordinary shares held by the Baker Entities except to the extent of their pecuniary interest. The address for the
Baker Entities is 880 Washington Street, 3rd Floor, New York, New York 10014. </FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(3)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Consists of 19,228,128 ordinary shares held by entities affiliated with the Liberman Family, including 13,520,540 ordinary shares held by Jagen Pty Ltd., for which
Lawrence Gozlan, a member of our board of directors, serves as founder and Chief Investment Officer. Bori Liberman, Helen Liberman, Laini Liberman, Justin Liberman and Nic Liberman share voting and dispositive power with respect to the ordinary
shares held by the entities affiliated with the Liberman Family. The address for the entities affiliated with the Liberman Family is 8 Oxford Street, South Yarra, VIC 3141, Australia. </FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(4)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Consists of 16,275,227 ordinary shares held by KiFin Ltd. KiFin Ltd. is managed by its sole director, Guardian Corporate Services Limited, or GCSL. The
directors of GCSL are Ritchie Linden, Conrad Rademeyer, Gregoire Lartigue, Abacus Managers Limited, Abacus Management Limited and Abacus </FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">168
</FONT></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P><FONT STYLE="font-family:Times New Roman" SIZE="2">
Corporate Services Limited. Meade Malone and Rajiv Balleram are the two directors of the three Abacus entities acting as corporate directors of GCSL. The directors of GCSL have shared and equal
voting rights with respect to decisions of GCSL, as sole director of KiFin Ltd., and as such may be deemed to have shared voting and dispositive power with respect to the ordinary shares held by KiFin Ltd. Each director of GCSL disclaims beneficial
ownership of the ordinary shares held by KiFin Ltd. except to the extent of their pecuniary interest. The address for KiFin Ltd. is Geneva Place, 333 Waterfront Drive, Road Town, Tortola, British Virgin Islands. </FONT></P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(5)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Consists of (i)&nbsp;987,723 ordinary shares beneficially owned and (ii)&nbsp;7,000,000 ordinary shares issuable upon the exercise of options that are exercisable
within 60 days of September&nbsp;30, 2020. </FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(6)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Consists of 1,400,000 ordinary shares issuable upon the exercise of options that are exercisable within 60&nbsp;days of September&nbsp;30, 2020.
</FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(7)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Consists of (i)&nbsp;900,960 ordinary shares directly held by Mr.&nbsp;Kempler and (ii)&nbsp;3,500,000 ordinary shares issuable upon the exercise of options that are
exercisable within 60&nbsp;days of September&nbsp;30, 2020. Mr.&nbsp;Kempler will retire from our board of directors effective as of October 12, 2020. </FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(8)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Mr.&nbsp;Gozlan joined our board of directors in July 2020. Consists of 500,000 ordinary shares that will vest and become issuable upon the exercise of an option within
60 days of September 30, 2020, which option will be granted upon approval by our shareholders at our annual general meeting of shareholders for 2020 on October&nbsp;12, 2020. </FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(9)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Dr.&nbsp;Levin will join our board of directors as Chairperson effective as of October 12, 2020. </FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(10)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Consists of (i)&nbsp;520,178 ordinary shares directly held by Mr.&nbsp;Sistenich and (ii)&nbsp;2,500,000 ordinary shares issuable upon the exercise of options that are
exercisable within 60 days of September&nbsp;30, 2020. </FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(11)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Mr. Spiegelman joined our board of directors in September 2020. Consists of 500,000 ordinary shares that will vest and become issuable upon the exercise of an option
within 60 days of September 30, 2020, which option will be granted upon approval by our shareholders at our annual general meeting of shareholders for 2020 on October 12, 2020. </FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(12)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Consists of (i)&nbsp;2,408,861 ordinary shares beneficially owned and (ii)&nbsp;15,400,000 ordinary shares issuable upon the exercise of options that are exercisable
within 60 days of September&nbsp;30, 2020. </FONT></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">169
</FONT></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="rom947560_17"></A>DESCRIPTION OF SHARE CAPITAL </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>General </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT
SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The following description of our ordinary shares is only a summary. We encourage you to read our Constitution,
which is included as an exhibit to this registration statement, of which this prospectus forms a part. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We are a public company limited by shares incorporated under the Corporations Act by the Australian Securities and Investments Commission,
or ASIC. Our corporate affairs are principally governed by our Constitution, the Corporations Act and the Australian Securities Exchange, or ASX, Listing Rules. Our ordinary shares trade on the ASX. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Australian law applicable to our Constitution is not
significantly different than a U.S. company&#146;s charter documents except we do not have a limit on our authorized share capital, the concept of par value is not recognized under Australian law and as further discussed under &#147;&#151;Our
Constitution.&#148; </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Subject to any restrictions
on the issue of securities in our Constitution, the Corporations Act and the ASX Listing Rules and any other applicable law, we may from time to time issue shares and grant options on any terms, with the rights and restrictions and for the
consideration that our board of directors determine. The rights and restrictions attaching to ordinary shares are derived through a combination of our Constitution, the common law applicable in Australia, the ASX Listing Rules, the Corporations Act
and other applicable law. A general summary of some of the rights and restrictions attaching to our ordinary shares are summarized below. Each ordinary shareholder is entitled to receive notice of, and to be present, vote and speak at, general
meetings. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Changes to Our Share Capital </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">As of June&nbsp;30, 2020, we had (i)
269,157,769&nbsp;ordinary shares outstanding and (ii)&nbsp;outstanding options to purchase 18,044,000&nbsp;ordinary shares at a weighted-average exercise price of A$0.68&nbsp;per share. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">From July&nbsp;1, 2017, through the date of this prospectus, the following events have changed the number of
our issued and outstanding ordinary shares: </FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">In December 2019, we issued 18,867,930 ordinary shares to institutional shareholders at an issue price of A$2.65 per share.
</FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">We issued the following ordinary shares upon the exercise of options over the following periods: </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">from July&nbsp;1, 2017 through June&nbsp;30, 2018, 2,063,518 ordinary shares upon the exercise of options granted in connection with capital raise
transactions; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">from July&nbsp;1, 2018 through June&nbsp;30, 2019, 46,776,951 ordinary shares upon the exercise of options granted in connection with capital raise
transactions; and </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">from July&nbsp;1, 2019 through June&nbsp;30, 2020, 875,000 ordinary shares upon the exercise of options granted to officers and employees.
</FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We expect to grant options to
purchase 7,000,000 ordinary shares to certain of our non-employee directors under the NED Plan upon approval of such options by our shareholders, of which (i)&nbsp;options to purchase 4,000,000 shares are subject to approval at our annual general
meeting of shareholders for 2020 on October&nbsp;12, 2020, at which time an exercise price per ordinary share will be determined for such options, and (ii)&nbsp;an option to purchase 3,000,000 shares will be subject to approval at a future meeting
of shareholders following the completion of this offering (see &#147;Management&#151;Remuneration of Non-Employee Directors&#148;). </FONT></P>  <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Our Constitution </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our Constitution is similar in nature to the bylaws of a U.S. corporation. It does not provide for or prescribe any specific objectives or
purposes of our company. Our Constitution is subject to the terms of the Corporations </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">170
</FONT></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
Act. It may be amended or repealed and replaced by special resolution of shareholders, which is a resolution passed by at least 75% of the votes cast by shareholders (in person or by proxy)
entitled to vote on the resolution. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Under
Australian law, a company has the legal capacity and powers of an individual both within and outside Australia. The material provisions of our Constitution are summarized below. This summary is not intended to be complete nor to constitute a
definitive statement of the rights and liabilities of our shareholders, and is qualified in its entirety by reference to the complete text of our Constitution, a copy of which is on file with the Securities and Exchange Commission. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Interested Directors </I></B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">A director or that director&#146;s alternate who has a
material personal interest in a matter that is being considered at a directors&#146; meeting must not be present while the matter is being considered at the meeting or vote in respect of that matter according to our Constitution unless permitted to
do so by the Corporations Act, in which case such director may (i)&nbsp;be counted in determining whether or not a quorum is present at any meeting of directors considering that contract or arrangement or proposed contract or arrangement;
(ii)&nbsp;sign or countersign any document relating to that contract or arrangement or proposed contract or arrangement; and (iii)&nbsp;vote in respect of, or in respect of any matter arising out of, the contract or arrangement or proposed contract
or arrangement. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Unless a relevant exception
applies, the Corporations Act requires our directors to provide disclosure of any material personal interest, and prohibits directors from voting on matters in which they have a material personal interest and from being present at the meeting while
the matter is being considered, unless directors who do not have a material personal interest in the relevant matter have passed a resolution that identifies the director, the nature and extent of the director&#146;s interest in the matter and its
relation to our affairs and states that those directors are satisfied that the interest should not disqualify the director from voting or being present. In addition, the Corporations Act and the ASX Listing Rules may require shareholder approval of
any provision of related party benefits to our directors, unless a relevant exception applies. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B><I>Directors&#146; Compensation </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Our <FONT STYLE="white-space:nowrap">non-employee</FONT> directors are paid remuneration for their services as directors. Subject to the ASX Listing Rules,
<FONT STYLE="white-space:nowrap">non-employee</FONT> directors as a whole may be paid or provided remuneration for their services a total amount or value not to exceed $500,000 per annum. Subject to the ASX Listing Rules, the aggregate, capped sum
for <FONT STYLE="white-space:nowrap">non-employee</FONT> directors&#146; remuneration is to be divided among the directors in such proportion as the directors themselves agree and in accordance with our Constitution. The capped sum remuneration for <FONT
STYLE="white-space:nowrap">non-employee</FONT> directors may not be increased except at a general meeting of shareholders and the particulars of the proposed increase are required to have been provided to shareholders in the notice convening the
meeting. In addition, our board of directors may fix the remuneration of each executive director, which may comprise salary or commission on or participation in our profits (or comprising a combination of each) as our directors determine.
</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Fees payable to our <FONT
STYLE="white-space:nowrap">non-employee</FONT> directors must be by way of a fixed sum and not by way of a commission on or a percentage of profits or operating revenue. Remuneration paid to our executive directors must also not include a commission
or percentage of operating revenue. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Pursuant to
our Constitution, any director who performs extra services or makes any special exertions, whether in going or residing abroad or otherwise for any of the purposes of the Company, that director may be paid an additional sum for those services and
exertions. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In addition to other remuneration
provided in our Constitution, all of our directors are entitled to be paid by us for all travelling and other expenses properly incurred by the directors in attending general meetings, board meetings, committee meetings or otherwise in connection
with our business. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">171
</FONT></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In addition, in accordance with our Constitution, a director may be paid a retirement
benefit as determined by our board of directors subject to the requirements of the Corporations Act. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Borrowing Powers Exercisable by Directors </I></B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Pursuant to our Constitution, the management and control of
our business affairs are vested in our board of directors. Our board of directors has the power to raise or borrow money or obtain other financial accommodation for the purposes of the Company, and may grant security for the repayment of that sum or
sums or the payment, performance or fulfilment of any debts, liabilities, contracts or obligations incurred or undertaken by the Company in any manner and upon any terms and conditions as our board of directors deems appropriate. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Retirement of Directors </I></B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Pursuant to our Constitution,
<FONT STYLE="white-space:nowrap">one-third</FONT> of our directors, other than the managing director, must retire from office at every annual general meeting. If the number of directors is not a multiple of three, then the number nearest, to but not
exceeding, <FONT STYLE="white-space:nowrap">one-third</FONT> must retire from office. The directors who retire in this manner are required to be the directors or director longest in office since last being elected. A director, other than the
managing director, must retire from office at the conclusion of the third annual general meeting after which the director was elected. A retiring director remains in office until the end of the meeting and will be eligible for <FONT
STYLE="white-space:nowrap">re-election</FONT> at the meeting. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B><I>Rights and Restrictions on Classes of Shares </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The rights attaching to our ordinary shares are detailed in our Constitution. Our Constitution provides that, subject to the Corporations
Act, the ASX Listing Rules and our Constitution, our directors may issue shares with preferential, deferred or special rights, privileges or conditions or with any restrictions, whether in relation to dividends, voting, return of share capital, or
otherwise as our board of directors may determine. Subject to the Corporations Act, the ASX Listing Rules and our Constitution (see &#147;&#151;Change of Control&#148;), we may issue further shares on such terms and conditions as our board of
directors resolve. We may only issue preference shares if the rights attaching to the preference shares relating to repayment of capital, participation in surplus assets and profits, cumulative and
<FONT STYLE="white-space:nowrap">non-cumulative</FONT> dividends, voting and priority of payment of capital and dividends in respect of other shares (including ordinary shares) are set out in our constitution or otherwise approved by special
resolution passed at a general meeting. Our outstanding share capital consists of only one class of ordinary shares. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Dividend Rights </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Under the Corporations Act, a company must not pay a dividend unless (a)&nbsp;the company&#146;s assets exceed its liabilities immediately
before the dividend is declared and the excess is sufficient for the payment of the dividend; (b)&nbsp;the payment of the dividend is fair and reasonable to the company&#146;s shareholders as a whole; and (c)&nbsp;the payment of the dividend does
not materially prejudice the company&#146;s ability to pay its creditors. Subject to this requirement, our board of directors may from time to time determine to pay and declare dividends to shareholders. All dividends unclaimed for one year after
the time for payment has passed may be invested or otherwise made use of by our board of directors for our benefit until claimed or until dealt with under any law relating to unclaimed moneys. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Voting Rights </I></B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Under our Constitution, and subject to any voting exclusions
imposed under the ASX Listing Rules (which typically exclude parties from voting on resolutions in which they have an interest), the rights and restrictions attaching to a class of shares, each shareholder has one vote on a show of hands at a
meeting of the shareholders unless a poll is demanded under the Constitution or the Corporations Act. On a poll vote, each shareholder shall have one vote for each fully paid share and a fractional vote for each share held by that shareholder that
is not </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">172
</FONT></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
fully paid, such fraction being equivalent to the proportion of the amount that has been paid to such date on that share. Shareholders may vote in person or by proxy, attorney or representative.
Under Australian law, shareholders of a public company are generally not permitted to approve corporate matters by written consent. Our Constitution does not provide for cumulative voting. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Under Australian law, an ordinary resolution is passed if a majority of the votes cast on the resolution (in
person or by proxy) by members entitled to vote on the resolution are in favor of the resolution. Under Australian law, a special resolution is passed if at least 75% of the votes cast on the resolution (in person or by proxy) are in favor of the
resolution. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">ADS holders may not directly vote at
a meeting of the shareholders but may instruct the depositary to vote the number of deposited ordinary shares their ADSs represent. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Right to Share in Our Profits </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Pursuant to our Constitution, our shareholders are entitled to participate in our profits only by payment of dividends. Our board of
directors may from time to time determine to pay dividends to the shareholders. However, any such dividend may only be payable in accordance with the requirements set out in the Corporations Act described above. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Rights to Share in the Surplus in the Event of Winding
Up </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our Constitution provides for the
right of shareholders to participate in a surplus in the event of our winding up, subject to the rights attaching to a class of shares,. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>No Redemption Provision for Ordinary Shares </I></B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">There are no redemption provisions in our Constitution in
relation to ordinary shares. Under our Constitution, shares may be issued and allotted, which are liable to be redeemed. Under the Corporations Act, redeemable preference shares may only be redeemed if those preference shares are fully <FONT
STYLE="white-space:nowrap">paid-up</FONT> and payment in satisfaction of redemption is out of profits or the proceeds of a new issue of shares made for the purposes of the redemption. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Variation or Cancellation of Share Rights </I></B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Subject to the Corporations Act, the ASX Listing Rules and
the terms of issue of shares of that class, the rights and privileges attached to shares in a class of shares may only be varied or cancelled by a special resolution, together with either: </FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT
SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">a special resolution passed at a meeting of members holding shares in the class; or </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the written consent of members with at least 75% of the shares in the class. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Directors May Make Calls </I></B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our Constitution provides that subject to compliance with
the Corporations Act and the terms on which partly paid shares are issued, directors may make calls on the holders of the shares for any money unpaid on them. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>General Meetings of Shareholders </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">General meetings of shareholders may be called by our board of directors. Except as permitted under the Corporations Act, shareholders may
not convene a meeting. The Corporations Act requires the directors to call and arrange to hold a general meeting on the request of shareholders with at least 5% of the votes that may be </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">173
</FONT></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
cast at a general meeting. Notice of the proposed meeting of our shareholders is required at least 28 days prior to such meeting under the Corporations Act. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Foreign Ownership Regulation </I></B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our Constitution does not impose specific limitations on the
rights of <FONT STYLE="white-space:nowrap">non-residents</FONT> to own securities. However, acquisitions and proposed acquisitions of securities in Australian companies may be subject to review and approval by the Australian Federal Treasurer under
the Foreign Acquisitions and Takeovers Act 1975 (Cth), or the FATA, which generally applies to acquisitions or proposed acquisitions: </FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">by a foreign person (as defined in the FATA) or associated foreign persons that would result in such persons having an interest in 20% or more of the
issued shares of, or control of 20% or more of the voting power in, an Australian company; and </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">by <FONT STYLE="white-space:nowrap">non-associated</FONT> foreign persons that would result in such foreign persons having an aggregate interest in 40%
or more of the issued shares of, or control of 40% or more of the voting power in, an Australian company, where the Australian company is valued above the monetary threshold prescribed by FATA. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Due to the impacts of the
<FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic, the monetary thresholds for foreign investment proposals covered by the FATA and its associated regulations have been reduced to zero. This regime may revert in the future to the previous
regime, which, in general terms, provided that in respect of proposals for investment in <FONT STYLE="white-space:nowrap">non-sensitive</FONT> sectors, no such review or approval under the FATA is required if the foreign acquirer is a U.S. entity or
an entity from certain other countries and the value of the Australian target is less than A$1,192&nbsp;million. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Australian Federal Treasurer may prevent a proposed acquisition in the above categories or impose conditions on such acquisition if
the Treasurer is satisfied that the acquisition would be contrary to the national interest. If a foreign person acquires shares or an interest in shares in an Australian company in contravention of the FATA, the Australian Federal Treasurer may make
a range of orders including an order the divestiture of such person&#146;s shares or interest in shares in that Australian company. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Ownership Threshold </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">There are no specific provisions in our Constitution that require a shareholder to disclose ownership above a certain threshold. The
Corporations Act, however, requires a shareholder to notify us and the ASX once it, together with its associates, acquires a 5% interest in our ordinary shares, at which point the shareholder will be considered to be a &#147;substantial&#148;
shareholder. Further, once a shareholder owns (alone or together with associates) a 5% interest in us, such shareholder must notify us and the ASX of any increase or decrease of 1% or more in its holding of our ordinary shares, and must also notify
us and the ASX on its ceasing to be a &#147;substantial&#148; shareholder. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B><I>Issues of Shares and Change in Capital </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Subject to our Constitution, the Corporations Act, the ASX Listing Rules and any other applicable law, we may at any time issue shares and give any person a call or option over any shares on any terms,
with preferential, deferred or other special rights, privileges or conditions or with restrictions and for the consideration and other terms that the directors determine. We may only issue preference shares if the rights attaching to the preference
shares relating to repayment of capital, participation in surplus assets and profits, cumulative and <FONT STYLE="white-space:nowrap">non-cumulative</FONT> dividends, voting and priority of payment of capital and dividends in respect of other shares
(including ordinary shares) are set out in our Constitution or otherwise approved by special resolution passed at a general meeting of shareholders. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Subject to the requirements of our Constitution, the Corporations Act, the ASX Listing Rules and any other applicable law, including
relevant shareholder approvals, we may consolidate or divide our share capital into a larger or smaller number by resolution, reduce our share capital in any manner (provided that the reduction is fair
</FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">174
</FONT></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
and reasonable to our shareholders as a whole, does not materially prejudice our ability to pay creditors and obtains the necessary shareholder approval) or buy back our ordinary shares whether
under an equal access <FONT STYLE="white-space:nowrap">buy-back</FONT> or on a selective basis. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>Change of Control </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Takeovers of listed Australian public companies, including us, are regulated by the Corporations Act, which prohibits the acquisition of a &#147;relevant interest&#148; in issued voting shares in a listed
company if the acquisition will lead to that person&#146;s or someone else&#146;s voting power in our company increasing from 20% or below to more than 20% or increasing from a starting point that is above 20% and below 90%, which we refer to as the
Takeovers Prohibition, subject to a range of exceptions. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Generally, a person will have a relevant interest in securities if the person: </FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">is the holder of the securities (other than if the person holds those securities as a bare trustee); </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">has power to exercise, or control the exercise of, a right to vote attached to the securities; or </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">has the power to dispose of, or control the exercise of a power to dispose of, the securities. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">If, at a particular time, </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">a person has a relevant interest in issued securities; and </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the person (whether before or after acquiring the relevant interest) has: </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT
SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">entered or enters into an agreement with another person with respect to the securities; </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">given or gives another person an enforceable right, or has been or is given an enforceable right by another person, in relation to the securities
(whether the right is enforceable presently or in the future and whether or not on the fulfillment of a condition); or </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">granted or grants an option to, or has been or is granted an option by, another person with respect to the securities; and
</FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the other person would have a relevant interest in the securities if the agreement were performed, the right enforced or the option exercised,
</FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">then the other person is taken
to have a relevant interest in the relevant securities. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">There are a number of exceptions to the Takeover Prohibition. In general terms, some of the more significant exceptions include: </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">when the acquisition results from the acceptance of an offer under a formal takeover bid; </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">when the acquisition is conducted on market by or on behalf of the bidder during the bid period for a full takeover bid that is unconditional or only
conditional on certain &#145;prescribed&#146; matters set out in the Corporations Act; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">when the acquisition has been previously approved by our shareholders by resolution passed at general meeting; </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">an acquisition by a person if, throughout the six months before the acquisition, that person or any other person has had voting power in our company of
at least 19% and, as a result of the acquisition, none of the relevant persons would have voting power in our company more than three percentage points higher than they had six months before the acquisition; </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">when the acquisition results from the issue of securities under a rights issue; </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">when the acquisition results from the issue of securities under a dividend reinvestment scheme or bonus share plan; </FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">175
</FONT></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">when the acquisition results from the issue of securities under certain underwriting arrangements; </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">when the acquisition results from the issue of securities through a will or through operation of law; </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">an acquisition that arises through the acquisition of a relevant interest in another listed company which is listed on a prescribed financial market or
a financial market approved by ASIC; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">an acquisition arising from an auction of forfeited shares conducted <FONT STYLE="white-space:nowrap">on-market;</FONT> or
</FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">an acquisition arising through a compromise, arrangement, liquidation or <FONT STYLE="white-space:nowrap">buy-back.</FONT>
</FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Breaches of the takeovers
provisions of the Corporations Act are criminal offenses. ASIC and the Australian Takeover Panel have a wide range of powers relating to breaches of takeover provisions, including the ability to make orders, canceling contracts, freezing transfers
of, and rights attached to, securities and forcing a party to dispose of securities. There are certain defenses to breaches of the Takeover Prohibition provided in the Corporations Act. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Access to and Inspection of Documents </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Inspection of our records is governed by our Constitution
and the Corporations Act. Any member of the Company has the right to inspect or obtain copies of our share register on the payment of a prescribed fee. Our books containing the minutes of general meetings will be kept at our registered office and
will be open to inspection of members at all times when the office is required to be open to the public. Other corporate records, including minutes of directors&#146; meetings, financial records and other documents, are not open for inspection by
shareholders (who are not directors). Where a shareholder is acting in good faith and an inspection is deemed to be made for a proper purpose, a shareholder may apply to the court to make an order for inspection of our books. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Legal Name; Formation; Registered Office </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We were incorporated under the laws of Australia in 1984
under the name Circadian Technologies Limited. In 1985, we completed an initial public offering of our ordinary shares and the listing of our ordinary shares on the Australian Securities Exchange, or the ASX. In December 2015, we changed the name of
our company to Opthea Limited. Our headquarters and registered offices are located at Suite 0403, Level&nbsp;4, 650 Chapel Street, South Yarra, VIC 3141, Australia. Our agent for service of process in the United States is Corporation Service
Company, located at 1180 Avenue of the Americas, Suite 210, New York, New York 10036. Our website address is www.opthea.com. The reference to our website is an inactive textual reference only and information contained in, or that can be assessed
through, our website is not part of this prospectus. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Listing
</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>  <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We have applied to have the ADSs listed
on the Nasdaq Global Select Market under the symbol &#147;OPT.&#148; Our ordinary shares are listed on the ASX under the symbol &#147;OPT.&#148; </FONT></P>  <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Transfer Agent and Registrar </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Upon the closing of this offering, the transfer agent and registrar for the ADSs will be National Australia Bank Ltd. Computershare
Investor Services Pty Limited is our transfer agent and registrar for our ordinary shares and currently maintains our share register for our ordinary shares. The share register reflects only record owners of our ordinary shares. Holders of the ADSs
will not be treated as one of our shareholders and their names will therefore not be entered in our share register. The depositary, the custodian or their nominees will be the holder of the shares underlying the ADSs. Holders of the ADSs have a
right to receive the ordinary shares underlying their ADSs. See &#147;Description of American Depositary Shares.&#148; </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">176
</FONT></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="rom947560_18"></A>DESCRIPTION OF AMERICAN DEPOSITARY SHARES </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>American Depositary Shares </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>  <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Bank of New York Mellon, as depositary, will
register and deliver American Depositary Shares, or ADSs. Each ADS will represent eight ordinary Shares (or a right to receive eight ordinary shares) deposited with HSBC Bank Australia Limited, as custodian for the depositary in Australia. Each ADS
will also represent any other securities, cash or other property that may be held by the depositary. The deposited shares together with any other securities, cash or other property held by the depositary are referred to as the deposited securities.
The depositary&#146;s office at which the ADSs will be administered and its principal executive office are located at 240 Greenwich Street, New York, New York 10286. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In June 2011, we sponsored a Level I American Depositary
Receipt, or ADR, facility and filed a registration statement on Form F-6 with the SEC to issue ADSs to requesting holders of our ordinary shares, which ADSs could be traded on the over-the-counter market in the United States. Under this Level I
facility, ADSs were issued under an existing deposit agreement with The Bank of New York Mellon as depositary. In connection with this offering, we are amending the terms of the existing ADR facility and the related deposit agreement, including to
change the ADS-to-ordinary share ratio from 1-to-5 to 1-to-8, which will take effect prior to the execution of the underwriting agreement for this offering, and have filed a new registration statement on Form F-6 (File No. 333-249327) relating to
the existing ADSs and the ADSs offered and sold in this offering as well as the amended and restated deposit agreement. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">You may hold ADSs either (A)&nbsp;directly (i) by having an ADR, which is a certificate evidencing a specific number of ADSs, registered
in your name, or (ii)&nbsp;by having uncertificated ADSs registered in your name, or (B)&nbsp;indirectly by holding a security entitlement in ADSs through your broker or other financial institution that is a direct or indirect participant in The
Depository Trust Company, or DTC. If you hold ADSs directly, you are a registered ADS holder, or an ADS holder. This description assumes you are an ADS holder. If you hold the ADSs indirectly, you must rely on the procedures of your broker or other
financial institution to assert the rights of ADS holders described in this section. You should consult with your broker or financial institution to find out what those procedures are. </FONT></P>  <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Registered holders of uncertificated ADSs will receive statements from the depositary confirming their
holdings. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>  <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">As an ADS holder, we will not treat
you as one of our shareholders and you will not have shareholder rights. Australian law governs shareholder rights. The depositary will be the holder of the shares underlying your ADSs. As a registered holder of ADSs, you will have ADS holder
rights. The amended and restated deposit agreement among us, the depositary, ADS holders and all other persons indirectly or beneficially holding ADSs sets out ADS holder rights as well as the rights and obligations of the depositary. New York law
governs the deposit agreement and the ADSs. </FONT></P>  <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The following is a summary of the material provisions of the deposit agreement. For more complete information, you should read the entire
deposit agreement and the form of ADR. For directions on how to obtain copies of those documents, see &#147;Where You Can Find More Information.&#148; </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Dividends and Other Distributions </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>How will you receive dividends and other distributions on the shares? </I></B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The depositary has agreed to pay or distribute to ADS
holders the cash dividends or other distributions it or the custodian receives on shares or other deposited securities, upon payment or deduction of its fees and expenses. You will receive these distributions in proportion to the number of shares
your ADSs represent. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Cash</I></B>. After
completion of this offering, we do not expect to declare or pay any cash dividends or cash distributions on our ordinary shares for the foreseeable future. The depositary will convert any cash dividend or
</FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">177
</FONT></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
other cash distribution we pay on the shares into U.S. dollars, if it can do so on a reasonable basis and can transfer the U.S. dollars to the United States. If that is not possible or if any
government approval is needed and cannot be obtained, the deposit agreement allows the depositary to distribute the foreign currency only to those ADS holders to whom it is possible to do so. It will hold the foreign currency it cannot convert for
the account of the ADS holders who have not been paid. It will not invest the foreign currency and it will not be liable for any interest. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Before making a distribution, any withholding taxes, or other governmental charges that must be paid will be deducted. See &#147;Material
United States Federal Income and Australian Tax Considerations.&#148; The depositary will distribute only whole U.S. dollars and cents and will round fractional cents to the nearest whole cent. <I>If the</I> <I>exchange rates fluctuate during a time
when the depositary cannot convert the foreign currency, you may lose some of the value of the distribution.</I> </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Shares</I></B><I>.</I> The depositary may distribute additional ADSs representing any shares we distribute as a dividend or free
distribution. The depositary will only distribute whole ADSs. It will sell shares which would require it to deliver a fraction of an ADS (or ADSs representing those shares) and distribute the net proceeds in the same way as it does with cash. If the
depositary does not distribute additional ADSs, the outstanding ADSs will also represent the new shares. The depositary may sell a portion of the distributed shares (or ADSs representing those shares) sufficient to pay its fees and expenses in
connection with that distribution. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Rights
to purchase additional shares</I></B><I>.</I> If we offer holders of our securities any rights to subscribe for additional shares or any other rights, the depositary may (i)&nbsp;exercise those rights on behalf of ADS holders, (ii)&nbsp;distribute
those rights to ADS holders or (iii)&nbsp;sell those rights and distribute the net proceeds to ADS holders, in each case after deduction or upon payment of its fees and expenses. To the extent the depositary does not do any of those things, it will
allow the rights to lapse unexercised. <I>In that case, you will receive no value for them.</I> The depositary will exercise or distribute rights only if we ask it to and provide satisfactory assurances to the depositary that it is legal to do so.
If the depositary will exercise rights, it will purchase the securities to which the rights relate and distribute those securities or, in the case of shares, new ADSs representing the new shares, to subscribing ADS holders, but only if ADS holders
have paid the exercise price to the depositary. U.S. securities laws may restrict the ability of the depositary to distribute rights or ADSs or other securities issued on exercise of rights to all or certain ADS holders, and the securities
distributed may be subject to restrictions on transfer. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B><I>Other Distributions</I></B><I>.</I> The depositary will send to ADS holders anything else we distribute on deposited securities by any means it thinks is legal, fair and practical. If it cannot make
the distribution in that way, the depositary has a choice. It may decide to sell what we distributed and distribute the net proceeds, in the same way as it does with cash. Or, it may decide to hold what we distributed, in which case ADSs will also
represent the newly distributed property. However, the depositary is not required to distribute any securities (other than ADSs) to ADS holders unless it receives satisfactory evidence from us that it is legal to make that distribution. The
depositary may sell a portion of the distributed securities or property sufficient to pay its fees and expenses in connection with that distribution. U.S. securities laws may restrict the ability of the depositary to distribute securities to all or
certain ADS holders, and the securities distributed may be subject to restrictions on transfer. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">The depositary is not responsible if it decides that it is unlawful or impractical to make a distribution available to any ADS holders. We have no obligation to register ADSs, shares, rights or other
securities under the Securities Act. We also have no obligation to&nbsp;take any other action to permit the distribution of ADSs, shares, rights or anything else to ADS holders. <I>This means that you may not receive the distributions we make on our
shares or any value for them if it is illegal or impractical for us to make them available to you</I>. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>Deposit, Withdrawal and Cancellation </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B><I>How are ADSs issued? </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">The depositary will deliver ADSs if you or your broker deposits shares or evidence of rights to receive shares with the custodian. Upon payment of its fees and expenses and of any taxes or charges, such
as stamp </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">178
</FONT></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
taxes or stock transfer taxes or fees, the depositary will register the appropriate number of ADSs in the names you request and will deliver the ADSs to or upon the order of the person or persons
that made the deposit. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>How can ADS holders
withdraw the deposited securities? </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">You
may surrender your ADSs to the depositary for the purpose of withdrawal. Upon payment of its fees and expenses and of any taxes or charges, such as stamp taxes or stock transfer taxes or fees, the depositary will deliver the shares&nbsp;and any
other deposited securities underlying the ADSs to the ADS holder or a person the ADS holder designates at the office of the custodian. Or, at your request, risk and expense, the depositary will deliver the deposited securities at its office, if
feasible. However, the depositary is not required to accept surrender of ADSs to the extent it would require delivery of a fraction of a deposited share or other security. The depositary may charge you a fee and its expenses for instructing the
custodian regarding delivery of deposited securities. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B><I>How do ADS holders interchange between certificated ADSs and uncertificated ADSs? </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">You may surrender your ADR to the depositary for the purpose of exchanging your ADR for uncertificated ADSs. The depositary will cancel
that ADR and will send to the ADS holder a statement confirming that the ADS holder is the registered holder of uncertificated ADSs. Upon receipt by the depositary of a proper instruction from a registered holder of uncertificated ADSs requesting
the exchange of uncertificated ADSs for certificated ADSs, the depositary will execute and deliver to the ADS holder an ADR evidencing those ADSs. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Voting Rights </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>How do you vote? </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">ADS holders may instruct the depositary how to vote the number of deposited shares their ADSs represent. If we request the depositary to
solicit your voting instructions (and we are not required to do so), the depositary will notify you of a shareholders&#146; meeting and send or make voting materials available to you. Those materials will describe the matters to be voted on and
explain how ADS holders may instruct the depositary how to vote. For instructions to be valid, they must reach the depositary by a date set by the depositary. The depositary will try, as far as practical, subject to the laws of the Commonwealth of
Australia and the provisions of our articles of association or similar documents, to vote or to have its agents vote the shares or other deposited securities as instructed by ADS holders. If we do not request the depositary to solicit your voting
instructions, you can still send voting instructions, and, in that case, the depositary may try to vote as you instruct, but it is not required to do so. In any event, the depositary will not exercise any discretion in voting deposited securities
and it will only vote or attempt to vote as instructed. </FONT></P>  <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">We cannot assure you that you will receive the voting materials in time to ensure that you can instruct the depositary to vote your shares. In addition, the depositary and its agents are not responsible
for failing to carry out voting instructions or for the manner of carrying out voting instructions. <I>This means that you may not be able to exercise voting rights and there may be nothing you can do if your shares are not voted as you
requested.</I> </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>  <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In order to give you a
reasonable opportunity to instruct the depositary as to the exercise of voting rights relating to Deposited Securities, if we request the Depositary to act, we agree to give the depositary notice of any such meeting and details concerning the
matters to be voted upon at least 30&nbsp;days in advance of the meeting date. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><I>Except by instructing the depositary as described above, you will not be able to exercise voting rights unless you surrender your ADSs and withdraw the shares. However, you may not know about the
meeting enough in advance to withdraw the shares. </I></FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">179
</FONT></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Fees and Expenses </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Pursuant to the terms of the deposit agreement, the persons
depositing or withdrawing ordinary shares or holders of ADSs will be required to pay the following fees: </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>

<TD WIDTH="64%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="35%"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="border-bottom:1px solid #000000"> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Persons depositing or withdrawing shares or ADS
holders must pay:</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1px solid #000000"> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>For:</B></FONT></P></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">US$5.00 (or less) per 100 ADSs (or portion of 100 ADSs)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Issuance of ADSs, including issuances resulting from a distribution of shares or rights or other property</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Cancellation of ADSs for the purpose of withdrawal, including if the deposit
agreement terminates</FONT></P></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">US$0.05 (or less) per ADS</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Any cash distribution to ADS holders</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">A fee equivalent to the fee that would be payable if securities distributed to you had been shares and the shares had been deposited for issuance of ADSs</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Distribution of securities distributed to holders of deposited securities (including rights) that are distributed by the depositary to ADS holders</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">US$0.05 (or less) per ADS per calendar year</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Depositary services</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Registration or transfer fees</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Transfer and registration of shares on our share register to or from the name of the depositary or its agent when you deposit or withdraw shares</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Expenses of the depositary</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Cable (including SWIFT) and facsimile transmissions (when expressly provided in the deposit agreement)</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:1px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Converting foreign currency to U.S. dollars</FONT></P></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Taxes and other governmental charges the depositary or the custodian has to pay on any ADSs or shares underlying ADSs, such as stock transfer taxes, stamp duty or withholding
taxes</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">As necessary</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Any charges incurred by the depositary or its agents for servicing the deposited securities</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">As necessary</FONT></TD></TR>
</TABLE>  <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The depositary collects
its fees for delivery and surrender of ADSs directly from investors depositing shares or surrendering ADSs for the purpose of withdrawal or from intermediaries acting for them. The depositary collects fees for making distributions to investors by
deducting those fees from the amounts distributed or by selling a portion of distributable property to pay the fees. The depositary may collect its annual fee for depositary services by deduction from cash distributions or by directly billing
investors or by charging the book-entry system accounts of participants acting for them. The depositary may collect any of its fees by deduction from any cash distribution payable (or by selling a portion of securities or other property
distributable) to ADS holders that are obligated to pay those fees. The depositary may generally refuse to provide <FONT STYLE="white-space:nowrap">fee-attracting</FONT> services until its fees for those services are paid. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">From time to time, the depositary may make payments to us to
reimburse us for costs and expenses generally arising out of establishment and maintenance of the ADS program, waive fees and expenses for services provided to us by the depositary or share revenue from the fees collected from ADS holders. In
</FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">180
</FONT></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
performing its duties under the deposit agreement, the depositary may use brokers, dealers, foreign currency dealers or other service providers that are owned by or affiliated with the depositary
and that may earn or share fees, spreads or commissions. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">The depositary may convert currency itself or through any of its affiliates, or the custodian or we may convert currency and pay U.S. dollars to the depositary. Where the depositary converts currency
itself or through any of its affiliates, the depositary acts as principal for its own account and not as agent, advisor, broker or fiduciary on behalf of any other person and earns revenue, including, without limitation, transaction spreads, that it
will retain for its own account. The revenue is based on, among other things, the difference between the exchange rate assigned to the currency conversion made under the deposit agreement and the rate that the depositary or its affiliate receives
when buying or selling foreign currency for its own account. The depositary makes no representation that the exchange rate used or obtained by it or its affiliate in any currency conversion under the deposit agreement will be the most favorable rate
that could be obtained at the time or that the method by which that rate will be determined will be the most favorable to ADS holders, subject to the depositary&#146;s obligation to act without negligence or bad faith. The methodology used to
determine exchange rates used in currency conversions made by the depositary is available upon request. Where the custodian converts currency, the custodian has no obligation to obtain the most favorable rate that could be obtained at the time or to
ensure that the method by which that rate will be determined will be the most favorable to ADS holders, and the depositary makes no representation that the rate is the most favorable rate and will not be liable for any direct or indirect losses
associated with the rate. In certain instances, the depositary may receive dividends or other distributions from the United States in U.S. dollars that represent the proceeds of a conversion of foreign currency or translation from foreign currency
at a rate that was obtained or determined by us and, in such cases, the depositary will not engage in, or be responsible for, any foreign currency transactions and neither it nor we make any representation that the rate obtained or determined by us
is the most favorable rate and neither it nor we will be liable for any direct or indirect losses associated with the rate. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Payment of Taxes </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">You will be responsible for any taxes or other governmental charges payable on your ADSs or on the deposited securities represented by any
of your ADSs. The depositary may refuse to register any transfer of your ADSs or allow you to withdraw the deposited securities represented by your ADSs until those taxes or other charges are paid. It may apply payments owed to you or sell deposited
securities represented by your ADSs to pay any taxes owed and you will remain liable for any deficiency. If the depositary sells deposited securities, it will, if appropriate, reduce the number of ADSs to reflect the sale and pay to ADS holders any
proceeds, or send to ADS holders any property, remaining after it has paid the taxes. Your obligation to pay taxes and indemnify us and the depository against any tax claims will survive the transfer or surrender of your ADSs, the withdrawal of the
deposited ordinary shares as well as the termination of the deposit agreement. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>Tender and Exchange Offers; Redemption, Replacement or Cancellation of Deposited Securities </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The depositary will not tender deposited securities in any voluntary tender or exchange offer unless instructed to do so by an ADS holder
surrendering ADSs and subject to any conditions or procedures the depositary may establish. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">If deposited securities are redeemed for cash in a transaction that is mandatory for the depositary as a holder of deposited securities, the depositary will call for surrender of a corresponding number of
ADSs and distribute the net redemption money to the holders of called ADSs upon surrender of those ADSs. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">If there is any change in the deposited securities such as a <FONT STYLE="white-space:nowrap">sub-division,</FONT> combination or other
reclassification, or any merger, consolidation, recapitalization or reorganization affecting the issuer of deposited securities in which the depositary receives new securities in exchange for or in lieu of the old deposited securities, the
depositary will hold those replacement securities as deposited securities under the deposit agreement. However, if the depositary decides it would not be lawful and practical to hold the replacement
</FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">181
</FONT></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
securities because those securities could not be distributed to ADS holders or for any other reason, the depositary may instead sell the replacement securities and distribute the net proceeds
upon surrender of the ADSs. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">If there is a
replacement of the deposited securities and the depositary will continue to hold the replacement securities, the depositary may distribute new ADSs representing the new deposited securities or ask you to surrender your outstanding ADRs in exchange
for new ADRs identifying the new deposited securities. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">If there are no deposited securities underlying ADSs, including if the deposited securities are cancelled, or if the deposited securities underlying ADSs have become apparently worthless, the depositary
may call for surrender of those ADSs or cancel those ADSs upon notice to the ADS holders. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>Amendment and Termination </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B><I>How may the deposit agreement be amended? </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We may agree with the depositary to amend the deposit agreement and the ADRs without your consent for any reason. If an amendment adds or
increases fees or charges, except for taxes and other governmental charges or expenses of the depositary for registration fees, facsimile costs, delivery charges or similar items, or prejudices a substantial right of ADS holders, it will not become
effective for outstanding ADSs until 30 days after the depositary notifies ADS holders of the amendment. <I>At the time an amendment becomes effective, you are considered, by continuing to hold your ADSs, to agree to the amendment and to be bound by
the ADRs and the deposit agreement as amended</I>. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>How may the deposit agreement be terminated? </I></B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The depositary will initiate termination of the deposit
agreement if we instruct it to do so. The depositary may initiate termination of the deposit agreement if </FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">60 days have passed since the depositary told us it wants to resign but a successor depositary has not been appointed and accepted its appointment;
</FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">we delist the ADSs from an exchange in the United States on which they were listed and do not list the ADSs on another exchange in the United States or
make arrangements for trading of ADSs on the U.S. <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">over-the-counter</FONT></FONT> market; </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">we delist our shares from an exchange outside the United States on which they were listed and do not list the shares on another exchange outside the
United States; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the depositary has reason to believe the ADSs have become, or will become, ineligible for registration on Form
<FONT STYLE="white-space:nowrap">F-6</FONT> under the Securities Act; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">we appear to be insolvent or enter insolvency proceedings; </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">all or substantially all the value of the deposited securities has been distributed either in cash or in the form of securities;
</FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">there are no deposited securities underlying the ADSs or the underlying deposited securities have become apparently worthless; or
</FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">there has been a replacement of deposited securities. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">If the deposit agreement will terminate, the depositary will
notify ADS holders at least 90 days before the termination date. At any time after the termination date, the depositary may sell the deposited securities. After that, the depositary will hold the money it received on the sale, as well as any other
cash it is holding under the deposit agreement, unsegregated and without liability for interest, for the pro rata benefit of the ADS holders that have not surrendered their ADSs. Normally, the depositary will sell as soon as practicable after the
termination date. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">After the termination date and
before the depositary sells, ADS holders can still surrender their ADSs and receive delivery of deposited securities, except that the depositary may refuse to accept a surrender for the </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">182
</FONT></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
purpose of withdrawing deposited securities or reverse previously accepted surrenders of that kind that have not settled if it would interfere with the selling process. The depositary may refuse
to accept a surrender for the purpose of withdrawing sale proceeds until all the deposited securities have been sold. The depositary will continue to collect distributions on deposited securities, but, after the termination date, the depositary is
not required to register any transfer of ADSs or distribute any dividends or other distributions on deposited securities to the ADSs holder (until they surrender their ADSs) or give any notices or perform any other duties under the deposit agreement
except as described in this paragraph. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Limitations on
Obligations and Liability </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Limits on
our Obligations and the Obligations of the Depositary; Limits on Liability to Holders of ADSs </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The deposit agreement expressly limits our obligations and the obligations of the depositary. It also limits our liability and the
liability of the depositary. We and the depositary: </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">are only obligated to take the actions specifically set forth in the deposit agreement without negligence or bad faith, and the depositary will not be
a fiduciary or have any fiduciary duty to holders of ADSs; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">are not liable if we are or it is prevented or delayed by law or by events or circumstances beyond our or its ability to prevent or counteract with
reasonable care or effort from performing our or its obligations under the deposit agreement; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">are not liable if we or it exercises discretion permitted under the deposit agreement; </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">are not liable for the inability of any holder of ADSs to benefit from any distribution on deposited securities that is not made available to holders
of ADSs under the terms of the deposit agreement, or for any special, consequential or punitive damages for any breach of the terms of the deposit agreement; </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">have no obligation to become involved in a lawsuit or other proceeding related to the ADSs or the deposit agreement on your behalf or on behalf of any
other person; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">may rely upon any documents we believe or it believes in good faith to be genuine and to have been signed or presented by the proper person;
</FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">are not liable for the acts or omissions of any securities depository, clearing agency or settlement system; and </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the depositary has no duty to make any determination or provide any information as to our tax status, or any liability for any tax consequences that
may be incurred by ADS holders as a result of owning or holding ADSs or be liable for the inability or failure of an ADS holder to obtain the benefit of a foreign tax credit, reduced rate of withholding or refund of amounts withheld in respect of
tax or any other tax benefit. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In the deposit agreement, we and the depositary agree to indemnify each other under certain circumstances. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Requirements for Depositary Actions </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Before the depositary will deliver or register a transfer of
ADSs, make a distribution on ADSs, or permit withdrawal of shares, the depositary may require:</FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">payment of stock transfer or other taxes or other governmental charges and transfer or registration fees charged by third parties for the transfer of
any shares or other deposited securities; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">satisfactory proof of the identity and genuineness of any signature or other information it deems necessary; and </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">compliance with regulations it may establish, from time to time, consistent with the deposit agreement, including presentation of transfer documents.
</FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The depositary may refuse to
deliver ADSs or register transfers of ADSs when the transfer books of the depositary or our transfer books are closed or at any time if the depositary or we think it advisable to do so. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">183
</FONT></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Your Right to Receive the Shares Underlying your ADSs </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">ADS holders have the right to cancel their ADSs and withdraw
the underlying shares at any time except: </FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">when temporary delays arise because: (i)&nbsp;the depositary has closed its transfer books or we have closed our transfer books; (ii)&nbsp;the transfer
of shares is blocked to permit voting at a shareholders&#146; meeting; or (iii)&nbsp;we are paying a dividend on our shares; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">when you owe money to pay fees, taxes and similar charges; or </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">when it is necessary to prohibit withdrawals in order to comply with any laws or governmental regulations that apply to ADSs or to the withdrawal of
shares or other deposited securities. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">This right of withdrawal may not be limited by any other provision of the deposit agreement. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Direct Registration System </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In the deposit agreement, all parties to the deposit agreement acknowledge that the Direct Registration System, also referred to as DRS,
and Profile Modification System, also referred to as Profile, will apply to the ADSs. DRS is a system administered by DTC that facilitates interchange between registered holding of uncertificated ADSs and holding of security entitlements in ADSs
through DTC and a DTC participant. Profile is a feature of DRS that allows a DTC participant, claiming to act on behalf of a registered holder of uncertificated ADSs, to direct the depositary to register a transfer of those ADSs to DTC or its
nominee and to deliver those ADSs to the DTC account of that DTC participant without receipt by the depositary of prior authorization from the ADS holder to register that transfer. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In connection with and in accordance with the arrangements
and procedures relating to DRS/Profile, the parties to the deposit agreement understand that the depositary will not determine whether the DTC participant that is claiming to be acting on behalf of an ADS holder in requesting registration of
transfer and delivery as described in the paragraph above has the actual authority to act on behalf of the ADS holder (notwithstanding any requirements under the Uniform Commercial Code). In the deposit agreement, the parties agree that the
depositary&#146;s reliance on and compliance with instructions received by the depositary through the DRS/Profile system and in accordance with the deposit agreement will not constitute negligence or bad faith on the part of the depositary.
</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>  <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Shareholder Communications; Inspection of Register of
Holders of ADSs </B></FONT></P>  <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The depositary will
make available for your inspection at its office all communications that it receives from us as a holder of deposited securities that we make generally available to holders of deposited securities. The depositary will send you copies of those
communications or otherwise make those communications available to you if we ask it to. You have a right to inspect the register of holders of ADSs, but not for the purpose of contacting those holders about a matter unrelated to our business or the
ADSs. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Each holder of ADSs may be required from
time to time to provide certain information, including proof of taxpayer status, residence and beneficial ownership (as applicable), from time to time and in a timely manner as we, the depositary or the custodian may deem necessary or proper to
fulfill obligations under applicable law. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Jury Trial
Waiver</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The deposit agreement provides that,
to the extent permitted by law, ADS holders waive the right to a jury trial of any claim they may have against us or the depositary arising out of or relating to our shares, the ADSs or the deposit agreement, including any claim under the U.S.
federal securities laws. If we or the depositary opposed a jury trial demand based on the waiver, the court would determine whether the waiver was enforceable in the facts and circumstances of that case in accordance with applicable case law. You
will not, by agreeing to the terms of the deposit agreement, be deemed to have waived our or the depositary&#146;s compliance with U.S. federal securities laws or the rules and regulations promulgated thereunder. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">184
</FONT></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="rom947560_19"></A>SHARES AND AMERICAN DEPOSITARY SHARES ELIGIBLE FOR FUTURE
SALE </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>  <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our ordinary shares have been
trading on the ASX since 1985, and certain ADSs have been traded on the over-the-counter market in the United States since June 2011 through our existing sponsored Level I ADR facility with The Bank of New York Mellon, as depositary. While we have
applied to list the ADSs on Nasdaq, we cannot assure you that an active trading market for the ADSs will develop. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Upon completion of this offering, we will have 9,309,221 ADSs outstanding (including 9,221 ADSs that were outstanding prior to this
offering) representing 74,473,468 ordinary shares, or approximately 21.7% of our ordinary shares in issue and outstanding. In addition, we will have 269,084,001 ordinary shares not represented by ADSs in issue and outstanding. If the underwriters
exercise their option to purchase 1,395,000 additional ADSs in full, we will have 10,704,221 ADSs outstanding, representing 85,633,768 ordinary shares, or approximately 24.1% of our ordinary shares in issue and outstanding. All of the ADSs sold in
this offering will be freely tradable without restrictions or further registration under the Securities Act, except for any ADSs sold to our &#147;affiliates,&#148; as that term is defined under Rule&nbsp;144 under the Securities Act. The ordinary
shares held by existing shareholders are &#147;restricted securities,&#148; as that term is defined in Rule&nbsp;144 under the Securities Act. Restricted securities may be sold in the United States only if registered with the SEC or if their resale
qualifies for exemption from registration described below under Rule&nbsp;144 or Rule&nbsp;701 promulgated under the Securities Act. </FONT></P>  <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Future sales of ADSs in the U.S. public market after this offering, and the availability of ADSs for future sale, could adversely affect
the market price of the ADSs prevailing from time to time. As described below, a significant number of currently outstanding ordinary shares will not be available for sale shortly after this offering due to contractual restrictions on transfers of
ordinary shares and ADSs. However, sales of substantial amounts of ADSs or ordinary shares, or the perception that these sales could occur, could adversely affect prevailing market prices for the ADSs and could impair our future ability to raise
equity capital. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Rule 144 </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In general, a person who has beneficially owned restricted
ordinary shares for at least six months would be entitled to sell their securities pursuant to Rule 144 under the Securities Act provided that (1)&nbsp;such person is not deemed to have been one of our affiliates at the time of, or at any time
during the 90&nbsp;days preceding, a sale and (2)&nbsp;we have been subject to the Exchange Act periodic reporting requirements for at least 90&nbsp;days before the sale. Persons who have beneficially owned restricted ordinary shares for at least
six months, but who are our affiliates at the time of, or at any time during the 90&nbsp;days preceding a sale, would be subject to additional restrictions, by which such person would be entitled to sell within any three-month period only a number
of securities that does not exceed the greater of either of the following: </FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.0% of the number of ordinary shares (including ordinary shares in the form of ADSs) then outstanding, which will equal approximately 3,435,578
ordinary shares immediately after the closing of this offering; and </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the average weekly trading volume of our ordinary shares (including ordinary shares in the form of ADSs) during the four calendar weeks preceding the
filing of a notice on Form&nbsp;144 with respect to the sale; </FONT></P></TD></TR></TABLE>  <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">provided, in each case, that we have been subject to the Exchange Act periodic reporting requirements for at least 90&nbsp;days before the sale. Such sales both by affiliates and by <FONT
STYLE="white-space:nowrap">non-affiliates</FONT> must also comply with the manner of sale, current public information and notice provisions of Rule&nbsp;144. <FONT STYLE="white-space:nowrap">Non-affiliate</FONT> resales of restricted shares under
Rule&nbsp;144 also are subject to the availability of current public information about us until a period of one year has elapsed since the securities were acquired from the issuer or an affiliate of the issuer. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Rule 701 </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT
SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Rule&nbsp;701 under the Securities Act permits resales of shares in reliance upon Rule&nbsp;144 but without
compliance with certain restrictions of Rule&nbsp;144, including the holding period requirement. Most of our employees, senior management or directors who purchased shares under a written compensatory plan or contract
</FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">185
</FONT></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
may be entitled to rely on the resale provisions of Rule 701, but all holders of Rule 701 shares are required to wait until 90 days after the date of this prospectus before selling their shares
subject also to Australian law. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The SEC has
indicated that Rule 701 will apply to typical options granted by an issuer before it becomes subject to the reporting requirements of the Exchange Act, along with the shares acquired upon exercise of such options, including exercises after an issuer
becomes subject to the reporting requirements of the Exchange Act. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><FONT STYLE="white-space:nowrap">Lock-up&nbsp;Agreements</FONT> </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We and our officers and directors have agreed that, without
the prior written consent of Citigroup Global Markets Inc. and SVB Leerink LLC, or, collectively, the Representatives, on behalf of the underwriters, we and they will not, during the period ending 90 days after the date of this prospectus
(i)&nbsp;offer, pledge, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right or warrant to purchase, lend, or otherwise transfer or dispose of, directly or indirectly, any
ordinary shares, ADSs or any securities convertible into or exercisable or exchangeable for our ordinary shares or ADSs or (ii)&nbsp;enter into any swap or other arrangement that transfers to another, in whole or in part, any of the economic
consequences of ownership of the ordinary shares or ADSs. In addition, we have agreed that, without the prior written consent of the Representatives on behalf of the underwriters, we will not, during the restricted period, file any registration
statement with the SEC relating to the offering of any ordinary shares or ADSs or any securities convertible into or exercisable or exchangeable for ordinary shares or ADSs. The restrictions described in this paragraph are subject to certain
exceptions. See&nbsp;&#147;Underwriting.&#148; </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Representatives, in their sole discretion, may release the ordinary shares, ADSs and other securities subject to <FONT
STYLE="white-space:nowrap">the&nbsp;lock-up&nbsp;agreements</FONT> described above in whole or in part at any time. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We do not currently expect any release of ordinary shares or ADSs subject
<FONT STYLE="white-space:nowrap">to&nbsp;lock-up&nbsp;agreements</FONT> prior to the expiration of the <FONT STYLE="white-space:nowrap">applicable&nbsp;lock-up&nbsp;periods.</FONT> Upon the expiration of the
<FONT STYLE="white-space:nowrap">applicable&nbsp;lock-up&nbsp;periods,</FONT> substantially all of the ordinary shares and ADSs subject to <FONT STYLE="white-space:nowrap">such&nbsp;lock-up&nbsp;restrictions</FONT> will become eligible for sale,
subject to the limitations described above. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">186
</FONT></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="rom947560_20"></A>MATERIAL UNITED STATES FEDERAL INCOME AND AUSTRALIAN TAX
CONSIDERATIONS </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>The following summary of
the material Australian and U.S. federal income tax consequences of an investment in the ADSs or ordinary shares is based upon laws and relevant interpretations thereof in effect as of the date of this prospectus, all of which are subject to change,
possibly with retroactive effect. This summary does not deal with all possible tax consequences relating to an investment in the ADSs or ordinary shares, such as the tax consequences under U.S. state, local and other tax laws other than U.S. federal
income tax laws and certain Australian tax laws. </I></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Material
United States Federal Income Tax Considerations </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">The following describes material United States federal income tax considerations relating to the acquisition, ownership and disposition of our ordinary shares or ADSs by a U.S. holder (as defined below).
This summary addresses these tax considerations only for U.S. holders that are initial purchasers of our ordinary shares or ADSs pursuant to this offering and that will hold such ordinary shares or ADSs as capital assets (generally, property held
for investment). This summary does not address all U.S. federal income tax matters that may be relevant to a particular U.S. holder. This summary does not address tax considerations applicable to a holder of our ordinary shares or ADSs that may be
subject to special tax rules including, without limitation, the following: </FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">banks, financial institutions or insurance companies; </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">brokers, dealers or traders in securities, currencies, commodities, or notional principal contracts; </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="white-space:nowrap">tax-exempt&nbsp;entities</FONT> or organizations, including an &#147;individual retirement account&#148; or &#147;Roth
IRA&#148; as defined in Section&nbsp;408 or 408A of the Code (as defined below), respectively; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">real estate investment trusts, regulated investment companies or grantor trusts; </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">persons that hold our ordinary shares or ADSs as part of a &#147;hedging,&#148; &#147;integrated,&#148; &#147;wash sale&#148; or &#147;conversion&#148;
transaction or as a position in a &#147;straddle&#148; for U.S. federal income tax purposes; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">S corporations, partnerships, or other entities or arrangements classified as partnerships for U.S. federal income tax purposes;
</FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">certain former citizens or long-term residents of the United States; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT
SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">persons that received our ordinary shares or ADSs as compensation; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT
SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">persons subject to Section&nbsp;451(b) of the Code; </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">persons acquiring our ordinary shares or ADSs in connection with a trade or business conducted outside of the United States, including a permanent
establishment or a fixed base in Australia; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">holders that own directly, indirectly, or through attribution 10% or more of the voting power or value of our ordinary shares or ADSs; and
</FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">holders that have a &#147;functional currency&#148; other than the U.S. dollar. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Holders of our ordinary shares or ADSs who fall within one of
the categories above are advised to consult their tax advisor regarding the specific tax consequences which may apply to their particular situation. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">For the purposes of this description, a &#147;U.S. holder&#148; is a beneficial owner of our ordinary shares or ADSs that is (or is
treated as), for U.S. federal income tax purposes: </FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">an individual who is a citizen or resident of the United States; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT
SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">a corporation, or other entity taxable as a corporation, created or organized in or under the laws of the United States, any state therein or the
District of Columbia; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">an estate, the income of which is subject to U.S. federal income taxation regardless of its source; or </FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">187
</FONT></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">a trust, if a court within the United States is able to exercise primary supervision over its administration and one or more U.S. persons have the
authority to control all of the substantial decisions of such trust, or if such trust has a valid election in effect under applicable U.S. Treasury Regulations to be treated as a U.S. person. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">If a partnership (or any other entity treated as a
partnership for U.S. federal income tax purposes) holds our ordinary shares or ADSs, the tax consequences relating to an investment in our ordinary shares or ADSs will depend in part upon the status of the partner and the activities of the
partnership. Such a partner or partnership should consult its tax advisor regarding the specific tax considerations of acquiring, owning and disposing of our ordinary shares or ADSs in its particular circumstances. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Persons considering an investment in our ordinary shares
or ADSs should consult their own tax advisors as to the particular tax consequences applicable to them relating to the acquisition, ownership and disposition of our ordinary shares or ADSs, including the applicability of U.S. federal, state and
local tax laws, Australian tax laws and <FONT STYLE="white-space:nowrap">other&nbsp;non-U.S.&nbsp;tax</FONT> laws. </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">This description does not address the U.S. federal estate, gift, or alternative minimum tax considerations, or any U.S. state, local, <FONT
STYLE="white-space:nowrap">or&nbsp;non-U.S.&nbsp;tax</FONT> considerations of the acquisition, ownership and disposition of our ordinary shares or ADSs. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">This description is based on the U.S. Internal Revenue Code of 1986, as amended, or the Code, existing, proposed and temporary U.S.
Treasury Regulations promulgated thereunder and administrative and judicial interpretations thereof, in each case as in effect and available on the date hereof. All the foregoing is subject to change, which change could apply retroactively, and to
differing interpretations, all of which could affect the tax considerations described below. There can be no assurances that the U.S. Internal Revenue Service, or the IRS, will not take a position concerning the tax consequences of the acquisition,
ownership and disposition of our ordinary shares or ADSs or that such a position would not be sustained by a court. We have not obtained, nor do we intend to obtain, a ruling with respect to the U.S. federal income tax considerations in the
purchase, ownership or disposition of our ordinary shares or ADSs. Accordingly, holders should consult their own tax advisors concerning the U.S. federal, state, local <FONT STYLE="white-space:nowrap">and&nbsp;non-U.S.&nbsp;tax</FONT> consequences
of acquiring, owning and disposing of our ordinary shares or ADSs in their particular circumstances. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In general, and taking into account the earlier assumptions, for U.S. federal income tax purposes, a U.S. holder holding ADSs will be
treated as the owner of the ordinary shares represented by the ADSs. Exchanges of ordinary shares for ADSs, and ADSs for ordinary shares, generally will not be subject to U.S. federal income tax. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>United States Federal Income Tax Consequences If We Are
Not a PFIC</I></B>.&nbsp;&nbsp;&nbsp;&nbsp;The description of the U.S. federal income tax consequences of the receipt of distributions and the sale or other taxable exchange of our ordinary shares or ADSs, described in the following two sections
&#147;&#151;Distributions&#148; and &#147;&#151;Sale, Exchange or Other Taxable Disposition,&#148; apply only if we are not a PFIC in the relevant year and our stock is not subject to the rules described above under &#147;&#151;Passive Foreign
Investment Company Considerations.&#148; </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Distributions</I></B>.&nbsp;&nbsp;&nbsp;&nbsp;As described above under the heading &#147;&#151;Dividend Policy,&#148; we do not
expect to make any distributions in respect of our ordinary shares or ADSs. Subject to the discussion under &#147;&#151;Passive Foreign Investment Company Considerations,&#148; below, the gross amount of any distribution (including any amounts
withheld in respect of foreign tax) actually or constructively received by a U.S. holder with respect to our ordinary shares or ADSs will generally be taxable to the U.S. holder as a dividend to the extent of the U.S. holder&#146;s pro rata share of
our current or accumulated earnings and profits as determined under U.S. federal income tax principles. Distributions in excess of earnings and profits will generally <FONT STYLE="white-space:nowrap">be&nbsp;non-taxable&nbsp;to</FONT> the U.S.
holder to the extent of, and will be applied against and reduce, the U.S. holder&#146;s adjusted tax basis in our ordinary shares or ADSs. Distributions in excess of earnings and profits and such adjusted tax basis will generally be taxable to the
U.S. holder as either long-term or short-term capital gain depending upon whether the U.S. holder </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">188
</FONT></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
has held our ordinary shares or ADSs for more than one year as of the time such distribution is received. However, since we do not calculate our earnings and profits under U.S. federal income tax
principles, it is expected that any distribution will be reported as a dividend, even if that distribution would otherwise be treated as a <FONT STYLE="white-space:nowrap">non-taxable</FONT> return of capital or as capital gain under the rules
described above. <FONT STYLE="white-space:nowrap">Non-corporate</FONT> U.S. holders may qualify for the preferential rates of taxation with respect to dividends on our ordinary shares or ADSs applicable to long-term capital gains (i.e., gains from
the sale of capital assets held for more than one year) and qualified dividend income (as discussed below) if we are a &#147;qualified foreign corporation&#148; and certain other requirements (discussed below) are met. A <FONT
STYLE="white-space:nowrap">non-U.S.</FONT> corporation (other than a corporation that is classified as a PFIC for the taxable year in which the dividend is paid or the preceding taxable year) generally will be considered to be a qualified foreign
corporation (a)&nbsp;if it is eligible for the benefits of a comprehensive tax treaty with the United States which the Secretary of Treasury of the United States determines is satisfactory for purposes of this provision and which includes an
exchange of information provision, or (b)&nbsp;with respect to any dividend it pays on ADSs which are readily tradable on an established securities market in the United States. We have applied to list the ADSs on Nasdaq, which is an established
securities market in the United States, and we expect the ADSs to be readily tradable on Nasdaq. There can be no assurance that the ADSs will be considered readily tradable on an established securities market in the United States in later years. In
addition, the Company, which is incorporated under the laws of Australia, believes that it qualifies as a resident of Australia for purposes of, and is eligible for the benefits of, the Convention between the Government of the United States of
America and the Government of Australia for the Avoidance of Double Taxation and the Prevention of Fiscal Evasion with Respect to Taxes on Income, signed on August&nbsp;6, 1982, as amended and currently in force, or the U.S.-Australia Tax Treaty,
although there can be no assurance in this regard. Further, the IRS has determined that the U.S.-Australia Tax Treaty is satisfactory for purposes of the qualified dividend rules and that it includes an <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">exchange-of-information</FONT></FONT> program. Therefore, subject to the discussion under &#147;&#151;Passive Foreign Investment Company Considerations,&#148; below, such dividends will generally be &#147;qualified
dividend income&#148; in the hands of individual U.S. holders, provided that a holding period requirement (more than 60 days of ownership, without protection from the risk of loss, during the <FONT STYLE="white-space:nowrap">121-day</FONT> period
beginning 60 days before the <FONT STYLE="white-space:nowrap">ex-dividend</FONT> date) and certain other requirements are met. The dividends will not be eligible for the dividends-received deduction generally allowed to corporate U.S. holders.
</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">A U.S. holder generally may claim the amount of
any Australian withholding tax as either a deduction from gross income or a credit against its U.S. federal income tax liability. The foreign tax credit is subject to numerous complex limitations that must be determined and applied on an individual
basis. Generally, the credit cannot exceed the proportionate share of a U.S. holder&#146;s U.S. federal income tax liability that such U.S. holder&#146;s taxable income from foreign sources bears to such U.S. holder&#146;s worldwide taxable income.
In applying this limitation, a U.S. holder&#146;s various items of income and deduction must be classified, under complex rules, as either &#147;foreign source&#148; or &#147;U.S. source.&#148; This limitation is calculated separately with respect
to specific categories of income. The amount of a distribution with respect to the ADSs that is treated as a &#147;dividend&#148; may be lower for U.S. federal income tax purposes than it is for Australian income tax purposes, potentially resulting
in a reduced foreign tax credit for the U.S. holder. In addition, the creditability of foreign taxes could be affected by actions taken by intermediaries in the chain of ownership between the holders of our ordinary shares or ADSs and our company
if, as a result of such actions, the holders of our ordinary shares or ADSs are not properly treated as beneficial owners of the underlying ordinary shares. Each U.S. holder should consult its own tax advisors regarding the foreign tax credit rules.
</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In general, the amount of a distribution paid to
a U.S. holder in a foreign currency will be the U.S. dollar value of the foreign currency calculated by reference to the spot exchange rate on the day the depositary receives the distribution, in the case of the ADSs, or on the day the distribution
is received by the U.S. holder, in the case of ordinary shares, regardless of whether the foreign currency is converted into U.S. dollars at that time. Any foreign currency gain or loss a U.S. holder realizes on a subsequent conversion of foreign
currency into U.S. dollars will be U.S. source ordinary income or loss. If dividends received in a foreign currency are converted into U.S. dollars on the day they are received, a U.S. holder should not be required to recognize foreign currency gain
or loss in respect of the dividend. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">189
</FONT></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Sale, Exchange or Other Taxable Disposition</I></B>.&nbsp;&nbsp;&nbsp;&nbsp;A
U.S. holder will generally recognize gain or loss for U.S. federal income tax purposes upon the sale, exchange or other taxable disposition of our ordinary shares or ADSs in an amount equal to the difference between the U.S. dollar value of the
amount realized from such sale or exchange and the U.S. holder&#146;s adjusted tax basis in those ordinary shares or ADSs, determined in U.S. dollars. Subject to the discussion under &#147;&#151;Passive Foreign Investment Company
Considerations&#148; below, this gain or loss will generally be a capital gain or loss. The adjusted tax basis in our ordinary shares or ADSs generally will be equal to the cost of such ordinary shares or ADSs. Capital gain from the sale, exchange
or other taxable disposition of our ordinary shares or ADSs by <FONT STYLE="white-space:nowrap">a&nbsp;non-corporate&nbsp;U.S.</FONT> holder is generally eligible for a preferential rate of taxation applicable to capital gains, if <FONT
STYLE="white-space:nowrap">the&nbsp;non-corporate&nbsp;U.S.</FONT> holder&#146;s holding period determined at the time of such sale, exchange or other taxable disposition for such ordinary shares or ADSs exceeds one year (i.e., such gain is
long-term taxable gain). The deductibility of capital losses for U.S. federal income tax purposes is subject to limitations. Any such gain or loss that a U.S. holder recognizes generally will be treated as U.S. source gain or loss for foreign tax
credit limitation purposes. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">For a cash basis
taxpayer, units of foreign currency paid or received are translated into U.S. dollars at the spot rate on the settlement date of the purchase or sale. In that case, no foreign currency exchange gain or loss will result from currency fluctuations
between the trade date and the settlement date of such a purchase or sale. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">An accrual basis taxpayer, however, may elect the same treatment required of cash basis taxpayers with respect to purchases and sales of our ordinary shares or ADSs that are traded on an established
securities market, provided the election is applied consistently from year to year. Such election may not be changed without the consent of the IRS. For an accrual basis taxpayer who does not make such election, units of foreign currency paid or
received are translated into U.S. dollars at the spot rate on the trade date of the purchase or sale. Such an accrual basis taxpayer may recognize exchange gain or loss based on currency fluctuations between the trade date and the settlement date.
Any foreign currency gain or loss a U.S. holder realizes will be U.S. source ordinary income or loss. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Medicare Tax</I></B>.&nbsp;&nbsp;&nbsp;&nbsp;Certain U.S. holders that are individuals, estates or trusts are subject to a 3.8% tax
on all or a portion of their &#147;net investment income,&#148; which may include all or a portion of their dividend income and net gains from the disposition of our ordinary shares or ADSs. Each U.S. holder that is an individual, estate or trust is
urged to consult its tax advisors regarding the applicability of the Medicare tax to its income and gains in respect of its investment in our ordinary shares or ADSs. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Passive Foreign Investment Company
Considerations</I></B>.&nbsp;&nbsp;&nbsp;&nbsp;If we are classified as a PFIC in any taxable year, a U.S. holder will be subject to special rules generally intended to reduce or eliminate any benefits from the deferral of U.S. federal income tax
that a U.S. holder could derive from investing in <FONT STYLE="white-space:nowrap">a&nbsp;non-U.S.&nbsp;company</FONT> that does not distribute all of its earnings on a current basis. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We will be classified as a PFIC for U.S. federal income tax purposes in any taxable year in which, after
applying certain look-through rules with respect to the income and assets of our subsidiaries, either: (1)&nbsp;at least 75% of the gross income is &#147;passive income&#148; or (2)&nbsp;at least 50% of the average quarterly value of our total gross
assets (which would generally be measured by fair market value of our assets, and for which purpose the total value of our assets may be determined in part by the market value of the ADSs and our ordinary shares, which are subject to change) is
attributable to assets that produce &#147;passive income&#148; or are held for the production of &#147;passive income.&#148; </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Passive income for this purpose generally includes dividends, interest, royalties, rents, gains from commodities and securities
transactions, the excess of gains over losses from the disposition of assets which produce passive income, and includes amounts derived by reason of the temporary investment of funds raised in offerings of our ordinary shares or ADSs. If <FONT
STYLE="white-space:nowrap">a&nbsp;non-U.S.&nbsp;corporation</FONT> owns directly or indirectly at least 25% by value of the stock of another corporation or the partnership interests in a partnership,
<FONT STYLE="white-space:nowrap">the&nbsp;non-U.S.&nbsp;corporation</FONT> is treated for purposes of the PFIC tests as owning its proportionate share of the assets of the other corporation or
</FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">190
</FONT></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
partnership and as receiving directly its proportionate share of the other corporation&#146;s or partnership&#146;s income. The determination of whether we are a PFIC is a fact-intensive
determination made on an annual basis and the applicable law is subject to varying interpretation. If we are classified as a PFIC in any taxable year during which a U.S. holder owns our ordinary shares or ADSs, such U.S. holder will be subject to
special tax rules discussed below and could suffer adverse tax consequences. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">The market value of our assets may be determined in large part by reference to the market price of the ADSs and our ordinary shares, which is likely to fluctuate after this offering. Therefore,
fluctuations in the market price of our ordinary shares or ADSs may result in our being a PFIC for any taxable year. In addition, the composition of our income and assets will be affected by how, and how quickly, we use the cash proceeds from this
offering in our business. Whether we are a PFIC for any taxable year will depend on the nature and composition of our income, assets, activities and market capitalization in each year, and because this is a factual determination made annually after
the end of each taxable year, there can be no assurance that we will not be considered a PFIC in any taxable year. We believe that we were not characterized as a PFIC in our taxable year ended June&nbsp;30, 2019. Based on the nature and composition
of our income, assets, activities and market capitalization for our taxable year ended June&nbsp;30, 2020, we believe that we would not be classified as a PFIC for our taxable year ended June&nbsp;30, 2020; however, there can be no assurance that we
will not be considered a PFIC in any past, current or future taxable year. As a result, our PFIC status may change from year to year. Our status as a PFIC will depend on the composition of our income (including whether we receive certain grants or
subsidies and whether such amounts will constitute gross income for purposes of the PFIC income test) and the composition and value of our assets, which may be determined in large part by reference to the market value of the ADSs and our ordinary
shares, which may be volatile, from time to time. Our status may also depend, in part, on how quickly we utilize the cash proceeds from this offering in our business. Our U.S. counsel expresses no opinion regarding our conclusions or our
expectations regarding our PFIC status. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">If we are
classified as a PFIC in any year with respect to which a U.S. holder owns our ordinary shares or ADSs, we will continue to be treated as a PFIC with respect to such U.S. holder in all succeeding years during which the U.S. holder owns the ordinary
shares or ADSs, regardless of whether we continue to meet the tests described above unless we cease to be a PFIC and the U.S. holder has made a &#147;deemed sale&#148; election under the PFIC rules or is eligible to make and makes <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">a&nbsp;mark-to-market&nbsp;election</FONT></FONT> (as described below), with respect to all taxable years during such U.S. holder&#146;s holding period in which we are a PFIC. If the
&#147;deemed sale&#148; election is made, a U.S. holder will be deemed to have sold the ordinary shares or ADSs the U.S. holder holds at their fair market value as of the date of such deemed sale and any gain from such deemed sale would be subject
to the rules described below. After the deemed sale election, so long as we do not become a PFIC in a subsequent taxable year, the U.S. holder&#146;s ordinary shares or ADSs with respect to which such election was made will not be treated as shares
in a PFIC and the U.S. holder will not be subject to the rules described below with respect to any &#147;excess distribution&#148; the U.S. holder receives from us or any gain from an actual sale or other disposition of the ordinary shares or ADSs.
U.S. holders should consult their tax advisors as to the possibility and consequences of making a deemed sale election if such election becomes available. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">If we are a PFIC, and you are a U.S. holder that does not make one of the elections described above (and below in further detail), a
special tax regime will apply to both (a)&nbsp;any &#147;excess distribution&#148; by us to you (generally, your ratable portion of distributions in any year, other than the taxable year in which your holding period in the shares or ADSs begins,
which are greater than 125% of the average annual distribution received by you in the shorter of the three preceding years or the portion of your holding period for our ordinary shares or ADSs that preceded the year of the distribution) and
(b)&nbsp;any gain realized on the sale or other disposition of our ordinary shares or ADSs. Under this regime, any excess distribution and realized gain will be treated as ordinary income and will be subject to tax as if (a)&nbsp;the excess
distribution or gain had been realized ratably over your holding period, (b)&nbsp;the amount deemed realized in each year had been subject to tax in each year of that holding period at the highest marginal rate for such year (other than income
allocated to the current period or any taxable period before we became a PFIC, which would be subject to tax at the U.S. holder&#146;s regular ordinary income rate for the current year and would not be subject to the interest charge discussed below)
and (c)&nbsp;the interest charge </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">191
</FONT></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
generally applicable to underpayments of tax had been imposed on the taxes deemed to have been payable in those years. In addition, dividend distributions made to you will not qualify for the
lower rates of taxation applicable to qualified dividends discussed above under &#147;Distributions.&#148; </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Certain elections may alleviate some of the adverse consequences of PFIC status and would result in an alternative treatment of our
ordinary shares or ADSs. If a U.S. holder makes <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">a&nbsp;mark-to-market&nbsp;election,</FONT></FONT> the U.S. holder generally will recognize as ordinary income any excess of the fair
market value of our ordinary shares or ADSs at the end of each taxable year over their adjusted tax basis, and will recognize an ordinary loss in respect of any excess of the adjusted tax basis of our ordinary shares or ADSs over their fair market
value at the end of the taxable year (but only to the extent of the net amount of income previously included as a result of the <FONT STYLE="white-space:nowrap">mark-to-market</FONT> election). If a U.S. holder makes the election, the U.S.
holder&#146;s tax basis in our ordinary shares or ADSs will be adjusted to reflect these income or loss amounts. Any gain recognized on the sale or other disposition of our ordinary shares or ADSs in a year in which we are a PFIC will be treated as
ordinary income and any loss will be treated as an ordinary loss (but only to the extent of the net amount of income previously included as a result of the
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">mark-to-market</FONT></FONT> election). The <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">mark-to-market</FONT></FONT> election is available only if we are a PFIC
and our ordinary shares or ADSs are &#147;regularly traded&#148; on a &#147;qualified exchange.&#148; Our ordinary shares or ADSs will be treated as &#147;regularly traded&#148; in any calendar year in which more than a de minimis quantity of our
ordinary shares or ADSs are traded on a qualified exchange on at least 15 days during each calendar quarter (subject to the rule that trades that have as one of their principal purposes the meeting of the trading requirement are disregarded). Nasdaq
is a qualified exchange for this purpose and, consequently, if the ADSs are regularly traded, the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">mark-to-market</FONT></FONT> election will be available to a U.S. holder. It should
be noted that it is intended that only the ADSs and not our ordinary shares will be listed on Nasdaq. Consequently, our ordinary shares may not be marketable if the ASX (where our ordinary shares are currently listed) does not meet the applicable
requirements. U.S. holders should consult their tax advisors regarding the availability of the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">mark-to-market</FONT></FONT> election for ordinary shares that are not represented by
ADSs. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">However, <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">a&nbsp;mark-to-market&nbsp;election</FONT></FONT> generally cannot be made for equity interests in any lower-tier PFICs that we own, unless shares of such lower-tier PFIC are themselves &#147;marketable.&#148; As a result,
even if a U.S. holder validly makes <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">a&nbsp;mark-to-market&nbsp;election</FONT></FONT> with respect to our ordinary shares or ADSs, the U.S. holder may continue to be subject to the
PFIC rules (described above) with respect to its indirect interest in any of our investments that are treated as an equity interest in a PFIC for U.S. federal income tax purposes. U.S. holders should consult their tax advisors as to the availability
and desirability of <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">a&nbsp;mark-to-market&nbsp;election,</FONT></FONT> as well as the impact of such election on interests in any lower-tier PFICs. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We do not currently intend to provide the information
necessary for U.S. holders to make qualified electing fund elections if we were treated as a PFIC for any taxable year. U.S. holders should consult their tax advisors to determine whether any of the other elections described above would be available
and if so, what the consequences of the alternative treatments would be in their particular circumstances. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">If we are determined to be a PFIC, the general tax treatment for U.S. holders described in this section would apply to indirect
distributions and gains deemed to be realized by U.S. holders in respect of any of our subsidiaries that also may be determined to be PFICs. U.S. holders should consult their tax advisors regarding the application of the PFIC rules to our
subsidiaries. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">If a U.S. holder owns our ordinary
shares or ADSs during any taxable year in which we are a PFIC, the U.S. holder generally will be required to file an IRS Form 8621 (Information Return by a Shareholder of a Passive Foreign Investment Company or Qualified Electing Fund) with respect
to the company, generally with the U.S. holder&#146;s federal income tax return for that year. If our company were a PFIC for a given taxable year, then you should consult your tax advisor concerning your annual filing requirements. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>The U.S. federal income tax rules relating to PFICs are
complex. Prospective U.S. investors are urged to consult their own tax advisors with respect to the acquisition, ownership and disposition of our ordinary </B></FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">192
</FONT></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>
shares or ADSs, the consequences to them of an investment in a PFIC, any elections available with respect to our ordinary shares or ADSs and the IRS information reporting obligations with respect
to the acquisition, ownership and disposition of our ordinary shares or ADSs. </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B><I>Backup Withholding and Information Reporting.&nbsp;&nbsp;&nbsp;&nbsp;U.S. holders generally will be subject to information reporting requirements with respect to dividends on our ordinary shares or
ADSs and on the proceeds from the sale, exchange or disposition of our ordinary shares or ADSs that are paid within the United States or through U.S.-related financial intermediaries, unless the U.S. holder is an &#147;exempt recipient.&#148; In
addition, U.S. holders may be subject to backup withholding on such payments, unless the U.S. holder provides a taxpayer identification number and a duly executed IRS <FONT STYLE="white-space:nowrap">Form&nbsp;W-9&nbsp;or</FONT> otherwise
establishes an exemption. Backup withholding is not an additional tax, and the amount of any backup withholding will be allowed as a credit against a U.S. holder&#146;s U.S. federal income tax liability and may entitle such holder to a refund,
provided that the required information is timely furnished to the IRS. </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B><I>Certain Reporting Requirements With Respect to Payments of Offer Price</I></B>.&nbsp;&nbsp;&nbsp;&nbsp;U.S. holders paying more than $100,000 for our ordinary shares or ADSs generally may be
required to file IRS Form 926 reporting the payment of the offer price for our ordinary shares or ADSs to us. Substantial penalties may be imposed upon a U.S. holder that fails to comply. Each U.S. holder should consult its own tax advisor as to the
possible obligation to file IRS Form 926. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Foreign Asset Reporting</I></B>.&nbsp;&nbsp;&nbsp;&nbsp;Certain individual U.S. holders are required to report information relating
to an interest in our ordinary shares or ADSs, subject to certain exceptions (including an exception for shares held in accounts maintained by U.S. financial institutions) by filing IRS Form 8938 (Statement of Specified Foreign Financial Assets)
with their federal income tax return. U.S. holders are urged to consult their tax advisors regarding their information reporting obligations, if any, with respect to their ownership and disposition of our ordinary shares or ADSs. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>THE DISCUSSION ABOVE IS A SUMMARY OF THE U.S. FEDERAL
INCOME TAX CONSEQUENCES OF AN INVESTMENT IN OUR ORDINARY SHARES OR ADSs AND IS BASED UPON LAWS AND RELEVANT INTERPRETATIONS THEREOF IN EFFECT AS OF THE DATE OF THIS PROSPECTUS, ALL OF WHICH ARE SUBJECT TO CHANGE, POSSIBLY WITH RETROACTIVE EFFECT.
EACH PROSPECTIVE INVESTOR IS URGED TO CONSULT ITS OWN TAX ADVISOR ABOUT THE TAX CONSEQUENCES TO IT OF AN INVESTMENT IN OUR ORDINARY SHARES OR ADSs IN LIGHT OF THE INVESTOR&#146;S OWN CIRCUMSTANCES. </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Material Australian Tax Considerations </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>  <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In this section, we discuss the material Australian
income tax, stamp duty and goods and services tax considerations related to the acquisition, ownership and disposal by the absolute beneficial owners of the ADSs or ordinary shares represented by ADSs. It is based upon existing Australian tax law as
of the date of this registration statement, which is subject to change, possibly retrospectively. This discussion does not address all aspects of Australian tax law which may be important to particular investors in light of their individual
investment circumstances, such as ADSs or shares held by investors subject to special tax rules (for example, financial institutions, insurance companies or tax exempt organizations). In addition, this summary does not discuss any <FONT
STYLE="white-space:nowrap">non-Australian</FONT> or state tax considerations, other than stamp duty and goods and services tax. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Prospective investors are urged to consult their tax advisors regarding the Australian and
<FONT STYLE="white-space:nowrap">non-Australian</FONT> income and other tax considerations of the acquisition, ownership and disposition of the ADSs or shares. This summary is based upon the premise that the holder of an ADS is not an Australian tax
resident and is not carrying on business in Australia through a permanent establishment (referred to as a <FONT STYLE="white-space:nowrap">&#147;Non-Australian</FONT> Holder&#148; in this summary). This summary is also based on the assumption that a
Non-Australian Holder is &#147;absolutely entitled&#148; to the ordinary shares represented by an ADS (see &#147;&#151;Nature of ADSs for Australian Taxation Purposes&#148; below). </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">193
</FONT></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Nature of ADSs for Australian Taxation Purposes </I></B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>  <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="white-space:nowrap">Non-Australian</FONT>
Holders of ADSs should obtain specialist Australian tax advice regarding their rights and obligations under the deposit agreement with the depositary, including whether the deposit arrangement constitutes a &#147;bare trust&#148; resulting in the
holders of an ADS being &#147;absolutely entitled&#148; to the underlying shares represented by the ADS for Australian taxation purposes. Apart from certain aspects of the Australian tax legislation (for example, the Australian capital gains tax and
withholding tax provisions, which are discussed below), there is no express legislative basis for disregarding &#147;bare trusts&#148; for Australian tax purposes generally. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">This summary proceeds on the assumption that the deposit
arrangement constitutes a bare trust, which results in holders of ADSs being &#147;absolutely entitled&#148; to the underlying shares. On this basis, holders of ADSs can be treated as the owners of the underlying ordinary shares for Australian
capital gains tax purposes. Dividends paid on the underlying ordinary shares will also be treated as dividends derived by the holders of ADSs as the persons presently entitled to those dividends. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Taxation of Dividends </I></B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>  <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Australia operates a dividend imputation system under
which dividends may be declared to be &#147;franked&#148; to the extent they are paid out of company profits that have been subject to income tax. Fully franked dividends are not subject to dividend withholding tax. To the extent that they are
unfranked, dividends payable to <FONT STYLE="white-space:nowrap">Non-Australian</FONT> Holders will be subject to dividend withholding tax except to the extent they are declared to be &#147;conduit foreign income&#148;, or CFI. Dividend withholding
tax will be imposed at 30%, unless a shareholder is a resident of a country with which Australia has a double taxation treaty and qualifies for the benefits of the treaty. Under the provisions of the current Double Taxation Convention between
Australia and the United States, the Australian tax withheld on unfranked dividends that are not declared to be CFI paid by us to which a resident of the United States is beneficially entitled is limited to 15%. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Under the Double Taxation Convention between Australia and
the United States, if a U.S. resident company that is a <FONT STYLE="white-space:nowrap">Non-Australian</FONT> Holder directly owns a 10% or more voting interests, the Australian tax withheld on unfranked dividends that are not declared to be CFI
paid by us to which the company is beneficially entitled is limited to 5%. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B><I>Character of ADSs or Shares for Australian Taxation Purposes </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Australian tax treatment of a sale or disposal of the ADSs or underlying shares will depend on whether they are held on revenue or
capital account. ADSs may be held on revenue rather than capital account, for example, where they are held by share traders or any profit arises from a profit-making undertaking or scheme entered into by the holder.
<FONT STYLE="white-space:nowrap">Non-Australian</FONT> Holders of ADSs should obtain specialist Australian tax advice regarding the characterization of any gain or loss on a sale or disposal of the ADSs or underlying shares as revenue or capital in
nature. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Tax on Sales or other Dispositions
of Shares or ADSs&#151;Capital Gains Tax </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="white-space:nowrap">Non-Australian</FONT> Holders who are treated as the owners of the underlying shares on the basis that
they are absolutely entitled to those shares will not be subject to Australian capital gains tax on the gain made on a sale or other disposal of ordinary shares, provided the shares are not &#147;taxable Australian property.&#148; Taxable Australian
property includes &#147;indirect Australian real property interests,&#148; which are interests in a company where: </FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the Non-Australian Holders, together with associates, hold 10% or more of our issued shares, at the time of disposal or for a 12 month period during
the two years prior to disposal; and </FONT></P></TD></TR></TABLE>  <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">more than 50% of our assets held directly or indirectly, determined by reference to market value, consists of Australian real property (which includes
land and leasehold interests) or Australian mining, quarrying or prospecting rights at the time of disposal. </FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">194
</FONT></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Australian capital gains tax applies to net capital gains at a taxpayer&#146;s marginal
tax rates. Net capital gains are calculated after reduction for capital losses, which may only be offset against capital gains. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">If a Non-Australian Holder of ADSs was not absolutely entitled to the underlying shares, and the ADSs were held on capital account, the
same principles would apply in determining whether a gain on the sale or disposal of the ADSs would be subject to Australian capital gains tax. That is, a Non-Australian Holder should not be subject to Australian capital gains tax provided the ADSs
are not taxable Australian property. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The 50%
capital gains tax discount is not available to <FONT STYLE="white-space:nowrap">Non-Australian</FONT> Holders on gains from assets acquired after May&nbsp;8, 2012 where they were <FONT STYLE="white-space:nowrap">non-Australian</FONT> residents
during the entire holding period. Companies are not entitled to a capital gains tax discount. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Broadly, where there is a disposal of &#147;taxable Australian property,&#148; which includes indirect Australian real property interests, the purchaser will be required to withhold and remit to the
Australian Taxation Office, or the ATO, 12.5% of the proceeds from the sale. A transaction is excluded from the withholding requirements in certain circumstances, including where the transaction is an
<FONT STYLE="white-space:nowrap">on-market</FONT> transaction conducted on an approved stock exchange, a securities lending arrangement, or the transaction is conducted using a broker operated crossing system. There may also be an exception to the
requirement to withhold where a <FONT STYLE="white-space:nowrap">Non-Australian</FONT> Holder provides a declaration that their ordinary shares are not &#147;indirect Australian real property interests&#148;. The
<FONT STYLE="white-space:nowrap">Non-Australian</FONT> Holder may be entitled to receive a tax credit for the tax withheld by the purchaser which they may claim in their Australian income tax return. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Tax on Sales or other Dispositions of ADSs&#151;Revenue
Account </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>  <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT
STYLE="white-space:nowrap">Non-Australian</FONT> Holders who hold their ADSs on revenue account may have the gains made on the sale or other disposal of the ADSs included in their assessable income under the ordinary income provisions of the income
tax law, if the gains are sourced in Australia. In the case of gains which are ordinary income, there are no express provisions which treat holders of ADSs as the owners of the underlying shares where they are absolutely entitled to those shares
under a bare trust. </FONT></P>  <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT
STYLE="white-space:nowrap">Non-Australian</FONT> Holders assessable under these ordinary income provisions in respect of gains made on ADSs held on revenue account would be assessed for such gains at the Australian tax rates for <FONT
STYLE="white-space:nowrap">non-Australian</FONT> residents, which start at a marginal rate of 32.5% for individuals and would be required to file an Australian tax return. Some relief from Australian income tax may be available to a <FONT
STYLE="white-space:nowrap">Non-Australian</FONT> Holder who is resident of a country with which Australia has a double taxation treaty, qualifies for the benefits of the treaty and does not, for example, derive the gain in carrying on business
through a permanent establishment in Australia. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">To the extent an amount would be included in a <FONT STYLE="white-space:nowrap">Non-Australian</FONT> Holder&#146;s assessable income
under both the capital gains tax provisions and the ordinary income provisions, the capital gain amount may be reduced, so that the holder may not be subject to double Australian tax on any part of the gain. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>  <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The statements under &#147;&#151;Tax on Sales or Other
Dispositions of Shares&#151;Capital Gains Tax&#148; regarding a purchaser being required to withhold 12.5% tax on the acquisition of certain taxable Australian property are also relevant where the disposal of the ADSs by a <FONT
STYLE="white-space:nowrap">Non-Australian</FONT> Holder is likely to generate gains on revenue account, rather than a capital gain. </FONT></P>  <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Dual Residency </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">If a holder of ADSs is a resident of both Australia and the United States under those countries&#146; domestic taxation laws, that holder
may be subject to tax as an Australian resident. If, however, the holder is determined to be a U.S. resident for the purposes of the Double Taxation Convention between the United States and Australia and qualifies for the benefit of that treaty, the
Australian tax may be subject to limitation by the Double Taxation Convention. Holders should obtain specialist taxation advice in these circumstances. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">195
</FONT></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Stamp Duty </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT
SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">No Australian stamp duty is payable by Australian residents or
<FONT STYLE="white-space:nowrap">non-Australian</FONT> residents on the issue, transfer and/or surrender of the ADSs or ordinary shares, provided that the securities issued, transferred and/or surrendered do not represent 90% or more of our issued
shares. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Australian Death Duty
</I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Australia does not have estate or death
duties. As a general rule, no capital gains tax liability is realized upon the inheritance of a deceased person&#146;s shares. The disposal of inherited shares by beneficiaries may, however, give rise to a capital gains tax liability if the gain
falls within the scope of Australia&#146;s jurisdiction to tax. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B><I>Goods and Services Tax </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">No Australian goods and services tax will be payable on the supply of the ADSs or ordinary shares. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>THE DISCUSSION ABOVE IS A SUMMARY OF THE AUSTRALIAN TAX CONSEQUENCES OF AN INVESTMENT IN OUR ORDINARY SHARES OR ADSs AND IS BASED UPON
LAWS AND RELEVANT INTERPRETATIONS THEREOF IN EFFECT AS OF THE DATE OF THIS PROSPECTUS, ALL OF WHICH ARE SUBJECT TO CHANGE, POSSIBLY WITH RETROACTIVE EFFECT. EACH PROSPECTIVE INVESTOR IS URGED TO CONSULT ITS OWN TAX ADVISOR ABOUT THE TAX CONSEQUENCES
TO IT OF AN INVESTMENT IN OUR ORDINARY SHARES OR ADSs IN LIGHT OF THE INVESTOR&#146;S OWN CIRCUMSTANCES. </B></FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">196
</FONT></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="rom947560_21"></A>ENFORCEMENT OF CIVIL LIABILITIES </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We are a public limited company incorporated under the laws
of Australia. Certain of our directors are <FONT STYLE="white-space:nowrap">non-residents</FONT> of the United States and substantially all of their assets are located outside the United States. As a result, it may not be possible or practicable for
you to: </FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">effect service of process within the United States upon our <FONT STYLE="white-space:nowrap">non-U.S.</FONT> resident directors or on us;
</FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">enforce in U.S. courts judgments obtained against our <FONT STYLE="white-space:nowrap">non-U.S.</FONT> resident directors or us in the United States
courts in any action, including actions under the civil liability provisions of U.S. securities laws; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">enforce in U.S. courts judgments obtained against our <FONT STYLE="white-space:nowrap">non-U.S.</FONT> resident directors or us in courts of
jurisdictions outside the United States in any action, including actions under the civil liability provisions of U.S. securities laws; or </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">bring an original action in an Australian court to enforce liabilities against our <FONT STYLE="white-space:nowrap">non-U.S.</FONT> resident directors
or us based solely upon U.S. securities laws. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">You may also have difficulties enforcing in courts outside the United States judgments that are obtained in U.S. courts against any of our <FONT STYLE="white-space:nowrap">non-U.S.</FONT> resident
directors or us, including actions under the civil liability provisions of the U.S. securities laws. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">With that noted, there are no treaties between Australia and the United States that would affect the recognition or enforcement of foreign
judgments in Australia. We also note that investors may be able to bring an original action in an Australian court against us to enforce liabilities based in part upon U.S. federal securities laws. The disclosure in this section is not based on the
opinion of counsel. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We have appointed Corporation
Service Company as our agent to receive service of process with respect to any action brought against us under the federal securities laws of the United States. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">197
</FONT></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="rom947560_22"></A>UNDERWRITING </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Citigroup Global Markets Inc. and SVB Leerink LLC are acting
as book-running managers of this offering and as representatives of the underwriters named below. Subject to the terms and conditions stated in the underwriting agreement dated the date of this prospectus, the underwriters named below have severally
agreed to purchase, and we have agreed to sell to them, the number of ADSs indicated below: </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>

<TD WIDTH="90%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1px solid #000000 ; display:table-cell;"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Underwriter</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Number&nbsp;of<BR>ADSs</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Citigroup Global Markets Inc.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">SVB Leerink LLC</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Oppenheimer &amp; Co. Inc.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Truist Securities, Inc.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">9,300,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>  <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The underwriting
agreement provides that the obligations of the underwriters to purchase the ADSs included in this offering are subject to approval of legal matters by counsel and to other conditions. The underwriters are obligated to purchase all of the ADSs (other
than those covered by the over-allotment option described below) if they purchase any. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">ADSs sold by the underwriters to the public will initially be offered at the initial public offering price set forth on the cover of this prospectus. Any ADSs sold by the underwriters to securities
dealers may be sold at a discount from the initial public offering price not to exceed $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per ADS. After the initial public offering of the ADSs, if all
the ADSs are not sold at the initial public offering price, the underwriters may change the offering price and the other selling terms. The representatives have advised us that the underwriters do not intend to make sales to discretionary accounts.
</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The address of Citigroup Global Markets Inc. is
390 Greenwich Street, New York, New York 10013, the address of SVB Leerink LLC is One Federal Street, 37th Floor, Boston, Massachusetts 02110, the address of Oppenheimer &amp; Co. Inc. is 85 Broad Street, 26th Floor, New York, New York 10004, and
the address of <I></I>Truist<I> </I>Securities, Inc. is 3333 Peachtree Road NE, 9th floor, Atlanta, Georgia 30326. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">If the underwriters sell more ADSs than the total number set forth in the table above, we have granted to the underwriters an option,
exercisable for 30 days from the date of this prospectus, to purchase up to 1,395,000 additional ADSs at the initial public offering price less the underwriting discount. The underwriters may exercise the option solely for the purpose of covering
over-allotments, if any, in connection with this offering. To the extent the option is exercised, each underwriter must purchase a number of additional ADSs approximately proportionate to that underwriter&#146;s initial purchase commitment set forth
in the table above. Any ADSs issued or sold under the option will be issued and sold on the same terms and conditions as the other ADSs that are the subject of this offering. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We and our officers and directors have agreed that, subject
to specified limited exceptions, for a period of 90 days from the date of this prospectus, we and they will not, without the prior written consent of Citigroup Global Markets Inc. and SVB Leerink LLC, offer, sell, contract to sell, pledge or
otherwise dispose of, including the filing of a registration statement in respect of, or hedge any ordinary shares or ADSs or any securities convertible into, or exercisable or exchangeable for, our ordinary shares or ADSs, collectively referred to
as <FONT STYLE="white-space:nowrap">lock-up</FONT> securities. Citigroup Global Markets Inc. and SVB Leerink LLC in their sole discretion may release any of the securities subject to these <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements
at any time, which, in the case of officers and directors, shall be with notice. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">198
</FONT></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The <FONT STYLE="white-space:nowrap">lock-up</FONT> restrictions relating to our
officers and directors described in the immediately preceding paragraph are subject to specified exceptions, including the following: </FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">a.</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">transfers of <FONT STYLE="white-space:nowrap">lock-up</FONT> securities (i)&nbsp;as a bona fide gift or gifts, (ii)&nbsp;by will, other testamentary document or
intestacy or (iii)&nbsp;to any immediate family member of the <FONT STYLE="white-space:nowrap">lock-up</FONT> party or to any trust or other legal entity for the benefit of the <FONT STYLE="white-space:nowrap">lock-up</FONT> party or immediate
family of the <FONT STYLE="white-space:nowrap">lock-up</FONT> party, or if the <FONT STYLE="white-space:nowrap">lock-up</FONT> party is a trust, to a trustor or beneficiary of the trust or to the estate of a beneficiary of such trust,
</FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">b.</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">transfers of <FONT STYLE="white-space:nowrap">lock-up</FONT> securities to a partnership, limited liability company or other entity of which <FONT
STYLE="white-space:nowrap">lock-up</FONT> party and the <FONT STYLE="white-space:nowrap">lock-up</FONT> party&#146;s immediate family are the legal and beneficial owner of all of the outstanding equity securities or similar interests;
</FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">c.</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">transfers of <FONT STYLE="white-space:nowrap">lock-up</FONT> securities to a corporation, member, partner, partnership, limited liability company, trust or other entity
that is an affiliate of the <FONT STYLE="white-space:nowrap">lock-up</FONT> party; </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">d.</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">transfers of <FONT STYLE="white-space:nowrap">lock-up</FONT> securities to any investment fund or other entity controlled or managed by the <FONT
STYLE="white-space:nowrap">lock-up</FONT> party or its affiliates (including where the <FONT STYLE="white-space:nowrap">lock-up</FONT> party is a partnership, to a successor partnership or fund, or any other funds managed by such partnership);
</FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">e.</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">transfers of <FONT STYLE="white-space:nowrap">lock-up</FONT> securities to a nominee or custodian of a person or entity to whom a disposition or transfer would be
permissible above; </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">f.</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">transfers of <FONT STYLE="white-space:nowrap">lock-up</FONT> securities by operation of law, pursuant to a qualified domestic order, divorce settlement, divorce decree
or separation agreement or other final court order; </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">g.</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">transfers of <FONT STYLE="white-space:nowrap">lock-up</FONT> securities to us upon death, disability, termination of employment or cessation of services;
</FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">h.</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">transfers of <FONT STYLE="white-space:nowrap">lock-up</FONT> securities acquired in open market transactions after the closing of this offering;
</FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">i.</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">transfers of ordinary shares or ADSs to us in connection with the vesting, settlement, or exercise of options and other equity awards to purchase ordinary shares or
ADSs (including, in each case, by way of &#147;net&#148; or &#147;cashless&#148; exercise), including for the payment of exercise price and tax withholdings or remittance payments due as a result of the vesting, settlement, or exercise of such
equity awards; </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">j.</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">transfers of <FONT STYLE="white-space:nowrap">lock-up</FONT> securities pursuant to a bona fide third-party tender offer, merger, consolidation or other similar
transaction (including a takeover bid under Chapter 6 of the Corporations Act 2001 (Cth) and a scheme of arrangement implemented under Part 5.1 of the scheme of arrangement under the Corporations Act 2001 (Cth)) that is approved by our board of
directors and made to all holders of our share capital involving a change of control; </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">k.</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">the receipt from us of shares of common stock in connection with the exercise of options or other rights granted under an equity incentive plan or other equity award
plan or program or pursuant to an individual award agreement between us and the <FONT STYLE="white-space:nowrap">lock-up</FONT> party; or </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">l.</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">the establishment of a trading plan pursuant to Rule <FONT STYLE="white-space:nowrap">10b5-1</FONT> under the Exchange Act or to a similar effect permitted under the
rules and regulations of the Australian Securities Exchange for the transfer of shares of common stock, provided that such plan does not provide for the transfer of common stock, </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>provided</I> that: </FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">in the case of any transfer or distribution pursuant to clauses (a)&nbsp;through (f) above, each donee, trustee, distributee or transferee shall sign
and deliver a <FONT STYLE="white-space:nowrap">lock-up</FONT> agreement; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">in the case of any transfer or distribution pursuant to clause (h)&nbsp;above, no filing under the Exchange Act or other public announcement would be
required or be voluntarily made; </FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">199
</FONT></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">in the case of any transfer or distribution pursuant to clauses (a)&nbsp;through (k), any filing under the Exchange Act or other public report or
announcement would clearly indicate the nature and conditions of the transfer or distribution; and </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">in the case of any transfer or distribution pursuant to clauses (a)&nbsp;through (e) above, such transfer or distribution would not involve a
disposition for value. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Prior to
this offering, there has been no public market for the ADSs in the United States. Our ordinary shares have been trading on the Australian Securities Exchange, or the ASX, since April 1985 under the symbol &#147;OPT.&#148; The initial public offering
price for the ADSs will be determined by negotiations between us and the representatives and will be based, in part, on the prevailing price of our ordinary shares on the ASX. Among the factors considered in determining the initial public offering
price will be our stage of development, our current financial condition, our future prospects, our markets, the economic conditions in and future prospects for the industry in which we compete, our management, and currently prevailing general
conditions in the equity securities markets, including current market valuations of publicly traded companies considered comparable to our company. We cannot assure you, however, that the price at which the ADSs will sell in the public market after
this offering will not be lower than the initial public offering price or that an active trading market in our shares of ADSs will develop and continue after this offering. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>  <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We have applied for listing of the ADSs listed on the
Nasdaq Global Select Market under the symbol &#147;OPT.&#148; </FONT></P>  <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">The following table shows the per ADS and total underwriting discounts and commissions that we are to pay to the underwriters and proceeds to us, before estimated offering expenses, in connection with
this offering. These amounts are shown assuming both no exercise and full exercise of the underwriters&#146; over-allotment option: </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>

<TD WIDTH="73%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD COLSPAN="2" VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Total</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Per ADS</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>No<BR>exercise</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Full<BR>exercise</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Public offering price</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Underwriting discounts and commissions paid by us</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Proceeds to us, before expenses</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
</TABLE>  <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>  <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We estimate that
expenses payable by us in connection with this offering, exclusive of underwriting discounts, will be approximately $2.9 million. We have also agreed to reimburse the underwriters for expenses in an amount up to $30,000 relating to the clearance of
this offering with the Financial Industry Regulatory Authority, Inc. </FONT></P>  <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">In connection with this offering, the underwriters may purchase and sell ADSs in the open market. Purchases and sales in the open market may include short sales, purchases to cover short positions, which
may include purchases pursuant to the underwriters&#146; over-allotment option, and other transactions that would stabilize, maintain or otherwise affect the price of the ADSs. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Short sales involve secondary market sales by the underwriters of a greater number of ADSs than they are required to purchase in this offering:
</FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#147;Covered&#148; short sales are sales of ADSs in an amount up to the number of ADSs represented by the underwriters&#146; over-allotment option.
</FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#147;Naked&#148; short sales are sales of ADSs in an amount in excess of the number of ADSs represented by the underwriters&#146; over-allotment
option. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">The underwriters can close out a short position by purchasing additional ADSs, either pursuant to the underwriters&#146; over-allotment option or in
the open market. </FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">200
</FONT></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">To close a naked short position, the underwriters must purchase ADSs in the open market. A naked short position is more likely to be created if the
underwriters are concerned that there may be downward pressure on the price of the ADSs in the open market after pricing that could adversely affect investors who purchase in this offering. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">To close a covered short position, the underwriters must purchase ADSs in the open market or exercise their over-allotment option. In determining the
source of ADSs to close the covered short position, the underwriters will consider, among other things, the price of ADSs available for purchase in the open market as compared to the price at which they may purchase ADSs through their over-allotment
option. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">As an additional means of facilitating this offering, the underwriters may bid for, and purchase, ADSs on the Nasdaq Global Select Market, as long as
such bids do not exceed a specified maximum, to stabilize the price of the ADSs. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Purchases to cover short positions and stabilizing purchases, as well as other purchases by the underwriters for their own accounts, may have the effect of preventing or retarding a decline in the market
price of the shares. They may also cause the price of the ADSs to be higher than the price that would otherwise prevail in the open market in the absence of these transactions. The underwriters may conduct these transactions on the Nasdaq Global
Select Market, in the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">over-the-counter</FONT></FONT> market or otherwise. The underwriters are not required to engage in any of these transactions and may discontinue them at any
time. </FONT></P>  <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We have agreed to indemnify the
underwriters against certain liabilities, including liabilities under the Securities Act, or to contribute to payments the underwriters may be required to make because of any of those liabilities. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">A prospectus in electronic format may be made available on
websites maintained by one or more of the underwriters or their respective affiliates. The representatives may agree with us to allocate a number of ADSs to underwriters for sale to their online brokerage account holders. Any such allocation for
online distributions will be made by the underwriters on the same basis as other allocations. Other than the prospectus in electronic format, the information on the underwriters&#146; or their respective affiliates&#146; websites and any information
contained in any other website maintained by any of the underwriters or their respective affiliates is not part of this prospectus, has not been approved and/or endorsed by us or the underwriters and should not be relied upon by investors in this
offering. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Other Relationships </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The underwriters are full-service financial institutions
engaged in various activities, which may include securities trading, commercial and investment banking, financial advisory, investment management, principal investment, hedging, financing and brokerage activities. The underwriters and their
respective affiliates may, from time to time, engage in transactions with and perform services for us in the ordinary course of their business for which they may receive customary fees and reimbursement of expenses. In the ordinary course of their
various business activities, the underwriters and their respective affiliates may make or hold a broad array of investments and actively trade debt and equity securities (or related derivative securities) and financial instruments (which may include
bank loans or credit default swaps) for their own account and for the accounts of their customers and may at any time hold long and short positions in such securities and instruments. Such investments and securities activities may involve securities
and/or instruments of ours or our affiliates. The underwriters and their affiliates may also make investment recommendations and/or publish or express independent research views in respect of such securities or financial instruments and may hold, or
recommend to clients that they acquire, long or short positions in such securities and instruments. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>Notice to Prospective Investors in the European Economic Area </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In relation to each member state of the European Economic Area that has implemented the Prospectus Directive (each, a relevant member
state), with effect from and including the date on which the Prospectus </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">201
</FONT></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
Directive is implemented in that relevant member state (the relevant implementation date), an offer of ADSs described in this prospectus may not be made to the public in that relevant member
state other than: </FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">to any legal entity which is a qualified investor as defined in the Prospectus Directive; </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">to fewer than 150 natural or legal persons (other than qualified investors as defined in the Prospectus Directive), as permitted under the Prospectus
Directive, subject to obtaining the prior consent of the relevant Dealer or Dealers nominated by us for any such offer; or </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">in any other circumstances falling within Article 3(2) of the Prospectus Directive; </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">provided that no such offer of ADSs shall require us or any underwriter to
publish a prospectus pursuant to Article 3 of the Prospectus Directive. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">For purposes of this provision, the expression an &#147;offer of securities to the public&#148; in any relevant member state means the communication in any form and by any means of sufficient information
on the terms of the offer and the ADSs to be offered so as to enable an investor to decide to purchase or subscribe for any ADSs, as the expression may be varied in that member state by any measure implementing the Prospectus Directive in that
member state, the expression &#147;Prospectus Directive&#148; means Directive 2003/71/EC (and amendments thereto, including the 2010 PD Amending Directive) and includes any relevant implementing measure in the relevant member state, and the
expression &#147;2010 PD Amending Directive&#148; means Directive 2010/73/EU. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">The sellers of the ADSs have not authorized and do not authorize the making of any offer of ADSs through any financial intermediary on their behalf, other than offers made by the underwriters with a view
to the final placement of the ADSs as contemplated in this prospectus. Accordingly, no purchaser of the ADSs, other than the underwriters, is authorized to make any further offer of the ADSs on behalf of the sellers or the underwriters. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Notice to Prospective Investors in the United Kingdom </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">This prospectus is only being distributed to, and is only
directed at, persons in the United Kingdom that are qualified investors within the meaning of Article 2(1)(e) of the Prospectus Directive that are also (1)&nbsp;investment professionals falling within Article 19(5) of the Financial Services and
Markets Act 2000 (Financial Promotion) Order 2005, or the Order, or (2)&nbsp;high net worth entities, and other persons to whom it may lawfully be communicated, falling within Article 49(2)(a) to (d)&nbsp;of the Order (each such person being
referred to as a relevant person). </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">This
prospectus and its contents are confidential and should not be distributed, published or reproduced (in whole or in part) or disclosed by recipients to any other persons in the United Kingdom. Any person in the United Kingdom that is not a relevant
person should not act or rely on this document or any of its contents. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>Notice to Prospective Investors in Australia </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">No prospectus or other disclosure document (as defined in the Corporations Act 2001 (Cth) of Australia, or Corporations Act) in relation to the ADSs has been or will be lodged with the Australian
Securities&nbsp;&amp; Investments Commission, or ASIC. This document has not been lodged with ASIC and is only directed to certain categories of exempt persons. Accordingly, if you receive this document in Australia: </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">you confirm and warrant that you are either: </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">a &#147;sophisticated investor&#148; under Section&nbsp;708(8)(a) or (b)&nbsp;of the Corporations Act; </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">a &#147;sophisticated investor&#148; under Section&nbsp;708(8)(c) or (d)&nbsp;of the Corporations Act and that you have provided an accountant&#146;s
certificate to us which complies with the requirements of Section&nbsp;708(8)(c)(i) or (ii)&nbsp;of the Corporations Act and related regulations before the offer has been made; </FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">202
</FONT></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">a person associated with the company under Section&nbsp;708(12) of the Corporations Act; or </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">a &#147;professional investor&#148; within the meaning of Section&nbsp;708(11)(a) or (b)&nbsp;of the Corporations Act, and to the extent that you are
unable to confirm or warrant that you are an exempt sophisticated investor, associated person or professional investor under the Corporations Act any offer made to you under this document is void and incapable of acceptance; and
</FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">you warrant and agree that you will not offer any of the ADSs for resale in Australia within 12 months of that ADSs being issued unless any such resale
offer is exempt from the requirement to issue a disclosure document under Section&nbsp;708 of the Corporations Act. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Notice to Prospective Investors in Canada </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The securities may be sold only to purchasers purchasing, or deemed to be purchasing, as principal that are accredited investors, as
defined in National Instrument <FONT STYLE="white-space:nowrap">45-106</FONT> Prospectus Exemptions or subsection 73.3(1) of the Securities Act (Ontario), and are permitted clients, as defined in National Instrument
<FONT STYLE="white-space:nowrap">31-103</FONT> Registration Requirements, Exemptions and Ongoing Registrant Obligations. Any resale of the securities must be made in accordance with an exemption from, or in a transaction not subject to, the
prospectus requirements of applicable securities laws. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Securities legislation in certain provinces or territories of Canada may provide a purchaser with remedies for rescission or damages if this prospectus (including any amendment thereto) contains a
misrepresentation, provided that the remedies for rescission or damages are exercised by the purchaser within the time limit prescribed by the securities legislation of the purchaser&#146;s province or territory. The purchaser should refer to any
applicable provisions of the securities legislation of the purchaser&#146;s province or territory for particulars of these rights or consult with a legal advisor. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Pursuant to Section&nbsp;3A.3 of National Instrument <FONT
STYLE="white-space:nowrap">33-105</FONT> Underwriting Conflicts (NI <FONT STYLE="white-space:nowrap">33-105),</FONT> the underwriters are not required to comply with the disclosure requirements of NI <FONT STYLE="white-space:nowrap">33-105</FONT>
regarding underwriter conflicts of interest in connection with this offering. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>Notice to Prospective Investors in France </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Neither this prospectus nor any other offering material relating to the ADSs described in this prospectus has been submitted to the clearance procedures of the<I> Autorit&eacute; des March&eacute;s
Financiers</I> or of the competent authority of another member state of the European Economic Area and notified to the<I> Autorit&eacute; des March&eacute;s Financiers</I>. The ADSs have not been offered or sold and will not be offered or sold,
directly or indirectly, to the public in France. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Neither this prospectus nor any other offering material relating to the ADSs has been or will be: </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">released, issued, distributed or caused to be released, issued or distributed to the public in France; or </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">used in connection with any offer for subscription or sale of the ADSs to the public in France. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Such offers, sales and distributions will be made in France only: </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">to qualified investors (<I>investisseurs qualifi&eacute;s</I>) and/or to a restricted circle of investors (<I>cercle restreint
d&#146;investisseurs</I>), in each case investing for their own account, all as defined in and in accordance with articles <FONT STYLE="white-space:nowrap">L.411-2,</FONT> <FONT STYLE="white-space:nowrap">D.411-1,</FONT> <FONT
STYLE="white-space:nowrap">D.411-2,</FONT> <FONT STYLE="white-space:nowrap">D.734-1,</FONT> <FONT STYLE="white-space:nowrap">D.744-1,</FONT> <FONT STYLE="white-space:nowrap">D.754-1</FONT> and <FONT STYLE="white-space:nowrap">D.764-1</FONT> of the
French Code mon&eacute;taire et financier; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">to investment services providers authorized to engage in portfolio management on behalf of third parties; or </FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">203
</FONT></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">in a transaction that, in accordance with article
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">L.411-2-II-1&deg;</FONT></FONT></FONT> <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">-or-2&deg;</FONT></FONT> <FONT
STYLE="white-space:nowrap">-or</FONT> 3&deg; of the French Code<I> mon&eacute;taire et financier</I> and article <FONT STYLE="white-space:nowrap">211-2</FONT> of the General Regulations (<I>R&egrave;glement G&eacute;n&eacute;ral</I>) of the<I>
Autorit&eacute; des March&eacute;s Financiers</I>, does not constitute a public offer (<I>appel public &agrave; l&#146;&eacute;pargne</I>). </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The ADSs may be resold directly or indirectly, only in compliance with articles <FONT STYLE="white-space:nowrap">L.411-1,</FONT> <FONT
STYLE="white-space:nowrap">L.411-2,</FONT> <FONT STYLE="white-space:nowrap">L.412-1</FONT> and <FONT STYLE="white-space:nowrap">L.621-8</FONT> through <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">L.621-8-3</FONT></FONT> of the
French Code<I> mon&eacute;taire et financier</I>. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Notice to
Prospective Investors in Hong Kong </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The ADSs
may not be offered or sold in Hong Kong by means of any document other than (1)&nbsp;in circumstances which do not constitute an offer to the public within the meaning of the Companies Ordinance (Cap. 32, Laws of Hong Kong), or (2)&nbsp;to
&#147;professional investors&#148; within the meaning of the Securities and Futures Ordinance (Cap. 571, Laws of Hong Kong) and any rules made thereunder, or (3)&nbsp;in other circumstances which do not result in the document being a
&#147;prospectus&#148; within the meaning of the Companies Ordinance (Cap. 32, Laws of Hong Kong) and no advertisement, invitation or document relating to the ADSs may be issued or may be in the possession of any person for the purpose of issue (in
each case whether in Hong Kong or elsewhere), which is directed at, or the contents of which are likely to be accessed or read by, the public in Hong Kong (except if permitted to do so under the laws of Hong Kong) other than with respect to ADSs
which are or are intended to be disposed of only to persons outside Hong Kong or only to &#147;professional investors&#148; within the meaning of the Securities and Futures Ordinance (Cap. 571, Laws of Hong Kong) and any rules made thereunder.
</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Notice to Prospective Investors in the State of Israel
</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In the State of Israel, this prospectus
shall not be regarded as an offer to the public to purchase shares of ADSs under the Israeli Securities Law, 5728 - 1968, which requires a prospectus to be published and authorized by the Israel Securities Authority, if it complies with certain
provisions of Section&nbsp;15 of the Israeli Securities Law, 5728 - 1968, including, inter alia, if: (1)&nbsp;the offer is made, distributed or directed to not more than 35 investors, subject to certain conditions, or the Addressed Investors; or
(2)&nbsp;the offer is made, distributed or directed to certain qualified investors defined in the First Addendum of the Israeli Securities Law, 5728 - 1968, subject to certain conditions, or Qualified Investors. The Qualified Investors shall not be
taken into account in the count of the Addressed Investors and may be offered to purchase securities in addition to the 35 Addressed Investors. We have not and will not take any action that would require us to publish a prospectus in accordance with
and subject to the Israeli Securities Law, 5728 - 1968. We have not and will not distribute this prospectus or make, distribute or direct an offer to subscribe for the ADSs to any person within the State of Israel, other than to Qualified Investors
and up to 35 Addressed Investors. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Qualified
Investors may have to submit written evidence that they meet the definitions set out in of the First Addendum to the Israeli Securities Law, 5728&#151;1968. In particular, we may request that Qualified Investors will each represent, warrant and
certify to us and/or to anyone acting on our behalf: (1)&nbsp;that it is an investor falling within one of the categories listed in the First Addendum to the Israeli Securities Law, 5728 - 1968; (2) which of the categories listed in the First
Addendum to the Israeli Securities Law, 5728 - 1968 regarding Qualified Investors is applicable to it; (3)&nbsp;that it will abide by all provisions set forth in the Israeli Securities Law, 5728 - 1968 and the regulations promulgated thereunder in
connection with this offering; (4)&nbsp;that the shares of ADSs that it will be issued are, subject to exemptions available under the Israeli Securities Law, 5728 -1968: (a) for its own account; (b)&nbsp;for investment purposes only; and
(c)&nbsp;not issued with a view to resale within the State of Israel, other than in accordance with the provisions of the Israeli Securities Law, 5728 -1968; and (5)&nbsp;that it is willing to provide further evidence of its Qualified Investor
status. Addressed Investors may have to submit written evidence in respect of their identity and may have to sign and submit a declaration containing, inter alia, the Addressed Investor&#146;s name, address and passport number or Israeli
identification number. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Notice to Prospective Investors in
Japan </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The ADSs offered in this prospectus
have not been and will not be registered under the Financial Instruments and Exchange Law of Japan. The ADSs have not been offered or sold and will not be offered or sold, </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">204
</FONT></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
directly or indirectly, in Japan or to or for the account of any resident of Japan (including any corporation or other entity organized under the laws of Japan), except (1)&nbsp;pursuant to an
exemption from the registration requirements of the Financial Instruments and Exchange Law and (2)&nbsp;in compliance with any other applicable requirements of Japanese law. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Notice to Prospective Investors in Singapore </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">This prospectus has not been registered as a prospectus with
the Monetary Authority of Singapore. Accordingly, this prospectus and any other document or material in connection with the offer or sale, or invitation for subscription or purchase, of the ADSs may not be circulated or distributed, nor may the ADSs
be offered or sold, or be made the subject of an invitation for subscription or purchase, whether directly or indirectly, to persons in Singapore other than (1)&nbsp;to an institutional investor under Section&nbsp;274 of the Securities and Futures
Act, Chapter 289 of Singapore, or the SFA, (2)&nbsp;to a relevant person pursuant to Section&nbsp;275(1), or any person pursuant to Section&nbsp;275(1A), and in accordance with the conditions specified in Section&nbsp;275 of the SFA or
(3)&nbsp;otherwise pursuant to, and in accordance with the conditions of, any other applicable provision of the SFA, in each case subject to compliance with conditions set forth in the SFA. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Where the ADSs are subscribed or purchased under Section&nbsp;275 of the SFA by a relevant party which is:
</FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">a corporation (which is not an accredited investor (as defined in Section&nbsp;4A of the SFA)) the sole business of which is to hold investments and
the entire share capital of which is owned by one or more individuals, each of whom is an accredited investor; or </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">a trust (where the trustee is not an accredited investor) whose sole purpose is to hold investments and each beneficiary of the trust is an individual
who is an accredited investor, shares, debentures and units of ADSs and debentures of that corporation or the beneficiaries&#146; rights and interest (howsoever described) in that trust shall not be transferred within six months after that
corporation or that trust has acquired the ADSs pursuant to an offer made under Section&nbsp;275 of the SFA except: </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">to an institutional investor (for corporations, under Section&nbsp;274 of the SFA) or to a relevant person defined in Section&nbsp;275(2) of the SFA,
or to any person pursuant to an offer that is made on terms that such shares, debentures and units of ADSs and debentures of that corporation or such rights and interest in that trust are acquired at a consideration of not less than $200,000 (or its
equivalent in a foreign currency) for each transaction, whether such amount is to be paid for in cash or by exchange of securities or other assets, and further for corporations, in accordance with the conditions specified in Section&nbsp;275 of the
SFA; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">where no consideration is or will be given for the transfer; or </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">where the transfer is by operation of law. </FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">205
</FONT></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="rom947560_23"></A>EXPENSES RELATING TO THE OFFERING </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The following table sets forth the costs and expenses, other
than underwriting discounts and commissions, payable in connection with the sale of ADSs in the offering. All amounts are estimated except the SEC registration fee, the Financial Industry Regulatory Authority, Inc., or FINRA, filing fee and the
Nasdaq initial listing fee. Except as otherwise noted, all the expenses below will be paid by us. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>

<TD WIDTH="86%"></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1px solid #000000 ; display:table-cell;"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Expense</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Amount</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">SEC registration fee</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">US$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">20,140</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">FINRA filing fee</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">28,190</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Nasdaq initial listing fee</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">150,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Legal fees and expenses</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,700,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Accounting fees and expenses</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">500,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Printing expenses</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">300,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Miscellaneous fees and expenses</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">201,670</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Total</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">US$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2,900,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>    <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;
</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="rom947560_24"></A>LEGAL MATTERS </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The validity of the ordinary shares represented by the ADSs
and certain other matters of Australian law will be passed upon for us by Gilbert + Tobin. Certain matters as to U.S. federal law and New York state law will be passed upon for us by Cooley LLP, New York, New York and Cooley LLP, Singapore. Legal
counsel to the underwriters in connection with this offering are Goodwin Procter LLP, Boston, Massachusetts, with respect to U.S. federal law, and Herbert Smith Freehills, Melbourne, Australia, with respect to Australian law. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="rom947560_25"></A>EXPERTS </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The financial statements included in this prospectus have
been audited by Deloitte Touche Tohmatsu, an independent registered public accounting firm, as stated in their report appearing herein. Such financial statements are included in reliance upon the report of such firm given upon their authority as
experts in accounting and auditing. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The offices
of Deloitte Touche Tohmatsu are located at Tower 2, Brookfield Place, 123 St. Georges Terrace, Perth, WA 6000, Australia. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="rom947560_26"></A>WHERE YOU CAN FIND MORE INFORMATION </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>  <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We have filed with the SEC a Registration Statement on <FONT
STYLE="white-space:nowrap">Form&nbsp;F-1&nbsp;under</FONT> the Securities Act with respect to the ADSs offered in this prospectus. A related registration statement <FONT STYLE="white-space:nowrap">on&nbsp;Form&nbsp;F-6&nbsp;(File</FONT> No.
333-249327) has been filed with the SEC to register the ADSs. This prospectus, which forms a part of the Registration Statement, does not contain all of the information included in the Registration Statement. Certain information is omitted and you
should refer to the Registration Statement and its exhibits for that information. With respect to references made in this prospectus to any contract or other document of Opthea, such references are not necessarily complete and you should refer to
the exhibits attached to the Registration Statement for copies of the actual contract or document. </FONT></P>  <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Upon the closing of this offering, we will become subject to periodic reporting and other informational requirements of the Exchange Act
as applicable to foreign private issuers. Accordingly, we will be required to file reports, including annual reports on <FONT STYLE="white-space:nowrap">Form&nbsp;20-F,&nbsp;periodic</FONT> reports and other information, with the SEC. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">206
</FONT></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We are allowed four months after the end of our fiscal year to file our annual report
with the SEC, and we are not required to disclose certain detailed information regarding executive compensation that is required from U.S. domestic issuers. Also, as a foreign private issuer, we are exempt from the rules of the Exchange Act
prescribing the furnishing of proxy statements to shareholders, and the members of our board of directors, our senior management and our principal shareholders are exempt from the reporting and short-swing profit recovery provisions contained in
Section&nbsp;16 of the Exchange Act. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">As a foreign
private issuer, we are also exempt from the requirements of Regulation FD (Fair Disclosure) which, generally, are meant to ensure that select groups of investors are not privy to specific information about an issuer before other investors. We are,
however, still subject to the anti-fraud and anti-manipulation rules of the SEC, such as <FONT STYLE="white-space:nowrap">Rule&nbsp;10b-5.&nbsp;Since</FONT> many of the disclosure obligations required of us as a foreign private issuer are different
than those required of U.S. domestic reporting companies, our shareholders, potential shareholders and the investing public in general should not expect to receive information about us in the same amount, or at the same time, as information is
received from, or provided by, other U.S. domestic reporting companies. We are only liable for violations of the rules and regulations of the SEC that apply to us as a foreign private issuer. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The SEC maintains a website at www.sec.gov that contains reports, proxy and information statements and other
information regarding registrants that file electronically with the SEC. You also can inspect our registration statement, as well as any other information we file with or furnish to the SEC, on this website. This reference to the SEC&#146;s website
is an inactive textual reference only and is not a hyperlink. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">We expect to make our annual reports and other information filed with or furnished to the SEC available, free of charge, through our website at www.opthea.com as soon as reasonably practicable after those
reports and other information are filed with or furnished to the SEC. The information contained on, or that can be accessed through, our website is not part of, and is not incorporated into, this prospectus. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">207
</FONT></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="rom947560_27"></A>INDEX TO CONSOLIDATED FINANCIAL STATEMENTS </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>

<TD WIDTH="95%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Page</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#fin947560_1">Report of Independent Registered Public Accounting Firm</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="white-space:nowrap">F-2</FONT></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#fin947560_2">Consolidated Statement of Profit or Loss and Other Comprehensive Income</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="white-space:nowrap">F-3</FONT></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#fin947560_3">Consolidated Statement of Financial Position</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="white-space:nowrap">F-4</FONT></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#fin947560_4">Consolidated Statement of Changes in Equity</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="white-space:nowrap">F-5</FONT></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#fin947560_5">Consolidated Statement of Cash Flows</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="white-space:nowrap">F-6</FONT></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#fin947560_6">Notes to the Consolidated Financial Statements</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="white-space:nowrap">F-7</FONT></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
</TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">F-1
</FONT></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="fin947560_1"></A>REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%; text-indent:-2%"><FONT STYLE="font-family:Times New Roman" SIZE="2">To the Shareholders and the
Board of Directors of Opthea Limited </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Opinion on the Financial
Statements </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">We have audited the accompanying consolidated
statements of financial position of Opthea Limited and subsidiary (the &#147;Company&#148;) as of June&nbsp;30, 2020 and 2019, the related consolidated statements of profit or loss and other comprehensive income, changes in equity, and cash flows
for each of the two years in the period ended June&nbsp;30, 2020 and the related notes (collectively referred to as the &#147;financial statements&#148;). </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of June&nbsp;30, 2020 and
2019, and the results of its operations and its cash flows for each of the two years in the period ended June&nbsp;30, 2020, in conformity with International Financial Reporting Standards as issued by the International Accounting Standards Board.
</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Basis for Opinion </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">These financial statements are the responsibility of the Company&#146;s
management. Our responsibility is to express an opinion on the Company&#146;s financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (&#147;PCAOB&#148;)
and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">We conducted our audit in accordance with the standards of the PCAOB. Those
standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to
perform, an audit of its internal control over financial reporting. As part of our audit, we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness
of the Company&#146;s internal control over financial reporting. Accordingly, we express no such opinion. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks.
Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well
as evaluating the overall presentation of the financial statements. We believe that our audit provides a reasonable basis for our opinion. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%; text-indent:-2%"><FONT STYLE="font-family:Times New Roman" SIZE="2">/s/ Deloitte Touche Tohmatsu </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>DELOITTE TOUCHE TOHMATSU </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%; text-indent:-2%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Perth, Australia </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%; text-indent:-2%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1&nbsp;September&nbsp;2020 </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%; text-indent:-2%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We have served as the Company&#146;s auditor since 2012. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">F-2
</FONT></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="fin947560_2"></A>CONSOLIDATED STATEMENT OF PROFIT OR LOSS AND OTHER
COMPREHENSIVE INCOME FOR THE YEARS ENDED JUNE&nbsp;30, 2019 AND 2020 </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>

<TD WIDTH="73%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Note</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2019<BR>A$</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2020<BR>A$</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Revenue</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">7</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">159,064</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">87,075</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Other income</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">8</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">836,821</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">783,830</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Research and development expenses</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">9</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(31,347,891</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(17,954,073</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Patent expenses</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(161,148</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(429,229</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Intellectual property costs</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(112,795</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(114,046</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Administrative expenses</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">10</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(5,174,755</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(7,001,507</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Occupancy expenses</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">10</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(108,904</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(33,846</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Net foreign exchange gain / (loss)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">362,574</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(400,608</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Loss before income tax</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(35,547,034</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(25,062,404</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Income tax benefit</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">11</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">14,636,973</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">8,533,123</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Loss for the year</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">21</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(20,910,061</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(16,529,281</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Other Comprehensive income</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Items that will not be reclassified subsequently to profit or loss:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Fair value gains on investments in financial assets</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">259,864</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">58,840</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Other comprehensive income for the period, net of tax</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">259,864</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">58,840</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total comprehensive loss for the year</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(20,650,197</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(16,470,441</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Loss for the year is attributable to:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Owners of the Company</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">21</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(20,910,061</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(16,529,281</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(20,910,061</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(16,529,281</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total comprehensive loss for the year is attributable to:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Owners of the Company</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(20,650,197</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(16,470,441</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(20,650,197</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(16,470,441</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Loss per share attributable to Owners of the Company&#151;basic and diluted (in cents)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">12</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(8.98</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(6.34</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
</TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">The above consolidated
statement of profit or loss and other comprehensive income should be read in conjunction with the accompanying notes. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">F-3
</FONT></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="fin947560_3"></A>CONSOLIDATED STATEMENT OF FINANCIAL POSITION AS AT
JUNE&nbsp;30, 2019 AND 2020 </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>

<TD WIDTH="72%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Note</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2019<BR>A$</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2020<BR>A$</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">ASSETS</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Current Assets</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Cash and cash equivalents</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">13</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">21,534,919</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">62,020,382</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Current tax receivable</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">11</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">14,636,973</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">8,533,123</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Receivables</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">14</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">295,786</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">284,391</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Prepayments</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">424,603</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">478,632</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Total Current Assets</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">36,892,281</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">71,316,528</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><FONT STYLE="white-space:nowrap">Non-current</FONT> Assets</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Investments in financial assets</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">15</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">714,118</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">289,980</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Plant and equipment</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">54,063</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">37,180</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Right-of-use</FONT></FONT> asset</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">16</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">243,510</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Total <FONT STYLE="white-space:nowrap">Non-Current</FONT> Assets</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">768,181</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">570,670</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>TOTAL ASSETS</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">37,660,462</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">71,887,198</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">LIABILITIES</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Current Liabilities</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Payables</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">17</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">5,951,942</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">5,895,034</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Lease liabilities</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">16</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">145,043</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Other financial liabilities</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">25,592</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">237,820</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Provisions</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">18</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">538,547</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">640,934</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Total Current Liabilities</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">6,516,081</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">6,918,831</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><FONT STYLE="white-space:nowrap">Non-Current</FONT> Liabilities</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Lease liabilities</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">16</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">120,033</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Provisions</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">19</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">24,844</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">40,197</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Total <FONT STYLE="white-space:nowrap">Non-Current</FONT> Liabilities</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">24,844</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">160,230</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>TOTAL LIABILITIES</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">6,540,925</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">7,079,061</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">EQUITY</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Contributed equity</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">20</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">113,021,993</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">162,102,553</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Accumulated losses</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">21</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(86,060,060</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(102,589,341</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Reserves</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">21</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">4,157,604</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">5,294,925</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>TOTAL EQUITY</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">31,119,537</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">64,808,137</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>TOTAL LIABILITIES AND EQUITY</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">37,660,462</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">71,887,198</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">The above consolidated
statement of financial position should be read in conjunction with the accompanying notes. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">F-4
</FONT></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="fin947560_4"></A>CONSOLIDATED STATEMENT OF CHANGES IN EQUITY FOR THE YEARS
ENDED JUNE&nbsp;30, 2019 AND 2020 </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>

<TD WIDTH="31%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Note</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Contributed<BR>equity</B></FONT><br><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>A$</B></FONT></TD>

<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Options<BR>reserve</B></FONT><br><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>A$</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Share-<BR>based<BR>payments<BR>reserve</B></FONT><br><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>A$
</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Fair
value<BR>of&nbsp;investments<BR>reserve</B></FONT><br><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>A$</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Accumulated<BR>losses</B></FONT><br><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>A$</B></FONT></TD>

<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Total equity</B></FONT><br><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>A$</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>As July&nbsp;1, 2018</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">98,403,149</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,989,067</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2,452,838</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">477,391</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(65,149,999</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">38,172,446</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Fair value gains on investments in financial assets(1)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">21</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">259,864</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">259,864</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Loss for the year(1)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(20,910,061</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(20,910,061</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total comprehensive income and expense for the period</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">259,864</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(20,910,061</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(20,650,197</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Recognition of share-based payment</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">21</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">967,511</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">967,511</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Transfer from option reserve on exercise of options</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">20</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,989,067</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(1,989,067</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Issue of ordinary shares on exercise of options</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">20</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">12,629,777</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">12,629,777</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>As June&nbsp;30, 2019</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">113,021,993</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#150;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3,420,349</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">737,255</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(86,060,060</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">31,119,537</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Fair value gains on investments in financial assets(1)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">21</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">58,840</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">58,840</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Loss for the year(1)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(16,529,281</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(16,529,281</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total comprehensive income and expense for the period</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">58,840</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(16,529,281</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(16,470,441</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Recognition of share-based payment</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">21</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,078,481</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,078,481</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Issue of ordinary shares on exercise of options</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">20</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">420,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">420,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Issue of ordinary shares</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">20</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">48,660,560</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">48,660,560</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>As June&nbsp;30, 2020</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">162,102,553</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">4,498,830</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">796,095</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(102,589,341</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">64,808,137</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="1">(1)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="1">Amounts are after tax. </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">The above consolidated statement of changes in equity should be read in conjunction with the accompanying notes. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">F-5
</FONT></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="fin947560_5"></A>CONSOLIDATED STATEMENT OF CASH FLOWS FOR THE YEARS ENDED
JUNE&nbsp;30, 2019 AND 2020 </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>

<TD WIDTH="73%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Note</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2019</B></FONT><br><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>A$</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2020</B></FONT><br><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>A$</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">CASH FLOWS FROM OPERATING ACTIVITIES</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Interest received</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">817,314</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">742,014</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Royalty and license income received</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">170,750</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">138,916</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Grant income received</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">77,745</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">62,500</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Payment of lease interest </FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(7,680</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Payments to suppliers and employees and for research and development and intellectual property costs (inclusive of Goods and
Service Tax)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(37,268,212</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(24,354,991</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Research and development tax incentive scheme credit received</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">12,017,247</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">14,636,973</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Net cash flows used in operating activities</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">24</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(24,185,156</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(8,782,268</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">CASH FLOWS FROM INVESTING ACTIVITIES</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Cash received on disposal of financial assets</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">339,046</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">482,978</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Purchase of plant and equipment</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(18,070</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(7,238</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Net cash flows provided by investing activities</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">320,976</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">475,740</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">CASH FLOWS FROM FINANCING ACTIVITIES</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Payment of lease liabilities</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(100,189</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Net proceeds on issue of ordinary shares</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">20</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">48,660,560</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Cash received for ordinary shares issued on exercise of options</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">20</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">12,629,777</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">420,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Net cash flows provided by financing activities</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">12,629,777</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">48,980,371</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Net (decrease)/increase in cash and cash equivalents</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(11,234,403</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">40,673,843</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Cash and cash equivalents at beginning of year</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">32,510,230</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">21,534,919</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Effects of exchange rate changes on cash held in foreign currencies</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">259,092</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(188,380</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Cash and cash equivalents at the end of the year</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">13</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">21,534,919</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">62,020,382</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">The above consolidated
statement of cash flows should be read in conjunction with the accompanying notes. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">F-6
</FONT></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="fin947560_6"></A>NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS FOR THE
YEARS ENDED JUNE&nbsp;30, 2019 AND 2020 </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>1.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE="" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Reporting entity </B></FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The significant accounting policies adopted in preparing the consolidated financial statements of Opthea Limited (&#147;Opthea&#148; or
the &#147;Company&#148;) and its subsidiary (the &#147;Consolidated Entity&#148; or &#147;Group&#148;) for the years ended June 30, 2019 and 2020, are stated to assist in a general understanding of the consolidated financial statements. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Opthea is a company limited by shares, incorporated and
domiciled in Australia and has its registered office on Suite 403, Level&nbsp;4, 650 Chapel Street, South Yarra, Victoria. The Company&#146;s ordinary shares are listed on the Australian Securities Exchange (the &#147;ASX&#148;) under the symbol
&#147;OPT.&#148; </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Group&#146;s principal
activity is the research and development of <FONT STYLE="white-space:nowrap">OPT-302</FONT> for the treatment of retinal diseases. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The financial statements for the year ended June&nbsp;30, 2020 were authorized for issue by the directors on September&nbsp;1, 2020.
</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>2.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE="" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Basis of accounting </B></FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">These financial statements are general purpose financial statements which have been prepared in accordance with International Financial
Reporting Standards (&#147;IFRS&#148;) as issued by the International Accounting Standards Board (the &#147;IASB&#148;). </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The financial statements comprise the consolidated financial statements of the Group. For the purposes of preparing the consolidated
financial statements, the Company is a <FONT STYLE="white-space:nowrap">for-profit</FONT> entity. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>3.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE="" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Summary of accounting policies </B></FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The consolidated financial statements have been prepared
using the significant accounting policies and measurement bases summarized below. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>Basis of measurement </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">The consolidated financial statements have been prepared on a historical cost basis, except for investments classified as financial assets, which have been measured at fair value. All amounts are
presented in Australian dollars. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Basis of consolidation
</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The consolidated financial statements
incorporate the financial statements of the Company and its subsidiary. Control is achieved when the Company: </FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">has power over the investee; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">is exposed, or has rights, to variable returns from its involvement with the investee; and </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">has the ability to use its power to affect its returns. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Consolidation of a subsidiary begins when the Company obtains
control over the subsidiary and ceases when the Company loses control of the subsidiary. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">All intragroup assets and liabilities, equity, income, expenses and cash flows relating to transactions between members of the Group are eliminated in full on consolidation. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">F-7
</FONT></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS FOR THE YEARS ENDED JUNE&nbsp;30,
2019 AND 2020 </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px">&nbsp;</P>
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Foreign currency translation </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT
SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Functional and presentation currency </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT
SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Both the functional and presentation currency of the Group is Australian dollars (A$). </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Transactions and balances </I></B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Transactions in foreign currencies are initially recorded in
the functional currency by applying the exchange rates ruling at the date of the transaction. Monetary assets and liabilities denominated in foreign currencies are retranslated at the rate of exchange ruling at the reporting date. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="white-space:nowrap">Non-monetary</FONT> items
that are measured in terms of historical cost in a foreign currency are translated using the exchange rate as at the date of the initial transaction. <FONT STYLE="white-space:nowrap">Non-monetary</FONT> items measured at fair value in a foreign
currency are translated using the exchange rates at the date when the fair value was determined. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>Financial assets and liabilities </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B><I>Recognition and derecognition of financial assets </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Purchases and sales of financial assets that require delivery of assets within the time frame generally established by regulation or
convention in the market place are recognized on the trade date, i.e., the date that the Group commits to purchase the asset. Financial assets are derecognized when the right to receive cash flows from the financial assets has expired or when the
entity transfers substantially all the risks and rewards of the financial assets. If the entity neither retains nor transfers substantially all of the risks and rewards, it derecognizes the asset if it has transferred control of the assets.
</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">When financial assets are recognized initially,
they are measured at fair value, plus directly attributable transaction costs. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B><I>Cash and cash equivalents </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Cash and cash equivalents in the statement of financial position comprise cash at bank and in hand and short-term deposits with an original maturity of three months or less that are readily convertible to
known amounts of cash and which are subject to an insignificant risk of changes in value. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">For the purposes of the statement of cash flows, cash and cash equivalents consist of cash and cash equivalents as defined above. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Other receivables </I></B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Other receivables generally comprise bank interest
receivable, other receivables from external parties and Goods and Services Tax (&#147;GST&#148;) credits receivable and are recognized and carried at original invoice amount less an allowance for any uncollectible amounts. The amounts are usually
received within 30 to 60 days of recognition. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The
Group measures the loss allowance for receivables at an amount equal to lifetime expected credit losses (&#147;ECL&#148;). The ECL on receivables are estimated under the simplified approach as permitted under IFRS 9 &#147;Financial
Instruments.&#148; This uses a provision matrix by reference to past experience of the debtor and an analysis of the debtor&#146;s current financial position, adjusted for factors that are specific to the debtors and general economic conditions of
the industry in which the debtors operate. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">F-8
</FONT></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS FOR THE YEARS ENDED JUNE&nbsp;30,
2019 AND 2020 </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px">&nbsp;</P>
 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Group writes off a receivable when there is information indicating that the debtor
is in severe financial difficulty and there is no realistic prospect of recovery. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B><I>Investments </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Investments in financial assets comprise of the Group&#146;s <FONT STYLE="white-space:nowrap">non-current</FONT> investments in listed companies. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">On initial recognition, the Group may make an irrevocable election (on an <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">instrument-by-instrument</FONT></FONT> basis) to designate investments in equity instruments as fair value through other comprehensive income (&#147;FVTOCI&#148;). Designation at FVTOCI is not permitted if the equity
instrument is held for trading. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Investments in
equity instruments at FVTOCI are initially measured at fair value plus transaction costs. Subsequently, they are measured at fair value with gains or losses arising from changes in the fair value recognized in other comprehensive income and
accumulated in the fair value of investments reserve. The fair values of investments in financial assets that are actively traded in organized financial markets is determined by reference to quoted market bid prices at the close of business on the
reporting date. The cumulative gain or loss is not reclassified to profit or loss on disposal of the equity instruments. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Dividends on these investments in equity instruments are recognized in profit or loss in accordance with IFRS. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Finance income </I></B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Almost all of the Group&#146;s finance income is earned on
short-term bank deposits, and as such, finance income is recognized when the Group&#146;s right to receive the payment is established. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Payables </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Payables are carried at amortized cost and due to their short-term nature, they are not discounted. They represent liabilities for goods
and services provided to the Group prior to the end of the financial year that are unpaid and arise when the Group becomes obliged to make future payments in respect of the purchase of these goods and services. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The amounts are unsecured and are usually paid within 30 days
of recognition. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Other financial liabilities
</I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Other financial liabilities in the
statement of financial position represent the year end <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">marked-to-market</FONT></FONT> value of forward rate foreign exchange contracts to purchase US dollars (&#147;Contracts&#148;).
These Contracts are used to settle US dollar denominated payables and expire within one year. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">The foreign exchange loss on recognition of the Contracts is included in &#147;net foreign exchange gain/(loss)&#148; in the Consolidated Statement of Profit or Loss and Other Comprehensive Income.
</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Plant and equipment </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Plant and equipment is stated at historical cost less
accumulated depreciation and any accumulated impairment losses. Depreciation on plant and equipment is calculated on a straight-line basis over their useful economic lives as follows: </FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT
SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Equipment and furniture&#151;3 to 10 years </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Leasehold improvements&#151;8 years or the term of the lease if shorter </FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">F-9
</FONT></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS FOR THE YEARS ENDED JUNE&nbsp;30,
2019 AND 2020 </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px">&nbsp;</P>
 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The assets&#146; residual values, useful lives and amortization methods are reviewed,
and adjusted if appropriate, at each financial year end. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">An item of plant and equipment is derecognized upon disposal or when no further economic benefits are expected from its use or disposal. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Leases </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Group has applied IFRS 16 &#147;Leases&#148; using the cumulative catch-up approach and therefore comparative information has not been
restated and is presented under&nbsp;International Accounting Standard (&#147;IAS&#148;) 17 &#147;Leases&#148;. The details of accounting policies under both IAS 17 and IFRS 16 are presented separately below. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Policies applicable from July 1, 2019
</I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Group assesses at contract inception
whether a contract is, or contains, a lease. A contract is, or contains, a lease if the contract conveys the right to control the use of an identified asset for a period of time in exchange for consideration. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Group applies a single recognition and measurement
approach for all leases, except for short-term leases and leases of low-value assets. The Group recognizes lease liabilities to make lease payments and right-of-use assets representing the right to use the underlying assets. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I><FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">Right-of-use</FONT></FONT> assets </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Right-of-use</FONT></FONT> assets are recognized at the commencement date of the lease (that is the date the underlying asset is available
for use). <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Right-of-use</FONT></FONT> assets are measured at cost, less any accumulated depreciation and any impairment losses, and adjusted for any remeasurement of lease liabilities.
The cost of <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">right-of-use</FONT></FONT> assets includes the amount of lease liabilities recognized, initial direct costs incurred, and lease payments made at or before the commencement
date less any lease incentives received. <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Right-of-use</FONT></FONT> assets are depreciated on a straight-line basis over the shorter of the lease terms and the estimated useful lives
of the assets. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Lease liabilities
</I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Lease liabilities are recognized at the
commencement date of the lease at the present value of lease payments to be made over the lease term. The lease payments include fixed payments (including <FONT STYLE="white-space:nowrap">in-substance</FONT> fixed payments) less any lease incentives
receivable. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In calculating the present value of
lease payments, the Group uses its incremental borrowing rate at the lease commencement date because the interest rate implicit in the lease is not readily determinable. The incremental borrowing rate is determined using market yields on bonds with
similar terms to maturity. After the commencement date, the amount of lease liabilities is increased to reflect the accretion of interest and reduced for the lease payments made. In addition, the carrying amount of lease liabilities is remeasured if
there is a modification, a change in the lease term, a change in lease payments (e.g., a change to future lease payments resulting from a change in an index or rate). </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Leases of
<FONT STYLE="white-space:nowrap">low-value</FONT> assets </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">For short-term leases (lease term of 12 months or less) and leases of <FONT STYLE="white-space:nowrap">low-value</FONT> assets (such as photo copiers and telephones), the Group has opted to recognize a
lease expense on a straight-line basis as permitted by IFRS 16. This expense is presented within &#147;administrative expenses&#148; in the Consolidated Statement for Profit or Loss and Other Comprehensive Income. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">F-10
</FONT></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS FOR THE YEARS ENDED JUNE&nbsp;30,
2019 AND 2020 </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px">&nbsp;</P>
 <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Policies applicable prior to July 1, 2019 </I></B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The determination of whether an arrangement is or contains a
lease is based on the substance of the arrangement and requires an assessment of whether the fulfilment of the arrangement is dependent on the use of a specific asset or assets and the arrangement conveys a right to use the asset, even if that right
is not explicitly specified in an arrangement. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Leases are classified as finance leases whenever the terms of the lease transfer substantially all the risks and rewards of ownership to
the lessee. All other leases are classified as operating leases. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Operating lease payments are recognized as an expense in profit or loss on a straight-line basis over the lease term. Operating lease incentives are recognized in the statement of comprehensive income as
an integral part of the total lease expense. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The
Group held no finance leases during the 2019 or 2020 financial years. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>Research and development costs </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Research costs are expensed as incurred. An intangible asset arising from the development expenditure on an internal project will only be recognized when the Group can demonstrate the technical
feasibility of completing the intangible asset so that it will be available for use or sale, its intention to complete and its ability to use or sell the asset, how the asset will generate future economic benefits, the availability of resources to
complete the development and the ability to measure reliably the expenditure attributable to the intangible asset during its development. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">As of June 30, 2019 and 2020, the Group is in the research phase and has not capitalized any development costs to date. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Provisions and employee benefits </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Wages, salaries, annual leave and sick leave
</I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Liabilities for wages and salaries,
including <FONT STYLE="white-space:nowrap">non-monetary</FONT> benefits and annual leave expected to be settled within 12 months of the reporting date, are recognized in current provisions in respect of employees&#146; services up to the reporting
date. They are measured at the amounts expected to be paid when the liabilities are settled. Expenses for <FONT STYLE="white-space:nowrap">non-accumulating</FONT> sick leave are recognized when the leave is taken and are measured at the rate paid or
payable. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Long service leave
</I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The liability for long service leave is
recognized in the provision for employee benefits and measured as the present value of expected future payments to be made in respect of services provided by employees up to the reporting date. Consideration is given to expected future wage and
salary levels, experience of employee departures, and periods of service. Expected future payments are discounted using market yields at the reporting date on bonds with terms to maturity that match, as closely as possible, the estimated future cash
outflows. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">F-11
</FONT></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS FOR THE YEARS ENDED JUNE&nbsp;30,
2019 AND 2020 </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px">&nbsp;</P>
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Share-based payment transactions </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT
SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Group provides benefits to directors and employees (including key management personnel) of the Group in the
form of share-based payments, whereby employees render services in exchange for shares or rights over shares (equity-settled transactions). </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The cost of these equity-settled transactions with employees is measured by reference to the fair value at the date at which they are
granted. Binomial models are used to value the options issued. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">The cost of the equity-settled transactions is recognized, together with a corresponding increase in equity, over the period in which the performance conditions are fulfilled (the vesting period), ending
on the date on which the relevant employees become fully entitled to the award (the vesting date). </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">The charge to profit or loss for the period is the cumulative amount less the amounts already charged in previous periods. There is a corresponding credit to equity. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Until an award has vested, any amounts recorded are
contingent and will be adjusted if more or fewer awards vest than were originally anticipated to do so. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>Contributed equity </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Ordinary shares are classified as equity. Incremental costs directly attributable to the issue of new shares or options are shown in equity as a deduction, net of tax, from the proceeds. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Revenue recognition </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">License revenue in connection with licensing of the
Group&#146;s intellectual property (including patents) to customers is recognized as a right to use the Group&#146;s intellectual property as it exists at the point in time in which the license is granted. This is because the contracts for the
license of intellectual property are distinct and do not require, nor does the customer reasonably expect, that the Group will undertake further activities that significantly affect the intellectual property to which the customer has the rights.
Although the Group is entitled to sales-based royalties from the eventual sales of goods and services to third parties using the intellectual property licensed, these royalty arrangements do not in themselves indicate that the customer would
reasonably expect the Group to undertake such activities, and no such activities are undertaken or contracted in practice. Accordingly, the promise to provide rights to the Group&#146;s intellectual property is accounted for as a performance
obligation satisfied at a point in time. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The
following consideration is received in exchange for licenses of intellectual property: </FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I><FONT STYLE="white-space:nowrap">Up-front</FONT> license fees</I>&#151;these are fixed amounts and are recognized at the point in time when the
Group transfers the intellectual property to the customer. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Sales-based royalties</I>&#151;these are variable consideration amounts promised in exchange for the license of intellectual property and are
recognized when the sales to third parties occur given the performance obligation to transfer the intellectual property to the customer is already satisfied. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">During the years ended June&nbsp;30, 2019 and 2020, the
Group&#146;s only revenue related to sales-based royalties. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Income tax </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Current tax </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Current tax assets and liabilities for the current and prior periods are measured at the amount expected to be recovered from or paid to
the taxation authorities based on the current period&#146;s taxable income. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">F-12
</FONT></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS FOR THE YEARS ENDED JUNE&nbsp;30,
2019 AND 2020 </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px">&nbsp;</P>
 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The tax rates and tax laws used to compute the amount are those that are enacted or
substantively enacted by the reporting date. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Research and development tax incentive </I></B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Research and Development (&#147;R&amp;D&#148;) Tax
Incentive Scheme is an Australian Federal Government program under which eligible companies with annual aggregated revenue of less than A$20&nbsp;million can receive cash amounts equal to 43.5% of eligible research and development expenditures from
the Australian Taxation Office (&#147;ATO&#148;). The R&amp;D Tax Incentive Scheme incentive relates to eligible expenditure incurred in Australia and, under certain circumstances, overseas on the development of the Group&#146;s lead candidate, <FONT
STYLE="white-space:nowrap">OPT-302.</FONT> The R&amp;D tax incentive is applied annually to eligible expenditure incurred during the Group&#146;s financial year following annual application to AusIndustry, an Australian governmental agency, and
subsequent filing of its Income Tax Return with the ATO after the financial year end. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">The Group estimates the amount of R&amp;D tax incentive after the completion of the financial year based on eligible Australia and overseas expenditures incurred during that year. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Group has presented incentives in respect of the R&amp;D
Tax Incentive Scheme within income tax benefit in the Statement of Profit or Loss and Other Comprehensive Income by analogizing with IAS 12 &#147;Income Taxes&#148;. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Deferred tax </I></B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Deferred income tax is provided on all temporary differences
at the reporting date between the tax bases of assets and liabilities and their carrying amounts for financial reporting purposes. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Deferred income tax liabilities are recognized for all taxable temporary differences except when the deferred income tax liability arises
from the initial recognition of goodwill or of an asset or liability in a transaction that is not a business combination and that, at the time of the transaction, affects neither the accounting profit nor taxable profit or loss. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Deferred income tax assets are recognized for all deductible
temporary differences, carry forward of unused tax assets (or credits) and unused tax losses, to the extent that it is probable that taxable profit will be available against which the deductible temporary differences, and the carry forward of unused
tax credits and unused tax losses can be utilized, except when the deferred income tax asset relating to the deductible temporary differences arises from the initial recognition of an asset or liability in a transaction that is not a business
combination and, at the time of the transaction, affects neither the accounting profit or taxable profit or loss. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The carrying amount of deferred income tax assets is reviewed at each reporting date and reduced to the extent that it is no longer
probable that sufficient taxable profit will be available to allow all or part of the deferred income tax asset to be utilized. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Unrecognized deferred income tax assets are reassessed at each reporting date and are recognized to the extent that it has become probable
that future taxable profit will allow the deferred tax asset to be recovered. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Deferred income tax assets and liabilities are measured at the tax rates that are expected to apply to the year when the asset is realized or the liability is settled, based on tax rates (and tax laws)
that have been enacted or substantively enacted at balance date. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Income taxes relating to items recognized directly in equity are recognized directly in equity and not in profit or loss. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">F-13
</FONT></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS FOR THE YEARS ENDED JUNE&nbsp;30,
2019 AND 2020 </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px">&nbsp;</P>
 <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Tax consolidation legislation </I></B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Tax consolidation is a system adopted by the ATO that treats
a group of entities as a single entity for tax purposes. Opthea Limited and its 100% owned subsidiary formed a tax consolidated group effective July&nbsp;1, 2003. The head entity, Opthea Limited, and its controlled entity, Vegenics Pty Ltd, are
current members of the tax consolidated group and account for their own current and deferred tax amounts. Members of the tax consolidated group have adopted the &#147;separate taxpayer within group&#148; method to allocate the current and deferred
tax amounts to each entity within the Group. This method requires adjustments for transactions and events occurring within the tax consolidated group that do not give rise to a tax consequence for the Group or that have a different tax consequence
at the level of the Group. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Other taxes </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Revenues, expenses, assets and liabilities are recognized
net of the amount of GST except: </FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">when the GST incurred on a purchase of goods and services is not recoverable from the taxation authority, in which case the GST is recognized as part
of the cost of acquisition of the asset or as part of the expense item as applicable; and </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">receivables and payables are stated with the amount of GST included. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The net amount of GST recoverable from, or payable to the taxation authority is included as part of receivables
or payables in the statement of financial position. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Cash flows are included in the statement of cash flows on a gross basis and the GST component of cash flows arising from investing and
financing activities, which is recoverable from, or payable to, the taxation authority is classified as part of operating cash flows. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Commitments and contingencies are disclosed net of the amount of GST recoverable from, or payable to, the taxation authority. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Reclassification </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Certain amounts previously reported in the consolidated
financial statements have been reclassified to conform to current year presentation. Such reclassifications did not affect net loss, shareholders&#146; equity or cash flows. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Immaterial error correction </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">During the year ended June 30, 2020, the Group corrected a
prior period immaterial error to the consolidated statement of changes in equity for the year ended June 30, 2019. Specifically, the Group corrected the subtotaled consolidated total comprehensive income and expense for the period included in the
Consolidated Statement of Changes in Equity for the year ended June 30, 2019, which had previously included opening amounts for those categories in the subtotals as well. The update of the subtotals had no impact on shareholders&#146; equity, net
loss, total other comprehensive losses included in the Consolidated Statement of Profit or Loss and Other Comprehensive Income or Consolidated Statement of Cash Flows for the periods ended June 30, 2019 as well as June 30, 2020. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>4.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE="" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Critical accounting judgments and key sources of estimation uncertainty </B></FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In applying the Group&#146;s accounting policies, management
continually evaluates judgments, estimates and assumptions based on experience and other factors, including expectations of future events that may have an </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">F-14
</FONT></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS FOR THE YEARS ENDED JUNE&nbsp;30,
2019 AND 2020 </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px">&nbsp;</P>
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
impact on the Group. All judgments, estimates and assumptions made are believed to be reasonable based on the most current set of circumstances available to management. Actual results may differ
from the judgments, estimates and assumptions. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Significant judgments, estimates and assumptions made by management in the preparation of these financial statements are outlined below:
</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>4.1</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE="" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Critical judgments in applying accounting policies Research and development costs </B></FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The majority of Opthea&#146;s expenditure is incurred as a
result of clinical trials for <FONT STYLE="white-space:nowrap">OPT-302.</FONT> During the years ended June&nbsp;30, 2019 and 2020, Opthea progressed Phase 2b wet <FONT STYLE="white-space:nowrap">age-related</FONT> macular degeneration (&#147;wet
AMD&#148;) and Phase 1b/2a diabetic macular edema (&#147;DME&#148;) trials. A key measure of the Company&#146;s performance is the level of expenditure incurred on the research of <FONT STYLE="white-space:nowrap">OPT-302.</FONT> </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Judgment is required in relation to: </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the classification of expenses in the income statement between research and development costs and operating expenses; and </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">whether costs relate to R&amp;D, and consequently if they meet the capitalization criteria under International Accounting Standards 38 &#147;Intangible
Assets.&#148; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The directors
have determined that the Group is still in a research phase and accordingly, no development costs have been capitalized as of June 30, 2019 and 2020. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Taxation </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Research and development tax incentive </I></B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The R&amp;D Tax Incentive Scheme is an Australian Federal
Government program under which eligible companies can receive cash refunds of 43.5% of eligible R&amp;D expenditure. Judgments are required as to the R&amp;D tax incentive refundable offset eligibility in respect of: </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the Group&#146;s ability to make claims and its continued compliance under the scheme; </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">R&amp;D and other supporting costs previously approved by Australian tax authorities; </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">estimated amounts, timing and geographical location of future costs related to the projects for which applications have been approved to date; and
</FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">assessment of whether expenditure on projects for which approval has been given by Australian tax authorities relate to Australian or overseas
expenditure. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">For the years
ended June&nbsp;30, 2019 and 2020, the Group has recognized an R&amp;D tax incentive receivable of A$14.6&nbsp;million and A$8.5&nbsp;million respectively within the Consolidated Statement of Financial Position, with a corresponding amount
recognized within income tax benefit within the Consolidated Statement of Profit or Loss and Other Comprehensive Income. The R&amp;D tax incentive receivable as at June 30, 2020 is based on the legislation as currently enacted as at June 30, 2020.
Any proposed changes to the legislation may have a retrospective impact if the legislation is passed in its currently proposed form. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Investment tax credits such as the R&amp;D tax incentive are outside of the scope of IAS 12 &#147;Income Taxes&#148; and IAS 20
&#147;Accounting for Government Grants and Disclosure of Government Assistance.&#148; Based on the guidance in IAS 8 &#147;Accounting Policies, Changes in Accounting Estimates and Errors,&#148; companies need to make an accounting policy choice on
how to present these incentives, which in practice is done by either analogizing with IAS 12 or with IAS 20. In the Group&#146;s opinion, the R&amp;D tax incentive should be presented by analogizing
</FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">F-15
</FONT></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS FOR THE YEARS ENDED JUNE&nbsp;30,
2019 AND 2020 </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px">&nbsp;</P>
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
to IAS 12 because the nature of the incentive is considered to be more closely aligned to income taxes, based on the following considerations: </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">The R&amp;D tax incentive is considered an income tax offset which will be offset against the Group&#146;s tax obligation if and when the Group returns
to a net tax payable position. In addition, whilst the Group is currently eligible to receive cash payments under the scheme since its consolidated revenue is currently below A$20&nbsp;million, if and when the Group generates revenue in excess of
A$20&nbsp;million the R&amp;D tax incentive will become <FONT STYLE="white-space:nowrap">non-refundable</FONT> and can only be offset against any future income tax payable by the Group. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">The ATO, which is the tax authority in Australia, manages the annual claims process as the R&amp;D tax incentive is included in the Group&#146;s annual
income tax return. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">The ATO is also responsible for making the R&amp;D tax incentive cash payment if a company is eligible for a cash refund under the program, oversees
compliance with the requirements of the R&amp;D tax incentive scheme and performs <FONT STYLE="white-space:nowrap">pre-issuance</FONT> reviews. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Income tax </I></B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Group&#146;s accounting policy for taxation requires
judgments as to the differences between tax and accounting treatments of income and costs recognized in the Consolidated Statement of Profit or Loss and Other Comprehensive Income. Judgment is also required in assessing whether deferred tax assets
and liabilities are recognized in the statement of financial position and if accumulated income tax losses can be used to offset potential future tax profits. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>4.2</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE="" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Key sources of estimation uncertainty </B></FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Share-based payment transactions </I></B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Group measures the cost of equity-settled transactions
with employees by reference to the fair value of the equity instruments at the date at which they are granted. Fair values are determined internally using Binomial models. The related assumptions are detailed in note 28. The accounting estimates and
assumptions relating to equity-settled share-based payments have no impact on the carrying amounts of assets and liabilities in future reporting periods but may impact expenses and equity. Should one or more of the assumptions and estimates used in
estimating the fair value of share-based payments change, this could have a material impact on the amounts recognized in equity and employee-related expenses. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>5.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE="" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Application of new and revised Accounting Standards </B></FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT
SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Amendments to Accounting Standards that are mandatorily effective for the current year </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Group has adopted all of the new and revised Standards
and Interpretations issued by the IASB that are relevant to its operations and effective for the current year. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">New and revised Standards and amendments thereof and Interpretations effective for the current year that are relevant to the Group
include: </FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">IFRS 16 &#147;Leases&#148;; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Annual Improvements to IFRS Standards 2015&#150;2017 Cycle Amendments to IFRS 3 &#147;Business Combinations&#148;, IFRS 11 &#147;Joint
Arrangements&#148;, IAS 12 &#147;Income Taxes&#148; and IAS 23 &#147;Borrowing Costs&#148;; and </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">International Financial Reporting Interpretations Committee (&#147;IFRIC&#148;) 23 &#147;Uncertainty over Income Tax Treatments&#148;.
</FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">F-16
</FONT></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS FOR THE YEARS ENDED JUNE&nbsp;30,
2019 AND 2020 </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px">&nbsp;</P>
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>IFRS 16 Leases </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In the current year, the Group has adopted IFRS 16, which is
effective for annual periods that begin on or after January&nbsp;1, 2019. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">IFRS 16 introduces new or amended requirements with respect to lease accounting. It introduces significant changes to lessee accounting by removing the distinction between operating and finance lease and
requiring the recognition of a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">right-of-use</FONT></FONT> asset and a lease liability at commencement for all leases, except for short-term leases and leases of low value assets.
Details of these new requirements are described in note 3. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">The date of initial application of IFRS 16 for the Group is July 1, 2019. The Group has applied IFRS 16 using the cumulative catch-up approach which: </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">requires the Group to recognize the cumulative effect of initially applying IFRS 16 as an adjustment to the opening balance of retained earnings at the
date of initial application; and </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">does not permit restatement of comparatives, which continue to be presented under IAS 17 and IFRIC 4 &#147;Determining whether an Arrangement Contains
a Lease&#148;. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Group has
made use of the practical expedient available on transition to IFRS 16 not to reassess whether a contract is or contains a lease. Accordingly, the definition of a lease in accordance with IAS 17 and IFRIC 4 will continue to be applied to those
leases entered or changed before 1 July 2019. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The
change in definition of a lease mainly relates to the concept of control. IFRS 16 determines whether a contract contains a lease based on whether the customer has the right to control the use of an identified asset for a period of time in exchange
for consideration. This is in contrast to the focus on &#147;risks and rewards&#148; in IAS 17 and IFRIC 4. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>Impact on lease accounting </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B><I>Former operating leases </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">IFRS 16 changes how the Group accounts for leases previously classified as operating leases under IAS 17, which operating lease payments were recognized as an expense in profit or loss on a straight line
basis over the lease term. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Applying IFRS 16, for
all leases (except as noted below), the Group: </FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Recognizes <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">right-of-use</FONT></FONT> assets and lease liabilities in the
consolidated statement of financial position, initially measured at the present value of the future lease payments; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Recognizes depreciation of <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">right-of-use</FONT></FONT> assets and interest on lease
liabilities in profit or loss; and </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Separates the total amount of cash paid into a principal portion (presented within financing activities) and interest (presented within operating
activities) in the consolidated statement of cash flows. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Lease incentives (e.g. rent-free period) are recognized as part of the measurement of the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">right-of-use</FONT></FONT> assets and lease
liabilities whereas under IAS 17 they resulted in the recognition of a lease incentive, amortized as a reduction of rental expenses generally on a straight-line basis. Under IFRS 16,
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">right-of-use</FONT></FONT> assets are tested for impairment in accordance with IAS 36 Impairment of Assets. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">For short-term leases (lease term of 12 months or less) and
leases of <FONT STYLE="white-space:nowrap">low-value</FONT> assets (such as photo copier and telephones), the Group has opted to recognize a lease expense on a straight-line basis as permitted by IFRS&nbsp;16. This expense is presented within
&#145;administrative expenses&#146; in profit or loss. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">F-17
</FONT></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS FOR THE YEARS ENDED JUNE&nbsp;30,
2019 AND 2020 </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px">&nbsp;</P>
 <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Financial impact of the initial application of IFRS 16 </I></B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Group&#146;s previous lease for Opthea&#146;s
headquarters expired on July&nbsp;14, 2019: the adoption of IFRS 16 did not have a material impact on the Group&#146;s results on the date of transition. Following the renewal of the leased office premises on July&nbsp;15, 2019, the Group recognized
a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">right-of-use</FONT></FONT> asset of A$365,264 and a corresponding lease liability of A$365,264 in respect of this lease during the year ended June&nbsp;30, 2020. The impact on
profit or loss in the year ended June&nbsp;30, 2020 was to decrease occupancy expenses by A$110,800; increase depreciation by A$121,754; and increase finance interest expense by A$7,680. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Under IAS 17, all lease payments on operating leases are presented as part of cash flows from operating
activities. During the year ended June&nbsp;30, 2020, the impact of the changes under IFRS 16 reduced the cash used in operating activities by A$100,189 and increased net cash generated from financing activities by the same amount. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Other pronouncements adopted for the first time in the year ended
June&nbsp;30, 2020 </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In the year ended
June&nbsp;30, 2020, the Group applied a number of amendments to International Financial Reporting Standards and Interpretations issued by the IASB that are effective for an annual period that begins on or after January&nbsp;1, 2019. Their adoption
has not had any material impact on the disclosures or on the amounts reported in these financial statements. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>New and revised International Financial Reporting Standards and Interpretations on issue but not yet effective </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">At the date of authorization of the financial statements,
the Group has not applied the following new and revised International Financial Reporting Standards, Interpretations and amendments that have been issued but are not yet effective: </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>

<TD WIDTH="85%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1px solid #000000 ; display:table-cell;"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Standard amendment</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Effective&nbsp;for<BR>annual&nbsp;reporting<BR>periods&nbsp;beginning<BR>on or after</B></FONT></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Amendments to IAS&#151;Sale or Contribution of Assets between an Investor and its Associate or Joint Venture (IFRS 10 and IAS 28)
Amendments to IFRS and IAS&#151;Effective Date of Amendments to IFRS 10 and IAS 28 Amendments to IFRS and IAS&#151;Effective Date of Amendments to IFRS 10 and IAS 28 and Editorial Corrections</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">January&nbsp;1,&nbsp;2022</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">IFRS 17 &#147;Insurance Contracts&#148;</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">January 1, 2023</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Amendments to IFRS 3 &#147;Business Combinations&#151;Definition of a Business&#148;</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">January 1, 2020</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Amendments to IFRS 17, and amendments to the basis for conclusions on IAS 1, IAS 8 and Conceptual Framework&#151;Definition of
Material</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">January 1, 2020</FONT></TD></TR>
</TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The new and revised
International Financial Reporting Standards, Interpretations and amendments listed above are not expected to have a material impact on the amounts recognized or disclosures included in the Group&#146;s financial statements. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">F-18
</FONT></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS FOR THE YEARS ENDED JUNE&nbsp;30,
2019 AND 2020 </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>6.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE="" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Segment information </B></FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Group operates in one industry and one geographical area, those being the biotechnology and healthcare industry and Australia,
respectively. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Group is focused primarily on
developing a novel therapy for the treatment of highly prevalent and progressive retinal diseases. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">The chief executive officer regularly reviews entity wide information that is compliant with IFRS. There is only one segment for segment reporting purposes, and the information reviewed by the chief
executive officer for the purpose of resources allocation and performance assessment is the same as the information presented in the consolidated financial statements. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Group&#146;s only revenue stream in the current financial
year is royalty income generated from licenses granted in respect of the Group&#146;s intellectual property that are unrelated to the Group&#146;s core business and the development of <FONT STYLE="white-space:nowrap">OPT-302</FONT> and that are not
under development. These licenses are primarily used by third-party licensees for research purposes. All of the royalty income of A$159,064 and A$87,075 for the years ended June&nbsp;30, 2019 and 2020, respectively, was generated from customers
based outside Australia. The Group does not have any major customers. All property, plant and equipment is located in Australia. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>7.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE="" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Revenue </B></FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>

<TD WIDTH="85%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2019</B></FONT><br><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>A$</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2020<BR>A$</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Sales based royalties</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">159,064</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">87,075</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Total revenue</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">159,064</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">87,075</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>8.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE="" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Other income </B></FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>

<TD WIDTH="84%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2019</B></FONT><br><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>A$</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2020</B></FONT><br><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>A$</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Finance income</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">755,776</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">721,330</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Grant income</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">77,745</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">62,500</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Other</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3,300</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Total other income</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">836,821</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">783,830</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>9.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE="" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Research and development expenses </B></FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>

<TD WIDTH="78%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2019</B></FONT><br><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>A$</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2020</B></FONT><br><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>A$</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Research project costs(1)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">31,347,891</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">17,954,073</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total research and development expenses</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">31,347,891</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">17,954,073</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="1">(1)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="1">The research project costs relate to the research programs for the treatment of retinal diseases by <FONT STYLE="white-space:nowrap">OPT-302.</FONT>
</FONT></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">F-19
</FONT></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS FOR THE YEARS ENDED JUNE&nbsp;30,
2019 AND 2020 </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>10.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE="" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Expenses </B></FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="80%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>

<TD WIDTH="74%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2019</B></FONT><br><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>A$</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2020</B></FONT><br><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>A$</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">(A) ADMINISTRATIVE EXPENSES</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Employee benefits expenses:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Salaries and fees</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2,020,795</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2,124,792</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Cash bonuses</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">414,423</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">288,811</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Superannuation/pensions</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">217,592</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">210,383</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Share-based payments expense</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">967,511</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,078,481</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total employee benefits expense</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3,620,321</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3,702,467</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Other expenses:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Insurance</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">377,181</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">500,953</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Investor relations costs</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">411,181</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">379,255</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Audit and accounting</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">138,156</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">330,318</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Travel expenses</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">84,103</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">66,420</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Payroll tax</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">87,247</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">201,172</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Legal fees</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">22,464</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">555,622</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Advisory fees</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">620,745</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Other expenses</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">401,009</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">498,680</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total other expenses</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,521,341</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3,153,165</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Depreciation of:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Equipment and furniture</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">19,898</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">21,754</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Leasehold improvements</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">13,195</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">513</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Right-of-use</FONT></FONT> asset</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">121,754</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total depreciation expense</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">33,093</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">144,021</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Loss on disposal of <FONT STYLE="white-space:nowrap">non-current</FONT> assets</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,854</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Total Administrative Expenses</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">5,174,755</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">7,001,507</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">(B) OCCUPANCY EXPENSES</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Operating lease rentals</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">78,883</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Short term and low value lease expenses</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2,239</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Lease incidental costs</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">30,021</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">31,607</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Total Occupancy Expenses</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">108,904</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">33,846</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">F-20
</FONT></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS FOR THE YEARS ENDED JUNE&nbsp;30,
2019 AND 2020 </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>11.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE="" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Income tax </B></FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="90%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>

<TD WIDTH="75%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2019</B></FONT><br><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>A$</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2020</B></FONT><br><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>A$</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(a) Income tax benefit</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">The major components of income tax benefit are:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Statement of Profit or Loss and Other Comprehensive Income</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">CURRENT TAX</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Current income tax incentive</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">14,636,973</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">8,533,123</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">14,636,973</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">8,533,123</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">DEFERRED TAX</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">In respect of the current year</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total income tax benefit recognized in the Statement of Profit or Loss and Other Comprehensive Income</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">14,636,973</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">8,533,123</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>June&nbsp;30,<BR>2019</B></FONT><br><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>A$</B></FONT></TD>

<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>June&nbsp;30,<BR>2020</B></FONT><br><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>A$</B></FONT></TD>

<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(b) Current tax receivable</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Research and Development Tax Incentive receivable</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">14,636,973</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">8,533,123</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(c) Numerical
reconciliation between aggregate income tax benefit recognized in the statement of Profit or Loss and Other Comprehensive Income and benefit calculated per the statutory income tax rate </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT
SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">A reconciliation between income tax benefit and the product of accounting loss before income tax multiplied by
the Group&#146;s applicable income tax rate is as follows: </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="90%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>

<TD WIDTH="72%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2019</B></FONT><br><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>A$</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2020</B></FONT><br><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>A$</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Accounting loss before tax</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(35,547,034</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(25,062,404</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">At the Company&#146;s statutory income tax rate of 27.5%</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">9,775,434</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">6,892,161</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">R&amp;D tax incentive on eligible expenses</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">14,636,973</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">8,533,123</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="white-space:nowrap">Non-deductible</FONT> R&amp;D expenditure</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(9,261,833</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(5,394,503</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Other <FONT STYLE="white-space:nowrap">non-deductible</FONT> expenses&#151;share-based payment expense</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(266,066</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(296,582</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Amount of temporary differences and carried forward tax losses not recognized</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(247,535</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(1,201,076</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Income tax benefit reported in the Statement of Profit or Loss and Other Comprehensive income</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">14,636,973</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">8,533,123</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">F-21
</FONT></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS FOR THE YEARS ENDED JUNE&nbsp;30,
2019 AND 2020 </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="90%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>

<TD WIDTH="76%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2019</B></FONT><br><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>A$</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2020</B></FONT><br><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>A$</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(d) Recognized deferred tax assets and liabilities in statement of financial position</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Deferred income tax relates to the following:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">DEFERRED TAX LIABILITIES:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Interest and royalty income receivable (future assessable income)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(56,114</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(103,135</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(56,114</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(103,135</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">DEFERRED TAX ASSETS RELATED TO TEMPORARY DIFFERENCES:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Accrued expenses and other liabilities</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">151,821</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">441,162</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Employee provisions</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">154,933</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">187,311</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Other miscellaneous items</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">276,942</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">546,964</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">583,696</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,175,437</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Less: temporary differences not recognized</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(527,582</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(1,072,302</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Net deferred tax recognized in the statement of financial position</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(e) Unrecognized temporary
differences </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Temporary differences with
respect to deferred tax assets associated with intellectual property and other miscellaneous items which have a low probability of realization are unrecognized. These amounted to A$1,072,302 as of June&nbsp;30, 2020 (2019: A$527,582). </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(f) Carry forward unrecognized tax losses </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Group had income tax losses of A$17,287,687 as at
June&nbsp;30, 2020 (2019: A$15,819,190) and capital losses of A$877,704 at June&nbsp;30, 2020 (2019: A$877,704) for which no deferred tax asset is recognized on the statement of financial position as they are currently not considered probable of
realization. These tax losses are available indefinitely for offset against future assessable income subject to continuing to meet relevant statutory tests. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(g) Franking credit balance </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Franking credits are a type of tax credit in Australia that is available to the Group&#146;s shareholders to reduce double taxation on any
dividends paid by the Group. The franking credit balance at the end of the financial year at 30% is A$330,630 (2019: A$330,630), which represents the amount of franking credits available for the subsequent financial year. Franking credits are not
recognized in the Consolidated Statement of Financial Position. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">F-22
</FONT></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS FOR THE YEARS ENDED JUNE&nbsp;30,
2019 AND 2020 </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>12.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE="" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Earnings per share </B></FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>

<TD WIDTH="76%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2019</B></FONT><br><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>A$</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2020</B></FONT><br><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>A$</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">The following reflects the income used in the basic and diluted earnings per share computations:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">(A) EARNINGS USED IN CALCULATING EARNINGS PER SHARE</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Net loss attributable to Owners of the Company</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(20,910,061</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(16,529,281</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">(B) WEIGHTED AVERAGE NUMBER OF SHARES</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Weighted average number of ordinary shares on issue for basic earnings per share</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">232,795,371</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">260,795,745</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Dilutive share options</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Weighted average number of ordinary shares adjusted for the effect of dilution</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">232,795,371</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">260,795,745</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Loss per share (basic and diluted, in cents)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">8.98</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">6.34</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Diluted earnings per share is
calculated as net loss divided by the weighted average number of ordinary shares and dilutive potential ordinary shares. Options granted under the Long Term Incentive (&#147;LTIP&#148;) and <FONT STYLE="white-space:nowrap">Non-Executive</FONT>
Director Share and Option (&#147;NED Plan&#148;) plans would generally be included in the calculation due to the conditions of the issuance being satisfied. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">As the Group is in a loss position, the options are anti-dilutive and, accordingly, the basic loss per share is the same as the diluted
loss per share. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">A total number of 18,044,000
options outstanding as of June&nbsp;30, 2020 (2019: 18,919,000) were anti-dilutive and were therefore excluded from the weighted average number of ordinary shares for the purpose of diluted earnings per share. These options related to the following
option plans: </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="80%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>

<TD WIDTH="70%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>June&nbsp;30,<BR>2019</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>June&nbsp;30,<BR>2020</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">NED Plan</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">6,000,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">6,000,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">LTIP</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">12,919,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">12,044,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">18,919,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">18,044,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">All 18,044,000 outstanding
options as of June&nbsp;30, 2020 were exercisable as of that date (2019: 9,905,000). </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>13.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE="" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Current assets&#151;cash and cash equivalents </B></FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="80%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>

<TD WIDTH="70%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>June&nbsp;30,<BR>2019</B></FONT><br><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>A$</B></FONT></TD>

<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>June&nbsp;30,<BR>2020</B></FONT><br><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>A$</B></FONT></TD>

<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Cash at bank and in hand</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,034,919</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3,020,382</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Short-term deposits</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">20,500,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">59,000,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total cash and cash equivalents</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">21,534,919</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">62,020,382</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Cash at bank earns interest
at floating rates based on daily bank deposit rates. The carrying amounts of cash and cash equivalents represent fair value. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">F-23
</FONT></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS FOR THE YEARS ENDED JUNE&nbsp;30,
2019 AND 2020 </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px">&nbsp;</P>
 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Short term-deposits are with two major Australian banks and are made for varying periods
of between 30 and 90 days, depending on the immediate cash requirements of the Group, and earn interest at a fixed rate for the respective short-term deposit periods. At year end, the average rate was 1.01% (2019: 2.36%). </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>14.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE="" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Current assets&#151;other receivables </B></FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="80%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>

<TD WIDTH="78%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>June&nbsp;30,<BR>2019</B></FONT><br><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>A$</B></FONT></TD>

<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>June&nbsp;30,<BR>2020</B></FONT><br><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>A$</B></FONT></TD>

<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Interest receivable</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">102,162</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">81,478</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">GST receivable(1)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">91,736</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">152,866</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Royalties receivable(1)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">101,888</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">50,047</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total current receivables</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">295,786</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">284,391</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(1)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">The GST and Royalties receivables are <FONT STYLE="white-space:nowrap">non-interest</FONT> bearing. There were no receivables with a material expected credit loss
recorded during the financial year (2019: nil). </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>15.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE="" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><FONT STYLE="white-space:nowrap">Non-current</FONT> assets&#151;Investments in financial assets </B></FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="80%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>

<TD WIDTH="78%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>June 30,<BR>2019</B></FONT><br><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>A$</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>June&nbsp;30,<BR>2020</B></FONT><br><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>A$</B></FONT></TD>

<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Listed Australian shares&#151;at fair value(1)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">714,118</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">289,980</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
</TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>

<TD WIDTH="57%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Ownership<BR>Interest</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Fair&nbsp;value<BR>at&nbsp;June&nbsp;30&nbsp;(2)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Disposal<BR>in the<BR>financial<BR>year (3)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Fair value<BR>gain/(loss)<BR>recognized<BR>in OCI (4)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Opening<BR>fair<BR>value</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1px solid #000000 ; display:table-cell;"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Listed investments</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>%</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>A$</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>A$</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>A$</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>A$</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>June&nbsp;30, 2019</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="white-space:nowrap">Non-current</FONT> investments:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Antisense Therapeutics Ltd</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.24</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">233,579</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(339,047</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">317,860</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">254,766</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Optiscan Imaging Limited</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.76</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">480,539</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(57,996</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">538,535</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total listed investments</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">714,118</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(339,047</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">259,864</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">793,301</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>June&nbsp;30, 2020</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="white-space:nowrap">Non-current</FONT> investments:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Antisense Therapeutics Ltd</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(482,978</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">249,399</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">233,579</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Optiscan Imaging Limited</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.73</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">289,980</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(190,559</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">480,539</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total listed investments</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">289,980</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(482,978</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">58,840</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">714,118</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
</TABLE> <P STYLE="line-height:8px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(1)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">These financial assets are investments in equity instruments and are not held for trading; they are held for medium to long-term strategic purposes. Accordingly, the
Group has elected to designate these investments in equity instruments as at FVTOCI as recognizing short-term fluctuations in these investments&#146; fair value in profit or loss would not be consistent with the Group&#146;s strategy of holding
these investments for long-term purposes and realizing their performance potential in the long run. </FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(2)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">The fair value represents the share (bid) price at year end and does not include any capital gains tax or selling costs that may be applicable on the disposal of these
investments. These <FONT STYLE="white-space:nowrap">non-current</FONT> investments in listed shares consist of investments in ordinary shares, and therefore have no fixed maturity date or coupon rate. </FONT></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">F-24
</FONT></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS FOR THE YEARS ENDED JUNE&nbsp;30,
2019 AND 2020 </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(3)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">During the year ended June 30, 2019, 49% of the Group&#146;s investment in Antisense Therapeutics Ltd. was sold for net proceeds of A$339,047. As a result, A$214,046 of
the previously unrealized net fair value gains recorded in the fair value of investments reserve was realized at this date. Subsequently, during the year ended June 30, 2020, the Group disposed of its remaining 51% investment for net proceeds of
A$482,978. As a result, A$249,399 of the previously unrealized net fair value gains recorded in the fair value of investments reserve was realized at this date. In accordance with the Group&#146;s accounting policy, the realized gain remains within
the fair value of investments reserve. The Group disposed of the investment in line with its Treasury and Investments Policy. </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(4)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">A fair value increase of A$58,840 (2019: A$259,864) in the carrying value of investments has been made through other comprehensive income in the year due to a net
increase in their market value in the year. </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>16.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE="" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Leases </B></FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Right-of-use</FONT></FONT> asset </I></B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Group has a three-year lease contract for its head
office premises in Melbourne, Australia which commenced on July 15, 2019. The agreement does not contain any extension options. The carrying amount of the lease at June 30, 2020 is as follows: </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
SIZE="1">&nbsp;</FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="80%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>

<TD WIDTH="87%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2020</B></FONT><br><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>A$</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Right-of-Use</FONT></FONT> Asset cost</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Opening balance as at July&nbsp;1</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Additions</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">365,264</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">365,264</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Right-of-Use</FONT></FONT> Asset Depreciation</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Opening balance as at July&nbsp;1</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Depreciation of <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">right-of-use</FONT></FONT>
asset</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(121,754</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(121,754</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Net carrying amount as at June&nbsp;30</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">243,510</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">F-25
</FONT></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS FOR THE YEARS ENDED JUNE&nbsp;30,
2019 AND 2020 </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px">&nbsp;</P>
 <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Lease liabilities </I></B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Lease liabilities are as indicated below: </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">At the commencement date of the lease of its office
premises, the Group recognizes lease liabilities measured at the present value of lease payments to be made over the lease term ending on July&nbsp;14, 2022, using an incremental borrowing rate of 3%. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="80%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>

<TD WIDTH="87%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2020</B></FONT><br><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>A$</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Carrying amount at July&nbsp;1</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">New lease</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">365,264</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Payments</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(100,189</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Carrying amount at June&nbsp;30</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">265,076</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Maturity analysis:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Year 1</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">152,723</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Year 2</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">127,713</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">280,436</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Less: unearned interest</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(15,360</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">265,076</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Analyzed into:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Current portion</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">145,043</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="white-space:nowrap">Non-current</FONT> portion</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">120,033</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">265,076</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">The amounts recognized in profit or loss in relation to leases is as follows:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Depreciation expense on <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">right-of-use</FONT></FONT>
asset</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">121,754</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Interest on lease liabilities</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">7,680</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Expense relating to leases of low value assets</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">9,669</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">139,103</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Group did not have any
short-term leases during the year ended June 30, 2020. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>17.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE="" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Current liabilities&#151;payables and accrued expenses </B></FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
SIZE="1">&nbsp;</FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>

<TD WIDTH="70%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>June&nbsp;30,<BR>2019</B></FONT><br><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>A$</B></FONT></TD>

<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>June&nbsp;30,<BR>2020</B></FONT><br><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>A$</B></FONT></TD>

<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Accounts payable (unsecured)(1)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">5,895,925</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">5,838,115</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Payroll related tax liability</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">56,017</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">56,919</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total current payables</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">5,951,942</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">5,895,034</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(1)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Accounts payable are <FONT STYLE="white-space:nowrap">non-interest</FONT> bearing and are normally settled on <FONT STYLE="white-space:nowrap">30-day</FONT> terms.
</FONT></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">F-26
</FONT></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS FOR THE YEARS ENDED JUNE&nbsp;30,
2019 AND 2020 </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>18.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE="" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Current liabilities&#151;provisions </B></FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>

<TD WIDTH="74%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>June&nbsp;30,<BR>2019</B></FONT><br><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>A$</B></FONT></TD>

<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>June&nbsp;30,<BR>2020</B></FONT><br><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>A$</B></FONT></TD>

<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Annual leave</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">320,132</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">403,479</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Long service leave</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">218,415</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">237,455</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total current provisions</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">538,547</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">640,934</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>19.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE="" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><FONT STYLE="white-space:nowrap">Non-current</FONT> liabilities&#151;provisions </B></FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>

<TD WIDTH="76%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>June&nbsp;30,<BR>2019</B></FONT><br><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>A$</B></FONT></TD>

<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>June&nbsp;30,<BR>2020</B></FONT><br><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>A$</B></FONT></TD>

<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Long service leave</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">24,844</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">40,197</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>20.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE="" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Contributed equity </B></FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>

<TD WIDTH="64%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>June&nbsp;30,</B></FONT><br><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2019</B></FONT><br><FONT
STYLE="font-family:Times New Roman" SIZE="1"><B>A$</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>June&nbsp;30,</B></FONT><br><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2020</B></FONT><br><FONT
STYLE="font-family:Times New Roman" SIZE="1"><B>A$</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(a) Ordinary shares</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Issued and fully paid as of June&nbsp;30, 2019 and 2020</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">113,021,993</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">162,102,553</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Movement in ordinary shares:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Opening balance</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">98,403,149</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">113,021,993</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Issue of shares on exercise of options</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">12,629,777</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">420,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Issue of shares</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">48,660,560</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Transfer from option reserve</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,989,067</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total issued and fully paid ordinary shares</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">113,021,993</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">162,102,553</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1px solid #000000 ; display:table-cell;"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Ordinary shares on issue:</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>No. of</B></FONT><br><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Shares</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>No. of</B></FONT><br><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Shares</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>2019</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>2020</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Opening balance</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">202,637,888</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">249,414,839</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Issue of shares</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">46,776,951</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">19,742,930</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">249,414,839</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">269,157,769</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Fully paid ordinary shares
carry one vote per share and carry the right to dividends. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Issued capital at June&nbsp;30, 2020 amounted to A$162,102,553 (269,157,769 fully paid ordinary shares) net of share issue costs and tax. During the year ended June 30, 2020, the Company issued 18,867,930
ordinary shares in a private placement to institutional investors and 875,000 on the exercise of options for A$49,080,560. At June&nbsp;30, 2020, the Company had no options outstanding, other than options granted to directors and employees and
described in note 28, as all options had been exercised or expired by November&nbsp;25, 2018. The fair value of the options at their issue date of A$1,989,067, originally recognized in the options reserve (note 21) was transferred to contributed
equity during the year ended June&nbsp;30, 2019. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">F-27
</FONT></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS FOR THE YEARS ENDED JUNE&nbsp;30,
2019 AND 2020 </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px">&nbsp;</P>
 <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>(b) Options granted to directors and employees </I></B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Company has two share based-payment schemes, the Long
Term Incentive Plan and <FONT STYLE="white-space:nowrap">Non-Executive</FONT> Director Share and Option Plan. Options to subscribe for the Company&#146;s shares have been granted under these plans to certain employees and directors. The Company
granted 8,844,000 options over ordinary shares under these plans during the year ended June&nbsp;30, 2019 (note 28). These options had a weighted average fair value at their grant date of A$0.22 per option. During the year ended June&nbsp;30, 2020,
875,000 options granted under the LTIP were exercised for A$420,000. No options were granted during the year ended June&nbsp;30, 2020.<B><I> </I></B> </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>(c) Capital management </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Group is not subject to any externally imposed capital requirements. When managing share capital, management&#146;s objective is to
ensure the entity continues as a going concern as well as to provide benefits to shareholders and for other stakeholders. In order to maintain or achieve an appropriate capital structure, the Company may issue new shares or reduce its share capital,
subject to the provisions of the Company&#146;s constitution. The Group only commits to significant R&amp;D expenditure when this is fully funded either by existing funds or further equity raises. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>21.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE="" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Accumulated Losses and Reserves </B></FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>

<TD WIDTH="64%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>June&nbsp;30, 2019</B></FONT><br><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>A$</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>June&nbsp;30, 2020</B></FONT><br><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>A$</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(a) Movements in accumulated losses were as follows:</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Balance at July&nbsp;1</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(65,149,999</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(86,060,060</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Net loss for the period</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(20,910,061</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(16,529,281</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Balance at June&nbsp;30</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(86,060,060</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(102,589,341</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(b) Reserves</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Fair value of investments reserve (i)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">737,255</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">796,095</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Share-based payments reserve (ii)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3,420,349</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">4,498,830</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Option reserve (iii)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total reserves</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">4,157,604</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">5,294,925</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">(i) Movement in fair value of investments reserve:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Opening balance</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">477,391</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">737,255</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Fair value gains on investments in financial assets</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">259,864</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">58,840</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Closing balance</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">737,255</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">796,095</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">(ii) Movement in share-based payments reserve:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Opening balance</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2,452,838</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3,420,349</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Share based payments expense</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">967,511</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,078,481</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Closing balance</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3,420,349</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">4,498,830</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">(iii) Movement in option reserve:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Opening balance</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,989,067</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Transferred to contributed equity</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(1,989,067</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Closing balance</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">F-28
</FONT></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS FOR THE YEARS ENDED JUNE&nbsp;30,
2019 AND 2020 </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px">&nbsp;</P>
 <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>(c) Nature and purpose of reserves </I></B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Fair value of investments reserve </I></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">This reserve records fair value changes on listed
investments. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Share-based payment reserve
</I></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">This reserve is used to record the value of
equity benefits provided to executives and employees as part of their remuneration. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><I>Option reserve </I></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">On November&nbsp;25, 2014, the Company issued options to purchase 49,726,672 ordinary shares with an exercise price of A$0.27 expiring on November&nbsp;25, 2018. The fair value of the options at their
issue date of A$1,989,067 was recognized in the option reserve. The same amount, A$1,989,067, was transferred to contributed equity on November&nbsp;25, 2018 following the exercise and expiry of all quoted options. The balance on the option reserve
at June&nbsp;30, 2020 was nil (2019: nil). </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>22.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE="" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Financial risk management objectives and policies </B></FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT
SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Group&#146;s principal financial assets comprise cash, receivables, short-term deposits and investments in
listed shares. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Group manages its exposure to
key financial risks, including interest rate and currency risk in accordance with the Group&#146;s financial risk management practices. The objective is to support the delivery of the Group&#146;s financial targets while protecting future financial
security. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Group&#146;s other various
financial assets and liabilities, such as receivables and payables, arise directly from its operations. The main risks arising from the Group&#146;s financial assets and liabilities are interest rate risk, foreign currency risk, equity securities
price risk and liquidity risk. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Group uses
different methods to measure and manage different types of risks to which it is exposed. These include monitoring levels of exposure to interest rate and foreign exchange risk and assessments of market forecasts for interest rates and foreign
exchange rates. Liquidity risk is monitored through future rolling cash flow forecasts. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">The board reviews and agrees policies for managing each of these risks as summarized below. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Risk exposures and responses </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Group has investigated the main financial risk areas which could impact its financial assets and determined the impact on post tax
(losses) or profits for a range of sensitivities. These can be seen in the <FONT STYLE="white-space:nowrap">post-tax</FONT> (loss)/profit impact for each risk area. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">For each risk area, the equity impact relates solely to
reserve movements and excludes movements in accumulated losses as the impact of these can be seen within the <FONT STYLE="white-space:nowrap">post-tax</FONT> (loss)/profit impact. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>(i) Interest rate risk </I></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Group&#146;s exposure to market interest rates relates
primarily to the short-term deposits. The deposits are held with two of Australia&#146;s largest banks. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">F-29
</FONT></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS FOR THE YEARS ENDED JUNE&nbsp;30,
2019 AND 2020 </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px">&nbsp;</P>
 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The objective of managing interest rate risk is to minimize the Group&#146;s exposure to
fluctuations in interest rates that might impact its interest income and cash flow. To manage interest rate risk, the Group invests the majority of its cash in short-term deposits for varying periods of between 30 days and 90 days, depending on the
short and long-term cash requirements of the Group which is determined based on the Group&#146;s cash flow forecast. This consideration also takes into account the costs associated with recalling a term deposit should early access to cash and cash
equivalents be required. Cash is not locked into long-term deposits at fixed rates so as to mitigate the risk of earning interest below the current floating rate. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Group does not have any borrowings at June 30, 2019 or
June&nbsp;30, 2020. The following sensitivity analysis (an annual effect) is based on the interest rate risk exposures at June&nbsp;30, 2019 and 2020. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">At June&nbsp;30, 2020, if interest rates moved, with all variables held constant, post tax (loss)/profit and equity would have been
affected as illustrated in the following table: </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="90%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>

<TD WIDTH="63%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Post tax</B></FONT><br><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(loss)/profit</B></FONT><br><FONT
STYLE="font-family:Times New Roman" SIZE="1"><B>impact</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Cost of</B></FONT><br><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>investment</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2019 A$</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2020 A$</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2019&nbsp;A$</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2020&nbsp;A$</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Judgments of reasonably possible movements</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">+ 0.50% (50 basis points)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">71,903</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">206,700</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#150; 0.50% (50 basis points)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(71,903</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(206,700</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
</TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The <FONT
STYLE="white-space:nowrap">post-tax</FONT> figures include an offset for unrecognized tax losses (bringing the tax effect to nil) for the years ended June 30, 2019 and 2020. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Significant assumptions used in the interest rate sensitivity
analysis include: </FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">The reasonably possible movement of 0.5% was calculated by taking the interest rates as at balance date, moving these by plus and minus 0.5% and then <FONT
STYLE="white-space:nowrap">re-calculating</FONT> the interest on term deposits with the <FONT STYLE="white-space:nowrap">&#145;new-interest-rate&#146;.</FONT> </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">The net exposure at balance date is representative of what the Group was and is expecting to be exposed to in the next twelve months from balance date.
</FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>(ii) Price risk
</I></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Group&#146;s investment in listed shares
is exposed to equity securities price risk and as such their fair values are exposed to fluctuations as a result of changes in market prices. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Equity price risk is the risk that the fair value of equities will decrease as a result of share price movements. The Group&#146;s equity
investments are publicly traded on the Australian Securities Exchange (ASX) and are designated and accounted for as investments in financial assets. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The investments in listed shares are not held for short-term trading. Their values are reviewed regularly by management and the board. The
strategy for realizing any part of these investments is determined based on the liquidity of the respective stocks, potential <FONT STYLE="white-space:nowrap">off-market</FONT> acquirers and likely developments in their values based on publicly
available information. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">F-30
</FONT></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS FOR THE YEARS ENDED JUNE&nbsp;30,
2019 AND 2020 </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px">&nbsp;</P>
 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">At June 30, 2019 and 2020, had the share price moved with all other variables held
constant, post tax (loss)/profit and equity would have been affected as illustrated in the table below: </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>

<TD WIDTH="52%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Impact&nbsp;of&nbsp;loss<BR>after tax</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Impact&nbsp;on&nbsp;equity<BR>after tax</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Impact&nbsp;of&nbsp;loss<BR>after tax</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Impact&nbsp;on&nbsp;equity<BR>after tax</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2019 A$</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2019 A$</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2020 A$</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2020 A$</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Judgments of reasonably possible movements</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Change in variables 10% increase in listed share price</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">49,988</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">49,988</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">20,299</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">20,299</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">10% decrease in listed share price</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(49,988</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(49,988</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(20,299</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(20,299</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
</TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>(iii) Foreign currency
risk </I></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">As a result of services provided by <FONT
STYLE="white-space:nowrap">non-related</FONT> entities in the United States, Canada, United Kingdom and Europe, part of the Group&#146;s financial assets and liabilities are affected by movements in the exchange rate. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Group does not enter into any hedging transactions.
</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">At the reporting date, the Group has the
following exposure to foreign currencies: </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="90%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>

<TD WIDTH="59%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>As of June&nbsp;30, 2019</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1px solid #000000 ; display:table-cell;"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2019</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>USD</B></FONT><br><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>A$</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>EUR A$</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>GBP</B></FONT><br><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>A$</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>CAD<BR>A$</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Financial assets</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Cash</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">551,719</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Receivables</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">101,888</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Financial liabilities</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Payables</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(5,135,089</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(51,269</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(4,351</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Net exposure</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(4,481,482</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(51,269</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(4,351</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="16"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>As of June&nbsp;30, 2020</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1px solid #000000 ; display:table-cell;"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2020</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>USD</B></FONT><br><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>A$</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>EUR A$</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>GBP</B></FONT><br><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>A$</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>CAD<BR>A$</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Financial assets</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Cash</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">61,680</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Receivables</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">37,547</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Financial liabilities</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Payables</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(4,878,718</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(14,887</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(34,144</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Other financial liabilities</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(237,820</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Net exposure</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(5,017,313</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(14,887</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(34,144</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">F-31
</FONT></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS FOR THE YEARS ENDED JUNE&nbsp;30,
2019 AND 2020 </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px">&nbsp;</P>
 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The following sensitivity is based on the foreign currency risk exposures in existence
at June 30, 2019 and 2020. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">As of June 30, 2019
and 2020, had the Australian dollar moved with all other variables held constant, post tax (loss) profit and equity would have been affected as illustrated in the table below: </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="90%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>

<TD WIDTH="62%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Post tax</B></FONT><br><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(loss)/profit</B></FONT><br><FONT
STYLE="font-family:Times New Roman" SIZE="1"><B>impact</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Cost of</B></FONT><br><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>investment</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>June&nbsp;30,<BR>2019 A$</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>June&nbsp;30,<BR>2020 A$</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>June&nbsp;30,<BR>2019 A$</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>June&nbsp;30,<BR>2020 A$</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Judgments of reasonably possible movements</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">AUD/USD +10%</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">285,185</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">319,284</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">AUD/USD &#150;10%</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(348,560</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(390,235</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
</TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">There was minimal or
insignificant exposure to the GBP, EUR and CAD during the years ended June&nbsp;30, 2019 and 2020. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Significant assumptions used in the foreign currency exposure sensitivity analysis include: </FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The reasonably possible movement of 10% was calculated by taking the currency spot rates as at balance date, moving these up and down by
10% and then <FONT STYLE="white-space:nowrap">re-converting</FONT> the currencies into AUD with the new spot rate. This methodology reflects the translation methodology undertaken by the Group. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The net exposure at balance date is representative of what
the Group was and is expecting to be exposed to in the next 12 months from the balance date. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Management believes the balance date risk exposures are representative of the risk exposure inherent in the financial instruments. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>(iv) Credit risk </I></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Credit risk is associated with those financial assets of the
Group which comprise cash and cash equivalents, receivables and listed investments. The Group&#146;s exposure to credit risk arises from default of the counterparty, with a maximum exposure equal to the carrying amount of these investments. Credit
risk is considered minimal as the Group transacts with reputable recognized Australian banks. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><I>(v) Liquidity risk </I></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Liquidity risk arises from the financial liabilities of the Group and the Group&#146;s subsequent ability to meet their obligations to repay their financial liabilities as and when they fall due. The
Group has minimal liquidity risk because of the high balances of cash and cash equivalents; however, the Group manages liquidity risk by maintaining reserves and by monitoring forecast and actual cash flows and by matching the maturity profiles of
financial assets and liabilities. The financial liabilities of the Group relate to trade payables that are all expected to be paid within 12 months. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Group&#146;s objective is to maintain an appropriate cash asset balance to fund its operations. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>(vi) Fair value </I></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Group has investments in listed equities which are
calculated using the quoted prices in an active market and are considered level 1 fair value measurements. The Group does not have any derivative investments where the fair value is estimated using inputs other than quoted prices that are observable
for the asset or </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">F-32
</FONT></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS FOR THE YEARS ENDED JUNE&nbsp;30,
2019 AND 2020 </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px">&nbsp;</P>
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
liability, either directly (as prices) or indirectly (i.e. derived from prices). The Group also does not hold any financial instruments where fair value measurement uses observable inputs that
require significant adjustments based on observable inputs to estimate its value. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Details of the fair value of the investment in financial assets are disclosed in note 15 of the financial statements. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The fair value of financial assets and financial liabilities
in the consolidated statement of financial position at June&nbsp;30, 2019 and 2020 is the same as their carrying amounts. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The methods for estimating fair value are also outlined in the relevant notes to the financial statements. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>23.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE="" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Subsidiary </B></FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The consolidated financial statements include the financial statements of Opthea Limited and the subsidiary in the following table:
</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>

<TD WIDTH="81%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Company
%<BR>equity</B></FONT><br><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>interest</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Name of company</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2019</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2020</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Vegenics Pty Ltd (1)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">100</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">100</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
</TABLE> <P STYLE="line-height:8px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(1)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Opthea Limited is the ultimate parent entity. Vegenics Pty Ltd. is incorporated in Australia and has the same financial year as Opthea Limited.
</FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Balances and transactions between
the Company and its subsidiary, which is a related party of the Company, have been eliminated on consolidation and are not disclosed in this note. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">F-33
</FONT></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS FOR THE YEARS ENDED JUNE&nbsp;30,
2019 AND 2020 </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>24.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE="" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Cash flow statement reconciliation </B></FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>(a) Reconciliation to cash at the end of the year
</I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>

<TD WIDTH="76%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>June&nbsp;30, 2019</B></FONT><br><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>A$</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>June&nbsp;30, 2020</B></FONT><br><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>A$</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Cash at bank and in hand (note 13)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">21,534,919</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">62,020,382</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">21,534,919</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">62,020,382</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(b) Reconciliation of net loss after tax to net cash flows from operations</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Net loss for the year</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(20,910,061</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(16,529,281</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Adjustments for:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Income tax benefit recognized in profit or loss</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(14,636,973</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(8,533,123</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Depreciation of <FONT STYLE="white-space:nowrap">non-current</FONT> assets</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">33,093</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">22,267</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Net loss on disposal of <FONT STYLE="white-space:nowrap">non-current</FONT> assets</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,854</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Depreciation of <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">right-of-use</FONT></FONT>
assets</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">121,754</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Share-based payments</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">967,511</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,078,481</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Net exchange differences</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(259,092</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">400,608</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(13,895,461</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(6,908,159</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Changes in working capital:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Payables</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(1,427,978</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(56,907</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Receivables</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">97,946</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">11,395</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Prepayments</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(132,346</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(54,029</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Provisions</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">65,497</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">117,740</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Net cash used in operating activities</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(36,202,403</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(23,419,241</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">R&amp;D tax incentive received</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">12,017,247</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">14,636,973</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Net cash generated by operating activities</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(24,185,156</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(8,782,268</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(c) Reconciliation of borrowings arising from financing activities</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Balance at July&nbsp;1</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="white-space:nowrap">Non-cash</FONT> additions(1)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">365,265</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:1px; margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Payment of lease liabilities</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(100,189</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Balance at June&nbsp;30</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">265,076</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(1)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Non-cash addition represents the new lease on the Company&#146;s office premises in Melbourne, Australia that commenced on July 15, 2019. </FONT></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>25.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE="" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Commitments </B></FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Lease commitments&#151;Group as lessee </I></B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Lease commitments are in respect of low value leases which
have not been recognized in the Statement of Financial Position. These leases are expensed on a straight-line basis over the term of the lease. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>

<TD WIDTH="65%"></TD>

<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>June&nbsp;30,&nbsp;
2019</B></FONT><br><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>A$</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>June&nbsp;30,&nbsp;
2020</B></FONT><br><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>A$</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Within one year</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">7,029</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">6,540</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">After one year but not more than five years</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">16,895</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">7,029</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">23,435</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">F-34
</FONT></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS FOR THE YEARS ENDED JUNE&nbsp;30,
2019 AND 2020 </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px">&nbsp;</P>
 <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Research projects and license commitments </I></B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Group has entered into R&amp;D contracts and
intellectual property license agreements with various third parties in respect of services for the Phase 2a DME clinical trial and the clinical grade manufacture of <FONT STYLE="white-space:nowrap">OPT-302.</FONT> Expenditure commitments relating to
these and intellectual property license agreements are payable as follows: </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>

<TD WIDTH="77%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>June&nbsp;30,&nbsp;
2019</B></FONT><br><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>A$</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>June&nbsp;30,&nbsp;
2020</B></FONT><br><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>A$</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Within one year</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">7,776,947</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">11,139,196</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">After one year but not more than five years</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">85,446</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">427,248</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">After more than five years</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">128,169</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">109,061</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">7,990,562</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">11,675,505</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>26.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE="" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Contingencies </B></FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Group is party to research license/collaboration agreements with three third parties with respect to which a commitment to pay is
contingent on the achievement of research milestones. Assuming all milestones are achieved within the timeframes stipulated in the contracts, those which could become payable in less than one year total A$382,790 (2019: nil) and those which could
become payable in more than one year total A$16,749,885 (2019: A$16,728,122). </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Under these license/collaboration agreements, payments are to be made only if certain research and clinical development milestones are achieved and royalties may become payable on any eventual sales of
products developed under these agreements. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The
Group had a bank guarantee outstanding at June&nbsp;30, 2020 in respect of a rental deposit for its office premises of A$57,281 (2019: A$43,841). </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>27.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE="" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Key management personnel </B></FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>(a) Compensation of Key Management Personnel </I></B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>

<TD WIDTH="66%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>June&nbsp;30,&nbsp;
2019</B></FONT><br><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>A$</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>June&nbsp;30,&nbsp;
2020</B></FONT><br><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>A$</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Short-term employee benefits</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,002,359</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,011,460</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Post-employment benefits</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">95,225</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">96,089</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Share-based payments expense</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">752,306</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">619,325</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total compensation</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,849,890</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,726,874</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>(b) Other transactions
and balances with director and key management personnel and their related parties </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">There were no other director and key management personnel related party transactions during the years ended June&nbsp;30, 2019 and 2020. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">F-35
</FONT></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS FOR THE YEARS ENDED JUNE&nbsp;30,
2019 AND 2020 </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>28.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE="" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Share-based payments </B></FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Recognized share-based payment expenses </I></B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The expense recognized for share-based payments during the
year is shown in the table below: </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="80%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>

<TD WIDTH="70%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>June&nbsp;30,&nbsp;2019<BR>A$</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>June&nbsp;30,&nbsp;2020<BR>A$</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Expense arising from equity-settled share-based payment transactions:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Director and employee services received</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">967,511</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,078,481</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I><FONT
STYLE="white-space:nowrap">Non-executive</FONT> director and employee share option plans </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">During the 2015 financial year, the Group introduced an ownership-based compensation scheme for <FONT STYLE="white-space:nowrap">non-executive</FONT> directors, executives and senior employees, the Long
Term Incentive Plan (LTIP) and <FONT STYLE="white-space:nowrap">Non-Executive</FONT> Directors Share and Option Plan (NED Plan). In accordance with the terms of the plans, as approved by shareholders at the 2014 annual general meeting, eligible <FONT
STYLE="white-space:nowrap">non-executive</FONT> directors, executives and senior employees with the Group may be granted options to purchase ordinary shares. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Each director and employee option converts into one ordinary share of Opthea on exercise. No amounts are paid or payable by the recipient
on receipt of the option. The options carry neither rights to dividends nor voting rights and are not transferable. Options may be exercised at any time from the date of vesting to the date of their expiration. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The number of options granted is subject to approval by the
board and rewards executives and senior employees to the extent of the Group&#146;s and the individual&#146;s achievement judged against both qualitative and quantitative criteria as determined by the board on a case by case basis. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The vesting condition of options granted under the LTIP and
NED Plan is continuous service. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>

<TD WIDTH="35%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1px solid #000000 ; display:table-cell;"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Options/Rights series</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Grant date</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Grant&nbsp;date<BR>fair value<BR>A$</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Exercise<BR>price<BR>A$</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Expiry date</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Vesting date</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">LTIP&#151;director</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">March&nbsp;7, 2016</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.19</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.48</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">March&nbsp;7,&nbsp;2021</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">June&nbsp;30,&nbsp;2016</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">LTIP&#151;director FY2019</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">November&nbsp;29,&nbsp;2018</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.20</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.855</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">November&nbsp;29,&nbsp;2022</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">November&nbsp;29,&nbsp;2019</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">LTIP&#151;employees</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">March&nbsp;31, 2016</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.24</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.48</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">January&nbsp;1, 2022</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">January&nbsp;1,&nbsp;2017</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">LTIP&#151;employees FY2018</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">August&nbsp;23, 2017</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.33</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.16</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">January&nbsp;1, 2023</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">June 30, 2018</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">LTIP&#151;employees FY2019</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">April&nbsp;3, 2019</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.26</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.855</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">April&nbsp;3, 2023</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">April&nbsp;3, 2020</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">NED Plan</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">March&nbsp;7, 2016</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.19</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.48</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">March&nbsp;7, 2021</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">June 30, 2016</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">NED Plan FY2019</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">November&nbsp;29, 2018</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.20</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.855</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">November&nbsp;29, 2022</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">November 29, 2019</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
</TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">There has been no
modification of the terms and conditions of the above share-based payment arrangements since the grant date. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>Fair value of options granted </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">A binomial model has been used to determine the fair value of all options granted. Where relevant, the expected life used in the model has been adjusted based on management&#146;s best estimate for the
effects of <FONT STYLE="white-space:nowrap">non-transferability,</FONT> exercise restrictions (including the probability of meeting market conditions attached to the option), and behavioral considerations. Expected volatility is based on the
historical share price volatility over the past four or five years. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">F-36
</FONT></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS FOR THE YEARS ENDED JUNE&nbsp;30,
2019 AND 2020 </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>

<TD WIDTH="44%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Grant&nbsp;date<BR>share&nbsp;price<BR>A$</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Exercise<BR>price<BR>A$</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Fair&nbsp;value<BR>per&nbsp;option<BR>A$</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Expected<BR>volatility<BR>%</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Option<BR>life<BR>years</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Dividend<BR>yield %</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Risk&nbsp;free<BR>interest&nbsp;rate<BR>%</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">LTIP&#151;director</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.38</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.48</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.19</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">65</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">5</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2.09</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">LTIP&#151;director FY2019</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.57</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.855</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.20</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">58</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">4</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2.04</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">LTIP&#151;employees</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.70</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.48</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.24</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">65</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">5</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2.09</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">LTIP&#151;employees FY2018</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.43</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.16</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.32</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">66</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">5</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2.09</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">LTIP&#151;employees FY2019</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.67</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.855</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.26</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">57</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">4</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2.04</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">NED Plan</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.38</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.48</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.19</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">65</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">5</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2.09</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">NED Plan FY2019</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.57</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.855</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.20</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">58</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">4</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2.04</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
</TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Movements in options during the year
</I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The following reconciles the options
outstanding at the beginning and end of the year: </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>

<TD WIDTH="55%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>June&nbsp;30, 2019</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>June&nbsp;30, 2020</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Number of<BR>options</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Weighted<BR>average<BR>exercise&nbsp;price<BR>A$</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Number of<BR>options</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Weighted<BR>average<BR>exercise&nbsp;price<BR>A$</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Balance at beginning of year</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">10,075,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.46</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">18,919,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.67</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Granted during the year:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">To employees and directors under the LTIP and NED Plan</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">8,844,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.855</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Exercised during the year</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(875,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.48</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Expired during the year</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Balance at end of year</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">18,919,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.67</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">18,044,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.68</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Exercisable at end of year</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">9,905,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.50</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">18,044,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.68</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The options outstanding at
June&nbsp;30, 2020 had a weighted average exercise price of A$0.68 (2019: A$0.67) and a weighted average remaining contractual life of 626 days (2019: 716 days). </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>29.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE="" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Events after the balance sheet date </B></FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">On August 21, 2020, the Company announced it had completed
End-of-Phase 2 meetings with the U.S.&nbsp;Food and Drug Administration and a Scientific Advice meeting with the European Medicines Agency to obtain guidance on the Company&#146;s Phase 3 clinical development plans. The outcome of the meetings
support the progression of OPT-302 into Phase 3 and pre-commercial development. No other matters or circumstances have arisen since the end of the reporting period which significantly affected, or may significantly affect, the operations of the
Group, the results of those operations, or the state of affairs of the Group in future financial years. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">F-37
</FONT></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="line-height:2px;margin-top:0px;margin-bottom:0px;border-bottom:2pt solid #000000">&nbsp;</P>
<P STYLE="line-height:3px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000">&nbsp;</P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center">


<IMG SRC="g947560g04e62.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>  <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="5"><B>9,300,000 American
Depositary Shares </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="5"><B>Representing 74,400,000
Ordinary Shares </B></FONT></P>  <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000;width:11%">&nbsp;</P></center>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="2">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>PRELIMINARY PROSPECTUS </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2020
</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000;width:11%">&nbsp;</P></center>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Joint Book-Running Managers </I></B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="47%"></TD></TR>


<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="6"><B>Citigroup</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="6"><B>SVB Leerink</B></FONT></TD></TR>
</TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Lead Managers
</I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="47%"></TD></TR>


<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="5"><B>Oppenheimer &amp; Co.</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="5"><B>Truist Securities</B></FONT></TD></TR>
</TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Through and including
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2020 (the 25th day after the date of this prospectus), all dealers effecting transactions in the ADSs, whether or not participating in this offering,
may be required to deliver a prospectus. This is in addition to a dealer&#146;s obligation to deliver a prospectus when acting as an underwriter and with respect to an unsold allotment or subscription. </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="2">&nbsp;</FONT></P> <P STYLE="line-height:0px;margin-top:0px;margin-bottom:0px;border-bottom:0.5pt solid #000000">&nbsp;</P>
<P STYLE="line-height:4px;margin-top:0px;margin-bottom:2px;border-bottom:2pt solid #000000">&nbsp;</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>PART II </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>INFORMATION NOT REQUIRED IN PROSPECTUS </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>ITEM&nbsp;6.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE="" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Indemnification of Directors and Officers. </B></FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Australian law</I>. Australian law provides that a
company or a related body corporate of the company may provide for indemnification of officers and directors, except to the extent of any of the following liabilities incurred as an officer or director of the company: </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">a liability owed to the company or a related body corporate of the company; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT
SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">a liability for a pecuniary penalty order made under section 1317G or a compensation order under section 961M, 1317H, 1317HA, 1317HB 1317HC or 1317HE
of the Corporations Act; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">a liability that is owed to someone other than the company or a related body corporate of the company and did not arise out of conduct in good faith;
or </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">legal costs incurred in defending an action for a liability incurred as an officer or auditor of the company if the costs are incurred:
</FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">in defending or resisting proceedings in which the person is found to have a liability for which they cannot be indemnified as set out above;
</FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">in defending or resisting criminal proceedings in which the person is found guilty; </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">in defending or resisting proceedings brought by the Australian Securities&nbsp;&amp; Investments Commission or a liquidator for a court order if the
grounds for making the order are found by the court to have been established (except costs incurred in responding to actions taken by the Australian Securities&nbsp;&amp; Investments Commission or a liquidator as part of an investigation before
commencing proceedings for a court order); or </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">in connection with proceedings for relief to the person under the Corporations Act 2001 (Cth), or the Corporations Act, in which the court denies the
relief. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Constitution</I>.&nbsp;&nbsp;&nbsp;&nbsp;Our Constitution provides, except to the extent prohibited by the law and the Corporations Act
and, to the extent that the officer is not otherwise indemnified by us pursuant to an indemnity, we indemnify every person who is or has been an officer of the company against any liability or claim (other than legal costs that are unreasonable)
incurred by that person as an officer. This includes any liability or claim incurred by that person in their capacity as an officer of a subsidiary of the company where the company requested that person to accept that appointment. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>  <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Indemnification and Insurance
Agreements</I>.&nbsp;&nbsp;&nbsp;&nbsp;Pursuant to Deeds of Access, Insurance and Indemnity, the form of which is filed as an exhibit to this registration statement, we have agreed to indemnify our executive officers and <FONT
STYLE="white-space:nowrap">non-employee</FONT> directors against certain liabilities and expenses incurred by such persons in connection with claims made by reason of their being such a director or officer. We also maintain insurance policies that
indemnify our directors and executive officers against various liabilities arising under the Securities Act of 1933, as amended, or the Securities Act, and the Securities Exchange Act of 1934, as amended, or the Exchange Act, that might be incurred
by any director or officer in his or her capacity as such. The underwriters are obligated, under certain circumstances, pursuant to the underwriting agreement filed as Exhibit&nbsp;1.1 hereto, to indemnify us, our officers and our directors against
liabilities under the Securities Act. </FONT></P>  <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>SEC
Position</I>.&nbsp;&nbsp;&nbsp;&nbsp;Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers or persons controlling us pursuant to the foregoing provisions, we have been informed that in
the opinion of the SEC such indemnification is against public policy as expressed in the Securities Act and is therefore unenforceable. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">II-1
</FONT></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>ITEM&nbsp;7.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE="" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Recent Sales of Unregistered Securities. </B></FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Set forth below is information regarding share capital
issued and options granted by us since July&nbsp;1, 2017. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">From July&nbsp;1, 2017 through the date of this registration statement, we granted to certain of our directors, officers and employees options to
purchase 8,844,000 ordinary shares under our equity incentive plans at an exercise price per share of A$0.86 and an additional 4,000,000 ordinary shares under our non-executive director share and option plan, subject to shareholder approval at our
annual general meeting for 2020, upon which time an exercise price per ordinary share will be determined; </FONT></P></TD></TR></TABLE>  <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">From July&nbsp;1, 2017 through the date of this registration statement, we issued an aggregate of 48,840,469 ordinary shares upon the exercise of
options previously granted in connection with capital raise transactions at a weighted-average exercise price per share of A$0.27, for an aggregate exercise price of approximately A$13.2&nbsp;million; </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">From July&nbsp;1, 2017 through the date of this registration statement, we issued an aggregate of 875,000 ordinary shares upon the exercise of options
by certain of our officers and employees at an exercise price per share of A$0.48, for an aggregate exercise price of A$420,000; and </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">From July&nbsp;1, 2017 through the date of this registration statement, we issued and sold an aggregate of 18,867,930 shares of common stock to certain
institutional shareholders at a price per share of A$2.65, for an aggregate purchase price of approximately A$181.7&nbsp;million. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">None of the foregoing transactions involved any underwriters, underwriting discounts or commissions, or any public offering. Unless
otherwise specified above, we believe these transactions were exempt from registration under the Securities Act in reliance on (i)&nbsp;Section&nbsp;4(a)(2) of the Securities Act (and Regulation&nbsp;D promulgated thereunder), (ii) Rule&nbsp;701
promulgated under Section&nbsp;3(b) of the Securities Act as transactions by an issuer not involving any public offering or under benefit plans and contracts relating to compensation as provided under Rule&nbsp;701 or (iii)&nbsp;Regulation S
promulgated under the Securities Act as transactions not made to persons in the United States with no directed selling efforts made in the United States. The recipients of the securities in each of these transactions represented their intentions to
acquire the securities for investment only and not with a view to or for sale in connection with any distribution thereof, and appropriate legends were placed on the share certificates issued in these transactions. All recipients had adequate
access, through their relationships with us, to information about us. The sales of these securities were made without any general solicitation or advertising. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">II-2
</FONT></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>ITEM&nbsp;8.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE="" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Exhibits and Financial Statement Schedules. </B></FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>(a) Exhibits </I></B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>

<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD WIDTH="90%"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom" NOWRAP STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Exhibit<BR>Number</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1px solid #000000"> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Description of Exhibit</B></FONT></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;1.1</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="d947560dex11.htm">Form of Underwriting Agreement.</A></FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;3.1*</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="http://www.sec.gov/Archives/edgar/data/1815620/000119312520253365/d947560dex31.htm">Certificate of Registration of the Registrant. </A></FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;3.2*</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="http://www.sec.gov/Archives/edgar/data/1815620/000119312520253365/d947560dex32.htm">Constitution of the Registrant. </A></FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;4.1</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="d947560dex41.htm">Form of Amended and Restated Deposit Agreement.</A></FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;4.2</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Form of American Depositary Receipt evidencing American Depositary Shares <A HREF="d947560dex41.htm">(included in Exhibit&nbsp;4.1). </A></FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;5.1</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="d947560dex51.htm">Opinion of Gilbert + Tobin.</A></FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">10.1&#134;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="d947560dex101.htm">Commercial License Agreement, dated as of October&nbsp;28, 2013, between the Registrant and Selexis SA. </A></FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">10.2&#134;*</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="http://www.sec.gov/Archives/edgar/data/1815620/000119312520253365/d947560dex102.htm">Biopharmaceutical Manufacturing Agreement, dated as of October&nbsp;
28, 2013, between the Registrant, Patheon Biologics Company Australia Pty Ltd. and Patheon Biologics Company B.V. </A></FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">10.3+*</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="http://www.sec.gov/Archives/edgar/data/1815620/000119312520253365/d947560dex103.htm">Form of Deed of Indemnity, Insurance and Access </A></FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">10.4*</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="http://www.sec.gov/Archives/edgar/data/1815620/000119312520253365/d947560dex104.htm">Lease Agreement, dated November&nbsp;
12, 2019, between the Registrant and The Trust Company (Australia) Limited, as custodian for the Newmark Como Property Trust. </A></FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">10.5+*</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="http://www.sec.gov/Archives/edgar/data/1815620/000119312520253365/d947560dex105.htm">Long Term Incentive Plan Rules. </A></FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">10.6+*</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="http://www.sec.gov/Archives/edgar/data/1815620/000119312520253365/d947560dex106.htm"><FONT STYLE="white-space:nowrap">Non-Executive</FONT> Directors Share and Option Plan Rules.
 </A></FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">10.7+*</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="http://www.sec.gov/Archives/edgar/data/1815620/000119312520253365/d947560dex107.htm">Executive Employment Contract, dated April&nbsp;
23, 2014, between the Registrant and Megan Baldwin, Ph.D. </A></FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">10.8+*</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="http://www.sec.gov/Archives/edgar/data/1815620/000119312520253365/d947560dex108.htm">Executive Employment Contract, dated May&nbsp;
8, 2014, between the Registrant and Michael Tonroe. </A></FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">10.9+</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="d947560dex109.htm">Form of Non-Executive Director Agreement.</A></FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">21.1*</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="http://www.sec.gov/Archives/edgar/data/1815620/000119312520253365/d947560dex211.htm">List of subsidiaries. </A></FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">23.1</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="d947560dex231.htm">Consent of Deloitte&nbsp;Touche Tohmatsu, independent registered public accounting firm.</A></FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">23.2</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Consent of Gilbert + Tobin <A HREF="d947560dex51.htm">(included in Exhibit 5.1)</A>.</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">24.1*</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="http://www.sec.gov/Archives/edgar/data/1815620/000119312520253365/d947560df1.htm#ii947560_sig">Power of Attorney (included on signature page to the original filing of this
 registration statement on Form F-1). </A></FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">99.1</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="d947560dex991.htm">Consent of Jeremy Levin, DPhil, MB BChir, as director nominee.</A></FONT></TD></TR>
</TABLE>  <P STYLE="line-height:8px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">*</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Previously filed. </FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">+</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Indicates management contract or compensatory plan. </FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#134;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Portions of this exhibit have been omitted as the Registrant has determined that the omitted information (i)&nbsp;is not material and (ii)&nbsp;would likely cause
competitive harm to the Registrant if publicly disclosed. </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B><I>(b) Financial Statement Schedules </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">All schedules have been omitted because the information required to be set forth therein is not applicable or has been included in the consolidated financial statements and notes thereto. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">II-3
</FONT></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>ITEM&nbsp;9.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE="" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Undertakings. </B></FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The undersigned Registrant hereby undertakes to provide to the underwriters at the closing specified in the underwriting agreement,
certificates in such denominations and registered in such names as required by the underwriters to permit prompt delivery to each purchaser. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers and controlling
persons of the Registrant pursuant to the foregoing provisions, or otherwise, the Registrant has been advised that in the opinion of the Securities and Exchange Commission such indemnification is against public policy as expressed in the Securities
Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the Registrant of expenses incurred or paid by a director, officer or controlling person of the Registrant in the
successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the Registrant will, unless in the opinion of its counsel the matter has been
settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue.
</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The undersigned Registrant hereby undertakes
that: </FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(1) For purposes of determining any
liability under the Securities Act of 1933, the information omitted from the form of prospectus filed as part of this Registration Statement in reliance upon Rule 430A and contained in a form of prospectus filed by the Registrant pursuant to Rule
424(b)(1) or (4)&nbsp;or 497(h) under the Securities Act shall be deemed to be part of this Registration Statement as of the time it was declared effective. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(2) For the purpose of determining any liability under the Securities Act of 1933, each post-effective amendment that contains a form of
prospectus shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">II-4
</FONT></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="sig"></A>SIGNATURES </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>  <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Pursuant to the requirements of the Securities Act of
1933, as amended, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing <FONT STYLE="white-space:nowrap">on&nbsp;Form&nbsp;F-1&nbsp;and</FONT> has duly caused this registration statement
to be signed on its behalf by the undersigned, thereunto duly authorized in Melbourne, Australia on this 9th day of October, 2020. </FONT></P>  <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="14%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="77%"></TD></TR>


<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="3"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>OPTHEA LIMITED</B></FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">By:&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="3"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">/s/ Megan Baldwin</FONT></P></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Name:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Megan Baldwin, Ph.D.</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Title:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Chief Executive Officer and</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:1px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Managing Director</FONT></P></TD></TR>
</TABLE></DIV> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>  <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Pursuant to the
requirements of the Securities Act of 1933, as amended, this Amendment No. 1 to the Registration Statement has been signed by the following persons on behalf of the registrant and in the capacities and on the dates indicated: </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE">


<TR>

<TD WIDTH="35%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="42%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="21%"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1px solid #000000 ; display:table-cell;" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Signature</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1px solid #000000 ; display:table-cell;" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Title</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1px solid #000000 ; display:table-cell;" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Date</B></FONT></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="10"></TD>
<TD HEIGHT="10" COLSPAN="2"></TD>
<TD HEIGHT="10" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"> <P STYLE="margin-top:0px;margin-bottom:0px;border-bottom:1px solid #000000" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">/s/ Megan Baldwin</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">Megan Baldwin, Ph.D.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Chief Executive Officer and Managing Director</FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><I>(Principal Executive Officer)</I></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">October 9, 2020</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="10"></TD>
<TD HEIGHT="10" COLSPAN="2"></TD>
<TD HEIGHT="10" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="middle"> <P STYLE="margin-top:0px;margin-bottom:0px;border-bottom:1px solid #000000" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">/s/ Michael Tonroe</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">Michael Tonroe</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Chief Financial Officer and Company Secretary</FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><I>(Principal Financial and Accounting Officer)</I></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">October 9, 2020</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="10"></TD>
<TD HEIGHT="10" COLSPAN="2"></TD>
<TD HEIGHT="10" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="middle"> <P STYLE="margin-top:0px;margin-bottom:0px;border-bottom:1px solid #000000" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">*</FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Geoffrey Kempler</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Chairperson of the Board of Directors</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">October 9, 2020</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="10"></TD>
<TD HEIGHT="10" COLSPAN="2"></TD>
<TD HEIGHT="10" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="middle"> <P STYLE="margin-top:0px;margin-bottom:0px;border-bottom:1px solid #000000" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">*</FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Lawrence Gozlan</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Director</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">October 9, 2020</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="10"></TD>
<TD HEIGHT="10" COLSPAN="2"></TD>
<TD HEIGHT="10" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="middle"> <P STYLE="margin-top:0px;margin-bottom:0px;border-bottom:1px solid #000000" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">*</FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Michael Sistenich</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Director</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">October 9, 2020</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="10"></TD>
<TD HEIGHT="10" COLSPAN="2"></TD>
<TD HEIGHT="10" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="middle"> <P STYLE="margin-top:0px;margin-bottom:0px;border-bottom:1px solid #000000" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">*</FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Daniel Spiegelman</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Director</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">October 9, 2020</FONT></TD></TR></TABLE>  <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE">


<TR>

<TD WIDTH="9%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="90%"></TD></TR>

<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">*By:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:0px;border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">/s/ Megan Baldwin</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Megan Baldwin, Ph.D.</FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Attorney-in-fact</I></FONT></P></TD></TR>
</TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">II-5
</FONT></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Signature of Authorized U.S. Representative of the Registrant </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>  <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Pursuant to the requirements of the Securities Act of
1933, as amended, the undersigned, the duly authorized representative in the United States of Opthea Limited, has signed this Amendment No. 1 to the Registration Statement on October 9, 2020. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE">


<TR>

<TD WIDTH="8%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="91%"></TD></TR>


<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">By:&nbsp;</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000; margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">/s/ Donald J.
Puglisi</FONT></P></TD></TR></TABLE></DIV> <DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE">


<TR>

<TD WIDTH="14%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="85%"></TD></TR>

<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Name:&nbsp;</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Donald J. Puglisi</FONT></P></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Title:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Managing Director</FONT></P></TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">II-6
</FONT></P>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-1.1
<SEQUENCE>2
<FILENAME>d947560dex11.htm
<DESCRIPTION>EX-1.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-1.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 1.1 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>OPTHEA LIMITED </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>[</B>&#9679;<B></B><B>] American Depositary Shares </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Representing [</B>&#9679;<B></B><B>] Ordinary Shares (no&nbsp;par value) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Underwriting Agreement </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>[</B>&#9679;<B></B><B>], 2020 </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Citigroup
Global Markets Inc. and </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">SVB Leerink LLC </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As
Representatives of the several Underwriters </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">c/o Citigroup Global Markets Inc. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">388 Greenwich Street </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">New York, New York 10013 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">c/o SVB Leerink LLC </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">255 California Street, 12th Floor </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">San Francisco, CA 94111 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ladies and Gentlemen: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Opthea Limited, a corporation incorporated under the laws of Australia (the &#147;<U>Company</U>&#148;), proposes to sell to the several
underwriters (the &#147;<U>Underwriters</U>&#148;) named in <U>Schedule I</U> to this underwriting agreement (this &#147;<U>Agreement</U>&#148;), for whom you (in such capacity, the &#147;<U>Representatives</U>&#148;) are acting as representatives,
an aggregate of [&#9679;] American Depositary Shares (the &#147;<U>ADSs</U>&#148;, and each an &#147;<U>ADS</U>&#148;), each representing [&#9679;] ordinary shares, no par value, of the Company (&#147;<U>Ordinary Shares</U>&#148;). The aggregate of
[&#9679;] ADSs to be issued and sold by the Company are hereinafter collectively referred to as the &#147;Underwritten ADSs.&#148; In addition, the Company proposes to issue and sell, at the option of the Underwriters, up to an additional [&#9679;]
ADSs, representing [&#9679;] additional Ordinary Shares (the &#147;<U>Option ADSs</U>&#148;). The Underwritten ADSs and the Option ADSs are herein referred to as the &#147;<U>Offered ADSs</U>.&#148; The Ordinary Shares represented by the
Underwritten ADSs are hereinafter referred to as the &#147;<U>Underwritten Securities</U>,&#148; the Ordinary Shares represented by the Option ADSs are hereinafter referred to as the &#147;<U>Option Securities</U>&#148;, and the Underwritten
Securities and the Option Securities are hereinafter referred to as the &#147;<U>Underlying Securities</U>.&#148; The Offered ADSs and the Underlying Securities are herein called, collectively, the &#147;<U>Securities</U>.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">The Representatives have also advised the Company that the Underwriters may elect to cause the Company to deposit on their behalf all or any
portion of the Underlying Securities to be purchased by them hereunder pursuant to the Deposit Agreement, dated as of [<I></I>&#9679;<I></I><I></I>], 2020 (the &#147;<U>Deposit Agreement</U>&#148;), to be entered into among the Company, The Bank of
New York Mellon, as depositary (the &#147;<U>Depositary</U>&#148;), and all holders from time to time of the ADSs. Upon deposit of any Ordinary Shares, the Depositary will issue ADSs representing the Ordinary Shares so deposited. The ADSs will be
evidenced by American Depositary Receipts (the &#147;<U>ADRs</U>&#148;). The Offered ADSs will represent Ordinary Shares and each ADR may represent any number of ADSs. </P> <P STYLE="font-size:18pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">To the extent there are no additional Underwriters listed on
<U>Schedule</U><U></U><U>&nbsp;I</U> other than you, the term Representatives as used in this Agreement shall mean you, as Underwriters, and the terms Representatives and Underwriters shall mean either the singular or plural as the context requires.
The use of the neuter in this Agreement shall include the feminine and masculine wherever appropriate. <B></B> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">As used in this Agreement,
the &#147;<U>Registration Statement</U>&#148; means the registration statement referred to in <U>Section</U><U></U><U>&nbsp;1(i)(a)</U> hereof, including the exhibits, schedules and financial statements and any prospectus relating to the Securities
that is filed with the Securities and Exchange Commission (the &#147;<U>SEC</U>&#148;) pursuant to Rule 424(b) under the Securities Act of 1933, as amended, and the rules and regulations promulgated thereunder (the &#147;<U>Securities Act</U>&#148;)
and deemed part of such registration statement pursuant to Rule 430A under the Securities Act (&#147;<U>Rule 430A</U>&#148;), as amended at the date and time that this Agreement<SUP STYLE="font-size:85%; vertical-align:top"> </SUP>is executed and
delivered by the parties hereto (the &#147;<U>Execution Time</U>&#148;), and, in the event any post-effective amendment thereto or any registration statement and any amendments thereto filed pursuant to Rule 462(b) under the Securities Act (a
&#147;<U>Rule 462(b) Registration Statement</U>&#148;) becomes effective prior to the Closing Date (as defined in Section&nbsp;3 hereof), shall also mean such registration statement as so amended or such Rule 462(b) Registration Statement, as the
case may be; the &#147;<U>Effective Date</U>&#148; means each date and time that the Registration Statement, any post-effective amendment or amendments thereto or any Rule 462(b) Registration Statement became or becomes effective; the
&#147;<U>Preliminary Prospectus</U>&#148; means any preliminary prospectus with respect to the offering of the Securities included in the Registration Statement at the Effective Date that omits information with respect to the Securities and the
offering thereof permitted to be omitted from the Registration Statement when it becomes effective pursuant to Rule 430A; and the &#147;<U>Prospectus</U>&#148; means the prospectus relating to the Securities that is first filed pursuant to Rule
424(b) under the Securities Act (&#147;<U>Rule 424(b)</U>&#148;) after the Execution Time. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">As used in this Agreement, the
&#147;<U>Disclosure Package</U>&#148; shall mean (i)&nbsp;the Preliminary Prospectus dated October [&#9679;], 2020, as generally distributed to investors and used to offer the Securities, (ii)&nbsp;any issuer free writing prospectus, as defined in
Rule 433 under the Securities Act (&#147;<U>Rule 433</U>&#148; and, any such issuer free writing prospectus, an &#147;<U>Issuer Free Writing Prospectus</U>&#148;), identified in <U>Schedule II</U> hereto, (iii)&nbsp;any other free writing
prospectus, as defined in Rule 405 under the Securities Act (&#147;<U>Rule 405</U>&#148; and, any such free writing prospectus, a &#147;<U>Free Writing Prospectus</U>&#148;), that the parties hereto shall hereafter expressly agree in writing to
treat as part of the Disclosure Package. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As used in this Agreement, a person is &#147;<U>Insolvent</U>&#148; when: (i)&nbsp;it is (or
states it is) an insolvent under administration or insolvent (each as defined in the Corporations Act 2001 (Cth) (&#147;<U>Corporations Act</U>&#148;)); (ii) it is in liquidation, in provisional liquidation, under administration or wound up or it
has had a controller appointed to its property; or it is subject to any arrangement, assignment, moratorium or composition, protected from creditors under any statute or dissolved (in each case, other than to carry out a reconstruction or
amalgamation while solvent on terms approved by the other parties to this Agreement); (iii) an application or order has been made (and in the case of an application, it is not stayed, withdrawn or dismissed within 30 days), resolution
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
passed, proposal put forward, or any other action taken, in each case in connection with that person, which is preparatory to or could result in any of (i), (ii) or (iii)&nbsp;above occurring;
(iv)&nbsp;it is taken (under section 459F(1) of the Corporations Act) to have failed to comply with a statutory demand; (v)&nbsp;or it is the subject of an event described in section 459C(2)(b) or section 585 of the Corporations Act (or it makes a
statement from which another party to this Agreement reasonably deduces it is so subject)&nbsp;(vi) it is otherwise unable to pay its debts when they fall due; or (vii)&nbsp;something having a substantially similar effect to (i)&nbsp;to (vi) happens
in connection with that person under the law of any jurisdiction. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As used in this Agreement, &#147;<U>Group</U>&#148; shall mean the
Company and its Related Bodies Corporate (as defined below), and &#147;<U>Group Member</U>&#148; means any one or more of them. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As used
in this Agreement, &#147;<U>Related Bodies Corporate</U>&#148; has the meaning set out in section 50 of the Corporations Act. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">1.
<U>Representations and Warranties</U>. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(i) The Company represents and warrants to, and agrees with, each Underwriter as set forth below in
this <U>Section</U><U></U><U>&nbsp;1</U>. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) The Company has prepared and filed with the SEC a registration statement
(file number <FONT STYLE="white-space:nowrap">333-249020)</FONT> on <FONT STYLE="white-space:nowrap">Form&nbsp;F-1,</FONT> including the Preliminary Prospectus, for the registration of the offering and sale of the Securities under the Securities
Act. Such Registration Statement, including any amendments thereto filed prior to the Execution Time, has become effective. The Company may have filed one or more amendments thereto, including the Preliminary Prospectus, each of which has previously
been furnished to you. The Company will file with the SEC the Prospectus relating to the Securities in accordance with Rule 424(b) after the Execution Time. As filed, the Prospectus shall contain all information with respect to the Underlying
Securities and the offering thereof in the form of ADSs required by the Securities Act and the rules thereunder and, except to the extent the Representatives shall agree in writing to a modification, shall be in all substantive respects in the form
furnished to you prior to the Execution Time or, to the extent not completed at the Execution Time, shall contain only such specific additional information and other changes (beyond that contained in the latest Preliminary Prospectus) as the Company
has advised you, prior to the Execution Time, will be included or made therein. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) On the Effective Date, the
Registration Statement did, and when the Prospectus is first filed in accordance with Rule&nbsp;424(b) and on the Closing Date (as defined in this Agreement) and on any date on which Option Securities are purchased, if such date is not the Closing
Date (each such date, a &#147;<U>Settlement Date</U>&#148;), the Prospectus (and any supplements thereto) will comply in all material respects with the applicable requirements of the Securities Act and the rules thereunder; on the Effective Date, at
the Execution Time and on the Closing Date, the Registration Statement did not and will not contain any untrue statement of a material fact or omit to state any material fact required to be stated therein or necessary in order to make the statements
therein not misleading; and on the date of any filing pursuant to Rule&nbsp;424(b) and on the Closing Date and any Settlement Date, the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
Prospectus (together with any supplement thereto) will not include any untrue statement of a material fact or omit to state a material fact necessary in order to make the statements therein, in
the light of the circumstances under which they were made, not misleading; <U>provided</U>, <U>however</U>, that the Company makes no representations or warranties as to the information contained in or omitted from the Registration Statement, the
Preliminary Prospectus or the Prospectus (or any supplement thereto) in reliance upon and in conformity with information furnished in writing to the Company by or on behalf of any Underwriter through the Representatives specifically for inclusion in
the Registration Statement, the Preliminary Prospectus or the Prospectus (or any supplement thereto), it being understood and agreed that the only such information furnished by or on behalf of any Underwriter consists of the information described as
such in Section&nbsp;8 hereof. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) The Company has filed with the SEC a registration statement (file number <FONT
STYLE="white-space:nowrap">333-249327)</FONT> on Form <FONT STYLE="white-space:nowrap">F-6</FONT> for the registration under the Securities Act of the offering and sale of the Offered ADSs (&#147;<U>ADS Registration Statement</U>&#148;). The Company
may have filed one or more amendments thereto, each of which has previously been furnished to you. Such ADS Registration Statement at the time of its effectiveness did comply and on the Closing Date, will comply, in all material respects with the
applicable requirements of the Securities Act and the rules thereunder and at the time of its Effective Date and at the Execution Time, did not contain any untrue statement of a material fact or omit to state any material fact required to be stated
therein or necessary in order to make the statements therein not misleading. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) Upon issuance by the Depositary of ADSs
evidenced by ADRs against deposit of Underlying Securities in accordance with the provisions of the Deposit Agreement, such ADRs will be duly and validly issued and persons in whose names the ADRs are registered will be entitled to the rights
specified in the ADRs and in the Deposit Agreement; and upon the sale and delivery to the Underwriters of the Securities, and payment therefor, pursuant to this Agreement, the Underwriters will acquire good, marketable and valid title to such
Securities, free and clear of all pledges, liens, security interests, charges, claims or encumbrances of any kind. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e)
Provided that (i)&nbsp;no Underwriter is resident in Australia for tax purposes and (ii)&nbsp;each Underwriter is a resident of a jurisdiction for the purposes of a double tax treaty between Australia and the jurisdiction, is entitled to the
benefits of the treaty and does not, and is not deemed to, carry on business through a permanent establishment in Australia, no stamp, registration, issuance, transfer taxes or other similar taxes, duties, fees or charges (&#147;Transfer
Taxes&#148;) are payable by or on behalf of the Underwriters in connection with (A)&nbsp;the issuance of the Underlying Securities and the delivery of the Offered ADSs in the manner contemplated by this Agreement, (B)&nbsp;the deposit with the
Depositary of the Underlying Securities against issuance of the Offered ADSs or (C)&nbsp;the sale and delivery by the Underwriters of the Underlying Securities or the Offered ADSs, as the case may be, as contemplated herein. For the avoidance of
doubt, income taxes, withholding taxes, capital gains taxes and taxes on dividends shall not be considered &#147;Transfer Taxes.&#148; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f) Except as described in each of the Disclosure Package and the
Prospectus, all dividends and other distributions declared and payable on the Ordinary Shares may under current Australian law and regulations be paid to the Depositary and to the holders of Ordinary Shares or ADSs, as the case may be, in Australian
dollars and may be converted into foreign currency that may be transferred out of Australia in accordance with the Deposit Agreement. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(g) Based on the current and anticipated value of its assets and the nature and composition of its income and assets, and
subject to the qualifications set forth in the Registration Statement, the General Disclosure Package and the Prospectus, the Company does not expect to be a &#147;passive foreign investment company&#148; within the meaning of Section&nbsp;1297 of
the United&nbsp;States Internal Revenue Code of 1986, as amended, for the taxable year ending June&nbsp;30, 2020. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(h)
Reserved. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) (i) The Disclosure Package and the price to the public, the number of Underwritten Securities and the number
of Option Securities to be included on the cover page of the Prospectus, when taken together as a whole,<B> </B>(ii)&nbsp;each electronic road show, when taken together as a whole with the Disclosure Package and the price to the public, the number
of Underwritten Securities and the number of Option Securities to be included on the cover page of the Prospectus,<B> </B>and (iii)&nbsp;any individual Written
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Testing-the-Waters</FONT></FONT> Communication (as defined below), when taken together as a whole with the Disclosure Package<B> </B>and the price to the public, the number of
Underwritten Securities and the number of Option Securities to be included on the cover page of the Prospectus,<B> </B>does not contain any untrue statement of a material fact or omit to state any material fact necessary in order to make the
statements therein, in the light of the circumstances under which they were made, not misleading. The preceding sentence does not apply to statements in or omissions from the Disclosure Package based upon and in conformity with written information
furnished to the Company by or on behalf of any Underwriter through the Representatives specifically for use therein, it being understood and agreed that the only such information furnished by or on behalf of any Underwriter consists of the
information described as such in <U>Section</U><U></U><U>&nbsp;8</U> hereof. &#147;<U>Written <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Testing-the-Waters</FONT></FONT> Communication</U>&#148; means any <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Testing-the-Waters</FONT></FONT> Communication that is a written communication within the meaning of Rule 405. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(j) (i) At the time of filing the Registration Statement and (ii)&nbsp;as of the Execution Time (with such date being used as
the determination date for purposes of this clause (ii)), the Company was not and is not an Ineligible Issuer (as defined in Rule 405), without taking account of any determination by the SEC pursuant to Rule 405 that it is not necessary that the
Company be considered an Ineligible Issuer. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(k) From the time of initial confidential submission of the Registration
Statement to the SEC (or, if earlier, the first date on which the Company engaged directly or through any person authorized to act on its behalf in any
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Testing-the-Waters</FONT></FONT> Communication) through the Execution Time, the Company has been and is an &#147;emerging growth company,&#148; as defined in Section&nbsp;2(a) of the
Securities Act (an &#147;<U>Emerging Growth Company</U>&#148;). &#147;<U><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Testing-the-Waters</FONT></FONT> Communication</U>&#148; means any oral or written communication with
potential investors undertaken in reliance on Section&nbsp;5(d) of the Securities Act. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(l) The Company (i)&nbsp;has not alone engaged in any <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Testing-the-Waters</FONT></FONT> Communication other than <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Testing-the-Waters</FONT></FONT> Communications with the consent
of the Representatives with entities that are qualified institutional buyers within the meaning of Rule 144A under the Securities Act or institutions that are accredited investors within the meaning of Rule 501 under the Securities Act and
(ii)&nbsp;has not authorized anyone other than the Representatives to engage in <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Testing-the-Waters</FONT></FONT> Communications. The Company reconfirms that the Representatives have
been authorized to act on its behalf in undertaking <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Testing-the-Waters</FONT></FONT> Communications. The Company has not distributed any Written <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">Testing-the-Waters</FONT></FONT> Communications other than those listed on <U>Schedule IV</U> hereto. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(m) Each Issuer Free Writing Prospectus does not include any information that conflicts with the information contained in the
Registration Statement. The foregoing sentence does not apply to statements in or omissions from any Issuer Free Writing Prospectus based upon and in conformity with written information furnished to the Company by or on behalf of any Underwriter
through the Representatives specifically for use therein, it being understood and agreed that the only such information furnished by or on behalf of any Underwriter consists of the information described as such in <U>Section</U><U></U><U>&nbsp;8</U>
hereof. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(n) Reserved. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(o) Each of the Company and its subsidiaries has been duly incorporated and is validly existing as a corporation in good
standing under the laws of the jurisdiction in which it is incorporated with full corporate power and authority to own or lease, as the case may be, and to operate its properties and conduct its business as described in the Disclosure Package and
the Prospectus, and is duly qualified to do business as a foreign corporation and is in good standing under the laws of each jurisdiction which requires such qualification, except in each case where such failure would not reasonably be expected to
have a Material Adverse Effect (as defined below). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(p) All the outstanding share capital of each subsidiary has been duly
and validly issued and is fully paid, and, except as otherwise set forth in the Disclosure Package and the Prospectus, all outstanding share capital of the subsidiaries is owned by the Company either directly or through wholly owned subsidiaries
free and clear of any perfected security interest or any other security interests, claims, liens or encumbrances. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(q)
There is no franchise, contract or other document of a character required to be described in the Registration Statement, Preliminary Prospectus<B> </B>or Prospectus, or to be filed as an exhibit thereto, which is not described or filed as required
(and the Preliminary Prospectus contains in all material respects the same description of the foregoing matters contained in the Prospectus). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(r) The Company has full legal capacity and power to enter into this Agreement and the Deposit Agreement, and each of this
Agreement and the Deposit Agreement has been duly authorized, executed and delivered by the Company. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(s) The Company is not and, after giving effect to the offering and sale of
the Securities and the application of the proceeds thereof as described in the Registration Statement, Disclosure Package and the Prospectus, will not be an &#147;investment company&#148; as defined in the Investment Company Act of 1940, as amended.
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(t) No consent, approval, authorization, filing with or order of any court or governmental agency or body is required in
connection with the transactions contemplated herein or in the Deposit Agreement, except such as have been obtained under the Securities Act and the listing rules of the Australian Securities Exchange and such as may be required under the listing
rules of the Nasdaq Stock Market, applicable rules of the Financial Industry Regulatory Authority, Inc. and under the applicable state and foreign securities laws of any jurisdiction in connection with the purchase and distribution of the Securities
by the Underwriters in the manner contemplated herein and in the Disclosure Package and the Prospectus. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(u) Neither the
issue and sale of the Securities nor the consummation of any other of the transactions herein contemplated nor the fulfillment of the terms hereof or of the Deposit Agreement will conflict with, result in a breach or violation of, or imposition of
any lien, charge or encumbrance upon any property or assets of the Company or any of its subsidiaries pursuant to, (i)&nbsp;the constitution of the Company or any of its subsidiaries, (ii)&nbsp;the terms of any indenture, contract, lease, mortgage,
deed of trust, note agreement, loan agreement or other agreement, obligation, condition, covenant or instrument to which the Company or any of its subsidiaries is a party or bound or to which its or their property is subject, or (iii)&nbsp;any
statute, law, rule, regulation, judgment, order or decree applicable to the Company or any of its subsidiaries of any court, regulatory body, administrative agency, governmental body, arbitrator or other authority having jurisdiction over the
Company or any of its subsidiaries or any of its or their properties, except in the case of clause (ii)&nbsp;and (iii) above, for any such conflict, breach, violation, default, lien, charge or encumbrance that would not, individually or in the
aggregate, reasonably be expected to have a Material Adverse Effect (as defined below). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(v) No holders of securities of
the Company have rights to the registration of such securities under the Registration Statement or the issuance of the Securities. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(w) The consolidated historical financial statements and schedules of the Company and its consolidated subsidiaries included in
the Preliminary Prospectus, the Prospectus and the Registration Statement present fairly in all material respects the financial condition, results of operations and cash flows of the Company and its consolidated subsidiary as of the dates and for
the periods indicated, comply as to form in all material respects with the applicable accounting requirements of the Securities Act and have been prepared in conformity with International Financial Reporting Standards as issued by the International
Accounting Standards Board (&#147;IFRS&#148;) applied on a consistent basis throughout the periods involved (except as otherwise noted therein). The selected financial data set forth under the caption &#147;Selected Consolidated Financial Data&#148;
in the Registration Statement, Preliminary Prospectus and the Prospectus fairly present in all material respects, on the basis stated in the Preliminary Prospectus, the Prospectus and the Registration Statement, the information included therein.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(x) No action, suit or proceeding by or before any court or governmental
agency, authority or body or any arbitrator involving the Company or any of its subsidiaries or its or their property is pending or, to the knowledge of the Company, threatened that (i)&nbsp;would reasonably be expected to have a material adverse
effect on the performance of this Agreement or the consummation of any of the transactions contemplated hereby or (ii)&nbsp;could reasonably be expected to have a material adverse effect on the condition (financial or otherwise), prospects,
earnings, business or properties of the Company and its subsidiaries, individually or taken as a whole, whether or not arising from transactions in the ordinary course of business (a &#147;<U>Material Adverse Effect</U>&#148;), except as set forth
in or contemplated in the Disclosure Package and the Prospectus (exclusive of any amendment or supplement thereto). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(y)
Each of the Company and its subsidiary leases all such real properties as are reasonably necessary to the conduct of its operations as presently conducted. The Company does not own any real property. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(z) Neither the Company nor any subsidiary is in violation or default of (i)&nbsp;any provision of its constitution,
(ii)&nbsp;the terms of any indenture, contract, lease, mortgage, deed of trust, note agreement, loan agreement or other agreement, obligation, condition, covenant or instrument to which it is a party or bound or to which its property is subject, or
(iii)&nbsp;any statute, law, rule, regulation, judgment, order or decree of any court, regulatory body, administrative agency, governmental body, arbitrator or other authority having jurisdiction over the Company or such subsidiary or any of its
properties, as applicable, except in case of clauses (ii)&nbsp;and (iii), for any such violation or default as would not reasonably expected, individually or in the aggregate, to have a Material Adverse Effect. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(aa) Deloitte Touche Tohmatsu, who have issued their audit report with respect to the consolidated financial statements of the
Company and its affiliates included in the Disclosure Package and the Prospectus, are independent public accountants with respect to the Company and its affiliates within the meaning of the Securities Act and the applicable published rules and
regulations thereunder. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(bb) The Company has filed all tax returns that are required to be filed or has requested
extensions thereof, except in any case in which the failure so to file would not have a Material Adverse Effect, except as set forth in or contemplated in the Disclosure Package and the Prospectus (exclusive of any amendment or supplement thereto)
and has paid all taxes required to be paid by it and any other assessment, fine or penalty levied against it, to the extent that any of the foregoing is due and payable, except for any such assessment, fine or penalty that is currently being
contested in good faith or as would not have a Material Adverse Effect, except as set forth in or contemplated in the Disclosure Package and the Prospectus (exclusive of any amendment or supplement thereto). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(cc) With respect to the Company and each of its subsidiaries, except as set forth in or contemplated in the Disclosure Package
and the Prospectus (exclusive of any amendment or supplement thereto): (i) no labor problem, dispute, slowdown, work stoppage or disturbance involving any employees of it exists or, to the Company&#146;s knowledge is threatened or imminent, and it
is not aware of any existing or imminent labor problem, dispute, slowdown, work </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
stoppage or disturbance by the employees of any of its or its principal suppliers, contractors or customers, that could have a Material Adverse Effect; (ii)&nbsp;the prescribed minimum level of
superannuation support in respect of each employee has been provided so as to not incur a shortfall amount under the <I>Superannuation Guarantee (Administration) Act 1992 </I>(Cth); and (iii)&nbsp;compliance subsists for all its obligations under
employment contracts, industrial agreements and awards and with all codes of conduct and practice relevant to conditions of service and to the relations between it and the employees employed by it, except as would not, individually or in the
aggregate, reasonably be expected to have a Material Adverse Effect. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(dd) The Company and each of its subsidiaries are
insured by insurers of recognized financial responsibility against such losses and risks and in such amounts as the Company reasonably believes are prudent and customary in the businesses in which they are engaged; all policies of insurance insuring
the Company or any of its subsidiaries or their respective businesses, assets, employees, officers and directors are in full force and effect; the Company and its subsidiaries are in compliance with the terms of such policies and instruments in all
material respects; and there are no material claims by the Company or any of its subsidiaries under any such policy or instrument as to which any insurance company is denying liability or defending under a reservation of rights clause; neither the
Company nor any such subsidiary has been refused any insurance coverage sought or applied for; and neither the Company nor any such subsidiary has any reason to believe that it will not be able to renew its existing insurance coverage as and when
such coverage expires or to obtain similar coverage from similar insurers as may be necessary to continue its business at a cost that would not reasonably be expected to have a Material Adverse Effect, except as set forth in or contemplated in the
Disclosure Package and the Prospectus (exclusive of any amendment or supplement thereto). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ee) No subsidiary of the
Company is currently prohibited, directly or indirectly, from paying any dividends to the Company, from making any other distribution on such subsidiary&#146;s share capital, from repaying to the Company any loans or advances to such subsidiary from
the Company or from transferring any of such subsidiary&#146;s property or assets to the Company or any other subsidiary of the Company, except as described in or contemplated by the Disclosure Package and the Prospectus (exclusive of any amendment
or supplement thereto). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ff) The Company and its subsidiaries possess all licenses,
<FONT STYLE="white-space:nowrap">sub-licenses,</FONT> certificates, permits and other authorizations issued by, and have made all declarations and filings with, all applicable federal, state, local or foreign governmental or other authorities that
are necessary to conduct their respective businesses (&#147;<U>Permits</U>&#148;), except where the failure to possess such Permit would not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect. Neither the
Company nor any such subsidiary is in violation of, or in default under, any of the Permits nor has received any revocation, suspension or modification of any such Permit which, singly or in the aggregate, if the subject of an unfavorable decision,
ruling or finding, would reasonably be expected to have a Material Adverse Effect, except as set forth in or contemplated in the Disclosure Package and the Prospectus (exclusive of any amendment or supplement thereto). Neither the Company nor any of
its subsidiaries has received any notice that any such Permit will not be renewed in the ordinary course, and, except as would not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect, all Permits are valid and
in full force. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(gg) The Company and each of its subsidiaries maintain a system of internal
accounting controls designed to provide reasonable assurance that (i)&nbsp;transactions are executed in accordance with management&#146;s general or specific authorizations; (ii)&nbsp;transactions are recorded as necessary to permit preparation of
financial statements in conformity with IFRS and to maintain asset accountability; (iii)&nbsp;access to assets is permitted only in accordance with management&#146;s general or specific authorization; and (iv)&nbsp;the recorded accountability for
assets is compared with the existing assets at reasonable intervals and appropriate action is taken with respect to any differences. Except as disclosed in the Disclosure Package and the Prospectus, the Company and its subsidiaries&#146; internal
controls over financial reporting are effective and the Company and its subsidiaries are not aware of any material weakness in their internal controls over financial reporting. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(hh) The Company and its subsidiaries maintain &#147;disclosure controls and procedures&#148; (as such term is defined in Rule <FONT
STYLE="white-space:nowrap">13a-15(e)</FONT> under the Securities and Exchange Act 1934, as amended, and the rules and regulations promulgated thereunder (the &#147;<U>Exchange Act</U>&#148;)); such disclosure controls and procedures have been
designed to ensure that information required to be disclosed by the Company in reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the Commission&#146;s rules
and forms. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) The Company has not taken, directly or indirectly, any action designed to or that would constitute or that
might reasonably be expected to cause or result in, under the Exchange Act or otherwise, stabilization or manipulation of the price of any security of the Company to facilitate the sale or resale of the Securities. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(jj) The Company and its subsidiaries are (i)&nbsp;in compliance with any and all applicable foreign, federal, state and local
laws and regulations relating to the protection of human health and safety, the environment or hazardous or toxic substances or wastes, pollutants or contaminants (collectively, &#147;<U>Environmental Laws</U>&#148;), (ii) have received and are in
compliance with all permits, licenses or other approvals required of them under applicable Environmental Laws to conduct their respective businesses and (iii)&nbsp;have not received notice of any actual or potential liability under any environmental
law, except in each case where such <FONT STYLE="white-space:nowrap">non-compliance</FONT> with Environmental Laws, failure to receive required permits, licenses or other approvals, or liability would not, individually or in the aggregate, have a
Material Adverse Effect, except as set forth in or contemplated in the Disclosure Package and the Prospectus (exclusive of any amendment or supplement thereto). Except as set forth in the Disclosure Package and the Prospectus, neither the Company
nor any of the subsidiaries has been named as a &#147;potentially responsible party&#148; under the Comprehensive Environmental Response, Compensation, and Liability Act of 1980, as amended. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(kk) There is and has been no failure on the part of the Company and any of the Company&#146;s directors or officers, in their
capacities as such, to comply with any provision of the Sarbanes-Oxley Act of 2002, as amended, and the rules and regulations promulgated in connection thereunder, that are then in effect and with which the Company is required to comply as of the
effectiveness of the Registration Statement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ll) Neither the Company nor any of its subsidiaries nor, to the knowledge
of the Company, any director, officer, agent, employee, affiliate or other person acting on behalf of the Company or any of its subsidiaries (i)&nbsp;has used any corporate funds for any unlawful contribution, gift, entertainment or other unlawful
expense relating to political activity; (ii)&nbsp;has made any direct or indirect unlawful payment to any foreign or domestic government official or employee (including of any government owned or controlled entity, or any person acting in an
official capacity for or on behalf of any of the foregoing) from corporate funds; or (iii)&nbsp;has made any bribe, rebate, payoff, influence payment, kickback or other unlawful payment, or (iv)&nbsp;is aware of or has taken any action, directly or
indirectly, that could result in a violation or a sanction for violation by such persons of the U.S. Foreign Corrupt Practices Act of 1977, the U.K. Bribery Act 2010, OECD Convention on Combating Bribery of Foreign Public Officials in International
Business Transactions, or any other applicable anti-bribery or anti-corruption law, each as may be amended, or the rules or regulations thereunder (collectively, the &#147;Anti-Corruption Laws&#148;); and the Company and its subsidiaries have
instituted and maintain policies and procedures to ensure compliance with the Anti-Corruption Laws. No part of the proceeds of the offering will be used, directly or indirectly, in violation of the Anti-Corruption Laws. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(mm) The operations of the Company and its subsidiaries are and have been conducted at all times in compliance with applicable
financial recordkeeping and reporting requirements and the money laundering statutes of all jurisdictions where the Company or any of its subsidiaries conducts business, the rules and regulations thereunder and any related or similar rules,
regulations or guidelines, issued, administered or enforced by any governmental agency (collectively, the &#147;<U>Money Laundering Laws</U>&#148;) and no action, suit or proceeding by or before any court or governmental agency, authority or body or
any arbitrator involving the Company or any of its subsidiaries with respect to the Money Laundering Laws is pending or, to the knowledge of the Company, threatened. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(nn) Neither the Company nor any of its subsidiaries nor, to the knowledge of the Company, any director, officer, agent,
employee or affiliate of the Company or any of its subsidiaries (i)&nbsp;is, or is controlled or 50% or more owned in the aggregate by or is acting on behalf of, one or more individuals or entities that are currently the subject of any sanctions
administered or enforced by the United States (including any administered or enforced by the Office of Foreign Assets Control of the U.S. Department of the Treasury, the U.S. Department of State or the Bureau of Industry and Security of the U.S.
Department of Commerce), the United Nations Security Council, the European Union, a member state of the European Union (including sanctions administered or enforced by Her Majesty&#146;s Treasury of the United Kingdom) or other relevant sanctions
authority (collectively, &#147;<U>Sanctions</U>&#148; and such persons, &#147;<U>Sanctioned Persons</U>&#148; and each such person, a &#147;<U>Sanctioned Person</U>&#148;), (ii) is located, organized or resident in a country or territory that is, or
whose government is, the subject of Sanctions that broadly prohibit dealings with that country or territory (currently, the Crimea region, Cuba, Iran, North Korea, and Syria) (collectively, &#147;<U>Sanctioned Countries</U>&#148; and each, a
&#147;<U>Sanctioned Country</U>&#148;) or (iii)&nbsp;will, directly or </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
indirectly, use the proceeds of this offering, or lend, contribute or otherwise make available such proceeds to any subsidiary, joint venture partner or other individual or entity in any manner
that would result in a violation of any Sanctions by, or could result in the imposition of Sanctions against, any individual or entity (including any individual or entity participating in the offering, whether as underwriter, advisor, investor or
otherwise). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(oo) Neither the Company nor any of its subsidiaries has engaged in any dealings or transactions with or for
the benefit of a Sanctioned Person, or with or in a Sanctioned Country, in the preceding three years, nor does the Company or any of its subsidiaries have any plans to engage in dealings or transactions with or for the benefit of a Sanctioned
Person, or with or in a Sanctioned Country. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(pp) The subsidiary listed on Exhibit 21.1 to the Registration Statement is
the only subsidiary of the Company. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(qq) Except as would not reasonably be expected to result in a Material Adverse
Effect, the Company and its subsidiaries own, possess, license or have other rights to use, on reasonable terms, all patents, patent applications, trade and service marks, trade and service mark registrations, trade names, copyrights, licenses,
inventions, trade secrets, technology, <FONT STYLE="white-space:nowrap">know-how</FONT> and other intellectual property (collectively, the &#147;<U>Intellectual Property</U>&#148;) necessary for the conduct of the Company&#146;s business as now
conducted or as proposed in the Disclosure Package and Prospectus to be conducted. Except as set forth in the Disclosure Package and the Prospectus under the captions &#147;Risk Factors&#151;Risks Relating to Intellectual Property&#148; and
&#147;Business&#151;Intellectual Property,&#148; or as would not reasonably be expected to result in a Material Adverse Effect (a)&nbsp;there are no rights of third parties to any such Intellectual Property; (b)&nbsp;to the Company&#146;s knowledge,
there is no material infringement by third parties of any such Intellectual Property; (c)&nbsp;there is no pending or, to the knowledge of the Company, threatened action, suit, proceeding or claim by others challenging the Company&#146;s rights in
or to any such Intellectual Property, and the Company is unaware of any facts which would form a reasonable basis for any such claim; (d)&nbsp;there is no pending or, to the knowledge of the Company, threatened action, suit, proceeding or claim by
others challenging the validity or scope of any such Intellectual Property, and the Company is unaware of any facts which would form a reasonable basis for any such claim; (e)&nbsp;there is no pending or, to the knowledge of the Company, threatened
action, suit, proceeding or claim by others that the Company infringes or otherwise violates any patent, trademark, copyright, trade secret or other proprietary rights of others, and the Company is unaware of any other fact which would form a
reasonable basis for any such claim; (f)&nbsp;to the Company&#146;s knowledge, there is no valid and enforceable U.S. patent or published U.S. patent application which contains claims that dominate or may dominate any Intellectual Property described
in the Disclosure Package and the Prospectus as being owned by or licensed to the Company or that interferes with the issued or pending claims of any such Intellectual Property, in each case as such Intellectual Property relates to product
candidates under clinical development as described in the Disclosure Package and the Prospectus, and (g)&nbsp;there is no prior art of which the Company is aware that may render any U.S. patent held by the Company invalid or any U.S. patent
application held by the Company <FONT STYLE="white-space:nowrap">un-patentable</FONT> which has not been disclosed to the U.S. Patent and Trademark Office. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(rr) Except as disclosed in the Registration Statement, the Disclosure
Package and the Prospectus, the Company (i)&nbsp;does not have any&nbsp;material lending or other relationship with any bank or lending affiliate of Citigroup Global Markets Holdings Inc. or SVB Leerink LLC and (ii)&nbsp;does not intend to use any
of the proceeds from the sale of the Securities hereunder to repay any outstanding debt owed to any affiliate of Citigroup Global Markets Holdings Inc or SVB Leerink LLC. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ss) Neither the Company nor any of its subsidiaries nor any of its or their properties or assets has any immunity from the
jurisdiction of any court or from any legal process (whether through service or notice, attachment prior to judgment, attachment in aid of execution or otherwise) under the laws of Australia. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(tt) The Company and its subsidiaries are, and at all times have been, in material compliance with all applicable Health Care
Laws. For purposes of this Agreement, &#147;<U>Health Care Laws</U>&#148; means: (i)&nbsp;the Federal Food, Drug, and Cosmetic Act (21 U.S.C. Section&nbsp;301 et seq.), the Public Health Service Act (42 U.S.C. Section&nbsp;201 et seq.), and the
regulations promulgated thereunder; (ii)&nbsp;all applicable federal, state, local and foreign health care fraud and abuse laws, including, without limitation, the Anti-Kickback Statute (42 U.S.C.
<FONT STYLE="white-space:nowrap">Section&nbsp;1320a-7b(b)),</FONT> the Civil False Claims Act (31 U.S.C. Section&nbsp;3729 et seq.), the criminal false statements law (42 U.S.C. <FONT STYLE="white-space:nowrap">Section&nbsp;1320a-7b(a)),</FONT> 18
U.S.C. Sections 286 and 287, the health care fraud criminal provisions under the U.S. Health Insurance Portability and Accountability Act of 1996 (&#147;HIPAA&#148;) (42 U.S.C. Section&nbsp;1320d et seq.), the Stark Law (42 U.S.C.
Section&nbsp;1395nn), the civil monetary penalties law (42 U.S.C. <FONT STYLE="white-space:nowrap">Section&nbsp;1320a-7a),</FONT> the exclusion law (42 U.S.C. <FONT STYLE="white-space:nowrap">Section&nbsp;1320a-7),</FONT> the Physician Payments
Sunshine Act (42 U.S.C. <FONT STYLE="white-space:nowrap">Section&nbsp;1320-7h),</FONT> and applicable laws governing government funded or sponsored healthcare programs; (iii)&nbsp;HIPAA, as amended by the Health Information Technology for Economic
and Clinical Health Act (42 U.S.C. Section&nbsp;17921 et seq.); (iv) the Patient Protection and Affordable Care Act of 2010, as amended by the Health Care and Education Reconciliation Act of 2010; (v) licensure, quality, safety and accreditation
requirements under applicable federal, state, local or foreign laws or regulatory bodies; (vi)&nbsp;all other local, state, federal, national, supranational and foreign laws, relating to the regulation of the Company or its subsidiaries, and
(vii)&nbsp;the directives and regulations promulgated pursuant to such statutes and any state or <FONT STYLE="white-space:nowrap">non-U.S.</FONT> counterpart thereof. Neither the Company nor any of its subsidiaries has received any FDA Form 483,
notice of adverse finding, warning letter, untitled letter or notice of any claim, action, suit, proceeding, hearing, enforcement, investigation, arbitration or other action from any court or arbitrator or governmental or regulatory authority or
third party alleging that any product operation or activity is in material violation of any Health Care Laws nor, to the Company&#146;s knowledge, is any such claim, action, suit, proceeding, hearing, enforcement, investigation, arbitration or other
action threatened. The Company and its subsidiaries have filed, maintained or submitted all reports, documents, forms, notices, applications, records, claims, submissions and supplements or amendments as required by any Health Care Laws, and all
such reports, documents, forms, notices, applications, records, claims, submissions and supplements or amendments were complete and accurate on the date filed or were corrected or supplemented by a subsequent submission, except as would not cause a
Material Adverse Effect. Neither the Company nor any subsidiary is a party to any corporate integrity agreement, monitoring agreement, consent decree, settlement order, or </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
similar agreement with or imposed by any governmental or regulatory authority. Additionally, neither the Company, any of its subsidiaries, nor any of its or their respective employees, officers,
directors or, to the Company&#146;s knowledge, agents, has been excluded, suspended or debarred from participation in any U.S. federal health care program or human clinical research or, to Company&#146;s knowledge, is subject to a governmental
inquiry, investigation, proceeding, or other similar action that could reasonably be expected to result in debarment, suspension, or exclusion. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(uu) The Company&#146;s information technology assets and equipment, computers, systems, networks, hardware, software,
websites, applications, and databases (collectively, &#147;<U>IT Systems and Data</U>&#148;) are adequate for, and operate and perform as required in connection with the operation of the business of the Company and its subsidiaries as currently
conducted, free and clear of all bugs, errors, defects, Trojan horses, time bombs, malware and other corruptants, except as would not reasonably be expected to result in a Material Adverse Effect. The Company and its subsidiaries have implemented
and maintain commercially reasonable physical, technical and administrative controls, policies, procedures, and safeguards to maintain and protect their material confidential information and the integrity, continuous operation, redundancy and
security of all IT Systems and Data, including &#147;Personal Data,&#148; used in connection with their businesses. &#147;Personal Data&#148; means (i)&nbsp;a natural person&#146;s name, street address, telephone number, <FONT
STYLE="white-space:nowrap">e-mail</FONT> address, photograph, social security number or tax identification number, driver&#146;s license number, passport number, credit card number, bank information, or customer or account number; (ii)&nbsp;any
information which would qualify as &#147;personally identifying information&#148; under the Federal Trade Commission Act, as amended; (iii) &#147;personal data&#148; as defined by the European Union General Data Protection Regulation (EU 2016/679);
(iv) any information which would qualify as &#147;protected health information&#148; under HIPAA; and (v)&nbsp;any other piece of information that allows the identification of such natural person, or his or her family, or permits the collection or
analysis of any data related to an identified person&#146;s health or sexual orientation. There have been no breaches, violations, outages or unauthorized uses of or accesses to Personal Data, except for those that have been remedied without
material cost or liability or the duty to notify any other person, nor any incidents under internal review or investigations relating to the same. The Company and its subsidiaries have been and are presently in material compliance with all
applicable laws, directives, or statutes and all judgments, orders, rules and regulations of any court or arbitrator or governmental or regulatory authority, internal policies and contractual obligations relating to the privacy and security of IT
Systems and Data, including Personal Data and to the protection of such IT Systems and Data and Personal Data from unauthorized use, access, misappropriation or modification, except as would not reasonably be expected to result in a Material Adverse
Effect. There has been no security breach or other material compromise of or relating to any of the Company&#146;s IT Systems and Data and the Company has not been notified of, and has no knowledge of any event or condition that would reasonably be
expected to result in, any security breach or other material compromise to their IT Systems and Data, except for any breaches or compromises that would not, individually or in the aggregate, reasonably be expected to result in a Material Adverse
Effect. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(vv) The Company and its subsidiaries are, and have at all times been, in
material compliance with all applicable data privacy and security laws and regulations of any court or arbitrator or governmental or regulatory authority, internal policies and contractual obligations regarding the privacy and security of IT Systems
and Data and Personal Data (collectively, the &#147;Privacy Laws&#148;), except as would not, individually or in the aggregate, result in a Material Adverse Effect. To ensure compliance with the Privacy Laws, the Company and each of its subsidiaries
has in place, complies with, and takes appropriate steps reasonably designed to ensure compliance in all material respects with their policies and contractual obligations governing the collection, storage, use, disclosure, handling and analysis of
Personal Data. The Company has at all times made all material disclosures to users or customers required by the Privacy Laws, except as would not, individually or in the aggregate, result in a Material Adverse Effect. The Company further certifies
that neither the Company nor any of its subsidiaries: (i)&nbsp;have received notice of, any actual or potential liability under or relating to, or actual or potential violation of, any of the Privacy Laws, and has no knowledge of any event or
condition that would reasonably be expected to result in, any such notice; (ii)&nbsp;are currently conducting or paying for, in whole or in part, any investigation, remediation, or other corrective action pursuant to any Privacy Laws; or
(iii)&nbsp;is a party to any order, decree, or agreement that imposes any obligation or liability under any Privacy Law, except with respect to subsection (i), (ii) and (iii)&nbsp;as would not, individually or in the aggregate, result in a Material
Adverse Effect. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ww) The preclinical studies and clinical trials that are described in the Registration Statement, the
Disclosure Package or the Prospectus (collectively, &#147;<U>Studies</U>&#148;) were conducted by or, to the knowledge of the Company, on behalf of the Company or its subsidiaries were and, if still ongoing, are being conducted in all material
respects in accordance with the protocols, procedures and controls designed for such Studies and pursuant to, where applicable, accepted professional scientific standards; the descriptions of the results of such studies contained in the Registration
Statement, the Disclosure Package or the Prospectus are accurate and complete and fairly present the data derived from such Studies, in each case in all material respects, and the Company and its subsidiaries have no knowledge of any other Studies
the results of which are materially inconsistent with, or otherwise call into question, the results described or referred to in the Registration Statement, the Disclosure Package or the Prospectus; the Company and its subsidiaries have made all such
filings and obtained all such approvals as may be required by the FDA or any committee thereof or from any other U.S. or foreign government or drug or medical device regulatory agency, or health care facility Institutional Review Board
(collectively, the &#147;<U>Regulatory Agencies</U>&#148;), except as would not, individually or in the aggregate, reasonably be expected to result in a Material Adverse Effect; neither the Company nor any of its subsidiaries have received any
notice from, or correspondence from, any Regulatory Agency requiring the termination, suspension or material modification of any Studies conducted by or on behalf of the Company or its subsidiaries; and the Company and its subsidiaries are in
compliance in all material respects with all applicable rules, regulations and policies of the Regulatory Agencies. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(xx)
Neither the Company nor any Group Member is Insolvent and there is no act which has occurred nor any omission which may result in the Company or a Group Member becoming Insolvent. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">15 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(yy) All announcements which have been lodged by the Company on the
Australian Securities Exchange are not misleading or deceptive in any material respect. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Any certificate signed by any officer of the
Company and delivered to the Representatives or counsel for the Underwriters in connection with the offering of the Securities shall be deemed a representation and warranty by the Company, as to matters covered thereby, to each Underwriter. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">2. <U>Purchase and Sale</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) Subject to the terms and conditions and in reliance upon the representations and warranties herein set forth, the Company
agrees to sell to each Underwriter, and each Underwriter agrees, severally and not jointly, to purchase from the Company, at a purchase price of $<B>[</B><B></B>&#9679;<B></B><B></B><B>]</B>&nbsp;per ADS, the amount of the Underwritten ADSs set
forth opposite such Underwriter&#146;s name in <U>Schedule</U><U></U><U>&nbsp;I</U> hereto. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) Subject to the terms and
conditions and in reliance upon the representations and warranties herein set forth, the Company hereby grants an option to the several Underwriters to purchase, severally and not jointly, up to <B>[</B><B></B>&#9679;<B></B><B></B><B>] </B>Option
ADSs at the same purchase price per share as the Underwriters shall pay for the Underwritten ADSs, less an amount per ADS equal to any dividends or distributions declared by the Company and payable on the Ordinary Shares underlying the Underwritten
ADSs but not payable on the Ordinary Shares underlying the Option ADSs. Said option may be exercised only to cover over-allotments in the sale of the Underwritten Securities by the Underwriters. Said option may be exercised in whole or in part at
any time on or before the 30th day after the date of the Prospectus upon written or telegraphic notice by the Representatives to the Company setting forth the number of shares of the Option ADSs as to which the several Underwriters are exercising
the option and the settlement date. The maximum number of Option ADSs to be sold by the Company is [&#9679;]. In the event that the Underwriters exercise less than their full option to purchase Option ADSs, the number of Option ADSs to be sold by
the Company shall be, as nearly as practicable, in the same proportion to each other as are the maximum number of Option ADSs to be sold by the Company and the number of Option ADSs listed opposite their names on
<U>Schedule</U><U></U><U>&nbsp;II</U>. The number of Option ADSs to be purchased by each Underwriter shall be the same percentage of the total number of shares of the Option ADSs to be purchased by the several Underwriters as such Underwriter is
purchasing of the Underwritten ADSs, subject to such adjustments as you in your absolute discretion shall make to eliminate any fractional ADSs. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">3. <U>Delivery and Payment</U>. Delivery of and payment for the Underwritten ADSs and the Option ADSs (if the option provided for in
<U>Section</U><U></U><U>&nbsp;2(b)</U> hereof shall have been exercised on or before the second Business Day immediately preceding the Closing Date) shall be made at 10:00&nbsp;AM, New York City time, on [&#9679;], 2020, or at such time on such
later date not more than two Business Days after the foregoing date as the Representatives shall designate, which date and time may be postponed by agreement among the Representatives and the Company or as provided in
<U>Section</U><U></U><U>&nbsp;10</U> hereof (such date and time of delivery and payment for the Securities being called in this Agreement the &#147;<U>Closing Date</U>&#148;). As used herein, &#147;<U>Business Day</U>&#148; shall mean any
day&nbsp;other than a Saturday, a Sunday or a legal holiday or a day on which banking institutions or trust </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">16 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
companies are authorized or obligated by law to close in New York City. Delivery of the Securities shall be made to the Representatives for the respective accounts of the several Underwriters
against payment by the several Underwriters through the Representatives of the respective aggregate purchase prices of the Offered ADSs being sold by the Company to or upon the order of the Company by wire transfer payable in <FONT
STYLE="white-space:nowrap">same-day</FONT> funds to the accounts specified by the Company. Delivery of the Offered ADSs shall be made through the facilities of The Depository Trust Company unless the Representatives shall otherwise instruct. For the
purposes only of the delivery of the Underwritten ADSs, the parties agree that where an Underwriter has an obligation to <FONT STYLE="white-space:nowrap">on-transfer</FONT> an Underwritten ADS to another party, that Underwriter receives delivery of
and holds such Underwritten ADSs as bare trustee for the person they are obliged to transfer those Underwritten ADSs to. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the option
provided for in <U>Section</U><U></U><U>&nbsp;2(b)</U> hereof is exercised after the second Business Day immediately preceding the Closing Date, the Company will deliver (at the expense of the Company) to the Representatives, at 388 Greenwich
Street, New York, New York, on the date specified by the Representatives (which shall be within two Business Days after exercise of said option), certificates for the Option ADSs in such names and denominations as the Representatives shall have
requested for the respective accounts of the several Underwriters, against payment by the several Underwriters through the Representatives of the purchase price thereof to or upon the order of the Company by wire transfer payable in <FONT
STYLE="white-space:nowrap">same-day</FONT> funds. If settlement for the Option ADSs occurs after the Closing Date, the Company will deliver to the Representatives on the settlement date for the Option ADSs, and the obligation of the Underwriters to
purchase the Option ADSs shall be conditioned upon receipt of, supplemental opinions, certificates and letters confirming as of such date the opinions, certificates and letters delivered on the Closing Date pursuant to Section&nbsp;6 hereof. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">The ADRs evidencing the Offered ADSs shall be registered in such names and in such denominations as the Representatives may request not less
than one full business day prior to the applicable Closing Date. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">3A. <U>Regulatory Event</U>. In satisfying its obligations under this
agreement an Underwriter will not be required to subscribe for a number of Underwritten ADSs which will result in the Underwriter or its Affiliates (a) being obliged to notify the Treasurer under the <I>Foreign Acquisitions and Takeovers Act
1975</I> (Cth) (<U>&#147;FATA</U>&#148;); (b) breaching published Foreign Investment Review Board policy (<U>&#147;FIRB Policy</U>&#148;); or (c) breaching section 606 of the Corporations Act (<U>&#147;Takeovers Prohibition</U>&#148;), (each being a
<U>&#147;Regulatory Event</U>&#148;), taking into account the number of Shares then held by that Underwriter and/or its Affiliates (or in which they hold a relevant interest for the purposes of Chapter 6 of the Corporations Act) (<U>&#147;Relevant
ADSs</U>&#148;). To the extent that this clause prevents an Underwriter itself subscribing for Underwritten ADSs, it must still comply with its obligations to pay or procure payment to the Company pursuant to this agreement for such Relevant ADSs,
and must continue its efforts to procure subscribers for such Relevant ADSs until 9.00am on the date falling three months after the Closing Date (<U>&#147;Subscription End Time</U>&#148;). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">If an Underwriter becomes itself able to subscribe for some or all of the Relevant ADSs before the Subscription End Time without resulting in a
Regulatory Event, that Underwriter agrees to subscribe for such Relevant Shares. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">The Company must until the Subscription End Time promptly
allot and issue the Relevant ADS upon notification from the Underwriters at any time after the date of this agreement that it has procured subscribers for such Relevant ADSs, or is itself able to subscribe for such Relevant ADSs without resulting in
a Regulatory Event, at any time the Underwriters request, provided that no subscriptions may be made by any person (other than the Underwriters or their Affiliates) unless they have confirmed to the Underwriters and the Company in writing that the
subscription for such Relevant ADSs will not lead to a breach by that person or its Affiliates of FATA, FIRB Policy or the Takeovers Prohibition. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">The Company is not required to repay at any time any amount paid by that Underwriter to the Company under this agreement in respect of the
Relevant ADSs, even if that Underwriter is not able to procure subscribers or itself subscribe&nbsp;for those Relevant ADSs. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">4.
<U>Offering by Underwriters</U>. It is understood that the several Underwriters propose to offer the Securities for sale to the public as set forth in the Prospectus. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">5. <U>Agreements</U>. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(i) The
Company agrees with the several Underwriters that: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) Prior to the termination of the offering of the Securities, the
Company will not file any amendment of the Registration Statement or the ADS Registration Statement or supplement to the Prospectus or any Rule&nbsp;462(b) Registration Statement unless the Company has furnished you a copy for your review prior to
filing and will not file any such proposed amendment or supplement to which you reasonably object. The Company will cause the Prospectus, properly completed, and any supplement thereto to be filed in a form approved by the Representatives with the
SEC pursuant to the applicable paragraph of Rule&nbsp;424(b) within the time period prescribed and will provide evidence satisfactory to the Representatives of such timely filing. The Company will promptly advise the Representatives (i)&nbsp;when
the Prospectus, and any supplement thereto, shall have been filed </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">17 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
(if required) with the SEC pursuant to Rule 424(b) or when any Rule 462(b) Registration Statement or the ADS Registration Statement shall have been filed with the SEC, (ii)&nbsp;when, prior to
termination of the offering of the Securities, any amendment to the Registration Statement or the ADS Registration Statement shall have been filed or become effective, (iii)&nbsp;of any request by the SEC or its staff for any amendment of the
Registration Statement, the ADS Registration Statement or any Rule&nbsp;462(b) Registration Statement, or for any supplement to the Prospectus or for any additional information, (iv)&nbsp;of the issuance by the SEC of any stop order suspending the
effectiveness of the Registration Statement or the ADS Registration Statement or of any notice objecting to their use or the institution or threatening of any proceeding for that purpose and (v)&nbsp;of the receipt by the Company of any notification
with respect to the suspension of the qualification of the Securities for sale in any jurisdiction or the institution or threatening of any proceeding for such purpose. The Company will use its best efforts to prevent the issuance of any such stop
order or the occurrence of any such suspension or objection to the use of the Registration Statement and, upon such issuance, occurrence or notice of objection, to obtain as soon as possible the withdrawal of such stop order or relief from such
occurrence or objection, including, if necessary, by filing an amendment to the Registration Statement or the ADS Registration Statement or a new registration statement and using its best efforts to have such amendment or new registration statement
declared effective as soon as practicable. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) If, at any time prior to the filing of the Prospectus pursuant to Rule
424(b), any event occurs as a result of which the Disclosure Package would include any untrue statement of a material fact or omit to state any material fact necessary in order to make the statements therein in the light of the circumstances under
which they were made or the circumstances then prevailing not misleading, the Company will (i)&nbsp;notify promptly the Representatives so that any use of the Disclosure Package may cease until it is amended or supplemented; (ii)&nbsp;amend or
supplement the Disclosure Package to correct such statement or omission; and (iii)&nbsp;supply any amendment or supplement to you in such quantities as you may reasonably request. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) If, at any time when a prospectus relating to the Securities is required to be delivered under the Securities Act
(including in circumstances where such requirement may be satisfied pursuant to Rule 172 under the Securities Act (&#147;<U>Rule 172</U>&#148;)), any event occurs as a result of which either of the Prospectus as then supplemented would include any
untrue statement of a material fact or omit to state any material fact necessary in order to make the statements therein in the light of the circumstances under which they were made or the circumstances then prevailing not misleading, or if it shall
be necessary to amend the Registration Statement or supplement either of the Prospectus to comply with the Securities Act or the rules thereunder, the Company promptly will (i)&nbsp;notify the Representatives of any such event; (ii)&nbsp;prepare and
file with the SEC, subject to the second sentence of paragraph&nbsp;(i)(a) of this <U>Section</U><U></U><U>&nbsp;5</U>, an amendment or supplement which will correct such statement or omission or effect such compliance;<SUP
STYLE="font-size:85%; vertical-align:top"> </SUP>and (iii)&nbsp;supply any supplemented Prospectus to you in such quantities as you may reasonably request. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">18 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) As soon as practicable, the Company will make generally available to its
security holders and to the Representatives an earnings statement or statements of the Company and its subsidiaries which will satisfy the provisions of Section&nbsp;11(a) of the Securities Act and Rule 158 under the Securities Act; provided that
the Company will be deemed to have furnished such statements to its security holders and the Representatives to the extent such statements are filed on the Commission&#146;s Electronic Data Gathering, Analysis and Retrieval system. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) Upon request, the Company will furnish to the Representatives and counsel for the Underwriters, without charge, signed
copies of the Registration Statement and the ADS Registration Statement (including exhibits thereto) and to each other Underwriter a copy of the Registration Statement and the ADS Registration Statement (without exhibits thereto) and, so long as
delivery of a prospectus by an Underwriter or dealer may be required (including in circumstances where such requirement may be satisfied pursuant to Rule 172) by the Securities Act, as many copies of each Preliminary Prospectus, the Prospectus and
each Issuer Free Writing Prospectus and any supplement thereto as the Representatives may reasonably request. The Company will pay the expenses of printing or other production of all documents relating to the offering. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f) The Company will arrange, if necessary, for the qualification of the Securities for sale under the laws of such
jurisdictions as the Representatives may designate and will maintain such qualifications in effect so long as required for the distribution of the Securities; provided that in no event shall the Company be obligated to qualify to do business in any
jurisdiction where it is not now so qualified or to take any action that would subject it to service of process in suits, other than those arising out of the offering or sale of the Securities, in any jurisdiction where it is not now so subject.
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(g) The Company will not, without the prior written consent of the Representatives, offer, sell, contract to sell, pledge,
or otherwise dispose of, (or enter into any transaction which is designed to, or might reasonably be expected to, result in the disposition (whether by actual disposition or effective economic disposition due to cash settlement or otherwise) by the
Company&nbsp;or any affiliate of the Company or any person in privity with the Company or any affiliate of the Company) directly or indirectly, including the filing (or participation in the filing) of a registration statement with the SEC in respect
of, or establish or increase a put equivalent position or liquidate or decrease a call equivalent position within the meaning of Section&nbsp;16 of the Exchange Act, any Ordinary Shares or ADSs or any securities convertible into, or exercisable, or
exchangeable for, Ordinary Shares or ADSs; or publicly announce an intention to effect any such transaction, for a period of 90 days after the date of this Agreement, <U>provided</U>, <U>however</U>, that the Company may (i)&nbsp;issue and sell
Ordinary Shares or ADSs or any securities convertible into, or exercisable, or exchangeable for, Ordinary shares or ADSs pursuant to any employee stock option plan, stock ownership plan or dividend reinvestment plan of the Company in effect at the
Execution Time, (ii)&nbsp;may issue Ordinary Shares issuable upon the conversion of securities or the exercise of warrants outstanding at the Execution Time, (iii)&nbsp;file one or more registration statements on Form
<FONT STYLE="white-space:nowrap">S-8</FONT> relating to stock options or employee benefit plans of the Company described in the Disclosure Package and the Prospectus, (iv)&nbsp;offer, issue and sell Ordinary Shares or ADSs, or any securities
convertible into, or exercisable, or exchangeable for, Ordinary shares or ADSs, in connection with any merger, acquisition or strategic investment (including any joint venture, strategic alliance, partnership, the acquisition or license of the
business, property, technology or other assets </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">19 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
of another individual or entity, or the assumption of an employee benefit plan in connection with such a merger or acquisition), or (v)&nbsp;offer, issue and sell Ordinary Shares or ADSs, or any
securities convertible into, or exercisable, or exchangeable for, Ordinary shares or ADSs, on an arm&#146;s length basis to any unaffiliated collaborators, manufacturers, distributors, or any other similar parties pursuant to a collaboration,
licensing agreement, strategic alliance, manufacturing or distribution agreement or similar transaction; <U>provided</U>,<U>&nbsp;however</U>, that the aggregate number of securities (on an <FONT STYLE="white-space:nowrap">as-converted</FONT> basis)
that the Company may issue or agree to issue pursuant to clauses (iv)&nbsp;and (v) shall not exceed 5% of the number of Ordinary Shares outstanding immediately after the issuance and sale of such securities,
and<U>&nbsp;provided</U>,<U>&nbsp;further</U>, that each recipient of such securities pursuant to clauses (iv)&nbsp;and (v) agrees to restrictions on the resale of securities that are consistent with the provisions set forth in the <FONT
STYLE="white-space:nowrap">lock-up</FONT> letter described in Section&nbsp;6(p) hereof. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(h) If the Representatives in
their sole discretion, agree to release or waive the restrictions set forth in a <FONT STYLE="white-space:nowrap">lock-up</FONT> letter described in <U>Section</U><U></U><U>&nbsp;6(g)</U> hereof for an officer or director of the Company and provides
the Company with notice of the impending release or waiver at least three (3)&nbsp;Business Days before the effective date of the release or waiver, the Company agrees to announce the impending release or waiver by a press release substantially in
the form of Exhibit B hereto through a major news service at least two (2)&nbsp;Business Days before the effective date of the release or waiver. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) The Company will not take, directly or indirectly, any action designed to or that would constitute or that might reasonably
be expected to cause or result in, under the Exchange Act or otherwise, stabilization or manipulation of the price of any security of the Company to facilitate the sale or resale of the Securities. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(j) The Company agrees to pay the costs and expenses relating to the following matters: (i)&nbsp;the preparation, printing or
reproduction and filing with the SEC of the Registration Statement (including financial statements and exhibits thereto), the Preliminary Prospectus, the Prospectus, each Issuer Free Writing Prospectus, the ADS Registration Statement, and each
amendment or supplement to any of them; (ii)&nbsp;the preparation of the Deposit Agreement, the deposit of the Underlying Securities under the Deposit Agreement, the issuance thereunder of ADSs representing such deposited Underlying Securities, the
issuance of ADRs evidencing such ADSs and the fees of the Depositary; (iii)&nbsp;the printing (or reproduction) and delivery (including postage, air freight charges and charges for counting and packaging) of such copies of the Registration
Statement, the Preliminary Prospectus, the Prospectus, the ADS Registration Statement, and each Issuer Free Writing Prospectus and all amendments or supplements to any of them, as may, in each case, be reasonably requested for use in connection with
the offering and sale of the Securities; (iv)&nbsp;the preparation, printing, authentication, issuance and delivery of certificates for the Securities, including any Transfer Taxes in connection with the original issuance and sale of the Securities;
(v)&nbsp;the printing (or reproduction) and delivery of this Agreement, any blue sky memorandum and all other agreements or documents printed (or reproduced) and delivered in connection with the offering of the Securities; (vi)&nbsp;the registration
of the Securities under the Exchange Act and the listing of the ADSs on the Nasdaq Global Market; (vii)&nbsp;any registration or qualification of the Securities for offer and sale under the securities or blue sky laws of the several states
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">20 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
(including filing fees and the reasonable fees and expenses of counsel for the Underwriters relating to such registration and qualification); (viii)&nbsp;any filings required to be made with the
Financial Industry Regulatory Authority, Inc. (including filing fees and the reasonable fees and expenses of counsel for the Underwriters relating to such filings), provided that such fees and expenses of counsel contained in clauses (vii)&nbsp;and
(viii) shall not exceed $30,000 in the aggregate; (ix)&nbsp;the transportation and other expenses incurred by or on behalf of Company representatives in connection with presentations to prospective purchasers of the Securities; (x)&nbsp;the fees and
expenses of the Company&#146;s accountants and the fees and expenses of counsel (including local and special counsel) for the Company; and (xi)&nbsp;all other costs and expenses incident to the performance by the Company of its obligations under
this Agreement. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(k) The Company agrees that, unless it has or shall have obtained the prior written consent of the
Representatives, and each Underwriter, severally and not jointly, agrees with the Company that, unless it has or shall have obtained, as the case may be, the prior written consent of the Company, in each case such consent not to be unreasonably
withheld, it has not made and will not make any offer relating to the Securities that would constitute an Issuer Free Writing Prospectus or that would otherwise constitute a Free Writing Prospectus required to be filed by the Company with the SEC or
retained by the Company under Rule 433. Any such free writing prospectus consented to by the Representatives or the Company is hereinafter referred to as a &#147;<U>Permitted Free Writing Prospectus</U>.&#148; The Company agrees that (x)&nbsp;it has
treated and will treat, as the case may be, each Permitted Free Writing Prospectus as an Issuer Free Writing Prospectus and (y)&nbsp;it has complied and will comply, as the case may be, with the requirements of Rule 164 under the Securities Act
(&#147;<U>Rule 164</U>&#148;) and Rule 433 applicable to any Permitted Free Writing Prospectus, including in respect of timely filing with the SEC, legending and record keeping. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(l) The Company will promptly notify the Representatives if the Company ceases to be an Emerging Growth Company at any time
prior to the later of (a)&nbsp;completion of the distribution of the Securities within the meaning of the Securities Act and (b)&nbsp;completion of the <FONT STYLE="white-space:nowrap">90-day</FONT> restricted period referred to in
<U>Section</U><U></U><U>&nbsp;5(h)</U> hereof. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(m) If at any time following the distribution of any Written <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Testing-the-Waters</FONT></FONT> Communication, any event occurs as a result of which such Written <FONT STYLE="white-space:nowrap">Testing-the-Waters</FONT> Communication would include any
untrue statement of a material fact or omit to state any material fact necessary in order to make the statements therein in the light of the circumstances under which they were made or the circumstances then prevailing not misleading, the Company
will (i)&nbsp;notify promptly the Representatives so that use of the Written <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Testing-the-Waters</FONT></FONT> Communication may cease until it is amended or supplemented;
(ii)&nbsp;amend or supplement the Written <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Testing-the-Waters</FONT></FONT> Communication to correct such statement or omission; and (iii)&nbsp;supply any amendment or supplement to
the Representatives in such quantities as may be reasonably requested. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">21 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(n) Each Underwriter agrees that (i)&nbsp;it is not purchasing any of the
Securities for the account of anyone other than a United States or Canadian Person, (ii) [it has not offered or sold, and will not offer or sell, directly or indirectly, any of the Securities or distribute any Prospectus to any person outside the
United States or Canada, or to anyone other than a United States or Canadian Person,] and (iii)&nbsp;any dealer to whom it may sell any of the Securities will represent that it is not purchasing for the account of anyone other than a United States
or Canadian Person and agree that it will not offer or resell, directly or indirectly, any of the Securities outside the United States or Canada, or to anyone other than a United States or Canadian Person or to any other dealer who does not so
represent and agree; provided, however, that the foregoing shall not restrict sales to or through (or distributions of the Disclosure Package or the Prospectus to) United States or Canadian Persons who are investment advisors, or who otherwise
exercise investment discretion, and who are purchasing for the account of anyone other than a United States or Canadian Person. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(o) The agreements of the Underwriters set forth in paragraph (n)&nbsp;of this <U>Section</U><U></U><U>&nbsp;5</U> shall
terminate upon the expiration of a period of thirty (30)&nbsp;days after the Closing Date. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">6. <U>Conditions to the Obligations of the
Underwriters</U>. The obligations of the Underwriters to purchase the Underwritten ADSs and the Option ADSs, as the case may be, shall be subject to the accuracy of the representations and warranties on the part of the Company contained in this
Agreement as of the Execution Time, the Closing Date and any settlement date pursuant to <U>Section</U><U></U><U>&nbsp;3</U> hereof, to the accuracy of the statements of the Company made in any certificates pursuant to the provisions hereof, to the
performance by the Company of its obligations under this Agreement and to the following additional conditions: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) The
Prospectus, and any supplement thereto, have been filed in the manner and within the time period required by Rule&nbsp;424(b); any other material required to be filed by the Company pursuant to Rule 433(d) shall have been filed with the SEC within
the applicable time periods prescribed for such filings by Rule 433; and no stop order suspending the effectiveness of the Registration Statement or the ADS Registration Statement or any notice objecting to their use shall have been issued and no
proceedings for that purpose shall have been instituted or threatened. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) The Company shall have requested and caused
Cooley LLP, U.S. counsel for the Company, to have furnished to the Representatives an opinion and a negative assurance letter, each dated as of the Closing Date and addressed to the Representatives, in form and substance reasonably satisfactory to
the Underwriters. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) The Company shall have requested and caused Gilbert + Tobin, Australian counsel for the Company, to
have furnished to the Representatives an opinion, each dated as of the Closing Date and addressed to the Representatives, in form and substance reasonably satisfactory to the Underwriters. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) The Company shall have requested and caused Marshall, Gerstein&nbsp;&amp; Borun LLP, counsel for the Company with respect
to intellectual property matters in the U.S., to have furnished to the Representatives an opinion and a negative assurance letter, dated as of the Closing Date and addressed to the Representatives, in form and substance reasonably satisfactory to
the Underwriters. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">22 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) The Company shall have requested and caused CMS Cameron McKenna Nabarro
Olswang LLP, counsel for the Company with respect to intellectual property matters in the European Union, to have furnished to the Representatives an opinion, dated as of the Closing Date and addressed to the Representatives, in form and substance
reasonably satisfactory to the Underwriters. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f) The Depositary shall have requested and caused Emmet, Marvin&nbsp;&amp;
Martin, LLP, counsel for the Depositary, to have furnished to the Representatives their opinion dated as of the Closing Date and addressed to the Representatives, in form and substance reasonably satisfactory to the Underwriters. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(g) The Representatives shall have received from&nbsp;Goodwin Procter LLP, U.S. counsel for the Underwriters, such opinion or
opinions, dated the Closing Date and addressed to the Representatives, with respect to the issuance and sale of the Securities, the Registration Statement, the ADS Registration Statement, the Disclosure Package, the Prospectus (together with any
supplement thereto) and other related matters as the Representatives may reasonably require, and the Company shall have furnished to such counsel such documents as they request for the purpose of enabling them to pass upon such matters. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(h) The Company shall have furnished to the Representatives a certificate of the Company, signed by the Chairman of the Board
or the Chief Executive Officer and the Chief Financial Officer of the Company, dated as of the Closing Date, to the effect that the signers of such certificate have carefully examined the Registration Statement, the ADS Registration Statement, the
Disclosure Package, the Prospectus and any amendment or supplement thereto, as well as each electronic road show used in connection with the offering of the Securities, and the Underwriting Agreement and that: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) the representations and warranties of the Company in the Underwriting Agreement are true and correct on and as of the
Closing Date with the same effect as if made on the Closing Date and the Company has complied with all the agreements and satisfied all the conditions on its part to be performed or satisfied at or prior to the Closing Date; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) no stop order suspending the effectiveness of the Registration Statement or the ADS Registration Statement or of any
notice objecting to their use has been issued and no proceedings for that purpose have been instituted or, to the Company&#146;s knowledge, threatened; and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">23 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iii) since the date of the most recent financial statements included in the
Disclosure Package and the Prospectus (exclusive of any amendment or supplement thereto), there has been no material adverse change in the condition (financial or otherwise), prospects, earnings, business or properties of the Company and its
subsidiaries, taken as a whole, whether or not arising from transactions in the ordinary course of business, except as set forth in or contemplated in the Disclosure Package and the Prospectus (exclusive of any amendment or supplement thereto). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) The Company shall have requested and caused&nbsp;Deloitte Touche Tohmatsu to have furnished to the Representatives, at the
Execution Time and at the Closing Date, letters, dated respectively as of the Execution Time and as of the Closing Date, in form and substance satisfactory to the Representatives, (i)&nbsp;confirming that they are independent accountants within the
meaning of the Securities Act and the Exchange Act and the applicable rules and regulations adopted by the SEC thereunder and (ii)&nbsp;containing statements and information of the type customarily included in accountants&#146; &#147;comfort
letters&#148; to underwriters with respect to the financial statements and certain financial information contained in the Registration Statement, the Disclosure Package and the Prospectus; provided, that the letter delivered on the Closing Date,
shall use a <FONT STYLE="white-space:nowrap">&#147;cut-off&#148;</FONT> date no more than three Business Days prior to such Closing Date. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(j) Subsequent to the Execution Time or, if earlier, the dates as of which information is given in the Registration Statement
(exclusive of any amendment thereof) and the Prospectus (exclusive of supplement thereto), there shall not have been any Material Adverse Effect, except as set forth in or contemplated in the Disclosure Package and the Prospectus (exclusive of any
amendment or supplement thereto) the effect of which is, in the sole judgment of the Representatives, so material and adverse as to make it impractical or inadvisable to proceed with the offering or delivery of the Securities as contemplated by the
Registration Statement (exclusive of any amendment thereof), the Disclosure Package and the Prospectus (exclusive of any amendment or supplement thereto). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(k) The Company and the Depositary shall have executed and delivered the Deposit Agreement in form and substance satisfactory
to the Representatives, and the Deposit Agreement shall be in full force and effect. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(l) The Depositary shall have
furnished or caused to be furnished to the Representatives certificates satisfactory to the Representatives evidencing the deposit with it or its nominee of the Underlying Securities in respect of which Offered ADSs to be purchased by the
Underwriters on such Closing Date are to be issued, and the execution, issuance, countersignature (if applicable) and delivery of the ADRs evidencing such Offered ADSs pursuant to the Deposit Agreement and such other matters related thereto as the
Representatives reasonably request. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(m) Prior to the Closing Date, the Company shall have furnished to the Representatives
such further information, certificates and documents as the Representatives may reasonably request. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">24 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(n) Subsequent to the Execution Time, there shall not have been any decrease
in the rating of any of the Company&#146;s debt securities by any &#147;nationally recognized statistical rating organization&#148; (as defined for purposes of Rule 3(a)(62) under the Exchange Act) or any notice given of any intended or potential
decrease in any such rating or of a possible change in any such rating that does not indicate the direction of the possible change. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(o) <B></B>The Securities shall have been listed and admitted and authorized for trading on the Nasdaq Global Market, and
satisfactory evidence of such actions shall have been provided to the Representatives. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(p) At the Execution Time, the
Company shall have furnished to the Representatives a letter, substantially in the form of <U>Exhibit A</U> hereto from each executive officer and director of the Company addressed to the Representatives. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">If any of the conditions specified in this <U>Section</U><U></U><U>&nbsp;6</U> shall not have been fulfilled when and as provided in this
Agreement, or if any of the opinions and certificates mentioned above or elsewhere in this Agreement shall not be reasonably satisfactory in form and substance to the Representatives and counsel for the Underwriters, this Agreement and all
obligations of the Underwriters hereunder may be canceled at, or at any time prior to, the Closing Date by the Representatives. Notice of such cancellation shall be given to the Company in writing or by telephone or facsimile confirmed in writing.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">The documents required to be delivered by this <U>Section</U><U></U><U>&nbsp;6</U> shall be delivered at the office of Goodwin Procter
LLP, counsel for the Underwriters, at 620 Eighth Avenue, New York, NY 10018, on the Closing Date. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">7. <U>Reimbursement of
Underwriters&#146; Expenses</U>. If the sale of the Securities provided for in this Agreement is not consummated because any condition to the obligations of the Underwriters set forth in <U>Section</U><U></U><U>&nbsp;6</U> hereof is not satisfied,
because of any termination pursuant to <U>Section</U><U></U><U>&nbsp;10(i)</U> hereof or because of any refusal, inability or failure on the part of the Company to perform any agreement herein or comply with any provision hereof other than by reason
of a default by any of the Underwriters, the Company will reimburse the Underwriters severally through Citigroup Global Markets Inc. and SVB Leerink LLC on demand for all expenses (including reasonable fees and disbursements of counsel) that shall
have been incurred by them in connection with the proposed purchase and sale of the Securities. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">8. <U>Indemnification and
Contribution</U>.<U> </U> </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) The Company agrees to indemnify and hold harmless each Underwriter, the directors, officers,
employees, affiliates within the meaning of Rule 405 under the Securities Act, and agents of each Underwriter and each person who controls any Underwriter within the meaning of either the Securities Act or the Exchange Act against any and all
losses, claims, damages or liabilities, joint or several, to which they or any of them may become subject under the Securities Act, the Exchange Act or other federal or state statutory law or regulation, at common law or otherwise, insofar as such
losses, claims, damages or liabilities (or actions in respect thereof) arise out of or are based upon </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">25 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
any untrue statement or alleged untrue statement of a material fact contained in the Registration Statement for the registration of the Securities as originally filed or in any amendment thereof,
or in the ADS Registration Statement as originally filed or in any amendment thereof, or in the Preliminary Prospectus, the Prospectus, Issuer Free Writing Prospectus or any Written
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Testing-the-Waters</FONT></FONT> Communication or in any amendment thereof or supplement thereto, or arise out of or are based upon the omission or alleged omission to state therein a
material fact required to be stated therein or necessary to make the statements therein not misleading, and agrees to reimburse each such indemnified party, as incurred, for any legal or other expenses reasonably incurred by them in connection with
investigating or defending any such loss, claim, damage, liability or action; provided, however, that the Company will not be liable in any such case to the extent that any such loss, claim, damage or liability arises out of or is based upon any
such untrue statement or alleged untrue statement or omission or alleged omission made therein in reliance upon and in conformity with written information furnished to the Company by or on behalf of any Underwriter through the Representatives
specifically for inclusion therein. This indemnity agreement will be in addition to any liability which the Company may otherwise have. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) Each Underwriter severally and not jointly agrees to indemnify and hold harmless the Company, each of its directors, each
of its officers who signs the Registration Statement or the ADS Registration Statement, and each person who controls the Company within the meaning of either the Securities Act or the Exchange Act, to the same extent as the foregoing indemnity to
each Underwriter, but only with reference to written information relating to such Underwriter furnished to the Company by or on behalf of such Underwriter through the Representatives specifically for inclusion in the documents referred to in the
foregoing indemnity. This indemnity agreement will be in addition to any liability which any Underwriter may otherwise have. The Company acknowledges that the statements set forth [(i) in the last paragraph of the cover page regarding delivery of
the Securities, the legend in block capital letters on page [2] related to stabilization, syndicate covering transactions and penalty bids and, under the heading &#147;Underwriting&#148; or &#147;Plan of Distribution&#148;, (ii)&nbsp;the sentences
related to concessions and reallowances and (iii)&nbsp;the paragraph related to stabilization, syndicate covering transactions and penalty bids] in any Preliminary Prospectus and the Prospectus constitute the only information furnished in writing by
or on behalf of the several Underwriters for inclusion in any Preliminary Prospectus, Prospectus or any Issuer Free Writing Prospectus. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) Promptly after receipt by an indemnified party under this <U>Section</U><U></U><U>&nbsp;8</U> of notice of the commencement
of any action, such indemnified party will, if a claim in respect thereof is to be made against the indemnifying party under this <U>Section</U><U></U><U>&nbsp;8</U>, notify the indemnifying party in writing of the commencement thereof; but the
failure so to notify the indemnifying party (i)&nbsp;will not relieve it from liability under paragraph (a)&nbsp;or (b) above unless and to the extent it did not otherwise learn of such action and such failure results in the forfeiture by the
indemnifying party of substantial rights and defenses and&nbsp;(ii)&nbsp;will not, in any event, relieve the indemnifying party from any obligations to any indemnified party other than the indemnification obligation provided in paragraph (a)&nbsp;or
(b) above. The indemnifying party shall be entitled to appoint counsel of the indemnifying party&#146;s choice at the indemnifying party&#146;s expense to represent the indemnified party in any action for
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">26 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
which indemnification is sought (in which case the indemnifying party shall not thereafter be responsible for the fees and expenses of any separate counsel retained by the indemnified party or
parties except as set forth below); <U>provided</U>, <U>however</U>, that such counsel shall be reasonably satisfactory to the indemnified party. Notwithstanding the indemnifying party&#146;s election to appoint counsel to represent the indemnified
party in an action, the indemnified party shall have the right to employ separate counsel (including local counsel), and the indemnifying party shall bear the reasonable fees, costs and expenses of such separate counsel (which, if the Issuer is the
indemnifying party, shall be limited to one such separate counsel for any Underwriter together with all persons who control such Underwriter within the meaning of the Exchange Act or the Securities Act, and no more than three such separate counsel
for all of the Underwriters collectively) if (i)&nbsp;the use of counsel chosen by the indemnifying party to represent the indemnified party would present such counsel with a conflict of interest, (ii)&nbsp;the actual or potential defendants in, or
targets of, any such action include both the indemnified party and the indemnifying party and the indemnified party shall have reasonably concluded that there may be legal defenses available to it and/or other indemnified parties which are different
from or additional to those available to the indemnifying party, (iii)&nbsp;the indemnifying party shall not have employed counsel reasonably satisfactory to the indemnified party to represent the indemnified party within a reasonable time after
notice of the institution of such action or (iv)&nbsp;the indemnifying party shall authorize the indemnified party to employ separate counsel at the expense of the indemnifying party. An indemnifying party will not, without the prior written consent
(which shall not be unreasonably withheld) of the indemnified parties, settle or compromise or consent to the entry of any judgment with respect to any pending or threatened claim, action, suit or proceeding in respect of which indemnification or
contribution may be sought hereunder (whether or not the indemnified parties are actual or potential parties to such claim or action) unless such settlement, compromise or consent (i)&nbsp;includes an unconditional release of each indemnified party
from all liability arising out of such claim, action, suit or proceeding and (ii)&nbsp;does not include a statement as to or an admission of fault, culpability or a failure to act, by or on behalf of any indemnified party. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) In the event that the indemnity provided in paragraph&nbsp;(a) or (b)&nbsp;of this <U>Section</U><U></U><U>&nbsp;8</U> is
unavailable to or insufficient to hold harmless an indemnified party for any reason, the Company, and the Underwriters agree to contribute to the aggregate losses, claims, damages and liabilities (including legal or other expenses reasonably
incurred in connection with investigating or defending same) (collectively, &#147;<U>Losses</U>&#148;) to which the Company, and one or more of the Underwriters may be subject in such proportion as is appropriate to reflect the relative benefits
received by the Company and by the Underwriters from the offering of the Securities. If the allocation provided by the immediately preceding sentence is unavailable for any reason, the Company and the Underwriters shall contribute in such proportion
as is appropriate to reflect not only such relative benefits but also the relative fault of the Company and of the Underwriters in connection with the statements or omissions which resulted in such Losses as well as any other relevant equitable
considerations. Benefits received by the Company shall be deemed to be equal to the total net proceeds from the offering (before deducting expenses) received by each of them, and benefits received by the Underwriters shall be deemed to be equal to
the total underwriting discounts and commissions, in each case as </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">27 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
set forth on the cover page of the Prospectus. Relative fault shall be determined by reference to, among other things, whether any untrue or any alleged untrue statement of a material fact or the
omission or alleged omission to state a material fact relates to information provided by the Company, on the one hand or the Underwriters on the other, the intent of the parties and their relative knowledge, access to information and opportunity to
correct or prevent such untrue statement or omission. The Company, and the Underwriters agree that it would not be just and equitable if contribution were determined by pro rata allocation or any other method of allocation which does not take
account of the equitable considerations referred to above. Notwithstanding the provisions of this paragraph (d), in no event shall any Underwriter be required to contribute any amount in excess of the amount by which the total underwriting discounts
and commissions received by such Underwriter with respect to the offering of the Securities exceeds the amount of any damages that such Underwriter has otherwise been required to pay by reason of such untrue or alleged untrue statement or omission
or alleged omission. No person guilty of fraudulent misrepresentation (within the meaning of Section&nbsp;11(f) of the Securities Act) shall be entitled to contribution from any person who was not guilty of such fraudulent misrepresentation. For
purposes of this <U>Section</U><U></U><U>&nbsp;8</U>, each person who controls an Underwriter within the meaning of either the Securities Act or the Exchange Act and each director, officer, employee, affiliate and agent of an Underwriter shall have
the same rights to contribution as such Underwriter, and each person who controls the Company within the meaning of either the Securities Act or the Exchange Act, each officer of the Company who shall have signed the Registration Statement or the
ADS Registration Statement and each director of the Company shall have the same rights to contribution as the Company, subject in each case to the applicable terms and conditions of this paragraph&nbsp;(d). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">9. <U>Default by an Underwriter</U>. If any one or more Underwriters shall fail to purchase and pay for any of the Securities agreed to be
purchased by such Underwriter or Underwriters under this Agreement and such failure to purchase shall constitute a default in the performance of its or their obligations under this Agreement, the remaining Underwriters shall be obligated severally
to take up and pay for (in the respective proportions which the amount of Securities set forth opposite their names in Schedule&nbsp;I hereto bears to the aggregate amount of Securities set forth opposite the names of all the remaining Underwriters)
the Securities which the defaulting Underwriter or Underwriters agreed but failed to purchase; <U>provided</U>, <U>however</U>, that in the event that the aggregate amount of Securities which the defaulting Underwriter or Underwriters agreed but
failed to purchase shall exceed 10% of the aggregate amount of Securities set forth in Schedule&nbsp;I hereto, the remaining Underwriters shall have the right to purchase all, but shall not be under any obligation to purchase any, of the Securities,
and if such nondefaulting Underwriters do not purchase all the Securities, this Agreement will terminate without liability to any nondefaulting Underwriter or the Company. In the event of a default by any Underwriter as set forth in this
<U>Section</U><U></U><U>&nbsp;9</U>, the Closing Date shall be postponed for such period, not exceeding five Business Days, as the Representatives shall determine in order that the required changes in the Registration Statement, the ADS Registration
Statement and the Prospectus or in any other documents or arrangements may be effected. Nothing contained in this Agreement shall relieve any defaulting Underwriter of its liability, if any, to the Company and any nondefaulting Underwriter for
damages occasioned by its default under this Agreement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">28 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">10. <U>Termination</U>. This Agreement shall be subject to termination in the absolute
discretion of the Representatives, by notice given to the Company prior to delivery of and payment for the Securities, if at any time prior to such delivery and payment (i)&nbsp;trading in the Company&#146;s Ordinary Shares shall have been suspended
by the SEC or the Australian Securities Exchange, (ii)&nbsp;trading in securities generally on the New York Stock Exchange or the Nasdaq Stock Market shall have been suspended or limited or minimum prices shall have been established on either of
such exchanges, (iii)&nbsp;a banking moratorium shall have been declared by U.S. Federal, New York State or Australian authorities, (iv)&nbsp;there shall have occurred a material disruption in commercial banking or securities settlement or clearance
services or (v)&nbsp;there shall have occurred any outbreak or escalation of hostilities, declaration by the United States or Australia of a national emergency or war, or other calamity or crisis the effect of which on financial markets is such as
to make it, in the sole judgment of the Representatives, impractical or inadvisable to proceed with the offering or delivery of the Securities as contemplated by the Preliminary Prospectus and the Prospectus (exclusive of any amendment or supplement
thereto). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">11. <U>Representations and Indemnities to Survive</U>. The respective agreements, representations, warranties, indemnities and
other statements of the Company or its officers or directors and of the Underwriters set forth in or made pursuant to this Agreement will remain in full force and effect, regardless of any investigation made by or on behalf of any Underwriter or the
Company or any of the officers, directors, employees, agents, affiliates or controlling persons referred to in <U>Section</U><U></U><U>&nbsp;8</U> hereof, and will survive delivery of and payment for the Securities. The provisions of
<U>Sections</U><U></U><U>&nbsp;7</U> and <U>8</U> hereof shall survive the termination or cancellation of this Agreement. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">12.
<U>Notices</U>. All communications hereunder will be in writing and effective only on receipt, and, if sent to the Representatives, will be mailed, delivered or telefaxed to Citigroup Global Markets Inc. at 388 Greenwich Street, New York, New York
10013, Attention: General Counsel, facsimile number: +1 (646) <FONT STYLE="white-space:nowrap">291-1469;</FONT> or, if sent to Opthea Limited, will be mailed, delivered or telefaxed to Suite 0403, Level&nbsp;4, 650 Chapel Street, South Yarra,
Victoria, Australia, 3141,<B></B>&nbsp;Attention: Mike Tonroe, with a copy (which shall not constitute notice) to Cooley LLP, 10 Collyer Quay, Raffles Place, Singapore 049315, Attention: Ferish Patel. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">13. <U>Successors</U>. This Agreement will inure to the benefit of and be binding upon the parties hereto and their respective successors and
the officers, directors, employees, agents and controlling persons referred to in Section&nbsp;8 hereof, and no other person will have any right or obligation hereunder. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">14. <U>Jurisdiction</U>. The Company agrees that any suit, action or proceeding against the Company brought by any Underwriter, the directors,
officers, employees, affiliates and agents of any Underwriter, or by any person who controls any Underwriter, arising out of or based upon this Underwriting Agreement or the transactions contemplated hereby may be instituted in any state or U.S.
federal court in The City of New York and County of New York, and waives any objection which it may now or hereafter have to the laying of venue of any such proceeding, and irrevocably submits to the
<FONT STYLE="white-space:nowrap">non-exclusive</FONT> jurisdiction of such courts in any suit, action or proceeding. The Company has appointed Corporation Service Company, 1180 Avenue of the Americas, Suite 210, New York, New York 10036, as its
authorized agent (the &#147;<U>Authorized Agent</U>&#148;) upon whom process may be served in any suit, action or proceeding arising out of or based </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">29 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
upon this Agreement or the transactions contemplated herein that may be instituted in any State or U.S. federal court in The City of New York and County of New York, by any Underwriter, the
directors, officers, employees, affiliates and agents of any Underwriter, or by any person who controls any Underwriter, and expressly accepts the <FONT STYLE="white-space:nowrap">non-exclusive</FONT> jurisdiction of any such court in respect of any
such suit, action or proceeding. The Company hereby represents and warrants that the Authorized Agent has accepted such appointment and has agreed to act as said agent for service of process, and the Company agrees to take any and all action,
including the filing of any and all documents that may be necessary to continue such appointment in full force and effect as aforesaid. Service of process upon the Authorized Agent shall be deemed, in every respect, effective service of process upon
the Company. Notwithstanding the foregoing, any action arising out of or based upon this Agreement may be instituted by any Underwriter, the directors, officers, employees and agents of any Underwriter, or by any person who controls any Underwriter,
in any court of competent jurisdiction in Australia. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">15. <U>Recognition of the U.S. Special Resolution Regimes</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) In the event that any Underwriter that is a Covered Entity becomes subject to a proceeding under a U.S. Special Resolution
Regime, the transfer from such Underwriter of this Agreement, and any interest and obligation in or under this Agreement, will be effective to the same extent as the transfer would be effective under the U.S. Special Resolution Regime if this
Agreement, and any such interest and obligation, were governed by the laws of the United States or a state of the United States. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) In the event that any Underwriter that is a Covered Entity or a BHC Act Affiliate of such Underwriter becomes subject to a
proceeding under a U.S. Special Resolution Regime, Default Rights under this Agreement that may be exercised against such Underwriter are permitted to be exercised to no greater extent than such Default Rights could be exercised under the U.S.
Special Resolution Regime if this Agreement were governed by the laws of the United States or a state of the United States. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">As used in
this <U>Section</U><U></U><U>&nbsp;15</U>, &#147;<U>BHC Act Affiliate</U>&#148; has the meaning assigned to the term &#147;affiliate&#148; in, and shall be interpreted in accordance with, 12 U.S.C. &#167; 1841(k); &#147;<U>Covered Entity</U>&#148;
means any of the following: (i)&nbsp;a &#147;covered entity&#148; as that term is defined in, and interpreted in accordance with, 12 C.F.R. &#167;&nbsp;252.82(b), (ii) a &#147;covered bank&#148; as that term is defined in, and interpreted in
accordance with, 12 C.F.R. &#167;&nbsp;47.3(b) or (iii)&nbsp;a &#147;covered FSI&#148; as that term is defined in, and interpreted in accordance with, 12 C.F.R. &#167;&nbsp;382.2(b); &#147;<U>Default Right</U>&#148; has the meaning assigned to that
term in, and shall be interpreted in accordance with, 12 C.F.R. &#167;&#167; 252.81, 47.2 or 382.1, as applicable; and &#147;<U>U.S. Special Resolution Regime</U>&#148; means each of (i)&nbsp;the Federal Deposit Insurance Act and the regulations
promulgated thereunder and (ii)&nbsp;Title II of the Dodd-Frank Wall Street Reform and Consumer Protection Act and the regulations promulgated thereunder. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">16. <U>No Fiduciary Duty</U>. The Company hereby acknowledges that (a)&nbsp;the purchase and sale of the Securities pursuant to this Agreement
is an <FONT STYLE="white-space:nowrap">arm&#146;s-length</FONT> commercial transaction between the Company, on the one hand, and the Underwriters and any affiliate through which it may be acting, on the other, (b)&nbsp;the Underwriters are acting as
principal and not as an agent or fiduciary of the Company and (c)&nbsp;the Company&#146;s engagement of the Underwriters in connection with the offering and the process leading up to the offering is as independent
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">30 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
contractors and not in any other capacity. Furthermore, the Company agrees that it are solely responsible for making their own judgments in connection with the offering (irrespective of whether
any of the Underwriters has advised or is currently advising the Company on related or other matters). The Company agrees that it will not claim that the Underwriters have rendered advisory services of any nature or respect, or owe an agency,
fiduciary or similar duty to the Company, in connection with such transaction or the process leading thereto. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">17. <U>Integration</U>. This
Agreement supersedes all prior agreements and understandings (whether written or oral) between the Company, and the Underwriters, with respect to the subject matter hereof. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">18. <U>Applicable Law</U>. This Agreement will be governed by and construed in accordance with the laws of the State of New York applicable to
contracts made and to be performed within the State of New York. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">19. <U>Currency</U>. Each reference in this Agreement to U.S. Dollars
(the &#147;relevant currency&#148;) is of the essence. To the fullest extent permitted by law, the obligations of each of the Company in respect of any amount due under this Agreement will, notwithstanding any payment in any other currency (whether
pursuant to a judgment or otherwise), be discharged only to the extent of the amount in the relevant currency that the party entitled to receive such payment may, in accordance with its normal procedures, purchase with the sum paid in such other
currency (after any premium and costs of exchange) on the Business Day immediately following the day on which such party receives such payment. If the amount in the relevant currency that may be so purchased for any reason falls short of the amount
originally due, the Company making such payment will pay such additional amounts, in the relevant currency, as may be necessary to compensate for the shortfall. Any obligation of any of the Company not discharged by such payment will, to the fullest
extent permitted by applicable law, be due as a separate and independent obligation and, until discharged as provided herein, will continue in full force and effect. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">20. <U>Waiver of Immunity</U>. To the extent that the Company has or hereafter may acquire any immunity (sovereign or otherwise) from any legal
action, suit or proceeding, from jurisdiction of any court or from <FONT STYLE="white-space:nowrap">set-off</FONT> or any legal process (whether service or notice, attachment in aid or otherwise) with respect to itself or any of its property, the
Company hereby irrevocably waives and agrees not to plead or claim such immunity in respect of its obligations under this Agreement. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">21.
<U>Waiver of Jury Trial</U>. The Company hereby irrevocably waives, to the fullest extent permitted by applicable law, any and all right to trial by jury in any legal proceeding arising out of or relating to this Agreement or the transactions
contemplated hereby. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">22. <U>Counterparts</U>. This Agreement may be signed in one or more counterparts, each of which shall constitute an
original and all of which together shall constitute one and the same agreement. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">23. <U>Headings</U>. The section headings used herein are
for convenience only and shall not affect the construction hereof. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">31 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">If the foregoing is in accordance with your understanding of our agreement, please sign and
return to us the enclosed duplicate hereof, whereupon this letter and your acceptance shall represent a binding agreement among the Company and the several Underwriters. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Very truly yours,</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>OPTHEA LIMITED</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Name:</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Title:</TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[<I>Signature Page to Underwriting Agreement</I>] </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">The foregoing Agreement is hereby confirmed and accepted as of the date first above written.</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Citigroup Global Markets Inc.</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">SVB Leerink LLC</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">By: Citigroup Global Markets Inc.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;&nbsp;&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Name:</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Title:</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">By: SVB Leerink LLC</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;&nbsp;&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Name:</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Title:</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">For themselves and the other several</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Underwriters named in Schedule I to the foregoing Agreement.</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[<I>Signature Page to Underwriting Agreement</I>] </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><U>SCHEDULE&nbsp;I </U></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="83%"></TD>

<TD VALIGN="bottom" WIDTH="17%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Underwriters</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number&nbsp;of&nbsp;Underwritten</B><br><B>Securities</B><br><B>to&nbsp;be&nbsp;Purchased</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Citigroup Global Markets Inc.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">SVB Leerink LLC</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Oppenheimer &amp; Co. Inc.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Truist Securities, Inc.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">I-1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><U>SCHEDULE&nbsp;II </U></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Schedule of Free Writing Prospectuses included in the Disclosure Package </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><U>SCHEDULE&nbsp;III </U></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Schedule of Written <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Testing-the-Waters</FONT></FONT> Communication </P>
<P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">III-1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">EXHIBIT A </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Form of <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Agreement </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Opthea Limited </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Public Offering of
Ordinary Shares represented by American Depositary Shares </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>_______________</B>, 2020 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Citigroup Global Markets Inc. and </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">SVB Leerink LLC </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As Representatives of the several Underwriters </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">c/o Citigroup Global Markets Inc. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">388 Greenwich Street </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">New York, New York 10013 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">c/o SVB Leerink LLC </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">255 California Street, 12th Floor </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">San Francisco, CA 94111 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ladies and Gentlemen: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This letter is being
delivered to you in connection with the proposed Underwriting Agreement (the &#147;<U>Underwriting Agreement</U>&#148;), between Opthea Limited, a corporation incorporated under the laws of Australia (the &#147;<U>Company</U>&#148;), and each of you
as representatives (collectively, the &#147;<U>Representatives</U>&#148;) of a group of underwriters named therein (the &#147;<U>Underwriters</U>&#148;), relating to an underwritten public offering of ordinary shares, no par value per share, of the
Company, represented by American Depositary Shares (&#147;<U>ADSs</U>&#148;) (the &#147;<U>Offering</U>&#148;). Capitalized terms used herein and not otherwise defined shall have the meanings set forth in the Underwriting Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In order to induce you and the other Underwriters to enter into the Underwriting Agreement, the undersigned will not, without the prior
written consent of the [Representatives], offer, sell, contract to sell, pledge or otherwise dispose of, (or enter into any transaction which is designed to, or might reasonably be expected to, result in the disposition (whether by actual
disposition or effective economic disposition due to cash settlement or otherwise) by the undersigned or any affiliate of the undersigned or any person in privity with the undersigned or any affiliate of the undersigned), directly or indirectly,
including the filing (or participation in the filing) of a registration statement with the Securities and Exchange Commission in respect of, or establish or increase a put equivalent position or liquidate or decrease a call equivalent position
within the meaning of Section&nbsp;16 of the Securities Exchange Act of 1934, as amended (the &#147;<U>Exchange Act</U>&#148;), and the rules and regulations of the Securities and Exchange Commission
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
promulgated thereunder with respect to, any Ordinary Shares or ADSs or any securities convertible into, or exercisable or exchangeable for Ordinary Shares or ADSs (collectively, the &#147;<U><FONT
STYLE="white-space:nowrap">Lock-Up</FONT> Securities</U>&#148;), or publicly announce an intention to effect any such transaction, for a period from the date hereof until 90 days after the date of the Underwriting Agreement (the &#147;<U>Restricted
Period</U>&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Notwithstanding the foregoing, the undersigned may: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;transfer the undersigned&#146;s <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Securities: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) as a bona fide gift or gifts, including, without limitation, to a charitable organization or educational institution, or
for bona fide estate planning purposes, </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) by will, other testamentary document or intestacy, </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iii) to any member of the undersigned&#146;s immediate family or to any trust or other legal entity for the direct or indirect
benefit of the undersigned or the immediate family of the undersigned, or if the undersigned is a trust, to a trustor or beneficiary of the trust or to the estate of a beneficiary of such trust (for purposes of this Letter Agreement, &#147;immediate
family&#148; shall mean any relationship by blood, current or former marriage, domestic partnership or adoption, not more remote than first cousin), </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iv)(1) to a partnership, limited liability company or other entity of which the undersigned and the immediate family of the
undersigned are the legal and beneficial owner of all of the outstanding equity securities or similar interests; (2)&nbsp;to a corporation, member, partner, partnership, limited liability company, trust or other entity that is an affiliate (as
defined in Rule 405 as promulgated by the SEC under the Securities Act of 1933, as amended) of the undersigned; or (3)&nbsp;to any investment fund or other entity controlled or managed by the undersigned or affiliates of the undersigned (including
where the undersigned is a partnership, to a successor partnership or fund, or any other funds managed by such partnership), </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(v) to a nominee or custodian of a person or entity to whom a disposition or transfer would be permissible under clauses
(i)&nbsp;through (iv) above, </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(vi) by operation of law, pursuant to a qualified domestic order, divorce settlement, divorce
decree or separation agreement or other final court order, </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(vii) to the Company upon death, disability, termination of
employment or cessation of services, </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(viii) in connection with a sale of the undersigned&#146;s shares of <FONT
STYLE="white-space:nowrap">Lock-Up</FONT> Securities acquired in open market transactions after the closing of the Offering, </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ix) to the Company in connection with the vesting, settlement, or exercise of restricted stock units, options, warrants or
other rights to purchase <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Securities (including, in each case, by way of &#147;net&#148; or &#147;cashless&#148; exercise), including for the payment of exercise price and tax withholdings or remittance
payments due as a result of the vesting, settlement, or exercise of such restricted stock units, options, warrants or rights, provided that any such <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Securities received upon such exercise, vesting,
settlement or conversion shall be subject to the terms of this Letter Agreement, or </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(x) pursuant to a bona fide third-party tender offer, merger, consolidation
or other similar transaction (including a takeover bid under Chapter 6 of the Corporations Act 2001 (Cth) and a scheme of arrangement implemented under Part 5.1 of the scheme of arrangement under Corporations Act 2001 (Cth)) that is approved by the
Board of Directors of the Company and made to all holders of the Company&#146;s capital stock involving a Change of Control (as defined below) of the Company (for purposes hereof, &#147;Change of Control&#148; shall mean the transfer (whether by
tender offer, merger, consolidation or other similar transaction), in one transaction or a series of related transactions, to a person or group of affiliated persons (as defined in Section&nbsp;13(d)(3) of the Securities Exchange Act of 1934, as
amended), of shares of capital stock if, after such transfer, such person or group of affiliated persons would beneficially own (as defined in Rules <FONT STYLE="white-space:nowrap">13d-3</FONT> and <FONT STYLE="white-space:nowrap">13d-5</FONT>
under the Exchange Act) at least a majority of the outstanding voting securities of the Company (or the surviving entity)); <U>provided</U> that in the event that such tender offer, merger, consolidation or other similar transaction is not
completed, the undersigned&#146;s <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Securities shall remain subject to the provisions of this Letter Agreement, </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><U>provided</U> that, </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(A) in the case of any transfer or distribution pursuant to clause (a)(i), (ii), (iii), (iv), (v) or (vi), each donee, devisee,
transferee or distributee shall execute and deliver to the Representatives a <FONT STYLE="white-space:nowrap">lock-up</FONT> letter in substantially the form of this Letter Agreement, </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(B) in the case of any transfer or distribution pursuant to clause (a)(viii), no filing by any party under the Exchange Act, or
other public announcement shall be required or shall be made voluntarily in connection with such transfer or distribution, </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(C) in the case of any transfer or distribution pursuant to clause (a)(i) through (vii)&nbsp;and (ix), it shall be a condition
to such transfer or distribution that any required filing under the Exchange Act, or other required public filing, report or announcement reporting a reduction in beneficial ownership of <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Securities,
shall clearly indicate in the footnotes thereto the nature and conditions of such transfer, and </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(D)&nbsp;in the case of
clause (a)(i) through (v)&nbsp;above, such transfer shall not involve a disposition for value, </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) enter into, establish or amend trading
plans by the undersigned pursuant to Rule <FONT STYLE="white-space:nowrap">10b5-1</FONT> under the Exchange Act or trading plans to a similar effect permitted under the rules and regulations of the Australian Securities Exchange for the transfer of
shares of <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Securities, if then permitted by the Company; <U>provided</U> that (1)&nbsp;such plans do not provide for the transfer of <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Securities during the
Restricted Period and (2)&nbsp;no public announcement or filing shall be required or made voluntarily except for any public filing or announcement required to be made by any party or on behalf of the undersigned under the rules and regulations of
the Australian Securities Exchange or required by any other Australian governmental or regulatory authority, which filing or announcement shall include a statement to the effect that the filing or announcement relates to the circumstances described
in this clause (b); and </P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) receive from the Company <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Securities in
connection with the exercise of options or other rights granted under an equity incentive plan or other equity award plan or program or pursuant to an individual award agreement between the Company and the undersigned, which plan, program or
agreement is described in the Registration Statement; provided, that (1)&nbsp;the <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Securities received by the undersigned shall be subject to the provisions of this Letter Agreement and (2)&nbsp;no
public announcement or filing relating to such receipt or transfer shall be required or voluntarily made by or on behalf of the undersigned except for any public filing or announcement required to be made by any party or on behalf of the undersigned
under the rules and regulations of the Australian Securities Exchange or required by any other Australian governmental or regulatory authority, which filing or announcement shall include a statement to the effect that (x)&nbsp;the filing or
announcement relates to the circumstances described in this clause (c)&nbsp;and (y) the <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Securities received by the undersigned upon exercise or settlement of the option or other right are subject to
this Letter Agreement for the duration of the Restricted Period. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the undersigned is an officer or director of the Company, the
undersigned further agrees that the foregoing restrictions shall be equally applicable to any issuer-directed shares of Ordinary Shares or ADSs the undersigned may purchase in the Offering. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the undersigned is an officer or director of the Company, (i)&nbsp;the Representatives agree that, at least three business days before the
effective date of any release or waiver of the foregoing restrictions in connection with a transfer of shares of Ordinary Shares or ADSs, the Representatives will notify the Company of the impending release or waiver, and (ii)&nbsp;the Company has
agreed in the Underwriting Agreement to announce the impending release or waiver by press release through a major news service or by such other means permitted by Financial Industry Regulatory Authority Rule 5131 (or any successor provision thereto)
at least two business days before the effective date of the release or waiver. Any release or waiver granted by the Representatives hereunder to any such officer or director shall only be effective two business days after the publication date of
such press release or the date of such other means of announcement. The provisions of this paragraph will not apply if (a)&nbsp;the release or waiver is effected solely to permit a transfer not for consideration and (b)&nbsp;the transferee has
agreed in writing to be bound by the same terms described in this letter to the extent and for the duration that such terms remain in effect at the time of the transfer. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The undersigned understands that, if (i)&nbsp;the Underwriting Agreement does not become effective by November&nbsp;30, 2020, (ii) the
Company, on the one hand, or the Representatives, on the other hand, shall advise the other in writing prior to the execution of the Underwriting Agreement that it has determined not to proceed with the Offering, (iii)&nbsp;the Registration
Statement is withdrawn prior to the execution of the Underwriting Agreement, or (iv)&nbsp;if the Underwriting Agreement (other than the provisions thereof which survive termination) shall terminate or be terminated prior to payment for and delivery
of the ADSs to be sold thereunder, then upon the earliest to occur of any of clauses (i)&nbsp;through (iv) above, the undersigned shall automatically, and without any action on the part of any party, be released from all obligations under this
Letter Agreement. The undersigned understands that the Underwriters are entering into the Underwriting Agreement and proceeding with the Offering in reliance upon this Letter Agreement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This Letter Agreement shall be governed by and construed in accordance with the laws of the
State of New York, without regard to the conflict of laws principles thereof.</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Yours very truly,</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Name:</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Title:</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">EXHIBIT B </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Form of Press Release </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Opthea Limited </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>[</B><I>insert date</I><B>]</B> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Opthea Limited (the
&#147;<U>Company</U>&#148;) announced today that Citigroup Global Markets Inc. and SVB Leerink LLC, the lead book-running managers in the Company&#146;s recent public sale of [&#149;] American Depositary Shares (&#147;ADSs&#148;) representing the
Company&#146;s Ordinary Shares, is [waiving] [releasing] a <FONT STYLE="white-space:nowrap">lock-up</FONT> restriction with respect to [&#149;] shares of the Company&#146;s [ADSs] [Ordinary Shares] held by [certain officers or directors] [an officer
or director] of the Company. The [waiver] [release] will take effect on <B>[</B><I>insert date</I><B>],</B> 20__, and the shares may be sold on or after such date. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>This press release is not an offer for sale of the securities in the United States or in any other jurisdiction where such offer is prohibited, and such
securities may not be offered or sold in the United States absent registration or an exemption from registration under the United States Securities Act of 1933, as amended. </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">B-1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>[Form of Waiver of <FONT STYLE="white-space:nowrap">Lock-up]</FONT></B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">ADDENDUM</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>[</B><I>insert letterhead of Citigroup Global Markets Inc.</I><B>]</B> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>OPTHEA LIMITED </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Public
Offering of Ordinary Shares represented by American Depositary Shares </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>[</B><I>insert date</I><B>]</B>, 20__ </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>[</B><I>name and address of officer or director requesting waiver</I><B>]</B> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dear Mr./Ms.<B>&nbsp;[</B><I>insert name</I><B>]</B>: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">This letter is being delivered to you in connection with the offering by<B> </B>Opthea Limited<B> </B>(the &#147;<U>Company</U>&#148;) of an
aggregate of [&#149;] American Depositary Shares (&#147;<U>ADSs</U>&#148;), representing Ordinary Shares, no par value, of the Company, represented by and the <FONT STYLE="white-space:nowrap">lock-up</FONT> letter dated<B> [</B><I>insert
date</I><B>]</B>, 20__ (the &#147;<U><FONT STYLE="white-space:nowrap">Lock-up</FONT> Letter</U>&#148;), executed by you in connection with such offering, and your request for a [waiver] [release] dated <B>[</B><I>insert date</I><B>]</B>, 20__, with
respect to [&#149;] shares of [ADSs] [Ordinary Shares] (the &#147;<U>Shares</U>&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Citigroup Global Markets Inc. and SVB Leerink LLC
hereby agree to [waive] [release] the transfer restrictions set forth in the <FONT STYLE="white-space:nowrap">Lock-up</FONT> Letter, but only with respect to the Shares, effective <B>[</B><I>insert date</I><B>]</B>, 20__; <U>provided</U>,
<U>however</U>, that such [waiver] [release] is conditioned on the Company announcing the impending [waiver] [release] by press release through a major news service at least two business days before effectiveness of such [waiver] [release]. This
letter will serve as notice to the Company of the impending [waiver] [release]. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Except as expressly [waived] [released] hereby, the <FONT
STYLE="white-space:nowrap">Lock-up</FONT> Letter shall remain in full force and effect. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Yours very truly,</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Citigroup Global Markets Inc.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;&nbsp;&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Name:</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Title:</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">SVB Leerink LLC</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;&nbsp;&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Name:</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Title:</TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">cc: Opthea Limited </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">B-2 </P>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.1
<SEQUENCE>3
<FILENAME>d947560dex41.htm
<DESCRIPTION>EX-4.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-4.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 4.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">OPTHEA LIMITED </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">AND </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">THE BANK OF NEW YORK MELLON </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">As
Depositary </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">AND </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">OWNERS AND
HOLDERS OF AMERICAN DEPOSITARY SHARES </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Amended and Restated Deposit Agreement </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;, 2020 </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">TABLE OF CONTENTS </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="97%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">ARTICLE 1.&nbsp;DEFINITIONS</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">SECTION 1.1.&nbsp;American Depositary Shares.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">SECTION 1.2.&nbsp;CHESS</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">SECTION 1.3.&nbsp;Commission.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">SECTION 1.4.&nbsp;Company.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">SECTION 1.5.&nbsp;Custodian.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">SECTION 1.6.&nbsp;Deliver; Surrender.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">SECTION 1.7.&nbsp;Deposit Agreement.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">SECTION 1.8.&nbsp;Depositary; Depositary&#146;s Office.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">SECTION 1.9.&nbsp;Deposited Securities.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">SECTION 1.10.&nbsp;Disseminate.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">SECTION 1.11.&nbsp;Dollars.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">SECTION 1.12.&nbsp;DTC.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">SECTION 1.13.&nbsp;Foreign Registrar.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">SECTION 1.14.&nbsp;Holder.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">SECTION 1.15.&nbsp;Owner.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">SECTION 1.16.&nbsp;Receipts.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">SECTION 1.17.&nbsp;Registrar.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">SECTION 1.18.&nbsp;Replacement.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">SECTION 1.19.&nbsp;Restricted Securities.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">SECTION 1.20.&nbsp;Securities Act of 1933.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">SECTION 1.21.&nbsp;Shares.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">SECTION 1.22.&nbsp;SWIFT.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">SECTION 1.23.&nbsp;Termination Option Event.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">ARTICLE 2.&nbsp;FORM OF RECEIPTS, DEPOSIT OF SHARES, DELIVERY, TRANSFER AND SURRENDER OF AMERICAN
DEPOSITARY SHARES</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">SECTION 2.1.&nbsp;Form of Receipts; Registration and Transferability of American Depositary
Shares.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">SECTION 2.2.&nbsp;Deposit of Shares.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">SECTION 2.3.&nbsp;Delivery of American Depositary Shares.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">SECTION 2.4.&nbsp;Registration of Transfer of American Depositary Shares; Combination and <FONT
STYLE="white-space:nowrap">Split-up</FONT> of Receipts; Interchange of Certificated and Uncertificated American Depositary Shares.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">SECTION 2.5.&nbsp;Surrender of American Depositary Shares and Withdrawal of Deposited
Securities.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">SECTION 2.6.&nbsp;Limitations on Delivery, Registration of Transfer and Surrender of American
Depositary Shares.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">SECTION 2.7.&nbsp;Lost Receipts, etc.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">SECTION 2.8.&nbsp;Cancellation and Destruction of Surrendered Receipts.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">SECTION 2.9.&nbsp;DTC Direct Registration System and Profile Modification System.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">ARTICLE 3.&nbsp;CERTAIN OBLIGATIONS OF OWNERS AND HOLDERS OF AMERICAN DEPOSITARY SHARES</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">SECTION 3.1.&nbsp;Filing Proofs, Certificates and Other Information.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">SECTION 3.2.&nbsp;Liability of Owner for Taxes.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">SECTION 3.3.&nbsp;Warranties on Deposit of Shares.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">SECTION 3.4.&nbsp;Disclosure of Interests.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">ARTICLE 4.&nbsp;THE DEPOSITED SECURITIES</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">SECTION 4.1.&nbsp;Cash Distributions.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">SECTION 4.2.&nbsp;Distributions Other Than Cash, Shares or Rights.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">SECTION 4.3.&nbsp;Distributions in Shares.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">SECTION 4.4.&nbsp;Rights.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">SECTION 4.5.&nbsp;Conversion of Foreign Currency.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">SECTION 4.6.&nbsp;Fixing of Record Date.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">SECTION 4.7.&nbsp;Voting of Deposited Shares.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">SECTION 4.8.&nbsp;Tender and Exchange Offers; Redemption, Replacement or Cancellation of Deposited
Securities.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">SECTION 4.9.&nbsp;Reports.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">SECTION 4.10.&nbsp;Lists of Owners.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">SECTION 4.11.&nbsp;Withholding.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">ARTICLE 5.&nbsp;THE DEPOSITARY, THE CUSTODIANS AND THE COMPANY</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">SECTION 5.1.&nbsp;Maintenance of Office and Register by the Depositary.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">SECTION 5.2.&nbsp;Prevention or Delay of Performance by the Company or the Depositary.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">SECTION 5.3.&nbsp;Obligations of the Depositary and the Company.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">SECTION 5.4.&nbsp;Resignation and Removal of the Depositary.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">SECTION 5.5.&nbsp;The Custodians.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">SECTION 5.6.&nbsp;Notices and Reports.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">SECTION 5.7.&nbsp;Distribution of Additional Shares, Rights, etc.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">SECTION 5.8.&nbsp;Indemnification.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">SECTION 5.9.&nbsp;Charges of Depositary.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">SECTION 5.10.&nbsp;Retention of Depositary Documents.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">SECTION 5.11.&nbsp;Exclusivity.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">SECTION 5.12.&nbsp;Information for Regulatory Compliance.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR></TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="97%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">ARTICLE 6.&nbsp;AMENDMENT AND TERMINATION</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">SECTION 6.1.&nbsp;Amendment.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">SECTION 6.2.&nbsp;Termination.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">ARTICLE 7.&nbsp;MISCELLANEOUS</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">SECTION 7.1.&nbsp;Counterparts; Signatures; Delivery.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">SECTION 7.2.&nbsp;No Third Party Beneficiaries.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">SECTION 7.3.&nbsp;Severability.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">SECTION 7.4.&nbsp;Owners and Holders as Parties; Binding Effect.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">SECTION 7.5.&nbsp;Notices.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">SECTION 7.6.&nbsp;Appointment of Agent for Service of Process; Submission to Jurisdiction; Jury
Trial Waiver.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">SECTION 7.7.&nbsp;Waiver of Immunities.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">SECTION 7.8.&nbsp;Governing Law.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">AMENDED AND RESTATED DEPOSIT AGREEMENT </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">AMENDED AND RESTATED DEPOSIT AGREEMENT dated as of
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2020 among OPTHEA LIMITED, formerly known as Circadian Technologies Ltd., a company incorporated under the laws of the
Commonwealth of Australia (herein called the Company), THE BANK OF NEW YORK MELLON, a New York banking corporation (herein called the Depositary), and all Owners and Holders (each as hereinafter defined) from time to time of American Depositary
Shares issued hereunder. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">WITNESSETH: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">WHEREAS, the Company and the Depositary previously entered into a Deposit Agreement dated as of June&nbsp;6, 2011 (the &#147;Prior Deposit
Agreement&#148;); and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">WHEREAS, the Company and the Depositary now wish to amend and restate the Prior Deposit Agreement pursuant to
Section&nbsp;6.01 of the Prior Deposit Agreement in the form of this amended and restated Deposit Agreement to, among other things, reflect that the Company has issued and sold American Depository Shares representing its ordinary shares in a public
offering registered pursuant to the Securities Act of 1933, as amended, and has become subject to the reporting requirements under Section&nbsp;12 of the Securities Exchange Act of 1934, as amended; and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">WHEREAS, the Company desires to provide, as set forth in this amended and restated Deposit Agreement, for the deposit of Shares (as
hereinafter defined) of the Company from time to time with the Depositary or with the Custodian (as hereinafter defined) under this amended and restated Deposit Agreement, for the creation of American Depositary Shares representing the Shares so
deposited and for the execution and delivery of American Depositary Receipts evidencing the American Depositary Shares; and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">WHEREAS, the
American Depositary Receipts are to be substantially in the form of Exhibit A annexed to this amended and restated Deposit Agreement, with appropriate insertions, modifications and omissions, as set forth in this amended and restated Deposit
Agreement; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">NOW, THEREFORE, in consideration of the premises, it is agreed by and between the parties hereto that the Prior Deposit
Agreement is hereby amended and restated as follows: </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman">ARTICLE 1. DEFINITIONS </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">The following definitions shall for all purposes, unless otherwise clearly indicated, apply to the respective terms used in this amended and
restated Deposit Agreement: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 1.1. <U>American Depositary Shares.</U> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">The term &#147;<U>American Depositary Shares</U>&#148; shall mean the securities created under this Deposit Agreement representing rights with
respect to the Deposited Securities. American Depositary Shares may be certificated securities evidenced by Receipts or uncertificated securities. The form of Receipt annexed as Exhibit A to this Deposit Agreement shall be the prospectus required
under the Securities Act of 1933 for sales of both certificated and uncertificated American Depositary Shares. Except for those provisions of this Deposit Agreement that refer specifically to Receipts, all the provisions of this Deposit Agreement
shall apply to both certificated and uncertificated American Depositary Shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Each American Depositary Share shall represent the number
of Shares specified in Exhibit A to this Deposit Agreement, <U>except that</U>, if there is a distribution upon Deposited Securities covered by Section&nbsp;4.3, a change in Deposited Securities covered by Section&nbsp;4.8 with respect to which
additional American Depositary Shares are not delivered or a sale of Deposited Securities under Section&nbsp;3.2 or 4.8, each American Depositary Share shall thereafter represent the amount of Shares or other Deposited Securities that are then on
deposit per American Depositary Share after giving effect to that distribution, change or sale. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 1.2. <U>CHESS</U> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">The term &#147;CHESS&#148; shall mean the Clearing House Electronic Subregister System. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 1.3. <U>Commission.</U> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">The term &#147;<U>Commission</U>&#148; shall mean the Securities and Exchange Commission of the United States or any successor governmental
agency in the United States. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 1.4. <U>Company.</U> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">The term &#147;<U>Company</U>&#148; shall mean Opthea Limited, a company incorporated under the laws of the Commonwealth of Australia, and its
successors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 1.5. <U>Custodian.</U> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">The term &#147;Custodian&#148; shall mean HSBC Bank Australia Limited, as custodian for the Depositary in Australia for the purposes of this
Deposit Agreement, and any other firm or corporation the Depositary appoints under Section&nbsp;5.5 as a substitute or additional custodian under this Deposit Agreement, and shall also mean all of them collectively. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 1.6. <U>Deliver; Surrender.</U> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) The term &#147;<U>deliver</U>&#148;, or its noun form, when used with respect to Shares or other Deposited Securities, shall mean
(i)&nbsp;book-entry transfer of those Shares or other Deposited Securities to an account maintained by CHESS or an institution authorized under applicable law to effect transfers of such securities designated by the person entitled to that delivery
or (ii)&nbsp;physical transfer of certificates evidencing those Shares or other Deposited Securities registered in the name of, or duly endorsed or accompanied by proper instruments of transfer to, the person entitled to that delivery. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) The term &#147;<U>deliver</U>&#148;, or its noun form, when used with respect to American Depositary Shares, shall mean
(i)&nbsp;registration of those American Depositary Shares in the name of DTC or its nominee and book-entry transfer of those American Depositary Shares to an account at DTC designated by the person entitled to that delivery, (ii)&nbsp;registration
of those American Depositary Shares not evidenced by a Receipt on the books of the Depositary in the name requested by the person entitled to that delivery and mailing to that person of a statement confirming that registration or (iii)&nbsp;if
requested by the person entitled to that delivery, execution and delivery at the Depositary&#146;s Office to the person entitled to that delivery of one or more Receipts evidencing those American Depositary Shares registered in the name requested by
that person. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) The term &#147;<U>surrender</U>&#148;, when used with respect to American Depositary Shares, shall mean (i)&nbsp;one or
more book-entry transfers of American Depositary Shares to the DTC account of the Depositary, (ii)&nbsp;delivery to the Depositary at its Office of an instruction to surrender American Depositary Shares not evidenced by a Receipt or
(iii)&nbsp;surrender to the Depositary at its Office of one or more Receipts evidencing American Depositary Shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 1.7.
<U>Deposit Agreement.</U> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">The term &#147;<U>Deposit Agreement</U>&#148; shall mean this Amended and Restated Deposit Agreement, as it may
be amended from time to time in accordance with the provisions of this Deposit Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 1.8. <U>Depositary; Depositary&#146;s
Office.</U> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">The term &#147;<U>Depositary</U>&#148; shall mean The Bank of New York Mellon, a New York banking corporation, and any
successor as depositary under this Deposit Agreement. The term &#147;<U>Office</U>&#148;, when used with respect to the Depositary, shall mean the office at which its depositary receipts business is administered, which, at the date of this Deposit
Agreement, is located at 240 Greenwich Street, New York, New York 10286. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 1.9. <U>Deposited Securities.</U> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">The term &#147;<U>Deposited Securities</U>&#148; as of any time shall mean Shares at such time deposited or deemed to be deposited under this
Deposit Agreement, including without limitation, Shares that have not been successfully delivered upon surrender of American Depositary Shares, and any and all other securities, property and cash received by the Depositary or the Custodian in
respect of Deposited Securities and at that time held under this Deposit Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 1.10. <U>Disseminate.</U> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">The term &#147;<U>Disseminate</U>,&#148; when referring to a notice or other information to be sent by the Depositary to Owners, shall mean
(i)&nbsp;sending that information to Owners in paper form by mail or another means or (ii)&nbsp;with the consent of Owners, another procedure that has the effect of making the information available to Owners, which may include (A)&nbsp;sending the
information by electronic mail or electronic messaging or (B)&nbsp;sending in paper form or by electronic mail or messaging a statement that the information is available and may be accessed by the Owner on an Internet website and that it will be
sent in paper form upon request by the Owner, when that information is so available and is sent in paper form as promptly as practicable upon request. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 1.11. <U>Dollars.</U> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">The term &#147;<U>Dollars</U>&#148; shall mean United States dollars. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 1.12. <U>DTC.</U> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">The
term &#147;<U>DTC</U>&#148; shall mean The Depository Trust Company or its successor. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 1.13. <U>Foreign Registrar.</U> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">The term &#147;<U>Foreign Registrar</U>&#148; shall mean the entity that carries out the duties of registrar for the Shares and any other
agent of the Company for the transfer and registration of Shares, including, without limitation, any securities depository for the Shares. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 1.14. <U>Holder.</U> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">The term &#147;<U>Holder</U>&#148; shall mean any person holding a Receipt or a security entitlement or other interest in American Depositary
Shares, whether for its own account or for the account of another person, but that is not the Owner of that Receipt or those American Depositary Shares. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 1.15. <U>Owner.</U> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">The term &#147;<U>Owner</U>&#148; shall mean the person in whose name American Depositary Shares are registered on the books of the Depositary
maintained for that purpose. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 1.16. <U>Receipts.</U> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">The term &#147;<U>Receipts</U>&#148; shall mean the American Depositary Receipts issued under this Deposit Agreement evidencing certificated
American Depositary Shares, as the same may be amended from time to time in accordance with the provisions of this Deposit Agreement. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 1.17. <U>Registrar.</U> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">The term &#147;<U>Registrar</U>&#148; shall mean any corporation or other entity that is appointed by the Depositary to register American
Depositary Shares and transfers of American Depositary Shares as provided in this Deposit Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 1.18. <U>Replacement.</U>
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">The term &#147;<U>Replacement</U>&#148; shall have the meaning assigned to it in Section&nbsp;4.8. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 1.19. <U>Restricted Securities.</U> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">The term &#147;<U>Restricted Securities</U>&#148; shall mean Shares that (i)&nbsp;are &#147;restricted securities,&#148; as defined in Rule
144 under the Securities Act of 1933, except for Shares that could be resold in reliance on Rule 144 without any conditions, (ii)&nbsp;are beneficially owned by an officer, director (or person performing similar functions) or other affiliate of the
Company, (iii)&nbsp;otherwise would require registration under the Securities Act of 1933 in connection with the public offer and sale thereof in the United States or (iv)&nbsp;are subject to other restrictions on sale or deposit under the laws of
the Commonwealth of Australia, a shareholder agreement or the articles of association or similar document of the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 1.20.
<U>Securities Act of 1933.</U> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">The term &#147;<U>Securities Act of 1933</U>&#148; shall mean the United States Securities Act of 1933, as
from time to time amended. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 1.21. <U>Shares.</U> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">The term &#147;<U>Shares</U>&#148; shall mean ordinary shares of the Company that are validly issued and outstanding, fully paid and
nonassessable and that were not issued in violation of any <FONT STYLE="white-space:nowrap">pre-emptive</FONT> or similar rights of the holders of outstanding securities of the Company; <U>provided</U>, <U>however</U>, that, if there shall occur any
change in nominal or par value, a <FONT STYLE="white-space:nowrap">split-up</FONT> or consolidation or any other reclassification or, upon the occurrence of an event described in Section&nbsp;4.8, an exchange or conversion in respect of the Shares
of the Company, the term &#147;Shares&#148; shall thereafter also mean the successor securities resulting from such change in nominal value, <FONT STYLE="white-space:nowrap">split-up</FONT> or consolidation or such other reclassification or such
exchange or conversion. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 1.22. <U>SWIFT.</U> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">The term &#147;<U>SWIFT</U>&#148; shall mean the financial messaging network operated by the Society for Worldwide Interbank Financial
Telecommunication, or its successor. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 1.23. <U>Termination Option Event.</U> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">The term &#147;<U>Termination Option Event</U>&#148; shall mean any of the following events or conditions: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(i) the Company institutes proceedings to be adjudicated as bankrupt or insolvent, consents to the institution of bankruptcy or insolvency
proceedings against it, files a petition or answer or consent seeking reorganization or relief under any applicable law in respect of bankruptcy or insolvency, consents to the filing of any petition of that kind or to the appointment of a receiver,
liquidator, assignee, trustee, custodian or sequestrator (or other similar official) of it or any substantial part of its property or makes an assignment for the benefit of creditors, or if information becomes publicly available indicating that
unsecured claims against the Company are not expected to be paid; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(ii) the Shares are delisted, or the Company announces its intention to
delist the Shares, from a stock exchange outside the United States, and the Company has not applied to list the Shares on any other stock exchange outside the United States; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(iii) the American Depositary Shares are delisted from a stock exchange in the United States on which the American Depositary Shares were
listed and, 30 days after that delisting, the American Depositary Shares have not been listed on another stock exchange in the United States, nor is there a symbol available for
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">over-the-counter</FONT></FONT> trading of the American Depositary Shares in the United States; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(iv) the Depositary has received notice of facts that indicate, or otherwise has reason to believe, that the American Depositary Shares have
become, or with the passage of time will become, ineligible for registration on Form <FONT STYLE="white-space:nowrap">F-6</FONT> under the Securities Act of 1933; or </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(v) an event or condition that is defined as a <U>Termination Option Event</U> in Section&nbsp;4.1, 4.2 or 4.8. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">ARTICLE 2. FORM OF RECEIPTS, DEPOSIT OF SHARES, DELIVERY, TRANSFER AND SURRENDER OF AMERICAN DEPOSITARY SHARES </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 2.1. <U>Form of Receipts; Registration and Transferability of American Depositary Shares.</U> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Definitive Receipts shall be substantially in the form set forth in Exhibit A to this Deposit Agreement, with appropriate insertions,
modifications and omissions, as permitted under this Deposit Agreement. No Receipt shall be entitled to any benefits under this Deposit Agreement or be valid or obligatory for any purpose, unless that Receipt has been (i)&nbsp;executed by the
Depositary by the manual signature of a duly authorized officer of the Depositary or (ii)&nbsp;executed by the facsimile signature of a duly authorized officer of the Depositary and countersigned by the manual signature of a duly authorized
signatory of the Depositary or the Registrar or a <FONT STYLE="white-space:nowrap">co-registrar.</FONT> The Depositary shall maintain books on which (x)&nbsp;each Receipt so executed and delivered as provided in this Deposit Agreement and each
transfer of that Receipt and (y)&nbsp;all American Depositary Shares delivered as provided in this Deposit Agreement and all registrations of transfer of American Depositary Shares, shall be registered. A Receipt bearing the facsimile signature of a
person that was at any time a proper officer of the Depositary shall, subject to the other provisions of this paragraph, bind the Depositary, even if that person was not a proper officer of the Depositary on the date of issuance of that Receipt.
</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">The Receipts and statements confirming registration of American Depositary Shares may have
incorporated in or attached to them such legends or recitals or modifications not inconsistent with the provisions of this Deposit Agreement as may be reasonably required by the Company or Depositary or required to comply with any applicable law or
regulations thereunder or with the rules and regulations of any securities exchange upon which American Depositary Shares may be listed or to conform with any usage with respect thereto, or to indicate any special limitations or restrictions to
which any particular Receipts and American Depositary Shares are subject by reason of the date of issuance of the underlying Deposited Securities or otherwise. The Depositary shall notify the Company as promptly as practicable if it imposes any
legends, recitals or modifications under this paragraph. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">American Depositary Shares evidenced by a Receipt, when the Receipt is properly
endorsed or accompanied by proper instruments of transfer, shall be transferable as certificated registered securities under the laws of the State of New York. American Depositary Shares not evidenced by Receipts shall be transferable as
uncertificated registered securities under the laws of the State of New York. The Depositary, notwithstanding any notice to the contrary, may treat the Owner of American Depositary Shares as the absolute owner thereof for the purpose of determining
the person entitled to distribution of dividends or other distributions or to any notice provided for in this Deposit Agreement and for all other purposes, and neither the Depositary nor the Company shall have any obligation or be subject to any
liability under this Deposit Agreement to any Holder of American Depositary Shares (but only to the Owner of those American Depositary Shares). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 2.2. <U>Deposit of Shares.</U> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Subject to the terms and conditions of this Deposit Agreement, Shares or evidence of rights to receive Shares may be deposited under this
Deposit Agreement by delivery thereof to any Custodian, accompanied by any appropriate instruments or instructions for transfer, or endorsement, in form satisfactory to the Custodian. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">As conditions of accepting Shares for deposit, the Depositary may require (i)&nbsp;any certification required by the Depositary or the
Custodian in accordance with the provisions of this Deposit Agreement, (ii)&nbsp;a written order directing the Depositary to deliver to, or upon the written order of, the person or persons stated in that order American Depositary Shares representing
those deposited Shares, (iii)&nbsp;evidence satisfactory to the Depositary that those Shares have been <FONT STYLE="white-space:nowrap">re-registered</FONT> in the books of the Company or the Foreign Registrar in the name of the Depositary, a
Custodian or a nominee of the Depositary or a Custodian, (iv)&nbsp;evidence satisfactory to the Depositary that any necessary approval for the transfer or deposit has been granted by any governmental body in each applicable jurisdiction and
(v)&nbsp;an agreement or assignment, or other instrument satisfactory to the Depositary, that provides for the prompt transfer to the Custodian of any dividend, or right to subscribe for additional Shares or to receive other property, that any
person in whose name those Shares are or have been recorded may thereafter receive upon or in respect of those Shares, or, in lieu thereof, such agreement of indemnity or other agreement as shall be satisfactory to the Depositary. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">The Depositary will refuse to accept Shares for deposit if the Depositary has received a written notice from the Company that deposit of such
Shares would violate applicable laws, rules and regulations, or the Constitution or similar organizational document of the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">At
the request and risk and expense of a person proposing to deposit Shares, and for the account of that person, the Depositary may receive certificates for Shares to be deposited, together with the other instruments specified in this Section, for the
purpose of forwarding those Share certificates to the Custodian for deposit under this Deposit Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">The Depositary shall instruct
each Custodian that, upon each delivery to a Custodian of a certificate or certificates for Shares to be deposited under this Deposit Agreement, together with the other documents specified in this Section, that Custodian shall, as soon as transfer
and recordation can be accomplished, present that certificate or those certificates to the Company or the Foreign Registrar, if applicable, for transfer and recordation of the Shares being deposited in the name of the Depositary or its nominee or
that Custodian or its nominee. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Deposited Securities shall be held by the Depositary or by a Custodian for the account and to the order of
the Depositary or at such other place or places as the Depositary shall determine. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 2.3. <U>Delivery of American Depositary
Shares.</U> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">The Depositary shall instruct each Custodian that, upon receipt by that Custodian of any deposit pursuant to
Section&nbsp;2.2, together with the other documents or evidence required under that Section, that Custodian shall notify the Depositary of that deposit and the person or persons to whom or upon whose written order American Depositary Shares are
deliverable in respect thereof. Upon receiving a notice of a deposit from a Custodian, or upon the receipt of Shares or evidence of the right to receive Shares by the Depositary, the Depositary, subject to the terms and conditions of this Deposit
Agreement, shall deliver, without unreasonable delay, to or upon the order of the person or persons entitled thereto, the number of American Depositary Shares issuable in respect of that deposit, but only upon payment to the Depositary of the fees
and expenses of the Depositary for the delivery of those American Depositary Shares as provided in Section&nbsp;5.9, and of all taxes and governmental charges and fees payable in connection with that deposit and the transfer of the deposited Shares.
<U>However</U>, the Depositary shall deliver only whole numbers of American Depositary Shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 2.4. <U>Registration of Transfer
of American Depositary Shares; Combination and <FONT STYLE="white-space:nowrap">Split-up</FONT> of Receipts; Interchange of Certificated and Uncertificated American Depositary Shares.</U> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">The Depositary, subject to the terms and conditions of this Deposit Agreement, shall register a transfer of American Depositary Shares on its
transfer books upon (i)&nbsp;in the case of certificated American Depositary Shares, surrender of the Receipt evidencing those American Depositary Shares, by the Owner or by a duly authorized attorney, properly endorsed or accompanied by proper
instruments of transfer or (ii)&nbsp;in the case of uncertificated American Depositary Shares, receipt from the Owner of a proper instruction (including, for the avoidance of doubt, instructions through DRS and Profile as provided in
Section&nbsp;2.9), and, in either case, duly stamped as may be required by the laws of the State of New York and of the United States of America. Upon registration of a transfer, the Depositary shall deliver the transferred American Depositary
Shares to or upon the order of the person entitled thereto. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">The Depositary, subject to the terms and conditions of this Deposit Agreement, shall upon
surrender of a Receipt or Receipts for the purpose of effecting a <FONT STYLE="white-space:nowrap">split-up</FONT> or combination of such Receipt or Receipts, execute and deliver a new Receipt or Receipts for any authorized number of American
Depositary Shares requested, evidencing the same aggregate number of American Depositary Shares as the Receipt or Receipts surrendered. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">The Depositary, upon surrender of certificated American Depositary Shares for the purpose of exchanging for uncertificated American Depositary
Shares, shall cancel the Receipt evidencing those certificated American Depositary Shares and send the Owner a statement confirming that the Owner is the owner of the same number of uncertificated American Depositary Shares. The Depositary, upon
receipt of a proper instruction (including, for the avoidance of doubt, instructions through DRS and Profile as provided in Section&nbsp;2.9) from the Owner of uncertificated American Depositary Shares for the purpose of exchanging for certificated
American Depositary Shares, shall cancel those uncertificated American Depositary Shares and register and deliver to the Owner a Receipt evidencing the same number of certificated American Depositary Shares. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">The Depositary may appoint one or more <FONT STYLE="white-space:nowrap">co-transfer</FONT> agents for the purpose of effecting registration of
transfers of American Depositary Shares and combinations and <FONT STYLE="white-space:nowrap">split-ups</FONT> of Receipts at designated transfer offices on behalf of the Depositary, and the Depositary shall notify the Company if it makes an
appointment of that kind as promptly as practicable. In carrying out its functions, a <FONT STYLE="white-space:nowrap">co-transfer</FONT> agent may require evidence of authority and compliance with applicable laws and other requirements by Owners or
persons entitled to American Depositary Shares and will be entitled to protection and indemnity to the same extent as the Depositary. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 2.5. <U>Surrender of American Depositary Shares and Withdrawal of Deposited Securities.</U> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Upon surrender of American Depositary Shares for the purpose of withdrawal of the Deposited Securities represented thereby and payment of the
fee of the Depositary for the surrender of American Depositary Shares as provided in Section&nbsp;5.9 and payment of all taxes and governmental charges payable in connection with that surrender and withdrawal of the Deposited Securities, and subject
to the terms and conditions of this Deposit Agreement, the Owner of those American Depositary Shares shall be entitled to delivery (to the extent delivery can then be lawfully and practicably made), to or as instructed by that Owner, of the amount
of Deposited Securities at the time represented by those American Depositary Shares, <U>but not</U> any money or other property as to which a record date for distribution to Owners has passed (since money or other property of that kind will be
delivered or paid on the scheduled payment date to the Owner as of that record date), <U>and except that</U> the Depositary shall not be required to accept surrender of American Depositary Shares for the purpose of withdrawal to the extent it would
require delivery of a fraction of a Deposited Security. That delivery shall be made, as provided in this Section, without unreasonable delay. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">As a condition of accepting a surrender of American Depositary Shares for the purpose of withdrawal of Deposited Securities, the Depositary
may require (i)&nbsp;that each surrendered Receipt be properly endorsed in blank or accompanied by proper instruments of transfer in blank and (ii)&nbsp;that the surrendering Owner execute and deliver to the Depositary a written order directing the
Depositary to cause the Deposited Securities being withdrawn to be delivered to or upon the written order of a person or persons designated in that order. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Thereupon, the Depositary shall direct the Custodian to deliver, subject to Sections 2.6, 3.1 and 3.2, the other terms and conditions of this
Deposit Agreement and local market rules and practices, to the surrendering Owner or to or upon the written order of the person or persons designated in the order delivered to the Depositary as above provided, the amount of Deposited Securities
represented by the surrendered American Depositary Shares, and the Depositary may charge the surrendering Owner a fee and its expenses for giving that direction by cable (including SWIFT) or facsimile transmission. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">If Deposited Securities are delivered physically upon surrender of American Depositary Shares for the purpose of withdrawal, that delivery
will be made at the Custodian&#146;s office, <U>except that</U>, at the request, risk and expense of an Owner surrendering American Depositary Shares for withdrawal of Deposited Securities, and for the account of that Owner, the Depositary shall
direct the Custodian to forward any cash or other property comprising, and forward a certificate or certificates, if applicable, and other proper documents of title, if any, for, the Deposited Securities represented by the surrendered American
Depositary Shares to the Depositary for delivery at the Depositary&#146;s Office or to another address specified in the order received from the surrendering Owner. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 2.6. <U>Limitations on Delivery, Registration of Transfer and Surrender of American Depositary Shares.</U> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">As a condition precedent to the delivery, registration of transfer or surrender of any American Depositary Shares or <FONT
STYLE="white-space:nowrap">split-up</FONT> or combination of any Receipt or withdrawal of any Deposited Securities, the Depositary, Custodian or Registrar may require payment from the depositor of Shares or the presenter of the Receipt or
instruction for registration of transfer or surrender of American Depositary Shares not evidenced by a Receipt of a sum sufficient to reimburse it for any tax or other governmental charge and any stock transfer or registration fee with respect
thereto (including any such tax or charge and fee with respect to Shares being deposited or withdrawn) and payment of any applicable fees as provided in this Deposit Agreement, may require the production of proof satisfactory to it as to the
identity and genuineness of any signature and may also require compliance with any regulations the Depositary may establish consistent with the provisions of this Deposit Agreement, including, without limitation, this Section&nbsp;2.6. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">The Depositary may refuse to accept deposits of Shares for delivery of American Depositary Shares or to register transfers of American
Depositary Shares in particular instances, or may suspend deposits of Shares or registration of transfer generally, whenever it or the Company considers it necessary or advisable to do so. The Depositary may refuse surrenders of American Depositary
Shares for the purpose of withdrawal of Deposited Securities in particular instances, or may suspend surrenders for the purpose of withdrawal generally, <U>but, notwithstanding anything to the contrary in this Deposit Agreement, only for</U>
(i)&nbsp;temporary delays caused by closing of the Depositary&#146;s register or the register of holders of Shares maintained by the Company or the Foreign Registrar, or the deposit of Shares, in connection with voting at a shareholders&#146;
meeting or the payment of dividends, (ii)&nbsp;the payment of fees, taxes and similar charges, (iii)&nbsp;compliance with any U.S. or foreign laws or governmental regulations relating to the American Depositary Shares or to the withdrawal of the
Deposited Securities or (iv)&nbsp;any other reason that, at the time, is permitted under paragraph I(A)(1) of the General Instructions to Form <FONT STYLE="white-space:nowrap">F-6</FONT> under the Securities Act of 1993 or any successor to that
provision. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">The Depositary shall not knowingly accept for deposit under this Deposit Agreement any
Shares that, at the time of deposit, are Restricted Securities or for which the Depositary has received written instructions from the Company that the deposit of those Shares would violate applicable law or regulation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 2.7. <U>Lost Receipts, etc.</U> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">If a Receipt is mutilated, destroyed, lost or stolen, the Depositary shall deliver to the Owner the American Depositary Shares evidenced by
that Receipt in uncertificated form or, if requested by the Owner, execute and deliver a new Receipt of like tenor in exchange and substitution for such mutilated Receipt, upon surrender and cancellation of that mutilated Receipt, or in lieu of and
in substitution for that destroyed, lost or stolen Receipt. <U>However</U>, before the Depositary will deliver American Depositary Shares in uncertificated form or execute and deliver a new Receipt, in substitution for a destroyed, lost or stolen
Receipt, the Owner must (a)&nbsp;file with the Depositary (i)&nbsp;a request for that replacement before the Depositary has notice that the Receipt has been acquired by a bona fide purchaser and (ii)&nbsp;a sufficient indemnity bond and
(b)&nbsp;satisfy any other reasonable requirements imposed by the Depositary. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 2.8. <U>Cancellation and Destruction of Surrendered
Receipts.</U> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">The Depositary shall cancel all Receipts surrendered to it and is authorized to destroy Receipts so cancelled. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">The Depositary agrees to maintain records of all Receipts surrendered and Deposited Securities withdrawn under Section&nbsp;2.5, of substitute
Receipts delivered under Section&nbsp;2.7, and of cancelled or destroyed Receipts under this Section, in keeping with procedures ordinarily followed by stock transfer agents located in the United States. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 2.9. <U>DTC Direct Registration System and Profile Modification System.</U> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) Notwithstanding the provisions of Section&nbsp;2.4, the parties acknowledge that DTC&#146;s Direct Registration System
(&#147;<U>DRS</U>&#148;) and Profile Modification System (&#147;<U>Profile</U>&#148;) apply to the American Depositary Shares upon acceptance thereof to DRS by DTC. DRS is the system administered by DTC that facilitates interchange between
registered holding of uncertificated securities and holding of security entitlements in those securities through DTC and a DTC participant. Profile is a required feature of DRS that allows a DTC participant, claiming to act on behalf of an Owner of
American Depositary Shares, to direct the Depositary to register a transfer of those American Depositary Shares to DTC or its nominee and to deliver those American Depositary Shares to the DTC account of that DTC participant without receipt by the
Depositary of prior authorization from the Owner to register that transfer. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) In connection with DRS/Profile, the parties acknowledge
that the Depositary will not determine whether the DTC participant that is claiming to be acting on behalf of an Owner in requesting a registration of transfer and delivery as described in paragraph (a)&nbsp;above has the actual authority to act on
behalf of that Owner (notwithstanding any requirements under the Uniform Commercial Code). For the avoidance of doubt, the provisions of Sections 5.3 and 5.8 apply to the matters arising from the use of the DRS/Profile. The parties agree that the
Depositary&#146;s reliance on and compliance with instructions received by the Depositary through the DRS/Profile system and otherwise in accordance with this Deposit Agreement shall not constitute negligence or bad faith on the part of the
Depositary. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">ARTICLE 3. CERTAIN OBLIGATIONS OF OWNERS AND HOLDERS OF AMERICAN DEPOSITARY SHARES </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 3.1. <U>Filing Proofs, Certificates and Other Information.</U> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Any person presenting Shares for deposit or any Owner or Holder may be required from time to time to file with the Depositary or the Custodian
such proof of citizenship or residence, taxpayer status, exchange control approval, payment of all applicable taxes or other governmental charges, or such information relating to legal and beneficial ownership, including the registration on the
books of the Company or the Foreign Registrar, if applicable, to execute such certificates and to make such representations and warranties, as the Depositary may deem necessary or proper or as the Company may reasonably require by notice to the
Depositary. The Depositary may withhold the delivery or registration of transfer of American Depositary Shares, the distribution of any dividend or other distribution or of the proceeds thereof or the delivery of any Deposited Securities until that
proof or other information is filed or those certificates are executed or those representations and warranties are made. Each Owner and Holder agrees to provide, in a timely manner, all proofs, information, representations and warranties required
under this Section&nbsp;3.1. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">If requested in writing, the Depositary shall, as promptly as practicable, at the Company&#146;s expense,
provide the Company with copies of any such proofs, certificates or other information it receives pursuant to this Section&nbsp;3.1, to the extent that disclosure is permitted under applicable law. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 3.2. <U>Liability of Owner for Taxes.</U> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">If any tax or other governmental charge shall become payable by the Custodian or the Depositary with respect to or in connection with any
American Depositary Shares or any Deposited Securities represented by any American Depositary Shares or in connection with a transaction to which Section&nbsp;4.8 applies, that tax or other governmental charge shall be payable by the Owner of those
American Depositary Shares to the Depositary. The Depositary may refuse to register any transfer of those American Depositary Shares or any withdrawal of Deposited Securities represented by those American Depositary Shares until that payment is
made, and may withhold any dividends or other distributions or the proceeds thereof, or may sell for the account of the Owner any part or all of the Deposited Securities represented by those American Depositary Shares and apply those dividends or
other distributions or the net proceeds of any sale of that kind in payment of that tax or other governmental charge <U>but</U>, even after a sale of that kind, the Owner of those American Depositary Shares shall remain liable for any deficiency.
The Depositary shall distribute any net proceeds of a sale made under this Section that are not used to pay taxes or governmental charges to the Owners entitled to them in accordance with Section&nbsp;4.1. If the number of Shares represented by each
American Depositary Share decreases as a result of a sale of Deposited Securities under this Section, the Depositary may call for surrender of the American Depositary Shares to be exchanged on a mandatory basis for a lesser number of American
Depositary Shares and may sell American Depositary Shares to the extent necessary to avoid distributing fractions of American Depositary Shares in that exchange and distribute the net proceeds of that sale to the Owners entitled to them. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 3.3. <U>Warranties on Deposit of Shares.</U> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Every person depositing Shares under this Deposit Agreement shall be deemed thereby to represent and warrant that those Shares and each
certificate therefor, if applicable, are validly issued, fully paid and nonassessable and were not issued in violation of any preemptive or similar rights of the holders of outstanding securities of the Company and that the person making that
deposit is duly authorized so to do. Every depositing person shall also be deemed to represent that the Shares, at the time of deposit, are not Restricted Securities. All representations and warranties deemed made under this Section shall survive
the deposit of Shares and delivery of American Depositary Shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 3.4. <U>Disclosure of Interests.</U> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">When required in order to comply with applicable laws and regulations, the rules and requirements of the Australian Securities Exchange, the
Nasdaq Global Market or any other stock exchange on which the Shares or the American Depositary Shares are registered, traded or listed or any book-entry settlement system, or the articles of association or similar document of the Company, the
Company may from time to time request&nbsp;each Owner&nbsp;and Holder to provide to the Depositary information relating to: (a)&nbsp;the capacity in which it holds&nbsp;American Depositary Shares,&nbsp;(b) the identity of any Holders or
other&nbsp;persons or entities&nbsp;then or previously interested in those American Depositary Shares and the nature of those interests and&nbsp;(c)&nbsp;any other matter where disclosure of such matter is, in the Company&#146;s reasonable opinion,
required for that compliance.&nbsp;Each Owner and Holder agrees to provide all information known to it in response to a request made pursuant to this Section.&nbsp;Each Holder&nbsp;consents to the disclosure by the Depositary and the Owner or any
other Holder through which it holds American Depositary Shares, directly or indirectly, of all information responsive to a request made pursuant to this Section relating to&nbsp;that Holder that is known to that Owner or other Holder.&nbsp;The
Depositary agrees to use reasonable efforts&nbsp;to comply with written instructions requesting that the Depositary forward any request authorized under this Section to the Owners and to forward to the Company any responses it receives in response
to that request. The Depositary may charge the Company a fee (to be agreed at the time between the Company and the Depositary) and its documented expenses for complying with requests under this Section&nbsp;3.4. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Each Owner and Holder of American Depositary Shares further agrees to comply with the laws and regulations of the United States and Australia
(if and to the extent applicable) with respect to the disclosure requirements regarding beneficial ownership of Shares, all as if the American Depositary Shares were the Shares represented thereby, including requirements to make notifications and
filings within the required timeframes to the Company, to the Commission, to the Australian Securities Exchange and any other authorities in the United States or in Australia. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman">ARTICLE 4. THE DEPOSITED SECURITIES </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 4.1. <U>Cash Distributions.</U> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Whenever the Depositary receives any cash dividend or other cash distribution on Deposited Securities, the Depositary shall, subject to the
provisions of Section&nbsp;4.5, convert that dividend or other distribution into Dollars and distribute the amount thus received (net of the fees and expenses of the Depositary as provided in Section&nbsp;5.9) to the Owners entitled thereto, in
proportion to the number of American Depositary Shares representing those Deposited Securities held by them respectively; <U>provided</U>, <U>however</U>, that if the Custodian or the Depositary shall be required to withhold and does withhold from
that cash dividend or other cash distribution an amount on account of taxes or other governmental charges, the amount distributed to the Owners of the American Depositary Shares representing those Deposited Securities shall be reduced accordingly.
<U>However</U>, the Depositary will not pay any Owner a fraction of one cent, but will round each Owner&#146;s entitlement to the nearest whole cent. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">The Company or its agent will remit to the appropriate governmental agency in each applicable jurisdiction all amounts withheld and owing to
such agency. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">If a cash distribution would represent a return of all or substantially all the value of the Deposited Securities underlying
American Depositary Shares, the Depositary may, after consultation with the Company to the extent practicable: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(i) require payment of or
deduct the fee for surrender of American Depositary Shares (whether or not it is also requiring surrender of American Depositary Shares) as a condition of making that cash distribution; or </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(ii) sell all Deposited Securities other than the subject cash distribution and add any net cash proceeds of that sale to the cash
distribution, call for surrender of all those American Depositary Shares and require that surrender as a condition of making that cash distribution. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If
the Depositary acts under this paragraph, that action shall also be a <U>Termination Option Event</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 4.2. <U>Distributions
Other Than Cash, Shares or Rights.</U> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Subject to the provisions of Sections 4.11 and 5.9, whenever the Depositary receives any
distribution other than a distribution described in Section&nbsp;4.1, 4.3 or 4.4 on Deposited Securities (but not in exchange for or in conversion or in lieu of Deposited Securities), the Depositary shall cause the securities or property received by
it to be distributed to the Owners entitled thereto, after deduction or upon payment of any fees and expenses of the Depositary and any taxes or other governmental charges, in proportion to the number of American Depositary Shares representing such
Deposited Securities held by them respectively, in any manner that the Depositary deems equitable and practicable for accomplishing that distribution (which may be a distribution of depositary shares representing the securities received);
<U>provided</U>, <U>however</U>, that if in the opinion of the Depositary such distribution cannot be made proportionately among the Owners entitled thereto, or if for any other reason (including, but not limited to, any requirement that the Company
or the Depositary withhold an amount on account of taxes or other governmental charges or that securities received must be registered under the Securities Act of 1933 in order to be distributed to Owners or Holders) the Depositary, after
consultation with the Company to the extent practicable, deems such distribution not to be lawful and feasible, the Depositary may adopt such other method as it may deem equitable and practicable for the purpose of effecting such distribution,
including, but not limited to, the public or private sale of the securities or property thus received, or any part thereof, and distribution of the net proceeds of any such sale (net of the fees and expenses of the Depositary as provided in
Section&nbsp;5.9) to the Owners entitled thereto, all in the manner and subject to the </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
conditions set forth in Section&nbsp;4.1. The Depositary may withhold any distribution of securities under this Section&nbsp;4.2 if it has not received satisfactory assurances from the Company
that the distribution does not require registration under the Securities Act of 1933. The Depositary may sell, by public or private sale, an amount of securities or other property it would otherwise distribute under this Section&nbsp;4.2 that is
sufficient to pay its fees and expenses in respect of that distribution. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">If a distribution to be made under this Section&nbsp;4.2 would
represent a return of all or substantially all the value of the Deposited Securities underlying American Depositary Shares, the Depositary may, after consultation with the Company to the extent practicable: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(i) require payment of or deduct the fee for surrender of American Depositary Shares (whether or not it is also requiring surrender of
American Depositary Shares) as a condition of making that distribution; or </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(ii) sell all Deposited Securities other than the subject
distribution and add any net cash proceeds of that sale to the distribution, call for surrender of all those American Depositary Shares and require that surrender as a condition of making that distribution. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If the Depositary acts under this paragraph, that action shall also be a <U>Termination Option Event</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 4.3. <U>Distributions in Shares.</U> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Whenever the Depositary receives any distribution on Deposited Securities consisting of a dividend in, or free distribution of, Shares, the
Depositary may, and if the Company so requests in writing, shall, deliver to the Owners entitled thereto, in proportion to the number of American Depositary Shares representing those Deposited Securities held by them respectively, an aggregate
number of American Depositary Shares representing the amount of Shares received as that dividend or free distribution, subject to the terms and conditions of this Deposit Agreement with respect to the deposit of Shares and issuance of American
Depositary Shares, including withholding of any tax or governmental charge as provided in Section&nbsp;4.11 and payment of the fees and expenses of the Depositary as provided in Section&nbsp;5.9 (and the Depositary may sell, by public or private
sale, an amount of the Shares received (or American Depositary Shares representing those Shares) sufficient to pay its fees and expenses in respect of that distribution). In lieu of delivering fractional American Depositary Shares, the Depositary
may sell the amount of Shares represented by the aggregate of those fractions (or American Depositary Shares representing those Shares) and distribute the net proceeds, all in the manner and subject to the conditions described in Section&nbsp;4.1.
If and to the extent that additional American Depositary Shares are not delivered and Shares or American Depositary Shares are not sold, each American Depositary Share shall thenceforth also represent the additional Shares distributed on the
Deposited Securities represented thereby. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">If the Company declares a distribution in which holders of Deposited Securities have a right to
elect whether to receive cash, Shares or other securities or a combination of those things, or a right to elect to have a distribution sold on their behalf, the Depositary may, after consultation with the Company, make that right of election
available for exercise by Owners in any manner the Depositary considers to be lawful and practical. As a condition of making a distribution election right available to Owners, the Depositary may require satisfactory assurances from the Company that
doing so does not require registration of any securities under the Securities Act of 1933 that has not been effected. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 4.4.
<U>Rights.</U> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) If rights are granted to the Depositary in respect of deposited Shares to purchase additional Shares or other
securities, the Company and the Depositary shall endeavor to consult as to the actions, if any, the Depositary should take in connection with that grant of rights. The Depositary may, to the extent deemed by it to be lawful and practical (i)&nbsp;if
requested in writing by the Company, grant to all or certain Owners rights to instruct the Depositary to purchase the securities to which the rights relate and deliver those securities or American Depositary Shares representing those securities to
Owners, (ii)&nbsp;if requested in writing by the Company, deliver the rights to or to the order of certain Owners, or (iii)&nbsp;sell the rights to the extent practicable and distribute the net proceeds of that sale to Owners entitled to those
proceeds. To the extent rights are not exercised, delivered or disposed of under (i), (ii) or (iii)&nbsp;above, the Depositary shall permit the rights to lapse unexercised. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) If the Depositary will act under (a)(i) above, the Company and the Depositary will enter into a separate agreement setting forth the
conditions and procedures applicable to the particular offering. Upon instruction from an applicable Owner in the form the Depositary specified and upon payment by that Owner to the Depositary of an amount equal to the purchase price of the
securities to be received upon the exercise of the rights, the Depositary shall, on behalf of that Owner, exercise the rights and purchase the securities. The purchased securities shall be delivered to, or as instructed by, the Depositary. The
Depositary shall (i)&nbsp;deposit the purchased Shares under this Deposit Agreement and deliver American Depositary Shares representing those Shares to that Owner or (ii)&nbsp;deliver or cause the purchased Shares or other securities to be delivered
to or to the order of that Owner. The Depositary will not act under (a)(i) above unless the offer and sale of the securities to which the rights relate are registered under the Securities Act of 1933 or the Depositary has received an opinion of
United States counsel that is satisfactory to it to the effect that those securities may be sold and delivered to the applicable Owners without registration under the Securities Act of 1933. For the avoidance of doubt, nothing in this Deposit
Agreement shall create any obligation on the part of the Company to file a registration statement under the Securities Act of 1933 with respect to rights or the underlying securities or to endeavor to have such a registration statement declared
effective by the Commission. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) If the Depositary will act under (a)(ii) above, the Company and the Depositary will enter into a
separate agreement setting forth the conditions and procedures applicable to the particular offering. Upon (i)&nbsp;the request of an applicable Owner to deliver the rights allocable to the American Depositary Shares of that Owner to an account
specified by that Owner to which the rights can be delivered and (ii)&nbsp;receipt of such documents as the Company and the Depositary agreed to require to comply with applicable law, the Depositary will deliver those rights as requested by that
Owner. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) If the Depositary will act under (a)(iii) above, the Depositary will use reasonable efforts to sell the rights in proportion
to the number of American Depositary Shares held by the applicable Owners and pay the net proceeds to the Owners otherwise entitled to the rights that were sold, upon an averaged or other practical basis without regard to any distinctions among such
Owners because of exchange restrictions or the date of delivery of any American Depositary Shares or otherwise. The Depositary may enter into any arrangements with the Company or persons acting on behalf of the Company to effect the orderly disposal
or such rights. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) Payment or deduction of the fees of the Depositary as provided in Section&nbsp;5.9 and
payment or deduction of the expenses of the Depositary and any applicable taxes or other governmental charges shall be conditions of any delivery of securities or payment of cash proceeds under this Section&nbsp;4.4. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f) Neither the Company nor the Depositary shall be responsible for any failure to determine that it may be lawful or feasible to make rights
available to or exercise rights on behalf of Owners in general or any Owner in particular, or to sell rights. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 4.5. <U>Conversion
of Foreign Currency.</U> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Whenever the Depositary or the Custodian receives foreign currency, by way of dividends or other distributions
or the net proceeds from the sale of securities, property or rights, and if at the time of the receipt thereof the foreign currency so received can in the judgment of the Depositary be converted on a reasonable basis into Dollars and the resulting
Dollars transferred to the United States, the Depositary or one of its agents or affiliates or the Custodian shall convert or cause to be converted by sale or in any other manner that it may determine that foreign currency into Dollars, and those
Dollars shall be distributed, as promptly as practicable, to the Owners entitled thereto.&nbsp;A cash distribution may be made upon an averaged or other practicable basis without regard to any distinctions among Owners based on exchange
restrictions, the date of delivery of any American Depositary Shares or otherwise and shall be net of any expenses of conversion into Dollars incurred by the Depositary as provided in Section&nbsp;5.9. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">If a conversion of foreign currency or the repatriation or distribution of Dollars can be effected only with the approval or license of any
government or agency thereof, the Depositary may, but will not be required to, file an application for that approval or license. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">If the
Depositary, after consultation with the Company to the extent practicable, determines that in its judgment any foreign currency received by the Depositary or the Custodian is not convertible on a reasonable basis into Dollars transferable to the
United States, or if any approval or license of any government or agency thereof that is required for such conversion is not filed or sought by the Depositary or is not obtained within a reasonable period as determined by the Depositary, the
Depositary may distribute the foreign currency received by the Depositary to, or in its discretion may hold such foreign currency uninvested and without liability for interest thereon for the respective accounts of, the Owners entitled to receive
the same. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">If any conversion of foreign currency, in whole or in part, cannot be effected for distribution to some of the Owners entitled
thereto, the Depositary may in its discretion make that conversion and distribution in Dollars to the extent practicable and permissible to the Owners entitled thereto and may distribute the balance of the foreign currency received by the Depositary
to, or hold that balance uninvested and without liability for interest thereon for the account of, the Owners entitled thereto. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">The
Depositary may convert currency itself or through any of its affiliates, or the Custodian or the Company may convert currency and pay Dollars to the Depositary. Where the Depositary converts currency itself or through any of its affiliates, the
Depositary acts as principal for its own account and not as agent, advisor, broker or fiduciary on behalf of any other person and earns revenue, including, without limitation, transaction spreads, that it will retain for its own account.&nbsp;The
revenue is based on, among other things, the difference between the exchange rate assigned to the currency conversion made under this Deposit Agreement and the rate that the Depositary or its affiliate receives when buying or selling foreign
currency for its own account.&nbsp;The Depositary makes no representation that the exchange rate used or obtained by it or its affiliate in any currency conversion under this Deposit Agreement will be the most favorable rate that could be obtained
at the time or that the method by which that rate will be determined will be the most favorable to Owners, subject to the Depositary&#146;s obligations under Section&nbsp;5.3.&nbsp;The methodology used to determine exchange rates used in currency
conversions made by the Depositary is available upon request. Where the Custodian converts currency, the Custodian has no obligation to obtain the most favorable rate that could be obtained at the time or to ensure that the method by which that rate
will be determined will be the most favorable to Owners, and the Depositary makes no representation that the rate is the most favorable rate and will not be liable for any direct or indirect losses associated with the rate.&nbsp;In certain
instances, the Depositary may receive dividends or other distributions from the Company in Dollars that represent the proceeds of a conversion of foreign currency or translation from foreign currency at a rate that was obtained or determined by or
on behalf of the Company and, in such cases, the Depositary will not engage in, or be responsible for, any foreign currency transactions and neither it nor the Company makes any representation that the rate obtained or determined by the Company is
the most favorable rate and neither it nor the Company will be liable for any direct or indirect losses associated with the rate. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION
4.6. <U>Fixing of Record Date.</U> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Whenever a cash dividend, cash distribution or any other distribution is made on Deposited Securities
or rights to purchase Shares or other securities are issued with respect to Deposited Securities (which rights will be delivered to or exercised or sold on behalf of Owners in accordance with Section&nbsp;4.4) or the Depositary receives notice that
a distribution or issuance of that kind will be made, or whenever the Depositary receives notice that a meeting of holders of Shares will be held in respect of which the Company has requested the Depositary to send a notice under Section&nbsp;4.7,
or whenever the Depositary will assess a fee or charge against the Owners, or whenever the Depositary causes a change in the number of Shares that are represented by each American Depositary Share, or whenever the Depositary otherwise finds it
necessary or convenient, the Depositary shall fix a record date, which shall be the same as, or as near as practicable to, any corresponding record date set by the Company with respect to Shares, (a)&nbsp;for the determination of the Owners
(i)&nbsp;who shall be entitled to receive the benefit of that dividend or other distribution or those rights, (ii)&nbsp;who shall be entitled to give instructions for the exercise of voting rights at that meeting, (iii)&nbsp;who shall be responsible
for that fee or charge or (iv)&nbsp;for any other purpose for which the record date was set, or (b)&nbsp;on or after which each American Depositary Share will represent the changed number of Shares. Subject to the provisions of Sections 4.1 through
4.5 and to the other terms and conditions of this Deposit Agreement, the Owners on a record date fixed by the Depositary shall be entitled to receive the amount distributable by the Depositary with respect to that dividend or other distribution or
those rights or the net proceeds of sale thereof in proportion to the number of American Depositary Shares held by them respectively, to give voting instructions or to act in respect of the other matter for which that record date was fixed, or be
responsible for that fee or charge, as the case may be. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 4.7. <U>Voting of Deposited Shares.</U> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) Upon receipt of notice of any meeting of holders of Shares at which holders of Shares will be entitled to vote, if requested in writing by
the Company, the Depositary shall, as soon as practicable thereafter, Disseminate&nbsp;to the Owners a notice, the form of which shall be in the sole discretion of </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the Depositary, that shall contain (i)&nbsp;the information contained in the notice of meeting received by the Depositary, (ii)&nbsp;a statement that the Owners as of the close of business on a
specified record date will be entitled, subject to any applicable provision of Australian law and of the articles of association or similar documents of the Company, to instruct the Depositary as to the exercise of the voting rights pertaining to
the amount of Shares represented by their respective American Depositary Shares, (iii)&nbsp;a statement as to the manner in which those instructions may be given and (iv)&nbsp;the last date on which the Depositary will accept instructions (the
&#147;<U>Instruction Cutoff Date</U>&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) Upon the written request of an Owner of American Depositary Shares, as of the date of
the request or, if a record date was specified by the Depositary, as of that record date, received on or before any&nbsp;Instruction&nbsp;Cutoff&nbsp;Date established by the Depositary, the Depositary may, and if the Depositary sent a notice under
the preceding paragraph shall, endeavor, in so far as practicable, to vote or cause to be voted the amount of deposited Shares represented by those American Depositary Shares in accordance with the instructions set forth in that request. The
Depositary shall not vote or attempt to exercise the right to vote that attaches to the deposited Shares other than in accordance with instructions given by Owners and received by the Depositary. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) There can be no assurance that Owners generally or any Owner&nbsp;in particular will receive the notice described in paragraph
(a)&nbsp;above in time&nbsp;to&nbsp;enable Owners to give instructions to the Depositary prior to the Instruction Cutoff Date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) In
order to give Owners a reasonable opportunity to instruct the Depositary as to the exercise of voting rights relating to Shares, if the Company will request the Depositary to Disseminate a notice under&nbsp;paragraph (a)&nbsp;above, the Company
shall give the Depositary notice of the meeting, details concerning the matters to be voted upon and copies of materials to be made available to holders of Shares in connection with the meeting not less than 30 days prior to the meeting date. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) Notwithstanding anything in this Section&nbsp;4.7 to the contrary, the Depositary and the Company may mutually agree to modify, amend or
adopt additional procedures with respect to voting Deposited Securities from time to time as they determine may be necessary or appropriate to comply with applicable laws and regulations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 4.8. <U>Tender and Exchange Offers; Redemption, Replacement or Cancellation of Deposited Securities.</U> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) The Depositary shall not tender any Deposited Securities in response to any voluntary cash tender offer, exchange offer or similar offer
(including a takeover offer made under Chapter 6 of the <I>Corporations Act 2001</I> (Cth)) made to holders of Deposited Securities (a &#147;<U>Voluntary Offer</U>&#148;), except when instructed in writing to do so by an Owner surrendering American
Depositary Shares and subject to any conditions or procedures the Depositary may require. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) If the Depositary receives a written notice
that Deposited Securities have been redeemed for cash or otherwise purchased for cash in a transaction that is mandatory and binding on the Depositary as a holder of those Deposited Securities (including the implementation of a scheme of arrangement
under Part 5.1 of the <I>Corporations Act 2001</I> (Cth) and compulsory acquisition under Chapter 6A of the <I>Corporations Act 2001</I> (Cth)) (a &#147;<U>Redemption</U>&#148;), the Depositary, at the expense of the Company (unless otherwise agreed
in writing between the Company and the Depositary), shall (i)&nbsp;if required, surrender Deposited Securities that have been redeemed to the issuer of those securities or its agent on the redemption date, (ii)&nbsp;Disseminate a notice to Owners
(A)&nbsp;notifying them of that Redemption, (B)&nbsp;calling for surrender of a corresponding number of American Depositary Shares and (C)&nbsp;notifying them that the called American Depositary Shares have been converted into a right only to
receive the money received by the Depositary upon that Redemption and those net proceeds shall be the Deposited Securities to which Owners of those converted American Depositary Shares shall be entitled upon surrenders of those American Depositary
Shares in accordance with Section&nbsp;2.5 or 6.2 and (iii)&nbsp;distribute the money received upon that Redemption to the Owners entitled to it upon surrender by them of called American Depositary Shares in accordance with Section&nbsp;2.5 (and,
for the avoidance of doubt, Owners shall not be entitled to receive that money under Section&nbsp;4.1). If the Redemption affects less than all the Deposited Securities, the Depositary shall call for surrender a corresponding portion of the
outstanding American Depositary Shares and only those American Depositary Shares will automatically be converted into a right to receive the net proceeds of the Redemption. The Depositary shall allocate the American Depositary Shares converted under
the preceding sentence among the Owners <FONT STYLE="white-space:nowrap">pro-rata</FONT> to their respective holdings of American Depositary Shares immediately prior to the Redemption, <U>except that</U> the allocations may be adjusted so that no
fraction of a converted American Depositary Share is allocated to any Owner. A Redemption of all or substantially all of the Deposited Securities shall be a <U>Termination Option Event</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) If the Depositary is notified of or there occurs any change in nominal value or any subdivision, combination or any other reclassification
of the Deposited Securities or any recapitalization, reorganization, sale of assets substantially as an entirety, merger or consolidation affecting the issuer of the Deposited Securities or to which it is a party that is mandatory and binding on the
Depositary as a holder of Deposited Securities and, as a result, securities or other property have been or will be delivered in exchange, conversion, replacement or in lieu of, Deposited Securities (a &#147;<U>Replacement</U>&#148;), the Depositary
shall, if required, surrender the old Deposited Securities affected by that Replacement of Shares and hold, as new Deposited Securities under this Deposit Agreement, the new securities or other property delivered to it in that Replacement.
<U>However</U>, the Depositary may elect to sell those new Deposited Securities if in the opinion of the Depositary, after consultation with the Company to the extent practicable, it is not lawful or not practical for it to hold those new Deposited
Securities under this Deposit Agreement because those new Deposited Securities may not be distributed to Owners without registration under the Securities Act of 1933 or for any other reason, at public or private sale, at such places and on such
terms as it deems proper and proceed as if those new Deposited Securities had been Redeemed under paragraph (b)&nbsp;above. A Replacement shall be a <U>Termination Option Event</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) In the case of a Replacement where the new Deposited Securities will continue to be held under this Deposit Agreement, the Depositary may
call for the surrender of outstanding Receipts to be exchanged for new Receipts specifically describing the new Deposited Securities and the number of those new Deposited Securities represented by each American Depositary Share. If the number of
Shares represented by each American Depositary Share decreases as a result of a Replacement, the Depositary may, after consultation with the Company to the extent practicable, call for surrender of the American Depositary Shares to be exchanged on a
mandatory basis for a lesser number of American Depositary Shares and may sell American Depositary Shares to the extent necessary to avoid distributing fractions of American Depositary Shares in that exchange and distribute the net proceeds of that
sale to the Owners entitled to them. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) If there are no Deposited Securities with respect to American Depositary Shares,
including if the Deposited Securities are cancelled, or the Deposited Securities with respect to American Depositary Shares have become apparently worthless, the Depositary may call for surrender of those American Depositary Shares or may cancel
those American Depositary Shares, upon notice to Owners, and that condition shall be a <U>Termination Option Event</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 4.9.
<U>Reports.</U> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">The Depositary shall make available for inspection by Owners at its Office any reports and communications, including any
proxy solicitation material, received from the Company which are both (a)&nbsp;received by the Depositary as the holder of the Deposited Securities and (b)&nbsp;made generally available to the holders of those Deposited Securities by the Company.
The Company shall furnish reports and communications, including any proxy soliciting material to which this Section applies, to the Depositary in English, to the extent those materials are required to be translated into English pursuant to any
regulations of the Commission. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 4.10. <U>Lists of Owners.</U> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Upon written request by the Company, the Depositary shall, at the expense of the Company (unless otherwise agreed between the Company and the
Depositary), furnish to it a list, as of a recent date, of the names, addresses and American Depositary Share holdings of all Owners. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 4.11. <U>Withholding.</U> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">If the Depositary determines that any distribution received or to be made by the Depositary (including Shares and rights to subscribe
therefor) is subject to any tax or other governmental charge that the Depositary is obligated to withhold, the Depositary may sell, by public or private sale, all or a portion of the distributed property (including Shares and rights to subscribe
therefor) in the amounts and manner the Depositary deems necessary and practicable to pay those taxes or charges, and the Depositary shall distribute the net proceeds of that sale, after deduction of those taxes or charges, to the Owners entitled
thereto in proportion to the number of American Depositary Shares held by them respectively. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Services for Owners and Holders that may
permit them to obtain reduced rates of tax withholding at source or reclaim excess tax withheld, and the fees and costs associated with using services of that kind, are not provided under, and are outside the scope of, this Deposit Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Each Owner and Holder agrees to indemnify the Company, the Depositary, the Custodian and their respective directors, employees, agents and
affiliates for, and hold each of them harmless against, any claim by any governmental authority or any other entity or person with respect to taxes, additions to tax, penalties or interest arising out of any refund of taxes, reduced withholding at
source or other tax benefit received by it. The obligations of Owners and Holders under the preceding sentence shall survive any transfer of American Depositary Shares or surrender of American Depositary Shares and withdrawal of Deposited Securities
and the termination of this Deposit Agreement. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman">ARTICLE 5. THE DEPOSITARY, THE CUSTODIANS AND THE COMPANY </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 5.1. <U>Maintenance of Office and Register by the Depositary.</U> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Until termination of this Deposit Agreement in accordance with its terms, the Depositary shall maintain facilities for the delivery,
registration of transfers and surrender of American Depositary Shares in accordance with the provisions of this Deposit Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">The
Depositary shall keep a register of all Owners and all outstanding American Depositary Shares, which shall be open for inspection by the Owners at the Depositary&#146;s Office during regular business hours, but only for the purpose of communicating
with Owners regarding the business of the Company or a matter related to this Deposit Agreement or the American Depositary Shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">The
Depositary may close the register for delivery, registration of transfer or surrender for the purpose of withdrawal from time to time as provided in Section&nbsp;2.6. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">If any American Depositary Shares are listed on one or more stock exchanges, the Depositary shall act as Registrar or appoint a Registrar or
one or more <FONT STYLE="white-space:nowrap">co-registrars</FONT> for registration of those American Depositary Shares in accordance with any requirements of that exchange or those exchanges. The Depositary shall notify the Company if it makes any
appointment of that kind. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">The Company shall have the right, at all reasonable times, upon written request, to inspect the books and
transfer and registration records of the Depositary, the Registrar and any <FONT STYLE="white-space:nowrap">co-transfer</FONT> agents or <FONT STYLE="white-space:nowrap">co-registrars</FONT> and to require such parties to supply, at the
Company&#146;s expense, copies of such portions of their records as the Company may reasonably request. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 5.2. <U>Prevention or
Delay of Performance by the Company or the Depositary.</U> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Neither the Depositary nor the Company nor any of their respective directors,
employees, agents or affiliates shall incur any liability to any Owner or Holder: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(i) if by reason of (A)&nbsp;any provision of any
present or future law or regulation or other act of the government of the United States, any State of the United States or any other state or jurisdiction, or of any other country, or of any governmental or regulatory authority or stock exchange;
(B) (in the case of the Depositary only) any provision, present or future, of the articles of association or similar document of the Company, or any provision of any securities issued or distributed by the Company, or any offering or distribution
thereof; or (C)&nbsp;any event or circumstance, whether natural or caused by a person or persons, that is beyond the ability of the Depositary or the Company, as the case may be, to prevent or counteract by reasonable care or effort (including, but
not limited to, earthquakes, floods, severe storms, fires, explosions, war, terrorism, civil unrest, labor disputes, criminal acts or outbreaks of infectious disease; interruptions or malfunctions of utility services, Internet or other
communications lines or systems; unauthorized access to or attacks on computer systems or websites; or other failures or malfunctions of computer hardware or software or other systems or equipment), the Depositary or the Company is, directly or
indirectly, prevented from, forbidden to or delayed in, or could be subject to any civil or criminal penalty on account of doing or performing and therefore does not do or perform, any act or thing that, by the terms of this Deposit Agreement or the
Deposited Securities, it is provided shall be done or performed; </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(ii) for any exercise of, or failure to exercise, any discretion provided for in this
Deposit Agreement (including any determination by the Depositary to take, or not take, any action that this Deposit Agreement provides the Depositary may take); </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(iii) for the inability of any Owner or Holder to benefit from any distribution, offering, right or other benefit that is made available to
holders of Deposited Securities but is not, under the terms of this Deposit Agreement, made available to Owners or Holders; or </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(iv) for
any special, consequential, indirect, or punitive damages for any breach of the terms of this Deposit Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Where, by the terms of a
distribution to which Section&nbsp;4.1, 4.2 or 4.3 applies, or an offering to which Section&nbsp;4.4 applies, or for any other reason, that distribution or offering may not be made available to Owners, and the Depositary may not dispose of that
distribution or offering on behalf of Owners and make the net proceeds available to Owners, then the Depositary shall not make that distribution or offering available to Owners, and shall allow any rights, if applicable, to lapse. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 5.3. <U>Obligations of the Depositary and the Company.</U> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">The Company and its directors, officers, employees, agents, controlling persons and affiliates assume no obligation nor shall any of them be
subject to any liability under this Deposit Agreement to any Owner or Holder, except that the Company agrees to perform its obligations specifically set forth in this Deposit Agreement without gross negligence or bad faith. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">The Depositary assumes no obligation nor shall it be subject to any liability under this Deposit Agreement to any Owner or Holder (including,
without limitation, liability with respect to the validity or worth of the Deposited Securities), except that the Depositary agrees to perform its obligations specifically set forth in this Deposit Agreement without negligence or bad faith, and the
Depositary shall not be a fiduciary or have any fiduciary duty to Owners or Holders. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Neither the Depositary nor the Company nor any of
their respective directors, officers, employees, agents, controlling persons and affiliates shall be under any obligation to appear in, prosecute or defend any action, suit or other proceeding in respect of any Deposited Securities or in respect of
the American Depositary Shares on behalf of any Owner or Holder or any other person. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Each of the Depositary and the Company and any of
their respective directors, officers, employees, agents, controlling persons and affiliates may rely, and shall be protected in relying upon, any written notice, request, direction or other document believed by it to be genuine and to have been
signed or presented by the proper party or parties. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Neither the Depositary nor the Company shall be liable for any action or <FONT
STYLE="white-space:nowrap">non-action</FONT> by it in reliance upon the advice of or information from legal counsel, accountants, any person presenting Shares for deposit, any Owner or any other person believed by it in good faith to be competent to
give such advice or information. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Neither the Company nor the Depositary shall be liable for any acts or omissions made by a successor
depositary whether in connection with a previous act or omission of the Depositary or in connection with any matter arising wholly after the removal or resignation of the Depositary, provided that in connection with the issue out of which such
potential liability arises the Depositary performed its obligations without negligence or bad faith while it acted as Depositary. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">The
Depositary shall not be liable for the acts or omissions of any securities depository, clearing agency or settlement system in connection with or arising out of book-entry settlement of American Depositary Shares or Deposited Securities or
otherwise. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">In the absence of bad faith on its part, the Depositary shall not be responsible for any failure to carry out any instructions
to vote any of the Deposited Securities, or for the manner in which any such vote is cast or the effect of any such vote. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Neither the
Company nor the Depositary shall have any duty to make any determination or provide any information as to the tax status of the Company or any liability for any tax consequences that may be incurred by Owners or Holders as a result of owning or
holding American Depositary Shares, including without limitation, tax consequences resulting from the Company (or any of its subsidiaries) being treated as a &#147;Passive Foreign Investment Company&#148; (&#147;<U>PFIC</U>&#148;) (in each case as
defined in the U.S. Internal Revenue Code of 1986, as amended, and the regulations issued thereunder) or otherwise. The Company may have been in the past and may be in the future a PFIC for U.S. Federal income tax purposes. Owners must consult their
own tax advisers as to the potential application of the PFIC rules. Neither the Company nor the Depositary shall be liable for the inability or failure of an Owner or Holder to obtain the benefit of a foreign tax credit, reduced rate of withholding
or refund of amounts withheld in respect of tax or any other tax benefit. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">No disclaimer of liability under the United States federal
securities laws is intended by any provision of this Deposit Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 5.4. <U>Resignation and Removal of the Depositary.</U>
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">The Depositary may at any time resign as Depositary hereunder by written notice of its election so to do delivered to the Company, to
become effective upon the appointment of a successor depositary and its acceptance of that appointment as provided in this Section. The effect of resignation if a successor depositary is not appointed is provided for in Section&nbsp;6.2. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">The Depositary may at any time be removed by the Company by 90 days&#146; prior written notice of that removal, to become effective upon the
later of (i)&nbsp;the 90th day after delivery of the notice to the Depositary and (ii)&nbsp;the appointment of a successor depositary and its acceptance of its appointment as provided in this Section. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">If the Depositary resigns or is removed, the Company shall use reasonable efforts to appoint
a successor depositary, which shall be a bank or trust company having an office in the Borough of Manhattan, The City of New York. Every successor depositary shall execute and deliver to the Company an instrument in writing accepting its appointment
under this Deposit Agreement. If the Depositary receives notice from the Company that a successor depositary has been appointed following its resignation or removal, the Depositary, upon payment of all sums due it from the Company, shall deliver to
its successor a register listing all the Owners and their respective holdings of outstanding American Depositary Shares and shall deliver the Deposited Securities to or to the order of its successor. When the Depositary has taken the actions
specified in the preceding sentence (i)&nbsp;the successor shall become the Depositary and shall have all the rights and shall assume all the duties of the Depositary under this Deposit Agreement and (ii)&nbsp;the predecessor depositary shall cease
to be the Depositary and shall be discharged and released from all obligations under this Deposit Agreement, except for its duties under Section&nbsp;5.8 with respect to the time before that discharge. A successor Depositary shall notify the Owners
of its appointment as soon as practical after assuming the duties of Depositary. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Any corporation or other entity into or with which the
Depositary may be merged or consolidated shall be the successor of the Depositary without the execution or filing of any document or any further act. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 5.5. <U>The Custodians.</U> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">The Custodian shall be subject at all times and in all respects to the directions of the Depositary and shall be responsible solely to it. The
Depositary in its discretion may at any time appoint a substitute or additional custodian or custodians, each of which shall thereafter be one of the Custodians under this Deposit Agreement. If the Depositary receives notice that a Custodian is
resigning and, upon the effectiveness of that resignation there would be no Custodian acting under this Deposit Agreement, the Depositary shall, as promptly as practicable after receiving that notice, appoint a substitute custodian or custodians,
each of which shall thereafter be a Custodian under this Deposit Agreement. The Depositary shall require any Custodian that resigns or is removed to deliver all Deposited Securities held by it to another Custodian. The Depositary shall notify the
Company of the appointment of a substitute or additional Custodian as promptly as practicable and, if practicable, prior to the effectiveness of such appointment. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 5.6. <U>Notices and Reports.</U> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">If the Company takes or decides to take any corporate action of a kind that is addressed in Sections 4.1 to 4.4, or 4.6 to 4.8, or that
effects or will effect a change of the name or legal structure of the Company, or that effects or will effect a change to the Shares, the Company shall notify the Depositary and the Custodian of that action or decision as soon as it is lawful and
practical to give that notice.&nbsp;The notice shall be in English and shall include all details that the Company is required to include in any notice to any governmental or regulatory authority or securities exchange or is required to make
available generally to holders of Shares by publication or otherwise. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">The Company will arrange for the translation into English, if not
already in English, to the extent required pursuant to any regulations of the Commission, and the prompt transmittal by the Company to the Depositary and the Custodian of all notices and any other reports and communications which are made generally
available by the Company to holders of its Shares. If requested in writing by the Company, the Depositary will Disseminate, at the Company&#146;s expense (unless otherwise agreed between the Company and the Depositary), those notices, reports and
communications to all Owners or otherwise make them available to Owners in a manner that the Company specifies as substantially equivalent to the manner in which those communications are made available to holders of Shares and compliant with the
requirements of any securities exchange on which the American Depositary Shares are listed. The Company will timely provide the Depositary with the quantity of such notices, reports, and communications, as timely requested in writing by the
Depositary from time to time, in order for the Depositary to effect that Dissemination. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">The Company represents that as of the date of
this Deposit Agreement, that the statements in Article 11 of the form of Receipt appearing as Exhibit A to this Deposit Agreement or, if applicable, most recently filed with the Commission pursuant to Rule 424(b) under the Securities Act with
respect to the Company&#146;s obligation to file periodic reports under the United States Securities Exchange Act of 1934, as amended, or its qualification for exemption from registration under that Act pursuant to Rule <FONT
STYLE="white-space:nowrap">12g3-2(b)</FONT> under that Act, as the case may be, are true and correct. The Company agrees to promptly notify the Depositary upon becoming aware of any change in the truth of any of those statements or if there is any
change in the Company&#146;s status regarding those reporting obligations or that qualification. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 5.7. <U>Distribution of
Additional Shares, Rights, etc.</U> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">If the Company or any affiliate of the Company determines to make any issuance or distribution of
(1)&nbsp;additional Shares, (2)&nbsp;rights to subscribe for Shares, (3)&nbsp;securities convertible into Shares, or (4)&nbsp;rights to subscribe for such securities (each a &#147;<U>Distribution</U>&#148;), the Company shall notify the Depositary
in writing in English as promptly as practicable and in any event before the Distribution starts and, if reasonably requested in writing by the Depositary, the Company shall furnish as promptly as practicable to the Depositary either
(i)&nbsp;evidence satisfactory to the Depositary that the Distribution is registered under the Securities Act of 1933 or (ii)&nbsp;a written opinion from U.S. counsel for the Company that is reasonably satisfactory to the Depositary, stating that
the Distribution does not require, or, if made in the United States, would not require, registration under the Securities Act of 1933. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">The Company agrees with the Depositary that neither the Company nor any company controlled by, controlling or under common control with the
Company will at any time deposit any Shares that, at the time of deposit, are Restricted Securities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Notwithstanding anything to the
contrary herein, nothing in this Deposit Agreement shall be deemed to oblige the Company to file any registration statement in respect of any proposed transactions. To the extent the Company in its sole discretion deems it necessary or advisable in
order to avoid any requirement to register securities under the Securities Act of 1933, it may prevent Owners in the United States from purchasing securities and may instruct the Depositary not to accept certain Shares reasonably identified in such
instruction for deposit for such period of time following the issuance of such additional securities or to adopt such other specific measures as the Company may reasonably request. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 5.8. <U>Indemnification.</U> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">The Company agrees to indemnify the Depositary, its directors, employees, agents and affiliates and each Custodian against, and hold each of
them harmless from, any liability or expense (including, but not limited to any fees and expenses incurred in seeking, enforcing or collecting such indemnity and the reasonable and documented fees and expenses of counsel) that may arise out of or in
connection with (a)&nbsp;any registration with the Commission of American Depositary Shares or Deposited Securities or the offer or sale thereof in the United States or (b)&nbsp;acts performed or omitted, pursuant to the provisions of or in
connection with this Deposit Agreement and the American Depositary Shares, as the same may be amended, modified or supplemented from time to time, (i)&nbsp;by either the Depositary or a Custodian or their respective directors, employees, agents and
affiliates, except for any liability or expense arising out of the negligence or bad faith of either of them, or (ii)&nbsp;by the Company or any of its directors, employees, agents and affiliates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">The indemnities contained in the preceding paragraph shall not extend to any liabilities or expenses arising out of information relating to
the Depositary or any Custodian, as the case may be, furnished in writing by the Depositary to the Company expressly for use in any registration statement, proxy statement, prospectus or preliminary prospectus or any other offering documents
relating to the American Depositary Shares, the Shares or any other Deposited Securities (it being acknowledged that, as of the date of this Deposit Agreement, the Depositary has not furnished any information of that kind). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">The Depositary agrees to indemnify the Company, its directors, officers, management, employees, agents and affiliates and hold them harmless
from any liability or expense (including, but not limited to any fees and expenses incurred in seeking, enforcing or collecting such indemnity and the reasonable and documented fees and expenses of counsel) that may arise out of acts performed or
omitted by the Depositary or any Custodian or their respective directors, employees, agents and affiliates due to their negligence or bad faith. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">The obligations set forth in this Section&nbsp;5.8 shall survive the termination of this Deposit Agreement and the succession or substitution
of any party hereto. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">If a claim is asserted or an action is commenced against a person that is entitled to seek and intends to seek
indemnification for that claim or action under this Section&nbsp;5.8 (an &#147;Indemnifiable Claim&#148;), that person (an &#147;Indemnified Person&#148;) shall (i)&nbsp;promptly notify in writing the person obligated to provide that indemnification
(the &#147;Indemnifying Person&#148;) of that assertion or commencement and (ii)&nbsp;consult in good faith with the Indemnifying Person as to the conduct of the defense of that Indemnifiable Claim, which defense shall be reasonable in the
circumstances. To the extent that (x)&nbsp;no conflict of interest exists in the conduct of the defense and (y)&nbsp;no legal defenses are available to the Indemnified Person that are different from or in addition to those available to the
Indemnifying Person, the Indemnifying Person may, by written notice to the Indemnified Person, assume the defense of an Indemnifiable Claim with counsel reasonably satisfactory to the Indemnified Person. After notice from the Indemnifying Person to
the Indemnified Person of its election to assume the defense of an Indemnifiable Claim, and provided no conflict of interest exists or no different or additional legal defenses are available, the Indemnifying Person shall not be liable to the
Indemnified Person for any legal expenses of other counsel or any other expenses subsequently incurred by the Indemnified Person in connection with the defense other than reasonable costs of investigation. Neither the Indemnified Person nor the
Indemnifying Person shall compromise or settle an Indemnifiable Claim without the consent of the other (which consent shall not be unreasonably withheld). The Indemnifying Person shall have no obligation to indemnify and hold harmless the
Indemnified Person from any loss, expense or liability incurred by the Indemnified Person as a result of a default judgment entered against the Indemnified Person unless such judgment was entered after the Indemnifying Person agreed, in writing, to
assume the defense of an Indemnifiable Claim. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 5.9. <U>Charges of Depositary.</U> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">The Company agrees to pay the fees and charges specified in the following paragraph only to the extent the Company is a depositor of Shares or
an Owner. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">The following charges shall be incurred by any party depositing or withdrawing Shares or by any party surrendering American
Depositary Shares or to whom American Depositary Shares are issued (including, without limitation, issuance pursuant to a stock dividend or stock split declared by the Company or an exchange of stock regarding the American Depositary Shares or
Deposited Securities or a delivery of American Depositary Shares pursuant to Section&nbsp;4.3), or by Owners, as applicable: (1)&nbsp;taxes and other governmental charges, (2)&nbsp;such registration fees as may from time to time be in effect for the
registration of transfers of Shares generally on the Share register of the Company or Foreign Registrar and applicable to transfers of Shares to or from the name of the Depositary or its nominee or the Custodian or its nominee on the making of
deposits or withdrawals hereunder, (3)&nbsp;such cable (including SWIFT) and facsimile transmission fees and expenses as are expressly provided in this Deposit Agreement, (4)&nbsp;such expenses as are incurred by the Depositary in the conversion of
foreign currency pursuant to Section&nbsp;4.5, (5) a fee of $5.00 or less per 100 American Depositary Shares (or portion thereof) for the delivery of American Depositary Shares pursuant to Section&nbsp;2.3, 4.3 or 4.4 and the surrender of American
Depositary Shares pursuant to Section&nbsp;2.5 or 6.2, (6) a fee of $.05 or less per American Depositary Share (or portion thereof) for any cash distribution made pursuant to this Deposit Agreement, including, but not limited to Sections 4.1 through
4.4 and Section&nbsp;4.8, (7) a fee for the distribution of securities pursuant to Section&nbsp;4.2 or of rights pursuant to Section&nbsp;4.4 (where the Depositary will not exercise or sell those rights on behalf of Owners), such fee being in an
amount equal to the fee for the execution and delivery of American Depositary Shares referred to above which would have been charged as a result of the deposit of such securities under this Deposit Agreement (for purposes of this item 7 treating all
such securities as if they were Shares) but which securities are instead distributed by the Depositary to Owners, (8)&nbsp;in addition to any fee charged under item 6 above, a fee of $.05 or less per American Depositary Share (or portion thereof)
per annum for depositary services, which will be payable as provided in item 9 below, and (9)&nbsp;any other charges payable by the Depositary or the Custodian, any of the Depositary&#146;s or Custodian&#146;s agents or the agents of the
Depositary&#146;s or Custodian&#146;s agents, in connection with the servicing of Shares or other Deposited Securities (which charges shall be assessed against Owners as of the date or dates set by the Depositary in accordance with Section&nbsp;4.6
and shall be payable at the sole discretion of the Depositary by billing those Owners for those charges or by deducting those charges from one or more cash dividends or other cash distributions). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">The Depositary may collect any of its fees by deduction from any cash distribution payable, or by selling a portion of any securities to be
distributed, to Owners that are obligated to pay those fees. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">In performing its duties under this Deposit Agreement, the Depositary may
use brokers, dealers, foreign currency dealers or other service providers that are owned by or affiliated with the Depositary and that may earn or share fees, spreads or commissions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">The Depositary may own and deal in any class of securities of the Company and its affiliates and in American Depositary Shares. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 5.10. <U>Retention of Depositary Documents.</U> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">The Depositary is authorized to destroy those documents, records, bills and other data compiled during the term of this Deposit Agreement at
the times permitted by the laws or regulations governing the Depositary, unless the Company requests, in writing, with reasonably sufficient prior notice, that such papers be retained for a longer period or turned over to the Company or to a
successor depositary, at the Company&#146;s expense. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 5.11. <U>Exclusivity.</U> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Without prejudice to the Company&#146;s rights under Section&nbsp;5.4, the Company agrees not to appoint any other depositary for issuance of
depositary shares, depositary receipts or any similar securities or instruments (for the avoidance of doubt, other than instruments or securities issued directly by the Company) so long as The Bank of New York Mellon is acting as Depositary under
this Deposit Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 5.12. <U>Information for Regulatory Compliance.</U> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Each of the Company and the Depositary shall provide to the other, as promptly as practicable, information from its records or otherwise
available to it that is reasonably requested by the other to permit the other to comply with applicable law or requirements of governmental or regulatory authorities. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman">ARTICLE 6. AMENDMENT AND TERMINATION </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 6.1. <U>Amendment.</U> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">The form of the Receipts and any provisions of this Deposit Agreement may at any time and from time to time be amended by agreement between
the Company and the Depositary without the consent of Owners or Holders in any respect that they may deem necessary or desirable. Any amendment that would impose or increase any fees or charges (other than taxes and other governmental charges,
registration fees, cable (including SWIFT) or facsimile transmission costs, delivery costs or other such expenses), or that would otherwise prejudice any substantial existing right of Owners, shall, however, not become effective as to outstanding
American Depositary Shares until the expiration of 30 days after notice of that amendment has been Disseminated to the Owners of outstanding American Depositary Shares. Every Owner and Holder, at the time any amendment so becomes effective, shall be
deemed, by continuing to hold American Depositary Shares or any interest therein, to consent and agree to that amendment and to be bound by this Deposit Agreement as amended thereby. Upon the effectiveness of an amendment to the form of Receipt,
including a change in the number of Shares represented by each American Depositary Share, the Depositary may call for surrender of Receipts to be replaced with new Receipts in the amended form or call for surrender of American Depositary Shares to
effect that change of ratio. In no event shall any amendment impair the right of the Owner to surrender American Depositary Shares and receive delivery of the Deposited Securities represented thereby, except in order to comply with mandatory
provisions of applicable law. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Notwithstanding the foregoing, if any governmental body should adopt new laws, rules or regulations which
would require an amendment of this Deposit Agreement to ensure compliance therewith, the Depositary and the Company agree to amend this Deposit Agreement at any time in accordance with such changed laws, rules and regulations. Such amendment to this
Deposit Agreement in such circumstances may become effective before a notice of such amendment or supplement is given to Owners or within any other period of time as required for compliance with such laws, rules or regulations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 6.2. <U>Termination.</U> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) The Company may initiate termination of this Deposit Agreement by notice to the Depositary. The Depositary may initiate termination of
this Deposit Agreement if (i)&nbsp;at any time 60 days shall have expired after the Depositary delivered to the Company a written resignation notice and a successor depositary has not been appointed and accepted its appointment as provided in
Section&nbsp;5.4 or (ii)&nbsp;a Termination Option Event has occurred or will occur. If termination of this Deposit Agreement is initiated by the Company or the Depositary, the Depositary shall, as promptly as practicable, Disseminate a notice of
termination to the Owners of all American Depositary Shares then outstanding setting a date for termination (the &#147;<U>Termination Date</U>&#148;), which shall be at least 90 days, and not more than 120 days, after the date of that notice, and
this Deposit Agreement shall terminate on that Termination Date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) After the Termination Date, the Company shall be discharged from all
obligations under this Deposit Agreement except for its obligations to the Depositary under Sections 5.8 and 5.9. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) At any time after
the Termination Date, the Depositary may sell the Deposited Securities then held under this Deposit Agreement and may thereafter hold uninvested the net proceeds of any such sale, together with any other cash then held by it hereunder, unsegregated
and without liability for interest, for the pro rata benefit of the Owners of American Depositary Shares that remain outstanding, and those Owners will be general creditors of the Depositary with respect to those net proceeds and that other cash.
After making that sale, the Depositary shall be discharged from all obligations under this Deposit Agreement, <U>except</U> (i)&nbsp;to account for the net proceeds and other cash (after deducting, in each case, the fee of the Depositary for the
surrender of American Depositary Shares, any expenses for the account of the Owner of such American Depositary Shares in accordance with the terms and conditions of this Deposit Agreement and any applicable taxes or governmental charges) and
(ii)&nbsp;for its obligations under Section&nbsp;5.8 and (iii)&nbsp;to act as provided in paragraph (d)&nbsp;below. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) After the
Termination Date, if any American Depositary Shares remain outstanding, the Depositary shall continue to receive dividends and other distributions pertaining to Deposited Securities (that have not been sold), may sell rights and other property as
provided in this Deposit Agreement and shall deliver Deposited Securities (or sale proceeds) upon surrender of American Depositary Shares (after payment or upon deduction, in each case, of the fee of the Depositary for the surrender of American
Depositary Shares, any expenses for the account of the Owner of those American Depositary Shares in accordance with the terms and conditions of this Deposit Agreement and any applicable taxes or governmental charges). After the Termination Date, the
Depositary shall not accept deposits of Shares or deliver American Depositary Shares. After the Termination Date, (i)&nbsp;the Depositary may refuse to accept surrenders of American Depositary Shares for the purpose of withdrawal of Deposited
Securities (that have not been sold) or reverse previously accepted surrenders of that kind that have not settled if in its judgment the requested withdrawal would interfere with its efforts to sell the Deposited Securities, (ii)&nbsp;the
</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Depositary will not be required to deliver cash proceeds of the sale of Deposited Securities until all Deposited Securities have been sold and (iii)&nbsp;the Depositary may discontinue the
registration of transfers of American Depositary Shares and suspend the distribution of dividends and other distributions on Deposited Securities to the Owners and need not give any further notices or perform any further acts under this Deposit
Agreement except as provided in this Section. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman">ARTICLE 7. MISCELLANEOUS </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 7.1. <U>Counterparts; Signatures; Delivery.</U> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">This Deposit Agreement may be executed in any number of counterparts, each of which shall be deemed an original and all of those counterparts
shall constitute one and the same instrument. Copies of this Deposit Agreement shall be filed with the Depositary and the Custodians and shall be open to inspection by any Owner or Holder during regular business hours. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">The exchange of copies of this Deposit Agreement and manually-signed signature pages by facsimile, or email attaching a pdf or similar <FONT
STYLE="white-space:nowrap">bit-mapped</FONT> image, shall constitute effective execution and delivery of this Deposit Agreement as to the parties to it; copies and signature pages so exchanged may be used in lieu of the original Deposit Agreement
and signature pages for all purposes and shall have the same validity, legal effect and admissibility in evidence as an original manual signature; the parties to this Deposit Agreement hereby agree not to argue to the contrary. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 7.2. <U>No Third Party Beneficiaries.</U> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">This Deposit Agreement is for the exclusive benefit of the Company, the Depositary, the Owners and the Holders and their respective successors
and shall not be deemed to give any legal or equitable right, remedy or claim whatsoever to any other person. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 7.3.
<U>Severability.</U> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">In case any one or more of the provisions contained in this Deposit Agreement or in a Receipt should be or become
invalid, illegal or unenforceable in any respect, the validity, legality and enforceability of the remaining provisions contained in this Deposit Agreement or that Receipt shall in no way be affected, prejudiced or disturbed thereby. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 7.4. <U>Owners and Holders as Parties; Binding Effect.</U> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">The Owners and Holders from time to time shall be parties to this Deposit Agreement and shall be bound by all of the terms and conditions of
this Deposit Agreement and of the Receipts by acceptance of American Depositary Shares or any interest therein. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 7.5.
<U>Notices.</U> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Any and all notices to be given to the Company shall be in writing and shall be deemed to have been duly given if
personally delivered or sent by domestic first class or international air mail or air courier or sent by facsimile transmission or email attaching a pdf or similar <FONT STYLE="white-space:nowrap">bit-mapped</FONT> image of a signed writing,
addressed to Opthea Limited, 650 Chapel Street, South Yarra, Victoria 3141, Attention: Mike Tonroe, or any other place to which the Company may have transferred its principal office with notice to the Depositary. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Any and all notices to be given to the Depositary shall be in writing and shall be deemed to have been duly given if in English and personally
delivered or sent by first class domestic or international air mail or air courier or sent by facsimile transmission or email attaching a pdf or similar <FONT STYLE="white-space:nowrap">bit-mapped</FONT> image of a signed writing, addressed to The
Bank of New York Mellon, 240 Greenwich Street, New&nbsp;York, New&nbsp;York 10286, Attention: Depositary Receipt Administration, or any other place to which the Depositary may have transferred its Office with notice to the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Delivery of a notice to the Company or Depositary by mail or air courier shall be deemed effected when deposited, postage prepaid, in a
post-office letter box or received by an air courier service. Delivery of a notice to the Company or Depositary sent by facsimile transmission or email shall be deemed effected when the recipient acknowledges receipt of that notice. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">A notice to be given to an Owner shall be deemed to have been duly given when Disseminated to that Owner. Dissemination in paper form will be
effective when personally delivered or sent by first class domestic or international air mail or air courier, addressed to that Owner at the address of that Owner as it appears on the transfer books for American Depositary Shares of the Depositary,
or, if that Owner has filed with the Depositary a written request that notices intended for that Owner be mailed to some other address, at the address designated in that request. Dissemination in electronic form will be effective when sent in the
manner consented to by the Owner to the electronic address most recently provided by the Owner for that purpose. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 7.6.
<U>Appointment of Agent for Service of Process; Submission to Jurisdiction; Jury Trial Waiver.</U> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">The Company hereby designates and
appoints the person named in Exhibit A to this Deposit Agreement as the Company&#146;s authorized agent in the United States upon which process may be served in any suit or proceeding arising out of or relating to the Shares or Deposited Securities,
the American Depositary Shares, the Receipts or this Deposit Agreement (a &#147;Proceeding&#148;). Each of the Company and the Depository consents and submits to the jurisdiction of any state or federal court in the State of New York in which any
Proceeding may be instituted. The Company agrees that service of process upon said authorized agent shall be deemed in every respect effective service of process upon the Company in any Proceeding. The Company agrees to deliver to the Depositary,
upon the execution and delivery of this Deposit Agreement, a written acceptance by the agent named in Exhibit A to this Deposit Agreement of its appointment as process agent. The Company further agrees to take any and all action, including the
filing of any and all such documents and instruments, as may be necessary to continue that designation and appointment in full force and effect, or to appoint and maintain the appointment of another process agent located in the United States as
required above, and to deliver to the Depositary a written acceptance by that agent of that appointment, for so long as any American Depositary Shares or Receipts remain outstanding or this Deposit Agreement remains in force. In the event the
Company fails to maintain the designation and appointment of a process agent in the United States in full force and effect, the Company hereby waives personal service of process upon it and consents that a service of process in connection with a
Proceeding may be made by certified or registered mail, return receipt requested, directed to the Company at its address last specified for notices under this Deposit Agreement, and service so made shall be deemed completed five (5)&nbsp;days after
the same shall have been so mailed. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">EACH PARTY TO THIS DEPOSIT AGREEMENT (INCLUDING, FOR AVOIDANCE OF DOUBT, EACH OWNER AND
HOLDER) HEREBY IRREVOCABLY WAIVES, TO THE FULLEST EXTENT PERMITTED BY APPLICABLE LAW, ANY RIGHT IT MAY HAVE TO A TRIAL BY JURY IN ANY SUIT, ACTION OR PROCEEDING AGAINST THE COMPANY AND/OR THE DEPOSITARY DIRECTLY OR INDIRECTLY ARISING OUT OF OR
RELATING TO THE SHARES OR OTHER DEPOSITED SECURITIES, THE AMERICAN DEPOSITARY SHARES OR THE RECEIPTS, THIS DEPOSIT AGREEMENT OR ANY TRANSACTION CONTEMPLATED HEREIN OR THEREIN, OR THE BREACH HEREOF OR THEREOF, INCLUDING, WITHOUT LIMITATION, ANY
QUESTION REGARDING EXISTENCE, VALIDITY OR TERMINATION (WHETHER BASED ON CONTRACT, TORT OR ANY OTHER THEORY). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 7.7. <U>Waiver of
Immunities.</U> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">To the extent that the Company or any of its properties, assets or revenues may have or may hereafter become entitled to,
or have attributed to it, any right of immunity, on the grounds of sovereignty or otherwise, from any legal action, suit or proceeding, from the giving of any relief in any respect thereof, from setoff or counterclaim, from the jurisdiction of any
court, from service of process, from attachment upon or prior to judgment, from attachment in aid of execution or judgment, or from execution of judgment, or other legal process or proceeding for the giving of any relief or for the enforcement of
any judgment, in any jurisdiction in which proceedings may at any time be commenced, with respect to its obligations, liabilities or any other matter under or arising out of or in connection with the Shares or Deposited Securities, the American
Depositary Shares, the Receipts or this Deposit Agreement, the Company, to the fullest extent permitted by law, hereby irrevocably and unconditionally waives, and agrees not to plead or claim, any immunity of that kind and consents to relief and
enforcement as provided above. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 7.8. <U>Governing Law.</U> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">This Deposit Agreement and the Receipts shall be interpreted in accordance with and all rights hereunder and thereunder and provisions hereof
and thereof shall be governed by and construed in accordance with the laws of the State of New York. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, OPTHEA LIMITED and THE BANK OF NEW YORK MELLON have duly executed this
Deposit Agreement as of the day and year first set forth above and all Owners and Holders shall become parties hereto upon acceptance by them of American Depositary Shares or any interest therein. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">OPTHEA LIMITED</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Mike Tonroe</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Chief Financial Officer</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">THE BANK OF NEW YORK MELLON, as Depositary</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
</TABLE></DIV>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">EXHIBIT A </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="35%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="31%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">AMERICAN DEPOSITARY SHARES</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">(Each American Depositary Share represents Eight deposited Shares)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">THE BANK OF NEW YORK MELLON </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">AMERICAN DEPOSITARY RECEIPT </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">FOR
ORDINARY SHARES OF </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">OPTHEA LIMITED </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(INCORPORATED UNDER THE LAWS OF THE COMMONWEALTH OF AUSTRALIA) </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">The Bank of New York Mellon, as depositary (hereinafter called the &#147;Depositary&#148;), hereby certifies that
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, or registered assigns IS THE OWNER OF
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">AMERICAN DEPOSITARY SHARES </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">representing
deposited ordinary shares (herein called &#147;Shares&#148;) of Opthea Limited, incorporated under the laws of the Commonwealth of Australia (herein called the &#147;<U>Company</U>&#148;). At the date hereof, each American Depositary Share
represents eight Shares deposited or subject to deposit under the Deposit Agreement (as such term is hereinafter defined) with a custodian for the Depositary (herein called the &#147;<U>Custodian</U>&#148;) that, as of the date of the Deposit
Agreement, was HSBC Bank Australia Limited located in Australia. The Depositary&#146;s Office and its principal executive office are located at 240 Greenwich Street, New York, N.Y. 10286. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">THE DEPOSITARY&#146;S OFFICE ADDRESS IS </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">240 GREENWICH STREET, NEW Y </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">ORK,
N.Y. 10286 </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">THE DEPOSIT AGREEMENT. </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This American Depositary Receipt is one of an issue (herein called &#147;<U>Receipts</U>&#148;), all issued and to be issued upon the terms and
conditions set forth in the Amended and Restated Deposit Agreement dated as of &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2020 (herein called the &#147;<U>Deposit
Agreement</U>&#148;) among the Company, the Depositary, and all Owners and Holders from time to time of American Depositary Shares issued thereunder, each of whom by accepting American Depositary Shares agrees to become a party thereto and become
bound by all the terms and conditions thereof. The Deposit Agreement sets forth the rights of Owners and Holders and the rights and duties of the Depositary in respect of the Shares deposited thereunder and any and all other securities, property and
cash from time to time received in respect of those Shares and held thereunder (those Shares, securities, property, and cash are herein called &#147;<U>Deposited Securities</U>&#148;). Copies of the Deposit Agreement are on file at the
Depositary&#146;s Office in New York City and at the office of the Custodian. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The statements made on the face and reverse of this Receipt
are summaries of certain provisions of the Deposit Agreement and are qualified by and subject to the detailed provisions of the Deposit Agreement, to which reference is hereby made. Capitalized terms defined in the Deposit Agreement and not defined
herein shall have the meanings set forth in the Deposit Agreement. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">SURRENDER OF AMERICAN DEPOSITARY SHARES AND WITHDRAWAL OF SHARES. </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upon surrender of American Depositary Shares for the purpose of withdrawal of the Deposited Securities represented thereby and payment of the
fee of the Depositary for the surrender of American Depositary Shares as provided in Section&nbsp;5.9 of the Deposit Agreement and payment of all taxes and governmental charges payable in connection with that surrender and withdrawal of the
Deposited Securities, and subject to the terms and conditions of the Deposit Agreement, the Owner of those American Depositary Shares shall be entitled to delivery (to the extent delivery can then be lawfully and practicably made), to or as
instructed by that Owner, of the amount of Deposited Securities at the time represented by those American Depositary Shares, <U>but not</U> any money or other property as to which a record date for distribution to Owners has passed (since money or
other property of that kind will be delivered or paid on the scheduled payment date to the Owner as of that record date), <U>and except that</U> the Depositary shall not be required to accept surrender of American Depositary Shares for the purpose
of withdrawal to the extent it would require delivery of a fraction of a Deposited Security. The Depositary shall direct the Custodian with respect to delivery of Deposited Securities and may charge the surrendering Owner a fee and its expenses for
giving that direction by cable (including SWIFT) or facsimile transmission. If Deposited Securities are delivered physically upon surrender of American Depositary Shares for the purpose of withdrawal, that delivery will be made at the
Custodian&#146;s office, <U>except that</U>, at the request, risk and expense of the surrendering Owner, and for the account of that Owner, the Depositary shall direct the Custodian to forward any cash or other property comprising, and forward a
certificate or certificates, if applicable, and other proper documents of title, if any, for, the Deposited Securities represented by the surrendered American Depositary Shares to the Depositary for delivery at the Depositary&#146;s Office or to
another address specified in the order received from the surrendering Owner. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">3.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">REGISTRATION OF TRANSFER OF AMERICAN DEPOSITARY SHARES; COMBINATION AND
<FONT STYLE="white-space:nowrap">SPLIT-UP</FONT> OF RECEIPTS; INTERCHANGE OF CERTIFICATED AND UNCERTIFICATED AMERICAN DEPOSITARY SHARES. </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Depositary, subject to the terms and conditions of the Deposit Agreement, shall register a transfer of American Depositary Shares on its
transfer books upon (i)&nbsp;in the case of certificated American Depositary Shares, surrender of the Receipt evidencing those American Depositary Shares, by the Owner or by a duly authorized attorney, properly endorsed or accompanied by proper
instruments of transfer or (ii)&nbsp;in the case of uncertificated American Depositary Shares, receipt from the Owner of a proper instruction (including, for the avoidance of doubt, instructions through DRS and Profile as provided in
Section&nbsp;2.9 of the Deposit Agreement), and, in either case, duly stamped as may be required by the laws of the State of New York and of the United States of America. Upon registration of a transfer, the Depositary shall deliver the transferred
American Depositary Shares to or upon the order of the person entitled thereto. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Depositary, subject to the terms and conditions of
the Deposit Agreement, shall upon surrender of a Receipt or Receipts for the purpose of effecting a <FONT STYLE="white-space:nowrap">split-up</FONT> or combination of such Receipt or Receipts, execute and deliver a new Receipt or Receipts for any
authorized number of American Depositary Shares requested, evidencing the same aggregate number of American Depositary Shares as the Receipt or Receipts surrendered. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Depositary, upon surrender of certificated American Depositary Shares for the purpose of exchanging for uncertificated American Depositary
Shares, shall cancel the Receipt evidencing those certificated American Depositary Shares and send the Owner a statement confirming that the Owner is the owner of the same number of uncertificated American Depositary Shares. The Depositary, upon
receipt of a proper instruction (including, for the avoidance of doubt, instructions through DRS and Profile as provided in Section&nbsp;2.9 of the Deposit Agreement) from the Owner of uncertificated American Depositary Shares for the purpose of
exchanging for certificated American Depositary Shares, shall cancel those uncertificated American Depositary Shares and register and deliver to the Owner a Receipt evidencing the same number of certificated American Depositary Shares. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As a condition precedent to the delivery, registration of transfer, or surrender of any American Depositary Shares or <FONT
STYLE="white-space:nowrap">split-up</FONT> or combination of any Receipt or withdrawal of any Deposited Securities, the Depositary, the Custodian, or Registrar may require payment from the depositor of the Shares or the presenter of the Receipt or
instruction for registration of transfer or surrender of American Depositary Shares not evidenced by a Receipt of a sum sufficient to reimburse it for any tax or other governmental charge and any stock transfer or registration fee with respect
thereto (including any such tax or charge and fee with respect to Shares being deposited or withdrawn) and payment of any applicable fees as provided in the Deposit Agreement, may require the production of proof satisfactory to it as to the identity
and genuineness of any signature and may also require compliance with any regulations the Depositary may establish consistent with the provisions of the Deposit Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Depositary may refuse to accept deposits of Shares for delivery of American Depositary Shares or to register transfers of American
Depositary Shares in particular instances, or may suspend deposits of Shares or registration of transfer generally, whenever it or the Company considers it necessary or advisable to do so. The Depositary may refuse surrenders of American Depositary
Shares for the purpose of withdrawal of Deposited Securities in particular instances, or may suspend surrenders for the purpose of withdrawal generally, <U>but, notwithstanding anything to the contrary in the Deposit Agreement, only for</U>
(i)&nbsp;temporary delays caused by closing of the Depositary&#146;s register or the register of holders of Shares maintained by the Company or the Foreign Registrar, or the deposit of Shares, in connection with voting at a shareholders&#146;
meeting or the payment of dividends, (ii)&nbsp;the payment of fees, taxes and similar charges, (iii)&nbsp;compliance with any U.S. or foreign laws or governmental regulations relating to the American Depositary Shares or to the withdrawal of the
Deposited Securities or (iv)&nbsp;any other reason that, at the time, is permitted under paragraph I(A)(1) of the General Instructions to Form <FONT STYLE="white-space:nowrap">F-6</FONT> under the Securities Act of 1993 or any successor to that
provision. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">The Depositary shall not knowingly accept for deposit under the Deposit Agreement any Shares
that, at the time of deposit, are Restricted Securities or for which the Depositary has received written instructions from the Company that the deposit of those Shares would violate applicable law or regulation. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">4.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">LIABILITY OF OWNER FOR TAXES. </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If any tax or other governmental charge shall become payable by the Custodian or the Depositary with respect to or in connection with any
American Depositary Shares or any Deposited Securities represented by any American Depositary Shares or in connection with a transaction to which Section&nbsp;4.8 of the Deposit Agreement applies, that tax or other governmental charge shall be
payable by the Owner of those American Depositary Shares to the Depositary. The Depositary may refuse to register any transfer of those American Depositary Shares or any withdrawal of Deposited Securities represented by those American Depositary
Shares until that payment is made, and may withhold any dividends or other distributions or the proceeds thereof, or may sell for the account of the Owner any part or all of the Deposited Securities represented by those American Depositary Shares,
and may apply those dividends or other distributions or the net proceeds of any sale of that kind in payment of that tax or other governmental charge but, even after a sale of that kind, the Owner shall remain liable for any deficiency. The
Depositary shall distribute any net proceeds of a sale made under Section&nbsp;3.2 of the Deposit Agreement that are not used to pay taxes or governmental charges to the Owners entitled to them in accordance with Section&nbsp;4.1 of the Deposit
Agreement. If the number of Shares represented by each American Depositary Share decreases as a result of a sale of Deposited Securities under Section&nbsp;3.2 of the Deposit Agreement, the Depositary may call for surrender of the American
Depositary Shares to be exchanged on a mandatory basis for a lesser number of American Depositary Shares and may sell American Depositary Shares to the extent necessary to avoid distributing fractions of American Depositary Shares in that exchange
and distribute the net proceeds of that sale to the Owners entitled to them. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">5.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">WARRANTIES ON DEPOSIT OF SHARES. </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Every person depositing Shares under the Deposit Agreement shall be deemed thereby to represent and warrant that those Shares and each
certificate therefor, if applicable, are validly issued, fully paid and nonassessable and were not issued in violation of any preemptive or similar rights of the holders of outstanding securities of the Company and that the person making that
deposit is duly authorized so to do. Every depositing person shall also be deemed to represent that the Shares, at the time of deposit, are not Restricted Securities. All representations and warranties deemed made under Section&nbsp;3.3 of the
Deposit Agreement shall survive the deposit of Shares and delivery of American Depositary Shares. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">6.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">FILING PROOFS, CERTIFICATES, AND OTHER INFORMATION. </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any person presenting Shares for deposit or any Owner or Holder may be required from time to time to file with the Depositary or the Custodian
such proof of citizenship or residence, taxpayer status, exchange control approval, payment of all applicable taxes or other governmental charges, or such information relating to legal and beneficial ownership, including the registration on the
books of the Company or the Foreign Registrar, if applicable, to execute such certificates and to make such representations and warranties, as the Depositary may deem necessary or proper or as the Company may reasonably require by notice to the
Depositary. The Depositary may withhold the delivery or registration of transfer of American Depositary Shares, the distribution of any dividend or other distribution or of the proceeds thereof or the delivery of any Deposited Securities until that
proof or other information is filed or those certificates are executed or those representations and warranties are made. Each Owner and Holder agrees to provide, in a timely manner, all proofs, information, representations and warranties required
under Section&nbsp;3.1 of the Deposit Agreement. As conditions of accepting Shares for deposit, the Depositary may require (i)&nbsp;any certification required by the Depositary or the Custodian in accordance with the provisions of the Deposit
Agreement, (ii)&nbsp;a written order directing the Depositary to deliver to, or upon the written order of, the person or persons stated in that order, the number of American Depositary Shares representing those Deposited Shares, (iii)&nbsp;evidence
satisfactory to the Depositary that those Shares have been <FONT STYLE="white-space:nowrap">re-registered</FONT> in the books of the Company or the Foreign Registrar in the name of the Depositary, a Custodian or a nominee of the Depositary or a
Custodian, (iv)&nbsp;evidence satisfactory to the Depositary that any necessary approval has been granted by any governmental body in each applicable jurisdiction and (v)&nbsp;an agreement or assignment, or other instrument satisfactory to the
Depositary, that provides for the prompt transfer to the Custodian of any dividend, or right to subscribe for additional Shares or to receive other property, that any person in whose name those Shares are or have been recorded may thereafter receive
upon or in respect of those Shares, or, in lieu thereof, such agreement of indemnity or other agreement as shall be satisfactory to the Depositary. If requested in writing, the Depositary shall, as promptly as practicable, at the Company&#146;s
expense, provide the Company with copies of any such proofs, certificates or other information it receives pursuant to Section&nbsp;3.1 of the Deposit Agreement, to the extent that disclosure is permitted under applicable law. The Depositary will
refuse to accept Shares for deposit if the Depositary has received a written notice that deposit of such Shares would violate applicable laws, rules and regulations, or the Constitution or similar organizational document of the Company. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">7.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">CHARGES OF DEPOSITARY. </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following charges shall be incurred by any party depositing or withdrawing Shares or by any party surrendering American Depositary Shares
or to whom American Depositary Shares are issued (including, without limitation, issuance pursuant to a stock dividend or stock split declared by the Company or an exchange of stock regarding the American Depositary Shares or Deposited Securities or
a delivery of American Depositary Shares pursuant to Section&nbsp;4.3 of the Deposit Agreement), or by Owners, as applicable: (1)&nbsp;taxes and other governmental charges, (2)&nbsp;such registration fees as may from time to time be in effect for
the registration of transfers of Shares generally on the Share register of the Company or Foreign Registrar and applicable to transfers of Shares to or from the name of the Depositary or its nominee or the Custodian or its nominee on the making of
deposits or withdrawals hereunder, (3)&nbsp;such cable (including SWIFT) and facsimile transmission fees and expenses as are expressly provided in the Deposit Agreement, (4)&nbsp;such expenses as are incurred by the Depositary in the conversion of
foreign currency pursuant to Section&nbsp;4.5 of the Deposit Agreement, (5)&nbsp;a fee of $5.00 or less per 100 American Depositary Shares (or portion thereof) for the delivery of American Depositary Shares pursuant to Section&nbsp;2.3, 4.3 or 4.4
of the Deposit Agreement and the surrender of American Depositary Shares pursuant to Section&nbsp;2.5 or 6.2 of the Deposit Agreement, (6)&nbsp;a fee of $.05 or less per American Depositary Share (or portion thereof) for any cash distribution made
pursuant to the Deposit Agreement, including, but not limited to Sections 4.1 through 4.4 and 4.8 of the Deposit Agreement, (7)&nbsp;a fee for the distribution of securities pursuant to Section&nbsp;4.2 of the Deposit Agreement or of rights pursuant
to Section&nbsp;4.4 of the Deposit Agreement (where the </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Depositary will not exercise or sell those rights on behalf of Owners), such fee being in an amount equal to the fee for the execution and delivery of American Depositary Shares referred to above
which would have been charged as a result of the deposit of such securities under the Deposit Agreement (for purposes of this item 7 treating all such securities as if they were Shares) but which securities are instead distributed by the Depositary
to Owners, (8)&nbsp;in addition to any fee charged under item 6, a fee of $.05 or less per American Depositary Share (or portion thereof) per annum for depositary services, which will be payable as provided in item 9 below, and (9)&nbsp;any other
charges payable by the Depositary or the Custodian, any of the Depositary&#146;s or Custodian&#146;s agents or the agents of the Depositary&#146;s or Custodian&#146;s agents, in connection with the servicing of Shares or other Deposited Securities
(which charges shall be assessed against Owners as of the date or dates set by the Depositary in accordance with Section&nbsp;4.6 of the Deposit Agreement and shall be payable at the sole discretion of the Depositary by billing those Owners for
those charges or by deducting those charges from one or more cash dividends or other cash distributions). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Depositary may collect any
of its fees by deduction from any cash distribution payable, or by selling a portion of any securities to be distributed, to Owners that are obligated to pay those fees. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Depositary may own and deal in any class of securities of the Company and its affiliates and in American Depositary Shares. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">From time to time, the Depositary may make payments to the Company to reimburse the Company for costs and expenses generally arising out of
establishment and maintenance of the American Depositary Shares program, waive fees and expenses for services provided by the Depositary or share revenue from the fees collected from Owners or Holders. In performing its duties under the Deposit
Agreement, the Depositary may use brokers, dealers, foreign currency dealers or other service providers that are owned by or affiliated with the Depositary and that may earn or share fees, spreads or commissions. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">8.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">DISCLOSURE OF INTERESTS. </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">When required in order to comply with applicable laws and regulations, the rules and requirements of the Australian Securities Exchange, the
Nasdaq Global Market or any other stock exchange on which the Shares or the American Depositary Shares are registered, traded or listed or any book-entry settlement system, or the articles of association or similar document of the Company, the
Company may from time to time request&nbsp;each Owner&nbsp;and Holder to provide to the Depositary information relating to: (a)&nbsp;the capacity in which it holds&nbsp;American Depositary Shares,&nbsp;(b) the identity of any Holders or
other&nbsp;persons or entities&nbsp;then or previously interested in those American Depositary Shares and the nature of those interests and&nbsp;(c)&nbsp;any other matter where disclosure of such matter is, in the Company&#146;s reasonable opinion,
required for that compliance.&nbsp;Each Owner and Holder agrees to provide all information known to it in response to a request made pursuant to Section&nbsp;3.4 of the Deposit Agreement.&nbsp;Each Holder&nbsp;consents to the disclosure by the
Depositary and the Owner or other Holder through which it holds American Depositary Shares, directly or indirectly, of all information responsive to a request made pursuant to that Section relating to&nbsp;that Holder that is known to that Owner or
other Holder.</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each Owner and Holder of American Depositary Shares further agrees to comply with the laws and regulations of the United
States and Australia (if and to the extent applicable) with respect to the disclosure requirements regarding beneficial ownership of Shares, all as if the American Depositary Shares were the Shares represented thereby, including requirements to make
notifications and filings within the required timeframes to the Company, to the Commission, to the Australian Securities Exchange and any other authorities in the United States or in Australia. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">9.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">TITLE TO AMERICAN DEPOSITARY SHARES. </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">It is a condition of the American Depositary Shares, and every successive Owner and Holder of American Depositary Shares, by accepting or
holding the same, consents and agrees that American Depositary Shares evidenced by a Receipt, when the Receipt is properly endorsed or accompanied by proper instruments of transfer, shall be transferable as certificated registered securities under
the laws of the State of New York, and that American Depositary Shares not evidenced by Receipts shall be transferable as uncertificated registered securities under the laws of the State of New York. The Depositary, notwithstanding any notice to the
contrary, may treat the Owner of American Depositary Shares as the absolute owner thereof for the purpose of determining the person entitled to distribution of dividends or other distributions or to any notice provided for in the Deposit Agreement
and for all other purposes, and neither the Depositary nor the Company shall have any obligation or be subject to any liability under the Deposit Agreement to any Holder of American Depositary Shares, but only to the Owner. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">10.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">VALIDITY OF RECEIPT. </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This Receipt shall not be entitled to any benefits under the Deposit Agreement or be valid or obligatory for any purpose, unless this Receipt
shall have been (i)&nbsp;executed by the Depositary by the manual signature of a duly authorized officer of the Depositary or (ii)&nbsp;executed by the facsimile signature of a duly authorized officer of the Depositary and countersigned by the
manual signature of a duly authorized signatory of the Depositary or the Registrar or a <FONT STYLE="white-space:nowrap">co-registrar.</FONT> </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">11.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">REPORTS; INSPECTION OF TRANSFER BOOKS. </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company is subject to the periodic reporting requirements of the Securities Exchange Act of 1934 and, accordingly, files certain reports
with the Commission. Those reports will be available for inspection and copying through the Commission&#146;s EDGAR system or at public reference facilities maintained by the Commission in Washington, D.C. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Depositary will make available for inspection by Owners at its Office any reports, notices and other communications, including any proxy
soliciting material, received from the Company which are both (a)&nbsp;received by the Depositary as the holder of the Deposited Securities and (b)&nbsp;made generally available to the holders of those Deposited Securities by the Company. The
Company shall furnish reports and communications, including any proxy soliciting material to which Section&nbsp;4.9 of the Deposit Agreement applies, to the Depositary in English, to the extent such materials are required to be translated into
English pursuant to any regulations of the Commission. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Depositary will maintain a register of American Depositary Shares and transfers of
American Depositary Shares, which shall be open for inspection by the Owners at the Depositary&#146;s Office during regular business hours, but only for the purpose of communicating with Owners regarding the business of the Company or a matter
related to the Deposit Agreement or the American Depositary Shares. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">12.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">DIVIDENDS AND DISTRIBUTIONS. </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Whenever the Depositary receives any cash dividend or other cash distribution on Deposited Securities, the Depositary will, if at the time of
receipt thereof any amounts received in a foreign currency can in the judgment of the Depositary be converted on a reasonable basis into Dollars transferable to the United States, and subject to the Deposit Agreement, convert that dividend or other
cash distribution into Dollars and distribute the amount thus received (net of the fees and expenses of the Depositary as provided in Article&nbsp;7 hereof and Section&nbsp;5.9 of the Deposit Agreement) to the Owners entitled thereto;
<U>provided</U>, <U>however</U>, that if the Custodian or the Depositary is required to withhold and does withhold from that cash dividend or other cash distribution an amount on account of taxes or other governmental charges, the amount distributed
to the Owners of the American Depositary Shares representing those Deposited Securities shall be reduced accordingly. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If a cash
distribution would represent a return of all or substantially all the value of the Deposited Securities underlying American Depositary Shares, the Depositary may, after consultation with the Company to the extent practicable: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) require payment of or deduct the fee for surrender of American Depositary Shares (whether or not it is also requiring surrender of
American Depositary Shares) as a condition of making that cash distribution; or </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) sell all Deposited Securities other than the subject
cash distribution and add any net cash proceeds of that sale to the cash distribution, call for surrender of all those American Depositary Shares and require that surrender as a condition of making that cash distribution. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If the Depositary acts under this paragraph, that action shall also be a <U>Termination Option Event</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Subject to the provisions of Section&nbsp;4.11 and 5.9 of the Deposit Agreement, whenever the Depositary receives any distribution other than a distribution
described in Section&nbsp;4.1, 4.3 or 4.4 of the Deposit Agreement on Deposited Securities (but not in exchange for or in conversion or in lieu of Deposited Securities), the Depositary will cause the securities or property received by it to be
distributed to the Owners entitled thereto, after deduction or upon payment of any fees and expenses of the Depositary and any taxes or other governmental charges, in any manner that the Depositary deems equitable and practicable for accomplishing
that distribution (which may be a distribution of depositary shares representing the securities received); <U>provided</U>, <U>however</U>, that if in the opinion of the Depositary such distribution cannot be made proportionately among the Owners
entitled thereto, or if for any other reason the Depositary, after consultation with the Company to the extent practicable, deems such distribution not to be lawful and feasible, the Depositary may adopt such other method as it may deem equitable
and practicable for the purpose of effecting such distribution, including, but not limited to, the public or private sale of the securities or property thus received, or any part thereof, and distribution of the net proceeds of any such sale (net of
the fees and expenses of the Depositary as provided in Article&nbsp;7 hereof and Section&nbsp;5.9 of the Deposit Agreement) to the Owners entitled thereto all in the manner and subject to the conditions set forth in Section&nbsp;4.1 of the Deposit
Agreement. The Depositary may withhold any distribution of securities under Section&nbsp;4.2 of the Deposit Agreement if it has not received satisfactory assurances from the Company that the distribution does not require registration under the
Securities Act of 1933. The Depositary may sell, by public or private sale, an amount of securities or other property it would otherwise distribute under this Article that is sufficient to pay its fees and expenses in respect of that distribution.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If a distribution to be made under Section&nbsp;4.2 of the Deposit Agreement would represent a return of all or substantially all the
value of the Deposited Securities underlying American Depositary Shares, the Depositary may, after consultation with the Company to the extent practicable: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) require payment of or deduct the fee for surrender of American Depositary Shares (whether or not it is also requiring surrender of
American Depositary Shares) as a condition of making that distribution; or </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) sell all Deposited Securities other than the subject
distribution and add any net cash proceeds of that sale to the distribution, call for surrender of all those American Depositary Shares and require that surrender as a condition of making that distribution. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If the Depositary acts under this paragraph, that action shall also be a <U>Termination Option Event</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Whenever the Depositary receives any distribution consisting of a dividend in, or free distribution of, Shares, the Depositary may, and if the
Company so requests in writing, shall, deliver to the Owners entitled thereto, an aggregate number of American Depositary Shares representing the amount of Shares received as that dividend or free distribution, subject to the terms and conditions of
the Deposit Agreement with respect to the deposit of Shares and issuance of American Depositary Shares, including the withholding of any tax or other governmental charge as provided in Section&nbsp;4.11 of the Deposit Agreement and the payment of
the fees and expenses of the Depositary as provided in Article 7 hereof and Section&nbsp;5.9 of the Deposit Agreement (and the Depositary may sell, by public or private sale, an amount of Shares received (or American Depositary Shares representing
those Shares) sufficient to pay its fees and expenses in respect of that distribution). In lieu of delivering fractional American Depositary Shares, the Depositary may sell the amount of Shares represented by the aggregate of those fractions (or
American Depositary Shares representing those Shares) and distribute the net proceeds, all in the manner and subject to the conditions described in Section&nbsp;4.1 of the Deposit Agreement. If and to the extent that additional American Depositary
Shares are not delivered and Shares or American Depositary Shares are not sold, each American Depositary Share shall thenceforth also represent the additional Shares distributed on the Deposited Securities represented thereby. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the Company declares a distribution in which holders of Deposited Securities have a right to elect whether to receive cash, Shares or other
securities or a combination of those things, or a right to elect to have a distribution sold on their behalf, the Depositary may, after consultation with the Company, make that right of election available for exercise by Owners in any manner the
Depositary considers to be lawful and practical. As a condition of making a distribution election right available to Owners, the Depositary may require satisfactory assurances from the Company that doing so does not require registration of any
securities under the Securities Act of 1933 that has not been effected. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the Depositary determines that any distribution received or to be made by the Depositary
(including Shares and rights to subscribe therefor) is subject to any tax or other governmental charge that the Depositary is obligated to withhold, the Depositary may sell, by public or private sale, all or a portion of the distributed property
(including Shares and rights to subscribe therefor) in the amounts and manner the Depositary deems necessary and practicable to pay those taxes or charges, and the Depositary shall distribute the net proceeds of that sale, after deduction of those
taxes or charges, to the Owners entitled thereto in proportion to the number of American Depositary Shares held by them respectively. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each Owner and Holder agrees to indemnify the Company, the Depositary, the Custodian and their respective directors, employees, agents and
affiliates for, and hold each of them harmless against, any claim by any governmental authority or any other entity or person with respect to taxes, additions to tax, penalties or interest arising out of any refund of taxes, reduced withholding at
source or other tax benefit received by it. The obligations of Owners and Holders under the preceding sentence shall survive any transfer of American Depositary Shares or surrender of American Depositary Shares and withdrawal of Deposited Securities
and the termination of the Deposit Agreement. Services for Owners and Holders that may permit them to obtain reduced rates of tax withholding at source or reclaim excess tax withheld, and the fees and costs associated with using services of that
kind, are not provided under, and are outside the scope of, the Deposit Agreement. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">13.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">RIGHTS. </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) If rights are granted to the Depositary in respect of deposited Shares to purchase additional Shares or other securities, the Company and
the Depositary shall endeavor to consult as to the actions, if any, the Depositary should take in connection with that grant of rights. The Depositary may, to the extent deemed by it to be lawful and practical (i)&nbsp;if requested in writing by the
Company, grant to all or certain Owners rights to instruct the Depositary to purchase the securities to which the rights relate and deliver those securities or American Depositary Shares representing those securities to Owners, (ii)&nbsp;if
requested in writing by the Company, deliver the rights to or to the order of certain Owners, or (iii)&nbsp;sell the rights to the extent practicable and distribute the net proceeds of that sale to Owners entitled to those proceeds. To the extent
rights are not exercised, delivered or disposed of under (i), (ii) or (iii)&nbsp;above, the Depositary shall permit the rights to lapse unexercised. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) If the Depositary will act under (a)(i) above, the Company and the Depositary will enter into a separate agreement setting forth the
conditions and procedures applicable to the particular offering. Upon instruction from an applicable Owner in the form the Depositary specified and upon payment by that Owner to the Depositary of an amount equal to the purchase price of the
securities to be received upon the exercise of the rights, the Depositary shall, on behalf of that Owner, exercise the rights and purchase the securities. The purchased securities shall be delivered to, or as instructed by, the Depositary. The
Depositary shall (i)&nbsp;deposit the purchased Shares under the Deposit Agreement and deliver American Depositary Shares representing those Shares to that Owner or (ii)&nbsp;deliver or cause the purchased Shares or other securities to be delivered
to or to the order of that Owner. The Depositary will not act under (a)(i) above unless the offer and sale of the securities to which the rights relate are registered under the Securities Act of 1933 or the Depositary has received an opinion of
United States counsel that is satisfactory to it to the effect that those securities may be sold and delivered to the applicable Owners without registration under the Securities Act of 1933. For the avoidance of doubt, nothing in the Deposit
Agreement shall create any obligation on the part of the Company to file a registration statement with respect to rights or the underlying securities or to endeavor to have such a registration statement declared effective. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) If the Depositary will act under (a)(ii) above, the Company and the Depositary will enter into a separate agreement setting forth the
conditions and procedures applicable to the particular offering. Upon (i)&nbsp;the request of an applicable Owner to deliver the rights allocable to the American Depositary Shares of that Owner to an account specified by that Owner to which the
rights can be delivered and (ii)&nbsp;receipt of such documents as the Company and the Depositary agreed to require to comply with applicable law, the Depositary will deliver those rights as requested by that Owner. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) If the Depositary will act under (a)(iii) above, the Depositary will use reasonable efforts to sell the rights in proportion to the number
of American Depositary Shares held by the applicable Owners and pay the net proceeds to the Owners otherwise entitled to the rights that were sold, upon an averaged or other practical basis without regard to any distinctions among such Owners
because of exchange restrictions or the date of delivery of any American Depositary Shares or otherwise. The Depositary may enter into any arrangements with the Company or persons acting on behalf of the Company to effect the orderly disposal of
rights. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) Payment or deduction of the fees of the Depositary as provided in Section&nbsp;5.9 of the Deposit Agreement and payment or
deduction of the expenses of the Depositary and any applicable taxes or other governmental charges shall be conditions of any delivery of securities or payment of cash proceeds under Section&nbsp;4.4 of the Deposit Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f) Neither the Company nor the Depositary shall be responsible for any failure to determine that it may be lawful or feasible to make rights
available to or exercise rights on behalf of Owners in general or any Owner in particular, or to sell rights. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">14.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">CONVERSION OF FOREIGN CURRENCY. </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Whenever the Depositary or the Custodian receives foreign currency, by way of dividends or other distributions or the net proceeds from the
sale of securities, property or rights, and if at the time of the receipt thereof the foreign currency so received can in the judgment of the Depositary be converted on a reasonable basis into Dollars and the resulting Dollars transferred to the
United States, the Depositary shall, as promptly as practicable, convert or cause to be converted by sale or in any other manner that it may determine that foreign currency into Dollars, and those Dollars shall be distributed to the Owners entitled
thereto.&nbsp;A cash distribution may be made upon an averaged or other practicable basis without regard to any distinctions among Owners based on exchange restrictions, the date of delivery of any American Depositary Shares or otherwise and shall
be net of any expenses of conversion into Dollars incurred by the Depositary as provided in Section&nbsp;5.9 of the Deposit Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If
a conversion of foreign currency or the repatriation or distribution of Dollars can be effected only with the approval or license of any government or agency thereof, the Depositary may, but will not be required to, file an application for that
approval or license. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the Depositary, after consultation with the Company to the extent practicable, determines
that in its judgment any foreign currency received by the Depositary or the Custodian is not convertible on a reasonable basis into Dollars transferable to the United States, or if any approval or license of any government or agency thereof that is
required for such conversion is not filed or sought by the Depositary or is not obtained within a reasonable period as determined by the Depositary, the Depositary may distribute the foreign currency received by the Depositary to, or in its
discretion may hold such foreign currency uninvested and without liability for interest thereon for the respective accounts of, the Owners entitled to receive the same. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If any conversion of foreign currency, in whole or in part, cannot be effected for distribution to some of the Owners entitled thereto, the
Depositary may in its discretion make that conversion and distribution in Dollars to the extent practicable and permissible to the Owners entitled thereto and may distribute the balance of the foreign currency received by the Depositary to, or hold
that balance uninvested and without liability for interest thereon for the account of, the Owners entitled thereto. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Depositary may
convert currency itself or through any of its affiliates, or the Custodian or the Company may convert currency and pay Dollars to the Depositary. Where the Depositary converts currency itself or through any of its affiliates, the Depositary acts as
principal for its own account and not as agent, advisor, broker or fiduciary on behalf of any other person and earns revenue, including, without limitation, transaction spreads, that it will retain for its own account.&nbsp;The revenue is based on,
among other things, the difference between the exchange rate assigned to the currency conversion made under the Deposit Agreement and the rate that the Depositary or its affiliate receives when buying or selling foreign currency for its own
account.&nbsp;The Depositary makes no representation that the exchange rate used or obtained by it or its affiliate in any currency conversion under the Deposit Agreement will be the most favorable rate that could be obtained at the time or that the
method by which that rate will be determined will be the most favorable to Owners, subject to the Depositary&#146;s obligations under Section&nbsp;5.3 of the Deposit Agreement.&nbsp;The methodology used to determine exchange rates used in currency
conversions made by the Depositary is available upon request. Where the Custodian converts currency, the Custodian has no obligation to obtain the most favorable rate that could be obtained at the time or to ensure that the method by which that rate
will be determined will be the most favorable to Owners, and the Depositary makes no representation that the rate is the most favorable rate and will not be liable for any direct or indirect losses associated with the rate.&nbsp;In certain
instances, the Depositary may receive dividends or other distributions from the Company in Dollars that represent the proceeds of a conversion of foreign currency or translation from foreign currency at a rate that was obtained or determined by or
on behalf of the Company and, in such cases, the Depositary will not engage in, or be responsible for, any foreign currency transactions and neither it nor the Company makes any representation that the rate obtained or determined by the Company is
the most favorable rate and neither it nor the Company will be liable for any direct or indirect losses associated with the rate. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">15.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">RECORD DATES. </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Whenever a cash dividend, cash distribution or any other distribution is made on Deposited Securities or rights to purchase Shares or other
securities are issued with respect to Deposited Securities (which rights will be delivered to or exercised or sold on behalf of Owners in accordance with Section&nbsp;4.4 of the Deposit Agreement) or the Depositary receives notice that a
distribution or issuance of that kind will be made, or whenever the Depositary receives notice that a meeting of holders of Shares will be held in respect of which the Company has requested the Depositary to send a notice under Section&nbsp;4.7 of
the Deposit Agreement, or whenever the Depositary will assess a fee or charge against the Owners, or whenever the Depositary causes a change in the number of Shares that are represented by each American Depositary Share, or whenever the Depositary
otherwise finds it necessary or convenient, the Depositary shall fix a record date, which shall be the same as, or as near as practicable to, any corresponding record date set by the Company with respect to Shares, (a)&nbsp;for the determination of
the Owners (i)&nbsp;who shall be entitled to receive the benefit of that dividend or other distribution or those rights, (ii)&nbsp;who shall be entitled to give instructions for the exercise of voting rights at that meeting, (iii)&nbsp;who shall be
responsible for that fee or charge or (iv)&nbsp;for any other purpose for which the record date was set, or (b)&nbsp;on or after which each American Depositary Share will represent the changed number of Shares. Subject to the provisions of Sections
4.1 through 4.5 of the Deposit Agreement and to the other terms and conditions of the Deposit Agreement, the Owners on a record date fixed by the Depositary shall be entitled to receive the amount distributable by the Depositary with respect to that
dividend or other distribution or those rights or the net proceeds of sale thereof in proportion to the number of American Depositary Shares held by them respectively, to give voting instructions or to act in respect of the other matter for which
that record date was fixed, or be responsible for that fee or charge, as the case may be. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">16.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">VOTING OF DEPOSITED SHARES. </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) Upon receipt of notice of any meeting of holders of Shares at which holders of Shares will be entitled to vote, if requested in writing by
the Company, the Depositary shall, as soon as practicable thereafter, Disseminate&nbsp;to the Owners a notice, the form of which shall be in the sole discretion of the Depositary, that shall contain (i)&nbsp;the information contained in the notice
of meeting received by the Depositary, (ii)&nbsp;a statement that the Owners as of the close of business on a specified record date will be entitled, subject to any applicable provision of Australian law and of the articles of association or similar
documents of the Company, to instruct the Depositary as to the exercise of the voting rights pertaining to the amount of Shares represented by their respective American Depositary Shares, (iii)&nbsp;a statement as to the manner in which those
instructions may be given and (iv)&nbsp;the last date on which the Depositary will accept instructions (the &#147;<U>Instruction Cutoff Date</U>&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) Upon the written request of an Owner of American Depositary Shares, as of the date of the request or, if a record date was specified by
the Depositary, as of that record date, received on or before any&nbsp;Instruction&nbsp;Cutoff&nbsp;Date established by the Depositary, the Depositary may, and if the Depositary sent a notice under the preceding paragraph shall, endeavor, in so far
as practicable, to vote or cause to be voted the amount of deposited Shares represented by those American Depositary Shares in accordance with the instructions set forth in that request. The Depositary shall not vote or attempt to exercise the right
to vote that attaches to the deposited Shares other than in accordance with instructions given by Owners and received by the Depositary. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) There can be no assurance that Owners generally or any Owner&nbsp;in particular will receive the notice described in paragraph
(a)&nbsp;above in time&nbsp;to&nbsp;enable Owners to give instructions to the Depositary prior to the Instruction Cutoff Date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) In
order to give Owners a reasonable opportunity to instruct the Depositary as to the exercise of voting rights relating to Shares, if the Company will request the Depositary to Disseminate a notice under&nbsp;paragraph (a)&nbsp;above, the Company
shall give the Depositary notice of the meeting, details concerning the matters to be voted upon and copies of materials to be made available to holders of Shares in connection with the meeting not less than 30 days prior to the meeting date. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) Notwithstanding anything in this Article 16 to the contrary, the Depositary and the
Company may mutually agree to modify, amend or adopt additional procedures with respect to voting Deposited Securities from time to time as they determine may be necessary or appropriate to comply with applicable laws and regulations. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">17.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">TENDER AND EXCHANGE OFFERS; REDEMPTION, REPLACEMENT OR CANCELLATION OF DEPOSITED SECURITIES.
</P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) The Depositary shall not tender any Deposited Securities in response to any voluntary cash tender offer, exchange
offer or similar offer (including a takeover offer made under Chapter 6 of the <I>Corporations Act 2001</I> (Cth)) made to holders of Deposited Securities (a &#147;<U>Voluntary Offer</U>&#148;), except when instructed in writing to do so by an Owner
surrendering American Depositary Shares and subject to any conditions or procedures the Depositary may require. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) If the Depositary
receives a written notice that Deposited Securities have been redeemed for cash or otherwise purchased for cash in a transaction that is mandatory and binding on the Depositary as a holder of those Deposited Securities (including the implementation
of a scheme of arrangement under Part 5.1 of the <I>Corporations Act 2001</I> (Cth) and compulsory acquisition under Chapter 6A of the <I>Corporations Act 2001</I> (Cth)) (a &#147;<U>Redemption</U>&#148;), the Depositary, at the expense of the
Company (unless otherwise agreed between the Company and the Depositary), shall (i)&nbsp;if required, surrender Deposited Securities that have been redeemed to the issuer of those securities or its agent on the redemption date, (ii)&nbsp;Disseminate
a notice to Owners (A)&nbsp;notifying them of that Redemption, (B)&nbsp;calling for surrender of a corresponding number of American Depositary Shares and (C)&nbsp;notifying them that the called American Depositary Shares have been converted into a
right only to receive the money received by the Depositary upon that Redemption and those net proceeds shall be the Deposited Securities to which Owners of those converted American Depositary Shares shall be entitled upon surrenders of those
American Depositary Shares in accordance with Section&nbsp;2.5 or 6.2 of the Deposit Agreement and (iii)&nbsp;distribute the money received upon that Redemption to the Owners entitled to it upon surrender by them of called American Depositary Shares
in accordance with Section&nbsp;2.5 of the Deposit Agreement (and, for the avoidance of doubt, Owners shall not be entitled to receive that money under Section&nbsp;4.1 of the Deposit Agreement). If the Redemption affects less than all the Deposited
Securities, the Depositary shall call for surrender a corresponding portion of the outstanding American Depositary Shares and only those American Depositary Shares will automatically be converted into a right to receive the net proceeds of the
Redemption. The Depositary shall allocate the American Depositary Shares converted under the preceding sentence among the Owners <FONT STYLE="white-space:nowrap">pro-rata</FONT> to their respective holdings of American Depositary Shares immediately
prior to the Redemption, <U>except that</U> the allocations may be adjusted so that no fraction of a converted American Depositary Share is allocated to any Owner. A Redemption of all or substantially all of the Deposited Securities shall be a
<U>Termination Option Event</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) If the Depositary is notified of or there occurs any change in nominal value or any subdivision,
combination or any other reclassification of the Deposited Securities or any recapitalization, reorganization, sale of assets substantially as an entirety, merger or consolidation affecting the issuer of the Deposited Securities or to which it is a
party that is mandatory and binding on the Depositary as a holder of Deposited Securities and, as a result, securities or other property have been or will be delivered in exchange, conversion, replacement or in lieu of, Deposited Securities (a
&#147;<U>Replacement</U>&#148;), the Depositary shall, if required, surrender the old Deposited Securities affected by that Replacement of Shares and hold, as new Deposited Securities under the Deposit Agreement, the new securities or other property
delivered to it in that Replacement. <U>However</U>, the Depositary may elect to sell those new Deposited Securities if in the opinion of the Depositary, after consultation with the Company to the extent practicable, it is not lawful or not
practical for it to hold those new Deposited Securities under the Deposit Agreement because those new Deposited Securities may not be distributed to Owners without registration under the Securities Act of 1933 or for any other reason, at public or
private sale, at such places and on such terms as it deems proper and proceed as if those new Deposited Securities had been Redeemed under paragraph (b)&nbsp;above. A Replacement shall be a <U>Termination Option Event</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) In the case of a Replacement where the new Deposited Securities will continue to be held under the Deposit Agreement, the Depositary may
call for the surrender of outstanding Receipts to be exchanged for new Receipts specifically describing the new Deposited Securities and the number of those new Deposited Securities represented by each American Depositary Share. If the number of
Shares represented by each American Depositary Share decreases as a result of a Replacement, the Depositary may, after consultation with the Company to the extent practicable, call for surrender of the American Depositary Shares to be exchanged on a
mandatory basis for a lesser number of American Depositary Shares and may sell American Depositary Shares to the extent necessary to avoid distributing fractions of American Depositary Shares in that exchange and distribute the net proceeds of that
sale to the Owners entitled to them. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) If there are no Deposited Securities with respect to American Depositary Shares, including if
the Deposited Securities are cancelled, or the Deposited Securities with respect to American Depositary Shares become apparently worthless, the Depositary may call for surrender of those American Depositary Shares or may cancel those American
Depositary Shares, upon notice to Owners, and that condition shall be a <U>Termination Option Event</U>. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">18.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">LIABILITY OF THE COMPANY AND DEPOSITARY. </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Neither the Depositary nor the Company nor any of their respective directors, employees, agents or affiliates shall incur any liability to any
Owner or Holder: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) if by reason of (A)&nbsp;any provision of any present or future law or regulation or other act of the government of
the United States, any State of the United States or any other state or jurisdiction, or of any other country, or of any governmental or regulatory authority or stock exchange; (B) (in the case of the Depositary only) any provision, present or
future, of the articles of association or similar document of the Company, or by reason of any provision of any securities issued or distributed by the Company, or any offering or distribution thereof; or (C)&nbsp;any event or circumstance, whether
natural or caused by a person or persons, that is beyond the ability of the Depositary or the Company, as the case may be, to prevent or counteract by reasonable care or effort (including, but not limited to earthquakes, floods, severe storms,
fires, explosions, war, terrorism, civil unrest, labor disputes, criminal acts or outbreaks of infectious disease; interruptions or malfunctions of utility services, Internet or other communications lines or systems; unauthorized access to or
attacks on computer systems or websites; or other failures or malfunctions of computer hardware or software or other systems or equipment), the Depositary or the Company is, directly or indirectly, prevented from, forbidden to or delayed in, or
could be subject to any civil or criminal penalty on account of doing or performing and therefore does not do or perform, any act or thing that, by the terms of the Deposit Agreement or the Deposited Securities, it is provided shall be done or
performed; </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) for any exercise of, or failure to exercise, any discretion provided for in the Deposit
Agreement (including any determination by the Depositary to take, or not take, any action that the Deposit Agreement provides the Depositary may take); </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iii) for the inability of any Owner or Holder to benefit from any distribution, offering, right or other benefit that is made available to
holders of Deposited Securities but is not, under the terms of the Deposit Agreement, made available to Owners or Holders; or </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iv) for
any special, consequential, indirect or punitive damages for any breach of the terms of the Deposit Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Where, by the terms of a
distribution to which Section&nbsp;4.1, 4.2 or 4.3 of the Deposit Agreement applies, or an offering to which Section&nbsp;4.4 of the Deposit Agreement applies, or for any other reason, that distribution or offering may not be made available to
Owners, and the Depositary may not dispose of that distribution or offering on behalf of Owners and make the net proceeds available to Owners, then the Depositary shall not make that distribution or offering available to Owners, and shall allow any
rights, if applicable, to lapse. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Neither the Company nor its directors, officers, employees, agents, controlling persons and affiliates
nor the Depositary assume any obligation nor shall any of them be subject to any liability under the Deposit Agreement to Owners or Holders, except that they agree to perform their obligations specifically set forth in the Deposit Agreement without
gross negligence or bad faith. The Depositary shall not be a fiduciary or have any fiduciary duty to Owners or Holders. The Depositary shall not be subject to any liability with respect to the validity or worth of the Deposited Securities. Neither
the Depositary nor the Company nor any of their respective directors, officers, employees, agents, controlling persons and affiliates shall be under any obligation to appear in, prosecute or defend any action, suit, or other proceeding in respect of
any Deposited Securities or in respect of the American Depositary Shares, on behalf of any Owner or Holder or other person. Neither the Depositary nor the Company shall be liable for any action or <FONT STYLE="white-space:nowrap">non-action</FONT>
by it in reliance upon the advice of or information from legal counsel, accountants, any person presenting Shares for deposit, any Owner or Holder, or any other person believed by it in good faith to be competent to give such advice or information.
Each of the Depositary and the Company and any of their respective directors, officers, employees, agents, controlling persons and affiliates may rely, and shall be protected in relying upon, any written notice, request, direction or other document
believed by it to be genuine and to have been signed or presented by the proper party or parties. Neither the Company nor the Depositary shall not be liable for any acts or omissions made by a successor depositary whether in connection with a
previous act or omission of the Depositary or in connection with a matter arising wholly after the removal or resignation of the Depositary, provided that in connection with the issue out of which such potential liability arises, the Depositary
performed its obligations without negligence or bad faith while it acted as Depositary. The Depositary shall not be liable for the acts or omissions of any securities depository, clearing agency or settlement system in connection with or arising out
of book-entry settlement of American Depositary Shares or Deposited Securities or otherwise. In the absence of bad faith on its part, the Depositary shall not be responsible for any failure to carry out any instructions to vote any of the Deposited
Securities or for the manner in which any such vote is cast or the effect of any such vote. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Neither the Company nor the Depositary shall
have any duty to make any determination or provide any information as to the tax status of the Company or any liability for any tax consequences that may be incurred by Owners or Holders as a result of owning or holding American Depositary Shares,
including without limitation, tax consequences resulting from the Company (or any of its subsidiaries) being treated as a &#147;Passive Foreign Investment Company&#148; (&#147;<U>PFIC</U>&#148;) (in each case as defined in the U.S. Internal Revenue
Code of 1986, as amended, and the regulations issued thereunder) or otherwise. The Company may have been in the past and may be in the future a PFIC for U.S. Federal income tax purposes. Owners must consult their own tax advisers as to the potential
application of the PFIC rules. Neither the Company nor the Depositary shall be liable for the inability or failure of an Owner or Holder to obtain the benefit of a foreign tax credit, reduced rate of withholding or refund of amounts withheld in
respect of tax or any other tax benefit. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">No disclaimer of liability under the United States federal securities laws is intended by any
provision of the Deposit Agreement. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">19.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">RESIGNATION AND REMOVAL OF THE DEPOSITARY; APPOINTMENT OF SUCCESSOR CUSTODIAN. </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Depositary may at any time resign as Depositary under the Deposit Agreement by written notice of its election so to do delivered to the
Company, to become effective upon the appointment of a successor depositary and its acceptance of such appointment as provided in the Deposit Agreement. The Depositary may at any time be removed by the Company by 90 days&#146; prior written notice
of that removal, to become effective upon the later of (i)&nbsp;the 90th day after delivery of the notice to the Depositary and (ii)&nbsp;the appointment of a successor depositary and its acceptance of its appointment as provided in the Deposit
Agreement. The Depositary in its discretion may at any time appoint a substitute or additional custodian or custodians. The Depositary shall notify the Company of the appointment of a substitute or additional Custodian as promptly as practicable
and, if practicable, prior to the effectiveness of such appointment. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">20.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">AMENDMENT. </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The form of the Receipts and any provisions of the Deposit Agreement may at any time and from time to time be amended by agreement between the
Company and the Depositary without the consent of Owners or Holders in any respect which they may deem necessary or desirable. Any amendment that would impose or increase any fees or charges (other than taxes and other governmental charges,
registration fees, cable (including SWIFT) or facsimile transmission costs, delivery costs or other such expenses), or that would otherwise prejudice any substantial existing right of Owners, shall, however, not become effective as to outstanding
American Depositary Shares until the expiration of 30 days after notice of that amendment has been Disseminated to the Owners of outstanding American Depositary Shares. Every Owner and Holder, at the time any amendment so becomes effective, shall be
deemed, by continuing to hold American Depositary Shares or any interest therein, to consent and agree to that amendment and to be bound by the Deposit Agreement as amended thereby. Upon the effectiveness of an amendment to the form of Receipt,
including a change in the number of Shares represented by each American Depositary Share, the Depositary may call for surrender of Receipts to be replaced with new Receipts in the amended form or call for surrender of American Depositary Shares to
effect that change of ratio. In no event shall any amendment impair the right of the Owner to surrender American Depositary Shares and receive delivery of the Deposited Securities represented thereby, except in order to comply with mandatory
provisions of applicable law. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">21.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">TERMINATION OF DEPOSIT AGREEMENT. </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) The Company may initiate termination of the Deposit Agreement by notice to the Depositary. The Depositary may initiate termination of the
Deposit Agreement if (i)&nbsp;at any time 60 days shall have expired after the Depositary delivered to the Company a written resignation notice and a successor depositary has not been appointed and accepted its appointment as provided in
Section&nbsp;5.4 of the Deposit Agreement or (ii)&nbsp;a Termination Option Event has occurred. If termination of the Deposit Agreement is initiated by the Company or the Depositary, the Depositary shall, as promptly as practicable, Disseminate a
notice of termination to the Owners of all American Depositary Shares then outstanding setting a date for termination (the &#147;<U>Termination Date</U>&#148;), which shall be at least 90 days, and not more than 120 days, after the date of that
notice, and the Deposit Agreement shall terminate on that Termination Date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) After the Termination Date, the Company shall be
discharged from all obligations under the Deposit Agreement except for its obligations to the Depositary under Sections 5.8 and 5.9 of the Deposit Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) At any time after the Termination Date, the Depositary may sell the Deposited Securities then held under the Deposit Agreement and may
thereafter hold uninvested the net proceeds of any such sale, together with any other cash then held by it hereunder, unsegregated and without liability for interest, for the pro rata benefit of the Owners of American Depositary Shares that remain
outstanding, and those Owners will be general creditors of the Depositary with respect to those net proceeds and that other cash. After making that sale, the Depositary shall be discharged from all obligations under the Deposit Agreement, except
(i)&nbsp;to account for the net proceeds and other cash (after deducting, in each case, the fee of the Depositary for the surrender of American Depositary Shares, any expenses for the account of the Owner of such American Depositary Shares in
accordance with the terms and conditions of the Deposit Agreement and any applicable taxes or governmental charges) and (ii)&nbsp;for its obligations under Section&nbsp;5.8 of the Deposit Agreement and (iii)&nbsp;to act as provided in paragraph
(d)&nbsp;below. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) After the Termination Date, if any American Depositary Shares remain outstanding, the Depositary shall continue to
receive dividends and other distributions pertaining to Deposited Securities (that have not been sold), may sell rights and other property as provided in the Deposit Agreement and shall deliver Deposited Securities (or sale proceeds) upon surrender
of American Depositary Shares (after payment or upon deduction, in each case, of the fee of the Depositary for the surrender of American Depositary Shares, any expenses for the account of the Owner of those American Depositary Shares in accordance
with the terms and conditions of the Deposit Agreement and any applicable taxes or governmental charges). After the Termination Date, the Depositary shall not accept deposits of Shares or deliver American Depositary Shares. After the Termination
Date, (i)&nbsp;the Depositary may refuse to accept surrenders of American Depositary Shares for the purpose of withdrawal of Deposited Securities (that have not been sold) or reverse previously accepted surrenders of that kind that have not settled
if in its judgment the requested withdrawal would interfere with its efforts to sell the Deposited Securities, (ii)&nbsp;the Depositary will not be required to deliver cash proceeds of the sale of Deposited Securities until all Deposited Securities
have been sold and (iii)&nbsp;the Depositary may discontinue the registration of transfers of American Depositary Shares and suspend the distribution of dividends and other distributions on Deposited Securities to the Owners and need not give any
further notices or perform any further acts under the Deposit Agreement except as provided in Section&nbsp;6.2 of the Deposit Agreement. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">22.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">DTC DIRECT REGISTRATION SYSTEM AND PROFILE MODIFICATION SYSTEM. </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) Notwithstanding the provisions of Section&nbsp;2.4 of the Deposit Agreement, the parties acknowledge that DTC&#146;s Direct Registration
System (&#147;<U>DRS</U>&#148;) and Profile Modification System (&#147;<U>Profile</U>&#148;) apply to the American Depositary Shares upon acceptance thereof to DRS by DTC. DRS is the system administered by DTC that facilitates interchange between
registered holding of uncertificated securities and holding of security entitlements in those securities through DTC and a DTC participant. Profile is a required feature of DRS that allows a DTC participant, claiming to act on behalf of an Owner of
American Depositary Shares, to direct the Depositary to register a transfer of those American Depositary Shares to DTC or its nominee and to deliver those American Depositary Shares to the DTC account of that DTC participant without receipt by the
Depositary of prior authorization from the Owner to register that transfer. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) In connection with DRS/Profile, the parties acknowledge
that the Depositary will not determine whether the DTC participant that is claiming to be acting on behalf of an Owner in requesting registration of transfer and delivery as described in paragraph (a)&nbsp;above has the actual authority to act on
behalf of that Owner (notwithstanding any requirements under the Uniform Commercial Code). For the avoidance of doubt, the provisions of Sections 5.3 and 5.8 of the Deposit Agreement apply to the matters arising from the use of the DRS/Profile. The
parties agree that the Depositary&#146;s reliance on and compliance with instructions received by the Depositary through the DRS/Profile system and otherwise in accordance with the Deposit Agreement, shall not constitute negligence or bad faith on
the part of the Depositary. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">23.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">APPOINTMENT OF AGENT FOR SERVICE OF PROCESS; SUBMISSION TO JURISDICTION; JURY TRIAL WAIVER; WAIVER OF
IMMUNITIES. </P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company has (i)&nbsp;appointed Corporation Service Company, 1180 Avenue of the Americas, Suite 210, New
York, New York 10036, as the Company&#146;s authorized agent in the United States upon which process may be served in any suit or proceeding arising out of or relating to the Shares or Deposited Securities, the American Depositary Shares, the
Receipts or the Deposit Agreement (a &#147;<U>Proceeding</U>&#148;). Each of the Company and the Depositary has consented and submitted to the jurisdiction of any state or federal court in the State of New York in which any Proceeding may be
instituted. The Company has agreed that service of process upon said authorized agent shall be deemed in every respect effective service of process upon the Company in any Proceeding. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">EACH PARTY TO THE DEPOSIT AGREEMENT (INCLUDING, FOR AVOIDANCE OF DOUBT, EACH OWNER AND HOLDER) THEREBY IRREVOCABLY WAIVES, TO THE FULLEST
EXTENT PERMITTED BY APPLICABLE LAW, ANY RIGHT IT MAY HAVE TO A TRIAL BY JURY IN ANY SUIT, ACTION OR PROCEEDING AGAINST THE COMPANY AND/OR THE DEPOSITARY DIRECTLY OR INDIRECTLY ARISING OUT OF OR RELATING TO THE SHARES OR OTHER DEPOSITED SECURITIES,
THE AMERICAN DEPOSITARY SHARES OR THE RECEIPTS, THE DEPOSIT AGREEMENT OR ANY TRANSACTION CONTEMPLATED HEREIN OR THEREIN, OR THE BREACH HEREOF OR THEREOF, INCLUDING, WITHOUT LIMITATION, ANY QUESTION REGARDING EXISTENCE, VALIDITY OR TERMINATION
(WHETHER BASED ON CONTRACT, TORT OR ANY OTHER THEORY). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To the extent that the Company or any of its properties, assets or revenues may
have or hereafter become entitled to, or have attributed to it, any right of immunity, on the grounds of sovereignty or otherwise, from any legal action, suit or proceeding, from the giving of any relief in any respect thereof, from setoff or
counterclaim, from the jurisdiction of any court, from service of process, from attachment upon or prior to judgment, from attachment in aid of </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
execution or judgment, or other legal process or proceeding for the giving of any relief or for the enforcement of any judgment, in any jurisdiction in which proceedings may at any time be
commenced, with respect to its obligations, liabilities or any other matter under or arising out of or in connection with the Shares or Deposited Securities, the American Depositary Shares, the Receipts or the Deposit Agreement, the Company, to the
fullest extent permitted by law, hereby irrevocably and unconditionally waives, and agrees not to plead or claim, any such immunity and consents to such relief and enforcement. </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-5.1
<SEQUENCE>4
<FILENAME>d947560dex51.htm
<DESCRIPTION>EX-5.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-5.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 5.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="46%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="45%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Contact</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Craig Semple</TD>
<TD VALIGN="bottom" ROWSPAN="4">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="4" ALIGN="right">


<IMG SRC="g945701g0921224119557.jpg" ALT="LOGO">
</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">T +61 3 8656 3349</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">csemple@gtlaw.com.au</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Our ref</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">CXS:1041902</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">101 Collins Street</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">Melbourne VIC&nbsp;3000</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>T</B>: +61&nbsp;3 8656 3300 <B>F</B>: +61&nbsp;3 8656 3400</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">www.gtlaw.com.au</P></TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>9 October 2020 </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The
Directors </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Opthea Limited </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Level&nbsp;4, 650 Chapel Street
</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">South Yarra VIC 3141 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dear Directors </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Opthea Limited &#150; Registration Statement on Form <FONT STYLE="white-space:nowrap">F-1</FONT> </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have acted as Australian legal counsel to Opthea Limited (<B>Company</B>), a company incorporated under the laws of the Commonwealth of Australia, in
connection with its filing of a registration statement on Form <FONT STYLE="white-space:nowrap">F-1</FONT> (<B>Registration Statement</B>) under the U.S. Securities Act of 1933, as amended (<B>Securities Act</B>), with the U.S. Securities and
Exchange Commission (<B>Commission</B>). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Registration Statement relates to the public offering by the Company, as set out in the prospectus forming
part of the Registration Statement (<B>Prospectus</B>) of up to 10,695,000 American Depositary Shares (<B>ADS</B>) (including 1,395,000 ADSs to cover over-allotments (if any)) to be issued and sold by the Company. Each of the ADSs represents eight
fully paid ordinary shares in the Company (<B>Shares</B>). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Registration Statement, including the Prospectus, is referred to in this letter
collectively (and unless the context requires otherwise) as the Documents. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>1</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Documents examined and searches conducted and relied on by us </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For the purposes of this opinion, we have examined and relied on copies of the following documents: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the Registration Statement; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">a draft of the Prospectus; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the Company&#146;s Constitution; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">draft minutes of meeting and resolutions of the Board of Directors dated 17 July 2020, 24 September 2020 and 9
October 2020 and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(e)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">a search obtained from the Australian Securities and Investments Commission as at 9 October 2020.
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="right">


<IMG SRC="g945701g0921224120119.jpg" ALT="LOGO">
 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="right">


<IMG SRC="g945701g0921224119557.jpg" ALT="LOGO">
 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>2</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Assumptions in providing this letter </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For the purposes of this opinion, we have assumed: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the genuineness of all signatures and the authenticity of all documents, instruments and certificates submitted
to us as originals and the exact conformity with the authentic originals of all documents, instruments and certificates submitted to us as copies or forms or originals; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">all relevant original documents continue in full force and effect and all signatures, seals, dates, duty stamps
and markings appearing on all documents and copy documents submitted to us are genuine; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">that each party to each document has all the requisite power and authority (corporate and otherwise) to execute
and deliver and perform its obligations there under; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">all matters of internal management required by the constitution of each of the parties to the relevant
documents (other than the Company) have been duly attended to (including, without limitation, the holding of properly constituted meetings of the boards of directors of each of those parties and the passing at those meetings of appropriate
resolutions); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(e)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">any documents which purport to be governed by the law of any jurisdiction other than the laws of the
Commonwealth of Australia are legal, valid and binding obligations of all parties to those documents and none of the execution, delivery or performance of any document by any party to the document violates or contravenes or is rendered invalid, not
binding or unenforceable under any applicable law under any jurisdiction other than the laws of the Commonwealth of Australia; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(f)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the Company will not engage in fraudulent or unconscionable conduct or conduct which is misleading or deceptive
or which is likely to mislead or deceive in relation to the issuance or sale of Shares or ADS; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(g)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">there is no bad faith, fraud, undue influence, coercion or duress or similar conduct on the part of the Company
in relation to the issuance or sale of Shares or ADS under the Registration Statement; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(h)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">all information provided to us by or on behalf of officers of the Company was true, correct and complete when
provided and remains so at the date of this letter, containing all information required, without us making any separate enquiry or investigation other than viewing the ASIC search, in order for us to provide this opinion; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the Company is and will be able to pay its debts as and when they fall due and is otherwise solvent as at the
time the Shares or ADS are issued or sold; and </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">page&nbsp;| 2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="right">


<IMG SRC="g945701g0921224119557.jpg" ALT="LOGO">
 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(j)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">all public records and searches which we have examined are accurate and the information disclosed by the
searches conducted by us is true and complete and such information has not since been altered and the searches did not fail to disclose any information which had been delivered for registration, lodgement or filing against the Company&#146;s records
but which did not appear on the public records at the date of our search. </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>3</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Opinion </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Based on and subject to the above, in our opinion: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the Company is duly incorporated and validly existing under the laws of the Commonwealth of Australia in good
standing (as such term is not defined under the <I>Corporations Act 2001 </I>(Cth) (<B>Corporations Act</B>), meaning solely that there are no current orders for the winding up of, or appointment of a receiver or liquidator for the Company or any
notice of its proposed deregistration); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the issue of the Shares has been duly authorized; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">on issue of the Shares against payment for the Shares offered under the Documents, the Shares will be validly
issued, fully paid and <FONT STYLE="white-space:nowrap">&#145;non-assessable&#146;</FONT> (for the purposes of this opinion, the term <FONT STYLE="white-space:nowrap">&#145;non-assessable&#146;</FONT> when used to describe the liability of a person
as the registered holder of shares is not a concept known under the laws of the Commonwealth of Australia, so we have assumed those words to mean that holders of such Shares, having fully paid all amounts due on the issue of such Shares, are under
no personal liability under the Corporations Act to contribute to the assets and liabilities of the Company on a winding up of the Company or subject to any call for payment of further capital in their capacity solely as holders of such Shares).
</P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>4</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Limitations </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This opinion is subject to: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the Registration Statement, and any amendments thereto (including all necessary post-effective amendments),
becoming effective under the Securities Act (and on the assumption that it will remain effective at the time of issuance of any ADS thereunder); and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the agreed upon consideration being received for the issue of the ADS. </P></TD></TR></TABLE>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>5</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Applicability </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The opinion expressed above, which is governed by and to be interpreted in accordance with, the laws of the State of Victoria, Australia, is given only with
respect to the laws of that State and of the Commonwealth of Australia that are in effect on the date of this opinion. We have not investigated and do not express any view about, any law other than that of Australia. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This opinion is limited to the matters stated in this letter, and no opinion is implied or may be inferred beyond the matters expressly stated. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This opinion is deemed to be given as of the date hereof and will speak as at such date. We do not undertake any obligation to advise you of any changes
(including but not limited to any subsequently enacted, published or reported laws, regulations or binding authority) that may occur or come to our attention after the date of this letter which may affect our opinion. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">page&nbsp;| 3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="right">


<IMG SRC="g945701g0921224119557.jpg" ALT="LOGO">
 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>6</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Consent </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We consent to the use of this opinion as an exhibit to the Registration Statement and to the use of our name under the caption &#145;Legal Matters&#146; in the
Prospectus. In giving this consent, we do not admit that we come within the category of persons whose consent is required under Section&nbsp;7 of the Securities Act or the rules and regulations of the Commission promulgated under that Act. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Yours faithfully </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Gilbert + Tobin </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>/s/ Craig Semple </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Partner </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">+61 3 8656 3349 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">csemple@gtlaw.com.au </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">page&nbsp;| 4 </P>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>5
<FILENAME>d947560dex101.htm
<DESCRIPTION>EX-10.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-10.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 10.1 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Certain information contained in this document, identified by [***], has been redacted because it is both (i) not material and (ii) would likely cause
competitive harm to the Registrant if publicly disclosed. </B></P> <P STYLE="font-size:36pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:36pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g945701g75p65.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:48pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>AND </B></P>
<P STYLE="margin-top:48pt; margin-bottom:0pt; font-size:36pt; font-family:Times New Roman" ALIGN="center"><B>OPTHEA </B></P> <P STYLE="margin-top:48pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>Commercial
License Agreement </B></P> <P STYLE="margin-top:48pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>Date: October&nbsp;28, 2013 </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Selexis 2013 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Certain information contained in this document, identified by [***], has been redacted
because it is both (i) not material and (ii) would likely cause competitive harm to the Registrant if publicly disclosed. </B><I> </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT
 COLOR="#ff4338"><B><I></I></B><I>CONFIDENTIAL</I><B><I> </I></B></FONT></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This Commercial License Agreement (this &#147;<B>Agreement</B>&#148;) is made effective on October&nbsp;28,
2013 (the &#147;<B>Effective Date</B>&#148;) </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">by and between </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>Selexis SA</U></B>, a company incorporated under the laws of Switzerland, with its registered office at [***], Geneva, Switzerland
(&#147;<B>SELEXIS</B>&#148;) </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>OPTHEA PTY LTD</U></B>, a company incorporated under the laws of Australia, with its registered office at Level&nbsp;4, 650 Chapel Street, South Yarra,
Victoria 3141, Australia (&#147;<B>COMPANY</B>&#148;) </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(SELEXIS and COMPANY, collectively the &#147;<B>PARTIES</B>&#148; and, individually, a
&#147;<B>PARTY</B>&#148;) </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Preamble </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">A.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">W<SMALL>HEREAS</SMALL>, COMPANY is a biopharmaceutical company engaged in the research, development,
manufacturing and sale of biopharmaceutical products; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">B.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">W<SMALL>HEREAS</SMALL>, SELEXIS is a biotechnology company engaged in the development and sale of recombinant
cell lines based on the SELEXIS Technology; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">C.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">W<SMALL>HEREAS</SMALL>, SELEXIS is the owner of certain Confidential Information, the SELEXIS <FONT
STYLE="white-space:nowrap">Know-How</FONT> and the SELEXIS Patent Rights; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">D.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">W<SMALL>HEREAS</SMALL>, pursuant to a services agreement between the PARTIES dated November&nbsp;26, 2012 (the
&#147;<B>Services Agreement</B>&#148;) SELEXIS has developed certain recombinant cell line(s) for COMPANY using the SELEXIS Technology and COMPANY has evaluated such cell Line(s); and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">E.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">W<SMALL>HEREAS</SMALL>, SELEXIS is willing to grant COMPANY, and COMPANY is willing to receive from SELEXIS, a
license to the SELEXIS <FONT STYLE="white-space:nowrap">Know-How</FONT> and the SELEXIS Patent Rights with respect to the recombinant cell lines, on the terms and conditions set forth in this Agreement. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">N<SMALL>OW</SMALL>, <SMALL>THEREFORE</SMALL>, the PARTIES agree as follows: </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="34%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Date: October 28, 2013</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">2 of 27</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">Opthea</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><FONT COLOR="#3366ff">Selexis SA</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Certain information contained in this document, identified by [***], has been redacted
because it is both (i) not material and (ii) would likely cause competitive harm to the Registrant if publicly disclosed. </B><I> </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT
 COLOR="#ff4338"><B><I></I></B><I>CONFIDENTIAL</I><B><I> </I></B></FONT></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>1.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Definitions </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition to the terms defined above, the following terms, whether used in the singular or plural, shall have the following meanings as used in this
Agreement, unless otherwise specifically indicated: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">1.1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;<B><U>Affiliate</U></B>&#148; shall mean any Person that, as of the Effective Date, directly or
indirectly, controls, is controlled by, or is under common control with the relevant Person. For the purposes of this definition only, &#147;<B><U>control</U></B>&#148; shall mean the possession, directly or indirectly, of the power to cause the
direction of the management and policies of a Person, whether through ownership of voting securities of such Person, by contract or otherwise. A Person shall only be considered an Affiliate for so long as such Control exists. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">1.2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;<B><U>BLA</U></B>&#148; shall mean a Biologic License Application for the Final Product filed with the
FDA or any comparable filing made with a Regulatory Authority in another country. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">1.3.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;<B><U>Calendar Quarter</U></B>&#148; shall mean, for each Calendar Year, each of the three month periods
ending March&nbsp;31, June&nbsp;30, September&nbsp;30 and December&nbsp;31 respectively. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">1.4.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;<B><U>Calendar Year</U></B>&#148; shall mean the period commencing on January&nbsp;1 and ending twelve
(12)&nbsp;consecutive calendar months later on December 31. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">1.5.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;<B><U>Cell Line</U></B>&#148; shall mean a mammalian cell line that is developed using the SELEXIS
Technology. Cell Line shall include, without limitation, any COMPANY Cell Line(s). </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">1.6.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;<B><U>Clinical Trials</U></B>&#148; shall mean human studies designed to measure the safety and/or
efficacy of the Product. Clinical Studies include Phase I Clinical Trials, Phase II Clinical Trials, and Phase III Clinical Trials. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">1.7.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;<B><U>Collaboration Partner</U></B>&#148; shall mean a Third Party with which COMPANY collaborates on the
development of the production process and/or commercialization of a Licensed Product or Final Product or to which COMPANY has granted a license for the development of the production process and/or commercialization of a Product.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">1.8.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;<B><U>Combination Product Adjustment</U></B>&#148; shall mean the adjustment of: Net Sales for any
combination product done by multiplying actual Net Sales of such combination product by the fraction A/(A + B) where [***], if sold separately, and [***], if sold separately. If, on a
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">country-by-country</FONT></FONT> basis, the other active ingredient, device or component in the combination is not sold separately, Net Sales shall be calculated by multiplying actual
Net Sales of the combination product in such country by the fraction A/C where [***], if sold separately, in such country and [***]. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">1.9.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;<B><U>Commercial License</U></B>&#148; shall have the meaning set out in Article 2.1.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">1.10.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;<B><U>Commercial License Option</U></B>&#148; shall mean the option granted to Company in the Services
Agreement to obtain a <FONT STYLE="white-space:nowrap">non-exclusive</FONT> commercial license. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="34%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Date: October 28, 2013</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">3 of 27</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">Opthea</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><FONT COLOR="#3366ff">Selexis SA</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Certain information contained in this document, identified by [***], has been redacted
because it is both (i) not material and (ii) would likely cause competitive harm to the Registrant if publicly disclosed. </B><I> </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT
 COLOR="#ff4338"><B><I></I></B><I>CONFIDENTIAL</I><B><I> </I></B></FONT></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">1.11.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;<B><U>COMPANY Technology</U></B>&#148; shall mean any Technology owned or controlled by COMPANY,
including, without limitation, any such Technology related to Licensed or Final Product, but excluding any SELEXIS Technology related thereto. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">1.12.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;<B><U>COMPANY Cell Line</U></B>&#148; shall mean the mammalian cell line developed by SELEXIS and
provided to COMPANY pursuant to the Services Agreement and any progeny or derivatives thereof. A Cell Line which has been [***] shall be described as such in this Agreement. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">1.13.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;<B><U>Confidential Information</U></B>&#148; shall mean any technical and business information pertaining
to materials and production techniques, products, processes and services, including without limitation physical working models and samples of the products, research, development, patentable and unpatentable inventions, manufacturing, purchasing and
product development plans, forecasts, strategies and information, engineering, marketing, merchandising, selling, customer lists, customer prospects, software codes, algorithms, names and expertise of employees and consultants, blueprints, technical
information, trade secrets or <FONT STYLE="white-space:nowrap">know-how</FONT> or other related proprietary business information and data, in any case whether such information is provided in tangible or intangible form, written, oral, graphic,
pictorial or recorded form or stored on computer discs, hard drives, magnetic tape or digital or any other electronic medium. Confidential Information disclosed in any tangible format will be labeled &#147;Confidential&#148; or words to similar
effect, and all <FONT STYLE="white-space:nowrap">non-tangible</FONT> disclosures will be declared to be &#147;Confidential&#148; or words to similar effect at the time of disclosure. Confidential Information shall include any and all material and
data created by the receiving party based on, containing or otherwise reflecting Confidential Information. Confidential Information shall also include any such information or documents which may be disclosed hereunder which the disclosing party
received in confidence from a Third Party. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">1.14.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;<B><U>Contract Manufacturing Organization</U></B>&#148; shall mean an entity of which at least fifty
percent (50%) of the business is directed toward the provision of services or products for <FONT STYLE="white-space:nowrap">non-affiliate</FONT> third parties. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">1.15.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;<B><U>Contractor</U></B>&#148; shall mean a Third Party contractor who: (i)&nbsp;develops the production
process for Licensed Products or Final Products by or on behalf of COMPANY or (ii)&nbsp;manufactures and supplies Licensed Products or Final Products by using such production process by or on behalf of Company. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">1.16.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;<B><U>Default</U></B>&#148; shall have the meaning set out in Article 9.2. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">1.17.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;<B><U>Defaulting Party</U></B>&#148; shall have the meaning set out in Article 9.2.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">1.18.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>&#147;</B><B><U>Deliverables</U></B><B>&#148;</B> shall mean the reports and other data delivered to COMPANY
pursuant to the Services Agreement, excluding the COMPANY Cell Line. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="34%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Date: October 28, 2013</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">4 of 27</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">Opthea</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><FONT COLOR="#3366ff">Selexis SA</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Certain information contained in this document, identified by [***], has been redacted
because it is both (i) not material and (ii) would likely cause competitive harm to the Registrant if publicly disclosed. </B><I> </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT
 COLOR="#ff4338"><B><I></I></B><I>CONFIDENTIAL</I><B><I> </I></B></FONT></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">1.19.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;<B><U>FDA</U></B>&#148; shall mean the United States Food and Drug Administration, or any successor
agency. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">1.20.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>&#147;</B><B><U>Final Product</U></B>&#148; shall mean any pharmaceutical preparation in final form
containing any Licensed Products for sale by prescription, <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">over-the-counter</FONT></FONT> or any other method, in any dosage form, formulation, presentation, line extension or package
configurations, including without limitation such Product in development where the context so requires in this Agreement. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">1.21.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;<B><U>First Commercial Sale</U></B>&#148; shall mean, with respect to any Final Product in any country,
the first sale of such Final Product for use or consumption by the general public in such country after Regulatory Approval as well as Pricing and Reimbursement Approval for such Final Product has been obtained in such country. For the avoidance of
doubt, sales prior to receipt of all Regulatory Approvals and Pricing and Reimbursement Approvals necessary to commence regular commercial sales, such as <FONT STYLE="white-space:nowrap">so-called</FONT> &#147;treatment IND sales&#148;, &#147;named
patient sales&#148; and &#147;compassionate use sales&#148;, shall not be construed as a First Commercial Sale. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">1.22.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;<B><U>Force Majeure</U></B>&#148; shall mean conditions beyond the control of a PARTY, including without
limitation, an act of God, war, civil commotion, terrorist act, labor strike or <FONT STYLE="white-space:nowrap">lock-out,</FONT> epidemic, failure or default of public utilities or common carriers, destruction of facilities or materials by fire,
earthquake, storm or the like catastrophe, and failure of plant or machinery (provided that such failure could not have been prevented by the exercise of skill, diligence and prudence that would be reasonably and ordinarily expected from a skilled
and experienced person engaged in the same type of undertaking under the same or similar circumstances). </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">1.23.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;<B><U>IND</U></B>&#148; shall mean an Investigational New Drug Application for the Product filed with the
FDA or any comparable filing made with a Regulatory Authority in another country. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">1.24.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;<B><U>Insolvent Party</U></B>&#148; shall have the meaning set out in Article 9.3. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">1.25.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;<B><U>Invention</U></B>&#148; shall mean any invention, idea, innovation, enhancement, improvement or
feature, whether or not patentable or registrable, together with any intellectual property rights relating thereto (including without limitation the Patent Rights and rights to confidentiality and proprietary information). </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">1.26.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;<B><U><FONT STYLE="white-space:nowrap">Know-How</FONT></U></B>&#148; shall mean information in whatever
form, tangible or intangible and on whatever medium, including without limitation, information and materials relating to Inventions and other <FONT STYLE="white-space:nowrap">know-how,</FONT> trade secrets, data (including without limitation all
data from <FONT STYLE="white-space:nowrap">pre-clinical</FONT> and clinical studies and other studies intended for regulatory submission), results, formulae, DNA and amino acid sequence information and developments. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">1.27.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;<B><U>Licensed Field of Use</U></B>&#148; shall mean all uses of a Licensed and/or Final Product.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">1.28.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;<B><U>Licensed Product</U></B>&#148; shall mean the recombinant protein listed in Exhibit 2.
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="34%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Date: October 28, 2013</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">5 of 27</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">Opthea</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><FONT COLOR="#3366ff">Selexis SA</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Certain information contained in this document, identified by [***], has been redacted
because it is both (i) not material and (ii) would likely cause competitive harm to the Registrant if publicly disclosed. </B><I> </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT
 COLOR="#ff4338"><B><I></I></B><I>CONFIDENTIAL</I><B><I> </I></B></FONT></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">1.29.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;<B><U>Losses</U></B>&#148; shall mean all and any liability, damage, loss or expense.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">1.30.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;<B><U>Net Sales</U></B>&#148; shall mean the amount collected by COMPANY, its Affiliates and/or its
sublicensees on account of sales of Final Product to Third Parties in the Territory, less the following deductions: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">[***]; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">[***]; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(iii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">[***]; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(iv)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">[***]; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(v)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">[***]; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(vi)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">in the event that a Final Product is sold in any country in the form of a combination product containing one or
more other therapeutically active ingredients, the Net Sales for any such Final Product shall be computed using the Combination Product Adjustment for such country. </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">1.31.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;<B><U><FONT STYLE="white-space:nowrap">Non-Defaulting</FONT> Party</U></B>&#148; shall have the meaning
set out in Article 9.2. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">1.32.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;<B><U>Notice of Default</U></B>&#148; shall have the meaning set out in Article 9.2.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">1.33.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;<B><U>Patent Rights</U></B>&#148; shall mean any and all of the following: (i)&nbsp;patent applications
(including without limitation provisional patent applications) and patents (including without limitation the inventor&#146;s certificates); (ii) any substitution, extension (including without limitation patent term extensions and supplementary
protection certificates), registration, confirmation, reissue, continuation, divisional, <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">continuation-in-part,</FONT></FONT> <FONT STYLE="white-space:nowrap">re-examination,</FONT>
renewal, patent of addition or the like thereof or thereto; (iii)&nbsp;any foreign counterparts of any of the foregoing; and (iv)&nbsp;any utility model applications and utility models (whether or not corresponding to any of the foregoing).
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">1.34.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;<B><U>Person</U></B>&#148; shall mean an individual, a partnership, a joint venture, a corporation, a
limited liability company, a trust, an estate, an unincorporated organization, or any other entity, or a government or any department or agency thereof, whether acting in an individual, fiduciary or other capacity. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">1.35.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;<B><U>Phase I Clinical Trial</U></B>&#148; shall mean a Clinical Trial conducted in humans which is
principally intended to obtain data on the safety, tolerability, pharmacokinetic or pharmacodynamic properties of a product. Phase I shall be deemed to have commenced when the first patient in the study has been treated. Phase I shall be deemed to
have completed when the last patient has completed his or her treatment being investigated by that Clinical Trial as described in its protocol, the database is locked, and data from all patients, according to protocol, has been analyzed for the
primary endpoint. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="34%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Date: October 28, 2013</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">6 of 27</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">Opthea</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><FONT COLOR="#3366ff">Selexis SA</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Certain information contained in this document, identified by [***], has been redacted
because it is both (i) not material and (ii) would likely cause competitive harm to the Registrant if publicly disclosed. </B><I> </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT
 COLOR="#ff4338"><B><I></I></B><I>CONFIDENTIAL</I><B><I> </I></B></FONT></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">1.36.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;<B><U>Phase</U></B><U> </U><B><U>II</U></B><U> </U><B><U>Clinical</U></B><U>
</U><B><U>Trial</U></B>&#148; shall mean a Clinical Trial conducted in humans in which the primary objective is a preliminary determination of therapeutic efficiency and/or to find an optimal dose range in patients with the disease target being
studied. Phase II shall be deemed to have commenced when the first patient in the study has been treated. Phase II shall be deemed to have completed when the last patient has completed his or her treatment being investigated by that Clinical Trial
as described in its protocol, the database is locked, and data from all patients, according to protocol, has been analyzed for the primary endpoint. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">1.37.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;<B><U>Phase III Clinical Trial</U></B>&#148; shall mean a Clinical Trial conducted in humans in which the
primary objective is a determination of therapeutic efficiency in patients with the disease target being studied. Phase III shall be deemed to have commenced when the first patient in the study has been treated. Phase III shall be deemed to have
completed when the last patient has completed his or her treatment being investigated by that Clinical Trial as described in its protocol, the database is locked, and data from all patients, according to protocol, has been analyzed for the primary
endpoint. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">1.38.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;<B><U>Price and Reimbursement Approval</U></B>&#148; shall mean any approvals, licenses, registrations or
authorizations of any supranational, national, regional, state or local Regulatory Authority or other regulatory agency, department, bureau or governmental entity, necessary to determine or set the pricing of a Product, and/or its reimbursement
level by the relevant health authorities, providers or other funding institutions, at supranational, national, regional, state or local level. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">1.39.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;<B><U>Regulatory Approval</U></B>&#148; shall mean any approvals, licenses, registrations or
authorizations of any supranational, national, regional, state or local Regulatory Authority or other regulatory agency, department, bureau or governmental entity, necessary for the manufacture, marketing or sale of a Product or conduct of Clinical
Trials in a regulatory jurisdiction, excluding Price and Reimbursement Approval. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">1.40.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;<B><U>Regulatory Authority</U></B>&#148; shall mean (i)&nbsp;the FDA or (ii)&nbsp;any and all
governmental or supranational agencies, ministries, authorities or other bodies with similar regulatory authority with respect to approval or registration of pharmaceutical or biologic products in any other jurisdiction anywhere in the world.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">1.41.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;<B><U>Royalty Term</U></B>&#148; shall mean with respect to each Final Product sold in a particular
country, the period beginning on the date of the First Commercial Sale in such country and terminating on the expiration of the last-to-expire or lapse of any Valid Claims in such country covering the Licensed Product, the Final Product, the Company
Cell Line, or any other Cell Line used to produce Licensed Product, or the development, use, or manufacture of any of the foregoing. In no event shall the Royalty Term exceed the 22<SUP STYLE="font-size:85%; vertical-align:top">nd</SUP> of October
2024. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">1.42.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;<B><U>SELEXIS <FONT STYLE="white-space:nowrap">Know-How</FONT></U></B>&#148; shall mean SELEXIS&#146;
Confidential Information and <FONT STYLE="white-space:nowrap">Know-How</FONT> owned, controlled by SELEXIS, or to which SELEXIS has received a license which includes a right to grant sublicenses consistent with the Commercial License relating to,
without limitation, the construction and development of recombinant cell lines for the manufacture of biopharmaceutical products and existing as of the Effective Date or obtained thereafter during the Term. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">1.43.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;<B><U>SELEXIS Materials</U></B>&#148; shall mean the materials provided by SELEXIS to COMPANY under this
Agreement and all modifications and improvements thereof made by SELEXIS during the Term, if any. SELEXIS Materials excludes the Cell Lines. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="34%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Date: October 28, 2013</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">7 of 27</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">Opthea</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><FONT COLOR="#3366ff">Selexis SA</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Certain information contained in this document, identified by [***], has been redacted
because it is both (i) not material and (ii) would likely cause competitive harm to the Registrant if publicly disclosed. </B><I> </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT
 COLOR="#ff4338"><B><I></I></B><I>CONFIDENTIAL</I><B><I> </I></B></FONT></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">1.44.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;<B><U>SELEXIS Patent Rights</U></B>&#148; shall mean Patent Rights which: (i)&nbsp;are owned or
controlled by SELEXIS, or to which SELEXIS has received a license which includes a right to grant sublicenses consistent with the Commercial License (ii)&nbsp;are necessary or useful for the use of SELEXIS Materials or the construction, development
and use of Cell Lines and (iii)&nbsp;are existing as of the Effective Date or obtained thereafter during the Term. Without limiting the generality this Article, the SELEXIS Patent Rights as of the Effective Date are listed in Exhibit 1 hereto.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">1.45.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;<B><U>SELEXIS Technology</U></B>&#148; shall mean the SELEXIS Patent Rights, the SELEXIS <FONT
STYLE="white-space:nowrap">Know-How</FONT> and the SELEXIS Materials. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">1.46.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;<B><U>Tax Authority</U></B>&#148; shall mean the relevant governing tax authority as defined in Article
4.2. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">1.47.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;<B><U>Taxes</U></B>&#148; shall mean all excises, taxes and duties with the exception of VAT.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">1.48.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;<B><U>Technology</U></B>&#148; shall mean all inventions (whether or not patentable or patented) and
intellectual property rights therein, including without limitation, patents, patent applications, <FONT STYLE="white-space:nowrap">know-how,</FONT> trade secrets, copyrights, trademarks, designs, concepts, registered and unregistered design rights,
data, work product, results, reports, improvements, business and research plans, analytic methods and results, experimental methods and results, manufacturing processes, developments, technologies, technical information, composites of genes and gene
constructs, cell lines, manuals, standard operating procedures, instructions and specifications. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">1.49.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;<B><U>Term</U></B>&#148; shall have the meaning set out in Article 9.1. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">1.50.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;<B><U>Territory</U></B>&#148; shall mean the entire world. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">1.51.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;<B><U>Third Party</U></B>&#148; shall mean a Person other than SELEXIS, COMPANY or an Affiliate of
SELEXIS or COMPANY. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">1.52.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;<B><U>Transferee</U></B>&#148; shall have the meaning set out in Article 2.3. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">1.53.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;<B><U>Valid Claim</U></B>&#148; shall mean any issued or granted claim of the SELEXIS Patent Rights that
has not been revoked or held unenforceable or invalid by a decision of a court or other governmental agency of competent jurisdiction, that is unappealable or remains unappealed at the end of the time allowed for appeal, or that has not been
disclaimed, denied or admitted to be invalid or unenforceable through reissue, <FONT STYLE="white-space:nowrap">re-examination,</FONT> disclaimer or otherwise. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">1.54.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;<B><U>VAT</U></B>&#148; shall mean value added tax and any other similar turnover, sales or purchase, tax
or duty levied by any other jurisdiction whether central, regional or local. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="34%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Date: October 28, 2013</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">8 of 27</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">Opthea</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><FONT COLOR="#3366ff">Selexis SA</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Certain information contained in this document, identified by [***], has been redacted
because it is both (i) not material and (ii) would likely cause competitive harm to the Registrant if publicly disclosed. </B><I> </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT
 COLOR="#ff4338"><B><I></I></B><I>CONFIDENTIAL</I><B><I> </I></B></FONT></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>2.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Commercial Licenses </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">2.1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Commercial Licenses</U>. Subject to COMPANY&#146;s compliance with the other terms and conditions of this
Agreement (including, without limitation, payment by COMPANY of the amounts provided for below in accordance with the payment schedule and terms provided for below), SELEXIS hereby grants to COMPANY a
<FONT STYLE="white-space:nowrap">non-exclusive</FONT> worldwide license under the SELEXIS Patent Rights and SELEXIS <FONT STYLE="white-space:nowrap">Know-How,</FONT> in the Territory, with the limited right to sublicense in accordance with Article
2.2, to use Cell Lines, Deliverables and SELEXIS Materials for the manufacture of Licensed and/or Final Products, and to make, have made, use, offer for sale, sell, import and otherwise exploit Licensed and/or Final Products in the Licensed Field of
Use, including, without limitation, the use of Licensed and/or Final Products in Clinical Trials (the &#147;<B>Commercial License</B>&#148;). </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">2.2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Sublicenses</U>. Subject to the provisions of this Article 2.2, COMPANY shall be entitled to grant
sublicenses to the rights granted under the Commercial License to any one or more third parties (the &#147;<B>Sublicensees</B>&#148;) provided always: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">2.2.1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Any sublicense granted under this Agreement shall be expressly subject and subordinate to the terms of this
Agreement and it shall be COMPANY&#146;s responsibility to ensure strict adherence by any Sublicensee to the terms and conditions of this Agreement. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">2.2.2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Any Sublicensee shall not, by virtue of this Agreement, be granted any right or licence, either express or
implied, under any SELEXIS <FONT STYLE="white-space:nowrap">Know-how</FONT> and/or SELEXIS Patent Rights to use COMPANY Cell Lines, SELEXIS Materials and/or SELEXIS Patent Rights other than for the purposes of the manufacture, use, offer for sale,
sale, import and other exploitation of Licensed and/or Final Products in the Field. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">2.2.3.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">COMPANY will notify SELEXIS in writing of any such sublicense within [***] following the grant thereof, and
[***]. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">2.2.4.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Notwithstanding the above, COMPANY is and remains fully liable and responsible for any breach of this Agreement
committed or any Losses caused by any Sublicensee, or any other Third Party or Affiliate to whom the Cell Lines, Deliverables, SELEXIS Materials and the SELEXIS <FONT STYLE="white-space:nowrap">Know-How</FONT> or parts thereof are made available
under any such sublicense<U>.</U> </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">2.3.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Transfer of SELEXIS Materials</U>. COMPANY shall not transfer the Cell Lines, Deliverables, SELEXIS
Materials or SELEXIS <FONT STYLE="white-space:nowrap">Know-How</FONT> to any Third Party, except that during and for the Term only, COMPANY may transfer Cell Lines, Deliverables, SELEXIS Materials and SELEXIS
<FONT STYLE="white-space:nowrap">Know-How</FONT> to Contractors or </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="34%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Date: October 28, 2013</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">9 of 27</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">Opthea</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><FONT COLOR="#3366ff">Selexis SA</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Certain information contained in this document, identified by [***], has been redacted
because it is both (i) not material and (ii) would likely cause competitive harm to the Registrant if publicly disclosed. </B><I> </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT
 COLOR="#ff4338"><B><I></I></B><I>CONFIDENTIAL</I><B><I> </I></B></FONT></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
Collaboration Partners (the &#147;Transferees&#148;) solely for their use in connection with the development of a production process for Licensed and/or Final Product, the manufacturing of
Licensed and/or Final Product for sale or distribution of Final Product in the Licensed Field of Use, or, the commercialization of Licensed and/or Final Product in the Licensed Field of Use, with, for or on behalf of, COMPANY. If COMPANY makes any
such transfer, it shall notify SELEXIS within [***] of any such transfer and report the name and address of any Transferee together with confirmation that the Transferee has agreed in writing to adhere to the confidentiality obligations and use
restrictions set out in this Agreement. </TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">For the avoidance of doubt, upon expiration of the last Royalty Term, the Commercial
License granted to COMPANY in Article 2.1 (and the sublicense and transfer rights as set forth in Articles 2.2 and 2.3) shall become perpetual and royalty-free. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">2.4.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Sale of Licensed Product</U>. If COMPANY (itself or in cooperation with one or more Third Parties) wishes to
sell or otherwise transfer Licensed Product to any Third Party in a form other than as a Final Product, it may do so subject to the following. (a)&nbsp;Such Licensed Product may only be sold or transferred to one or more Third Party(ies) for use in
Clinical Trials, for further research and/or development and/or for formulation for ultimate sale in the Licensed Field of Use as Final Product; (b)&nbsp;Any sale for financial consideration of Licensed Product in a form other than as a Final
Product will be deemed a &#147;Net Sale&#148; of Final Product and Royalty Payments will be due on such sale of Licensed Product in accordance with Article 3.1.3 as if the Licensed Product were Final Product; and (c)&nbsp;All sales of Final Product
incorporating such Licensed Product will be deemed &#147;Net Sales&#148; of a Sublicensee for purposes of this Agreement and will be subject to payment by COMPANY of the royalties set forth in Article 3.1.3, and will trigger payment of the
milestones set forth in Article 3.1.2 if a Final Product produced by such a Third Party is the first Final Product to reach the appropriate milestone trigger point. COMPANY will ensure that sufficient records are kept by COMPANY or available to it
to document the Net Sales of Licensed and/or Final Products to determine the amounts due to SELEXIS under Article 3. </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>3.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Consideration </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">3.1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Payments</U>. In consideration of the Commercial License granted to COMPANY pursuant to Article 2.1, and in
consideration of the right to sublicense the rights granted in Article 2.1 pursuant to Article 2.2, COMPANY shall pay SELEXIS as follows: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">3.1.1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Commercial License Execution Payment</U>. COMPANY shall pay SELEXIS a
<FONT STYLE="white-space:nowrap">one-time</FONT> fee of thirty five thousand Swiss Francs (CHF 35,000), due upon execution of this Agreement. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="34%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Date: October 28, 2013</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">10 of 27</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">Opthea</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><FONT COLOR="#3366ff">Selexis SA</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Certain information contained in this document, identified by [***], has been redacted
because it is both (i) not material and (ii) would likely cause competitive harm to the Registrant if publicly disclosed. </B><I> </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT
 COLOR="#ff4338"><B><I></I></B><I>CONFIDENTIAL</I><B><I> </I></B></FONT></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">3.1.2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Commercial License Milestone Payments</U>. COMPANY shall make the following milestone payments to SELEXIS
with respect to the first occurrence of each such milestone event for each Licensed Product: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">3.1.2.1&nbsp;&nbsp;&nbsp;&nbsp;[***];</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">3.1.2.2&nbsp;&nbsp;&nbsp;&nbsp;[***];</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">3.1.2.3&nbsp;&nbsp;&nbsp;&nbsp;[***];&nbsp;&nbsp;and</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">3.1.2.4&nbsp;&nbsp;&nbsp;&nbsp;[***].</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">3.1.3.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Commercial License Royalty Payments</U>: In addition to the milestone payments under Article 3.1.2, during
the Royalty Term COMPANY shall pay SELEXIS on a Final <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Product-by-Final</FONT></FONT> Product (including Products deemed Final Products in accordance with Article 2.4, parts
(b)&nbsp;and (c)) and <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">country-by-country</FONT></FONT> basis a royalty of [***] of Net Sales of all Final Products sold worldwide, where said Final Products have been produced from a
Cell Line [***]. If Final Products have been produced from a Cell Line [***], then the royalty rate shall be [***]. Where royalties are due for the sale of Final Products directly by COMPANY such royalties shall be paid for each Calendar Quarter
within [***] of the end of that Calendar Quarter. Where royalties are due for the sales of Final Product by a Sublicensee, payment shall be made within [***] of the end of that Calendar Quarter. For the avoidance of doubt, no royalty payments shall
be due for a Final Product in a specific country after the Royalty Term has expired for such Final Product in such country. Where royalties are no longer due in accordance with the foregoing, the Commercial License granted to COMPANY under this
Agreement shall become perpetual, irrevocable, fully paid up and royalty free with respect to such Licensed and Final Product in such country. At any time during the Term, SELEXIS and COMPANY may agree to remove the royalty in its entirety or in
part in exchange for payment(s) as negotiated. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">3.2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Mechanism of Payment</U>. The payments due to SELEXIS under this Agreement shall be made by wire transfer or
electronic fund transfer to the credit and account of SELEXIS as follows: </P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:18%; font-size:10pt; font-family:Times New Roman">Bank Name :&nbsp;&nbsp;&nbsp;&nbsp;[***] </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:18%; font-size:10pt; font-family:Times New Roman">Account:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[***] </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:18%; font-size:10pt; font-family:Times New Roman">To:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Selexis S.A. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:18%; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;[***] </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">3.3.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Payment Terms</U>. Except with respect to royalties due pursuant to Article 3.1.3, COMPANY shall make
payments due to SELEXIS under this Agreement at the latest [***] after receipt of invoice. All fees and payments, including without limitation under Article 3.1.3, do not include any applicable VAT or Taxes. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="34%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Date: October 28, 2013</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">11 of 27</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">Opthea</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><FONT COLOR="#3366ff">Selexis SA</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Certain information contained in this document, identified by [***], has been redacted
because it is both (i) not material and (ii) would likely cause competitive harm to the Registrant if publicly disclosed. </B><I> </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT
 COLOR="#ff4338"><B><I></I></B><I>CONFIDENTIAL</I><B><I> </I></B></FONT></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">3.4.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Records</U>. COMPANY and its Affiliates and Sublicensees shall keep true accounts of Net Sales of Final
Products and COMPANY shall deliver to SELEXIS at the same time as the payments due under Article 3.1.3. a written account, including quantities of Net Sales of each such Final Product, broken down on a <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">country-by-country</FONT></FONT> basis with respect to those payments. SELEXIS is entitled to have such accounts audited by an independent expert of its choice. Such independent expert shall be bound by confidentiality
terms at least as restrictive as the terms of Article 8 and shall be authorized to disclose to SELEXIS only the results of its audit. COMPANY shall provide access to all information reasonably requested by such expert. The cost of any audit shall be
borne by SELEXIS unless the audit shows that COMPANY underpaid SELEXIS by [***] of the amounts due in which case the cost of the audit shall be borne by COMPANY. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">3.5.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Single Royalty and Milestone.</U> For Final Products covered by more than one SELEXIS Patent Rights, COMPANY
will make one payment to SELEXIS for royalties on any unit of Final Product sold by COMPANY or Sublicensees, irrespective of how many SELEXIS Patent Rights may cover such Final Product. Each milestone described in Article 3 shall be payable only
once in relation to each Licensed Product, irrespective of the number of Final Products which incorporate that Licensed Product and undergo the events triggering the payment. All fees and payments, including without limitation under Article 3.1, do
not include any applicable VAT or Taxes. </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>4.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Taxes </B></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">4.1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>General</U>. All Taxes levied on account of any payment made by COMPANY to SELEXIS pursuant to this
Agreement (other than Taxes on income, gains or profits levied against SELEXIS by any competent Swiss tax authority) will be the responsibility of, and shall be paid by, COMPANY pursuant to Article 3. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">4.2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Character of Payments</U>. The PARTIES agree that, for purposes of determining the applicability of any
Taxes, the payments to be made under this Agreement constitute payments for tangible property and license of intellectual property. However, in the event that the governing tax authority (the &#147;<B>Tax Authority</B>&#148;) qualifies differently
such payment, any additional taxes that may be applied (including without limitation any interest and penalties that may be unpaid) shall be paid by COMPANY. </P></TD></TR></TABLE>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">4.3.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Withholding by COMPANY</U>. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">4.3.1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">All payments by COMPANY hereunder shall be made in full without any deduction or withholding whatsoever and
free and clear of and without any deduction or withholding for or on account of any Taxes, except to the extent that any such deduction or withholding is required by law in effect at the time of payment. If any such deductions or withholdings must
be made from any amounts payable or paid by COMPANY, COMPANY shall [***]. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="34%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Date: October 28, 2013</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">12 of 27</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">Opthea</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><FONT COLOR="#3366ff">Selexis SA</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Certain information contained in this document, identified by [***], has been redacted
because it is both (i) not material and (ii) would likely cause competitive harm to the Registrant if publicly disclosed. </B><I> </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT
 COLOR="#ff4338"><B><I></I></B><I>CONFIDENTIAL</I><B><I> </I></B></FONT></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">4.3.2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Each PARTY shall execute and deliver such documents, deeds and other papers and take such further actions as
may be reasonably required to lawfully enable SELEXIS and COMPANY or their respective Affiliates or Sublicensees to mitigate withholding taxes, such as take advantage of any applicable legal provision or any double taxation treaties, for the purpose
of assigning to SELEXIS full tax credit for amounts deducted or withheld by COMPANY pursuant to Article 4.3.1. </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>5.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Intellectual Property </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">5.1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Ownership</U>. Each PARTY shall retain all right, title and interest in and to its Inventions and <FONT
STYLE="white-space:nowrap">Know-How</FONT> which exist on the Effective Date or which are thereafter developed independently of the performance of this Agreement. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">5.2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>COMPANY and SELEXIS Inventions</U>. Any Invention developed hereunder by or for either Party, solely or
jointly with the other PARTY or any Affiliate or agent thereof, shall belong exclusively (i)&nbsp;to COMPANY, to the extent [***] (&#147;<B>COMPANY Invention</B>&#148;); or (ii)&nbsp;to SELEXIS, to the extent [***] (&#147;<B>SELEXIS
Invention</B>&#148;). Any SELEXIS Inventions shall be included within the scope of the SELEXIS Technology licensed to COMPANY under this Agreement as provided for in Article 5.5. Notwithstanding the foregoing, such ownership shall not be construed
to transfer to either PARTY ownership of or any license or other rights in or to any of such PARTY&#146;s underlying Technology which may be included or embodied therein, or useful or necessary to use in connection with exploiting such Invention.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">5.3.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Other Inventions</U>. Except as set forth in Article 5.2, any other Invention developed hereunder solely by
COMPANY shall be COMPANY&#146;s sole property and any other Invention developed hereunder solely by SELEXIS shall be SELEXIS&#146; sole property. The PARTIES do not anticipate that there will be any jointly developed Inventions hereunder, but if
there are any other such jointly developed Inventions which do not relate to either the SELEXIS Technology or the COMPANY Technology, such Inventions shall be owned jointly by COMPANY and SELEXIS (&#147;<B>Joint Inventions</B>&#148;). In the event
any such Joint Inventions arise, the PARTIES will use commercially reasonable efforts to cooperate to protect and/or exploit such Joint Inventions, including, without limitation, by sharing in costs incurred with protection of such Joint Inventions
and sharing in revenues generated by the use or sublicense of the Joint Inventions. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">5.4.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Notification</U>. Each PARTY shall promptly notify the other PARTY of any Invention arising in connection
with this Agreement provided that COMPANY has no obligation to notify SELEXIS with respect to any COMPANY Inventions developed solely by COMPANY. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="34%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Date: October 28, 2013</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">13 of 27</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">Opthea</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><FONT COLOR="#3366ff">Selexis SA</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Certain information contained in this document, identified by [***], has been redacted
because it is both (i) not material and (ii) would likely cause competitive harm to the Registrant if publicly disclosed. </B><I> </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT
 COLOR="#ff4338"><B><I></I></B><I>CONFIDENTIAL</I><B><I> </I></B></FONT></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">5.5.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Improvements</U>. In the event SELEXIS possesses, acquires, creates or is licensed (with the right to grant
a sublicense consistent with the terms of the Commercial License) any improvements to the SELEXIS Technology which are necessary or useful for COMPANY to use in connection with the use of the Cell Lines as licensed hereunder, such improvements shall
automatically be included in the SELEXIS Patent Rights and/or the SELEXIS <FONT STYLE="white-space:nowrap">Know-How</FONT> and thereby disclosed and licensed at no extra cost to COMPANY in accordance with this Agreement; provided, however, that any
rights granted by the foregoing will be subject to COMPANY&#146;s compliance with any bona fide obligations owed to Third Parties (with respect to which SELEXIS has notified COMPANY), including, without limitation, and royalty obligations owed to
Third Parties. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">5.6.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Third Party Patent Rights</U>. SELEXIS covenants that if SELEXIS becomes aware that COMPANY&#146;s use of
the SELEXIS Technology in accordance with the terms hereunder would or would likely infringe any Third Party proprietary rights, SELEXIS shall use its reasonable commercial efforts to resolve such potential infringement at SELEXIS&#146; cost to
ensure COMPANY&#146;s freedom to continue to exercise the licenses granted under this Agreement, including without limitation by using its reasonable commercial efforts to obtain a license from the Third Party owner of the proprietary rights which
entitles SELEXIS to continue to grant the rights to COMPANY as provided for herein. Should such efforts not be successful, SELEXIS shall inform COMPANY in writing and thereafter the Parties will discuss the matter in good faith for a period not to
exceed [***]. Thereafter [***], save that SELEXIS shall not have such right if COMPANY agrees to [***]. If COMPANY [***] and if COMPANY [***] relating to COMPANY&#146;s permitted use of the SELEXIS Technology hereunder, then COMPANY may deduct any
royalties actually paid to such Third Party to the extent related to the use of the SELEXIS Technology [***]; provided that in no event shall the [***] of the royalty amount that would have otherwise been payable for such Final Product. The
obligations set forth in this Article relate solely to Third Party rights related specifically and solely to the SELEXIS Technology licensed hereunder, and do not apply with respect to any other technology or materials used by COMPANY at its
discretion in connection with its exercise of the license rights granted hereunder, and specifically exclude any such Third Party rights to the extent relating to the Licensed Product(s) produced by any Cell Lines hereunder. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">5.7.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Enforcement of SELEXIS Patent Rights</U>. If, during the Term, either PARTY becomes aware of any
infringement or potential infringement of the SELEXIS Technology it shall promptly notify the other PARTY in writing and the PARTIES shall consult with each other to decide the best way to respond to such infringement or misuse, provided that
SELEXIS shall remain free to take any action as it deems fit in its sole discretion. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">5.8.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>COMPANY Publications</U>. COMPANY shall have the unrestricted right to publish or otherwise disclose the
results and data obtained by the practice of the SELEXIS Technology in accordance with the terms hereof, provided such publication or disclosure does not include any Confidential Information of SELEXIS. The name of SELEXIS shall be given proper
recognition in such publication(s) as scientifically appropriate. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="34%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Date: October 28, 2013</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">14 of 27</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">Opthea</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><FONT COLOR="#3366ff">Selexis SA</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Certain information contained in this document, identified by [***], has been redacted
because it is both (i) not material and (ii) would likely cause competitive harm to the Registrant if publicly disclosed. </B><I> </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT
 COLOR="#ff4338"><B><I></I></B><I>CONFIDENTIAL</I><B><I> </I></B></FONT></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">5.9.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Further Assurance</U>. Each PARTY agrees to execute and do all things at the cost of the other PARTY (if not
specifically agreed otherwise) as the other PARTY may reasonably require to give that other PARTY the full benefit of the provisions of this Article 5. </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>6.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Representations, Warranties, and Covenants </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">6.1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>General</U>. Except for the representations, warranties and covenants contained in Article 5.6 or this
Article 6, the PARTIES do not make any other representations, nor give any other warranties, express or implied, nor undertake to any other covenants. The PARTIES expressly exclude any and all other representations, warranties and covenants.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">6.2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Representations and Warranties by the PARTIES</U>. Each PARTY hereby represents and warrants to the other
PARTY that: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">6.2.1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Corporate Power</U>. It is duly organized and validly existing under the laws of the state (or country or
other jurisdiction, as the case may be) of its incorporation and has full corporate power and authority to enter into this Agreement and to carry out the provisions hereof. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">6.2.2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Due Authorization</U>. It is duly authorized to execute and deliver this Agreement and to perform its
obligations hereunder and the persons executing this Agreement on its behalf have been duly authorized to do so by all requisite corporate actions. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">6.2.3.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Binding Agreement</U>. This Agreement is a legal and valid obligation binding upon it and is enforceable in
accordance with its terms, except as enforceability may be limited by bankruptcy, fraudulent conveyance, insolvency, reorganization, moratorium and other laws relating to or affecting creditors&#146; rights generally and by general equitable
principles and public policy. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">6.2.4.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>No Conflicts</U>. The execution, delivery and performance of this Agreement by it does not conflict with any
agreement, instrument or understanding, oral or written, to which it is a PARTY or by which it may be bound. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">6.2.5.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Intellectual Property Rights</U>. Each PARTY represents that it has valid and sufficient arrangements and
agreements with its directors, officers and employees (which term shall include agents, consultants and subcontractors) such that ownership of intellectual property rights in and to any Inventions made by its directors, officers and employees vests
in such PARTY. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="34%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Date: October 28, 2013</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">15 of 27</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">Opthea</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><FONT COLOR="#3366ff">Selexis SA</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Certain information contained in this document, identified by [***], has been redacted
because it is both (i) not material and (ii) would likely cause competitive harm to the Registrant if publicly disclosed. </B><I> </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT
 COLOR="#ff4338"><B><I></I></B><I>CONFIDENTIAL</I><B><I> </I></B></FONT></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">6.3.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Additional Representations and Warranties by SELEXIS</U>. SELEXIS hereby represents and warrants that, to
the best of its knowledge, as of the Effective Date: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">6.3.1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">There is no pending litigation asserting that the use of the SELEXIS Technology or the SELEXIS <FONT
STYLE="white-space:nowrap">Know-How</FONT> constitutes an infringement or misappropriation of any intellectual property rights of a Third Party; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">6.3.2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">SELEXIS has the right in and to the SELEXIS Technology, SELEXIS
<FONT STYLE="white-space:nowrap">Know-How</FONT> and the SELEXIS Patents to grant COMPANY the rights which are granted to COMPANY under this Agreement. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">6.4.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Additional Warranties by COMPANY</U>. COMPANY hereby represents and warrants to SELEXIS that:
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">6.4.1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">To the best of its knowledge, there are no Third Party intellectual property rights or any other rights that
may be asserted against SELEXIS claiming that SELEXIS was or is directly infringing or is helping or assisting COMPANY in infringing such Third Party&#146;s rights in connection with COMPANY&#146;s exercise of the Commercial License granted by
SELEXIS hereunder (except to the extent that any such Third Party rights relate solely and specifically to the SELEXIS Technology and/or SELEXIS Materials), including, without limitation, the development, manufacture and commercialization of
Licensed Products and/or Final Products as permitted hereunder; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">6.4.2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">As of the Effective Date, to the best of its knowledge, there is no litigation pending against COMPANY in
connection with the use or ownership of the Licensed Product, including, without limitation, the infringement or misappropriation of any intellectual property rights of a Third Party relating to the Licensed Product, and COMPANY has not received any
written claim that the use thereof infringes on any intellectual property rights of a Third Party or a request or demand from any Third Party for the licensing of any intellectual property rights to such Third Party in connection with the use of the
Licensed Product. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">6.4.3.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">COMPANY will use commercially reasonable endeavours to not knowingly misappropriate or infringe the
intellectual property or other rights of any Third Party in connection with its exercise of its licensed rights hereunder, including, without limitation, use of any SELEXIS Technology, Cell Line, or Deliverables, or development, manufacture or sale
of Licensed and/or Final Product hereunder. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">6.5.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Third Party Intellectual Property.</U> Without limiting the warranty set forth in Article 6.4.3, COMPANY
hereby acknowledges that in order to make, have made, use, offer for sale, sell, import and otherwise exploit Licensed and/or Final Products in the Field it may require licenses under Third Party patent or other intellectual property rights that may
be infringed by the manufacture, use, offer for sale, sale, importation and other exploitation of Licensed and/or Final Product and, other than in the case of Third Party patent rights provided for in Article 5.6, it is agreed that it shall be
COMPANY&#146;S responsibility to identify all such intellectual property and satisfy itself as to the need for such licences, and, if necessary, to obtain such licenses. COMPANY agrees that, with the sole exception of Third Party patent rights
provided for in Article 5.6 and for which SELEXIS provides indemnification in Article 7.1, SELEXIS will have no liability whatsoever for any infringement of Third Party patent rights. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="34%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Date: October 28, 2013</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">16 of 27</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">Opthea</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><FONT COLOR="#3366ff">Selexis SA</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Certain information contained in this document, identified by [***], has been redacted
because it is both (i) not material and (ii) would likely cause competitive harm to the Registrant if publicly disclosed. </B><I> </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT
 COLOR="#ff4338"><B><I></I></B><I>CONFIDENTIAL</I><B><I> </I></B></FONT></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">6.6.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Disclaimer of Warranties by SELEXIS</U>. EXCEPT AS EXPRESSLY SET FORTH IN THIS AGREEMENT AND WITHOUT
LIMITING THE GENERALITY OF ARTICLE 6.1, SELEXIS DOES NOT MAKE NOR GIVE ANY REPRESENTATION OR WARRANTY TO COMPANY OF ANY NATURE, EXPRESS OR IMPLIED, THAT THE SELEXIS TECHNOLOGY WILL BE USEFUL FOR, OR ACHIEVE ANY PARTICULAR RESULTS AS A RESULT OF ANY
USE THEREOF BY SELEXIS OR BY COMPANY PURSUANT TO ANY LICENSE GRANTED TO COMPANY UNDER THIS AGREEMENT. EXCEPT AS EXPRESSLY SET FORTH IN THIS AGREEMENT, SELEXIS SPECIFICALLY DISCLAIMS ANY WARRANTY OF NONINFRINGEMENT, MERCHANTABILITY OR FITNESS FOR A
PARTICULAR PURPOSE. </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>7.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Liability and Indemnification </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">7.1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Indemnification by SELEXIS</U>. During the Term of this Agreement and thereafter, SELEXIS hereby agrees to
save, defend and hold COMPANY, its Affiliates, and their respective officers, directors, employees, consultants and agents harmless from and against any and all Losses resulting directly from (i)&nbsp;any Third Party claim alleging that [***]; or
(ii)&nbsp;any material breach of SELEXIS&#146; representations, warranties and covenants set forth in Article 6; except in each case to the extent that such Losses were caused by willful misconduct or gross negligence of COMPANY or any of its
Affiliates, Collaborators or Sublicensees. In the event COMPANY seeks indemnification under this Article 7.1, COMPANY shall notify SELEXIS of any claim as soon as reasonably practicable after it receives notice of the claim. COMPANY shall allow
SELEXIS to conduct and control the defense against the claim (including without limitation to settle the claim solely for monetary consideration), shall (at SELEXIS&#146; expense) execute and deliver such documents and other papers and take such
further actions as may be reasonably required to defend against the claim (including without limitation to settle the claim solely for monetary consideration) and shall (at SELEXIS&#146; expense) cooperate as requested by SELEXIS in the defense of
the claim, provided always that SELEXIS may not settle any such claim or otherwise consent to an adverse judgment or order in any relevant action or other proceeding which includes any admission as to liability or fault without the prior express
written consent of COMPANY, which consent will not be unreasonably withheld. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">7.2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Indemnification by COMPANY</U>. During the Term of this Agreement and thereafter, COMPANY hereby agrees to
save, defend and hold SELEXIS and its officers, directors, employees, consultants and agents harmless from and against any and all Losses resulting from (i)&nbsp;Third Party claims in connection with [***]; (ii) Third Party claims relating to [***];
or (iii)&nbsp;any material breach of COMPANY&#146;s representations, warranties </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="34%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Date: October 28, 2013</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">17 of 27</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">Opthea</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><FONT COLOR="#3366ff">Selexis SA</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Certain information contained in this document, identified by [***], has been redacted
because it is both (i) not material and (ii) would likely cause competitive harm to the Registrant if publicly disclosed. </B><I> </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT
 COLOR="#ff4338"><B><I></I></B><I>CONFIDENTIAL</I><B><I> </I></B></FONT></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
and covenants set forth in Article 6; in each case, except to the extent that such Losses result from the willful misconduct or gross negligence of SELEXIS. In the event SELEXIS seeks
indemnification under this Article, SELEXIS shall notify COMPANY of any claim as soon as reasonably practicable after it receives notice of the claim. SELEXIS shall allow COMPANY to assume direction and control of the defense of the claim (including
without limitation the right to settle the claim solely for monetary consideration), and shall (at COMPANY&#146;s expense) execute and deliver such documents and other papers and take such further actions as may be reasonably required to defend
against the claim (including without limitation to settle the claim solely for monetary consideration). SELEXIS shall (at COMPANY&#146;s expense) cooperate as requested by COMPANY in the defense of the claim, provided always that COMPANY may not
settle any such claim or otherwise consent to an adverse judgment or order in any relevant action or other proceeding which includes any admission as to liability or fault without the prior express written consent of SELEXIS, which consent will not
be unreasonably withheld. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">7.3.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>No Incidental or Consequential Damages</U>. In no event shall either PARTY be responsible for any incidental
or consequential damages, including without limitation, lost profits or opportunities; provided that the foregoing shall in no event limit a PARTY&#146;s indemnification obligation under Article 7.1 or Article 7.2. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">7.4.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Limitation of Liability</U>. SELEXIS&#146; cumulative liability under this Agreement, whether in contract,
in tort, or otherwise, shall in no event exceed the aggregate consideration paid by COMPANY to SELEXIS under this Agreement. </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>8.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Confidentiality </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">8.1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U><FONT STYLE="white-space:nowrap">Non-disclosure</FONT></U>. During the Term of this Agreement and for [***]
thereafter, each PARTY shall keep Confidential Information of the other PARTY confidential and shall not (i)&nbsp;use the other PARTY&#146;s Confidential Information for any purpose not expressly permitted under this Agreement, nor
(ii)&nbsp;disclose the other PARTY&#146;s Confidential Information to any Person other than those of its agents, employees, and consultants (collectively, &#147;Representatives&#148;) who need to know such Confidential Information for a use or
purpose expressly permitted under this Agreement. Any such Representative who receives Confidential Information pursuant to this Article 8.1 shall be bound by written obligations of confidentiality and <FONT STYLE="white-space:nowrap">non-use</FONT>
with respect to the Confidential Information that are no less stringent than the obligations set forth in this Agreement. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">8.2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Exceptions</U>. The confidentiality obligations set forth in Article 8.1 shall not apply to Confidential
Information that (i)&nbsp;is, or becomes, public information other than as the result of the violation of this Agreement or other </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="34%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Date: October 28, 2013</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">18 of 27</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">Opthea</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><FONT COLOR="#3366ff">Selexis SA</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Certain information contained in this document, identified by [***], has been redacted
because it is both (i) not material and (ii) would likely cause competitive harm to the Registrant if publicly disclosed. </B><I> </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT
 COLOR="#ff4338"><B><I></I></B><I>CONFIDENTIAL</I><B><I> </I></B></FONT></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
act or omission by the receiving PARTY or its Representatives; (ii)&nbsp;was lawfully known to the receiving PARTY or its Representatives without restriction on use or disclosure at the time of
disclosure hereunder; (iii)&nbsp;is hereafter lawfully received by the receiving PARTY or its Representatives from a Third Party authorized to make such disclosure and without restriction on use or disclosure; or (iv)&nbsp;is approved for release by
prior written consent from the disclosing Party. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">8.3.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Authorized Disclosures</U>. Notwithstanding any provision of this Agreement to the contrary, each PARTY may
disclose Confidential Information of the other PARTY to the extent such disclosure is required by law, provided however that the receiving PARTY gives the disclosing PARTY reasonable prior written notice to enable the disclosing PARTY to take
appropriate measures to protect its Confidential Information and fully cooperates, subject to commercially reasonable efforts, with the disclosing PARTY to prevent or limit to the greatest extent possible the disclosure of Confidential Information.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">8.4.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Use of Name</U>. No right, express or implied, is granted to either PARTY by this Agreement to use in any
manner any trademark or trade name of the other PARTY including the names &#147;CIRCADIAN, VEGENICS or OPTHEA&#148; and &#147;SELEXIS&#148; without the prior written consent of the PARTY entitled to such trademark or trade name.
</P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>9.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Term and Termination </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">9.1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Term</U>. This Agreement is effective as of the Effective Date. Unless earlier terminated pursuant to
Articles 9.2, 9.3 or 9.4 of this Agreement shall remain in full force and effect until [***] (the &#147;<B>Term</B>&#148;). </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">9.2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Termination for Default</U>. In addition to any other remedies which may be available at law or equity, in
the event of any material breach of this Agreement (the &#147;<B>Default</B>&#148;) by a PARTY (the &#147;<B>Defaulting Party</B>&#148;), the PARTY not in default (the &#147;<B><FONT STYLE="white-space:nowrap">Non-Defaulting</FONT> Party</B>&#148;)
shall have the right to give the Defaulting Party a written notice thereof (the &#147;<B>Notice of Default</B>&#148;), which must state the nature of the Default in reasonable details and request that the Defaulting Party cure such Default within
[***]. During such [***] period, the Parties will cooperate in good faith in order to resolve any issue(s) that may have given rise to the Notice of Default and/or cure such Default. If such Default is not cured or the issue(s) that may have given
rise to the Notice of Default not resolved within [***] after receipt of a Notice of Default by the Defaulting Party or if such Default cannot be cured, the <FONT STYLE="white-space:nowrap">Non-Defaulting</FONT> Party may, at its sole discretion,
terminate this Agreement by written notice effective upon receipt. For avoidance of doubt, if the Default is cured or the issue(s) that may have given rise to the Notice of Default resolved within [***] after receipt of a Notice of Default by the
Defaulting Party, the <FONT STYLE="white-space:nowrap">Non-Defaulting</FONT> Party may not terminate this Agreement. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="34%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Date: October 28, 2013</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">19 of 27</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">Opthea</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><FONT COLOR="#3366ff">Selexis SA</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Certain information contained in this document, identified by [***], has been redacted
because it is both (i) not material and (ii) would likely cause competitive harm to the Registrant if publicly disclosed. </B><I> </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT
 COLOR="#ff4338"><B><I></I></B><I>CONFIDENTIAL</I><B><I> </I></B></FONT></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">9.3.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Termination for Bankruptcy</U>. In the event that a PARTY shall become insolvent or make any arrangement
with its creditors or has a receiver or administrator appointed to the whole or any part of its assets or if an order shall be made or a resolution passed for its winding up unless such order or resolution is part of a scheme for its amalgamation or
reconstruction (the &#147;<B>Insolvent Party</B>&#148;), the other PARTY shall have the right, at its sole discretion, to serve immediate notice of termination (with the sole exception of the circumstances expounded in 9.5.2.2) of this Agreement,
effective upon receipt. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">9.4.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Termination by COMPANY</U>. COMPANY may terminate this Agreement at any time by giving [***] written notice
to SELEXIS. </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">9.5.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Consequences of Expiration or Termination</U>. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">9.5.1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Termination of Licenses</U>. In the event of a termination of this Agreement by COMPANY pursuant to Article
9.2 or 9.4, all and any rights and licenses granted under this Agreement shall terminate upon termination of this Agreement except for the licenses which have become perpetual pursuant to Article 3.1.3. </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:11%; font-size:10pt; font-family:Times New Roman">In the event of a termination of this Agreement by SELEXIS pursuant to Article 9.2 or 9.3, all and any rights and licenses granted under this
Agreement shall terminate upon termination of this Agreement except for the licenses which have become perpetual pursuant to Article 3.1.3. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">9.5.2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>SELEXIS Technology and Confidential Information</U>. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">9.5.2.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Subject to the provisions of Article 9.5.2.2, upon termination of this Agreement under Article 9.2 or Article
9.3 where COMPANY is the Insolvent Party, or Article 9.4, COMPANY shall dispose of all tangible embodiments of the SELEXIS Technology and SELEXIS Confidential Information, including without limitation the SELEXIS Materials and Cell Lines, and render
inaccessible or useless all electronic embodiments, of SELEXIS Confidential Information provided to COMPANY by SELEXIS hereunder, except that COMPANY may retain one copy of the SELEXIS Confidential Information delivered hereunder in its secured
legal files only for ensuring compliance with the terms of this Agreement. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">9.5.2.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Where the COMPANY is the Insolvent Party, SELEXIS acknowledges that this Agreement and the Commercial License
may constitute a material asset of the COMPANY and as such the continuation of this Agreement (and the exercise of the Commercial License) may be of benefit to both Parties, in particular where the Commercial License has been sublicensed. As such,
SELEXIS agrees to provide COMPANY or the COMPANY&#146;S receiver or administrator the opportunity to make submissions for maintenance or restructure of the Agreement. Any submissions must be received by SELEXIS within [***] of the COMPANY
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="34%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Date: October 28, 2013</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">20 of 27</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">Opthea</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><FONT COLOR="#3366ff">Selexis SA</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Certain information contained in this document, identified by [***], has been redacted
because it is both (i) not material and (ii) would likely cause competitive harm to the Registrant if publicly disclosed. </B><I> </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT
 COLOR="#ff4338"><B><I></I></B><I>CONFIDENTIAL</I><B><I> </I></B></FONT></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="16%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
entering into insolvency, receivership or administration. SELEXIS agrees to take into consideration any such submissions received within the [***] period before making any decision to terminate
the Agreement under Article 9.3. If no submissions are received within the [***] period or alternatively after due consideration of any submissions, SELEXIS shall have the right, at its sole discretion, to serve immediate notice of termination of
this Agreement under 9.3 and the COMPANY shall dispose of all tangible embodiments in accordance with 9.5.2.1. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">9.5.3.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>COMPANY Confidential Information</U>. Upon any expiration or termination of this Agreement, SELEXIS shall
dispose of all tangible embodiments, and render inaccessible or useless all electronic embodiments, of COMPANY Confidential Information provided to SELEXIS by COMPANY hereunder, except that SELEXIS may retain one copy of the COMPANY Confidential
Information delivered hereunder in its secured legal files only for ensuring compliance with the terms of this Agreement. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">9.5.4.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Accrued Obligations</U>. Expiration or termination of this Agreement shall not relieve the PARTIES of any
obligation or liability accruing prior to such expiration or termination. </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>10.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Miscellaneous </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">10.1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Assignment</U>. Neither this Agreement nor any interest hereunder shall be assignable by either PARTY
without the prior written consent of the other PARTY; provided, that either PARTY may assign this Agreement and all of its rights and obligations hereunder, without such prior written consent, to an entity which acquires all or substantially all of
the business or assets of such PARTY (or the business or assets to which this Agreement pertains) whether by merger, consolidation, reorganization, acquisition, sale or otherwise; and COMPANY may assign this Agreement and all of its rights and
obligations hereunder, without such consent, to an Affiliate if COMPANY remains liable and responsible for the performance and observance of all of the Affiliate&#146;s duties and obligations hereunder, and provided that [***]. This Agreement shall
be binding upon the successors and permitted assigns of the PARTIES and the name of a PARTY appearing herein shall be deemed to include the names of such PARTY&#146;s successors and permitted assigns to the extent necessary to carry out the intent
of this Agreement. Any assignment not in accordance with this Article 10.1 shall be null and void. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">10.2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Compliance with Governmental Obligations</U>. Each PARTY shall comply, upon reasonable notice from the other
PARTY, with all governmental requests directed to either PARTY relating to this Agreement and provide all information and assistance necessary to comply with the governmental requests. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="34%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Date: October 28, 2013</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">21 of 27</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">Opthea</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><FONT COLOR="#3366ff">Selexis SA</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Certain information contained in this document, identified by [***], has been redacted
because it is both (i) not material and (ii) would likely cause competitive harm to the Registrant if publicly disclosed. </B><I> </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT
 COLOR="#ff4338"><B><I></I></B><I>CONFIDENTIAL</I><B><I> </I></B></FONT></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">10.3.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Counterparts</U>. This Agreement may be executed in any number of counterparts, each of which need not
contain the signature of more than one PARTY but all such counterparts taken together shall constitute one and the same agreement, and may be executed through the use of facsimiles. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">10.4.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Dispute Resolution</U>. The PARTIES agree that in the event of a dispute between them arising from,
concerning or in any way relating to this Agreement, the PARTIES shall undertake good faith efforts to resolve any such dispute, with the matter being referred at the request of either PARTY to the General Counsel (or chief legal officer) of each
PARTY and, if remaining unresolved after [***], then to the Chief Executive Officers of each PARTY (or their designees). If after [***] of the matter first being referred to the General Counsel the PARTIES are unable to resolve such dispute, either
PARTY may seek any remedy available pursuant to Article 10.16. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">10.5.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Entire Agreement</U>. This Agreement sets forth all of the covenants, promises, agreements, representations,
warranties, conditions and understandings between the PARTIES with respect to the subject matter hereof, and constitutes and contains the complete, final, and exclusive understanding and agreement of the PARTIES with respect to the subject matter
hereof, and cancels, supersedes and terminates all prior agreements and understanding between the PARTIES with respect to the subject matter hereof. There are no covenants, promises, agreements, representations, warranties, conditions or
understandings, whether oral or written, between the PARTIES other than as set forth herein. No subsequent alteration, amendment, change or addition to this Agreement shall be binding upon the PARTIES hereto unless reduced to writing and signed by
the respective authorized officers of the PARTIES. For the avoidance of doubt, to the extent of any inconsistency between this Agreement and the Services Agreement, the terms of this Agreement shall govern and prevail. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">10.6.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Force Majeure</U>. Neither PARTY shall be liable to the other for loss, damages, default or delay due to
Force Majeure, provided that the PARTY affected by a case of Force Majeure gives prompt notice of such case to the other PARTY. The PARTY giving such notice shall thereupon be excused from its obligations hereunder as it is thereby disabled from
performing for so long as it is so disabled, provided, however, that such affected PARTY commences and continues to take reasonable and diligent actions to cure such cause; and provided further that if any Force Majeure delays or prevents the
performance of the obligations of either PARTY for a continuous period in excess of [***], the PARTY not affected shall then be entitled to terminate this Agreement, which termination shall be effective upon [***] written notice to the affected
PARTY. Such a termination shall be irrevocable, except otherwise provided by the PARTIES and upon termination the provisions of Article&nbsp;9.5 shall apply. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">10.7.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Further Actions</U>. Each PARTY agrees to execute, acknowledge and deliver such further instruments, and to
do all such other acts, as may be necessary or appropriate in order to carry out the purposes and intent of the Agreement. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="34%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Date: October 28, 2013</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">22 of 27</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">Opthea</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><FONT COLOR="#3366ff">Selexis SA</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Certain information contained in this document, identified by [***], has been redacted
because it is both (i) not material and (ii) would likely cause competitive harm to the Registrant if publicly disclosed. </B><I> </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT
 COLOR="#ff4338"><B><I></I></B><I>CONFIDENTIAL</I><B><I> </I></B></FONT></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">10.8.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Independent Contractors</U>. The relationship between SELEXIS and COMPANY created by this Agreement is one
of independent contractors and neither PARTY shall have the power or authority to bind or obligate the other PARTY except as expressly set forth in this Agreement. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">10.9.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Interpretation of Agreement</U>. Articles and other descriptive headings used in this Agreement are for
reference purposes only and shall not constitute a part hereof or affect the meaning or interpretation of this Agreement. Whenever the context so requires, the use of the singular shall be deemed to include the plural and vice versa.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">10.10.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>License Obligations</U>. Nothing in this Agreement imposes any obligation upon a PARTY to enter into any
other license or agreement with the other PARTY. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">10.11.<U></U></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Notices</U>. All notices and other communications required by this Agreement shall be in writing in the
English language and shall be deemed given if delivered personally or by facsimile transmission (receipt verified), mailed by registered or certified mail (return receipt requested), postage prepaid, or sent by express courier service, to the
PARTIES at the following addresses (or at such other addresses that a PARTY specifies by like notice, provided, however, that notices of a change of address shall be effective only upon written receipt thereof): </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="18%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="10%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="70%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3">If to COMPANY, addressed to:</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3">OPTHEA PTY LTD</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3">Level&nbsp;4, 650 Chapel Street</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">South Yarra</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">VIC 3141</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Australia</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Attention:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">CEO</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Facsimile:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">[***]</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="18%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="16%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="64%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3">If to SELEXIS, addressed to:</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>Selexis S.A.</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>[***]</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Attention:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">[***]</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">With a copy to:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">[***]</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Facsimile:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">[***]</TD></TR>
</TABLE> <P STYLE="font-size:18pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="34%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Date: October 28, 2013</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">23 of 27</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">Opthea</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><FONT COLOR="#3366ff">Selexis SA</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Certain information contained in this document, identified by [***], has been redacted
because it is both (i) not material and (ii) would likely cause competitive harm to the Registrant if publicly disclosed. </B><I> </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT
 COLOR="#ff4338"><B><I></I></B><I>CONFIDENTIAL</I><B><I> </I></B></FONT></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">10.12.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Binding Effect</U>. This Agreement shall be binding upon and inure solely to the benefit of COMPANY and
SELEXIS (and their permitted successors and assigns) and nothing in this Agreement (express or implied) is intended to or shall confer upon any Third Party any rights, benefits or remedies of any nature whatsoever under or by reason of this
Agreement. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">10.13.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Severability</U>. If any term, covenant or condition of this Agreement or the application thereof to any
PARTY or circumstance shall, to any extent, be held to be invalid or unenforceable, then the remainder of this Agreement, or the application of such term, covenant or condition to PARTIES or circumstances other than those as to which it is held
invalid or unenforceable, shall not be affected thereby and each term, covenant or condition of this Agreement shall be valid and be enforced to the fullest extent permitted by applicable law. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">10.14.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Waiver</U>. The failure on the part of a PARTY to exercise or enforce any rights conferred upon it hereunder
shall not be deemed to be a waiver of any such rights nor operate to bar the exercise or enforcement thereof at any time or times hereafter. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">10.15.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Survival</U>. Articles 1, 3.4, 4, 5, 6, 7, 8, 9.5 and 10 shall survive any termination or expiration of this
Agreement in accordance with their terms. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">10.16.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Governing Law and Jurisdiction</U>. This Agreement shall be governed by and construed in accordance with the
substantive laws of [***], without regard to principles of conflict of laws. Any dispute arising out of or in connection with this Agreement shall be subject to the exclusive jurisdiction of the courts of [***]. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="34%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Date: October 28, 2013</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">24 of 27</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">Opthea</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><FONT COLOR="#3366ff">Selexis SA</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Certain information contained in this document, identified by [***], has been redacted
because it is both (i) not material and (ii) would likely cause competitive harm to the Registrant if publicly disclosed. </B><I> </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT
 COLOR="#ff4338"><B><I></I></B><I>CONFIDENTIAL</I><B><I> </I></B></FONT></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">I<SMALL>N</SMALL> W<SMALL>ITNESS</SMALL> W<SMALL>HEREOF</SMALL>, the PARTIES, having read the terms of this
Agreement and intending to be legally bound hereby, do hereby execute this Agreement: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="8%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="38%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="8%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="38%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>SELEXIS SA</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"><B>OPTHEA PTY LTD</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Signature:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ Girod PA</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Signature:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ Megan Baldwin</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Place, Date:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">Plan-les-Ouates, Nov&nbsp;15, 2013</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Place, Date:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Melbourne, 7&nbsp;Nov 2013</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Name: Girod PA</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3">Name: Megan Baldwin</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Title: Chief Scientific Officier</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3">Title: CEO, Opthea P/L</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD COLSPAN="3" VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="3" VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Signature:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ Regine Brokamp</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Signature:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ Robert Klupacs</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Place, Date:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">PLO, Nov 15th 2013</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Place, Date:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Melbourne, 7&nbsp;Nov 2013</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Name: Regine Brokamp</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3">Name: Robert Klupacs</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Title: COO</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3">Title: Director, Opthea Pty Limited</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="34%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">25 of 27</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">Opthea</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><FONT COLOR="#3366ff">Selexis SA</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Certain information contained in this document, identified by [***], has been redacted
because it is both (i) not material and (ii) would likely cause competitive harm to the Registrant if publicly disclosed. </B><I> </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT
 COLOR="#ff4338"><B><I></I></B><I>CONFIDENTIAL</I><B><I> </I></B></FONT></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>EXHIBIT 1 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">SELEXIS PATENT RIGHTS </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Patent 1. </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="20%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="79%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Title</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">[***]</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Filing date</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">[***]</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Application Number</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">[***]</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Grant Patent Number</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">[***]</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Geographies</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">[***]</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Status</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">[***]</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Patent 2. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="20%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="79%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Title</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">[***]</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Filing date</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">[***]</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Application Number</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">[***]</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Publication Number</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">[***]</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Geographies</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">[***]</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="34%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Date: October 28, 2013</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">26 of 27</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">Opthea</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><FONT COLOR="#3366ff">Selexis SA</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Certain information contained in this document, identified by [***], has been redacted
because it is both (i) not material and (ii) would likely cause competitive harm to the Registrant if publicly disclosed. </B><I> </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT
 COLOR="#ff4338"><B><I></I></B><I>CONFIDENTIAL</I><B><I> </I></B></FONT></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXHIBIT 2 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">LICENSED PRODUCTS </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Vascular Endothelial Growth Factor Receptor 3
soluble proteins </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="34%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Date: October 28, 2013</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">27 of 27</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">Opthea</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><FONT COLOR="#3366ff">Selexis SA</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR></TABLE>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.9
<SEQUENCE>6
<FILENAME>d947560dex109.htm
<DESCRIPTION>EX-10.9
<TEXT>
<HTML><HEAD>
<TITLE>EX-10.9</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 10.9 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g945701dsp00040.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">[<I>Date</I>] </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">[<I>Director
Name</I>] </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Private and confidential </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dear
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><FONT STYLE="white-space:nowrap">Non-Executive</FONT> Director Agreement </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are pleased to confirm your appointment to the board as a <FONT STYLE="white-space:nowrap">non-executive</FONT> director of Opthea Limited (ACN 006 340 567)
(<B>Company</B>), as well as, to the extent requested by the Company, its subsidiaries from time to time (<B>Subsidiaries</B>)<B> </B>(together, the<B> Group</B>). </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>1</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Term of Appointment </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">1.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Your appointment as a <FONT STYLE="white-space:nowrap">non-executive</FONT> director and Board chair of the
Company will commence on&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(<B>Commencement Date</B>) and will continue until your appointment is terminated in accordance with clause 12 of this letter.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">1.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Your appointment as a <FONT STYLE="white-space:nowrap">non-executive</FONT> director of any Subsidiary will
commence following the Company providing you with a written request that you assume such a role, subject to you returning a signed copy of your consent to do so. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">1.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Your appointment is subject to <FONT STYLE="white-space:nowrap">re-election</FONT> and retirement by rotation
under the terms of the Company&#146;s constitution (<B>Constitution</B>) and the ASX Listing Rules. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>2</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Time Commitment </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">2.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Company requires you to commit sufficient time to fulfil your duties to the Company. This will include (but
is not limited to): </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">chairing and attending meetings of the Board and Board Committees, which are to be held regularly on such
number of occasions each year as the Board deems appropriate; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">attendance at the annual general meeting and any other general meetings of the Company; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">participation in operational and strategic reviews. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">2.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">In addition to your role as a member of the Board, you may be appointed to specific existing committees of the
Board and those that may be established from time to time. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">2.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">By accepting this appointment, you acknowledge that you are able to allocate sufficient time to meet the
expectations of your role. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman">Suite 0403 Level&nbsp;4 650 Chapel Street
South Yarra Victoria 3141 Australia </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman">T&nbsp;&nbsp;+61 (3) 9826 0399&nbsp;&nbsp; F&nbsp;&nbsp;+61 (3) 9824 0083&nbsp;&nbsp; www.opthea.com </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman">ABN 32 006 340 567 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">2.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">You should seek the agreement of the Board before you accept any additional commitments that will affect the
time required to be allocated to your role as a <FONT STYLE="white-space:nowrap">non-executive</FONT> director of the Company. Such agreement by the Board will not be unreasonably withheld. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>3</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Role as <FONT STYLE="white-space:nowrap">non-executive</FONT> director </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">3.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">As a <FONT STYLE="white-space:nowrap">non-executive</FONT> director, your role will include (but is not limited
to): </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">providing support, mentoring and guidance to the Company&#146;s chief executive officer, and where appropriate,
its management team; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">contributing to the direction of the Board on matters pertaining to corporate governance, strategic development
and board performance; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">ensuring that the necessary financial and human resources are in place for the Company to meet its objectives;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">being involved in preparing and settling agendas for all Board and shareholder meetings, as well as meetings of
the boards of the Group; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(e)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">providing a leadership interface with shareholders, banks and key stakeholders; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(f)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">performing, to the best of your abilities, and knowledge the duties reasonably assigned to you by the Board
from time to time, whether during or outside business hours, and at such places as the Board reasonably requires. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">3.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">As a director, you must comply with the Constitution, all applicable laws and rules in connection with your
position, including without limitation the <I>Corporations Act 2001</I> (Cth) (<B>Corporations Act</B>), the ASX Listing Rules and any relevant policies adopted by the Company from time to time. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>4</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>[Role as Chair </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">As chair of the Board, your role will include (but is not limited to): </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">providing effective leadership to the Board in relation to all Board matters; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">representing the views of the Board to the public; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">facilitating the effective contribution of all directors; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">convening regular Board meetings throughout the year and ensuring that minutes of meetings accurately record
decisions taken and, where appropriate, the views of individual directors; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(e)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">guiding the agenda and conduct of all meetings of the Board; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(f)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">overseeing <FONT STYLE="white-space:nowrap">non-executive</FONT> director and senior management succession; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(g)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">promoting constructive and respectful relations between the Board and management.] </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Page 2 of 5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>5</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Performance review </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">5.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">During your time as a director, your performance as a director (together with the performance of the Board as a
whole and the performance of the Board&#146;s committees) will be reviewed in accordance with processes agreed by the Board from time to time. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">5.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Board may make recommendations in the relevant notice of meeting to shareholders regarding your <FONT
STYLE="white-space:nowrap">re-election</FONT> having regard to the outcome of those reviews. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>6</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Remuneration and expenses </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">6.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">In your role as <FONT STYLE="white-space:nowrap">non-executive</FONT> director [and chair of the Board], the
Company will pay to you (or as you direct) on a monthly basis, in equal instalments in advance[, and inclusive of superannuation contributions that are payable by the Company to you]: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">an annual director&#146;s fee
of&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">[an annual fee in respect of your membership of Board committees
of&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per committee.] </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">6.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">[The Company will grant to you on the Commencement Date, under the terms of the
<FONT STYLE="white-space:nowrap">Non-Executive</FONT> Directors&#146; Share and Option Plan (Plan) attached to this agreement [and subject to shareholder&#146;s approval at a general
meeting],&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; options (Options) to purchase ordinary shares (Shares) in the Company. The Options will: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">vest as follows, subject to you remaining in office: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">-</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">[<I>Vesting terms</I>] </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">have an exercise price per Option
of&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(<B>Exercise Price</B>); and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">have an exercise period
ending&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; years after the Options grant date.] </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">6.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">[It is intended that any amounts payable and any equity based award granted pursuant to this Agreement shall
comply with or be exempt from the provisions of the Section&nbsp;409A of the Code and the Treasury regulations, notices and other guidance relating thereto (collectively, &#147;<B>Section</B><B></B><B>&nbsp;409A</B>&#148;) so as not to subject you
to the payment of interest, additional tax or penalty which may be imposed under Section&nbsp;409A.] </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">6.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Your remuneration for acting as a <FONT STYLE="white-space:nowrap">non-executive</FONT> director will be
reviewed by the Board on an annual basis and may be adjusted from time to time according to prevailing market rates taking into account other companies and giving consideration to their size and activities. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">6.5</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Any increase to your remuneration will be subject to shareholder approval as part of approving the maximum
aggregate amount payable to <FONT STYLE="white-space:nowrap">non-executive</FONT> directors under the ASX Listing Rules. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">6.6</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">You are entitled to be paid or reimbursed for reasonable <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> expenses that you properly incur in attending Board or committee meetings, dealing with the Group&#146;s business or in carrying out your duties as a
<FONT STYLE="white-space:nowrap">non-executive</FONT> director of the Company. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">6.7</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Any expenditure incurred pursuant to clause 6.5 that is
above&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;will need prior approval of the chair of the Audit Committee, or if you hold this role, another member of the Audit Committee.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>7</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Independence and conflicts of interest </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">7.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">If you have not already done so, please provide the Company with details of your directorships of other
companies and business or other interests, so that you have given a standing notice of your other interests to the Company. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Page 3 of 5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">7.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">You must use all reasonable endeavours to avoid any situation where your interest may be in conflict with, or
be inconsistent with, the interests of the Company (including as a result of other directorships which you hold).<B> </B> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">7.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">You will not to seek or accept any appointments or offers of employment that conflict with your position as a
director of the Company or that could reasonably be perceived to interfere materially with the exercise of your judgment in relation to the Company. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">7.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">If your circumstances change in any way that may affect your status as an independent director, you must
immediately disclose this to the Board. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>8</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Personal Interests </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">8.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">As an <FONT STYLE="white-space:nowrap">ASX-listed</FONT> entity, the Company is required, under the ASX Listing
Rules, to disclose to ASX details of directors&#146; interests in its securities and in contracts relevant to its securities. This can include margin lending arrangements. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">8.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Company is also required to enter into an agreement with directors under which directors are obliged to
provide the necessary information to the Company. By signing this agreement you will be taken to have agreed to provide such information to the Company. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">8.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Company has implemented a <B>Securities Trading Policy</B> with which you will be required to comply at all
times. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">8.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Securities Trading Policy sets out the circumstances in which you will be allowed to deal in securities of
the Company and the circumstances in which prior consent of the Approving Officer (as defined in the Securities Trading Policy) will be required in order to deal in the Company&#146;s securities, but always subject to the insider trading provisions
of the Corporations Act. A copy of the Securities Trading Policy will be provided to you under separate cover. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>9</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Independent advice </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">Occasions may arise where you consider that you need professional advice in the furtherance of your duties as a director and it is understood
that it may be appropriate for you to seek advice from independent advisers at the Company&#146;s expense. You will comply with relevant Board policies when doing so. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>10</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Constitution and policies </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">10.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Company has developed a Constitution and a range of policies which govern the conduct of Directors and
employees. You will be expected to familiarise yourself and comply with them. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>11</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Confidentiality </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">11.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">You must keep confidential Board discussions, deliberations and decisions that have not been publicly disclosed
by the Company. Confidential information received by you in the course of directorial duties remains the property of the Company and it is improper to disclose it (or allow it to be disclosed) either during your appointment or following cessation of
your appointment, unless that disclosure has been properly authorised, or is required by law. In addition, some information made available to the Board may be subject to confidentiality undertakings in favour of third persons and use of that
information in breach of the undertaking could expose both the Company (generally) and yourself (personally) to liability. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>12</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Termination of appointment </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">12.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Your appointment will be terminated immediately where: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">you become disqualified from managing a corporation under the Corporations Act; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Page 4 of 5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">you are removed as a director in accordance with the Corporations Act; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">you are not <FONT STYLE="white-space:nowrap">re-elected</FONT> to the Board by shareholders at a general
meeting. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">12.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">You may resign from the office of <FONT STYLE="white-space:nowrap">non-executive</FONT> director by notice in
writing to the Company. If you intend to either resign on a specified date or not seek <FONT STYLE="white-space:nowrap">re-election</FONT> to office, please give the board of directors (<B>Board</B>) one month&#146;s prior written notice of your
intentions so that the Board can revise its plan for the succession of skills and experience on the Board. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">12.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">No such removal or cessation in accordance with this clause 12 will give you any rights to compensation or
damages and no fee will be payable to you for any period after such removal or cessation. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">12.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Company may set off any amounts that you owe the Group against any amounts that the Group owes to you as a <FONT
STYLE="white-space:nowrap">non-executive</FONT> director at the date of termination, except for amounts that the Group is not entitled by law to set off. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">12.5</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Upon termination of your appointment, you must return all of the Group&#146;s property (including property
leased by the Group) to the Company on termination, including all written or machine readable material, software, computers, credit cards, keys and vehicles. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">12.6</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">You must not record or retain any confidential information in any form after termination.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">12.7</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">If, on termination of your appointment under this letter, you hold any other office in the Group, you must
immediately resign from that office and you must execute a resignation letter in a form required by the Board. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>13</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Miscellaneous </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">13.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">This letter may be altered only in writing signed by each party. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">13.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Any provision by its nature intended to survive termination of this letter survives termination of this letter.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">13.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">This letter is governed by the law applicable in the Australian State of Victoria. You irrevocably and
unconditionally submit to the exclusive jurisdiction of the courts of Victoria. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Yours sincerely, </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Director </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Opthea Limited </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">I, &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, accept and confirm my appointment as a <FONT
STYLE="white-space:nowrap">non-executive</FONT> director of Opthea Limited on the terms and conditions of appointment as set out in this letter. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">I have
read and understood and agree to abide by those terms and conditions of appointment. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Signature</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Date</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Page 5 of 5 </P>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>7
<FILENAME>d947560dex231.htm
<DESCRIPTION>EX-23.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-23.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 23.1 </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We consent to the use in this Amendment No.&nbsp;1 to the Registration Statement on Form <FONT STYLE="white-space:nowrap">F-1</FONT> (File <FONT
STYLE="white-space:nowrap">No.&nbsp;333-249020)</FONT> of our report dated September&nbsp;1, 2020 relating to the financial statements of Opthea Limited. We also consent to the reference to us under the heading &#147;Experts&#148; in such
Registration Statement </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">/s/ Deloitte Touche Tohmatsu </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Perth, Australia </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">October&nbsp;9, 2020 </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>8
<FILENAME>d947560dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.1 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Consent of Director Nominee </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Opthea Limited is filing a Registration Statement on Form <FONT STYLE="white-space:nowrap">F-1</FONT> (File No. 333-249020) with the
Securities and Exchange Commission under the Securities Act of 1933, as amended (the &#147;Securities Act&#148;), in connection with the initial public offering of American Depositary Shares representing its ordinary shares. In connection therewith,
I hereby consent, pursuant to Rule 438 under the Securities Act, to being named as a nominee to the board of directors of Opthea Limited in the Registration Statement, as may be amended from time to time. I also consent to the filing of this consent
as an exhibit to such Registration Statement and any amendments thereto. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Jeremy Levin</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name: Jeremy Levin, D.Phil, MB BChir</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Date: October&nbsp;9, 2020</TD></TR>
</TABLE></DIV>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>g945701dsp00040.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g945701dsp00040.jpg
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M 0$! 0$! 0        $" P0%!@<("0H+$  " 0,# @0#!04$!    7T! @,
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M3R [@?SII-[ ,_M&QS@7D&?^N@_QHY7V"Y8!! (.12V "P4$D@ =2>U %?\
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MI.3NS[&C1A0@H05DBU4FP4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 C(K A@"#V-&PFDU9F5=>&M*NB2]J$
M8]XSM_E6T:\X[,XZF P]3>)1_P"$)T@G)$Q'IYE7]9J'-_9&&>]R_9^'-)L&
M#PV4>\?Q/\Q_6LY59RW9TTL#AZ3O&.IJ8 K([;"T % !0 4 % !0 4 % !0
G4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0!__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>g945701g0921224119557.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g945701g0921224119557.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  U *H# 2(  A$! Q$!_\0
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MHCS\17G*?LJ6YS][KVN:Y,1=ZC>W;M_RSWL1^"CC]*]\^&$,L'P_TZ.:)XY
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,@ HHHH **** /__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>g945701g0921224120119.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g945701g0921224120119.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  * )X# 2(  A$! Q$!_\0
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2$N$DVKVM^O\ F$Z/,FKV/__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>g945701g75p65.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g945701g75p65.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X1#^17AI9@  34T *@    @ ! $[  (
M   1   (2H=I  0    !   (7)R=  $    B   0U.H<  <   @,    /@
M   <Z@    @
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                                                 $%B:7)A;6D@
M1&5V861A<W,    %D ,  @   !0  !"JD 0  @   !0  !"^DI$  @    ,T
M,   DI(  @    ,T,   ZAP !P  " P   B>     !SJ    "
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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MYZ/_ -]&OJKXC?\ ).=<_P"O1J^4J]C+TN21P8I^\A_GR_\ /1_^^C1YTO\
MST?_ +Z->K? O2--U:?6QJFGVMZ(U@V?:(5DVY+YQD''05[!_P (=X9_Z%[2
MO_ */_XFM*N,C2FX..Q%.A*<>:Y\D^=+_P ]'_[Z-'G2_P#/1_\ OHU];?\
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M,G'EV*CAY22=SY)\Z7_GH_\ WT:/.E_YZ/\ ]]&OK;_A#O#/_0O:5_X!1_\
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MEKX&RYJ?W&U/$WTF?1%%,AFCN($FA=9(Y%#*ZG(8'H0:?7EG:%%%% !1110
M4444 <!\3?A];^*])DN[&-(]7MU+1R 8\X#^!OZ'L?:OFNOLZ:1(H7DE8*B
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M9$*\H1Y4CZH_X6;X._Z#]K_X]_A1_P +-\'?]!^U_P#'O\*^5\T9K+^SZ?\
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M_:_^/?X5\KYHS1_9]/\ F?X!]:EV/JVU^(GA2]O(;6UUJWEGF<1QH-V68G
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M>-QD$?RKQJU"5)ZGOT,3"LM-R<]:^0_%?_(Y:U_U_P __HQJ^O.U?(?BL_\
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60JW13<I/=B44M@Q1114E!1110!__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>g947560g01f75.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g947560g01f75.jpg
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M>$$[1W)A<&AI8R!T>7!E.B @(" @(" @("!!<G1W;W)K)B-X03LF(WA!.^*
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M 0$! 0$! 0$! ?_  !$( *@"8@,!$0 "$0$#$0'_Q  ?  $  00" P$
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MF-8/&)G&(.L6F660DN*Q-[?)Y=2V.LQSIQ%K!URY%RQ:)7%D'CA\W:ME[ZJ
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ML5F#<%GSF;P/:[A(0?QGN2/;M8MFL"2R7CIX22G.W!BU#R@#%<CB79Z*OX5
MDC [+K:9Q=(G;F&+E8H-B:XMS8?#OE2Z0 K)P0 1NW'._P WP=&[^[,[;)S4
MV%[IYIM3Q] \32AG+\^8NSUE/+($H?'VD]L(S DX3Q(9%3YG8-HL9)R',-74
M$!V-;0]+K1[HXK;5MTNV75 IQDYW @#SYW@CS8WY^#C6M?FB>]C<!CGFAF8L
M$QS>=G_;G"8EL^QWE'$L+P/M"BVZ-]-LR'Y).QJHR1,UL*9',B!95(0'0L5-
M2.* +UK.ET2K)11=32ID@:02D'RB"2K3@8&,;P.L]1^"O1#>:8\T6QCE>*US
M=@8_DHE&.8ZP;>!GK # AC;#%D'G8C,V31N0,G%2TH#N)6/EY;'$6"-K<0#^
MFF;61.'HZT)'%1SYXB^O?42A.-Q_\PI!WG(P,=&!UYR/BS65NZ#FX^/MML/Q
M'E=;"-TAQ%D_!&$]PEA0YN#P? <KNX7FNUD]9#\9X#)'RV1<H'86&?(DYI<D
MUB\=8<+V[&0D*6*+V*E",G&<')&,'&1Q.-V?^]24PYKS%2V_([L@8X?:L2<:
MR\-P\3-33.V*L:9*(NB4:9GTLC0G!N1'48,9&Q9<H^2:,BD%EIZ<&FR:Q$#C
MXG9T%LN^OPU#3Y(5Q\QQU[LC(SYCBK+VK<W)P)NHW)8^P5&XD.#Q_-\BS%%L
M'3)MFS$\OG!XGAA V0*.<JX&CIA;)6# DX#1B0F,9%)BW===;-FPJHV%W&AG
M1U1*" 3OW8SNW#(X_#NW;O/6[_2I*:4II2FE*:4II2FE*:4II2FE*:4II2FE
M*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4I
MI2NK]*N9<9P8[L-X>9CW,[]C.\87G+<00RYC&?YNSY(8).(7&%0$>&LXQU&9
M8/G2"%J140[-\_88X6.GZEM$[N=Z)>JH%^2!J4G<00 "#DDY^Z'4<='54Q;J
M.9?;A<Z">:^.007$+"1;YW&PXIA:Q](ENA!2.!H_CQOF%*1E+8K5P$M=%X\;
MZC/&3=ZI)$[F[M^D/4=*)I0/F\W8#_WH% :-Q\G.=PWY)[=W&O=NBYESN*RC
MFO?!E_'?J1JLI_G_ )F5N$P9CF7'2(Z(Y/LV1Q$L,GF)\K)CHR43B<=ECPA8
MB <(#I*Q<.&@]4DT'-**KMHU!*@, \%))X:NL;]^*JN3]K/-&<D#\=3L9@[9
MUA4B]W0Y/REE'$&WB9C<;9:?0Z5XN:0J&R8UO"+X+FCQ3*UDDL)+Y5F>-,8P
MR3R7&_4&(""ZBZ1+G%,IZ,J.X '@<YW)R-P&< GIWXW[L:MO_,N-].TJ);99
M9&,7[7=R<\QUM6W:;0I]AO+&3SK'&0=KG+=%,\ZP_+T:/%\:R=68#'4?D+:&
M91AI8-&3QF-T< F99S:_<.V,/K\_#X^GIXYJ)4E6<Y&2#N WX&,8&!Q(W\1U
MYJT-PVV=[E+FCFTW:-"R6+&_JGX$P0.YJYAS F/)-$,'1.%[,Y!#<X86O"#7
MM'32,P[(SXLOA:$A7A=Z2;PE,*Q<-&=*JW-HT!\DD]1.G."25 @]/Q$XZ#QZ
MMQ?-2-DTEWU0G:5CD2V$/8?C7?3@G-^9V)&8R6"$'V%88%R&%GS**2*(7M9(
MTESAG+6J86H<O'R"2E5G;(\,=MD%M*E2<9/F(&X'M!W5".X'F1V(AN*\&XPV
M>XD@<,%">: [6]T.>.O>52^5%\A0G$4G=.YC:?E^0'T]EDV+6QYTX8@(Z?,*
M";J/2#9%0?8_>7KJB%G?J)/DJ2/-D?%U]-0+E'F>V]P),MQLLPHABM:/Y;YI
M%'MT5T8'S&/0;(A+$:&#!$#?K03)THQ!DUEA;)J<_9=5B)V-1RDJ?1FA! /,
MQ3HBZ9$51U)W9SN1I^/)/1G>-_03CB"*Q?;<R"WFP[ >'XZ*C$>7R_C?(F\Y
MQ;.<+[S)_B/)H**;BIVVF$?8-,@RS$$VA>6\:G4VR+'*L.RIBQ"1D51[=^+=
M7U-&V-%-8R3DX(2,*2"#@8W[]V_H(QTGHKG99YC_ +[I(^'/I":Q9G@GF;9'
MA3:MG2T1EA;;C"(;),<&":QU>L9CN#)3=-L/$AI=(FU$09MC&1UFXF\^B'$V
MN6:;9O\ C^'\^/S4"QU#!"BI.1G<<>?.<@;SGXA7:2AD=MB,/BD3L=N2%D8C
M0*.VOWJZSIX]M"BVHVUV[=.;U'#ERYHVHLNNX44665OO45ONONNNJJG5RZ4I
MI2FE*:4II2FE*ZT.1N;WY3A^3,IP8/M*Q^6&8\RME#&S(P2W 2,8^--\<SZ1
M0A,TZ%M<'$VXQ4O0!U2N')$R-C&KKI6C]WT+HZF_6KP?S[K;XMP:GQ&FY39<
M2VXEXK2 M2,**4E.<ISN/77%MH_#99MF[W<;'(L]SD/6YY++CS+D1+3BBTV[
ME 6X%@ . >4 <@G%6?\ 9!V9O$[QCYQLJ^8'60]J^Y>^4'T)'J5A/LA[![P7
MC\K"^EI]D'9F\3O&/G&RKY@=/:ON7OE!]"1ZE/LA[![P7C\K"^EI]D'9F\3O
M&/G&RKY@=/:ON7OE!]"1ZE/LA[![P7C\K"^EK>3L=W=!]Y^ X-F4?'*Q G(X
MQ'BLAB]A.\VUCYLJ):OB(=D:5'"%2[4<[75:($E!0V]XFE:XN8M;KZHV<U=;
M+3KC1():<6V2.@E"BDD9WX)&[-=_8=$AAB0D%*9#+3Z4JQJ"74)6 K!(R K!
MP2,@X)&^LQ=4ZJTTI32E-*4TI32E-*4TI6IG,?,<MM^8YMF<^ME?=3C?'NY*
M6MIUN,V\8GS12'X&S=+>A#&YL[-(K?&"DA9/IBW#CD)HI#)=%.N.QJG<^I56
MVBE%3:SNZ,C<#UCI[^L5Y2;F.6V:09+E&01^0-PD+#2O.F']RCS$<,G43&XI
M9YIPC2-HPF8,Q#_'I63K(I#XNQ&.HJ7EI2&(-EW#@)'@Q-N)(#%1UG&-QP",
MGIP<YW_&:O&4<REVY2$#*6(Z5YIA$O.;Q\B;Z8WEB%3&/C<DXRSOE%G8+F*L
M#?D(85C?623#='#+PV91B8#7@]TI:4N(.4&#EFJ&HY&X'<!@]! W[_CJJ+<S
M1Q<D]VBRMKF/<^0R5LMEV2)MCK(Q_,2,CFV1'.7%1BV38AEP[+(C)FQ."SMN
M&8 B0&(!X>W 1ZBHF(6@6-:-M*:COW#!ZL;O-CSCJ[3FH<YFGL.G& ,V;VMW
MF;8)CW&F7MX64T3HG%F.IV4RC'\2X[8K$9$2$H3DK%85:^.9&R9)I9/YD@&C
M8\+>^4#N4+$W-7+)BHH@Z0.@#I( ))XXX# &\]'36>8+:YC>/;J9[O 8.Y3=
ME7(V'X;A$^R<$V*D/2A\&D1B3AG X18)3(MSBA$V\L?/5C3EJNUM0228-U++
MU5%0SN Z@2>W'<*LC)>Q[#>5<PY?S=)G\Y1F.;-H)39-,$!)L6U!M\/EI%+)
M.Z?A&3@ \=,IO:1F1:Q$TZ?OQEC6QDE<!OO15575$*(  ZE:A\.[N%863GF&
M^U"<1X[#JY,W.1.%S7;K@';/DJ)P_),3&BLF0C;%'F,;PT:ESA_C<J:3D\:9
M#6#EXE&"T;ALB(-K7$AAQ*Q5PBM#'P]&/KY_KPIK.<[L@E0W=!/3]>GHW[A4
MS3WF5^#\HYWC6<<C96W)3AO$LSQ3<&!P_+<DA9)BD1ER&=(. <A ]6X4_P G
MQ($B5&M#BN-8;DV.XK4(IU3MA"8NZX;41G'F.::B!NP-V,C<<'CU'AG&<5<.
MW?F:>'ML.2QDWQ;E7<FT@D6)Y-,8[VX/\LUIMVQR0RX4=F9E<!@X:/A34A87
M$R)-_'0F299.P,0(DG1:+C!)?H#]"-"HGI ZLG SNW?7&,]=;$M*EII2FE*:
M4II2FE*:4II2M?O-&]ZQW8MAR"Y,CF,Q&52LWR\)Q<D -S5Y!![!(A LBSA<
MVH881&:.%U&]D"ZGI#K1"=JUQ.CB]\C1KT)QE;+:G;W<6+:RZVRX^'BEQT**
M$\BRX\<A *MX;(&!TD9W5KFUFT<?9.PS;]+CO2F(2HJ5L1RA+JS*EL1$Z2X4
MH&E3X6K)'DI(&_ K3G]D'9F\3O&/G'2KY@=;S[5]R]\H/H2/4KCWV0]@]X+Q
M^5A?2T^R#LS>)WC'SC95\P.GM7W+WR@^A(]2GV0]@]X+Q^5A?2T^R#LS>)WC
M'SC95\P.GM7W+WR@^A(]2GV0]@]X+Q^5A?2U-6V_FZ4CRWG6 XER7MQBF/ <
M\O,,6DJC&8#4V?LS# ?<^8M50)+%4/04:ONAJHJ.K3-JC6ZEEU&R]MUU+=?V
MBV0E[.1F)4B7'D)D2.;I2REP*2KDUN:B5I QA!&[?DBMWV&\)]MV[N$RWP;;
M.A.0H?/5N2UQU(6CEVF-">26HA6IT*W@)P#OSBNP\BNFNBDM97]ZLG8K;QI7
MCSJEM+[>/:[E::U&NFU[M*4TI32E-*4TI32E-*4TI32E-*4TI32E-*4K6E/7
MK2GX=*5^<:=VGEII2G&G=IY::4IQIW:>6FE*<:=VGEII2G&G=IY::4IQIW:>
M6FE*<:=VGEII2G&G=IY::4IQIW:>6FE*<:=VGEII2G&G=IY::4IQIW:>6FE*
M<:=VGEII2G&G=IY::4IQIW:>6FE*<:=VGEII2G&G=IY::4IQIW:>6FE*<:=V
MGEII2G&G=IY::4IQIW:>6FE*<:=VGEII2G&G=IY::4IQIW:>6FE*<:=VGEII
M2OW2E?.YRXY2=YUW)+(5K<GRI=T2/&MM;:\^VW!9);*TX5X5X451OI2O_.I2
MEU.U6FO2>Q_[V;1_)C_UG:\#^%,8\(&T^?PYL]L2,1\QJQ=;+7/Z:4II2NUK
MS A5-UL?A+U"[HC9T& *MU>%;:*)U$-.%U+;Z6WVTKP]:^VVOWM>3YG^V3/Y
M4_\ ]0U]++=^YMM_F^&/[!%;RN-.[3RZMZO*<:=VGEII2G&G=IY::4IQIW:>
M6FE*<:=VGEII2G&G=IY::4IQIW:>6FE*<:=VGEII2G&G=IY::4IQIW:>6FE*
M<:=VGEII2G&G=IY::4IQIW:>6FE*<:=VGEII2G&G=IY::4IQIW:>6FE*<:=V
MGEII2G&G=IY::4IQIW:>6FE*<:=VGEII2G&G=IY::4IQIW:>6FE*<:=VGEII
M2G&G=IY::4IQIW:>72E?NE*T3?N@'^*W@+_I9Q[_ . .XG6X[!?OIMW\2;_@
M9%<M\,_^[F_?\RT_YS KJL:]#UX9II2FE*EC;1_&VVV_ST*_W?>ZYIX3_P!R
M;?\ SB/\,_7H/]CM^^2__P P'_,8=?03&_P<P_D37^P3UQ*O6M572E-*4TI3
M2E-*4TI32E-*4TI32E-*4TI7J65HG;6M:\*4IQK7_/K?A]C2E=4;./[I-FV)
MLW9KQ&-V8Q>1,\29DRKBEM)'>XXJ&<R)+&D_D,'M/K!D<"ETA%YJ@'JE4987
M*6L.FNE:$'G0NF%.W[,^ V^[3V*W7Z+>;3&CW)E;S3$A,PO-I0\ZR0X6V%(R
M2T3Y*B,$;\YK69VU$2#*>B.1Y*ULE*5+1R6DE2$K\G4X#N"L;QTCHJ*:_NH?
M(]:\>0[#O.=-?1WIK._8W;2_P@L?H3_T:K3V9P?P27_8_2U^?90V1O$=AWG.
M&OH[Z?8W;2_P@L?H3_T:GLS@_@DO^Q^EI]E#9&\1V'><X:^COI]C=M+_  @L
M?H3_ -&I[,X/X)+_ +'Z6GV4-D;Q'8=YSAKZ.^GV-VTO\(+'Z$_]&I[,X/X)
M+_L?I:?90V1O$=AWG.&OH[Z?8W;2_P (+'Z$_P#1J>S.#^"2_P"Q^EI]E#9&
M\1V'><X:^COI]C=M+_""Q^A/_1J>S.#^"2_['Z6GV4-D;Q'8=YSAKZ.^GV-V
MTO\ ""Q^A/\ T:GLS@_@DO\ L?I:?90V1O$=AWG.&OH[Z?8W;2_P@L?H3_T:
MGLS@_@DO^Q^EI]E#9&\1V'><X:^COI]C=M+_  @L?H3_ -&I[,X/X)+_ +'Z
M6GV4-D;Q'8=YSAKZ.^GV-VTO\(+'Z$_]&I[,X/X)+_L?I:?90V1O$=AWG.&O
MH[Z?8W;2_P (+'Z$_P#1J>S.#^"2_P"Q^EI]E#9&\1V'><X:^COI]C=M+_""
MQ^A/_1J>S.#^"2_['Z6GV4-D;Q'8=YSAKZ.^GV-VTO\ ""Q^A/\ T:GLS@_@
MDO\ L?I:?90V1O$=AWG.&OH[Z?8W;2_P@L?H3_T:GLS@_@DO^Q^EI]E#9&\1
MV'><X:^COI]C=M+_  @L?H3_ -&I[,X/X)+_ +'Z6GV4-D;Q'8=YSAKZ.^GV
M-VTO\(+'Z$_]&I[,X/X)+_L?I:?90V1O$=AWG.&OH[Z?8W;2_P (+'Z$_P#1
MJ>S.#^"2_P"Q^EI]E#9&\1V'><X:^COI]C=M+_""Q^A/_1J>S.#^"2_['Z6G
MV4-D;Q'8=YSAKZ.^GV-VTO\ ""Q^A/\ T:GLS@_@DO\ L?I:?90V1O$=AWG.
M&OH[Z?8W;2_P@L?H3_T:GLS@_@DO^Q^EI]E#9&\1V'><X:^COI]C=M+_  @L
M?H3_ -&I[,X/X)+_ +'Z6GV4-D;Q'8=YSAKZ.^GV-VTO\(+'Z$_]&I[,X/X)
M+_L?I:?90V1O$=AWG.&OH[Z?8W;2_P (+'Z$_P#1J>S.#^"2_P"Q^EI]E#9&
M\1V'><X:^COI]C=M+_""Q^A/_1J>S.#^"2_['Z6LP]E'[H;@&XG,(W$.>L0C
M-MZLOO9B\=S-'*2F0(@9ECEQ5!")2A^_Q_CY2'OC5RC9"*D5K2@@N5K>#>.Q
M!-T#0-:7MKX'MIMBK>B[/NQ+K;PO1+?MPD$P"H@-+E-O--J2PZHZ$OHU(0YA
M#I07&M>2MFT4&YNJ8;#C#P&I#;P0"Z!O5R92M0*D $J0<**?*2%!*]/8S&FV
MS^VE4E+:UK3UN-*T[?WO]O:];7)ZSP.?CZ#T@]V_=OQ7SQ<BUI7-.Y*G_M8;
ML_)7<GE/7I/8_P#>S:/Y,?\ K.UX)\*O^\':?^6L_P""BU;&MEKGU-*5^75X
M4X^30G'YOK_?YJ 9..-;8^9R<TF0V2[-]MD&LPT_RD^GF,$Y7TVA.F4.:AVH
M2H</TM?:YC<A4?+NE7U%:766MK$4TJTK52Z_][YWLNR=TVLN5U8MBXB%PW5N
MN\[=<:24NON(3H+;+Q)RDY!"<#&":^D\5]#%LMBEZCJ@Q0 D ]$=LG.2.-9R
MW<WO>_\ -VDOJ4^_F\;Q_P#AM_A_3K9_:<VL]WLWRR3^@U/XP8QT.9ZO(&,>
MGW5X]GO?^*4]^&\;\VNGM.;6>[V;Y9)_0:AXP9_'] ?24[/>_P#%*>_#>-^;
M73VG-K/=[-\LD_H-/&#/X_H#Z2G9[W_BE/?AO&_-KI[3FUGN]F^62?T&GC!G
M\?T!])3L][_Q2GOPWC?FUT]IS:SW>S?+)/Z#3Q@S^/Z ^DIV>]_XI3WX;QOS
M:Z>TYM9[O9OEDG]!IXP9_'] ?24[/>_\4I[\-XWYM=/:<VL]WLWRR3^@T\8,
M_C^@/I*=GO?^*4]^&\;\VNGM.;6>[V;Y9)_0:>,&?Q_0'TE.SWO_ !2GOPWC
M?FUT]IS:SW>S?+)/Z#3Q@S^/Z ^DIV>]_P"*4]^&\;\VNGM.;6>[V;Y9)_0:
M>,&?Q_0'TE.SWO\ Q2GOPWC?FUT]IS:SW>S?+)/Z#3Q@S^/Z ^DIV>]_XI3W
MX;QOS:Z>TYM9[O9OEDG]!IXP9_'] ?24[/>_\4I[\-XWYM=/:<VL]WLWRR3^
M@T\8,_C^@/I*=GO?^*4]^&\;\VNGM.;6>[V;Y9)_0:>,&?Q_0'TE.SWO_%*>
M_#>-^;73VG-K/=[-\LD_H-/&#/X_H#Z2G9[W_BE/?AO&_-KI[3FUGN]F^62?
MT&GC!G\?T!])3L][_P 4I[\-XWYM=/:<VL]WLWRR3^@T\8,_C^@/I*=GO?\
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MJ4*SB_&3CELD_;N;I<N;;:6D!"BS">:DJ=;;;\DJ:05)&!I!(2-2215QX1K
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M9$T:I-)TV2J[:T0EZ""YCC_A$\':+PEV]V1E*+J@%R9#; 2FY)2,J<:&X)G
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M@T2<'$H\;%R:-2*.GV"),#(XU(@KEV+-!"[!=)RR?,W%]M>*B"]B+I!=!*K
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MI2HTMB;*EID.(*N1DQEA]+3T5Y"D/-AQ"AA8(G:D%I*4@9PX5JW_ '25)2G
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ME*:4K25S%ZE:[%Y;2GKUW>;TO^TAD#41N(/ BHNC.GS(2?ZA_/74NW/[9-Z
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M3VP=C??Z+^3E?04YJ_[G_61ZU.K+GVE99^!;+OR)T]L'8WW^B_DY7T%.:O\
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M8UDLVUM:OR#:Q981$PZRJ3GK/B%7"**U@RQ9%!8T:60;$Y>4;(D""#(<Q
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M<C44[/8MV*["D<SBQX[8YH2N*N4MAQ]V$RZ^T!*<>*%QGBXVM+;BD)26P27
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M6SVE\^=[7) UVU*/V(Q4BH[IE2^5U52@2MR-S=#(J@JHQ1I<F9H+JV4M;:U
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MET51-/HEUO/J6V\;J<HT^23U@GLQ_>.^O2CA\L#BAO\ N'Q_!YZS*"\U"+F
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M^EA;>%(D%I>I(25#*?<F]'Y;B.79NVVOX#QD1NPMA[/R<R$3'*YN>MH=/9S
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M?;%',\Y0F>'ML)+;]("JTGC&09=B4+(,VCNL)&-1F9Y%A10$7&H-(:YDQV+
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MD->AQ&Y2%9+;S9(ULO(R-;:\#(R%)(2M"DN)2H;#]HN\$C-2-V(<P6C8_F\
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MQT.QVBAM32D:,Z "0H6-M6Q9N,S<RR- L)9/2A8(4 (328QTEF!KC<1)+@P
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M)[Y9+X)03$ED<Z& VX>B2!T)5P? W#J=&\#E!Y46<WND*!K:_M=526L4X[R
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M3N?/2+>I$V8GHDMO2%0^2-W:N#K(D/2%%D6MV"\T5JAQTN.+<6E7^K:;+94
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MK+PT)DDB! K&DBK;<4MJ:2E3J'505.ZY;JG XB(ZB4ZG5(0E15(+16'%+0H
MNI9<<2C%1%RMZG$N+6EM;8FI;*8C804+E-KC-JTL*4D!A*PDH2E8)Y-3B$J4
M:M.";+MY(N2P@\> %J9,6![#1KO.=N?5J7P1W@1-JAN <RJ)L35U<G6Y B]A
M.',+GC4XL>J65J8N&#[G+Y6FS;+FEQE:D*Y<HLZ52N>'[48>.>%QM*L2 \C4
MTG4%E>HZ](RHU';G;5(<0A8Y *NAYKS3<Z)9)BAM93ADM+PXK>D)TC3J.X9&
M;JL*Y)R5GO-XN-"T3IZ2X@V6Y%Q(-+/;0X23--K6Z>69&S!C2TT[34'#"!JV
M1P%PFN^Z&Q4?G8^H2528L5W+2^GQ7WY<I*$A:UQK6]&"CI2L6^X./R6 L[DJ
M7K8WD:<K1J( )%G;Y3#$.,7%%"42+BR^4IU*;,Z"AJ,]I3Y2@G0Z,#) 2K2,
MX!JX+;WFNW:9E'!TPPNQDBV7Y%G7-)J*C\V-(6@#(9(W'+9)%8/92L(*(.6Y
M6Z$G'[M>7"K4XK;)!CF/J$$!Q=*1H11#E>+GXKL4+YRN7*4TF6&=!?FE],5+
MJ$J(5R2U$N)^UZTE!(2KE!*N9$-P9EHDE(CHC1D+,4N:TLP^15*4A1 *>52
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M^+N2BQ)MLRUS!&$H,RT^0XR5\D7&G,(60ES 4AUEET!23HP<B&T^R#5A0F9
MOUKVBM:IRK>J7;7/MK$M+(D<C)9"GF0I;.I3;D:7+866W$\J"D [=,>8WR+
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M&.?75&/;&!_ZX'_K&LOSV'^%QOR[7KUK'BFZ^]EP^12?HZ==48]L8'_K@?\
MK&G/8?X7&_+M>O3Q3=?>RX?(I/T=9&;/"(XMGPE4808D:(XT<46JQ=MW=$JW
MRP-SE%*H**4LK=2VZMM+JTYZEMU:<>%=<E\)3S3TFT%IUMT)8FZBVM*P#KC$
M E)."<;L]->FO !$E1H.U"9,:1&+DJUZ ^RXR5 ,S@HI#B4Z@G(SC.,C/36W
MGF'#*KO:F5LX=JNX/<=3UO\ [X)33_?7[U?OZYB,8/PG/5UFO1;WW8_B(_\
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MK^^5Z1[Z=CUQ1]QC&/P?17]CZ8' =@IK7]\KTCWT['KBC[C&,?@^BO['TP.
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MS^38C]3TP. [!3)XGM-.1M'O:#&?R;$?J>F!P'8*9/$]IJ]X5M9:1TATR(C
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M\9W6K9ZTM7QN;$-QA.-N*A27%Q 8J 4*3-99CH4&Y#,A<T,,JP_WK)R:F?9
MYESS,KTV^"QETM?G>!@L93Q!M00W:L658+&B! %'8^R9MD6T>8#*LVE@U-*Y
M(>ULNI97/[.%GQ6T&$V]+:''D@6R2Y,BE7*%2E<Y>2EUYU2E%3JUZE%9.5J.
M^M,V[3*&T4A4Q=[6^XQ%63M!;XUKN 1R*4-HYA$<<CQHR$(2B,VUH2&P"&T
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ME,G&))B7#L9G$1@MSTB]0LM(.I*L^BI @1J^=F4.G:M6]2U&SQJH -^>HCK
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MT*(/_P"LV?S\/C/5L$!<T6QO)LPY(Q4 Q)G(V)Q9+,F0"6Y5" X(<A B;XF
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MHWM6D&\<4_+SO"P3#[K.#1[$1G.2"1P5&,TES94,$ECB+*-RI(->BLT%R-<
MLBJNFB2JPOHISC4,9&\?KJ(0HK".A1.-_'XLU#6/N:(89D)G(<?RW&YSM3*X
MT@4#R@>Y1I/$((*X@>2I 7BD1/,);CO*^2X>G>3DP9P"1!F#PF2+D7#%%F'=
M4=6W6P"TGS;L[\=_UWU,6U#&,*R2/)"NK>>E(W>?H^*IB>;R]HXY.%K/]SF
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MCUH"5SE)Y% "473*-+*/8J7DABB["0BHZ,])ZR>CCC\_UX Z$@82<X"3E6[
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CK;[FGQ:4ISEG^K;[FGQ:4I2VVG;I;;2O=I2GQ:4KRTI7_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>g947560g01q44.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g947560g01q44.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_X6$,:'1T<#HO+VYS+F%D;V)E+F-O;2]X
M87 O,2XP+P \/WAP86-K970@8F5G:6X](N^[OR(@:60](E<U33!-<$-E:&E(
M>G)E4WI.5&-Z:V,Y9"(_/@H\>#IX;7!M971A('AM;&YS.G@](F%D;V)E.FYS
M.FUE=&$O(B!X.GAM<'1K/2)!9&]B92!835 @0V]R92 U+C,M8S Q,2 V-BXQ
M-#4V-C$L(#(P,3(O,#(O,#8M,30Z-38Z,C<@(" @(" @("(^"B @(#QR9&8Z
M4D1&('AM;&YS.G)D9CTB:'1T<#HO+W=W=RYW,RYO<F<O,3DY.2\P,B\R,BUR
M9&8M<WEN=&%X+6YS(R(^"B @(" @(#QR9&8Z1&5S8W)I<'1I;VX@<F1F.F%B
M;W5T/2(B"B @(" @(" @(" @('AM;&YS.GAM<#TB:'1T<#HO+VYS+F%D;V)E
M+F-O;2]X87 O,2XP+R(*(" @(" @(" @(" @>&UL;G,Z>&UP1TEM9STB:'1T
M<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP+V<O:6UG+R(^"B @(" @(" @(#QX
M;7 Z0W)E871E1&%T93XR,#(P+3 W+3$W5#$U.C4T.C4V*S U.C,P/"]X;7 Z
M0W)E871E1&%T93X*(" @(" @(" @/'AM<#I#<F5A=&]R5&]O;#Y!9&]B92!)
M;&QU<W1R871O<B!#4S8@*%=I;F1O=W,I/"]X;7 Z0W)E871O<E1O;VP^"B @
M(" @(" @(#QX;7 Z36]D:69Y1&%T93XR,#(P+3 W+3$W5#$U.C4T.C4W*S U
M.C,P/"]X;7 Z36]D:69Y1&%T93X*(" @(" @(" @/'AM<#I-971A9&%T841A
M=&4^,C R,"TP-RTQ-U0Q-3HU-#HU-RLP-3HS,#PO>&UP.DUE=&%D871A1&%T
M93X*(" @(" @(" @/'AM<#I4:'5M8FYA:6QS/@H@(" @(" @(" @(" \<F1F
M.D%L=#X*(" @(" @(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)2
M97-O=7)C92(^"B @(" @(" @(" @(" @(" @(#QX;7!'26UG.G=I9'1H/C(U
M-CPO>&UP1TEM9SIW:61T:#X*(" @(" @(" @(" @(" @(" @/'AM<$=);6<Z
M:&5I9VAT/C$V-#PO>&UP1TEM9SIH96EG:'0^"B @(" @(" @(" @(" @(" @
M(#QX;7!'26UG.F9O<FUA=#Y*4$5'/"]X;7!'26UG.F9O<FUA=#X*(" @(" @
M(" @(" @(" @(" @/'AM<$=);6<Z:6UA9V4^+SEJ+S1!05%3:UI*4F=!0D%G
M14%304))04%$+S=107-51VAV9$<Y>F%'.7=)1$UU34%!-%%K;$Y!*S!!04%!
M04%"04%304%!04%%028C>$$[05%"24%!04%!44%"+RLT041K1FMB,DIL04=4
M04%!04%!9B]B04E104)G445"055%0F=51D)G:T="45E*0W=G1T)G9TQ$06]+
M0W=O2R8C>$$[1$)!341!=TU$07=11$$T4$5!.$]$0DU41D)15$5X=V)'>'-C
M2'@X9DAX.&9(>#AF2'=%2$)W8TY$03!914)!64=H55)&4F]F2'@X9B8C>$$[
M2'@X9DAX.&9(>#AF2'@X9DAX.&9(>#AF2'@X9DAX.&9(>#AF2'@X9DAX.&9(
M>#AF2'@X9DAX.&9(>#AF+SA!04519T%P045!07=%4B8C>$$[04%)4D%135)!
M9B]%06%)04%!04A!445"05%%04%!04%!04%!04%11D%W24=!44%(0T%K2T-W
M14%!9TE$05%%0D%114%!04%!04%!028C>$$[05%!0T%W449"9V-)0U%O3$5!
M04-!44U$06=10T)G8T1"04E'06Y-0D%G35)"04%&25))>%%614=%,D5I8UE%
M54UP1VA">%=X46E00B8C>$$[571(:$UX6FDX0U)Y9W9%;%%Z4E1K<4MY63-0
M0TY546YK-D]Z3FAD55I(5$0P=4E)2F]-2D-H9UIH2E)&4G%3,%9T3E9+0G)Y
M-"]0128C>$$[,4]4,%I85T9L85<Q>&18;#E76C)H<&%M='-B5S5V63-2,61N
M9#1E6' W9D@Q*V8S3T5H66%(:4EM2VDT>4YJ;RM#:S535FQP95EM6B8C>$$[
M<6)N2C)E;C5+:G!+5VUP-FEP<7%U<W)A-G9O4D%!24-!44E$0E%514)1645#
M04U$8E%%04%H141"0T53355%1E523FA)9UIX9UI%>28C>$$[;V)(=T9-2%(T
M4TY#1E9*:6-V17I*1%)$9VAA4U5Y5VE9-TQ#0C-04TYE2D5G>&15:W=G2D-H
M9UI*:EI&1VED:V1&53,X<4]Z=WEG<"8C>$$[,"M0>FA*4VMT3515-5!2;&19
M5U9P8EA&,658,5)L6FUD;V%7<')B1S%U8C)2,61N9#1E6' W9D@Q*V8S3T5H
M66%(:4EM2VDT>4YJ;R8C>$$[*T1L2E=7;#5I6FUP=6-N6C9F:W%/:W!A86YQ
M2VUQ<39Y=')Q*W8O84%!=T1!44%#15%-4D%$.$$Y531Q-T971B]M2G!(;E<K
M:S V6"8C>$$[>79E>C(X:U5E;W!016MS8U5(<51A9&-*85-Y9VIM+T,V359!
M0U%0=$9D<6A6:CEZ<68U;"M5=DDY<G%6>$QA<VM&,G-6>%IA:W,Q-28C>$$[
M96E'.#%-43(V3F1X,UA!=D9B>G!5;FYU4'1(<FER,51&6%EQ-T9867$W1EA9
M<3=&6%EQ-T9867$W1EA9<3=&6%EQ-T98;F8U:"]L=B8C>$$[<69M3%=L,4]W
M;6@T+V\O-FYC5VPQ3$U)<"M/;U=L,DE744I-:5)3>#(P:5--<3%.4E971TMQ
M:6IZ:#57;CAM85I,<71V939:8U-7,B8C>$$[:EA53%=Z+U=#.$]N>7E04#EA
M37@U8S5,5W1$1C,V-'$Y07A6,DMU>%8R2W5X5C)+=7A6,DMU>%8R2W5X5C)+
M=7A6,DMS2B]/8B]Y6"8C>$$[,3,O>D<V6"]!3C%/,GA6;3)+=7A6,DMU>%8R
M2W5X5C)+=7A6,DMU>%8R2W5X5C)+=7A6,DMU>%9I4&YZ+VIR*U-F.$%T=FHO
M04QP="8C>$$[.6ER3'-69&ER<U9D:7)S5F1I<G-69&ER<U9D:7)S5E-A,S@V
M950W;E94<$9T<FQH3G%G3D1:4C--5%16-F-E06)L561X,7A63V-69"8C>$$[
M:7)#9GIM+SAL.60O.'AU;"]W1&14='-66G1I<G-69&ER<U9D:7)S5EES;FUB
M6')Q-SAX,E9R<%9X1DQP>6HY15A%=',O<#-,8U-R9R8C>$$[971*85)04U94
M4VLV:&Q)4$EB-'%H3')6+W=!>4ET2#!I6DY+:&QU6G!,9V$W>30R.7A"0VMC
M>E).8C(P575P4DTU2TI19E='-4=I:R8C>$$[3'I,4DMP1F$K6F9/-70O2TYR
M3RMP:E5B<3AF.4MY;E-:1$$Y:V)X:VEA-VM7,G!!>C(X9$%!<U1!<W)Y0TY1
M5DMR,4A&6%EQ-T98628C>$$[<3=&6%EQ9SE9,6I4.4@P*U153E%K359R1552
M;5)(;&-V2S9X4F]K8U-U-W,W=7%Q<7%34V-6670U<W8W5%5,:GE"9C)5;VUS
M-WI7;R8C>$$[<#=A6F$P94M84S<Q,%E6;V%&4T1I<DYC5F1I<G-69&ER<U9D
M:7)S5F1I<G-69&EQ1696.4M3.$9K.3=!=#1304Q:<%5%=%=O44]"4"8C>$$[
M3&5O-UEQ.$DO25,S,5(O3E4X3W!F6&XP6C=.<G)23%!5<C%.4T5F0G)/6DA5
M<$MS84])-VU*,2\P64U&8V9(=CA3<C9#>%9,9DTP,B8C>$$[<5%E5SE6;3!L
M4RMQ>%=D=RMN;W%I4FIC3$5X:4%1:T)I6'!S5'9I<GE8>F(U:C@R,T@U6%=6
M=')M:C,P;'ID,VQO,3%Q<W%1=W!%<R8C>$$[9712:4%44D57,'9*-&M48U<V
M5G)5;VTT0W(R>D9867$W1EA9<3=&6%EQ;S-P=E)B3V)&63)U='945UES<V95
M5C5&47@V5C=9<7AU8B8C>$$[5R]..%=V5V5J1S$P.'I8=')D6&E30V%B:49T
M2DQE3FQ0-W5T5TXR=%!K8U9:1' U,4EW139I<TM82$DP1G5Z<VY(='4V<6$O
M4FEQ2B8C>$$[>%8R2W5X5C)+=7A6,DMP5#5Q.'172&UB47)J4F(Y-45T8FMX
M;#)I-&-G67!&;%@T6D9K:EEC:T969$=5:EEG-'%W-WI(-5,P5%(Y8R8C>$$[
M.&AZ,F-C<'599%5H<T)03$Y,25=H:#!Q-U)E4W,S1&Q32F%T>'%F<'A6-E!I
M<G-69&ER<U9D:7)S5F1I<G-69&ER<U931SAT8EDK9"8C>$$[.4QK35-'439F
M9G-82VIL5EHW24$Q.7-6955F:VXU43%R45!-23%F5C5$1%DS1FTY;F)#5RM3
M-'1X2S5S;UEK=%0V,'!04#9O>6HO:28C>$$[<%E"5W12:7(S6$9867%W;C@U
M=B]!0U@Q,R]Z1S98+S-5-V)&5V)9<3=&6%EQ-T9867$W1EA9<7AQ+SA!+TIK
M-D8O,GAT62\V:71->"8C>$$[5FMU2W5X5C)+=7A6,DMV369Y>#@K*V)03E!M
M9E56,5)B84A3;V)53EE286-5=6)D;CE8:2]Q,V%U>FE21C0X63-336YK,W=F
M0EA&6"8C>$$[<#)+=7A6:5!N>B]J<BM39BLR*U K-F)F67%Y-T9867$W1EA9
M<3=&6%EQ;'9M3%=*3D@P:30Q2F)2-WE/,5(U<#0T,E)'155A33=-4"8C>$$[
M54MG,#0Y3592;&Y,4$YB2DI006)A6F=E8T1-<FQD+S5K2E4O4FEQ=&ER<U9E
M9F%N*UI8:W4S+TYF5&9,:S)O:$Y64S)U3$HT:DA*=R8C>$$[5S5V2'1*64E4
M3'@Y34\V4FUG-61A1'%137-'2U)J>%9S='!0*UAU;V%:<F9N,U5*<&9*;&@U
M96UH=%)C,G1Z2F)+,3EC<S!V07I2,R8C>$$[2TES2$)"5&XV8E!8;6YX-T5:
M5W(Q;D9867%W;C@U=B]!0U@Q,R]Z1S98+S-5-V)&5V)9<3=&6%EQ-T9867$W
M1E5.*VLY3B\U831F*R8C>$$[4FDO,7A6:FPY9E=*+TU44DI28U)'2F1),5I7
M9FUV14TQ>G!P544Q<%5H5%0U67%Y4#E*-F(O>3%W+SA!27AF-C1Q:49:5U5-
M<$)5:28C>$$[;TDS0D)X5G9&6%EQ-T98:V8U5%AN;&TW.'I.9%=L=DID95EB
M=E1';#%J5DQM-VMU-WDQ9&)H1BMO6&%'3TM/0GE/3$)55F9I4GA4-"8C>$$[
M86Q6-C5I<5)E9'9.4V56+TPX;7%M,F4X:T5S1G9"8DIZ<3AT>DUS2T$K;6LP
M;$]4-SA),F)W56YB1E='-GHU,S!46&1B.&=7=',W+R8C>$$[048K8E593E)E
M15)Z3D-S53)L6%1$:F1E;7-%:$AQ:EI7<C=D8U9E;C1Q-T9867$W1EA9<3=&
M56PX-V8X;UIR+T%0,GIR=CA!-4U0:28C>$$[<6-3>7A1>'1,2S9X>$E+=3=K
M2V]!-VMN<&ER2$<X.6%F9$U9+TPY<F-E64I1865P6DMO=%%F93AL361U861W
M:G,S=&ER6#9/.#=A<"8C>$$[=G%';W<V2F%T+W@V85EV<C-&4$)R=318:5 X
M05E106IS,DMS46LO2F)Y5$0K85=L83)&=35B<W=Z86Q+<SEZ2DUS;#5:4U=Y
M47I/,"8C>$$[<&51:V5R>7!Z-#%69'5T8FAN:TEC1C=)<$Q0>59B4W8X4DY.
M8GIM6%5.4C!X-W)58E,P:VAH<S='55A+2V)E9E1R9$57,W5#0T="9"8C>$$[
M;68X079&-DQ6<6MV6BMA8WEN26-W07A7=3E$<T14-DU#;TQ8=%AG,&)1=%(Q
M:316;F<P,C%M=3556#=24T-.<$=!.7E&>%8U8C4X+R8C>$$[35!1.6,O3%,R
M5V4T=#=,5V15=3=&;V1).5ET351B-G9%:V]54TI$2650;W1Y-5)Q4E$Q07!I
M<C)$1EA9<3=&6%EQ-T9867$O3T\R="8C>$$[3%4R.%)-2T5L1G%E23A0;&Y4
M-'=/164U<$HS93%0.$%L+SA!;$%.5V=K:'9.36PP>4\S;%=&1W5)5FMU6G55
M6FAE9$<Q0TQG2&DY5B8C>$$[:6969V]Y:%=J56Q1*T8T;5-U4G8S9CA!2&8Q
M<W1N:W5S86)P54=R,S!.;6M%='!&8U-P8GEX:FMJ>'$U0TUH8T)I<%AC5C-Z
M3V=,028C>$$[<TU#6#-4*U<S+VMU+TLS+T%'>4Q$+W%':GIM6F-Y,W-J>4MU
M>%8R2W9(4'EH.&UA5F]0;D,X1G!R43%/-71,5V5X=4)$;SEZ67AS."8C>$$[
M56QT0DE7=DAE5T-::VQT1TI65%@Q2&QB*V)&6'-E2W%&+W Y:'%&<$Q:6#ET
M1F578W<T>E<P-DQ,131R5VI)-$MK5DAC67%X6'IT1"8C>$$[1$)Q4&MA1T9&
M:6AI,3%%:FI10E965C!Y.4%644YG04]G>%9M3TMU>%8R2V]/>3%E>79:<&]9
M4%8Y4T$P;$5K13!153!"<'EK4D)7:B8C>$$[03 X3CA64FU+<4XW9E=6:&%3
M,VPY8U(R='!!=DMA-&UD630P6'A:;4E!>%8T.2MD8VYM+WIL-4EN2&Q/0S1T
M=$=S6$XU<4XU4$DQ:28C>$$[8C(R:6IB;$9"1W=%:GAJ:TI#6D]#='@K2&Q8
M3#E03TU:6$E7149K,S5F.$$U87DR;FQB4S0O3S!J83=R='5H.558:SAT-6)1
M+T=Z4B8C>$$[2DA(2U1%5VI1<7!K-#AI4E=V5$E:6D%Y2DA*3#!"5E960W%!
M1D%O04YG04UR5G9&56QU+RM5>C!V+W1N86HO>69S8U994BM72&QV."8C>$$[
M=SE+.'A44#5K=GAC46961U-E4#E*>EAZ4&-&8E5,2C9-<V-9:BM/2S1E;U R
M6E9J*WEI-'%K,S5D95AK;B]-;E=(=CE0=#=E4%0U-R8C>$$[,SE(:&10=4E,
M<6QV96AB960Y4F%#4#%V56DK,'8Q:51M=$14-V5+=F%*230U63)J:U501S1+
M=6I!1E=5:6A"0C9G-'%W4#A!3FI4-R8C>$$[1%0O>7IM<W)#,FES-T]'.#!T
M66)A0D9I:5%F<%,R3D92049!<65W>%9N,DMU>%8R2W5X5C)+=7A6*V1&<B]V
M3D8O<4PK<D]O>"]34"8C>$$[8S!(;7$U3D1S5F9D+W=#5S,O:W4O2S,O04=Y
M3$0O<4=J>FQP8WDU1$DX:7)S5F1I<GEV.'5).4QT+WI",74Q6'I(2'%E<D-/
M-6MV9"8C>$$[4&AT=%-T;VA),3)0<D5S6#%M.'5R56A*=WE-26LK1FI3;S-"
M5E5V2D]L*V)R=GHQ<4TQ-W%&,&1&<UIB:4\R=54Q4G)G>GE7=#,V628C>$$[
M171T-G)W2W)O2%-64D)'55ID:G5-2W978T-S4C@K9CAD9GE4+W="=#AF.$%D
M3G9S5EID:7)S5F1I<5<V5U%,-U=39&=,>% K;T\S>"8C>$$[5DLU9D]%=6]Y
M=F$K5DQ5871+:D9*=%)D:DAP,$I";W=--$1'6C$O:VA$8C=-5GA657-F2C90
M9%)A:C5G=51R5W%22&Y!6E8T5VQU,R8C>$$[:F)7,5=60T]Z=5=F+TMX5D5E
M9'8K54TQ+W=$-UHQ,R]!36U(>%9/<U9D:7)S5EEX94QO63@T5SA5=FQJ,3E5
M;55Z=S8Q-DYI9F=G.28C>$$[1DAK.5(U4F-$,'I+:2]9<G1T541&5THO;'HU
M4FXP9GHW<G0Y9&5:3D@Q8E5*,'5:3'I48D=Y=%E,,D-3-W56=4-:6FQA5S@Y
M2E165B8C>$$[4U)Y4',O>6I&56HO04-F5S9V9GI-,798<'10=6)34R]T-W8V
M>7HO6%!21&98:V%.06)M>7-Q;FE7-#AN9&="44-.4G=#<C(O1E=%+R8C>$$[
M;DXO-4PV-R]!3UDS4R\X075P,C)+<S)X5C)+=7A6,DMU>%8R2W9Z;W1F.$%E
M84PO049&+U9N55DO<$AU841Z5F-M:#)+=G4O.'1V+R8C>$$[04-89FQB+W1K
M5T@O049$4C5Y,'5:8VAK95)6,DMU>%8T2#58.'$K66)V.$%.8E9T6#!Y2V94
M-%ET4W5:3'I71W4U3T8Y1D9Q82MP028C>$$[,6]*2$DY3TI*24DQ6D]$02MO
M0W!#06Q5>2]+:7HX<7HO;6QR+VU(4UIR,#-/<E)8>E-7.7IP<E=A3'=V,#E9
M*W4W15--2$MR>&I29"8C>$$[:"LY+V591F5Q*V%O=DU%=FPS54EF3'IW>#8Q
M3$-Y5U5T=WA33DAB8FYY5DIF:5934W9W:V-Q5C)X5C4V-F5E8F1V>3!S+TU.
M=F)+:R8C>$$[1C5A>#-.>6)U4S1V5W95,&DV5U@Q9UEV5$Y4>DQ/2FTS.&5U
M2W96.%9D:7%N8S-.=F$R,'1Z8U-,1F)W23!K,')M:6]I1&MZ350P028C>$$[
M07)I<C4V+TI4>4HK64]P-C5Q9#DU-G5,=3@X=C-%4657,'5R>5(T-W4W:T55
M<U5J5W9,84U13V%X>4MV5E9+9D0X3U9N;FI-4G=I:B8C>$$[,5%(,%!&1D9$
M16M54TQ(16=#<$=G0W%O1W=!03)!>D93=7A60S9L<&QH<61Q,7!F46EE,F5O
M94II44-#0W!";U)S47AX5E=T-V5',R8C>$$[:%='1F5-86)+=%-A8C$V;75+
M<6U+=7A62F)V+T%*5%!3+SA!=&YA:B]W06XW2$98:C-L:#E9='9Z<#%H=$AT
M.4YN=3)U<&]D5&EI9"8C>$$[6DI)-T=7+U8S9$M8.&AJ4$)Z3% O;S9F=G%*
M>%!)<T95>"],>&)M,2]-,U9T6'9D03%+>C%$5F\O4VY4;&1834545%1I5FDP
M:VUN,B8C>$$[54I29FDT=6)H>7%J9V=+,&]Q.7%X5C4Q*UIE=394<G8U5U0V
M;G!.>70S65,V:' V4EA#06A734]S45%Y8V511E%(:EE!.40Q1E)I<B8C>$$[
M,%A&6%EQ=U0X=V9+6&PK2'EZ<FUQ>%=P5%5"1$QC0V1:6E%22V9I3$%C*U!5
M*T=&5U)A8C5/.'5A6F1P95=6<#96=V=)5B]5;&%G628C>$$[54]Z37<V64Q6
M3V-69&ER.#9,6"]!2&UI+W="4F8Q6C%'4#92-VUG.#%82F]D:7(W=B],8B]W
M06PS-5<O-UI&:"]W0E$P96-T3&U8228C>$$[6DAK5F1I<G-694XO;'!P,G!V
M.$%M,35L,68V<$5.26Y';WA*9G@R,6A"-G-Q-F=Q0DMW<4QP<4-*=51Y:VE2
M=FDR*T5S<6M(-5!T-28C>$$[5C!Z.'HY6'8W84M84S(Q94]32T132%-Z-7A0
M4&1R24DS:71B:31M:C16-&HY>D=I;W9X-S<T5F9194)722MF4"M/=C5*+S=B
M-"\W<"8C>$$[=#EI<DQS5F1I<D9.6G(U:C$T95AK06)2.4]-9'AR-SE22DQT
M2F(R6# W4WEJ*UAI=E(X5E902VUP;3<Q:E@T:G%&;F1#2S=7:V1S="8C>$$[
M2$DK<5<S>"\S<W9W:79(<#%(6'1I<DHX5F1I<D@O4#EN8EA0:S-75%!'2$YV
M6EA-.$).455L4T(K3&=J=4LT<6Y6;EHR,6YB2F)7<R8C>$$[66EG:D)#4G(P
M1E18.5IX5E=X5DLY8SAY859O>5)I-VM:-VUC.&)7>&=6<')M6G9#2T9+<S-U
M9G-J=5%-5EE+;&PU<7903V1P9%A6;B8C>$$[3%EA:&140SAT6E=U=S8R*VU7
M>G=,8S)S:V-B1D]C;DE!;V]:951H=5)+8D95=2],6%0Y6F<O3EAZ3DUU<#-T
M,V]$=G%2:G171BM.4"8C>$$[:G5:3E%6;E=(,6]L='95:DEC3U5L2DQ&=4DT
M9S1&978T<6\S=&Y"93)C.6YC071B,TUB=WI+<DY'>%-24W)!3VA6;$Y$,55G
M:G1I<B8C>$$[>5AZ+T%0;'0U6CAT+VPP:6%C8G=J5'(K>DYO2F)Y-5I&5S8Q
M:4M2,6%%3W-,:&97255U:%!E<&(T<U9E=UEQ-T973V9M3B]Y9W5U9B8C>$$[
M.'=K;C9S5EI(:7)S5F1I<C@V3%@O96%,+U58.5=D4FHK:V4U;U!.5GEA2%EQ
M*S<O04UT=B]*9"M6=CA!=&M72"]53DAN3%,U;'E'4B8C>$$[-49867$W1EAL
M6#5C95902BML+VU"<D9Z;V,V=$EI,S!(,64S,'%E,&EJ5C<Q1VUI83E)*W)4
M+U8U62]3:E=,:GA514AL>'%&6'%U2R8C>$$[<48O<49H<#EP3&4S.7I&6C)C
M23546$TW<D9%9W)3<D\U0V=64&,T<7A8>G9,1DYQ6&MA848Q:VEK,3%8:FM1
M:&Q:5S!Y.4E:4TYI0R8C>$$[359::FEQ5"MA3F1K,'%W4F)335A'<E@P9W1D
M2W1#865P8T]#45=P=4DT,55Y4TAS<6Y&5EAY-6]C5VDV5DA:3$DQ>$]786$X
M=35+928C>$$[<%!C4VYL3$TY3S=S96Y11%EB1$96;6I7,71&<4=S=$9%:V)F
M5S%&5E5!,"MQ5S5P=#<T<6TR2W5X5DIF3S,O2T=A+R]!3G,V-R\U328C>$$[
M4&EQ6C,Q+UI71G!,95@P.&1R85%,>FUU2FU#4F]O-W-Z54%X5FIN-EHX>&59
M2W!O15(P>E-Z+S!V3#)-*W))4"M84S!C06ME16LQ0B8C>$$[-$DT>%9.3D0X
M<V%4;S=3>E<V=E!F,T%!=3E3=5=-,3%.5&-"-5<S-&HY;$9O<2]S9UEQ<#-F
M.$%Y;65L+W=$8D\Q2"]!2E R3TMS4R8C>$$[.&EE44@X=2MD=%1V26)84W)3
M>6%+-&EH5WA32DQH;W!R:$IB9%A224EM:5='2F5$9G9(.5$P8F%M2W92.%9D
M:7)#9GIM+SA!2F989B8C>$$[+TUB<&8O9%1T<U9:=&ER>GIZ26PS9F5F8C)Y
M3V\S='1A5W5L869.1D)A6$UT=6YQ5#-&.'-J:U)S=%-6:%%B*T=+<TXX,7EX
M5V5V-B8C>$$[9&\Y.7).,"MJ,SA5-V%R1F,S,3)74T=/1U=4,652;31E;GEI
M-'160TXY>716-4969GE:93,K=C-E=7@S3C%R3FMM;3-O=')A3U<X=B8C>$$[
M-'!40UE5:U9P0DDT*TIU6$MG1WEK9DUQ<S X:6TW="].974V8SDY9#-D<D99
M86)C4DID>GE80E-386$K4U%Q6D-X2$I957(X<T-S-B8C>$$[>%8K9$9R+W9.
M1B]Q3"MR3V]X+U-08S!(;7$U3D1S5F9D+S5B9BM3-SAR9CES:7<O-FAO.#5A
M6$UU47E027$W1EA9<3AM+TPK2%4T9B8C>$$[>F$X>7AV2EHO56=T-4DQ=&)A
M:$QC4U)V3F5+.%)K=%AV2C%J85)/56HP=#!#;&=Q;F-J1EAR3TMP4C5T,%<Y
M,79Y+V0V6EI8:6%F8R8C>$$[,T%54C-K:T@Q:U(X6$1&;&HU>&9(469#=UE&
M5#A1,T=+<TTQ,WEZ*VE.6#AG1F(V6F\W9E5O3$ID4&HO04AD9VYO-E9D<'IH
M9V(Q2B8C>$$[12]U.6<P<E5"-FYR:7(P:5-33TM.<$I'0U)O0WIU>$%52T)5
M:VLY04U667@U66IL,795<%!.=#!P1G9+:E<O;"M">"]D,EI)3%A&1"8C>$$[
M,&4W2W$S=$=%2%AL:7)*-7!O;UEN;6UD631O=U=K:V-H5E92=5-39&=":7)Z
M>GDQ*UE.>E!F0U(Y36$T:#$V4#E*,F%A92\Q:5=&128C>$$[4T-$:&-+4D=O
M-V9%1V]'-41T56Q74T1Z5'$W.&93.'%A<39T548R8E1O=W!(.'=K=D9E:#EL
M3T)81%A03G(P.5!Y>3!D468Y-DPR,R8C>$$[4V@W5CE,,3EV.#99<6M(;E<O
M.$%/1#9+>39N<#A7;C9"24I&,7$T<TQI4SEU,'1J1DIZ2&\O5E5!:DI#.&Y2
M;5E$.6MF85962&564"8C>$$[3$4Y-V(R,G,K84AU9%(Q3DAD<D='+T5A<F)2
M3$EY=T],94Y5:5=D-&=R3S=,>D1%:C12.$]+<WEX5C)+;TM44F1,:S%"9%)E
M,U9R,28C>$$[3FMN<6512'<Q03,V2&=T4C=9<3AO+TQB4V18<V9Z:C@Q1V54
M5#5,4U%8,'=30F1/93EJ3GIF2DQ#<S P4"MN14UN23A*4GA8-%)U428C>$$[
M2TMV6DU69&ER0V9Z;2\X04IF6&8O36)P9B]D5'1S5EIT:7)!9%0O.&U4<78O
M8D<P<B]Q2S%,1E58:%$W1E9,>6@O>6YN;40O04Q:5R8C>$$[:V8X0552<5="
M3$]-5F9N4F$O-WI29C9I+W%Z<4UF,&HS3D(U<75443=&6#-F*U<S+VMU+TLS
M+V))<U K;V%03U=L>DQK36IY2W5X5B8C>$$[,DMV069Y2C!F>D5N-6MA-7$K
M<C)E<DM,:7IM5T,Y,6%W8E1I+W%836-Z,&A72F]66FY,3S-'97)'<D9$,4-L
M-SEI:#)+<U(X*V8X028C>$$[2%@X:R]W1&)F2"]D3G9S5E9035I0;416;#AQ
M4E9/;GAQ;'HU:FM(,E1!>%!P5V1F-7)G<E8O0TU%2#=A;D956G%N;75Z<S=O
M-E9P8R8C>$$[1&%R<E-Q2V%B86M!4DM2.$Q817 O9'=*+W)F168R5F)&54Y$
M-51U.55L4S8X,C-#86=6265(4C114G P3$MA<5-J9D9C3W O8FPR-R8C>$$[
M<6EN1E5D;T]N,D9R<5=U4U<Q=$9"2DQE2C9R>&]Q32\K:7=T.%)50W9X3W@S
M-VLT<6Y/2W5X5DIF3S,O04-H;78O.$%B3W4O*U1$-"8C>$$[<6Y72W5X5C)+
M=7A6-$(K4E!M2T184'I,,2LW94A36'9(=$I792\P;S-95U1N8WAY4T=/3SEU
M1$EI4$Q)5V9J8D)3,B]+=C)L3#,O1B8C>$$[0T0Q;3)M=71(=G)71T]/86%E
M,VQI:FAN9#0T;EHP2VA:2&I"9%9*3D=+:6](5$98:B]M,WEN-7,P3#AR<DLP
M;G8W3S%S<D\W<W8P;"8C>$$[<$YR15HT-5I:=%AI:T17.7=W=&I"1W)31&I%
M25-&031G.3A693)9<7=(52\O2FLV<B\R>'1++S9I=%-X5D8T54]X5E,X;V8X
M<#4U9R8C>$$[+W=#,E9P2"]!1D5A;&=3>FI&6#4P5W8K.#!8*V]V-G,V:D@Y
M23EZ465A<FLP3WA6.3,O;'0O-4QV>70O,GE,1"]Q1VIZ;'!C>35$228C>$$[
M.&ER<U9D:7)S5F1I<58K6F9-5FPU93!L.5-U,&MM45-1=U)144)$3$Q.8U-R
M1$9';G%.1VQ79'@Y<&=",4IX5C5,*V)(-3 K54Y08B8C>$$[>6ID5W-J6&1Z
M1DQ(<B\Q9%9P-F1T4' Y>$A"-B]E374Q>7 T,$QC4514<%<W2&=L345G8VM%
M;VYY>C5T,$LW,#!26&9N3%,Y1G1B<28C>$$[4G)N53=H3E%S>'%L.5!)45AC
M<TI85S!I24A"155T27%"4GE1:DMK<S P;GIP*U57:U=9<SE..'AA2&$R-$I9
M;VPO83%:;3-:,UEY1B8C>$$[;F1J=7I-4U0S=TMJ4"M6;2]L="\Q3FUJ9CEX
M0S$O-G%9<6=.3B]-;CAU,'9D5EHO3D]K2W-L,')2:S,Y<T%Y:3%G5W$O=DYX
M>55J1B8C>$$[568X03AR3B],8B]Q8DY'+S=I1G(O=T)6359D+WES,SAT=CA!
M<6).1R]W0S1H82\Y5DU64VIZ9BM9,S5E,TAL3%<T25!.1VM3>GDR1B8C>$$[
M,&M54U@Y<WIS-U%S1E9616Q34V5G>%9.+W=$;%IV-6)F.51:;S,O8U%T9BMQ
M;4MU+W=#5FTO;'0O=T)46F\S+T%(14Q8+W%P:7)V*R8C>$$[5FTO;'0O,4YM
M:F8Y>$,Q+S9Q67%J=$DX-&55=&%U5W1D2#%U=S%+-E)$2SA&;F11>GE#345+
M6$MX<WA#9W-"6#-X5DUO8E,P:%EV1"8C>$$[1$A'>F)&:U5+4U!M0FEQ<FER
M<U995"MC,R]K=G)V.$$U:F1,+W=#-FYB67%Z8D97039N+T%/5$HQ6"]T:F%6
M+S%&86QI<4QW;V1I<28C>$$[;#51+S54>GI"+S)Y=$DO-FE.4W=*6GAI<C@V
M3%@O96%,+U58.5=D4FHK:V4U;U!.5GEA2%EQ*S<O=T%T=B]*9"M6=BLR4EEF
M.5$P928C>$$[8W1,;5A)6DAK5F1I<G-69&ER<U915W,V3'!U=&%D2G R<%)'
M83!L2TUY2S=X<T=J8U-2<VMK6E(P6DA537)+=TE)>%8U<BM:=C59928C>$$[
M4F11,69Y5#E:,'!#1'%%5VMU<V)Y4G$Y:D99,TUY44]%6F5A<3!#,')V4V\V
M135:1$Q+24E"-7)4,%5E5W9,9S)';%=D4#A!;4AI+R8C>$$[-7!Y=%<O.$%$
M6&QZ+W$Q5V8O4U!&+WI4:7)V.$YE6% K<E9:+W=$4U!&+WI4:7)$4$HR9R]L
M=5!/2&TS5#E,,"M'92MT<')A9E5#.28C>$$[<D%)251C4FU-45=Z0E%31DYQ
M5VM&2T)Z,7)50E9M9BM'=DQN+U9Q<R]W1'!(:2\U<'A6,RM'=DQN+U9Q<R\X
M07!(:2\U<'A6:D@U;28C>$$[850U2W-V23)R4V%N<#91,E4P471P6G)+0S-7
M9%!R3')#<DDX=G!X2E)P0CAB<T9(56Y&53@P;E102VUQ85A:-FYB851B3&(S
M,$5D>B8C>$$[0W-L=$=J:$IK1')Y57(X3%5B8UEQ:2\X3F584"MR5EHO=T13
M4$8O>E1I<G8X3F584"MR5EHO.$%34$8O>E1I<GHR.3@R*U-T1CAY6"8C>$$[
M979W85!Q14PV1THY179H0F%W5S!62GIA,UAQ:U-V03<Q;V=I5F%U*R]"1T9$
M:7(Q4$9867$W1E=%+VY.+W=#4RMU+RM9,U,O*S9N8B8C>$$[67%Z8D97039N
M+S5-;E9F*S).<%@O559Q5TMO=D-H,DMQ6&Q$+VQ04$U(+V)+,&HO04MI3E-W
M2EIX:7(X-DQ8+T%(;6DO=T)29C%:,28C>$$[1U V4C=M9S@Q6$IO9&ER-W8O
M3&(O=T%L,S57+S=:1F@O=T)1,&5C=$QM6$E:2&M69&ER<U9D:7)S5F1I<D5F
M4&XO2%@X:R\Y=#AF.28C>$$[,#(K>%9L,DMU>%8R2W!*8BM7+TM':&%H<69M
M4T=Y=$Y.=3=U279Q=6]G3$-$2$=8;&535G1K6&1M85(K<F)&:65);W%J8E18
M9$5V8B8C>$$[;')7>C%#,G5B<&95-5%1>E)Y4T0P4W%Y,5935#A":U%.-&-H
M6'%-5E),,VQO;#%&85!01W0Q3W)Y43(W36]K9$EI;VM:54HU345-:28C>$$[
M.&E/;%(T-'%H=&(P5%1.8C R5%1D5&@Y93!L2TUY0C-J64Y'-&M2:VMJ6DA2
M;&11=UI70D)X5EAS3$<P,"MX=')#>FE%1FYA4DI"8B8C>$$[47(Y;$DT,4-)
M;W(R0VEM2W$K2W5X5FDR=69L:C5+,7DO3B]Q3FQ+.31B:C8T6F]R=3=T>C8T
M:&IT>$E046QJ05E244EO.$XK-TY65B8C>$$[;$]+=7A63&9-,"MR46583E9N
M,&50,718:7,W:#E/:4E$8S=L66U-2S!*1F%V45EQ.'@Q>6(X>71E+TPV2%-M
M.'9897 S9'IC<D]D428C>$$[:V4P<W!F4G,Y544P2'(R,#=7:DQ*3&)W2512
M04)Y-D1P:7)+=CA:+VU$+S5B-CDO-VE/;68Y5CA663-D6%@U:U0K86)Z5U(U
M1G5L:28C>$$[=6)'>G,Q:2]31VTX9S%R3F1337A0<C!O=W5G0CAS5E8O=T)*
M9FU.+S%);#,O=T)X1%10*W$K1EAF<$PX>'8X07%23'8O=4EA6B\Q6"8C>$$[
M>%9:;W0Y*UI';F59=%,Q5B]);#-*2&979&QA<$=.43!W37)7:W0Q27I(.2\P
M8C8P2V9,07))4#A:+VU$+W=#5RMV9BLT:G!N+U9F1B8C>$$[6'EX1BM16#4T
M>'AO;BM%-CA60S$O4T9H=E%5+S,Y;35J,FI!04-I=TU&,R]!0V]8.#AF*W!3
M+S=M1F@O,5=W+WEL1'5+4$1D+W=!<28C>$$[1B]02"]Q578K-6A99CE6<V8U
M4V@S1F9$9E-(;%A89GI',&)Y=F\K:U1E46)U5UA48DLR=$I*1C%(5$%R3D)%
M<UI95FXV17)M;4IS="8C>$$[:DI.0SAY96)R-U59-V)5=DM&>G!&;W=9=F93
M,VQJ37%K0V](0T-6,U!)-V)$07)*.%9D:7)S5F1I<D9V>D4Q=EAD3#!/4G1)
M<V(K928C>$$[85)7+S!Z5%E98G%70FQ+.$8Y0U1M-V5R57)Y5T=12G5Z0V<S
M5E-E-4AM-U8W,WE5:S)K>E-X861C5RMO-FYR:$U.=D,W2%1P-'!/3B8C>$$[
M<DQ);#-',W$S02M";U%2,WA6-D1I<G-69&EQ:&8R54XY63-.;$]+=UA55'=Y
M:B]):U5Q,S1(1EAJ568O041J4D9&<#!T=$0U;&YJ=28C>$$[2C)G;&QU9G$T
M8FQ-;VM&>DQX959Q3DYY:EI31%9(:E9G4U)S<7(V=B]W030W4V%L-6EV=%IL
M.'I33CEB;75P;W)74S%6;%0V,TER="8C>$$[>5I*67DW;V]+;RMX5VMD2V5M
M05979&9L<C5'4&MR>38R:F9817963GA*8TDP5G5,5TY"249(<'%N3U9J5&I8
M:WIK:VXU67%Y=D98628C>$$[<3=&6%EQ-T9867$W1EA9<3=&6%EQ-T9867$W
M1EA9<3=&6%EQ-T9867$W1EA9<3=&6%EQ-T9867$W1EA9<3=&6%EQ-T9867$W
M1EA9<28C>$$[-T9867$W1EA9<3=&6%EQ-T9867%O,W-Z=S)C.#!D3V-C8G5N
M259&5E5K5D%)>%9)-R]Z2&57;"],6DQ%.7I*0W%.23A535E58WA51"8C>$$[
M.35C>&XX34MT5V9M835U3&@T2DDR=%=30U,U-5-W25%5:4MH-F5L8WE'=C=W
M9'-664A99FXW1#9!;#%7>45#;$EM171H>'9996-T,28C>$$[.59-9G%'4S,U
M1D-666Q!>3!R43%&0W%Y3%)F>E)T3E<P;38Q4TLS=DER93%L:FDT1W=E85=1
M4WIV8G),2$9B5#-$;%!5:65T44115B8C>$$[<'5+:%9,5G9Z379.4&95-"]4
M<S=H.5 Q1T14;%-+5W)0-G%O>DUY9S%2,3E25D-B:&U:5C5!:SA3<6IQ,S5X
M,D]L86QD5TXS83-3+R8C>$$[5E=D4F1F5C1"1$HV8R\Q9'5$3F5Q,S)W,4%Y
M<5=P4F%S5D1+<&(U;"]02U139DUD-6]T<G!R6&XV3EHT<C8X8T-+351+:4]I
M4D):6B8C>$$[;F5O:RM)<T8T,#<Y;%A.+WIK1&])9&\O<3DP6DEZ86E6:&(R
M-G=G,VE&-#9816PV:TQ,=%1K2#1M=%9*6&9&5599+VYH<$]O-G@K:28C>$$[
M8DM+8S-)=FLP.3)N=#!H54TY>$A">C1T8VU5<E=51V]4=T)O5U=Q<C!F,#E3
M+S,O04$O.&E7+S9Q-$913W4V<&-A3&]M;V%Z9'I),28C>$$[<'!T=$YE6$-X
M=TU836-%6FMC2T1-;TQC5C(S=V=7858U3B\P3E0U3R]W0U=8568K:T]$+T%,
M3'-Z4'E'6'4K,6IX:&U6:"M:,$]O+R8C>$$[-%9M<S5,6F)4>E-,;&]29$@P
M3'%-5S9%:FI"-FIR3'ED94)P24M61D]88D5L17A.1FMG;W9Z9T5E:6%2<60W
M6G945E5U<%0Y5%-/928C>$$[1T-/>F-R2SAK<W,Y<U-!:6QV:%%N66IR4V]6
M4G8O>FMK:C!Q,S%3>'0W95<S;5-6;&EU2EDT-5I$1&-F5FU3,BMR>5AC5356
M:'IF:B8C>$$[2CA+8BLR2V]U>"]-4'IE.7108S9L<$9R67A1,E Q>&9I=E=C
M=$I.3$1!<VMB,C!4=WA-24]B>7EH9E15,5IA5F]&4S=14'IM=CE8,28C>$$[
M=E-.3"MQ,DYT2G%Q=W-S8C-*338K<D5:5T%I031.>$$U9C-G-4E666)S1G=Q
M>4\V."MV1E!P-E)M2T]/.#%'9E1:5&9X4S),<6):1R8C>$$[95-71DII4%=1
M0DLX9U%T3R],-%-Q;$1F;2LX1VE,<6PQ<# P:7109%$K:EIX>'I&571:231Y
M-W1.8U=W<GEM4D=55DMV>4<T6&QI<28C>$$[:G)8-3(R9&@U9D=Q,FQR3&94
M5%AK*VY79&US55-&-VE#2#%V:F8V>31J:DLP<G-853=-;DE5=TML<U@O041K
M3&)1=S-D>'%M;GE7."8C>$$[3G1%<V\K<DE,:5)Q<W%-4%1A5T)G07IJ-#DQ
M+VU+:W%'2V]Y9C@O=DPY=6MR>E$S84-+-U-X22MQ>$TS<5-";59M4F)W=D=H
M0S%(<28C>$$[0E-A-T1:<4MS=CA!2FYM,F)Z6' Y>&8R9D-#1T-C44):558R
M87-%531A<TTX:V1#2FA4:35"1S1.0TU#<VAS<%I*64]5=D5U2&M1;"8C>$$[
M45%$=V1K<E%L=C5F2$969D9867$W1EA9<3=&6%EQ-T953G%F+TA.=2]W1&I$
M2B]X131Q>&970E!$<CDU23%T8U!(36M*:FMH=#5P;"8C>$$[4$931#A584].
M:FA1<#9E9%1B57!B;7AS-798:# K-U=!6$U-<T5B5'4P3%))5VQ64'1&1#!X
M5D173G@K8U8S2D%&6%1,8E1(:FM,,R8C>$$[9#5$2W0Y4FM:8F1H06MH:CE8
M:V]K;%9X1U!I-$%!<6-#5EAY9$XK6D,V+S98;51M,FYY,C!K:3AO-UE+:S9,
M87)X16QU6'%#-U-L928C>$$[9D5N-'1Q24-65V,T<6]8=6XR1B]%<TXY8E)8
M54MU:W%X>F]S:6E33F=Y3T%W235+=W%$,D]+<2M+=7A664E)0D\Q=TDQ13=+
M23)L-"8C>$$[:FU556MQ<&)R449I45!F1E8K2W-E+TU7,'5R,SAV=DTY;F%1
M=F-89'IP3CE$8G=2<5=E4U-3,F154E9'-5IM3D%-;$$Q24LK3"\X028C>$$[
M;%A0-6@O.$%5<F%V+W="248Q+S%4>F]0>FU,*V,P.$)F4VYK84PX>4Y&.&@K
M5'1.,')446LV5TXT,G R=#E%5C1-:WE016IC;F=A3R8C>$$[4G=X5F%T*S!7
M2VYJ;6EZ14=:23<R,$IH8R\X04LV2DQI,VEV;V]Y5V=23# V471K*VY--UAI
M,4E';TUT,U57=DPQ0CEL=6EC5RM,2R8C>$$[:W-Z.&U7:E=N;&UX='I:>#)0
M<'$O1S)I:%,R055Y359D;UEW:7AV27!$=6]555EN1E4V>%8R2W5X5C)+<49L
M<#EH65).1%DR,%9R0R8C>$$[>G9+,&-#3$=P:VM9<S=K2T%/5$UA:SEZ:7%V
M:7%Y84='948T6FM75T=64VMK8F=-<DMW;U992%EG:G%-5EAG0E%!0E%$64%D
M2UEQ:"8C>$$[=% X03=H+RM-,"\O04-E9D955&ER<U9D:7)S5F1I<G-69&EQ
M>68P4%%K.69J-DA%*W(V;$](0VYX8W$W57 Q<FEQ02\U,78O04IC+R8C>$$[
M*U-72W4O-3%V+VQZ+W=#4U=+=2\U,78O04IC+RM35TMU+S4Q=B]L>B]W0U-7
M2W4O-3%V+T%*8R\K4U=+=2\U,78O;'HO=T-35TMU+R8C>$$[-3%V+T%*8R\K
M4U=+=2\U,78O;'HO=T-35TMU+S4Q=B]!2F,O*U-72W4O-3%V+VQZ+W=#4U=+
M=2\U,78O04IC+RM35TMU+S4Q=B]L>B8C>$$[+W=#4U=+=2\U,78O04IC+RM3
M5TMU+S4Q=B]L>B]W0U-72W4O-3%V+T%*8R\K4U=+=2\U,78O;'HO=T-35TMU
M+S4Q=B]!2F,O*U-72R8C>$$[=2\U,78O;'HO=T-35TMU+S4Q=B]!2F,O*U-7
M2W4O-3%V+VQZ+W=#4U=+=2\U,78O04IC+RM35TMU+S4Q=B]L>B]W0U-72W4O
M-3%V+R8C>$$[04IC+RM35TMO-C(K<F5I=C%B:#9'+T0P-F-/=3E/3S-81E94
M1EA9<3=&6"\R43T]/"]X;7!'26UG.FEM86=E/@H@(" @(" @(" @(" @(" \
M+W)D9CIL:3X*(" @(" @(" @(" @/"]R9&8Z06QT/@H@(" @(" @(" \+WAM
M<#I4:'5M8FYA:6QS/@H@(" @(" \+W)D9CI$97-C<FEP=&EO;CX*(" @(" @
M/')D9CI$97-C<FEP=&EO;B!R9&8Z86)O=70](B(*(" @(" @(" @(" @>&UL
M;G,Z<&1F/2)H='1P.B\O;G,N861O8F4N8V]M+W!D9B\Q+C,O(CX*(" @(" @
M(" @/'!D9CI0<F]D=6-E<CY!9&]B92!01$8@;&EB<F%R>2 Q,"XP,3PO<&1F
M.E!R;V1U8V5R/@H@(" @(" \+W)D9CI$97-C<FEP=&EO;CX*(" @(" @/')D
M9CI$97-C<FEP=&EO;B!R9&8Z86)O=70](B(*(" @(" @(" @(" @>&UL;G,Z
M9&,](FAT=' Z+R]P=7)L+F]R9R]D8R]E;&5M96YT<R\Q+C$O(CX*(" @(" @
M(" @/&1C.F9O<FUA=#YA<'!L:6-A=&EO;B]P;W-T<V-R:7!T/"]D8SIF;W)M
M870^"B @(" @(" @(#QD8SIC<F5A=&]R/@H@(" @(" @(" @(" \<F1F.E-E
M<3X*(" @(" @(" @(" @(" @/')D9CIL:3Y-96=A;B!"86QD=VEN/"]R9&8Z
M;&D^"B @(" @(" @(" @(#PO<F1F.E-E<3X*(" @(" @(" @/"]D8SIC<F5A
M=&]R/@H@(" @(" @(" \9&,Z=&ET;&4^"B @(" @(" @(" @(#QR9&8Z06QT
M/@H@(" @(" @(" @(" @(" \<F1F.FQI('AM;#IL86YG/2)X+61E9F%U;'0B
M/F<P,7$T-#PO<F1F.FQI/@H@(" @(" @(" @(" \+W)D9CI!;'0^"B @(" @
M(" @(#PO9&,Z=&ET;&4^"B @(" @(" @(#QD8SID97-C<FEP=&EO;CX*(" @
M(" @(" @(" @/')D9CI!;'0^"B @(" @(" @(" @(" @(#QR9&8Z;&D@>&UL
M.FQA;F<](G@M<F5P86ER(CY&:6QE($YA;64Z(" @(" @(" @(" @(" @,30W
M+F%I)B-X03M5<V5R;F%M93H@(" @(" @(" @(" @(')R,3<V,S8R)B-X03M,
M;V-A;"!4:6UE.B @(" @(" @(" @(" Q-BU*=6PM,C R," Q-CHP,SHP-R8C
M>$$[15-4(%1I;64Z(" @(" @(" @(" @(" Q-BU*=6PM,C R," P-CHS,SHP
M-R8C>$$[4V-R:7!T(%9E<G-I;VXZ(" @(" @(" @,BXV)B-X03M);&QU<W1R
M871O<B!697)S:6]N.B @(" Q-BXP+C F(WA!.T=R87!H:6,@='EP93H@(" @
M(" @(" @07)T=V]R:R8C>$$[)B-X03OB@*(@,R!W:&ET92!T97AT(&-H87)A
M8W1E<G,@8VAA;F=E9"!T;R!K;F]C:V]U="XF(WA!.R8C>$$[5&AE(&9O;&QO
M=VEN9R!F;VYT<R!A<F4@<')E<V5N="!I;B!T:&4@9&]C=6UE;G0Z)B-X03L@
M(" @(" @(" @5&EM97,M0F]L9"8C>$$[(" @(" @(" @(%1I;65S+5)O;6%N
M)B-X03LF(WA!.U1H92!F;VQL;W=I;F<@8V]L;W)S(&%R92!P<F5S96YT(&EN
M('1H92!D;V-U;65N=#HF(WA!.R @(" @(" @("!";&%C:R8C>$$[(" @(" @
M(" @($=R861I96YT)B-X03L@(" @(" @(" @0TU92R8C>$$[)B-X03LM+2TM
M+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM
M+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TF
M(WA!.T9I;&4@3F%M93H@(" @(" @(" @(" @(" Q-#<N86DF(WA!.U5S97)N
M86UE.B @(" @(" @(" @(" @<G(Q-S8S-C(F(WA!.TQO8V%L(%1I;64Z(" @
M(" @(" @(" @(#$V+4IU;"TR,#(P(#$V.C(V.C0P)B-X03M%4U0@5&EM93H@
M(" @(" @(" @(" @(#$V+4IU;"TR,#(P(# V.C4V.C0P)B-X03M38W)I<'0@
M5F5R<VEO;CH@(" @(" @(" R+C8F(WA!.TEL;'5S=')A=&]R(%9E<G-I;VXZ
M(" @(#$V+C N,"8C>$$[1W)A<&AI8R!T>7!E.B @(" @(" @("!"87(@0VAA
M<G0F(WA!.R8C>$$[*BHJ5&AE('!R969L:6=H="!C:&5C:R!I<R!C;VUP;&5T
M92X@4&QE87-E(&5N<W5R92!M86YU86P@8VAE8VMS(&%R92!C;VUP;&5T960@
M<&5R('!R;V-E<W,N*BHJ)B-X03LF(WA!.U1H92!F;VQL;W=I;F<@9F]N=',@
M87)E('!R97-E;G0@:6X@=&AE(&1O8W5M96YT.B8C>$$[(" @(" @(" @(%1I
M;65S+4)O;&0F(WA!.R @(" @(" @("!4:6UE<RU2;VUA;B8C>$$[)B-X03M4
M:&4@9F]L;&]W:6YG(&-O;&]R<R!A<F4@<')E<V5N="!I;B!T:&4@9&]C=6UE
M;G0Z)B-X03L@(" @(" @(" @0FQA8VLF(WA!.R @(" @(" @("!#35E+)B-X
M03LF(WA!.RTM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM
M+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM
M+2TM+2TM+2TM+28C>$$[1FEL92!.86UE.B @(" @(" @(" @(" @(&<P,7$T
M-"YA:28C>$$[57-E<FYA;64Z(" @(" @(" @(" @("!R<C$W-C,V,B8C>$$[
M3&]C86P@5&EM93H@(" @(" @(" @(" @,38M2G5L+3(P,C @,3<Z,#DZ,38F
M(WA!.T535"!4:6UE.B @(" @(" @(" @(" @,38M2G5L+3(P,C @,#<Z,SDZ
M,38F(WA!.U-C<FEP="!697)S:6]N.B @(" @(" @(#(N-B8C>$$[26QL=7-T
M<F%T;W(@5F5R<VEO;CH@(" @,38N,"XP)B-X03M'<F%P:&EC('1Y<&4Z(" @
M(" @(" @($%R='=O<FLF(WA!.R8C>$$[*BHJ5&AE('!R969L:6=H="!C:&5C
M:R!I<R!C;VUP;&5T92X@4&QE87-E(&5N<W5R92!M86YU86P@8VAE8VMS(&%R
M92!C;VUP;&5T960@<&5R('!R;V-E<W,N*BHJ)B-X03LF(WA!.U1H92!F;VQL
M;W=I;F<@9F]N=',@87)E('!R97-E;G0@:6X@=&AE(&1O8W5M96YT.B8C>$$[
M(" @(" @(" @(%1I;65S+4)O;&0F(WA!.R @(" @(" @("!4:6UE<RU2;VUA
M;B8C>$$[)B-X03M4:&4@9F]L;&]W:6YG(&-O;&]R<R!A<F4@<')E<V5N="!I
M;B!T:&4@9&]C=6UE;G0Z)B-X03L@(" @(" @(" @0FQA8VLF(WA!.R @(" @
M(" @("!#35E+)B-X03LF(WA!.RTM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM
M+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM
M+2TM+2TM+2TM+2TM+2TM+2TM+2TM+28C>$$[/"]R9&8Z;&D^"B @(" @(" @
M(" @(#PO<F1F.D%L=#X*(" @(" @(" @/"]D8SID97-C<FEP=&EO;CX*(" @
M(" @/"]R9&8Z1&5S8W)I<'1I;VX^"B @(" @(#QR9&8Z1&5S8W)I<'1I;VX@
M<F1F.F%B;W5T/2(B"B @(" @(" @(" @('AM;&YS.GAM<%109STB:'1T<#HO
M+VYS+F%D;V)E+F-O;2]X87 O,2XP+W0O<&<O(@H@(" @(" @(" @("!X;6QN
M<SIS=$1I;3TB:'1T<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP+W-4>7!E+T1I
M;65N<VEO;G,C(@H@(" @(" @(" @("!X;6QN<SIS=$9N=#TB:'1T<#HO+VYS
M+F%D;V)E+F-O;2]X87 O,2XP+W-4>7!E+T9O;G0C(@H@(" @(" @(" @("!X
M;6QN<SIX;7!'/2)H='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q+C O9R\B/@H@
M(" @(" @(" \>&UP5%!G.DY086=E<SXQ/"]X;7!44&<Z3E!A9V5S/@H@(" @
M(" @(" \>&UP5%!G.DAA<U9I<VEB;&54<F%N<W!A<F5N8WD^1F%L<V4\+WAM
M<%109SI(87-6:7-I8FQE5')A;G-P87)E;F-Y/@H@(" @(" @(" \>&UP5%!G
M.DAA<U9I<VEB;&5/=F5R<')I;G0^5')U93PO>&UP5%!G.DAA<U9I<VEB;&5/
M=F5R<')I;G0^"B @(" @(" @(#QX;7!44&<Z36%X4&%G95-I>F4@<F1F.G!A
M<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" \<W1$:6TZ=SXU-# N
M,# P,# P/"]S=$1I;3IW/@H@(" @(" @(" @(" \<W1$:6TZ:#XW,C N,# P
M,# P/"]S=$1I;3IH/@H@(" @(" @(" @(" \<W1$:6TZ=6YI=#Y0;VEN=',\
M+W-T1&EM.G5N:70^"B @(" @(" @(#PO>&UP5%!G.DUA>%!A9V53:7IE/@H@
M(" @(" @(" \>&UP5%!G.D9O;G1S/@H@(" @(" @(" @(" \<F1F.D)A9SX*
M(" @(" @(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C
M92(^"B @(" @(" @(" @(" @(" @(#QS=$9N=#IF;VYT3F%M93Y!<FEA;$U4
M+4)O;&0\+W-T1FYT.F9O;G1.86UE/@H@(" @(" @(" @(" @(" @(" \<W1&
M;G0Z9F]N=$9A;6EL>3Y!<FEA;"!-5#PO<W1&;G0Z9F]N=$9A;6EL>3X*(" @
M(" @(" @(" @(" @(" @/'-T1FYT.F9O;G1&86-E/D)O;&0\+W-T1FYT.F9O
M;G1&86-E/@H@(" @(" @(" @(" @(" @(" \<W1&;G0Z9F]N=%1Y<&4^5'EP
M92 Q/"]S=$9N=#IF;VYT5'EP93X*(" @(" @(" @(" @(" @(" @/'-T1FYT
M.G9E<G-I;VY3=')I;F<^,# Q+C P,SPO<W1&;G0Z=F5R<VEO;E-T<FEN9SX*
M(" @(" @(" @(" @(" @(" @/'-T1FYT.F-O;7!O<VET93Y&86QS93PO<W1&
M;G0Z8V]M<&]S:71E/@H@(" @(" @(" @(" @(" @(" \<W1&;G0Z9F]N=$9I
M;&5.86UE/F%R:6%B7U\N4$9".R!A<FEA8E]?+E!&33PO<W1&;G0Z9F]N=$9I
M;&5.86UE/@H@(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @
M(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @(" @
M(" @(" @(" @(#QS=$9N=#IF;VYT3F%M93Y!<FEA;$U4/"]S=$9N=#IF;VYT
M3F%M93X*(" @(" @(" @(" @(" @(" @/'-T1FYT.F9O;G1&86UI;'D^07)I
M86P\+W-T1FYT.F9O;G1&86UI;'D^"B @(" @(" @(" @(" @(" @(#QS=$9N
M=#IF;VYT1F%C93Y296=U;&%R/"]S=$9N=#IF;VYT1F%C93X*(" @(" @(" @
M(" @(" @(" @/'-T1FYT.F9O;G14>7!E/D]P96X@5'EP93PO<W1&;G0Z9F]N
M=%1Y<&4^"B @(" @(" @(" @(" @(" @(#QS=$9N=#IV97)S:6]N4W1R:6YG
M/E9E<G-I;VX@-RXP,#PO<W1&;G0Z=F5R<VEO;E-T<FEN9SX*(" @(" @(" @
M(" @(" @(" @/'-T1FYT.F-O;7!O<VET93Y&86QS93PO<W1&;G0Z8V]M<&]S
M:71E/@H@(" @(" @(" @(" @(" @(" \<W1&;G0Z9F]N=$9I;&5.86UE/F%R
M:6%L+G1T9CPO<W1&;G0Z9F]N=$9I;&5.86UE/@H@(" @(" @(" @(" @(" \
M+W)D9CIL:3X*(" @(" @(" @(" @/"]R9&8Z0F%G/@H@(" @(" @(" \+WAM
M<%109SI&;VYT<SX*(" @(" @(" @/'AM<%109SI0;&%T94YA;65S/@H@(" @
M(" @(" @(" \<F1F.E-E<3X*(" @(" @(" @(" @(" @/')D9CIL:3Y#>6%N
M/"]R9&8Z;&D^"B @(" @(" @(" @(" @(#QR9&8Z;&D^36%G96YT83PO<F1F
M.FQI/@H@(" @(" @(" @(" @(" \<F1F.FQI/EEE;&QO=SPO<F1F.FQI/@H@
M(" @(" @(" @(" @(" \<F1F.FQI/D)L86-K/"]R9&8Z;&D^"B @(" @(" @
M(" @(#PO<F1F.E-E<3X*(" @(" @(" @/"]X;7!44&<Z4&QA=&5.86UE<SX*
M(" @(" @(" @/'AM<%109SI3=V%T8VA'<F]U<',^"B @(" @(" @(" @(#QR
M9&8Z4V5Q/@H@(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP87)S951Y<&4]
M(E)E<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @/'AM<$<Z9W)O=7!.86UE
M/D1E9F%U;'0@4W=A=&-H($=R;W5P/"]X;7!'.F=R;W5P3F%M93X*(" @(" @
M(" @(" @(" @(" @/'AM<$<Z9W)O=7!4>7!E/C \+WAM<$<Z9W)O=7!4>7!E
M/@H@(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @/"]R9&8Z
M4V5Q/@H@(" @(" @(" \+WAM<%109SI3=V%T8VA'<F]U<',^"B @(" @(#PO
M<F1F.D1E<V-R:7!T:6]N/@H@(" @(" \<F1F.D1E<V-R:7!T:6]N(')D9CIA
M8F]U=#TB(@H@(" @(" @(" @("!X;6QN<SIX;7!-33TB:'1T<#HO+VYS+F%D
M;V)E+F-O;2]X87 O,2XP+VUM+R(*(" @(" @(" @(" @>&UL;G,Z<W12968]
M(FAT=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"]S5'EP92]297-O=7)C95)E
M9B,B"B @(" @(" @(" @('AM;&YS.G-T179T/2)H='1P.B\O;G,N861O8F4N
M8V]M+WAA<"\Q+C O<U1Y<&4O4F5S;W5R8V5%=F5N=",B/@H@(" @(" @(" \
M>&UP34TZ1&]C=6UE;G1)1#YX;7 N9&ED.D$W-#(X04,Q,3=#.$5!,3$X.#DU
M0T(R-D1#-3E",#(R/"]X;7!-33I$;V-U;65N=$E$/@H@(" @(" @(" \>&UP
M34TZ26YS=&%N8V5)1#YX;7 N:6ED.D$W-#(X04,Q,3=#.$5!,3$X.#DU0T(R
M-D1#-3E",#(R/"]X;7!-33I);G-T86YC94E$/@H@(" @(" @(" \>&UP34TZ
M3W)I9VEN86Q$;V-U;65N=$E$/GAM<"YD:60Z.45&1$-#13<Y1$,V14$Q,3DQ
M,S%&0D(Y.3A&1#<P-S,\+WAM<$U-.D]R:6=I;F%L1&]C=6UE;G1)1#X*(" @
M(" @(" @/'AM<$U-.E)E;F1I=&EO;D-L87-S/F1E9F%U;'0\+WAM<$U-.E)E
M;F1I=&EO;D-L87-S/@H@(" @(" @(" \>&UP34TZ1&5R:79E9$9R;VT@<F1F
M.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" \<W12968Z:6YS
M=&%N8V5)1#YX;7 N:6ED.D$V-#(X04,Q,3=#.$5!,3$X.#DU0T(R-D1#-3E"
M,#(R/"]S=%)E9CII;G-T86YC94E$/@H@(" @(" @(" @(" \<W12968Z9&]C
M=6UE;G1)1#YX;7 N9&ED.D$V-#(X04,Q,3=#.$5!,3$X.#DU0T(R-D1#-3E"
M,#(R/"]S=%)E9CID;V-U;65N=$E$/@H@(" @(" @(" @(" \<W12968Z;W)I
M9VEN86Q$;V-U;65N=$E$/GAM<"YD:60Z.45&1$-#13<Y1$,V14$Q,3DQ,S%&
M0D(Y.3A&1#<P-S,\+W-T4F5F.F]R:6=I;F%L1&]C=6UE;G1)1#X*(" @(" @
M(" @(" @/'-T4F5F.G)E;F1I=&EO;D-L87-S/F1E9F%U;'0\+W-T4F5F.G)E
M;F1I=&EO;D-L87-S/@H@(" @(" @(" \+WAM<$U-.D1E<FEV961&<F]M/@H@
M(" @(" @(" \>&UP34TZ2&ES=&]R>3X*(" @(" @(" @(" @/')D9CI397$^
M"B @(" @(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R
M8V4B/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z86-T:6]N/G-A=F5D/"]S
M=$5V=#IA8W1I;VX^"B @(" @(" @(" @(" @(" @(#QS=$5V=#II;G-T86YC
M94E$/GAM<"YI:60Z.45&1$-#13<Y1$,V14$Q,3DQ,S%&0D(Y.3A&1#<P-S,\
M+W-T179T.FEN<W1A;F-E240^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IW
M:&5N/C(P,C M,#<M,394,34Z,#DZ-#0K,#4Z,S \+W-T179T.G=H96X^"B @
M(" @(" @(" @(" @(" @(#QS=$5V=#IS;V9T=V%R94%G96YT/D%D;V)E($EL
M;'5S=')A=&]R($-3-B H5VEN9&]W<RD\+W-T179T.G-O9G1W87)E06=E;G0^
M"B @(" @(" @(" @(" @(" @(#QS=$5V=#IC:&%N9V5D/B\\+W-T179T.F-H
M86YG960^"B @(" @(" @(" @(" @(#PO<F1F.FQI/@H@(" @(" @(" @(" @
M(" \<F1F.FQI(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @
M(" @(" @(" @/'-T179T.F%C=&EO;CYS879E9#PO<W1%=G0Z86-T:6]N/@H@
M(" @(" @(" @(" @(" @(" \<W1%=G0Z:6YS=&%N8V5)1#YX;7 N:6ED.D$W
M-#(X04,Q,3=#.$5!,3$X.#DU0T(R-D1#-3E",#(R/"]S=$5V=#II;G-T86YC
M94E$/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z=VAE;CXR,#(P+3 W+3$W
M5#$U.C4T.C4W*S U.C,P/"]S=$5V=#IW:&5N/@H@(" @(" @(" @(" @(" @
M(" \<W1%=G0Z<V]F='=A<F5!9V5N=#Y!9&]B92!);&QU<W1R871O<B!#4S8@
M*%=I;F1O=W,I/"]S=$5V=#IS;V9T=V%R94%G96YT/@H@(" @(" @(" @(" @
M(" @(" \<W1%=G0Z8VAA;F=E9#XO/"]S=$5V=#IC:&%N9V5D/@H@(" @(" @
M(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @/"]R9&8Z4V5Q/@H@(" @
M(" @(" \+WAM<$U-.DAI<W1O<GD^"B @(" @(#PO<F1F.D1E<V-R:7!T:6]N
M/@H@(" \+W)D9CI21$8^"CPO>#IX;7!M971A/@H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"CP_>'!A8VME="!E;F0](G<B/S[_VP!#  $! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0'_VP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" $@ <H# 1$  A$!
M Q$!_\0 'P !  (" P$! 0$           @)!PH$!08+ P$"_\0 51    8#
M   ! P\'"04&! <  @,$!08'  $("1$4> H2$Q46%Q@X.5=8E[?5UADA-768
MMK@:(B,Q-W1WL[0D,D%YEB535%59E3,T0M@V47%VLM39_\0 ' $! 0$  @,!
M              $" P0%!@@'_\0 4Q$  @$! P<&!PT%!P,"!P    $"$0,A
M,00%$D%1<;$R87*!D? &$R*ALL'1!Q0S-#4V4G-UDK.TM15"TM/A%A<C5&*3
ME5-6\2159)2BI,+4U?_:  P# 0 "$0,1 #\ W^, 8 P!@%6/BIW3U;1-9U#-
MN>)#7T+AAW0G/41N63OB-0_6,K8;&Z%J*N4D-KM@7LJ^'I$DE;99)-S.7OZL
MUT96EO3-<49A.[_J410:BDZUK6DFMET9._K2HNW8X=2/MOJ=%W8L5H[1"11;
M+XGM7>'$+FD4'@HVESB$\Y0/M]UNI5.!Q\5H!G*2=G$.+2F12E)# 0UM4-JN
M/JS]J',X6BT<+W'2K7#RJ4V4:VU>DTKC.MY^.MQSSI,;)B%IU_UNR%55.7RO
MY3-0\US05<">6*4&P\:UIG"@Q*Q.3"[/999+ \%J )GDI8@,1^OVL) (11;P
MH]=-*->RM?,7/8,C & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@#
M & 01\2Y\Z"BG$714RYML6-51.X+4EHSUTG3Y&UTH>6B)PBLYE*G(JO4*=V:
M4""P71R:&9I8I&_"<F>,)EKF_B8WIQ;FUN/&HTTE5555=UZRCKK_ +)ZNB;"
MQS"&WY8$*7<W>%AQCV+'XPSCCQC;T)<]O7VVUQ.$EK$O# YKYM''6/LR:*)H
M\A6MHD4CFQSV2=[:G-OK'>G?OO+%*BN3K)IUU42:=U^MOGH6S==>*@Q\>V'+
M(/)>%/$DN./PN+HI>_75SYS"EL.BDK*>R[?G0X5CKK"C*$G<60EG^ZLQ8D2I
M&0U*J\X4B)(&=H(PTE72BM5&Z/AK)P\W7S#^HJ$J3HFOVZ2-$)N:",%@Q=KF
M"-L;Y2@99&B N1)7Y$RO$@:4KH449H*HEO>W1( S6]$K3P^0>QEJC:>IM=AF
MS!!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8!C.V:=K:](D3!;6B
MZ>7Q1/*H3-B6=4N=6\H$IKF7,T[A;MI0S+VU;LUBED?9W@E.)3M&J-1 3."=
M6B-/3&A6F'.NU4?F,2*^)N6UW2"?K=54+*=T$F,2JRYV)VE&DXWE!$U$#;Y6
MIA87T,!63ENA"M1#V^>JXL?,T$8,VQ)'TEL"!*$6KI2MSU>?B5T>J-?D=^K?
MUMSG_%%2^#5GRUNEZ++OL&!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# &
M , 8 P!@# //RR*1N=Q630>9,C=)8A,H^\Q251QW3 6-+_&Y$W*6A\9'1(;K
M9:IN=6Q8J0K4QFM@/3'FE#UL(MZP#!LTXZY6L9WJ!^GG/U42]YH).U(J:<Y!
M#&9S65T@8C&Q0R-T;.5)C!)6UG6,K.X-;:9[*A;W1K;W1(G)<4:=26+5JJ3:
M3Q5<=^TXO;/Q,^N/1COO[*I7@1Q6]<2//@]_);\%^C'5O[O)L%GRY=*7%ED6
M#(P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P"D'U1K\COU;^M
MN<_XHJ7P;L^6MTO19=]@P, 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!
M@# & , 8 P!@$8^V?B9]<>C'??V52O!8XK>N)'GP>_DM^"_1CJW]WDV"SY<N
ME+BRR+!D8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8!2#ZHU^
M1WZM_6W.?\45+X-V?+6Z7HLN^P8& , 8 P!@# & , 8 P!@# & , 8 P!@#
M& , 8 P!@# & , 8 P",?;/Q,^N/1COO[*I7@L<5O7$CSX/?R6_!?HQU;^[R
M;!9\N72EQ99%@R, 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & ,
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M+F:E3ED&.#AM$F1(]K5HP;4JMI$:1-L\PS9"8@KUA0!DYV , 8 P!@# & ,
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M!VS\3/KCT8[[^RJ5X+'%;UQ(\^#W\EOP7Z,=6_N\FP6?+ETI<6618,C & ,
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M[7#V7YM_N^R?TOKO78+U+'G[,<//SD_,$& , @!:'>\;+G#[1W*5?O?8?0[
MIVV2>)UN[(&FIJ@<A:\NOA!W\X$K('6)I -&G&PU![L+<6%E?]D5JX ,":$:
MT;JNY:JXO<M>_#GK1/R+3PK,+Z=&Z<^(I9;;T$I1+DSQ'^7H,@=(IQE 5Z0X
M"E -P@3BI.D/0\A;#0[V&67LM=V'9^]KHU6$)-]:4%W[[1I4Y*ISXR[<%U*O
M.R3?6#<WHN0>E&I$A1I&Q%S?<2%&W)4Q"= D1):RD1*9&F1E  G(2IB2RRB$
MY18"B2P ++ $(0ZT)'%;UQ,_,A8"F5H**  LHMK0%EEEAT !8 )"0@   =:"
M$ 0ZT$(0ZUH.M:UK6M:P0[3 & , 8!QEIYJ5&K5$(E+D>F3'GDMR(:,M8O-)
M*&86B2#<5:!O I5##H@@:Y<B1A-,!M4K3$:&< "#,4EUS%=(6!9#AR'?;7%)
M[4] ULB5JY=R@<I9G2NYYT,_21W?$39TTX* L);;;D<-1F,X'EX5F('PH+,
MQ,WZ<QJZF*Q;UZZ<W,3OP9-2WJKA3K.0=PV+<Z#PLHAU>T"[VAG1S;<<EO+F
M*/.-D\[Q3EUDJ9#SDOC]COYTC111OM)M;;'3(Y&A,8].4;1B#&!GB2N@97F?
MF]IRQDM&CDUY+5$GRG*M;N:[=58%X7A3TQ://W"M355<E:$4W/6.6]!O*NJD
MDDBDN1U_')UTE;L_@,512"#N+K%%R)H@$HC"5&!E6;3(4H"F\:9 H2'($U,2
M:<JK8N:]))W;RHKLSGSOWJOJ[K:.T/8[^^P*GY>WR>![A?6*FN-06[Y#S=S_
M  NA(6]09G6HG>%$<^2F8V_V'."507&/W8TNL5BY9*R0&#9,&DTDJK%-.[%5
M;='6]M4C75?A2KV@$X3@$$@4&Z// 46$\\)>B0G'! '1AH2M"%HK1@]"'HO0
MA:!K?K="WK7EV.,_7 & 4@^J-?D=^K?UMSG_ !14O@W9\M;I>BR[[!@8 P!@
M# & , 8 P!@$6^Y/B4]@^BWT#]DTMP6.*WKB?)&;?T<@_N27_(+S[TS'\BYG
M^R\W_E+$]9M/A+3IR])G-SRA@8 P!@&[;ZDM_L7[6_QIK3[.#,^/O=9^?6=_
MJLV?IF2'G\C^*V.Z?XMH;<>?G!V1@# & , 8!&WHOG^%W:TI5TWM*YZN:8E%
MI^@6.U3W7+:92E-$M;FH#V^R)RC+FV%'+8RD80K8V_.!P38B-0\+4!Z;:]6,
M0J=-FK%)X=[]I@'ANC.:Z\42>=\[=<W'U&V2MA0(U2J>]E2?JF)M;<ED3^V$
M.L=*=97)FEB5*I!&9-'U#NWB*,6+(X]LHS1'LZ\A.+)MTJDJ;(I;,>^LP-XK
M5G=FU*WU"U\-QQ]<IU<!UU1AR00"(0R1/SE9[[6;;!:@F$V"_E&K6BMZT6/B
M^QY=.DJ14E9G*NJ^8Y6?J)NRMM7A%+7S<UVOKU==;Z$D_#N;;Q!0A)G1ZFP9
M3/HM9%TP> V'=T6CD:O&5THU6,O0P=[GZ&/(&](@6R5 R(G).$A&WC?8ZCBC
M^ZI3'-0-2,)4K=2C2;2K1/KO[LGM@R, C'VS\3/KCT8[[^RJ5X+'%;UQ(\^#
MW\EOP7Z,=6_N\FP6?+ETI<6618,C & , 8!&@7QQ2_1H.^U(C )+X!$;H3M:
MEN>GUIKI:;)K5ON4HAKH/S92C&*PKQEJ70M TZZB:%2G20V(ECWOSVP[(=X9
M7K8$LW;A*4XP:+$*DW?J6+>"_KS8D>_@_P#6G87^W]A3@_G&C5WD&5Q[S;.G
M $PE+8/\VV[HWJ%A"S2)U(6IS#4[S7%":A,6T 8F]UL6Q&W8_9!:I8*KVO#7
M@O6^Q$_JOJFLZ3@[%6E0P*)5I7\93:2,4/A+"W1R/MI6]^N-$G;6M.F3^<JC
M=B4+5A@!K%ZH9JM:>>I-,-&(VVZN]L]_@A'GKKXJ'3WH\W3]FTEP6.*WKB9U
M9_T2U_JY%_IBL$.QP!@# & <9:I\S1JUGFZE7YHF/4^:HBM'K%/L!0S?-TA.
MQ T<I.]9[&05L8-&&B #8@^7RZ BXS=8L;W.EM<IJ:Z%3RIJ:8?('I&NK8I,
M0R1Z=O$K8HR^N2S;^-.6W+W*#RXH0B!J%"<#$L-/3E@&EVH%H^;M7M)68(5$
M^)AW#:O*UC\SUO7MO<5\]-=ULMW/S]<':RZ7&PU,KJK=7%M,(BS'"IQ!'';Y
M(R[ <G11('EUU'&]+' M)II3Z^L*-S&HQK5TDZ4NCSUOK1TILHV^IDW>.[/D
M5R\Y5U9,LMB@+Q?Y)[KO/[1Y<"\!HJ4>T\ZD["E]PP7^4S1VU[2HFM-'9-YW
M)G+RS!ID&R/,TVR6]*(U1M4:YGCUW+@:PGB/69SS#>\^O)HYPNP6ER@[%'A6
MTNC/B*W!SA8=LRFO*.I*:MC7 *>AJ]N8D$?.J>8EQRNG9><M/M&XVA\C+&U)
MC3G%V,=Z'(JZ,4DG6M*P3I>\6\+U7"Y7O"_</(-T>22>$!A>CBBS=%G%B*.!
MHP&AZ :4+R"+,#K?K3"Q:T( M;#O\^MX.(_7 & 4@^J-?D=^K?UMSG_%%2^#
M=GRUNEZ++OL&!@# & , 8 P!@# & 1;[D^)3V#Z+?0/V32W!8XK>N)\D9M_1
MR#^Y)?\ (+S[TS'\BYG^R\W_ )2Q/6;3X2TZ<O29S<\H8& , 8!NV^I+?[%^
MUO\ &FM/LX,SX^]UGY]9W^JS9^F9(>?R/XK8[I_BVAMQY^<'9& , 8 P!@$&
MO$O8H!)>"^I&>TYP[5M7QU5NRJ4SIGA#K99L9;6Q6A=/;)SKUE*-<YM%PJ$1
M!4RBZ?V$+W$C7MO4*T28\Y80\Q8XK7?MIY]7#;<4-^$%>_.E6],2%OM"]8XG
MN&UDJFHZPK^N>(>E>9JM;TMT]"7/TU'VJ42>UXN%!M\D$OLB30^B8\Z+(^RL
M<(CY<2C*V5O;FM6*!R34FJTNVN47@DM7,EV]L^?&M>HA#T/,UBE3/J>(7563
ME>D^K-3R<*G6J8HX1'ZU3'WK*9G*KD9G5F:Z]B\'&E$[,;6!>ZRIW=6-"DC#
M^M2H3F<2SO;7DT=%Y5<:W4HTZM_U)W>'U+ARFAG9 OM&\[:D]>7+<U43>1]&
M(("WVFAF-<3UVC#RQN8:R9V6%JF5+M"G715>TI!&*XXY-ICF,MU\]1I1B6-:
M)52=%6GGKU\Y.+!#"EX]%TKS8QQ"1W=/FN M4_LB%5#"C%Z1W<EDGLBPW4+/
M$8HS-3"W.KJM7N:S9AIYQ2+:%H:TC@^/2MN96UP<$PJ3>&QOJ2JSQW;/Q,^N
M/1COO[*I7@1Q6]<2//@]_);\%^C'5O[O)L%GRY=*7%ED6#(P!@# .O=G5M8F
MMR?'E<F;&=F;UCJZN2TX"=&WMK<G,5KERL\S>BR4R1*2:H/.'O0"RBQC%O00
M[W@&GV=ZJ"YS+[0W-@<\6>=S>5$#:H]]TN2M'NQ-9-S,#W[YI50C9 J=QS99
M?G);,.:@E0F46E^V@#MY8[GNG]W_ (4?L#^TGO&/[.][^_-'QUG[[]Y:/C/?
MGO>NEXCQ?^+CXWQ7^+XOQ?E'#[XL/&^(\8E::2A@]#3;IH.6J2?DNZFE=6J+
MR6R3=J=SMK>[0DQVX)Y6DJ%(Y-LU6E1>5]HV]%7,@"A*X1-C'N35CS1'WYL5
M!4-S[)/?,M?2<9*@N+5PZ^Q*"O2^_?SG8NB[_*:K57T[4TWU47.R8W/?*]%\
MO,3JSTY!T[(XRA:%WGL[>G!TE]I6=(?6BT;)K/LZ5+'><SY_.$,T6G"3/C@)
M& S:1M+1(0%)2Q&V_9J6XD+@@P!@$:>I8S=M@51/ZOJ&)U8]ZLRM+#@CJ^61
M:<MK[<95RR-K(\VKV]LC%,6G[I$Y/MFI6+BE+C&C"O-"$Z?:KSPP]$*J)INM
MS3P_JC)%8++;4-BE/;$+KF'*T(&],S KRT)-9B=R( G&!:>YGR2H*D,9S2C"
MR-)4Z5,^ 5 --&:I1B( 6H!TU5ZU3ULR=@@P!@# & 1CBGQS+[]&/D?[5>V<
M%U+>^$23F"%;/2W%/15^/>W%@[B6ULU))G+GZ/L+AR/RM<1,<BLCCE<M3=!&
MQPM:!R!P B8'V'RB4;?MFZ?GY3/E#4]JE37%(L0A&DXK&*?6UK=]SW+JWDM.
M<*IE5(4K#JPFMEZM^3Q?4C]L[&#6U?U+J0^W4J?9"BWJNZK9V&",'M0WNR1C
M\C"TI/;;;9M[<_9WES<%)PCO=RHMBKZZLT];OZC.LBU.L;)M?OCP3'.6U!+F
MYIJ6Y3^85%D]*5U'&VKX0\I5G**5]EKFX/\ (H\_KG9>0R*W>XB4%S[E[:WO
M+4G(*A\<'*E=%*%I1J]:5(N]TK=@^?1HK^=[NB0?LB1*9[*)1Z].2/V<96R!
MG>N+"+V49&P@V2(SR^O$5L -E[%L&PA];Y-#A.1@# *0?5&OR._5OZVYS_BB
MI?!NSY:W2]%EWV# P!@# & , 8 P!@# (M]R?$I[!]%OH'[)I;@L<5O7$^2,
MV_HY!_<DO^07GWIF/Y%S/]EYO_*6)ZS:?"6G3EZ3.;GE# P!@# -VWU);_8O
MVM_C36GV<&9\?>ZS\^L[_59L_3,D//Y'\5L=T_Q;0VX\_.#LC & , 8 P"$O
MB/:J??#O2&KO568BK7W #]NE5,HR'"V2'/VZ:?<@.NF]9O3:OF&II[GM,2)Z
M$%@5K]DIY ,#*8O&%W[T*L5ACKPZ^;;S%2W&_+MC]0W2"U>M7'Q*R[*KB8<[
M6&CFG45,\Q<_P:;Q#G25S^<553K3$J$EDP2JMM5KS9/:DT>G5"@?7E7&&1O1
MN36D4/:9P&W))7:-*.Y.=S:2;>E2KI=LO/8^+XBLRZ[RYYY@=.*N;^G:=E"*
MPY0SN$W[)<^;+;W*VN$*BI S1IYCK8W2^!(6YF6!42 QI.L%@LJ//"=D?&R.
M^UXE."0HDY:33PNBI*CVU=/93<3M\*=E-BO*.X8;"J*K/4+N6[(R"M*#L5ZM
M]AK[S&P7<T^*3JUI"(;S8]N(%BE2;8TS<1!5OSXI$N4$I3C3$I DG5UO>%[2
M3PV*Y+8MA9+@R4#^*]P#VUU!:\ N"B9;2<Q8JT>N>B*UJ.R(D_&NU:OD>Z)@
M5E6A<+#(]6O!(H:K<FJ(1Q/,DRML<)@ZUE$': 5RMC[W,W98\#<912==*K4D
MZ-4:<6DL-KY[[VGJR)XF?'G4%D5KTG<D8\0^YZ>@+7S9.5CYSO!X' UU</HH
MI5;T9*D'MN_@5RE(W3P:186XZ\\.5-Z=P,"E/&84$>PC)*BT4VWB\5NW$DO!
M[^2WX+]&.K?W>38)/ERZ4N++(L&1@# & 8JO5UK)CI2W'6ZGE#'J@15K-C;0
M?'-4-$A:X#N..)<L5J%1>A'$@*8QK=AVG 8I$/UH$Q1IXBRQ L50^?W0GJ<_
MJBZK)KV,/4ZA%24E8L&!<"-PFHW\[H&.T0Z2TUCC+;**V0QC43;+I<XN:T.+
MK'AS;;!'%C@>G<7/;FVJ6/?ZJO=7SNO!;^SGO')?&K-_[*6<_&6FG[R\3[V7
M_IM'1]\K)_(\?X[1T_\ %=CI7'6>16*RAVZG)TM':>+I5:==*JG6KAIX*E=&
MZJ/H90F(,=?0R(P*,)S$D;A$88(A'DIIHCS4S'&FI(S-*<P\?D&<82@1)RQF
MBUH1@@[&+\^]Y^5'9/3X P!@# & , 8 P!@# & 1CBGQS+[]&/D?[5>V<%U+
M>^$23F"&O;X[ONC0?!=DB*S*62,D?<9\Z):0MWL^(\;"F%@-$KI20Q2WF%?.
M9#'(E;9-4,S++H@\PF1K!MK/[\C;)"4BUP3I4PAR0UT3;NO4=*ESN>RNU5:I
M<B=GA2RYF>>08;%0W]4%ZS"'OD_52@JH>@VGIALJ=FG5E3:;5K3KI:J)T<W6
M4J*PKQX8*^2O[]LA2]$Q0:E%[.W%ISA#,N4[FL,51X7NFJKO*5>Y9STM1_>%
MZ-M(4(ZLS[,1(7+G:,5QX?T+M2"7O.2*PIIUC%DV->Y<.5N0I,_62@L"EI\!
MTF,+14_6K$TSTHAR=S4+P>-))Q3;5%RO*=4FVM%+"CQNO=:51MED;.$22)0
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M8;$@7&C;VEW?4B4#RN'&Z:O.J>MF5L BQ8O9%&UCU!SUQY(7U>HO;I9!8#U
M8NS(2G MKCM<0V235WD<U5;6$"CC,[(HD_-46/$G5GR!];'%&B3;3-3PM;Q5
M%M.6I4J][HBNCU1K\COU;^MN<_XHJ7P:L^6MTO19=]@P, 8 P!@%:W,XM;\1
MOQ/0_P#'35P\+?\ ^@JAG>M?_P =X+J6]\(EE."# & , BWW)\2GL'T6^@?L
MFEN"QQ6]<3Y(S;^CD']R2_Y!>?>F8_D7,_V7F_\ *6)ZS:?"6G3EZ3.;GE#
MP!@# -VWU);_ &+]K?XTUI]G!F?'WNL_/K._U6;/TS)#S^1_%;'=/\6T-N//
MS@[(P!@# & , J^\6KM"H^0N2[&!.I-3":?VI!)I'ZIK^]F)=*X#92A 4RHI
MHVO,11IC2Y@WLT=DH7%7$%*A)J5&#21\H8QN6PZ&HJK6-SU.CYKWAACJ(K^$
M?-Z=L*Z^BIS!>O.*>G[ G46B#_9*KF7C\[G">^SI' ]"V2"QY2LE\D<)@B&
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MA.#)%ON3XE/8/HM] _9-+<%CBMZXGR1FW]'(/[DE_P @O/O3,?R+F?[+S?\
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MIDP7&3S&62-P>)9,9&L*(3ISGV4/;NZB2)4B/SO25(G)*!MO$D'@@P!@# &
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MK;6E<:5OIM)>8(, 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & ,
M8 P#C+42-R1JVYQ2)7!O7ICT2Y M3E*D:U&J*&0I2*TIX#"%*9228,D\@X R
MCBAC+, ( MZV!7K>/AC\]WG<L/OA7+.@ZDL.OZ_65C"EO.]YS:B6^,P]U?7"
M22!O9FZNU3,4@,E#PX#52A2G$6=(/-&PIS$H);$0"1I3:5+G?6]5OI3@6#G-
MS>H,V:H0HSS=ZUK9AR8@TS>@Z\FM;&, A;UK7YM:WO\ -K\VL&3DEEEE "64
M !98 Z" LL(0  '7YM!" .M!"'6OZM:UK6O^& ?[P!@# & , 8 P!@# & ,
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M^^< >_Y1?STU-]8T/^^< >_Y1?STU-]8T/\ OG 'O^47\]-3?6-#_OG 'O\
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MA",YJ34I:*44FZTK5UDBGK^4S7W]!?B?_P!JF?\ _8SW_P#N.S__ .[YG_\
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M2WHLZ-LOY*FJ&5*([6 [ ?HW8:!A=KTCCQ =6S XS''A)74S9G62UPJ?SBY
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22JJ7OU$R,$& , 8 P!@# /_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>g947560g01v78.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g947560g01v78.jpg
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M%A<B6'&2F-/8\",D,CAX@;&X&"4S-T)U=\$90[*W"B8U8K2U\33_Q  = 0$
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MYW8GV6+8<;BH63TE+50X!C649ID^X> XS/C>-718]1>Y3"!&UL8A3X%2[23
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M:R$*,<VTH733$BQAN.J8I:X<"GKY<]V8UM6I(-F])NT;=@D%3H45%11^T0B
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M(%K.-&PRJUVCQ#:P\&_J[!N-MP[)]G=\,^GIQFC>*5,N*#V<)=62R-%5-@!
M.96 .7AYDXY@B/.>F;INXR^.7:_AWM\YR3,-_P!^=;J;E<)^P6VN5<7?"GL-
MM!MAMCD'$CN6'A=MN_6LV4S0VSW IL$JRIC":?+#<?K$L#<2692H#[(1JH
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MC@M%C,\F?P81A.SVZ8UE#N-F&^..LP\:RR^OR::VI;H4;-NX8]0QT(\LBHJ
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MM+5V7U.G<VXGO$]Z3O S]D@IC!)R,F"(%:[IO9^_N=-UBTO0#I^M6%Y:+LE
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M0GSC@16V>T3_ !E]M>TVGL6'931+?L*VXD"\N_>D:QJ+L$2=-=92A.G[H_\
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M@.%K):P_8.S.CC6M1;963W#:@IY&1N3,;"I,%(5U"@KD".6.U2]-E;+=1&\
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MK(:VR)MS>*$(0;99$?9@5U9'#65U?V_0- M-&LPEESO+X#Q.8+CJAC:I0\4
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MWO1W&MB= ML\<5S"1MZ]G^I6.G:NI-ZIM"KEA3#+SB02%K<:(0%$R K:28Z
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M6.5 4H6WCH(^A'*F/$VN<VJO<Y4C)F$5KHW)REH54C(/(3RB.'GF<_'/45L
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M)2EH[H_82  00>!SYJ..E=D.V*W+EG2M5?<*'# N5J*W$%!B-RB3M,C@3R@
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M'G$QST_]!W:'E[B/=E**AM.02?(\L_/SJ\F7\ 6[@FU^39/CVY1,N:P8M>6
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M:+:ZAJ6HI-G:*<NU%:K1AD.WD@N+9=4TCO'2Z4AU87)4IM)4H*2!4EQ3-3:
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M7=M"- [LZ&AS4<Y"8.AS%C)J,F)"$B88V6/=]'UN_.G+M/&\$N(0VI(G8WM
MSQ..D]#SBO3G^%;V%:+[2.V]YVI[365\KL[V%81JC-HVPI5GKNN+7L1I3ZB
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M:JBKB;.PG5/)4C%$CFE5$Y_IN1O2Q%5SG-;YZE>O+=MM)2$K1X825AH!6X0
M-O$85.)Q^'8NTWM$[)=A;=J\[2:OI^B6*AO2]>O,MAP$PEIMIP_K5.$I0 D&
M-X->B+T:GHEZ_/L=O,KXI=LB8#K(J%,9HKJQL!)P*5HJ]N897U!HO<CR2".S
M8/83/-A9 V9L0<BJK]=U+4'TKFW>1!)W%)W@RK<4YS$B1' #I%?+S_$)_B:[
M0]INU2['V9]JKO2.S;:5K>N["S]V=5<I62EZTN=PW#(0E*2D%"G%9"9.#GI
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M(R5TI\&<VCLZQ^Y)?(1WZDLHH:Y]3(5(Z5\4^(&A.QT4-%Z1,>9C2P,BBF=
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M4!PW'C%=]"4)PB=H "21!V@ #^7^]5;J6HU;7=_"UW!VOW!PR'NK"LHPO)J
M28QCY!AR[:F- %(G9&K9'1#3D,F=V;FRM1G5$YDB-<E:W=##[+RIV-.H<5'1
M"@HD#K"9'F!5)YI3K;C:%%*W6UM @Q.])2 ?(DP9D03(/"M*>&WPHVWLX-D'
MW&Z$-M*VW!)=#//76],>556];,3 KX2GU]B$4"I0SWBE+!VPLCQI(GN](VSH
MO_<KUE<M/6S*FP 8.Y"03P(&9D8/'G%>:;]MRP?O;1Y$$7;J5G&()@GAF1$Y
M',<JKK@F"O+'B(M<@QYD\-)28R_&,MG8V6,6SN;(JJOZ(":-J+&3+C-/,<=W
MF5O(5F7L&"(ZBK:!.?>T^YM5WMM:IW>\L-)4O[.V%Y(!!*@8,Y2!!&,B>D^S
M2WOA8OW3NSW9UQ:6C*BHJ20)(*$IP005!2L\.8&[S7*:ZE32E-*4TI32E-*4
MTI32E-*4TI32E-*4TI32E-*4TI32E-*4TI32E-*4TI32E-*4TI32E:)_290Y
MS8[[8=#1'IB\%?M:-/4%I5!$PY9*1EEJ[) 3YS@YWDCX]&+C"L$K2*\VI7(2
MR2"%;=@]UZ9[/6$._I ]YM="0$)B21LF>.)/AX&9Q!%:WKRTA")3)*"H<> /
MRY@F#$\<36$6U65;A[<[J[>YOG5G4D8=C&4.L<AL*ZHG'L*RK.J;*DG/)<RP
M*@GI:I+-AUJR.J?8QUX\Q3#97AR13['VLTS4+S24(:4E\M)"W&$H 4E($@[B
M>D\!U&36.TU]M+Z3,*4@)*.<$D3/V8/2.6>=>IZBL1K2J -$ECG')%AFCFBD
M;(R1KXVN1S7-56N1W/GS:Y4]CE3ESX@2@**4G )2)!'V3$9YCA6YH^R)XQUF
M/(^?QS4WTJ:K>[G[EXCM/AEYFN:VHE32T]::4YY)@HDU@5 ).0-352%30M-N
MK-T*BU=?$Y2#2Y(H(&/>]$U488=NWDVS+9<<<*4 #CXR$S@' F2> YU(XXEI
M"G%& D%4GR$Q\3&!SKRVY3M/6;AY+=9YE%1)%+DF19)E$M%WDL^AQF?*[P^_
M+HJ$<J24, $)]@@?( 81IL8L)4[.N61%]":/IPLM(L[99'?-A!+1X%4@0K,Y
MR3)('(UH-[=..O/+CPF8F23)Y& !QX@&<^59\>C>IJS$]],RJ:MB 1G81BT@
MPP[N41@M=;9*TZ4EB.5>T$FL 8A.IK8VQ&$]@CG*3T:![1047EJAM#*6BV2O
MNVX4%;1M.^>9&<9'SK/Z#WA8<6<"1 CJ8\L\(SQ,<ZM'Z5+.=\^%7B2O"]DI
MLK/G]*;P[@<%N BUQ5J16;>\9-3G5/B&V&Y?5VKA,79+LQN[G]L2:&T=DY.S
MX99RO>.Q).;5LR(($_LF3P^SS\SF('F>N->F4X[L-M'Z2+BPV7W9WHX4*+#-
MD#>!; L&%XO^)_B*VPSZ?$\>X/MD!;JSVVI]M<WI,=R.QN"A9+?(['*X3)#\
MP.9.;/*PXY\JH^+:D@*R%$D)!!.Y7$\08C/2(X5W<1^^>#[9V_$SN/OF+GVX
M7I(\'X\LZ'V_VL'XOMXN'3?&FV J<ZKY^&8#@^VXH=OMU<1W0V[S3!6U ]U5
M0[>.K<H&O<UL,OR"2_B%C@?W_?Q_O- )@" F "=H(!B#)/,$R.@(@ 5GSPB<
M.^<;R^D4XV]ZKC#=L<SP;9STA^24D&99EO=Q&4>ZN#OQC9S9S+Z6DV]VQQ*9
M-EKW&0;V]!M&Q9C/!*23:Y(.:&0$+60D*@H@)2!(E(.(CB>/.M8GHS(=W=K[
MST5^[>641V#5V\.V>]V587N;A^_6\.9G<;VY];AN>5>/\(N\=/NID^/;);-9
MUE!#1,TP.Q-K[['\@+Q(,+'<GJLB@LD!5,OBOG!B(^R)'BD9(&1'*>=;H^-F
MYW^SHOT8^]V=)O+PNS%^D.X<]O\ )^$HC,]J[^F-GM\YS9OY6[@YKM4=E$.8
MNL,=HZF3'<5K\X7%*@6V,)R"B.R=!GT;Z?WY5((\0$'PD@YGA\8^D^=;W-*D
MII2FE*:4II2FE*:4II2L6^,K;S+-T>'K/,.PAC",D-BHSPZYQ,87C4%!DU+D
M!U$PV=\0XTMP'5S@P/*F@!>1-%#93PUTI4L=[I;S-IJ-I=/MJ=2RXF4I7L.2
M!NG:LX,*(VDF(&<TF".G'T'3G_[K0%B>& Y5A#<F%*D28B)I(\$K7-E;!*QL
MD230<TZ']+D21CU58W]3%_T477=5:BG>R&D]XEYOO$*"C&1P&".!P>0$P:N4
M[%A1VQ /.>7^X_E\)OIP4;O[C;;[UXYM_CAT9V%9M:WA^88J:*(^"O:)0S1R
M9-2F1-@L1+!US!CU>2/,3859##R)%JQB2);:'3.V>DV"&T732=ERY"U%(F05
M *"N0)3N(C.,XP*2@G:2" 1!'',D><\,_"<9KT4Q/26*.1$5$D8UZ(OKY.1%
M3GZ_@5-<PZ^1(^1@U3&0#UJV.]N1Y1B&TFY&4X2&+8Y=CV#Y3<XV":QTHI5U
M6TQ9M;'/"V<5\[%+@A11V$COG54A;-$K^MM1E <?8;482XZE"L22%$#'PF3Q
MQB,T&2!U(_G_ 'Y]*\Z-:'=;P'Y1NKN%DYV17^1RC&%VYD%>"I:AU8=:%&-7
MU8=9758(=:&**."'7#,18YC"&SG&%F$]TL&6-&89M+!K:'$(6\LDDE:A!XRH
MXC!/ 8P*NFVP!),\\CACSQ &>''\:IW:O#KK+][=O,<Q<;O1]/F%-EY!CI'#
MQ5^/XM?5,EO)V[&+(^>T&.6B@"C<U#V6A32Y(:Z(Z5MGVLNVV=)-JI)"[TF%
M%7V-H*C(CQ!1!($@IB3/ T;@[0D ?:'#C$XG@>$_'F.%>H^FB?!4UT,B<I(A
M(&/1$Y?IM8B.\O+EY\_7Y^WSUQ11DD^<?+$_C$BJ0&W$@QS'.O,QA06[DG'Q
M7>B9(L,[7;3:7C+RKTD3LR\5N^ZE<&9-0'N3MCLU)9SD]XM<?@XOLZ,P2QJR
M2Y(2,9PJ4"6"8")\9T*JF(WP,C;B!XN!,3PVY^)&*P']&KF(9>V).2[9;J\(
M.4<<OYH^-6;9/#UXC=_\DXR[7>H+%]](=NZ^VV3R/,2]E3)FBC!RM _)J2&+
M"H@KF*..VC<9&J*@9X';X?V?#!C]J?[X5=?8'>WAWQK=/A1I>&^3/]S-X-TN
M%/=H7BPSP?C)WKO=Y<?W9CX?LXR'=,GC)X8<SP++JJO9BNXV/5XV(Y(9N'MR
M?59YD#1J&HDQVDKX+%2%9!$ $$"!!R!X3B>/F(R<Q5&4NP6YVW/H,]P.)>VQ
MC;G',IW9X3N%Q,8W3PCB!XF\DW4S&'.=Y]C[F^(W-I,W(CP?";*]:-6SV9NV
M;S"!2);.NKYVU,\D9:HDCO(S 4J1 Y3P^O&LX>">WWWX5>*?C;V]K.'R^.W:
MQ7"]B4Q;@%VFXBKW*,"SW;HZWRV0_C1VOWAXPL_QBOL@"S;(/:_,\:I:W$2\
M=L\>  OZHZ[+%F14I$A)Y$F51&8'A(',1(,YG' U&[;[R</NX_II*G$=J-_\
MFQ/=+;?--SK#B2"W0XAK2[N]W<^R79^QH!."K939BON/R,-VPX>#*R?/LPRM
M^/R046;XG)48S<75M)<W82A"@C($$""!Y\28P>74@Y%>F#2J=-*4TI32E-*4
MTI32E<.7DG/Z/VJJ(G^[FJ<]#P/.H$P/D.D3SK0%Q44E/F'$AO.$ZO=:"RW&
M*A'0GPH0DMR#M_B8YJ"0.8UK*M@+:J.%DZ=<MA':F->X0H5&]Z]F[91H3MP\
MEG]:_*0M()0D)((*CQDF< <0(G-<1[>N-_IQE#:G@&K<A>U9 6M2@H*  ,1$
M1DDYJQ.U^,XQL7O#@6X3!$J,=I+_ +ME%?,00+5UE9DBLJBLG&":[PT4JGF4
M,NSM>ZQSKC\=S"XSIG>Q][VYTC])Z(\]8M)6];_K TR/_- !4F9A"N$PD\<)
MQ-678G6AI^M(1=N%#5T2TI3RLM \%G'B!X?LQD[N5>EK';RJR2DK;ND/"LZN
MR$@+!/KC!SPBAYF(^*<8P2688B"5BI)%-#+)'(QS7,<K51=>>UH6VHH<24K$
M;DGBE1 )!\Q,5WEM:7$A2#*3(2>H!(D?*IUJ2IZH;<//\9VUPW(,URX]E=04
M%;*:<0C'DSR*]S1Q @0X&23V%E9F3#5]77"LE*LK$H8$6*0B>-CIF6EW;Z+-
M@;[AY26T-Q/_ )#M"C_E$DF8$ R15-YY%LRY=.D)8927%K)C"1N@8R3$#S/"
MO+I-9;ZNG(<)#BHT5A+869#+:MLK2UGL[8PJR,)LS:_(*VN)LB"BWN-DKPX@
M"CGD$Q=C#.R ;U%I-C>VNEZ=;J>8:++33#@#"BH!($E/B!'"8.>5>;M5O-.N
M]0OW@T\[N=<?0X7P$C<3X5 ),G)R"$DQRP-G_HLIL@C9NZ#E$@EM:IFL1T^0
M!B0APS%$XI003TJP0HL+2*$0*N'5XO9L[J2+"8D]O!:&E\5]H3:&>T5P%7 N
M'5M-D*""@)2.6W<O.#F8,&.0KL/8=P+[/6@0CN4!U8*"=Q69D*F$C C !\X/
M#<+Z_7K1:W2O+SL<'N[8<:V,>BNMK'/%VYX%N)W?'CBLLQ(M;OIRKAHNZ6KS
M3@VV[,RR8I9\G\+WAWWRFIOZ$N4@5:O8D47L.[CI!6JJ& G= \20F/\ ,#XC
MY<!$?>\C6O#T;.:SD<(Q>4;%;J\)V8<=Q'!9Q '[3XQA_$7Q!YSQKG;NC;>9
M:4"ZTV9RW+[3::;*P:D0^PB K\;E[$H6FF$@1SB7Z5,L'=D$)W#]D  3R(\O
MQZU>S"=[N&?&LTH<3X.YLVS^UW+]'IQ1E;][K4'&;O/G&>TF=4'#+E&;WE[Q
MD<.N;8)DE?A^>@[FT$.-X/E$NZ.#9&%EN37(<=&^K$J:.9_?/_>H0?V@ )$2
M!PG@#T@YY5]W?#EN;MEZ%PC>6SP[:W&,NWUVZ]&;%C&;8'Q$<4F09CN&!N1O
M_P /=EE#MXF9O(VHV]L,JCMJEU]/M&RP6%]ME( ,CJR"NA-5$&5@=-Q@@1(2
M8C'\ZS"X#LJW]X7]Z^/+;^CX=,KRS>#%LIV%J ^ ';+B&*NL,H-LGXYG93>,
M7:G>+C W%QT7+L0W6L":K$<DIL<#Q*VQF\QNNJLIQE]O&D@<,Y^D?U_&I#!"
M<XSF,SB4P.G'CF9GE5?;>9[M>/Z:/"*_8[=?.LV/S8/B]Q3B?VYGS_>"PW#P
M+<C&1,7R&F/WIVRW!2+#<5X9L7&I0L-X:+[",=HAKG)LK@+QK*LVQ.WE>/'^
MO]_W^$T,[<P!B,#/4 QQYG->B;2I*:4II2FE*:4II2FE*:4II2FE*:4II2FE
M*:4II2FE*:4II2FE*U5>D4VVNTM,-WI%EC,QJGKZW ,I EDG0JG3(,M$%Q^[
MJ8FP3030G7-U%69+&^4.5H\5)8,EGBK)H4W?L1JK=AJ/NZTI)NU!M*E$^&1R
M B3($3@B1'7!:Y;%U@.)!44^ I Q"C.['.8_#/$5A1DV)5$=$+9U;XY.<;4(
M9R:])/T$5[7-55\N?4U4>U4YIR<UR?HKU2T?=6Z^RZF4[BC/%2!&WR@21^!S
M6LK2EK:MI2MP1!7S''$8B#\ZRT]&_F!\=]N+M^3DA<E14-QZ?&\2LK,TY]8!
M(!*\VWIFV<\\T%&87-'3L KW)65Y]&0K((23IG$<I[=6%M97X4Q;AE!(.Y((
M!4I"5'=PR5%1R8@P.$UL^B/%ZWA;A6XF9!,S*E1S/*/D),XK;NB<D1.?/DB)
MS]OSZTKC6<K5WZ2E]#*/LB(XV5<L9E.2$AU:1LF$3$WT"#9#<&+(YC0B!;Q<
M1KZXN%9CY&V5B)"))7S6YM;N_8%IY6KNK0TVXA#)*BY/A,C:4Q$J W0.HF>1
MP^M$>Z;-Y05JC<GC!\R(@F,2"8Z21A'DMO5BXR%5"11.E[%B/Z4:G-ZL3J5?
M+U+S57*JJO+X%Y(FNK6K5PJ^=6ZM123,$ A Y$0<Q$08GRFM244I9"0=Q0!!
M."KEGD,R8&8,]9RV]&]@E>:W--S)V]M:6&2V5+ 2KWN0>JQ2=U$/5C>?1$,/
M:BVQ<D;$:KSRBI)>J1W)G(NV5V]<:FXVI:5H:)22"9)R1CAP _#E6Y:2WW5H
MF 2'0%$G!3!!@",C$&>N,5MI<QCE:KFM<K'=35<U%5KD141S>:+TN1%5.:<E
MY*J<_/6GUDZZGC#2.5\@\#WKRYO?%&YR\D1$YN<U57DB(B<U\D1$^#2E</#$
MD)A,D%'D+&9)&.4^")Q,$<W+MF0SN:LL3)>EO:-8YK7]*=2+R32E=S6M:KE:
MUK5>[J<K41%<[DB=3N2>;N2(G->:\D1/@TI7SV42-8Q(X^F-R.C;T-Z6.;SZ
M7,3ER:Y.:\E:B*G->7KTI7TYK7<NIK7=+D<WJ1%Z7)ZG)S1>3D^!4\T^!=*5
M]:4II2FE*:4II2FE*:4II2OEZ(K7(J=2*U45.2+S3EZN2HJ+S]BHO[-/A2O,
M5O=BV0<*^Y.48;DTK:C$C[:P.P6]LY8P:3(,9L2B2ZP,(\GNX3KVC&:^LO:E
MDG?1GB1V\@\-9;5<A?8NS6KV.H65O;N;&;BV;#22,SM@;E;B2),$&8X@Y$54
M;7&(^U()Y_+F1, \(Y\S:3 <HBGW*VNR'&;D%;&3<W$DJ[*OL85C<R:\@BOA
MHB!)7H4TJ@;="%!]3XS!UF$D8U'R.UD.TZ;5W1[F%LK=0ED)*3+J1WJ)X\B,
M'\<DU.O9L\*I.('6"/Y?$UZNZ">0BFK9I4Y/D$A<Y.2MY+T(G+I5$5O+ER5K
MN;FKS:YSE17+PY0A1'0G_P!?APJW'GY_*?\ >!6'OI#BK,/A.W,GK+)]6USL
M.%N)VDL$;/C!VX&)@Y57SRO?&BBV>/$65<8/VB*8(5.&UDKR&QNR.C)97JMB
MEX$I[T*@3G;! _$P/(2K@#4Z1)^&1\>G\Z\^$^Z-+CE:N/F9-0TBL8LBPGVX
M $[().IR3=B01$_H5$562(C8U:Q/-7=;U[R5V96IXJ*0$@D;<8'49@B!PZ\0
M *N"M(3D<(D2. R.O3A\8K95Z-W:3(++,+K=^WKBP*,JOBHL9B.'E@*-"'-E
M*M+QT<O2Z$*S*:%%5))%',2)7+8)U#'"HWEW;#56K^Y0AE8+=L $;2<J4F%;
MAF"#Q@\_(U:K7WVU4Q!G&08Y"1PG_>:W>HG)$3V:T02!GSYSSZTKCH9U]?2W
MKZ>CKZ4Z^A%54;U<N?2BJJ]//ES55Y<]1I74T89CD>P>!CTYJCVQ1M<BJBHJ
MHY&HJ<T547S\T54TI7S&&)#,21"*-$08L:ESQP1,F*6)G9Q*3*UJ/G6./]"-
M97.Z&?HMY)Y:4KN[.-6)$L;%C1$1(^AO0B-Y*B(SET\D5$5$Y<DY)R]6E*YZ
M&=?:=#>T1O0C^E.M&*O-6]7+JZ>?GT\^7/SY<]*5UH..C^U2"%)>:N[1(F(_
MJ=SZG=:-ZN:\UYKSYKS7GZ]*5W:4II2FE*:4II2FE*:4KY>WK14YJG[/VHO_
M +<M 8,CC4")$?#^=:C^,FGJL$XCMOLK$ CC;GV#9%+E)#8UC98V.%VN)5M*
M7,UG*"4Z"KOYPB"9(W%35PM4-+(X:L"CAZE[.'+E]%_8%\EIILOM() 4MQ6"
MB.@$JE(F3G%<O]H[+#+=G>H8/?+<##JP"4I:&=Y('V@3!"L$<!X<8V;ES5Y9
MH]C7O8U9/)R-<U/-S4<U/T?5YKR5R)Y=7E\&NLZ6'PWL<3XBTHJ;424%S@9Y
MD"/E7(+DM]X3O("7T!#J<*#8/A(C$J)//E'&MD7H^B8I.'/$QF$R2%ANM([X
M&5(HUJ<IEN;$G*Z^*"%$CC"&R&>P96]DCH):SN<PTY$#V32>:M;9>9U.]2^E
M*'?>7=Z$R4IR"@ D D;"GB!SQ7J'2UL.:?9.6ZE*:5;-;5+ "E0D!9($C*]Q
MQ,XR>-9QZQ-7]:7.*>S/S_B6N,$FS$RZQ+%Z7!36X]7W!K<8QF_D==%EUEU2
M"&I3%9@(P>HR9I-J+/;55=D&-RP-$8T64CK?LYLK<Z?=:I<V:%727"FTN%@[
MG6XXIF1*%#]G$ \ZY)[1M0N+>YM=/9O%BV<0/>;=! 2VLG$QGQ)()GARQ$V+
MW2"QG$Q93!YXX ZT2<NQG5>:QBA#/(*(?ZN:11Q.?_X>?ES<WR>G4K2[=+#K
MUT/ VDKSP2!)P1PF!G\1QKECEJEU]ME@G>XI*(F222!DQ(Q/Q@=*V">C[V_R
M;%L,R+)<CKGT\F<9!-D@=+,YCYZ8,JJK 8@IWP/D$0XF2MDNK6$1\@PUI;&#
M1SFNADM+'SMVIU%C5-5?O6P-SBE-P)*4I:.""9)*I@SRKT;V<TQS3-/M[19_
M\" Y/[2BZ (5F !RB9C\:V)ZUNMAKYZ&(Y7HUO6Y$:YW2G4YJ<^35=RYJB<U
MY(J\DYKR]>E*ZV##1N1\8\$;TY\G,BC:Y.:<EY.:U%3FGDOGYII2OB((."0F
M6$0:&4UZ2&21011R%R-8D;7DO8Q'3O;&B,1TJO<C$1J+T^6E*[ECC5B1JQBL
M;T\F*UJL3H5%9R;RY)TJB*WDGZ*HG+ER32E<]#.OM.AO:=/1U]*=?1SZNCJY
M=73U>?3SY<_/ESTI76T8=D\I3!X6$SLBBG);%&V>:.!7K#'+,C4DD9"LLBQ,
M>Y6QK(]6(G6[FI7=I2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE
M*:4II2K8;R[;@[M[9YCMY8$D 19+33!C68K87E5-I"^,VFN!8IV/@E*I[84*
MS&B(9(-),*QD\<D3GM=7M+A=G=6]VV 5L.H< 4)!"5!1!&,$ CB.)YQ4JD)<
M!;7]E22"8X&#!DXXGZ9D5YS-RL@O]B;TK;K=JNM*?(!E>^!U?36UO37=4TB8
M,?(:(T&$URU1SAY',%.>VT E_P F;!VC&OF[MH^N66JMH?"2+@#:ZVD@92/M
M;8YR.! _G6D7^GW%FXL.N-EE:RI"@!P5T)4>0C^R3</@JW0Q6ZXJ,/&H+<B:
M5^WN:),KZRUK6)WS(-N)H@Y9+(0)ZD20"E$>'L1[D8/(21%&X>-6Z]V[<1=V
MS.QDGNU>):@#PGF,& 0 ?YQC)=GVPV\^E3B0=LM@XXI21N!(.3QP28SCCZ/(
MG-?'&]KD<U[&.:Y/4YKFHJ.3YE1>::Y'$8X1B.E;/D8/'G'">=:@_2CWM503
M;)6X@4UYDD<V<!$4U837LM5Q$@2E,-MFC&3#*1"'D-;CXD,CR(AX/$"W)VA"
MPL7>^P+[[.INE""II36Q1"5*A2L08(P1)/D,U@=?:0JW:45D*2XDP% 2@$%1
M'.0)'E/")K4UAN6;H;HYWBV!5>'"XU%EU@;7#WA5D3>6U17AU1]B5;2440 (
M;9H>[C!(OBY8(M@:(KY2TEA'(Z!KVMO:9I[EPTE(==<4TE2V_!' 1*Y/R$\2
M!DUK^G6J+NXV*W=T%<0HDP/,",'\ ( XUZ9^'39ZJV:VYHL7K870M&"B1Z/>
MLLTDK^J4@DJ=W^(4:81)(8:7-_CEESS$S_XLK]<,NGE/W#SRE*4IYPN+DR-Q
M^Z.*0)X$GC6]MH#3:6D3L0,3D_B>?_N9J_NK>IZ:4II2FE*:4II2FE*:4II2
MFE*:4II2FE*:4IJ!P#\#2M77I4X,.-V7Q&GOZ<NQR"ZW!J4PXR!8(Q*@ZL#L
M3+XBTEF:]LPQN)+>U8X#(Y9R33("(G!('+9A;-V/MW7M:9"%([I*>]N&UB2M
M*2)C*><?(\>%1&2!YCX?W_*M#X6WE)57M=E%(QE-D=/9U]W4W PXTI(=M53Q
M% $N:1!-$0V.>%K9828YH9QU?#/&Z"18T[%>Z:Q>6SML&D-]X  I$I5((4!)
M) D@!1F8F(P*JI;22 9Y\QR!_GR^L5Z2.#7BI#W^QB:@M:=<=S["*N@'R8"-
M[)JFP6PA+A%O,>G;))(M38DU-HR( Y![.L<*Z F&8=P=@;P_6M(N-)N%MNP
M25(YG;QDC^1B#Y$$"FL!*B!PF!/'K'_L#I6OKCQXK)=Y"LDX?,4KYP, QC+;
MB@W&LK <"0S.,APK(1Q8Z2H@<XR:LQFER6FL)+$R9 K2^.K0HAF0T#24R#:N
MRO9A;I8U2[4.ZD*82D@$#BHKF<_8*1P29DDP!%&">'GGA.?AP_$&.&:U32;9
MX51K$451(M0+9UUED( /=:XH^@'L1I\A#$GEC0>(LZG88/&^7N[7*Y(DL*R6
M6*R#Z!K%NM.FWCELI/>-VZG&R1N!($1QR.?'J9Q(BXD*3Z>9R9@_[9KUW[15
MM&#@>/24,21AEUXY+'+$D,KVS1MD8DL?)%8YK'-_0_\ #ZO+S37 %!>XE9E2
MO$2, E63M'(3RY1^-6[8 3'0G)XYJYFI:J4TI32E-*4TI32E-*4TI32E-*4T
MI32E-*4TI32E8T\4&Q0.^6"L C);4Y9BY+[_  S(%&[WX7;QC3CSP$B-G$D.
MJ;<*6>KMZ]A8SR1"5E')$/%",'RNC:N]HNH,7C*B"E8"DY*% G@M((W>4D<^
M4UC-6TMK5[-RR=2DI=(E4#O$\I0J/"2,$].$'-><.NW-W2##%(RO;MIZ+ R(
MZ/'[&4&VK+-BN@L*HJBO>444M89%,&=VF0P$CDQ2P('*L*OF],V=U=75O;7+
M=L%I>9+DMD97MW$ '(!\,8,YZ8\YW]C96EY>6J[@MJM[H,@+\0#04 A2N *Q
M*MQD1  !,&MWGHTRA;#8"OM8Y$98V5QD9EZ%VS)I0[XF_L2;<*9&-8K7UYDL
M@$<;HXG0C#C1K%&QK&IYJ[0.W*]7O?>V%L/+N%J*53P@ <>9$'B>,5Z*T7W=
M.EVC=L\E]I#"-BT" 005*QU"RI/Q&>M;$GRQQM1\CD8BI\/[.?+R^%-8:LI.
M 3CR_P!J\R.:;U8#B>Z&\:S9"^(J+>K>MTD,=-?&%2M)W0RHYA8\ %:1,8'/
M 5"X,P)A A$70V*5TC98V>BNR+UJWV:TAA]02YW12 EO:3)41NQDD$23!\L"
MO/O:VRN7>T.K+;25L%U"E=XX%;=H2/"2 E(.V9@"3DC,3G;P"RXG<E%Q?"8S
MK2@,-CASC)":JRK@ZRCCD'DL*$*.S%$G-O+T.22O;V,214HDY%F40TR&MK[&
MP[6=K+.PLW],M"%W3S:D$D!24S$SD01G/^]9#LAV3N+N[9U*YE-JRXEQ,':I
M<"8D@[ID3RQ->C3$:1F/8]553&="BAPQ2IS1><K6HDCU7X5<[FODKN2?"J>>
MN!J5*XQQ4J8R=Q),?+G\.5=SR3).8 _!(@=>0Z_@*J74:4TI32E-*4TI32E-
M*4TI32E-*4TI32E-*4TI32E-*4TI32E-*4TI32E-*4TI32E-*4TI3^_9_P -
M0@3/.(_"E:?_ $ET8)^;[,5!6,!QR#5&89"/F$SW/-LA8G5M/:X8/ U4C6N&
M*L\>R.UD/[9SBXJ**KB8U;F371O9VUOU&X<+^W8V &2$P>>^")SD#,?:YE,:
MWV@2"RV.Z*P%%4A2A!Q@PH8P"<?=@\:UR-QX$(P&YJHR:.\J3(K.DR&J5HES
M468_E!8UAKFJL9#&*L4C)6R#EAOG!,A(#)G@DZC>V#&IV[MK<)1N.] 5E)R3
M!\$2F.1Y_*M=8?=96'N[*28(,JD$ "1F.0X@XGJ2=UG!WQ$9GN]@>3P96/6V
M65X-;'T#+"K';55^1('2U%J$1W60DQ B^TM5J;3I(:*AE>47!"'#*@0O ^T&
MEITG4G[5MX+;;;20GC"H.[Q95!(YGB0.I.\::\NXM4N.'Q$!68F" 0,8YXZX
MC'#4J^YSS>[)3\WSDZ6VS.T#'#N4F"AJQL;CJ9BXW8;74T#6>$@XS9DVM<X
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M).Q4<.4 9D"N1'SCU%[XS).R'J:!+>0.FZ'64"OYUV[3<'4&WE(/=N-=TWC
M5*%S(@_92>49(@YFQ<)W3U4 <<H/+^^HK&RZ*P+).(+>_+*-19,++W'RL^@1
MDD10)Q,I20WU[7DQNDB+!R3*!KO)P"(U2&06Y@>.YX\D2LVC1&[QK0+5I4H*
MI5! "ML)V[CDX!',9!G-7#03&1$B>)Y3_/CY=#5L/!*;<;=[!<+1$CH\QS$*
MEM$5R10$5H05G>6($KE1Z)#;"4\U0]&-269IRPPOBD>V:.XUU]VST1U:%E*G
M$%"E84.[(@I(4"!XC@@!0B)BI;@!#14,'>,SQ@#EP&08XYY&,^H'$ZJ*EQVJ
MKH>71 )#RZ>:(JN8USE3FJKYJJ^M55?6J\^>N)D@DQPY9G^?G5ND>$<I )^)
M%5%J%34TI32E-*4TI32E-*4TI32E-*4TI32E-*4TI32E6GWV#RX_9G=4/ B3
MALT(V[S&+%9:PAHEDF0OQ^Q2G;7F.E@4,R8]8(AS6SCR!RN85%/#)"R1M5@L
MBYMB^D+80^TM]!*@%LA8*TDIA0D Y24D<S5"Y[XV[XMU%%PIEQ-NL '8^4D(
M5"@4F#! 4E0,01!SY_\ ':MES1"G4 BF4Q <%A#.Y)7O(A.B0QI9#BU[X\HS
MME**E-53""9I2"G=M*_EZPLWK,6MFM@]TTMAM5NA*E0EM21M&2=T3$DJ/(F>
M/EJ[-P;J^1=N;[@7+J;E:FT K<2K*B$I2$ST2$CF!FKV<,6?9;MWOOB-'BY9
M,E/N5:6:9SBS8H2A)!:7&2NRS&)B,0ROL0;(?&,=)+B(4 P:T% +%:;-7'C<
MU]HVCZ<JW;OTNI8N HD)!&ZY4, 9)Y @;0#/D#73/9QJM\[?JTY>ZXM#:J*2
M4I";:"3N!0D$P3/B40 >9 %91<:.^NY%;D[-F,7L),7I++"ZB^O\BKXR8LKN
M(+ZVO:]U3CEP,:/^3PL<%!(+8V8HA%N2VQD;6F44HT916J=ANR]KV@+M[?+"
M;>V=4TJR*BDN;3!4I:5)<"8S*5 >5;)VR[3W&A):L[1LK?N&TN)O0$J2@'(A
M"@ILG&04GD08-:XB\ JP(@FDT(H<,(\< D,0L<48P\2=,44,3&(R-L;?^S:U
MG)O->E/->?>V4VP8#%NVTAMM!;; 0CP C;X?#/XD\1D\ZX8N[>?=<?<<<6M:
MBMPJ6KQPJ8VC DC 3 $QB16SKT:U)CXFSS>[T\,%S5WV3T]K;QMZF9#:U>06
M5?;9(WK;'*/+<6,!4YH+F.@KC^]5X!)]8*#8%>9.T;2F=6U$*>[]7O2T!9VD
MI;&4I$ #',@2>=>DNSZT.Z3IJD,]RGW5"BD;B"O@3*B3Q)P3UQ%;+=:] F>8
MK.TU&E-*4TI32E-*4TI32E-*4TI32E-*4TI32E-*4TI32E-*4TI32E-*4TI3
M2E-*4TI32E-*4TI6!OI"\8I[78I^3%Q0-NL)R_"[#'RUAZBXR+W)*W$[("&9
MLD:QQ6E->GPSME<X7KB'(G9UBC3#Y_LM<W%MKUB&%*"7EEMP)44A8C 6 1N'
MD9$_&K'40DVJR4@D9!(!CS&"1PDQ](FM:TCL?NL0BCB9#$>+%TNY(B2+(UO)
M55[D1R.1R=//DU>;?-/@7MI%PS>@E.Y"U YRF" 9 X<XX<3\M)<6ONP"I49@
M$F!Q@03&<8R(YU<CA%XB\&X?UW&I-R""*\ Z2TS'$"XH$)=D!*UXRV6$5?2Y
MJ29;-;,F+HJ@A\,EX/:.;6/G=4VC1><=L^S]T]JHNK9)4=1/<I3PV.!2H4#R
MX'<09$23FMAT2]9%NM*W#(44D$D@%) (&3$$0 /@,@U8K$\Q\-3*;P\>,6ZS
M'(\JS&T%CF4J,2WS7(;+*[44<A(XDEAAL[<R.)Z1QL<UK7,B9$K&ZWVTTA3%
MCIUF8)9;&X@ 9B58Y<9(\SG!C$E\&\4^<I6"E*#E*3P20GA()$'D1)S4TV?L
MVR<1>T5@8R*9EED5_7*/(YJ*QT^)7]BPZ%K%1\L\'A"A+"]CX5'LRIG=,T$+
MF8GMPT4:+;@3"+@2 <03B8Y"/GRYFIH.;]Y1,E15$D3&23/'RCA,\XKT6C*U
M1X%8G)JPQJU/8G0G)-<45,F>,F?C-;K7?J%*:4II2FE*:4II2FE*:4II2FE*
M:4II2FE*:4II2K.[^;50[U[29KMI-9S4SLFK1XA+6"-9W5]G6V8-W4F2#)+
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M*;M3D]6F0YL#2U-CC$U77%05-Y4VXTT->9:2=O8^$J%85MJ'8QD'.*)&K_$
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M4; GC*1^UCB1-9C1].N ZF[ 4IM8[Q)+:A*5@*!F3 @\8)Z"!66O&+L>7?Y
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MU*]]0RW:UJK+8. AZ9745ZI9HV_K4G=TY?&>O+K54=EM<42!8KQPR(5'$)/
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M2M*BF?M 2#G;B83 !XP"3,R,)B:ZX+BKKLI=*6>V"26Q#D@?')"K&,%S/"[
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MLM8LZK:K0D 3A(]ZS0G$8\<#% Z+HZFRS%9&J=$J,DE8 >R-\SQ'/AARXGA
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MG&-K"R;1(Q)D#A#LNZE/?*.> 0/_ ("-(@/ GA=)&<,K[E-PRI(4'40H2)4
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M7(!$<4LA0JLEVI/E$\,2?$/C&#Y=1B A< G<<)P)$"6R28(D@<3G@K\()+,
M*T1QTQSXIK8(4B1H93N85;F.)7Q934FAA"DG)%$R8N<2";O321E'FBBFLZ2
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MUC;EO*$0=EI;V4Q8Z22]!K;W<(V'L27S.5G_ '6!%MZDD63O<;V=M#_B.E4
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MAQK<A(DJG=VG%#KLI>DLCPX!"RC28Z>A= 352.26%A3)(VCRCDL_3,9_'@.
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M O;$ 80>64D+N%8=+#-W:1+&D;VW22E)&T'B)R(/'/GR/^]05IU["I8D$3Q
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MEL[,A'W\-<#: S.9!20U,@,*FAR"@11PE>8B.DC>U)IT?'-!37?(4!"(B=W
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MO+9>[*QG=TBZ?/6%NN;2KO'("2J=RYP)D<@<<0?@1)K;4VEH -MK;I/("W9
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M(/Q03_M4-S@X+.>/CX_Q4Y)[$^CV(J)]"*J?L54^'3:C[@_<_I4=[GWU?_\
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M-0T?3+&_[\H:*[BV$(>:(!* I)R4I$*!,#(X36X]D+>V;UC3-1O;NQMV&G'
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MZ51W#,9Y0]I_9FR[/=H39V# M[)^U8>80$A*0XM;X6V#]DD!*"8@00. )KZ
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M4/),%!,^()ZB3^T>-6NJ=D,V'6VO"]QK47++,Y"Y):U8GT2PQ#H(.$E!8LL
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M2M0W8*H'V3@\LFN6:5[(.W3^MMV%WICMM:)N&N_OMP7L;[Q(<<0U"-Q2G<H
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MB_K6E6JFD7%\RTIU"'$!94#W;L!MQSPPTA9,)6[L23(!P8[]Q^+3ABVBS ;
MMR-Z\'Q++)Q:HZ>JL[1RI3@7DC8Z4_)SQ6D5F) 6SGL=7'9.;4"FPO9./-)
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M62U1>.AVHI-225!+!$4V9&ND9T_"WG,W87CN_8PL]VLMK"BE!2L"2DA:DD$
MS$53>US2;?N>]O6A[PR+ADI"W XRHE(=06T+!02")GC585W$5L/;+DC -S<=
MFGP_:VHWLR41TQ<!]1M1>U$M]69R2 3#":M'/4PN+EEA@DF#1\$)L(Y!0T,L
MAM;A.R6E +=4P@X(4\E6TM@@QN"L9.>(D":K)U.P7W@3<MDM6J+UP>(*1:.(
M+B'RDI"MA0))B4R H D V^R3C=X2\2R%<4R#>K'0<A;5XS=/JV Y(=/'5YE1
M@9+BYLKJ^H+ABBNJ&T LPNTE:]PQ+'/:QR/:VHC3[Q:-Z6%%$K3.Y RVHI6
M"H$[5 @P.(Q5NYKVD-.=TY>MI<V-+*=CJB$/-I=:4=K9 "VUI6F2,$$U5S^*
M3AQCW7;L>_=[$F;HNO&XLW%G&SHY<L>$EBS$4N%B\ _*YP:I,W%O%?R@5')&
ME=VJHQ9!9W)9[\,K[H)W[X'V 8W[9W;)_;C;YU6_2^FB[]Q]\9]ZW]UW4F>]
MV[NYWQW??;<]UN[SEMG%4]DG&?PI8CC^+93D.]V(U]%FD>3D8V8C[0N2P PN
M_*Q;++=X((1-A7T6/9"$746M_9BATHAL$D<AZ<D59DV-VM2TI865(V!0P "X
MG>@22 5*00I*022#PJFYKFDLMM.N7S*6WN]+:O&K<EAPM/+A*2I+;;B2A;B@
ME 4"-V*R9J9ZV^JZV\I#Q+BEN:\.UJ+:L+A.K;2KL1XS +&O-&(E&,!-$FB)
M$*'DD@(@ECFB>^-[7+:J24J*5 I4DE*DD0008((.00<$'@:R27$+2E:%!:%I
M"D+3XDJ2H I4E0D*2H$$$$@@@@Q4?W%?BO\ K_F:A4TCS^1]*=Q7XK_K_F:4
MD>?R/I3N*_%?]?\ ,TI(\_D?2G<5^*_Z_P"9I21Y_(^E.XK\5_U_S-*2//Y'
MTIW%?BO^O^9I21Y_(^E.XK\5_P!?\S2DCS^1]*=Q7XK_ *_YFE)'G\CZ4[BO
MQ7_7_,TI(\_D?2G<5^*_Z_YFE)'G\CZ4[BOQ7_7_ #-*2//Y'TIW%?BO^O\
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MTE757[@]:UL[VXIOMA7&J/OEM]PUY/O]A%IPB&[+SCX[FFT6*#B9F9NS+E[
M\@AW*SG&"_ I*<:)IY]757G0TYK(@RY(R(&9!D,KLRRX^&%BZ#TK;>42@-;#
MM[I"QNG@"4\.(K7KQ%^UK'OK&GNWS*]*-F0ART: =-TI[:X+AYLE!0!)2E?V
MH )D5@)A?!)Q3;$Y;LZU<+XC\NK,8X,-N=J+_)>%3>78[;X@3<*NW;W:SNZP
M^S=O#F&.'W&,XO4YC3UU,?7UR"D]C#)#(G1,./D%W5L^AXA5N@KO'74INV7W
M);4TRV%CND*"5*+9)!,^69.#8TC5+%RT'=:BZEK2+>U6YIMW9L$/HNKIY;2S
M=.MJ6VTEY*4$"#@\H&5Q^WW$MM=N3Q-Y)C/"=+Q!@\76)[*FT<6=9OM/'5;?
M7F*[4UFW61;<<1(]UDT;KC&:@H4O(YS=MA,YJ[U;2ZK &(69&;/:3;NMVR57
M/<>Z+>"MC;VYP+=+@=MR$D!1PD!PH( 23P K**:U.VN=1<;TPWZ=5:LRGOG;
M7:PXU:IMUV]^E:_&TA04Z56P>2O>M*1N5)I[,-E>)7;63CAVXQ;AA$WNKN,5
M/$<.W#Q_-=N<>P_"R,BV<H=J[+"=S*O-KRARP/#=MS*<NXQ)V*T65>*T!ZUX
MHM3;2RC0S(<MW/<G57"F39X6VIMQ2UA+RW4N-%"5)*W-P"]Y1"A.1%4W;74K
M<ZS;M::F\1JT*:?0[;MLM;[1NU4S<(>4AT,VY05M!I#NY"MJ0E9(%96O ";'
MO;Z/JY/H",UQ_9O:>'"N(O*8+V"NH<SR/9'!\>7A[OLOQ<RS#/S*>GW&FRJ_
MQV=E79S594L"W;H081(]2"\'<WZ02A3SI7;I[LE2$OK4+A*% 0@*:"4JRD$<
M)-55Z(KWS0EJ0MY%G:AF_="@EM]=DRW[@MYI2@IXHN"ZXV2E122-^  -L7<&
M_$^[7WZQ>W_5^[_6MHE757[@]:=P;\3[M??IM_U?N_UI*NJOW!ZT[@WXGW:^
M_3;_ *OW?ZTE757[@]:=P;\3[M??IM_U?N_UI*NJOW!ZT[@WXGW:^_3;_J_=
M_K25=5?N#UIW!OQ/NU]^FW_5^[_6DJZJ_<'K3N#?B?=K[]-O^K]W^M)5U5^X
M/6G<&_$^[7WZ;?\ 5^[_ %I*NJOW!ZT[@WXGW:^_3;_J_=_K25=5?N#UIW!O
MQ/NU]^FW_5^[_6DJZJ_<'K3N#?B?=K[]-O\ J_=_K25=5?N#UIW!OQ/NU]^F
MW_5^[_6DJZJ_<'K4IOT.JZ*ZLZFC)R.UKJFR.K,>"F!!,OK 0.8@*F$-M"1*
MP,FT)CC!@*L2A@1Y9V2ED0CLDD;%* 5)!)2"0"HI)"03!40"3 XF 3T!-2N*
M<2A:D)6XM*%*2V E)<4 2E 4HA*2HPD*40D3)(%:(MGN"OC>VDS##]Z[^EVW
MS/)]\L2WKQ;B8Q;"F-H<YJ2M]H;[<ZMN,TR?*-Q3,(S=NT&Y;:C!*AV!5]:0
M%B5B=#5CY!7K-8Q9QZYLGD+93WR$L*95;*<E39#!2T4MI0V%H[YO<M6\F5 3
M! !TFTTG6K5]J]6W;NNWK5XUJ+;*>[>2;[?=!3SCMPIEX6ER$,([@(4EI1".
M\22H41MGZ-'B<PQ_#QMW60KCFT5QPI;L YZA&0T9MEPZ\36[G###M-N$T!1+
MXHN_QC,,UAJ\Q@7#O'0*W+DS YDM?6V8)!L[M_;K-PXH%3HNF2B$KVW%LU<E
MYN1MA*D(E!*]I*"@02DBJ-MV?U)GW"W2"W:+TR[#\K0I5AJ-YIHM']A2LJ6V
MZZ$/?JN\"7N^5A*A-ZL?VDXXK^PX<\"39*RVMPG8[9'(MKMQ@;HOA=R;;&^-
M!V@RG"*N\V+R,$6\WWIK7<"Z(QKQ%I9^ T]7CM<E5=B]XGLIS:"E621<.%T/
M+?>2ZT4BZ0ZF7D+*7TDI8*6P%1A94HRDD 1>M6^M+.GL>YJM6;*S<M7TK_1C
MELLBT<82NR<2A=\A5PHM[I4PA#:=BQN*B>_AYV0XHN$5:/)I>%VUW^(W&X-^
M%_:.YQS'L^VGJKS:;<C9+#KS'K_ \BGS7+:NB-V[RTN_CM+#)<.M,EA'LJTO
MO%)80O *(C<.6UWN3[Q[OW=Y=/!2FGE)>;?6E06G8@J#B0F E03@B#QI86NJ
M:5L<_1J[TW&DZ9:K0V]:I7:OV33C:V%]\XE!8=+FY3C2G %).Y)&TFE=I^$;
MBPX0*K&SL?PC)MW;G+.$S$=E;2^V:O\ 9Y,\V&SO&]Q<YSY:C%J_B +KL'O]
MM+"'.X:)QBLN)1B\7B/,QB45P,S)G;FVO"H+4&4HNW'PEY+_ ';Z%-MH!4;<
M;TN#NYCPR%$!<R*I6FF:KI*6U-,NW2W=*:LU.6B[3O[)YI]]_8TF_(9<MU=_
MLW'>4EL*+9&TBF:[A=XTL<S'8#-\YVXWMM;NBX3KG;'.3N#_ '$X8=G+"FS
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MLZJ=Q-PZJVLG5N3 '4XDX$+ BPX[*80H@4L,N0IZV=8;0'+4%+ET3[PQ<+4
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M[]4MO^K]W^M74JZJ_<'K3N#?B?=K[]-O^K]W^M)5U5^X/6G<&_$^[7WZ;?\
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LN1/R7VX_QZ;%=/J/6GO#/W_X5?EIW(GY+[<?X]-BNGU'K3WAG[_\*ORU_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>g947560g02a85.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g947560g02a85.jpg
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M(" @(" @(" @(" @(" @(" @(" @( H\/WAP86-K970@96YD/2)W(C\^_]L
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MFZ4IT5I[JU9++!!@# & , HX\IWRYO"3]<FP?U4J8.D.;:>S\R\?!S& , 8
MP!@# & , 8 P!@$;>Y?R0.UGU;;S_5A*,%CFN*[R0P[_ #>Q_P!3:_\  TP0
MYF , 8 P!@# & , 8 P!@'F9J/4+0V6BD=PZ2I.,GAZ2DB:-G\?34>BG;;3<
MXQ>(N6;P/ILIQL3:.F[ALX9<+HKHJI;[I[ :9]==\/(;5=NPKK3*NWD2N]JW
M/#(MPQ\6O7'JMV\A@$7N_P!$-6$KA 8744OJX/JTY5;E.-0Q7<0DDY71256X
M19[#JXQ:;46L/TFUU;GC73*F9N:1:(1.#!DX["8O'8='T7I4BB"BP0;'@R1
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MLM[\8?C\_)/M+^E.ON?;?T+_ )X6O[FOO\Q<CP^4/R5_MK/X+4U#<_5I\&,
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M-7@DPQ9$F;EJD,M4P9DW (;RZZ>ST>M2,UF.H6BBO,Y:V$8B)I[V>GPGA4#
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MLM[\8?C\_)/M+^E.ON?;?T+_ )X6O[FOO\Q<CP^4/R5_MK/X+4U#<_5I\&,
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M6G1AX;^PVXI)8+FUJYI/CLNCX*CJM[J;&\7BL7@\?%1*%QP#$(J!::L <9C
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MP<Q@# & 4:^QQ_FDNO\ ^7'8[]HJT,&[3GOA'X47E8,# & , 8 P!@# & ,
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M P!@# *-?8X_S277_P#+CL=^T5:&#=ISWPC\*+RL&!@# & , 8 P!@# & ,
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M$IL2BT>C^XEX='N@&SPZVV8D@[DF.BC]5/9FZUJUDL6M'7+'%&P#@YC & ,
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M+S?RJEU/'SDLB:>"# & , 8!1QY3OES>$GZY-@_JI4P=(<VT]GYEX^#F, 8
MP!@# (QT)^-7NQ]9R*?L9]1\%>4>'S9)S!!@# & , 8 P!@# & , 8!J0=FO
M8U_6^>=V8NX@UX634E57XXMNS9?5T?CD9,*1E_'240)'@E9RPFKIS%P4A=S9
MXL.9F(]*^(IRARW'>Z1^[1B/]QY,]/?2GDCDB?(EPY2=C<6K6-E6QLIWBZQM
MI2E:QNMXE!VEBIRG*2HV[*4G.P=E)U.4[O86D_6SLU*:HG]:2C)K)SC6DJ)4
M:P36#JL]IBGZF@5#U77M+U<"1C-=5=#P,&A@)%55QP.C\<'(#!R2[MQNHZ?O
M=T&^JS\D\56>DGRKA\]76=.%E=_3CLVVZO%LR/@@P!@# & :OW?>%^1M7MC9
MTP@ZG8IU7Y"RX[#J6@%"UEUG-@)& 6K[KX1B$JE$ME\9,6:"BSJ:H=D87==@
M%E_2K%\XITI'TG,;V4$E!TBXTQ2JE5MN6KP6-&Z4:PI@T\3:!P<Q@# & , 8
M!1K[''^:2Z__ )<=COVBK0P;M.>^$?A1>5@P, 8 P!@# & , 8 P!@# & 5F
M='_E9^6GZX=3?L/=7,&I90]E_'(LSP9& , 8 P!@# -6'R[=A.M%S]D8-"JW
MOB,Z=G^F)=V)EM6V?TO[:=B8'&GDCG%#7,-FL<.4A7Y7:(V&.VJ4)&.),%<E
M4C, GDWB7+\&Y=[/-1TC%[-6OJO?M1C6E4UB^G1XI%VWC1AL5@'1KKY%(7*B
M$TC@^-'G+.0$*OEE*IK.3,WE!PL-!U+.F0Z65[#X^8)/X_!HJ::)N1,,%@6R
M>Z[;5!PJ,2Q;KWU[5@WJ][)T8(, 8 P!@%''E.^7-X2?KDV#^JE3!TAS;3V?
MF7CX.8P!@# & =%)Q! \ *!Q4I.PHB0:[-VDKC#>,NSX-7G;7;A\+;3*.RV+
MK.M.->=-=#<;,,N==]N=F>V_&F^@$<J\ZS2.O)G(YFV[2=@Y)O-IJ.GL]C\D
M#]8^ ,S.C(9$*^0U*;1SK?'3XEBI$('%1"S>(GHUOM[V<OTUDBCT@]="MUW+
MMXZDJL$& , 8 P!@# & , 8 P!@$9+!^53UK_P!GG8__ 'Z9P7<^*[I$F\$&
M , 8 P#@E"; *,(F2KE-D,$L79,B\5]+U31@P;J.GCE7T-=M_5H-TE%=_1UV
MV]'3GT=>>?:XP#22[36AUE[$=Y9O:U2]\.F!&&=@"$."IVS,B_98?V%I@".>
M=:'H2(5F!C4 <0HXTK^PJ 7M&H=$I5"6/%A69)GL[3(),47A-Y\3LHM1QC+"
MN"I1OZV,L=U:/!X)+ W>\'$8 P"L_P AOD4@'46B;=.5Q-*EG78F#$JQB[6H
MW4CXEA^(%+9L*"P$/+K#K&!$E[1WBT?2G@R3.!(H:R,2E+85'PCQL_D@QWPU
MU[N)J,:M9TQQX)NBW8TH5^.O)SV]/1*G:MK:1]9378J8S/O,E,IM**.[!0<!
M$XYTHK6)V(X@%@]<IY,H58U6W1.7%AP80;9*V',HO&HT0WFT=>RQ$N-8,1=E
M9XTPHJINKKDTFFE1Y+/#!DE'WG$ZDUM4W5R:7RTM.(S'LEUBJCLDVC,"J&Q;
M."@A=D,7R:X?:2Q<$^9;.!<A"'AZ:#K=!^L/;,2:S9)$BW](1P=7BL&UC)++
MBT>.]C?KIN?$7UY<I>ERDXF78I=/G;7G3;E-7L/9RFGI:;<<;:[>CMQ[>NW'
M'.O/M\<\<<\8+:<]\(_"B]#!@8 P!@# & , 8 P!@# & , K,Z/_ "L_+3]<
M.IOV'NKF#4LH>R_CD69X,C & , 8 P!@&JMY)^CGD)[9=H;!=".FG7MU1@DP
M)3K2\J8.=?:C[C280F#%^^#\O?=J#K+DL2?(%/? 8.TCT($*MA[5FKHILLGJ
MX7>?/G_OI&45&E77>FWLYO<L]U<>%#8$Z40&9U=U8IBOK!$V(#F,4C"XHV*M
MBYV?86Q&:R1LJHVTE%R#@L='SAXHQ4:K(/6(,6T'L%&@1NS21&:<8,2Q;I3W
M*BZMQ*7!!@# & , HX\IWRYO"3]<FP?U4J8.D.;:>S\R\?!S& , 8 P!@# &
M , 8 P!@# & , 8 P!@# (R6#\JGK7_L\['_ ._3."[GQ7=(DW@@P!@# & =
M!*^'/,7DG#,&VD[OD 8X:QI[RWU9R%SR.<^H!N]G>N[75L65]%@ORYUV;\).
M-^5M=D_2XY TQJUZG^1]6YXK8K'HUV#\>L;92]F\*U?XX;%J.OH7( ZA))5P
ME8&\U[MEJR-#N-.=EG[*.]9@*BB6FVB/K]N.$U!V;A1_64WK)2T]EO/'G4UW
MFZQ@XC & 1*["='^M/92(6?&IU6L?"'[:8QUM*;:@ 8!$+IT?PV0Q>6PD\QL
MMD'5/[%X=*83#SH+WV5*BTW<:$MWXQ^-;\L=Q4VG59D3CGAWZ^'82/"J6_V<
M'6BG9ERVK(NRPJP88UOF<2+L) !-57*PE!52M7%>ZQZ;US'(G$EQ,=KF/Z@F
M41CCZ+K!#3%0FX%VWHFJ)4=:89;ZX5>_>RRVL*WAU.5M7]1UX(T 0&KX5%Z^
MA01-99QJ)BL.",H\ '>Z7.ZKESLT%#VJ&[ERJJY<[Z;+N%5%E-]]AENK;>;Q
M93=[''^:2Z__ )<=COVBK0P;M.>^$?A1>5@P, 8 P!@# & , 8 P!@'02LF9
M"Q>2&8[&W4RD D 8)@H@R)"@SR5F6 YRZ%QMH8.N6804Z.O4D!;<D8>-!3%5
MUHZ(.4&B2RN@%=?QN^^_^B5M_P#.TZ9?]V<&J1^U_P#ED4: FWD2IZY>YEG$
M_%M99AAV=NZ&VJ &,.U?3U!Y&!T8H"HZ=<"C"KBV?4NWKHG7#XPBLR_Q&C D
MT0W_ ,H26P5[+4?K9)K)_:;^9/\ IKL5VWGUB@HK:7CTL:AX.23+;&+1D'87
MK1.Q4<W9!G[\:DYBU=V$>EQ'DT4;,P2&PL6XT9."23Y_RB/;.ETQEI;I5]S1
M.+!!@# & , 8 P!@# & , CS-^VG6:M;B@_7V?WK6,0NRR>!_,&K$]+10^7R
M+DP[=#P2;,2NOJLFM(R3%Z,C*+OW.M)2;-T-!:$'S=9#06CI6CIKYXGW5UVL
MZV6Y:5ATE6-X5I.[:J?=UI8M?1F5"RLHBFPXGH#+<DAC9?=7G4&=42 R#=M[
MHT 'ED0IG9B453:;!1TK3 JX\IWRYO"3]<FP?U4J8-PYMI[/S+Q\',8 P!@#
M & , 8 P!@# & , 8 P!@# & , C)8/RJ>M?^SSL?_OTS@NY\5W2)-X(, 8
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M# & 4<>4[Y<WA)^N38/ZJ5,'2'-M/9^9>/@YC & , 8 P!@# & , 8 P!@#
M& , 8 P!@# & , 8 P!@# & , 8 P!@# & 4:^QQ_FDNO_Y<=COVBK0P;M.>
M^$?A1>5@P, 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P"C
MCRG?+F\)/UR;!_52I@Z0YMI[/S+Q\',8 P!@# & , 8 P!@# & , 8 P!@#
M& , 8 P!@# & , 8 P!@# & , 8 P"C7V./\TEU__+CL=^T5:&#=ISWPC\*+
MRL&!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & 4<>4[Y<
MWA)^N38/ZJ5,'2'-M/9^9>/@YC & , 8 P!@# & , 8 P!@# & , 8 P!@#
M& , 8 P!@# & , 8 P!@# & 4:^QQ_FDNO\ ^7'8[]HJT,&[3GOA'X47E8,#
M & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# (XRGM]U?A%WQKK;
M+KUK:/7M,.!/$=K I)63:4$'$AU?;QQARUWW]4S+2;08_P!HR'?KM2DBX:J\
MA6;[VN/;%HZ5HZ:G)KCMEUIM^T[#I"K[PK>=VW5&SW6PZ_C4F8$Y)%^1970"
M9Y>L$%.=EM )]1*/R)1CLZ3CQ]9$(;V8%%DFFX--)-IT>3U*O?*=\N;PD_7)
ML']5*F#<.;:>S\R\?!S& , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!
M@# & , 8 P!@'@K0M*N:4@,FM*VYK'*[KJ',=",GF4M*-@X$,T6=-V#;9V^=
M[Z)\+/B+MF-'-$_6.R1-XS',$'#UVW04 CJ:\A/2..T[&+_.=GZ@%T[,Y(1A
MT9G;N6,TA1:5AN7_ +_1Q%#GVR21J.)BB;B3#7+%!W&VC!X].)#VC=5;479E
M5JCPSP\Y[M=Q+@45%G18TV$(L# 4RP9E1!<6[;D!A460;INV!$<_:**M7K!\
MT62=,W;955NY;JIK(J;I[Z[<B%(GL<?YI+K_ /EQV._:*M#!NTY[X1^%%Y6#
M P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8!BRZV-T$JQD[+KU(
MZYB5PKZB/@?(;9B\@FE?#]DSPM4[S(8U%9+#SQ/5U&4S+(9PPD8[EH9<CG[G
METS:N&3D54KC5KH='UT?<:X-U]8.[!OR%1^;2*JYU,9 2O+QIV)L>J4(,#='
M+1:T)&]4;XN2\-9),#%C0BQJFDI"5K4;&6,@157%1^L$WX*S7W#YSP-IQ4<\
MU)?ZDW2BTHUFZ:Y8'=]&NG?9\7=='5E,ZVM:CM.IU3^3^O+&[)>B 8!;1.=P
M>R+>;TO(J6D34L1(S!\/C'*MCO7Y,2S1B,@'H"#6C<ONV9K!*2:>-7)P=--E
M-.KPPQHJ.M-%G+F ^&<X'[ ]?;^N#R(]S>RS_K?.W%A0"&75((G((N@=>"'(
M5[OZ*81)ZS]V,G&J;A9BNBNIJ@EISOZ/'/&";>#2C%55'1/Q+O<&!@# & ,
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MM(5'N,55WF+%VQ=LW1G5;5J[170:\^I45##<WU4^;))8(, 8 P!@# & , 8
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MZHD+[-.6#GUP8V/<;^H7W]2HKNW5]%9)334:4&U7:C_^O^)<K@P, 8 P!@#
M& 4"6_)([%'WCW,RD\%C0=#LOY!TEBQ\HQ##457#N]4D$U7Q%=LU3475VU31
MTW5XV44YXTTXVVYXXS4><O?W,S)-Q=%7+O1XSO/=E-%.DO<08,MNL2)(CU8[
M!L!X]A/8J\?/WSRI9<W:,V;1N547=.W2ZB:#=N@GNLNMOHDEIMOMKKST;5'B
MLGO1FS3]9#!\^.Y_:18'VDVM]L8I,M7/X:220>#ZN1D-KMK9PV.S29[EXFL/
M8O[ K$J2C4+/M&+%5NEQV<K.84 8$&7>CLI&UF$C=+<3JO=[]/.F.>>[&Y6R
M^_%<PJ8#V$>+S0L]D7)""ER%42TZ\"MSLX[?NMXP>> '<N+N XX#6_7QDQ/I
MPLQ[D5LYH/))1*+R8?,ZS%HM=RKV=;Q>'1CC6N1XS9?>TF:A\A,Q8.-C1J6
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MB =#1^BY!R.;/1:.E?/5F=EM<M0:RGX#;6M6VLU]]&X/X'[3F,<2GWZ=\/\
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MLFI(64&ND'PXD.?()NF3]@]:J*MGC)XV52<-73=51!P@HFLBINGOKMR(<4\
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M]^8 -F1QQ[X:?F<]S^?GSP1U,0ZVLXS;:]LD)U(9&]75*'_@^\&@!XA*P)+
MZVKF5S-)08/;OM>"D?K(>LQC_NCWL$E93-'?MOF[R-LXJ+7#*GGSU+0CY*O'
MK$-:S!1>$R(K\)8$-K-6%N2S@,%9D9#3U*E*=A:DD)-(=)=-&#A(CK)3*:D6
MD0U8PCZIW&RX)P_ O@;KN6^O35UQ,B0#J[+!U/UP EE@ZB+CKV\+E[!!IS$6
M 8N'&S6Y)K=QHV*=""<7C@R41_F'WG*8:2VVCD6?/]]]9(,YCYU!@\9@WW)=
M22KV5_Z.;7G1NDH5/EK1D(AI:D_6' MTY18T<B)DD,F(RY+LO<E/(_R@!:-X
MX=+6'>1U^U2"H,V4<:1V)MH^DQW$\+J!5TIEPZ4D^NBJ9-9]?0# 5(F0^8V,
M$)&9[9=CCC\8F):-NP,ELMP]=.U]@HQ=.(3%I'G#WW5'Q%CQN9 $7C9!R^#O
M=_6\*A7Y+JIX& @70N.QXF2,#++D0QW+9=#)S/QH.+PL)%#<BJ^RN+CK'>,1
M9F(Y'0(;'K/W)2^0, G*O,]*R:7D)2Y=F9$Z+IA7H[]*:Z&3H!U2BX6D)M1E
MK&OP\ K'>EG\\.3Z,1WW]FS\TR%MWQJ7J(-EFI^2\/!;5^.-.6^GO FR AHV
MS# (O'!8T*XURX=!]MH=70TRK. T_ )+Q3M;0<JT>.H+$XA%W4-F88>T>ZM(
M=+(TY:-V#^(*&':<B,Q]+A 9*"3)%I*&I@&Z*B2(5]_'IW\3F&^MC626P(M0
MW/9"[5;.84Y.QE,9'VHF1[U1*[5EE2)K.4&'!(<E#WUM%/?'EDYX<2K>,0]1
M^X;)-9 VD@GGQ\\=3Q$IZ15Q*G)1X\.2!)R6E1>6.U&VHQJLLZ,=C:Z[)N&.
MS]LR2(I-.)+6@2-Z+-W23Y..K+;I.="K=B^;"UX:=E#'-.].;'#TA:=;V59/
M .33ZPJAE0:0UD4TV=QH)2<(HJ)Q01O(0L&IQ^Y7,<TOHE(7P0/&3;4,=7:1
MB1 WK44^$!7+#7M;RTI7#A4Y46\=%=1?:"*:6)899>!RBNY2S=E=P"[LL]K>
M?0NP!>IA=,2EROR3(P@>T+KHZH*K-WCY5O[F<;H[HB[3QRQ5'YUUZ3R WQA0
M1D(@C!S;]E.W\)@S"HMB#1&/QUB?J ?$:HA2<2,QB,L1$;)DEA-.159V8-#3
M(AX\>G$'456 _!H'&0VGHMSQQQJWAIF_[XGO3OC\A!F(J0)M8TU!Q,K2\:IB
M4MA8N%<F3 ^$L+;:Q.1#C[^./7L8-M7ET2TJ:W#:I:''3,*UYV8B7$Q'3 1-
MKSP\/.!XEMXYF;H[+F$CM60$J]F$)BC*0H(,A?,UD4[$S_LW.'QEU)RXXP:&
M@QKB_6?(E%4_(#A_<(X0EQ5\F\/N)@*G3=C7W;MWN\,E20<PZR\S*2U61+R;
MW<.AD1@(24+[-$&I(^<J6YJ:NR"F&##W*]%,&;^05D9&RP;IRBHL/DC%48]0
M7 H<+B5SP6/_ &OF?6UZAQ4%&G32%6#:\,G2<?FH.,S\18<P4:1-Q,OA+K[^
M#ZH='E*7(%P&DG=J UC< ))HD&8PNX3<$V*#K0&ZNKIY[3R<=ZBR*$E:M.A;
M8<2)"EH[(TH57LCBP-C"2,ZD+Z6OS%BFB+9L6D&EB2M"3>\,GLLAS*ICPP5E
M)8<NF:L.Q%Y8%</GOPW</.X^VM:]0J.ZNME4MB2IEM6/2*5UZW+K(:M5BJ$+
MEG7F-I$EFVJBVK=5\F-U=*(:K*ZH[J\I\**<:\;<@W5MZNI-W!!@# & , 8
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M7X(2.ZJ4ZS*4Q8D5M"6R'WG+G)W%J5VFTI_"&)&V.8>RJ.RNH44$G;I@>3F
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/EM_4MD$4$_122TTU%/_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>g947560g02f26.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g947560g02f26.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_X5Y4:'1T<#HO+VYS+F%D;V)E+F-O;2]X
M87 O,2XP+P \/WAP86-K970@8F5G:6X](N^[OR(@:60](E<U33!-<$-E:&E(
M>G)E4WI.5&-Z:V,Y9"(_/@H\>#IX;7!M971A('AM;&YS.G@](F%D;V)E.FYS
M.FUE=&$O(B!X.GAM<'1K/2)!9&]B92!835 @0V]R92 U+C,M8S Q,2 V-BXQ
M-#4V-C$L(#(P,3(O,#(O,#8M,30Z-38Z,C<@(" @(" @("(^"B @(#QR9&8Z
M4D1&('AM;&YS.G)D9CTB:'1T<#HO+W=W=RYW,RYO<F<O,3DY.2\P,B\R,BUR
M9&8M<WEN=&%X+6YS(R(^"B @(" @(#QR9&8Z1&5S8W)I<'1I;VX@<F1F.F%B
M;W5T/2(B"B @(" @(" @(" @('AM;&YS.GAM<#TB:'1T<#HO+VYS+F%D;V)E
M+F-O;2]X87 O,2XP+R(*(" @(" @(" @(" @>&UL;G,Z>&UP1TEM9STB:'1T
M<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP+V<O:6UG+R(^"B @(" @(" @(#QX
M;7 Z0W)E871E1&%T93XR,#(P+3 Y+3(S5#$T.C4Q+3 W.C P/"]X;7 Z0W)E
M871E1&%T93X*(" @(" @(" @/'AM<#I#<F5A=&]R5&]O;#Y!9&]B92!);&QU
M<W1R871O<B!#4S8@*%=I;F1O=W,I/"]X;7 Z0W)E871O<E1O;VP^"B @(" @
M(" @(#QX;7 Z36]D:69Y1&%T93XR,#(P+3 Y+3(S5#$T.C4Q.C Q+3 W.C P
M/"]X;7 Z36]D:69Y1&%T93X*(" @(" @(" @/'AM<#I-971A9&%T841A=&4^
M,C R,"TP.2TR,U0Q-#HU,3HP,2TP-SHP,#PO>&UP.DUE=&%D871A1&%T93X*
M(" @(" @(" @/'AM<#I4:'5M8FYA:6QS/@H@(" @(" @(" @(" \<F1F.D%L
M=#X*(" @(" @(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O
M=7)C92(^"B @(" @(" @(" @(" @(" @(#QX;7!'26UG.G=I9'1H/C(U-CPO
M>&UP1TEM9SIW:61T:#X*(" @(" @(" @(" @(" @(" @/'AM<$=);6<Z:&5I
M9VAT/C$Y,CPO>&UP1TEM9SIH96EG:'0^"B @(" @(" @(" @(" @(" @(#QX
M;7!'26UG.F9O<FUA=#Y*4$5'/"]X;7!'26UG.F9O<FUA=#X*(" @(" @(" @
M(" @(" @(" @/'AM<$=);6<Z:6UA9V4^+SEJ+S1!05%3:UI*4F=!0D%G14%3
M04))04%$+S=107-51VAV9$<Y>F%'.7=)1$UU34%!-%%K;$Y!*S!!04%!04%"
M04%304%!04%%028C>$$[05%"24%!04%!44%"+RLT041K1FMB,DIL04=404%!
M04%!9B]B04E104)G445"055%0F=51D)G:T="45E*0W=G1T)G9TQ$06]+0W=O
M2R8C>$$[1$)!341!=TU$07=11$$T4$5!.$]$0DU41D)15$5X=V)'>'-C2'@X
M9DAX.&9(>#AF2'=%2$)W8TY$03!914)!64=H55)&4F]F2'@X9B8C>$$[2'@X
M9DAX.&9(>#AF2'@X9DAX.&9(>#AF2'@X9DAX.&9(>#AF2'@X9DAX.&9(>#AF
M2'@X9DAX.&9(>#AF+SA!04519T%W045!07=%4B8C>$$[04%)4D%135)!9B]%
M06%)04%!04A!445"05%%04%!04%!04%!04%11D%W24=!44%(0T%K2T-W14%!
M9TE$05%%0D%114%!04%!04%!028C>$$[05%!0T%W449"9V-)0U%O3$5!04-!
M44U$06=10T)G8T1"04E'06Y-0D%G35)"04%&25))>%%614=%,D5I8UE%54UP
M1VA">%=X46E00B8C>$$[571(:$UX6FDX0U)Y9W9%;%%Z4E1K<4MY63-00TY5
M46YK-D]Z3FAD55I(5$0P=4E)2F]-2D-H9UIH2E)&4G%3,%9T3E9+0G)Y-"]0
M128C>$$[,4]4,%I85T9L85<Q>&18;#E76C)H<&%M='-B5S5V63-2,61N9#1E
M6' W9D@Q*V8S3T5H66%(:4EM2VDT>4YJ;RM#:S535FQP95EM6B8C>$$[<6)N
M2C)E;C5+:G!+5VUP-FEP<7%U<W)A-G9O4D%!24-!44E$0E%514)1645#04U$
M8E%%04%H141"0T53355%1E523FA)9UIX9UI%>28C>$$[;V)(=T9-2%(T4TY#
M1E9*:6-V17I*1%)$9VAA4U5Y5VE9-TQ#0C-04TYE2D5G>&15:W=G2D-H9UI*
M:EI&1VED:V1&53,X<4]Z=WEG<"8C>$$[,"M0>FA*4VMT3515-5!2;&195U9P
M8EA&,658,5)L6FUD;V%7<')B1S%U8C)2,61N9#1E6' W9D@Q*V8S3T5H66%(
M:4EM2VDT>4YJ;R8C>$$[*T1L2E=7;#5I6FUP=6-N6C9F:W%/:W!A86YQ2VUQ
M<39Y=')Q*W8O84%!=T1!44%#15%-4D%$.$$Y531Q-T972F9M:G K<%@O04I5
M828C>$$[,C!U5R]H,4M7-70T<E-F5%IP-$I),FYL14)L:V%";$II:5-6<$A$
M9D0X3E0P>%9H,VQA,R]->7DX,&$S8E=N,74V*W)X,TU51&$W3B8C>$$[9695
M2D%L-T5T9S!C>%=51FI9:5%Y3D-P<2\X065B-%9:.35!.'A8=FU0>6IP*W,S
M,$UC1C-D0U0Q;V]#>&I$4GEV2#A*8C1Q9D(S=R8C>$$[2WE$1EA9<3=&6%EQ
M-T9867$W1EA9<3=&6%EQ-T9867$W1E5K,'E8>DIE-F)A6&AU-TY$8W=X>D9"
M85-N:C9I0G%6*W,Y<31Q:791."8C>$$[>"\X04QD6B\Y26MV+UI4:7)V43AX
M+SA!3&1:+SE):W8O6E1I<G91.'@O.$%,9%HO.4EK=B]:5&ER=E$X>"\X04QD
M6B\Y26MV+UI4:28C>$$[<G91.'@O.$%,9%HO.4EK=B]:5&ER=E$X>"\X04QD
M6B\Y26MV+UI4:7)V43AX+SA!3&1:+SE):W8O6E1I<G91.'@O.$%,9%HO.4EK
M=B8C>$$[+UI4:7)V43AX+SA!3&1:+SE):W8O6E1I<G91.'@O.$%,9%HO.4EK
M=B]:5&ER=E$X>"\X04QD6B\Y26MV+UI4:7)V43AX+SA!3&1:+R8C>$$[.4EK
M=B]:5&EQ1C%75'I,6F%:95AI,VQM-U<P16MY;V)354%M3D,Q1"]P4'1I<60T
M<3=&6%EQ-T971B]K,R\U3&934"MJ;B]Q2VQX5B8C>$$[;6U+=7A6,DMU>%8R
M2W5X5C)+<TXX-E=P=G9-;6<V9DID6&M&<$Q$9E-Y<%I89'I:1C-I.4%)5V4Q
M:VA:=5!.<4%M;2M39TQ227%0*R8C>$$[0TY*+S5B9%HO=T,T-7$O+T%'5C5:
M=VAH>$8S*T-.2B\U8F1:+W=#-#5Q+R]!1U8T.$E8:4QV.$%"1VLO.'1U<R]W
M1&-C,68O04Q+."8C>$$[945,>$9"=F\X96HK869+<C)6.7%:1C-Q33%V8WA8
M3W V:&1X4U)F;W4Y;31T1F-Z>7AM:VM3341X<4--:DE!0FQ%=E)-<EI-3FIT
M3"8C>$$[5S=T9DQ55C%#:SA1,'0S16-Q:#$U05=O0F]W27)1;DIW-7-:2S!E
M;#9:86%Z<$5L<F%1,CAH=5I&3'A2;VA+;3!N3DMQ0G1T:W X:R8C>$$[4C5S
M0SAX4R]M1U!/;79R;S!/<4-:6F)T.4]U4DIQ1%=P:"]16D5%85<X<V8V3#0O
M6#9-2#E8,5!5*TAH>'$R5DTP=W9,:GI"63(O-B8C>$$[53AN=V593'E.2$YK
M3$A6>F5%3DIE=V-6;E=/.4)U94YV8WAW;5)N2$9536Y$8FM#<7)E5DQJ>C59
M+VU%67(V,C%7-#AQ>7AT;S%R8R8C>$$[,U(Y4TU0<#A30T\Y8T8S;41837-D
M>GIL:VI65T)I261Q-'%G8G9Z5"MB375P>&%H83)$.'1-<TY3;79.3F)48C)+
M,FQL4G):;W)/3R8C>$$[43-(*VM4,%9X2&-+;D1D=4MT.%%#<E5F-6@O;D)+
M,F]Q;6=O=F]S.'1L>3!R56=X:&ET<C):;TI!.'-C8E1.2F%W>'$P56I*5U55
M-28C>$$[5F]&6%@O-6]F;51*9&%V8F%0<&1R3DY9,TM)1FMS=%)L1G9!8FDO
M9S539E9F5VMU968Q1T]J47AH561Y<B]986EQ9F5A=DXO-6I7928C>$$[<"M8
M<E139$=6,#%#3S,O5$1.85AD>71V2F-33$4O<'IW;%DQ*W(X=6)I64Q64G,S
M5VEQ0G9F3VXU;F%4-5DX<5AD=F]-;7183C592B8C>$$[2G)S6#%7-%,V:&YG
M4T]79$=3=G=V2D@V<4I69C<P3'-1,4U64S(W."MF;G!B>EAD=69,*VXX-%9I
M551#,#%A5DEM<D=*2E<Y0DI28R8C>$$[2DIY66]L=7I/;C=F43%66D0K6"MT
M965R;GI(<7-0;4-X;'1,1S=31SAS>3A.=SAA>DY:5UEN9VIL8W%S56-5:&9I
M<%@Y-'I046=X<R8C>$$[1U93=$0U<5@Y05=M;S-/=$YQ9S%Y*SE7*VAG=7AA
M1S!I,4]Q3F-2,C933'AN=#!%54MY3C93>'5Z;C=+;D98;S-M6"]!2E)Z5F8X
M028C>$$[;41U4"M45%EQ;4]+=7A6,DMU>%9H9C5.+W=$:W0Y22\V3V8K;W%8
M1E=A67$W1EA9<3=&6%EQ-T9867%X4'I*+WEM;FPS+VU&,4PY9"8C>$$[=&LT
M35I*;FQR0C)+=7A623ED+S536'E:+W="=&5B+W5J-FAK2CAM55=A-55Z64YQ
M;FU0>4QO6&QF>2]0-7-U571K;'19:W1(9$I8628C>$$[;C!53&=E:7).5'!8
M=#!Y>45*4U!P1F]+:C56.#@O;$AR1W4R.6QO1CE(8V%U=V1R85 P-VQ4.$UB
M1GEP;%)6<G<U9"MM4VYH;D58228C>$$[1VQ&3754>DPU8V971S!23E9S,C%L
M0E8Y349X16)O1&IZ,VA$96]0:%!,<#!Y;$M9-'%H<$Y5,'E+*VIS2DQY0DPV
M5VAI=$=K451.>28C>$$[5U)L-'AK.&I664I#2T1O:F9Y;D955&EQ55)E8U!+
M53!T-T1&<F1H2DQP<74K;WAP9%%S,75S6C1U6F='<D=&8EDX<55X5E(P=E5V
M228C>$$[<5(S*W%A5F1A5W-C>4,O,4\K=%I,8TLX9%A56$4X<UHS5W-59S5U
M9C)7,S)/2W!T8C,Y:F-Y,T5.=F-25%,R:FE+-FIJ9%AA2U%Q2"8C>$$[0U-!
M16Q7-'-$43EJ:7%V:7)S5F1I<G-64S=Z3"]W06\U<78O041",T@O2G!S5E1(
M1EA9<3=&6%EQ=W8X;2\X07E7*VMF.4A0+U563"8C>$$[:7).35991$1"<D]Q
M-GIR>DYR,2]A4E=L*V)A,W0W63(V>')'='9#+S=C36IF86M09DQ)>$)$06Q&
M9C1E,5@O<5HY5R\T2S O-TIS;"8C>$$[=T)(15AF-&4Q6"]Q6CE7+S1+,"\W
M2G-E04QX1C,K2'16+S9M9E9V*T-T4"MY8DAG0SA25B]*8VUP2G)7=E=&,W%6
M>'%-3F]B6#9U,28C>$$[,3926E!6:5IN04U34D1C*S)6>49--&QL=5)3>%!Z
M2B]Y;6YL,R]M1C%,.61T:S1-6DM(;DMF>DQ"-6$Q0V)Y,41&4')+45-.87AZ
M328C>$$[5DA)25-/04-U1V5T3TMT444W16IR;&A90C4W<4QF;5).*UDS;%15
M=%<P4V,V6'!F<6AZ<#=X>C)Z4U0R37=N;65P:FU"6&MI2TAJ6"8C>$$[8TU&
M-49L0D-7=$<P,WI(3"MC165R=S)6,4AP=#):3'4W=C=Q2V5#5#9P4%E2<D):
M3TA(<%5I=49$0D]83E<U8VQ8<5AQ=E(V1')V+R8C>$$[04-K=FMZ+W1R>F8Y
M,&95344K4UES,7EP;2MC+RMC:3=3-G502DAK9W=1>5-H26IY2TM7<%<S:'!7
M9S<P>EED;GE!;6).8DU*.&U%+R8C>$$[.#0Y869F>&9M>'!%:W1T2VMA<&1C
M;EI'049B5U%B:VIX3UI7=GE23U!9:FUX9TXS=5=R9FPU-31U4$Y/<39H6E@Q
M=D1P.7AD6$=O828C>$$[9D<P-W)W=7!D1T]M4G4P8U9S:WEU<FUV3F)S9THP
M:C4O14Y+,F],5'9Y-B].;3,K<7$O;59W27)'*W17;6PQ2S=V2%=39C8P8E=1
M;R8C>$$[64QD2G!)>E!$>6QE:$%J*T92:7%$:"]+3#AY;&QG:R]X3$UN2S0P
M-%AK:C9N9%,S6G-,4V$X964R*W525SEP2DIZ1C)H5W%R=E5F<R8C>$$[<5-Q
M;B]L<GE&*UE';F5C3&)5.5$X>#-&-6\Y=6)H1G-M=G!P22]Q>DY-3&5+4S-K
M9U!R4W%R>$TP-U1"=FA+,&(W5TMP6D@K5FYN6"8C>$$[-CE03E!D5V,Q=F$S
M3C%D-E)B4WIS,%)-*W0R*W)#3FQ3,&AE1EA&<G=K3%-4+T5A<4%O-&Q63V11
M+TPO04UW87)F,E8Y8R]O-U0O<B8C>$$[3G<T.'A79&U(6DHW2#%9<FE/4#%4
M2$=:<%1,8CA89&M4-$I(2%=M2W0O;#<U0S@Q*U<O348O<75O-FA:,V-E=5)V
M3G$P34-3>'-L."8C>$$[8F@U:UI'8W5*5D-81'AC=4U8=TI(.$(S>%8V2&ER
M<U9D:7)S5E,W>DPO>6IM<2\X=V1X+WEA8D95>'A6,DMO8E5T53!Z4S=.-S-5
M-R8C>$$[>4-X<S0V0U,U=5I%:&E8:V%#<G565590=FEQ:&$K661!=3E3:S!U
M,3%/,'5.5&AJ5V57>&EN:F5D26U#;%I':59I-%%I4E-'27 X428C>$$[.&-6
M63,K5&8O:W0Y22\V3V8K;W%81E=A67%W>GDO.$$X9%AZ3B\R,6TO-FA,9DQ9
M8VUU4V1:3D1S5F1I<5=E5E K57(X>F9/>"\U328C>$$[2$MP<S1S<WE$2FEF
M;50O;$Y03'8O34QQ6#8W8DIW67E44$Q71'-69&EQ4C8W+WEK=FMZ+T%,83@S
M+V1(,41)5#5-;W,Q>7!M:S%H<"8C>$$[;78R5FIB,F-D+V%.2&)22D-J3F%3
M5DEJ54M#85A0=&EQ23E$>D@O>3-79B]!16E3+W=$6E1I<G91.'@O.'0Q;B]W
M0DEK=CA!,E4T<28C>$$[-S!0368O3&1:+SA!4TI,+T%.;$]+=3E$>D@O>3-7
M9B]!16E3+W=$6E1I<G91.'@O.'0Q;B]W0DEK=CA!,E4T<3<P4$UF+TQD6B\X
M028C>$$[4TI,+T%.;$]+=3E$>D@O>3-79B]!16E3+W=$6E1I<G91.'@O.'0Q
M;B]W0DEK=CA!,E4T<3<P4$UF+TQD6B\X05-*3"]!3FQ/2W4Y1"8C>$$[>D@O
M>3-79B]!16E3+W=$6E1I<G91.'@O.'0Q;B]W0DEK=CA!,E4T<3<P4$UF+TQD
M6B\X05-*3"]!3FQ/2V]F54Y-.'=8=&AC,F(V:"8C>$$[84ET>D4X3$U,3U-O
M16EL4U(O<%!V:7%C-'$W1E=(9FUL-4TQ2'I8;U9P86%F2VE83FQE>#-G:FMN
M;715;$-X4U)&1VYT,6564#<W:R8C>$$[2TMD>%1V:7)'=DQ8-58K9$Y),5,W
M=4ET96DP.7)M>FEG;3%',%5Z4WHS16%7>65Q,6YC;SET1GA7,FM7<58U0BMG
M-&I#<DE0>5=6,28C>$$[+TQ04E9D>DDT1G='8V=!:R]7<&0V1&)!<DYS5EE:
M-68O=T-/<C5M+S=A>F8Y46QV;'-/5%A*3W-M:#)+=7A63%!+;B]!0VQF;6(U
M,B8C>$$[4"]*9S563FY&;&U16DU"+TU4>DQO4&PW>E U8W9T8G9O=%!T1V<Q
M0TI:<#(T<5AB-G-1;RLW3$U54U1S>&MG4"M6,"]L5B\Q33EJ+R8C>$$[04UJ
M4#=-=CA/6&-F:W=P,R]+-F9Y<2\V;65X+S5'9C)9*TA,=5!Y5VYF.$%+-F9Y
M<2\V;65X+S5'9C)9*TA,=5!Y5VM.1BM94&MN>B8C>$$[2#5Y.&]73V@V>F$V
M:&1X-FY03SA%3#%94G)P3CAP86AP5VAC6EAK9U%.=WEI.5=Y:&TW1EA9<3=&
M6%EQ-T9867$W1EA9<3=&6%EQ-R8C>$$[1EA9<3=&6%EQ-T9867$W1EA9<7=V
M.&TO+TIB-E(O,&,O=T155DQI<DY-5EE:-68O04]/<C5M+S=A>F8Y46QV;'-/
M5%A*3W-M:#)+=28C>$$[>%9,4$MN+TM6*UIV;EDO.&U$;%4R8U=76D)K*V0O
M.$%N3'HK-CAP+SA:3#<O:45/8D1S,S9Z-VU%*U0U,7ID=%1S5F1I<E!0>48O
M."8C>$$[;DXU5B]W0TUT-2\S5&)R3F8R;"]D:C,O04LR8T]B-U=Z4TYR<U9D
M:7)S5F1I<G-69&ER<U9D:7)S5F1I<G-69&ER<U9D:7)Y,WEZ*R8C>$$[8V5O
M*UEF>D1G.'-$4T1O5G5)<FEA94Q6>3A7;U-I14%+:TU!05%-4S1F-V(Q4E@X
M2S1Q.5-X5C)+=7A6:&8U3B]W1&MT.4DO-D]F*R8C>$$[;W%81E=A67%W>GDO
M+W=!9%AZ3B\R,6TO-FA,9DQ98VUU4V-U-E)O,&MJ0D511FYD:E%!1&-K:S5.
M0T)4>D)O3'HR9'5M<%=R5#9H1R8C>$$[2C=#251X;#=I26IK2DE6-59K4VTO
M2F%J07%R*VQT2R]36#9,*W519G!,:#9V,4@Q53EF,"]W0V8P<3@K4'941E5.
M-54O=T-5<CAZ9B8C>$$[3W@O-4U(2S5S-'-S>41*.#<O.$%/6&XY,354+T%/
M36PY+WA#2$YH,F(Y6CEZ0V9*.#8U=3)P,DMU>%9N;C5#+RM4;3AQ+SA!1U<X
M+R8C>$$[-W!T,6UV-U,O=7@W+W="8D](3CER6G!',3)+=7A6,DMU>%8R2W5X
M5C)+=7A6,DMU>%8R2W5X5C)+=7A6-#$K6$1A.4XU;3!U-6PQ;28C>$$[0TA1
M2C%U:G R9UAT-&US,W).8D)O2E=G=D1'<&HY3GI29W-S;%9"2%1F0W))+U!F
M-6]86&QN5FI9+U8Y4&EJ4EDU0DQQ1C5.13AQ4R8C>$$[:&E$2$9A,G0T>7)7
M2U%&-4-O2$)I9FA&8T-S-#!U-79R;7=I;78W4#9H9'18,7)4,49M-$5-4G1)
M;7I"9T]1-F)(8T$W67%I<U996"8C>$$[*U1F+T%*3&934#A!;S4O-FEP8U9:
M<&ER1%!,+T%0>#%F33,O04<Q;2]W0V]3,WDR2$IR:W@W5B]+6&TO5F12.'AW
M86QQ2UA0;'$O="8C>$$[23!S3DYI5C1:1$MH:V9H-FEZ1&IV=T5H<%-58D5+
M0655;%EN6B]L+S5X=')N44=/;6E1,CEN-65-.7@V.$E.<DIO<5-'-71T,DI*
M;B8C>$$[36=65$A697149W!.<')P4&Q8>F10*V%A95IR+T%%-%=D:$E49$]P
M;&AD63)B5#!T:U@T1V%5,T-.>5(O.3 X9#%Q,BM05D10+TMN+R8C>$$[04-L
M9FUB-3)0+TIG-4-B2TQ,36=Y9D\O+T]8;CDQ-50O=T--;#DO>$-(3F@R8CE:
M.7I#9DHX-C5U,G R2W5X5FYN-4,O=T1K-79+=B8C>$$[+T=7."]W0S9B9%IR
M*S!V-W-E+SEB3TA..7):<$<Q,DMU>%8R2W5X5C)+=7A6,DMU>%8R2W5X5C)+
M=7A6,DMU>%8X,&9L4C5S5%50>B8C>$$[03AR85A(97).<$9Q<S<V3G!*=55N
M87I&>EHS5&=C:W1R6GDY=DA#66Y74C,O=D9)3S)+<#<K94@V2G1F>D%T8C(W
M3G90-G5L2F(S128C>$$[3C-B6$4X545-8EAK-6Q0;S-D;5<Y4TI*:S1H6$Y!
M4G1Z,TMV84YF.'AA4#5F<U!R*W%Z;4,R3')%=D-/4UHR9'%K2VM52WE33V%!
M;28C>$$[:7%D9U0P=TMH3D0X.&56=&0Q0V94.4MV=G).,V)P-G-I96Y+:6Q+
M:%=+3S9+:VY";4-V=THT;EIQ2$95;R]*=B]W06QV<$@O045C+R8C>$$[.5)5
M=4MS,'A6:&YL+W=$-#9V;6(O=').+W="46QV;'-/5%A*3W-M:#)+=7A63%!+
M;B]+5BM:=FY9+SA!2F<U5DYN1FQM45I0;F8X028C>$$[-7DX+W5V2V8O1U,K
M+W=#25$U<T]Z9G)0=5E4-5!N6$XR,4]X5C)+<S@O25@O=T%N3C56+S1Y,VXO
M9$YU<S$O85@Y,E!F*W1N1&TK,28C>$$[<S!J83=&6%EQ-T9867$W1EA9<3=&
M6%EQ-T9867$W1EA9<3=&6%EQ.#(P2#AW9DTY.2M9:S-L*RMJ:G1B1T\V=DE)
M-&8P6F9R23!52"8C>$$[<65I+S$U-4)B9G9&4EI+*VY1,31J<41I<D5F>E4X
M=BMC8B]Z,B]+.# K1WEU66]O.41/;UAM;E)Y27E":DDQ<VLY;$QC27ES951'
M3B8C>$$[=5A4-"MG57$Y3R]-6'E*0C5Z,%<S,"M384M#4S!U:W9)1W5)0F11
M;#%J94EI4T%V1GI(0UIQ9D5+1V@W57=+>'9Y>BM2,FTV55IO3B8C>$$[43%/
M9E9.3V$R:W1O26HV='1C1#9X8U)88S=Y,U5-=V0R964S56II16]+9SAQ-'%M
M+W=#4S!34F9L;F]S859#24QG3%5K;6=U<&4U<28C>$$[8U9:=&ER1%!,+SA!
M>#%F33,O8E=B+W%%=#AT:'EA-4HQ:S!/>%8R2W!:-54O=T-5<CAZ9D]X+S5-
M2$MP<S1S<WE$2C@W+SA!3UAN.28C>$$[,354+T%/36PY+WA#2$YH,F(Y6CEZ
M0V9*.#8U=3)P,DMU>%9N;C5#+RM4;3AQ+SA!1U<X+S=P=#%M=C=3+W5X-R]W
M0F)/2$XY<EIP1R8C>$$[,3)+=7A6,DMU>%8R2W5X5C)+=7A6,DMU>%8R2W5X
M5C)+=7A6-&0U8VDO3&E4.#@U+W%-9"](-6ET<G$W95%Y0S!A3U-E4F)V,5=0
M128C>$$[1S=32D$P<6IL44=S5F%R-E=+;U@X-79++VU05R]/:&TY1S9I,"M+
M3TLS9V4Q,'$U=FAC=VU'4EI%:VMT<#,T9V97-3!R>&E/+V5I="8C>$$[:%8W
M:G!D.4IF,D56,TIA5#),4SAV.49U9VEZ2T%X549H1S!I:FM">4%R5V@S;V%G
M0E56:7)#+WEB+SA!2F(V4B]W0DA0+U563&ER3B8C>$$[35996C5F.$$K3W(U
M;2\W87IF.$%52F(U8D1K,7E4<DIO9&ER<U93>GEP+WEL9FUB-3)0+T%#64]6
M5%IX6EIK1U0U,R]!3V-V4#=R>28C>$$[;B]X:W9V.$%I14]B1',S-GHW;44K
M5#4Q>F1T5'-69&ER4%!Y1B\X04IZ959F*TUT-2\S5&)R3F8R;"]D:C,O<EIW
M-79T8DY),G5X5B8C>$$[,DMU>%8R2W5X5C)+=7A6,DMU>%8R2W5X5C)+=7A6
M,DMV079Y=3AI9FU8<&XU:5<R<#9V<'5P5U=I1#%Y5G9T5FDQ27!Z:&-!33!6
M>"8C>$$[0T-/6E=L8F0Y+T0W4W%V9F-69&ER<U996"M49B]K=#E)+S9/9BMO
M<5A&5V%9<7=Z>2\X03AD6'I.+S(Q;2\V:$QF3%EC;7539%I.1"8C>$$[<U9D
M:7%79590*U5R.'IF3W@O-4U(2W!S-'-S>41*.#<O=T1/6&XY,354+S1Y6#,O
M04)#2$YH,F(Y6CEZ0V9*-'8K6'5G,E=V96-.4"8C>$$[,'4K64QA4RMR2DM'
M6FQ$0T-&-794-4E#=S5M4&HX3RLK,BMB8E!->&=31W5)<W,Y;2]+2TUA5C5X
M,6,V6DMS9'!$>3!+,W1N;'5)5B8C>$$[2T<S;&QL.5%H2D-04VXO9'!)=DQJ
M>C5F16QC>%)Q=#1I+V8Y<E!H4T,R.'(V5R\U6EA&.4A9=U-A.40V.7IE5%A*
M=F]P;W)73S1H="8C>$$[,4U!2$=Z8W))>$1Q>$QF1G0P>3 U1#1L6#9F:"]A
M:71L4#A!25@O>6,S;%@O:DQE9CDP,C9Y;G1,*S=(=B]7<T]B-U=Z4TYR<U9D
M:28C>$$[<G-69&ER<U9D:7)S5F1I<G-69&ER<U9D:7)S5F1I<G-69&ER<U9D
M:7)#+WEB+SA!2F(V4B]W0DA0+U563&ER3DU694-A-RMD*V@K5"8C>$$[9D]8
M;692<C-43'DW;D=O:6(Q8F8P949*3%=#9R]E4TDQ9F@X37IC1VUN3TYH:$I$
M+W=$43 S;&(O<7@V;#DY="]W0E9C="]*6D\U:B8C>$$[<S<O;V%B>70O=T)7
M4%5V=G1V.$%Q<FHK4WED>3=/+S9';3AR9CE74%5V=G1V*W%U4#5,2C-,<WI(
M.&QV4&1H-3 Q4'I4<6QL87HR:R8C>$$[4WE78UIJ=4](2V]H8B]F8D]->$TK
M27=.1FY&-FQL1$HX-R\X-65F,UAL4"]!27E8,R]%26,R2%IV,6XS34HX;GIX
M8C-&>&)4>#-&=B8C>$$[2SA-.%1"-'!O,DMU<DMA:&Q954E)4&-:=7E,86M1
M3EDQ8UA.>F1#*W5"8S-G274U+U9F;DU#-GE(,4=R5B]J4E<S-V=(23A!<7%7
M,28C>$$[4V98.61U3&%E,6XQ2S9M=')Q63-.,4)*3DDP8W,W1W!L:U5T4FY*
M3F52,WA%26<S4S)Y,SAH9B]!0V,S;%@O:DQE9CDP,C9Z0C=3+R8C>$$[=7@W
M+T%.8D](3CER6G!',3)+=7A6,DMU>%8R2W5X5C)+=7A6,DMU>%8R2W5X5C)+
M=7A6,DMU>%9J9C5G96(W:GEP;T@V570Y3V962B8C>$$[5%!&04Q:1$ET0DEF
M:61J1D9C=GA245-A4FY&56<P3#@T3D]V=&)V8E15-#=84TY*=&)32S9H,6DT
M=3)71S0Y4DQC:W=T3$)$0S!3=B8C>$$[9$)/66QQ9F@K06-T;%5D*U1$<$HK
M5VUJ4$=W9$=&=U9:5%5%1S9L,T)'2W,Q>%8X4V9N9"]W0U1B.#!F.'A-6"]5
M3$1M*S=0+W5V:28C>$$[,50U<TEZ3EE/>%8R2W9O,R]N14PO941Z6B]Z1E=V
M.$%Y6F).2C)L.5DY>F1$:RMH8S$W2C@W+S@U968S6&Q0+T%)>5@S+T5)8S)(
M6B8C>$$[=C%N,TU*.&YZ<FTW86Y9<3=&5V5F:TPO04]4;3AQ+SA:8GHO04QP
M=#%M=C=3+W5X-R\Q<S1C,S)T;6MB6%EQ-T9867$W1EA9<3=&6"8C>$$[67$W
M1EA9<3=&6%EQ-T9867$W1EA9<3=&570Q+WDW<$=V,D@Q1%995VUT9S9Y<45L
M;&=D6%=T1U=31F\U1D\U-DYI<5@R2#5E95,W0R8C>$$[.6MV3%A3;VML:VE&
M=559=DI#<UE%631P03=.16QF46HU1E9"4$56-EEQ;'8U37%&+TQB4G=O;T(Y
M66]","\S<6QX5FUM2W9I5#@W=B8C>$$[+TIT*V%0.$%M2FDO-FA98S,S6B\Y
M,3A7<69.:$=:<D(R2W5X5CE'+S@T:&8W=V5B4"M9<3$O-4UT;6LW4RMS935U
M:'EF475A.6LK9"8C>$$[+W=$;DQZ*S8X<"\X6DPW+T%):$1M=S=.*W,K-6A0
M:RMD8S-B53=&6%EQ>GHX:&8O04-C,VQ8+VI,968Y,#(V>E@Y<&8S63DO-C)C
M3R8C>$$[8C=7>E-.<G-69&ER<U9D:7)S5F1I<G-69&ER<U9D:7)S5F1I<G-6
M9&ER<U9D:7)S5F1I<D,O>6(O=T1*8C92+S!C+SE2575+<S!X5B8C>$$[.%-F
M;F0O-4YV>E(O>D5X9CE1<T]B-W,O*S8K3%90;6U8-50V5EI8*VLV.&I146TY
M67=,1'%&,6%7=#=B,FM1:FYA4C4Q;F18:&I:9R8C>$$[9TUY23-';G9K=%1)
M9VIU.35&+VIU5TE41#@P9DID;7-';B\T9&AT:G P2'%&3&Q91G1P1W-L5S-6
M8G5755-/2C1$2DY4,6Y65S5L;"8C>$$[-D%5:' X>#,T=68V9#EV9C5*:T5Q
M+TYN>7IO96@R4&QD9$AA,6UG97EM:FUV3%=E0V,S57-.,4EJ6$)A26UQ=BMX
M6#=)*T1Q:'!05"8C>$$[6DI337(W+S!):TAP4"]/25@K.$AM>B]M2W1F*U1,
M6G(K,'9R2'5:=S50;UA.97EF3R\X07IL-2]D954O*TUL.2]W05%H>EED;2]7
M9B8C>$$[8W=N>69/=6)T<61I<G-66C4K478O:S5V2W8X07AL=E K-F)D6G(K
M,'8W<V4O=T17>FAZ9F$R85)T9&ER<U9D:7)S5F1I<G-69&ER<R8C>$$[5F1I
M<G-69&ER<U9D:7)S5F1I<G-69&ER<U996"M49B]!2DQF4U X06\U+S9I<&-6
M6G!I<C1K+T\W+WEB9FUJ+T%*:5EV*V]72$XY,B8C>$$[9B]D9D9Q;GI94FUA
M=V1I<G-69E)V+T])6"LX2&UZ+VU+=&8K5$Q:<$\P=G)(=6)O8VXP3&UV6E!N
M9CA!-7DX+W5V2V8O1U,K+W=#228C>$$[435S3WIF<E!U650U4&Y83C(Q3WA6
M,DMS."])6"]W06Y.-58O-'DS;B]D3G5S,2]A6#DR4&8K=&Y$;2LQ<S!J83=&
M6%EQ-T9867$W1B8C>$$[6%EQ-T9867$W1EA9<3=&6%EQ-T9867$W1EA9<3=&
M6%EQ=W8X;2\X07E7*VMF.4A0+U563&ER3DU69D5N-3-F*U1B.#!F.'A-6"]5
M3"8C>$$[1&TK-U O=79I,50U<TEZ3EE/>%8R2W9O,R]N14PO941Z6B]Z1E=V
M+T%#6F).2C)L.5DY>F1$:RMH8S$W2C@W+T%03UAN.3$U5"\T>28C>$$[6#,O
M14EC,DA:=C%N,TU*.&YZ<FTW86Y9<3=&5V5F:TPO=T-4;3AQ+SA:8GHO=6TS
M5V$O=$PK-TAV+U=Z:'IF83)A4G1D:7)S5F1I<B8C>$$[<U9D:7)S5F1I<G-6
M9&ER<U9D:7)S5F1I<G-69&ER<U99;BM:;FUB6%!,=FQX8C=224EB:E5*3&U+
M0DDW9T)L-%!5>45+6G)8:W=25"8C>$$[465O3599:#5.+T]F5717=4HU-WEZ
M*W4V5S%R4&,R86%86C-$,VA&=&1W,FA:;U!5;5IH3C8O<7%O549&0G)Y<%A#
M<G9Y-3@Y9F],>28C>$$[8G K;&%H-6$X>'!E5R]R97%Q85!E36\Y4V0U1C-#
M9GES34-S;"\U5W1P+R]!1DQN;5@O=418=B]!1%)I<C5H+TY$4E!/5W4O;49R
M;28C>$$[<S9B-5(Q*U=W=G!O-4QD>G!D,'!+<D)':'%#;3-X26,R,FHQ34E1
M;VYD:$M"3$8O.$4O;4@O,4IU=CA!+V--=78K84UY=GHR3'99*R8C>$$[1UAF
M-$HO35 O<51D9B\W:&PQ+WI2:BME>&0V*T=89C1*+TU0+W%49&8O-VAL,2]Z
M4FHK97AD-BM'6',O+T]01V\V>#5,<SEF5%AV2R8C>$$[,VU'1CE1;F=K=&=M
M:S-B,5=/37$Q84IT=6,Q971Y>&Y+-'1K4E%E=B]W1$LQ=% O04]P8SAY+SEW
M83DO-6]Z1%,X92\U>4@Q1%=F3R8C>$$[8U=G9F](>7(U:&Y/;G9D1S5$-E1D
M<%%43$=%<%9.+W-(37I26EEW:U1,=5EY1F@T,2]G;CAW+RMP3C$O+W5'6%@O
M3D=B5#@Y:3<R2"8C>$$[:&PS*T-F>D0O=T-P3C$O+T%,:&PQ+WI2:BME>&0V
M*T=89C1*+TU0+T%+:S-8+SA!=4=86"].1U U-T8S<C1:6EHK53)J*V-03#,U
M:R8C>$$[-D1R;7%E569-15=N,D5L>3%W-C989$U12F)+94)A2T4S*T]68W<Y
M8G%)5&="13E755EK4'!R+VQA,FXO05!5=65:9BLT3F4O.#!:<28C>$$[,F$K
M1#@P8D-A94]%95AV35-'4F=G9512-WA%2$DP<7I&2T%$=51I<DTX5F1I<G-6
M9&ER<U9D:7)S5F1I<G-69&ER<U9D:7)S5F1I<B8C>$$[<U91=7 V5'!E<3)J
M5U=Q5V-&+UIU45AT<FU.2F]I46%G;$A$2V%9<7-S=$,P4WAV3&DY<W10=')7
M.'5G<3-6>D1$2$A,2T5&145J<28C>$$[07IC4C!Q9'-64G5+=7A69U9T*UHP
M.7)Q5W51*UID3V@P<7<P4S1T-THW=3)U2C<K4V$U=D5I:W0T-#=E2S!2>GI3
M661+:TYT43EC5B8C>$$[4C=F;3$K6'DV6DIQ:F%S0EEX4W!#.'AG=4%+>6AM
M:F-$,"M44DU),DEL03150BM,1E5&669N6#5$=6]U56LY,V)Z96\X670S<V)X
M,R8C>$$[3DQM5S%J665L1DEP.5=30FQ103$U9D14;CA/2V\S+VQB6#5E;48U
M;#%94U)X>%%4:WAW,T0Q4S5A1EEU05=-;#)R9'<X:U=R3'I8:R8C>$$[0EA&
M5F)Y+RM9,VQV>D)R<F%0<%)N;6M7>4=O9E=89VQI:4MF5TAT;6IR2W%-2D5K
M:4E:5U5D>#%69T9755EQ.#@X>69M-T1O9FYU2"8C>$$[>79*65)Y>'5B35-8
M2#%N:F-5=E=K57E25V]I8C%)-$)&>6QB,4)X53%X5DAW9FY,*UA%.$EM5%97
M14I26F9593!V23$T=E)L<5AH5R8C>$$[:#1-2DMD9E0O9699*TQ&6%,O;3,U
M3VAV-5EP8GAF<6EX23!-,&-6,4Q.3$E:-VU",6IG4T%L,%$R5&YM:DYS0V%"
M44=+<79C+VUX*R8C>$$[6'1T8GE8175S2C9%66-M5EEP,U5I3DQE4G5"4D<U
M+T1F454T,7)Y,G)1,%93*T0X-F9*:C9R9#(P,7<P3FA&67=A:&%8-6IU1#8V
M4R8C>$$[:5EY3#91:35O,%EG,E9V:65P;W9W-'%Z,$5%06IO9#DY:CEX>%8R
M2W5X5C)+=7A6,DMU>%8R2W5X5C)+=7A6,DMU>%8R2W5X5C)+=28C>$$[>%8R
M2W5X5C)+=7A62C=J>6@U8W5,:31U6G)-4%!D,VQR<59W+T]11G)Q>$5A,CAM
M>F)C0D%N=VHT5%1C1W!Q<3AL,&UX+S5X,78T-R8C>$$[;E(T=$I&:&$S3C%F
M5&%G.# X;'-K575L,&=C>5-I-$12>'5L-F945E1W24Q!9TAB1E=7,C)L9FQ$
M8F$Q8W%"83(X>7A7,G1,8WE8-"8C>$$[.4HT-#=M82]384)$8TU5:FEM-5-U
M94-X;FPK,$MG2V]J4B]Y,"]+1U<V=4@P;7AT3&DV=&MT8D\W348Q2DTX67,S
M:6UT-#5+4W-66B8C>$$[5$)'9#DR06\Q4FER271).&UE5W1(=CA!-B]P=&]B
M939-371U5T5S>DM9-7)L-WAW55IY:"]F>D]Y:VEQ.&E&;W4R2W S:7%4-FAP
M;28C>$$[;E=2,5A7261-;'9R*R]T-&],>4,S6F96=4EO3UEJ4E9M:VEI0E54
M=G9Y5W9J,'A6-7HU6G-F>4PQ5T<R,2M85$E.1W5P=$LK<C)S3R8C>$$[<C-5
M561W*VM*8F969E<Y25A-=SE0,$9A3#%8*T]I:T4T<6U'=#)(-45796UX=F4S
M5FEK5VTV9$(Y5E<S=C50<DLR3G-*5$,P26=M.28C>$$[6F=28WE$:W4W.'%-
M5WA65VXX="]K5WAV3' W;E19:U-'3T,W365P3D1&1$A/:TMX9D%K-G!#,&E7
M.%A&,4%:9V\S>%9#85(K5W9K5"8C>$$[>DQO=FQN5W1!=&8P8F\O<5=M<%!A
M>DDX='A-='-:<$QE3FYA9#%J4'%857!L4'AL*U9#96AX5C9N:7)S5F1I<G-6
M9&ER<U9D:7)S5B8C>$$[9&ER<U9D:7)S5F1I<G-69&ER<U9D:7)S5F1I<G-6
M9&EQ>6%A2T-'4V%:>$A&17!E4C).07%Q2VMK*W=X5C5R1"M3+VM05G)+,S%/
M>"8C>$$[=4PV1F(R,6TY2S=I6DEP6&AV<G8Y26AN4U-'=DI79FEO9&9S9D,T
M3TMO1%5V>3 O2V936G)04SE5,4LU4S1S-TM#.5)*6D8U1W@P428C>$$[4VE2
M<%=3240P-45U,E=65%1M0CA)0E5N1E4W+T%#,W-0>2MG,6I63E0X=&%L9%AL
M>G(T93AK9W5M;#1X4G@S57=L4T=/5T].;W=T>B8C>$$[3$E84G%S0S%45&M+
M<7918U9D:7)S5F5C5U@U5RM2=%,P938P<7IV8C)31S!S-V9Y+TIC4GE#3U=*
M=$UU1W5K94]4,&Q(<DQ,3#A43"8C>$$[5F1U3DYM>%9J2&U0.' O>6PX=$QA
M<'(K=39R2$AC>#-+4DQ++W="6DHU=TY"8UA-:DIB>5!'1D8Q>EHR6EDQ66=N
M<E%Q<C=4>4@K528C>$$[.3$U<'5*-V)Z3'%R-C5(<5!P4FXQ2W@R.3E-6FUM
M34MV8BMH4V0T2FQ:<49/64M,>&%G=W$Y6CAT95@W3'DW;T9H;V1I,&HR;6Y1
M<B8C>$$[0D,X>$131E5&2W560VEP.6=-0W!L:7)S5F1I<G-69&ER<U9D:7)S
M5F1I<G-69&ER<U9D:7)S5F1I<G-69&ER<U9D:7)S5F1I<58K828C>$$[9$ML
M,6IY>'$K:W=V-E5U;S)6>F%2>3E/3%1X3D='*V=T:7)Z93@O265X.'A.1G%7
M<UA,,D8Q94<Q;G9R5TM',VMM:E=(5%ER43)N<B8C>$$[4#E9:5E#849:4V5$
M3'1S2S!F1E4T:2]*5%%,5S)S-U=W=41$1F$V8G%M;'EZ3F(R>&YM6%9#<$13
M1TY)66E)2U!X5# V2&QV,S5+<28C>$$[4&M4.',Y53AR-B]997!E9EAB0W=T
M9%%0,7IJ-F9/8E5P-V0R:$-03&-41E4K<71+>D\U<3AM>'!S1EAP5TMU>%8R
M2W9+52]*,C0Q0R8C>$$[-5,T=G)R-G!0<&0Y97DV9% V87I/>3-/<GAA;W1Y
M:FE25VIK35-08DY55BM);G!S>7%G,R]/4#!D:&)M,#AU*UE(<S='-6UH;C%3
M,"8C>$$[=DQ+,VYJ=6IB1FI"1R\Q4#E(2#!W,&I&:UES1S(V54Y6554S-5)8
M1FAQ;'9C,E8P.3-(2G$Q<$]G-'!&.51S8F$K=6169%=9=51-6"8C>$$[=4QG
M>#%!<E)L,F]'8D98<65+=7A6,DMU>%8R2W5X5C)+=7A6,DMU>%8R2W5X5C)+
M=7A6,DMU>%8O.6L]/"]X;7!'26UG.FEM86=E/@H@(" @(" @(" @(" @(" \
M+W)D9CIL:3X*(" @(" @(" @(" @/"]R9&8Z06QT/@H@(" @(" @(" \+WAM
M<#I4:'5M8FYA:6QS/@H@(" @(" \+W)D9CI$97-C<FEP=&EO;CX*(" @(" @
M/')D9CI$97-C<FEP=&EO;B!R9&8Z86)O=70](B(*(" @(" @(" @(" @>&UL
M;G,Z<&1F/2)H='1P.B\O;G,N861O8F4N8V]M+W!D9B\Q+C,O(CX*(" @(" @
M(" @/'!D9CI0<F]D=6-E<CY!9&]B92!01$8@;&EB<F%R>2 Q,"XP,3PO<&1F
M.E!R;V1U8V5R/@H@(" @(" \+W)D9CI$97-C<FEP=&EO;CX*(" @(" @/')D
M9CI$97-C<FEP=&EO;B!R9&8Z86)O=70](B(*(" @(" @(" @(" @>&UL;G,Z
M9&,](FAT=' Z+R]P=7)L+F]R9R]D8R]E;&5M96YT<R\Q+C$O(CX*(" @(" @
M(" @/&1C.F9O<FUA=#YA<'!L:6-A=&EO;B]P;W-T<V-R:7!T/"]D8SIF;W)M
M870^"B @(" @(" @(#QD8SIC<F5A=&]R/@H@(" @(" @(" @(" \<F1F.E-E
M<3X*(" @(" @(" @(" @(" @/')D9CIL:3YR<C,S,S$V.#PO<F1F.FQI/@H@
M(" @(" @(" @(" \+W)D9CI397$^"B @(" @(" @(#PO9&,Z8W)E871O<CX*
M(" @(" @(" @/&1C.G1I=&QE/@H@(" @(" @(" @(" \<F1F.D%L=#X*(" @
M(" @(" @(" @(" @/')D9CIL:2!X;6PZ;&%N9STB>"UD969A=6QT(CYG,#)F
M,C8\+W)D9CIL:3X*(" @(" @(" @(" @/"]R9&8Z06QT/@H@(" @(" @(" \
M+V1C.G1I=&QE/@H@(" @(" @(" \9&,Z9&5S8W)I<'1I;VX^"B @(" @(" @
M(" @(#QR9&8Z06QT/@H@(" @(" @(" @(" @(" \<F1F.FQI('AM;#IL86YG
M/2)X+7)E<&%I<B(^1FEL92!.86UE.B @(" @(" @(" @(" @('-T,3$V+F%I
M)B-X03M5<V5R;F%M93H@(" @(" @(" @(" @(')R,S,S,38X)B-X03M,;V-A
M;"!4:6UE.B @(" @(" @(" @(" Q-BU*=6PM,C R," Q-3HQ,SHU-"8C>$$[
M15-4(%1I;64Z(" @(" @(" @(" @(" Q-BU*=6PM,C R," P-3HT,SHU-"8C
M>$$[4V-R:7!T(%9E<G-I;VXZ(" @(" @(" @,BXV)B-X03M);&QU<W1R871O
M<B!697)S:6]N.B @(" Q-BXP+C F(WA!.T=R87!H:6,@='EP93H@(" @(" @
M(" @0F%R($-H87)T)B-X03LF(WA!.RHJ*E1H92!P<F5F;&EG:'0@8VAE8VL@
M:7,@8V]M<&QE=&4N(%!L96%S92!E;G-U<F4@;6%N=6%L(&-H96-K<R!A<F4@
M8V]M<&QE=&5D('!E<B!P<F]C97-S+BHJ*B8C>$$[)B-X03M4:&4@9F]L;&]W
M:6YG(&9O;G1S(&%R92!P<F5S96YT(&EN('1H92!D;V-U;65N=#HF(WA!.R @
M(" @(" @("!4:6UE<RU2;VUA;B8C>$$[(" @(" @(" @(%1I;65S+4)O;&0F
M(WA!.R8C>$$[5&AE(&9O;&QO=VEN9R!C;VQO<G,@87)E('!R97-E;G0@:6X@
M=&AE(&1O8W5M96YT.B8C>$$[(" @(" @(" @($)L86-K)B-X03L@(" @(" @
M(" @0TU92R8C>$$[)B-X03LM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM
M+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM
M+2TM+2TM+2TM+2TM+2TM+2TM+2TF(WA!.T9I;&4@3F%M93H@(" @(" @(" @
M(" @("!G,#)F,C8N86DF(WA!.U5S97)N86UE.B @(" @(" @(" @(" @<G(R
M,#8P,S0F(WA!.TQO8V%L(%1I;64Z(" @(" @(" @(" @(#$W+4IU;"TR,#(P
M(#$T.C4Y.C4W)B-X03M%4U0@5&EM93H@(" @(" @(" @(" @(#$W+4IU;"TR
M,#(P(# U.C(Y.C4W)B-X03M38W)I<'0@5F5R<VEO;CH@(" @(" @(" R+C8F
M(WA!.TEL;'5S=')A=&]R(%9E<G-I;VXZ(" @(#$V+C N,"8C>$$[1W)A<&AI
M8R!T>7!E.B @(" @(" @("!"87(@0VAA<G0F(WA!.R8C>$$[*BHJ5&AE('!R
M969L:6=H="!C:&5C:R!I<R!C;VUP;&5T92X@4&QE87-E(&5N<W5R92!M86YU
M86P@8VAE8VMS(&%R92!C;VUP;&5T960@<&5R('!R;V-E<W,N*BHJ)B-X03LF
M(WA!.U1H92!F;VQL;W=I;F<@9F]N=',@87)E('!R97-E;G0@:6X@=&AE(&1O
M8W5M96YT.B8C>$$[(" @(" @(" @($%R:6%L350F(WA!.R @(" @(" @("!!
M<FEA;$U4+4)O;&0F(WA!.R8C>$$[5&AE(&9O;&QO=VEN9R!C;VQO<G,@87)E
M('!R97-E;G0@:6X@=&AE(&1O8W5M96YT.B8C>$$[(" @(" @(" @($)L86-K
M)B-X03L@(" @(" @(" @0TU92R8C>$$[)B-X03LM+2TM+2TM+2TM+2TM+2TM
M+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM
M+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TF(WA!.T9I;&4@3F%M
M93H@(" @(" @(" @(" @("!G,#)F,C8N86DF(WA!.U5S97)N86UE.B @(" @
M(" @(" @(" @<G(Q.3(Q,#0F(WA!.TQO8V%L(%1I;64Z(" @(" @(" @(" @
M(#(S+5-E<"TR,#(P(#$T.C4P.C4U)B-X03M%4U0@5&EM93H@(" @(" @(" @
M(" @(#(S+5-E<"TR,#(P(#$W.C4P.C4U)B-X03M38W)I<'0@5F5R<VEO;CH@
M(" @(" @(" R+C8F(WA!.TEL;'5S=')A=&]R(%9E<G-I;VXZ(" @(#$V+C N
M,"8C>$$[1W)A<&AI8R!T>7!E.B @(" @(" @("!"87(@0VAA<G0F(WA!.R8C
M>$$[*BHJ5&AE('!R969L:6=H="!C:&5C:R!I<R!C;VUP;&5T92X@4&QE87-E
M(&5N<W5R92!M86YU86P@8VAE8VMS(&%R92!C;VUP;&5T960@<&5R('!R;V-E
M<W,N*BHJ)B-X03LF(WA!.U1H92!F;VQL;W=I;F<@9F]N=',@87)E('!R97-E
M;G0@:6X@=&AE(&1O8W5M96YT.B8C>$$[(" @(" @(" @($%R:6%L350F(WA!
M.R @(" @(" @("!!<FEA;$U4+4)O;&0F(WA!.R8C>$$[5&AE(&9O;&QO=VEN
M9R!C;VQO<G,@87)E('!R97-E;G0@:6X@=&AE(&1O8W5M96YT.B8C>$$[(" @
M(" @(" @($)L86-K)B-X03L@(" @(" @(" @0TU92R8C>$$[)B-X03LM+2TM
M+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM
M+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TF
M(WA!.SPO<F1F.FQI/@H@(" @(" @(" @(" \+W)D9CI!;'0^"B @(" @(" @
M(#PO9&,Z9&5S8W)I<'1I;VX^"B @(" @(#PO<F1F.D1E<V-R:7!T:6]N/@H@
M(" @(" \<F1F.D1E<V-R:7!T:6]N(')D9CIA8F]U=#TB(@H@(" @(" @(" @
M("!X;6QN<SIX;7!44&<](FAT=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"]T
M+W!G+R(*(" @(" @(" @(" @>&UL;G,Z<W1$:6T](FAT=' Z+R]N<RYA9&]B
M92YC;VTO>&%P+S$N,"]S5'EP92]$:6UE;G-I;VYS(R(*(" @(" @(" @(" @
M>&UL;G,Z<W1&;G0](FAT=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"]S5'EP
M92]&;VYT(R(*(" @(" @(" @(" @>&UL;G,Z>&UP1STB:'1T<#HO+VYS+F%D
M;V)E+F-O;2]X87 O,2XP+V<O(CX*(" @(" @(" @/'AM<%109SI.4&%G97,^
M,3PO>&UP5%!G.DY086=E<SX*(" @(" @(" @/'AM<%109SI(87-6:7-I8FQE
M5')A;G-P87)E;F-Y/D9A;'-E/"]X;7!44&<Z2&%S5FES:6)L951R86YS<&%R
M96YC>3X*(" @(" @(" @/'AM<%109SI(87-6:7-I8FQE3W9E<G!R:6YT/E1R
M=64\+WAM<%109SI(87-6:7-I8FQE3W9E<G!R:6YT/@H@(" @(" @(" \>&UP
M5%!G.DUA>%!A9V53:7IE(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @
M(" @(" @(" @/'-T1&EM.G<^-C$R+C P,# P,#PO<W1$:6TZ=SX*(" @(" @
M(" @(" @/'-T1&EM.F@^-SDR+C P,# P,#PO<W1$:6TZ:#X*(" @(" @(" @
M(" @/'-T1&EM.G5N:70^4&]I;G1S/"]S=$1I;3IU;FET/@H@(" @(" @(" \
M+WAM<%109SI-87A086=E4VEZ93X*(" @(" @(" @/'AM<%109SI&;VYT<SX*
M(" @(" @(" @(" @/')D9CI"86<^"B @(" @(" @(" @(" @(#QR9&8Z;&D@
M<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" @(" @(" \
M<W1&;G0Z9F]N=$YA;64^07)I86Q-5#PO<W1&;G0Z9F]N=$YA;64^"B @(" @
M(" @(" @(" @(" @(#QS=$9N=#IF;VYT1F%M:6QY/D%R:6%L/"]S=$9N=#IF
M;VYT1F%M:6QY/@H@(" @(" @(" @(" @(" @(" \<W1&;G0Z9F]N=$9A8V4^
M4F5G=6QA<CPO<W1&;G0Z9F]N=$9A8V4^"B @(" @(" @(" @(" @(" @(#QS
M=$9N=#IF;VYT5'EP93Y/<&5N(%1Y<&4\+W-T1FYT.F9O;G14>7!E/@H@(" @
M(" @(" @(" @(" @(" \<W1&;G0Z=F5R<VEO;E-T<FEN9SY697)S:6]N(#<N
M,# \+W-T1FYT.G9E<G-I;VY3=')I;F<^"B @(" @(" @(" @(" @(" @(#QS
M=$9N=#IC;VUP;W-I=&4^1F%L<V4\+W-T1FYT.F-O;7!O<VET93X*(" @(" @
M(" @(" @(" @(" @/'-T1FYT.F9O;G1&:6QE3F%M93YA<FEA;"YT=&8\+W-T
M1FYT.F9O;G1&:6QE3F%M93X*(" @(" @(" @(" @(" @/"]R9&8Z;&D^"B @
M(" @(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B
M/@H@(" @(" @(" @(" @(" @(" \<W1&;G0Z9F]N=$YA;64^07)I86Q-5"U"
M;VQD/"]S=$9N=#IF;VYT3F%M93X*(" @(" @(" @(" @(" @(" @/'-T1FYT
M.F9O;G1&86UI;'D^07)I86P@350\+W-T1FYT.F9O;G1&86UI;'D^"B @(" @
M(" @(" @(" @(" @(#QS=$9N=#IF;VYT1F%C93Y";VQD/"]S=$9N=#IF;VYT
M1F%C93X*(" @(" @(" @(" @(" @(" @/'-T1FYT.F9O;G14>7!E/E1Y<&4@
M,3PO<W1&;G0Z9F]N=%1Y<&4^"B @(" @(" @(" @(" @(" @(#QS=$9N=#IV
M97)S:6]N4W1R:6YG/C P,2XP,#,\+W-T1FYT.G9E<G-I;VY3=')I;F<^"B @
M(" @(" @(" @(" @(" @(#QS=$9N=#IC;VUP;W-I=&4^1F%L<V4\+W-T1FYT
M.F-O;7!O<VET93X*(" @(" @(" @(" @(" @(" @/'-T1FYT.F9O;G1&:6QE
M3F%M93YA<FEA8E]?7RYP9F([(&%R:6%B7U]?+E!&33PO<W1&;G0Z9F]N=$9I
M;&5.86UE/@H@(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @
M/"]R9&8Z0F%G/@H@(" @(" @(" \+WAM<%109SI&;VYT<SX*(" @(" @(" @
M/'AM<%109SI0;&%T94YA;65S/@H@(" @(" @(" @(" \<F1F.E-E<3X*(" @
M(" @(" @(" @(" @/')D9CIL:3Y#>6%N/"]R9&8Z;&D^"B @(" @(" @(" @
M(" @(#QR9&8Z;&D^36%G96YT83PO<F1F.FQI/@H@(" @(" @(" @(" @(" \
M<F1F.FQI/EEE;&QO=SPO<F1F.FQI/@H@(" @(" @(" @(" @(" \<F1F.FQI
M/D)L86-K/"]R9&8Z;&D^"B @(" @(" @(" @(#PO<F1F.E-E<3X*(" @(" @
M(" @/"]X;7!44&<Z4&QA=&5.86UE<SX*(" @(" @(" @/'AM<%109SI3=V%T
M8VA'<F]U<',^"B @(" @(" @(" @(#QR9&8Z4V5Q/@H@(" @(" @(" @(" @
M(" \<F1F.FQI(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @
M(" @(" @(" @/'AM<$<Z9W)O=7!.86UE/D1E9F%U;'0@4W=A=&-H($=R;W5P
M/"]X;7!'.F=R;W5P3F%M93X*(" @(" @(" @(" @(" @(" @/'AM<$<Z9W)O
M=7!4>7!E/C \+WAM<$<Z9W)O=7!4>7!E/@H@(" @(" @(" @(" @(" \+W)D
M9CIL:3X*(" @(" @(" @(" @/"]R9&8Z4V5Q/@H@(" @(" @(" \+WAM<%10
M9SI3=V%T8VA'<F]U<',^"B @(" @(#PO<F1F.D1E<V-R:7!T:6]N/@H@(" @
M(" \<F1F.D1E<V-R:7!T:6]N(')D9CIA8F]U=#TB(@H@(" @(" @(" @("!X
M;6QN<SIX;7!-33TB:'1T<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP+VUM+R(*
M(" @(" @(" @(" @>&UL;G,Z<W12968](FAT=' Z+R]N<RYA9&]B92YC;VTO
M>&%P+S$N,"]S5'EP92]297-O=7)C95)E9B,B"B @(" @(" @(" @('AM;&YS
M.G-T179T/2)H='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q+C O<U1Y<&4O4F5S
M;W5R8V5%=F5N=",B/@H@(" @(" @(" \>&UP34TZ1&]C=6UE;G1)1#YX;7 N
M9&ED.C,X,S=".#0X1#A&1$5!,3$X.4(Q0D8S,T%!-30W0C0P/"]X;7!-33I$
M;V-U;65N=$E$/@H@(" @(" @(" \>&UP34TZ26YS=&%N8V5)1#YX;7 N:6ED
M.C,X,S=".#0X1#A&1$5!,3$X.4(Q0D8S,T%!-30W0C0P/"]X;7!-33I);G-T
M86YC94E$/@H@(" @(" @(" \>&UP34TZ3W)I9VEN86Q$;V-U;65N=$E$/GAM
M<"YD:60Z144P,31"0SDS1$,W14$Q,4$U,4%!.3(U-$(T.4-$,C$\+WAM<$U-
M.D]R:6=I;F%L1&]C=6UE;G1)1#X*(" @(" @(" @/'AM<$U-.E)E;F1I=&EO
M;D-L87-S/F1E9F%U;'0\+WAM<$U-.E)E;F1I=&EO;D-L87-S/@H@(" @(" @
M(" \>&UP34TZ1&5R:79E9$9R;VT@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B
M/@H@(" @(" @(" @(" \<W12968Z:6YS=&%N8V5)1#YX;7 N:6ED.C,W,S="
M.#0X1#A&1$5!,3$X.4(Q0D8S,T%!-30W0C0P/"]S=%)E9CII;G-T86YC94E$
M/@H@(" @(" @(" @(" \<W12968Z9&]C=6UE;G1)1#YX;7 N9&ED.C,W,S="
M.#0X1#A&1$5!,3$X.4(Q0D8S,T%!-30W0C0P/"]S=%)E9CID;V-U;65N=$E$
M/@H@(" @(" @(" @(" \<W12968Z;W)I9VEN86Q$;V-U;65N=$E$/GAM<"YD
M:60Z144P,31"0SDS1$,W14$Q,4$U,4%!.3(U-$(T.4-$,C$\+W-T4F5F.F]R
M:6=I;F%L1&]C=6UE;G1)1#X*(" @(" @(" @(" @/'-T4F5F.G)E;F1I=&EO
M;D-L87-S/F1E9F%U;'0\+W-T4F5F.G)E;F1I=&EO;D-L87-S/@H@(" @(" @
M(" \+WAM<$U-.D1E<FEV961&<F]M/@H@(" @(" @(" \>&UP34TZ2&ES=&]R
M>3X*(" @(" @(" @(" @/')D9CI397$^"B @(" @(" @(" @(" @(#QR9&8Z
M;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" @(" @
M(" \<W1%=G0Z86-T:6]N/G-A=F5D/"]S=$5V=#IA8W1I;VX^"B @(" @(" @
M(" @(" @(" @(#QS=$5V=#II;G-T86YC94E$/GAM<"YI:60Z144P,31"0SDS
M1$,W14$Q,4$U,4%!.3(U-$(T.4-$,C$\+W-T179T.FEN<W1A;F-E240^"B @
M(" @(" @(" @(" @(" @(#QS=$5V=#IW:&5N/C(P,C M,#<M,394,34Z,#DZ
M-3<K,#4Z,S \+W-T179T.G=H96X^"B @(" @(" @(" @(" @(" @(#QS=$5V
M=#IS;V9T=V%R94%G96YT/D%D;V)E($EL;'5S=')A=&]R($-3-B H5VEN9&]W
M<RD\+W-T179T.G-O9G1W87)E06=E;G0^"B @(" @(" @(" @(" @(" @(#QS
M=$5V=#IC:&%N9V5D/B\\+W-T179T.F-H86YG960^"B @(" @(" @(" @(" @
M(#PO<F1F.FQI/@H@(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP87)S951Y
M<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @/'-T179T.F%C=&EO
M;CYS879E9#PO<W1%=G0Z86-T:6]N/@H@(" @(" @(" @(" @(" @(" \<W1%
M=G0Z:6YS=&%N8V5)1#YX;7 N:6ED.C,X,S=".#0X1#A&1$5!,3$X.4(Q0D8S
M,T%!-30W0C0P/"]S=$5V=#II;G-T86YC94E$/@H@(" @(" @(" @(" @(" @
M(" \<W1%=G0Z=VAE;CXR,#(P+3 Y+3(S5#$T.C4Q.C Q+3 W.C P/"]S=$5V
M=#IW:&5N/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z<V]F='=A<F5!9V5N
M=#Y!9&]B92!);&QU<W1R871O<B!#4S8@*%=I;F1O=W,I/"]S=$5V=#IS;V9T
M=V%R94%G96YT/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z8VAA;F=E9#XO
M/"]S=$5V=#IC:&%N9V5D/@H@(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @
M(" @(" @(" @/"]R9&8Z4V5Q/@H@(" @(" @(" \+WAM<$U-.DAI<W1O<GD^
M"B @(" @(#PO<F1F.D1E<V-R:7!T:6]N/@H@(" \+W)D9CI21$8^"CPO>#IX
M;7!M971A/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @"CP_>'!A8VME="!E;F0]
M(G<B/S[_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_VP!# 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0'_P  1" #^ 58# 1$  A$! Q$!_\0 'P !  (" P # 0
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MIQ!97:VY;B=R69P3B:*.-H[RDFKV=KY.U^/5=_Q%J($
M            A;7MP;66E%DLXB=.Z]IHT[N<E3,A<BOZQT3YFWL4F>(\G4NB
M)MUP=D")8LQ:NZSD:1T<2$N1_<^"U5P7V[,5:MXD_&KG=?;!N;\TNL7C#VK^
MU\"@]L&YOS2ZQ>,/:O[7P ]L&YOS2ZQ>,/:O[7P ]L&YOS2ZQ>,/:O[7P ]L
M&YOS2ZQ>,/:O[7P ]L&YOS2ZQ>,/:O[7P ]L&YOS2ZQ>,/:O[7P ]L&YOS2Z
MQ>,/:O[7P ]L&YOS2ZQ>,/:O[7P ]L&YOS2ZQ>,/:O[7P ]L&YOS2ZQ>,/:O
M[7P ]L&YOS2ZQ>,/:O[7P ]L&YOS2ZQ>,/:O[7P ]L&YOS2ZQ>,/:O[7P ]L
M&YOS2ZQ>,/:O[7P ]L&YOS2ZQ>,/:O[7P ]L&YOS2ZQ>,/:O[7P!#G=[>K9_
M1VJ8_;$TUVH::-<AL)IKQ.UQ?8^PDS@G<':-RR2E.!QCMK.G3\HRD\25)S,,
M,^3N3U2?G''DO$SG$2BMYVO;*Y;&!$   .!>HK%Y(JCJZ11MA?UL0?,9/$UC
MTSM[HJB\EP:W1CPD,=4+DYYK(^8LKX],^+LVYIE^+6[NC?PHX2."LDX#K7-1
M51E9.-RY5A7G-P8,/,6PM;F%1OFR<(QSESGS',9URV>VC%AYRYYRY:.'3AOY
MRYYYY3^KSSR N]+Y<A4_*/C!E3?=-6;YU43 GZF_#71D71@0
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M5= $H:OF^M%Z@$       *7)1\8,J;[IJS?.JB8$_4WX:Z,BZ,"
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MS=545L^Q&[A>TQYRN*]$S\K[IA3UDB#7CUU^OCXW?+O*UKI&<NGE55T:M/\
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MG'A9ZS_GO5OI4 L^1^)CWZ>G'A9ZS_GO5OI4 L^1^)CWZ>G'A9ZS_GO5OI4
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M&;5]*DAWMODI\FC#K+5!!"&OL'3F.MK<N2"N]DUGFFLW=+LM[)<O_P"ZD2*
MTQUPTJZ\D4AFMD"70".3KIDVI/)2@73RQI]FXRE5LS!6H]R+761+9<XMQ>:!
MN1D\-K6K1->')7)V"+$\TXPQ9<A5MNGGQ32T2XI<BS^$V10+8 %2D([Y1O\
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M=BD=[_OG[;5A^0K7(>+_ $2>[GA%[JP_F&$.APO:U#P'TY&SH.'+X
M                        &L#U$M7MX]C+:M-XB]JE[S:UQJW*E]D=1Z6V
M'CU(R"G83$+!ADFN.K[)I] C98ML/(9S7C5,XFVXVI=D7>VI9*$BYIBG;$*,
MO!^&7(N*6EFT^R:OJG9]ZSMHGE?4V/ZH*82:MK4F+0=RK&,%0"'%1RM7EF21
MUWKUA+CK=@T0=UCZ!4M0,3E$V_A.P+F9$M5I&M4WFH4RI021@;F+?SG?P
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M2.]_WS]MJP_(5KD/%_HD]W/"+W5A_,,(=#A>UJ'@/IR-G0<.7P
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MNS_12XW>VK;-A4"  %+DH^,&5-]TU9OG51,"?J;\-=&1=&!  "I2$=\HW_\
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MY"M<AXO]$GNYX1>ZL/YAA#H<+VM0\!].1LZ#AR^
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M^2F3+&W-<     0+ZFOP*[4_J2CO+_5PQ,=VI6YH].)D87MBG^_T)%R@YHW
M %)W9$W>?MK?I/73SI:4&YX.=T.P??G9?GU A4]*J^U5?HY'FP#W><T
M !ON=BD=[_OG[;5A^0K7(>+_ $2>[GA%[JP_F&$.APO:U#P'TY&SH.'+X
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MWO\ OG[;5A^0K7(>,?1)[N>$7NK#^880Z'"]K4/ ?3D;.@X<O@
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MBD=[_OG[;5A^0K7(>./1)[N>$7NK#^880Z#"]K4/ ?3D;.@X<O@
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MU8?D*UR'B_T2>[GA%[JP_F&$.APO:U#P'TY&SH.'+X
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MZL/YAA#H<+VM0\!].1LZ#AR^
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M'Y"M<AXO]$GNYX1>ZL/YAA#H<+VM0\!].1LZ#AR^
M                    4N2CXP94WW35F^=5$P)^IOPUT9%T8$  /.:[)3[Z
MI,OJ$HW_ &\N'HKT">U^$OMVRNAM U>TO4?[3_3*%!]^-6     =_J3_ %>I
M_P"MVK?^?1X</Z)/</PA]RT?/,,9.#[9I<\NA(]A$>+S?@ 4G=D3=Y^VM^D]
M=/.EI0;G@YW0[!]^=E^?4"%3TJK[55^CD>; /=YS0      &^YV*1WO^^?MM
M6'Y"M<AXO]$GNYX1>ZL/YAA#H<+VM0\!].1LZ#AR^
M                     4N2CXP94WW35F^=5$P)^IOPUT9%T8$  /.:[)3[
MZI,OJ$HW_;RX>BO0)[7X2^W;*Z&T#5[2]1_M/],H4'WXU8    !W^I/]7J?^
MMVK?^?1X</Z)/</PA]RT?/,,9.#[9I<\NA(]A$>+S?@ 4G=D3=Y^VM^D]=/.
MEI0;G@YW0[!]^=E^?4"%3TJK[55^CD>; /=YS0      &^YV*1WO^^?MM6'Y
M"M<AXO\ 1)[N>$7NK#^880Z'"]K4/ ?3D;.@X<O@
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MZ10WM62=(N/R6Y\+%)9BC' OC/C#@1=KY*RY+W^?(SR!0
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MU#HQELBQSY?V7N\+//O6O\.A)$"@
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M"[J8T6J7/"0^).2Q^.+5O/*8I^/Q^/*&[J*Y-7Q\=E\'U]Y%K0$0
M                                      *->JHQ;/+]KNGQ+-4G1]PL
MVH8GN9<+;"R%"Y/#+C.@S/0"A;2,YS)XY0%$VM#UDSAL7<%_)9C'*71M?T9Q
M/+6>9B_'XU)Q:S3MG97TMQWX]&E<JGA/47VGI;4_53W*7.=1.1/K5<MZO%=6
MK43>X<3A@F744M>,*H@YRY]62"<NDCA5;<+%T@@, C<3/@$9-:Y^_P!G>UTU
MN9"Q7=3;5T]%=.^B[V5F^_Q-:DNU&U6\%(L,GYIZ#$/R#8;=+J!:FUFV8P%>
MN)K795YV[<T.OMW2]8M,6*U=9J*VPLM^FQ2\]%$LC88R*D/*0AX-2G!:/B4&
M\[732WEDM4VK<>;O=HS_ *N;H[FSSJ.SS7>S%K%C7\8LC8F"NM<.,!.9Y*PU
M;5C:UXTO?3:\L,:.4E<W&IY;GAP63:1(*_D"6><-59HT[M#5J!6(M))6Y%R:
M\:_&G'J7T 1     ->V6:U5U6'4IW LR"UV[IG&L>GY$MFZS4'/MANT:1;*O
M%F[/'O\ +$C0LD2AB='MU3L$5)<(X8F4-?").A+):$Y9V/)@G=[L5KV3RY4E
M&RY;:V(]3K?+J859QI\E=Y]&'UTO362E=C$:Q[HPB/1RR[AMN9QIND^J*-OC
M##+9;REK6**$JHCF%)2;5/43XN8/JCF*Q)>V%/QWRMHY]Z36;6F=I/)<=N]E
M:UVC$FVF_P#NY8V.^E5U=9L\:8DGH?>13&2FJI6ZOK9J*5:W6G 6=B8F#VHJ
MWR71]3.*W6S3AO?Y?.E\TED<.(MN/0VKDG#0R&OQR%8QCV-U^M'5Y24M7\%U
M?B6:;;))-?42WHSVH7UQ G*,6]&&=G:D]7U^OK56U+=EJORTW*MQHV0CCQ$X
MZM>6U;.[C,P0%FXN4?J!@:TZ^K5F*.R%#0N4"+C%):WXWR.]FGRJV>6=U?33
M)72WNVU=@-S)39%AW([W.>\].76=3*5V%3.E/Q>O;<<;>N-]L:GTS":G2M3H
M^UNZO'+(O=L2LY$D0\H(W*%:Y[8%JLX4E9:*SWI>*T;=_E:Y\C86 B
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MZTK-34@V,M@3C!X1DRA8O0FE-D::XXW-QHKO:M*UE+O_ *63SRTWKHV(0(
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M*J74G [' TLEQ/:S%9)6>!>1)1V!7:\.,/6<"+=VWI=MVYS/8%
4                        _]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>g947560g02g78.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g947560g02g78.jpg
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M 0$! 0$! 0$! ?_  !$( *@"70,!$0 "$0$#$0'_Q  ?  $  00# 0$!
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M='63H[2UP=4D,S="5G:5L]3B\0@E)C1C<T1%8G*D@K+#)V1EA*+_V@ , P$
M A$#$0 _ /?QIAAIAAIAAIAAIAAIAAIAAIAAIAAIAAIAAIAAIAAIAAIAAIAA
MIAAIAAIAAIAAIAC1#$^5FW'92S%N!QYBO:AMK=1G VZ[*NUE<[E'E HSB:=2
MPIBZ3M03B5B<7F,$E"/41UH08NQC%L;(I*$ZO0B!1TLQ4=7L3[!H"6.I&N@7
M4>?7]>F(.SS_  B3'N)9MO'!QW&^.I9'MM4RAV'H L6S'+(U-<PY=DDAA88X
MLK&6V$#X.&XNA#4O/7IN3+3 U)73C'5&(R(.+92F[ L1$9.WK\(:]6H Y^7K
M.@T&FG,<\;%\2<I5CDC$LYSK<7(,#88A6"A>W5V<F,5S47R,$(/L_P"(XODH
M4SN8F\68VDHQ=X]DS83CX50*3DD^$*CS=H,"_>W1]LQ*5/+34DZ\M.?(D>(G
M7^SG\N)+(<IML+%XFC><'6YK'MV-Y?,#V/HZ49=?B9TC.8JTJ0E,2I!1H5W/
M6T@C WI1.2"GL9;/ (QTP)%DF;$@Q7<,-K:Z:'737]';\F*AD'E(]BN+<?8K
MRG.-S>,A,"S<%?R3%1]J1?'K)I&PZ2:IV1BQT='EBZ<>CE%4TI.<?,&@N,NK
MNHS[L<[I5&C$-K:D:'4<CR\?9^GQ=OBQ>#K?+M%9QK,,R7S_ (\[%, Q['4M
MR](D2JCH1#(MEX SE.+9&Z?-6RR!,'D&/D&12(%0=Y1D>;N4Z#EUU:U3HPVG
MER//J\NAT_7B*M_^].6[/,;X#E.,L-#L[37<3N>PYMA@T,/Y&6P\-3D6:6LE
M['#964.(+.EF#5L3!LF+UFYCJ-Z*)-5VLY0O'W-7+$5 ).IT !.NFO5Y.6,#
M"W+;F\:-<UQO<+M<#8=RWMOW.;1<$9I ([B@4XQC'83NXN(O(]EL=EL;CL4W
M<5A\?"&3DHA1B+ EV*2#1L]D3%5=Y4:Q'9U:'4$,1RT/@@GJ\NF@.I]6F-C#
M'E(MC9'#,@W M-R, 4Q/%L@I8G/2-2XVW?L,GN:-KV>/JQ!R(2FKF8D&[MN^
M&1UI'7!4F,4J48-7(ZQ1U8Q+M.H&G,C7]&.N1Y2O8J,Q5",U+[D8*XQWD@[)
MXS""8I*1&S4AD$(M4OFHAG"0P1_.$WT,2LHO+D'<<;W1ENNS<&^H4'S-1=B.
MUM=-#KYL=K('*0[%,6Q;%,VG6Z#%06*9NCRDOQ>=3-JF&$HAZ"C9%[,;5 30
MG<'B QR[09F)4?L%  S^JC J19O$%T$V 5CRT/+EU:<^SGX_)C-%B^9$V3,D
M->-2 X@U;OF#]BX2=LGS)VE8X:O&;IO>H@Y:N4%$UF[A%2])9*^Q1.^ZRZVZ
MK$N.UIAAIAAIAAIAAIAAIAAQI3NUX:88^<:=^GQTTPPXT[]/CIIAAQIWZ?'3
M3#'W3##3##3##3##3##3##3##3##3#&DOE;#N[5K--LPK Y/<25PJDEE0[N1
MQQL@G^*(;O,,M6K"-M<;2F!#<DLB)*50..F%CR$N"0U%H]=O2(FPJZJWHT59
ML3IISUVZ^+=KIZO&>7/Y>W$"XJY4"98GV08-DH7(,?W99#/Y;S;B*0R;> ?&
M;*<N0DMBA=T56Q3DC$L9CV:<A9.SK&&;P-"BMF),?%FKU:YG+YDO'DG2KLDQ
M$KJQY$<@?!&X<].8.H 4ZZC4\NK7&/)SE/L\[@MP^QW<&P"S?$&SEKL6S)OQ
MRECF#YZ0$G3@S"<F&(Y-MF#)OBA3W2A,.5".XY&L=KEHNRR,+/KGW9B"/&JP
MAXQ'8 &'+=N"CEV_I[.>NFHTT'7J+GE/+MYER?M4W42/%&%\?8\S1$MF]VZ_
M#TECF8O=>BT8B#B41Z,28+DRXUAN-!PF=L9B)6)FC?&Z;&7Q*:<51-)2/1'D
M7&F)0J[@-=1NVGEH?T<^H]O(CL\6,IC/*]Y!V_0*= =R&W8>US9$MG&W?<9A
MN.Q',594CN>.9AFX_";F'#"M<51JD3/BLOGH.,*4'@Y7>F*FR1NX2R:,$4"#
M#:#H03IJ0=1U #77KT/+7LZL2+RTV;LPX8V68CET/FF3L-3"6;G]LL$R$^V^
M.[Y'DEE&)R?6'Y"BV-EKXT]6E)U9O>Y919/L367.E6XO@!OO<];KF" $D$:^
M"Q&IT&H'+4ZC]>F-3,PW*<H1B';[N^F\2F^^U_@"/YZV$ ]KLYWL08%AK<Y+
M#TTR\ !9\@P^Y>%0%\2QR?:/1D?0/2>)B1[?KCU.*N4OI(7:C$^BZK^#KHVH
M4DCDNJ^,\^WGS\?CQM<<\JIE.*P[>6*RCMXPYCO/.S[+V$,82".GMVP '@LP
M-W!Q8%-X3+U,US3&</,V7"(R955+PJ/8OD\W/E&381#PA4B6JT%L2;1X/,Z$
M$Z[>?(D$: GQ^,D#GUXQ^=\O ;1VQL<XJ[;HR%(CMW&4-I62IC(,FY44VTXR
M*XSAP>9MLDR/)44VURG*C*(Y%0D(,'"FIC!81= R[?*28@%%"57[IAL!.@.N
MH!'(;CKXM"0-?D)Y>85W+7+KM(9%-N58/A_#TOR1F?;U-MRTH#D-U@1+%L?A
M\'F+R 6PS'N8(+C/(;')N1YK+11D/&PJL;B" 1P-<)396/OVQ,<-8;--=Q(
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M:#1_(LO:R")1.PNTVS2BP&M$NMZ9IJU"2AZR%R<L8<#2"U+[7RS%3<" -S@
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M,,-,,>B'D.'*UN/,E(4NKTNF;C]W#CVJ770K'WP??[O?[7=UYVXV&O$V;_\
MN5CYJ-4X]Y=R'_)WPQ_[-_\ KC,,>E]M6G2$^-:<:VTK^JFM0QT['[\:=^GQ
MTTPPXT[]/CIIAAQIWZ?'33##C3OT^.FF&'&G?I\=-,,.-._3XZ:88<:=^GQT
MTPPXT[]/CIIAAQIWZ?'33##C3OT^.FF&'&G?I\=-,,.-._3XZ:88<:=^GQTT
MPPXT[]/CIIAAQIWZ?'33##C3OT^.FF&'&G?I\=-,,.-._3XZ:88<:=^GQTTP
MPXT[]/CIIAAQIWZ?'33##C3OT^.FF&'&G?I\=-,,.-._3XZ:88^Z88M^2TK4
M2\X=WI-W#\/0W:B.L>/GB!TT.O5IC^>EE[C[N^Y7CW>=3NFX_AYPV2^/Z]>D
M.#/Q8RG7KZ*;^E3X\#=UO_*)Q-IU=\4]/]F4L6)K9\<YPTPPTPQZ=.2<64MV
M9X_I2ZO"A2?4I3X*4IDV<=S7F'.?WXS?^-,P_IDV/HQPE^*G#'^KN2?U95QZ
M%-87&T8:88:88:88:88:88:88:88:88:88:88MN6'>QN-GSU$K7%0H4H6M;W
MJ=*M<7#F*[RB%RM+;ZIVJU1HG6^EEU;*75NZ&[AT-6&NGZL>1V'?PD[<YD4:
M])P?8 &E#84*;F3M\9R?/I"F!'.$:K6NS*HC#SE,:UI:FKQ=/+D$*]*5K2_A
M9=P] IW [?>N7VK7&&14?=*&"6M';26%Y&GBCD$4?22ITLB](JD1@DDCES&-
M4;BJ(23QQY?=EZ!W21H@C@;&9=QTUV@[21KIU?+CM,/X1MNK+1IU-!?)_"R4
M/96NU'LL89%R(\C32QCVWU[HZWP^H+;VLZ=MW<JZLHW_ ..K9JN__9]MQ65I
MR<:</QVW*A*KI(EER_X 6!IA*Q?_ #=%.[Q:XICBR)D,BY??,8UUD"QE!IUZ
ML!M&GCY\O'BH%_X1!N_CX%25'^3K2"1=%%FX5DA><9,&@4FY!9!NP74,/<-H
MC[$7R[IJBS5N<4L<K.4$T;K[UD[;J</<"FL3BK!QQPW/9)=17AW23EHPS2*(
M4G:0E%5F<!=5"L6T .D6XJ1$Z1\MS!$T!WLB*FATT.X@#0ZC3GSU&F+6L_A*
M^XM2/*RZS8U$KXH@1M#K2>S+$VNCR)>]*B]@M4U3$U1J9&]"ZU:UC>YHYN2N
MHI1*ME:5U='_ +.N9"P*IXMR46FC,PK&"<6#$#M,HAZ3I#&&!4N%VZC377$G
MOPK[#)WC=Z,':9/O6P-\$M^#KS'+77GBL6_PC?=3><$QBSD_Q-\E/CT2X*/6
MY&R'<<-"G**KEN3$B:8@J_(CUVZ"ZZ+UFW6;*HHJJV*W6)WW6T?W/ML0RV3Q
MIP^*\$C13V-DO0PRJP5HY9>FZ..16959'96#, 1J1B;WVQ;UC]S[^]P&1-L>
M]E(U#*NFK @$@@$:8H#3^$P[@7Y;K QV1PMX=Z>Y:]96F7IFX+=4L[5;G;?K
M:CBB]YT]K:@O<Y1Z3TQ"U%6JMMM$[^%=_P#LYYHD73OQ9DR0;5;IGKV%BVOI
ML;I#($VMN7:=VC:C0G48D'&%8ML%*X7U(VCHBVHZQMZ]1H=>7+3':)_PE3<<
M$%A39G8Q%! 62(K.(Z7)Y6G# 6?;MKK+'"X4@ZQ*DT*HM[U$[%E6*J]B5U]E
MM]UM;J4K+%_V=LQFEFAAXNR26:N0MB**">26!FU*K-&LI>(L 2 X4G0Z=6(M
MQ? BJ[4;JHXU1F$05QVJQT##Y"<?F_\ X2SN)%"@QXIL<B(T'(K7=T?,O\LS
M9F*.VL%;4'UP8BXQ,FS)VLE[K47=62R]&RMUJ:U;+ZTI6,?_ &=<REEF@BXM
MR62:N5$\,<%AY8"XW()HUD+Q%UYKO"[AS&HP;C"NJJ[4;JH^NQFZ(*^G7M8\
MFT\>A.F*)]D_YF\CO&WKND_T7:K?N;,Z_P!)LK]#M_3Q)[\ZGQ2U\Z'VX_9M
M_"=LW/'"#1ILTQXZ=NEDFS9LVS3*EW#EPO?:DB@@BEBRY19992ZU-)).VZ]2
M^ZVRRVMU:4K!O^S=G"*SOQ/E2JH+,S5+2JJJ-2S$N   "220 !J<1'&54D 5
M+9)(  ,)))Y  #F23U#'-Y_"<\XCG;H>0V8X_8OV+E=F]9/,SRQL[9NVRMR#
MEJZ;+XKL6;N6ZUEZ*Z"UEBJ2MER:EMM]M:4@G_9OSB15=.*,I='571TJ6F5T
M8 JRL'(96!!5@2"""#I@>,JH)!IVP02""8001R((/,$'D0>K'6^R?\S>1WC;
MUW2?Z+M3?N;,Z_TFROT.W]/$/?G4^*6OG0^W#[)_S-Y'>-O7=)_HNT_<V9U_
MI-E?H=OZ>'OSJ?%+7SH?;A]D_P"9O([QMZ[I/]%VG[FS.O\ 2;*_0[?T\/?G
M4^*6OG0^W#[)_P S>1WC;UW2?Z+M/W-F=?Z397Z';^GA[\ZGQ2U\Z'VX?9/^
M9O([QMZ[I/\ 1=I^YLSK_2;*_0[?T\/?G4^*6OG0^W#[)_S-Y'>-O7=)_HNT
M_<V9U_I-E?H=OZ>'OSJ?%+7SH?;A]D_YF\CO&WKND_T7:?N;,Z_TFROT.W]/
M#WYU/BEKYT/MP^R?\S>1WC;UW2?Z+M/W-F=?Z397Z';^GA[\ZGQ2U\Z'VX?9
M/^9O([QMZ[I/]%VG[FS.O])LK]#M_3P]^=3XI:^=#[</LG_,WD=XV]=TG^B[
M3]S9G7^DV5^AV_IX>_.I\4M?.A]N'V3_ )F\CO&WKND_T7:?N;,Z_P!)LK]#
MM_3P]^=3XI:^=#[</LG_ #-Y'>-O7=)_HNT_<V9U_I-E?H=OZ>'OSJ?%+7SH
M?;A]D_YF\CO&WKND_P!%VG[FS.O])LK]#M_3P]^=3XI:^=#[</LG_,WD=XV]
M=TG^B[3]S9G7^DV5^AV_IX>_.I\4M?.A]N)PV[?PET=+\KQN*;CL# <.8RD"
MM1;W*$7R*6F:<,)N5$K!I24@G\)CZEL/JI51$X:'O7#H FHB47'.!:!%PSUW
MBGN$<2\.Y1/F]:[5SQ*GWRU5I03QVHZR@F2S'')NZ=8= TJ(>D6/61594?;>
MT.**-VPE=EEK-)RC:8Q]&[^*/<I\%FZE+:*3X.H)&OI['3(-)02)4019$AQ(
M>B^'/Q[I!XQ?LGJ%CAH\9.VZBC=TU=-U$UF[A%2])=%2Q1*^ZV^VZO#<;-U]
M7:.?R$:^SEKCP[\H37CO]W>UI\.0\=_]'#!^N]=SC\7G_C"Q_N:V/%O=\_'F
M$_\ ^!H?TK,,8BZW['$L-,,-,,;1MC^[NNS3;A),B)8_]TEW*MV+W'S(!=+*
M0U!NL]PXREZA5R8[&Y5?5)!K#'+2QJF(ON6</4+JKHII*5NX7G>36L_XYO95
M3>".Q:>,QO9:1(1T.50SMO:**9QJL3!=L;:MH#H-2/>'<E=8NYOPU(VNB5[Y
M\$ DZYU?70:D#_.YG7D!XSC/=+E[)/:G9;;M&$\*6TIQYQ#FG'M4IW/<'^]7
M67'<9XH(U%[(OTVK_P#=AQT'W0@[)1R'^8A[?_5'DY^3J&/OO]LK^#:,'^40
MZI__ $/74?N,<4_'LA]*S#^Z\/=&#Q++\U!__(</?[97Y(P?Y1#KZ!]/N,<4
M_'LA]*S#^Z\/=&#X,OS4^GA[_;*_)&#_ "B'7T#Z?<8XI^/9#Z5F']UX>Z,'
MP9?FI]/#W^V5^2,'^40Z^@?3[C'%/Q[(?2LP_NO#W1@^#+\U/IX>_P!LK\D8
M/\HAU] ^GW&.*?CV0^E9A_=>'NC!\&7YJ?3P]_ME?DC!_E$.OH'T^XQQ3\>R
M'TK,/[KP]T8/@R_-3Z>'O]LK\D8/\HAU] ^GW&.*?CV0^E9A_=>'NC!\&7YJ
M?3P]_ME?DC!_E$.OH'T^XQQ3\>R'TK,/[KP]T8/@R_-3Z>'O]LK\D8/\HAU]
M ^GW&.*?CV0^E9A_=>'NC!\&7YJ?3P]_ME?DC!_E$.OH'T^XQQ3\>R'TK,/[
MKP]T8/@R_-3Z>'O]LK\D8/\ *(=?0/I]QCBGX]D/I68?W7A[HP?!E^:GT\/?
M[97Y(P?Y1#KZ!]/N,<4_'LA]*S#^Z\/=&#X,OS4^GA[_ &ROR1@_RB'7T#Z?
M<8XI^/9#Z5F']UX>Z,'P9?FI]/#W^V5^2,'^40Z^@?3[C'%/Q[(?2LP_NO#W
M1@^#+\U/IX>_VROR1@_RB'7T#Z?<8XI^/9#Z5F']UX>Z,'P9?FI]/#W^V5^2
M,'^40Z^@?3[C'%/Q[(?2LP_NO#W1@^#+\U/IX>_VROR1@_RB'7T#Z?<8XI^/
M9#Z5F']UX>Z,'P9?FI]/#W^V5^2,'^40Z^@?3[C'%/Q[(?2LP_NO#W1@^#+\
MU/IX>_VROR1@_P HAU] ^GW&.*?CV0^E9A_=>'NC!\&7YJ?3P]_ME?DC!_E$
M.OH'T^XQQ3\>R'TK,/[KP]T8/@R_-3Z>'O\ ;*_)&#_*(=?0/I]QCBGX]D/I
M68?W7A[HP?!E^:GT\/?[97Y(P?Y1#KZ!]/N,<4_'LA]*S#^Z\/=&#X,OS4^G
MA[_;*_)&#_*(=?0/I]QCBGX]D/I68?W7A[HP?!E^:GT\?:<O;*OAVCB/Q;B'
M7]ON$?X:?<8XI^/9#Z5F']UXC[HP?!FU_P#L0_\ \HQGSLGY4'&^[@D:@Y>-
M7XBS %26+(X]*25"2-95$T[F]E\H@TFH'CE)$W%.'*3"4BE 8TU&7JK-=ZQ5
M"& )HKI/$O"><<*V8Z^9QQ,DZ;X+=5I):DV@!=$DDBA<21$Z21R1HP&C@-&R
MN;B&=)E+(W('1E8;67LU&YAH>L$$@\QKJ"!L@+D4'8=U>G?2ZER-W:I7M]NV
M[AW?[/PU[VM:'6/E&)R=1IU$]?8-/+U=?CY_)C^?'E__ .WC<M_[56Z?_I#9
M+UZ0X,_%G*O_ &IOZ5/CP1W6_P#*)Q+_  BG_5='%AZV?'.<-,,-,,>F_DG?
MY&D _I6??WFSC7F'.?WXS?\ C3,/Z9-CZ,<)?BIPQ_J[DG]65<>AG6%QM&&F
M&&F&&F&&F&&F&&F&&F&&F&&F&&F&(9S>\O:XUG-UM>W6(26O'N?_ ',]KP[G
MP_\ 9IB4]?7U:><G3M_1U<M=<>"W9_EL.XVG[:('C[=Y&=GLSPON#E64\VIR
M([/XG?D^+2(5BZL*G 5Q!X\:2R"5@(V)2R+IX])*6/E:%TE&32]D7=K6^X+6
M53+8FO7^%+/%M/..",BRO)FKPT+0RRS7K7._*,RW;$)H17Y+56T;\8Z,="0[
M!XE&.:K80CHHLPCR^2MFUN>R'>6/IT:5>BD4QHW2M$$=.B;GX>H&A.,J,@\I
MWA3%T0CLLP#%R4C-E=P&_P"ED9Q^CDN2X^@T(A^8Y,$0@CO+6(@86\3D<6>!
M%"!4'$'QX4-CZHI^-KT]NZK1.RH=S;.<SMSU<]LQUX8LAX$JV;YRZM?NW;F4
M5YVNKE>;33=+E\E>>..*:W'!))8$J2>"RXFESNM B2549V:WFLB1"=X8XTL.
MHC,]=5*RAU)98V90NTKH0<8+33<L FFT;9;BG)V8\M2H*!R3N2OS["(A-GR\
MQ[!GI'";S%R#A&6*O8P_L;K1\VYAS8TB18![Q[U1JW9*7677[K3X=L4^*^,<
MTRW*<KJS3Y=PX,BNVZ:"IWY''G*9F5-4)90LMB%;;0M&\W2(&9QKIC);J24,
MM@GLV'59;G?<4<I,O1EJY@!$A*'\!NCWA@NAT Q/6"\VX,@.V3-$>/Y\4.X5
MD"#-AC7 ,K)R,GFN*N(UN:@^26L))8]1#5PD=!Y.C(9U+IGE030>: O&*47"
MG1M%BD=/83.\FSJ]Q)D]BOD0@SFNTDF8Y]5CKQY-:6SPW=RY[L=]IO=F"?+;
M,J5*>5RF2&=)#9F@EVQ6(+RK:JPTK"M;UK, (:LA8V8RER.81-"%[W=9D4R2
M3J RGP%=?"5LN<A9YPME7.L/8.M^H.*Q^DHWRY-F64HM+I>!.&< YIRWC>88
M/VO YT0B;@SCZ1$[HP]=&V@T<X;XKC[TQ8BV(.;NQTIJF7Y'G.5Y);=>!YK5
M@UN"LMJ99:J4YH8<]R?*\QJ9UQ--2CMK#?KQ"RBPM)(K9G/'#JT:COB*_EM5
MY[,:G-4C4/F<TDZ2.KO5LSQ25J:2LFZ)VV:L /O*%N1/@-K^BL_4RAO(WZY"
M(E<?&LD3W;WN]D&.B>+7Y0K#EY.7@3U_($H(7."PIXNY3P_7(H]N7?C&9XP^
MM=O%$[R3RMZF]VJ RWA'@;+XXK\.74<_X3KYA%F<<<5M:T-Y(ZYO102301*<
MW]SY&B21J\*%%!$::#$I*9\RS68M$\TE2^\+0,6C,ABU;HF8*S$0=*-Q7<QU
M/,G7%^[GCHB8[6<#X4;;T<+Y?*%C\=R7E.2S">S.]WC^6PS!DGCD+Q; (6/Q
M\N$A6,(;$A%L#=&QSQV3R/E&1Q9P2$1X -0>MK'AJ"6GQ-G><-P?G&4Q106,
MMRNM4HTPE^I<SNM8N9G?N27UGN9G<M2]_+#(B19=EE>TL<MBQ(R-5NLLM&K6
M]TJMAF=)IY))GUB>.LZQP11+$5CAC1>C+ [I9V3554 CGO2W$8>R!L_!Q:*9
M4"3)24$]E+W%V(6"QY0K@(?@K:D>Q5G)D9&/QC8-%;I%DDB/M:-@SUTC-44[
MI1;<X19)N=.#N'\WH<63V;6635!6BXQ3,\V<0"+/9<[XI@S3)9(9(Y6FM=[Y
M=')O:9%:D2*I"ERN(YE<K2Y>(XYUDZ0Y<8*X+%JJUJ30V0RD;8]TK#0*?OG-
M^>FN+ZQ[E?8$$!8V#&,=;8"B@8=R:C4V8D,)?$C3]W+8R_$;Y"<@=U7M2*/8
M^BBQ1*(NFZHV/%U;I1'&%)4K<<I8W\KX[FGS&:',.)8A-)W17ABKW(XX42I8
MCEX*C@3:3$DY+F,JRR6(AWM9?O8"'$\4^4JD*M#18JN2AF>,EF,B%<S+GQE-
M &Y:(QWH-YW8D IM]P"ZV@9+R'CK%F.K8"*VI92E,2F!_'63D<PO<\M-V2,*
M"S",92+ 4X.=QTXQ\1CT7A0\;+7Q&\Q<Z:-X_21#Y:[;6$>?9ZG%F6Y?F&9Y
M@;\O%&65K=2OF&6ME,>1MPJ;LU2SEL4YNP9@M^.Q:N.]5(Q$%=K'>\E56N&I
MU/<^>:&"'HEH3R1R-%-WP;0N]&DB3,G1M%T3(D0$A.[4!=X<C![<T=@$>Y0K
M<@8.615Q5E#<E6FK3P@7( JVXSFY/&TFHN,?,R QV9OW%5+]*N<-E++9!6U=
M2^R^VJMNZ\-P7Y^ >'H83:7?;RTP&":6"8</>^&-JVV6-XY4A'#W1:A7![WU
M4:CEC%W7A3-KS-T9TAEUWJKKWYWH-^H8,I?OK=UC\/%#8Y4P7 <EQ:W'[3%K
MB&341E_*\P4E&-HA,DH08R/$7Z^/\%TNG$4.\4L1$8Y'TF1,1:DB\D,J-)WK
M*L;+:5K/EF=WLML]_/F:W*<N4Y74%?,;=1KL676T6_G9[RM0'7-H[%@O'-JR
MUZL#!0YUQ!;%6&Q&(>AZ*46+$IDBCDZ-IHVZ*M]\1@! 430KIX<C#J'.*]O\
M0Q9EMCE1]D&D><3I<=D^67-[RG8.J##Q_#63YZUD&.HK&K@<>/DZ9 !QY@3B
M%&*HYC&[[&PT.*&O",HB>3SVWF>5/EB4.G6DLF6U0W1]^B:6?-\MHM!F%FP)
MK$$1H36'CM[Q(]@%Y9I9$CK6K>G'7LB<S[#,1/(=6,15$KS2AX43:CMTJJ&C
MT("<E502Z3N]&\G[.GT 86RUY%8W'L5"A-[]Q';H7(GCUQEK,\$3>3&@5_+D
M)#DALTGV),T2Q^X6L'.(!C*31\!UL9%@4="81)..Z27Y#52U8L9I+*$6QWY
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MJ%<86D5,>!:Y+5HR65/%9B$'0 LOA.4;@!PF:'"<%; ':Y''4,DCCKCCXK/
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M:FY J)**,J,WCNR]QTK8%R:U[J<071<:K'F]3**]::H4-RL^7K=$TFVQ7EK
ML;*=%JLX(#[T0A=:1D&R)=NXQM(Q#:[6#[-!X)#?YIUYC$NXVW)X<QS ,D+B
MHA+&4XR,Z'NW^+QK %9AP:8CF4@,]A1^/3=Z;=95%"8F&#J K<?F;)<Q.%5K
M#Q23743;,6.)S#AW-\POY<LMNJ]++UE5,SD>8YO)%8RR>C<KSTDA7+)9;,TW
M3=_PFJ\$0,$5<:L[SI*B(^@;<^FJ:#HP5D#J0Q)<!0-NP[@3S+>(3(<W6;1I
M=D*,%9A%,PGX/%I7N#S(.%DHC"2-[C+>=I?'9$R!R..TR6,927'./D8^W5X*
M2(8[G!2VU,H$$!UGC)SB8.&.*JM"S%4M937NV:N0Y0\L=NY&%RK)*EBN\U>?
MW.D>OF%]IV&HKR+2B.L4TLRHZU&F@9P6$A0-+)H54GI)2#H07T9%T!YD%CR(
M .,=X'D^/G\Q;E3!:9%2%^:L39O#@YWD1N#BQ=[*#S&R6,:R!N.*DH_'WLL<
M G$00;,2RPEHO(6C.QRBPK=5+/WLML091PY%%4B09-FN2RSTLO::S$E6!S4?
MH&DBCGG2JLZVV9XEE85W<JSZ:TU<&24EB>D20!WT4[B-VIT) W$%= =/"TZM
M<5?*&4MK\@QCBW%./7V<8W$8HJ\/34<^@&/['DPR$YAI1DI/R)]+*!-V7>WG
MT@$=$@UF(D3$8 X-7BNK#O3TSU'+<LXE@S+,\TOIDMBW:5(*<B7K^RI06Y$X
MH1P'+8UB00&>Q+.'EEMWEA$NR#:8#O"41$,@5>; HH+-M/A$](=3KH - %4G
M34ZZ]G<-N@Q_E;%%8U& \O:3*<2;"4OR-8=8AFT9CQ'">#%,+L1T*?L#9(D=
M926KMY(W3LN*CBPBRUJ'2;$;:*O=2Y!PU?RO->^;,M1J=*MG-3+S \S6;$><
MYW[L/)<1X8XX'K;4KJD4MA93NF+QG1,1EF1TT ;<QC9]0  8XNC 4@DL#J3S
M"Z=7/KQ.L3Y18?&:0Y@@1S"U 14IL8HB('.AZ3-O&]OT0>1[.X<<RI+$6R2.
M2G%["UBTITAM*QC2QM,+Q*:*32N%M=S][(N.T>4M8M1<::RR+(7:SGMM+&1R
MR/WJ6)RY1(7?PFJR.6J"4DMBHMK;M&LFBFMR&FFV)2) !N_SSII\(#PM.K%^
M7Y@Q\=VJ2KJ/)#&+MC>WR2XI!883R'C]M'%9P8W#(247*7F/+9,C-!,]*1\@
MZND)]W#4HB,CX]=S3(+]H[;C6]@,IO5^)ZN_+GM-#GU?-)\X.7WVLK2BR UI
M:R7^]C3EHQ3QJ((%N-;EL2*O>".AD:;>AA.CA08F01[UV[C*&#;-VX,1KJ2N
MT ?AZ:#&'>1MPC.#[SS^9,?-XM-Q49D<6%HKE@D=D868-H*'C,<,'1"DD"GV
M@YQ*W<9=EPDL:#KC(OKHD6'J(N^'';LOR%[O!\&47VM4I;->U(5CFL035&NS
M6;$,$PKS5WD6JEE(IJKR"&3HS%("N+=Y LYD7:P4@<P"&V@*2-00-2"5.FHU
M!Y=6+6BVXB.D]TXO<5EB',G@T)(W\W90J#1B(@6+Z0!47Y6 "RS8.UB0APPL
ME%@.Z7R&\>N9,#VY%ZX9DB+KI5]S9X?L1\,2\/Y7;=))ZZ4GN7;-N=T@F,<5
MZ6)I7M2JYK&85*XD6&&1HT5XXTU$!*IFZ5UY!BVU0H!(YJ#H%&F[3<=-2-3H
M2<9,K[_HF003E[*-Y!QIE9/"6><*KO8))2A485'3M.^1XO./I5(9FC+[2,/R
M 9D[YY19,A46.5"NH^M>X&H#&^NKP+:C8U'L9?F65G.<DSA4O5HHI8I*1%?,
MX4K5Z9J=';H0UD70Q]+()EG 61I&J]\@@-HR/T<D9*$Z$-S0ZEMVJL6UZ]!H
M1U:8JL?WY8J$S*,R.\%DUNW"RN)G55A@^+V%D4 &RI#;<X4&W+R>YM:2MFZ5
M38^J]>D=C=J;U>ZPKT035&?@?-):EFN)\M9IZMN$+))9,1:?C%N(E$@6MN,9
MI'H)-OA=\:HH,7W[$180,IT?D5/4NO*N(N7A=>X:CR<^OEBZ8;R@^)HN5K:\
MLRY('PV#X5 5S(;"V.,F9%(8MDF1)"883L.$S9&:=89&WFP>/MT#$_GPF\="
M0])=%9<UO;,!-M;X"S6S%X!RJ!)+N<3^Y$$Q7+<OBS.OE\$3TI9LGL_?Z[4Y
MIV:&A1EZ2[+WI9J,&DEF6R@/^>2%C D8>&Q1G)W 2+H#N"\W?D@W*PY")0.^
M,&@\QV!4>Y/A4%CVWF;XR5[!K!]'F-\K2^6STJEE;&<=NEH8>]?"HK(A,-3?
MN3L1D- 2QP<S?LDDFBKW*3\%3,F83A,MN7;&?4LQ NF39F.5U*E&(Y7F,_>L
MTB1RVJ\MPQB&W7Z802.CDN$D%@#8-751$Z>#IX#NSG>B[@#HK!=25.FNA'+%
MR)[X\8,\:97AB#?*ATQ*"F5'+8[-QP\L\RRED;',:A#0EEND9R1#(PS,1Y\%
M?%AUY.$9<5%H/&2@(B-E+-_*C%N>"LR?,LJN%LL@BJQ98K04I)(DRHT,PLW7
MCRKOG+[EEX9TF2)Q'=RH2LCB>.2LZ5HH]\($=?OA+%R"W/?O0*#)HZKJ"">:
MR:<M"&!8SC/=]^+\>YF#.ALTR?DT<"S#BR;W. ZL=7BF.HC'\-E81,@.'"K.
M;+4.+3QS*U'4M8NF<)%JN0JHTI4P^45-786CP1F=_)YEDIY;ELD^4YG2"S"P
MMK,+<^;Q7:D^;Q/3'0"BM4+4=7N2A9EDC$**L.)VL(KCPG<+(C:C31%$91A&
M=W/?NYC11RYZZZXUZ8VF4,>PW=9%9),3BW9XK I:/ED@H.:S>9!XAEMB3E#7
MJ0E(G;%S/3<>.N)I:#7E+U(B8C"[&PX^<W-G+G?LQIW$N<+VJ]2 =XB]5DJP
M&1J5.:WE3QUF#1P(ZTH;$"T^F%9#'#9#]"B[E6V1EVS*6/A;6#'0,P5QN&A)
M&X@[M-3J5TU/CNW/&9-N\P(0)#$RF7@$%Q/%RJ6.8#(8/"&#(=+KC4:*V$)"
M:'9(D!&2N)RX1D)2?RUPDV*)/6,8%A =P2RB 6TR/*.(*<=YLT&4SW<TLQ',
M+]>Y==Y*@ALQ='7A?+X(ZZT5->*A55FB*/9EFFZ8ZS32O$VT1[PB*=BE5&C:
M@\R').[F6;D>0 73JZ^[G<ACO-C$:-QP+F;-L2R]F7.LK4FS(*R<#I7F2^(5
M=Q&/5"FC5I*/1JR*W4;GWU1+TU>_MO5 BZ-*6KS<*</9ADSRR9A+3=H\JRC)
M*HIO,ZR5<H%L);GZ:&$Q3V39!:O'TJ0["!/+OU5-*D@ 0-SDDE;< -&D*^"-
M"=0NGX1T)UZAC* YRDH,U)SSARZS&YAYG,&:Y/?'7BHI5LIBW(>"V^.XQ!7(
MRZ7J#[F@V;IK2<K&Z*7QY+H[3S59^?\ ]AMUJ#N=SPUH%5<H2W#E.35N^$$H
M89GE^=MF%F\LO>@DWR4B*T5G06#H8&6.#GBL;8+$G>5,DK:$C\!XPBH>>F@(
MU(ZO'S.)-D64\?2+%L(;7YI"!;)M,-D-H*#.,G04I"<1,\6A'+3(9&,@!,C<
MRJ#BFMC!L?EETSB<$=.Y$Z;BQK65/4K"=^-KY9>KYG=89--,:=3C/I[JY;=C
MN9J^9SJ]".S/+76K=E<NT%44[5Y5KJTDCUD/1B9G4QK]\ W-6 7>I5-BD,0
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M#2W][P5;#]!&Q;986*X2UN))UG&5<2ABRQ5U+$,P$U( OTRSM(5Z30.[J [
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MUP"UM&.;X:88]-_)._R-(!_2L^_O-G&O,.<_OQF_\:9A_3)L?1CA+\5.&/\
M5W)/ZLJX]#.L+C:,-,,-,,-,,-,,-,,-,,-,,-,,-,,-,,:3=F(^K[E)>6S1
MI3HJTRYLPX=_M[2HY_A7X^UP[FF)G_ CY\M&U[.;'['R$\QC*#*&%NR%9:ZK
M>M_1UN[MG'O]SM=K]7'AQ_#6# ^0]F+8J1KRZOU=OJQC2YVK6J*W749W=NM:
M_P"YTKW?Q4_QU-KJ/)Y/'_TYXAC\.:G3Q.OHJ:88<U.GB=?14TPPYJ=/$Z^B
MIIAAS4Z>)U]%33##FIT\3KZ*FF&'-3IXG7T5-,,.:G3Q.OHJ:88<U.GB=?14
MTPPYJ=/$Z^BIIAAS4Z>)U]%33##FIT\3KZ*FF&'-3IXG7T5-,,.:G3Q.OHJ:
M88<U.GB=?14TPPYJ=/$Z^BIIAAS4Z>)U]%33##FIT\3KZ*FF&'-3IXG7T5-,
M,.:G3Q.OHJ:88<U.GB=?14TPPYJ=/$Z^BIIAAS4Z>)U]%33##FIT\3KZ*FF&
M+F ;7$6[A.^]GQX5MK7HD^]7[U.W]_N]JE="1XR.7JU]0\GRX8R^@^(F8%CT
M5&UMM4[.W7H*4[EM/AX?]GWO@U3+]GG_ &$?VCY<3!2?TCES\WG';V$<NO'C
MSW_(6MM^F[A"RG0VIY!QY2E*?!QVY80NK^NM==W[G//A]SVYC8_W-;'C'N^<
MN.(1V9#0_I688V$9Q'YS8XFWAQJ6OZ/F$;A.$Y<KEPQM]8QH-D)M++L*@,F1
MB"Y03)6-F"<LE ''4N'U'L"E<E*1J4R%=*./GSKJBVRU\M:]D$T"%6FLYE *
M,>:--)5:#W1DIS6J10LW002VZ[;W3O,30PCIE5=,AG\?$$>3<;5;LHDCJY?D
M5QLZGX;2K#F26_<*MFU3+\W$P1%N6ZV678C%'+[JM5MV66K([;L,=A.09\(R
MZTQV S%D+&\7E;*3''L9@N26>+5<ES&+0XZ3A,$[,#%%8]'"$R.MF,59G3#=
M9)GUUN2;V]6+MM;#Q/4JR4&MRT*MN:!H8UFLU'NBG7GL1)9M=[Q$33)7B+3M
M%&06Z/4^"&QHG<[S+,8,Z3+*^=YEE=2Y';L25,OS2/*6S6]4HV):&7]^SAJU
M66]86.HEB=&5.EVKX;(1+'*?!S@.=01A*\E3N7R5!QE=+L4GF4!^4W\0AR>0
MWM,>%FA)DHJX!HR^)5'VKA2ZEQ91S'%#CBU!(P@U0L.#'BDJV7@IUJ\)%$]/
M6I/22Q8[T7ON-E?E*:\^_22,",";HAJ8R3F>ZS!/7S#+X[F:9A=M*^<+WGF.
M;19M+2HC,G]S9DDC):NMVF8P8)R9F:J;#;1.J+DIR.H:I?&>4$J4K=T>:#MG
M:IQ__!, X?A[O;I\7'X.6<:_C/FW/7[Y6.G9_@-7]'/_ *X]+]R/_)SPQS_^
M'S#]'_?&8\O[?TXV;3[;U<<<U6HUNNZ*M:\:6<:\*\*\*]KM_A[?]FM5!!UT
M^3['V'U''2""/M]B/TXB>[:LIQK_ +3N[=:U_P!SX_#_ .;J.(8^<U97Q.[T
M?[NF&'-65\3N]'^[IAAS5E?$[O1_NZ88<U97Q.[T?[NF&'-65\3N]'^[IAAS
M5E?$[O1_NZ88<U97Q.[T?[NF&'-65\3N]'^[IAAS5E?$[O1_NZ88<U97Q.[T
M?[NF&'-65\3N]'^[IAAS5E?$[O1_NZ88<U97Q.[T?[NF&'-65\3N]'^[IAAS
M5E?$[O1_NZ88<U97Q.[T?[NF&'-65\3N]'^[IAAS5E?$[O1_NZ88<U97Q.[T
M?[NF&'-65\3N]'^[IAAS5E?$[O1_NZ88<U97Q.[T?[NF&.=FU52MU.+2[AQ\
M'2E?UTII]O/^S#$L0;;.DQ<HJ*,_]&ZVM:W)TKP[=OWOO?A[7=[\"PZR1^C^
MSSZ]G/LPT/\ UY?KQFU'\=M002_H6]MO0(74X]!2G_ N[?\ AJ0MJ0!R /;_
M &CJ'E'BQ/M\HUZ].LGQ\P=.?CT/7CPSS80T+[F,ZA7KIXQ8E-X.Y 6[>C1*
MQX@S:O=R60VB[M@#;+-G!EZW24O5:B4'""Q!>Q-FDNDHM;?;Z)X2=H^$\ND4
M*S1UK+JKN(D9EL6& >0@B-20 SD$("6((&F/"?=119^Z9GE=VDC2:_EL3R10
MM8D1):%!&:.NK*\[JK:I"KJTK 1A@6UQDMNCV=9-P1"87D>0Y"'S;'Y=9K$8
M0B>9SR 9&$C;DS!EHS=8DRF#C\J @+%4RCA-R$3+QBQX]Z8B3O5)67KULEX@
MIYG9L4XJCUK48:>R8FJVJDC_ 'N-F%ZE++!+*044K(8Y]JZ% $T%AQ;P1FO#
MU"CFEG,XK^6S,E*@MB/,<MS.&+2:=$?)LWKUKE>L&$S!H!-5$CZK*3*"US[;
M-GL/RCA^F8IBTW*SMJ_G,A@S.&;5L0#LJR*-K1P3'"JAJ?N24A%I1]J;I)+$
MH^QL'KWODA;]UU=;_%03HYQG]BE?.7UVR>J4K166LYW?>E#,)7E3HZJI$YE:
M/HM96+C:750AYDW?"_!5'-LD]V[R<4Y@DF86<O2CPADL6;V:K58:LQFS%Y;,
M*UEG%H"M&(V,BQ2/T@_!$$[K<!LMNN36$,&F)&2'G(3&9TR'SB,IPO(<5;29
M-VHG%<A1-(F82 RL;1ITYRU3(*V.!SP81M3;4>]2HY/(\T;-J;6'CA1XK$U9
MGK3=\5)VAVZS59RD9E@?=H&*@AU=-3MU.O<8<.Q\,YK'1BGM2Q6*%7,(XLPJ
MBCF=-;0<BGF=-99Q7N1;-S()"&B>*4!!)L7>OR3O\C2 ?TK/O[S9QKSSG/[\
M9O\ QIF'],FQ[NX2_%3AC_5W)/ZLJXM)G_"'01%DS?M]H\KM0?-6[Q&BF7X[
M:I1)RE8NG2^VV'74I?2R^E+Z6W5I2[C2E:T[==DC[G.?RQQRK-ENV1%D76Q.
M#M=0PU'>IT.A&O,\_'CGL_=YX(KSS5Y(,^,D$LD+E:%8KOB=D;:3?!*ZJ="0
M"1XAU8_:O\(0%\>UM)D]*?\ KAC_ !_^3:ZG^YKQ!^6RSTF?_A,4ON_\#?D,
M_P#]GU?[PQ\^R#QGDE2?UPQ_YF:?<UX@_+99Z3/_ ,)A]W_@;\AG_P#L^K_>
M&'V0>,\DJ3^N&/\ S,T^YKQ!^6RSTF?_ (3#[O\ P-^0S_\ V?5_O##[(/&>
M25)_7#'_ )F:?<UX@_+99Z3/_P )A]W_ (&_(9__ +/J_P!X8?9!XSR2I/ZX
M8_\ ,S3[FO$'Y;+/29_^$P^[_P #?D,__P!GU?[PP^R#QGDE2?UPQ_YF:?<U
MX@_+99Z3/_PF'W?^!OR&?_[/J_WAA]D'C/)*D_KAC_S,T^YKQ!^6RSTF?_A,
M/N_\#?D,_P#]GU?[PP^R#QGDE2?UPQ_YF:?<UX@_+99Z3/\ \)A]W_@;\AG_
M /L^K_>&'V0>,\DJ3^N&/_,S3[FO$'Y;+/29_P#A,/N_\#?D,_\ ]GU?[PQ<
MT'Y?$%+9]CN%/-KLH"(3[(V/L>=>J94 $;0ZV0)D#AK4JJPMBK.]XW&NCB+U
MRV3=(*JMT%;$E+5*VZLLQX$SK+*5B_9EH&"LG22"*>9I"NY5\%6K("=6'6P&
MFO/&6R+NR\)<19O1R7+X<Y6YF$IA@-BG7C@#B-Y#TCI=D95VHW,1L==!IB<]
MA95HMREO+4*T5MZ%UEO9E<G6M?\ 2I9M/CJ=>''N\+J<.[W_ (-:7CK;$;(]
M?&K>4:;CZOT?KQN*5%LWG\:Y*RZO=I7A3MTK2O;I\/W_ /\ S3$F@//7K\QZ
MO$=1U#'5K&1U>ZWM[?WJT_LIIB&T=OJ7V8^=C WQ>G];3#:/L%^CAV,#?%Z?
MUM,-H^P7Z.'8P-\7I_6TPVC[!?HX=C WQ>G];3#:/L%^CAV,#?%Z?UM,-H^P
M7Z.'8P-\7I_6TPVC[!?HX=C WQ>G];3#:/L%^CAV,#?%Z?UM,-H^P7Z.'8P-
M\7I_6TPVC[!?HX=C WQ>G];3#:/L%^CAV,#?%Z?UM,-H^P7Z.'8P-\7I_6TP
MVC[!?HX=C WQ>G];3#:/L%^CAV,#?%Z?UM,-H^P7Z.'8P-\7I_6TPVC[!?HX
M=C WQ>G];3#:/L%^CAV,#?%Z?UM,-H^P7Z.'8P-\7I_6TPVC[!?HX=C WQ>G
M];3#:/L%^CAV,#?%Z?UM,-H^P7Z.'8P-\7I_6TPVC[!?HX=C WQ>G];3#:/L
M%^CAV,#J?^#T_77^VFF&T?8+]''ZIQQA9=T5K>RG#OTI_96E-,1 T^P'Z@,=
MAZS218+VV64MITJ_M6T[U.-*]K\5/ATPTTZO(.TZ:]IUY?;ECQB9VA<5R%RL
M6YF'3-2.)AC4M:IHV2V84@(!U(VNS#'!"'#WTOO410"7$I>U!,&;AXLDQ7?N
M6S1^I:S<KUUV?A"Q/4X.LSUQ-TL>:+J8*_?4JQ-)EZ6&6OH3)L@:1F"@N%#,
MHW 8\G=U*A3S/NJY?1O&J*\_#9"BY>&75WLI7SN2C%)=)"P&6ZE>-&<B-I&1
M)#L9L9 ;P\:%<=X+E&.R&.1:(/&[*)V BJ7*"OLCCX\]5=Q]!4A'MNALI8ZI
M>Y2(N1MK%N$;U%LGJQEM6Y@UL6OO,@N);S.&VEMS+;:?I4/"J5'E4+*0DN;1
MH5Y% Y8R-O91&?#;3&*XWRJ;+.'KF6297"M?*TIBO,.Z1+F<=:0O64RUN&+$
MP;5Q*\0C6!##'(TZ_>T!.#NRO'RY7)".1))BZ1S;%T4:2828E37%![,4*Q]-
MS4,.I8]D^080":/%9!&0,FN&&R01RE>D2:,54Z-25;*CG6R<16@E,U(;L5:[
M.T+QP->BR^S:K1V(S:AJV9640S2PAXTE!U1F!W)KO&@<"9:TV:+F=K*;-_**
M:6X9[BY18SNAEN83T; RVWF5"NCM9J5K9BL2P,-)4C("RD=$]S;]91MZ/38
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M126"PDHCSQR+?CR[! T'8WD0Y$<784<C7S1TM:2Q2P.8IHI(9%TW1RHT;KJ
M1JC@,-001J.8((Y'%PDB2*'C99$;\%XW5T;0Z$AE)!T.H.A.A!UQ),A6L4$.
MZVUI6E4;N%:?@N^#_7V2#K&O:,3$\OE!TT^0G^S'A<Q_#&<RWD;AKW&1CF+7
M\0W/;GYS'I9'L7R[+9%M(X[NBEZHA.V,PQNZ)-[$UW%2%"[M&\6W68(LG-+E
M2#:V[O626&K\%Y7I4CNK8CGK2P2W:]%6BFEMB0]-994)(&WHU(<ABPY(<>+.
M,:$=[NN<1;LTL90]*:EF%:Y6RF[G,J6:M3*C !4H*\J ,W2"9U,*-&J-X4B
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M:X=S.UG-0^+B6=6B=!#207#!:TZ3JB\G$)I:DO<A5]>[:+0G($8H_I;<\9,
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M':J["Q#J]KMV?+<;*&B@>9[>ZF95IV8J,\\268.^UBGEDC%<2Q](N\-N4,%
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MNRI%-&E<QS2E8C;@*.Y7:^^$#8>1T.G5F/C?:E'\9;Q=X65L2;7\8,)4&@N
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MX-EILC6VI,R0M4,N,&CFJK>7"I>J1-LWK''#C)C4[H_&+Y<8XD<;LR&AB,9
M*0:^$+!T.L9U8Q(?#Z35D*H9=VX<+K=!E;73+SNU#@G=/H-.@[&'@],?P"H
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M28-FO4BQ5\,JQ'#L4T/#TC6!-FM&:":ND$4+W:FM4!KI<P2+(K ,MUE7?O=
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M+5-)LS8LFJ*39HT;I)H-T$DT44[$[+;:5U545410JJ JJH"JJJ- J@:
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M^X)H)(JK7D@640RK,X(1 Y)C;*'?'BX6>AL/S@@;VLC,A(#7S',$6PAN&$9
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MU:]4N5%E[6K5JUM4H@V12LHL[.S,[,[-UL[%F)[2223RY::Z::=@Q.
M!H    .OD!R',D_*2>LXV:0G%#4"$NNN;6VUL0K_ ,"E.UT-?O=ZG:[>J9<
M]O\ 9]O)ZL3A2?T:_P#3[=6/('CDS'XIOHR(0D&+ELP-;-Z6X1D-@C.1D8H3
M*2%?<M/4(U>)+CE4[;2+4UU#>@R(V+"B=O3![VC>QQ:^9]XR6&6;@:ND-P9>
MQIVV>TT*3HD2SV>EWQN#JACW LFCH='74@JWB_C"W6J=V._)9REL[4YIE<<>
M7QVI:<LMEZ.7K5,,\1&DJ3]&5CE#0RC6.3:'$B9A[U(F&@\&E)S'VW_&$#7,
MY/C!6698A&X(KF:6BKY*,RJV&15"YX,%7Q@))UQLS82%S&G92*E2\-J#O>O;
MQ;!1./#L[V;,$5K-+MH1TID@HV<J3+H)!"]%GG;:SB:2$/7>%9E2=(['2[5#
MN#2X[IPT*%RQEO#F4Y<\^;5)KN<9?Q)/GEV$VXLW6*HO210FG7MM'>BM-4>6
MG--2[W+N88R.OLZW/0+%&!B< S)G(:ZQB5EQDF0VV,L%2292@MU0U&MW9MMD
MH+-\4-X]UY32ZG9MW$T*5:*,;EU!"*3CBM'/\FLWLS2UE^6.MU((T3.&S*"O
M FC.1&U.2O>:7H]=685DW!M YTY2<$<69=D_#TN79YG\3Y5+=GEEX6CX?MW;
MDVY(U>=,U@OY.E<3@;41K\I0QZM"JMX6"FXZ1X"E63GY?;7CZ5XSQBJ/9IM(
MQ,CJL@+V%;%'5S][:Z7*G5VK-RG>TM08+&RJC>]%6ZKU2BMMEFRY1#FD%)(\
MWM07+@9BTU>(11E-%VKM"1!F4[M6$: @CP1ISY]Q1:X<N9M)/PMEMS*LI,:!
M*EZP;,XF#.9)-[36&1'!0+$9YBI5CTA# #?OR3O\C2 ?TK/O[S9QKSIG/[\9
MO_&F8?TR;'O?A+\5.&/]7<D_JRKC)O+W)V;*T6:]@/9WMB%W66W6I];,#8O8
MULI2E:6TLZEBR70TI3N4IPI;2G"E:4UCTLSZ:=/-RT ^^OIIX@/"\G4,9EZ5
M-CN-.J=WA$][PDDD\R3LUUY\]>L\].>-8DTY/7 ]C]?K?MXP\V2Z.[H;&N+X
M8C9;3C7A2EJ06VE/@[5*<.]VNUJKWS8_+R]G^-?U^%H.7C_MYB3O&E\3J^CQ
M?0Q']>3YPSQK_P!X3%'JUB?^ ;3I['Y>7^6;Z6'>-+XG5]'B^AA[WSAK^83%
M'JUB?^3:=/8_+R_RS?3P[QI?$ZOH\7T,/>^<-?S"8H]6L3_R;3I['Y>7^6;Z
M>'>-+XG5]'B^AA[WSAK^83%'JUB?^3:=/8_+R_RS?3P[QI?$ZOH\7T,/>^<-
M?S"8H]6L3_R;3I['Y>7^6;Z>'>-+XG5]'B^AA[WSAK^83%'JUB?^3:=/8_+R
M_P LWT\.\:7Q.KZ/%]##WOG#7\PF*/5K$_\ )M.GL?EY?Y9OIX=XTOB=7T>+
MZ&'O?.&OYA,4>K6)_P"3:=/8_+R_RS?3P[QI?$ZOH\7T,50-L%Q&.)CR3'!F
M+V1 8_9$ASYKCR*MG; @/<I/&#]FY3$V+-GC)VBDZ:N4;[%D'"*:R-]BB=MU
M(&:9@5>:1E(YJTC,#XQJ"Q'6.6H.AT.)DJ58V#QUJZ.OX+I#&K#4$'1E4$:@
MD<CU$C%<Y-R .6^^;E,!RB%:7!L@;8T5;:V]NVKO (MW;2M.]6V_CVZ=OM=W
M5N/PF_\ T_JQ>O\ XN'Y'_\ WG'I8C,+:JL4J*HVTX64I6M;*=NM:<*TX5I3
MX?Q]SMZILQU/,C3]'ZL05>K7GKST[!K^GK[.6O/7%T]@ OP2?F6^S0,P\?ZL
M3%03XO,?["/U8=@ KP2?F6^S3>W;ZA[,0V#R>8_2P[ !7@D_,M]FF]NWU#V8
M;!Y/,?I8=@ KP2?F6^S3>W;ZA[,-@\GF/TL.P 5X)/S+?9IO;M]0]F&P>3S'
MZ6'8 *\$GYEOLTWMV^H>S#8/)YC]+#L %>"3\RWV:;V[?4/9AL'D\Q^EAV "
MO!)^9;[--[=OJ'LPV#R>8_2P[ !7@D_,M]FF]NWU#V8;!Y/,?I8=@ KP2?F6
M^S3>W;ZA[,-@\GF/TL.P 5X)/S+?9IO;M]0]F&P>3S'Z6'8 *\$GYEOLTWMV
M^H>S#8/)YC]+#L %>"3\RWV:;V[?4/9AL'D\Q^EAV "O!)^9;[--[=OJ'LPV
M#R>8_2P[ !7@D_,M]FF]NWU#V8;!Y/,?I8=@ KP2?F6^S3>W;ZA[,-@\GF/T
ML.P 5X)/S+?9IO;M]0]F&P>3S'Z6'8 *\$GYEOLTWMV^H>S#8/)YC]+#L %>
M"3\RWV:;V[?4/9AL'D\Q^EAV "O!)^9;[--[=OJ'LPV#R>8_2P[ !7@D_,M]
MFF]NWU#V8;!Y/,?I8=@ KP2?F6^S3>W;ZA[,-@\GF/TL.P 5X)/S+?9IO;M]
M0]F&P>3S'Z6'8 +\$GYEOLTW,?'ZA[,-@\GF/TL=YK#!S>ZE:)65X<.'"VG:
M^#C7A_;[*4U+J>W$V@'4!YOT\NSGSTQ6W3!%LP6L33I;3I5W<I2G'A;][N=O
MX>U\&F(: <]/'\I UZAR/(#Q#Q>?'AZWLD(H)Y2#=F]FT;(2V-I3J(IO (R0
M5BSUTZ<[6,/-0[E,W069JV3%FEAY9RAUN6ZY-F2PRJK2CWJQOW3@!9Y.&95K
MS+!,<RE*RR1=,JA5J&0&+?'J7C#H#O&PL'T;;M/CCNW2TX>Z#5DOU9+M4</5
M@]:*R:CN[OFBP,+ BG*"&=HIF7HVZ58VB)3?O7,[=^6S1&\,37'QS#.]5S#$
M8W [O=B-;E\S9'VZ.!KIQ%"XP@ZCTCQ/&H^Z8.%%6HEF(*E!UX&2*-$DZN'0
MUNFY9"F739A7M17^'5LF:S_W?%D^7U,W#J)T=1-#?FE#@!I'D2-Q+"&UVJY*
MN-)L\JY%>RVQD7'3T5JY=_WY/Q7GV:<,O$S4YHI7JVLHJU7C<E(8X)I8C7M%
M -SQ*&P\V'9^>8JR0I"2A4,(A&0F$E9.B!##,8S"N(FZL,/C<?2!<,[BYV:O
M00*4NQ90R!ASMHY*-FMUJS5\E:JU6SW$^5K>J"PB226:C0LJ+F$U /6%B)[<
M0D6:.NLLL"ND<MA65"W(J=&&E]SSB-\HS0T)IH(:&91VD>23(ZF=M#F!HV8L
MMLM ]2Q?>O7MO#-/7HNCS*FC)(NY&NKE!)1894PB#)R9E.YM&(Q+DIA.H]@E
M? L//J%)&D\"MPX A#H02-D@PRRQF<,VA&@>MMPQN.;T>6%WCZAPK#T8S*2.
M%JM::: UZTN9#,[$02(K(9)5L65C21_"CC,ADY.7)7HU6[[I%L3G(*\UI,PO
MU*ET7<PK</GAZE9,MH/ L%:2C0EGEAA 2Q/T"0:&%8E#B=Y,\.1)9I.\>9,3
M4MI7CFP]3M_^A6/OU][XM<CXV/\ XFS?_P!RMY/_ (&K]NWQ#Q8]2=R+_)UP
MQ_[&8>7_ .;YAU^3M\F/0RKC8>\3MON02KQI2O\ H4[5:TMKQX<.-:]W6I;V
M[?U?;[=6.E[ 1Z^9U_1RY:=1Y'7Y,=+W)QOBR7F_N:FZ3R>O]F(='Y?5^W#W
M)QOBR7F_N:=)Y/7^S#H_+ZOVX>Y.-\62\W]S3I/)Z_V8='Y?5^W#W)QOBR7F
M_N:=)Y/7^S#H_+ZOVX>Y.-\62\W]S3I/)Z_V8='Y?5^W#W)QOBR7F_N:=)Y/
M7^S#H_+ZOVX>Y.-\62\W]S3I/)Z_V8='Y?5^W#W)QOBR7F_N:=)Y/7^S#H_+
MZOVX>Y.-\62\W]S3I/)Z_P!F'1^7U?MP]R<;XLEYO[FG2>3U_LPZ/R^K]N'N
M3C?%DO-_<TZ3R>O]F'1^7U?MP]R<;XLEYO[FG2>3U_LPZ/R^K]N'N3C?%DO-
M_<TZ3R>O]F'1^7U?MP]R<;XLEYO[FG2>3U_LPZ/R^K]N'N3C?%DO-_<TZ3R>
MO]F'1^7U?MP]R<;XLEYO[FG2>3U_LPZ/R^K]N'N3C?%DO-_<TZ3R>O\ 9AT?
ME]7[</<G&^+)>;^YITGD]?[,.C\OJ_;A[DXWQ9+S?W-.D\GK_9AT?E]7[</<
MG&^+)>;^YITGD]?[,.C\OJ_;A[DXWQ9+S?W-.D\GK_9AT?E]7[</<G&^+)>;
M^YITGD]?[,.C\OJ_;A[DXWQ9+S?W-.D\GK_9AT?E]7[<?:8G&TK2O4R7F<?_
M -M-"_DT_3^SV?+AL\NOZ/V^WY,5X=CP<SOMNHBG;P[UMO:[O<^#\?=_'W)"
MQ/7]O+\N)@NG5I\OF^3S:^?%PF1Z#,,ZLL3MLI:C=7CW*_Z-WX/9V_P4U =8
MUZO'@?!&NO/0CQGQ=6G/3J!_1S./#[BIIA1[O.W#)9MR',,4#DMTFXM]!LB0
MT=0J[BT^&[OC9%B^(M:)JJ),%8VUD[-J3L1<6!#SD*:=LW[ >Z9..\90V9+P
M5E9RZI7O2&*TMFI8?HUGJN;Z.J-J 7$S0L4U7I8EDC5D9U8>,N*DR&3NN\1#
M/<RO9/$+&5R9=F=&+IGIYC$F22QR2IH66,U4MQI*%;O>P\%ATDCB>-LM.4)E
MA@]C1JQ:Y4(22,L,CL$E0#'9B4V^#CZJ+><. DHE&2;4&028F1]"IZ\8+'CA
M(TBXE,BD8H,SK5WPFX5@CBN,QHI#,U1R)6XA3-7A!-820PTR6EKQOLB#NSNZ
MB&**21O!Q3[I5R:QE21QYQ):J1YI&&K1\#3\-Q62J9@U>W;S31(+LT72V3##
M''#%*UNU:A@3P]-/&M^QQ+#3#'IOY)W^1I /Z5GW]YLXUYASG]^,W_C3,/Z9
M-CZ,<)?BIPQ_J[DG]65<;Y3L:;E;+J7V6UK6E:5I6WC2O:^'O=W^WMZPP)'5
MC9B/)J#U\]"-3KJ/9\GEQ$[W#PYTI6^YHE=6M:UX]!3X?PT_5_K68.?:>OS=
M7Z_DQ+LU\GJ_5KS\HY?*2=*?7"0VO_@:=/P)T]FH[_MM_P";$-GD/SA[,/<2
M&^*)^93V:;_MM_YL-I^"?G#V8>XD-\43\RGLTW_;;_S8;3\$_.'LP]Q(;XHG
MYE/9IO\ MM_YL-I^"?G#V8>XD-\43\RGLTW_ &V_\V&T_!/SA[,/<2&^*)^9
M3V:;_MM_YL-I^"?G#V8>XD-\43\RGLTW_;;_ ,V&T_!/SA[,/<2&^*)^93V:
M;_MM_P";#:?@GYP]F/T3PH-MNI7J)*O;_P"12GQUX=S[W<[^F_\ 3^C3UZG]
M6&SEV?IU/F 'Z\:J-D (9&.4*Y:A^[;W591+(NTA^LDWL3O7ZE0VG!2CBQO9
M?<DG<K?99?TNV]1.RY2MMMU]M*UNI)J>?/KZ_%KBJP 2+4:\B-=/_K.G(GR_
M+U^+&8T3W\.9%&H])H[L]W2.P<D""I &<J%=I#6]R*,L4"0]>]LXW5IN&]ZS
M5RBK<BNG8LE6ZJ:EEM]MUM([6/B]8]N)-0-=67KY\FZ_F@<AH-!IKVC%P\^2
M3_!LTW/?GW:']:W38W9ZQ[<3;E^$/,WT<.?))_(TW/?GW:)]:W38W9ZQ[<-R
M_"'F;Z.'/DD_D:;GOS[M$^M;IL;L]8]N&Y?A#S-]'#GR2?R--SWY]VB?6MTV
M-V>L>W#<OPAYF^CASY)/Y&FY[\^[1/K6Z;&[/6/;AN7X0\S?1PY\DG\C3<]^
M?=HGUK=-C=GK'MPW+\(>9OHX<^23^1IN>_/NT3ZUNFQNSUCVX;E^$/,WT<.?
M))_(TW/?GW:)]:W38W9ZQ[<-R_"'F;Z.'/DD_D:;GOS[M$^M;IL;L]8]N&Y?
MA#S-]'#GR2?R--SWY]VB?6MTV-V>L>W#<OPAYF^CASY)/Y&FY[\^[1/K6Z;&
M[/6/;AN7X0\S?1PY\DG\C3<]^?=HGUK=-C=GK'MPW+\(>9OHX<^23^1IN>_/
MNT3ZUNFQNSUCVX;E^$/,WT<.?))_(TW/?GW:)]:W38W9ZQ[<-R_"'F;Z.'/D
MD_D:;GOS[M$^M;IL;L]8]N&Y?A#S-]'#GR2?R--SWY]VB?6MTV-V>L>W#<OP
MAYF^CASY)/Y&FY[\^[1/K6Z;&[/6/;AN7X0\S?1PY\DG\C3<]^?=HGUK=-C=
MGK'MPW+\(>9OHX<^23^1IN>_/NT3ZUNFQNSUCVX;E^$/,WT<.?))_(TW/?GW
M:)]:W38W9ZQ[<-R_"'F;Z.'/DD_D:;GOS[M$^M;IL;L]8]N&Y?A#S-]'#GR2
M?R--SWY]VB?6MTV-V>L>W#<OPAYF^CASY)/Y&FY[\^[1/K6Z;&[/6/;AN7X0
M\S?1PY\DG\C3<]^?=HGUK=-C=GK'MPW+\(>9OHXJ 3?< [(XZ$R7A3,^#1,J
M+-8X&G>2E<+/X/=*RBZ3:/QDL6Q7F;)CV,OY.\4ZUQTE)Q8>-$S]X^+IG;90
M?C08S J1UCK^3 $$G0@@#70!M?*>8Y_H[?)SS.6,-GC!>Y-2E:U2O[7&G'MV
MT^_Q[OXJ=WX-0Q#77J[1^OGS'D'K'C.F/(%-<8Q;,O+,9PQ]- ;B4QLOD822
M?Q=L75 *RA6*;,\<2X=&JFD%4' Q"0% +(.Y>-W#9RBV>JW-W+=;I:UG8.&K
MD]#@:_;K2B":/,"J3M&)1")Y*$#S=&P*N8DE:0*P*EE&H(U!\M]T'*:>>=V/
M),MO5VMU9\B662FDYK&V:<&=W8JO?"E6B6Q-7CA>1&1E1V*.C:,*SOLVX9\C
ML.B^5@N-9YB_%3_%4?)YFQVKF A.8?CN>V3TY%K!#-.03(P8>C2;%K"#[1E9
M:6;C'1KH47"2:%4F><X9S?*I;$]*2Y5NWEO2IE]L9>E:Q;JFK%,9&,5>-%=&
M:S$[GHRZQZD'75M.[H7#'$5:C4SB#*\PRG)Y,HK2Y[EASN3,*66YB,RL5!"@
MLWIII(I8TR^PB*)DB>?P6 4A,7]CRLK@N68WE=K%\HEHJ])R/!MA;#O6.F1V
MT\R[C6:AXPP@BYE^TH-F-J-C\T%+)TNM8*BKE*VNKJT'O,SQ((+-&:BT]*.=
M4AS+9F'2=Z&M0N5I)FLB-6WU]=L<D?(L''-?PUU/@ W,OSFKG"5,VFIR2VN'
MQ-DG>_NHN8YSE5^&I'E[3RQ]%="B2>"8:B,PDZ.3T3\=X$@[-F.))X.FFZJ=
MQ:1CIJVCQS='-8W,"=RD?/M1)IM$+01LLY$L&Q)*]N82*(#[W;Q)JLSL<(67
M*VL@B%9[]5J^25IX6K&6/):\U=-)8FDC:QTL4:NS(08RA?:I8,0>6(<;61?3
M)LPBO<89A3M17UK6.+[]6],36LK!.M+O>>9H8DE4K.LRQEY%5D#*"1F=R5.;
MV>%L<DJ5@$]R4;R%N9D\/CL9Q[? D"U[]CAH/.'CUZZR//,>1UJ-;!(@5Z-3
MK[>]5>*,VZ#%:U915#C/&WXSYL-.N2L!XO\ X"K[/T]6/6_<A'_].N&3J !!
M?//7\\9@.6@)_3XL;[$MXTUM2LI39=N=NX6TI2M9%L^X5[5*<?Y6''\7M[6I
M;6[.KRCVXZ7JH_SUT_\ M?J\WK]6.?/'F_D6[F_TBV??6PTV-V>L>W$=R_"'
MF;Z.'/'F_D6[F_TBV??6PTV-V>L>W#<OPAYF^CASQYOY%NYO](MGWUL--C=G
MK'MPW+\(>9OHX<\>;^1;N;_2+9]];#38W9ZQ[<-R_"'F;Z.'/'F_D6[F_P!(
MMGWUL--C=GK'MPW+\(>9OHX<\>;^1;N;_2+9]];#38W9ZQ[<-R_"'F;Z.'/'
MF_D6[F_TBV??6PTV-V>L>W#<OPAYF^CASQYOY%NYO](MGWUL--C=GK'MPW+\
M(>9OHX<\>;^1;N;_ $BV??6PTV-V>L>W#<OPAYF^CASQYOY%NYO](MGWUL--
MC=GK'MPW+\(>9OHX<\>;^1;N;_2+9]];#38W9ZQ[<-R_"'F;Z.'/'F_D6[F_
MTBV??6PTV-V>L>W#<OPAYF^CASQYOY%NYO\ 2+9]];#38W9ZQ[<-R_"'F;Z.
M'/'F_D6[F_TBV??6PTV-V>L>W#<OPAYF^CASQYOY%NYO](MGWUL--C=GK'MP
MW+\(>9OHX<\>;^1;N;_2+9]];#38W9ZQ[<-R_"'F;Z.'/'F_D6[F_P!(MGWU
ML--C=GK'MPW+\(>9OHX<\>;^1;N;_2+9]];#38W9ZQ[<-R_"'F;Z.'/'F_D6
M[F_TBV??6PTV-V>L>W#<OPAYF^CASQYOY%NYO](MGWUL--C=GK'MPW+\(>9O
MHX<\>;^1;N;_ $BV??6PTV-V>L>W#<OPAYF^CASQYOY%NYO](MGWUL--C=GK
M'MPW+\(>9OHX<\>;^1;N;_2+9]];#38W9ZQ[<-R_"'F;Z.'/'F_D6[F_TBV?
M?6PTV-V>L>W#<OPAYF^CB^L7;LXU/Y@ZQU)H'D#"V1+!-\D"PO*=(%0A,8JW
M60:$Y'#3.-YYD6'R!J"(NFP^3"FDEI*(NJ_"/9$ &")/%B1J!!'(X#4@'4$>
M,C4:'LY\_/IKXNHXR&D#])R%=WIWVW4JA?PKQX_\&M:_V?A_#W-0^7$&/+33
MGV?+J/U\CIVZX\+,)BT_/[RLYR/'<88RLCB7=5N>S2;8ER8X*!;QC&>Y6=2(
MJ[/E2CALR9BU;T&@R[HK[W#MV1:#V+=T]=MVZO?LCGJQ<%Y?%;G:!+T,^7QO
M&CR2F:Y8M0H(DC!9G&K/R "JC.Q55)'BCC.GF-GNN9Y9RRG'<ER:U1SVQ%-+
M%!66IE5#+;4SV9IF5(X252$ZDL[RI%&KR.JG8#OUE68C6UR.+Y.B$W27DF4X
MJ8=K2?/H;)]N,AR@C*<LQ3'Y'!&;5N>A&1YGC2?LD9*_+U0'2)ACX.3M$C"K
MF]HTM.&(,OBSJ84K%8B&E/&HARMZ1N.)*4%V6*RS&*S4KW*KF%8]7A:W(A=T
M4,V1[HES.Y^$JS9M2OAK6;TYG:UQ%!FHRJ(PYO=RBM9RZ-4L4,SO97F*+:DF
MTBLQY;#*(89FV+I/UT7'!\-,,>F_DG?Y&D _I6??WFSC7F'.?WXS?^-,P_ID
MV/HQPE^*G#'^KN2?U95QZ&*TI7NTXZPN-HQ\Z"WO?KK[=,,.@M[WZZ^W3##H
M+>]^NOMTPPZ"WO?KK[=,,.@M[WZZ^W3##H+>]^NOMTPPZ"WO?KK[=,,.@M[W
MZZ^W3##H+>]^NOMTPPZ"WO?KK[=,,:&-NSSJ/?/R]%].'\:7;5:=WO;,A->U
MV^[_ *_#IB9_P8_T^MB/[?\ KIIC69F?=/N/PB+Q6^A,Q; <!XMVK;<IC/RT
M'@V-LTNX,;/6/+3I#<U WTXC^:8?BHM#0K>Z&2?% =R]5=M).^<."%1E!Z$Y
M8C33EHH[#V=?9U_;7$JHK#F-6+L!J677L"G3:3KS.IY#3$[0#E"IP"RCDV)9
M9A8PGCJ[<5NUQSCC*3>916+("1FW?%#G,]@"1@R(\>.9@*PT">LOR0=ES7I)
M>E$S MN'1M.73!CS\8U;0Z]@UT_;Y<2F,: @\]J$KI\([>7EU\7[=.K%.51/
M3+J"-A-L[Y?)Q3+*.+Q\7<Y+>@HPY2);<))N4#RI.7RO%<=+*B5XM&7HYVHV
MA#@>XO4;FXB6F09X-<OX=)Y/7^S#HO'NY;===NI_"VZ::Z<CU\^7/733&1FS
MK>ZKNM*/1K_$1'%MSO!V$=P\-O>3(7+[Y#C?.*T[8@52B8T2,LCA\>2Q\7M<
MB+5S*2HUV,>W/VKM5V+9S*VOBTY:]>O]F)7CV#777PF4\M!JNG4=>8.O9VX[
M6U7>,?W'91W!X^+X%RUBYGB";H !!V;QD>'9JL[\=XFE=T?EJK:4&JC<BN7V
M0GY8>#'MW M:!MQ!A4FD2<N1]A6))&G5]N?E_;@Z!54A@=PU]9'+ES'+GV:@
M:8PT@7*8R"5\H%DG![ Y!)'B4H^R[AC"D/M4L"2=;.N!HI&)&5)R287,'K1&
M(94.W99@T772ZZ7,WV+D'J0V^XZ@F]EW\SV<]!\@Z]=/'IZ_DUG,6D8.AW>"
M2?%M8Z ::\B.1/R\]#J!!V#N4 W6/X# I9EN5-'+C(>%=G>6D&X*.P/HF+G<
M7O@5P@\;C[D8P/2; %H%>Q8V"BEI@\&3O=N[9&_.T1)TAN;M\6OB[=.S$QC3
M<5 ZF<=9_P U-W/GY#V<_$!B989RJTLQIB>DMW%8K?'T3*.[LIC69P>0 5G<
M_=;>MQ3C%J,-,P5D':7P*VUA)H8(8RA4A(*$[QA@L4&,%UV:1*(<@#4=>NAY
M<]/)XL2M$"Q"GJ*@@@\MRZZZ^/J)\7DU&)YC7*-R>3&<4Q1OMDE0V5SB3YS$
M2Y"02DM%0,0C6 6>*)#+I]'GTLQL E&0(X1B65&KL FWA4=*O92$?Q!9BV4H
MY+,([^KEUZ^/Q#37Q>7U8E,>FOA#0 =0U)+$@#KT!Y<^?CUQ17/*<&QF(,?Y
M8-;;WH]/.[W"]=O(-EEH#*WTT!9N$S62@"L_$PN+2.?8U<A8M!2A4XT'X^GX
MUP_<M([&SI\VT/- K?R!*Z:^+4?;^SRX=%X14-^#KNY=1'7H>H^<>73'1*\J
M@J/'V2/FSS=I%(UAG#6;LO+R:7#XC+<>QK*N6YUAQZ-&0<S'DR<Q,QR00=T9
M'HVNH^UE48<T?-W0HA>'%'(;_)U>7]F(]#U>$.9('+74@ ]>O5H?V8O.(;U\
MKI;0-ZVY+)< BH@WMPR!NWCD+C\=+NRPTZQP'(I5&HXR,J7H-G2+F\Q'[!1X
MHBMTDMT#N0L& -F[; Q\0QT8GQ$Z>SE^O$"@WH@).X(23_\ 4 =?T:^KQX_*
MN4-TH#=IA#"K/+L/RO10#$".<L>A<8L6EL&Q>ABLNC*,T9*R,Q>-T(O.YYG!
MBU8XH@0(<T#FXK>4I9'[T A20M&K;@-=>K4:=7(:ZGQ<^KGB&B%6.A'7M.O6
M=>0 TU("]?ETQ:F2-W><8[O9N@(<O&TL01?<-MEVX%,>K19!R:E]NX7#<[R6
M2R4C,;GUI0<\B!,4$8C!3!I<$=!P4IJ32</%T'8T2=WDU T^7$0J[-2#J59M
M=>0VL !IISUYZ_*.KGB2\Y[^I'B;-D@P]&L .LA)1N8[;,?D)1=DX/$K%9;N
MJ(24!C!FS#/8R445'M9+':M)<26(-Z!PSRTP/;&G:%0JHMH2-->H=>G7U>+$
M%C##4MIR8Z:$\EYGU=7KTZ\0B=Y6M4?CTG.1.W D6<P##DOS#F0&[RR "4AP
MZ+;@\C[:+ \/)N8NXMR([?Y#Q9*WRKCJ**VL8G8+?6MWL@+L8PJW^3Q:]?ET
M[,3=%ST+#F0%Y=>JAAKSY<B!X^>,\<"Y6D\OR;NMQ7+W*)(A@O- D+'C"#-J
MRZN@.2<60++<58/4F:2"%Q**JS$S#KE^D]4/A4?#E""[PF0>NE9@>9!\1]1Z
ML4V T4CQCF.P@D'S\C^D]0TQD_J.)<-,,-,,-,,-,,-,,-,,-,,4D^ "2H(7
MC4E$#3\>/CG@<X#,,VY$47%$6ZC5^.(L'::K9XR>-E5$'#9=.])9*^ZR^VMM
M:TTP!(Y@Z'M&(QQYEJ3[9S(C&643I2285D!!D Q+ER0/G)(O"RA!>QD$Q%E\
MV\45<O:/'*J G%N5"SA1:4JWLX%/WMV1;H]),JTRH'R=HZQU\B?+RT)ZM-/'
MKBH"6!TY-UD#Q_\ U :>+Q@>,ZCER'FVW[.['V^[=H[LKT5JV0,>74KW>YMS
MPC;_ &VZ[OW.?Q?D_C&S_NJV/%_=\_'B#^(:'])S#&*FM]QQ/&?^S_=KC#;X
M 3$Y&Q=+L@N0.<L?9YAKF+S4=$DATKQZ!DP$<V,HOHZ=N*C'",H>J+MD%&-]
MUR:/!>G0UI=JV?Y%<S67I*EV"J),MM998$U=YR\%J6&1S&5EBV.#"H#$-UGE
MCHW!7&64\-UA#F>4W<R>OG^6\0T7J7XJ:Q7,MK6JT2SK)6L&:)EMR%D4QDD#
MPN6(RW)9PQ7DZ,8?@V(,>R_'\2Q4UG]MC>:3$?-"Q-[/9,C)WJ]" Z/QU)%!
MN[M<)I(W-+[J)*)V],K6RM;KS)\MNTIK]F_:KVI[QJ\Z]=ZZ(M6$PJ-CRRDD
MKH2=W6#RYXQ7%.?Y1FU7)*&2Y;=RVGDZ9B MZ['>FEDS&V+<C=+%6K!563<
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ML^W#L %>"3\RWV:;V[?4/9AL7L]9]N'8 *\$GYEOLTWMV^H>S#8O9ZS[<.P
M5X)/S+?9IO;M]0]F&Q>SUGVX=@ KP2?F6^S3>W;ZA[,-B]GK/MP[ !7@D_,M
M]FF]NWU#V8;%[/6?;AV "O!)^9;[--[=OJ'LPV+V>L^W#L %>"3\RWV:;V[?
M4/9AL7L]9]N'8 *\$GYEOLTWMV^H>S#8O9ZS[<.P 5X)/S+?9IO;M]0]F&Q>
MSUGVX=@ KP2?F6^S3>W;ZA[,-B]GK/MP[ !7@D_,M]FF]NWU#V8;%[/6?;AV
M "O!)^9;[--[=OJ'LPV+V>L^W#L %>"3\RWV:;V[?4/9AL7L]9]N'8 *\$GY
MEOLTWMV^H>S#8O9ZS[<.P 5X)/S+?9IO;M]0]F&Q>SUGVX=@ KP2?F6^S3>W
M;ZA[,-B]GK/MQ]I 15/^)2\RW_#AIN;M_5AL'R>O]>N*@UAP]O=2ZU&WM5X]
MJVGP=SMTI_K\>H:DZ>3JP"Z>3RC]I.+G1'H))=*I9;2WAW.%/B_U[>H8CH.?
M:?'X_/BWB$*#$+ZWKM$K[J]WC;;6G]:GLIJ.I[3Y\"H/7VD^?Y-/MY>>*7[F
ML<\00]&G[--Q[3Y\0V+V>L^W#W-8YX@AZ-/V::GM/G.&Q>SUGVXY6XWCME:5
MM8H4K2M*]I-/X/Q:;CVGSX;%[/6?;BXV4<',4NE(MT[;>UVNAM^#C_\ EK3X
0:_XZAB.GR_H)'ZOMZ\?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>g947560g02q76.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g947560g02q76.jpg
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M67&5F+0:(B5!4F&4V"114Y;1UB<H,C9#>8&1DY>X_\0 '0$!  (# 0$! 0
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M*4'HBG *8TXLL!9IA8C  "$6@Z%"N\ 8 P!@# & , 8 P!@# & , 8 P!@#
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M&?2ON?E^"T/'CUH\47NY(^2ES)[/=+^[>-8*DA, 8 P!@# & , 8 P!@# &
M, 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & 0-\4S
MYM'Q ?8SZ5]S\OP6AX\>M'BB]W)'R4N9/9[I?W;QK!4D)@# & , 8 P!@# &
M , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8
MP"!OBF?-H^(#[&?2ON?E^"T/'CUH\47NY(^2ES)[/=+^[>-8*DA, 8 P!@#
M& , 8 P!@&(_L3H"=Q6\5LZ@]CKHW6/!D;@%G="0U$\$I6JUVVX9*2EL>/O[
M;Z31[LMH'F-CEUT,[+LH1*R4SVMUA0O6D0#D0LEAUG1894RQYV\:;$]Z)/=T
MVK?M5T.GF?,+ NF%@GS".(2T+)13]T>:;&7%(ZG."TJ Q:WJ57B3!&0@W]\0
M9J-*WZ- 6-I7^O%FI1$4F\<NFG;1\"B.0KIZZL7E^P;!MZK37&_&.13%)!*X
ME53/_'*>7)VN,1YPB[6L;Y99G2*UF;WI^6.3<;87PHM1!#HTH$0"-D..= :5
M:++#;K=J2KZC&S%^_O$G;>0[WEMH<O3%-93KU+;%"5!/ZS8GWH9[K1 NNVQ8
MP?)Y+1U1TBP21\KKFFOHX,46GQ:1Z'?3PVP_3L0Q_?JH<"!9QC54:I1/%TQH
ML*MT3;K7'#%;"K?#F[E4POPAXM8;CJ[.C^AX#&>B5D;K"5MDS<^C>A7.%7'(
M$B!QB\>?D*B?3Z-MHYI!F&932*,DB:(49IV9SB].4;/9"PE']MK!+#:J+#?6
MGK94_@6WE:5N17NUHNR:7/85FQ7M-W?'B1VK6%I5>SM*2>TC3;@97\!C5F-#
M6IA3##I<SS,;?4P"TS]!8@]PE]DK0BU/F=P>A-HDM6B2K'8T]KQ=&^;';LR,
M[>#&, 8 P!@# & , 8 P!@# & , 8 P!@# & , U->Q^YXTA[$MRE[CD'BDQ
M]VC$\<F&O$,&ZFYSX!HUQ92=EF,XJJ=I'8='2*W$JDHW0]OTNF$Y6/"P1GJ:
M-M0>J-*89$L*IPQ6-4Y-98ND7J\V7I-A;C"*S2.TE%W256O<MEM\V9(Y-(PV
M7Z\53-+/K5N?V)&N50-\M"GV]%&+,*:UIQFTLG.6RE>=YQP-363-_J"HH4EG
MDELPK1TVT>*K\)$M,$# & , @;XIGS:/B ^QGTK[GY?@M#QX]:/%%[N2/DI<
MR>SW2_NWC6"I(3 & , 8 P!@# & , 8!8Z9<Q\V6+(E\PL'GNCIW+7720+I*
M)E4T"D\B<@H$2=M0A7O;VP+G-9I$W)$B!)I0J,TF1)4Z4GS""2RPB:O>_67K
M3)DR),G1HTY"1(D(*3)4J8HLA,F3$%A*(3IR"@@*)()* $LHHL(2RRPA  .@
MZUK0@YL 8!1++6E<1M2Q+(]7\)85<70/K7&53+%&)K4QULE#D4\29N8CT* @
MUH02)W((=7U(WB3IW=R)*7.!:A46 W0'VV>-1R.FOA\?8&1B/DSV?)9(<SM2
M%L-D,C4HD#:I?WPQ$00-V>U#<U-B ]U7B4+C43:@2F'B(1IRRP/MX P!@# &
M , 8 P!@# & , 8 P!@# & , 8 P#5(Z=YAG?9O45GL<P\19#-:TE/05S5?6
M_(EQT1T0YU'%Y1S["&FRIK&3VBG^EJ=@D])BD67IG5!)++:5B=[5&&I&T*A>
M$1(AD4DE11::6,E))XTQ3<6UG3!K-UYM@WAAXB<AXQY6?8&9'C84[T!5#C$S
M8E!5%81@R/*X6SG- X_7*M^E"J#- T(R1-\54R1^/8TVRVXUW<#"!*C11UJZ
MUK5UJZNM=KVOGVDJL$# & , @;XIGS:/B ^QGTK[GY?@M#QX]:/%%[N2/DI<
MR>SW2_NWC6"I(3 & , 8 P!@# & , 8 P"T$IK"52)]7/#;?=P0I$KTFT3&H
MLCIDUB;O5TA"8S:(R65!*7\6UAI(URGU]]7>16I/TE]61Z3I" +#2N#6DT6Q
M4D/1]3WQIFF+=9"EZ 8T<[&*!FQAM8%35M,?N@M;3A":XJ=GZ"$7I@[ '?D\
MS7E NT"EYP$81;ZBOX>@B"+8!H.>?-'K6];V$7F4$$7FB_,+S1!%Y-[\@M;\
MF] 7^P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & :>O4,=96_JBS)%S
MI<GB&O5M+>UK[CU2U+3<,Y21QJ174_4/MZZ^=ZMD%O,RE<NB595@QMD/F3C,
MS@>L2UQ;V:%(%9ABI^)&5-46M&/BIMMRR3PJEO=,JX9Y&R-X>A-8)N$N/DM*
MO<FD=2)>;J=2UR]S5$@;IDX1!-!60AD.EK>U;$UH9,%$644_)&T9C>G=2U92
M,TY, LT8I*NM*N>LZ]-28F"HP"GY:Z/3'%9,]1R,JYK(6B/O+HPPU Y-3,NE
MKTWMRE6UQE&\/RI$QM*M^7$D-2=R>5J1J0G*@*G%4G1E'&@ P1D^(5W_ "/C
M^:6)$*&C+QTPT>(S9G(SE"JUJZR.B8E5E>5W+9"W2.3/;3$)37[W-/O7;8TJ
M91S96_UU&7Z2.3(::DCY;LE;="^K'6HVZ:J>:3;<4\\4L7SX<Y:/L;Q3:DF?
MA:73#YDXV-9UIWSQ#>Y94^J#DN_(Y2I<C?V*T:Y/:7Y8\ G22JU\-E,><HW/
MFF9SQ8=%7%F<7!R6DM9J8S0M&#UDU1)36#:K@T^:OJQ,X/)#LEUROS&5Z)S\
M[=#4RB\OP*\;+],"NHR#8]G:0>ATDWL6MA7['I",.A# I$ (A:&(D"!Z1CT7
MO1+MKT@3QA\]@?2]ZTG!L9FC-#;@[*$(.MZ( ;H U0_(6F"<9O0=@/AI'YNA
M>A=O)L@2GR? #[YWHPF"+V'8/@[S]'[$'>PI=A]:$7L)H2=E""/8 3TC!H>]
MDNV_1ED&B\U@?1[V%0$L9>@: W"V88'1@='DEZ$<F%HP"D!0RC0@ _0GA($0
MP[)=/*6H+3"V%C>Q!V89H>PB (+?L)J?6BQ>D5%[&E*WL&C3@;,+T( %X2"$
M .B776S#S$X?.8WL(=&%! (0AB$WZ"41O0P^C4F; F.%H8231B+,T$#\A>D8
M] WHEVUH91QVO.8'T&] (T8(81Z&W!V6:+10O0D#T$]3O984Y9HC2M# ?#2/
M0=B]"[>31 5.]? #[L7HQF +T'0--OG;/T(>MB2ZUM4 O0S1DA* ,80 WI&#
M1F]DNV]%:($+S6%\'O>E //+]'H#<+9NPZ_(>$K0Q)1_R:G1(_\ -P#][=TF
MA[+]$Z>=I5I'O>F1ZV#TNQ;#H>C-(-EB2^76][7:'M$$/D%M1H(@[V!\.0SR
M)Q&//4NECN&+Q6-M#U()))9&C<&-@CC!'&\QV?7V0.[HD2M[(RM382>O6.SF
MH2MY*5,I/$H]&F/$6!#37BJ^&?L(1:[ZY!\@R#5&M;Z#J\(M%DB- ,(@[DNA
M /WLD>RDP]!4GAV4,@HP!Y(C!;4G]V7X7W 7BJ>&>'0M[[ZY!\@""U&_-Z#J
M\6]EFB+"$(=!DN]C/ULT.S$P-"4DAT8,XH "3A #4G]V7X7W%DIMXG/AS*[N
MI-Z2]T\FJ6F/-=J$O3DGORLCD3<:]M$7*:@*%)<D$5K:TQ.H+*\T0M:&2: >
MP"+%K0:D_NR]3+X:\5'PT=F!*_'[X^\X:KU/6]]#U7HO1WEUKSQ&[D^B@)?*
M+7_3AC"B\GEWZQY BWH-2?W9?A?<?@'BJ>&>/1>P]]\@Z])H[8?/Z$J\O>M$
M V,?I-&24.RMB#KR$Z-T#:D?D+3Z-,WH.PU)_=E^%]Q)&H>C:)Z"BRF<4/:\
M(NF&(W-8R+)75+XEL&.HWUO3H5BY@5O,3$[-Z9_2(G-L7*&,]06[%(')N7#1
MZ2KDIQHAIK--=*IQ+IB>D8=#WLEVWHLH@X7FL#Z/>P*- $6$&@MV]FFAT8'T
MY!>AGI=Z&%264(HS0!!^A/"0.QZV2Z^4L\I,+R,;V+6S#M&; ( @M^PFD:]$
M+TJHO8TI&]EZ/.+V<5YX'T@BT,(1ZT+6A!T+6AA$ 6M"UK>M" /01@%Y-_E"
M,(1!WY="UK>MZP#]8 P!@# & , 8 P!@# & , 8 P!@# & :^5]\IJH=T9?U
MHI_#QZ?L5UN5'83!&+BY"[(A:8B-)[921=JL.:1RK[EL&F?Q>[ALMBAT:8K/
MEU>MTN1/"1GV:5+_ "NB\DP73JDG**IL<7S[4G6FQ/+H,KO&K7/8S2L7@LFY
MP8^5X373%&8!3]0I+6;[:E3%7D38$3.U!G3Q'VS[U&M]+ E D VQ^9V4 ].F
MT[.<R5.;BH1(Q5XMNM:YNE*LEA@@8 P"##UX?%'.4#E,&9)!<E?&R;IJ>]<E
M3BMK2?X78$:NJRGAY=Y:[1V0M.BR@QYPW(7INW$7MO>X]MN7>:<@/5HV]8D$
MZSYLDLMBHEP6*HRRO:%%5MS/X.?95'5$SJ6.OX#Q'U B94:]T<'QU4J76M9]
M(9 ^/;V[*%3D\R"2R1W=Y'('9:>8H<GIU7K3-A$?Y@1:+;G%O[T>*HES)8$S
M>2/DI<R>SW2_NWC6"A(3 & , 8 P!@# & , AQXBGS??=7L<=.>Y.;X+0\>/
M6CQ1Y@Z(@G:)'Y22OT5/_P##!_V0/]V>H5QLK+^A7/\ JK/Z+=_[$?W4.8X;
M;VEI\M;?MS^=M/[4OORYR8_$=#U'T->+?6EL2V411M=([+EL?1PIC;USW)Y(
MRQ9Y?4+08\.NQM45:2 -9SDZO*IM?%)R5'MG;FG:QS XMOY[EEI2_: T+/2.
MB]'7&]6EE>+I"WG?)N%C=KM;7JQL+2U5E915K>;5_*JSLK&-I8Q4I_*VEKJ6
M;L[3;T;96=[O*L;>\6UFG"T<(V=7*TG&$I*.LWJV<4HZTI-2;2U4JNJN@JY=
MHU3PP3>D1?GN87TPL2":6Y%TD^96UDJF'/\ >3C4L4<EM>K:?$ODZ5[*!&@G
M.#-=!;DT/,P:U"R)B94RH[?S(Z>TI'EL]"7NY72Z:#M[>=ST5>9Z,G:6VE+Y
M8:$L]*WJSAI"&E59W:5BW>:6=MH=V=K8W.UC"]?+3BEL.ZV7Z+5ZL[>VM+U&
M$;6WLU>%&-A93O+L(2=D["LU+]E5C>$XRFFX4314-H<851#>06^W69WFIMLL
M==\UVU,5#FX1T^NGV/=+O=MM+7%(M'$T81R)D?H(57[$H7OCC,I$DDQKG)""
MF&.A9D9BS!HWE3?;WRLGHFVN>CEHJWTARCT5=%97>U6D+"\<G+'15K:7J]7B
M5O.[VUA?G?K>-G86=SN\[LK.[R=O>/E9J-K>Y0L]'J\1MKQ_2(V-RO%HY6B^
M2G"^RO$5"$%%3C*S^2@W)VDE.LOV8T5<:/H"/^Q*_P#Q@_\ #.B_(V7[JS_!
M'N/B_*6G[R?XI=YNZ_<P6M!X5O70=:UK7:=B:UK6M:UK7X$>=_R:UK\FL\_?
M# E'PD<J%%**5YN=$DDE_P"5W%Y+#/$Z[H!MZ&T>VVV[&56\6_ZZUVFR!G-3
M[ P!@# & , 8 P!@# & , 8 P!@# & , 8 P#6G\1GQA>FJ+M>P:!KJNJ\Y3
M*CTUKV%16_>KF2RG;=V-L\G46A;Q-.:(PU11BIJ1I*Z02%=,WP^>W<2:)BCS
MMLZ'!&C5!)&2,$]M6T\(TPPJJUQ]"3Z:X&PM4K>^--7UZVR:ROPR2)##8XF?
M+:TU1]B#93J4U)0KYR6RQ308PT%2A3HQX*;8_KX&1%JP)V[8DA90MC&\WA3F
MW<Q<+ & , 8! WQ3/FT?$!]C/I7W/R_!:'CQZT>*+W<D?)2YD]GNE_=O&L%2
M0F , 8 P!@# & , 8!#CQ%/F^^ZO8XZ<]R<WP6AX\>M'BCS#$/Z$C_94_P#!
M!GJ-<?H5S\UN_N8'"K?Y^V\K:>W(K:#SJ75K*&R:P1^71F5,X5X6Q[;A%A6H
M@NC:L9W#1(C2S2]>M-C@M1F^<6+^14&:#Y!>06E]N5UTC=K2YWVPA>;M;.S=
MI8VE=2;LK2%M9UHT_P!FTLX36.<57# BRM;2QG&TLIN%I&NK)9K6BXO/?%M/
MF9=MBZRZ.C,'B%;,=NRU!!H%(&231.. 4)#D+0YQN3*)I'R@"4I#E*MD9I@K
M5RIMC#@>KC2.1JE+V2T@<CS5(_E6_);D]>;[>](VVB;I:7V_6%M=KW>'&2G;
M6=YNT;G;MZLE&%M;72$;K:7FSC&\SN\8V+M79Q45L1TA?(65G8QO%HK*RE&=
MG"J:BX3=I!8IMQC:-SC!MP4WK*-<2GI'T-=DOK!BIB2V3)GBKHTY =F6&K%1
M8FI&M(4R!8A\H@$@5JDC2KEDI4L;<L4J&YA/DC\8S)4(W=?M1L7?0&AKKI*W
MTQ=]'7:RTG>;-V5M?(0?RLX2C=X3S;C&=K"ZW6-M:0C&TMXW>P5M*:LH:M+2
M^7JUL8W>TMYRL8/6C9MK533DUDDVHN<W&+;C%SDXI5=;,Y]<UC=Q^Y@_D+7M
M[:=B>Y'G?//KPP_:3RH\YN7Y5<3L')_ZET?Y&7OK4V/\YH?8& , 8 P!@# &
M , 8 P!@# & , 8 P!@# & :T_:W7%I0"]+?I:A+B@7B<.#U)#BYOX9LPY%D
M%O*:Y1+1DFKXP9T%432=#8&W(SM[T!MZ(8Y/\"%&F 4GZ3)MB1#)%*B;3BOO
M*26&3_9=6WOU=^1GMYM;SVKGVE&U33#?SFI15=!TZB@FEV9GYKI@\N.M^CJP
M;GJ.ITC"Z(H29YT>2KF=(E;5!* !B),G3B+) */-XUQ>._GQWEZ\$# & , @
M;XIGS:/B ^QGTK[GY?@M#QX]:/%%[N2/DI<R>SW2_NWC6"I(3 & , 8 P!@#
M & , AQXBGS??=7L<=.>Y.;X+0\>/6CQ1YAB']"1_LJ?^"#/4:X_0KGYK=_<
MP.%6_P _;>5M/;D=K-HQ# & , W<?N8/Y"U[>VG8GN1YWSSZ\,/VD\J/.;E^
M57$[!R?^I='^1E[ZU-C_ #FA]@8 P!@# & , 8 P!@# & , 8 P!@# & , 8
M!KH3KK^%4/,O$CIKJZ^^D^=[=MZV78'+L?INE):N'NJD\+9C:RGG,SM!ZGE,
M=FUFV-(E[P1:JV2/[B\G2YN PNB:,)&D#@=%?CXV<^1=*M&DFDOVFWAG3'%4
M2PRIA0S2\AN]V2#E?G-\Z2;MM%_N]*5HY7*VF(4S8I1V0LB+2HEQ*]K1%E(F
MIT"\F*]NK6A*+0MKEM4A1%@2D%!U)5TJZ95=.C82*P0, 8 P"!OBF?-H^(#[
M&?2ON?E^"T/'CUH\47NY(^2ES)[/=+^[>-8*DA, 8 P!@# & , 8 P"''B*?
M-]]U>QQTY[DYO@M#QX]:/%'F&(?T)'^RI_X(,]1KC]"N?FMW]S X5;_/VWE;
M3VY':S:,0P!@# -W'[F#^0M>WMIV)[D>=\\^O##]I/*CSFY?E5Q.P<G_ *ET
M?Y&7OK4V/\YH?8& , 8 P!@# & , 8 P!@# & , 8 P!@# & :?'5?15N.G8
MULP6V.D_$SK2L3ND[RATRB7-59W(UPN*4?7M--9_,LBJN<U=3;L_)WF479I?
MJPUD8F;GN5M1H$\L;DS*G+4B/X^/CU&5)45%#)8N2JVWC5-[.CUU-E/@J6V9
M/.(^1YG<YCX=;DGYQIMZLT^3-QS1)%,Z7P%B/E*N0-9Z9&<WOBIY$L4.R0Q&
MD$0O-4%[3$>3T0!CE36E3*KIT5P($]>]E=34%*)0KEW17AR<FPUATA>X[#;7
MC/0/1]L2>$/LS6P:$RJ1I*YD]-!BQ<V>&]9H#!&(Q/=LHD3R ,N=DT:?5Y E
M)/"DFWE1I8TRQ3KZUT&3/G*5W+,ZS;WV\&FH$DI5J"SV:0T1-G^;UC84-<&E
MI=X[/XX?*(Y'7R/$OI3BH)'&%IDD W[0:5(I=(&]P2*\$.FROI^,>G"NY%]\
M$# (&^*9\VCX@/L9]*^Y^7X+0\>/6CQ1>[DCY*7,GL]TO[MXU@J2$P!@# +$
M*Y#TX!4I AJ&B%*("@X*-0KZ,L%$J/2A,%I.<I1D\M+R4B@TG0!G)BERTL@P
M0B@*U(0:.&)PWOU+O*"06UTPOL64UP72%%@<XI"H#-U:\?2T_P#45*&P'VR6
M%N1IM!Y2VHTK0J*S=#ENS2@$[)<$'H##!Z4!*"BI6KV[%LIS\Y<^.OG0BEZ;
MR)96%-,D=,.$%U=8[>\WE#TB3^B,V$UO8'+G.((7,[9VBBQ$*9(T@"4,P[2@
M0RPDFAAO?J_U+RX(& , AQXBGS??=7L<=.>Y.;X+0\>/6CQ1YAB']"1_LJ?^
M"#/4:X_0KGYK=_<P.%6_S]MY6T]N1VLVC$, 8 P#=Q^Y@_D+7M[:=B>Y'G?/
M/KPP_:3RH\YN7Y5<3L')_P"I='^1E[ZU-C_.:'V!@# & , 8 P!@# & , 8
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M4N9/9[I?W;QK!4D)@&-/Q1?U2<^>W!R9[ST63'-=*XC9+JR]EG'F<UQ@# &
M, JSPJ/FZ^1OW0L_^-<<US9EF^E\3()@@AQXBGS??=7L<=.>Y.;X+0\>/6CQ
M1YAB']"1_LJ?^"#/4:X_0KGYK=_<P.%6_P _;>5M/;D=K-HQ# & , W<?N8/
MY"U[>VG8GN1YWSSZ\,/VD\J/.;E^57$[!R?^I='^1E[ZU-C_ #FA]@8 P!@#
M & , 8 P!@# & , 8 P!@# & , 8!KR^()<]]S+I)-#-5AXL-><VUQ +';9
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MYWSSZ\,/VD\J/.;E^57$[!R?^I='^1E[ZU-C_.:'V!@# & , 8 P!@# & ,
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MHL!/^;_[>B0EZ-W_ )QOGB_+FN;,LWTOB9 _@=#Y^S/(J\[:K2W?D<7'0?6
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M'[F#^0M>WMIV)[D>=\\^O##]I/*CSFY?E5Q.P<G_ *ET?Y&7OK4V/\YH?8&
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M\,/VD\J/.;E^57$[!R?^I='^1E[ZU-C_ #FA]@8 P!@# & , 8 P!@# & ,
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MFR3QZ 8 7D%H->F4(>J7\Q T'W*ORX (0 Z]Z_"  0@"'2^F_($(=:T'6O\
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ME2BJJF*VMK&[V;M;>UL[&S32=I:SC9P3EA%.4VE5O)5Q()_')^%S_/VZY_\
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M7=*[&BA6@)#6YM5IEJO1F]:)3'%FBWH._+@%DHG-ZSEE<V3:.N@>JXS&ZGB
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MV0JBM)MLJD$B4L#NK43IR02V?+$;A'&(J<*69LCB=)$$2E36[BH=7CUH&_\
M6N+KTTKZ"E(CPH0Q5%TE6CC-(4A7]$TBAHE8NJBE6:GX+&F%EKZ90)FEP*L9
M)6[LKC/E!$V7&R=X;W2-M+RS,$*BC0P1AEBC> 0ERQ3QP=55U^$4G>_"0Y*3
M/IM"'K2N6*[:+O:,PY(QLC4C4R=EJR@*\8(RK5N+NE:7EH)6T R2%P9W@Y@:
MIBC=#X"YO<2;1[F*417X]>STY["KJ@YFGC[1Z-ANQ4RQ^;.G6ZCJAU;F:--
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7YBEP6&^F,)$>+TWF"-$664  E)+(_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>g947560g02v46.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g947560g02v46.jpg
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M 0$! 0$           H%!P@)"P0& @,!_\0 01   0,%  $ ! L$" <! 0
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M=G5>R&1[5PJHN'-:J+A45%PNQ45-Z!51%PJX7H78O3Y"G_\ %P\8O^/#E_\
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MJH]^D\]2A5U!CB@)?7HDOV\[Y_"/+_YST)47^'#NEM?Q'%Z_7F_M?)G>_O\
M1PDU:O%S8B@.33Y!O7_[R]MKK7]06Q*F/P5]P5AZKG]<7 YNX<LG^:]!$8BU
MZ"88H"2YZ*U]X7N+V,]A>^_GBH]<.^_1;JO?EM!N;3NJ>N'R3$_2H^&W% *
M4 H!0"@-$O7BA%OY1^>KL)/J09)L1_.Q&(YF3?-XY['H>KO(Q%MRM]EA)WKT
MUOD^;V> D(B \R.=9S<./9[3<*62:"%&DE>2,7)[E=^W/3WE3&W&=FW*;MRF
M]JA:* 4!K!\37J][J]OKR%?K!V]0N=O3P6>8TS$ZI]5_I#^ NX/=[(J%IR(6
MG[(U_=T?Y>-3[MOYNH/@5+Z",Y*3\I)X;O.4]%9I8* G,^B=^K#UA[183W51
M*HC<+_=M6? K?ZNTZ*W<E9X3_.4E;UY@9PH#CF2G[4RC\2R#\W>5.#0GN/T9
M^([9ZI$<O5\JJ/?I//4H5=08XH"7UZ)+]O.^?PCR_P#G/0E1?X<.Z6U_$<7K
M]>;^U\F=[^_T<)-6KQ<V(H#DT^0;U_\ O+VVNM?U!;$J8_!7W!6'JN?UQ<#F
M[ARR?YKT$1B+7H)AB@)+GHK7WA>XO8SV%[[^>*CUP[[]%NJ]^6T&YM.ZIZX?
M),3]*CX;<4 H!0"@% * T5=K:L*F/(SS;L*.Z_D<P5'R#G!G*1;#2?83^&$H
MZ*WHQ.NYE,MPP7=L*Y2:/].)#\-G@!^R8#(#C G#PERC>7?_ (>.M6WY.K[<
M_87IL:NY-Z?W<[439C&MA>E-F].=3>I:]KVM>U[7M>UKVO:_PVO:_P#;:]KV
M_LO:]O\ Q>A8?E11-%/-57/!))+#)1113+'!--/#&^6>>>>5[8X888VOEEEE
M>V..-KWO>UK4!832_4F@NA )R3ZBV0+E ..$!0XN]<CST6NA>0 V,FC)-NUF
M D ](QN6QLDQD$.E@UN[C$O".4RL:+E6/QE["JHJ;S#SQ*JIK\[[F614P616
M[W\@ZJ2J6>*B:J:G8&W<TU$U,+WQSPSQO;+#/&]\<L;VO:][7M>A5V]/!9YC
M3,?JGU7^D/X"[@]WLBH6G(A:?LC7]W1_EXU/NV_FZ@^!4OH(SDI/RDGAN\Y3
MT5FE@H"<SZ)WZL/6'M%A/=5$JB-PO]VU9\"M_J[3HK=R5GA/\Y25O7F!G"@.
M.9*?M3*/Q+(/S=Y4X-">X_1GXCMGJD1R]7RJH]^D\]2A5U!CB@)?7HDOV\[Y
M_"/+_P"<]"5%_AP[I;7\1Q>OUYO[7R9WO[_1PDU:O%S8B@.33Y!O7_[R]MKK
M7]06Q*F/P5]P5AZKG]<7 YNX<LG^:]!$8BUZ"88H"2YZ*U]X7N+V,]A>^_GB
MH]<.^_1;JO?EM!N;3NJ>N'R3$_2H^&W% * 4 H!0"@(P?6P;E'M7R@036T9A
MT2Z)E8_9.H-.=!B)WRQKB0C]:H\T3*3;IFD7CN_-M2Z,$@XN1Q(D8'[0AT.T
M_NQGLF.M\H@.ET*>/4G@\7HKFMSG5SM3:J*N=BKA.C&S*IC>F<DFX6+&A!@X
M*&'LA(<0Q:"Q0H:U19#A@T>W3:,1[!DVP3;M&3)JBDV:M6Z::+=!--)+#!/#
M'&PL/0XQ<9-U\6BJ*#K)%7%LLX0S<H(N+X96157;)N&BCA%-2^.:J";IMFKA
M;)/%PCEE93$#6UIWQU <=7[2UQVR8U+W OMG:Z&X9=*)CHEQ%'DEES0=8.(>
M2P1(MK;9"OK1 $@-BVOQL4:P>+0F)"V@0/&<<\WC]T+E=M14RW&Q,+NZL87I
MSUGQWAPB\=@_*FQX7$ HV-Q*(=N=Y1>+QT.U28B $= =8[6$A HIDACBBS&B
MAC1LQ8M4<<4F[5!)%/&V&%K6!^U<KM759YJ&<75/JO\ 2'\!=P>[V14+3D0M
M/V1K^[H_R\:GW;?S=0? J7T$9R4GY23PW><IZ*S2P4!.9]$[]6'K#VBPGNJB
M51&X7^[:L^!6_P!7:=%;N2L\)_G*2MZ\P,X4!QS)3]J91^)9!^;O*G!H3W'Z
M,_$=L]4B.7J^55'OTGGJ4*NH,<4!+Z]$E^WG?/X1Y?\ SGH2HO\ #AW2VOXC
MB]?KS?VODSO?W^CA)JU>+FQ% <FGR#>O_P!Y>VUUK^H+8E3'X*^X*P]5S^N+
M@<W<.63_ #7H(C$6O03#% 27/16OO"]Q>QGL+WW\\5'KAWWZ+=5[\MH-S:=U
M3UP^28GZ5'PVXH!0"@% * 4!8^?\U:"VC.X+M.>:D@\@VCK(X)D,!V6J$;,M
MAQ4@&>)/F:(J;C+,I.D&671PP+1O,HI'3S.Z@\X*(L%56V8JBJF<+OW]_P"^
M5+X4*"@% :P?$UZO>ZO;Z\A7ZP=O4+G;T\%GF-,Q.J?5?Z0_@+N#W>R*A:<B
M%I^R-?W='^7C4^[;^;J#X%2^@C.2D_*2>&[SE/16:6"@)S/HG?JP]8>T6$]U
M42J(W"_W;5GP*W^KM.BMW)6>$_SE)6]>8&<* XYDI^U,H_$L@_-WE3@T)[C]
M&?B.V>J1'+U?*JCWZ3SU*%74&.* E]>B2_;SOG\(\O\ YST)47^'#NEM?Q'%
MZ_7F_M?)G>_O]'"35J\7-B* Y-/D&]?_ +R]MKK7]06Q*F/P5]P5AZKG]<7
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M^=.8/+AS3#)3!X7MWQRF!DMW#N?=+]S*-/=,NWZ$DWALN2;1DXYFH*W.%;X
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M2"O(0$ASR4S<VT(N,',1&$QA,<T%-5=NU-B9W[T[QLMH6B@% * 4 H!0"@%
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5L-FM"@H!0"@% * 4 H!0"@% ?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>21
<FILENAME>g947560g03q94.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g947560g03q94.jpg
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M(" @(" @(" @(" @(" @(" @(" @( H\/WAP86-K970@96YD/2)W(C\^_]L
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M(D$6(U&X"A<R-F%Y@20E.'%XD:%"4O 8,S1#1'*2L<'_Q  > 0$   <! 0$
M             0($!08'" ,)"O_$ $(1  (! P,"! ,$"0(& 00#  $" P $
M$042(08Q!Q-!410B83)Q@? (%2-"<I&AL<%2T0D6)#.RX?$E0U.28J+2_]H
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M*8I3%*8I3%*8I3%*8I3%*XCM\S8)&7>.VS1(H#^\<KI()]@ CUYJF*7OX'X
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MK99M,8Q1BXD"Q&28^6F[>^$7-2:<%.54H]XM\G=32FT:84U%@'CJGN-J7IK
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M9Q HE3$"? @'?8%'L?GY[')Z5<!^6+<M5VCE9N4CE,Y#AV4HB!BB B(=]=
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M**OY:X3=N6,$_*]4D&#IPW1!-8FWL5N[N]M(WG;;%8+(&N!M179Y,9"9W^6
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M/)(+AQ@#T4^GW5KG5OTF_#G1;:.2ZNI[N>X7_H8M-L[ZX%\SKA!&R6K1@R9
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M!R01@CD^IIJ9V56:K*'4<R*8).HP[@6:0_4.'+TBR94"()H@8YUU1,8H%*(
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MLK@.LR[<HI&WE?>A5F-9<V@[6VSCF0*@JD9DP=.E%8Q8ZH=)^X()D!10AB]
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M.U7+)M=;_:26Q_48I\G)1M-:I1+.,91:CYN4&CR;630.YF5V F8%.+5FV5<
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MJK:(*ZUR%MM8E&4W7;%'-9:%EHY8'#*0CGJ15FKINJ !Y$52,4W0@!B&[(<
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M)J:&[@G4*C_M3\Q0]@!D$\X/<C/W\X];?1)G5H?+OI9^Z=2:_F"?X<!@73;
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M[)&0> ?F-0$U34MBG9!V:&E9VKP+E<HI,T%#)D42,  X,0!\U&X.%##X)$,
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M;)Z1$Z8LR&(02 ==4 9M#I.5DU4,<ZMMFU+2+[2[9+226[MIH9)KJ"&ZMK+
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M,X)Y';OV[]C4=O&#>O(_B+M>2#<UC?L]=;+]4CU((CD?:*%HNQDI-]N <?\
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M+FY$=CNX)?7E5VA$TBDR2*K6&(I$L-<7:0V=9;%%0:NRF]U;,EW#-\J1@.<
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M"R"7 ;:<-NR,##;NQ%4_@)%-#=:S<E4MK:4K&%F)!DN%8+*8N5RN]"%!!(
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=IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4K_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>22
<FILENAME>g947560g04e62.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g947560g04e62.jpg
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M'P3BC?/U5V7R5[X \*<')+-8F]EJY>]3DO9.],QZ$&)P4:N$=G',)NBW+*C
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M=JM9BGFRV*F5NO+)*MUD!50514(JBLD)B+)*I'*<BB1R"4Y#D. &(<I@,0P
M8! 0]D^M6%X8,%8,K!E8 H5(X(8<<$$$ J>1QV[\ZJ&M#*TB.I965E=&4E65
ME/*MU+W#*?C*001QVXXUO/LBW1;[6R,=7V%'R3N3QRD9-F)9"(G):3@T"#X8
MECLE*-7)&Q4"@":;"T/9&/(DD5FQ"+[A6)FOQ$V=X:%I;<N2Q&TLJW,GV*>M
M#!9<\-]EQ"NA<D]VEI1Q2L6,DOG<=.M=>%'B!XPHD%*'$9[?>$4K$1-6MV9Z
M:#@<5\\8G5 @'"PY"2>$*HBA$'RAMS)REA)$1<G8*S.U)>69E=!#V!-D218G
M'^D9NS1CV2CA=H"/"A&K]R0H&3.!Q*<HCGZK#3>>:*I=K7UKR>7YU4R&)QZB
M1!-'%-T-WZ6DB0\A@!RIUJ2]9R$=:O/>Q]W&/;B\SV:ZL0GC)^5%(U>:>#S$
M/9UCF?@$-R PYAZ=L)3 H43 )3%,4P#P8# (>T! >0$!#D!+[0X'@?RAJ4U*
M1Y!X//(X[<<?_L?/[B??QZ:A5_(]76"W8\@\]Q]/(]"...2>/F]-4$S!A&JS
M:KJ?I[)G S@B==S'-2IMHF6.(]QQ!N4"HQ[TX@)BJH%2:KJ<^:1*HJ9V2S\'
MFKD*I7NN]F  *DCDM-"!Z#K/)D0<\$,2RC@(Q Z#16[MHXZX9+V)BBI702SU
MX@L=:U]\>$ "P3M]ZR=,4C<>8H9C*/KM/W+6S;C; BI,TA(XXEGY$K;55!,=
M6.7$004GH-!8Q2M)EH4"BZ;E%)&8:H%:.Q*JFQ>,4&^MET=VT3-$(X,Q7B)I
M70 !*!RPJ6F4$R5Y#\ASU/7=C(G8S12I_"SQ1ROAQF/9;9L6-MV[(3+XIN2]
M9N?+;(44<@178 !YL8Z$O1)Y$Y#I7GKL5PTQ%V&)C9V$?-Y.'F&+62C)!H<%
M&SUB\1(X:N43AQRFLBH0Y>0 P<\&*4P" 9'L5YJD\U6S$\-BO*\,T4@X>.6-
MBCHP]Q5@0?=V[$C7T6HW:F2IU<A1GCM4KM>*U5LPMU13UYT62*5&]ZNC!AZ$
M<\$ @C7I:XZ5:-&C7Q<N6[-NN[=KHM6K5%5PY<N52(-V[=$AE%EUUE3%3112
M3*91550Q2)D*8QS 4!'7Z 6(5069B J@$DDG@  =R2>P [DZ"0 23P!W)/H!
M\YUGIDOJU]-?$DLX@KMO.P:E,,U3MWT?6+4&07#!RF82*M7Y<?-K0#%VB<!(
MNU=BBX1. D53(8!#4NI; WGD(Q+5VWE#&PZE>>#V177W,GM;0=:GU!7D$=P2
M--DN9Q<+=,EZOU#U"/YO!^8^4'X/T'@Z[/"_4IV#[A9=I7<0;M,(6VS2"I$(
MVJ'NL=7+;*+*& I48JJVLT'8)143"4!3CXUR<HF*!@#N#E-DMF;KQ$;39' 9
M.O @)>Q[*\U>,#WR3P"6&,?2[J#[M=(,KCK+!8;M=W)X"&0([$^Y4?I9OT _
MY]7>U&=+]&C1KB,BY,QSB"H2N0,L7VF8RHD%Y7UU=+_9H6GU6)%\[0CV(2-@
ML#V/BF1GK]RV8M"N'29G+QP@V0 ZZJ9#*:=*YD+$=2A4LW;4O5Y5:I!+9GDZ
M5+MT0PJ\C=**S,0IZ5!8\ $ZYRRQ0(9)I(XHUXZI)'5$') '+,0!R2 .3W)
M'?56OC+NG3^?AL]_:1Q!^]^GWZR]X?O5W%_$N1_J^DGPKC/[X4O\JA_U]23C
M/>7M#S1.)U?$&Z;;ME*S+"((UO'V:<<W"P+<%$PBC"P%C?R:H 4!'N3:F+P
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MD:8-FK9DW09LVZ#1HU230;-6R2:#=N@D4")(H()%(DDDF0 (FFF4I"% "E
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M@<;!_<]'2&_-/6_^^-R/_M_5>?LN^(7]_P ?Q5A?_+M/7UM8;_DA_P HL_\
MC:]^J= [I.4NSUZX0.U)!.<JTW&6&&5DLQY^G&"4K#O49"/6>0TWE.0AI5ND
M[;HJ*QTJP>QSPA10>M'#=11$_*QXK;^LP35Y<^QBGB>&0)CL1$YCD4HX66*@
MDL;%20'C=74]U8, 1Z3;N'C=76I\9&#+S/88<J>1RK2E2 1Z$$'T((UL+JN]
M/>C1HUC'UV=[YME^Q&[IU26,PS-N!,ZPIBDC-422L<:Q1ZP7JYLRI"#I$U3I
MQGY8Z2;@(L+?,U(#"'F2<V1X6[8&Y-U538CZL;B.G)WRP^QN(7'LM9N1TGVB
MST=:-\NO'8X^3ICW!?\ 8<?($/$]GF"'CY0Z@?,D'O'0G/!'I(R?/I:"0VC9
M:Z$=@Z9/4',-CD&EQ9)U+>)4P 3$KLU?32E@E\?@V J:17*^))9U"QC9P=ZS
M;Y,Q$YLA5RA(QK9&Z4W!C_%.+>VT?L*-78V-NV#ZS15/+ACM\\\\#(1K*Y 5
MC2R @(/0Y,5-.?;[8K)?&(D'1=3]RTG4S1<<\<F E5YY FA+^\ /P5FR0-RK
M=?M]6E6<[6+7"15DKDY'*@O'S,#.,&\I$2K%<ONK,Y&/=-W;54/8H@L0X>PV
MLIS0RUIIJ\\;13P2R0S1..'CEB<I)&X]S(ZE6'N((U8B.LBJZ,&1U5T8=PRL
M 58'W@@@CZ->WKEKUI<ND[ )[?1O$SKN8S@,G#8)+EFQP=28%.X8SN4H.@/?
M@3 -XE?W5H>GDB:XR2E)UL8KEZOYF,KQTW(.YF)UCD?%"KX;;!VUL_;?DV-R
MG"5+5Z8A9*V&LY2(Y&TTZ]UL7_/N2&&L_P 2-0DUH%.BO-AS%>#-SQ?\3MW[
M]W=[14V>-QWJ>,@#/%<W#4PLWP532N_9JN*]FHQ"Q;C(DF<R04F#^9:@81J%
M/JU K4/3J37XFK5:OLDX^%@8-DA'QD<T3Y$$F[5N0A"B<YCK+JF RSEPHJX<
M**KJJ*&RS?OW<I<L9#(VI[MVU(9;%JS(TLTTA[=3NQ)/  55'"H@5% 50!M7
M&8S'8:A5Q>)I5L=CJ42P5*=2)(:\$2^BQQH !R26=CRSNS.[,[,QZ/232[1H
MT:-&C4"[E:$C?\/VUH1(#2\#'.K/ *E* K$D85LL[.V2'V?A-D1U&F*(@3N=
M$5-P9(ABR_8N8?#;EQTA8BM<GCH7%Y^*8+4BQB1A_P WE,<_H3Q&RCLQ!@/B
M9@4S^SLO$J!KF/JS93'L "XLT8GF,2'_ )U LM4@D+S*K$@H"%W+!9R(E/W*
M (\" %Y_\>WC^T>!^7@/:(ZVK4H@$?%]>.3[R3^@\>O\@^C7SBNY%YV(4D#Y
MQV^?Z3_W#44L,JN:9;Z[;6OAKKUR=C9@K18I%6SQ-@\3<+L'**@&379OT$U&
M;QNJ4R+ALNLBL4Z2ABF<;N'BR6,O8Z3E$NU)ZO6I*O&98V198W7ADDA<B6-U
M(:-U5E(91PEQ>7DQ&6Q^4B597H7:ULQR!7CG6&5'D@F20%9(9XPT,T;JR2Q.
MZ."C,#NJE@5KB'.V,,WXI344Q?<9AG&3D,V*84ZTE?F9HF/=HE#N,-8=/I5@
MNB4_X&>D;H&.+)1N#;)C;J?<&ULWMG.D+G,=7DGJV7(!NMBI%GFC8]A[:D4$
MRL1S[3&7< 2JW7L ^&J;%\2-I[]V@C-M+-9"*CD\?$&*X@;BA:C7FC Y)Q$M
MFY7D0-^T;"Q1EC7>,0Z/:IW6I=*>]6<DWU&.K!L_Z5K"6D6F$\=-&N<=Q2<6
MZ5:F=+N(>4LT@W>'2,(MGT=BY@R@:=*  F8SN7G2BK=5--(^KZV"8]G;"W#O
MMHT;)W&.+PYD4-TA9$@5E![,CWG:6S']_%CE 8$D:A^8ZLGF*6(#$01 3V@"
M1W*ESS](A 6-O<TQTU)5JO7*/6:]3*?"1E:J=3A8NN5FNPK1%A$04#"LD8Z)
MB(QBW*1!HPCF+=!HT;I$*FB@D0A0 "AJBIYYK4\UFQ*\UBQ+)-/-(Q>2665B
M\DCL>2SN[%F8]R23J7(B1HL:*$1%"(J@!551PJ@#L    !Z#7O:Y:]:-&C4
M;I-MN-=W6 \F;><M124E3,E5MY"N%_ 16?UZ7 H.:];H(ZP&(VL-4FT6,]"N
M!Y(5^P1(X(JU4705=L'F;NW\K2R^/D*6:4RR*.2$FC^3-7E [M#8B+Q2KZE'
M)!# $)K=6*[6EK3#F.52I/O5O577YF1@&7W<COR.1K!WT<S,^0JQ5MUG3CS,
M_.ZONQW+LQ"UHRZJJG\S)FS6>$GX6)%;E5:$KM]K<K,Q[E0>T8Z_Q;9F)F+9
MN1*U/&+&TYY\#O'&H%J;GQ\<LW2 /[)C@@EBEDX["6:I-'&ZC[^HY;AV8F/;
M9GD1+F+G/,M"9@G)_P"+9V5E7WE4E4L#\TJ@=@-3%Z2_\UK=/IAP[]H'.FWP
M6^[JK^;\C^H&N^ZOM2_X^#^<=:T[+_\ @[VG?5IP3_I=5=0'<GW19_\ /65_
MIT^GBA^T:7Y)6_4IJRVF72O2F.]-5C.^DY[ 8_&8IJ7.OXAK!<FGB^WQFY&[
M/<'89A"7\+WRO Q*]9*N3K\>)!/HE+D4P(75^;;#Q>"6['N]JTV1F]A$GH2S
MXB&,Q\]NGV]6"@>DRR-V/)U#KY#;JQPAX+K"GF]/J/VRS=7'O\@@GG[TCW:;
M.U0>ICK+7K8?-7;TOHK;_;&KZG/AI]W>VOR\_P!'GTT9[[47OQ2_K$T=$_YJ
M[9;]%;C[8VC1XE_=WN7\O']'@T8'[44?Q3?K'UJ5J#:=]*U>DI?C3TN/K3R7
M^8XMU>7@S^U]]?F%?YE[42W3ZXK\K/\ +%II75&ZENC1HT:-&C1HTK3Z2]^$
M.F7]::0_Q\>:O+P6^1O;\PK_ "6]1'=?]R_RIO\ 1::6U1NI=I6G G_-1[V/
MJLU3_1O:/J\\K_P%;9_/MC_M'<&HE6^ZZ_\ DB?J*6FEM49J6Z-&C1HT:-&C
M2AH%^.+Z[HF'^<.SOIH)@'_RZU:\@UVP#QQQX[!R>^9<BA$>?'C+5B_$''NB
M[][0??P[\+ /[3N+>I/_ ,L]>G-#_BNOLN/D'S25[V1/[GM"_MWN']U1Q?\
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M/?IC75.ZD^OD@F@D@BDU(DFV323(W30*0B!$2E $B(D3 $RI%(!03*0 (!0
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MQ5W2@)E3.'B&5.5,"B<P /S;W. -T;C$ (1<[F#&$[],:W[)!!7GLJ#DD=@
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MF2/B&K692(&[<'VN=HJY7D-Y<DCK_:SIGSE_X/Q\LBD":7[#!W[B1P>7'XM
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MM8I&K+R+%!A ZMV;RAR(B0?0ITM$1[O+!/=M6"ZAF(W$59XG,,4U,>+LJ+6
MM!TB"(-)^.;BE%/7!@#@J4I$()LDS"':1>'X4."CQ$II-X39]9Z4^WYW GI,
M]JB&/'F5)GZIXT^<P6',I'J5L=AQ&Q&0OJG]D2T\O1WS2B+4LLD.-S#(O(AR
M=6+HI6)2/1;E&-:ZGCI22APS!IXU/ [>=\%GQ<@QJ.0D7MSH[<$VS%VFJ0]H
MK;4@ 4B+)9RHFE,1J!  B,:_<(+MD^Q-G()-4$V(N>[?#:EFFEOXEHL=DWZG
MEC*D4KCDDEI50%J\S$\M-$CJYY,D+.QE$<\+_J@LQM".OA-SQV,_MZ()%7G6
M16R^*A7LL<$DS*EZK&/BI4LRQR0KTK!:2&-*YUQQWEW'&5HXLC0[;%3Q02*J
MY8)+>7F8\!X 2R,,Z!&39<&'L Z[4B*H@)D%52"!QH7+8'+X.8PY2C/5//"2
MLO77E^F&PG5#)V[\*Y9?1E4\C6V=K[WVKO*L+6W,U2R(Z \M9)/*OU@>W%JA
M,([=?@_%#20K&Y!,;NO#&2--&I5JM^Y+=/B7:[4%;+D2;2&6=-UC5FE1RR*U
MIM+M,!*5./8F. MH\BH 1]./O!C& "!#K*/%6K-S,-G['SV]KZT\16;V>-U%
MW)3*RT:,9X),LO'#S%>\56+JGE/<((UDD2";\\1=M>'N,:_G+:^TR(YQ^)@9
M'R.1D'("P0D\I &'$UN;HKPCLSF1HXG3_P!UN["Z[B\BS.1KN\2;BHGZO@8-
MJL?U35J\V45490D8"P@8R:0K*N'KQ0I%9&07<O52D%8J26_-E;)Q>S<-!B<>
MI*H3-;M2A5GN6W51+:L'N 6"JD40)6&)5C4D*2WS(\0_$3+;ZSUK.YB549@(
M*5.-C[+C:*,S0U8.H\\*69YI6^//,\DS!>KI7.RW9'2$5$VJ@KGY, &*8?"Y
M#GY3C[3^T.[W.0$!_P!\-3"3(5*@(0"Q)QZ*>(U[=BS\?&XY' 0-SP1RI.JG
MGNO8;HA8MSV9QSPH[>A].?F/'T^O<][@2 >K/%LDSY3@FF1RSJ[=0# !UEBF
M;OY5,@\#X:20J,&Z@]WBG6>&'@4$S'@6X,M/?;V<R$J"&D"]HT X*QJO) YX
M#,3RQZ4Y+'TK;?&XJV+A^#TD#V7"O9Z3RP'9HX2![V/3(P]541\\]3 -Q=(G
M $C3,8V+/%K8G:SF7!:LJ@@Y3$CEGCV'654)(% Y2*)DMDR8SPA# 9)S%0L#
M)-CBB]#G(7B_N*+(92M@J<G77Q'6]ME/*/D9@ T?()#>R0@)SV999K$3#E-?
M1KZ@[PQO8+9F6\4,_6:#);]\BOM^"9"LM7:F/ED=+0#!609W($V0""DU''8N
MW"QCL<ML)JG=;YU NYS;7B;=W@^^[?LV5\+#0,@1(L'Y$3IMY>%D6ZA'<):*
MW('17]5V6MRB+66AG_@KI)NVQ$GC9['K.V3AUPF:R&W\G4RV,F\FW4DZT)!:
M.1""LL$R CS(9HRT<J<@E6)5E<*P36ZL-VO)6G7JCD'!X[,I!Y5T)!X=2 5/
M!'(X(()!58HV5NH=Z/3-O<59EQ[8]XG39--NW-"R?42+DF<6,)-^HN=%!VKZ
MP;T-ZNHY,[E,;W51O3)J>.X=T"[,%'5A<O+VM4-H>+L:W\;<AV[O/R@MNC8Z
M3'?>-0 S*.AK:J%Z4N5@UF*+A;=9PL*K$8YLEMIC#/$UW%]1,<J<\Q!CZ GD
M1D^K12<(S<F.0<L3L7B;K]]*W*\(UDS[DV^,I55%-5[5,LTRY5*:BCG*!O+N
MI%&%EJ:^6(/)3C VJ80*8!^_" E$U=9#PGWW0E9/@5KL8)"V,?9K6(I /OE0
MRQV4!]WG5XC]'KI[AW'B)E!-KRF(Y*31R(R_02%:,G_Z7;7 Y]](LZ8V&(-\
MXJ.5I_<#;$D5!84[$-+L:OFG(@)6P.K?<8^JTMHR,MP#I9I.2D@V0 ZR,2\4
M\%NNKQ/@]O?)2HMBA%B:Y(Z[.0LPCI7[[IKUWGLL_'R0T2(3P#(HY(YV-S8J
M!24F:R_N2&-_7W<O($C Y]>&9AZ])UF75]OF_CK[9<I&6MXU4G]IW3FH4VE9
MJ)A!)>4B[3D\>TP)NF99)I%S<[(2\:L:/>9=FH:#@HJ!?NVN+($[N4L#XLVG
MR^U/"?'VL?MVQ%G]XVHC!:R96.2"C\ZMT-)'$L;CK7'Q22RR2HK7Y0L<*::D
MK9'<4T<UU&IXR-NN. %@TWX.>EF+*>#.RJH4D0KR6TW+3ZA5\?U2M46DP,95
MZ=3H**K%6K<*U38Q$#7X-BA&Q$1&LT0*DV91[!L@U;(D#@B210]H\B.?K%B>
MW8FM697GL699)YYI&+22S2L7DD=CW9G=BS'WDZF2(D2)'&H1(U"(JC@*JCA5
M ^8 <:PC])?^:UNGTPX=^T#G5I>"WW=5?S?D?U U']U?:E_Q\'\XZUIV7_\
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M!%=&0;?R^Y/!;;>/PM3VVXF6MV6A\^M7XACRF<1W\RW-!$>EI8QTARYZN0I
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MI02R2/+(\LKM))([222.Q=W=R6=W9B69F8EF8DDDDDDG715"J%4!54!54#@
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MD[5=FB;<J#@H2L0\;7JY$1L# PS-"/B8:'9-HV+C&+8@)MV;!@S31;-&R)
MJ:*"1$R ' %#5)3SS69I+%B62>>9S)+-,[22R.QY9W=R69B?4DDG7THQV-Q^
M'H5,7B:-3&8VA!'5HX^A7BJ4ZE:)0L4%:M B0PQ1J %CC15 ]!KU=<M+=&C1
MHT:-&C1HT:-&C1HT:-&C1HT:-&C1HT:-&C1HT:-&C1HT:-&C1HT:-&C1HT:-
E&C1HT:-&C1HT:-&C1HT:-&C1HT:-&C1HT:-&C1HT:-&C1K__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>23
<FILENAME>g947560g12q20.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g947560g12q20.jpg
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M_6>J>B'.7(<ZWKN)!LK886QR!]="7A7R\9;D,&UJQ6U.3?MI3D654,10"@%
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M][6$!'!SS"%PO>U[6SPSRQO>U^O2@.30"@% * 4 H!0"@% * 4 H!0"@% *
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M44--=<"R<Q+! %\32HK'S9XQ8  $&PH^=@@@\/!PL,'@WQ9*&A!0"@% * 4
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M[5-C7@-B26G</V?I<+[!ID_NYS3K&TERXD;"/!29#K9KT>DKK;VLHJC1D8J
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M*YE7TNQ:>"1UU<YK"@% * 4!E'"G\GOK%_4M7_75T5KFR\_9'DBPBA!0"@%
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M:XKF=3PZ/)\:)]S;6'T),>@EF^+YDR:$% * 4 H!0"@% * 4 H!0"@% * 4
MH!0"@% * 4!&W<OWH&UG=MG/T8.BA8YKBN9JGA?^38X?W<MU@]"S+H)9OB^9
M.BA"N#BJ>]4;_?#X>?[>>N56.:XKF5?2[%IX)'75SFL* 4 H!0&4<*?R>^L7
M]2U?]=716N;+S]D>2+"*$% * 4 H!0"@% * 4 H!0"@% * 4 H!0$3-^/>*[
MI]TS8WT//*A8YKBN9U/#H\GQHGW-M8?0DQZ"6;XOF3)H0@UQ"I?E:%X#0E^%
MW(C,]^N^?=;XC).A=:Y9YD$)+E^:V5'2\IV;9P\FEE,V31W$<') C'B^'JK
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M4JV5M?HIYY\_]-G1;G[FUN?/:N*N5O\ =UOY^?FJQS7%<QLEV9>%G&KG-<4
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M>A9ET$LWQ?,G10A7!Q5/>J-_OA\//]O/7*K'-<5S*OI=BT\$CKJYS6% * 4
MH#*.%/Y/?6+^I:O^NKHK7-EY^R/)%A%"$..(IY/O>KN<;.>A-[T+'-<5S/F&
M$?XD3_HI?^YPKU'N7ZG=/5K#[J!T7;_'VW[6T\<CE5LG$* 4 H#W+?8SGD^'
MSWKI=_5B-*\\/*K\X?2O[3?W%@=QZ#^1]'>K1\4ST-5U\?5% * 4 H!0"@%
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MN6^QG/)\/GO72[^K$:5YX>57YP^E?VF_N+ [CT'\CZ.]6CXIGH:KKX^J* 4
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M"CW/N8]E)KK\<K ^<!3Z5!1[GW,>RDUU^.5@?. I]*@H]S[F/92:Z_'*P/G
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M^7K2G%RI,MXPP/GE%:SI6F%2-J*JTWBEG3--[GN-._=+W^^/;4__ )/95_\
M>Y67F^OW?S,?.+ZK_>7_ +3H5?8C=R/5N+%%WR=K,\FHYYW@2,',@-_6B2F2
MO&$&7)B949*IM%=!_;%\$4E52B3K&5" QUJ+940R3# ,$\@A<L\)*.JJUKC3
M+^9E&2DVJ-8-UUD\NK57,EAMT_)@;1N*6S#JNJ *CI4'FIN%OQ^-"]YN7V^T
MT(L/XV-$S8=41(E64U&5U9+-R"045@@Z;MT4,9IC!C!*!@# R5,:T]M:;=V-
M7LV9D38^XB;V)(RB_7NCLA\PRH9MXNBRF16%**CY)4+\.=+W0< IF,%IL.G)
M+9:N,UWKE986)//KS5$=2$BXI+F3T,XLYJT_/M_@75QHOS\)Q_#9OX'8#<35
M\99.E.3=;DHTX8Z-2CG(B>L2G(+$!3DB,TW3Y8$$;9"0];6H_E!PK:=N$V<B
MZ ]X^C<J5,,U>_Z^-IJF@JAT51KM_..YM;-^[#.DN2&R+U/:XR7,0,+J*Y(4
M:+\RL]3BF/G@WW,&H.&(7XZ&*=.(+N?MX<)*K>-6;MG,/F?(-Y>P2A32<F(B
MLN $B2D,:*M*X;V=$[IKDQQQ5K.H$D1PZ_NG8B2VLQG(8<Q9@N-S1<FJ#+?C
MV%/D@4U<D&/1U1WF&.FM1H9JYU>"(BOU&$7$'!QEQVV &&.VF77BN#WFDW7L
M7/SIUBUB?<=JS0)2$_RYISR>935V,&T=76*TXDD%SK2Y%J)+*D?2A[NI?1VB
MZ$HIXI?!2F0?.BJ:TFI&([P("T56GOHN^F-.JN6TV%-NZRE%47QW(S&C*\II
M3IUFE7:-4N[7CE%*X4C>'6A'3Q700DHLQ7J 9?J^E2 7P2VT;NW$8LME,T]2
M7TLB*(HD1*8TZZ>UUI[,#7ZYQ"'FWE5^-E4@QE@.B&UDB0ETL)/!PJA )[@D
M)H,1K&HH6E&&B)R2U,Q9X$%%R(RRA1S9N'!4E"+**^<<:*,:"BW[]F.&...'
MLK_ V_.>W#FB.2GJQDF+VZY$ADQ] 3G'<"L_WDF+2\[MBI9DF+66R&O'[ A2
M672XLD^\7+R\N'D<$ZNY8'DA.0&<NY9JAU)"F"QS;7=3&K:6TCH3XE[B<+4'
M=J=!Q)-:B:ALXN\5V\I'\'(WWA(4ASG$B&49[07(<)6=*,EO6%Q#2DJ/,W':
MN W7*1.B,H=735)L7!JF_.E&J;L\>LQ]O\0.3R;>.''BTD@VBNB3LF9'CK;3
MV1C#W)#)Z?#2^HI;T80L<XH:2C8([]5@LGB"MJ!LTJ9HA#)KM\)SH"L +J[J
MY5>&&5<_<2*:6Z;M45),&>,2LQ%8+IE9YQ<PY,:4R*CM;#UO'4)R_+SV=R1]
ML<01T8R:J2>BD=B$%<.QA-<*H(Y'"B'SC5;B2J/ 2F[=BJ8UK2AH8/B=OT\S
ME.1DG6IM#LE*BB3Y=,CJ$^'R#ES;\+Q3$,MR$3+H1:#U-.S4LT66BJ.R\!7&
M""X%Y#-X+HK.2C@"L&R%,NOJZZ;_ .!S9$XB;V&>"E'$91XUL%W[J3+0&,Z%
MMWO1.:CW04S=B(-6Y!3EI9<L'I3=2;+/W11,4EP1.MSH72C8"JG&/$.I*(HZ
MF*EM>Y\<FUMZMM/:6(P7*><RQLGODP@AME1^V20V8NHA98LXDPHYHND5UQ@Z
M,V^X_6Q$R<;6.N)G*9]J.(5$1!UUM&DI6,(J0.<$3BPQ>'N]ZJ;=H!0'B>V#
M^R&N(#&FPNPL8-)IZEW:D63]-T6M<1P1/+*HO#MV-I2=C(0S*XHI^PJ(0/+!
MI,02IE3-$4=*)C'A1\RJ>4 N&!A_0_0SR%V'2SHSHKI#/I+:W&6DK.\6CNL=
M%0O$;'S-[O%U25L](6+GK*P4ZNSA1RU:.E7^1TGTI>CK];W-7%6WF?-KSCO.
MIK><LK.U]#S$Z4UZ>DZTKMH:C_\ U)W$A_DGII^9B9/_ ',U^H_W:;M_?"W_
M /L=G_\ *FA^FS_LU?\ K'_IB_\ X*?$7V"XA30V#6)_1HD25.*G:Q45N91,
MU':TR1H@Z$)94CUUDJ[)"D(<R;!,)H6)88F=3PL0<Q,!2PN?@B6Z+\HG0R'0
M3I!'0EGI"6DXRT?=K[_29W971IWBTMX.S\U&WO"I'S-=?SF.M355,?U6B-(_
M[4N2O?F?,-VMI9>;\YYWXO5^%K:EGGK9:N%,R;4)2K**^_9L-G7L0EZ+&DGG
M2*>X4UII3.0<IC3'8[2BS%L/FRPHZN]FVTD$DWVR\'*OCN/"THXJ2(@.H^HD
M7@S&%^$/J.E%O_A1?SIU>RN :Z[-R.H,&1W9(:ZD2D$W=18 VW***&F)C6)E
MU696A+CC<D3)8Z4 :+V;S=^Y>E*K245D)6=Q=O/M/Q<RDXQBY14/BM*J2SJU
M^#]_NP,%4N)"_&BFK2W(&NS81D9,=.<=@&&Y.YUR&A9 4M6T/;)KEU,)4A9I
MD$9BYL%>+H[V>XRJ8&9CB** Q1M.EM%;N#,-7\TZ]797:;:=NV$@XZ_S0] F
MTQ8]?\7SZR]>5I5 =YF5HX9WVV/Z(6<Y9@4%<1NQF:4&S%K?E)0?+F1U=/;7
MJ0NR%8BNJ20!8Z9(A3%9XIOKPKQSI[]I'>7I^V0CB:6_K2V9.?<J^K)+AP(Y
M([#8,$F9HQ2Y*@#>"1ER+1TIQD6O".:XV5?6>/7Y95$0VVN!1G(@1 RGG5#)
M$<3D!)4KU/#'&C2KOQKWK=@MDME9W#&D/6! E*7W)'1^2DR=5=[L!.8<(*1S
M!#B=QI0\=9*IU.17X637B]X^6D0W*Z8T'BO-U)>)E7(QZIE$DJ1%$$=,:)>_
MW8Y;JX[S))CVB=26X(N?\8.-=$8AM]0@R7Q$;MB8Y'+V0D^8Y97HH(/*2&G+
M6#4GP@G2 Y 4ME01FRXW3DC!Y(KL=#W5'1'09\PSA4LZ[GM6Q5PV<<>&-*QY
M1-KIU6&.D8'9K(9N=\0;J[.S+"8<7M)??CUDC91DSTIE];HM1%(7[5<6ZW%N
M*&\]3;I?!<ZMMZ'U)S*3\?3>2R&4I(047O:IN2IBWCGC[<JY$])IF^7(3B2,
M71C!Z],3_<3K@UF/M'BI58I9OMQ4D*1([8CM.$!Y)D)AGC2?85UK%F6,!DI%
MPSI-.,/@VVFU937R@B5=J6#>-=B;V(U%N#L%*D77Q-L=0 9.;/U7V!VB.MI>
M14!<4Y"<<*J,0ETB&3AG$VJDB24M?;^HH;H-LL^(X_7]599AK.3$F =(.,%3
M;O2[ZX^PY>R$Z2='DV,#%O+A8O";<PBW*6"C25(H67Z<5I=G,E$+5 .L]U&3
M#Q#:>*L3.I)DZV"J6J*HIER%VH?7'>T@VL:!4H]^S###%_FCI[UW4P[8R.PY
MR"AIB0LTGL#D-#*2,Z73,:HP/%N.;[S*&VBH2(EQ!(60R(C"0Z<R<RQFJ 'R
MY=?(B(K?71RAHK<$E2K?NKNZUO,#A/B 'YI<\'E2,1HS?9LR.=HQ^(JJ,L8#
M/MMOISZ4![L"A@1]A'X!-P,I-:9HBR;.G!ZI*P=<(IA5Q9I=O!DCRB*XTKO2
MKEAZ6KGQZC')FXBKGB%'EEQBPBW5E'CMP3D302@,FR"==;O:NN1 ,Q*CQ4&V
MQ==) Q8J004%=HI28L.%5R8I<PO9Y/E],3+[6@7:&KECNV+;EF\=O=D<Q5WU
M= [B1$;[E9=N-EVRT=8C*>"9(Q=:<2L#'F[.NVJ[WNYF<J1F"DMH@O!S@ M)
M626Z7.I")Z4MIUC#<4LT5PW"G7LJ^YM>Y8[NLUI%/$)D=48FN.,HMV.6^]'I
M$T/RTXW=A+9(E%2ZU)+U7VUED):D1?$B<P9BG(JZ-75X^Z$9L);J(-A/5$(V
ME/)V$2+D;@@:N>>#:RW-+VY]1O)!WG=9=& -RG!0$;KBB1@9=1T"\DGE$P>;
M6P.S FO#.4S@3CC-BKJ$I9E<TJ0LVJMMTBY2A5=3&<XTYM.K!2*IX46QUSV;
ME7>^_J-9-GB4NTRE-%Y/V!6<QXY<<;0A+BDY09],+*DW6-L*RY5=,?&CJ2I0
MRUD:ZDE'(B<!*1"YIV)R2V$=11EY%77</DJHB4&KNJVJX4W4KMZ\,*O<8?CQ
M)956'&=R2(=:"/A&3?G)<E!E.V0WRPPU9"CZ&X+FQ)7&^O2EKTQ'PGKY9 D=
M93L6JMQFB(:OCB Y<GJ&V [*@ :N&UY4PZVM^]9U+ ]@58!>UU7ETJ";+%EI
M-9"L6+J!?(H?  47,V3@()TIG>^98V$&-C@9+YWOD"-CF'E>]\;T(L_9+DR1
MU""@% * 4 H!0"@-"3#_ -H>JG]O;B_9>V1H"(NV_ORM4>[5NKZ3M%*SAF^'
M\48S]#_S1Y2/ZURG":,GG^(0KWO]*?VL(>K">2X_P9R67I/LRY%C>PIZ C)!
MGLR?V0R) ;CF5U]7+)$@-5JNYK-PG'[,<+T<LB. D[@3*<D(+41$L8H;<6!8
M8<FJ+Z(F!XXYK.&5N(Y579L_CL77_,P0:>]%3K;LHG9&URR:I]>4T6PJH?8X
M"4<<"=':(W5 KXE0P"!,&[Q"]&VDAB^*SL>B]VH0!00PSU]/L;"DJY.N:SKG
MGW^\Z]ON[59LNJ9(I:4' HX<+1VT'T[,6AKP-BVW(@R\:4RI5'C9,;;6$592
M4#PL,H8;@ 8[?7$<T?1V>A!JBFY&T?1VR&.#KF]^.%.XZ5J;Q04<6X+:+.:+
MF 5MCH]C*<T9$+81:VU1#1=A!EE5;2DZ&NI2&DN9SN)0/ICD4W]:*D*3AV<
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MKFDQ/,JJ2&>!2E,<D6&4$P%3Q P4@D\Z('D9)!J&!4KB>#+"AXF\2P&(]A+
MAVQ QY7CN/W Z6X^%YBLY;>K/P-!M%X*[81%)TM; ]AD&>P;C@.D1E9$P.!Y
MYX&L4PV5L8PSRQ&MGCE>UP, 5M8];%]+'0UW7N#UI%,N51>9E(5HG82BEF'@
MK@!E59UCIYQ &*"N54+ @EU%=$!R5#H 08)DT*&'CC86KWLW(G)R>CIY%)22
M)-+2DLF53DQ,3BH!)/3D\D!@6)$2)(M@$6*$RA8(,N5*EPPP"X > 06& >&.
M-A#'G0P6(]QV\:>C*:3O,M%:+.5J&'0W$=?';#C)98Y$U]O#*Q,V(BK13+''
M(LJIN18\!ECC<(?"]K4!U1F(XH.+#=<1R,8]-N!H*[@7VDNF66VQUAKKKM5C
M"^ZEMNJ8J;F=1%=S+IPVM.!231RQQ95C1A14AC)P<4;(#)#+5;!Q3]>C;<03
M2SXY),>NQE'3QU/QZ#ZY^L8_J\4OD:\<C>O2SZTB>-\-.]=E/U'D#ZO->- T
M$4U%A8C-[=GLLAF 7>S21<FRDP').+MIEW*L,]&!>S5*%DL%614@NQ55912C
M(*+6,=$3:XN.@@SRSQ65)PF1:_GWFU'/#D1/8 J5><5QN[BI%;4',2+.=CMA
M? )N-5QRQ5' 5!54LV&76U+'/+%050L<#YS'+*Q@P);*_,2K63H=K:.H^MB1
MQLQ&;;%+-F5!,QLV$2V*<?.N-'>!PZ1MZAY%#9MVMY =)DR7L&,.XT-'6Q<\
MU-,)&@ ,2+:]P&305%JE(/B JV%=1,*ZLW"T:,L!!5%8VAG&P;5%%'"1<4\Z
MHFFVH'V\8.F2XID9#/'$D07(@9&+YBU>][L]FXXB9K9KJB7;5T: H52+LM3.
MK3.NF18QB%VFL*(R>84%9M7*H05T)3/F$E*'.GTOU*:-#)B>*.*)F3+9!A5[
MV9M:-X[Q*%R&+"9=B)1-048H3LUD.Q0JCM8!2+-A*+E[$?$@IK<++"N702(>
M&)5( 55()/"+AGC6(HA@X.M.N19,3T4O $)@(R2H8*R6D@Q4Q DQ-50LBV8:
MFGD,$'$J34 \R1/+ Z6"#,X9%"V6(EK@!7P%J][[S@[.?]A[V_G-C]<6_0+/
MV2Y,WU0@H!0"@% * 4 H",&QCQ:##=.KCD?+J;;,;I78!: ,KSK7$QNHI<8W
MK)L>7*@CJBN:)D013(^> )<,0?',87/$,.V6>5L;@1.V>/Q5,LDQ!*D4;X:E
M1<Y8N9,QL$V5D()N3"AN)$EY<AAP&QRY-M['PF?0U5#/0PF!ES(BJME#I1:/
MA"$"XQ<N8O4VG54]H:35'7-/!I95WI[S3GJ1X?\ S/\ AR?F#5/_ /1NLM=[
ME[_Q,=2'_B_>7_M.",S"SH78[$DCB7Z(+#/9<N1%*RFB,B*@V6Y5P6(I):\F
M)J&0=2]O3(*6A!JZFU2:>>4##-7L@"!@S< GZH\4*'')M4="Q48MM)UHUBUM
M_P#*B5&PCKUDFA69QPMM+ 286"9\V1$]L_NS1X&>O&,Z,*Z&X3;;QS5CA3)U
MI#N;4>JI"ZCA@0R1BCB+9WS,&BH6>)DG3O37L_@<7!+T)-JCN5'#LS'*R(ZW
M"A..X*=LZ08H28:1(KC:)[ !91Y(35$4RYM&C!$4<L5O-1R)*1M2];LBA8SD
M#<*^[^;_ (FWTF7=1T>4W+*I;9^%<E1RQM'D9#I8TR1P*GE4B.7%)+C2SP(P
MB_D?%43IB3%0N?S,FA@\P$XAD'A@-D:$&$V4X^^GX$4$^+M(T02*+).XT7 I
MT=1WJ/';A3\Y.@\8Y(J=I ]SLF0(<.KHP^2BVCQ9[*2@:>7K()@4<J,8Q10"
MZ-8*YX06KQZZ^RN??UDDH F+7"*8L1FJN[-Z[G'.?77](+T&2YE88R-B_9=D
M)TRP_"R"*96BAH1NDGB]5PFWLS10J:R10"%S)8 ?Q@6#\]X>?+@LO<;F]E7J
M]\I&!/SPQY]8J$'LJ]7OE(P)^>&//K%0#V5>KWRD8$_/#'GUBH![*O5[Y2,"
M?GACSZQ4 ]E7J]\I&!/SPQY]8J >RKU>^4C GYX8\^L5 /95ZO?*1@3\\,>?
M6*@'LJ]7OE(P)^>&//K%0#V5>KWRD8$_/#'GUBH![*O5[Y2,"?GACSZQ4 ]E
M7J]\I&!/SPQY]8J >RKU>^4C GYX8\^L5 >5F:.";KG+,TS1+9/BX:Z-HO+L
MQ2K+.#;,L!BKXS=O)[_<3[$0,UP+;!"P6;(PK@S3<%2R*DW/AE<362<4R%N!
MAW'T9\MO2GHMH.X: N&CM 6]TT="VA8VM\NVD9WF:MKQ;7F3M96.E+"R;4[:
M48ZEC!:BBFFTY/\ /7[HSH_2%ZM;W;6M\C:VVIKQLK6PC9K4LX6:U5.[3DJQ
M@FZS>-:45$M;>T(:^?\ SBM;?S5,G_WBU]W_ 'C>FG]D]%__ $FEO_F34_0W
M17_;Z0_QKM_I"Y+A8:XZS<-1LS,@&^('K]-YB77(TE_(^746!& +?P:J0II0
M9*Q$6:)&S5,SMU/,?,U<\G6 \5B%8J+X5Q;=5=,NF&DNF^EUIK2MA<;M>HW2
MPN2L]'V=O96'FK"=K.$G&\WF]6GG&[:6L_.ZK2C2*:;?WM':/L-&7976[RM9
M6:M)VE;:4)3UIZM56%G9QHM546K7.K>S<K?9NI8C;6&TZ]MX3 !+I[Y839,M
M^9(R$QO&ZUL!C/#2S/!J1_(8!SH> 28R5?/U0=)JF"2:7PK@#JH14A^4-^N?
M7OX-/F_XF_BRWHHE(<CHS?V.C%,SDYK+S4<!Y0VB#>%P22^3.E3!A*3GO)#B
M2$LT!<\*,#D0(%L;^"& )CF5QL#818-/<?P6'+IVLY,+(7;"(2N4?PK(T(I@
M@$L0Z;N:0Y(3H]35-:.%5HRK))E830X[3!4\L=3#B$.(>/!JJ0HE,L"UA:\T
M^ZOXF@HK8NGT/.>,#34V:UF"2FQ,CFV >!U&>T+L(%2>H6O"EK(R&HW&*RS"
M:W$5IA,9VKSE6CMS8RE9W(H&0(1E/=!@!O!6N>ZGOK5U_/<3^]E7J]\I&!/S
MPQY]8J$'LJ]7OE(P)^>&//K%0#V5>KWRD8$_/#'GUBH![*O5[Y2,"?GACSZQ
M4 ]E7J]\I&!/SPQY]8J >RKU>^4C GYX8\^L5 /95ZO?*1@3\\,>?6*@'LJ]
M7OE(P)^>&//K%0#V5>KWRD8$_/#'GUBH![*O5[Y2,"?GACSZQ4 ]E7J]\I&!
M/SPQY]8J >RKU>^4C GYX8\^L5 /95ZO?*1@3\\,>?6*@'LJ]7OE(P)^>&//
MK%0#V5>KWRD8$_/#'GUBH#3.P6Q^O#EB5RH#=GJ&%]=6#K2()**BRBQU565#
LYEYMX,N23DTBNCG#IL<2]L 2Q8$487.]L<,,LKVM0JS]DN3)PT(* 4!__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>24
<FILENAME>g947560g12r10.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g947560g12r10.jpg
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M 0$! 0'_P  1" $= 5,# 1$  A$! Q$!_\0 'P !  (!!0$! 0
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MXZX8<]#D235*9E/J5NIU,VV+S$3.R">93$3-547O;V$;OI]KE?KP>FD_%8X
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M_/\ )_\ K#-?Y>?QMT+\?-_T:/\ &/[J'YJ?BB<;/Z1;'_W(/Y/7+S^?Y/\
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MXF?)7R/R\%4=.GBI[X>9Z3]Z*_)Z?JX'U-P_:\/@I\V'0]?3JXJN^6H+2
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M]VMR+\5MO\K,>'C_ -4E[_\ )SYGS'WVMV/R+]PYSY73]C2S?!YO<Q
M                          4Z1+P]US_%74S]*"S07\'''/FTKBP0 *4E
M'A&N=/Z/.''[IVP-F'O\7I3B]'#^EWP[]&QI    1/YZ>X9YG^*?R*\D$Q$U
M]"KAJ[I51TZ>*GOA=16/X-J]_,>)_L%O&EN<X 0-Z4SP:/2 ^)GR5\C\O!5'
M3IXJ>^'F>D_>BOR>GZN!]3</VO#X*?-AT/7TZN*KOEJ"T@   ,C3S,9[M;D7
MXK;?Y68\/'_JDO?_ ).?,^8^^UNQ^1?N'.?*Z?L:6;X/-[F(
M                   "G2)>'NN?XJZF?I06:"_@XXY\VE<6" !2DH\(USI_
M1YPX_=.V!LP]_B]*<7HX?TN^'?HV-(   ")_/3W#/,_Q3^17D@F(FOH5<-7=
M*J.G3Q4]\+J*Q_!M7OYCQ/\ 8+>-+<YP @;TIG@T>D!\3/DKY'Y>"J.G3Q4]
M\/,])^]%?D]/U<#ZFX?M>'P4^;#H>OIU<57?+4%I    9&GF8SW:W(OQ6V_R
MLQX>/_5)>_\ R<^9\Q]]K=C\B_<.<^5T_8TLWP>;W,0
M      'X,,T*TW--WT+++UVW,,,VQIIIIIC.VV^^^V<:ZZZZXSG;;;.,8QC.
M<YQC #\D'DJ2BU"8XI00;KC<HX@S0THW3;MUW+,+SMIOKG'>VUVSC/\ %D!J
M@    *=(EX>ZY_BKJ9^E!9H+^#CCGS:5Q8( %*2CPC7.G]'G#C]T[8&S#W^+
MTIQ>CA_2[X=^C8T@   (G\]/<,\S_%/Y%>2"8B:^A5PU=TJHZ=/%3WPNHK'\
M&U>_F/$_V"WC2W.< (&]*9X-'I ?$SY*^1^7@JCIT\5/?#S/2?O17Y/3]7 ^
MIN'[7A\%/FPZ'KZ=7%5WRU!:0   &1IYF,]VMR+\5MO\K,>'C_U27O\ \G/F
M?,??:W8_(OW#G/E=/V-+-\'F]S$                       !CF],I)GV/
MW?6^)GT;T^YP4'FJ4"QVF3Y;7([3CC6,L)F$OPY$3.B**J6Y&QSD9C/JQ+U-
MCS"%N7G#0<ULS>H:RT"S9P-E$:IF*K3$[+1>=FN)F8^J)N[GZ'*)<:;$A\EY
M&4#5U.<?=D,M>Z_=:[XD<J;'MFD) EWCL=>-5-EUB]Q>M8E$K+:5CL8:B2+*
MS;YDTMNR59Z?[ML@5-8>EBN\:IFJ=DWJB+^*;U:O';LU+RP0    ITB7A[KG
M^*NIGZ4%F@OX...?-I7%@@ 4I*/"-<Z?T><./W3M@;,/?XO2G%Z.']+OAWZ-
MC2    B?ST]PSS/\4_D5Y()B)KZ%7#5W2JCIT\5/?"ZBL?P;5[^8\3_8+>-+
M<YP @;TIG@T>D!\3/DKY'Y>"J.G3Q4]\/,])^]%?D]/U<#ZFX?M>'P4^;#H>
MOIU<57?+4%I    9&GF8SW:W(OQ6V_RLQX>/_5)>_P#R<^9\Q]]K=C\B_<.<
M^5T_8TLWP>;W,0                       &-CTQ-25]=_()<GL3EGR5IV
M)T1Q:K*S)=3\0@,;M"@9DTV=R'EE0L<D>(!)['9V*4V 9)%*=I>D4D@RUG3P
MQM:U)+TN5X,:D9LIO$1,13/LIM,WO>*;[8F+1KZ]NW4L#Z+F!L-)1_E!QK99
M4AEZCCOR&20)\=F3C=0?&6,Y<WNCZ?L@DJ.Q&@$+6R2-)JTS=LRNETL;$4O6
M/.7)N4:J&AL:5B@FJ9FTSOB^VJ=DS&OG3,[NNUEI8)    4Z1+P]US_%74S]
M*"S07\'''/FTKBP0 *4E'A&N=/Z/.''[IVP-F'O\7I3B]'#^EWP[]&QI
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M&>[6Y%^*VW^5F/#Q_P"J2]_^3GS/F/OM;L?D7[ASGRNG[&EF^#S>YB
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M,QGNUN1?BMM_E9CP\?\ JDO?_DY\SYC[[6['Y%^X<Y\KI^QI9O@\WN8@
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MQYO<Q.O?_LZ?YO;Y_P#;[/ZP']QU_P >,8_[LYSV?^.,?Z/ZP']
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MQX>/_5)>_P#R<^9\Q]]K=C\B_<.<^5T_8TLWP>;W,0
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M\/'_ *I+W_Y.?,^8^^UNQ^1?N'.?*Z?L:6;X/-[F(
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M7XK;?Y68\/'_ *I+W_Y.?,^8^^UNQ^1?N'.?*Z?L:6;X/-[F(
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MS&>[6Y%^*VW^5F/#Q_ZI+W_Y.?,^8^^UNQ^1?N'.?*Z?L:6;X/-[F(
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M@/B9\E?(_+P51TZ>*GOAYGI/WHK\GI^K@?4W#]KP^"GS8=#U].KBJ[Y:@M(
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M[M;D7XK;?Y68\/'_ *I+W_Y.?,^8^^UNQ^1?N'.?*Z?L:6;X/-[F(
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M8^^UNQ^1?N'.?*Z?L:6;WU[]O5KK_F]OG'^GVF>K^L>;W,3KW_[.G^;V^?\
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M?BMM_E9CP\?^J2]_^3GS/F/OM;L?D7[ASGRNG[&EF^#S>YB
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MKV[+:OC15Y8F;>"]]^]<P"0   %.D2\/=<_Q5U,_2@LT%_!QQSYM*XL$
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M\3,4XE$4XN%BWIC#BF9OA5UQ&N+6FTLS$=*.1@
M         *=(EX>ZY_BKJ9^E!9H+^#CCGS:5Q8(                1YNW^
M'_$_QAG;Z,_(P&8V5>#TPD,#
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MFTNK:M)T4(W!M<41IZ-<B5D&:'IE:4XT@\G?0PHS?3;&V0W(
M                      4Z1+P]US_%74S]*"S07\'''/FTKBP0
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MFRH-&S$_HDN1.:0PU&ZJ\=TF0Z:("\;GJ )FGFQ33SNE,ZXB-L1&Z9ZEPX(
M
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M-?V%'\L2]V9-G)QFID<>%<3VCR5O$QO[;6O^,1.K\]<V @D
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?_FA7G?GOG7]\\[\]WB:[3,6V=O[EQ1>(F^WL_>__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>25
<FILENAME>g947560g14j65.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g947560g14j65.jpg
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M 0$! 0'_P  1" $1 ET# 1$  A$! Q$!_\0 'P !  (# 0$! 0$!
M  @)!@<*!00# @$+_\0 5Q   00# 0 !  8$"@4&"@8+!0,$!@<! @@ "1$2
M$Q05%A<A5Y88&2(Y5IBWU=;7(S%V>;@D)28R.'@**#,T-D%1<W>7)S4W66'8
M*4)24UABDK6VTM3_Q  < 0$! 0$  P$!             0(#!08'! C_Q !(
M$0 " 0(#! <%!@4!!@0'     1$"(0,$,1)!46$%<8&1H;'P!B(RP=$'$W*"
MDM(40E+A\6(5%E16PM,7&).4(S-#E:2RU/_:  P# 0 "$0,1 #\ [^/ / /
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M/S;9O+P@\ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \
M\!6W\O=V6GSI\<'4=TTG+W4"M*"1.+OXA+V0\,5=!'I&QX8#=N41\@'%@[K9
M464?-<Z/A[E/&J^V^FFJNJ:F@U0DZDGHWZTCS*$6?RE]IS.Z/BVI43<"X>05
M]=M=<^_([HPB\+7<6+:4EZSEW.3&+R75S''&L.?2&.<[6?86S>)9CKG0=-V:
MVB*2:@S(Z-Q'-I>O7U6W2EM.+.]-]%"?;9I2^>\_>4_)E\A\6B/)T]KN4$[D
M-J]P?)JQMBK=H]"V[ZVN<N2GKB6+UT&49QE%RSDD9JH%+-H0[#;-C922MQ6A
M-4^MOJR<T*FE[4V]VAIWLZE3?J;=^6ANIE\GMUVU+ADWI6_'1NEI]\WO"G/D
M"=,@$.W0<<LW;0X&;2^M5<N8ZJ_:X,''[A8RX>K8F@ KH[$IEQN[11HF&RM&
MK_=U-Z_$MJ_AU$1!GRR]TAH/W14!N[71"^+:O@)&> 98XB4$U4@,5:]?V_1%
MOCMF3>,(##R5<0:L4I5]L>8F7K5H51>D%LI[)JJBNA2H4*):EW:2?&TMQJM'
MPDDMTQ\F'40_X\_C-C55]+P2K>R>G^>2?2-@W19RU8@Q#F*4]2A.:$8\^9RM
MBQAPP_?MI.XE7D2^XC4?I=Y.:,&:2#5TLT$5-.U7*;IIJB%,W;2YV2;YQ#)^
M OD&E_0%^_!O+*@F&X&E>XZ\[!EURP-DT"D&A605ESX"D0^*$"KX<[+L7=76
M?B1BU]@1,=AZ1&N$2.Y!GKHE@9=,;:>M+2\8\22=\WK:\2^4;@"A8[,'0RH[
M@IGL&361#4QX99I)SM;!JY=0D@X(NAJYMEN!7-E%$4A1-@W=9=[8((N]4T<)
MB)+9J>].F.V9\C2OR>]0=0_'[-Z[ZZ@S4[>G,<@C9FAK,YK9M8RV>QZ\)=AP
MMSK;43/*,&DDRRE5@X%5+8HMP?>#1H8^,. HV0/**;)BT4JJ4W#U3Y+51QB6
MNJ"0X.8]&\<?&O8=U]033-^]*5#SY;5_64IJ/!AHXO-@,/D%A_HRC36)#1+1
M"$1)1FUA(\MA-4D3'CEY$]=9</MDD!+550K)M)3>-TOS9'/B^ ]Z$V7'G4EB
M_(4TLX!T/7X.P;QYYGE85@"@"K6R:X2G,8!<TD(4! S$$6KU5^@V57/GY,C+
MP@YZ:,MTE\_8:!5LIM;,0VDY<V_JU78DC=_PZ7K:_2GQWT=<UWS!U/;,E<AO
MQG()4]'AA3DBVB'1MMPJ.)*,8^-$"4<#(O'0HE/9L/0W738Z.'6R[Q5PX5"M
M)50M(I\:4WXE6_*_RWSVT/E+? I'>U:R+C?I:TK]YDYOJ(08@2TQK:;<Z#('
M^4;>DN@_Z)VC&NG"[&UA\);2'"C5R0T":,LM$%AR"XVZ$J='M*'4[PT^&ZWN
MSUO6#&)SUSV]4/8<@)](7]T5S[ U^STH95DBTYXJZVOC)FG,A::MH["*^E-L
M0,0[M>O+MEC!PBS*2J6R<:I&).X4U)(BQS1VW%A":]U)O9EW:J32N[V:Y)7Z
MS_>I.N.X**ZJN>4W1?G1G.%/QGHN*AZ$LF)\\5=>?QN9H%4C$!KN,=,2V*AR
M5X02U9&Y>GQQTF1/"'$:-/&>P;\-$)#UT0I5+5DJG#E2U4FITO#6_3368,PL
M#OCKQ:>=$T#!;A3C$IM7YCX%PE4%K%(;#Y!KSO3DFID)8LD)1,([$) Y;+-/
MPTLUB:$X3-)N'Q]=99SG4>SU1$5*LVK*AU-7NU4Z5U;IC<N)<AR54O2U*S*W
MX3<W8/\ "PKS*<-,57O/(I"P%^5ZJ]9D=)4,GY6O \6C,EC)M^B@_AKQ:+L2
M[+1 BR5>.VB:";<8;3B%#O,-P^&K;XS<G+X0> > > > > > > > > > > >
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MAY5@'&BXS&FSQWJ-$! HU'?9?7=_L]V:,,M!'4W"M"F$E"4Z]Y-3P@\ \ \
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M-IM1V:+29CJ3T^B1'3M'&,?)[\+_ -&,8_Z<]X_\'TB\*OAJ_+YEM_AD> >
M> > > > > > > > > > > > > > > > > > > > > > > > > > > > > >
M> > > @ST_P!4W5MI53<DVL+H&#3VDP\E#UJ7IFX#M9;1C,QQA"4F&'X(ALN
M@?/#4VP0D7071=. C1 7G;#7*VBPTJH34)SQ1^\*^/GG:!])/.I C:>+3]<Y
M,IH/CQ6>'"5;1ZS;)AT<K^RK8C\(74_#A]BV!#8N,!2DYE19!X@J6=-A[,@:
M*O'8FTXBW#13";<3KO\ !$;K)QC'S=\K_1CZ/_T>/4?]MM$>%7P5?BI\JRW#
MPR/ / / / / / / / / / / / / / / / / / / / / / / / / / / / /
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MNY1&*-VNG^E=*HI_R_ 8'7%\UU:[YPPA.9X[V:;G$7#\[4%O0L$F]C)I6.2
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MTM<BA4C/OHL$>+Y63UW3('QD:F#X8EJAE5359M&BV^ZVB:.4--%=G"($>*;
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M4MD1E_O]FG]=SM]37Z!&V]7)J?L8A!I#&8Y Y'6DVL4B-MOG>=ZLQG/5I6L
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M%)VS=#GC.0Z"'*/M'L5T3T=T[[5]!=#]+9K^#Z.Z0S^'@9G'5=.'5LNFNNC
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MR&$L;]CY"Y.99!)V%X6#*V+RJS=K'&P''+M.UK*'$FW*5"3MV50"4;")&]8
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M:/E")1XINY=J[9$;ESZY+J6B-I>$'@- 4C_Z4=)?_']U_8_3WA7I3U?-F_\
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MZ:?=U39';ZVNV_WCZ-\::"'L^ > > > > > > > > > > > > > > > > >
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M4U<I?FKLV6,ED&9ROM4VT^6GBO7INOW4EQ4]4Z]3E)/\*>\Z'_4P/ / / /
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M@WY[3.<F8YEIVV=PRG6<!3Z@SKU[T7O]3E[,)LG,WWWS.[]^]::XF.M?8SO
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M_$IV5=?3O5W>#6\7=P@WS^/<ZV57U(3NIK@KN-<Z1<RQL)B^K-#](<1C8_\
M.>C!6%JR\^GHT2M65,99)X*F9A$>2>#@J4*G3>I33GG;=N75S+\_# \ \ \
M\ \ \ \ \ \ \ \ \ \ \ \!SBW=TM>03Y1R<;%7C.1&\/[<X2YU@?.C.2MV
MT#G/.%[<X2F?WE.BM:Y1SF5E1TNS)"B%D*)KO8?^C-L(9$6+1,DT=#HJ5LSK
M[M3?)IPO6^>1T=>',> CGUO>)WF[G&U[JBM:S"X)7"8\@I$ZW@L9DTND$IE1
MTP,C$::[ H:)/2I:/-#AM@3F1 "#,$@<.9'CK<8^V&_=514I:4I=;2\78@1\
M+%\6->?.%QKV[9%D6S8L$ZYZ/AAF<V+7%B5@J1&L+"([1YG'HG880*^BP48+
MRFU3KQNEAS6.^,P@ZQ$&A+L<B-5I)VA*$X33W;X;U=]=&BX/PP/ <V7R2=07
M36WR&0P/![IGT-KJJ0?!9:8Q,)8PZ'-6VMY]?R:O9BZCU%.DMW'8SBR(2R;P
M:2B%2$>0HQ@P0F,9<224$EP:(Z4I;+M+>U&]VIZ_=C56>U=6@Z3?#F/ 53_,
M?)N@H#Q;,+(H>ZW5+9@TAKPC-'L< JN)[+1)FU*_BK2+Q>9ZG&&M?,7&YUX[
MDY=H&-&BPULG'QJX-$@0?[#5*3:34Z^7KU8CW<%M$W?RS5?3M2]D3O>=")G!
M)C?50R*RHA%.>JKH1Y6!@2/H\76;S=N\MKH*^IH[%6  =LVYB;04'G8VY)@8
MKK'11<5+W9:M=*SEN5>>"GC#=HF6KW/# \!S3]2=$=J\^F_FS+)7L6G4@JGE
M_DVQ:0&QN-I1:)T+'+1L/H6/2!_#8V2)RUEM*8K7@=E))98Q_=XK(I%&M3CX
M6*C L-%@HZ))[%M:FG-YA4\-S;B%I.\L3^*FS#<WJR^(;))I-+".4GTI*:V>
M2N1WXVZCC#M%S7U9V /95E?>U:59(9W#6#";M]7"<VCSN5QN6+26.[F',>'Q
MUJR&:E#5HE3I&]JZO&G<6B^&2M7Y4;7@--<VBII8]]V]20%.SHP+8 J%DXN#
M6U?\J+#3[*)T-%9X05:.(0G*#RK&1'94-* <A@,3(/#IX9$DY#NH-4J7HG;?
MNYQOZH?4RCPYTUV)!#].#; Z^*R*Z:?J+XLUZUAU:V1'#-<]72OI3L*6U+TD
MG(4@#;\+Z = 8 +9P%[(Q&N[4(9CK^<!$PQ@JY(*C:5+FSB:YXI4TS3U.=>+
M4:6.NWPY#P'-HKUW(*X[9ZDF%+]"7CUM'.<H?T2M>U$[2T+)&MAW66+1=>E.
M9>4N?8TR?RELMSTV2(L;AMZ*QQZ@@S>.&,O?RF3MCR0D;BRM$[,/<E=-MMQ=
MPTN&D3>5?PJ]#VK?E6]4XN^P;#LJS(7U_8C(B;FE86I5H,*%.QB%$QT(@,:M
M*.Q\M&HM$R^DC9C8$X12DL1%+"',O%C2$B;*D K4-62E*R:?C)=!X8'@'@'@
M'@'@'@'@'@'@'@'@'@'@,+.5M7<GE$6F\E@,+D,T@V[Q2%2XY%@9:40_<AIA
M)_O%C[]BX*Q_=\GKJF\V$NVF7.FN-%L[ZXQCP&:> > > \85'(\"<G'H0$&#
M/).6_'I([%"V(]S(3F1[ 3DT<7:((JEBV10H6,_$7^[AY^'C6#+[;[LS;II@
M>SX!X#!)E5M96*\C)&P:Z@DZ(0HK@[#7TRB,?D[R)&\;([8,1ET;'OEP)7&S
M9OM@@*W:.\;((YPM]*6F=0E\3._ / ?&1'#S ]^(+L&10449.AQ,81:H/AY$
M>^04;/6#]DY35;/&3QLJJW=-7"2B#A!11)5/=/?;7(&I#_.'/$K?A2LHH:F)
M(4C8D2 CI(_5T',/P((!];\""A7A$$Y<"Q(7Z^_X2-8J(,QWUMON:*/UL_2+
M+XOO-S^$'@/#VC,;WD.9;O'@>\KR#VC.9-L)8;2',;W?8)[Q[)K+?)+(/8EC
M!#83ES]PV?8P[RWROC[3P'C02MJZJT0Y 5E 8570)Z4>&W@2"14%$1#LT1^S
M_$"[D;'V ]FN4??9)??'ZJ.[MS]DG]LKO]37Z ,U\!BDT@D'L<"XBMAPV*3V
M,.EFSEU')I'1$I N7#);5PS<. YQF^'K+-%]=5VRJC?91!;751+;3?&-L 8.
MCSKSZW"1Z,H453B$<B,EQ-(I'T:QA*82,3'7ZGU99'A6@35@%DNOV:?T'1K=
ML4Q]33Z'7\G7Z!9?%\-=W W'X0> U,YH.BGDZUM!W2U2NK,T(M3&EB.:YAZ\
MZU+,446[(IK+50VQ_4BS0;H(-7N"&'+=%!%-%731+37467$2XX;C8#..1X<9
M-2,>!#,9#)$A:,B.LQ;%J9/H@TG* 1$T400T?%$@Z#QVB+3?+KZ#TG3E-IA'
M1=7780]GP#P#P#P#P#P#P#P#P#P#P#P#P#P#P#P&%NZWKM_.15G/H%"WME Q
M+D $L)W%@;F<AP3S*^SP**EBS'<^/$NMG3G9R-:$$6:^7"^54=LJJ?6"7I-N
M!FG@'@'@/&"1R/1I(@A' (8 @6,EI&51""V(I(G(3SQ0B</$$V*"&CPR:(++
M/BQ1SA1\1>*J.GBZR^^V^0/9\ \!@D@JVLI;*8M.9574$DTV@RBJT)F$@B,?
M,RF'JK;8W65BT@)#W):/J*[XQLKN)=M-E-L8VWSG./I\$OB9WX!X#Q9%&HY+
MP[N.RP %E$?(9;9?@Y$*8FP[W+-V@_:9=C"2#EDYRU?-6SUME9#?[!VW0<)?
M5613WU P!Q0=%.YUK:#JEJE<V9H1;&-+$<5S#UIUJ69(I-V9366J!MC^I%H@
M@@@V>X(8<H(HI)I*Z:)Z:ZBRXB7'#<;9\(/ 8TK#(>N0D19:*1I8K+P[*/2T
MFJ"%J$)0 &Z$DAP.1/=VN7)L.P3,ETV0PFHY9-="I+1!!/5\ZPJ!^$)@4&K2
M.,H?7$+B=?Q(;NX4'1:$QP/%(XPW>+J.G>[(("9L!C7=TY55<.-D&J>5UU%%
ME<[*;[;9 RSP&!SZK*QM8<R$6C7,#LD2->Y)#AD^B$?F(X>1R@JUR_9,I$.(
MMFKW+999OET@DFOE!55+[3[-3;7(2UHX/):4;2C!W!'["GZM9/JN1?-ZS>M*
M_B;9W72!/;?8DA!'*(C1:(HD-E5-GR<?W'Z.]E-\KZJ9WVSD)?$VEX!X#4T<
MH.BH?+G%@1&EJFBT\=JDW#J;1RN8>$ESE<ULKN86<208&:F5E2VZRVQ-11[M
MN_V55V=;*Y4VSD67I+CA)L /'(]'LEM@ (,#V/F7DC.[!Q;$9DU(2&B"3\Z6
MRR00R1,ODFK5-X4>?;/G.C9#19??5%/&HA[/@'@'@'@'@'@'@'@'@'@'@'@'
M@'@'@'@'@'@'@'@'@'@'@.2[Y%^9^BK6[?Z9Y3J9A.P< NF$QSY-H].HPD11
M!,+JY\YQM.B(O7RI-/7+%)_*[^C_ #S.3 9+.[P@Q9.W6R6GWE)3<=*6DDVD
MX]V-[4JIMSRE2M)6EC 6_5?<M:4-!>E8*UD//./D$NWM_IR?2F1U[O+#,-/0
MO6#5ER;0TE'F:CN584*E5?P9608C(:(L)I8.@Q8!7<JC,@=+;OQ8IEIM/95*
MUA56;;3E:/1W6]J"5VO:?R'2KL,A3L\T&PF/$/RU'7U#)UG,=X_**GDG(B4]
MFUO1*1;4.^LAJ5&7$^,BQDAF-HP>!QW2,[U5-X.QL @U(.!-FG9G@FVY4S+2
M34M;IM=IV(U\K]3]^59\<B44D4B>T/9E65QP6TIF,%*V4>197E240T(#+6*V
MMIQ1-Y?E:W9M)0DQCMB';FKF05-01%G%AAT VU/(2LF+4J77:Z;J=N,O<G\*
MU40WIPCH?^.^Y;#OWC^H[0M5G-FT^-)2\<?=S^-1J+'SV\:G4EC;"3I,(:R$
MQ8@!D8L4R+QJ41\#&Q$Q NQ\K'1H S,(BFHYU1+B(W1,=5Y=M":WA!X!X!X!
MX!X!X!X!X!X!X!X!X!X!X!X!X!X!X!X!X!X!X!X!X!X!X!X!X!X!X!X!X!X#
MC*N"NNE*XZ3Z8?Q>%V8\KKXANCI5W/4(*.M"VH>Y 78=X49=DFK<"MJEND?1
MAU*MNHXJB+'ZN<"2\@8I+*Z+ZN$=!U3IA72=25+TM":OK";V6W:8ZXV=!KP^
M0;DD%Q-1\3=[09"<4)2_09(;(ZZ-2H??W1W4O1<KGO1E82XB'I:V9]]\K\1,
M&8G6/5Z:KF40W\;0G\B.F(.,V'#PBFK:<S#:[*4H<MKXKZSOWP>)T#U;WS>U
M8?)13]E;/%1:=$]T"3-!MZT/-I!4;>OY^RC//A*#2&+4F,4>8GT+WP2=+V'<
MDTS::)]O+*I8AQT>-A$02I3HB-:);?&]4W:MOB(43+<F]+4[B^0R%\V"R\CG
M3NH+_C/4%PP:\:T8U[&Q0R'0P5 LRFC8;2%R2OG2\:K.Q4_%'\2F+>37.RCT
MFNR0/)1 X+-H(:#*A1CUZX$BF=S6S*GCOE)IS9V3<6ZSHLYXG!ZS*#I.Q94&
ME$=D\[J>O9?(@,WC:,-F(@[(HF)+%A\HB+9X00BYYJ_=N$BL>2?.] SW58?J
MX5PW^OD8:AM6<.)6CZN1N+P@\ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \
M\ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \
M\ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \
M\ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \!I64]$TU#)*5AT@FB+:3
M]!^YD0Q#2,VY$_BK),B.3([ PY)%FN\'K(O4&[A5-?=HLBXPG]DJGOL!X?\
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M<Q4Z,#'JI<54X.)52UJFJ*FGV-2<,?Z8KI_;A>/_ ,Y[/_Q7[^^?_"C[._\
ME3HW_P#)_P"^?)O]X>F?^/Q?TX7_ &SKC_\ !EYU.I5578RDNE\ZGZH.S:YP
M&1E<O-2M\VT<0,@Y78"74L,N=6.'SA/3.4LO6;/9QG11PHGKC977^1_MEZ#Z
M)]G_ &TQ>CNALC@]'Y*GHS(8RR^!M_=K%Q:<5XE?OU5U35LJ;Q:R/H7L[FLQ
MG.C,/'S.+5BXKQ<:EUU*E-JFN*5[J2LK:%V /KPNQKWIR:VI52$3?<N0C><3
M4) ["9VBR5W0K@A9!.N%)1M&(4(9V[&!;%HC+XJRP:CP=.3PTDQFAED?SNQ^
M4GGHNDM_9R[O4&6 >HQXF%7+)+MC2==%J$LF.UC80R$$9+<(I<U,XI5,RB"\
M+>"H'&9A*TBPVY8:*7::U\-)-9-J:&MFA$<Q:&B01I&]3PTG7N>\QT5WUSL8
MV5:MG=F(F=R1, &C1"E[5&R.6RF/6&XJB7Q6%B'T2;N)8<@UAM5XU-DP>'C&
M+J(.RQ5^W #R)9H$/U'"?+O,CD?4XA] :6E=,QM6QS?1-@NJVJ4)+7,@J06N
M=#1:QYU*7<\('(:;ED&&1N(U)/7CM)2OS)]P8'#0" '+DMHNV"-9W)-]3:TX
MZD5K"^24E7,Q;5=*8)0<!LH(M=PVQD;DZL4K&NV!^HH_S)-Q("KYYO1<D(6B
M3L6 =40.5@V#Z&0 H,T''Q1(=]_8J:Z"[.^^Z(6J<SOW-1O-VU[U+<DWM2,Q
M,K1,!@$ /4G#;_(R:9WA*!5BQ&#3-1XS1#RFKU^?T@8NP !1DNRDL=6M+ 8;
MHFLII*G+A'=GX(M,[XY=\Z=A\EW=N9HN;$@TBK9B7B#RO9[.*X/@+''O9/8V
M8' !\T7491;\MXC8:+FRKMU 0Q=[8B\N7DHYR95KQ.ODUYJW$4<8[-WK=XGG
MR3LNQXF,E+DQ0L<V(U59S2J+<:C[LT<M/SG(V%0R2O(?1V'-9,9/<4\L.&W+
M'2T?CIB(U:*T.,R$6>RE!ULT>N B^NJE>.M[:/B2'L7I^C*HM*L:9GMC16.6
M);CE9O#HX4D<?'$7/^A)9&N'# B59DM6L@)"GD>CRS1B\P6D2?X2WQ]XQO\
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MFVUYJ$L:U T;F 815'39;FHH.@ 5I&C8^U;(;$1&\JE4%&G0#"+-2 0.A,)
MZ.B'3P79YSII.]3IK$3SMH;Q(66A:QWD618%[ 2@;KVYZ^DX+9[@CJ*EE:<_
M]B0*1HM"&6@]0@'=E(\X*1TFX&BW)6.$!)1P+&JO-F2 R3;\ \ \ \ \ \ \
M \ \ \ \ \ \!5+VS/IC54=^4:SJ\//(K/:\^,&OYK"Y,/U;[/X_*HPOW\:
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MKRH*J/#(\ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \!*+AO\
?[:W*/_QJ _\ ]I.>%6E75\T=QWA!X!X!X!X!X#__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>26
<FILENAME>g947560g17z07.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g947560g17z07.jpg
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MS*E3-U1'M<\%=/'-XA!_$,W &_V=03R89_A(X^"7V&SOA#][/W,>T_VZ:O\
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MV=*MM+$LK;?$PW3=S=078W.#CM(J-YSHJ6X4%3"G#68$)11EHB I)9X,(R_
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M!0&:1CW6H8\=T+^E)I5K?X7OR<:T]3NWUC<SN]7.[5Q\>U]GM3U?*_/<VZ*
M4 H!0"@% =?KB$<0"\>[9":J%=QYL@59+LII.E/CO5/1L?8R:G* Y@S=\E)5
M?[M2Y.:9%.%,%,BJ8WVI$Q5:)XA"&E%UF\SP! @,D8U5:1:K3XTJ+9ALZ<Z^
M3IF_P^5[8=YM]1>3YG^39IB Z&L(B$2V<T_'U3V;;CP13Z+[D.H%DLJQ6TZH
M_4T<VJ8@G1XA;ZQ=5*$QRSD6BV:@7*BLJ5HDD\.:ZQRV/%^EEDU"HH!0&!RG
MW,)'^H;O\WE&A,<UO7$KSX)W@H]%O$2@_>*K0M:<^6\M(H4(I[W]X]N5Y*>P
M_HB>%"8YK>N)#&&.X]%'BU8OFNE5GCDMRX''EF][XFRJD@4 H!0&I]??"=+7
MD'W_ !!$ZQ3S6[WLS0YGZTN$2XBJ%A0'18]DP^$/B?R,&'Z<)[KTYV-7=#6S
MJ>B?7WX^+UU[4T?UB\>KLCK[5ZT-=B@% * X1S?HXX/H15_H#%=)K-WN:P?,
MFE?8+P<NX=O7+K=V]= ]5;5WO9M=?$5$?F WZ_,HW:;UH!0%7V^?$7<6GD@1
M=%[!UR/3^[I"1"SF5+F)A9$+MYGH*S,450,V#AM=>9%4P51%:2Y?:B8I=C%"
MR>U$<45R.)3(HP0YDN+*-=OF3;VO9N9+G4V><]GM=(IGH9K%6.:DEN9K1YF%
M'27>P;442ZHH)"DWA7622D4BN'4<^G&""B=3T\-.R/@&0T\P>)8 'S(AJC:Z
M"1%"!0"@*T>,EX+'?'R;Y"^[;4+0Y\?&CQ1-6 ^X7"WBFCGS/1J$2S>]\3;-
M""M[BT]XO('C;U%_&' M"5GY)<&?!7(.,* 4 H!0&$\/_OL>(W]9-6?0?G6&
M?.?DX(S0YJ\O%ELU5+"@/.2XV_A;MU_I77W\*$&5[)['#O4TY^D,_JW1YKO7
M7MRX]3E[1;%7E>ASXL4 H!0&:1CW6H8\=T+^E)I5K?X7OR<:T]3NWUC<SN]7
M.[5Q\>U]GM3U?*_/<VZ* 4 H!0"@% =9KBXQ!M=M5/JW#S+*Z(N?71KM>(4-
MSH\ANV FGLRD/>8U9<1F@E!/"=((V-+,#.05A.,(\4&&PRD5SKRR5/!-L^:5
M"]\:&2')2JW).NQ-JB6U)JNVN-*;"RGA(1F!"NIPL.V3BB*IQ=+$A,=Q()?9
M=2VJ,(+D01TLLL(RM(ZBPXUQ2EA/,\P#[%36<E);9$M;L8/+(\-R%98R;SKC
MER=G1]ZY[2SRA44 H# Y3[F$C_4-W^;RC0F.:WKB5Y\$[P4>BWB)0?O%5H6M
M.?+>6D4*$4][^\>W*\E/8?T1/"A,<UO7$AC#'<>BCQ:L7S72JSQR6Y<#CRS>
M]\39520* 4 H#4^OOA.EKR#[_B")UBGFMWO9FAS/UI<(EQ%4+"@.BQ[)A\(?
M$_D8,/TX3W7ISL:NZ&MG4]$^OOQ\7KKVIH_K%X]79'7VKUH:[% * 4!PCF_1
MQP?0BK_0&*Z36;O<U@^9-*^P7@Y=P[>N76[MZZ!ZJVKO>S:Z^(J(_,!OU^91
MNTWK0"@*!N,_*+D8CXUL25Z.V^H0&X^2)++X/:AGMLU1R--USQK^V)5@D;M4
MAN4]$K:<<&&Y$E,ZJ H@RK(J[%3?:C0/IKI32 @HO!5K3/!KXRC1T>.RO1GA
M4LQX>MWA;2768-^Q@C0TZ2\4-PF?C9OL6T7)3;+$@Q2B-[C&GNHV<>&%=$!3
MEY08XPN9EJ**H:035^R2 MK"LN<]^UU].WP/:B9%"!0"@*T>,EX+'?'R;Y"^
M[;4+0Y\?&CQ1-6 ^X7"WBFCGS/1J$2S>]\3;-""M[BT]XO('C;U%_&' M"5G
MY)<&?!7(.,* 4 H!0&$\/_OL>(W]9-6?0?G6&?.?DX(S0YJ\O%ELU5+"@/.2
MXV_A;MU_I77W\*$&5[)['#O4TY^D,_JW1YKO77MRX]3E[1;%7E>ASXL4 H!0
M&:1CW6H8\=T+^E)I5K?X7OR<:T]3NWUC<SN]7.[5Q\>U]GM3U?*_/<VZ* 4
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M$QS6]<2&,,=QZ*/%JQ?-=*K/');EP./+-[WQ-E5) H!0"@-3Z^^$Z6O(/O\
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M/=A!5NK>%/!2GHV;MA,*A H#2<HZTZY3@IIJU-4 0G+ZRBD,TM'5I1BIB/\
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MA0"@% * PGA_]]CQ&_K)JSZ#\ZPSYS\G!&:'-7EXLMFJI84!YR7&W\+=NO\
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M!0&:1CW6H8\=T+^E)I5K?X7OR<:T]3NWUC<SN]7.[5Q\>U]GM3U?*_/<VZ*
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M&9<'(3,(#,:V]-A,@0LQ1<PPLLKX89""98XVOGE>[EOH7F_['(L^B?TX_P#
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M78H!0"@.$<WZ..#Z$5?Z Q72:S=[FL'S)I7V"\'+N';URZW=O70/54U=]O\
MFS:Z]./<)B3GT7Z_R ;_ "^7JZN?\:_,HW:;U^/^O'JOSZ+]?3R^7JZN?\:
M6]OSMSOCR^7E:_/GT\N73_PZ_P#VT!U_.+I(7O0[)ZRR''LQ2/'DW#Q?(,=
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MIPGNO3G8U=T-;.IZ)]??CXO77M31_6+QZNR.OM7K0UV6)Z=3;"L2N5IJR";
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M,!C#/5AQTK+S);"T);'',5-;ZVJD\ ;@BB'S1H4P-D*.E72E/!6GIQ).4(%
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MN%O%-'/F>C4(EF][XFV:$"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% *
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M * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4
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MCTO[2GX6U_OR\Y]4%05"L,[YZY&(CB>.XQ'<41;-EE\5A,Y!:@BT73O>:&(
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MI)CQMLAK2,MRLT7,UU:9$!.?R)F[HU)IQ9<4EMM9(+S1C;?"74O)L''@<9.
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M\PY[_E>//6E0#X9S5[YASW_*\>>M*@'PSFKWS#GO^5X\]:5 /AG-7OF'/?\
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# __9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>27
<FILENAME>g947560g20b36.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g947560g20b36.jpg
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M:?:F\6Z(<N5)VH05 R$KB=I,X! CWF>LTCP'JMPZA_4'DV3*5;DL AQU29!
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M/&0U;&+)B.3]X28[\2G1IJ\H'LAQPHCB,,C=@R=M@I8!'I=DF1R2D1WDF/\
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MN[N/?A5YY\_;[_W_ &^VN&XYQ71CF(@?.!$ 3R09X^^<@C:8D='*GA../O\
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M:B-]RA24)D^E 6E2]PYW$H"4F1Z>F0:K+U,8GCF6[C]+V,9=C]/DV.Y)O-:
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M",&3]3 6 C7,431]:G6.B(*]CEC37$:N_"M/(CC,]U+*D-+)QR0@I>/EK)0
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M[_?_ &KV"#UAQS1T/8=-5K'29C#93A4^Z./F= ;7D;F98['WN3,;,+:((V,
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MI4^T$NVL*&DGWU.S'KV;45LNZH!V0;AE';28836-.RWC!CQ[5E9,>:$VR!'
M&<@$E"")A6L:I67TI32E-*4TI32E-*4TI32E5]ZC -!C&'Y.YC5;B&Y>'V1R
M.3_J(5U*-ALXW=RG:T4?)G$(OE/38[POA-2LG]HD=Y'SD8'WBK' 2A0':?H"
M"?X5^3CXG>"EP[K$SV>H5%"SJIQ;,X#^WM:9LNFCTUB1B(GE4MZ2?WKSRKU5
MZKR[A/)O'=N6-7#J@ +EA#H,9])4V9/,RF>LDR.U>U_#FY%QHA8F3:7"VS)F
M Y^T$9X]9Q$?I-#A,5>$1$YX^_/E.?OX_EY_+[IK@W%<Q$QCY?>.IC]>*]&"
M/4"#P(@?Q[3[Q68 /A$7[HGZ*G*^WC_L_EK$<,B 8F>\_,3TG/?CWK(:09/2
M(SSGG^N_TKIO\,#+@5F[^=8K\T-KLDP04L3$(Q7K-QZWC,0;F]W<CTK[VP/V
MJU?W0B.Y1K%1?7O@_<*3>ZC9.3L=MOQ#9!RM;3@3$<'TF.9@9Y@^)_&RRWV.
MDWR<EAY]A1Q(4M)4V"<841)&9)R.W=R)<$;VN8Y&*JH]JJOT-Y>PS$=[_0UZ
MP4(GMZ8B_P#JKKWI34]!DX^1Y@\#^L\"OGE#A0(5GO/ZSGY_UQO4;,SMKFP4
M>C4<U0=R';\QZ#45KHRC7AXC,'^Z*<G 0L:^0A%56M3&7;STG/\ IV'MU'ZU
MD)?P2"H#N"8[R,_[Y]Z] ;UA6<O>UJ.3A7<<(Q'E8?U$:OEB-DN#,:U/(@2S
MA\>@1J8[C'I !(@@S,>D?FXC]V8'6I4O#:0(.Y)',G$J/),\&>D2.*XH]3F5
M@S/?S/IT-[70Z8\#%(ZL_P"K:6AB(RW&U6^%0&0R;B,B\N\ XY5$3CY!^+FI
M?C/%K[()*=/8;MH!G.7%D#YK /&$@GW^@/ -H&- 9<*0%73BGN,E.$IDS)
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MUQGK7O:1!P"))B>A/6#T)(4#UG$]<R!BJJ\MY1/*<*G\7"?G_;_GQ[><)U1
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M-B-AEORHZ'95A2!,,XXLR'ZJBENU'A?4;ZW7;Z<L*#3S3A9E.4N%+IZX"IX
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MTI32E-*4TI32E-*4TI32E-*4TI32E-*4TI32E-*4TI32E?"JB>57CW_R]_\
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M[HP J!R,&*WBK<:M8- *-N52X-JI4H3RLI&8!'I  @R2(%9L]IC.[&.Y9>Y
M6:*CE1\6A@@5LBOCW%3G-$*_%D4@AY<<\20XM=80ZIT>1',EA&:K?1$L=KV4
MU]U&J:A97%GM1OLV7EJR@;W-Z2%;,^E20D8R3)$#$^B6+J656JUY#RH4O_)
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M&%A8CY'RYVN>)ZE(YXW+KRFQ\1MOBZ\U)'D>:XVI:T-PR%83M4=Z^J@I*3/
MFO3KW17$+MRV4 O!E)"=RI4I)28Z2%8C=P(/-="MM-W\$W7HX]YB%[ LQO%&
M2='C2&F+5SC102BULSA$[9<;UD&5O''<U>/;6_LKUB_92_;K2XA0$J292%$
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MY+MR7:VRD6,QSBFM,!AS'"QXM$:$"'#6U8,95B2G2D!)+/1K7&D"F>@ 0"#
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M8V*SU@JY$?W/0;1^$1WID5'*]/;Z.WAONCO*M2SYS/\ 7]3GY5,0E4$J2G$
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M7D<1 QSF3WZ)R_N;.Q;9#JC?7(#SBB0K\(V20A&02'%I3O)!"@E:2-M;3<W
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M=M:+)?9M$)0&P!#;I!+;:B,D-I.]>1*@,Q*:QO(M0^MP$!3B@H@<R@"0)X!
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M.QS\3BS1DA'MFR 5MJ\0Y<APE.]-<8WJ.M:47;%MQUC\*=CB$@@#8LJ!]1)
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MO#DN'"JV6P^]?H4T>YKRHJ(CE:Q[>]$<O"W6S89NGV3 0"M$Y]:73O0H&3M
M X$" )ZU)<.AQAA0PL1O3G"HVS$2 .W!F8JUGQ FASCI>OLW@!7Y:[V^P3<$
M!QB>(:I7RL;MI!'R1$-'(\(8\URC<..57_0J.5R-2]0*=094?_/0UO5P/6CR
MR8$ ?D,@0.<"<P,9LG4#(9=<@&9#:MSJ!//Y8]63B">35E\>NH^=].&P^8^D
M^6R;A52*:1H(TCAX 0DF,>Y##DIR\TD:\->SEKNYGEKWQ7>XM6A !*5/L$21
MMV+4H9[G>@B<PG'6KK&/Q%\%2"XAIT<Y4IM05CB# ,< CH:J=M'*R_;W%LKL
M,=MHD<6)W%QCUI63V27/DRZJTE5,0=:P WF/.GF P4>$T#WR3/8HWL1Z\^_Z
M!XJ39Z);O70EI-NV0X"D9;;"2F,!16H';R1!@Q%>/:[X7-[JKJ;3_$4XJ02=
MJI(S)R($0)XG$U7?*Y>]_4+>28-G\Y0XU".H<AG"*YZB)ZG8M-7''^Z/8*_B
M/)?&]0<4[W1@E+)1[@<CKWCJZUMM;+!-GIPGSCM"'U03Z4.'!21MP1/.XQ /
M1Z%X-MM*=;>>2+F^!!90H$H0H@ [@#L($R"H'J> !6YW@L#Z:-LYF89#"%\G
M7)^%8YC(5&DW*\DFB(.%0Q&HQY#$E*CSWT]6.;!KF2W%<(KTJS>:J>=O'PVT
MC8ALE8W+29;ZON*1Z2KDA,0(R"<GT38BU;.\!;SB2#(F)&4I!'I /I '8$]:
MW_I'Z.<:P;!*[?S>BB!7;CY)<2,RP7$HK2!K<-9-65)@RYU8(D=DD<8LYK4K
M),CT^$#6#:ZQ9)CZK?.RP?VA*5D,,S&^Y\L2IU2S*F4D#:@ME(,2.]83+;CC
MH;92$J;"O-<Y#2U9::2<@[DY4,[8C&*@S<#*-W=\=P8W39F%_5UM=/R^GK,Y
MO:JN."3. %HK.+40@Q2-A_A[:L:63( Z>M.2>R)!LW.DC,)DK[&GL(8N[-ZX
M!6@J4V]"D-E284O<94H@=R28^]J';I1+3WD!32E%!;D))4<G:/1), 2,<B(K
MH]OKNGBW33LG^S.#.$F)[;T$>CIZ\;(+GY3D]JU@L;J6,B%9.')=8N219H>*
M$YX YDLGJ.:]ZX+RA=+;::6CR6U']IZ@XZHY6ZL*,$<I$@P)&,"I&FDE#EPX
ME*5OJ/E@9*$C (2<&3 )@]3[U5#9W8?>38S;N;OGN% J0Y69C,NHJ;\27Y^-
MD.;F2(.RR438KH-= J1W)K6; 0TZ0\XH\=XAO$4:W73J2\U;E!0A8"5C<?RM
M]"HG< LY!!Q&!&*C24K+A;6H[A"-W0IPH^Y)YF1_*#R8;GFY&<S=X[B;-OHF
M.-8-MY8.F.I6V+Y2X]45T9M@YBSZN+,N)<R<6 ,=9Z+Y\=C0F+& W:(<MKFX
M;LF&A;KNE-6[.XJA*$R77"XH[AB(]4$G'$UCK4\RA3A=+FQ*EQB=PRGC/$F#
MSU%=#^ES8/*\@SF)G5Y:R;DH&QX\8Y6 &&/!CJ[Y>'#B1 AAPH85>1PX\8(A
M-<1[U12$>]_JFFZ=;V2/+M@=BE!:G23YCA 2DJ*B2?S X$ \QD5Q6HZBJ[)6
M\J3 Q 2)S$0 #VP(_A7<JNC+#@Q8R^X L&OM[M3C[:W7'''U^^9.:T8X$\\]
MN<U[=*K32E-*4TI32E-*4TI5-]VMJHV*IE-Y!QUN5[4YLVP)NIMXV&^R6N-9
M-=^*YEC=4QKW2XDY'/D9ACL,7S,@J.R2G8ZS98Q+29#B-BFG4A;1!!0H2D@X
M((X&)$P8Z5&/-8=1<6KBK>X;4%MOMDI<;7,A:5)A4[@"0")BN+^X.TF4=)&9
MUNZ.W\C]L]B+H[9=-?!D+.#45]WZ"%QC*Y(6E<VNL!LBLJ\F:,@"2(E4>;Q9
MP%C6OD/C?P,BXLGQ;MK79N*+[(2F';2X)&UP0D*<;"L$<%!.X1(KZ0\/>.;/
MX@:7::1K#[5EXLL&DIM+QU"$,ZML24)96XK_  GAC8F/63Q*JK/G5CAD[,+.
MPPE\T5#<233XE;:1'0+"LE.>GXG6O!WD"\,26YQ81HIC@/62(,H+W1Y 2D^?
M'].OM-4+>]$+;*DAQ)"T.)F00I/IR/R ^J J/RD#&4'&7G;6X0MJZ944/MK2
MH;5H,+.Z-I"I3ZL',C%>>"7V\^?M^2_FB?E]O;RO^>H>>D^W^QJOIZ@3) '!
M]MT=<?*MNARQL1JN<C>.5X7Q_E]^/''">4YX\ZB5S R2!/4SQ'7[3_*I4!9'
M  XQ&8C[Q,B3C'L:V2*<Y^U1KZ(DY3U%:CBO1?"*QKOI8U/'#GM<JK_PHFK:
MO@(Y *@8(/'?@B>,?6M@#)EPF/.I R0C17.:5/1-[\<#()A!D<JKVL&H!JYW
M:G?RJ<7A4 =><#!!Z?/[?6KPEMWT243!.PXSDSC']?(['$//D!;Z\"N<,B(Y
M8LF01[F*OLUZI",+O\>41'M14Y1ZKYU>K=$[<>Y!'\.D=P9Z$9,DH0=@>>)Y
M_)M^7J&1P<X^8BH7R0UEN]D<O9FG#^#X3#^6E[O7M,*PAQI>-S8\X47 :3)H
M$NGEP\TR,[8\V:2I&:1C&$M-;2I57;9/@YI6XLDHLV4:FZ&_-"B-,8.Q2B^T
MI!-\^RI"TKM&#Z6TN0FXNP$I2XU;W0&'>.^8M-DRMX@I_P"<>4I?I:<0L&V;
M<"DJ2Z^,K*22TP2=R5O,FK:!-18S0Q*R.2#CE/7PXM13QH88T2-7QHP1Q*ZM
MJ8#!(!K8X1BCP*^+%>UK&# &.YB-'K7K6X\M2W%%94M2W'7%C<5*DJ<<6Y)4
M2HR2?429F9J@*60@!*=B("40-H0 (2$\0($#@8$"!6ES<S=#,'&L?B6R6<V5
MZ :NOCK89O<3Y/+D5T9P9HL=?)<J/))N(L_)FC170,(E!:R2+<:)X?U/6GO)
MT^WF)4NY=0LVR4@@;@H>IQ2ID!$($>LP0##>Z@ DW+KK=NA*0D/.* 2E(&4B
M20KTY""%$D>D2)%AL"Z:AP8E;F_4<9M-2I/:3%]H*4DRRL+>ZG(Y&BMAPB3[
MG(\DM$_=R(H)%Q>V $4$JRK:@DK&H_T3X0^'>G: AJ[OD_C+_P O]H\ZN09E
M6U*3A"$E4I2D")X)))\OUOQ@7%.6>B[VAD?CG)#MPA6"&6C*D("@H!6[)W<)
MA(Z183L[99HE5:[D4P,;P:H=!D8?LW'^42.UM>J/K)^XC:YQ*R8:$HXQJO"J
MTI\?IC &>SD7D\41E1W[CV](0D!+:3Z4@R !B!]O;M$5Q*$**E..JWN+DJ6>
M5%4D[CR3G)ZG(/>V:(B(B(B(B)PB)X1$3V1$^R)J&IJ:4II2FE*:4II2FE*:
M4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4K$W
MEY4XW52[J\L8E35P6-)*GSCBC1@-<1@V>H8SF#:I"/8-B.<G<][6IY5-6..(
M:0IQ:@E*1)), 9@9]R0![FKDI4M00@%2C,) ))@28 DF!DP.*Y2=1?4!?76X
M6(UDZ%<X-BD 5O&)\K:8WDT^VG2DD>B61CK VU%((&/7>NRIFF+;>B19M.)T
ML;1R."U;6UJU&WMG%KL[4MNA:V_)NBHF-KCR!*6TISR-P*@1,5UFG:8ANSN7
MT['[C:T4;D+;"%*F6]Y'I48 P4E0QP*JAC6*5<O(<GG8WEGRM=61(,\]25^7
MTSGQ3R)0UF5CZUWXDP+2B7Y^DF,D5\"01LZKGC;.DU\;D;MZYT^X\O3K];Z+
ME"G@MA0W+5O!4'DMQZA(,J!)DB9KH[9I.I)_YFTVOH(;&YM 2 E(PE1P1S"L
M$C$S->*;NZS$\O-MW8XJ[+20"0<DH!KET^(EO#M^^V=W6$ZEGS;>"*;(D$$\
MS:^?%<<D&:,C0"*^33=-OM8%VM-X$W+KBT7*'1^U4$I3M6E1R$H'I.8(';B^
MXOTZ0"T&=J @#<!"DR=OIYB(Y'4\3-9FDV4LL@SG)MZL*-(K:K))TN?EV.6E
MY-QZ^QG(']DZTK#OJZZSCW%<19*3*FV@^C/^1EBBD:U <LP#J&K:"I>GIN5M
M.[]P4D(+*R!"7&I@@J3 48!DGD<0*;L]1;0\I""I12H%Q4*!P)()P<3SGGM5
MC]I,QQ,\*PV%R)TC'\PERK:PQ:=.8DUETRWG2[)9(Y QAC2I$&08C_FFM8LD
M#&RCN:=+&-$Q$ WBWEW*DHNG5J6+A:1EU4?LGQF [)VJZ3@YSDK0JV6VMD[[
M=H)4ZRD^H\2$G!(X ,X%5_W,W=)T>Y,>YM:>5=PLZG3L;RK;Y@@2SW4HL<I
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MD5",:K7(G#W-E<,*5YS:VB/W7&ELGM^5:4R)Q*=R>FXD$#8"XVDB%I@P1M4
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MT;V6UI "RG@U\EIIX9$1AI$8[C,%YWXCUERXLXM%!5F?*<_\,\5J2T[#BE7
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MU458VO%OAIQ)6-8M_3$ N*3(.!'I^4#$$"/;87'P=^)MNK8YX.OEB)"VTM.
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M$-M9*W09C>X<CA0!@@9JA-),%O)U 6F9=WSVV/3<^108Q)[E6MO]T+!A%O\
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M;@838'Z>]PQ1S18LB.#',ABQY5GBXI@G!FUU<:6$EK1&]%Q!0#-?*AP2(Q\
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MV+'U_KMCPD66P@A,.0!Q,Q6_%*;E\6UM:*#Z7/+=#[R&FD*Q.UP(7YA2#.T
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M>(;-SS2O<VEG+SD!QMJ2  I:3^](((3 '.<5KEZ-=I*!^S)<_P ,!>5 S'0
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MI!4#*2E0(.Z!CF(KP,ZZA3*BZOJ[&Z1T6NG1"0*F5?3$O+2A&YS;:6UD>E-
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M&M-&B11QY149)E2P.,]8RJT+GR10ZVWB078<4TPAM ;662\^E)=>;!*T!0]
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M%O;,-..I"%O/(9EQ14VCT@J<24F%(*CM"C@Q(P:B4N^>2SLKMPY=;LS*# I
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M.>==7+EZ%A#UW= BWPE32W'?+(&T8#9A9CYD0:RDVP8L@LK2XVPD)'4N)X)
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M8=/$G19M?)*LR8\A_E)$!@G'.4*,EM;IA@/H?2P\G;Y3*U[AZPI0+B$\^6L
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MU? ^LW"G75(GTI! ' P,' $GJ#R#)YXO4E?$1O8@&(WCCM1$XX_+^6MM '
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M+MA6L+5:MA0;L_PMR^0/+2^'E*@QRLIV@J@J.!7H&@6UT+!"EA>PNE;9DX1
M)2F8@'. 8SUG-2,;Q_)\JV^RX0%%,^0I*:CJY_?$C3,J9&NL5NAU%<,B\S;B
MKQR+=5<IP>ULAUQ'!&5I+,\<&LU35$735@E+$/V@>\Y<>@-);2TV7!@E0*=P
M)_>S&9K8V=DZTZ^M.[RG1O:3T94J275#(VJ),<"#TS6'V_HLBS&@S6'!?!($
M6,2H]'<&="AE/-LY<>5&Q4:S$:.3=Q0 DMBJK4;'ASX0I+0O/W'K>:FE^QL6
M/(:5<VMR%J<2A.;0-*+9<,2I(\Q/I)B #&*M9L7$7+RT!Q;;B2I8W$[70#M
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M&XQBM'N1+LPUMG6XW5R<F4"F87&+8Y+4E(Y92L0-M2O2=#Q:<+M[?GV!"HI
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M*=KA-_><-7+1XML#^;S /_0/M[_/ ^F1"O07A(2II4$\N'/0$C$>\<< \BI
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M[SF09BF].99$/J@PG'<8BG;2[/7UHRJ;>%>U<NR5\ZEF7)[ P6C;Z4CDT.K
M)JO"*)(M L=*57"NT6S:U5-Z;AQI-Q<6P%N%"8<1) Y(*CR !TB*CU2_=0ZS
M<-M#;N0%I$_D4!DCH)/)CDP<BL_U(;DV^/9_LG$P>'-6#'M,1W8M39%)0S[&
M[DTSI%%BI#QF":*!$J;&8(QN4-,GR N9VNKXZ%CTNS&HW%U;7BT-*:MUVK(2
MH!#EQN(#I)P$F " "!N'6!4U]J#H99<0T) !  G&"20!S]/8&9K!]6N6SY%I
MMEB.)AN*ZLN@X7NA>75U)$<B3;:JNA8_C33":(;8-3VL%8/(O_2+[&)%<K0C
M5I:Z6RB[U!=O?E 0P7[12]P WH]"' 9 C<8$<D =*IJ-^\Y:-NLB'$Y0-I&U
ML&2"(,$C'MTBLYU9YU8V6T^,P*Z%9U]SNPT1LXE'F(6NH*^AR]L6?749&M^8
M#&L[Z"22DF4]Q(5.QP'.[SE(RMK:I&K#3+TH6Q8O^4XX2 2')+:@>"G*9,1$
M]:N=U%QW3TJ;9 "4B$\J*\;C'.<P1S/7IZM_]S+B1T\U$P,&PC9MN:"9B^2R
MA2$?34%3CUAB]CD=I1C$WY@)KMEC7RH;"E(VJ"^R],CWQHA'6KM1;ZPWIMVX
MC\+;K0HK$*"FW'-R GI!! 69Q)$YJTZ@X_I@"&@#Y:TYP=X2KF<\C (S.>E9
M0>;W&)=*3KO\-D3,PQ&GA81B@H<GNH)D.XI+859?RXC6K(?-K:F'- X$8JBL
M)(81W<-/);J;5;/\%J8LM[3MK=+#^Y/I\IN4*V ]0($<R20!R#99ZB\[8NI#
M8#B2M"BH02I"$"([YX,$8X)BHWM\VMW=&U>R%66!<MXA[,PK&#.4]8S'HF(G
MLX>2 "B.E+='HZ$6/O1IG#)8_P#2R*A50+8[RU;L]43:[VE62O)O H@E1:6I
M(V \0DA4B>N0*OM]1>N-/<1M""%*0H$9E 0J<]/5(/V.<^G+KVZMND@-5!KT
MEY"0F/[=GMH4M[X\C"8];)M8+P0N>T=O)%C+<?EO8]&E$)Q>P4DI'#EOK=JR
MU:V8WI<L'EJO$E!"4E*UD*2Z.H0 3S!..]1L7S[]@ZT1M<02,XW$<$2).(F
M3@1%>?<.PR_/^F/&JD8X#[%V<5])DMT,4F+.OH.-T\2]P^%=,+WAC2FV<6:V
MQ9Z 7RI%'"G'9Z[3*^.[%O8ZTVMBX#ULE"+ME,#:E2EKW)^0$B)P(&*M;>N+
MFP4VZI04A7D)3F2G@J Y($C(^L\UL>2X9FVZ/3/&Q1I+^>#;G-:"3/C%B+,L
M*F ^DFNKX<UT9"%LX-!*'!FPV(:2V+5707,>&(,+8\=]=65KK-O?::2V'F=Q
M:D$!?_FI5G&_CI\Y$58PBX7;+M[DY3+4@$$I(_9E,Q.WJ9/TFMI@].60[E[
MX793(L62S;[*,IA8U')92 1;C%\B#C;[-U)(.B)&?'R6D_W ,@X&!*DU8\MJ
M- \N%=W[:M15=VS190\!@80T\A(7YB3!!6"02D$>P,U(VUL9\A:O,4!(2>B8
M.5 00%"2)B<5/NW>RN-9UT^W%C:VDTU=#S!+#'"C+%9;X_+I:P-1(99ND1B
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M5NNH&BS*^Z<\%S2S?@+*^L(.3/@,/EV*QKV&5TJ@;;N1?DIS8!0L$4,<<J-
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M" ,C!G*M)(M1M5%([UO38UXSH-KLAJX*'$D$9C.('W(^QGVYQ%;NK;N&U%9
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M!ID/(RI\[FD.K05H=0HIP%)2P5^61SP.8ZD'@"KKG:T@J4@%;92L P2A;B@
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M$%XE1I'J+$G":KQ1S(Q!/2+,J_F;+AQXK:WF6D)"&ED'S%%)*I<,25IR K,
MI@YJ:R2RA"VD!2?,)*PHRG<1^X.A'()B!(!Q4);2VN1[.;J9#$P\SNZJF-..
MG(94B9!BT]C+"NA%<Y'#;+C0I:1HTP@G-9*"5AFDC%,U<U#K@2EUI6US'J(D
M8Q!P9!S/(B>2,:YYMOS%,+ +6_@2)$DPDB""#$9DX$P3/02QK\?W)QMFX>!\
M@07=^-52#0<_'[!KG_.,+%<[O'$0RD!+BD>\<,_K=Q$AR)%H2RXMT/-FZM&U
M) /_ #END9#A_,XR9]+"B"0)!2=Q( @F2VN"RK\+<D.E:CY+JI*5-\!*N@=
M@1@'!!F0* [I[Q[D=/&34VW^U)(,5=RH$^SL,,LX3K.LQ4Z2@)#R;&H?K";
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M9?6]$S' 5.SER)Z;D>-51ZZJ(',B8Z$1'OVDQ]N:R[2X\J0M *DX&])*!'/
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M)Q_=QOK4R-L_NS[F.>W7^/$ 5W=TG:VS'5+?7N!Q$=#[_:9[@:RJPZ_)G_\
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M1S2TCRHS1Q3.=*:R9U*+>V*$J#CERTIH%!!2EQ;B51)C  ]1@XD15BH6\AQ
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MDY& -HY.[(-1[N/U&87_ +=-L8?X=E$^NP?>*189;D$^I%!0M<RDL\;D%DL
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M*UHG#9.PVFY??N)\IIU3[C94208:4$A4 E.X@!/7J35A<;:MK9I"PIQ&U"B
MJ%*,!)1(B)Y)V@3D1%;#UH;]X5.P6=4T3Y\VVRK:W'FXS118ZS',BVKZJ;5R
MS'<".T8)-:+YQ4E6BR/28-KH@SD5'1H2+FX*Q(;0&TDGF?*2-P':4D3.!D">
M+@4M,0XJ5_B%O$)'I4E;@A,_HKTX!.2)G8.ICJ*Q&!@F.G2CRHA<\VG.7&J4
M-9$**O@7^*FJ*R2^69T9(=G,D2&-M*\\TTN##C <>.CI 6NK'GWB]HA"5,()
M5@J2C<"M!_>09@$P9Z0*HB&+12 KU*4I6]!(*@I05#F,>7P!'4DQ !_C'^HS
M :CI=V)L+5UC7/JHWX+85Z1"&F6&1XG7Q8&1Q@P_EI9P+ GH%@T?)A1BMEQR
M,D%&]5:NDRMJU:.XVQN%*4)@BX6HH@\R /4(@="15;<(0JZ4M:%%]MM*83!!
M&\G>>LX@SB#C.?C'^H[;^FZ6MB[&U2TKVU+P8_8UC0/D3)N04-1$;D,5(S(T
MEPW0"&B^B1\N%#DBL8AQF(QSA,M?"E%NU0)<83<[S((/F.A8*9Z1/3!$"0,T
M:V(-P\%#_F&V@V.J?+4Y.X3.21!S[P<C1M@-]ZVCZ/YM?<8]?09^!9BS\42#
M&*0TTF1VT^RHVJR(5D,T):UJA.8E@( )4%!'&JECC/)=D HLV"GU*0Z%G\@*
MK=*5"0/SS@8SF15&%)2\;E;A5^R6V&T@21)[P8$G)^D<UD.GG<[/<OV3WLAU
M& Q; V,;@Y/FN"09ED&*I';AWII#&2K)4#70#8L.1-D%'*80<P\JOCQI3)'<
MX:Y2@^6TT0&VO+N75@20YO0TH$D&$E*9/L1[494$+#H'[1Q'EA&9(2XM4<Y&
MTP(CW$":Q'3!)ZAP;D;V8W<Q<?JF[D8M<;@38;T)'K*ZYKJ2#1X_,0\2?9EM
M*BT?$:R[6L,&<DN'+EB*)ZR NL?4E;#+=L"5%+C3Q) +S0)?"E;22D-JD(,*
M( G )FB@$N%Q8A8*%-(GTM;QY:0#SO"AD'!$"9K+;!;9;JMWCSBIW%SR0U-P
MML\O8C,:EHUBS\7@U=#"?0I-KX3:BYH(=O%/"EBCE(=QHCI*R$$YT:T)1<!+
M%NA25MI+J2I9AP-@*0@B()W# Z"#S J]Y3C>YUWD[!"1E(4H J$QF#)[G,\B
ML?MILOA6SO4!M=92IEI?0[S)KFHD2\C0)K =V2ADQH$B2<(8SS)91;,@Q1I#
M3N0D8SO6DC<HF50Z+I*&WD!3*_+6H#!05)(4H'D0LS(R8,]*ONK?R-\*E8;]
M)GF"5'C]X 0,=4R02:W;=ZBHME\EK,_H,=I: VW^>T\VW=C]; JW.QRQFOH[
MIKFUT:,KE^8/"(%D@2J$<F0K"N81ROL2%M/.M%PJ-N24%4;_ #6BE:$$\D1F
M8F. :JM*'&6EI!"5M$J(C>9'S@D*B1/'Z?SU<Y"RICGS'&G-(M=GV&9;")Z:
MLX,*3,4@$:JKWB]>8H6OX[2A1..6.Y2XE+MZXI!E"DNK'02I 6M)@X 7,?PX
M%5"%(L;?SAZFTA"MIF4;T%78R4XG_-$^\S[]E2WH(N;T;D(MQC5)G=2YA'+Z
MLRF=!R>-Z07*1JO+8TA!*L<OU(?A6?O.XB\S<I=5CSV6GTQP2D .QV.\# YG
MGFJ6>;4M&%!IQUL#D[ F4YB8.Z,C.<]:TGJZ$.\P&YRFJ>CVS,5QW/ZHC3.5
M%-5%J<B<48B-51HYL6<U7 (O<U[VHU.55:O@?BE.<(=#+V>9* AR23&TD9]^
M?>EJ9LTI,[FRXTH$<%*RH#!/*2(R)]HKZ^KY[+W:>UR."UKF6N 8[E44G)FM
M5\!*&V=(1'.(%%8RND$50O1R*G#GNX[UON9%TA0SYK32\@]4%!GGC: 9_3I2
MVDVBT$X;NG$>\DE4_(B ,YC'05 ^27@<MZ@>F: -&.BR,KQK)BL ]%&XE@6
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MY3VRG,DM5_"]YGKWJJKW$CO,21)/^Y'0_P @>L*W]H*4-E2T]4C=/'7/>.!
M[],D,X\"SS%\ICN(V#:D)B=PKU1S&-LE8^G,]W"*OI3Q-C-(]SG?[^555>[Q
M<4A)D#!/)'Z'^?&9Q6&S<+\W>O"LC$$@=S/N/Y&37];JP[ZZ()U$XCXCCE=+
M" J!(]SO3]%557,[AM1"(K$<J=RHY6KQRER=N),1D<]X/ /2)$<#WBLNV=80
MZZIU((5!2I92$D9!@@R0#$XZ#-5YW:W>PC8G;4&3;AY?6Q;;%+2+?0:AEC&D
MWLX83M8:HK833?,S)4F*60%H1H[ZB=G<C&*J%08*<@8D<=9F8/4=,DGFK2RN
M\N@+5K<DI@;02-P,DDP>F#V',55_..OS8.78-ML"PC<?<JSFH*4T5;3FIZDY
MR"1Z)+-;)&>-S7=K#M$Q[>_N56N1%59FV'73^Q05=@D*).1W'7$Q/'0&MFWI
M^I)0IMY3%NB"%+<CS "?>3/ZQ4)[L[]=275'AEGMS!VCK=OL0NR0?G9YY\BX
MOW184H4MHHPV0XT6*4I #:KT4JC9ZC6JBJUZ;%'AJ_O&G$.6RVTNI@ET[$GF
M""1!!P1R.X,5E:-?Z?X;U:PU9-_YUUIUVS=(\K(+S"]P"\IVC)00"00.9S53
MJ2PS/;G<44.,^927.3DCT5B;YM]>^LRJH;\N<CV$"5CG6D- RXW=Z;B,43F$
M<CD:O%>'K866N7.AZ@%,@NN--$Q!6@CDJ@@+3!08E5?8/QGTZS\=?#KP]\0]
M*;3??A+5MVZ 3YH_"7* I87Y>Y8%H\%H) .Q4\R371W'NE#=/<JNC6]]O!N/
M/%,[)"Q8V76T2*-RHG:UHJHD5J(Q%5$XXY:GEO/.O8;?PSIL J<W8)4 H)C&
M#(S]IGVX'PTYJZFW%AFQMT03(\C<>8_,21^F1,9%929\.*%/;S:V=W><O0KV
M7MC=6XWE:O*$>V>4Z.>GV>[E?*\+PJZRAX<TN,;E0./-Z<G! !XF>9Y]J(\0
M:BV0II+;:AP4VR,=#TR""1!'\<?=(Z"4#''%C"@A$)C1B8QLV.J-8U$:G(I
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M>TC6GC2&$"5K2,81J$8Y$>QKD1'-144KV:4II2FE*:4II2OY<G+5_E_S]_\
MG]=4C^NW.1[YI7)C=*HK+S'*6%<U4"XBV65Y2::.SB5$YIS'RZ<$AW?.&=*0
MQ JHU,(;B>FB->YG:C4\'UP$WCCQ*E.KN;O>M1E1\IY24S\DI2D=@(S7J^DH
M3^&4G:G:ABV4@!*B$E5LTLGTI(RM1)D@ G!$S4!['5M-,Z1ZM_X-6G%;9IF;
M;)DF%3R&3?PRYLZ^$^4VP*BE?%CPP C$['R A8UHD:-%=K#?2!;-NR0ZJ[E2
MTP"I)8"0DDDY!]1]\1-9+"0N]4VH';^%*H& "5J"C YDI/W&,5Y=A2U=3M_U
M$556,=8.KW@M:ZNAPU"#L  <1C@Q1KY:$0G!$Y@448QM8U$:SA=-Z!;.R?VB
MDVZFRHA12DK7N2/D%'(@$#@=;F0H7C!* 6@IW>DY$D<GOB<9P/D#]_3R6GM<
M]ZK946L@N)40<)Q]2+%J^YY!@CUV0#5LL@(SAS["/+=.[G>E->B/D=Q?2:ZU
M+07:W"U##;0=:29.Q6]*29Q,@G& )C.*L60;FWC@W*TE.2"$MK5P 28@0<F<
MYK:=E\9QVKR7>J764%1#DGV^P=Q5BP*4+'+8W^519[/3<84)HYL:#%%-&UZ
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MN@TG5;AM]MM3A+;JDI,CF4@_O@[=I)$ YZG@CK1M-/QFRQJ-+QP$8 2#8Y6
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MG"*B9-V0K4+R<I#K))QA0)1 ]O1C'))QS45N@(TRWP KRP3VDN!23[R"9GH
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M:V.UB*UG8TSD];CN<KG)PK415O2F9R)C@Y[1_OTZ9R!F)LU/H<6IV$22(@=
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M8^3XZ"S4@! 82XH)<:UB*%I.Z,5CB.:_Z4R6;%A3BPZZI]QLI\P*43M*D[D
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M8ZWE-O*:#B86M>Z2 3M$ $D3B (D#J>:Z0=->"NV\I=U*J2K&%D8=BLPB.?
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M4Z^%(KD5G$CH'X"S!R/Q5P!P8R%=?<GDCIP*MM0?QUW&!^&9GD3)5W[DD\P
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M$LSY54'^%_A1Y#G#4+40R]BZF]:>4_:M!A]3PMTLOA+"]OF,*4VV 01D(@3
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M_J-=&EQE8Q8XF,4N7O4H05%2<  Y VX$3,''(R>M<]YSRRI06H-H.029B/\
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M:+M/CV]LK-\UR?*JF@EW-U97%A=S)-0 84MWVA9DZ3'CHQ@"NC!(HPB,U1(
M3&J,9E^9UT%JQ;VUL+4-(<:2G:J4@^8H ["J!!,D;3F"?G6IO?$+ZEAU*@EQ
M1/I' *HD@3R9YP9B>*N#59[O]M-;6MOB55@=[&RJMCU=WCUS43@UA2P\KS2%
M4]DFHL*^Q<>-+K Q1D>485A%"^1$DS1*0NIU/0[._(4"JR(2 H6Z4CS4).XI
M6F E0ZG<"!$CBI-.\87=O =2ET()4@J)*DSU229ZYC@34"8-U+]8V/;CYCDL
M?#MO[.KRZDQ^-*Q"=3W+,>BU81OL<>C5TJ+;BN6G')MIAC.E6<QI'37(59*
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MHCD&CCJ(@%<8(V#3@/:H3*JC.JL5O#8<*$]",]?:#&.I,=:R'5.MRM;1]2R
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M@<GF#!YY'UG.!VJ&XT4L*2NT="@@ J22#/<<@R8R#'>,5,6TN:[3W-JDZAW
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MPW;:A=KZK=<\IM0ZJ&TJ45$\ @8)ZC.\1:>(W0"Z_96PYVMH"R!VF   .1W
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MYK!R'C<G< AD5$;-AG8&=!<Y>>&2P![T1%8Q[5:Y9[A"/4S>-*;(3Z@M,".
M=R@4*^8)!X$X-+=UUN+BT?\ ,&X%*VW-KJ5 C:83)29())"8[B<9I.G/#KXJ
MS*F/CTL<A6N22R' .Q5^GM4G:)58Y&HWRY.$X\ISK5*\/:8LAP6ELI2S^;R6
MRK,XF02.?W<X/05US'Q \5VS/DM^(=80D #RDZA<@@@?E]*P -LF)]B*W&#T
MLR457M=" AFM[EBQHXO4:B?2KO3&U'(G*\<JO"+X7CG4J=$M6Y"+9E(B%0TV
MD>T&#/S$^YS6MN/%NK7) ?U.^?4%;B'+VX/K.5;I<.<8P.L>U>^HKI+/1X#D
M674\5A)6/U\B[-&C 8C9(JP3I;RL -B-2=%8%TF)(8Q"^H- N<HB/:O(>+_"
M%O<:9<WELREN\M6UO-;0D!24 J7N'I&!) B3GK$^Z_!/XS:WI'BO2-$U74;B
M[TC5KMBP+=RZI_\ "N/J#33K9=5*6T+*=P28()'7%5^G7+78QOK9PQO40+F5
M2V[6)X;ZEC!&IE1OCA7N8BKSQQQPJ)]^7^&=RM NVDGTH>:4D$P2IP03'0$[
MB >GR KT3^UAIK3EQX9U$#<]<Z;<VJUP 5-VS[7ED@==BU2#D0<37Z&*63\W
M60Y'/*$ -_/''AS&N_[_ .7'Y)QKW@*!$@XY_KK7PLL$*(/,GMWY/;ZUD2-1
MPWM7CA6KSRB*BI]TX7QY3QJO^ACY]/UJB" M)4"4A0D#F)S'OV]Z_-AEU#(D
M;]754]A(IAVF8*T)$1BH1F?V#[%CD151'KZH'N1%5W;Y=Q]OG_PZ /%FM-*2
ME*FUW"0-I2HE+_K@* )@=1((,C=7WW\7W'W?@QX N&7"Y:AG3U72P=R2K^[T
M)MU+4#'J*#M]TD'.!WFV+I T^#TXAM:USH@G.[43E7(-J<JJ??GN_+VXXU[K
M9HV,I&.$G!YP3T,\GD\\&O@^_<W/F8F3USGOTS'WKT;\N:W;/(%5?_0*B?ER
MK7?]_P#WZG=/H($<S] "3SV$U;;_ .*C&"DCZD%('U*H'SGI4M="/_SMA_2.
MQ%_L&B+_ )Z\P3 <>CJI<9__ #/] /M7J;W#7_I1C_\ MG[?+WKHUJ^H:X#[
M'?&@O,YWV@X#N+MOMA0[?VF9]9.+R)N,97NHNXV&UO22_=24;(;:!F>TF-[6
M9X7.:W:V2L+$MK-T\GS"H??1K"?3)6X]ESZ15Y1 F3PD\"/5'O/6.,U=R@^*
M1TS7>*SLQDUV\&*U,3:[97>J*+,MLK7'+2YVNZA=X+#9+:/,*FJFR?GBUV6Y
M?7%EQ12PPYH,;+%NI,40SM"C^OZ^U6[3GV)!SU&3_0K0]X_BI;>XGM;GFY6U
M.UV[^X5/@^ZVV.W</+K#:[.ZG:W<>/D/5Q@G2AN4;:W/(%-9PLLR/!\GR>[=
M28LH:^WSR90$DXA%N\9;.OH:JA)F#C!/3_*5"?F.O2<YQ6[S?B-8'7;>9-U(
MVF+9!CO2QMGCV[5!O+E64U<^CW2VVZ@=MM\</V4C;07&!R6K5^G:6MGF![#+
M&9,[',>;CL.QO+6MQVS;<,52#,=<1[@B9GY1CG/>KA;#[VX?U$[68SN]@4>^
MBXME7XLVN#DE8RLLT=2W5A0S"-2-*L:JRKRSJR06JOJ"UN,=OJU\6VH[>QK9
M<>415*E_2E-*4TI48;U;I56R6T^X&[=Y7V%M3[>XQ99195M5\NEE-B5@5,6/
M"668$5)!&IP-3F&)%\O>B:FMV57+[3"5)2IY:6TJ482%*,"3T$\FH+E]-K;O
M7"PI2&4%Q03E12G)@=XKD:OQSMCD3G_8KNXO_P#-X2B+_?D'_/ZZZ=/@[42<
M/6Q'_2I2NI[#^O>:Y3_C;3.C-Q]DCMU)B<\5_"_'-V/<B_\ D5W;1$]_][PE
MWO\ _P!?X3QSPJ_^.JGP;J(B7K<9 R5B9_\ E,^\<8I_QKIA.6;B )G:E1$$
M< $])^H&#TJ)OQ\7+ISSO($BX_L5GF+9)E%&.JWHW/@"PB'N$/8> ^5,M,)H
MLGAW*6%=,S6RBBH0RWRP.JJ']IK6J,.YKJU[('/"]ZVX6U/VQAI3BU J*4I0
M/WB42"HR$8]1!F(K8H\>)>TYJS4[J']W"\2JWLUK4;8WKJ0E3J;8J\L.;5;5
M. ;HV@X@"I5#UM=-]U;X"V^V4SB.MKMSNM?74.K'B,00+;-LSP.3C]96B_%A
M("CPC *3', IHY/2*"IQZM$P2(UZZC'A&[>"$%ZV!<:#PDQ"5&!.1"@" 0!
MSD\B,^+[!A+BU-/J#+WDE)2,.!))(P83Z3&0>..*P4[<GHPFR22'[0;K<E?W
MKQ+Q/E%5>?9;KV]E7SJ\^!+P8_$6<B1^94&.PW=?Y9 Q5/\ CW3(S9NSUE#?
M;,>GOU)GO7IJ]S>B*M]14V5W34CO"JR1B2*J\\HKE2[3GSY^_/W]]6#P+?$8
M>M3['S<R3QT/O@=J'X@V"S'X=TCD>EN9[",2?XXSUB;=[<+I!M8V'LKMI]SH
M('[G;?FN'296,+ZM5"R.)/?$!Z5R[_>)4V/!CL4JL"UI7N(_A&M6USP1>LE&
MYVV]3J6I"5D!:\)F<Q,"8^?))D;\;6%QOVVCY*&EO*'EM@E#1!6$G;G$QT(!
M^1EFKW*Z(:\ZR';+;IE>J+]39&(=Z\HB^7?C:.5.$1%Y<OA/?CWO_P"!+R3%
MQ9C)23ZTCTF.?K('7,\15H\?Z>H;3;O!"8*$^6T  >)("?5C(S,F28,_S8[G
M=%<XSBMV>W69RG\/S>*>/TY2[7S^B\)SYYU7_@6] _\ $VA^2EG_ /F$_:K5
M>/=,$3:NGD92T<?KCB>N*^B!N'T20Y3))ME]TSO;QPY96(J]./'"._&_'A53
MGN]O;C5/^!KTX#]L3[>;@GW"B!C.:M_X_P!,X%H[\MC4$^^)Z#^/S]5GNET5
MV)>6[,[K"3RC4^<Q-$X^W/%V[N^WM^:KJW_@.^.2_;B(S+D?QQ@9P,U4>/=-
M!*C9NE')PT , 9D@>^/XX'@C9_T2@.,QME]TS]OE.^5A[E3\N.Z[Y;^O"I[<
M\*O.JGP'>]7[? QEP1'!YZ]3_M51\0=-]03;.A*SZMJ&E2G_ .4$D^Y,#H<U
ME[3=;HIGM:P>S&ZH&M3V^;Q%%5>.$_AO514_GY555?U6@\#7IQ^(M@3,9< S
M[X@^YJG_ ![I@_\ 8W8]D-QSCD"![]/I6"9N!T4*]CI&S&ZA6L7N1KI6(/1%
M]O9;OCRG/LOY:J/ E[_\3;&#QO<,_P#Z@2.O$4'Q!TT$[+5P'B4AE2@,<!.3
M/L,#G(K8IVZ_11*CB"/9?=42-:U/JEXDB<(B)XXO41.?R3_+A.'_  )?$9N+
M4 _]3@^\E(^GMQS5#X_T\G_PK\SSY:8,8'.(_C6N?M[T5O5$+LYNF5J.159\
MWB3VN1/S:ZY[55?LBK[<\+H/ =Z)(?M?;U.'Z2DX.>PJX>/]/$*%J\E0G/EM
MD9&<$$]>!UYK9";M]$Z0&00;)[K!1&HBJDK$6-_L[+WPGZ*G'Z??5?\ @2_Q
M#UM&/R^:8]OZ[\U0^/M.))%LZ"<G]DD9/,8C/8#Z5KB[A=%HNX@MDMRY)5Y^
MF3.Q037+[\*0=E(<G*K]2N8OA?'.JI\!7L^IRWCJ '.H'<QW^4GO%/\ [0-/
M E-JZ5CB4M ^^,$<<1Q'.)]8NH/IMI(;H^/=,DJ07SP6\S&(%B(J=O<K(%%)
M?[>[>_SQ_%[\9B/ "O\ S+IL3@;6E$C'NG.,<GCF*QG?B&V2%(M' L=7'0@0
M)B-JE8QC"1T(%>.KWDRS)U>_;#IRV]A#1[ALGEK;W(5"5B\HU9$FQJ*]2-3P
M]K@OX\\M:BIQI=68\$^&%;->U]IA_9N#"24N[1)*BV@$QS(,'B(-9MAJWBW7
MT%W1=%4^U(!N-VYI*B1@+4H;HZQ(R9Z3(U9B?6EFC5 +(XV!5QT5JQ\<!2XR
M0;'\HC62,:KEMT\(UJ>I9JJ<(JN5RJYW%77Q<^%VCA0M+6_U=P3#B&2$*,9'
MF*7 !&02([Q72,> ?B-JY"KNZLM.;)$I#Q\U([A"<DB<@>X)-;91] -I=S6W
M&X^=VEU.(O=(.\YI4TO=QRCK&T)/F.YX_-JJJHGLGCB]2_M%W@*FM!T&RL&P
M3Y3EP/-=3T"I:'E29&%*D#IR:ZBP^!C"EAS7-;N+QPG<I*=S:=HB4[E',\0!
MGD'I5K< Z-MFL:415I84PX>WNFV[GV!>Y%Y[VMEJ5C7+]O3&Q$5.$1%5>?+M
M6^)OC?7UN"\\0.-,.$@LVJC;)VJP4D(RK:,?F$9Z8'H>G?#OPAHH0;?1[=Y]
M$$// /K44]2EP% /,DCI5L*+%=L<7",;*\DYP4:C(\( HL=O;Y1O>J-5&\I_
MZ-WM]ONG+%W3MWFWKEW?+F5!93"CB25E14>\C/7M72AB\0D-VC;-FB,*"=I"
M8Z(0-@@<8!&?:MW!N&*H1&8WBU)5<<]LD\=)TM%3PCD>3AJ+[>Z.\_=4]YT>
M)46@"=.TRRMYP%J27'8]_,W@J]Y@#Y5&K15W!/XZ_>?2<[4J+8$G@ <<=OL<
MUCK'<G.;-50^13Q#7E/1A/9!$UO'':C8K1+Q]D3E4XUBW'BC6[B4KOWT(X\I
MHAIL=,!L)S'7CN#4[&@Z0Q)19MJ4(EQXEU1]H7(Y^^.>*U$\Z=*=WR9LR2[[
MN/)*55\\\JI'.7GRJ<_DNM0Y>7#QEU]U9[K6I73YCJ!^M9Z+>V;C8PTD"8"6
MFTC[ <=X@X&:\W<O/NO\U7]/Y\_=?^W[ZA4XM1_.O'!2I23]Y./F*GA X2GY
M>6/OS_/Z5_32$8J*PCV*GLK'.:O_ /JJ?^/C50ZL92XM)$9WJ,]<\]<_4U86
MVCRD<\;$Q_'I_MQ->QMI8-;V_.2'-\?2]ZD;[_D]7?\ QU*+N[C+Y4@F"".O
M<2>U6EE@F?* (Z@P?;^NGO7C*1QG*Y_:JJG"\,:G=[?Q)[+[?9$\+J):MY!7
MS$[9)09S^6._(D]2".LB2$\3MZI,$>^><Y/SQ$<:Y;XKC]Z$@+6JA2Q%:YI&
MECC<CD=SRCN6JCD7[HO*+Q^FI&;EZW4'+=SR5I5.]K<VX 9@)6E0/,G/.9Z5
M:]:6UT@H?90XA28V*2DI/_J!!!P>WSFJOYQT5[/Y<ICQJE:*:7N5#5#G0D[U
MY7N4(D6*Y4^_?'=S[>>=>C:#\7_&^@%#;.JO75N2"&-0*;I$)CTRI2E@$"#Z
MC@=(QY]K7PO\(:N2XO31:W!!_:VJU,+5NG)"$E$&9_*(YZ9KFO1IN[M?,):[
M,;KY#C$CN]1/PNXLJ$QD:JN:D@M+)CBDM_-LB(1KE545%Y5->N:7_:&M;A*6
M_$?AIFX)&U3]B$%9&?4&W"$S(D1/7$B*\WOO@CJ%J5+T'7GV@E14AJY45I09
MQ"@2>.?1P?:1MM;U&?$8VA<T<ZWH=QJ^&WT_2RC&L9OB/&Q$\OF00X]D!7N1
M?XS32D<O*.5_#43M+#XD_"O5_+2;FZTEYU0)1>6RFVVR<>M: IL)F<\G@ \U
MR]YX.^)6E!2C;VVHH0%;5,K0XXI&2?0H(5N^7&,UM=5\7W<6NE/A;B=.FV-M
M,AN<"<E7.R#%YK2L\=KH]@F0-"[V5?*IPOTHU.->DV_A?3M1MFKS3M20_;/I
MWLN)"%H6V>%I(42 >F!P,9QQ;GB_4+)Y=MJ&G^4\THAQM3@:6E4P=R,P>>IR
M,>\T4/QF=JPM"MUTO6L4GTJ9U/EU-+8Q5X[O29.IX+G=J^$Y>U%^_'.HW/!+
MR<HNK;(&W>E4X/, $9/,]:E;\<VLG?:O3/*%(6.!B85$9CB<3W,I1/C:=/H1
MM:NP>YHWIY1H9&%D&UJ>W#R7(G>$1.?H3A?;[\1'P9>=+BU/3\JQG)@^F?KV
MBI_^-=/P5,W2 <B2D YS@&9]B(,SUDY8?QQ]C1)P/8_=EB)X^B5@[$\?ROD_
MSU;_ ,&ZC_[^VXCA61T_[8B3(I_QKIO_ +BZG_T@D_J?]YG-0MOK\6;I[WMQ
M!,=G;.[P5L^!,9:4-T"7A;953:"&\;#C=^.E:\1!/(&4!['#,%ZHJ-(@WMR;
M7PMJEJ[YB'63Q)4E8D8P(&">AY ^58USXMTJ[1Y2V+F3(V[$[A(Y$]O]>H%4
MFF?$6RF'")!I*[)/2$$@HA+%]0%R(C'()Y?EK*5Y:O"O1B+XY1$\IQLW]/U4
MV[IE@%#;Q0$.O;E+"%%(@B/S 0"<F <BL.PO]$>U&S0Z+M+:KI@+)2A(VEU/
MID)PE6$JX "C)'6@FX&^.;XEE\VOIA#.?*QT\X]D64;UI@C0A2&#5@0J0K2S
M)DJ8]6R&J61((YS>Y45?(_A^PA]C5KIYTV[Z;U1O%.I*@VD*622I0,;5[BHD
M  %(S,5]9?VF[VXTZ_\ !6FVK2W-&'AYH:4RT5!EU:%%EP);@C?Y:+>0"%;2
ME0 W5/.)8GU0[@1(H(KR8]#E,;PY/EJCN:]K/+BS23[5%X<G#P(!Z*OA$XYU
MM]4^)_PYT .)>U%[4[A!V;+-HJ!6G\R5.%*6SN)@!)!&9[5\\6/@GQSK9;4U
MIS5C;N@J#ETHMF5=0@%;D)$94E(.8/(JQ6$?#]L;62*WW'RN3/E$X<9 &+(D
MO;SRHW65BLB6YG"\<#8)$Y\=OCCRW7O[1+P2NW\-:*S9I)*6W[P!Q[@?M4MH
M)3Q&23"@>G/?Z1\#T.%#NOZK<7:C"EL6I4RW'^4J6$.$3))3((,"3,WLVSZ:
M]I=OO36NI(0C#1/4GG#\U-+PJ\KZY_4,KOS:A$;[_2J(B:\1UGQMXF\4K4YK
M>M7;B"5(+04$,>7)! 8:+:01^4%70 G)->N:/X/T#P\TE.DZ:PTZ!LWJ25N*
M()DK6XG?).9!$=,0*L[77&/XX-K:*ACFD,3ALNP'WM8J<\.&!JHBJGA4548O
M*^=:AK4+*RE=M:-./C]]\;D_/8F$D3_FD]2:VZ["YN4I2\^IMH*E3;2B@)'(
M2)"A@8!SR<FO/;Y=D=VCAS[64L=WM$ ](\1J)[(D<7:QR)PG'>CU]O/&H;S6
MM2NQL?NG/+@CR65>4S!Z%">@[=LR3S-;Z986X!;MT*6,A;H\Q0('*208(Y!$
M'^>N\KQV\KQ_S^7]_C[^=:DJ)Y@^Y!*A\E%4_I[5GA4" #':1'\/]J_GCC\_
M[U7_ +5U2A5V ![B/MQ7SJY2@J/;_:K*:ICN0?8?[U?N[@'[?Z4^RI_X<+_G
MSX_5-5!C!4HB(S$G]>W7FJ$C!&#VZ"#C]/G\A7PJ(J<+[>W'VX_+A?"_VIJ@
M]))"H$R.?](Q]YDR2:N!,I!,@B2([\#^OT%:#F.V.%9W!- R.B@6 C-5%]:,
M)_#E1>7IW-^E_/'#V*QR+YYUM-,UK5-%N47.EWMQ9O(A7FVRPRI2TF4[DA.Q
M0GHH1T@BM;J6DZ?JK"K?4+1NY9,_LW6PI"0<&#!6,=B#V(Z\^MS>@9@9+K[:
MNZE4TZ.YYHD0DF2QH'JO=V0YP'ML8?/A.$(9BM3M<G:JMU] >&/[0.IVS;5G
MXHT]&K6X*4FY9"&KM" )+AW>A1$2J E1$@"<UXGXA^"EHZM=WX8NGM.?)*RR
MXHJMRN?RI !*4F8VE!'_ %)_-4%0]QNI;I\G-#E-59V57'*C%GM:YBN$WPBM
MLH87UQDX3E&S8<>2]4X+)Y^K7O6@^+O"7BIOS-#UMM%PX0!:7H\IY!&5( 4
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MUVBD7392#'F-J9*Y2KE(66U#J 9%>@:9\3_!NK;4L:Q;H4L2$W.^V6!V4'$
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M0)?B-T&1W.7(O"QBAB]!6)5\<"L:R;)RFVD8JKO6B?O%2!8C@SM*9]ML#_\
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M_P!OW_7WUG>_\?Y]*Y6, >W3'RZS^O>:\1L/QP__ %E7&5?_ ';?_!4T@3)
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M2"(W?;&8^=:&^^"OQ/TY*BYX8OU) )*K4H?$#K*%*[]>?F*LWA.<],.Z*#7
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MO'NJJJ>?'ZJO'\UYA7=/#"&TSVP8'M(C](X%2V_A+0RL&XU DD"2M2U))ZB
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MBN1&^%[4<OW3CCA=:188"O0I?/0$CIQQ' Q, $'/%>JI=NG[<HU&VLD%2?\
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M]L=S[J38C>QO+5[^QI7*B<D1%5%Q3XIU94E#+*!TEL*,XC$8XYQU/6*WMO\
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M<]!UJZ#V]Z*B<>41%7POZI_<BK_8OC2J'KC]8^=4!N,LP3I1ZHL*QDM1"QC
M^LFUE4-0:AQEH((.HNF_$[PILBMJV"T8';EXH<XH<JXD\.O,2%$B-0]L]'5)
MXD_*>O7KS_I6;>ZE?ZBBV1?WEU=BRMTVMH'WBXFVM$*4I+#"58;;2224R>9)
M$Q70!/9/*+XXY3V\>%U2L*>)P3T_KFOG2JU])Q#D"( G"M*QPW)XY[7(J+QS
M^7.E 2,@P>XJK>4]+F)Y1<'M9@A.>9[GJCFHO"N5%_1/YKX74:FT*.?M_O\
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M[#(P*C/)=_\ L:\,0C0B3GAHE08T]TX1$1J>$3AJ<+X7W\:O)>< 2B0)D@"
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MN!*2![3["9]N*B+'X@'UWZ0H_E;<\M(B8]*4!4?6.?>LI+P'+)3"_B>["/\
M6:K2QZ<<)&]K>!JT0:F T8W>.>!(QRHBO3N5>=6.73>V?^73N)$;3)CIQ/4X
M&#/VR+?073"FK;475 RDJ=N5]><K*,].,9(@"OFIVROWV-=7P\DO[0DZ4.*%
MLV"%X"JKVJ_GYP*E[4'RYSV,7AJ^>%7C6*7V3)3M)Z%(P3R 9S,C'^U;UO1M
M3;.YX>2RE)<<5<+2=C:?SD $F2GTCG/OFK293:U&S^,#Q+'4$_(I@5?;V#$9
MZS2N8JE8UZ)R,(D5>6I]/'+>/X4UB%"WW0A/[I!D#I]  /\ 2<D5NDNV]M;G
M4;P[+&W21:,+4 I]:<!X@F<J&X@_ND) D15+XF";C;IY9ZL.<:NJ12.X;GM9
MZDA[EY?*,I4=PKE[O1&[N00^.>2N>J[=#9M&LE()$3C!ZY/N?Z,SYY=:NQKM
MX5/./NI#BH0  @ *./80G P:O)CFQ%S%J00KC."N8@D:\*R8[1]O'L]HAIRO
M/CRBN7CW\>-8\IQY4E21!@3R(.8[=XQ]:ZS2G-,TY 4Q87Q=,2/.5L5\\209
MZG(-94&P-'%5R@RE1/5RO562W-9W+[KPB=OOY7GW7]%U"0HB"M!">/R]>/OS
M/SYK;#6&$$K1IET-W9Y[!]P#$1)&,'GI'WOV3G(KGUN8H0G'A"EBF9[_ $HC
M#B>C5^WA47]575NTD8*#[>D?/@@@]OG-2#7&%1OM]2:'4AYPH&03 45">8&T
M8G,37\)A6XN/N4JU=!E,9GES2PF@,Y/R:> X;6\)X15"]$X\HOOJOE[8*FN<
MR)'OB,<=C%57>VUT(9UB\MG%$_LWT)"21P-\X SDCCWKV1]P\9J'-#D^WTFB
MD,7AYVM=-@>$\N:9C!D8BK_],"U$]E54\ZN M^=FU0Z$QGOF,1'WZQ6([:ZX
MK+=^M]LSZV' \0.Q0",YG('\*S1=Y,.C1^ZKCUK/I56/8QJO\(O"_6KE15X_
M+GQXX^UI="2=K:23B8)Q'!/3L3S.>AJ2W\/W5YZGKQY:!R''$A$@P1  ($SC
M G$XS$^7[\%D">,4CMY3AB=RM;SPB+VL3M7S[HB-YY_DJZ%+SY"2"D "#& !
MUC[8&0>Y,5MF]-T72-KMTZRM:1_A$;M^,DD$CZDQQB*K7ENX4R-#_%[NQ_":
MPQ'(.3.0ZN.Y.%5L2*)CS'<C>%3M8K4Y3O5$7G62SIRE>H)4L#C!*2>TC'SS
M[XFM)J7C6W;WLVKMM:)!$%:DE\IF)2V#('O&")DB1450]PP9+/!6XW77^1R3
ME1KC/5M9$$-5X4J-8R3(<BKX8UR#<O'*\(BZSTVA1^ZE,Q.0%#Z <Y^P/L:Y
MNXUY^X9<?_$W=VVF9*%[$H5T2DRDY,<2H8P16<S*PM<88,0L<#)F$1O='-/G
M.*K_ '=V,&]'.[7>$=VHBKY\:>4V")4!UP1/;M/7M%86GWU_?-.N&T6@)*@V
MV775*<((@9D9$G$@8[UAJ*[S>Q.Q#8#;1XJM&OS-;9%(]'*B*[_=)T?M<UKE
MX1/F&JO/CE%\V+;:480H*'7CDGF.O$Y^TBL]BYU)A)<N$NV0'Y2+H* @\[2<
M1CGOWJ6H!\F@-8</SC&IPJQYP7P9;4^[6JCG1BJG_L$Y7\D7QJ!=H% @ @X]
M0$ 1TD",<9Y["1&UL?&3K;H:5=MW8."TZ@!?/1<PO@Q*CUP.#*^';P653)$"
M84XGL<B.:95:]O"IY3WY1/LJ<IQY7[<X*F'&20D[HCCD>\"9YX'O,5U:+C1]
M:24+2;:Y5 0%#:EU61&XP". ._ &*M/6Y%BVXU?\G;L XQ&=HY"(SO1RIPG?
M[=R)X3GPJ??WTWMN&'?S"0%=1$8,\YZD&,\UIKG3]1T%W\1:EU3)(*F4D%"I
MSSD9' DCD#VAVYQV_P!H;8MQ2PQ6='(>I#PR"0C$'SRAXKE158]&\\MY['?\
M347A4N0K9"'<B,&)&>I,&1G)S&1QD5?:M]<MR]:/+M;Q'K>8946@X!^901))
M)B-LY.#,R?X?U,B()P0N;$,/EKP=C0.&[\G-3L5>$3^+SW<ZJM3XPT#MZ =9
M/(ZCWGIV%+/2=) \R^N@'0(*7#N<&T$P09C[?;FM2E]0=D9[D$<CD7GCM<]_
M/'Y=J.5/Y?KS^FK2W<*'J.S.-QR3GVG_ +?*L]*_"[/+@=(& D*&!UGTA0XR
M"<F(@5X&[]73'=RND,157GN&9/"^.>5&G"KX7E?[$T_#W.?5P,D21)X$QUSS
M'%6B[\,+*D[%)!B/3,D?-7S^];93]1$IKT::0JHCDY1Q$Y5..?+7*GCWY3A?
M[_*6E-P@=^OI,\^W'SB.G:BK#PW=G:T^AE:A(\P$9/65<], SB!F:E&MW?Q:
M_:@;F)"/WIVKZ@V,)PY..4<WA'+POW:J<)[>.%M+D2'6@2>3P9GKC X($3Q[
M5&KP]=,$NZ7?*(Z)0L &1'I22<3[@S/0BO5+P[:;).#"<R&9_#OI0:HUSO*]
MKV.1R<+QQPB+X\ZO_9;9;6I)$2,8X'3D<@8Z]JA7<:[;8NK>WO&?RCSVU$@@
M$""$Y4,@Y]B>M8.3L;M_*Y1;EKQISVM*0KFM1WNG8Y7(G'V3PGV3A.=72?\
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M 3/) J?NYJIRBIY]O/\ SQK2'^,])G!Y_P!JVO\ 7]?U\JK17]07SVZR[/\
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M1.?OJGX58GUJ^TCO\AGM4IUO1B$J3IQ]2BD':F"0.AVC '*N!WKRDW)S*6G
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M82"1@Q'ZU-M9,WSN!LC *.F$_ACSC$\\AB.7RYCC+Z3%1..%4;N/T\:JEU8
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MPZW=V@GS[#]J[K=0FW]$RB/MY@]^>O@GI572F1/01P(/J)X@]#$0,SGOV/\
MA];%[U[+1.IJTWT )N4[R[Y8'N=#G_M!7Y%87(H'1_TM[491:7,RN/(&.T+N
M1MEG #-*17S QP6HE?$L8Q'JM408CH".T^I1Q]#70W2K:^'<*UR+Y147E/S3
MCSH>#U]CP?G3CBOS0]9OPO,SL<\L\PPW<6-%H91K"1 H&8_()(BI96UA;R'R
M)C9?I&(A9WR[>P3$^7CA7^+N1.!O?"*W7U/)>:A:ED;D& 5*W025=)]A7U)X
M._M!)\.Z0SIYTR^4\E+8==:N6TI<6VCRPI*2T8&T1$G &<U0 _P[=[@.<H<J
MCO1.4Y+63&+Q^:=B.\^WCG[^?MK"/@]P<NV^/^E0^?Y=QZ=0![S@]PW_ &GK
M9,>9:ZD%$\%;"@._(2"1'^U0CNUT.[X4-ILZ.5?UQWW.[E92UZ?+6#.V:7#,
MXG,<_N%Y;Z%>=JHWZN7)PG'/%[7A1UI-R/,97YMLMH;2O!+C*Q,I&);/?I6+
MJ7]HRQOW='<4SJ"1I^KM:@9;MEG:BRO[8A(2LPO==)@& 0"9](%203H<ZB@J
MO9:T[TY7MY6S:O'CRO$;G^Y%Y]OOK /A"Y!]/D$C_P#-4"/_ -/&>172H_M,
MZ)^\C41CE5I;J/7LX!'$8G)^0AG?WI$Z@\=V7W1N;654/K:S",BF3E&>P0CH
ML>M.0O8A([45RL:O#7*G/WX5>-3VGA:[8NK=Y268;=0LP[) 203M!3),=./?
MB=5X@_M$:%JNB:MIJ3=!R^L+FV1OLD#U/-*0D%25&,J&0K':1%2<[I!ZF1^6
MK5N3V14G2VHG/'W42*O*?=$_/\]89\)WG[K29',*ZB1@YQ,9ZB(ZUTC?]I3P
MU)W7#R<_O6/3/3= Z8'' ,5]:=)/4RO/TUB>5]K"3[_KR-$Y_G_GJO\ PC?C
M_P F.N7<'W/>3S^AJ\?VD?#$_P#B'LGKIZXGCKWZST]JB787I;ZBKK8O9>YJ
M65WX5;;3;=6=<YU@9CU@3\/II</N&@U1KECE%W-Y5$<JHGA-9%[X6O7KVZ>#
M(*7KFX=20LB4NNK6) '8YR/YG3>&_P"T#X=TOP[H&F//N)=T[1=*L'0+'=#E
MG8L6ZQN"AO&YLP9$\]8J66=(O4J;A%=5#X7SS/E.]_'LT3N?T\?]NH$^$KWJ
MTA*1_G=(DG$">X_B8ZUM5_VD_#2.'WB1B!8 X@DX4K@_]CFO>/HMZC#IVOL*
M=G<OE$+9/7SQRJ=L9.?R\?Y)JX>$;KJ& .Y=_P!!6$Y_:;T(&$&^5$G]E8-I
M G_,5+2!.8PKK/.<U%Z"]]IBL23D< //\:#BV151>$]N\3$7A.?R\IY^VID>
M$G^%KM@.9)4L_*(F! XY[5K;C^TYIPGR6M162! 5^&:S[>I4\=P/M-;K5_#=
MW&G/:MCE]D]%5.60J54^WE$>60WCV\*B<ISRJ*NLMOPB#A3Z2.R&H3'$C<9@
M9!QDR.QKG[W^TY<KWBWTZZ7QM\R]2F,#E+2)$Q/YS[YD5-.*_"T;)>-;/]J+
MAW/\,J0D4"KRB*CA@$K^/=%_>^47CPB(NM@QX4MT?G6ZN!D)0A&.TI!)CC))
M)FN&U3^T'XGO$J%K;6=J"3ZG7'WU&29*@Z0G<8]A(@0*LSBOPHH9V"$RL;7A
M^GGM&]7*WW7O*55(O//*\O7G^6MY;Z+9,26K9 "3*5K!5'97YN1T)GIQ7F6M
M?$/Q3K95^.U:Y4VJ(:866V"E6"%);"3M4(F#D$ULN>_#:Z:-HL8-E>].1X;C
MM.-'\'R7Y)I)DGEK_EJ^(]A+"QF%5&]D6O!(DE5$1K%^GBZZ9LK9M2[OR$M
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MORUL$@)$ 0/Z_6M!R9)ZSC ^TG_?K-;8V-'8B-: +6IX1$$Q$1/RX1NJR>]
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M=$9R8!<$<' R.HFOJ_I"QN51&B5.?=1,XY_/RS^_C[^--UQ'Y#_^F?X15_\
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MK(L)9%7'KH0F#5(XH[1L1K43W1&IW.7V[W\J[W5?*Z[6VL6F4)2VVEL)2.
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M+6ZWCGAU\6X=5 4V"HI@DJ"<]Q''(F.3!Y\CLOC5HSFNVFG-I4JR?N2TJ_\
M++*&7U*"&UH;"E++9)VK*P@%/3))R.S>9R:NR'"E.>,PC>B4;E[7#,-ZM>U4
M545.%15:OLJ<<<JJ:XBX3Y3J%C$DF(. #!,?/Y3,=(KZN86WKVC)"R%W+3>U
M9P9 C;DP ".%$D*B8&*E7J&PYE]0,R6K1!G>)3(4**U12&-Y[D>U.?I?P[C_
M (D\*B)J0'8ZEZ/0HP1,#(@Y@\<XY'/MI=)_YBVN])=2%.LJ6Y:!9"B%(G:
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MIV&W#W7W/WOR6V9@TN!6QMH<ZVOR#:*=2PRV<7(K'(]M<H%D%/79L*!7*%,
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M=$?N E)MU>7SO=_*.DXCB>8Q/6M/X@^+-IIUV]=)U)AFX45J1;:>4J6B0HI
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M]E\/CJ'KW+\K:5,E&>WK,L8[N?/V2$Y/O]UX7W7QQQB+\(W)_*&%G$#?L_\
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M4JDD\D_>LY%Z<>GF#?[?Y7!V&V8AY1M/2"QG:S)(NUV#Q[_;3&PL.,./[?W
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M+J:T3DXXX>R$D-'-5?*^W\^/&LMGPKIS)W;'5J X4D!) S!@X]XSV[5S=_\
MV@_'=V@MHN;:T200?*;*EP09*5**I4 8$X,9%7$VL^''5XVHDJ\:JZ1CNQ"F
MC0&)*(SE55#3"H^49%\HJO*J^Z_JNXM=*M[<#RF6T'&2D$C G*N\?RP:\RUO
MQOX@UXJ7J6K7ETE6%,J=4&U#W:00D@&#G ,'!F>B>VO2MB.'L :7&">2-6N5
M',1WU)[\\^.57^7O]U36S2TE.>IB0,)QCCZ#^B:Y-;KB\3"1,#L3U Z>_4Q!
M[FTD"IKZN.V/"C" -K43AC6MYX^RKQQQ^GM_;YU)[# [#CK_ *]:C[D_H/X
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MD&1GYU6S+^F#!\J,:0>,'U3*Y7J\?/*N]^5\\^.$3GG[^W*\QK:0X(4)XC<
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M1D_-5 Q57^WE%U:66R02D8_J*JE:DSP=P((C$'VF.N.W2MSQS#J3%V.9516
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M2U_5K,_Q$W2_UKI23W/W-/Z"G2U_5K,_Q$W2_P!:Z4D]S]S3^@ITM?U:S/\
M$3=+_6NE)/<_<T_H*=+7]6LS_$3=+_6NE)/<_<T_H*=+7]6LS_$3=+_6NE)/
M<_<T_H*=+7]6LS_$3=+_ %KI23W/W-/Z"G2U_5K,_P 1-TO]:Z4D]S]S3^@I
MTM?U:S/\1-TO]:Z4D]S]S3^@ITM?U:S/\1-TO]:Z4D]S]S3^@ITM?U:S/\1-
MTO\ 6NE)/<_<T_H*=+7]6LS_ !$W2_UKI23W/W-/Z"G2U_5K,_Q$W2_UKI23
MW/W-/Z"G2U_5K,_Q$W2_UKI23W/W-/Z"G2U_5K,_Q$W2_P!:Z4D]S]S3^@IT
MM?U:S/\ $3=+_6NE)/<_<T_H*=+7]6LS_$3=+_6NE)/<_<T_H*=+7]6LS_$3
M=+_6NE)/<_<T_H*=+7]6LS_$3=+_ %KI23W/W-/Z"G2U_5K,_P 1-TO]:Z4D
M]S]S3^@ITM?U:S/\1-TO]:Z4D]S]S3^@ITM?U:S/\1-TO]:Z4D]S]S3^@ITM
M?U:S/\1-TO\ 6NE)/<_<UQVZ]O\ ZG>VDZY>IO:#/R;D66RVPNW^W!<=S'$L
M/->Y9N;G.1GRNTM7LJ<ASVQO:'":H=3*B"2V6#E!BRQR ?LR%%99JJ]+A2"!
MDD\G,?U_4UVMZ3NDC8OHFV:H=ANGC%Y^)[=T!I,X,&TR7(LKL9MM/0;K2XG6
MF265E)^;LSC^:D1H*P:F.5[V5U;!C=@&*L)*C)YJRFE4II2FE*:4II2FE*:4
MII2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*_+EUP]-O6U_2<ZXMW=DL)W
M*S?:[?+?+H6VPSW;:-6VQH=U@&#8YTX9C3]0NU( 17$N)NT^>XKG&W>Y8*M\
MF*?%<VN+.Q;%)@!"Z5(DI@ QB3_&0?GB.T1^]4AY[O-\7>*O4(_ HG4)(W(@
M8OU>EML1M>G/;\^RNU\W&MW*2KZ,IW2?F(]N16N^ESG>UY95IGM1>99NRU$-
M=3,CKMOKBIJ:J0H0G&1!V]<Y_-N$F(_TB<U-N:8Q\2V#U#+M]CG4OU3RMG:K
MJ1Z?-I!YV+93IGEGO-D,ZZ9,RRO>K=N;D#.F[\&_&\6WCJL9Q^LR:N@0L.P^
MWL34UKC=P^PB1(E,Y_VP(Y^^/ZS3TQ,"8.).#NQUSCISUFJYXCOW\6/*,KZ0
MJ?-L)ZE:O\2V_P!AJ/J2J[+9&CC[<9D+.,(W)@;O9;9 I.F\I<$RG'<K'@8\
M@&7J$P>THK8@CX[LF[ #WF2/K52$PHXY,"<\@=^,DY!P/S5V?^'5B>7X%T!]
M%&$;@4-YBV=8ATI[ XSF6,Y-"E5N18_E%'M=B];>TM[7SF#FP;>LLXTF'8Q)
M8V28\L)1&:TC7(BK505*CC<8^4U<K2K::4II2FE*:4II2FE*:4II2FE*:4II
M2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*
M:4II2FE*:4II2L'D^.5&8XUD.(W\5)M%E-';8Y=PW.5K9=1>0)%9915<GEJ2
M(<HPE<GE$?RFE*_&MAG1+\0>\J]M39]MSNHIMS,IV[^$KNW73(UZ6-0]#FQM
MITWV ^IBSA.$Q U&9FVDZBQQLG[00+*'O#0L);3?Q"*Z53_7L?K]\Y^U2RG,
M&"/4.AW$&0#/21@]OG-G]S+_ .+1NSMWU046X<CJ9Q"/BFXVVN0EQW:/::.:
M[J8N+=?&#1@5?3S/!TRU*;DX0WI3BW^;Y#04&;]34G+96,8R[)KZNC9-G^TE
M_6K?2(X/(@S!QUS(S\OL)J[/Q;=G.K/J[?L9TV=-^"Y--H*+&,ZZC,PW2O<W
MM=D*&JW5QC'2X5TRUJYK"P3)XUSE>)[FY7)WQR#:Y*>G'8AVRHHUK/I8%F%7
MJ)(3).9Q$3CKU'R'S)Z5RQZ@=GNOCJ2WDS'>NEZ<]\L#3K.V Z7^D[J/QB;B
MV64H\#QO(Z2BW#W\OJ^&6,U'BP67LOGVU-7?1R1XQR;T8VX\HOX[4QY"JC:)
M!(.TJ(SDP, >Q)GZ5YL?Z5-W1X9=4;ND;J$;UH673-\*3'>DW?2-M1FE-"V0
MW*VQZ>MJ*'=B9D6]IV5-#MW P7):VP!N;CMQ=,/=,JK?')-+:S3+7DH.@,S
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+-*4TI32E-*5__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>28
<FILENAME>g947560g25k68.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g947560g25k68.jpg
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M 0$! 0$! 0$!_\  $0@!0 )= P$1  (1 0,1 ?_$ !\  0 " P " P$
M       ("08'"@4+ 0($ __$ &<0   & P   00($ 4."0D)  (#! 4&!P !
M" D1$A06"A,5(3E8E[@7&!HQ.%17=GB3F+?2UM?8(C5S=+4C05%24U5687&2
ME:'1U1DD)5ER@9;3U"@R-#="8I&4HB<I176QLK;!\/_$ !P! 0 " P$! 0
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M@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# &
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M@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# &
M, 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P
M!@%*7L>7X)CG;[\^G/G3W/@O4\=]D?RHNMP4& , 8 P!@# & , 8 P!@# (A
M<K=4?3(*K02K(>&%[C#TTR:M1Z>=O ;/YRGXGPBF+U2^5O;_ '*;K-40R=:0
M,G_'A(2(\$TQP.$K]K)$M6]O4^*Z[&!<T>(G3W4UJOU102&6:P2&/1U[DRQQ
MEPZG$RG(F%Z9V)40FU"K6FC]I6<J>TQJ?TMB2H])RC_2EB93Z.F4"7%I)OCY
MS67+G=-I77UW=% 6;6\?IR-197> J6;Y3&+XBUI7#$J<MQHK(ZSHZKG%:1^H
M95!5J=P2O:\<$GTA?&DF4PHQ2U!1.+@I0@XI)-.^E]+)O-+)W67-<^3,ZHGH
M3JB<]C7G0%AP;G[574I#F%]?;!JZ86*[R!JEECN2ERJ^MWUKET0CS4*6J*T;
MS9]."F56X((V@D$'"2M6ZE!.DP-)13SN^#M:RU?/7)9<&6&X*C & , 8 P!@
M# & , 8 P!@# -'7ITQSUS$PL\GZ'NBM:78)"Z[8V%TL>7,T53/3L!.-8>B:
M]NJI.->:C1%F+W#:4!I;<@+,7+AITA8S@B4F]$WV*YX\SJ_F0JUH71@K^J'=
MPV-&TDP@5;ES^,G2Z81=Q;U;LUOD=9RG$:IV;W=H;W%W9CD8#=.[4W.+FVZ5
M(4"L\D+.S=LEJ_?WTYD@<$# & , 8 P!@# & , 8 P!@# & , 8 P!@# & ,
M 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P"E+V/+\$QSM]^?3GSI[GP7J
M>.^R/Y476X*# & , 8 P!@# & , 8 P#P<GCZ*6QJ0Q5R.<$[=)F-VC[@H:'
M!4TNI")Y0*&Y4<V.J$PI:V.!1"DP:)P1FE*D2D)2E.8 TL M 1\IGDNMJ.E2
M2815^LMX=&RL6NG6=/,9VYR)H9Z\8G%*Z,4?;FDT!"$DEC4IA@9C3"C3FI,O
M=DR$9!+JO"H$W]_?T\^.AM*(4I35?/2F20*I*RA$B6I%"!8_Q"!16-/2M"L4
M)U:M$I=&9J1+CTBI6E2JE"<T\9)ZA,G.- (PDL00NWJV_*1G:_#SY[99[+[+
M:5]V()A)RI$C9W-/?UO!W5S3-[,CUOV*PTT6*6BU6#%9$]B[*XS=JBNT21X:
M4HHD$M+$#SV(P+NULK=BSX9\[9V[;ZDDJYIN!U6^6[)(>WK$KU>5F&6W8RY<
MYK70YWF8H/":Z*4IQ+33?<YM1Q&O8LU(&=%[4WHPH3#2" &JE C!%].K)>=O
MUMFT\ 8 P!@# & , 8 P!@# & , 8!4+XM9UUJ895T4H#E:77--K '8U>RR_
MZ]K>LK&LKEVE9LP-3!;2RK&VR9;!4)EB6PQJDT78T9DJ;8SHEH6OLM*=0Q]E
M8W47A:[NU9<&VKOAFN6ODME>Y7#'N*+Q8^D*TA=9\U7#%*<D/3/A2],UY8D[
M4P40:3H+C3E]IK*=4Y;SFWS9V<FRX6=7%U$+#&H\1)&F1GV YN:!]4MFGA6.
M/>_OST[+YDW5GFKVDFL\[NZMRZWEDN=C:7B0,WB2<;-9'3<9\3^:R:O)/UI5
M$2;N>S^9*$:&B/5_<%PHF8F&E6&)M>9,XIXG''0#(G=U2(#N\%I K5*E*M.$
M<&28;LLG!746[WEJEK:]CI&P8A@# & , 8 P!@# & , 8 P!@# & , 8 P!@
M# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , I2]CR_!,<[??GTY\Z>Y\%
MZGCOLC^5%UN"@P!@# & , 8 P!@# & , 8!'A===BI%RQ(1R1T.Z$)52A.2Y
M(7_ED"%Q*(.&46N1@<NEV]Q E5@"%0G O0(5H23 :5(TQ^C"0 8BY=0REHD<
M9B;CR5TBGD$P+?#8XW^Z_+)ONB7&TJ9:]"]*(Z:,1)/0TRM.9Y%RA-M1[9YB
M71Y@1A"!DGT=+*^)UTC_ -H>3/WH\ WQ'71:]L;8[.,<>HBN7I"U*J,R(Y@4
M/C*</R^<@<SHJ^R:.FJR?)_5!L[^[(M^77M2PWW_ " >9P!@# & , 8 P!@#
M & , 8 P!@# & 4I^/7]A)!_PRN//SW1O!DI>,_LR]1=9@QC & , 8 P!@#
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M8[-$R3.%NM2)$Q,!A<87&NKH8]^1:T;R5]ZR;35[>7)9^CK9A?,7?%L/7?\
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MX!]BEZHPX!8V5S( /?D$H--9ME%:]_\ A#"2[''[U_)DF"]_7\'Z_D \G@#
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MUE1EUC4@HSD6%IIY(W%I=DH_:VZ<]%7JQGG.Y)"@2?3FCKBF*Q4+"DQR5+*
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MR*U["?T"I:K.=5S3%G.!;<70!1CRY/",2E"H$MQX1MVN[\FBZLT_/F6)8*C
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M/4%)1'!*"+8M34;W4FWNNZW>K/._#LS.JG!A& , 8 P!@# & , 8 P!@# &
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MGU@[#Q2;)WGPR[,O/;7RW+ BBBR"RR22P$DD@ 4444 )99198= ++++!K00
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M@B5(4[OI$W:<B4QVQE%K=($>E(0Z-]&)\[S-"#RN , 8!":)?".= ?@3<?\
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MO^=]3_T90^;K[@/TA4OP;:G\N>:Z6_(T_O.']<SD^SN4U8, 8 P!@%I7@?\
MPMW&O\IT)\V.WLYR^$C\W.C_ .-U/X"N>UZ%?&L=]VI_K1/8S9QX;#& , 8
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M!48 P!@# & , 8 P!@# & 0FB7PCG0'X$W'_ .?;N+!9^)'[4O5 FS@J, 8
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MAKGM\D?FHD*YM4L)CFI2BR\23SU5\]-<VN/)-Z>4SGAOIFR;:ZF\0.E)!<$
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M_0\+3P[J)=\E%U)3DLI*+G5G.2@GFH)J*=G:Z35_F>6/L& , 8 P!@# & ,
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M90^;K[@/TA4OP;:G\N>:Z6_(T_O.']<SD^SN4U8, 8 P!@%I7@?_  MW&O\
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M\@]K'I.X*4ZL+JF6HW)>D4 I-6ZKY6X/6_OV&[:/I6O>=JJAM,U8U*F:"P9
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MU(="97OJK:*S6G8BSG!48 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@#
M& , 8!SV>/-(T2)!SC'3.9N3;[<A1CJ.T"'WKB'6%-XI#H[2<+@4VL"/P5DK
MI]C3HIGLF@NGZ=A)5O)28V)4Y*A%)52HDH1$/JM?A<R4WF[-K196NVW9:\.9
M+?P9I'&I%Q>'43C?-D:9HW>%ZPQ.7R#'Y&Q<XOH8G8+FRDRZK5,IDDI=Y*Q2
MM(E3/ITE-<@%+7):M2%H4GN>(O)*SOO.][V5][71:^^A:Y@J, 8 P"E+V/+\
M$QSM]^?3GSI[GP7J>.^R/Y476X*# *%ZX^S+\4#\*ZL?F1<I8+2TA]E_GD28
MP5& , 8 P#%/#I^RN\2O[]^6_F]MN"7I'L]K+>\$# .1#V5'_&/A]_SOJ?\
MHRA\W7W ?I"I?@VU/Y<\UTM^1I_></ZYG)]G<IJP8 P!@# +2O _^%NXU_E.
MA/FQV]G.7PD?FYT?_&ZG\!7/:]"OC6.^[4_UHGL9LX\-AC & , 8 P!@# &
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M67F&DF!-+%YO$G*@1>:,&Q!%YH@B#OR;WY!:WK?OZWK!:6D/LO\ /(DY@J,
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MB]WJ?XSC!1IIK1*4>CG/T>_OP,F<8\+M>EIIMY\(NVEKR?%'3W@QC & , 8
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MNK'R:UK6M:_\B/E/?UM>]]?W\%I:0^R_SR),X*C & , 8!B7AU  +J_Q*]B
M$6]3?EO6MB#K>_)]+XV^][^MX)>D>SVLMY]I*_N1?^8'_9@@>TE?W(O_ # _
M[, Y$O94(  <?#\\T 0^57U-Y?-#K7E_Y,HCZ_DUKRYNON _2%2_!MJ?RYYK
MI;\C3^\X?US.4#.Y35@P!@# & 6D^"#K0O%MXUT+6A:V9T)Y=;UK>M_^3';V
M_?UOWOK^_G.7PD?FYT?_ !NI_ 5SVO0KXUCONU/]:)[&/VDG^Y%_Y@?]F<>&
MPQ[25_<B_P#,#_LP#YT47K>MZ+!K>O?UO0 ZWK?]G6]:\NL ^^ , 8 P!@#
M.3GV1(W\('7'0:V_+COF$]( K%U2U=!8*T5@YU!)H:9*W,0U]FFV[-*;BC:+
M4AVM1Z<$UVQ5V3MQ0QD(C#/1E X:3U2?:9::DT[135U=YW79:_"_!J_/1[]]
MCK)&Y/"NF#"XWQ9'W<QPJ E<9RA?[M<\L=6M.&T],2Z\V %]]#P>NGLPHU:9
M&DL$G F]Z..EJ=44>7'6Y4879;JR]A%35926OC*WFR3?E7[OI)R3&, 8 P"E
M/QZ_L)(/^&5QY^>Z-X,E+QG]F7J)%>+1V*FX=X1NJY4CV2QSUU:B:OJ!4/\
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M%X--OC/P5V+QO/IYCHMP8Q@# & , 8 P!@# & , 8 P!@# & , 8 P!@# &
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M8!R(>RH_XQ\/O^=]3_T90^;K[@/TA4OP;:G\N>:Z6_(T_O.']<SD^SN4U8,
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M/S<Z/_C=3^ KGM>A7QK'?=J?ZT3V,V<>&PQ@# & , 8 P!@# & , 8 P!@#
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MTLK.C1I2P8(;;=WK[^]]7QS)(X(& , 8 P!@# & , 8 P!@# & , 8 P!@#
M& , 8 P!@$1.T.=93T=6L&;(!)V")V34-\TGT372^7MKD[0MQEM+SIMEJ:-3
M%$S*T+UJ.RAN(<V%8N:%(7%H-<$[PE(6C0>@*A*=K]::\Y"%A\#_ (JG](TE
M ^QJP9>C+'JAOLLP<X32>UZ[:0.]R6[-KQGB%@8H=8;-H$=(G,_>R&'W;,<G
M<MG3H0*%01^>4$6WY)MIVO:]N-E:_EU/P!]CO>#>'6@ZXP:=ZU_;7/T</?\
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M[3+DL%!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8
MP!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@#
M& , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8
M P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@#
M & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & ,
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MW0L >LW67W%.=_RH+*_="P!ZS=9?<4YW_*@LK]T+ 'K-UE]Q3G?\J"ROW0L
M>LW67W%.=_RH+*_="P!ZS=9?<4YW_*@LK]T+ 'K-UE]Q3G?\J"ROW0L >LW6
M7W%.=_RH+*_="P!ZS=9?<4YW_*@LK]T+ 'K-UE]Q3G?\J"ROW0L >LW67W%.
M=_RH+*_="P!ZS=9?<4YW_*@LK]T+ 'K-UE]Q3G?\J"ROW0L \G6EEV%(+ GE
M;65 H;#7^&PZMYPE50:R7NQVAW:+&>[084Q"A2_U;5JUK<FM;5S@8>06W.B5
M2E=$1A:THTH\C0&]< 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# &
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M>2=U96MHWU]661)V-?97W3^#SS#^<GKK)*DAL 8 P!@# & , 8 P!@# & ,
M8 P!@# & , 8 P!@# & , 8 P"/=U_\ K Y0_"$>?FR]'8)6DNSVHBWXC?\
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M&IJ;$A"!M;&U 06E0M[>A2EE)42%$E**3)$B8HLA.066226 L 0Z _;@# &
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M>A&\FL+:@,<O0CW9U/1A6". E/='(Y.$LQ>K$<);;U;?:;+P0, 8 P!@# &
M1YC7V5]T_@\\P_G)ZZP"0V , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8
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M^LN /INN4/C/<\_+36WZRX ^FZY0^,]SS\M-;?K+@#Z;KE#XSW//RTUM^LN
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E$D.- H"0H(.V7HLXL0@)=X P!@# & , 8 P!@# & , 8 P#_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>29
<FILENAME>g947560g29f80.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g947560g29f80.jpg
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M*$48K:*.QUD>3D!S>XO('HF/J4KJZ!(BZ0TU,:D"*5DDE-)Y^/2V3(8(C &
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MVC/'T*;3DX:(2J"BM+E>@]^8*SO\ 8 P!@# & , XGCZ#Q[R7XZD\I^*>/\
MD[QDGQ[Q'9VT^EOBG;\8\4V?K9'C'=]SWVME]OM_V< Y> , 8 P!@# & 8HR
M_@KPUG]TMW(N;<8J2E-XM2UH=$EG/=>QUPE0G>/ +*CSVM7'HAZ='V/%D)@,
M#XYEJW9D D1!:UB32-+HE):#,W*4W+1.SR'.F_"?B+95S1_D18'&ZFIA>,7.
M9U3):$@@4?<I>E6QSL?@VX'.BE$,QP<HSLLK<9<G+2M?'1$$"95"$1!.P!-R
ME-RT3<O()1PGXB3:\&;DK+N-U-2.^V!2T+VJUW>!1];,T[I'B@$1UY-=CD0C
M%K['"2B28Z^K@J7=@*3)2VA:C"D3:*";E*;EHFY>0XJ_@UPZ=+X3<GW'C13*
MWD$D<T3X1;2B!L1DQU(6U,!&VR8QQ$D\!\I;4I1*=NDYY1C^A*(3@2.).DY'
M=AE.4IN6B=AT<;Z>W""'W,+D3%N+5+,-YBEC_.A6JV0EJ2S;<QE)KD=(Y)M\
M+*TKV[O1KPZ&."SM]ZH$O5;'O>S18&5%*64Y72FY2T2,CH-6D K,J4D5_$&&
M'DS><2>RY>6P-Y+>"1S^:+0N,LE[L$@(=+'Z0K@A5NK@;X3E9^M&&"WO6#!7
M& , 8 P!@# & , 8 P!@# & , XB->@<2S#F]:D7E$J#TAIJ-22J+*5I3!$J
MDI@R!C"!0F."(H\D6]&$F!$ P(1:WK .7@# +.6EQZHZ[CBU%NU5"+&.*A4Y
MK@HR7,*)Y$7!+,"Q@G\4!M669V667:C,>\MH]> M8)F;Q#_M)B]A&9M7-JU/
MI5SUK,4^@XH<:VIZ;)$VTA6Z!\99G%[%:'-)&&\A6VSF%5J"G(E*41A90?%W
MF.U867 6A87H(T47 %J)[*;6@X$WI=TNB<Y:IVZ[3CE<1.,!#=43030]8%MU
M!L<LC-*I0Q-K[-81V>1U1$IHR0L?<=ZQM<HC2H]E?$*,9:=Q0#T2I+,T O8
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M3OM9EN$(0A"$(=!"'6@A"'6M!"'6O!H(=:\&M:UK6M:UK7@UK\FL&#]P!@#
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M="7=36*/%$@F 6G;6:L>QC&@$M\H!"ITD(!J!*%RB^DI[I66\@RR^+AUBO\
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M].3Q]/2?=7_GQQBC?)%'SSX]U<1(I;8L6#$%7"5OF!R05?S5ZAHUVWPJYHT
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MD8 P!@%KZ4])?%_87N/W_<?\II-VN2]J+J/</E+8R8#(DA@'G!=:+TL?./\
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MV3WZQ9\%USK<!L7$OO.N<YA]5";NV>:SN8P!@# & 6AY!G)$]"7>H<+#W4:
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M.[.DY':%LT10=D!UM5KPGE=YL1H-[T$(2S=A&+80Z%$D?HW08>\_Y4ZC[L1
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MY,7IQ&0.6%(P!@# +7TIZ2^+^PO<?O\ N/\ E-)NUR7M1=1[A\I;&3 9$D,
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M5"X)K<1ZX/O$M>" P"$Z+>>OU)/7K1'V)^->64>?H]Y&ENH^3%Z<1D#EA2,
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M34U"Y7SDY&<2):C<D:1Q;E:5P;UZ8A:A7HE!2I&M1JB@'IE:140,PA2F4DF
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M3@>[R" 0E]=56BM*7-XBK$YN"C1!):<C1ZU:@/4FZ)(**(*T8:+19)990.R
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M@XQL=?!B_//Y&^S"V>]9ASR'VR>_6+/@NN=;@-BXE]YUSG,/JH3=VSS6=S&
M, 8 P!@&,!?"GB05R!'RK+XYU"#D8/8C!7&&$LNIQM:-M\C&/&G?Q;MAD!C/
MO;.9(P@T^C:MB;1N.T0MD;&9N4IN6@R?P8& , 8!$ATY/.JZP'MRQC[,=)X+
M(]S1\GWDM^"LI*?)%*^"35"B(-5+%L2DB1(E( (T]2I4LZPD@@DL&MB,-.-&
M LL =;$,8M!UK>]ZP#7MXQ7%*JQXU\>JVEW%#G(BEE>T=4T'DZ--P_O%<G22
M&)P)@87I,G6I8F8F6$D.2!244J3C&0H  )Q0Q%C"+=BC225MB6CXD(J-N*)I
MPR<3:^DKFRK;2L"N[MB*J VYPAYCV'"UJM"O5QF5<([Q=6=0M;#]*6]2:C40
M\18CD:@.CB![UX2QZ[6L..%V-/YZ0H(TYIPI\I&)T;KSCW3ET*K%J^@>I'3M
MC6>R(HNE9V+CG?3HW/"*.6>OO"=EL,:L.#3--I1.5;@Z-T\VB*[*",.3LMAQ
M<.E#HXRA3'Z,YK*5F;IX^/B)RC:2>0TF[VK9J25DKI37'*<TDBO>/M>47Q>G
MD[GE,\0NHC'#9[%87#E<97<:>3DCBC$SPA4_K$(8XWR&/N2U&<X*) <-?M:Y
M.)"4*-.4P$,I*IX+=,IPIMI.U2^;<YB)4D:2B<+DVYS4W.5\M!EQ\9I3]%KG
M5_DUOC[H9++6A^;XD.Y1:8?M(RRZ8C-+6VC[3=I? I_6Y\XY4<B)^Q1RS(>^
M0.7"BDLG!KE'W1?&)&D0N[<6YHA:4)PJTQ8AE[\.M;UE;M;>ELLNDM"A5G$D
MB1S, L]R'^8"\O4]9G\E/>#,-ZUK:>4I&/S:CWZC:?X!/GTTQ8X-8O> \$]0
MJYI&O]_5WG=9]=&=YG[AQ!@# & ;]'P=;T7=:>MSD=[[YKGS>[('#K'#QEPU
M[0K!NG!6]>#>85/J]&3D9U YXP!@&O3UF%\-C-T\=91;BNG)36!E:6BQ):HN
M7J33W@ A53DR305>EL",_BY2G.\\5LK$0X1Y\$[EKFI"0_LX$ODI;H0G<606
MS2G.RU093E;Y,UTIDT7%Y>Q.O&CCNZ19O:&F,N5%U(OCC5'[$>+>86QB60"/
MJ&AO9+9D1":06@T(F\Q.F;;$?4R=XFJ,LF2N9!2US/+"(.]ZV7TP8& , B4Y
M7^EIZ17J\ZD?NRH7!-;B/7!]XEKP0& , 8 P!@# & , 8!YN/6N=VEOZL_.$
ME>Z-R(T<PI0P)2M:F3&"+WQ2H(.C @.- (0-B ,.AZUL.Q!%K6_"'>M>O^U]
MPO@G!^)^%*&OX4P=4J:+&6M4L-%6Z[5JM214;P7@B!4D,%-2P1.!Q01PJ-)P
MN*"))SA:6O\ '"K5FFKU4BH:O3TT*J,,+BHJ*DI(5%^4UEY+<$+2<FG*<Y-/
M.1DI99&DRI,I&\1U6!.>2>)(J=$HDJH)1@3!)U.B%I!VR#M!V6=HD\DW98A:
M+-+'X!ZWI%C)BY%#%"L8L#0.*%I10X5P?E0MIK*ARJ:*'*5ZG"U-6IJPZFJC
M7DT_R&M.33DZM3-.3G)I0*QW.U69R4&O^II4$;J#D!4:WCA2,0:;HA<O;BPU
M#+[!C;4"6/++#X_&U#^U2*SY&<YL443Q]X>VD"IS<E34_P HDPF@A&WRE^2J
M-:U_ V":QA; .%8.R15ZW2X'KE4I'_RV$,7JQ2NJT--6ZQ68:"EJ]6JZHJ>M
M14]#0TKAHZ.&EH*M5E2Q14E5H(H?W*&L5F"KUJKQ8#I:.&L4=)#_ .GH*Y1P
MY<4-'!#E0Q113A@4,42;<3ABBCR4E21H^#?SWXW,G$R6<8TL>?)&@:M7.WU:
M;*QU2H0KR;?/KER:IC.W(!*F0L,WJ-\ASTZQ+\"%(VZ0!?DR!U.:DZ%8)UE'
M5*K38U5;&2+&_%BKQTW_  ])A-57#44,='%@F'"%'2U.HT;K<-7IZEA6AKE#
M15O\MA5)0=PBI**&DBC@[EA1TL-0I*DL&X0CAA59AH.Z56::K#HHE24L7<LN
M&DH(H(HJ-47T8LI*)J4W%]^$T<_2!D_^ZH/_ /1FROSFQ<_># G\UJ']0?A_
MD%>_]E6_X:F_ ;)/P7]P0.',SD>- N1K@%\8VP)@T:DE2$ MVJP[T$8B1CT$
M6]?EUH6];WK\NM>#/*7;#X1P?A##&+D=0KU3KT%'@RMPTD53K-!68:.**M0N
M&&.*ACC4$32;2B:;5JL._P"*%!34%4K:IJ&EH7%6(7"J6CCHVUW.%32C2;4[
M)HW@L\[G;A@# & , 8!JZ1)_J^+]5&3QBRBZ%LRW7CF(\.$.F;EU:K506_#(
M_('DE3!X6'A''VXVO'-;!FPTEK:*[5[0D[8RF]'(S#EZ5:[KA8]Q-32DK,BQ
MN<G.+YT&T7@K& , 8!$ATY/.JZP'MRQC[,=)X+(]S1\GWDM^"L8 P!@&,=L^
M<1Q/_6US^Z]9@&3F , 8 P"SW(?Y@+R]3UF?R4]X,PWK6MIY2D8_-J/?J-I_
M@$^?33%C@UB]X#P3U"KFD:_W]7>=UGUT9WF?N'$& , 8!OT?!UO1=UIZW.1W
MOOFN?-[L@<.L</&7#7M"L&Z<%;UX-YA4^KT9.1G4#GC & :__5S'66KWI-$G
M;K6'?#Y6:=J897"U_'U)%:R8/C+48?!)X\MO(!"X-<L=Q6QIK@QT2:DPHNZP
M&;SL5J*FAB3L+LE$X9R<I6.<G.VQZ-6E6RD2M<&E,%6\*^(ZNKW*9O-;*>-%
M&G0%VL;274_<H:96<9%&ELU"@_Y<&4J6?:,U]"V;VUA<A*0MF]H-)][$8KW.
M5[NNOS<1E-@P, 8!$IRO]+3TBO5YU(_=E0N":W$>N#[Q+7@@, 8 P!@# & ,
M 8 P"VS]3-/RIV5O\HJFM9(^K]D[7O3]!8N\.RW:9.2C3[5N+@UJ%BG9"1.0
ME)V<</NDY!) .R46 (0.G^+Q0']QM/?5G"O_  F 8V<R*$HMOXH<C%R"EZG0
MK4E,V&H2+$=<P],J2J"HRXC*/3J"6<!Q)Q0]:&6:6,(P"UH01:WK6\ R3^+Q
M0']QM/?5G"O_  F /B\4!_<;3WU9PK_PF 53%:QK:"JE2V$5[!X<M6D!2K5<
M5B;#'E2M*$P)P4RI0T($9J@@)H0FA)-&,O1@0CT'0M:W@%<8 P!@# & , U6
M25G'DOJ1(M1??(F),;7S[4()#($SAQS6M%EVO*;9GRH4>VV&(-75&:OKODXC
MF[7MP3.!4\E$,N>4HE3<MI-O2N:$66J',YJ:OFK&GQ7/5HMF;4V"L8 P!@$2
M'3D\ZKK >W+&/LQTG@LCW-'R?>2WX*Q@# & 8QVSYQ'$_P#6US^Z]9@&3F ,
M 8 P"SW(?Y@+R]3UF?R4]X,PWK6MIY2D8_-J/?J-I_@$^?33%C@UB]X#P3U"
MKFD:_P!_5WG=9]=&=YG[AQ!@# & ;]'P=;T7=:>MSD=[[YKGS>[('#K'#QEP
MU[0K!NG!6]>#>85/J]&3D9U YXP!@&G)U;[,NAYY3/E<7&^\*^3%516: <:3
MHZK^.E5<T.9M6M3PC9BG%'*Z*F=A5%*$A[BL3D*'$AFDKDUR)L*:]KTZC:$!
M1#Y^/N\F<M@NLFGG>4X4[7G6BR?2S:VXYJ7);Q[HA8\(7-L=U=-5@I=6UZK0
MJEGEO<CX0QFKD+M3A#F]DU,YI%0S4Z^M"7EW*@BHLV+%N:\#5I6:*W>]>LO+
M@P, 8!$IRO\ 2T](KU>=2/W94+@FMQ'K@^\2UX(# & , 8 P!@# & , 8!;V
MQ+.C=8(&]RDK;83FG<U@T*8NNZCM>WEY9P"1'B&X-53PN:NC2CV .P@<'5&C
M0&';"F+4B4# 4()3_P!I;3"_E!R'AUA<<KQ@L/@7)UXE4NJV:QV.M0>&'+]$
M)Q>79A6HF]'I8Y4:C;TVU"DXLK1ZU6F3%=KMG'%EZ$+0S)\7E7Q+[?&XJO\
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MG*_TM/2*]7G4C]V5"X)K<1ZX/O$M>" P!@# & , 8 P!@# & , 8 P!@# &
M, 8 P!@# & , 8 P!@$2'3D\ZKK >W+&/LQTG@LCW-'R?>2WX*Q@# & , 8
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M-*!VM>$"*7IR>=5U@/;EC'V8Z3P61[FCY/O);\%8P!@# & , 8 P!@# & ,
MQDL/SI^-/[!<C/\ X5!@SF>M;(C)O!@8 P!@# & , 8 P"UETK[H;*W?UO'R
M,5Q,;:)&T:C$>MJ82*!P%>68]-Y3Z)[E,4B$\?FT:2/#=5C6%%%G+2UW3H4"
MH2)(J/7I1E2G;.6>5_GD:YL#J;DTQ=6Q98UF4DIE5IR_E1#93^$Y-"2*3UA
M^,;CPC%$9)-*ZYJGQ]@VQI*SM%"LK5NI!W=60,R6RAX?7:M71VDK:^QL3L<-
M]T-USRLINZV<T[\TE:KG(O5_ #EN'EMQ_P"4G*;GS'^2.N.4<NQ@@L$8>(D5
MHO6MWE&F&.R98KD\;MV4;4=QJ+L"LA.LCZW7_LCB$YR+QP\[8PXH9-0PM3E.
M<4[KLRTZ26[! 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , PPY
M=E\R7F-2.'<9HM4JIAEE.VXSO,XE%F2R(6G#K <82_(JY55M'&N!/<8?S-20
MYI-5K9'-X?ILWH2@D1_<ZWL94L\[U*RR^V?1=),A9Z55"\I4-*7-6](FJ.%\
MDW5_"TI1?EC<$=PF1'W3%HC,6OD)43E4<Q<*V:[H20,Q*P(DG((P]<\R1UES
ML>YSJQU"!.J:Q.)J:G.))Q*65.RS)MM:XU9=<K42Y<#^&EE<3U')&47%R)1\
ME+-Y,7$BN"7S5NIQMI)"B<$$!BL ):TT2:)S.6X1?D^*(U.U:96V@V,T1>T.
MQA$H.&(HE%DI*2A4KY^Y$@>" P!@# & , 8 P!@# & 4&^1Z;.#D<J9K#-C[
M>,).B6L,68W0) @%  :/2Q;_ .X,[XT(CMA'^0OM]V#^R'6 6R=Z3E[W.H58
M:RX7<+[ VJ8L[(41#8F!N,23C4>T\B7IQ)C#CSB]1EN\1&4I3A([:KO0*.]!
MW09I:O-/XE=D12Q2SR3#K7/4$@-+&:1N$QLK1Y01Z$83LT']LOO0:V#O ?V@
M=KM!_+K6 7.P!@# & , 8 P"V<TNJFZW<T[)8EM5G GE6@+=$C1-)Y%HLYJF
MPY0I2%.*= ^.J%4<@-5(EB8M864).-0D4DA,V80:$ %(?&KXO?21H3ZX:\^\
M6 /C5\7OI(T)]<->?>+ 'QJ^+WTD:$^N&O/O%@#XU?%[Z2-"?7#7GWBP!\:O
MB]])&A/KAKS[Q8 ^-7Q>^DC0GUPUY]XL ?&KXO?21H3ZX:\^\6 /C5\7OI(T
M)]<->?>+ 'QJ^+WTD:$^N&O/O%@#XU?%[Z2-"?7#7GWBP!\:OB]])&A/KAKS
M[Q8 ^-7Q>^DC0GUPUY]XL ?&KXO?21H3ZX:\^\6 /C5\7OI(T)]<->?>+ 'Q
MJ^+WTD:$^N&O/O%@#XU?%[Z2-"?7#7GWBP!\:OB]])&A/KAKS[Q8 ^-7Q>^D
MC0GUPUY]XL ?&KXO?21H3ZX:\^\6 /C5\7OI(T)]<->?>+ 'QJ^+WTD:$^N&
MO/O%@%UHE,X?/F4F20661J:QU2<I3)W^)/K7(V4]0B.&F6$$NK.J6(33DB@
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M '$Y!IN"3T/R%X7.>PQFD,8BCI)F=%(YF6M-BS0>L+"L?"VXDM0K,0 UO83
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M5JR K#I,R*"U7DQR2KS!F6FS6<@SE/QG)3NJM5R"IA$D8W9.PNZMPLN'MZ1
M\JAO929L4*5KP00%8>?&9,D*(T9L9BV,R-"'6U;"[$HQB3T%(S#E]5T747.D
M:D,KGYU 1&#SJT3(8GC?DUABT\03QV0.J=_ELGB<>=BV=IKUW<I$4UNRH]M(
M7LQ19:I8I5I4 RE.6:=T\Y>.N;,9++0O1[8W2!A=(RYMC+*8Q*VT#3(XT\/$
M.BT]0MCNB)5+DQ:P<7F<>7G%IEJH*0Y8:VJQDN:!>C3#!<7 & , 8!86B/\
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MN2AA2FVVVDDE-NQ"Q6N[/FL(WOCR0+Z=72L^OZ;?=S/T?^-PK^S:]_!UG_\
MF4SHO_F0_;A)-.(E1LT^X50YE:;Y990AEMI\@;?1VUQL?FM\@CN;:_(NY+%=
M8\U GD;E41GL6:RYZZ09\:)W#'YG5.;2<ZE-:)^:V5S:_P ^.&*"..".&*".
M&**&.").&*".%M10Q0N3ABAB344+2:::=J+DU8U:I*6AJ2DYJ5ZM4BN2>GY2
MR*"IX&T2&S(^D2/6Y(E>HZ_Q]C>$CX955@5$H5-Z=MB:>-M+:=';+DRL$3:8
M\AA2!6)O9FJ-M\(1 B(HF<I_XS7SM]^=YQ&.GU1L4CXXXA<9P<D-631>89XU
M#VGP*9ZBY.HGWQ5LC$*88^UI0@Y:6H8VM[0S(&YM&1%2DR0*1H5)G0,ISGGL
M\TI;$C)-?2=5.\BKZ8OL&CK_ #&K&_R;!)6\-B5:_1]/M.4GWM(M$4'_ (H>
MZTH3C&6+2%:,Y8WA2*3C#!#!1C=QOB[-:3Q;#/+9TVO#HL>ER5A(4Q,^+Q\^
M9.M9.=D#8TBZ(*W4 K)#5,>020YR>7-0TI7*3*8&=#7A[/="P^?GYV*741SB
MI!V-@>V1RE=@S)4_2FF9,NDLJ<XV.0B+H-]BD@K./[.C\5C[6H9VE;$48'!:
MO:EDJ?B'!UV\R1:I,1*4 RW/,O/\?\&.MX]/5!-69:GJ2Q'>N)%):LD-#2B3
MN12%^5ZJ27*K5=7]L;$9K6)O&I5OEK.+BYEC2H75R(C\:1,,O@ZE(YNCR"<N
MBU:[-6@R2MKBW!;@>7Q_>Y!-&1PD:.MVUY+85484LSJUU>?:BA@:7F,RZ*RN
M,R)I5G6_)U+JUR5G>$ W%OBSTV)VM\CJ%RT$^GY7PS;"TNNG=0NH-%:_\HV)
MMCA\><(RUG;D#/Y1-;W)THUV4F+E&HWHDY7I5Q]@H2S2DQ!823Y #9(MKT@V
MX&VYSS^X^:WI_5\L,"X;MN[B9$J>6AXDTE"MJA4JG!<=9:]88\R2^/N52+H,
MXQ]H05/6NPM:6)("W55$$*R0#>%+@_F.XRHI9E\+[K>-E0)N#-9!F!<R=)M:
M4@6(W>RGMG:W5SA1+.QKK=_&RJG^T!3) V=P/+>WNZIW(0!=G%S$V.*IL1M0
MT4>:4C( 8G\-GPVG3/\ T]Z9D,H:Y,JE%G%:;)764T#'PNT/7Q\R0U*@IYMB
M3BE3OD'=W&-KAHZ1AZ5_=8:YQMZD3>H>V=V<U+(J0-K:$WIXMOQ95;)Q C<-
MJ-RK>,S27/;ON1TI,&>7V"-@<UY3OQT6UJX5(SN:6(QZ&-BB,-1E4QA$[E)F
MY,^.Z52]JU;R<ZK]+2@G;/7ISSG?.5^KB*B;.(%)(C5(G)E<Y.0IC<2C.D4@
M=!F)4Z2&2NWI@T+$^FHEJ/TXC<[LF9"TXT\U.>@"T$EI23T1ZE8,3^?)\$=2
MEX3T2V2&<R)C;Y8R&6,HJY3*F9+-9 OC*P=6W7([[2ED1Y_5O#8C23*=2Q^!
M/$*<@"-Y9'1S0(2&@]X>UKD,S?%Y%HEH+U0:OMQ.4VU+E2\"YQM*;-LF,)*)
M&42S-;!!(A F9G+&(>]JQB)BI[^L5#*)&%PD"QO+[U&@1G#"=W$I>=OWER\&
M!@# & 6%HC_K<_KZL+_X,N 7ZP!@# & , L):GSK<8_63.?<9:.#*NBU>]&O
MC7')RLZ@A$=K!KY]]+UV;H.B%'T+B[WG+D#JK2H5)X"37)$D8U25*N[&]!5$
M)U)Y)9P1A+,&'6M[Y]'@_"4<$$='@^N1T<<*B@CAJE8BACAB65#%#%# X8H8
MDTTTVFFFF4Q.CFYQPISDUE0IIJQIIVIK.2,=/_\ !:[EG*V?M?(NAK<3V5':
MOJYW6<2;*DSB; "XNSV9O2HV9A S/T:ESDFL :Y@7- TJYI,:BG-"L+5!*&5
MQJ>AIZ"DR*Q0TM!2-*+(IJ..BCR78HLF-**3DY.4G)R+(7"X5DM1)-VIIK-H
MLZ#)5HX&5,A,GC@[RBP)/(K+B]BQ*929<&MHRN=V^S4-5MS^N,9JVK:#0TN0
M$I:?B@$LA+C&G=;WCC^$2M^UII"TTDFYV22\N:>E\;.C;.G522$^>JUTGM"0
M+[%@KW7<A='IWAVW<^//L9L^)JE"MW:X*UN<CDP6BVI. 4QFJN42IQ.3L8GQ
MX=2VWNCPGQ*RW/Q:7Q&0RKCC3[Q"#J[E\0;IY$C;6D5SEM<S3I7@I+/)%:KS
M<AK@E\"9,$I.W3%]6@0)=@&$UAWMA=QNK>K<BUP3<YW77<2D<.<<<H1.IE&Y
MBH<Y+']L15>)W&-QDY@11F7IJ@G9=G5(ED:9='7-T3)ZXGP3Y)'RXD[1?2LQ
M:M:9+M_CRC;/H)O;Y[&?:-T&TL5GIK8<YW84TD+='WYB9D,J50_R*R&2]'7J
M::/+<1&X;'''RC+#ZTCKDO1+'19&FE::Z B;!'&]66A3A.R7S\VZRP<FX%0
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MC'D*-O2.PW A<K4$J] W.?'[M<V988,# & , UF.LYYT,#]0D7]X=I8!LSX
MP"$KJ\^;!U)_8VXR^_/D)G[F+'"7%[PY@GK]7./6^]*US>F]7$: F?30T>;U
M'3FL-96?11XL2)ND%@L+F>^6.RM@:SC[(\R9Z<G3D#<92%G.<Y-$9S'85&Q*
M@%.<MFSK&'7R-&FQT):4:N0KF=&I^:N.O#/&[QHQ@]KUPW;@VW!^#[E_Z&J7
M\VH_*]",X)U;-Z-[WQU9F2</[TY&L%0(90X0VLM:B5Q6,[6;1K;:Y#T%[A;D
MOAT?;ZAE4MG;.0TN46-:FE?)Y"J4K]5FX$,763F2OXN-76]&C8KRHK+Y <G8
MW;5@LD2KR*N-;PET7A0#60:P721RMIC,4XO21UTVR)LDB!A*<)6NO:<QR/&$
MQYR3,*BI71P4E2LXUX98^$E9I?D5LK=MZO\ +1D0Y5WM:53\@5;%&T;?8\+I
MRJY^QM,5KV9[E<'>;/#.QRN&ACDP\JD6O-ZC;8F8:SKXPU_@[9<E(+;$4;(&
MK&Q$A8G*_I4GHT26FWI+9/4SY7S"R6.#<?;,M:=U(J=C3D-KR]'":K=%K\77
MDB72B)FS-VXNSID<(7%7I/!G=O>D]5*E"V72J90,4A6!A!D9:QE2SRNNZ5;>
MK;[.F4C(BOTW)*!VY-QS^:W%?!,3X_<<WX<"AS-2D8A,GMV>2>[HW<!\)<)8
MRUKLIGCY$,ALE;HX^6J%?'V9:#2GRRN>6U"K!RE8E>[7.<DE+/*VW-?Q78PV
M1>W)5LD]OMT4L.WS:_:#C%L7FZ&FVMTD#=8ID!Y+.#=4!K(X48TA;R#K"AM8
M,:>,#:INZKFP^LC VNY.=\EL28$DTM-NU6WYK>*_,C*SCI:5E3ZSK_(,EDAD
MC7$2SF5GA=C1Q!!4B>R&^3S +V3#7)BKU.[HZC92_(-=M<LD:R>R">GQIRL-
ME8TL<4M$@LT8>:[H]]KMXK/AS)#87)$KCLUR:SV1LIF;JK>BC#-'*IG%39*B
M(U"KM-L9W68)P2VMTI*!49%QFDO:Q1%7]OC4:4JIZ:N;!)E!$<!7Z==D]O\
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M *O_ .0W_P#M'GTCQ!X#8G>+& O9E6-,89WVPESZM>NC-MGX-Z\ACO&CJ#2
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MI:T"I:&SM*5")M4O#NH0)3C1D(SW5R-3EEF+E0C0.;\LYRA_0.A/W7L/^J6
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-@C&8)PPIJ;G?\#__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>30
<FILENAME>g947560g29k54.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g947560g29k54.jpg
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M,E%T1$935&-DDM+4_\0 ' $!  (# 0$!              $" P<(!@4$_\0
M5Q$  @$! P4)" P*"@(" P    $1 @4A,0,$$D%1!F%Q<H&1L='P!S(U-G1U
MH<$3%R)#4E2#E+*TPM04%D)359*3L[7A(U9B@I6BTM7B\3.C%24T1-/_V@ ,
M P$  A$#$0 _ -_@
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M9*VNB(TI#,8*PO;(]IGR.+2E1[-NN4R4:AW.;NRN;Z28P$
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MMPND;_LE;UNK#HRJ-F.0$9=BUK=[$-!T-4Z4TM3%S>,3K2+6 *
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M^L&I3_E8-"K9Z5UB<C^=_P#74/?._+K_ #-$3_U@U*?\K!H5;/2NL3D?SO\
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M7$2XV3=S%4_F9^$3P[_*[\Q?JB> 6HPKXCZ:2\,"@ &KYZ)B_BOP?^6^V/\
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MTPDG+G2I>S8F;$@H            *.EWWR(R?(L+OIM'@9/>OE/LEXH&,
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M:C30_1,I,,)U.UU-UTQOKC; 2WBV^4RT!
M       4>>9GX1/#O\KOS%^J)X!>C"OB/II+PP*  :OGHF+^*_!_Y;[8_P %
MWL>JW%>,F8<7//J6<'A.Z9XDVQQ[-_B>:&L$-['*0      &Z_Z'U^Y2<_\
MX]]2_2ONP<V6EX1S_P MSK]_E#M:Q? UC^:;,^HY NA'XCZ0    !&/MG^1G
MUQ_5COO_  JE8$TXKA722< @                "CI=]\B,GR+"[Z;1X&3W
MKY3[)>*!C       C'R'\#:[\NG5OTI[E $G
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M6%WTVCP,GO7RGV2\4#&      !&/D/X&UWY=.K?I3W* ).
M                      "CSS,_")X=_E=^8OU1/ +T85\1]-)>&!0 #5\]
M$Q?Q7X/_ "WVQ_@N]CU6XKQDS#BYY]2S@\)W3/$FV./9O\3S0U@AO8Y2
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M[?=TT!I+">!J+K]]^HL) J     4>>9GX1/#O\KOS%^J)X!>C"OB/II+PP*
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M1&4Q4SAKJTO6X6\VR\X#&     4>>9GX1/#O\KOS%^J)X!>C"OB/II+PP*
M:OGHF+^*_!_Y;[8_P7>QZK<5XR9AQ<\^I9P>$[IGB3;''LW^)YH:P0WL<I
M     ;K_ *'U^Y2<_P#X]]2_2ONP<V6EX1S_ ,MSK]_E#M:Q? UC^:;,^HY
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M;1X&3WKY3[)>*!C       C'R'\#:[\NG5OTI[E $G
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MVK-TQ*L5<3C,WN%"G>PZ$3@ @   *.EWWR(R?(L+OIM'@9/>OE/LEXH&,
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MW.9YG&2S7-;<LS.,YR]:R>1R.2SO)5Y3*Y2KO:**4YJJ>I*]FP=]L?*/N
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MY_\ Q[ZE^E?=@YLM+PCG_EN=?O\ *':UB^!K'\TV9]1R!="/Q'T@
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MZE^E?=@YLM+PCG_EN=?O\H=K6+X&L?S39GU'(%T(_$?2
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M& !HF^<?[JC:?]7'F[].MX;/[F^-L\%G].>FC>[3WFYKC6ST6458C:)HD
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M /CWU+]*^[!S9:7A'/\ RW.OW^4.UK%\#6/YILSZCD"Z$?B/I
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M?/1,7\5^#_RWVQ_@N]CU6XKQDS#BYY]2S@\)W3/$FV./9O\ $\T-8(;V.4@
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MAL3\5G/^Z'P]TO@"U?(\KZCU6X?QOW.^=,V^F?54U^UC^C']@Y[.OCR
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M5[8^O^N8]7ZYZK^$!+B)<;)<&> (  HZ7??(C)\BPN^FT>!D]Z^4^R7B@8P
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M;-9V5 ;@E!KIH(>/_?HF^-DDP (   "CI=]\B,GR+"[Z;1X&3WKY3[)>*!C
M T3?./\ =4;3_JX\W?IUO#9_<WQMG@L_ISTT;W:>\W-<:V>BRBK$;1-$@
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MP_C?N=\Z9M],^JIK]K']&/[!SV=?'D      1CNGX;^//RK67]'2W@!)P
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M$;/CL2G6M=0.;S('"")%)!)9I30L>%BC?&WLXW).ZO*8D5>+X7KGTZ^'62V
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M,S\(GAW^5WYB_5$\ O1A7Q'TTEX8%       (QPC^5UT3^1'ES_:KIX 2<
M                     4$>8NP*;C%O<R1":0E+I+[&C3Y%EUPNG1[MSAB
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MJN++MEM<F5CAT71H7^8O,U=Y#))&8L/7*/8Y"-.F"MR]2Q=S;Q;;EO7R(NT
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M<_JZ_70W+:DF:91'_=20MW<%$78=LEMJ:2M222:G%ISMIB]7*$YPOX2TT"H
M                         %'2[[Y$9/D6%WTVCP,GO7RGV2\4#& !HF^<
M?[JC:?\ 5QYN_3K>&S^YOC;/!9_3GIHWNT]YN:XUL]%E%6(VB:)     ,57C
M\$-B?BLY_P!T/A[I? %J^1Y7U'JMP_C?N=\Z9M],^JIK]K']&/[!SV=?'D 5
ME>9C[EKW!^0J1?I3<!-.*X5TGZ:_:Q_1C^P?H/S'D      8:X&^Z&^2C\DG
MC^_0NJQAK[Y\G0C]%/\ XJ.-7]DN5%0                !1YYF?A$\._RN
M_,7ZHG@%Z,*^(^FDO# H   'H.K2UOK8O97QM;WEF=4:AO=&EU1IW%L<D"LK
M8A4A7H%99R58C4D[[DJ$R@HPDXK?8LS3;3;.,@=(.IVHU$48X&?5E<G0>,+D
MKI&H8="(R9%(\YHCCU"-Q8X[NV;-#2N2*%*D]*K0(TZA.<H/-*,TW-,VV Z/
M?_-%5=,HZM;+::E+ZT5);T;NN/,V#$>S.ZRN,,4ICB)OE3:O0N"1_BRQJF+T
MG=F)0464X8,)U-.P67N68)3:F-:A]/2E_P!&0$M4U<A2;($-;0%&AW:9"P;H
MDL.CJ=)NQ2Y1HKE;+LG);M"=FF3JRRU4A;LZ91O2@O0]R)4FZZ[8$'86J+QI
MB5K%[)'6)G7.")G;%ZUJ:&]O5KFV/$'I6!O6*4B<DY2B8TRI2G9TAV^Y#80H
M/)1%D%G&:[ <Z                            HZ7??(C)\BPN^FT>!D]
MZ^4^R7B@8P -$WSC_=4;3_JX\W?IUO#9_<WQMG@L_ISTT;W:>\W-<:V>BRBK
M$;1-$@    &*KQ^"&Q/Q6<_[H?#W2^ +5\CROJ/5;A_&_<[YTS;Z9]537[6/
MZ,?V#GLZ^/( K*\S'W+7N#\A4B_2FX":<5PKI/TU^UC^C']@_0?F/(
MPUP-]T-\E'Y)/']^A=5C#7WSY.A'Z*?_ !4<:O[)<J*@
M"CSS,_")X=_E=^8OU1/ +T85\1]-)>&!0
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M7[6/Z,?V#GLZ^/( K*\S'W+7N#\A4B_2FX":<5PKI/TU^UC^C']@_0?F/(
M    PUP-]T-\E'Y)/']^A=5C#7WSY.A'Z*?_ !4<:O[)<J*@           !
MG.,8SG.?2QC^'.<_:QC_ .>0!^):@@THL\H\DPD[77<HXLS3<HW3;'JM=RS-
M=LZ;Z[8SC.NVN<XSC/IXSZ0 _KUXG!NI&32\';E[&Z$^KU]=W*TVTUW,U+]/
MU>Q>FQFFNV^,9UUVWTQG.,[8],"D#S,_")X=_E=^8OU1/ +T85\1]-)>&!0
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MW_WB!&E1HZ,5Q.EC3,Q&PE1[']$D_P#B'A9_S;M?_<!']'LKYZ>H>Q_1)/\
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MCOL$WVVQ,,6]_P"\,O.7+UG+?[3_ /4L(O7/9'_3^I J]'\F>6'T03* @
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MV&?$^;RM95KF290B.V/:[_O$0M'&5%4QAI:3T6]]W8ZL-^VCJ'B;R2=2=?\
M.DPF-K<A(^0.9.T:QZ>KZ)M#-:;=>ZABKY4>1EED+N8SN<-<WE0S.SX662F-
M;4!B_=O,,<B"2CL;R53I2=U4NEINZ,4\,=6TO0 H
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MUSMKC;TO58UVSKKG;7&?2SG77.<>GC'I ?T
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M:1X=SS"4Z0G<YR<2E*PS<I*F+VW.VVT3DZYP7K)B.V
M                                                  'V_M@#U42)
M$W)243>D2H$2?7.A"1$G*2I2-,[;;YU)3D:%E%:YWVVVSKIIKC.VVVV<>GG.
M0![0 ]5$A1-J8I$W(TJ!&1C;!*1$G*2IB<;[[&;X*((T+*+QN9OOOMC33'JM
M]MML^GMMG.0/:           'JK$*)Q(RE<$:5<FR82;E.L3E*2,FIS=#R#,
MDGZ;EY,(/++.)WSKZHHTO0S3.N^NN< >T
M
M
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MBH8MM\/),2SB3&H-63_KX"+IT:HVS_Q,V,!71DJ8F641B_N:9%&I(TMS]'I
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M\_?FSV-^UF NV/G74/<WU3^&7G[\V>QOVLP%VQ\ZZA[F^J?PR\_?FSV-^UF
MNV/G74<*CD5[1&UJSB4^F52S&-6 3-TYQ</J*8U^^-:Z,L1+VB5%NKU>5D(%
M20_TCTJI#LQ$';>N%'E.!/K.Y)X7:D^>?4B38$     '$2#_ +!>_P#RAR_0
MC@!BWFW^3M0?Y%JL_P!AF(":L7POI-"3R&::;=_=HYSIKG/V04I_ASKC.?\
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M2QNDL1?+%:'M!M&8JZ+FQO<%C4C9%E:V03N(279Q-VJ[5CCL6LO6^W]H"
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M$H0E:BF[+EM7S-,C71U1N"5/@0[M^5S3>N6(YVBQ@"       (^V1\.G-_\
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MFOMVXM38O=?9BMO1G$B9>UF2/?G.H?B'0GS7L/ZT@('OSG4/Q#H3YKV']:0
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1HUV+W$ZF]]>F>HON @ #_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>31
<FILENAME>g947560g37q51.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g947560g37q51.jpg
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M87%R>8$H0G21H28G,S9(4H:BL=-#8FB"P</A_\0 ' $!  $% 0$
M      4! @,$!@<(_\0 51$  @$# P($ @4(!0H$ P4) 0(#! 41 !(A!C$3
M(D%1!Y$4,F%QT0@5%B-"@:&Q,Y/!U/ D0U)4559B<H*2-)33X1<E\41%4V.B
MQ!@F-5=S=++"_]H # ,!  (1 Q$ /P#W\=--'331TTT=--'331TTT=--'331
MTTUYQ]W[3W'M*X^+/LJ8YR[4XHROA[.$QVAM2T69UU7J2SAX70=:VS7-J;GK
M%NJ$Z^VU#;HN\T]@8N+DWK2+^"19J_7$?&' GHVLF -H W;AD]\YR1@8(QCO
M]YYXXT^V@/$SY![CLE7:OM4Z&H]2H%;X.Q/)!6T]O2NMMF.=F<OM$T_<3EEI
MBIOZQ(04MFIGN+*L5ND3LZ.T;,M#&:K< XC7D>,SAJTJ!SG/?&.> <9/_P!/
MMTBH7Q<MWDXQ-N6-CU/QK8T/9U6TWL?2M#AM_P E)[DCJ/LSEGKCCC*8VC17
ME1C#KS6X?8(+#*W.H.#U2#NC).OI1!'+L4KTU4K@D<DC.>,#(&>^3V_B.>-<
MS>_B [XM7)"M:_U&>'I2M1<Z>4?&PK'XX^/5-NCU[X;%HY!5%6R4ABWCN/C8
MS:DU%)DV$.W?&:HJX7(D.'2BL^FJA1M)/^B"/L\^T^O/ _CJQ_PRML;EWMP(
MXK[EW]*5V=VEL_3U0N]AGJTGT6DXBQQ@92-F)!@*%@(Z(L$C'N6SJP0L)&CK
M\1+D=Q\&9S&-VQUM6L &8#L"1\CJ=?35NCIIHZ::.FFCIIHZ::.FFCIIHZ::
M.FFCIIHZ::.FFCIIHZ::BCSRNEJUOP<YE[$HLX^K%VH7%3D-<Z=9(Q:125>M
M-7U);YNOS<>1:"(&^BI9BT?M%K0M*#MQJ4A6,9QEJH[C[Q_/7F&XX^('S3V+
MO_PYM&6+=5Z.XT+ON,T5S+E,H;M0[XF>04IR!N>@G-L*MDC+O&-#Z"B[9@++
M(4Y=79P4Q5K[#$UE*@!C@88$J?;;W_B<?;]F,&5="\7/DG4.-%<LM,U/5-JB
MUQP E^=.SK/O/<EB5?)JN0/(W;FK9ZBQ4G5-8(CINS.X2D-Y"O3DC%U^+C,)
M(SD6DEZ3=3B@.?D#\\_AJP*"<$GEMO '?L/4?XSJ1+;Q#-ZL^1VP-.Z@IL/>
M[+MGG+G0E'1O/9TRQHVO8=MP#IW)?$G#-Z=0'\Q#P3=X%][ZHX^/N9:5=2CE
MO98E,N#$/73:-N2>R@\#W<KSSS_CVY1.J?&FW#:-: V1L_2^A]91NP>#Z.6V
MHSN-K;1G(QK*LN0%+XV&H^P\UO3,_:G;ZX7:]0<Q1(;7%/M4^]4[8T/R24Y(
MCG --@]"2 V#V'H3ZGC@'))Q_:T\WXF/)3=,U11J"^T18M>SWBL:<V37JCFW
M0\/=;+Q[X7TG<.LKL>L;(K<!>ZB^KLQ?6+MM6+1'BF(6>BG9'N<X.EDV:J%
M]CG:?NRV"/\ Z:D#HCQ1-OQS?B7QFN-#BKIR%WOKCPZK!JBPR]AD\.]NZJWS
MI.6N?)3>5B:MHY102>D'FHMP.;$SCR982+Q[0%.7,9FT9"%HR#+$' !;]Q!X
M'?USQ^_O@Z<SDS:]@[IYZ;9XVV#E]M'A?J'1'"FJ<B:M,:IGZ72YJ^6VVW?8
ML%;-FVR?MM>FR6#6VFHVEPS*0I+1<="GDYIT]LST@3L !:M&  < ^8CGT  _
MGGU]N/73%17B ;6U?LGD >,WS2^2\:K0OA6PVB;!9X2_0E'VGL/D63D QM6P
M]?:LT70]J7J8MFV(ZHQ=J9:ZID1EF_7%"$*9K<$P</0-7%1A>,'+YQSVQC.2
M!@>^=)^2\;S>K;46EMKEXRU"O5N9B]Z/MZW:8?;KM=#UR[T7R"G]'RJ9]GJC
M4]^VKJ:FS;.M/[<K9VP=:R5:KKYR.E.VTE*QS]]TTV#. >3C X!.5SP2<$@D
M#OSZ=QIV[OXK&RT;UWSI"R:TKVL]<MJ[R0@-);*',[1^,[6E]5:/G=FPT[JK
M;D!JRX<?WUNEVT/)/W^LK';JA=]=QC1$H^#9YIJFIR#5-G (.>V1[9..>0<>
MG (/N-=KC1XCFZ]EEU=5J[4M-CU[K#3WAWDW]?.1._SU#:MKL?,W4M9N;"1U
MX\Q1&M,MDY!AEV3; IPM>>[<OYI6K5AA7'HAJ4T9<$]^[8P.,+W_ ,>@[_9>
MITU9HZ::.FFCIIHZ::.FFCIIHZ::.FFCIIHZ::H/\3W97(%OS8XNZ2U).<T'
M%;NO&SD=>)>A<)[=IBG;"E[C4+;J6*J5GGI/>DC%4O%3@!V62:2J4N'DHDDJ
MR(UB7[=#Q*&KUQAB=O!4>8$]PW; )SP#^[2*KWB)\\>,U M-,Y.:CU?L*Z\-
M. .M^4?+BUXO;R-V!9[9<(W=$;#4.H0M)I\QKUU/GL>NJT*]W(4NRJ,$Q7<Y
MV#C[$-,(Q*U7:I/!/F<JO'VKR3QQ@]L9[?;I7TOQ8.3-QDM?:83QLH]=W[M/
MD#3M1TNW7TV]M7:!>5BR: M7(*2L!Q;-U'4]NXL\/'4R5I$=6T5),?;)"2KE
MP@I\L)+!B\M4VCOGC&?0GN%]#@\D'T]1Z:COQG\57E7]'2M1\?4]5;;VO4-*
M<Z.9VZ+ANK<\S7:X]T[I/FCNW5,%JS4MGK= ELVBQLH.JBB(NW6"*@*K 5N*
MJKR8:F78A"9M591N]AY0,#/)4')Y_M[Z>]SXO_(FX72.SI[CCJ5WK2R<A^(/
M'.LGVAL^ZU*_YLO-'C#2-]4F:L</!:]LT5"1.M)"X#CKPW;NY25GV U,X-E%
MR#9;UQ0G'\/XG&J;![^A/;V8CW]<9_QG3=2/BY;791#S?$QKU#2SZSX+>(-L
M6V:DA=E/C:4G]D\1N7E#T*M^W:NZ6"T.<V!+>0DZ_8',DQ=UN%F9. =0<TX<
M#F05U78.,'@L@!(YPRY'KCC/(]??4@K#XHO(*H2&[-57'5&AJ_OJC;=XST77
ML/$VO?&RZ_>8KDQJ:V[<BH6O5;7&D9[:-XV32XFCS["6CHNMUJJR+$+VWO;!
M58>$<-7[5NW/([8)YP.QQSDX )[<Y],'3!$\;CD-8=-JV_0N,^HB,J1P1+S;
MVQ%V_:MRC'*&-3Y&;AT+=*#0OAE D%/'\P/51;/5I6Q(BPPZ7I8^:;294!41
MJNP9QGN<#]X')Y],\_P[Z+!S2YGV'DC;JX^O=9KNL('Q@>(7'JA1M3,X!.?F
M?V/QZ3LN4H-P!BMQ@Y:"L;6>KMBLCYQ-24PFX.;!7HUTFJP===.&JX& 1W*$
MG/N"1D?+V_GQ.[A!XBUSY?[>)IYQJB"IMCT]J>XR'+P36P24N33W(*(WU==)
M5;3<8DL>S2\19V>J-E;)%)2F6[U-.3370F"QV'#D35K+M&<\'&WC&01G/[L@
M'&><C/',2]*;-O\ N"QWKE+MOQ$[]QNLU,\22\\7H'CDYQK]_HU-/I6W#:TI
M?'>QZL>P[*RS6S=R5P )[.R?RJ%9XY]9F=@KK1M!Q(FRVKB,<!<Y0-GUY&[(
M/L.WH._KIBV_BY[[X\\4V]Q4PIW(:_5RP<^]L7^&NLCN!YL3&F]'\S]C:LJC
M5FK6NIK72J!46-?:-JK&['VM;Z[" DH6+K<="6%\X=':-5* L1V'E [8R5!]
M3D\^P/?N/690O%9VDRY;6C2ELT75:7K14KL&KZEL5JG=AQYMQ6>FZ4<;;BHF
MJ;CB=>6/CC'W"=/'R,3.ZNO]_P!?V>AP;<UDDI*6? %5W[5NW(R#G@$XQD<X
M/&<G''(!']D>:=XKNW=TQFIX#8]*7HK:)N8WA]U^1UI4Y';VN+\C6_(_9$M7
M7ZK@QVQIAO6-A:J.Y@W,8QMVIKI8J_M:/P_]-[KI(8MS-O\ '^/\?SU79@_9
MA^>".%)'(/?W! (/OJ?W!GG-MKEE)U:Y6BDZ#H>F-T5S<5GTE#1FZGDER-;L
MM.[75K*1#?M5S%6B&LB)^).9FPRU(EW['6TH:+J-A3(O9AM)B:M9<9'.01GC
MCD9R#_9CGN#Z"T?IJW1TTT=--'331TTT=--'331TTT=--'331TTT=--'3348
M]L\*^(>^;]7=I[JXS:,VKL>J#9@@;M?M8U&TV5BVC7"W<:S5*R\4Z=/&,8[(
M5W&,7Y'32.=E,Y9! <I"*:J"1V)&>^"1G7>LW%/C/=-Q5;D);=":DLN\J2%B
M"I[8FZ%6Y&^P"(K+C,.N.LKJ/))@/"*>/%03KU\N813MTJ)*S4X-E;3)P1DX
M/<9X/WC2*C^!?"B*;;<91G%'C\P:;Z;%9[E;--4TT -D,S2V9\C.U"'$)1)-
M%6'/Y1X:KQ@";'A,^@:9A*7N&FYCC))QVY/'W>VE)1^'G%/6B( >O>.FF:4.
MK6R0OE='6=>5B&1#7:7H2-72]N8(8QP4@LDMKI&*7*32<?$)&N97&/7!VQ"(
M4T))[DG/?)/OG^?/W\Z</46F-3:!H\?K/2>NJAJO7L2[E'\72Z+!,*Y6XYW-
M2#B5E3LHB-"!FV4^D'1W1L!$A.2$SY4I3A*<-4TYG331TTT=--'331TTT=--
M'331TTT=--'331TTT=--'331TTT=--)^V52LWRK66CW2!B;53KE 3%5ME8GF
M+>4@['6K#'.8B=@9F-=C*UD(J7BWCJ/D6+D1&[MHX, R%C(I.6FFCC^*_&N*
ML"+7&:(U1'V8=NHU^1/LZ+7FTNF[ZRI+_6VO+7\0"P0YS/TF@2DE3:Q*9)EW
M#5Q^\B6)0LW)A+:KD^Y]?7W[_/UUH-.(?%IA7Y&J,N/>H&M9EM7.](RD""@U
MP43(:??S\Q:GNLG;%###<](=V6P3D\XK9$*BRRTO(/EMLN'9B+:9/N>^>_K[
M_?\ ;I0LN.&@8VUM+W'Z;UNRN;&Z+V,RM+:H0H9YK?B:_'J@EQ!)H:8=BL:]
M9A%0E2Z"X>JJ8T0>39CTX!AID]LG';&?3.<?/G[^=(]WPNXD/JH"BO>-NE75
M-::S>:9:5@^NJP6$9ZH?6J-O3G7S./7'9;M*JNZPT/;D1#= VH+-%1LX! I-
MBU<B:9/N??OZ^^L=7X4\0Z2S;Q]/XTZ2K#%JXNSQNS@M<5>,;#>[*I,3K?8C
M_ 6D<(>7][H4%#5*X/E)R[LD%&LV$P9X$*4X:9/N?F?O_GSIOJ[P7U[!\KZ?
MRC-//'8M-Z.)H#C=IUA5*-7->Z$H\JSJS*T9JSB"@&EIF'TLUJ;2-BD3TXZC
M*G RD]!P4<!G(HRV:KN.,>YR3ZD_;IVMZ\2^,')_-85R+X_Z@W<2ENCNZH;9
M] K5R/7R.U@6^#%N)R/>&:L9%;5JJ4C1DQ'2>6K7X@U<^W#Y&J D=B1]Q(_E
MK%>.(G%O932Q,;[Q\U!;&EL8ZYC+$&:H-<=IE&&GRRQM5-3Y6P\Z!:Z7/3?Y
M%I H6:X.7DPQ66HGSE!&F2.Q([^I]>_S]=(B4\/C@O-1%3K\IQ#XZ/8&B/Y^
M0IT&745(^#5PMJG<6BS-8J*1#)8-8FP61*9Z9@D-_@LE,#'(NX\SL8RI:;F_
MTC\SZ=OEI5DX9\2R[*LFXR<;M*KVG<(^?C+1?5:YJ^;-.-;7!*JUJ5(2?PWU
MSO+-6%KK=ADLJQ(S< M4-)NW4:K+;+3)]S\]8G/"WB,\NVK-D.^-.D7-^TC
M5FJZBMY];50L_KJN4H/MZ5#5.27&*<Q#"F"[_D@!LM*:N19#07L#$(133)YY
M//?D\_?[ZDWTU31TTT=--'331TTT=--'331TTT=--'331TTTBWNN*#)7V!VG
M(4ZMO=DU:NSU0K=Z<Q#(UJ@JM:'D3(6.O14VL*G[&(G'T%"NY1@W.AL]<1;
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MJ[J&,>9D1O*8R:C28ZVV6SMUE0LEP):&LD:J[$$>A/!/N/<GWU<QX5/^;,X
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M=E=Z5=[.%V+4QO(7=560@1;0C;2Z^(PC9T)5FD5Z9K"K,6QM60D+%(^2CA
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M9SVZS15E).S+#4P2LK,C*DJ,RLA =64,64H3M8$ JW!P=624\\0!EAEC#*K
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M954!4,CY<*R QJK%R6 4 G)7#&R6RW&+.85;&.$EC+<OX:X0LKG>_E3"Y8D
M#.0.G-\FM/1+8YVEH;6(K?#KU&D"H#DZ5M$(64:E.SLFZ%Y]3"1I4?&3+040
MO.41$)OJNHK52H[-4"4H)24A =B80A=!DJI?#J N[DG'[+8MAM%?,R@0-&&*
M^>7RJ V[!)P3C"D]NV#ZC+,RG."K,GV6C*IO) "G#087N99+0)6\P,F8![Y5
MQ95C;2#D2VSHI<##'YQ@N"O!*QGJ&DZUHU=UBIGF5&JEWK(0'-/$LJ!?U1RU
M02T<7[!(!#MD R<?3%6Z*S.5+"$[!"S%3,Y3!(8+Y0-W?<PSY1@G6>&YS:]>
M>V5+UNQQ8W3>*<8*V]I();HE71H]NMVERN)()!9-N=DT0A!7KM24*2R&LP@K
MVX>K*&1@KQLF7\,%9(F'EI!5ROF1H#X<0W1E@"QD0H45L X)>G:R,;E(8;=P
MW1RKG=,84 *K(NY^''FV[#D.0"1)2D[?UQL/"4U2U1L@[RC"U19EKCY="<Y(
MG.51;]#9\I"5A,-11A('! E1ZGF0K&)VEN%)6#,$P9MJ,8V#1RA9$66,F*14
MD&^-T=<J"0PX!XU$S4E13D^+$P +#>N'CRC%& ="R\,I!Y[@Z7;Z3CHL67$D
M_9QX,9[9.]<A:A[]N_;U#K0COV^?;S=^MIY(XQND=$4>KL%'S) U@56<X168
M^RJ6/R )TP-UY0:PI^5A'(DFW6$E[88C4AF-0VSQQDKET5.3I8(RR(%Q(LF,
M@V:E4E!E)5A24PE5U';:9E02^*[R1Q K@(K3>,(BS$@[&>!X]R*X#^4X(.)&
M"T5DZEPFU55V\V2Q$>TN  "-P5@X5F4LO*Y&-,2]YNY]XAM'U)GA3EX"*; ?
MOCC(*94R^)N&#T_8(T S%B=2,?) &8+X0Q 4)J<F<)@'ZV'AF6.DR#2P5"H_
MBA@\E3]'FA=PFU?!/G\3&'W*BKN)U,ITO(7"-*V?&EB)"H!A8?&C<*6W'>N"
M5(! P<X(TD \^YF58!>1>NXULEV()F1G4\A\U,-V!EEJI2TKBE(+EQ*QB%M\
M>?S"<C(,V<'2H6O-UX5++'1*64D#S2N#Y3YB#'"5 8#*DY([')XRITH2%9YW
MVD*3A54C)'ER#( 2",'L">Q Y;67YQ7]P)Z1I+0#$V&T]+-F<.W:RR_AK&#A
M)\8!DPS?*,4,3-@?M'./5&[*@HG8<-^RD1C]:724L8TB@0EUP3&I3Q$"Q!7<
M.&>.=' +!04W*ZEL ;:=-T2#SN9"JACEW.XH5+ K%R ZN. 001D,!G7G:_PD
MG>]WVCPRUC7+/,*D&,!RRJ:6B',$UB719".TEL[+UX@@&;')1Y'8@"="0APW
M$^R3T###D0L=!TO?*^Z5<D-4\+QK0I-F,QMF821(74QHA1'5R3&^X@@8*D,H
MT;K:J.AA$M/G>:DQ?Y[!C*,XXE&&VE0 X*DCDJV=VO5+X5/^;,X ?['G';^R
MNK]=QKDW^NW_ #-_,ZGWTU;HZ::/V=--(:P[,H%4R1%@ML)'&&DREM5O1F>8
M]NW,Z,G#-ODSK)$MVYS8%@62+0$F1I5Y,]M*HN-%2@F>IACP"Q!=2V K-PBD
MN251L *2V,*"=;$5)4SX\*"5P<8(0A>6"C+$!0-S*"20 2,XU'VQ<SM61;A3
M.#!.6IQ@N!X)&M$C8+Q[\4>I:72UD+A'JE0L:U-4C.-8_0(19$HS U?6-IIB
M51GG<?Z("H<'D*Q.6\OG4@8=2"A;.I6'IVX2C+*D0QR&)+@^@*@<')PW.5/U
M@,:8:V\[+$$3C,'4H*#$AJ,WKV*4R1T+UX>1E!*2V&5LI>5K@YMJW01KC#A#
M)3I66ZT&9#Y^;KR5\"EH0,\><L[*<(&.,QJ0K>*!C(=5C.59S&)>+I0#F>H/
M!SA=B!ES)D MD\A5R?1MP 8;2S,RO+_;E@=>R9VM(F:CH60E0KI9 Z6BIFM!
MSZ3IO'C,7.(FW1[GS-\K64,>184H(IT1$1/U?>)=Z^-'3Y)& 8HW'FGQ@@.P
M(\JGSC!AR2&<LV_'T_;8MK,K2G;GN\@/EC/8;0>\C8!R.020H!;R2VIO*R-_
M,Y?[+>84T2C(G#H$-Y3X@;P F>SUTI2,#F*",IE+R/ $O'KM"EN2&PB/EOUR
MF4A[@[+M#90S./JTIXPP7.%89 (+&??YB'UNI:[?&1LIP#D<".( G,JX&<G&
M73( 4$/'Y>-NN>I6SGKE9E(EW>&LBH&<35P8D*/"[)KERU^:,FPDBP7>7;>5
M2_*):\#SGTU((QU_SC4.Z!JNH=@^TE48\B2L4$^*Q8X-3'C&,^(@PC4X9\OT
M:F4-BG505. "J<;(FR L1VG; V2,@[2?\XV>$.#OF0G%EJR'AO&X48*[>=:5
MFQ7]I*SE1AM4C4,X:O75IQVR0(@@QGS+*X$7$*TE6'CU!XY)B@& ]/08 !8E
MO)"X!XP5W  U#J+C F[B 'S\%I& \LLRGM$,8:92<CL9!N\BL-@<7L'$J@(V
MX_='+G*!-;<%9UG78-7L_*DI0)&ATB4LEA5E>$+$9R4^582W"V6#8%P8.<3U
M!??G)IX?K"IKWY ;.2\D)X8,!(0I"T\3:QFFC*C-.!'L(&)&_P!7@YYC.0$C
MDSR/V.2S,-#:9VDR;,'R7UL9APU*0*8NULT*4V#7]E2SA+92'0,YP&(KE>0A
M:L )Z1/.M6')T9/E2Z2J@1*R9"$V*2DR;0::V1,08W!!C0RR*5(.Z.60X,XV
M6M14Y8AJ?<#(N0#"W(J*IC]:)>"YB7GRG)4<(!I: W/O^#/EKBQ;%8N&DBX8
MX0Z0[E1.'()N@0^ 9;A<G:81F;LTNU0,..Z&K046/"",UH/(Q]05RL'%><<M
ML,M2JX\:YSE )@X&8XHHCD9"FG4#+R%=,VJA=2/HP^JH#"&(G/ATJ[BT;*<Y
M:60XXSN;;@J-+!CS2W+$C[FLL/)X;MPNO-9*X-B)R!<=;7Z<D$U81SY.31U7
M%(8[O0X*]ED-Q%0V$)3F1I^I[J"B^(E0_"XW4LVY\6ZG'EC$+D/4U<CC$@.&
M2,9$<AUIR6*W$G!\(<GCQX\#?5/C,GBKE(H47L3PQ(RRX>R$YZ3Z2)'-46&E
M,>IZ2_@<N5H7*TNX-H5 _.J904R'5EB& Q^42#O<O%>HW:-U%Q*1]8R YGI%
M5"-P+":)MA>M92P5:A<FGIH7&&P\DQ">121I2=- DB*<DC*\&.4%@M,.,-&0
M&EF=.02HC&[); >BO<WM32N&^)EG9JR0R1J7EY'#>A%@F#8&K_D+@KXHS%:/
MT-ECC\K../>.<#2W'ZF9:FZJMTYPPEC..0 DVTYI4(Q$[R,?%JXX1B/F0.!D
M*3J.FL-;%G!C<<E<EHRP_6D',BJ@RL+OR^-I7DE@-/\ UG<FK+AA&*[>ZX_,
M17E0S7("92&5965"<?#Y#VK[^L4$N19]OY3(0HHLK'V7F7@N=!4$+%5PLS $
M(7"2')<#]6^U^3&^/+@['(R%;$=+15<',M/*HY\VTLO&W/F7<O&],C/&Y<]Q
MIRL9PK'?&<9QG]F<9QG'_OQUOZU=?O331TTT=--5_P#'?_+M\1;_ +O$3^Q^
M>Z:N/U5_ZOYZL Z:MUY\^-_*6\Z>D>3U5A25=ZQ3SFYT3((NP-RA_JW/*FW1
M#=NW>M3,R9<24].#PDCIVH:6[4X0 R1.5=<+>>I*VV7*HIXXXY88S#L#1;RH
M-&9I0=LL3E@[1,2"56,MGS%0>LMUDI:ZBAG>1DE97!"R!22)Q&APZ,F"NX 9
MW%E).%!)G3&<\Y@X@(<ZS8O#D=B;9=1-I#EF8;AY&-FSEL(K<Q,I<#F(\B!$
M<)SA;H \$6(ON$ZR=>+@"2@VN/K 2R<>8 @#P"<A=QQG&X*N<,67(W2;Y\E2
M2"<+F-3G)P/,LN,$E>PS@YVYXUI27/2=$U([94FNMQ@8&?N$R4[GL$2(.-F\
MK]5+EKYD ;2*'!/,$>3,T(+C+<Y"-FV-NNY&'ZJA7)7C/BN-QC<@ @1E@)5"
M8PI96#@J0RK<O2H']+4M@<DJ(UP PR?,Q_S;!OL8$8(9=9!\\)T+MV!U3*X]
M6T<6-"VC"9(!R1$"]BXM0<$*Y=X0XS(RS0),*;Y)Y3#RIJ F<(47KN0$&2A0
M*V-OFD&=\0D09 DX!)_6!2LB$.JK@J3=*#]BI8G&/\T_*N5=@%9<C;@JI(\Q
MV[SW#K5WF_KQXI(;97[)4R^N_;K=(;)G8O"HZ5;PQB(<LL">F&5^X2$.6T:X
M[J&5*LX4/.,S%+UG;)RBRK+ SD   2C)[+M7;-O^MN58F *E<DE=T=4=-UT.
MXHT<B@XP=T;<$AN6!CP#@9\0<G[#B4E3V%1[T CFH6F%L" _,Z(YZ(SEOCS9
M1W<L\Y2[;XRK&<)R<(\*SC/ESG'72TU;25@+4M1%.  28W#8SG&0.1G'&0,^
MF<'4+-35%,0L\,D1/;>I /<<'L>01P?0Z676UK!K0?RD9%!RYDY!E'-TX[Y.
M^=!:!Q\LY^93K&C'RQG/S5^S&<]622QQ*6ED2-1R6=@J@#N26(  ]23@:N56
M<A45F8X "@L23P  ,DG]WW:;.9WMJ:!6L3Z[1"CH*L"@LUE?*P<;G+,HE+:"
M,%"PNDJ;GPLJ?1(A>"^3 UY3&RWNU0DJ];#N#!-JDN=Q9DV^4$ AE<,"1MVM
MNP!K<BMM=,,I32E<!MS+M&TJ&!\V.&#*5Q];("Y.FC?<S]0@R1#!-CF%IPG"
M,,HUNA1BE;$<  ,3E\%SZKA8ELQ8($:?>XR(F4(04HXF7K&T1C(:9QL+\(BD
M@0"H "O(K LA 4,H)<XX =EWTZ>N#\$1*2P7ER>\ACR2JD8R"V03Y1D9)4,F
MG7.&CA(K#>J61TV\I2!>XP(;8X0L@2BBH5Y%KPE445<F+&4?UC,"E8_K%B$O
M"W6EN5W38S;&*EA+%M.)XX"P\Q.P%S(6P1X*-)V!"YEZ9K656W*-RY*B.1B/
MU;2#.%QV4*?7>P'ID_F>;].&?T#TNTH6ES[0F1Y:D1@^)),0H2%*]/)%_$G$
M>Q'V3A!74BW&A>4X6O%%ZTH"%_5."5#,/%B.S*5$A!RR\J(,,,<O)&H^L&(]
M-5H)!= 0< &.89.8@,>3WD)/L(W/.,:Z(.<&JE!&=Y%6YHE8!N<I^'QQ5("5
MFMZ(F4YE1*4@PV\A@.4ISDB8J3<83[5HL^=A>KK:021*#SP# V2$I&P,3#.6
MK(T&<<K)D (6UA/3]<#@&(]N_B+W,O?,>!@0LQ&<@%,9+C3B0_*G2$PM*$7$
M;+*E82E3^/D A[J)@2?,Y$W.V1A:E(4G)#)QD1!ESY1JPK,E'?K9(2/'9"&"
M>>*5029I8%\VTKAI()@O/*QLWU<'6F]IKD_S0; SY)(R<;$D/&X-PLB9XX+;
M>^1IVX*^TFSX%^3ULKTRHR4K$*/EF3DZTK$DR%8;C-D_905)*G.1X[C5A>.Z
M<]^M^&MHZD T]5!-N (\.5&)!4.#@,3RC*PX^J0>Q&M22FJ(<^+!+'@D'?&R
M@$,5/)&.&!'?N,'G2M_;ULZPZ.FFDQ9KI5:<T6^L\]&PK= B&[O7"!E((64X
M(L+?'F<'2/*T87D(EX3E:?-V[XZUJFLI:-#)4SQPJ%9O.<$JHRQ51EFP.3M!
MQ@Y['6:&":H8)#&TC$A0%'&6X4%CA02>V2,ZC=:N8-"A2O&L&P>6%VU6)OV4
MX#'-%/3ORLQ-5.$I?D%YP-7T@-P=N%L9LT)@9E$5A*>>K.K*&F\18XY)I(UE
M\C$1%G@J(J>:)1AY#(HE$ZCP\21 LI()*R]-8*R<INP@<QX"*9&Q+&SHV 54
M@LHC.&)$AP1D8+0/.>>0!=N6E#"[0WS&. @5+D:.'4=8'HHVME'@[7&4.I5^
M*1 =LX&#X;D L'63"L*+H2]9",G_ "17"U-?"2KS8\.C2)XW#>!R]1X@VI@!
M,C<P4%CO)TQ(P7]:ZEHJ>49CCS^O=U(*^-D",K@G)W'. ?JAM['SNN+QLX,T
MBH>GX0WE3 :$=@>O7C=M'31>PBF"\*1]A$,]>Q:VD;[=RZ8F9.!E1@>76@_5
M]94&-H(%@BWJLC$#RI*7I\M+,H1'AFFHI2=A4),0_'?:'35/"&\68R,$8J"=
MI9U E4+'&=Q61$G3!8'<BD,-WD9^:Y&[O=$=NXNP; .TPJ82%PQC94+=ZT9:
M[';X9VA"ELQ!6]:%R(_L\"]\[S[\>&6&ZR8@VZCN9V$W!0SQTJR)XT@421O4
MT]0<0J"N_P LLBJ/U<0@<%I'&)!;-;@600;L/+MQ#R5<1.F&E<,2C;HE# AF
MW8P@P/OBQ:KM:O$O4>[/;,]=QW"W;T4R794F0;#>,Y(:HB\D:8,4J\!-[!!'
M&.P<9>^X6H B+6G'9](5]77PUK54YG9'I-A)?R;J51(N'Y4^(C&15\BRF0+Q
MR>=ZAI::E>F%-&(U<2EL($W 2$HV 3W1AMR2VS:6))U=YUV.N<UYXMNQ\$3Q
M$N;LA,LI8^45;BN/W4016'+:$B=96:W3PT@$7U'0Y!=;AXDH,M7.".))@-&$
M96O"_-NNG=*FW!=NUHIB5=(V3>K! YW@DF**69U&50$"21AX: ]KTM&6IZM@
M65EE7S*6! VJ<>3+8:01# !+ $#UUCS4HQQ*9.XOOP\A/7A'BQPK-$T!T^^#
M1DL[40F,/1!C]@VE!.ZF:W"@L6RC&R0Z%IX.2?)4B&) -K8)E95"R(^!&Y)X
MA186!;,B1L5()!UU7AR!2I?<3NP0L:L<^( 2P4,"T@+AL>1Y "2!SF?1=3<L
M)4IJW:I?+R(LLN/,S,98&0ZE(T>P3LT,%2</ENB/N5&LC=F/$:%"3'"%7J P
MMR*U*B=&CVS&,)X3>4(IW0I.@D)V[GV&5R"2Y>,%&^JJZN\#<K;AO#LP().&
M666-MH#\KO0ID [0XWJ<;B-YS$T\[Z?2]9SE3"[EMBY=R[-XJ1:LF=HV'..)
MI\\; <2A&:6=!HDP\ Z*W0#'Q&-2[[O$H7ULPU,P"#,4ZAH%2.9!E1"&BIH@
MZ;)"$>>3?X4HDE-.&?\ 5*NL,E,RJS;I8\B0EE;(8RJ#,_9U#2!(%RZG;XF
M=YQK8''7 .4R]8=OG#]PHKYLYJTTF!L#-PX9AFE1[%ZW,-N4,,WE*94\B&8
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M>(:C&!*PE*?">SQ>2EQ+(ZC#%3@J#OC0@[ V6!SD;BJK(PP'C&&)5<G8,<K
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M4$ISQGD1,966T?#'55IV)^'M*:^S\.D,2(W"*I4[!86[7#?,D^,;U[#9ZJV
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ML8P20S!G  8X"+G+'8X W ;E*,5<@&.UKYSSJEYQ"5Z%K4>HO]5)3DBER?T
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MJ&F,C=I2#)4V=\INI.<+(7!BDR@RTN.FURK%O*"T0#'D%F>E1P3DX7*Y('<
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M2REXMC9+!MQ5NT:11^0,3A^CE0JQF5%*LN S$;3$(QY7+KQXBH,@X+R.V&)
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M,R1G(YMKIBQ/V61M(1M5'C*3 ,@:N-E26&2.&5)(I'1&8.I62,NQD;"M]4)
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M8;E090  2-+"PP^$"F1AP]<.8ME<0,6[N2E'K=S+@H]$F8EKZ1Y!T'/K2=*
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M4*S&0:X%V5\U-,N&8GAA>T:Y?(]N38>S1_J&8!&,4"4B< "DKQ5PF?RAF24
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M/.R>(2N9F9^(85BO#?*3""BOAPT,FC@;8 ,.,LSC=8<B<'D,>NX)G/(VV_\
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M1U"244\#L)H)%P",;&R,#GRD C'?) Y^SOGCI94.)%DF@3<T<E'()!N.//\
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MYFJF#8?G]5TILH[DQRRD?2=!-"LT=541JZD@S120L5&2=T<RQ21GOY753QV
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MPL"3A5WBRA1@MZC )XYQ@\Y].3[#&.=7>9E)27RHP4N7PF7&Y0OG;C((8MV
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M4:-ZF;.%5RWFW0(2"E:^H=9:!4/'H2KMVY0X$G*O4&A46B"]H9:<I0E>&TB
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M1G8Q!(W*3@J$ !XSC(/(-<J$2F.:C"M#*X%102D([*QQ)&) =R-A60D D8(
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M=7FY,8R#$@27"G$GKG#8C@"L(;^Z:^[<-^_HH.A.?+SU=9[;258H#?;=%4L
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M.O:/AK++</AY\8:-HH3=([;TXU3"BIXDE);K^)+A*)(E;='#&4>4K)L "L&
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M>\<T4$=7254L3/3RQ2PA!(CM"ZE9%5!N"\,^\>D?#BE^'OQ%N4T]/T5!\/\
MJ#HZF7J<5-ON%RJ;)>;-0U,4-SI;A27":H-+)3Q54<B5-'(9I=S,X,4'@MV8
M+&\]K.JY=[)K:O$I$#7H=C4Z%:7%PCW1V:&GG)*"''0+EJPF'V5"4Y?$\GN
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M798TSM169B% !9CEC 7GW)-+O(<?J%'.)%FBU7>1:OI4<?,M'K!DAY5&SSV
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M=77?#NJD\:#HCJJVR<_Y/0]9TS4/",$V1W'I6X5X/B['EW7)]Z!TC\ L)$D
MRN5%$R")V_A4.%A'[Q#.,=(:+/E"?5R)"V>5^CE??T\$[KPG&,*SG.._4^DL
M(4 R0AL8;;M SZCELCD'C)." 2>->?O#*6)6.7;DA=^68+V + *"0.#@ >P
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M 6?E^=:P8[_+_HTV!C_X_D_\NGZ)WT=Z2+]U73$_(29.GZ9]/_ZW+_Y2J_\
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MQMQJ1O\ 0J[Q_?\ +[_N[;_Q7ZZ;]+Z/_8=/_P!T/]UUY9^A5=_O!4?U4_\
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M=9/#/V$]Y743CB'E]8IFSQ]/E]ER&R40TZXE:VG*"Q3:EN&F;^:0:9,W,"?
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MVOUUWZ747^PJ;_N@_NFO%/T*KO\ >"H_JI_[]K]_H5=XX_9S\ON/_P .V_\
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M65G&,=L9^>>L3=7S*"6ZA4 =R;A$,9[?YS4I%\'K_,P2+X;7^1FS@+TM=3G
M)/\ ]CQV!.DW>J%X1=5I%HM *_PS?FAZ[*RC%C&3>MI&2D7C=@8S!C'1[:4=
MN7CUZZP!LU;B:G64Y1H])7?..L4_6<\,$TPO^_PXGD"I7([L54E55%<LS,<
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MK$$_6YP/3SUU.O!->9/E5QOU'N?Q!.9UIV3R1A= R%7K7%R)@L35ZJE2%/\
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M.%C4GBO.8IS>*M:XVS:HAW$W&ESE=AUM-5BWUC*_+CNIQV/+UKMCOYLMI)N
M@\X_6"E2<>7DYHY[?,5\:FD9"&'AR0U*'O@,OZV/VX;:>V![?1M%<+;U;:M_
M_P \HH*A-HI[]07.Q5XRVX"GK:7\UW1\D ":'=&QR!(P9B)!TKE97]*9 B>J
M6C9N':_)UBRQ*(:V93C.,8P)>NIDE>QYN^$Y2YAV.5=D95D6<*PN9HNIZN'
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MJKLZ\<QR4TJ+WQCQ&39R<X)!'OSKRCJ6[?$"WO-^B'PWM<Y!;97P=3TE7.X
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M,S-'UC NU+A0O3L>#+3X>,GCG8Y4KGCRK)*>#WY&O,>HOR8[IB:IZ.ZCI;G
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M+7H.O1@@I#C& ''&H(X1^N4I5?K==Y8)ZVIMJ2W#=]):68'?&D1V!_)Y$1%
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M&>IFE?=-4S.>V7D:9N_IXK@\<\!3Z\>WH%/9+5:J=HXK2;>@7<D-/0T]DI&
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M68LH>&'G&8X(T-2>WPA+8:1CB&NEVKGQ+<IAN)X:I:! #@'RQB&(#OD'' /
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M?,G&<X<L1!7C*L$QA.<H5%MTG<Z-S)05\38[)-'YL>P!$R#D#G8.1R==W_\
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M43H\0-RH*UE621E9O"VJ<<J6QK57X:_,F_%R78&WB2*C*#DI)9C*V5TK !9
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M!..V/]&?U/G_ .?60 #MK 23W).>^3KGR=$ITRG*).MQ#O"L=L^HR#C.<?\
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M)4V'7->>>MW\_KQK-RG/?]OZC@)$Y_9C]N,_XJ?]76"2DI9N)8(I!Z[T5O\
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MF#['Y'1].CA+^^)Q8^\'J3^;NFF#['Y'6L7FYP:/CL?EWQ0-C_47?NH5X_\
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ME \:%,U.$RVJ9;W/S.NY^8/1?U+:F^SFG_W-TTR?<_,Z/S!Z+^I;4WV<T_\
MN;IID^Y^9UP+7JWC31JM9;M;M6Z:K]3I\!,VFSSTCKVGACX2NU^.<RTU+ORX
MA59$SC8UHY>NB82K* !6KMGMVZ:98^I^9UW4Z&T2M*5HTQJ52%IPI*L:YI_9
M258QE.<?\S?LSC.,XZ:9/N?F=<"Q:OXSU(,4XLNKM,PP9RPPE4B"/M>T\29"
MQV1\.,@H=OG$*KSO91^831H/Y8(9:4Y5COWZ:9/N?F=*'\P>B_J6U-]G-/\
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MFM2*OL*1K8*?:*S5@/)6-K]N:SY*7:VKMFU0J!ZGMQQZY(P>1CMGUQVQGC3
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MYFJ6F>QK&POU[.OC2QM348!V9A3+!I>K4]<,XJIMH-XU7:..3R%..,DGCC[
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MW&<>V,Y[88'';UY 'H(Z:QZ.FFCIIKRF?X7C_F^- _[9-0_L2WMTUF@^N?\
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M #V,'? W3%9U\N"U_=2V-#:&IV[)N"=-K;&.V621E)E9>/SF<>2Y$,6F[_\
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M;(_?G[A[:M/ZKJW1TTT=--'331TTT=--'331TTT=--'331TTT=--'331TTU
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4Z@0C <-7)&J'()[8YQ]GL![:_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>32
<FILENAME>g947560g38g34.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g947560g38g34.jpg
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M3VWUPHZ>ND$-,[:XVWQG./2!C<9MZIIJ<TC$-M"NY;)5(B'GZ<>C,UC1XXI
MY%[+,?FV@D43=O\ :(G<+H_!Y)JWR&)^V2]R>K^TT](4>A(G ' ' ' ' ' '
M ' ' ' ' ' ' ' ' ' ' ' ' ' ' (7[$06>V92U@06KI'#(=8DA$(-8=,9]
M"&MCQF('D";!\PE:T+?.6K X7C:K7!J+ID-U1[*4,0Q)\S(-&:S%R*K/VBM.
ME?%,_KN>I'#EPJBH@K71P*[8TTM9-;V6SG4HJZF:?.F0%Q?M&*3,4$<@J793
M939)Q\U/;*EY\VL?1:-6[5V]_0KBK2V6M&N.:HM;:*R)H\;C201O;O)6A:R;
M:LX)47>:7U_ R]T6A-;>F0>&I]>NMDK0CN)E/C!V0KBFI^52 DU9*O\ 9NV<
M%7BB*>FRZN=PBX<TGXU++.#(X X X X X X X X X X X X X X X X X X
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M-%1XXV3TURKOG81WHZ)57#JRR3@@X X X X X X X X X X X X X X X X
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M@[V=/8M,G\#D/8JKQ4A#EUX\=W<R)'$<C<B:NMF+J.2B:IZ;PR,2)J^URQ=
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MLW162SJESSZT/2)P8' ' *Z.@W\HODO_ *Q>9?W6>IG!J+^W]J^Y8OP9' '
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M&:B+J-22NPSZ/-#<.D<6%BFD"%B)H!FQ ;(U":VLWCP$6B(),QZI]/V'M_\
MB?@NV?9GL]L'#=GY>RYNQXY$V;B%,EQRY?P,%'@_Z39\$$J"*5@YV_#.F01M
M.%R,/!NQ_#^(?/[*V+,V;C<;BXL;'/AQ2C2@<,2B^::IGQ)T3C:BFPTW4TG5
M1QNL.]NGKZ$!Q$?%L @$6."!135)B,$"&+8:+&LF^N-$&; >R21:,VJ.F,:)
M-VZ2:2>N,:Z::XQZ.>/'?G52V+-9@'4"/"D@$MEE/66<1LT\!$%4\HK(*-=W
MS';1?+5;1?;*J.-L:[[Z);^G&R>N< ?' X0,KR.,HJ%(2$@*&IMVX[YD./I
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M[V +'8:I#H)(+>%F:W,W94-$2N?&)97.S,&[C4DN4S%(O+1,.',9,3D5=[3
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M)IPLMEVN3:X)QEF2E4/4F(6*)SN+BR!Z%[GAJ&%]U'H-;IM9I7IU+%. . .
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M8O..L4?"-,YQ_LI+6*XQZW[LK8Q_G\@MJ_!>IH-<?9SL=,K1GFFSR%]05.I
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MJS0?.<,<.1:N&2N^CEK[%R@@JF%?=%U]^&1*O ' ' ' ' *Z?*Q&TI;TCLD
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MQLMD?NDVDI\4*-U;=*+@O>I+I)-MTXWIW5O;5],D6C<@' ' ' ' ' ' ' '
M(]FU6PJQ%&:DN8%".!^[%9HBUE,L"-$W(PD@8&/-F0$V,9K/QI5JU(CWZZ"C
MUD\:MEVRZ2C=';0#-1H]J)'L1;+"^&8YJ@R:X=/'A!SA!LEJBE[P_(+NG[Q;
MU--?:.GCEPY7W]*BZRBFVV^0/MX X X X X!YE^^;Z8UEY'L7E!*0DMFR2MQ
M,=F NKFSB]DM+C4#54M)WUA",07KW8<;WTCA"M(;6HM%*U 2&T['BT3=>D%7
MZ>TW&T_EHW2^=J7X/K?/KP.W\OHFNY%V:I$S$:TZWRJVXW&)/%[!)V]USB%C
M&!CJ1AQI"DB,IDL[Z\VZB<K>"GWSZ3D1%92(!83!QEP+&NUV1XJV;"P5H\Z5
MK^9K+/)JCIDVFCTH\'&. 5U>/C_?'?\ _K%;U_L)3O!7E#T^[+%>"%4_E'<#
MA(2C#]J!SLTZR(2Z5@;>KN.CR<F7D,LD %IFK#,GK<'A<W:\ C*0N>XD4&'!
MY5AJ6,QBP247<B($_.QVJE57+BO;%Z/=:45J-VX\+6?.JR?%DP^.FK)#4U(R
MT.0@A:KH=)+HL*=5-7$F11;S&)5]*O@SW=*6M]7#UXP(22=:S>;A@!A\N<B$
M.E$8AI=L%>QY6.AY:KIE5T[_ .?07M5U=%5^Z99>9E3+_ME[FE"&?]9@W3N(
MZQQCC_;9NNQ]X1]@:D#C;7;_ +DU5= NHRS'.TMO47&=E).Q6TRJRURF+PZ\
M>2T[\^B,[L6="A%Q5FBX"6*]3CZ$TT+D0-2VG)P;/8T!$9&XS(8W#2H);WC;
M.4MO=R*WN[A-9LZ]BX0623"G2_->UWFR7!#";+K^.VS7%@57+TG2\2LN$RNO
MY0BQ<Y9O5H[,@3^.&TF;S77?9JZ4&$G.C=SKIOE!7.BN-=LZ^C(9% _C%\)\
M<Z:]L+$O4[?1.VGE.$S=:U8$2@*$&PUUG%;0TZ0E<R?I2V2Z2 RVB\[=Q-LP
M%#XZ']ZP1DF[;*CT6(C_ *3VS_%'M#VYV7LK9.UI.SY4C9DR'$13,')F2YN,
MQ<$B/#PXB>YDZ;! U*F3/]J1!*EN9-F1;N[\*"5U&SMB8/9D_$3\,YSCQ"<-
M)D:BAERW$HW! E!"W\Z344;BB4*2K^9Q>B[GFQVY'MN?R4V=_1[-/[-DN 9+
M%_XLQW_[$(_^/;\ [W@#@#@#@&L=06K5\GL^ZQ,;LB!2$J6G(!V+&@YA'BQ
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M=F9W-%V+9))LS=2J1&'+9LDDW15T1233UZ<YVV\_1=R5EW$HR-Q)VHS96(B
M)PQA9'71A(Y&0BPS9OMG/MU=BPR+3%UHLGKZ,HH8"[Z+9SG7=PWQC&V1#!*1
MC\VA]90R%SH=%F)2%Q:,1)%Q$Y,6DS LWCT?&B=BBJIB'0UP-6=N&BV^HW1J
M1T11REMDBIOONFF!+/ ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' //M<$UB<=\R
MD$&$&K>0DY*:K8&S)RVG@!SY$+CX&%]H$KVS2_>J!2@$F3;S>,&7J4;Z=6(#
MR8.ELHO";]A."D<&TJPO6[SS2I9K=>7"L2SJD6X6?U,JRUY8O-3!Z]8@?((L
MFQ[>GNS/8>CQDG0'MDF33,C 5'9L,!%2"#%!NP2D"H[62I#VZ ]$RFR130U&
M:OEWI/ZHG>)10!!HT&B,78[#@ !BD.%LU'K\DNFW2].<[NB15T^*$WJZFRCA
MZ2)O7A$@[56>/G3ATLJMN(9%P"NKQ\?[X[__ -8K>O\ 82G>"O*'I]V6*\$*
MU>RW_;!:=IBL?ZS"NH/6FSYB0S_MLW/86\ZTF$7BB*:FO[DC5943I.G99DMC
MT*"^Q,2?H[>NCG&!>'7Z+U?T-Z;8LJ-TW6-@6Q,%'&D8KF'R&9F]62.71%RP
MCPMR358"F>G^E?F"/N^& @:AC9R1)N6K%MHHX<)Z;"*[2U(TZJ5K)*RI6.M9
M^FVQ;,Y?G[:N=5JMAVW_ &M6F8=S6;"F+[T8W> (@2+_ "+#MU?WM85%XX.3
MU3;LD44Q7G;)67=ZY]YL9P0< < B"M/XZ=A/Z7PO_0.C^ 2_P##9Y"V\_C;V
M+O3DB!#R:;AJ26C+UHP?/ASQB['O!BSEV/(XT9ND'F^5?=TT76JJ2&Z+E+U-
ML;@?5$(Q\H!4@FI^0R))OOCW=[)73)X00;Z((-T66BS$>-2RU0T0QLEA1#=;
MUU%=E%U/6UQJ!E' ' ' ' ' ' ' *.)V0NAUY%V4FM1["$ZUA%O49 (4+B'9
M+LHU9P3:PD;31K@A+X #Z:MZC/3JSQS=9$Q&I)<V1L-+RZ-PY[8BHRP89\6E
MZ\O?*GF:X<;I\%>G?DN2ZY%X_*9' ,7S-X7B6X@.9?%\3K87\<UA>3XG$MV"
M>TRE\8Q'/>_C&1?M==D_B&&?NGM,9T]MZV,XX!HAT&_E%\E_]8O,O[K/4S@U
M%_;^U?<WJGTXC-8P6:63-"*8>'U]$Y%-I665QG9,9&XJ(>'39#?7'[]M68QB
MY<9UQ_G;83]7'[\XX,YE(EIUE<9&$=9([7$=-M^]<\/77W)L]R/3AQ/2N([8
M\??YE5=SAA.91#8](8_K*Y#2776&L',D R',<K!6=QUZ\4JHT,?5-IU1IT:B
MK^6RIE5KBM.,3SNZ-7+2NJ-,ZTS 9&W(_/;R<6!/"EA65([%^0T)#*I>Z QJ
M)-R:(JM#1Z'@8\)AT/B4/BP1@07>LH_&!V3KHN?5)GBT;K=F=$K)62]^9L]P
M!P!P!P!P!P!P!P!P!P!P!P!P!P!P!P!P!P"OGR/N[R_8K&0%+DX9'<S"W:<B
M<DDAZVK2JB6)[GK<@ R-Q.!$ZFZ_WW)\$; *NE(J7DS=E%=Z\%O=YGN5<#1A
M35K'7A[\F54K?G:FBXW67F2-T*6:;=4JR9-44FF\>?63#B@M.<V%9&P&10BU
MIQ$)1&74QM6M:?GQ,C%Y&$*QXHVD%<QK<(2&.@(],D)&,#!&B+-]VFF=FU<W
M X(=#)Y5%X2$>R:9R0#$8V-]VP1D$G,#P(1AEX[08-,/2Q5PT8-?>GSILR;>
MW<)^W=N$&Z7K++)Z; 5^]S7K,E?WBB(CG;4@/(=VI6]8/V3A)TS>LW70SN0N
MU=M'2&ZB#EJY04T6;N$=]TEDM]%$]]M-L9R-0Y1_M7^<)9!P9- ?)?V<D/5W
MJI*#=;-UBM_6Z?C?7KK/&F64<E9%?-Q/=XQ"=1:3C79NX7C*:I2=.$'/J-EV
M$5=H*J:>UUSD:A57R5WR2SJ:?^,CQ:ENB$C&GB]<]67DF<1)F!E=O11"Q3%N
MOWJT:9[2C<(5EVNHR/"Y3.45218>);,TW@;5DV6U]9DT;-OTS<9BYTF3AIV*
MQ,W#X>O]/(FSYLR3(WDE%\&5'$X)6\H4GN0PU22>2,;DM111PP0PQQOYHE#"
MG$E5K>B2JZ5?YF]:EWW/S%' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' *.
M#!"Z'7D<0E5MO81\BQ>[ZYJZ"C89V2[*?"Z[<S*M)V8A#*2U\.Z:B*@.SBQ8
MTR7.'QDEN;1E%"U@1N$*3PBC*(,S,R^BIU^U/N:X<<KV6JXUK2M//F7C\ID<
M Q?2;PM26JP%.7Q=2=("\'%X7H?$[2U$)E1-+!A6.:N\F$Q>55D4\$-V>&F5
M%4],+>LIKC(&B7CX_P!\=_\ ^L5O7^PE.\%>4/3[LWRF,NCL B,JG<O*-@<2
MA4<.2V4&WFV=&8>.QL8Z,&RCK;&,YU;#QK-R[7VQC.<)([9QC.?W<$S*Z0[:
M8PCII-9?-(W\,L7M.SM*X;G4.,+)?.:V<6Q$W2@8(?1K*L+1(.=J.JQG!*E4
M4?M H]V.KAOMJ:V<JZX5%=W3@K</'OSS[S-+"E);L18'7:AR0'X$Q7DSGLA=
M8;5&:)(HUY0TD#.JOCKW6>0&MI(T<SZ^W< /-&Y&)MQDDAU66<'05),\N'&@
M+B^[Q_CZHL%X(. . <2Z*;E!9NMC;9)=)1%777?=/;*:NF=-\:J);:*)[9UV
MSC&Z>^N^F?\ .TVUVQC. ([B515]!B[X]%PC@:5*;;*$W>Y^1D/B"^S-@/\
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M:J*H.@TX/+65>PS;7?VS="YOASO5)=AL@C"NJHM/J[^.2?3.E#=K@@X X X
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M5\^ PL6"P6&PL<USXI$M0.:TUO.KBHDVVH8*[D";JH(84Z,LZY\T?L' ' '
M' ' ' ' ' ' ' ' ' ' ' /+G'T.PTE\PC.4$HWVFE5?PZ_9_%14][ =)9Q"
M1<*ARLGD*6L:H+LA7='W)&I;0RFCQPSC!.PI30#<K'%-29:;N\%<.%1R64#_
M "W2LFJUKFU6M;\$Z/D[>HS@XQP!P"DR(7VWZS55YB[DR_#CC$;[Y3,=#'$A
M5PB Q84MZS=08C7_ ,?6]7?9M'$Y@<#.)._PFKJ+CB!8JLGENQ6S@;:JX5^E
M?<VP\<5"N:?H0/*9*P,,YY:@B)E7C64)YTEL9KB- 4PM00:3^OLHJC*QT5W6
MFUHM\KN$75\6)<$A164^8-]]AF)U?O/B_3E0L#X(. . . . . . . . . .
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M>:Z+Z)*9QZR*FVOJJZ9QOKZ<9X!WG ' ' ' ' ' ' ' ' ' ' ' ' ' ' '
M' ' .@^;(M\PNHC\RQ_YK8A4Y(]C'QD=\PLXZLY49)'W07WGXDW"JO$E6B91
M5MHQW<IJ(:KY5TVTP!Y>*G3"][_(#:_7"+2 5)^M\&[Y6-Y KE.AWS8E%;<C
M$<Z_];J3Z_PN-EVBCD7-8;++.:V@^F_N>Q*..PE>K#'+G5Z3&;X'([)/6%0I
MZ-7?1Y+@Z-GJFX.,< < < < < < < < < < < < < < < < < < < < < <
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MKZ%2D63?-9$3G-K2^0R222]TU8#3:>]G?)VK;7KQNZ62LB^K@R. . . . .
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MI&7/:,WJ.I<I(#;\AAP[*OU7 5>K)6X(. . . . . . . . . . . . . .
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MFV59$A90:]279D!Q!FNLT?,7:*S9VV65072424WTR!'Q2C:3-B)%'S-/5:7
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M!!9PR%^$P4'(TSV.OZYE=+:,AGLS2'(H29BF#GB^T<!!:NMN*I>EN+5*Z]Y
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M?$@MES5^5ZY.FGJ6A<$' ' ' (=[$?S?[S_H=LW^Q1O@&9U]_$&$?^D(U_\
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M>%883#K;O"L<0>*%V#9-&11Y999TT2T11D )57.B9D;LZ\K.YH\Z6U.6%6+
M+)8D2=>3>)3H<(*K BK^(2(1)&8TT@U:/E13]R'=O$6A#1B08/\ W1?=-?9B
M_9/-=,MG;=50#,N 1O,;CJ6O#8&-3VS('#)#*-DM8Z$E$L!@BIG"Y!L(0W'L
M23YLY<HN##YB';KIIY17,/V I)3<@]:MU0H]# B/;?JR'4ER)7L;2 U: +'6
M\X1?6C"VJT15BY[Y5D^LC17,Z*!\1R3^B.G]W^J&@<YMH*([-GV^B&PM'H[Y
M6S,P>7I2HZ"B;0)6W6XVMSKE1F%GI&:QUA#RSM')+V[8=(W9%$2\60U#&%5T
MV[M39! 23<*XT0'NU$0HZTHZZ<3&_P!K762#%;%>8L:CXD<%E0N]KN4Y1!@9
M9H<+^NPCVT\53>MGNI8EG11B(R=VR\=;:*-&?K[:;)X$O]EZ>?F34/*C"S :
M5%$F!,69:MGP<D/>-WC JQ>M</F;P:\;**-WS5VRSAXV<-5%45VN<.$M]TLX
MWX!CFMBU_O-U*STF\2WL9(/\PJP+61"-IBF"]=)/)G>-8=Y,:C,;KH:Y?;,\
M-L>W1SE3&%4\[ <,1LVM[ ?2D9 Y_"IJ2@QMU&IJ/B<I"2)[$)$Q>OQKT#)V
MHA\\7 F69$448.AA31J];O1K]JJAHNS<)I@9QP!P#JB3D((]4T66&CLXV9B-
M2K[9LVVQL7)-&+ ;J]6]3;'Q$LX8M6S3"GH=/UFR2:>Z^Z>,@?$'E\4D+>./
M ,D!&FDPCWS;$W0HJR(-I+%O9"%OF,"NU652*@\HR $K@HQV7993,#-\+9U?
M-LJ =VX:MGB>J3MN@Z2T7:NM$G"*:Z>KEBY1>LG&NBNNVNJ[-XW0=M5L8PHW
M<H(KI;:*IZ;Z@<_ .B8RB-%(\G+1T@"OHJJ/6+)R1J49+@=Q;?115P2U+)K[
M,,L$$T55%G?M_=TDTE-]U-==-LX [1F\:D&C5^R73<LWS9!XT<I;>LDX:N4M
M5D%TMO\ Q)JI;Z*:;?\ '7;&?^/ (S.7K249/2**R.WZQ!2B(B6YZ51LO/(N
M./QL*[V%Z,RQT,[*)$1(]WN;"IM';YL@@Y4,"]$-U-R#3"P4>GM9F%6]-X;.
MNN5YDX5*X[+1O[%9R[U(QLR/-L5&9NMB!L,\2>#7#ENLT+!W[,F-=)*;MWK)
MRDY;**);8VX!+=??Q!A'_I"-?_"LN 9?P!P!P#RX]]NY]&]3^JOBN$7%T"H7
MO&YLGJ]L0C.]XNX>T1J]&"UOUQ;G=8YM*:0N;?=6:[S8+DIJ/3CVF-(DPR\W
M*9]TU8?7]BNQ>U.W>U9^R-DXC 8;$X? 3=HQS-HS<1*D.1)Q&%PT4,,6&PN+
MF.:YF+EN&%RE X88VXTU##%^/:6TI&RI']5B/CN7%/ADTD0PQ1[\<,V.%M1S
M)2W4I<2;WFTVJ)JK6@M'^6CIN=O&D(X*\&_1^ORTJNBIHB'GT7*U6K)(,9EM
MA1R-B9D"3;=-(XZW+1<B4;'6&K4^%=9<L$_=BC!?V;E/[/M+^"7:KLML/'[?
MVAM#L_.P>SH)4<Z5@\5M&9B8U.Q$G#0J5!/V5AY434<Z%Q;\Z!*!1--M*%];
M@NU& VAB96#D+'*;.WU"YLJ5#+^27',BWG#B9D23A@:5((JNB=%=>U)S9==,
MYPQK)W/(<VL<FP^*CH$XDH9&8OQN4"3K5\SC2CS4PX:[M0QETFLDSW34;!RS
MA/;9$8^W0\=.^H\Z6U.2.V+ )<<E$9BDWB4ED<(=(LID! R(07,11XY<$&C=
MM(AK!VX>!EUG@@NS33((M]MW@DHTUQER.>)( 9EP"/;"MNK:E9#R-HV+":[8
M%EW+88[FDG#1IN069-MGS_5FH7>--7&HY@FH0)*)9V2'#TEG[[=!HDHMJ!AY
M+LYUQ#2,O#B]\T^,E@!#5R:C+ZQHDU/#$-HNSF^JCP2L6T?(XS#"#&7>C9#U
MOEAVW/>CX6KHZR+1Z,[4'V HN2UZYMJ/7%61NK6;IHQ<V*+G$<?0E%Z05%MQ
M[/>3MR*@;WL@X-AFP]OAYE9\Y+C&[7199\UT5$H]#HD;:ZQL)$9DS>R*,9RM
MY !<U/R-"601 \]J_5N,>!925,I/M7[N#Z-#@5V,+NG*@/1J:$N6J^$2C+=<
M6_/W_P >1+<<E<7F $;*8G(@<FC)C3V@J0 "K$N%):>\[LLY8DV"Z[-UZKU-
M1GOA%;?.CM-1MMC"^FR>!#K"]BP !*XY!#LWB0:;3#1TI%(@4D0AA)I*FR26
M7=[@0;IVD3+:MD6SE5;+%LOC1-LYWV]&J"N= H\Z6U.$59M;G9K):V"3^%&+
M$AJ#1U+X&+E(0A,HJV?LQA!BXD<9:/E301%XP-AGS50DR;:.&A88Y2SNB_:[
MJ@9QP!P#K"BX88V7D!E0<Q:@6)!\X,D<MT$@XY)O[P4=J/W'JZL6>C5M[5\M
ME5)+"*'KK[>HGZ< =<PF,2*HCW R3 2*!60'HF,78EF+I$A*(LX/M)-'6:B"
M^^CDW'W44D[8T+2SN]&.(\:1>(HJ#'FJ('>NFK9\V<,GK=!XS>(+-7;1TBFX
M;.FSA/9)=NX05UW27072WW2615TV343VVTWUVUVSC('/P#JQ1P,=2>+!"PXN
MB/*$@;]48];ODV1D,[5'EQ+K=LHIJW(BWR*S,@R5SHX9NDE$'"::NFVN /V(
M,"CXYJ7!D61<4]UW49$ASE)XQ>):*[HY6:ND-MT'*&5$]\:+([[I*8QZZ>^^
MF<;9 PF27'4<-DR$+E]HUW%9@ZCS^7-HK(YK&PDB7B@IH:?E),D%)DFI'>/C
MF,<D+U^9U;9'-&H$RX<.4TACW= #L8=95>6&AJZ@4YB4T:[,M26KF+2 4>;Y
M8Y,&X]EUA88Z<I^R3/QN0A%MO6_T!<(5'+83>,7**84:S1$G3W^:Y0_]&D9_
M]CIP6+-]7]39'@@X X!K;=G\K/3S^GB:?W6.Q7 /(E?OEEZ<QV_;[BY?P>=(
MK',P^\[BA9NQ)65JQ&33\W#;)D\7,S<^DZZ;25WH7EA,2[/D-7<B.._>2"GO
M18@X]HZ5]A[,?@GVI[5[#P':#9^T-@2<'M&&?%)E8S%;1EXF!8?%3\)'\6"1
MLO$2H6YDB.*'<G1U@<+=(FX5T.-[3X#9^*F8.>L<YLGX>\Y4N5%+_P!R7!-A
MW7%B9<3I#&DZP*CJE54;MS\)'=JA>TQ_M$*J7H#U^Z+*UI'Z9.2LE2C^&+-[
M&82][;;82G*%HS1U,;(:0O:'&7##8ED^CKI)GV[;89G#K+WX_MMV)VKV$VIA
MMD[7Q&S\3B,5@)>T9<S9TW$39*DS,1B<-#!'%B<+A)BFJ/"S(FE+B@W(H&HW
M$XH8>PV=M.1M;#Q8G#_'4N"='(:Q$,,$>_#!+F-I039JW7#-AOO)U335$F[N
MA]XTN6A!&RQ5M5N3KL.]0&E9R/FT<>1(<1=*#$F8][(6Q)04V?/E#071BS5=
M:N'V3(CW1-;XFQ]O\<?OHZTHZZ<20 QD1(Q J01XJ-.@3HUB8"&PSYJ3$&!!
M-LD]&E!1)DJNS(#B#-=%VR?-%EFSMLLDN@JHDIIOD0[+@$,O^QE "R<R"DKL
MJH>6KL2<.SP<]GT8;/(>&B^&V903D:"Q/100RC&'K'YD</<(I@??Q^"V6>7S
M3VP4>G+OT,;W[?=5$_@?K=D:.QF2E'(./8Q:,+VV-&V3;9X\"C==3.=GA=HS
MTV>.1B&-WJ#/7+I5#1OCVG!:-UHFZ9VRZDA2FS*C#&]J\FT^KP7(3,;)&E(5
M*)-'&14G$D1YUT6**Q\J]3<NH_J)CDH=/7:C7<?L-CTC<*[Y:!BN[42^?GS,
M7B%R=<&[2"12!V?3+9C*-'8ZMHU%)?"V[4YH)(/A3X?#@PE_HB]^'%AQ,6Y9
M"&V^6I-@_8*):.VCE%,6CT9-V-],[[)XWURIIKIOLGC;&=]=%,[ZI[[:^GUL
M:[[)J8TVSC&-LI[XQG.=-O0(1H/NJG2L4ED[&6M7!"$0)0BE.)@SFT;<Q>'*
M"&"!0IK*#R1+<6!R/%NFI-WDHZ:X0'.FS]3.K1PBMN!F$9E$:FH$9*8=(0DK
MC)I#+H/(HV58FP95KA11'+@<5&KN6+U#"R2J656RZB>%$]]/6];3;& .]X X
M!BQ22PN'KLF1@Y&XRX//4LL&I!^.$*%R)>21Z+HY:I+JM]GSTG+9C%@">4]5
M%WI^2A!VOM'Y5FDN!W;0F.?N";5B_:.W(1\F,,-VSA)98615&CC*3 @FGMMN
MT=J""XLGHW7QHKLP(LG>-<H.4=]P.?9JVV<I/=FZ&SQ!!=JB[V13RY1;.E&R
MKENDOG7*J:#E5FT571TWPFLHU;;J:[;()9U ^(P<#1YEH1/%AH4>H0#B='Q5
MZW'M-RDA+L0 $;JX=*));/C1TF.#"FN-\KORC]FP:Z*N7**6X'[(&!0I08B2
M(LF*QHCH'#HNG*2"Q4JHT=O]1PY)3;51X]]P'D'^S9OJHKHQ8/7F^NK9HX53
M ['@$6$;RI40N';%K=K(8YD4K,P2/MR$[B[)8[-XZ52 R"'ATG)1/<G)P1Q=
M ,8!,M5R8PJLD.>M47>^J.0H]/;R*BO.B8%2'I74QT$19& ICL)!B8HJ-<I/
M!Y$>]JJWW#1ZS=(;;HN&SE!315%9+?;133;7;7.<9X-P9OI]T6<=R/YH?:G_
M );[Q_Z8RC@S#FNJ^IYG_/-X_P#NGV?[M02TNNW7:6V] F/5BO( 1D,=DE:B
M$&$O VU?$B)!G#2:3F+$=E40TQCS[5RV9N&2FC_"6CG*Z*Z2?M?X._B%L+L%
M'VABVW*VC-6U8=E+#?Z?AY$]PO!/:+G?%^-BL-NU_JI6YN[^]2.N[15^:[1;
M'Q6UH,'#AHY$#P\6(<?QHHX:J:I*AW=R7,K_ -.*M:4M2M;:>>-#Q?\ D*J+
MO_U2M:U>J,Z@%;U[8AL],)>:EM0/AX48XK.>@6ZZK.-V2=-.<K%3(YIHFQ%N
M=\;./:*8T1T44U^D_%7\6>S';7LQ!L?9$C:\O%P[4PF-<6.PN&DR?A2)6*@C
M2CE8W$1;[<Z#=7PZ-**L2HD_Q; [/XW9>-CQ.(F8:*7%AYDI*3'-BCWHIDJ)
M.D<F!4I ZO>K6EF>P0/3]L-NPLQMLT:K<E'%AN8O6(EF,D(@K!HE(2]=O[*P
M]29+ICI#,IWM#U'S^7$EG"K-0% @@@>*%#Y6K*_YP/LN'UYZ>'W(K@/3*0@*
M@)UC*)P!)J.FO5R$ZN H0F-$%*QZS/H6E[J<'JE55U)%9X,#(F,ET;.?A M@
M=%QU/4TS!+DC(5S_ .[_ -E0U0O7Q^VH!@YL-2381-\RJN#M?M83EH-#Q*+3
MXBWOA&-7R^R9LF$K,I7 PU@5S#(I)XZI(I5%H_!&S )'G+=K&%X<-;R;O95K
M=MNEK5H[5O1^1O%?76B:6B9N;Y4F,4"1SLA0P'KQ:.LDCI0P=C,6!.K8SK)J
M^<,3#%BZ-NQ-R2MCH$D2& PXRT"2;19XFD;CY\93I3DZY_;JOL8NVZ*QMM7%
M[A-Y2<)V1;H3N3&@4M.R6;&XO7X#MI9DNL0B-CE?D9,XC(C#)8G#T9"\"CQQ
M \YBNRJ3MDW(N&VP5NGIN_\ JJ$GWU1$ZM*#2R' [%T6%34)K%"41F3++&-Q
MX&\ADBB9E_!9162<'M<%(B+LRQ,F%C,ZE PX$'FH"U8QD;+W1L0"?+WWU7D:
MW+=+[W L6;>"W)!VI:,*V\/BTQ?PYZ+EBP3L3<+.YK?(J.0[E85$)FV?#]8-
M7YV*B=M8[%SLF*-$1YMV-^%BU6FG'147=G7CSUV@*]889(V?6G5ZZDT._P F
MMT)?Q>-5E85D0V&;8&UE(:X0C^XL)*A.I,"-:R#&1BQU$B5W$,%8X]75!2*2
MCR8E<^>M_J8T_P"O$TTO$E9P:5QC6/JVFI>HX21$%LF];#6ZWB>K^T<?OFA)
M-FK ](<.6E_K(M]#"\N<-&VVB0X;AP["MJ<J=U:_4P:/=0Y@+@/9V!YL!B$%
MWE 2D)C(N,/;*6 14X5>6N]-VKJSET\DA,'+IEK8X-C)1,5+LV"6*]#OF13?
M9\W8@0KE;+/GDJ=+>?>]=;;Z)S2&@GI.FP86=?$9C.BA.I6(<&+B\A&GCO9\
MK7"$E9R*RJ["NA%,"[H@0N$-&IE->./ZNB:T4'BF(L3F/"[WOPKPXT==:OOG
M>PNG$NGT4C/MI;&-9K'Z0H^KT5Y"#;2P>W?P*<-)39CEKO)ADB";)V2#;_*#
MI\8A<A3RRQML:!G!SAP(4$JNBJW;R\/=".X1X\YG$Q$#4=W(S(SJ*S:K'YB<
M-@1<>1D%:UQ!J-CBE9Z:ZGUE1T:+2:HG\R1 Z.EP(\C)/3ABY=MG+UZ%>"5%
MUYY^%NAA,8\<%H1"OQD."6!4:31C3(NF'D1V@9AU7I7=HXHEN;N3(,\2D+1I
M<\H$56>WQ(WPL^VCYXE$#&Z$E=1PPM)A6ZYKC5>=JYTJR4=NC4Z)F1PHM-H4
MPIX8O"UVU8C1\Q+LE!(B:=,Y$=@#]<Y(-FA6%Z@NKDKBC%,HP>+'A-MO&TB9
MX;BS:4P$JJ97U_\ +ES7AX1T7\;EB-HO$HI![DC<?8!XO%4RRB\-U?NEK3CD
M/@H!>X!CHQL==#I<4>0]^HN;!K1N>H;'V9!K82#8"3C<R%WLZW?!_;2G6NG2
M4(=TIFL!HGL?6PR1PU4E:E+;5Q&Q$;&F(Y&BLF8)VP\5GLU]^(%,_--AZV*#
MA4Y?,6ZJFT6KZ/;-WJC;4:"C8C=7WUY_\+@9"KT:8RHD7-R&7DH]F<O;</3C
M03&X"9DAA_.;H3LZM6)_]H &TH42WJ.*NC->CE<A27N:!,@K%"0D>\<HN@J_
M3ET/VUZ@3R(3PM**XG47%B\@P3/#$JVG;52Q%P4(IJ L&UB1^)3"/5M'2X8/
M4[AY$K%J6"0LG$#!N/O 43:)1*2M[1"N7?I]:<[I_>V-!NOLJH^FNR:9HH@3
M#-.H NK0;I/=7.7ZT$T[)3M^\;^^%#9QV(%,;F!P4>>F)5U/I4[A1:22]<D^
M*('"H-UX>[?2G31(W[K[^(,(_P#2$:_^%9<$,OX X X!Y"/*?TM[6=M.LGB'
M+=:*1D=R-:UZJ2(?.<1P[ PRT=7G5>]4G$5RYTF\NBFKI,KI"9+C38;N]V;[
M#LX=ZH87;Y5]1_"7MELGL/VDQFUML2\;,PN(V)B=G00X"3*GSE/G8[9V)@<4
M$Z?AX5+4O"35%$HW$HG E"TVX>F[0;.G[4P*PV'BE03%BY<ZLZ*.&'<@ESX(
MJ.""8]ZLR&BI2E;V*N*$\2/DQ =@.O<ED?3>PP$;BG8"C9?)3I"9TDJR#1N)
M6M$9'("KE$;:A BLD/#BWKO9!BQ=NUO9>R;MU5=]-,^K_B!^-/9+M1V0VUL+
M9V'VW!C=H2L-!(BQ6#PDK#IR<=A<3'\2.7CYT<*^')C2W9<58MU-)-M?/;'[
M,X_ ;1PV+G3<)%*DN:XE+F38HWOR)DM;JBD0)_-&JUB5JOD>Y"7U#;![L&'M
M!L9K5Q H6 )/8#%"(J0,BXJUB$(E\.5L21OPZZ6DL=?!Y'\F#6CQRV9QV$$Y
M;A@Q<R$PR)C/Y7/NB/!_4>8-F-_#MK#%,M;#@'8."5P5#B2C(O'\]@K1LFW2
M<AEJV"GI($H@<G8T''] ZS111J *R)5\W?2SX3'A6_=>27ON7 A&R>BYJ'ND
M9C4P4-+1S:62\E(*/9 PB<<LR.2>45<6BT8F3"56! XX;CE9N(U.Y2(%D)&R
M;M91,GAX<Q?+NI$#E0M:Y]*\>/)OC?DJ<2<(-U]NN)P+J><$2:"HW)3/5I+K
M_.64^82.6Q4D[DP&FEI5(F!,9(FQY<B&EU1L''NZY%PE-Q+UTR*&ACY(7(&(
MC:OS=53OX>Z>1^>M_0Z#T,28E2<IED^?0XQ7I&M<$9/+1L=CBT#ZH5EU7Q('
ME?LY#\B/ID7CD.E+E8ZH"549,IALR9>R<,$GN0;;^_BWW9F;1OKY8,'HBK:N
MC-H8>$*TIZN:O7CY<2R'UU*7<-TC[0O+4R@!@SN.%3 B'%/QT1DD9LC5G!2;
ML7*L121%@NJ3T*U=:<:Z_P /POJ:V1;HE<-<1D>#@ML5SN2BB86508[(Z_(O
M_@ED"NO=7]:QN%A+LT69OHE#XC7>TRBNYA0X;>SE6+N91L53BS]Y*P;KY_6O
M??DEWW6R"O4\++*&@%/3@W)@CJ)3V,V45,UC9-G15U(I>!MEK;)@P9/B)+'Y
M$>)3F0H/2\D(F'"JS65''\K!)#3; ,\8A7C]DS]V=URDTQM1I-0$K##X\1']
M>$9,P-L3!*0HN^KUI3RX(!D"8T)ZZJI3"2SG8+.G!?55XE&Q:V@_=X^-KJL
MK:E-?-+D]#\U_P!>9E%+JGMH.Y8%'B)K'IJV+QJ*.K%U82V631U73H=+90%E
M,VD$<&F*U:0DW&XP^BPX=\:#3HLHY91_=EEH3"U/?IY?7AI^2\>4CKF$>^P%
M^/F,E'?LY1+Q4<':-=K0CL;']2FTO@DD6E4XC8<A$[!D]$V9-)P+.2!!G('%
MQRYZ42-R Q(=Y.+6K5?'QO1<<J=%EPE09U L*8=?Z?C$L,QZ(S^$4_>8!N+>
MC%).&B-@V[E@I$339KK)#3#=>KF2;X2T3T-RA%IN[WU#GBC9KH^(B-WKTJM<
MJUX7?+N(V9>-N<8@TL$/+A#-YD^$+"*]DPJ,[C-:K'FIUV+E4J$15I'-HH($
M,38*[P<-+8B$?A8PXP@C9=6/"V#@8!!BN*_'Q?!47@[\>IW2/0.S IT_(HK/
M:H'.G$\[ S;403@D@,16T'EU*=DR ->]0#F1Y:S)6MWEZ!1 EFGG+0D!C)E#
M=1@W,@Q43"MJ4T[J45NJ7NE_P\Z"VFK#VE>1VS8G 88K7<HCA1B!1F3HBE*S
M5/=J*N^/"WK,I&&+9(Z<[$!;//Y9"!&@R20989&AC-B2!.XD":TX_=/C72G?
MX\LQ\=!M<<5%5O.81#A$EDLW?2H$O !Q4&9CINQ+EE4 $*A3;<_&=]*F!63&
M <6:NXVZ19CH+@/$', <D <IB 56G#7+*ZT=5GSO7C)W6CIO-*0DI0\=L("2
M=DX=8@(W(8N).#I98$CL,Y S326V 0+&2"!4M6.T--LX(ZRDY5PVL>5;;:BG
M&Y->3"5SRNZ_7+D8=7W0XDM%XAO-I A%9,F(BD8E?R\*CIX@S@T;ZPU_2;FN
M0;N6,9C%"$.5LV"?M=%,CT6?#%MW@]P2C;*4M=W34*Z67!:?SSS,IVZ326+2
MV)F*OL0(&0B\-5CNTAD\<([F9&BU3O9Z.A<[KNLS=6T;,:T7E-U)2!\,0KR+
MGD](P]36,%I-(0<U@ 5UO[7&E>&NG1YE1/72;UA9X>1&B;-R'%QGL,]>^YE#
M!AJO(^Q5N5O8?R^Q-2DH5G4FU@F]:GB)"3S=?19\ZLY(?%D!X04J!!AP\/).
MOOQ)-Z>_S7*'_HTC/_L=.!%F^K^ILCP0< < UMNS^5GIY_3Q-/[K'8K@'A>[
M%>)3R723L?V3E48Z<V%(HO,>Q]_36+'QTSI-%B<B\RM^9R>.%VJ)2TQQ)!(B
M$+,7FJ#]@S>(>V]DY;I*Z;Z8_J;\/?QG[)=ENQ^QM@[2P^VX\;L^#&0SXL)@
M\+-P[<_:.+Q4'PYDS'R8XDI<^!1;TN&D:B2JDHG\-MGLUC]H;2Q.+D3<)#*G
M?!W5,F388UN8>5*BWE#(C2^:!TI$ZJCY%U?@'Z/]N^K9SNR_[#440J']J$ H
MH!7FE@%(-)Q$E+Q-W?2QU%^/@4SDJVP<?\Y1O!1!XN-5?M2"J#'??=-;='RS
M\6^VFR.W/:' ;5V-+QTK#8;8TC9\R''R94B:Y\O';0Q$3AADXC$0N7\/%2TH
MG&HG$HENI)-][V?V;/V5@IF'Q,4J.9'BYDY?!BCBA4$4G#RTFXY<M[U945DF
MDJ.MZ%R,:ZTW,SJW &32^MR]GN;?A]ZRJ9(#9,D+G\]KZ0U&0CJ!05A9NVC(
M%:*U\\@+!@"8.&\*"BZZ?CF9]['C29_RP[VOTI:F5_7OU/DD_1[$L@=%PDW+
MQA-*GZW,1AQNX"/TAI&9FK%HV:KS "+3,J?+V@X56LXB(%OL[?E P&P%1R!A
M1JF5U*A7/G]+_P .NJKF176?5"W*R[-UZ_:#F1VLHC8DVG2=CNM! YQ%JT-U
M;;4(B?7*%)M["<2-"!1,_,(G(V<,<UNWB#4LR,R%A)$'#8$";A6S]\52OGZ+
M-Y-8W1>=V/ W5/$++BPNNX[).PLWK\T)CAYK8CB17\&M\!NTF11.1:L/A\/'
M7;,7#HH$3T-SN1,8I)7*L5<AR;.0A7Q=%RM3ZTZ+GPV0;]7XM'9#51N%D3+5
M2&WX:OF<D)A));8$HL(\5ZV6+UU1V?R>6G2Q5)VP!2>(),\[N%!K(#"VP5@.
M:ZJI+(A7/I3I=,AGL!TWL&]&0B*E+JR\ CHO8@[$ZDT99[V9DO8-8W+5A%,J
M&K_]G512L*A'K7:-H\N2@0^10L<!E#025?%K+(R..BITK;3I:CZ\-;]U^0-U
M?N/%JAYK*935A.&E;'Q<-B084%DHO!"PAQ%NG"%VYG+A9Y) -9" XD]#@9OX
M8'VM<G)[%*"7+_6(-8J,Z^_OZFRD?HB+QR\9Y?#,]/G$DG\(AT((@B5B3TK#
M1[2(&YL:2?"8>3DSR*CEW:DRW1;H,0;5L"PS>N 6C!S*)0H5"O#[+ZYFKL+Z
M<3F,5,?K0K**\DZ;ZN:6J=HF\#SH0'(Q+KR*'#X2^+_+,Q!GF,FF2VIIQ*GP
M<UJVCR#B.L!S>3-HZ[UD(K=ZJUV^]^_?#[I[TPD=D41$ZGD]E9?F(VTOARR.
M$=Y2:T F[1 V(PK/4$1*2):3.4: >3*/HP"0%BJLF31@4?.M70:2(M7; *T=
M?+EIEW?P1&PZBVE ^R=5O8B%&&*K"3M_,L2G+<*('5%$5K![13M2KX*Q3L%I
M(&#$RVM:O(\8&"JZ)1DAI#H]NY>)M!8A.!A6SZ?=:=./U,LFO1*:FIO Y=&K
M)C 1<+?\MNZ7$G$/:OI(=^*]E(O<H,,@=((%#33=A64:UI+5U'S,/59!7:B[
MA:017=Y GP5O7E3RH8+GQLR%A&XS'1\\AAL*#BM0(GX5*XX><PNPYW74_P"G
M<[EDJE[)$XMEZ[LM3K"?9'RA!J:(+NK#W*'49-JU,C3PM5I3/SWO7R7=VHOH
M#8K0A$F<@G]?3>. Y"C)\$#,:/-)O%RR5-4_5 I&#R)0F;)L8G"W4"DTQC4+
MW+,VY0Z1ASF4FB2T7=K&1&]%3V_KEIRRIV;7H+-)838G;CL*(2YXSD\#+I!V
M@*2. +,5%5.G J1#FB9V0.]\K3V'=:K CTA4V0317$WA)HT\2)@74G3E(5IE
MIYWOW-^2?2-ROC6M4F3#;/+B@QJ/QT16 )H!.0555O((S7>M+O4X/*"+)9K+
MG\34/U*_))"G,P( $TYDGN(B\:.1PF?G(:<O>GOZ;!3KJA812FZ[JT/+&VKQ
MACLD%($A6SP8%K-E?5=W,%B9"!L5RK<K\'HUY.@5=0<:S(CR;:M\.]QVH]=H
M@+X%:/E:SXTIUSI4RV.=)(@%FXJ7Z2A\''PZR",T@$(C,.J?$6 !79ME)DHQ
MHO+:XE<N"-/C^I9\X^0I7#4=52SEZ.28&%5B:H5?CGSZF(GNDY-)6+:UY)(K
M M([85M2(.8CC.<1(Y 8]:-GUO8BS&#M(3,X_$7_ +LUKS6/$XW,HR:CAI0D
M/(J>[ Q$BAD^"N?CUSSX\<_^57;Y:X6>@?CWK,/)DM69@OW,ET_6$:N6[S,:
M:6H^[-6<*A^[IFJN/<K0P5+V4476%K+"5%@ZFXE50;EKOL-P?F?2GA1%NG>I
MVX8=(NX[YHI[)TRZK=A7;97U-%/9N&]22]9%3U%-=T]_44TUV]133?3;T>C?
M7;7.<9&8?S0_N7U/*%]+IY#/M!_A12'Y:\')N0Z>;]1]+IY#/M!_A12'Y:\#
M<AT\WZCZ73R&?:#_  HI#\M>!N0Z>;]1]+IY#/M!_A12'Y:\#<AT\WZCZ73R
M&?:#_"BD/RUX&Y#IYOU'TNGD,^T'^%%(?EKP-R'3S?J/I=/(9]H/\**0_+7@
M;D.GF_4?2Z>0S[0?X44A^6O W(=/-^H^ET\AGV@_PHI#\M>!N0Z>;]1]+IY#
M/M!_A12'Y:\#<AT\WZCZ73R&?:#_  HI#\M>!N0Z>;]1]+IY#/M!_A12'Y:\
M#<AT\WZCZ73R&?:#_"BD/RUX&Y#IYOU'TNGD,^T'^%%(?EKP-R'3S?J/I=/(
M9]H/\**0_+7@;D.GF_4?2Z>0S[0?X44A^6O W(=/-^H^ET\AGV@_PHI#\M>!
MN0Z>;]1]+IY#/M!_A12'Y:\#<AT\WZCZ73R&?:#_  HI#\M>!N0Z>;]1]+IY
M#/M!_A12'Y:\#<AT\WZCZ73R&?:#_"BD/RUX&Y#IYOU,-L;RO]_3E?3L(5OO
MWH88ALG%$6W[+:60]Y8$ CYH\0]LVKE%PC[9NLHG[5!5)9/UO724TWQKM@-R
M'3S?J>VFOOX@PC_TA&O_ (5EP<)E_ ' ' /"O4?E2[YQ"J*QB<=O?X='XO7D
M+CH(?^S"FG?N(8)&QHT8S]Z?5XY>N?=F39!#WAXY<.EO4]HX756VW4V'-NPO
MAYOU)"^ET\AGV@_PHI#\M>!N0Z>;]1]+IY#/M!_A12'Y:\#<AT\WZCZ73R&?
M:#_"BD/RUX&Y#IYOU'TNGD,^T'^%%(?EKP-R'3S?J/I=/(9]H/\ "BD/RUX&
MY#IYOU'TNGD,^T'^%%(?EKP-R'3S?J/I=/(9]H/\**0_+7@;D.GF_4?2Z>0S
M[0?X44A^6O W(=/-^H^ET\AGV@_PHI#\M>!N0Z>;]1]+IY#/M!_A12'Y:\#<
MAT\WZCZ73R&?:#_"BD/RUX&Y#IYOU'TNGD,^T'^%%(?EKP-R'3S?J/I=/(9]
MH/\ "BD/RUX&Y#IYOU'TNGD,^T'^%%(?EKP-R'3S?J/I=/(9]H/\**0_+7@;
MD.GF_4?2Z>0S[0?X44A^6O W(=/-^H^ET\AGV@_PHI#\M>!N0Z>;]1]+IY#/
MM!_A12'Y:\#<AT\WZCZ73R&?:#_"BD/RUX&Y#IYOU'TNGD,^T'^%%(?EKP-R
M'3S?J/I=/(9]H/\ "BD/RUX&Y#IYOU/4]X\2Y&0]%>HY\NX][+'.OM7%RCOV
M*#?WHB2B@UZ]<>P:I(-D/;N5U5?8MT44$_6]1%)-/773$5TNB.*+-]7]3<CE
M(. . 4T>:6\+0Z\U/UBLRGY/\H3<?VDP,9F_@L>/^Q9%^N?89H10^&R@2;$*
M>\-]LI^T58;K)>GUT%$M_1MP:A2;OIZ%&'TNGD,^T'^%%(?EKP<FY#IYOU'T
MNGD,^T'^%%(?EKP-R'3S?J/I=/(9]H/\**0_+7@;D.GF_4?2Z>0S[0?X44A^
M6O W(=/-^H^ET\AGV@_PHI#\M>!N0Z>;]1]+IY#/M!_A12'Y:\#<AT\WZCZ7
M3R&?:#_"BD/RUX&Y#IYOU'TNGD,^T'^%%(?EKP-R'3S?J/I=/(9]H/\ "BD/
MRUX&Y#IYOU'TNGD,^T'^%%(?EKP-R'3S?J/I=/(9]H/\**0_+7@;D.GF_4?2
MZ>0S[0?X44A^6O W(=/-^H^ET\AGV@_PHI#\M>!N0Z>;]1]+IY#/M!_A12'Y
M:\#<AT\WZCZ73R&?:#_"BD/RUX&Y#IYOU'TNGD,^T'^%%(?EKP-R'3S?J/I=
M/(9]H/\ "BD/RUX&Y#IYOU'TNGD,^T'^%%(?EKP-R'3S?J/I=/(9]H/\**0_
M+7@;D.GF_4?2Z>0S[0?X44A^6O W(=/-^H^ET\AGV@_PHI#\M>!N0Z>;]31_
MOUY&.Y5S4[&XO95Q_,@)A98<\T8_L]JL/[(LUB\R'(._>0$'%O%/9LRC]'V"
4CC=MM[?VFZ.RJ2.Z8JA2R7U/_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>33
<FILENAME>g947560g42j16.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g947560g42j16.jpg
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M(B,S-G-UF+*TN!DD,5ET=[;5US)"1TA1=H?')B<H041A9&?_Q  = 0$! 0$
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MC%1,CD*#<Z?%1AJ''&B[9J1)MG3ML@JF%6]>SLPZJOK>TDQ@P8 P!@# & ,
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MYCKW_:O!E8>K+[R_H'UN?/Y^,IXS_P QU[_M7@5AZLOO+^@?6Y\_GXRGC/\
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MB/[C]X_TAWEY_P!U]1?]MT!_X\QH2V=J]XK9?XC^X_>/](=Y>?\ =?47_;=
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M1JVD0Q-0)JC37)E>O%=#N+@<$# & , 8 P!@# & , 8 P!@# & , 8 P!@#
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MYGEP!@# & 4K]?\ Y]+R%^Y[T^_6,WP7]FN>_9B748(& 4Q=</O'US_47/\
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M=#WJ;=ZU43<MTE-0P*5.G%FS/K1V!.5Q<!=1TC8EHCNN/8$JYUX:M&7<..1
M7OU\[(:->.4T!\:\A'79E#MY0\123#CNR\.;0UINZE,O/*8+=^&I57#6M^BZ
MW^K>[D7TX(& , 8 P!@# & 00J7YQ7NQ[MG0_P#ZL[K8*?(CSI=T"=^"1@#
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MY*9K"6S,4M+$8^DP2D:PMHV&JF-'BC!!)ILCIP.<JZ4JXU=:85K>2IP8, 8
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M]LDT8!\;1?\ EUOZ53^_MGW=Y-_5W,'[ES5^!L#^<M_S]M^UM/;D>+/='(8
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M<-W"2:Z"Z"FBJ*Z*NG"B2R*J?.VBB2FFVNZ:FFVVF^FW&VO//'/'.08>7 &
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M*-;(=K19@*C"SF<H;)R==6."QH%14IMN(8,Q_+=NF.;Q=U+W=LW7WW&Q\&#
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M>*-SQ08S#BR^@M==V? INY^CJ4<4]%)U>"5[:;KA>T=&&"!@# & , I7Z_\
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MW&PF#CI*J>DY*C3HE>J77Z^)8YXMOFTO'[[F/6?Z'(?@F?+ESI=[)X8)& ,
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MGHQ HSC@4UJ_6UK7OXKI2)\X,((]@?PV/'S_ ,5VH^AMG@U82X>*)W8,& ,
M8 P!@&CNRU#17M!0EK=?IJ0,!XW:T.)Q1\;CRR"!X NZUT7%2$-N[0=,N2@
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MS\(3!QTDJ-O26BZTI>J74>!8_P"+;YM+Q^^YCUG^AR'X)GRY<Z7>R>&"1@#
M& , 8 P!@# & , @A4OSBO=CW;.A_P#U9W6P4^1'G2[H$[%$TUDU$E4]%4E=
M-DU4E-==TU$]]>==TU--N.==]-]>>==M=N.==M>>>.>.>.>>,$E8H113QSV"
M.AI#??3H-;<L0&5Z86VVY8],[:F!7A)E69I;?GG47UEM&1/]6]9E5MM!E+6
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MNP>%U+E5XW4Z>,$# & , 8!2OU_^?2\A?N>]/OUC-\%_9KGOV8EU&"!@# &
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M4:)R(!>-.L*;M6R)@$N2@V=M0T.VBDEG-D3>UYA4U1]=:4%'5>+@LZ;DX,0
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MSZF&^;6(^\C:OZAK_/C_ .E+Z^9^YV;OY1D![[(_T6QX3_BVAT2Y^?GDC &
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M,(7_ -\YI/>N4/"B+1TKBWK#C-KVD=IDDC-&XE<).R,MCCEM+)I=$!EU3O\
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MHZ2NE726C1JBO5*U3Z2QSQ;?-I>/WW,>L_T.0_!,^7+G2[V3PP2, 8 P!@#
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MX!O=KW1NR/T-S/!4.7'G1[T81XMOFTO'[[F/6?Z'(?@3Y<N=+O9/#!(P!@#
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M)7.NFM&C26*I54;^!8_XMOFTO'[[F/6?Z'(?@F?+ESI=[)X8)& , 8 P!@#
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M & , 8 P!@# *5^O_P ^EY"_<]Z??K&;X+^S7/?LQ+J,$# & , 8 P!@# &
M, 8 P!@# & , 8 P!@# & , 8 P!@$1O(#^ ;W:]T;LC]#<SP5#EQYT>]&$>
M+;YM+Q^^YCUG^AR'X$^7+G2[V3PP2, 8 P!@# & , 8 P!@# & , 8 P!@#
M& , 8 P!@# & , 8 P!@# & 4K]?_GTO(7[GO3[]8S?!?V:Y[]F)=1@@8 P!
M@# & , 8 P!@# & , 8 P!@# & , 8 P!@# /SNG;5BANZ>N6[-LE\'UCATL
MFW03^'OJGI\-97;1/3X>^VNFOPMN/A;[:Z\>GGGCCD#\'!\#LW3=\&Q'+59Z
MB-1<\$F?+=4BXYTU;L$UN%O5[O5]E$^$6NNW*ZO.^G&B>W.VOI B[Y ?P#>[
M7NC=D?H;F>"H<N/.CWHPCQ;?-I>/WW,>L_T.0_ GRY<Z7>R>&"1@# & , 8
MP!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , ]:F9$*I$5DBHU1$.JX
M0+JIOFNZ0M=JGPLZ1(J:J\ZL56R//"KA-SRENBGSQNIQKKSQS@'[6[A!V@BZ
M:KHN6SE)-=NX;J:+(+H+:<*)+(K)[;)JI*I[:[IJ:;;:;Z;<;:[<Z\\<X!2Y
MU_\ GTO(7[GO3[]8S?!?V:Y[]F)=1@@8 P!@# & , 8 P!@# & , 8 P!@#
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M@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# &
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M!SL@%98U?7P]Z):?84]//Q6>O?YGH#_V'!E7M?6Q]A3T\_%9Z]_F>@/_ &'
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M8NF#'<DE=D3"C@8%98U?7P]Z,-'L?&[/&I-C274?KM9\R;PH#80L&ZZO"(.
M(0X_I&'VDE5F9RFUQ_Q:,CLJ92<D- LI+-' UJ^81Z('Y(FD"6#TM;:U7MTK
MQP-!AK;\>!-/XP==$NL0L8G7K2P7(]>N:37G:(D?2\2[ 3@MK!T(!RYVA\=K
MLY)Q8:4*DT%I):-=2ZN70.-NVR!50;?ZSK6F+VTU-T=V&S"I9Q]A)TQ_%%ZP
M_F#JG]D\$U>U];'V$G3'\47K#^8.J?V3P*O:^MC["3IC^*+UA_,'5/[)X%7M
M?6Q]A)TQ_%%ZP_F#JG]D\"KVOK8^PDZ8_BB]8?S!U3^R>!5[7ULY^O.K0%#U
M7]BU];"DZCKCX]^O=\>?(.MX;$/CGXK^M%\6?&OR>##OC'XN^,2'L/MGKO9/
M;GGL_J_:5_ACI!MUJV\,>DZH\'(8 P!@# (GW?LCI?'6;=RX1:-]&M^[+NG&
MWP&[9'6L=>57"^__ *B*.G&RBNW_ *NFNW/_ .V#5A+AXHYRZ*[9@Z1I&G:8
M']Z?$1(6%1U;7]8L3[KLY:3)R<9P*)B8LV+N&:%3.$6BY)$5H\6;(KK)(*+;
M))JJ::\;\^5&PRMQBXY-;2BTG%JQM&FFJIII4::O35S.<HQ<I-NCJZIM53K@
M[M1:SXUQ$0O&-=RIL?MGJ[V'C-^SF,QN8">M\XD-BP$,.!TM&8&3B,E,2"/Q
M=_J6-A=4BB[-)IZ$1Y5#9-QQMMKMQPM(SA-QM(2A-4K&47&2JDU6,J-55&JX
MIU+5T8I8*M'7&K\&6!#.J-#C/:5-H>3.$'W)'DB>F4^L:>2HM\:D:O*.]3,M
MFTMD$G,:<.J6J[1EH4+.]!C&'#18W5H,5?,W<&U?^UW<>GB/3'K7!F_LT;KC
M=!'6,-X6EJ3F=@2+=K$F:L&691UDK(Y6658B&'-:P5(>R9[H(,&D;8LF>J#/
M9R@N,-XB:_A80'M&A\;&< =I64G7Q6\0Y*--9>8G;RSGLATT*;/.4R>M@/G$
ML8+I\Z\B#/#9R)X9>Q,M6X&%2.@ZUE5F-K@)MYHUL%K$4H)H9C=KVO#62T31
M>F":0A]&XA-0<6))Z$3I!_JZ(A73[A[PP=>U>O#B-V(VMU/GKQU'\%=?:C#&
M)<=8Q5;DC.0Y\!(-GTEEA9GR*ERS9W,VX065.O1<34G))DR-SMY%&05[-Y$S
M:2.5N#!UJ@03&5IW]1KRQNH54346MP!9NH!+]';%Z(G4>?&.#P9=IS3R"_Q>
MYX+MGPO<D(H:KP;DG'B0&1M1\;UY$'1CHD8<D0K\]?OQ/*SZ<T;\@*0KX^$.
MREC0-;":K@QA_,)4%-N(J-0@7#AM)U8<7C3&2ZF2-9PHZ59%F#@4H9!,WC4<
MU^!\#!K=:[W7O]YYW/3;K>XX'<I5XJ+<A]6W <G'IK8,9."-F?%:<-5A1Z.R
ML6:&ND.*?K?A-VR?H.M>(NWX]=_KI7V\*OY\=I[,+U.H".KLU0D#4&M1RT#=
MCP3:6SC6),259OJ\(PDXSAG,EVB;:1!W545]ZV2(A=#Q=M&VS$V1),79)L]"
MK^4EC7LOPP/RZ=1* 1(I%FT0.,B#?=\BT<C[+M(=LR $R7!@E &";&:MTF%3
MD"FJ3][3S--"K'3INU67A^^[1MRD%6_GOV])^6K.HM-52I%2HD=(C,OB+O1Z
M-FD@FDR)'/2D/G ML*X36/[#&T/8M+(FR@ZOV;%"!C2DA?'V$;;'MDR285^>
MKW(D]@P8 P!@# & , 8!&.A/OJ]V/><BG^3/J/@UX1X>+).8,& , 8 P!@#
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M:1TC [\<<L[1F<YM*"Q^?* Y*UB,TB-^H1"KX!,W=K-):7"5C:!*H73,F6E
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MVW]2[W95UG&6*%IJ.";8(2TK/AYF>MC9.;NP;^0/TM+!E/(5UN\CB:0AP*6
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M'F]_9\1]L>_D;?I#?N-P/-[^SXC[8]_(V_2&_<;@>;W]GQ'VQ[^1M^D-^XW
M\WO[/B/MCW\C;](;]QN!YO?V?$JS\EOE8^S/^LK_ /D-];;ZVWUQ_P#VH_+'
FXZ^6/R#_ /\ G46^+OB[Y+?_ ._VOV[_ /B^R_ZP*C'1K?6I_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>34
<FILENAME>g947560g42m12.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g947560g42m12.jpg
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M-W*7M+76V"(Q25&(,E6YR-4C05-6=I2S)$-QD=3_Q  < 0$  @(# 0
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M#9AH;&;C$2^SZ>EME3X4[TEZ&<"K9=23%4#/ 1XGFDDR@;+,5-DY_O521#6
M[N57F3;JDIXH 99*1VH1)II@4^(5/FU7XS3IBU=[%CULPBE;+R<F\'3>J2&W
M-[O=+T@U[O5I-':5%F]6EQN2470R\3* LDPO*2@@-DYDQ"N;C5F::+%P3Z>E
MO9LOLL16CI7DP+B5#\Y)K%7J^J=]V+==/M]AX>))OQ&[\D/2HQK-N]"@</N)
M5V@0I3=;?WS%UDB@ZZ6@S8@76HWWE.T7L^7QDYQ)8;E%44%J&6P+FK66;X9F
M2()K ?,3#"[ZPQ)T5/FU>.ITNNQ,LI[-57WMWH"BM[;?8U0C6>-/9DE]X$HJ
MW$?LAQ>XGA!^&IC<:RBS']8@W<GJU#_=V\3"PY16Z@BR684\G.MHB6?."$"X
MC"&*Y5425Z557.JJ>SV8$+)K<4OPI!>\C[3=O]D,#$3\46#M26XL2WMH_&DR
MFM!+@5-.G4Z;N61,DUS&8]Z?%_O0@Y9?*MU>66LREA6%!1E4$G9/,"U$W"J8
MP.*Y)NM(L%=7!.FEG$R'->P;I+:T(VMTJO+9T/"(-_Y*?S+U1XH[_D01V+L1
MG]5<FV12=CS4%D%EXNUIHCZ.&4B'5*.$XO8R\3(2>LG#!LH75 HE6MU\"3B@
MI<\ZM5HPO=]RUDZI$V ?E] N&6\79MHMYPU+;EB1O[G[NQ4.(PU,BR3$-OM1
MP73CJ'2 5*'$5X3HAL>/I$D(Z0::XSLU!0(*XS.554W@GBJ7SH[K[\V'&^M*
M4TM*M%K6G @BJ[Q;"S#J:DZW:EO?:Y;F9\[,3X3:<K-=[,K9>3DO7V &.QI
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M,.IFM<IJ@CY'4Y @^,G6HFY-249#D!0/++023AI4>"6W"28WBJ\JCBB*)_M
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M=<?V'UC\)7X8/_F>9_V1*G_4J?(]NT_D^3_T^7]T?&5EUQ_8?67EQX^4"4&
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M^[4_^FT&9%JXUUCY1_1OZRL<_P#NU/\ Z;09D6KC76/E']&_K*QS_P"[4_\
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M@% * 4 H!0%9>Q/C1>&AY%>(?_"]5Z$Z'OKDB+-*$"@% * 4 H!0"@% * 4
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M*Q^+]X#JYUDM#/;OUNH7E^&MZ+FLLXH4% * 4 H!0"@% * 4 H!0"@% * 4
MH"LO8GQHO#0\BO$/_A>J]"=#WUR1%FE"!0"@% * 4 H!0"@% * 4 H!0"@%
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MO%RTO4=B]AF'-3/<D8\0,W#3:9\* 16HQDA!6U]'.I#C707>YLGZ:-)9]K$
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M@% * 4 H!0"@% * 4 H!0"@% 5E[$^-%X:'D5XA_\+U7H3H>^N2(LTH0* 4
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MB35SZ.#FDWNJFSZ.5/V%X(FXFM#SF[E7!O&E>,V9*'R% * 4 H!0"@% * 4
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MX-8T?C'1#.2VGYEQL'4RG&G7+Y@WRY2&0MKW#$#OEZ9N/W$9;W09+F90R?\
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MM=?VFP74E2L?B_> ZN=9+0SV[];J%Y?AK>BYK+.*%!0"@% * 4 H!0"@% *
M4 H#&\RIP*Q$$JI!A#6W.758V?*<.VVT&G#.-P@GFPJ%A4- !6"IY)%6U; 7
M(@E!JA(XG9GC &)TJ8+7%!S!8K]A5KP95YU+$-201<21*1(JVG>G-E(/2*TF
M,UR8H+> 54&Z.W1VKIWIHM.'-+()24I*RPZV0Z#X@3@2 Q5]*7L',T6^+1)*
ME*8:*U]M\1<E0J* K+V)\:+PT/(KQ#_X7JO0G0]]<D19I0@4 H!0"@% * 4
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M^+,T ZGFNWJK:]"T?AQ>=%RLGW0J4>PW^=&TG7&V/].S-"7A#O=+,Y4(% *
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M9:RRME1PP\3@ PI$8$R(%'1O8M*TM-%RM"I5_O5X1FDGZVR/H&TZ X^@% *
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M[9"B""999Y"TOP_9%S66PT*"@% * 4 H!0&FO\+<_P /[_59_P MM;"=P?\
MA5_0?^L&'RM^]_SO^6::];"&'% * ^H=P6O%;:9>2TQZ8.>M*^Z)Y;;HOY\O
M\"2=FL7BLGS7SHBT*NEG*% * 4 H"LO8GQHO#0\BO$/_ (7JO0G0]]<D19I0
M@4 H!0"@% * 4 H!0"@% * 4 H!0"@.)7_R$M?9*C^YC4!!KA4^+,T ZGFNW
MJK:]"T?AQ>=%RLGW0J4>PW^=&TG7&V/].S-"7A#O=+,Y4(% * [/P[/SFX@7
M75;OL$Z-4+180>:^?$64T*GSV_A/OC(T+JSQ?Z6296UO<7\CYOKFV^[V(Z_E
M/QG\W!RQ&NG7K9CQ0"@-YWX*'X,VTOEU;OH G5K1W<OPSD3U9.]ZC,WDKZ.;
MY\/--K.O#C*B@% * 4!7=LQX>7#.^V]NO9]&H2L(M[I18C0@J_WJ\(S23];9
M'T#:= <?0"@% <[P_?TH[Y>7N+O98@ZA+PAWNEEF="#0"^%.>,.BSJ@1UZWY
MZK:?N)>2=M]?VOW#)9@<J>,0>AAY\PUK*]A,:* 4!];72CP--2>K) OJK:E:
M([I/*++_ *ZRK[]/.UR/H)/HI?,A)-UA3ZB@% * 4!6/Q?O =7.LEH9[=^MU
M"\OPUO1<UEG%"A';:38$/6>)LY-NQUF1C@[[BZ/$5G(*JC(:@KN&5Y%;,;(&
M-E9P#EDD@4+*[H)FSY@V-CB&3 'OA;(3F8W$I5=-C?L2;?(1-[_6<OJ,OG]N
ML)?];H32'ZW]UG3D7B</)R*"ZDMW5(PO*K7R&P<R8B[-Z\*B@W<RXXQ8Q@ND
MR+I',I&0!DL8+C8J 9>X0X P6=L1 L\<0S5];^ZSD&SQ(I'>J7BMLW3]8=J+
MD.,5Q5VSL= "\EY&2]\;#E\5!*<ALI<<"^>%A@;"W$"OECS\<>=;E"D/UO[K
M,^:X[B+DWRN[X?>$$.F&G,UH\0I*+C+3V9#S3UM"7'(L-? ,L.SSYRY(X54$
M8?(4([CA80 0/,*][\MK TDJIU5:84)P4*FFO\+<_P /[_59_P MM;"=P?\
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MD1T](Q9[VD,\TPS4H%!EIN,Q=3D!2?2==FXK. XM#2M]-]M*EZOO3K=6[I,
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M;[\17$G*RT\E1Y*+*5#D<JC90T@F,I+:$PC:6IR7(I)'.%%,.,&:^S8)=3.
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M)%+FTZI.F&]MV_L+4:%10"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% *
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M_'0'\+H"$4#+ E$5)*A$@02Y,(NG$P0RA<OB9Q  +8!@XX@ @8G3F((05L,
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MK'?;PG\[DWS?M@/=A04>SA76.^WA/YW)OF_; >["@H]G"NL=]O"?SN3?-^V
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MU7,HH2N1;KG,(X+A+MQ=-IY@ND+PZ 8-D"ZX"CJ A=0%1QSQ,%3P+Y$A39?
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M.YKY8WL&[5Y?!#'.AAX'S0CMV[=2EZT/S2:__IU$_AA6@.Q4 H!0"@% * 4
MH!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@-6B=>*QL-JAL_M1#4=LV&%
MEL)$Z+*N6/O1O/A17LS*\T68HG,!S2'(C<3\@ QQ,L2V(:6$)@%:V(HHV?+G
M<?10II-U[-F//EZ=O_HXUM^Y\G^^&A.8M;XNH?+T[?\ T<:V_<^3_?#09BUO
MBZA\O3M_]'&MOW/D_P!\-!F+6^+J'R].W_T<:V_<^3_?#09BUOBZA\O3M_\
M1QK;]SY/]\-!F+6^+J'R].W_ -'&MOW/D_WPT&8M;XNH?+T[?_1QK;]SY/\
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(0"@% * __]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>35
<FILENAME>g947560g44c18.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g947560g44c18.jpg
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M 0$! 0$! 0$! 0'_P  1" "  >8# 1$  A$! Q$!_\0 '@ !  (# 0$! 0$
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ML03:/'C71ZBCHYT;.W*&JG"2ZNN^DX5@@L7K"3PQ3J*C,%FC210W30CF <,
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MUC0)&V0'\+)J>C::DZ[;;1133LC>J8 ;,;!OT>_Z1/<#^2W7G^N;USFG=/\
M7;3_ $</I,^>@_N=O8MK?I]_W=1RQ#Q"?IF]3OJQ=Q?[J]*<T'!_KA9_4V_S
MX,F/=8]8*/IB'Z%?RH#NKU2HZTXS(I\.I-],[B=RBN(@</TW)W]>69L/-S.&
MA2AF3&8PS(H2A. 14CK-.!$] 2,?J+ M=?<6+;AN];2O4Z%6PCRK5,MDR0QL
M]9S#-LTD:LTC(")!#&W2\LRN.5!U ;$<RX9U[5*,T5235%K:<M>Y8BBU&!+E
M+GBK6)(XH(YV4P&W.AK=)4EA?GE;K9MU,WXXUTK&O!3.<6&[D240")-SMDSY
MT!$/RB++7VG)R4/6+4* ;O%$O<_?[Q!F.:*K<;+^X(\J\Z\;1!T$*B68OT:@
M/-*44MMU<SD!4!/G( &_F&1>9C>N2-5IK";$I,5*HLLB(6_\J!&:28J#OR*6
M=@-AS-MOF/@;_HV4RQK!8Q;U;R*7OF&Q)B !3( 7(/FFF[C139FFP?.-72Z7
M#5RJJS;[J/$FR*CM1#5MK[KGPEJL\@B2Q"\A',$61&8CK\FQ._D.X'6 -]ML
MO2Z1JL%=K4^G78:Z-R/++6FC1&]3_6+H"JGF4!F 4L>4$MU94IX_OT.*U^LQ
M#?[6W+D=XO\ 6V#]>B^CV<GO<H]D5WT+9^G:=G>1G.<]!8QC&,8QC&,8QC&,
M8QC&,8QC&,8QC&,8QC&,9%*^+UM2"6A45-4O4L&M&>6I$;<GG.UCW";IN* 8
MQ4!&J@YGGX;CM.765*'"A*W(_J-&<1H<QX9L"[ER92629LWE"?,/R_D\FWZ>
MW*@><_Q\N_Z.S,8_:%XA7FG]2?OV6O\ _P"?^.OL'OG^&.KM/O#^.?G#^*B]
MFA'Q&NXCVQ([&XE-G-PO%)%'(A+B,\C0E_\ JY'=?>HB8%H;7I(\U]PX14]^
MNX7'E?=5%$?>/M4M5E?7?<:]A4/I*_\ _./(QJVW?9V.XZ-/-MYC^GR9G/0>
MR*Y:5#W?ZZ2>WH_UZGO9NK:TC]97-,-I&QAC)>OK0&S67UC+Y)$ YT_%@%J
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M29(BS;MG4LY9#]&;W9R95;,$W"NF^Z8&CT\RQ3!H [K">>&4.O4L9EY04?<
M&39=CNVPWR"+38:[WC1>U2>.\T,,ES\%<J-"YYGG%7G*S0E&++7#.67EC#,0
M,B?4*$"J.]P0TE#I%"9])5P=5QVH).ZB4B;06+$!=A3QO/JUL9@UV-3>OG;B
M,/HINP*NUC\(+*[QYUJ$CG,6#[8%<0P6D5HWBF?E@2L_1N(8RLTW2PS*.:6$
MF,ILQ+Q-Z@A$,:B0:@;>H:5*\=F&S4@66_-J,"V(6M3H]2H:EVDS".M<43K/
MSQJ(K,8$JF64329';Q_?H<5K]9B&_P!K;ES XO\ 6V#]>B^CV<VO<H]D5WT+
M9^G:=F<03QI_$MEL'ALK<W)6;1S)HI'9"X:H45%=T&RYH0S)*MT=U"/*FR2*
MCG9-/;?GV^VFO'.W_5SSFVTWN<T+NGT+KZC;1[=.K:9%CA*HUB!)2JDC<A2^
MP)ZR!N<TNO\ =[U;1]>UO2(N']-FBTK5]2TZ.:2U;625*-R:JDCJOJ0[K$&8
M+U D@=697\L-XDWELKCT$Q+_ &.9OBOT[W3N_!P?RYJ/Z1FM?BUI7QNYCY8;
MQ)O+97'H)B7^QQXK].]T[OP<'\N/Z1FM?BUI7QNYCY8;Q)O+97'H)B7^QQXK
M].]T[OP<'\N/Z1FM?BUI7QNYCY8;Q)O+97'H)B7^QQXK].]T[OP<'\N/Z1FM
M?BUI7QNYCY8;Q)O+97'H)B7^QQXK].]T[OP<'\N/Z1FM?BUI7QNYCY8;Q)O+
M97'H)B7^QQXK].]T[OP<'\N/Z1FM?BUI7QNYCY8;Q)O+97'H)B7^QQXK].]T
M[OP<'\N/Z1FM?BUI7QNYCY8;Q)O+97'H)B7^QQXK].]T[OP<'\N/Z1FM?BUI
M7QNYCY8;Q)O+97'H)B7^QQXK].]T[OP<'\N/Z1FM?BUI7QNYCY8;Q)O+97'H
M)B7^QQXK].]T[OP<'\N/Z1FM?BUI7QNYCY8;Q)O+97'H)B7^QQXK].]T[OP<
M'\N/Z1FM?BUI7QNYCY8;Q)O+97'H)B7^QQXK].]T[OP<'\N/Z1FM?BUI7QNY
MD[_#,\2CN=V#[GPFE;LL&%2V 2:N[0D#ID'K$'$2:!:(LP+D4NB5&/%EN4?;
M$7&KAMNGSHKKSIS[/'.O[XCQ=PE5X<KTYH+<]@V9I(F698U"A$#@KR $DD['
M?.G]S'NG7N/;NJU;>E4]/73ZL%A'K33RM(9I6C*L)>H !=P1U[YT[9!,[)D*
M[)^G_P!1_JR]W_Z]Z1Y3SC]!_P 5ROF/Z1_@V34RN4S\MSQA_P"*)W?_ )VO
M/Z7C&>NNXU["H?26H?\ SCR,ZK_S9_\ ;3_7*VLZMFMQC&,8QC&,8QC&>EH9
M,)AW$>3*DM #LDS,N@>CYUJ'<F!S5\Q'E7 S57ADL28LBA)FS?*(;.FS4B^;
MH*Z).W&BGP8XS()3&AE5&C64JO2+&[*SQA]N8(S(C,H/*S(I()4$5W.VVYVW
MWVWZMQN =O)N 3U_E.>;GWE,8QC&,S*%V-85;OGA.NYW,H$2(,]AS\A"Y.;B
MSY\/WVXWW8O'8-\Q7<L]]^.-]FRRFZ.VW'&W.G//''.8]FG4N*J6ZM>TB-SJ
MEF"*=5<=095E5@K =7, #^7/I693NK,I/42I(.W9U$9X9$^=+M1S(L:+%&8C
MA]J):$2+QZU%ZDWRQ0EJ.;N5E4F7! DX<$7W#;1+AV^76=N/='"NZFUQ(HHV
M=HXXT:3EZ1D15:3D4(G.5 +<B (O,3RJ HV  RA).VY)V\FY\FYW.W]_7^G/
M)RYE,8QC&,8QC&,8QGIAC9F.D4#$?+DP19KJXT;% S]V,(MM';99D[T0>LE4
M'*.KIFX<-'&J:NO"S9=9!3C9)7?3;XDBCF0QRQI+&Q4E)$5T)5@RDJP*DJRA
MEW'4P!'6 < D'<$@]HZCGF9]XSTFQDPS&DPS0J2:AS2C!4P*;/G2 TLJ*475
M&*$V*2NK5^H.5<N5&&[I)79FHX7W;\I[*J<[?#1QLZ2-&C21!Q'(R*7C$@ <
M(Y',@<*H<*1S  '?897<[$;G8[;C?J.WDW'GV\V>;GWE,8QC&,S9"R[':PQS
M7#:P)LWKQZZ]^O(&A*CJ,,=O/=]'/OMS%TW^H-=U[Y33<>^%6.ZONZ>BOM_=
M--=N,8TJ;65N-4K-;5>5;1@B-E5V*\JSE.E"\I(V# ;$CR'/KF8+RAFY3UE=
MSRD]NV^V8V8,F)$4?G) 6)'395RH])F##YT3*$7BW/MEG;\@]57=O'*NW_4H
MNX645WY_?MOSSEZ...&-(H8TBBC4*D<:*D:*/(J(H"JH\P  'F&4))))))/6
M23N2>TD^7/-S[RF,8QC&,8RW?PF_"8M#Q*;,V)$-C%?]6X$90;VQ;2#?5)Z9
M>(ZHO%:RJ_=X@JS)3HBT51V+%]T78>OQ+Q$R91>E'D>CA_B_=+[I::$DNA:%
M,LFLR*4MVT(9-*1AUJAZU:^P/J5.XK \[[R\B#;Z?I_2[3SC:(=:(>HRD><]
MD8/[9ZAU;G/T@Z9IFL.O580VF:9AH> 5I  Z(.+18&ALDS8,TMMU5EUUE=U7
MA(J3>*N"9LV3<.RYPN[>EBSUX1>.7*OEEW>1WDD=I))&9W=V+.[L2S.[,2S,
MS$EF)))))))R0_,!U #J  Z@ !U  =0 \F;.SYQG"[XI'\3'NE_S"DO\3>OV
M=R[F7K%<]+3?0Z.>._NB/9AI']F:W[UUC))4*SI.5=7H&!L(K4AR$#!]M.;E
M?61><I 6M3AQ,G(WT%2H*J=9:P$/DC+54*>1Y$0N5ZS.7F9"%/JL4&?/.N5J
MC:E#K-J6HE^*R[T1IZU--@EHZA&4A6R=4O= TB&-A)$W26(37KQQ21!BVQUG
M#L>@V^$M/KZG-HUBA%%K+:Y)JG$%NOK&AV!+;DTY>'='[\C@D%A6@L+T-&V+
MUV>S!9:-4WR!W54,]*WU63L67B@\O'9M$)$)&RL^3BZ$I(C92'W;1@4?&1B6
MJ!S!/??VK4LX$[MQ.B:Q3E3W5FFFI)M;D6/3+BO'.\<M>>*1X(DF,"/#)O-)
M$\]<21IMZJ,2 R$A-MF)'.^$('FXBTEXIJ<<U:_2M0Q7+,M1;<L5N I4ALQ5
M+A@GE)V29H2L(#3;[H 9&7CM4@:BEQ<>'&IF,>V@;=C)(&[1(V8C%)TO'T]-
M$3@<MUA@ZO($B+2<.&VPHV(=S-RP6<.3Q5.--N!6ITSO^34@\KQUG6E$KPR:
M*:9GK"4[F*2/6;($J.5#"2.1:X8!8H^F;GE'$'@>#AYHJT4]Z&35[#PVH.+5
MU9:>H-6'J;$$W"E!N]I80S*8;$#WGC+/8F%5>AF1^CW_ $B>X'\ENO/]<WKG
M/NZ?Z[:?Z.'TF?.Y?<[>Q;6_3[_NZCEB'B$_3-ZG?5B[B_W5Z4YH.#_7"S^I
MM_GP9,>ZQZP4?3$/T*_E#<[B\_CM]6\TJ*-=7;QXM/L5&YD!TM:USE=3BJ.Q
M<*H>,\*1LH&%1<XXM &!KD8C8P6-!7S,H*!'9)[Z8;--=26TDE29+=@5THVN
MGN)(O?%AX9:]R*I'^#95C<SHD*"=44AE1Y-QL.8P2I/5FTG3VU"?7-+[PT>:
MO*:%&*Y5OZ/9U6;:9)7GB%&26ZYI232(R/+%#ROS;QY-[JA7\&"=2*<K87(
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M#RX*B4:J-%B49D+?EX".-D5>-5-AIAE[5Z-<\ZZZ/62J#QORHV7154LPV(;
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MVOH?Q*W]H8\$U.V?X1/JL?-*XWY]\A^[J*]<F/';QA[7T/XE;^T,>":G;/\
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M<\L* 1 \?WZ'%:_68AO]K;ES5\7^ML'Z]%]'LYONY1[(KOH6S].T[*]*7_\
M#M3_ ,M()_2PK.N:!ZQ:+Z)T[Z'#GFGCCV:<7_VHX@_>UO-EYMLB^2PZ36W#
M*.[#1RR)]MIQ&1$/ML8Y26&D"[9X0E-2S:+ QSU@+VT?K,"1LR/8/MD%4.4&
MCA9?=PW33W6TT?$="QJ6DS4ZO_&DL474AT0JL-ZM-(ZLX*!DCC=E!!W8 ;$G
M8S'@/6:.@<2UM4U$CO6&CK,3!HI)D>6WH]^I7BDCAVD:.6Q/''(5*\J.S%E
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M_:G= BXD1%]F1B;%(NZ=*#&V%'Q?"E83W:-F!I-0OTH(U>FH<4G968S6+D$
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EFNZ7J-.)M(L1K+:I6:\;2&Y081J\L2*7*H[!0>8JK$#921__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>36
<FILENAME>g947560g54a02.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g947560g54a02.jpg
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M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" #L E # 1$
M A$! Q$!_\0 'P !  (#  ,! 0$           <)!@@*! 4+ P(!_\0 4!
M  8" 0$!!Q '!08' 0$   ,$!08' @@!"3@1$EAW>)>W"A,4%188&38Y5W:6
MM;C6UQHS-7F8MM@7(599M"(C,3=SU20E5)*5TM0F)__$ !P! 0 " @,!
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MG J
M                                       !B<[EQ$"ADHFBAAE<I)B[
M(X/64;@L>72R9/\ R@3YGX,\8CC;CDL>'MQ,QQ2-Z/#DHO-0;ADI4)4V)RDH
M#1*%]4/6F=2.FXPTI+-3KKC4HVXI8NB2'EFKQY?+7LNC(6U6"\MT@<6\OFPK
M;J"Q(5!7N%'S:*R!5'^'HJ0%1=W8WUS%G"U/D[D^I-3P+"R71L4'\IB'%">I
MXYSXY3DJTYI_')?=[_CDK S(SNX=SGO^.]_V>YSW>YW *GG
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M2^SB22U!.9IR+G+##A847CGSF8EYS,+P]D88\D]\9ACW_=RQXY \H
M                                                  !AU@Q)1.X1
M*8<DETL@"N2,JYI23:"+&U!,8JJ5%<X)GZ-JGEJ?6;!V;3N\5)2WAD>&A1F7
M['<VMP0FJ$AH%<T$Z3M'P2<UI/DME7 YN<)E""<2YI5'5FVQ>V9=&[JM38:
MN,E8([6K*CAS77=M7-/)'%HQ4?%>1WE.L;VI^;WM(@SX5/'CQ[B<Y\F&JQ*S
M6D:X3O4?6?6_JS].27T12< JJ3VVS[]N=EOD-9"6IPFK@CK&!NB56_GEY<\K
M3R'"0O:PO//CCG$]S5Y_\3>0+YS<$4VW)P)<E_<7L@8P
M        "O/:72EYV-DEMR?F51AK7NM%5_7-+8.;(K6EP^8M%MJ;5M!WE&28
MP@YQC]K8PFAX6Z%(#.7-NC<'>\">3L7?A)F\>/&@E.73/NPNMTKJ-*MN=6K<
MULZ;EK6/%-O-@JLM36VBMG;E(:J#E4?B=22.P9+*;(OO)*\1^4PB3R1TCL:?
M9.9$&/),_P <6*8BU(L32&]:9EZP+0M110II.;2=\]"O36$]>)=U"5BEPAD1
M7K3LU*Q=&&!8K4&<\<F'J5+4D./.,YXXXXYS--SSSSYXXXXYRRY_NX H9.
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M7)M)5IS7!O3N7*KAN4+D>!F2A(2OY1+>$1IY99:KE(J]8R,]CF]X!YP
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MIKF)U @XYO5;W["T"^D^R'V#4(^H[S_'6K>@90]2C5KO!:3:H_M'&0/6YP(
M  =W?J3SL3;,>6/(?091@\9;YG'G=!]?5?9]4.PU7@M7V(O6TAU*CHAG
M    "LV%?+#;%?NY]1_O';B@6?F0[479 69 5          /CI33X\S_ ,8,
M\_F]Z'M'>WXD;GO1*7[W6#@:[PJFVE]F$QP=W-4 ">=4>UEJ;Y4^N/IGA(^=
M[ZW$/+>UDSVO4#<J'"J/9IO44A]=<>.SG         @C:7LQ[&>(BWO1](0!
M'?3[[!>D?DB:V>AJ%B(;EJ783%>];[3;L20
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M@8A.,S39K&Y$IR+Y.2DYX5BA25BT]Y>".*+.3B;6;=__ %"= 0QE@
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M[T?2$ 1WT^^P7I'Y(FMGH:A8B&Y:EV$Q7O6^TV[$D
M    !BDZG4.K&'2:PK!DK/#H1#69=(91*']:4WL[&S-I&2A:X+U9V6.!1))6
M'/<XX[XPTSG DG PXPLO($IV(@6-[M:GRY\K2,QV^( Y2*WSWQ)7K'@Y&IW9
M\<8V]OD9>6A2@5IDZJ/OB23QF2QG%CDI3.[JY)'GU@1(E#NT."-.)DY3E8O>
M:K;4?*A])_Z,]03T156!9>9'K@^(M. H5N=1G];I#Y:[)]V;9\3#>M:[2?F4
MFQ\4)X0SFL   $-27M7=.WRG;1^X;N4*1W+7[F9*.^+9^*$N5&(R
M       &G]S:,T#L!,'29VLBL"4+%[&K;&]C-M6PTL0B+RK92([S/8'$TLB*
M8X582=D3$(DDICB-O5IC,3G,LOAX7.#BK$IRPZ$^W4:;=275'7JONE7MLRM=
M4PY[551J/L4K@TMFS&VSB?,KRZQJ8S5[DB:<RA*YR8F1/DT=G67.KLG<2%"B
M1.*MRPY*-SQXP%H&\^&V^*'DTK M9KSX@0;Z'QG[%1 4-4^I+V#=K/$W*_\
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M;'Q0GA#.:P   0U)>U=T[?*=M'[ANY0I'<M?N9DH[XMGXH2Y48C(
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M!\@$<6G($4%(=9ECE9(LI2OMMLG?9AFO5:[=!?4!4 ""-I>S'L9XB+>]'TA
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M;J,9<XYO5;W["T"^D^R'V#4(^H[S_'6K>@90]2C5KO!:3:H_M'&0/6YP(
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M4G-*^%\M2*R\XLX3M@>R3IDQ>QE4?2"9>4DYRFD]>$Y2Y^>TN] J
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MU@   -F=(^W#I!Y9NJWIV@8^:[[?$;*?I&3?O]7-W)_"H-BF]5&?6W'D$YL
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M^YPXRRQQYR[G>\99<<<\]WGC@ 5H0KY8;8K]W/J/]X[<4"S\R':B[("S("H
M        !\=*:?'F?^,&>?S>]#VCO;\2-SWHE+][K!P-=X53;2^S"8X.[FJ
M!/.J/:RU-\J?7'TSPD?.]];B'EO:R9[7J!N5#A5'LTWJ*0^NN/'9S@
M  01M+V8]C/$1;WH^D( COI]]@O2/R1-;/0U"Q$-RU+L)BO>M]IMV)(
M   #DH]5H?\ (?3+Q[SST8. ^B[U''O(NQE/V5736KG!:;5!ZVC.(8>PS@
M  [DO4FG9BVZ\I9E]#\''CC?4X^Y>UY,]CY/.?J7!*#52_>*8ZOA\^-D
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M3'8FV4LSOC@<W(*ZMI1(<GV4&K9%'+#RA/L80LVV=EG*W.3[7+2I=)?L!4
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M3-+*K=OQDMBC+RYF-"O42;*^QK36J&36*,D3G-FI9$T6$M05_;":#I)+"6^
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MP.,X,4G24,_
M
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MF=X:5B9Q:W9K<4Q:QO<FUP1F')%[>O2'$JD:Q*<:F5)C2SR#,RL\<N1![
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M4[Z.XX!,5[UOM)] @
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MCN. (KWK?:3Z!
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MB^KN'P].W_S<:V_4^S_SA 9BQ?5W#X>G;_YN-;?J?9_YP@,Q8OJ[A\/3M_\
M-QK;]3[/_.$!F+%]7</AZ=O_ )N-;?J?9_YP@,Q8OJ[A\/3M_P#-QK;]3[/_
M #A 9BQ?5W#X>G;_ .;C6WZGV?\ G" S%B^KN'P].W_S<:V_4^S_ ,X0&8L7
MU=P^'IV_^;C6WZGV?^<(#,6+ZNX?#T[?_-QK;]3[/_.$!F+%]7</AZ=O_FXU
MM^I]G_G" S%B^KN'P].W_P W&MOU/L_\X0&8L7U=P^'IV_\ FXUM^I]G_G"
MS%B^KN'P].W_ ,W&MOU/L_\ .$!F+%]7</AZ=O\ YN-;?J?9_P"<(#,6+ZNX
M?#T[?_-QK;]3[/\ SA 9BQ?5W#X>G;_YN-;?J?9_YP@,Q8OJ[A\/3M_\W&MO
MU/L_\X0&8L7U=P^'IV_^;C6WZGV?^<(#,6+ZNX?#T[?_ #<:V_4^S_SA 9BQ
M?5W#X>G;_P";C6WZGV?^<(#,6+ZNX?#T[?\ S<:V_4^S_P X0&8L7U=P^'IV
M_P#FXUM^I]G_ )P@,Q8OJ[A\/3M_\W&MOU/L_P#.$!F+%]7</AZ=O_FXUM^I
M]G_G" S%B^KN'P].W_S<:V_4^S_SA 9BQ?5W#X>G;_YN-;?J?9_YP@,Q8OJ[
MA\/3M_\ -QK;]3[/_.$!F+%]7</AZ=O_ )N-;?J?9_YP@,Q8OJ[A\/3M_P#-
MQK;]3[/_ #A 9BQ?5W#X>G;_ .;C6WZGV?\ G" S%B^KN'P].W_S<:V_4^S_
M ,X0&8L7U=P^'IV_^;C6WZGV?^<(#,6+ZNX?#T[?_-QK;]3[/_.$!F+%]7<>
M"Z=>+;Q4V.*8RN=;\2U"%61GSA$+.XSXP.3F%Y<X<Y7!ECQEQCESSCSSCEQQ
MSW.[QSQ_< S%B^KN.FO5'LN:V>(*G?1W' ,<5[UOM)] @
'      #_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>37
<FILENAME>g947560g58w10.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g947560g58w10.jpg
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MTM/4V"$T-WB6M;:WUR(U. I7(R0QU24Y8;-!47&9L=GP_\0 '0$!   ' 0$
M              (#! 4&!P@!"?_$ %$1  (" 0(" @P)!@T#! ,!  $" P0
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M0PRM\UFGM[]RK;1XCT;4KL>GT[G37)=(J:]' :]J)CI5YN2K:+301HO2MU=
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M+9D1DK]--#TI&X[TALHT2'/@Y%^)*-5F)(6]=#B+)QA=-PS?,EU&SMJNG?\
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M9CJ\9?.7VX]+%TU.V_QO]IL?_$TY'\5O-/LQU>,OG+[<>EBZ:G;?XW^TV/\
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M 8X7@E660-^24C*AW#;';E4[[=617L[E%JW7>MB^UQT@ ;#B$4?05><.X)*
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M5$41<V=S*.MHB25<*JHH),)(L1P#/%%UD%TD<&[U3)15%5/"V6:>=K1M=II
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MD8[L\DC%W=C\[,Q))^<G(9WW^Q+;7T=R_P#D3VK/Q)\G]:_LN]]FDS+.Q_\
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M'7\V1/&.K;LF3:VC3\+H> R?:I?G=&^$/S6'V9+ VM#I&80$G,X[L8')I7K
M7,1<?7<MV;%ZQ.02Y%N*NX-M47RZC8-=GO(-SUG8)S^#KZCL1L#M^?Y]OSGY
M\]F-=47D5@09NI]QHU>*A4+YRL. ^Y9'%]T2 P4MM(P>:BD93K*/$M9B<"4(
M!,2H,B26E!@.;++%46+$2PQ1?O&+'(/F8GO><=6W4-]P>OJ/5\VXR\O/[E+)
M^*''J?3^%ZLVIL.6XZ_V6^C)N!01";Q'6\@C<+(F0TQW!=8Z$S!:[8$4V[HT
M20Q?J6',B/<:WNG:V;(47F8#< ?/N=OG\ _7^89EO##D8:Y.:0C&P9%JO;6K
M3WS/%VQE+:D'0@J<P*O8B!-D9CKYF@<.?.FORKPHMB!+**M%%\454LFB?>;9
M9L,O*2-P?V'?Y_G_ %_JRB\-ZD/(27:6W/R$<:&T9#-5Z]F,OU9$3^P^1[6#
MMY%/8MMAK!7!B0O3L018@(8D </'Z3(<J=FA^5AU(P ".,2XXA@R(H P7<DD
M D!=SMMOMX?#_P!MNO?,)CW5SV"5U>_-(:+@DNV8%YIZCXBW%0[9$K8:]FF6
MWPJA>/3.*2*;ZUCLJ%HYKXIC<6DBAR2.26:1K!TJU<8-4V"@WVW.W(6\ WZM
M]QU$CYOS]7@/6,]7;/.W:!W6FU8EM.#/]8;8X]\V^-6E97EQ\WI(Q0&2C-FF
MH\9"DQTT>P(3(7<=<#26;650\I&V:<A8IV:N'8VSY9JP9YR[$$'<%68$CQ0V
MXVW/YO#_ *Y'@;G7R;X[$^H?MT["6VZN-VA^<YF-S0K+-QR%'84'@<@OK>,-
MHOI:#.XP<!9!(.N91DSX6_E$:'/;R'P((QQ73+$6S(N0-R '8LOYNHGK\)W&
MV^VW4#DWDN8NR-7E.HIL"$L <D"Z"WM"FLL4Y%<AY2&UW'8&^T\T.JO-7C1V
MMY.ZBCE\><@A+#7 AD44DYLNN\9OKEEVHERR'E'>CK[Y=QL-SN2>H[L/S>'_
M +9*>E^?F[I>]X&"MP\<1NHC7-D_N_%L$6FI D7A,*UGK&^PXA(G+%S&QRJA
M&<X)YVS!D+#G(<4Y8/%\LGRRPUNP5'?;-N% Z]O#N0/SGP;^'KW^;JZ\P)'J
M=;6DWDM!Z[T)"C<VVUR[Y(<50 Z1[.+1R.CE-(,WJPR<&C;.$'WR; EX+D_/
MBV 1\]9CT'" >Y1_FV2S9[R#K);8!5;P>-\WA'_]S@M0=4/>TR,Z#?[!XVZ_
MB6N-J<I9+POD9R/[@,2.4C]TQ^\EME)8Y'76O1 YQK-16/Y,^^E) A)<G>)*
M]AR;1H.=&F"@'-WQW"AMN7YCMU;[GKZ_FW'Z_#MDL!ZH$MD',#7W'B0P'2KB
M([5V1M/68(GJ[=A#9TY@A+7(8X:'D-E9!H)AJE)S+&P.]LXA&=CEI-$LWBJ)
M]#%V*6:O&><O>EMSN #UC8=9VZNO?YQ\P_QRM_3SYX<EHMQ[X#K\A(6VGNJN
M36S95H,#ODQN.13/=[W9A*;;(<14Q.(N>B]VMHF]5 .X8+LE.RYAD,C^)MY9
MBUS%@7/@ZP/V#/64$ML>L ,0!L-NK?8[_-ON1L/G_-FQCDGL.6$N9O!;CC'I
M";C4:E!+<&^=GK ";X,]D8+2<6'H0N$/';%=%1W&C<[F(XQ*0ZM\FA9C%VPM
M\DNP?ND<_<A '*QVW(V _5OOU_Y#J_;FJOB)R%Y!&-B\ ^1LGWEM66X<ZMX\
MP->[3TK(Y+F2U3$HQ ",T::V;ZVA&;?!E!GD+5A[)P1*#>X0.-'CEL6<+8KK
M**LC91LX '>A"#\_7MOOU_/N>K]FV7QZF$;YAS68\<H_QL"\AW>NQJ.X)/O!
M[QTW5#-$3![FQCP%MK>/(S29IE!U\G)=<V0R&YQHS\X8LTV*'@#AUB4'LA0@
M;[[;]6W,.;]NPV/7X/G'43X<DK6'*F+ NF$CRWUD0V/MT!">/<UV.'4WC)&[
MS9DI)Z_:2&Y<)L*6"AO@CDVWD((D ?FQ@Q5JKBTQ=LD7"%TKJ,\*GGY3L"6V
MZO -S\PZNK\PZLJDYZFG+ZY@S%VG%'2^$A6X8#N>\=N[Y 2?(:-T0FH0:EP<
MIS0U'WUQM=Z_9M6@:/!+WBS50C?,A,EVHY=VNR+D7;?F/Y7+^3U[_J[[K'ZS
MM^S).RZE6U-CEX(+XZ<?(K+EK\,H-S7VVCL;:KR%9 (C/1WAXC64%<BH/)<)
M)/LDT7BR10TA'HFK@DW1>$!>;G-5JSPH "2VVS%1L-]R/"3UC8>#\Y_5GH:U
MY;378&Y^F?O!2Q*,0_G9I;;\%G&JDY*3.1"+RV% $]O:]E01JX39-?G_ !38
M3.(ESB0IF[*"30IN2LLB%&78L%=N<>'D/A_5OL?^^W[/\<W'TR#%,8IC%,8I
MC%,8IC%,8IC%,8IC%,8IC%,8IC*M;'!3G0$Z,<Q^.+X"%V ' HY[XUK*#S6)
MZMY+:PBC59RH+G!I[?$1"=GPL1@\6U=NIWA;Q=M92*S?(EKP@[0$LB!WZCX/
MF_.#^K]7YQ_OFY/CYN^(\D](ZNWW F,H&0[;,-#3:.CYG'GT6D[08:;8N$$2
MP9_C;-)7#NY61>LEGP4PU[P9CQ4N!?C2CQGA&Q(/A'5DQ4SS.MI%_K,M^DS;
M/]SY=727!OR9TCZN_P"_FS@?LJ?R@\3_ %Z/['6R2];K1AO/X<XFIN3QJ)(2
M,2M(Y!"L$E)>'#I/$E'Q",X+JHHY'&J&.:HWORR25G>*5\\\<;7O:^W!,:M@
M5HH9IS$XABL$B"20@A5F(!(C)_+V!/+OL-\P[2VJ+J-)KUBW5IK9A:S9H &[
M!"'!DEJAF5>G103%NP < DYN,1ZI>IM8PY]KR!:ZWAR7C[I#P;!YS5V8 FK%
M"V%NXGDG"QT<.M;M_D]U-)HE(F6*#:_>+7RM?_3K\\%7[EA;=JWINCRJ=RO#
MM.6NQW\(-AY8B#\Y8Q-N>OYLW8O9:T?2:4FFZ=INO\45W7D#\<ZI6O1@#P$4
MHJUA>4^ (+*!5[WK'5FDXL_Q*%29/!DR&8$2#U_@.&HV;CA^+MRHXQ9,&]KW
ML@R:V4L@U1M>]DD$T\+7O\FMC1IR(B<S/R(J<[G=VY0!S,?G9MMV/SDDYHB:
M0332RB..(2R/((HEY(HP[%NCC7^;&F_*B_,H ^;(5WW^Q+;7T=R_^1/:M'$G
MR?UK^R[WV:3,K['_ ,N>$/[QZ/\ ;H,[-JN8<^A.*8Q3&*8Q3&*8Q3&*8Q3&
M*8Q3&*8Q3&*8Q3&*8Q3&*8Q3&*8Q3&1-OS]A>Z?HFV-_1YFF>KX1^T?ZYJ X
MA?\ $WB_^[OI3^VL9IAO"?VG_7.&Y-<2-7\J&4#SFQ.?PN9:KD3J5:PVIJ68
MO8%LW7YDBRL,,*QN2M$7>"34X.Q29F!SY@_8/T4&UU6W?6R"J; 8C?;;8]1!
M (.0G&.F7QTC8 :,7+[<ETE1Y&ZUY2R3:$ZV$O+-G; VMJ7-6\(7F\G)C5,"
M,=%(+*L\  P>';8-E%K-LVZ[APNJSWG/ZAU%=@-AL?#_ )[[[^'?.6V1TY=!
M;-?;6-%"NSP,HVMNW5W(A>6Q.7M0\@@^VM/ <8W!I1 7"@-XS%J#Q=U\%FIE
MC(&JSARJZQ32<)M5&[ 8C;P$ $;$=6Q.YWSBXUTT>/\ &G8HCXQ;AD)09RCA
MO,14M+)XE("IC>$-BSR*)&C1)Z#N\>"3K-\X>G N"R#:S_O6 3((,01&X,<[
M?J_)*^#YB=\REUT^]"/ \L!JK3NS*9<R&W.<Q?"1,K+6W:U=@7J23-2X7+%"
M%]^C@_Y0'/!5W?"[C&Q>W?<;IL<Q_P E*_X'?VY<.5Q:.3F+R.%3 ,/D<2EX
M(O&)/'RS?!T+.QX\P<"S(<DUS[N#E@2'.G+-VAG;Y*S=91/+]&5Z9#X/!GMA
M HF-!1$= #VHD$ %CPH44Q2Q09#!(IHDQ'#V:./^E%JR9H(MFZ6/^E-)/#"W
MZ+4QE(RG3LT$3X_*\<\7^R1<32W*^W]'Y0'EJ#"?Q#:CR;/9\C)8T=P#9CV^
M8PZ1>8C&I$*3;(,U^]JIKN$D72;(N<[\W5OMMX.K;;;;_+,?#],S0(M9V\>2
MC<\G*$N1NH>59<U+9^@?,F-R:99*,X^9(D78#PA06:NK=Q(@:.2 _P"5@@RC
MB4<$MFXU)CF/ZOR2O@^8[^WP^'\^^9;,NGUH2=%-MES:T[L[W3NO4>_)C9E(
MF3=+&=:4;C6L-P#X9A%KL0>20IK\\#U<G:S[+OMTGK3Y=K8L<QZOU @?L;??
M_4Y'$NZ5G&V;R[8LD/R7>:H'<>X4MU;AU8UVF^9:EVE)F3X24#B9G"6XW!J]
MC84H(1(,FC)R/*.5U;IF#!1HQ#-A;/><[ ;#J&P.PW _4?\ SY]ML_7=72RX
MX[U<;(<RJ1[H"Y;4W/&M\RM*&3]L ;JS^'Q&T,CB[5'Q>>8)C10W&SQFU<V=
MKMR__GT':67<3LP'8?FZEY>L?-N3_OG-F.G%K601G6PD[O7EH<F6H=D2#9>N
M-TG=Z$C^YXH^E<:'1.2Q<9-#@<CBG"3(<:FDZ YB\\DU71%5H\;7(.\56>!B
M-]@NQ&Q&W5X=_P#/.5UUTY./&KE]1KQ=QL?/+2FZ]G;[A=SDSS/.,YSMH2N%
ME.,@)$QS@L?%69.%+L,7Y#,O9U_YLB8).,U5%&"Y.^^W6 /!MU#P;;=0SDPW
M3[T("#:Z!L5IW=EJ_E,:Y@1JZ\B9*+Y;:/.9"Z?I$E,0F&+J*=]DQ+O(9/!N
MY3QLVM<IG=+*ZC',=R?S@*?V#;V#,"UGTO./NIYCJJ61:8[U59:+V%,]B::@
M1K96)77FMWNP['KS0%'HTJ!PLH"D"\B?.G2IEX6DB"^*=V,B:)+/TGK!8G<=
M76 #L/#L=P3^OJ&>GI?I5\;-''M.DX[)-Y26.:$+F)7JS64\VF^DFKHM/SF)
M#%_L5C#OFUDU1EM[%'RC;-NL@#9OW3HRU!I''CPDX>#!8G?P=?A.W7L-MAO^
M8;#]?5DR[^T3+)7R&XA<B=?ICW1W1DPGT5G A^]3&V,::W1$;QV7.FCG/'+%
MR8ATC#0V6"QBET_#FC$TT;JV=N4F[I@$;,#\XZOU$>#_ +;C_',-U;TX..VH
M=UM=VQ9QLMR^CIC9LDUKKH].WA74VG9+N3Y6.S3^K(9FT2M&B$M25=MWN*Q(
MDQ:-WKE(6S88]X[PP6)&W5U[;G;K('@W/ZNK_+KSTICTXM33.):C!NMN<GPT
MQTR"FD4C>[ &[3#3=AJ(;!?KD)7%9K-W8]_C*@[]15)!K8@+\/$-F;1,,_89
M8K*+,<W63LO7\VW5U?F'_GAR=,>*&F6?%I_PZ @WT7TB^U>:U'80")*)F6D6
MD QZ-+N&YH@F165//[D7Q)V8?I/5W1=VX?NL5U55+9,\YCS<WA.^^_Z]]\P>
M_!C25Y$I)[K33YS5X;8<&,O_ (\T\&\B6#Y4ABM9+YG[MIIX0MGW3W?+M+I]
MS'YG[MOE7?\ G_G^6>\QVV_^W-_C_P"#->'*?IV;*;GM3L>-FL64NA,&XG,^
M+&1AIRCGW'G9A:.A;KLP<>W,]C<<,1S;.HT&'@9%['!C"+2@F8S+-W17$/8:
MSLR(,#OS$C=N;J4'K/SC<C8_Y_LZLGW0'!K8FNY=P %S@G'R,*X,<<9D,;&
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M$_UZ/['6SEJR;-?XIC%,9$N^_P!B6VOH[E_\B>U9>)/D_K7]EWOLTF9?V/\
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M '.V%_&DD_\ <J?#6L^5M3]/M?>X^*'"?T7X=]2:;^&QY7-K?]SMA?QI)/\
MW*GPUK/E;4_3[7WN/BAPG]%^'?4FF_AL]9[L_91%HZ'D-ASE^P>H*M7C)[+3
M[IH[:KX9)+MG39<@HBX063RR3515PS34PRRPSQRQO>UX)-7U65'BEU/4)(Y%
M9)(Y+MET=&!#(Z-*596!(96!!!((VR;!PMPS6FBL5N'="KV()$EAG@TC3XIH
798V#1R12QUU>.1& 9'1@RL 001OG_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>38
<FILENAME>g947560g59e21.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g947560g59e21.jpg
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M 0$!              $" P0%!@<("?_$ %H1  $$  ,$ @H,"P0* @(!!0$
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M*)K?\)WTCUIY*+AD^H%J%S?XS^'*)K?\)WTCUIY*+AD^H%J%S?XS^'*)K?\
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M+HY>T2ZW'6C(HY*26F;99J9)4=+JDAX*2@ZNX61$!98S%.-9EKALOBJ#7 4
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MG1&GK$<0'^\"VVZ5J)F?!XAU)Y.B-/6(X@/]X%MMTK43,^#Q#J3R=$:>L1Q
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M%7%I(2%LX6':2ZDLE9,D2*:HJ(2.^TPP&2R R#OD50?DV)QX[MQ! Y\]0_\
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MDKXKS?6.#_\ D4[8<%[X1>3L>I3\:%TM]6O=KZ':[_>7I[C7LE?%>;ZQP?\
M\BG;#@O?"+R=CU*?C0NEOJU[M?0[7?[R]/<:]DKXKS?6.#_^13MAP7OA%Y.Q
MZE/QH72WU:]VOH=KO]Y>GN->R5\5YOK'!_\ R*=L."]\(O)V/4I^-"Z6^K7N
MU]#M=_O+T]QKV2OBO-]8X/\ ^13MAP7OA%Y.QZE/QH72WU:]VOH=KO\ >7I[
MC7LE?%>;ZQP?_P BG;#@O?"+R=CU*?C0NEOJU[M?0[7?[R]/<:]DKXKS?6.#
M_P#D4[8<%[X1>3L>I54]W^.OP]]WM5)JU@?FM6Z@"5*;..I:2M"L?78R(TWF
M0S"6&*\B@?C+=?F9:KN3T=;[!AEAVZ 3'3ALKEC@^&;W&O9*^*\WUC@W_D5+
M=HL%:01B$68/Z.QXO_A[JC/AE\:30OAY:9Q'K.DZX[BJCF;Z:,XY6=:.R]?K
M$WG+3HN&H/9?+#&]C21XTE &[ -UL#*!,J?P:""WBIPN".7S#Q>XU[)7Q7F^
ML<'_ /(J7[1X*YQ=[81<>7X.QR[G_P"E7X_&A=+?5KW:^AVN_P!Y>GN->R5\
M5YOK'!__ "*I[8<%[X1>3L>I3\:%TM]6O=KZ':[_ 'EZ>XU[)7Q7F^L<'_\
M(IVPX+WPB\G8]2GXT+I;ZM>[7T.UW^\O3W&O9*^*\WUC@_\ Y%.V'!>^$7D[
M'J4_&A=+?5KW:^AVN_WEZ>XU[)7Q7F^L<'_\BG;#@O?"+R=CU*?C0NEOJU[M
M?0[7?[R]/<:]DKXKS?6.#_\ D4[8<%[X1>3L>I3\:%TM]6O=KZ':[_>7I[C7
MLE?%>;ZQP?\ \BG;#@O?"+R=CU*?C0NEOJU[M?0[7?[R]/<:]DKXKS?6.#_^
M13MAP7OA%Y.QZE/QH72WU:]VOH=KO]Y>GN->R5\5YOK'!_\ R*=L."]\(O)V
M/4I^-"Z6^K7NU]#M=_O+T]QKV2OBO-]8X/\ ^13MAP7OA%Y.QZE;3>'QQ'H:
MXC[*D=[PZR9:892+WF19#C2)=1V6D+ RDI-Y/<I0XEXL=^/],,)HA!1"#R$,
M*90W@9#%PR)V#[&,)P^-X'BNSF(S83C51U'$(&Q/EK.E@F+&SQ-FB.\KRS1'
M7&]KO>R$C/)P#@0-G7LP6X66*T@EA>7!LC0X ECBUPR>UKN#@1Q&70N9Q%O,
MDUOG31/LD]ZU*R6<S\G\0K50CYF(B^;!@_91)HJ%X\?PAO9:*)GVZ+ZKN39$
MG @.DFMKRV39ZCC=9$,/C=UQ MU8A",>JB)"WDF'4QD@$5Y/<1W%.))/?JHA
M&C@6>8/7%>C! U 9ZG:2/[O=.?RY='+Q740-K4;=S=?\&KV<2<RF)R38PXCY
MIX)Y*^/:Z'(Z'K2VFU)""$';*^89=(?".O$R%QK!B&$T,F;['A@9PM11D6ME
M:>8+/^8\?G5;N&3MSL-&W#^X1^EFIQ6+$6<=RGIO@>!E::TEP.-@1DPH*FB5
MGH[S9=HMM9;JD['DME#V)=ND.[(2<5$)"V5P+ *("@GE+P"][B3DW3P',Y@=
MWD.6:M@I<7_;QO,QQZW*[*@0?>U)XD$8\.A/DTF1>EM9S0DL)2BXVY-QQK"+
M]G> <)H*0=(JT= .H08%>&)*()H0K<=KAE3I'/,Z=)?EW<@<LL\LL\^[EPZ%
M:F8-I]\]7M:I/%V"F/A^H4OI.P$;11%DQAI$YJJ0ZVE()7!1&!,ZN1R3D&3%
MG8+ D"?$846METYI[S*6%6#)I+3&^,,Y2I :3P#LLN(X9Y]&? 9<N.7S%:9M
MK>(KO9L)P_-OVPHO1NQ^]-;-T]<H@<T@HL0S5K@\I/BF4U!(-H1!7BAW//%Z
MQLIF7",G9/5#7S%RKFCLT;;HJ&2-',E4T58:T.SR.6ASLLP<LM0X$#(\LP>'
M<.?#C>J3]T7'I1MAQ'ICDZ)XA?TT:]<-S5AWO1]QTGR&U34K26X%XNT@$$<J
MO/MUI#=B@J^E<%03 "+<L[45N"F>ZCB<!HOCEF0-U-8 2 7D '(Y>'D,S]O@
M4N-;??B P#-NO,2[C6U?D0ONOK3/\RPTL0(U7VV1X@DB"HCPF-:9#T+.1XN4
M)[Q^9;YHFF)+H)#(JJ>6,A[B#8$P>J*4:6G/3GP(!SRX@G+,>'/N='',\5$^
ML7$]X@SJ/<*J6IT+ZO'H3XC3H=T8'H\CEC2$AOU@+" D+0Z&^PGJNO\ 74I0
MS<*FD9G3S8LW,22"AY!(@:@KJPPCE*D+6@O )][W3ED>(&660[IYY_,K^;Y?
MPTM!/F]W3_=^N]%2/Q7?\/VK(**E*(E$2B)1$HB41:]2'% U)49(38]!<+_"
M3ER2Q(90)=-Q/()2!U^5PE(=&S8:/+HZ#@T#JU=8*F4T(<,[9'', YB *8I2
M^!G(JM+LL\NYGEF,\NG3GGRX\N7'DK4Q%.L=3B+*@4>*1Y1SAF7W?!C\L>2C
MR79/D1C%T<RXDTG<Z$%92(E@EU.N JD^R$C5Q,\0!<KA9]0H((Y]T9_,IAHH
M2B)1%UP"NDFE)01BJHG&5A( (&55* .EAE),+*O;5TLPH$0Q<C1(!2L1.]H"
MF0@@SG:9KM?(3M<;K"+L:(E$2B)1$HB41*(N^X5/F#F/]-[=S_,B_P"H'+YW
M?:5)Y_,W[ H.XKGGAX?GSDS]_@0N5VWL??G/4_R+G[M(N2VW_-NY_G4_WABK
M57T&O"THB414FDWB":W16]'8QUI5?;A/QU<OX45J/XP?3]:<6]L ]LXV?KF;
M"(H):**"6MD,<+8#&S1"P8H1T  P$(#CSUS:?":5B>M(^S*ZKEV9)5IV;,%/
M,9_ZS-#&]D9#??. +G- (< X$+?U-FL5N5X;$;*T3;0)J1V;=>M/<R);_JT,
MLC7R D9-.36NS&DD'-=U)>\NO\8'8X('E1X/0>66:-(#!M%;!=<FV<#.!N5Z
M]>+8LY,5!<2/6'2PO9<P\;6"%QSSZW\MJN7-H\,INJ-<^>P;U<VJO85::YO8
M!ISE&X8\Z<G-.9'(YG)6ZFSV)6VVG-9! *4XK6>S+,%3=3G5E&3.]@+B6N&0
M)XCY%A:YQ)-7$6.4"6@UB0E^/5T-?[8<K8B:0EHBU#C84"Z6N)3\N60+9LE6
M)'30&%B+CQ3Q#8 H1TEVR2& ,"X\FUF#1U(KPDM2U9-[G-#1M2-@="\,D99R
MB_U=[7. #9=)<"'-S:03D1[*XO):DI&.M%:CW>4,UVK&Z9LS"^-];.7*PQS6
MDZH2\-(+79.!"L;"$ZLV?VP>=S(2WXF)!%4LE7L_F"Z8^/G!<D\BIAG$Q.=:
M:F&U))%*J '854F$*1%&Q' #&R%+BXX[;#L2@Q.%T]=EEC&OT?ZU6FJO<=#7
MAS&3,8Y["'C)[06DY@',%:K$,/GPV5L-A]9[W,U_ZM9AM-:-3F%KWP/>UCP6
MG-CB' 9$C(C.-FCNQKN^)@RA%O.U5,/$=<=K613YIG.Q/9+K=;!!S,/=KM%]
MGD<!JN-=:H(0HJL23%0>^ 8>>9;,SC:U[XD&T&%6;WM=%.]U@R3PQN,$[:\\
MU8%UB&"RZ,0320@$O:QYX EN867/@&*5Z7MA+ P0".&:1K9X'V(8;.0KS3UV
MR&:*.8D!CGL&9X'(D9_&/]XM:I,?*XP6L_![JB.GO%6*+*TVG*WF8ZTJ/#N2
M<_E)CO1:2B+:=Y)G'<! ETPAJ1L, ($P> N93BQ@X%%7:+";EF6K#9.N-D[Q
M))#-%7F95=HM/KV)&-AG;7=PE,;SD 7#-C7.$V=GL6J5X[,U8:'N@8Z..6*6
M>%]INNLRQ7C>Z:!T[2#&)&-))#3DXAIY$);J:_;!.T5DQPXW"*OC-L9ZMX%T
M,-Z,DJ^&2640T@P[V*>=:&D%72WP5$4(J(;3!!!,<L^R7 [#@*('.'[087BD
MYKU)I3*838B$U:Q7;8KM>(S/6=/%&V:(/(!<PD\<\L@2(Q# ,3PR 6+440C$
MH@E,5F"=U>=S"\06&PR/=#(6 D->!T9Y\%])1W1UYAR2245/UX*"<YQ<&P*N
M&2+4="TV&,"]U2Z(S!I#=J2DG&\R0G0JV[42<U]0)VRMF$;-=JIXX!L1<V@P
MNA;;2LSO;,1"9'-@FDAK"R_=US:GC8Z*N)G^]9O7-[CG:6$.,4\!Q._5=<K0
M-?"#,(PZ:&.:P:[-Y.*L#WMEL&%GOG[IKLN+1FX$"6YDF%@P)'+@E:3E8PBL
MILY(X:J?*):DMG,1EY<36VDERB2CE3JF?,G5E73R80!,J,)UP_9,L;!8"9XY
MU^_6PRI+=N/,=>$QA[FL?([.61D,8;'&USW%TDC6@-:3QSY E85&C9Q*U'3J
M,:^>42%C7/9&W**-\KRY\CFL:&QL<XEQ R"ZF$9W8.P384G?'??5W&2EXPVS
M??<R'8PU'NF63TU3%[727@D(RD:)=JJQ3K%$N6$(B#]L%@Q\ARI@,.C#\2K8
MG"^>KOMVR4PNW]>>L_6UC'G*.>.-Y;I>W)X!:3FT'-I N8AAUG#)F06MSO'Q
MB5NXL0V6:"Y[!F^!\C [4QV;"[4!D2,G F9*SU@)1$HBX("FFFCQ],+*)$PI
M)>)3-33P#9<4\G8*& @I#,^4#$R,%,3H8(PA3(P&'8S@$)F#?/$/*]J0]A<Y
M@>TO9I+V!P+F!P):7-!S;J );F!F <L\E46/#6O+7!C]6AQ:0U^D@.TN(R=I
M) =D3D2,USJJ5*41*(KG<'SS-[+_ *;DZ_NF/Z^:=K?SDQC]L?\ \K5]![,_
MD#"OV1GVN54?PF#^+Z8WZ5T1?9B2ZW_L5?VA[*?[S'_0G63C?Y'Q']E?]K5X
M;Z_0]>-I1$HBO%!7#SV/GZ.T^6&X4CAD1VX5\XTV0ZIBE5BQ00D9U)XMRYYO
M1^&\5E...D^5.6N0&&(%KIF*E@83K'[GB1XN6XK&]O\ 9[ L0DPJP[$;N(00
M,M7:N$87=Q23#ZL@U,L7S4AD968YGX0->[>;LMDW>A['.VE7"+EN$6&"&*%[
MBR)]B>. 3/!R+(A(X%YSX9@:<\QGF"!]V%PX]JGV_)RC89I-B/77K?W O,1>
M6)!9L<)31#=)H4HW3(SB<BP4;YX@M9AA#)*FGJ9E-5"9],.IQLT54B0P]-_V
M0]F*-'!,1;:M8A5VA[(]J'850MXA+:-5H=8:*]>)UACX07"6.2)LD3XY62,8
MZ-X"'!KTLMJ'1'#)3T=D">5D+6;PD,.MQT$.R]ZX.(<"T@D$++0^%GMGA)Q2
M)54A$K=<ZVUVP\F0=<4YQ4E-636\\50TBH!J,74*Z,D5\FS:J3%)YI"$:-+!
M800GF8(!@J*>*:Q3[)VROM:[%8GXK8K0VK-.ZRO@N)RVL-L5(FS3MQ*J*PFI
M-;$\/$L[6Q. >&O+HY RX,"O[X0.%=CW1LDC+[,+63,D<6MW+]6F4ZAD6M)(
M.7#(C."MG-197U)6D9N2THQD,OJYQS)HJ*P929,BJC=4FB83"BTFO%/:2NIF
MVDHA&54$ N17@2)DT,54@P L\TTYB#N]FMK,+VKAFL85'B38(65I!-?PRYA\
M5B.VV1\,E22U%&RU&6Q%SGP%[6AT9<0)&$XM[#Y\/<QL[H"YQD;IBGCE<QT9
M:'-D#"2P@NRR< 20X=PK+T7A_;1."!1]C$QD(PK!"9"_*0"2*^F46DA1BAJ*
M0B0YI33(P,+H;X/,!#40A0#[B!1+EL0<+J(.(R7E@=SQ)MO-F8,=;L])=F%\
MW8,,,K:-QV'QXI:CWM;#)<2; :3+TT9#F5W3:B2(R1)FP7&X3>=5[,$;=UNG
M3AIEC$SH&')\[82[>.B:>;PW++CRXKXJF@NT"-K\!LL?8R8'' K11)'%(AO-
MGCR&2BYRK&2 W924(S!6LWP3CU<6<,B::YAD3$D.'C=2_P"%'M=0M5%MULU-
MCSMG&79#B(M38>'FG;;A[\3K1">QAD>)&$4GXA#"0^2L)M;21'QF.[1V$WFU
M.S3$W<[MLQ;O&&80O=I;,Z'5O!$X\GZ<LN/XO%=G*W#OVKA:)U*8W^R$%/;3
M:+,H\_D1-D%BKT@1:0DC$ODP#LH1\BN \[6,7=W;90-)NNI97/$R: )GPR1P
M7$O>UA?L@;+XSBD>$4+L\EFRZZRA-)0O04,3DP[5V>S#+\U=E2ZZIH>91!*X
M%K7/C+V N4V,'OUJ[K,L3 Q@B=*ULT3Y8&S9;HS1->7QA^8 U#F<CD5TVNFB
M&Q^TK8/O.*6XU;M<L\2D;I2R]Y'8<<E'?)R@G!JZ?&K(R>S@1,G6]SJ8, ="
M14C$QF$ 8*Y&A2]S1>PM[:';C9[9BS'3Q2Q:[)=4?B,L-+#[V(/J8;'(8I,1
MN]AP3"K29(',,TI:"YKM =H=E33PJY>C,L#(]V)!"UTLT<(DF(U"&+>.;O)"
MT@Z6YG(CI"A=E0/+DA30FZ\-)C+"G,RH\CS  8>>)<@K%W8E&S9-92U/-1'*
MDDFR&*GJ&:V<4C14@D%2!TXH&2Y0J.-AN;N.85A^#R8_:NPQX/%39?=>&J2)
MU65K'PRQB-KGR[X21B%D;7/E=(QC&N<YH.-%5L366TXXW&PZ0Q"(Y A[20X.
M)(#=.1+B3D "2<@LKV)U;E_5U<;"/*J6@6*/= S=#(=C+=[9?[&>*( H&4@^
M;;KO:"FK(B@(E*Y,TF*Q&QH,^G&@\+FBH8!HD.9Q=G]IL)VF@LS89+/KI3BM
M=JW*EFA=J3.C;*QEBI;CBFC$L3VR1/TEDC2=+BYKVMN7*%BBYC9VLRE9KBDC
MD9+%(T'22Q["6G2[WKAP(/<R()KQ6_6&E$2B+L;I"M9)Q7[I:C9"S4<TC!:N
M2,V2<E8,M@=$2\5'L7:>2C@3%#-YDK#7,XEA,!\@K!9XYWM[Z+>[C>Q[\1B8
MPZV[T1%Q8)=WGKW9>"P/TZ2X%N>8R56EVG7I=HU:=>1TZLL].K++5EQRSSRX
MY9+KJN*E*(E$7L2_!</,KN3\_P R_P#")LU\&^SI_:1C'[+A'_;*J]9V7_(=
M/_':_>)%N=XBWF2:WSIHGV2>]>0KHF<S\G\0K50CYF(B^;!@_91)HJ%%\':@
M0EKZ^=A)+8:*JF7UL_)PLKRXY76LF'*I*[@Q+"DDI+31#^'6HS5;9(P9*-MN
MDL,"206,C@%_^7ECCB4DDY ]P9#N>'Q])[O=5>8AX4.GT&2W&DRQRW7LCN2'
M96V0F*,T<9]*YUGL]U[5M1%9DO%$=N&+9%BS8/HB FXH+<Q$[G-X[@94$\/$
MT=."#E)>X@@GF #P'$-Y+H#/!^TMSUSA'6M*0I+:;=UK=ST?<!22RI6=[1G&
M)G5(3F674\%1H2H@G2*^4Q7%)=-X'4\U<VEC%RZ3<0EF;14HV3(7N)+N&9RS
M&0(.67,'AW%VMN$?I%?656U7&8#I-LU=E,.>E>0#DBO(U.BA/X ]C)>=#$QC
M*N3SRD\OG:X(*]8_B7P3Q3"1W/ND&S1 8FIV>>?'++D,LLLLLLLLLO L.\C!
MI5G%"O&QLO-:FZ%R<&;LFI;$*TX/Q4V<'G./$\^CL61[3.>41W!@M-)%5E9+
M02^(5DA-#5%!1+IN"X9$5;DUNZ>X6Y9 #(]S( !<HQP;-+#D3['PZI$9B6FY
MM4YHT?LO+KDFI]NE_JDDQ6."?;TD)S[<JBK.0D\#ZP#99<)P8\<(*IT00OW-
M+I5\4W @>00>&;00. Y'N?)Q/C4O(?#7U:(*DF+#I0WG*ZA,VN3)U9E<U+K]
M<3]-R#%3#(BD$C%S**J9[J'G@;Q&%.*[UL>#<1U5RQ5L3H"B&$9#)J/ 9\B7
M#( 9$_)]BC^ ^$AJ%KTYE-Y-X&8I =%XL6X/9"S-<TOV63,.P\X28J>J1U#8
M;N5#I5@MX8@+<B'=-+YJA<AV9/ 4@R!Y2+'2%Y.7(9'/@ ,STG(<2I";7#:U
M=:;0TW8Z,@NP) T0=!UX:]@CO!4',HZV?+*)0R*Y#.=NR.<#(%4-VQ+J'4PP
MRRPRM^7"U%&HDN/PN?C!^T*!=\OX:6@GS>[I_N_7>BD?BN_X?M6045*41*(E
M$2B)1$HB\IA5(EMC2*B)FLL0;MP;.ZCL^$=?VF;O;*I-NA'<-0D8R9=DFMJ2
M76Q49IM9K+C>'&<83Q0#Q-03%8U=,;Q5/+%$]=Q*]P/XQ:X:>#@0'\!P&6>9
M/(<0>G-96X-6WPGE]F)[0HKF(I.Z/QIA5^-%U)(2654,(65GS&EW [6RVR&0
M24H,-QI9U<Q<KO+I)M*7$M+  4U4P0;Y0,D5.8X Y9;LCY\B1GX<\@.CN<5U
M4K($M.+?9$D=MP9++!>C+XE48ISE6TV,MH7NYG!K<"OI#<4Y*4Y[/ND2$4"#
M'@AB9W*PRT&8=%2DP4Z=4%,BB))VYF.[_7A\?R?(>C*1EIR)!!8[+B!D[B0.
MDG/IZ1PY+Y-S3]WN&\!/-SQM/>#T=W%-FQER>K6.S&CJ &J#C5I"'-HA\(D?
M)8-F%W78,GD>4BH*6AK0:X<ZJF+BL9]EE27#-P!;D&#+@/QAI\9YCYO MN/"
M[8KLB^,-D8X76Z\FHTF3N]LNWX707@5<18,A"I9RI@S$Q: CFM<XH,@8(<^.
M@JA4<VG*'931@L<,99C"7CI^7AX@K;CF0>'XHSRZ?#X>E9-#NJ,S,':*5)7<
MFSTY.YFKC>B H0+.$KKA8.2!FN7DH%60'N5:<"MI72T=I".-+';AEIG6@J*
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M&EA- RQ2SU67'S&&1DK&=D6-Y&S>,+FDZ!J(!X9CIS.SI@;7L)HI\/QN0D&
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MC/F!P^=9''$@)<G-,D\$=#?3<('QSQ<)*D=@N^,W8#D0-BDQ1#K0?2.A.,B
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MGFW&NWETRHL]S(":J'(_L<2CZ,>4R:&X$4+*R(74T^!_$_:<DS/'(@'WO',
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M2<5,^?42XN Y(L":/"CA8 "C8;-T<T^Q^&QQB9\LE# =0A,F^(WE RN!C_"
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M7&OH5&)EI94,C:[;I9+V4*HA;'IUCL<O%?\  "8LU:]&1TZ-8#LU>20=M55
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M0>T2CUDMP"F"Q)-;R.H*Y5#2P;CFQ0L3BPJGC(F2:BDNSJ9PFG+!\$MD225
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M+P1D%>44W8=ZR >NZDL9?'#;&+=L7+!#FKF\BHBL73C)<H<[,Y@NY99DC/T
M<%7HU,<VZI\,W0]JQUKE)+AV17HZ(LY,=/@#><C*>L"==.*IK]?ZZUTMN'5X
MBYRZ4LER3=9QWN/BZ3=C=U*YU)0U%*/%5D'/>21EF3^,!JS)R )[G=)X\/#D
MNKG;5>)'1P<%\I#L&2X^))CUE.M)CH_,,..!-V,-.Y^3.TUJ8W808Y]/..1&
M49 54TVK9"I93(>S4#"(%#>2)B/8<C7$29DY D9Y.S&67 $@Y$ <%Z'$?#,-
M)2PQ,<L,\$XEAGAGC?'/#/$L%CECECE:U\<L;VO;+&]K7M>U[7M:]J*TNQHB
M41*(E$2B)1$HB[[A4^8.8_TWMW/\R+_J!R^=WVE2>?S-^P*#N*YYX>'Y\Y,_
M?X$+E=M['WYSU/\ (N?NTBY+;?\ -NY_G4_WABK57T&O"THB41*(E$2B)1%0
M7B,--VO6%H_;S/(/4\;.;'0/99NP>^ -P)[7[]RN#B5<#S9OBK)))-3LQ31M
M8"&+X)>&%C@AD#L6(F/-;503V,.K15V6'N=BN&[SL7>[UD/9+1*\.A]^QK&$
MET@(#![XD99KI-EYH8+]J6=U=K6X5B6[[)W1B=-V.XQ,+9?>/<]X ;&02\^]
M .>2IN6U">3@<.\4"QY'K9+161FB GK$[?G-3GA.BD0,]$AHS(BFRUZ/W2WW
M2IJ%W2<P#4,4YPFD8 Y84JK%[F"Y,,'0^T5B67:+#*M6(4FW\+LT8L1?B3*1
MU4";;Z\M6:*=[]\[)^B5S X%L@S RWKL;@CBV?Q&U9F-QU#$H+LN'LPYUW,7
M0*K;$=F&6%K-RTEFJ)KRW(QG279V)UBT7"C9K2DW9KBC6T\CN=183C1$2,SL
MYO)*/+C$L[3)$^Z4Z>GD]B]S"0;6RIANX((14',P*H"JX1L4LCY%-G@^SG8D
M-R'$:6$NCF?5ECBJ/Q*PQTE;?EKIFXG8L#-CI&F(1!HS+S('$,TZK%MH3:FI
MRX?<Q5LD3;,4DEMN'0/;'9W(<V%^'05SE(V-PEWA)R#0PM#I :LLF2)=U@X:
M.J:0U=?'XYY_/X.=NMZQV''<[3T']NNYSW7)#<C=(M\VOD#!!$5"]T=$R"(&
M'(*=#QOVVEECY8;3U[5_!]DL%CAPNS-BCM]%%JH3SNP[5/-O+<T+8G2M+8WC
M=QY-,Q</QF-<T[J>I1Q?:S&7S8G6BPUABEETWH(6XAIABW=6*5TK8W!TC#O'
MYN$0:?Q7EI'"6)/5-?\ 5N'V/K3#NQ:Y)3]<TA%W;/S\UH>ZG(L:CN%6+GY8
ME@5EED@PHXN1WJ"T+@P&S=1)I!DNFXB*ZB;*HN.2I3);DPS!J%;",/Q:2W9E
MM";$[.$67VJ9ED#KMTUQ&7;Z=TA[%AU-C(9^$>6Q^_F.FW$\8O6,5O89'5K1
M53#AM;%J[*ML1,+:5,6'2!FZ@8P=DRZ72 NR8P.D][M1TV;3"9VLL2-:,4&0
M&VRD%"/IJ6FRHW%%HR$(:+N%8Q7EEU-U5!+'$U2<CA[JN*^%RX!<<NJ@&R((
M1$<MACV> 0UJ^$48*<5J&O%$YC&787P6M0EDWKYHG@.8^677+ED&D/#F@-+5
MQV.RV9\6NS7)*TMB21CGOIRMFK &*/=LAE82U[(HM$7,D%A:XEP)5FZVZU*4
M1*(E$2B)1$HBN=P?/,WLO^FY.O[IC^OFG:W\Y,8_;'_\K5]![,_D#"OV1GVN
M54?PF#^+Z8WZ5T1?9B2ZW_L5?VA[*?[S'_0G63C?Y'Q']E?]K5X;Z_0]>-I1
M$HB41*(E$2B+8CPGEQ@MOB$ZUK4H+#10&$2<3MNXU=^**,DM$F5'C9YEB^2T
MH. 8NCE@!3XQ4N!D>&PPS-BEP@[W&S"QOY_[*<%^QL#M%#AD-N>\^"IV/%1C
MFEMO<W$J;G;F.N'3.(C:]SM )# XGWH*V^ NB9BU-TSHV1!TNMTKFM8 8)1[
MYSB&@9D 9GGEW5>I+W6:HT Z2[ 3$_\ +&68HV/V5;!X>"&]KZ5F]G0^OQ6$
MGM!&0&,\&HIL8FQ@G L9)J4&YV@91R2'@HEFUF65R:>.6XF78VTW'ML\!PBC
MGA6*;/;.V8VXY8QY^"W,6@Q,R6YI[M2U'=?=,$.\D-:VV5TYC=8#HGR-=M1B
M3.Q,.MV)2)Z]VY&3595%F.NZ MC8R*1CHA%J=I:)(RT,#@S)P!4.;B<2TC*B
M3&"E <S;AEI$CM[*#E3%Z6D#59G!-T)3:"^U3:DT5G7J-F0Z2[ES*+A@D&,H
MJ(Z>5)&3)HH$ K D38&WV2]CJ3#)<2CQ["-DGX?B%*.M)!A4^U%PV'1VX+3(
M[<./XC=JNKA\#7D1QMD<]K6N+HB]IQL1QIL[834LX@)H97/#K$=",,#HWQET
M;JD,;]>3R/?$M )(R< 1-LMLY@[C\0N'&Z>VN8T6QF<TO@0&;)?O+S72.VT5
M*C5 3'['A=Q*+A+HZN^G&JGP4!0;:R=-YE,QU)87D=0*HAX@-I<)N7]D-@,6
ML,V7NXGB3-K\<.#83[4V92R>7$9Y*.(.KQUW314J\4;IV6(6,#@V.&":-TS'
MC*L118AB]=AO1P0>UM46; L,;FT1M;+"'EX:97N.@L<3D<W/:0T@\+89@*LK
M[1LAH-J4=)F0Q(-A!"3M58*4I];4B13(3 CA[V-81/+<E)KB26H)(C].F5)W
M.=,=SA32[C+99)990'#+!*8U> 7XL+V9NV[.&;97;V-XU-)M1C<>!6</Q3#[
M^(TBPXIA6'25Y;(H4&-CJ5I*E>1U9V4CHP7F,1;A=/>BCCGPV**M5:VC5=:;
M-!-%%)GN+$S7M9O9"3(]KW /' $Y9FF'%A=;#>^WJFYF6^&Z^54_%T1@2@,P
MUT%S16UI726.F(SO8L0K96XI,Y&K3[GIZ:WL"9H\6(YXG4_ V)D4SQP['V+:
MMZELG%6N4K%**/$\6=AHO0.K8G:PN6[+-4O8M"_)[,1M;R22<O:QSQHD+ 'C
M/6X])%+B!?'(R5Q@KB;=/UP,G;&!)' X9@PLR 8&D@<0#P6M:O15I4HB41*(
ME$2B)1%[$OP7#S*[D_/\R_\ ")LU\&^SI_:1C'[+A'_;*J]9V7_(=/\ QVOW
MB1;G>(MYDFM\Z:)]DGO7D*Z)G,_)_$*U4(^9B(OFP8/V42:*A5*8^@,1*4S;
M/SGL9%<$SB^YMFM)>#&67A&38>JE'D6,V(HPC%D,<DH/-O'32:;+'60ONU5Q
M110TX57=1@8,0<?',?)_7]>E3F<@!PR!S\.9/\,EATK:G;&6D?9X]K^[X;;#
M,V^CJ-X^=;G>I)T=_,!!L1EKD;&%.+VD@)1AKR.2'::QW5:K7<CFCI.:3W[I
MJIPVZD=6&0P"G,9 '/AGPZ<_L]/S*ET.:53Q)3!V[A5)%9D?:H[!S4)!B\H/
M9->A.>TG6W5AJ,C4+)KL5)S2 6RY4.;H^A YDVGPLJS= :9=[KC]24&007 F
M %BDD9@]T#,9'NDY\>C(GEQ[@.1S5D3NC.QRT[7(U%5\0R! SGXA#9W9=YPL
M"\SLH26A-!XM&063%J\DF$PJTVN"PEV-(T0PU,FLNK%[-]J)PA@%FW+G4I9*
M,Q__ ,D9<,N/#/TD].?=6 A<.?8U(08Q0PG]%T@$"[0G(W(;8>CUFYKQX@[#
M3K.CQG%S[ IC)C[--*3L9[=>YYKA,>3SC.Q3TE*+C-YW(5UUP%#1-0\(/#+D
M>0RRS(X9]WG\G!8L@<*Z9D&(%.#,'S%!AHNSAX:N:5.1=[9>("VEJ4?R4Z''
ML\I)"7@WLR*N@SVW))>AH)5.J*,KDU]":*2H(.26<4%E-*2[,Y\<]1=X.YET
M<LOGZ0IV<FB\Y+Y2<( Q>$4%-6=A-F3VPDAO##%UWGD1JN%TM5\.^"R#6LD6
M8V)595&OBRT^5QWID=0(Q/8(I2-QUU+(K]BC,='$#++N'P^#Y!W>.?%9FUM&
MWN09L#MIQN]HGC;<WXE3=V>CY$!6ZU]'W.[IUDF/FRW,!R0-^RLQ[O2' ,32
MO8H" W8QR!)XBF<B&-/Z_KG_ %X."9\^'<R] &9^4#EW"? MF=%2M,_$O=R9
M&FS.C,E.L@[>\=#:FVR"M+[983Y?9=(5W,G05DWR2F68K=<A\AFL61E:Y 0T
M4"!'[G&[8"]4#.UBJ')PX<<N9 [OA4'^/)KE^?),YNNQO1111D?!XQUIX\FN
M7Y\DSFZ[&]%%$R/@\8ZT\>37+\^29S==C>BBB9'P>,=:>/)KE^?),YNNQO11
M1,CX/&.M/'DUR_/DF<W78WHHHF1\'C'6GCR:Y?GR3.;KL;T443(^#QCK3QY-
M<OSY)G-UV-Z**)D?!XQUIX\FN7Y\DSFZ[&]%%$R/@\8ZT\>37+\^29S==C>B
MBB9'P>,=:ZU8W]U:;J6>7' \7TA(J67S-J:PL0)L&F):<4"MU1#1Y0.Q: 4*
M%P[7M?,8P,&'A:__ !96HF1\'C'6NR\>37+\^29S==C>BBB9'P>,=:>/)KE^
M?),YNNQO111,CX/&.M/'DUR_/DF<W78WHHHF1\'C'6GCR:Y?GR3.;KL;T443
M(^#QCK3QY-<OSY)G-UV-Z**)D?!XQUIX\FN7Y\DSFZ[&]%%$R/@\8ZT\>37+
M\^29S==C>BBB9'P>,=:>/)KE^?),YNNQO111,CX/&.M/'DUR_/DF<W78WHHH
MF1\'C'6GCR:Y?GR3.;KL;T443(^#QCK5T.$T*,?UG?CB[EKZ6EO/;;;YZ-KO
MD;:^TU%3:KHV ?"LWUO%$<Z:D+18FK)I@$X3R.IY800$2U[AXWM>UH'\3Z24
M//YAR.?<'0H!XP"GWJO/1I]J2.[3K4:\FS.&XE5K,EX/?N+DO0NM):/DI$F8
MAKZB5"4%#/$H6'%)X@YC=7&XEK8Y7MU>QE^IAN/UK=Z=M>NR&TUTKP]S0Y\#
MVL!#&N=[YQ &0^5<YM72M8A@=FK3B,]A\M9S8PYC2X,G:YY!D<QOO6@D\?D6
MO?QHXC_DE3F][ ]&%>S]N>S'?>#R=GU*\E[4-H^]DGEZOKT\:.(_Y)4YO>P/
M1A3MSV8[[P>3L^I3M0VC[V2>7J^O3QHXC_DE3F][ ]&%.W/9COO!Y.SZE.U#
M:/O9)Y>KZ]/&CB/^25.;WL#T84[<]F.^\'D[/J4[4-H^]DGEZOKT\:.(_P"2
M5.;WL#T84[<]F.^\'D[/J4[4-H^]DGEZOKT\:.(_Y)4YO>P/1A3MSV8[[P>3
ML^I3M0VC[V2>7J^O3QHXC_DE3F][ ]&%.W/9COO!Y.SZE.U#:/O9)Y>KZ]/&
MCB/^25.;WL#T84[<]F.^\'D[/J4[4-H^]DGEZOKT\:.(_P"25.;WL#T84[<]
MF.^\'D[/J4[4-H^]DGEZOKUUJQMY!;>33:ROJLA(:.0PQ%/*JQ!4[IB:3#S$
MP!P$-GCL:@%2^&0H@86.8PN&.0@F&%KWRRQM=VY[,=]X/)V?4IVH;1][)/+5
M?7KLO&CB/^25.;WL#T84[<]F.^\'D[/J4[4-H^]DGEZOKT\:.(_Y)4YO>P/1
MA3MSV8[[P>3L^I3M0VC[V2>7J^O3QHXC_DE3F][ ]&%.W/9COO!Y.SZE.U#:
M/O9)Y>KZ]/&CB/\ DE3F][ ]&%.W/9COO!Y.SZE.U#:/O9)Y>KZ]/&CB/^25
M.;WL#T84[<]F.^\'D[/J4[4-H^]DGEZOKT\:.(_Y)4YO>P/1A3MSV8[[P>3L
M^I3M0VC[V2>7J^O3QHXC_DE3F][ ]&%.W/9COO!Y.SZE.U#:/O9)Y>KZ]/&C
MB/\ DE3F][ ]&%.W/9COO!Y.SZE.U#:/O9)Y>KZ]/&CB/^25.;WL#T84[<]F
M.^\'D[/J4[4-H^]DGEZOKT\:.(_Y)4YO>P/1A3MSV8[[P>3L^I3M0VC[V2>7
MJ^O6U#@X7-'-?YS<>:.Y$A+>&W\U.=M9.AKN-H'U9O'T]DER2P71W4EHZQ@0
M-#DS80 XY +$00L-CCU;AY6MX3M'9@N8YB=JK()J\]ISXI&AP#V%K0' .#7
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MMXUA>T&W.)XI@UQEZA/7PUD5F-DK&/=#0KQ2@-F9')[R1CFG-@!(.1(XKT7
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M>I.]@0=T.436>@>GK5%N)>F/P+1C8<0[-$AJY7%K(W9DX^BP\"4-8W>;9M;
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M;VIM6:6!7+%2>6M.U]4-EA>8Y&AUF-K@'-((#FD@Y'B"0J5^(MIOZLL+?0%
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MB79F-C\YV#U[,4=N3)D-?#,$88HK%*BZ>Q<K2R%[K%QS(&Z6UY'O][)+*XM
M;EK>S^Q=N)8(O-(F)VM\XTHZ9NG6QTH/V(%%(>J$N+#@B61T1N=VD$JZR#</
M%0W0*12%%AJ3K:I0Z28SD5+*!  ^I]D*R[&[K+$=^>)T%2O@.+7+-!\=B*62
M6E;CBWD8F;$YHF+8W5GS0!S:\S]30Y_"!@M)T#Z,$K9K,^.855K76OKR1LBN
MU9)=W*Z%TK280Z1MEL,SFFQ$S2XM80<G*[O2B@(;K/.V,+KYH*/DQRM=228S
MGJ*&>DOU<?+*CU(B]W.&8&2F@J=SBP_TE3)/)M8XY'4) =QL=G)69!/P4;PV
MAN113.GIF5PJLFA>RGB5*NRS)9KU8Z<\M^NP/U26F/;8AXNBBG<:["U@?:.
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M/HAGB+35<]L=YMJ>^V2NZM!)J,9B?%7CA-/\*QFH.AC!W)U"-[9"6^^:[,/
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M!<3QH15<)V@K2X7%2PR;%JT-S%;]"/";PN5X75^R:<D,4=U\+(&W()1.VN7
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MN:;ZB=7GDUB"#@MG%NP3C#S,MXT4ZN.?= R' >'[,^@K8L"""7!"+EP@P
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ME>Q:U\\^KM';/X8Y\CS"_5)@HV?>=]+QPP%Y$(&K(/SD=^&'X7C^-P"QQ<G
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MK$/<T,D?&Z)Q+6D!XT.(R<"!SRS6LKWK-6&Y!"\-CO1-AL@L:XOC9(V5H#G
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M=B&<I%@P>13,<JI1*%E6)'W"#TR-I*<K64([D@D73W8E%\5$N8LGFSI4J#@
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M;\WA]8GBF<1K^=I/].)UZ+:>ZC=[U5?.)?N)[GE'OG;\WA]8GBF<1K^=I/\
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M2B)1$HB41*(E$2B)1$HB41*(E$6(2#_^ O?_ ,H.7]RG:*6\Q\H^U5MX>?\
M #T<_0^UG_P695%5)_\ ))_C=_S%7!HJ$HB41*(E$2B)1$HB41*(J*\07S,M
MGYSD;[*O2BK9S/R?Q"L]#,*JH\/Q0-:;98 L-&K%%L "GPO<(&PC72\[!!7'
MA\8:X8=K]9A<8846^-K=D$SSZN5RKTM/<])ZU)7@05N7*7/9\)=#5$T-Z/2>
MM/ @K<N4N>SX2Z&J)H;T>D]:>!!6Y<I<]GPET-430WH])ZT\""MRY2Y[/A+H
M:HFAO1Z3UIX$%;ERESV?"70U1-#>CTGK3P(*W+E+GL^$NAJB:&]'I/6G@05N
M7*7/9\)=#5$T-Z/2>M/ @K<N4N>SX2Z&J)H;T>D]:>!!6Y<I<]GPET-430WH
M])ZT\""MRY2Y[/A+H:HFAO1Z3UIX$%;ERESV?"70U1-#>CTGK3P(*W+E+GL^
M$NAJB:&]'I/6G@05N7*7/9\)=#5$T-Z/2>M/ @K<N4N>SX2Z&J)H;T>D]:>!
M!6Y<I<]GPET-430WH])ZT\""MRY2Y[/A+H:HFAO1Z3UIX$%;ERESV?"70U1-
M#>CTGK3P(*W+E+GL^$NAJB:&]'I/6G@05N7*7/9\)=#5$T-Z/2>M:]>*:Q4]
MK:$[7!*^P+T%4A(2=ADDVG /"9');#L%B'8'$J2C!(6C!<43#,.^28;+C==A
MEB&/AEC>BJ8T!S2!Q!&7,^A7R18R*N0N*:;NQ\B+Q4 ;M<<RBYP*J%P3%L,!
M+@"C$8A'##&L&)@)V+/*V?69X9];UN5KW*G0WH])ZUW'@05N7*7/9\)=#5$T
M-Z/2>M/ @K<N4N>SX2Z&J)H;T>D]:>!!6Y<I<]GPET-430WH])ZT\""MRY2Y
M[/A+H:HFAO1Z3UIX$%;ERESV?"70U1-#>CTGK3P(*W+E+GL^$NAJB:&]'I/6
MG@05N7*7/9\)=#5$T-Z/2>M/ @K<N4N>SX2Z&J)H;T>D]:>!!6Y<I<]GPET-
M430WH])ZT\""MRY2Y[/A+H:HFAO1Z3UIX$%;ERESV?"70U1-#>CTGK3P(*W+
ME+GL^$NAJB:&]'I/6G@05N7*7/9\)=#5$T-Z/2>M/ @K<N4N>SX2Z&J)H;T>
MD]:>!!6Y<I<]GPET-430WH])ZT\""MRY2Y[/A+H:HFAO1Z3UIX$%;ERESV?"
M70U1-#>CTGK3P(*W+E+GL^$NAJB:&]'I/6G@05N7*7/9\)=#5$T-Z/2>M/ @
MK<N4N>SX2Z&J)H;T>D]:HOQ+F"1:V@.[]EG8)[W/#:=;-&$UN. :$B%G'F!#
M3SZU,P+E8N25DT >&N&1&LCG2JA>QCK"9LL:R"%Q*IC!K;D..H=/2K7QU&I-
MRM)"';VQT@K019$10S5T02!U0(F,(F%\\2XV96(S5P<^MM?K,!\^RWQQZM[Y
M7M>]%26MS.8X]WFLY\""MRY2Y[/A+H:HFAO1Z3UIX$%;ERESV?"70U1-#>CT
MGK3P(*W+E+GL^$NAJB:&]'I/6G@05N7*7/9\)=#5$T-Z/2>M/ @K<N4N>SX2
MZ&J)H;T>D]:>!!6Y<I<]GPET-430WH])ZT\""MRY2Y[/A+H:HFAO1Z3UIX$%
M;ERESV?"70U1-#>CTGK3P(*W+E+GL^$NAJB:&]'I/6G@05N7*7/9\)=#5$T-
MZ/2>M/ @K<N4N>SX2Z&J)H;T>D]:>!!6Y<I<]GPET-430WH])ZT\""MRY2Y[
M/A+H:HFAO1Z3UIX$%;ERESV?"70U1-#>CTGK3P(*W+E+GL^$NAJB:&]'I/6G
M@05N7*7/9\)=#5$T-Z/2>M/ @K<N4N>SX2Z&J)H;T>D]:>!!6Y<I<]GPET-4
M30WH])ZT\""MRY2Y[/A+H:HFAO1Z3UIX$%;ERESV?"70U1-#>CTGK4;2U&Y-
MLQ^[QW!L;("/@9:CGP*8K@D#I81\4)%-YYE@<C,2%,Q\KVRQL)@6$L-CCG:^
M.6%[XY432T=STGK5;N'&P"+IT0TM[B[!OC(X!J'K4,HM]OC0BH8MW,>'&=_W
M9F 8BU55RH)(7$4D!BKG#)_J%[X&S1DU@,+E Y#/GD,U+F@N<2.)<2>)YDJ[
M7@05N7*7/9\)=#52HT-Z/2>M/ @K<N4N>SX2Z&J)H;T>D]:>!!6Y<I<]GPET
M-430WH])ZT\""MRY2Y[/A+H:HFAO1Z3UIX$%;ERESV?"70U1-#>CTGK3P(*W
M+E+GL^$NAJB:&]'I/6G@05N7*7/9\)=#5$T-Z/2>M/ @K<N4N>SX2Z&J)H;T
M>D]:>!!6Y<I<]GPET-430WH])ZT\""MRY2Y[/A+H:HFAO1Z3UJB_$#A]23H:
M;(XDQ2>IXYR:C!6 /D8BP!PODU7IGV;&Z;%*>/V3&V%\+6S&R"ZT3.^066=@
M\\"K8QN9X=SI/2/"MB<(^9B(OFP8/V42:*% 6X&_NK.B)>*#.S4BV8(,TO?O
M"8F6*,K+5SBJ#@4$4E)2Q22IJZ0VT/%13+KC@/V"3DSND1L8%QN8PHJ@TNSR
M&>0S/$<OG5S+7M>W5M?JVO\ EM>W_A>W\M%2E$5?=@]GHAUA*Q"<EY:4D4"<
MIWCK6^.\DU"5%VZG*TJ"*H;-1SN*67,9)2>>S1C]C2T>L"FD+!X7-#A]EPZI
M2 3GEW 2?D'-6"HH2B*%XGGIAS.NR\W68$[ U&$9)4HJ>UW*SG$U28CJ2B90
M\;S:YY=($BKM0;@' ; .) $/)!@6PH0)K,0+.UB9>GCS!^SE\AXJ:*(E$41R
MQL! \"E44].<V1'"Y)R&#A1NG)8DAFQT57C2<& ,H%D4P\%E'"5#!$(T5%.
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M]$T/^"[Z)ZD\HIP^_7JTXYSD)_&]$T/^"[Z)ZD\HIP^_7JTXYSD)_&]$T/\
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MQ@YA:V!H;K^R&,+6Q&RSM^2B+CG6JV%-/-I*DW$%02E YW0/IAU'3S:>=/\
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M/B?'EQ/SYD?_ 'W-MR4E)B$F)J(B)I!'1D<@32DA(2B9=/3$I,3RX90@FII
MH&"4(D")0$(J3)E0@BY8N$&""'@'ACC8J5SZ(E$2B)1%J/WR_AI:"?-[NG^[
M]=Z*H?BN_P"'[5D%%2E$2B)1$HB41*(J!<0>=ID@UI:WAP<IM)&>$T[@0EKZ
M:5'LW##I02"%*&+I(FSQA')JR&=,7('B"8>RP)*R>:'+%C!, Z4S-6,@E4T
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M%$%-(8GRIGM0O<,IS(S()&?/(Y>'N>%6'3DY/1T\@D)! FEI262*IR8F)Q4
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M0YJO)FZU,]<:2*_W,6=SKLX'X^) 4%-<)HY-"*#]TWROKYXJ 73"(!<,H4'
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L(%WK/0OUH&#6>060G7FFZ '?J"#A8];CG?._7=6V-\<<KV*II /'HZE__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>39
<FILENAME>g947560g60r81.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g947560g60r81.jpg
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M(" @(" @(" @(" @(" @(" @(" */#]X<&%C:V5T(&5N9#TB=R(_/O_; $,
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! ?_; $,! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! ?_
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M>=3%'X^Q-Z1H9&)D:.0,J;VIG9VIO)3H&QJ;$"=.B;V]$G(2(DA!*9,2424
M 0GM_P#K#\,2W_!48 P#0-V\:JTO]RKM[G2FQ6U\JITD#S!'RM[:LRIGED<Y
M2Q&QA[5A<ZUE476+#%<?4K6@.UQRG29 Y.B9-HDMS7!/$IM7V9[TGZ4<ZBN/
M-;\=6>9LM<>[0XJP9ZY6;,'&>V//;0D#U-'=CCL<<7<^16)(I*]EZ5-4592S
M$*=<4@VJ(4.&DVE[@O4J0;OZ,DEZ#>'9K7\FM:P08N*$0L<J6SH<0BXYNY1=
M+"'&8B8&D4J7PM$XN#PBB"V0[2;=U472.[LZNB5@/6&-*=Q<W!<4D I6J33
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M & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & ,
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M<'?BD4?KI*L%I^?+Z4O2RV/!48 P!@# & , 8 P!@# & , 8 P!@# & , 8
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MK\F=MW+R^O)L& QM;S"]:T68A2#+UHH!&M &06(.M$%"$63K0=Z^U%B$ O\
MF %L.M;V,1SL 8 P!@%2O1S^\1R8_O&N??[QLPP6EM7T8?@B6U8*C & , 8
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M;T\A[X/YOP-:!OWA?;/A:[H']\)Y[?\ IS9V=SLWKS6J[?$_[W;YX[- [/\
MJ=FQ?[_$_P!V ?S13UV@[RYKWK0=Z,[&I7K8A^]V"!O;R+N!U[_: 6C-[[==
M@]=F^\ T4]? [RYKWV=OB=C4K#W_ /N]SM>1>'V?[^]XO>_W=W &BGKX/:N:
M][T/>Q]C4KUW@?"[H0Z\\[[@]?![1[V/0NP786'O:[H#PGKL_P"G-?;XG;V^
M:E?9X7;_ #.SSS_SG9[WB=O=[??\+_=@#93WV"[%S7V['K8>UI5[UHOX/>"+
M7GG7>'OL'V#UL(0]X/:6+N[[X#93U\/NKFO7;L/A]K4K%W-=FN]W^QY#XF][
M[=AV'P^[K>M;T+LWO8#93U\/NKFO7:'6B^UJ5B[H_?[1#['D/B!W\'L 'P]Z
M[-]H]][7= _NRGGMWV+FS6NYV:UMK5;WHSW_ (>]^>-:V#L[/M>M:%[V]^+[
M^M: :*>>T/:N;-ZT#L'K36KUL1GO=@P[V\;[H/YWVO>ABWVZ^V:[N^\!K.;4
MQ#['7('.<,4>D*]O1"0$*%"-\3B+3;-&HT44%')2  +\<TTS>C G#WW^S1FM
M:U@$9)OQNJY!;E&-":)L:=M?%%DA>4*8<J)1N86V):6-^EJ?4M$%1I&H[#T_
MB;%X9_::#N[WV: WTR<;JNCCNVOS)#XPWO#0O)<&Y<4FD8S$IZ<S9B<PL!TK
M-*V:4+0-]\P!A8MAWO9'8+00@;L\)Z[-]BYK[?$UL._-2O>M%=NNT&]>>==I
MF]=NM&:V$.M[UO96^SLV V4]=@^Q<UZWL0=E[VU*]Z"'79WM#UIY#X@M[[>Z
M(.R]![=:V$79O8@ BGKX?=7->M[UKP^\U*Q=S?9OMV/L>0^)K>^SLT'96]:U
MO6]B[=;"!S$X58>_Y4<G-[>[W/)TQJ?N_P O>[_B*E/?[?@]WL[G=[-]O>[=
M=@'(P!@# ()=15?;S!QZ9YM2S6ZOTEK2_N-%GR*.M%GPNGCY+6E>WK!)79T8
M53NQ9=!H0WMLC@[6],CB@DLC2-3VE7F,ZLE:4M$D.$K;GED\W=\CW)ON*]^F
M!8?+&Q^1RQAY ,;XP+./%!6W6=L)7SEC0=^/@[8L/DBVV) TDPAE27+8\JA[
M_&:Q1N$40K)^RLYR= SJ6=I5!0^$E&]O M))+)IW:V)K8L]J6U\B+]<%!@%!
M/)+?(V,6_P!5)E.Y0W P1Q\X=<89/64V(CL].BW'(N=W5R9B<H%6$8H]K'+2
M76*01G8'*5S]I$OL#:LHN82*1LL7:&1%&!=6M%V63E?/;91M=O+;?FYGG?O>
M-LYZB,@XFPTWBG'>/,[;F6QN1L2DUD\PKLYBNIMLQ.,3P396UNTT\3%'<]HJ
M(+.VLN0JT[3/YFZ)F8A$T%PYY>HRK3JP U&^;:R62C';;-9.*ZTL^4WMT+OQ
M2G!WXI%'ZZ2K!$_/E]*7I9;'@J, 8 P!@# & , 8 P!@# & , 8 P!@# & 1
MNY.AGK#5=BV1!;6EL"<:^K2:R=$S,K'6KPQO3LP,;B](3'L,T@<H=_!V<D+2
MGD,[LT ,2['V=Q3O2@(E<ZOV_D;BA<<?(PV*$+_/Y18RLY>8K*>I8WPAM<$B
M8:=,2%K()@41AC2-$4:0:K+-5-BAQV>L4 -7F)@)$Z81U6[?S;,OP#BKER%L
M2*'!R6)6] D*$<J6KE!*1(F)!KM&<H4J!EDDE U[XC#!A '7O[WK (?3/J(\
M%X$ZBCS]ROHQ5*P;'K<(B,_8["GXM@WW1:+@,!4R:9&[[_VL.BF,>QF?:P:$
M/X."4F\[.V_D[=G(4H]:'JI6-'.,T/;>'J3DO5:6R;3;X3,N1TFX\771;>UQ
ML45E+\1&:RF%Q0.$*P2N9NC*F2I)1'$1YJ1C;WL,?=$[LM;W%'[CW.- :*X3
M\,M#:%TSB)8?1^+JU^-U*BHSQ,Z.&K5Z.#IUFK4Y8JK3A1UEY;4G"DU6E3:Z
MW2^)KX'1N*Q6'A&I6I0CJ)^6H:U2$)5917G1IQDYVV72<UJ*2*_NA3U&^4,/
MN"<T-.R^2W+&CTU2.,Y2LL?0.MW6'3,@:)=%F9L<$#@_O092*!RM$_O2%9&
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M)U7+B](6NEK>]Z.JGMLW[ZM=I72NGRFQ@_PH*Y1A;!@Z=\7&%Z,&2SB#RHE
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M6K-YR;=XGH46/*OMEQ<^>9D]T;[Q[)!I+57'&-% W_.);C^/M4U_8Z8L7O\
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MX[1N/GBL35I*E&G4IQ5*I*3Q'&.RDTXQ<81<=>T[3UU"T;>4OH Y\SGLQ@#
M& >4;DWQQMODYRNFDO8;UJ'JFUW37*<<HF?!M9=Q%8SVDX;!'U];))Q_,XWO
M,DUQTLP"!8%"D+L2WD$0EKZ)A3:TX/!#NJ5X,M]5+)P;2\I*][\M\FKJ^2;]
M%O5FG[/)R.Z1M,'P2NZFV$ =I]=P/81L)6Q%AV5K[7W2][!KN]@-[#K6\&(_
M; & , 8!4KT<_O$<F/[QKGW^\;,,%I;5]&'X(EM6"HP!@# & , 8 P!@# &
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M0B5IW1N@,I:4T)XK1!R3&A4)3(EQG95[C%7XUN4 "<UR&\'JZ)NVG!V<VRI
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M7-!+ALO>DQCDC0+&]:I1@-[NSR4JY(>87K82U!0MZ%H#2?F_E/\ _P"LX_\
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M>+-VV=R#YF6E9,'8>5L7XFK:(CS4],')NIY13;"AY"-,M2)&7=%P^R([&[
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M2ZLV_P A]@_GY,_AS[G3!ZU(/_GMO&'BE%6!P0%;][9),JY'3[DJD<%.@_\
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M#KL[1 [#?AZUVZ[=A[=:[==O\N"I61U(%S8X2+IY%$+$"W0^=)X_")4)U/>
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MUHS>O%[= WO6]:'_ #=]F_?][> ?-0ZI)I1_4HYPG$&%G$FWNL,*-*&$PLP
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M-A1!I5PYN1L:^,,\X;##FZ4EQ=0E$PJ'=&>:$]8@4 4>$M*4IR1C>7^>1NW
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M<Y6!^&X/ZUA_70/JG\6/P8N.7Q#U#^SZ/9^8YNXWQ@# & , 8!C,U K,ALM
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MC /F@]4[\9;SE^/I;^I4+S[@_1]^0#^W-)>JP9K'AA\:P^IT?65R!N;P/*C
M& =1(/N"]_V0Y?H1V=/PA^(-.?8^D_X*N<K _#<']:P_KH'U3^+'X,7'+XAZ
MA_9]'L_,<W<;XP!@# & , US;=?L5GUW*8:_PR SXEQ:U)S7&K.C39+H.JDB
M$H2R-*']B=D3@D5HT#X2A6"%I*8H(\'QDNP* %BT!49TTZGO.&W E>9EQ1<.
M.#!'.)\5JNZ'R6UQPYA:JU>3S--43P\3>H%O& *AZ7UN\M*F2AD)TL-CT=<
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MC]IX;U&+/;\ ?CJO]G5_XC"GIJS1!N$8!\T'JG?C+><OQ]+?U*A>?<'Z/OR
M?VYI+U6#-8\,/C6'U.CZRN0-S>!Y48 P#J)!]P7O^R'+]".SI^$/Q!IS['TG
M_!5SE8'X;@_K6']= ^J?Q8_!BXY?$/4/[/H]GYCF[C?& , 8 P!@'02M2\(X
MM)5D>+)-?TC \J6,I0D5.!!CP0W*36PL] A$!:N)&M 0$U(C&!4I!L1*<031
M@WH.DJ-Z95M\JK%D:PGDY-N9CG(S*D;WE]A?(/AO3_'2KXY.MN<<)D95=3:"
M-".4RPYK6+%[8UM3^X+ 'QTTQV< Z=$Q>P"TK<B74[W\/:W*7(X*C & <%T^
MYKC_ %%7^CF8!55T+OQ2G!WXI%'ZZ2K!:?GR^E+TLMCP5& 8_+97&X'%9+.)
MB]-\;B,-8'B52F0NIX4K6PQV/MRAV>WER4C^"G0-C:D4K59PO>*3D&#W[P<
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MP<'16(:I6<,0HW=M[S;&"!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# &
M, 8 P!@# & , 8 P#R.\F. '.VQ>7]QV=5G#'T?H4NN69/Z*S.*EUU@U6-R)
M9E,A7G)I[:;)<O)+5(HW>:$"*D+FW/O%U^DB-Q7&@5R'Q J"#AE3C9)N^6:D
MFTGR6LKV6>R2Z.4];20(P)4P#-#"8%.2$P)FRA&:&$L.A:&(@(21#T+6]"V2
M$)6Q=NRPZ!V:P8CD8 P!@# *E>CG]XCDQ_>-<^_WC9A@M+:OHP_!$MJP5*Q.
MI-_M'T\?SZS?W)N:66AYRZ_0R)>9+H7XHG+S,8!@# & 87PU_#[YJ_FM\#/V
ME<]<PS\Y]7H1GCYD>F7Y%LF5)(R\UOP-N6OYLM\_LLE>"8[5TKTE#E5?>OK?
M_@*'_J\W9]7X+X'A/JU#U4#YNQ?PO%?6*WK)&>YR3CC & 8J@_"JZ?WYW1?[
MM_(S-?>Z5\GZ/VGAO48L]OP!^.J_V=7_ (C"GIJS1!N$8!\T'JG?C+><OQ]+
M?U*A>?<'Z/OR ?VYI+U6#-8\,/C6'U.CZRN0-S>!Y48 P#J)!]P7O^R'+]".
MSI^$/Q!IS['TG_!5SE8'X;@_K6']= ^J?Q8_!BXY?$/4/[/H]GYCF[C?& ,
M8 P!@$-.?UA7-5G%:R)S0LHXT0^Q&33 -,]\N9 .+T4!A5/[<CE*.4O7GF.I
M4RUQCY[@BCQ;F^-;4I?3T*9R6$I#3!8)BDVDTVMT=NS*W7W%(O00.9UMQ7VN
M::6@D&,,@R4ESG%5<=9ZT5 ]GE2%ATA9Z?Y-+>8_*.K9#!PH-@.35C F6N=;
M VM[H-J)2Q("(H7GR9OK:;Z6M5._.[ODZ/4+@QC & <%T^YKC_45?Z.9@%57
M0N_%*<'?BD4?KI*L%I^?+Z4O2RV/!4TCR2Y UUQ5H>U>1-L.?FJOZCAKK,)
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M=:U@QGZX P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# &
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MZYAGYSZO0C/'S(],OR+9,J21EYK?@;<M?S9;Y_99*\$QVKI7I*'*J^]?6_\
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M,5FIU!">PU4DD,<=@FMZLK0M?5A;^].S?T>1=;SZ"ZK!C& , 8 P!@# & ,
M8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8!4KT
M<_O$<F/[QKGW^\;,,%I;5]&'X(EM6"I6)U)O]H^GC^?6;^Y-S2RT/.77Z&1+
MS)="_%$Y>9C , 8 P#"^&OX??-7\UO@9^TKGKF&?G/J]",\?,CTR_(MDRI)&
M7FM^!MRU_-EOG]EDKP3':NE>DH<JK[U];_\  4/_ %>;L^K\%\#PGU:AZJ!\
MW8OX7BOK%;UDC/<Y)QQ@# ,50?A5=/[\[HO]V_D9FOO=*^3]'[3PWJ,6>WX
M_'5?[.K_ ,1A3TU9H@W", ^:#U3OQEO.7X^EOZE0O/N#]'WY /[<TEZK!FL>
M&'QK#ZG1]97(&YO \J, 8!U$@^X+W_9#E^A'9T_"'X@TY]CZ3_@JYRL#\-P?
MUK#^N@?5/XL?@Q<<OB'J']GT>S\QS=QOC & , 8 P!@# & , 8!P73[FN/\
M45?Z.9@'FKX<WC84 Z)/3QHSCXL*)Y6\N8:MI"A%&P"/U!!+9#,7&S[Z=TY0
MO'!&:%KLIXG:M3HHXE1)2HA'3"S#I$F*,%VO+FWL4FWVY+K>7+;;9I,ORXV<
M?J]XK456/'RK$)J*$5=%T4=;#58@FNCTL"(Q:_2I_5!"#2Z32^0*W2425QV$
M(G!]=W!9L(?&[NA5MMMOE-X8(& , 8 P!@# & , 8 P!@# & , 8 P!@# &
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MO_*AS$^H+ XN6Y?>CXCUZ?3!_+W._P#*AS$^H+ XN6Y?>CXCUZ?3!_+W._\
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M#BY[E]Z/B<[UZ?3!_+W._P#*AS$^H+ XN6Y?>CXCUZ?3!_+W._\ *AS$^H+
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M7)W<[)+C&E^DVZ'U2W:K\@U8(AKQ"]UJVN\ELY]:_9;//.^QVR+S<%!@# &
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M , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8
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M//GX4B<C0/;V]N@B3OOVMW;W]25][6W;9%KN"HP!@# & , 8 P!@# & , 8
MP!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@#
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M[VJ^./RVUK])<"SW/L8],_A][5?''Y;:U^DN!9[GV,>F?P^]JOCC\MM:_27
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M5'HDTFCZA:F%W%*0AZ;3E2<?E12'N'IRU(C2A>6J"$?=, '?E1Q2?L\4P !
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MD(*66=[Y\ZS5M^78WSG^%G32L!LBE8)83&ZECDK1U9?\8MMY:CPM*V:RJ?\
M,_BK?L#7/3LBCH%TJ+9H355G% 6O0AG,#N\)FIK*VC>ERE.(;RMGR=R=^\Q(
MSIQWFXL*N/-=9T;6#RR.O)QT=;*B\P.5R"_$][<EH];<699D!- VIR1HHU'F
M<+Q(]R-U?]()DP1)JAX%;(<X+V@64DMMWLZK+DSZ>K.YG#CPQO65/]_62Y\;
M:"BEQS";UY(:XDL6G[,TQUMK2D>2%<WC'JE+3L]6HWE-)+D' //UJVD]"=%K
ME.UC(D5(-PN$1)M:7MXD7V+.R3[6FNS=S=)P)ST]+AO.0WM.+8KFE_+[)J[J
M#(H%%'>1AGR>#V'R3K?@["*:=QN3C"T:-(^LR6@+*32N1,R(TR,F.J8B.+'U
M ['+ N7FS_*WYC62LL_[M^IMOT^UCN[#X 6HTR@X%0P&GV^K'";U'*UT48D5
M7-S^@>H=QSE-1NDKC3?:]-6W4K<Z+'QQ9VN5OCK7C],'*!:5FQI>C>D9*%<&
MMON\FNEWY<TVK?Z&IZEZ;G("',T/BDGK2B%\G+AW!6+)>0:6;&K)I2N^*,X,
MD\L%!T1E:MSHH2N3,24W5T5'E\53+G%8-OF;:Q1I( L8.6VS=FY-=:Y<[;B6
M'5V^\?0?YY-"?^9*<]#P3^4FA_KM/T2.BX2?$6E/JE3\B#&?2YH(8!(?I??A
M7<Z/BJX6?_=.6.:']TGY0T_LW#>NQ1N7@'\0R^T<5ZG"&ZJ4XW\BJND=0^<(
MC '5AXE5GR*@-9+4UE+4B^\%-P6% W"$N+N6.$*-UVGCU>0M1J=%+PR4Y;/W
MA.5']KV)G$]NFOSVC?7>SZ+7RY=^3OL[%V40XH3YEY:QVUF:JZJJ5O8;MN^S
M+&N6OY_+ULHY%UU9<+GK+$ZJF<&>D)YR96VS.6Q&Q94-RDBV&,,HJ=N<*Q:6
MXB<KVJ)";JULWDDK\F:;:?:N3)\R.EG/3^1V#R%F%PRZNJ@EFI%SLJV] N\F
M:FUYD)]'P3@Y":),BZLUQ85)OC$6^T2%X2Q/:L;,I:ENGL]1I8J-0 #6LN7)
M-+FN[^CO*W9SQOE-..;50SM4M;VM8DNE/#@NLG UJG9DEI:%P/ET_P B&Q4P
ML)I]VC#K"8O"%ALJD(8_8,,2UF4KE@[$1-T2W%5$I;.X+9M=_*W<JY7?EL^3
M/D>ZZNW:YN.,\BHMR7IJ)Q6T31TX]4A/JWDTU,KYU U#F3=.8C,H-)38Y)68
MU6WNFGYGE\9>B&<MZ:W-E>FZ0$KHB%@DHA6Y<N>U_;VRS(FPGIZ6*]7?#[?M
MR9.\1/?6;F;+[,;^/=UV?71\;L#D3:?%U^@T"C<LB88')9E#(Y7U*.B.6OSF
M3&BY%/$Z>6)XDV;=$J5D>VXF]DTN5IYI/8GV7O\ Y[Y9._%U#%Y3P=;:<9FF
M-U;Q@L>P9 ZLZUZ>%SH"/RCCW=%;I3TKB\F/+S*I&XS2PFYUD3O(G@YX=AJG
MJ0.KJXNQAVU8B^WG\4_R.';E3WJ5&I8Q-LFD?*:#V?(GE/.:RLN<1&B'R%01
MT;G@UL8*5LN@ZOKE\(;V]_-9&Y_(LMUE<G=(:6L.23<3RD5-<O!?Z=-UMYK7
M(80;@UR8A4&:J3<SZVE4;L,/!)ZLJRD4H6,YU;+^)SE789I$8Q$]0Q(=,&U\
MAU31*/5E) '1DW;\ZOLBF#"PDMR5&^B6TWS9V3SVIY]N;ZK7Y).<6X'R=/NF
M;W)ROK.'(9Z^QE_C$1E42N'4PB]9UX9+6IU:*?KV!;KZ-*6U._D(6V3VC8[P
M_NDCG\QBS-I6F;(DS0.(P<0[9)7MSI+/M=^;=TMFQ8APPA4/Y96#RL23JY%S
MQ-X5!8Z1"W2^>0KO$&M[C<EOI\D#BLBCW;[I7[[$'-+=*9'!ZM6P4$$IYRC2
MV15RU,SM*5QJ1[>WMZ1?*V78N;FO?+;M>QY&EIIQBNAXN2QV=K;H<=3EP\R>
M-',=\L53+%:65P\[CW#N/34LK1/!PQT_SXNE$FXQPLUL?P2-&V)HQ.I66X%I
MET39VZ5B;JW.DU;?>^=^:^[=SF*\D>+MP7K.29R@HZG(O:$H@=*QQ@Y"H[<F
M ;.XUO=;6?-I<\*VC14;(;Y>W-K/,%SE!MP]!#5DO?7N406T^[!5R1V3B$[9
M.]L[K?[=VU9F0\[^$SSRH<+%<T$:KN0+UG!+E#159+9OHHQ5$[PM9;!5E?RM
MJ..:',R-^:3(RK-,F;2(#^P&>%ML+'M0=O0E.V_:GV7\2)7(+CK'>-=VO-FK
M*@H^44%+9K8QD)H"11R4ME1$N<FXP<;*T#.EB>"TQ9T9C5EM3C3LVA\;CZF-
MDN\W@UE3;<3=5\J(*B+X%^F]MJV[6WRK*SOTKK4EZ[XE/=D\,^E'6%J5]&ER
M7CZP\<))>-:V6VDKDZ?W%<.9]6:^/JXX[H')(ZO3#94KCFSVEV++** VKU)I
MPCT0$ZB+;.;P:Y]^_K%[.5LKWM;I3[+$.Y#TU^3DVE,R<'Z/5"W(91">2L(E
M"9J<J[98M)S+CO\ J:U&E2Q-D/HJ-6,NC+BP0%R52T^[K3LV6CG#H,+:2E;0
MGO+I)-UEM><=NVROE>_/ELM8V;?W35LZ7+>3#54\8IQBKVRWR^5U=P3;@?#H
MFC;[5X>\0Z<*;G%FCD7/21Q(]6G3=F.LF\RHE9FD#PFD>BUSL]+4A C6R6VZ
MM=[<TY/?N:[#NE7##D$USB67-7M#\;XR6X*K+713BTYRDH^H$SN[\=X73[,]
M2W;+7[='U.IA)8\)=+6=BCY #H3&8H ]T+D;HZ$L8FZ2MGR9I6Y;NV?9DL[Y
M'%@W"^^:H9X6Z5A0E4M4MU5W+JK[0+<+9:&(<_GW*??'A].OMT50ZIR&-L:6
M-XHH$3-KA@82]16"GQ5C@Q)K+%DC*6"EMOOBUR^:I9;>6_CO.SK[IE*B'^#R
M2T*ZI.7/3-R@X^63('AV;V^1NBRI:DZ:-;\8%D7"M=8V)2J(2WU&'R0M45--
M RJ&=07*#MDNBLYN #ENNLGVN3>_=9&ES^G%RD),J]C2,=2$-E://%M9%7IB
M=*[;O,L0H?DHKMMUBKP[2:BIA;07!GC9@6^I&:IK$JF"H"G%<CE/:)*H*D0.
M2;;SSOVM6OMM=O:2JX>\-+,IRUJ[DTAK"H*N2UFQ<I6Z53FN9+MZD_(!5?MQ
M,-@Q,N3I00R-K"$,3;F8YVD Y.[/"A!,1MK=#@J&#;DX[$2:=[/:T[;K*W1G
M[6MG*WJ#?@$<WOS0N2O[&9I@0\^/TH^E'S D/_0D?]53_P#D@S]1\%\#PGU:
MAZJ!HJO_ &];_NU/QR.5G),1<?T!OQIU,?%E>_ZD!SYM_22^(N#?VMBOX,]O
MP)_M](?]BCZUGL/<X)RBFW+Y).;-J^&22AJLD9A_'A"UW-II2QA>KA:IC>KG
MGT&,KQ6MFEHJS7N31:(-XY4DBM>PYU.6MK:X3)>MD1?R";"RME>[VY<^S;LV
M<E[\Q@\ZXW<A9Q-9NGW%8$T0SD?:W"N^[,?16(L<7>G9'QQ>:D>;'KIF; PM
M$*?II"AI:-,M?2Y*ICA '>325_D+&S)F)M0283=6Y;I-=-[V?-M=^JU\[?MS
M$X+*^2EA6Y,5,/K*4;D7'>C:NKU;-2$ZISCTGA'(&:6;-5"0U2S.!C"F71UT
MC@4CHV'^6K'%$)(8!,4G >8"=K;;7=[9<BMRK<0=Y3\>B./4PLU_<*?J&Q:U
MLI'S!34Y1SO')H7!(TIL^K>)+6@?XHE@],V+&6FU'27UO8+8BKE(W-$XFS5,
M7U[KAU7JTD]:5(E/G>5MU[7;MF]EK7VI6S+$%=$7 FJ/@1-X,QQUQMWBA'(J
M<]5=.7]5%6F6MK_Q_<JAL",IY6@99,&,31B,?"WR,NRID<FA>K8EL2=#69NE
M)\H8A6ZN^>_BN6V?+NVK99Z7F'"6[+]N>+7U:)B.IUSMR(J^4R*&5+<$N;)5
M!J8IKC%RRK&+J45J19HAKFOM*5V;R*&KE2..EMS&WP "2-E2.2!:EBAV$W2O
M;/G:6>:Y.KEOU$D;)X=LS=1K755')%!"]3RUXI<BIL_6).YC,Y/,553\K*'M
M^R))*)W-'&62R22I57]6*&>.E.CB:E+ UQF)MXV2/(4);<">=W\V2[8M++I?
MYFT[-@U[-R^<3RLK*?;#V^IHTUHN.5@JZ^A55M3 !QC22>*X'8T#JIMN]BL5
MUBR&2JXJZ32RYG$44N?1%*&9F9]-*V*B%;*^7/G?ESV]&SD6^]ZW8WPEY.5G
M%I:* 16M5@K6JWEE3:*MI':T@7IZ(8[ZLTFQJ^>7.QG.'.K[;);4Z.T\?+;$
MH*%)U#S(&EHC3O,&]H$^G/\ ,LVF\WSWLKO+IR7(N]$@ZQICDLEY&PA;;M?Q
M23T?0A((7QK<FRWPIRX0SMU;&P-;=<LK@4!VLF%V3I$I?HR2>IF2=@K6 2IQ
M88NWF.[G,Y)+A6ZWN[VY;<[[_P O\MXV/PPA5D<G*QY+.,ZN1J=*]CLR:%$1
MCU\\A8Q%WA>_+*P4L:M%&XG;\?A$=9&\%=G%S*(((8;'K7.>$RJ?I'<]D3"/
M#6=K9=BOL:VVORY9Y<AJ+E_QONRRI+=AU2MD*>VSE!P]=>(<O<);*E<=,J<X
MUXL4UELQ,UIX\]>[5F*9[BFA[W&T:QF>%3O%X@V)31-[ZZO48$II6O?)WRY=
MEUMYEWG(Y2\?IE<HX8<OXP4M=**!L=RUY%D<_M^5QF1LA<Q25T&#V:TO;9&%
M+(U%GJX>KW,T/F%UL*&JDD8D]92DUP2/+*\"$[)YO.W(N?VY\TS)IAQ-D$_B
M?3YAELJXO>I7&F:LLCO%[L9$4[$V6XL?$*[Z9%,Q,#PB=43V^.UK3N-3#:5W
M[OD.]*GLM4)S:D@#1-UY65M965N3RD^RR:*TW_@H[<8*MXWRMTA%0>YNJ*CX
MDQ&^8,C;'XR#719%7SJ5N#P99R^)UM*S11IG=YK[O(W8TTB[@Q-LV9&;W5#C
M# L<9&V0MBZ!K-MY\K:WJ^[-;=EEV9$BJ1X[26Y>FE,ZA*K"&UX3:O)"Z9RS
M5F82\-D 2U2\<[)/9S<C9B'J(1AS,ATBK%.%?#]J81&DKTQ.K,>F8&-K<4Z1
M)*\?3[?D);=NRV?.DN^^WG,6LC@'>#UR1!,X'"Z>AM=QF](W-(@*(%U="FTF
MJ&WCSJFRF<2)#1B^X]V$@5K71H7M!%SL5/\ V."&XAEC)CL>L:B@NK/:VURW
MVWV[<URV:VM])V40Z<$YK]70P8+&ZHAS9#*IZ?S#9B6,FEL89)87&F:6L_69
M)%1;;'D^I(XK&^<I-,LC=Q>=WU2>XA<!H^[XIP.5]^V3^\O:YKBG.G3>\-@G
M'MJ*J>B*E<J*K_A' YHP0";&K6KD!(>/-]5U;,TLF2N!%>L0DZE S1.3IH8;
M(TC])G.1V?/2'A2E;DR%ZDPERNWFW=NU]JNFN^ZO;=R\F9UKPYOZ*)45IG\9
MJ(BU_)^0-9WG-00*QF&/Q*6QB&(IO$VJD*Z):*Q:R89%ZSB\]<G6,K)"2I-G
MLN]TLDE2IG>9HJ/:Q&MMY<FL]N=L^[>[<]CH ],FR9S'+>66] J,>9Q.F<D4
M7+/<QS!##G=[ZDW*'EQ+T#+(GJ%MCDE1FUQ;4$;RWE*TM:YU?FM:@4($"=&4
MH.!RV6NO]$O2GD?V^.G1=\C66=%*SA5*HZJF4CY0+8.R(B*N:3H69=4!X^L3
M*4J2V/1-PQ^+5R\OD#LESL5)5479K0&\JXRX,4EVE=Y&!,)4DLW>^6:YF^2Z
MN]FU\C,UIK@M=46MB.R&3UK3K2\)^1E2WV\\DVN9&N]L"C,"XI5]2LFJO2(V
M$)GM4=+I3'I$R*.V8%Q$^O)1(WQ62"4&%,KV]NC*V7MRL.2:VO8\N2[;>_DO
M?9M[2-'\(._[(W_CW_Z+8)I\O5^9-.X/Q#UH?W2$T_<Y<L$1_M%]-?B,P9_N
M2U_V<B_1BLSQV+H7H.++:^E^D[')(---7XP3AC\77+?]7JGS'4Y.O\C+3V2Z
M8^B1.R\[J>X+:M,5O'^Z3J1Q>\;KG2GR=*H5*ZMH&/19.]1QE&M+-3(7J1V!
M:]7)3' TDX1$7(E)*+21T4M[JVXS);)OG2[;^'MRQ?0]3%$EA:^6V!3[=5(C
MJJX_7C$TUBW_ $Y#&5[K3D6IL)!$MO$VF#O&HE&9ZSKZW>2GV%;<W<HTAP9S
MH_(7PT3LE9Q+B^3/-K)/DM?JS\4CF3;F/:<UI*C[MH=/2Z6%R7E=QTJ6U7<F
MU8I=BDB(61RDI.E'-DK]QJA0_P!?.#\_-MBO1CL].TP3*H(F:BR$T9>GA]3.
M,7$);[K)M9<S,TN>\>4D%Y(2V#0V'U]*X@+A1R<N2DH$V*'IPGEEW)3KMQV0
MQY',G!4A9D$7;'E]M9TA;+%HVH>AJ$I.Y8\2G:MX01F("4DUGEY44WN3UK^C
MVY8NP/G):*!?,4JN?.ML1JH_06L";2Z544[4>[/3!RQM>U*"M. $QA_9&18D
M1TV\Q=LL^,N:!O,?3'!J>:AEC\^/+'(%XPME??=+/9:SV\M]G7?<75X*C &
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M"Z,V/ K58T+D%"D/6P]'$3W,*E[$ZN*T1N?M=?Y6ZR36"!@# & , 8 P!@#
M& , 8 P!@# & , 8!$+J#?@$<WOS0N2O[&9I@M#SX_2CZ4?,"0_]"1_U5/\
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M1N"5&ZEM3PK&W*E*!:0G6:)..2*2P")&*MVDVMJE==3-6%=- D@HLDKG!SE
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M9T[T!H:3<GH^BW)MMZU;-MW;_M>5G^O_ -,IP(_*KR\^4RL?J4RW^U_W2/\
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MH\Z*VT:> .$9^UA1':%I4V-IZ0+N]^7;L1E;=3B5/>.[E7.(%6X_42:G:X8
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CZ]Q?G/\ V=A;3Y3Y3YI;_P#IGE'@^3_Q?PO%/\42DEL1_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>40
<FILENAME>g947560g60u79.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g947560g60u79.jpg
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M @,! 0             ! @,'! 4&" G_Q !7$0 "  ,#!@<+! X) P4!
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M"@6$PJ'"D.EI--155URI#$KDUKK?KU'SDCB.;+9/';!#B;8$HKH<FNO@K1'
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MX :3ON6NBI50Z6-.C74MYQ\/%B3!\ZVI7K:0G0F7PUNB^BR9"A04 H!0"@%
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M+?(%D=YNM*10%%9)]\=URP&.'!APTG2E;KE@JT6";I5])G#0J* 4 H!0"@%
M* 4 H!0"@% 0W\?#Q8DP?.MJ5ZVD)T+R^&MT7T63(4*"@% * 4 H!0"@% *
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M73KB=+N6)U><1Y.2RV8O0RL#@*:PS%RQOB'CEE;E0&/T*;^Z1;'.;-DP5M?
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M%10"@% * 4 H!0"@% * 4 H!0&,FE_Z*&OOS6-/ZN"H#)N@% * 4 H!0"@%
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M4*%10"@% * AOD3Q\>M7T:^P7\^(TH67 B\:'JC)D*%10"@% * 4 H!0"@%
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MD"3G P"K=1[F$((NJ7P"'Q5^-Y,2BHZJE7I1-N]N^F+V/!7N]WZME2AC% *
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M]O5V?'0"W=.KGT.WKY=+LZNSX^WMZNSXZ _JW/E_>Y<_U\N?+_\ OK[* _:
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MU@^E&UQR$R[H%2"M@UW)!6U! ''##'3A\K""T*.E;DTMC=6MNI&6U"!0"@%
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M#(V">C(Q0^KJQ[,,++$HF)1$ZI'Q[AE2)0R:%"!S QQ]]Q$__#6RG[E^XO\
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MZ5I2ZN#J8Z\)?47;Z%]@82<,[:7L_5UG07PW!-251[-F9HBD@Y.$FDY9B9Y
MO1:1(\P++"$:52R$]UC.RSFX\"IH^<"%<@II0PQ-/Y_'I)B<+3HVZQ52I2BO
MN]:NU4.?Q3Y*@W1>3D=P,+335N3Y\VB94O.=(?$YLR[W?LI3L7?4%1+$D2,9
M04RZBOKV8CAFX)[N%B$G B)J/%$?N7!J%DK(*Q@B^/A$0IQ7-M0J][$J-MT]
M%,,6MSS,X5+4B=YQ8H[,I,(ZZ1O-*T[)F@F09'U3:QV/H5G=*AV97(RDZ3VN
MV0#.!%<1W+FT0%)#<"^&O+R9<=;3$9QW0CXX)H1%<Z5=**YNK54G3T?"3N4L
M="HH!0$-_'P\6),'SK:E>MI"="\OAK=%]%DR%"@H!0"@% 8R3S\*NE'G,NSU
M-MM*$K"+=[49-T(% * 4 H#3P]E1_"#P\_DUN#_&ZNUO;N>?#NT^;N4/US)A
MY?._BA<\D=G/-5ZOMHU>* 4 H!0&\I[&:\7N^?.PF#[-QM7YW_*I^$/.ORI'
MV,DW)D3B?)W-8.N(V'*U^=H* 4 H"*GB2[D3=K([M9(^AEXZ9Q,+.QZ7++TR
M;QO!S->(VQ>-$-IJJ0T4X)I.-JJ1UVOGW1J8R4:.K)9&) M8V1,6&5%I& %%
MH4G5NKI2Y8OKIJU/'T/*72Z3I*EV#T]Y2O*NI\RN\=QN%/'>VEZVO."#S! @
M9"#(IQ!1<;H=ZGDXT\/+(-PA9K(@(1G(*P)<#&]\;B'2MR:Y'BO31=2]I"^I
M;!;.0?NQL]"B=)_"YDXHYYX;\S$$;8G8.2<-AXK8;J><8,J,V@X[I$4GVJW[
M(+Y>#5QA=CJ"L"IMDZ^D4JE**B5,EUC)\?'J+T3A3[]-*ET*:=*MTO3PQV:S
M91H8Q0"@% 0WR)X^/6KZ-?8+^?$:4++@1>-#U1DR%"HH!0"@% 8Q1)^D-MG_
M /KL-?RH2J$O"'=[69.T(% * 4 H#S+^)UXR7>SSC'']G&K7V]W/G@%,\O91
M["PFL\\N-97,9':3S!^MY'DQ0"@% 4L^?S*=_P F%[ZK-5Y;/GP)SP\ULX/J
MFUG8Y(XVR9S^R=O+/6FCCX/&'\C&O]1D:_-@W.5G0"@% * 4!C!NK.+IUHU-
MV!GUDMU"=CLB6,',]4%!<ZB.E-PXH(Y/(8(1=-%,PS^:20M?)14""7G@L*I4
MH*EH^6*H<*7L)A2;2;HFZ&&^@FTNQ\[R8NHLO[4<*"<FN#&IQS)C5T.?+^=,
MIIBSBX&H3++[C+.V2':5PCLJGJBBFJ!W%#3S]G&IM8+ODL&.8*#B8DE@HEXW
MNHJ=++?\5*1YL@B7].INB^5=1&PC)9Z4(^/Q?N+*SV932D1^/L>.@X\68V:;
M#8SO7%^36>(FKQ<HZ0;X>Y%$<RB1R3QPG0,H)@F%)J*NEJ=4JT2K6MZNP]*7
MIS]TJ?;PDK7!AO![@ZZ +*@*YB@0.J;M5'O!P"<BNA81"15J+ZPA-H]F<(XI
M^9%SIHJ,2NBN<LKI%\+YDL[T*O%X^E4?I57UF55"!0"@(;^/AXL28/G6U*];
M2$Z%Y?#6Z+Z+)D*%!0&,6XVQAC5#7IX3D38@LF*#=<$6M=*8P3D+L^Z\LRK+
M3&B5'"$<IM*7"Z07)JCY**1HR*E'+9%B8P-L,,A;#!B4JO9CZE4PP]_ANI_R
M]6K^^:U?Z+U;0BV>M>\KI0?C/\W^8]_ANI_R]6K^^:U?Z+TT(MGK7O&E!^,_
MS?YEK)!VKW;>SM@US!:%-!/#B"4E>1#)03<-KF,UT!3A28(FQ2P!L8>"Q("@
MF90+K=S0@9K#,!'&(V Q$.8&2[0BV>M$J."_OG>OQ>5/;R%T_?X;J?\ +U:O
M[YK5_HO30BV>M>\C2@_&?YO\Q[_#=3_EZM7]\UJ_T7IH1;/6O>-*#\9_F_S+
MDZU[RRI+VQQK7&7M8RL&KN<).&;4->3)O1Y8(JR2VGVRV(>2!RB:Q&F(EF\C
MCT*G0C ADSAD"3%"[ATA;"!PTUB2J-53K?3"GM)(Z@"@-/#V5'\(/#S^36X/
M\;J[6]NYY\.[3YNY0_7,F'E\[^*%SR1V<\U7J^VC5XH!0"@% ;RGL9KQ>[Y\
M["8/LW&U?G?\JGX0\Z_*D?8R3<F1.)\G<U@ZXC8<K7YV@H!0"@(K=PM*]G]F
M5;II\PZ@C-M%?#@66"B; :+,_8D9F,M;:3#3;MH@>=C[(88+(CK;SG7U9RD2
MJ?DKI:T@(1A/QLUP3IT7AB4.J+#5$X=;V+=T5UF26IL/.;4_7@=HRBMQ"NGV
MR?>#O55+7778C!#*NCB8W4[AI4.,,XZ<S*^"5*BV.#I-SRNY#?<<"Y 0W<$#
M,1$])UO]+TGTW&GQ,$YZ(3;/<V/"-=]70:AZ39DE-(<&LZ1I.KNS9&5!)TEK
M5]_R40A*4#:LDMGVC>SSU^88T;N>22K?D*+6\ YDI/;AH<-O7%BN&/0_1JNI
MZC)1I*L-]$U$XJ*E'2J6Q.ESIMUUWQZDPB@,15G>/7-)V]9.C0#SLO[%O%IN
MMZ&VBVPRRL782*UD%-<V.,C'PSN'N657(AJA=4:Z(( :5E%,N$KF29!(4$@^
MHB:.E:752WUKAT,H/6;B/ZW;8R>MQ3%8DA@+!=KNE^L1P/)B*;69DUQVQI#&
MBIXR!#CB-BBA.YK-Q_!@("@9,@(Y_/-03E$DG&TDUB?L)<+AQVT?(VJI/T/K
MV&,LB>/CUJ^C7V"_GQ&E N!%XT/5&3(4*B@+*RKLGKI!)Q'3IPGV%8;4'"6-
M'4 C*LJ,6/#BX3(BA '3:.5=RZCCJ98F.."":')8#A%Q1@@Q<\,Q,+7$T;P3
M9:?_ &AN@/ER:>_O,PM^-J"CV/H8_P!H;H#Y<FGO[S,+?C:@H]CZ&8YQ=OMH
MP1GC:!4.[H:G$TQ;6HE$1E$UL7#Y<@KAD(Q3"1X1,."O' N?P)',,RAO(H(+
MB6,XY #7P%QOA82TZ0W/#8]K,C/]H;H#Y<FGO[S,+?C:A%'L?0Q_M#= ?+DT
M]_>9A;\;4%'L?0S(F.I/C67VN5?$2R&QI191XP<)DG?'3M0'LUSAM.,9E% J
M5<#:4%-),&"!H/,L< !-YBE3&&8(^. F-\;"*-8JA7- * \R_B=>,EWL\XQQ
M_9QJU]O=SYX!3/+V4>PL)K//+C65S&1VD\P?K>1Y,4 H!0%+/G\RG?\ )A>^
MJS5>6SY\"<\/-;.#ZIM9V.2.-LF<_LG;RSUIHX^#QA_(QK_49&OS8-SE9T H
M!0"@% 8K[2Q#-<SMH-G1A)$3LYJJ[1D= ?S9EV#4Z<FV\U!P(A$I'YDZA*[E
M0DVZ(T5P$ZJ.%OG2R@7>!,R"FYCI=BW? @E-+5K3N=&J/V[=1BCHKHA-&KDJ
MN5]R.\],'&BK4?*+2*$M<M$&%JX\PE0XXVNL@FE=]M5W+Y]:;&!1#.!&VD.3
M")G%49'6<S. R& $,+11*)818ZXW%ZFD1?<;&?\ 4->V3BZ(E;<;WKFR$9QC
M*""X%=_:RO2:(C!CZ0UN!']9"4<B(:2Y$5[N-09K466,^XJ#<Z7FC-^068]U
M%(R4"),RK\49,$+T6W"W"VL'1U5:/91:T];1*IP?3<?*VE:2Y(W>#RDE)=\T
M[&O!=E)W1B3ADG*+W<TW/=8>D@QY&">HJ95F1.YG :.G(V1;C@J!9J]X674]
M,<%U5/+"L6.%*)75K2Y:^OEJ2AT*F)&Y^[^NVA$.J$U[&//%NMX$:Y%OMQ*#
M+*C\?BSCCB*(@L-K"'21EPJ98I?-24KAC )Z*D@&E=:/IR86&-X"887$Z)5^
M-9;W8#B1ZV:UR\A0U(PDAC+)E'CAQOMV-1AJ;CCR$FW,+_O%L6+\T.XH+@49
M::^G[@*@(V6(*H9!R"R4U8LFHPA=1&$J%M-KE]-%5I;;C&CCX>+$F#YUM2O6
MTA.A,OAK=%]%DR%"@H"-GBV_H,O7Y[M+_76UZH2L?1%U,XM<@XQ938UL.-X0
M?)C?:C\>$:K9MJ*@P#M8.*19X%"Y #(^?3D$TM)*V63#J\1+&$*RP43\EI'"
M41%)OFDY<*IZB5B+!WZG_P %H'2)-I.]7.M/4T1%PX;D.-ECA7S%)LF3*;80
M6@KS5)1:"HGJR@U6.;8^O$**:DNK:*@-XP\'*_5Y8/.(Z=&=AEQKHA@D$D-9
M,(#@J6"GC5VBVWK]"I\>BFI&2*C^=22^^7-:TXHJ<B2NIJUF8D/(K[1^(ML*
M<5Y!DE^L=XZNPB^6P&Z@PB;-9QE:E^>B>#,9"4F(Z,E)X"*UTIM7/Y'PU!X*
M9HR*LN14,BJ)<$M9<)WUJJWZK\"L33EPW)-1M.F+I##>][K35C362-U<QEEH
M3\:@V_H_I>]8N!JQ1XK=[69I? ?C+J9,S5"PH#3P]E1_"#P\_DUN#_&ZNUO;
MN>?#NT^;N4/US)AY?._BA<\D=G/-5ZOMHU>* 4 H!0&\I[&:\7N^?.PF#[-Q
MM7YW_*I^$/.ORI'V,DW)D3B?)W-8.N(V'*U^=H* 4 H"$3C7%MSQ(ZBLYJ\0
MVH6&60*RZ+(J1IJL I,QF)/R0&S[W<TO!D#Z4]5B%2BX&^<).1F0H!J)H4RU
MAE J?3"PY046AI6^GIPIKVWTPKUT3RYT%#V4<FL[N.SP++D?.E[RM.R[#A69
M?<:L3W&T+NQX+!^(B4E%D\-;:63V;*<>N9)M\_9<+HR(&WVTN6.")IPM014K
M14N23:K1O6U6_P"+KC7Q*K\U1=*^R>MDI<:^16XDXS.M25-;RB#0S)#0\#*G
M+&N\>.]&3-C""V0\&[U2'!,$6D9.08TNZV9#R&Y!##F6 @S"LEV>DM=1-08J
MZL5=N"QIC2Z]UHS<0H8Q0$?DRZPNUW;^Z3;)M!%:Q-C0VT-OT^8E/$<HEN14
M<,RL:%&BP#V!0$I8PY3&!..#*4=/FC/=TI*3$<KCD(5P+@@B:]ZUK;A?0HJ]
M:(V-(^%E.C-<[$C7:) 9)> ]<=-=F-*FJNL&4%X9U;"MK8V8@72:>HQ9#1VL
MO1("CQBE%4(Z4#<8[F">RH,KH"F 5( &Z%HHDZT;JW#%>L&DUM=<3JX5TIUY
MTIXWT)M'7EM.ALH3SX><\.-P%W/)\FR:9,JQ.:8R3 !BRC);M=JBF@8D\,<,
MB2::*$A!+=\"%\A[W$N)<3B@=:710X)+%1;$MAL>="W5UY=7/_QY_K_;_>Z_
MBY]GZJ&,="W5UY=7/_QY_K_;_>Z_BY]GZJ A?VW;C?<7$RA$FX4-(7R@.BDZ
MF02JVG%%8N"9QG^ @L3 0*@"8##'L$**'87#'$2P8F>'2Z.65KW@2;=56[VH
MB.Z75-KO]O(RM?!5%_\ Y;L+_)[>^[JR46Q=",-7M?2S!S;R6D36ESP*32]8
M&.Y6%),HHS+?TD'TEDEDQJD5)&=JQBC-UO@9XN9=>9THU#IT(8=-+-5+(!X6
M.*9I14"I .L5%3O52ZKHN6Y<MQ>!.)1=^TTFTK[Z4Q>I7[]FNEC-:MC7=/3-
MD?"^KFN!>5?>Y0%M##:$3-A)C+/L79 @\#36;TC.18:PIE+7F)=GF3+M5$@E
M=/7BIK -&()0P.>>4)X][#6E5<DJ.F-=E2T4&BUW\6CIQ0/6ZPZTD\'JV<ID
M_IBZF]L;%KC>SNB"% KH4IOR/VX]HZ:X)F-9<;;/.%"):38\$<*394R:JJI"
M*J"6&S-JQ(Z?;:BHI"NH)!PB/>8:-5:6.I8])2.L+HHHL$VF[U74Z.E:4>K'
M!&6_@JB__P MV%_D]O?=U6HMBZ$5J]KZ659PG")-/@.;") J 1)$]Y=V"Q0D
M2"P*E"I<'81YA@ERY8"P8 ( 0>.. 00>&(8>&-L<,;6MRK"\7O?6<AX0^)#U
M$G]L;6Y=>75?G;GGG?\ ]>>77;J[+\[6_5VWJ"!T+6Y=>75?G^7G?]G;SRZ[
M=79?G;MZNN_,#S,>)S;EQ)=Z[?LV,<=NN][W_-QJ]M[]=_\ [WZZ^WNY\\ I
MGE[*/86$UGGEQK*YC([2>8/UO(\F* 4 H"EGS^93O^3"]]5FJ\MGSX$YX>:V
M<'U3:SL<D<;9,Y_9.WEGK21QC;P>L/KRZF:U[_EY]OM(0[;=+E>W5V7ZK=?*
MW7?G^;!N<K/H6MRZ\NJ_/\O._P"SMYY==NKLOSMV]77?F Z%K<NO+JOS_+SO
M^SMYY==NKLOSMV]77?F!_5 * 4!C-N:6GTYJG/Y75H7,#80>+W2'$X@!A'**
M-G9D0SL5Q0SCAPS;Y-RB =\AM<VOX^T95Q9I@ZO?%.#,Y6$JE57#61#\)4SN
MPHSFY0Y+:^^[1US9T:36UCOO^5E/4W:[WNK[-'7SKXM-2YQ86G,K.EOPFY'D
MU98=Q(T"Q3UB$?MMOE!"3823HHM%2FJKH^]U*E'6Y8NC6+QK>RG>*,//4([C
MP=."/Q)UB"$)VLZ1X_BR&VWI@@;&O-I$U]3@M.D%P=ZE14='4XSS7TYL*SJD
M25EA%&C(^JI3>;1Y=+NTT53 AIHOO:T:==*FIW7N][$KW3 E#X;YS%2U<2%4
M;:!\;>+BG),T&GA+\A-(_'CBP>^,JNPJ\&!X-%,V>.1JDQLX"Q]F(;%Q-"):
M E)!4NW<"S:R1RH K%CA3"['5[<3/"A!@+Q.]9W9MIH[L7",9HK74I;?L:JK
M4CLZYQBB873E%75$0PH!8N$<J:'1"J@33+!GA"]K8FL0"X0^ F..%L1,+I$F
M]33Z&1][Y\.S9V<YQGPO$R7'JK#^[\5Z;Q?+K[<SZ,-QS0'EJS.QZ15]>1F<
M&VE/.12SU8RD*DMLDFKB*:3WB%WPL9E4<,(V,+*))*]UA<35U:U26U4HU7T[
M<;&\<SAUZI-/6V;=T$1G/,OL$HS;K>N&W*8F68E!L9J3MV1B-IK@N$9GWT9C
M4$(PB*APN7*@M,,JGF! U!/!+*  !D,6@B=5#=2D6I5NA>NE?6;-W0M;EUY=
M5^?Y>=_V=O/+KMU=E^=NWJZ[\QB'0M;EUY=5^?Y>=_V=O/+KMU=E^=NWJZ[\
MP(V>+9C:VC3TY7RZINTPOUYYW[=UM>;=?/*_/XK7YVM?KMRO>]"5CZ(NIG'K
MD'&% * 4 H"RL)VY\5!M]O5P_P"7;]5[V[-BX&[>5[<[?%?G:_Z[5BCQ6[VL
MS2^ _&74R9CH6MRZ\NJ_/\O._P"SMYY==NKLOSMV]77?G0L.A:W+KRZK\_R\
M[_L[>>77;J[+\[=O5UWY@:>/LJ*UL9!X>=K<_P VMP;]>665_P#ONKGZ\KWO
M_AV5O;N>?#NT^;N4/US)AY?._BA<\D=G/-5^OMHU>* 4 H!0&\G[&;QM?A\/
MB_7U;8S!?JRRM;\VXU[;6O:U[=79>U[=O5UWY_G?\JGX0\Z_*D?8R3<F1.)\
MG<U@ZXC8;Z%K<NO+JOS_ "\[_L[>>77;J[+\[=O5UWYZ_.T'0M;EUY=5^?Y>
M=_V=O/+KMU=E^=NWJZ[\P/VUN5N5N?\ C>][_P#K>][W_P ;T!^T!!CQF]>B
M\KK.H\H/C5I,W"@Z&ER9RDDPX!-J!!#SS7)&;C.)Q\[$!S.9WL1*<:(@&VNO
MAN9DXN8H?4S2DVUL$L>)-Q1!H7@=*TBT6UC1M4UW)._6G=2F)B)PM-39JTO<
M<B;%M?78BQXA-:P;&.=2A^/]H6]+)Q]R<O;&#O'7&!% ^H/<ZP!)5@Z$&H99
M2I,69U&;SBO+B&DJ2NI+"&[E; 3$U%C%5U2TFM25&]K3=Z6I+"KHK)R'K#*T
MS[+*$KK/#[XJ;$C:1W:Y%J48#0]A-0 H7< LHO2)GM+A<YW1UJ3^1V1*#NA:
M.'9)[7;SD"NN'&Z/@BF$,!3.%!A-84FE%"W2B>C'773DK?1.E4MRIMVES94W
M8:Y0R7-6+F!B@]RXP8U@#1?+H&"PUP\LK!& ,_[@P.?1$"R_NYXXWZJ&(Y%
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MLU7EL^? G/#S6S@^J;6=CDCC;)G/[)V\L]::./@\8?R,:_U&1K\V#<Y6= *
M4 H!0%LYGBF.9SB>0X?EU$+.*,I&:2TTWNCFSAE-"-MY5)B '[X*A$P3/))H
MJ'?OLDKD#A0^DG2Y=1)&BQHL"-@"='79>8/Z;:;:NP/*;FDM@;%2_L_-"@P<
MX_*O&?-FSNPSS8,28N!*6SK&9F!H[T&RS3;E(M\\JW]KQCIU23TGOU5%SM;
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M.5K-UM$5-$CTXHF4]2.+2FO'^Y.%.;*?GB>'/7. "\:=.%&U7^TFDL=;;O\
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M&\*L'5EL-DBM%E1%14PF!BDGC^(0M'$FDDXJ)UHTDM]:MM[Z[S8%H8Q0"@%
M* AOX^'BQ)@^=;4KUM(3H7E\-;HOHLF0H4% 1L\6W]!EZ_/=I?ZZVO5"5CZ(
MNIG%KD'&% * 4 H"RT)^-0;?T?TO>L7 U8H\5N]K,TO@/QEU,F9JA84!IX>R
MH_A!X>?R:W!_C=7:WMW//AW:?-W*'ZYDP\OG?Q0N>2.SGFJ]7VT:O% * 4 H
M#>4]C->+W?/G83!]FXVK\[_E4_"'G7Y4C[&2;DR)Q/D[FL'7$;#E:_.T% *
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M% 66A/QJ#;^C^E[UBX&K%'BMWM9FE\!^,NIDS-4+"@-/#V5'\(/#S^36X/\
M&ZNUO;N>?#NT^;N4/US)AY?._BA<\D=G/-5ZOMHU>* 4 H!0&\I[&:\7N^?.
MPF#[-QM7YW_*I^$/.ORI'V,DW)D3B?)W-8.N(V'*U^=H* 4 H!0"@% * 4 H
M!0$-\B>/CUJ^C7V"_GQ&E"RX$7C0]49,A0J* AVV>\9W"OF'3MZP>OU7@Q>[
MVHB/[VO'_99=FLI@% * 4 H#X<*?X#9T\^O=WUAWK6"+%[WUG)>$'B0]1)O4
M$"@/,OXG7C)=[/.,<?V<:M?;W<^> 4SR]E'L+":SSRXUE<QD=I/,'ZWD>3%
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MYN9Y" ?:)L;;IF@VXR)OFX'JVE\PG$-S53:O,U")W9TN2]K%1SO@%:N[%A*
M.*/NQ-Q&&I%D \6;8I*^+X^-1DBO3;PTEHK7HT>')AR)ZE@9YK&CO&?6]J67
MM^<V=X?EI48D,.V"D4N#"<VAM+-EO-U(KO5Q3R+D\Q#IA;Q54(EB34 UHN7
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M%K?L'B]6&.0BW<M52&N=; 3B(^^ S-&V1#ED<,D4P;YE6<J!WF 75W[$RDV
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MS0JBYW-%[-6%=9& !*#.(P=0R8H;I%)%P@ " CI+W!<6:>$"#@0R4[D\0@[
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MJ=-CI B#62/Y$@&%G4E- !6;[ B]A"OB.DAUE6&T<U01%2RJ4BEQSA1&3P<
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M;74(NF&UM%+*!0=61RBU8[=&,JB<$+D;(%U:R:HW31C0(09ZQ Y<KD+WL-T
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M6$U5$K]ZVW_RZ.1'203HI/4;28SGBZ'0PCYA(66L.<D)/D-\GWX@L=FO^?7
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J)!.)U& R81I25S(X94,<R9&P+X"6!P&,#B8X6S%$RR&2!)IU2=^S<?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>41
<FILENAME>g947560g61k18.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g947560g61k18.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_X8L3:'1T<#HO+VYS+F%D;V)E+F-O;2]X
M87 O,2XP+P \/WAP86-K970@8F5G:6X](N^[OR(@:60](E<U33!-<$-E:&E(
M>G)E4WI.5&-Z:V,Y9"(_/@H\>#IX;7!M971A('AM;&YS.G@](F%D;V)E.FYS
M.FUE=&$O(B!X.GAM<'1K/2)!9&]B92!835 @0V]R92 U+C8M8S V-R W.2XQ
M-3<W-#<L(#(P,34O,#,O,S M,C,Z-# Z-#(@(" @(" @("(^"B @(#QR9&8Z
M4D1&('AM;&YS.G)D9CTB:'1T<#HO+W=W=RYW,RYO<F<O,3DY.2\P,B\R,BUR
M9&8M<WEN=&%X+6YS(R(^"B @(" @(#QR9&8Z1&5S8W)I<'1I;VX@<F1F.F%B
M;W5T/2(B"B @(" @(" @(" @('AM;&YS.GAM<#TB:'1T<#HO+VYS+F%D;V)E
M+F-O;2]X87 O,2XP+R(*(" @(" @(" @(" @>&UL;G,Z>&UP1TEM9STB:'1T
M<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP+V<O:6UG+R(*(" @(" @(" @(" @
M>&UL;G,Z<&1F/2)H='1P.B\O;G,N861O8F4N8V]M+W!D9B\Q+C,O(@H@(" @
M(" @(" @("!X;6QN<SID8STB:'1T<#HO+W!U<FPN;W)G+V1C+V5L96UE;G1S
M+S$N,2\B"B @(" @(" @(" @('AM;&YS.GAM<%109STB:'1T<#HO+VYS+F%D
M;V)E+F-O;2]X87 O,2XP+W0O<&<O(@H@(" @(" @(" @("!X;6QN<SIS=$1I
M;3TB:'1T<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP+W-4>7!E+T1I;65N<VEO
M;G,C(@H@(" @(" @(" @("!X;6QN<SIS=$9N=#TB:'1T<#HO+VYS+F%D;V)E
M+F-O;2]X87 O,2XP+W-4>7!E+T9O;G0C(@H@(" @(" @(" @("!X;6QN<SIX
M;7!'/2)H='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q+C O9R\B"B @(" @(" @
M(" @('AM;&YS.GAM<$U-/2)H='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q+C O
M;6TO(@H@(" @(" @(" @("!X;6QN<SIS=%)E9CTB:'1T<#HO+VYS+F%D;V)E
M+F-O;2]X87 O,2XP+W-4>7!E+U)E<V]U<F-E4F5F(R(*(" @(" @(" @(" @
M>&UL;G,Z<W1%=G0](FAT=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"]S5'EP
M92]297-O=7)C945V96YT(R(*(" @(" @(" @(" @>&UL;G,Z17AT96YS:7-&
M;VYT4V5N<V4](FAT=' Z+R]W=W<N97AT96YS:7,N8V]M+VUE=&$O1F]N=%-E
M;G-E+R(^"B @(" @(" @(#QX;7 Z0W)E871E1&%T93XR,#(P+3 W+3$W5#$U
M.C(V.C$T*S U.C,P/"]X;7 Z0W)E871E1&%T93X*(" @(" @(" @/'AM<#I#
M<F5A=&]R5&]O;#Y!9&]B92!);&QU<W1R871O<B!#0R R,#$U("A7:6YD;W=S
M*3PO>&UP.D-R96%T;W)4;V]L/@H@(" @(" @(" \>&UP.DUO9&EF>41A=&4^
M,C R,"TP-RTQ-U0Q-3HR-CHQ-"LP-3HS,#PO>&UP.DUO9&EF>41A=&4^"B @
M(" @(" @(#QX;7 Z365T861A=&%$871E/C(P,C M,#<M,3=4,34Z,C8Z,30K
M,#4Z,S \+WAM<#I-971A9&%T841A=&4^"B @(" @(" @(#QX;7 Z5&AU;6)N
M86EL<SX*(" @(" @(" @(" @/')D9CI!;'0^"B @(" @(" @(" @(" @(#QR
M9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" @
M(" @(" \>&UP1TEM9SIW:61T:#XR-38\+WAM<$=);6<Z=VED=&@^"B @(" @
M(" @(" @(" @(" @(#QX;7!'26UG.FAE:6=H=#XR,C \+WAM<$=);6<Z:&5I
M9VAT/@H@(" @(" @(" @(" @(" @(" \>&UP1TEM9SIF;W)M870^2E!%1SPO
M>&UP1TEM9SIF;W)M870^"B @(" @(" @(" @(" @(" @(#QX;7!'26UG.FEM
M86=E/B\Y:B\T04%14VM:2E)G04)!9T5!4T%"24%!1"\W44%S54=H=F1'.7IA
M1SEW241-=4U!0311:VQ.02LP04%!04%!0D%!4T%!04%!14$F(WA!.T%10DE!
M04%!05%!0B\K-$%$:T9K8C)*;$%'5$%!04%!068O8D%)44%"9U%%0D%514)G
M549"9VM'0E%92D-W9T="9V=,1$%O2T-W;TLF(WA!.T1"04U$07=-1$%W441!
M-%!%03A/1$)-5$9"451%>'=B1WAS8TAX.&9(>#AF2'@X9DAW14A"=V-.1$$P
M645"05E':%521E)O9DAX.&8F(WA!.TAX.&9(>#AF2'@X9DAX.&9(>#AF2'@X
M9DAX.&9(>#AF2'@X9DAX.&9(>#AF2'@X9DAX.&9(>#AF2'@X9B\X04%%46=!
M,T%%04%W15(F(WA!.T%!25)!44U2068O14%A24%!04%(05%%0D%114%!04%!
M04%!04%!449!=TE'05%!2$-!:TM#=T5!06=)1$%114)!445!04%!04%!04$F
M(WA!.T%104-!=U%&0F=C24-1;TQ%04%#05%-1$%G44-"9V-$0D%)1T%N34)!
M9TU20D%!1DE227A15D5'13)%:6-9155-<$=H0GA7>%%I4$(F(WA!.U5T2&A-
M>%II.$-2>6=V16Q1>E)4:W%+>5DS4$-.55%N:S9/>DYH9%5:2%1$,'5)24IO
M34I#:&=::$I21E)Q4S!6=$Y62T)R>30O4$4F(WA!.S%/5#!:6%=&;&%7,7AD
M6&PY5UHR:'!A;71S8E<U=EDS4C%D;F0T95AP-V9(,2MF,T]%:%EA2&E);4MI
M-'E.:F\K0VLU4U9L<&59;5HF(WA!.W%B;DHR96XU2VIP2U=M<#9I<'%Q=7-R
M839V;U)!04E#05%)1$)1545"45E%0T%-1&)114%!:$5$0D-%4TU514954DYH
M26=:>&=:17DF(WA!.V]B2'=&34A2-%-.0T962FEC=D5Z2D121&=H85-5>5=I
M63=,0T(S4%-.94I%9WAD56MW9TI#:&=:2FI:1D=I9&MD1E4S.'%/>G=Y9W F
M(WA!.S K4'IH2E-K=$U453504FQD65=6<&)81C%E6#%2;%IM9&]A5W!R8D<Q
M=6(R4C%D;F0T95AP-V9(,2MF,T]%:%EA2&E);4MI-'E.:F\F(WA!.RM$;$I7
M5VPU:5IM<'5C;EHV9FMQ3VMP86%N<4MM<7$V>71R<2MV+V%!07=$05%!0T51
M35)!1#A!.514=W!01$I$2E@P-59+4'A::V$F(WA!.VI#:&]Y:TU$-V<Q>%8U
M5EEF:T\Q;SES-BM96F56=&,V3&1";'1W1%A28EHW96<U4T]!6G5F2W!"-#E+
M3FER3B]*5GIQ571P<4U';U@F(WA!.S!U;WDR5V]81G)(9%1P0VMJ4G@X95!)
M5SAC16126'-G>%9K3TMU>%8R2W5X5C)+=7A6,DMU>%9*+TY8;#%.9C R1WIA
M9')9=UAL;F4F(WA!.W!+;DDW,FQY:R]%<4=114])>74K=W)Y<%5$1E=!-EHK
M561Z-55S1S%',CAX6$IN,'I1-VUW:F5'2DEM3$<X:W9X2E8R;E5$-'942S@F
M(WA!.V9E;W=Q.4DP2V5A-#!45#=I6G5C,#%T1$I)-3=S,%E*3S-I5&=62%EQ
M-T9867$W1EA9<3=&6%EQ-T971V9M5BM7.%AN8414;$XX,6HF(WA!.TYP<W-S
M<4U586%+4EIO5VIA3U=%4U))-FML83$S-#%516-J:7)(3%AY2'%N:TLS+T%%
M:EEE6DQQ6#8S<6UK5SEX8FU',S14>%0S.$XF(WA!.W)*.5EA5EHU1V8P-3)6
M6&IA36A1;TYE27A6-G1I<G-69&ER<U9D:7)S5F1I<G-69&ER<U99-35,+W=#
M;#<O,C),=CA!-#!W;%=2-$8F(WA!.V1I<G-69&ER<U9D:7)S5F1I<G-64S=Z
M3"]W06\U<78O041",T@O2G!S5F0U82\U4GI3=BM93S,O04]44S1Q;4]+=7A6
M,DMU>%8R2W4F(WA!.WA6,DMU>%8R2W-A+TU(+VIG,G8O04<R9$0O-W)&<&ER
M2F-69&ER<U9D:7%7870U;SAT85!*2$9Q*W)75VY34V=T16PS8U)137EG,$HF
M(WA!.U533712:$5395-O2"]L63,U92\Y5%)P4"]39&)F.#$T94$Y>7$Q;C4U
M.&LS,3%(85=8;4148G$V;5!'1S-H=DE*2DAB=U9&8W-4.',F(WA!.V5%.7EP
M,VM69&ER>FY79DIN-6LS4&UY*S%,5"]!1$-T='!5,G V5&0R;&\P.7E1;'!:
M=U-*97=T16]#56UK6E<T2W=$,"M)9S1Q;E@F(WA!.S5F>#9K;')R2S-K.$TQ
M,DY7=7A.3$1#.$UB3CA/-GAT3$MY:C),;C4T5EI44V8X06Y8+V=4+WI69U8Q
M2B]W0V1F*T)0+TY72W5P4"\F(WA!.T%$<B]!34-F*V%S5F139BMD93,W2BMN
M.7)&6%5N,BM.9F8T5"]W03%9<39K*S-X<C<O0V8K87-69'AN<#ET82\V<#A0
M.6)&5GEH="LF(WA!.U)".$M#;CA4:7):-F5(=FER>4Q4+TI0-6\V5F]S<VUS
M95IK=6QT.4)U-U<W5C5,;3A74S9A-VQU0DQW;3E+=BMI<TEU6F)K3VQ#;W@F
M(WA!.U8V4C5B13,K2$Y,;S8O-WAW52M%+W=#*VPO>7-65$EI9G,V+SA#9BMA
M<U9D4V9F-#$Y=FA0+TY72W5P4'8X82LS=VXO04IQ>%8Q2B\F(WA!.S4Q+S1%
M+SA!3E=+=7!0.$%Z<B]W2B\U<7A6,4HO=T-D9BM"4"].5TMU<% O041R+T%-
M0V8K87-66&ET0EAC.7E.<U934'IT<&5U87 F(WA!.S57,4-W,$LW1FQQ,#9+
M3%,U85-71E993W)%1U-%1U9!>6=Q4VYX8C=5>%8U,V-E5B]W07AD2# X4')E
M=G<V:%I483%O2F%+55A&>DLF(WA!.WA85F)90F\U2&5"3&8T;55-;VIC3T8U
M9D-Z2$98<F-R=$9'.'-K<V-C4TM79#)&1E912VMS4S%+1$95;$AN:GEE4E5E
M63E+24EQ1#DF(WA!.V%G<'8P+S-B:7)F*TXO2T@O57@V6"\P:W<O.$%66$95
M>3 O57)057)F-GIP,3EB,W1V>4M'83-:6E4U1'%V2DA)<4U69D]F+T%$:S@F
M(WA!.T@O>&YP2$EG;CE(2&]+9C=V8C-/8GIS9BM*>'12,%-F569Z9VAV;U)$
M3&]T26A*851I3#9W0VAK<WA60S0Y2&MY;'1U1F5)46Q14',F(WA!.W-U6$A1
M.% X6&8P-R]J*T-W3V$K:5@K6$YB3W4O;D9O;7%I2#9U8FY5-UDK;7HK<3-W
M9TIY9#9*>F1U4$IM;TMK:S5(5C0K1%1M4&0F(WA!.RMT8V-R;F(V.7!0=#AA
M*R]W;B]M<D]A8WA1=$Y6,'4X;G5,93!V24QM-'1'0UAC355I3SA417-!2D95
M:V]A;W<S.$1I<4MX5FIN:W8F(WA!.R]P92\Y=&DW+W=#3DU*5FME0EA9<3=&
M6%EQ-T9867$W1E9L>&-15S!%;'AC4TI$8G=O,&LP,&I"55)&1E=:;4Y!04%+
M:VY&5DA4=%,F(WA!.S W53=/3SDP,C9H=F)+6&PV5GIB>4Q,13-":6IC6%%S
M<&]Y:TAF<FEQ2#AY+W=$2T]A<B]!37=D>"]Y86)&6&57=CA!;$A.2R]W0UDF
M(WA!.T\S+S5.3&EQ631Q-T9867%W=CA!3FHX=TQN>4XU9'1T5G1R1DY1;'5,
M>$Q147E3;4912&EK:TQC;%=1+S=Q<%-N9DPY3F<X5V9$9$TF(WA!.UIY-%)B
M1'1.+T]N>FIQ5VIN5DQ44G1+9$9S-W4O:W1J9EA3>DI&66Q&:W%$84)35SE1
M8T],1E1V=4-$;59046--=45N<4)Y-R]I=T<F(WA!.U-X858K6F8K8VE03G9L
M-D=Y:W9F3&1I-#%#=VDQ2T%26#!P<$1-1TMQ,6)D84XX3SE+:C-Y565Z=4E3
M26PY2DDU9'E01C-!-S-V3V$F(WA!.WAU475O-G)P96U10S0Q2SAG<W)C='=%
M,7I):U-&<44P-4]61F%+5&EQ2WA6:E@U9R]W1$A"=&8K,GIO9B]D671-5E14
M>DPO>6IM<2\F(WA!.SAW9'@O=T%M;7A6-6IF.$%L2S X>"M8.4-J=41';W,T
M,&Y6;FE%:F-M=$AJ5&<Q5EI#:VIP2E94=G=P:%%H4$PO=T-7.#)K-G!O=#8F
M(WA!.S)P<DQ&;W1R3&%1,C!6=C919$I!84%S,'-P059N8G!U,W<X:7A8:U9,
M,%1Y2B]V4'$S+V)2;"\U3E)9;%AH+R]!1&Q"+W=!<&YP2"\F(WA!.T%'>FHO
M=T%N,GID.6HO>$].<4]J>#-.,C1R2E!Y,"\X;4PU6B]W0S)J0B]X3$U,=$@K
M-4QB:"MP.7%:>7)N4$DO=T%L2R\T<S@Y<DXF(WA!.RMJ,79O<C<P-WA,2T<Y
M9VQ,:39U>4IP,'542D-P;55H:T5-:F9$44XP1TMP=G)*+T]196%R,71,16)A
M0TY5,'(V:VIT87%P,#113V0F(WA!.U)Q4T=M1EIU24I.5R]K2%=Q<6,O;"]*
M<50R=7-T95%1=S-:,6$W33!537IZ4G$S=S=,23!55$U08V]0;&A6;$Y:+S5&
M+W=#0U O3D\F(WA!.T)85FXO:U@O04E)+S@P-'$V<R\X:2\X04)(+VUN1EA6
M;B]K6'0K,&9P+UIX5C%:.79G6#,K22\X,#1Q-G,K,W=,-R]%9BMA8U9D>6XF
M(WA!.W Y:&$O=T-S9D0O5GA622]05G9.8RM3=&-I53A73FQ/46]E,E%/1FI,
M1TXU3'E/5S-22D%#:G1):$%5:S1Q;#,U4W9Z+TPO5&Y31TLF(WA!.S,U=&-S
M26]B:7AU-&=7=5I394TR;7@R.6\Q5W%F,V%#;E$O141I<D4W02]N8W5J4VYZ
M16QV2D-D075V,&=S>C)Y3#EF3C-*4VI7<74F(WA!.S(Q;G@T,$A$>%!+<'=Q
M.4@X=&UB+T1M;#!29CDT-$MF168X0693+S5/0E5R,40X>5!+*VYP9%-88SAK
M549K.&MD>F-M,79406I1<UDF(WA!.S5+>DQ!62]H9%-P26%M2V]',R]/8CAV
M<FU.6F)B57A.13@T=$DS:G0W>&QA-6-65T5&64-056)S=EA&5U%A4#5N,"]7
M2C=M0W@Y47HF(WA!.U=Q4GE44GIW,TYS47-X8U)K0V5+4&M#66XK>E=L359E
M868X04]4<&LO=T%#-EIY54%F<&%,8T5N+VHQ=6996G-/>E W-&9&<7IF4U@F
M(WA!.WIT6C8U<E9K>4Y:-FAC,GI24G1$13!-,&M:5TYN.5)K6&E24E,O>$5E
M3RMD2DQ(13AW2$-%:45&<3DY93-D;3,Q<31K=5!1='I$0C8F(WA!.W)S+T-*
M1E!'3F524$96<G-"=&MC:U%)4W)U2UEN,4(Y-C%N+T%*1B\T22\X,#5X<G-8
M:R\O3U)X6F9+=6Q04#E15WE.+W=#;F-0<4TF(WA!.U8W2D9#-S(P=VEM16QG
M9E=1<7<T<BLW87)-<#(T-W%S*S@U1'I.+VA/*UAY=E).9#E.4EEN:D5E2C5+
M1TMR3U9I3$)/6$5/471A5G@F(WA!.U8U.61Y+VUU3$QJ-6YT<EHW0CEB,$PP
M-4=N:58T<6%R8D=K0U<X3&5Q:DAG1TUR27ET>4LX;#1J1EAP6&U1>F8T9#%8
M-%9P.51U4#(F(WA!.VHO=G!V.&Y&5TIA1B]W06-45"\K66%(+T%*3FI#:$A9
M<6DO27AK.416=4MG:CE)>3=K:V8W<6DY:FE5=D0O.$%N2C1V+VI04T]105 F
M(WA!.S9/4%$Q+S-E,W--,V99+SA4:F%J;SAF>F1U2WE0.'1A+W=$2WAF3$Y/
M=C929R\T;&U&,FHO8VQT=R]5*S!Q>C=F079V.%(O-7!Z;%@F(WA!.T]E3R]K
M5#9Y*V(O4'-D,6%Z=S,X9#%#=#5.3$Y$3DA,2C8Y,WEE15)7=&QW4FI5-W)U
M,5111V]X5C=,:7)(4$IF+U,Y+W=#,GAD+S@F(WA!.V%94W)).$-U>%8R2W5X
M5C)+=7A6,DMS5R].1G)69GDY,34W<317,71L=$AA5U)Y-$)59%EX-F1X6DU7
M;"MW<2MS;TI)0G%0:$MQ2"\F(WA!.T%#:'1,93 O3#=3-V4S<S5R0S-5,T)I
M=$QI0U,Q9$9E-6M99G5P8FDK8TME5E9*;6)K=$0S<&ER25!-=B]+3V%R+WI"
M,T@O2G!S5F0F(WA!.S5A+S52>E-V*UE/,R]W0U13-'$X+W5.1G1.8S!05G1+
M=3):8F4V,4155FM:06I-2V%J37=O2D9K43=J.7!334M%1B]Y<F92:D9:=W8F
M(WA!.V0S:G@R3V]187)%1V5-<S%X8CAL6#%(369.,4M&54E**WEI.39K<5=9
M9590*U5P,6HO;4(P+SA!-5!8=4)72&8X-5 O05!+0V%:+S(F(WA!.S%O=BMO
M5S5Z661M9C-W*TQ6;2MK=FUB3VYC1E%V9CA!94]F+T%)>'8O=T%23U8U9F]0
M=4Q+2$U0=B]/361I.&(O=T-C;E!76'EN<',F(WA!.W(R.#DS64QD<W,X3G1.
M1$$V>4Y!+W!Y17DR=#%604]996IP.$I)3E%35E9E>' Y:&1Q8D1B1E=.+VU$
M+T%-8T<Q+S=B3V@O.3%I,'@F(WA!.U9.4$UV+TM/87(O>D(S2"]!0V%B1E=(
M-D8O>'A.4#A!*UEA2"]K,DU+161I<4XX:68W>C9T+S(P6F8X06LQ1FE5=D0O
M05!N2T0O;$TF(WA!.SE)+S=:>"\U4'1M-S=(+VEC8E5D2&IU8G1X5U-F;' O
M-4U8>7HO,C!94#A!:5=96&%0.$%C;'1W+U4K,4TU5GIN;'8U2%,V5DA&<D\F
M(WA!.VYA2$ID>6%"8DYB=%E36%5U;D]J=39-:S=24C)%55A%3$I&=UIY>F\W
M2U=5,3565E(O;5!Z<"M9=&HU=$=N860U6&MU9$8K=&%D0TPF(WA!.S1)6E1*
M0F-'8C8S2T=35E5J.5 P,$,X>#A0,FXR6F-65&8X04PK-W5*-UA76C5B2V$P
M:VLQ83=:-U=9=VU332]$.$Q'2U-73W8K<34F(WA!.TAV:%9'-G(U=E-W,4YT
M3UA43'DX;E-'3S1K3G5B64MQ4W9):59-,#A2<51#,U%91EEZ869N;#59=DHU
M64QB5#<K5U-#,VUU-4]0,5 F(WA!.VE)3&%:;TI:03,Q;FE1<VE-3FIV,492
M=FEQ82M8+WI-,#=89C!62F%A6&9X,G5S:VEY=35H8DMH<$1*3E9L13=39T9)
M5W X1TMO>C@F(WA!.WA,,C=T9GDO.'I83G%:8F$U9S!M.6QG=4EN0U-2>4QB
M3U9D2%9G>7-P1E%2.4=49TQK1F9.=FM8>G)$-FPT9DYN;698:7=%0G-51V\F
M(WA!.S9I24139$1-2DAG;4UQ;&]Q<G-H;W9):C1U27IO3E1O4G0T8U(U+TQZ
M8U1(;3=Y=CAX96-O,#!A*T=K96$Y66TQ439W-U=4>#9H<7DF(WA!.V].3&%,
M:VDP;FQP5EI$>%!);'%J<5)V:FDP231H>%)(1'<O-TI:6G1T:C%E-F9K6G%E
M<%@O=T-6,FM85B]08U@Y,CAL-DAU<FE5>E,F(WA!.W5%=EHQ6&Q*2WAC.%95
M2TMN=#1:<$Y805)Y>4$U5S5-1%E#8R]M2F,V0D(U4G4W:GI"83-6>G!K36M$
M>7<R5'9(8VQH36YP=D<P36LF(WA!.TUL565J9D,Q84$W2'!M3WE5+WEZ=EDW
M<GE,<# X3VQ85VMO<7EO;6LS:SAT>F-1:4M6,$5B4S-*.51O=G=H:4]);W5W
M1TMS46HX.&8F(WA!.VU89GAA=&%A>#53:W,W26%69GET>$A&;&U3.&MT-# Y
M9#5403E,64)Z5&0O=$HX2D=&6&]N;'52+W=$1&UL+W5M4#A!;V-(.'8K*VPF
M(WA!.SDX0W-4,&8K-G9E,RLU3%5T=CA!;R]N=V]2,DMR+TMZ1F9.3W-5470O
M;T]N.4MF-RMV4$5J06QH=B]/5')S9DEU;4%O5B\S3%)B;6XF(WA!.R],3&,K
M0D]B1'-Z*RM(>&%S,S!L.# U,#=G<48W+W9(4"]X:F8O:4IY=DPY0CEX6E$U
M:#DK96\O*RMM*SEF-C5X:G-8;"\U,5,V5&(F(WA!.UA'9S9J23DR=FU#,4UR
M84I"851A9$-Z4#9K1'IK=F926%!P:4].3V)/<3A/24MU,4=&5EAO974S;7%7
M96@S;#-P5FMD5#%+2T9M<S<F(WA!.T5/:V9Q>3 K1E,W;%9!<C%.96Y49D98
M:S9E95!0=7-A3F%1*UHO3$9X64Y,<3-L.6QU26]$0D1#+W=#:S=6,U-B-GI,
M-FIC:48T1THF(WA!.U=!3&-';U9*>%8V<#5K:V(O1'5Q:C R+S-J=4XO:"\S
M,#-V:7)%=$,O=T-/2G O+T%$1%$O=T1*<UE523=&55@U1V1H0G%W0T9V.$$F
M(WA!.V-J3'5+9C<V:3A335-L-&8O=T$U4$U4-7HP:7%L9CA!8V-D:E0O9C=E
M0D]B=G-F*TIX=%(P95 U=3-&6D@K5W8O:WAF3$\Q9CEY34<F(WA!.S,K>7I#
M-U(O=5,R-&9Q9F%8<5!T*S9B-S$O<FY+=6-P,DYH63)&<6QP65<P5G!A>#$Y
M3S-G4EDT,35-5V)I:4%+2W-35#<T<7(T<7@F(WA!.WIY6"]!3DPS+W1S6&8O
M1VU%<6QU<W%R96,W-5=!6E<P>7A"0C-"0FYV3599+V%F;#4U3G-R:S-.;'!Q
M,FMP:6UT>4E*2EEK359W-U F(WA!.TI'55(Q5&E7:TI!<#A/,4MC5F]Q;4=L
M-EA9-EAQ;FQE=W-9+U-T66(R8C P3$TU*TMX=3)9<S=L;5ES>D5K:S%*>%9K
M2#5N9BM3,C@F(WA!.S)F.$%B1S%$+W%&:WE74#9H-S%F1FUD;S9X,DMV<E0O
M04IX."]W1$I384PO04U:3"]W1#=Q1GAN2F$S*RML-S-962]P1%!R>7ES-S8F
M(WA!.S)E,79923=Q,FMP-FM%>4Q*1S-%:&A65T)";U%$;4MZ5G-64S=Z3"]!
M36\U<78X07I",T@O2G!S5F0U82]W0U5C,'(O04IG-V8O:S F(WA!.W5+<U P
M:BLW=F8X071P86PO=T)2."M&0T]X5E8X<68X<%1R2"]-1' O=T1Y979C0U=(
M9C@U4#A!+TM#85HO,C%O=CA!<49U8S)(6FXF(WA!.SDX4&DQ6G9P3#5M>G S
M0E5,,R]E3V8X031X=B]!35)/5C5F;U!U3$M(35!V+T]-9&EO5%=&:E!D5SDS
M3F)24S-6<'HK<3-$;W)34F4F(WA!.V]V1B]48VIK;DID;7 Q1TMQ*TMS82]-
M2"]J9S)V+V):,% X03=R1G!I<6%E6F8X06Q(3E8O=T-93S0O-4Y.:7)$.4,O
M-#1M;B]W1$TF(WA!.TY$+WEB1T9#3WA61RM24#DU.5<O-V%-=B]*<4Q%<&5(
M+W=$3U5(+TM:-E(O,GIJ+T%-;C)Z9#EJ+W=!5&IA:F\X9'ID=4MY5#AT4"\F
M(WA!.T%#679L;B]T;W=F.%-Z0S=2+W53,C1F<69A;6-Q-7IS5F5E-C<K8FM7
M:RM:-3E%1VY#-U=$561,,#%P-V4T-7E+9%1J;&M:;F=73FXF(WA!.U9O=E(R
M444X*U=X0G%-5E1B.'8Y470W=3$Q;39I4UI9-617=3-26F]*;TI!4&@K,49+
M:5-)9EIL0G=Q:'1664XU,'932R\X04A.<U(F(WA!.W5#4#DS,VYJ:7$W1D-'
M6F=V;4AY-E18+T%(=6PV06XO04M6.3$T67%M;C5M>6]F>3(X,3=.=F\Q+W=$
M<W0S=%I08DI9+W%(=E,K3#@F(WA!.S=2,6IS5F974"]/4#!Q<BM5=6EG:'1P
M3"]O<D@O:B]U1#)'8VQR9C<V6'9D:&HK:U!2;%E.5VQD='1W4BMV359M-6U6
M5DQ-47%Q2VLF(WA!.VY9041&6&Q%4#5X>&$Y<#$Q6FY36%9,<E$W>E5"8U=5
M<EAY9G4W>5=W0W(V8U-&;&)H-FAF8FE$47)T:%8V2#5B;5%E6$Y,,F(O94\F
M(WA!.T0Y:'8Y.4MF1$%R13E(3EER,"\Y<DQ5=BMO*V9#:$A9<78X04MZ:&9.
M3W-60B\S:# X-T%N<$YE94%W2EEB+WIK-TER95)D34%"+S0F(WA!.S8P6%93
M3VQR8RM)>EED;68S=RM,5FTK:W9M;D]N8T91=F8X065/9B]!27AV+W=!4D]6
M-69O4'5,2TA-4'9Z,6LX1R\T0G9L-%IX:G,F(WA!.U8T3E%#3V@S,S(O6&EQ
M5&5C9DUC9FQV>7IQ1W533$<V5T5F<7-K,'!H42]%1F]85DI72%AB:6I%;EE!
M;D98;E8Q*V%6<C5M<U!Q33(F(WA!.VYY5T4X1W0V0W-01FUU:V8O8W)B3S1E
M4TM0,#0R051K;TQF1W)+>6XT<4)6-E8U:VQ8+T1U<6EJ9C=X,T@W3&8W-F(R
M>%9I5VAF.$$F(WA!.TA%,"\O;4=H+W=#5%EW;U(R2V]V>4Y)<7=A<T-$+W@P
M6F5I:R]W0S9O=D%9;$QW+R]N2C5G,VY04T-++SAC-#E14B]U.79(3C,R4"\F
M(WA!.T%"3TYQ3VIX+TXR-'))+WDQ3E!Z1CAS;B]T67=F.%-Z0S=2+W53,C1F
M<69A6')*=',R+RM1,SE--59Z;"M+=7A6:FYK=B]P92]W1&(F(WA!.UEU+RM.
M34I63'18+T%/53%V9CA!=&TR4"]**SAX5G9&0T@O-F%0>34O=T%X,'8X03-4
M-W)&53(O33<O>5<S;7HO=&IA:"\Q0WE:3$@F(WA!.SE1.398>%IN84]S9&ER
M-C O=T-C9E X07E5;6DO=T1'4R\X02LV:&-:>5=T+W9P93DR1U V43E%>D9:
M=7A63'9-=CA!>6IM<2]W1$TF(WA!.TAC9CAM;7A6,VQR+T%*4GI3=CA!;41T
M+RM44S1Q=R]34#=U.2]W0S)L<5@O049(>C1523=&5EAY<"]Y;$]S9CAW3VXO
M05!*-CEW2EDF(WA!.V0O>FLO=T0X;TIP;B]B5VDO=T-O5S5Z661M9C-W*TQ6
M;2MK=FUB3VYC1E%V9CDT-2]W1&I'+SA!>$4U6&PK9RLT<V]C=RLO.#1X,DPF
M(WA!.W-69&ER1W9Z0B\T-$YR+S(R9$0O04\V>&%9<6UN;5@O04I2>E9F.$%M
M1'50*U1467%W+U%V*T]*<"\X07I$42\X;7AH46IS5E)V:U0F(WA!.R]E9E9V
M*S)J3"]Y86EX2UAH+SA!>FQ"+WEM96MF.7,T+W=$2CES,V99+SA!130R;S90
M2&,S8FES:R],5"]W06U,-5HO-V%-2"]%<W<F(WA!.W4P9C=K='5(-FXR<&Y+
M=6,W1E5K.#%E8TY).'-2-F)*<69Q0U!5-S9(5&]844M64U=C359E47-Y8UDQ
M-$AK9"]L:7)&=DM0-6EF;"\F(WA!.T(K;798.'IA5$8V=7$S37-83RMT;#5)
M,TAI-C%F9%0R3TMO1%9F>D$X:'8U=74U,#AY85<P1&%F6F]S;W9B8V]84V$W
M3$M'1#!Q;V0F(WA!.U-2-VI&5C,O04-S1'E(+S%-;6QF.4IT=B]W03$T5E50
M.&9E4F8P.6]-=CA!:5!3+U-H=DI8;68V-V(X554R3GEG6FIZ,DA*9TXK-4<F
M(WA!.TMP;"M9=C5I+VPY8R]L.35N=')B>E!P33EX4'!..4A$1$AF5WIU-W9B
M3W%Q<7$U2EEK,$%'4W@O55!E<C5#+U,K:R\X='-(+T%#3E0F(WA!.RMU9&0K
M67@O>F\O34]U-$ID>G8P=G!0+T%#,G=F.&I5+W)J*UEX+WIO+TU,=U,W;C%$
M*U)8;C=Y3%EF;&)O.7!F95DY3'1,<4]3.4TF(WA!.VQV4&4R.&-I:#<V9&QQ
M:D]#2W%W23ES-69714A,26IV8RM!.4EE;S9.-6LX=38R:W(V3'%L<'%A445#
M6G)/94LT0T9Q;%%X:EIU3F$F(WA!.V)6>D=:2FII<D103UAN=GDO67HV<C5A
M=DI(9W9F,$Y,<4AR=49%2'!U-70Q5&QY-65O6D0P-# Y.%9B.'8O;40U2FDP
M2%19<$YA=%4F(WA!.VMJ=%E&9%1)2VAL:E5%2$-R1CE,.#4K5D5J=2ME<5<V
M.#<O54I&<30S4U,Y;61'*U1+=TEX46I0.&(K568K<G1B9CA!0FI&5E1Y,34F
M(WA!.S4X;U%E63E6;6TQ93)32U=Z<U5J9&Y!1$UK=#)702M19&9V>%-X3"]!
M2GE-.#,K5V16.&PV9D)P=7!16&-Y87!&23AC3&-M0T,R=48F(WA!.TQ%1'16
M9TUZ97IP0T]912MB6&Q&>&902#%Q1"MB.$0O045Z;R]W07AJ+VY"=R]$;#-+
M5C-C=W1A5$MR5DIJ64%!2'%19F))6F,X1$4F(WA!.S=J:VU%2E=.;C-"+WES
M8GE,+S%F3%0O:UE--49Z,#AS3"MY,4,P:G9,2UIB:3%M0DU5,%IQ<D%%9S!0
M>D=+<2M+=DY03G8U:2M73E$F(WA!.W1R<E-Z8T-Z=61+,3-2-#5F<F)24D-5
M439Z04I:26%U4WE2;4(K4DE&2U8K>E%L5FM0;4AZ;#50:S!$530T.60P.35(
M=$HQ4D9U;T,F(WA!.U-41W=!040Y8U99<F]V;6IY>6UJ5T-0<3EK<G)B>$)L
M3GA%0T-%04E)3%E523,O1F9L8B]!2W9&:B\P:W<O.$%.5TMO=GE6-74X<5$F
M(WA!.U<K<4-B5W)#279F>4]G935H5W%M3TUC:%9T>'1I579&+W=$;DI46&1%
M=G9.*VMY,E=O5S$Q175N;%=K:&UJ:U5.-GI':$MK:71-,U F(WA!.UI-=T]+
M>E1J-F=%,51Y5#8W6B\W+VHO-$YF-C5U9D9H,VHU=4YW2'5:1BM85W!A9$0K
M64AL>6%A-FAJ:&HQ0T9P2DAK5E96461Y>$HF(WA!.V]!37<Y9FMI8TIO:'-W
M>$EL>6999BM.=DIN+U8O=T)/+W=#:W5$+VUV3UEC,4]S5E5,=E0W0S@Y2#8U
M8E)84#%A5F)I,SE:1FLY3V$F(WA!.T]V0U)/45!&,7)S=S-'2W$K2W-$,#5F
M>EAT=DTO;5<R=6Y454Y%;&=L;3AT6#AO=&)D26)G,&%/,F5+3&Y.26<Y5&=*
M2$E0-W1Q9S@F(WA!.VQ/2W-:5%=0*V-I-#=E-VAH,$=/6# T>$Q96$8O4' W
M,TUS=W4T-GAZ9E9P8F5"23)T=65Y>#%',S=W;D959DQR+S4X5TM85GAC84@F
M(WA!.UI854U4-FUX.45";4U6=%I)9%!A0T=/-&%8+U-B<%@U4FYM-$)P56)(
M1E4U.&UE6F905W4V2DUU<3999$@Q5U<Q;6MT8FEA,&QH5DHF(WA!.T1)>5<O
M2S)K:VQ&94A#4C!--$Y4>#=&<U939E18+U!34%-D46QU-#%N,5)2;W)7345H
M<U5I6FPT9G!605EI>#1T4G%S>$)Q85)Q2T$F(WA!.VQ60U<K=68X-4A+64QI
M8GDU65!*3$E6=4Q,,6]"1D9'5G,V3W-G;CE1;78Q;F)F:B]L:FI65FQN:S-5
M4'I0=4Y494QZ6G!T;&$R2#$F(WA!.T='6DQM,&]$.6-K3EI93U Q:3101TE(
M:GEP4FE+9S<P0W)-8U9D:7%H*VHW1#8O*VM0<3!8-E$Y3#9V.6,T3#8S;SAU
M9G K<%1L=S4F(WA!.V9&>')3=4MR-W%/85,R;&IG;#E#9#!:67 K269G-49&
M9FED;31N96AX5C5Q<S,U,' U4W9)6F)E4V)864QI3#9V9'=386)&3F17-70F
M(WA!.SEZ2$A)<VQT8G8V=U@Q9E4U.5@T5DA!67%L.&UU9CA!3U-486UY4658
M9$YH<V]B951H3%!,1$M*6E)!<F]R0T\U:69K,'E'34]/2S F(WA!.V9K5C)X
M5EIR=FTO."].13 S5#5&.'8R*W!45')&0DU)8EIR;59,:C9N13=T24QE-U)F
M5&MU;6MJ-3A65TY5<CAF2F%Q<W X=UAV-6LF(WA!.V%H-51-+VQQ3T]Y,39+
M*VE54E1X8V96=$$T16Y*8FII<U(T='E01G!.;&]P-4@T5E5Q=3<S.#AR5%-T
M0VQS3E!T.5-V>D)/;7,R.34F(WA!.TIB4E5C,U58,60R849K6#%"8F5P>3E,
M-$]65%)V:$)646UN-G8O>FM1<SA&=%!O;6YT1DMT=#8K;WIT0V929#1R5F)G
M*VI"9$HV9VHF(WA!.V,S1%5Q3U<Q0T)11E9N6&MY.#@S,V5L4WDK83='1%0Y
M4T9Z36M51G5W6D1B<3,W;'E22DXX5$PQ*TPV0FEQ9EEQ-T950W5G-D=K<S@F
M(WA!.WDV9&),3F130V$U:T5-66%344%!3S5P5FTK16)N1E9(5CE/-#9694YP
M9'!:+W!.64I$6F9766E94%=#;C O5D51.5%P>7!Y-#<P-EDF(WA!.W$X.750
M3C-M>&9*-F%M=FQ#4U!723<U<F$W=&8P6$Q/4D0Y6&%E2U-#0EI5:VM6,CE/
M1FY,2T5C<U-+3'56879F4#-M:4Q62C1,8C@F(WA!.W5P<')3,G5D4W0R6F\U
M;$US5FEK8VM&>$4T=%=4+U-636E2>#=H;D%P2C1H54A:+VUN<DYV86%-,VU$
M>48K:EHY6'8Y4# R2#%#,%8F(WA!.UAV6DQI2U)Z2$IB9W$P6G11+W X;7%R
M<651>%9K5CER9FU$-G)O171P-5IJ4U,K,5=+>C%32U,P;6QE3WE*;SAW5E9I
M14I)4$QL27@F(WA!.U)!1'4W54=&5T\S+T%/65!N:4,V=DQ+2#AU-5I8=&YV
M>D9Q2#%753(X,&-!=7IB0D522&9L2CE8:$9A:TU8+UIQ;%%Q33 O.'<O36PF
M(WA!.S-F5U549FQN9#(Q;F,S,79:6$9X3W)Q.%5D>$Y,2#E:.4U7<$)I:6IH
M1'E&;E=N2E(P4$Q&6' S-DTP,R]L:V@O=T-282\P>%9%-'$F(WA!.VQM<F5:
M9$4P;3DP*WDQ0S4Y0S4Q5U@P3$=09S=C,W%Q,$I25T-$;$EQ,5EG5DE(56I&
M57IX5C)+=7A6,DMU>%8R2W5X5C)+=7A6,DLF(WA!.V]F.$%35VYF<$@Y1R]7
M;V8P:C90,6XV;#9I*W8V2$QH-G9P,34X3V9W.'%5<G1I<4EX5C)+=7A6,DMU
M>%8R2W5X5C)+=7A6,DMO97HF(WA!.S%,5'(W,2]Q5C%$9&966FYT<FXP6D9K
M.4]E3VY/2U1I5'AD86EQ;F-9<6E-5F1I<G-69&ER<U9D:7)S5F1I<G-64VI8
M=DM0;'I8-3<F(WA!.T-F5TQ*3'E45$I';7-X27HX5F0Q-'1Y4E-&8T9D:7)G
M:D95="],4S%T<E1Y>$QA,G-35SER8C9T<E551453:$DP:E16-W!64D979U8F
M(WA!.U9!;T%-5EI4:7)S5F1I<G-69&ER<U9D:7)S5F1I<D4O35!K4%),-U=R
M=GI08U-84#$O.$%25&%A26]P;6AI15-49E=68V5L=VLY5&TF(WA!.TM6-3!P
M=%1&53$X;E-Y>2M59$1L;&1P2EI.4'17:VM9;&U:;6A5:VMN8VMN1E4S>%8R
M2W5X5C)+=7A6,DMU>%8R2W5X5C4U<5!K:E,F(WA!.V9,6FIV.4]M=2]R3W!E
M6EED46Y:-3-#:#<K-6E794E*2#9A3DAX5V=6=WA(:FER,%!&6%EQ-T9867$W
M1EA9<3=&6%EQ-T9867%X<C@F(WA!.W9V.$%J9S-8+V):,7HO=7-894MS;'A6
M,DMU>%8R2W5X5C)+=7A6,DMU>%9$86XO>'IB=B]!27=Y9CA23TMP9#5*+S51
M>E%0*S)D868F(WA!.SAM17A63W-69&ER<U9D:7)S5F1I<G-69&ER<U99-34U
M+W="-&1,+S=A*VTO.5)C94MP-7%&-&QL65A.-4EP84\R:65:,5AQ4D=P66<F
M(WA!.U8K5TMS33%B.#%)=$DP9#E9,4Q33&DS,"M-27IZ97!#-4AQ<T54-$5:
M;4I,34)S34Y+,W S-6]X-FID6'1R6F%44$Q0<#AN;S-A97(F(WA!.T-V0C9K
M54):9T<S5FA686EO239G-#!R2B],,G1R<D9G,3!,9#=6:VQL9VMH:TMS=V%*
M:7 S47-V8D%Q6EEQ-T9867$W1EA9<7AF>F@F(WA!.S4T+W<S<6UG,E V4&MV
M4G)D=SA":VIA:&E#2T0X2V-737)S5T9%1DYU5$4P531Q<"]L=&-T3C5A;&U%
M17-9;#%B5VXT4T)69&57<C,F(WA!.UHT=7!/>D1O4FER2V9596XY,#-Y<79H
M+W)9<31Y4#A!-S99+U-V.$%81EAE;RLO-W!V=E@K=4MU.5(Y+S-49F5V.6-6
M9#9J+T%/*VTF(WA!.RLY9C8T<3<Q2"\S,#,S<B]!1GA6,W%0+T%,-F(W,2]R
M:7$U4U-+;%-V<V%F=TIX5G9&5T9E62]0.$9H-6YV9DQ%.6I/.%-A2V1583DF
M(WA!.W0T-3=L>5I*>F),171V8GA3=5(K,'HQ,CA+8FA63U!*37%J>6)O06\S
M+TA/=% R5R]W0CA,-UEQ<'HK9F9,341Z2SAT>5)B=DI(3DHF(WA!.TA9,W-K
M871%>%=196]K3$EE3$M184A&54A$*V$S:U=B-G V3CE.3#EF1$Y9.$Q+.6(Q
M,5%C;4U6269J0VIC.&-65&93+TY/:F%P4$PF(WA!.V(R8GIM949"2DI(3F$S
M341C1TI!64-A3T]U-%!41E5Z.5I..6TR+WE'+W!I<G975'=B+V='*UAH:7)V
M5U1W8B]!24)V;#19<3<Q:S@F(WA!.T<O-$)V;#19<79"0D92*T\S-CA69&ER
M>D,X+TU#,S$Y9G%J,D9X85,R2&UY3%,T;5=/965+45=.,T1Y;&MM4TE246PK
M9G=O>C<Y:64F(WA!.V=66C$U;6U4+T1E<6EJ8C)D>"MY,RLK,DAH:7)$3'I2
M3DPQ>GDX;6UA<$%,;7AN:FA-<TI::W%9>7-I+T5H5G1M54A9-%5,=$@X=&$F
M(WA!.TQO,#$S4' X0FIN=C)2-WE:-4I:<$I7:EAG<%HU5V1T:#<K+UA&5U%E
M4EI&1VPS86M.6#8O9#E&66HK.6)U0FE5<VHY6DYT;3,O>4<F(WA!.R]P9U9W
M;5$Y;2\T0G9N-%EQ-S%K<%=J9CA!,VA8=WA6,W%R5VQ'+S1&=C99<6=V34AM
M1%(O3#)K>C9V<D9X.58P*S,T0V%B:3<P36HF(WA!.W)'9T-X:#-.6&-$65EQ
M<C9:<59L<6UM,FUP,DUN<E=6.41(8S)S=D9L-7A424A2=4Q"5T9664=H1F-6
M4U X=G8K3T1D9CET;EA0.$$F(WA!.W5S6&5+<VQX5C)+=7A6,DMU>%8R2W5X
M5C)+<%(U;3@R*UAF3$9L2&9A-V5,6E<P,&]G:61L9'DP<DM70VA9,61Q:TME
M,DMO-U5I1S F(WA!.WDV24Y164I#0T]L3T)X5DQV2E O04-H;6=F.$%B3W10
M*U1#67%X1T-Y9W8Y33%A>'5+*VAD6'5Q=U,X5%)U16PW3W)54%DP3T9#5V$F
M(WA!.V(K6&UK5T9X;VMY6$XQ33)G975.4%=2;V=O5S5J0U-+=VIJ5#1D:7EG
M56]4469$4E%P6E@U82\U4S(X+S5G268K5#!M2T=9645U>%8F(WA!.S)+=7A6
M,DMP4F,K8G9,;'0U:W1F3%4Y-G%A-652;6$R<W5,;&UJ06,X=5%5;W8X061T
M,5 V>&EQ1#@X+S=W-E@O=T)T9E1F*V]U4$8F(WA!.U5X.'HO=T1+3C9T+WI"
M,T@O2G!S5EEV668W=S(O=T1X:50O:4EW;U8X5E(O:U X030U3C,O=T%X.3,O
M>65/2E-Y5$%R<U9D:7)S5EDF(WA!.V(K8G5L:E50260K:3)Z,U9Z03A-.7-S
M3VUW87A-<G)+;TQ25U9W5FIK66]Z2V%N6E-4:7%D*U1O<$EF2U=I4E-O.&-I
M5T9S2&IK=&\F(WA!.S=*,5E1<E98=%EI631'2&5.5%)E9S99<6=F>2LO=T-/
M1&1F.71N6% K-GAD-'%Y6$9867$W1EA9<3=&6%EQ-T9867$X92\U>6-S-T<F
M(WA!.U1Y:'!6,V526%4X3G1Q4$=30S!U;7189$IR85I#07AI=5EE6$QJ479'
M4U)61C-E:%9$,6954#A!:FPS4"]'0BMV*V]C5E,O>50O>6@F(WA!.VUG9CES
M-C O-4U*:7)'3DDO=3<S+W1P86PO,4AZ-%5)-T96+VQR+VQ,8GHO04IG268K
M5#!M2W-W=TID:7)S5F1I<G-694]A+UI755 F(WA!.R]/4W9L-C1E2S9K=4QV
M5'DP36DS5$-#3C1O8C%(3#(X:U5G9%1'=U5#2U)!:D5S,C<O17$Y03@X+W=#
M.$]L+SET9E1F*V]U4$95>#@F(WA!.WHO.$%+3C9T+W=!=V1X+WEA8D973#)(
M*SA.=B]!35EK+W=#26I#:%AX5D@K42\X06IK,V8O369D+W=$2C0T;$Q*34-U
M>%8R2W5X5C4F(WA!.VHO>FM*2F](*T)O6617=#=E-6%A*VA&:70U2DI&8DI+
M;UIP2&QA2V4Q:TMI05-55EA,1G%556Y&57ES+TQV;6584B]*0C!,5TQ+># F
M(WA!.S-3<F10<CET6BMT8U=L=VAS;6EI345R4V,U65DS649&:U!X0VI&<7%!
M5E5W+TQA3SA4>3%+<SAY4WI,<3)T0V%54FQ!-VI6-W--=U@F(WA!.VLS144W
M,'%A67%Y;FI05#=A,2\Q5#1F-C)+=4EN-T]V+T%N+T%*<7A6,4HY+VI8,BM%
M+S@Q67$V:RLO>'(W9D-F*V%S5F139BMD9BLF(WA!.T)0.$%Z5FER<50O>G(O
M=THO=T-A<U9D4V8K9&8K0E O0416:7$U43%0:4E*.6A4*TIX5C5*+WIK1D8U
M:G5B8E%B2'EV<3DO<#)V,TXF(WA!.WDV4E<Y;%!.8GA447-&5G97:U1H1W)#
M4F\Q:DUK:6=L:4XV,596;$=V<"M:0CAW6%%S,W-9+TLT,&U663)L1%-Y1SE%
M:UI,4W%04V,F(WA!.U9I36=49WA887)B.%)I<6(K4U).+V<S44M-=% P9&%B
M8U0O=FAF.$%+>%9J96HQ.4LX<G5F,&QQ5E-.=BM0.$%N=V]2,DMT*UA1-3@F
M(WA!.S(S;D5G9C=J-&5O<B]U-E0S1TMS=G!0=CAA*S-W;B]M<D%L,4HO-3$O
M=T-"4"].5TMU<% O3W8O04%*+S5Q>%8Q2B\U,2\T12]W1$XF(WA!.U=+<GA7
M;2LU.71S5F525'AE6DQR+VY)5S-B4SE9=C5D07,W8W9R96QV4$UL;DA+8EIL
M06EJ8C T<$8O95%S-%1M5F1G5%0Y;%9-9%@F(WA!.T@U:4<Y638T8DM04V8X
M4U=(-DU32W-J;3!-='8V6$9H-E)5:51K6E!556MT6&I247!*5FTO;5E49C1B
M,5@T;' Y5'5++T-F.3ET+VPF(WA!.UE&63%99C=W,B\X07AI5"]!26E-2T9F
M1E5B-49%=C9,=2M,2T8K=C-E>%5K+W="-C-E;WA+6&IN+T]1;FY0>FAO,VYM
M>'-.2S%M-7,F(WA!.TQ6=$QJ;F5',6-X<3!J6$5Y1FHQ,S1O0FTQ-TXP.$UG
M4$5,84TP>D=Q4VIY.35J,4\Y,#=4-7)Z>B]F:3EU1G9N=C=B-CAL<CE85S,F
M(WA!.U=)=T%.8U(X6&51=6%$;#AF445C6%IC:DQP67AK44EB8E9Z4'8U35EZ
M<V)L0B]L8C4K.#E8,S5J95@W1S@Q*SEU<E,U=4I%;G0U-5,F(WA!.SAB<4QE
M5F='6&%V>$M$:G)T2&IH:4UO:F1'3$E384PV<'!.6#=3,"\Q5"]Z5FUH8W!J
M2#5I,R]N4S P84-0>6A"1DQQ=#=C3&%E<E F(WA!.TA*2DA!:W-B9U1T-EEF
M:C9B.%=Q>4UT3FHQ>%903D)85FPP4%0Q,6AL9E9L=#1H<45I04)7=4%G17)!
M3#A)0F5P,GA62U!Y*R]W0T\F(WA!.T1D9CET;EA0*S9X9#1Q;&5T+UA,;GI4
M9E%F6#=U,V=T-$Q9>'A7.'IX2T1*-FA9,%5I<%!%655-1&QT+WI7-%A#,CDQ
M96QM,6-.1$HF(WA!.V-8>4M6,'!8:$1+=G!S.5=F;$E63$1K14)R.&9%1E-Z
M2WIE+W-V3F5G47!Q3C5.0F546$5D>$103SAQ37%7:W-I-TY8;WE!-&]E:#0F
M(WA!.T5U>%8R2W5X5C)+=DXO>F8O4S P;6LR1VME4V),>EIQ3C!,:C9V9&%L
M8DIC5W1N-F9P=31K36Y"53ED07ER5U9+<T(Q-EEQ>C=59BLF(WA!.T]89&)5
M+V-38F8W031Q;"]K;B]L1$Y!+S=:,7 O=T%M17A6:D=K9C-D-R\R,'13+S9J
M-3A+161I<2]Y,2]W07!B968X=T50+T%#96LF(WA!.WA6;4="3'-69&ER<U9D
M:7)Z669P834O3T%M,3AK,E5/;C),9C=K9DXX.71'3'5B,7)0.$%C;3%N8C!M
M4$)L34UV2#%#05%+2TU66DXF(WA!.S4U+S-H,'8O04QA*VTO.$%56$AI<5DK
M6B]W1&Q'.5<O-6<W:B]K,#)+<UAS4#DT8F8O:D5N+T52:%%R-'%J+TEF+TA*
M=2\X06U0=2\F(WA!.RM4>'A+6&=F+T]4;B]K>#=$+W1J>&8X05568UIU*W@K
M56Y',4A2-5!M-V-6;"\U4"]W1&LQ4$Q(+TU62B]W0E%S,EE(868X06-N-$XF
M(WA!.S)$-FXR5&Y,=6$W1E5U,51Z0G!/;#-.:F)8,'I24S9L2TQE,'!(2S9T
M25-!07IO<DQ(57-!0S5!<6%9<6QF-69F.&-'-B\W8D]U9CDF(WA!.S%I-WA6
M3&(O05 U4R]69BM-1G O>DYW;U9-5E%$+SA!2UEE5B]W1&U*=78K;T=F1EAO
M5T),<U9D:7)S5F1I<G-64S=5.5,P-FPS<'8F(WA!.S%Q2#E)+U4U3&XV;#9I
M*W8V1S9E<C9D969$;CA02VQ+-UEQ:'9*4"]!0VAM9V8X06)/=% K5$-9<7AJ
M4U W=3DO=T,R;'%8+T%&2'HF(WA!.S1523=&5B]L<B]L3&)Z+VU!:"\U4%-9
M<7I$06PR2W5X5C)+=7A6,DMS53@R86QP,3E9,E@Q2S9H=79Q=74V9F)84&]Y
M3$HV8SAD,T@F(WA!.WII:S1K.%A7;W%P,T=+<'HU;B\U4G96=BM93S0O=T-4
M5%EQ>&5W+S-H="\K35-F.%)'1D-V:7%0.&@O.&-M-R]!3UDK-R\U4$A%<&4F
M(WA!.T(O.$%/5&XO04I-97<O-UDX6"]55F-:=2MX*U5N1S%(4C50;3=C5FPO
M=T-4+W=$-4Y4>7@O=T%X56XO54Q.;4(R;B]C;C1.,D0V;C(F(WA!.U1N3'5A
M-T95<3%V>71O5W54,DTR<3)X=5<P-E(U8E9$2DMS66521$<S3TY'5DI154I7
M:VES2T5J=6-64VHX=&)#>'1V3$UT=F)7.%4F(WA!.TYV0G$R=%)147AO<4EK
M86%V9'%I26]!0W%Q-T%$<&EQ1'954E!.,G%H5D-J,$Q064-N85A#:%9X5D%3
M2W)E8B]!0W=R045'-75Q9S<F(WA!.VHO94=B1E=F*VA"=BLW6&9R<TU#6&5H
M0B]V=&9U2'IX5C-O468W-U@W:#@X5F0V14@K*S$K-&901E9Y;W%I:6=+3W1!
M2UEQ,VER1B\F(WA!.TUN:W)3=%(Q0S8Q=2MK;6YD9$YK<U5S>5570E4Y451L
M,4MO<W=C=D=T9C-N16=D35929FMM2E0U3C!!,6(O:FY7;C=49C<T6#-X5FHF
M(WA!.V5J9T-+.$$V1%5T4T<K+R]!0B]Z*T]&0T]X5G9Y-F=B>F)E5G(O>'HT
M96A)+W=",U-E1TMS=CA!4E1F9'0O.$%,8BMU0DQV4E1X8B\F(WA!.T%)3G9N
M-#1Q-S!5.%<O-$YV;C0T<3<P53A7+S1.=FXT-'%V04%&0BM/+S8X5F1I<GIZ
M6'9*3VLV56)F549K;G4W,C@X>#)D-C X-5$F(WA!.TUJ,T9X0VI)=F]P0T-G
M5TI1=DU-=SAC2W-U.'I1<"]H=E945G1R3S0O86(O04@R>#AC0W-A<U Y-&)F
M+T%)>$HO=T%21T9#=FEQ3C@F(WA!.VEX<61,=3)*878Q*S<V37=(.38S64A%
M<&5"+S@U3DM&+TUA=T%R+WAX-&5P2B\T*W)J>'ID.6HX<$].<4]J>6Y.,C1R
M3'9Y:$%B.# F(WA!.W9,24YA1S9K-D5G+S=Y>F1X;4(R;B]C;C1.,D0V;C)0
M-E,Q<E9V.$%G;2]R;DQU879X5C)+<V$O3#<O:F<S6"]!1S)D8R\W<D8S:7$F
M(WA!.U<S+R]!0VPK<2\X04=#,"\U;3152VU+;T(O.$%L35!++W=$>D4S6"]!
M1D%Z-'%Z3'I&<FQN;T]H6"MT6'%U.7!P,$0S339X04Y)56HF(WA!.UAK46]9
M<4-D=35W>&E344(Q4UAN=6PO.#5#*U=.5BMT+U5.1C%E9C9J8E-8;#%33WI8
M:$)&5&TO>%A1<E1K3FAV;5A045I9,5DU;74F(WA!.V)737-3,W%V+T]19FQN
M4V9Q9C91,%A6-%!R.71(93)N=U=48S1*<3A(*T,V86QE2C)/+W1J1%%:6EA1
M-4=L3U=)-7,Y.'(K63=$>DPF(WA!.V]&;')L9W-I5VPX:&MI4UE"6D%!>%5H
M9W!C5G%V635I5&=9:V<X=WI"=$Y-:6PR2V]B52\K3V)D+W=$1T=4+VE*>%9,
M=DI0+T%#:&TF(WA!.V=F.$%B3W10*U1#67%X:E-0-W4Y+W=#,FQQ6"]!1DAZ
M-%5)-T96+VQR+VQ,8GHO;4%H+S504UEQ;6YN1'IR-68X;V%:2'%E=5101&$F
M(WA!.U-Z3&)2=$A&2DUX:UI78T1J1T=0,EDR,WEE4$9+6G%)<W%30GI9=&)F
M;C<K6&1Z1DQ.8E-A:%!$055785-05')X,5%Y='AJ1$99:48F(WA!.S5T<W1E
M<'DT-DQ+3UDK-6E-9U4W-R]N250X=$Q#96%#*W5,-C%N='E24$1.<#DT:F]2
M=5%Y=$=#1&E.1FQ)=71V9W9I0S9E:S5I<S,F(WA!.UEQ-T973V5E9CDT9$PO
M-V$K;2\Y4F-E2W!J-6XO=T-58C%B+T%*9S=J+VLP,DMS6'-0.$%E1S,O04]-
M4V8X4D=&0W9I<5 X04EF.$$F(WA!.WAY8G8O;5!U+W=$:SAC4VPT2"]Z:S4O
M-4UE=R\W63A8+U568UIU*W@K56Y',4A2-5!M-V-6;"\U4"\X06LQ4$Q(+TU6
M2B\Q0WI:9V0F(WA!.W O,THK1&1G*W Y:S5Y-VUU>%9I+VY(>G=F3&UP84A:
M1%1P3#@V>D\P04U4:%A5<55&155G:5)Z-FY,:5=8-%9:<2]$:7%6*U5T8C$F
M(WA!.V943DMN=')N>7IQ,W%386IQ9#!V1DQ5:C W=E5:-VU0<F-$9C U5G(W
M-'%H3'$K,3)86#<V+UAY>G%N;UA%5G5K9%9T9599=69+;RLF(WA!.W-F-5%W
M;U@O04M2,78O<5=D52\T1S$O-TM-5E%R6$AM02M93D9V.$$O1$]P*VA95%13
M5#=7=DMK;'1*179%9E=.+VEC67!2;FXO5DXF(WA!.V(Q>GE4<FUJ,E!L:E9F
M<FUO5U4Q=F)I4F)25C5Y25%T5#E93D)82C1P0TUG5#!+1'EE0F%6*U@S-3$V
M5CEB+U(O;'$Y9RMV5SAL;F0F(WA!.U5E=V)N0DQ4;6YX5'13=D5B:F9/9VXR
M:' U5F91,C1O=WE(2E4Q>GE.*V0R=7I7,#)P*U=B=5HW4S-3>G11;C9/:%=/
M0TEK<$=Q4E,F(WA!.V]O0SAJ5&)":C$K;FAF1&4U=G%S<TUJ>F4T+VQN9F$Y
M-60X:392;W5O*U=.5D8W6GA-:S1J1F]Y,6%2;3)B-G=+-TYM:'IY17!K:FLF
M(WA!.U,U55)16C5P1W!Z86A#.&MU;C-7;D9'-&E+-T599'1Q.&PY2U-552MN
M2VMO-T971RM99E!)=%!-.3,U5T]M6$YW5&\W86MT,6)+.#<F(WA!.VMV4#E7
M15%G:E)M4%AK5S5F4C-X5E0X<BMB26)(>7IP1FQC-E1Q-EA&<EI7.$UY9F\R
M-TY(:FE65T@Y,S1J1E5J,#=76F]5=6A*;RLF(WA!.W)G>5AT-T]N*S0V-BMX
M4&1Y>6]F<V0P8TA#:$9F<#EV*W)2<2]W1#-$<G(O04MP-'%U,%1Z0V)8>D1C
M,VLR:V%U<T5L<$A#<F9O-C8F(WA!.U!X<DLW154T941$1E=.9FYX93,O04IN
M.'!73FIO=6@V>&,S34]O>#-%:69O-C97:V%W5&]4=6XX,&DU;#9$2D='55-L
M>5E:66MX;U F(WA!.THY0G1F>E4P3W=V8DMW.')A;W-D.4Y:>GEY3G Q>5A$
M5TTS<GAH0T%!07IB3G0P-E5/*V)F3'%D4$UG;5A++W1A27=M3VE!.#%E6"\F
M(WA!.T%->69-1B]F-FQC955D56EU3'A4*S5G,"LU4TI+4FA%4D9935952V]!
M1F-),65'3U!H175I*TA)>7-V<2]W1'AZ62\Y5W96+RLT8F0F(WA!.R]W1%90
M3V)C=%!,0SA3.71)-W!)-5E6;$)):G5),FAL1D-2.%5B9TUV5'9I<79I<GI(
M56908C8Y8GIX4C9.9F,Y1SAY<%IV.59G;'4F(WA!.W<X96Y8151Y5$U9-"]G
M-4LR>6UV>D]&52LQ>GIH8C-7:6%H87<V5G$W5%0R,#!582]O,C=&5V5-<4(O
M9"M*=TMK5G!R:VMD<D1',FHF(WA!.S9U1U-.5EEF;S8V-F=!9C<W=V]69C K
M,R]6;S%F+W5(6%@O5E!&55@U5#AZ<' K;C-%3C%P3W)O.&PS8U1+0G Q,F9G
M:VM,2V1O+T0F(WA!.T9,>40X.71/.'@K6G9/,6YQ5VIE6&19=6)/4%19-V0U
M4#!F8W)34EHU;DLP2V9Y=4TR=EIU;VAJ0C1J5%)M9UI65'IZ+T$S;C,O<58F
M(WA!.W19+S913&HO04IO>F%F>6AH+VY.2&=Y6DHK5S-L=GIF<$AN+T%%2%9,
M+WDQ<D5.;%HS1'E8178Q0S501E1B>6]$44HO37=Z1#$R<G@F(WA!.WIX15)/
M-UII>'E"<W9P:B]!0GI9+W=$5G(Q9B]!3&AT,R\Q5'I1=55Y4$9867$W1E=(
M5&57+T]-6&YT.5AS=%8Y5'DO9&]6=3E.=7 F(WA!.S4R.4IZ0G=$,FMA2W-A
M9DA&1V%-5RLQ23-5:D973S-V;#<X*WIO,6QA85AR=6TR3C5A-F)B5VMS,&MJ
M6&9Q,V-,,&UU6&5A>4UH86$F(WA!.TU!-VUI;6]O>%E/<7%%,3-29CA!;DE/
M=VIV6DY',6U#+U<U=F)R-FYA3#E7-3(Y=$Q)2'17370Q0U W=FLT;%5L+V@T
M<D=".7!65UHF(WA!.S-U:"MC8G%W;6A'<4QB>FI5-V$V=%1$27EJ-FQ&8W!*
M3F)Y4#9F<4AN0W)#;&1Y44-E3F-667=V:W8X04]#,#!F:' S;4]%875N,30F
M(WA!.WA4,V,X.3%'5&,S3G!*1#9N<7=S<F-);V)H1B]D+W4K64,Q,V)&5FQN
M-54O4&4P4E5J.#!78V=-17E3=&-%5$@Q=G%#43(W<'ET2W$F(WA!.T9U,$UR
M0W!Q<F)H:41Y5EIT-5!S9DXY;D1Q865:=%%I,4=35%5*-4Y*:VE#0F\Y4%E+
M24EP945.=7!K5VIC:GA06')I<68T<3=&6%DF(WA!.W$W1EAN169K+W=$37%Y
M5%9O3%175G9,86%E,75D2V$Y=DQR-GEO9S%$-GA,8GE43$=Y3$9,8CAK<7-2
M8C1U0C5)9T]+;V)89DPS-3@F(WA!.S,P.34Y4CAW86195V1Z-F=I=#%*6F]L
M94=25E9*:%IR24]$=$@X5F52-&QQ<GDT2W%Q+U4O=T$W<EAZ3%IR2F5W-FAO
M570W<7,Q>6(F(WA!.V8V<D<P5FMB9&8P6F)S,'-3=GI%=V(T:U9U=GAK:D95
M>CAW95AV4&5S85)P8E=M<G9P;7 R.%8O2&5O2#E#3U$S3FY.1&)/-&<Y87(F
M(WA!.W=Z3D4T2W5".7!U26)I<7%P3')0:R\X04]H:S K4%)033%R8F]U:C(R
M;C9Q.7DP,')V95)2,T-Y6$U236)53%!.1V5E>G1X1F5N1FPF(WA!.U<W9GEV
M*V5S5C-:<5!.3G%.3VI3-F$W1&E/831K;6%E95<R+V5.6DMV1&<X2U-C5E=G
M5G5!1S)+<S@X<5<S;4LR.'4R34AM4S9I=F0F(WA!.V-J:G!F,U5!0WAY4U9/
M-F=*0TM5<"MW35946$9867$W1E5V.'<V6DQQ;6E8=6YW,U9X6GDS351*2&17
M:WAT<#!B<4-K=U=1>&UV-U@F(WA!.T4O3$9726%(-64O339W,%!Y.4)E-FAA
M86AQ;6PS.#!M<%-'-G5K4S=S-5E:;S$Y4C)J;5HU16MM5U1G5D-F0T%#=$)I
M<5984&QJ."\F(WA!.UIR0DE4-6XP.%A+,DM+6FM54C$Q1DY213-R9D1A+S-F
M,4EE:U8S56YQ:#-/2V]J4W)$.#="-6DQ1WIV.5)J:S!E2T(Q,#-5,BMQ2T@F
M(WA!.VM.>$=95V%+3T@Q5$EK06M%=%%K8DU114,P-6Q62&$Q-5<O34MB6$Y5
M,4A4=%91451X-F0Y4W-P3'4U:&E%;'!C=WI80VA)-#-71EHF(WA!.S0T-45:
M9TA,8V=+04$X;%5P,6IY>BMF3C=Q8S$S8F59=%!S-V1:+U9S8D-*;45A4D=3
M,VLY2V0O<7!A6E9%56DO<W,S3&1G<$M9<6HF(WA!.V1$,$@X-S1B<E1*9%DX
M>5=.>D5L,4=D5W0T;V\Q4C=22496;&DO,%98.58U=6)-95%&3U!(:G5-5F5J
M-'$W1EA9<3=&5G-S<5)24$LF(WA!.S5O:V%L;5!86E)5-'%G-7174T%G5%%0
M151U03AK0S$K*UA&5V]T6FAL8TI&13!J;F]Q>5<U3S-S2F-65G9R8R\O3$9.
M.3A0+T%&57@F(WA!.U8S,75F+VQI;2LK2"]Q<&ER=G)C+W=$>7A49F9$+S%5
M>%8S,75F.$$U67!V=F@O-G%9<3<V,U O04US53,S=R\Y5DU69#EB;B]W0U<F
M(WA!.TMB-S1F*W%M2W4K='HO.$%,1DXY.% X03%5>%8S,75F+VQI;2LK2"]!
M2W%9<3<V,U O>7A49F9$+W="5DU643,V9710-68X06MR8B\F(WA!.T%05EA&
M5F5054AL45-25W-R;V5J2S!"0G!T,45M2W)V<F,O+T%#>%1F9D0O04Y6359D
M.6)N+S59<'9V:"]W0W%M2W4K='HO.'-5,S,F(WA!.W<O.$%65$989E<U+RM7
M2V(W-&8K<6U+=2MT>B]!4$Q&3CDX4"]65$989E<U+W=$;&EM*RM(+W%P:7)V
M<F,O.$%Y>%1F9D0O,55X5C,F(WA!.S%U9B]!2EEP=G9H+S9Q67$W-C-0+W=!
M<U4S,W<O=T165$989E<U+RM72V(W-&8X07%P:7%R8GII94PQ07)*.%1+5F%L
M4559<65H238F(WA!.VIX>%95>%8R2W5X5C)+=7A6,DMU>%9$86XO>'IB=CA!
M-'=Y9CA23TMS6CAW45%3*UI*9E9J5U1J6C(Q3U-H<59L=5!(0VA#45<X54<F
M(WA!.W-A6$IB5SAF<FEA8F=O0W!Y4#%/96DX<6)63TMP2%DS+W=#9FQN1'EB
M5&]D4W%K4SA,-#)58S-0-C%35B]W1%):;S0Q0G0R,E0T-D4F(WA!.T0T:6%Q
M5DQ*3D1V+T%-,6US4618,#-41&5T4&(X;&IK93-23&1P2%<T<%-3.4QY26E+
M>3=Q4&DX5C-#;TQ5>BMA<'9B>$Q13TQB.4LF(WA!.W=V85!'3$%G-F5Q3C9K
M9%I7-4MJ<U4U37ET24-(-&EN1$-Q03AX*V%V>FDP<2]L8411<F4V,#)B56YT
M3D\K<E<P;#-..5=%6F%+830F(WA!.SE/-E1G<W(O04%S-55#3VTV='E!=TMI
M3#=74'IV6%@O04MV6C9*<#<V3G=N8C8T,TAN>5-A47=X,"MU2V8S:T-O=DQH
M<S4U154K2$8F(WA!.U5&8C9R*V9C5G!::5133&%A-DXQ8W@S4FM&<59&=%=.
M<F52=48U1%$W=79*2VYI2VU-=%-Q<F0W-6<O-7E"-#9L3EDK5W1/0W%!9$LF
M(WA!.W1:;FI-<'$P9CDK-C-O:G%%36QE3S%13B]&5FUN:VEF>EI.;TUB96%R
M9&)B5E9D;%I6.4E&:T9/3$])6DIO=S%A+UIB9G)283A1<6XF(WA!.S)+=GHK
M<V]9=G%C2'=,+V1P,D@X;WIT24%52%=Y3S<V62]+<51Z;$@U13AP2F]517HR
M0FHQ4#8R-$YK3%9:1&-826<Y5EI75S50-S F(WA!.W$Q671G0E%H=5AW.'1R
M9C<V6'9C+T@Y25I,4'%0-7@R96TV36)05')E.6M0,6PY6F$O.$%2*W-Q:7IJ
M-G5O1G!,1D1Z84%T>4UA=4LF(WA!.V=B9&II33%N-E,O3F)63D8P=E5,3S)E
M>79,:3!M86$Q84<S=#!78FLO<"]766)P-7 T,DU947AP1S5O-5!Q2&IH5F1"
M<#,U=5=7;#8F(WA!.V@V*W!386IF4S(X9C%B:610<D)+>E1&+W$O.$%O=&]K
M-V]&:%@Y.39A1W)-1'-&=TLW>3=,*V)J95ET4$]U4E-X-EEZ=3$V278P96(F
M(WA!.V163F]+26%..5IO2C9C4VQ4>34Q<DAW;W%M-UA(-6E.<4=I>E178U5.
M=4=V+W="35=T;$Y&3D560VXV;E=3-%=#5W)B9C-91R]W0G$F(WA!.V=X5DLW
M4S4O3U,S,$Q2149V8EAE;VE/-4]T>5AY44-6;E)Y64915W1X1$1'6E5&4&@U
M:&%I=&%'<7%H865:+WIF=F9,1VTV;&%A0F(F(WA!.VY56C)L1CE9,TUB5VI)
M1795:E%H2G)L5U%',D5J-S%Q94HR2'=L5D,S*W!F;CAP<UI,9E1,4C-E,FLK
M=GA23&(K:W,V>D5X.$),9'$F(WA!.R]W0553<4-054E.5'5H;U%Q:34Y6B]0
M1U)85S$P4%0T6&ET-V526DQG27=L;F5.4%AI5DDW+S105&1M,UII2TQ11G$X
M<U929FM,5E F(WA!.WID=DY9:R]X;'!&='!U;DYA:W%,9#1N0S-+>DU&-&Q*
M-3,K3TEG<T=&3G1M1S8T<7I45"]!3S1F+VI.4"]W06YN>%9%-'$W1EA9<3<F
M(WA!.T9867$W1EA9<6]A:'<K;UA0<58T96LO4&HQ<'A.859X5FIM<R]5+W)+
M9G!R.4(O5V5!.5 V-7@Y5# V;6Q053,T,7)H5E(P,SE%9E@F(WA!.V]V,%HO
M:"\V+W=$1C9(,6)H-C%E2C5C3TAX9EER5VYB1E4K+S4R5"]!2F,O*U-U0EAF
M.$%/>68X=68X07E6>%8S+T]Y9CAU9B]*6$8F(WA!.UAF.$%/>68X=68X07E6
M>%8S+T]Y9CAU9B]*6$989CA!3WEF.'5F.$%Y5GA6,R]/>68X=68O2EA&6&8X
M04]Y9CAU9CA!>59X5C,O3WDF(WA!.V8X=68O2EA&6&YI+SAQ9S1J:"]G8FI4
M-&%F57%5-U5Z22]E+S!V=%)S>DQY+W=!+S!20B]H,SE%9F]F-"]Q,S90+S-M
M*S(S<65N-E F(WA!.S=V.$%V3UA+;C=692M5>74Y*V%5>"\U,E0O;'HO=T-3
M=5)6,R]/>68X=68O04-6>%8S+T]Y9CA!3&XO>59X5C,O3WEF.'5F+T%#5G@F
M(WA!.U8S+T]Y9CA!3&XO>59X5C,O3WEF.'5F+T%#5GA6,R]/>68X04QN+WE6
M>%8S+T]Y9CAU9B]!0U9X5C,O3WEF.$%,;B]Y5GA6,R]/>68F(WA!.SAU9B]!
M0U9X5E@P<C%0<68W,VHV=G%Z97!X<G@U97$Q858S<%A&55AI<G-69&ER<U9F
M+UH\+WAM<$=);6<Z:6UA9V4^"B @(" @(" @(" @(" @(#PO<F1F.FQI/@H@
M(" @(" @(" @(" \+W)D9CI!;'0^"B @(" @(" @(#PO>&UP.E1H=6UB;F%I
M;',^"B @(" @(" @(#QP9&8Z4')O9'5C97(^061O8F4@4$1&(&QI8G)A<GD@
M,3 N,#$\+W!D9CI0<F]D=6-E<CX*(" @(" @(" @/&1C.F9O<FUA=#YA<'!L
M:6-A=&EO;B]P;W-T<V-R:7!T/"]D8SIF;W)M870^"B @(" @(" @(#QD8SIC
M<F5A=&]R/@H@(" @(" @(" @(" \<F1F.E-E<3X*(" @(" @(" @(" @(" @
M/')D9CIL:3Y-96=A;B!"86QD=VEN/"]R9&8Z;&D^"B @(" @(" @(" @(#PO
M<F1F.E-E<3X*(" @(" @(" @/"]D8SIC<F5A=&]R/@H@(" @(" @(" \9&,Z
M=&ET;&4^"B @(" @(" @(" @(#QR9&8Z06QT/@H@(" @(" @(" @(" @(" \
M<F1F.FQI('AM;#IL86YG/2)X+61E9F%U;'0B/F<V,6LQ.#PO<F1F.FQI/@H@
M(" @(" @(" @(" \+W)D9CI!;'0^"B @(" @(" @(#PO9&,Z=&ET;&4^"B @
M(" @(" @(#QD8SID97-C<FEP=&EO;CX*(" @(" @(" @(" @/')D9CI!;'0^
M"B @(" @(" @(" @(" @(#QR9&8Z;&D@>&UL.FQA;F<](G@M<F5P86ER(CY&
M:6QE($YA;64Z(" @(" @(" @(" @(" @9S8Q:S$X+F%I)B-X03M5<V5R;F%M
M93H@(" @(" @(" @(" @(')R,CDT,38U)B-X03M,;V-A;"!4:6UE.B @(" @
M(" @(" @(" Q-BU*=6PM,C R," Q-#HU,CHQ-28C>$$[15-4(%1I;64Z(" @
M(" @(" @(" @(" Q-BU*=6PM,C R," P-3HR,CHQ-28C>$$[4V-R:7!T(%9E
M<G-I;VXZ(" @(" @(" @,BXV)B-X03M);&QU<W1R871O<B!697)S:6]N.B @
M(" Q-BXP+C,F(WA!.T=R87!H:6,@='EP93H@(" @(" @(" @0F%R($-H87)T
M)B-X03LF(WA!.^* HB R,2!H86ER;&EN92!R=6QE<R!C:&%N9V5D('1O(# N
M,C4N)B-X03LF(WA!.U1H92!F;VQL;W=I;F<@9F]N=',@87)E('!R97-E;G0@
M:6X@=&AE(&1O8W5M96YT.B8C>$$[(" @(" @(" @(%1I;65S+5)O;6%N)B-X
M03L@(" @(" @(" @5&EM97,M0F]L9"8C>$$[)B-X03M4:&4@9F]L;&]W:6YG
M(&-O;&]R<R!A<F4@<')E<V5N="!I;B!T:&4@9&]C=6UE;G0Z)B-X03L@(" @
M(" @(" @0FQA8VLF(WA!.R @(" @(" @("!#35E+)B-X03LF(WA!.RTM+2TM
M+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM
M+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+28C
M>$$[1FEL92!.86UE.B @(" @(" @(" @(" @(&<V,6LQ."YA:28C>$$[57-E
M<FYA;64Z(" @(" @(" @(" @("!R<C8P-C(Q,R8C>$$[3&]C86P@5&EM93H@
M(" @(" @(" @(" @,3<M2G5L+3(P,C @,# Z,C Z,3,F(WA!.T535"!4:6UE
M.B @(" @(" @(" @(" @,3<M2G5L+3(P,C @,#,Z,C Z,3,F(WA!.U-C<FEP
M="!697)S:6]N.B @(" @(" @(#(N-B8C>$$[26QL=7-T<F%T;W(@5F5R<VEO
M;CH@(" @,38N,"XP)B-X03M'<F%P:&EC('1Y<&4Z(" @(" @(" @($)A<B!#
M:&%R="8C>$$[)B-X03OB@*(@,S S(&)L86-K('1E>'0@8VAA<F%C=&5R<R!C
M:&%N9V5D('1O(&]V97)P<FEN="XF(WA!.R8C>$$[5&AE(&9O;&QO=VEN9R!F
M;VYT<R!A<F4@<')E<V5N="!I;B!T:&4@9&]C=6UE;G0Z)B-X03L@(" @(" @
M(" @07)I86Q-5"8C>$$[(" @(" @(" @($%R:6%L+4)O;&1-5"8C>$$[)B-X
M03M4:&4@9F]L;&]W:6YG(&-O;&]R<R!A<F4@<')E<V5N="!I;B!T:&4@9&]C
M=6UE;G0Z)B-X03L@(" @(" @(" @0FQA8VLF(WA!.R @(" @(" @("!#35E+
M)B-X03LF(WA!.RTM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM
M+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM
M+2TM+2TM+2TM+2TM+28C>$$[1FEL92!.86UE.B @(" @(" @(" @(" @(&<V
M,6LQ."YA:28C>$$[57-E<FYA;64Z(" @(" @(" @(" @("!R<C8P-C(Q,R8C
M>$$[3&]C86P@5&EM93H@(" @(" @(" @(" @,3<M2G5L+3(P,C @,# Z-#0Z
M-#0F(WA!.T535"!4:6UE.B @(" @(" @(" @(" @,3<M2G5L+3(P,C @,#,Z
M-#0Z-#0F(WA!.U-C<FEP="!697)S:6]N.B @(" @(" @(#(N-B8C>$$[26QL
M=7-T<F%T;W(@5F5R<VEO;CH@(" @,38N,"XP)B-X03M'<F%P:&EC('1Y<&4Z
M(" @(" @(" @($)A<B!#:&%R="8C>$$[)B-X03LJ*BI4:&4@<')E9FQI9VAT
M(&-H96-K(&ES(&-O;7!L971E+B!0;&5A<V4@96YS=7)E(&UA;G5A;"!C:&5C
M:W,@87)E(&-O;7!L971E9"!P97(@<')O8V5S<RXJ*BHF(WA!.R8C>$$[5&AE
M(&9O;&QO=VEN9R!F;VYT<R!A<F4@<')E<V5N="!I;B!T:&4@9&]C=6UE;G0Z
M)B-X03L@(" @(" @(" @07)I86Q-5"8C>$$[(" @(" @(" @($%R:6%L+4)O
M;&1-5"8C>$$[)B-X03M4:&4@9F]L;&]W:6YG(&-O;&]R<R!A<F4@<')E<V5N
M="!I;B!T:&4@9&]C=6UE;G0Z)B-X03L@(" @(" @(" @0FQA8VLF(WA!.R @
M(" @(" @("!#35E+)B-X03LF(WA!.RTM+2TM+2TM+2TM+2TM+2TM+2TM+2TM
M+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM
M+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+28C>$$[1FEL92!.86UE.B @(" @
M(" @(" @(" @(&<V,6LQ."YA:28C>$$[57-E<FYA;64Z(" @(" @(" @(" @
M("!R<C8P,S<R."8C>$$[3&]C86P@5&EM93H@(" @(" @(" @(" @,3<M2G5L
M+3(P,C @,34Z,C4Z-#<F(WA!.T535"!4:6UE.B @(" @(" @(" @(" @,3<M
M2G5L+3(P,C @,#4Z-34Z-#<F(WA!.U-C<FEP="!697)S:6]N.B @(" @(" @
M(#(N-B8C>$$[26QL=7-T<F%T;W(@5F5R<VEO;CH@(" @,3DN,"XP)B-X03M'
M<F%P:&EC('1Y<&4Z(" @(" @(" @($)A<B!#:&%R="8C>$$[)B-X03LJ*BI4
M:&4@<')E9FQI9VAT(&-H96-K(&ES(&-O;7!L971E+B!0;&5A<V4@96YS=7)E
M(&UA;G5A;"!C:&5C:W,@87)E(&-O;7!L971E9"!P97(@<')O8V5S<RXJ*BHF
M(WA!.R8C>$$[5&AE(&9O;&QO=VEN9R!F;VYT<R!A<F4@<')E<V5N="!I;B!T
M:&4@9&]C=6UE;G0Z)B-X03L@(" @(" @(" @07)I86Q-5"8C>$$[(" @(" @
M(" @($%R:6%L350M0F]L9"8C>$$[)B-X03M4:&4@9F]L;&]W:6YG(&-O;&]R
M<R!A<F4@<')E<V5N="!I;B!T:&4@9&]C=6UE;G0Z)B-X03L@(" @(" @(" @
M0FQA8VLF(WA!.R @(" @(" @("!#35E+)B-X03LF(WA!.RTM+2TM+2TM+2TM
M+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM
M+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+28C>$$[/"]R
M9&8Z;&D^"B @(" @(" @(" @(#PO<F1F.D%L=#X*(" @(" @(" @/"]D8SID
M97-C<FEP=&EO;CX*(" @(" @(" @/'AM<%109SI.4&%G97,^,3PO>&UP5%!G
M.DY086=E<SX*(" @(" @(" @/'AM<%109SI(87-6:7-I8FQE5')A;G-P87)E
M;F-Y/D9A;'-E/"]X;7!44&<Z2&%S5FES:6)L951R86YS<&%R96YC>3X*(" @
M(" @(" @/'AM<%109SI(87-6:7-I8FQE3W9E<G!R:6YT/E1R=64\+WAM<%10
M9SI(87-6:7-I8FQE3W9E<G!R:6YT/@H@(" @(" @(" \>&UP5%!G.DUA>%!A
M9V53:7IE(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @
M/'-T1&EM.G<^-#4N,# P,# P/"]S=$1I;3IW/@H@(" @(" @(" @(" \<W1$
M:6TZ:#XV,"XP,# P,# \+W-T1&EM.F@^"B @(" @(" @(" @(#QS=$1I;3IU
M;FET/E!I8V%S/"]S=$1I;3IU;FET/@H@(" @(" @(" \+WAM<%109SI-87A0
M86=E4VEZ93X*(" @(" @(" @/'AM<%109SI&;VYT<SX*(" @(" @(" @(" @
M/')D9CI"86<^"B @(" @(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP
M93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" @(" @(" \<W1&;G0Z9F]N=$YA
M;64^07)I86Q-5#PO<W1&;G0Z9F]N=$YA;64^"B @(" @(" @(" @(" @(" @
M(#QS=$9N=#IF;VYT1F%M:6QY/D%R:6%L/"]S=$9N=#IF;VYT1F%M:6QY/@H@
M(" @(" @(" @(" @(" @(" \<W1&;G0Z9F]N=$9A8V4^4F5G=6QA<CPO<W1&
M;G0Z9F]N=$9A8V4^"B @(" @(" @(" @(" @(" @(#QS=$9N=#IF;VYT5'EP
M93Y/<&5N(%1Y<&4\+W-T1FYT.F9O;G14>7!E/@H@(" @(" @(" @(" @(" @
M(" \<W1&;G0Z=F5R<VEO;E-T<FEN9SY697)S:6]N(#4N,C(\+W-T1FYT.G9E
M<G-I;VY3=')I;F<^"B @(" @(" @(" @(" @(" @(#QS=$9N=#IC;VUP;W-I
M=&4^1F%L<V4\+W-T1FYT.F-O;7!O<VET93X*(" @(" @(" @(" @(" @(" @
M/'-T1FYT.F9O;G1&:6QE3F%M93YA<FEA;"YT=&8\+W-T1FYT.F9O;G1&:6QE
M3F%M93X*(" @(" @(" @(" @(" @/"]R9&8Z;&D^"B @(" @(" @(" @(" @
M(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @
M(" @(" @(" \<W1&;G0Z9F]N=$YA;64^07)I86Q-5"U";VQD/"]S=$9N=#IF
M;VYT3F%M93X*(" @(" @(" @(" @(" @(" @/'-T1FYT.F9O;G1&86UI;'D^
M07)I86P@350\+W-T1FYT.F9O;G1&86UI;'D^"B @(" @(" @(" @(" @(" @
M(#QS=$9N=#IF;VYT1F%C93Y";VQD/"]S=$9N=#IF;VYT1F%C93X*(" @(" @
M(" @(" @(" @(" @/'-T1FYT.F9O;G14>7!E/E1Y<&4@,3PO<W1&;G0Z9F]N
M=%1Y<&4^"B @(" @(" @(" @(" @(" @(#QS=$9N=#IV97)S:6]N4W1R:6YG
M/C P,2XP,#,\+W-T1FYT.G9E<G-I;VY3=')I;F<^"B @(" @(" @(" @(" @
M(" @(#QS=$9N=#IC;VUP;W-I=&4^1F%L<V4\+W-T1FYT.F-O;7!O<VET93X*
M(" @(" @(" @(" @(" @(" @/'-T1FYT.F9O;G1&:6QE3F%M93YA<FEA8E]?
M7RYP9F([(&%R:6%B7U]?+E!&33PO<W1&;G0Z9F]N=$9I;&5.86UE/@H@(" @
M(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @/"]R9&8Z0F%G/@H@
M(" @(" @(" \+WAM<%109SI&;VYT<SX*(" @(" @(" @/'AM<%109SI0;&%T
M94YA;65S/@H@(" @(" @(" @(" \<F1F.E-E<3X*(" @(" @(" @(" @(" @
M/')D9CIL:3Y#>6%N/"]R9&8Z;&D^"B @(" @(" @(" @(" @(#QR9&8Z;&D^
M36%G96YT83PO<F1F.FQI/@H@(" @(" @(" @(" @(" \<F1F.FQI/D)L86-K
M/"]R9&8Z;&D^"B @(" @(" @(" @(#PO<F1F.E-E<3X*(" @(" @(" @/"]X
M;7!44&<Z4&QA=&5.86UE<SX*(" @(" @(" @/'AM<%109SI3=V%T8VA'<F]U
M<',^"B @(" @(" @(" @(#QR9&8Z4V5Q/@H@(" @(" @(" @(" @(" \<F1F
M.FQI(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @(" @
M(" @/'AM<$<Z9W)O=7!.86UE/D1E9F%U;'0@4W=A=&-H($=R;W5P/"]X;7!'
M.F=R;W5P3F%M93X*(" @(" @(" @(" @(" @(" @/'AM<$<Z9W)O=7!4>7!E
M/C \+WAM<$<Z9W)O=7!4>7!E/@H@(" @(" @(" @(" @(" \+W)D9CIL:3X*
M(" @(" @(" @(" @/"]R9&8Z4V5Q/@H@(" @(" @(" \+WAM<%109SI3=V%T
M8VA'<F]U<',^"B @(" @(" @(#QX;7!-33I$;V-U;65N=$E$/GAM<"YD:60Z
M8C-F.6(P,#<M,F0X8RTV,#1A+6$X.&,M.&%A,#!B.64R,C,S/"]X;7!-33I$
M;V-U;65N=$E$/@H@(" @(" @(" \>&UP34TZ26YS=&%N8V5)1#YX;7 N:6ED
M.F(S9CEB,# W+3)D.&,M-C T82UA.#AC+3AA83 P8CEE,C(S,SPO>&UP34TZ
M26YS=&%N8V5)1#X*(" @(" @(" @/'AM<$U-.D]R:6=I;F%L1&]C=6UE;G1)
M1#YX;7 N9&ED.D8X,30Q,$1#-#)#-T5!,3$X.38P.$9#.30T13$Q,$%$/"]X
M;7!-33I/<FEG:6YA;$1O8W5M96YT240^"B @(" @(" @(#QX;7!-33I296YD
M:71I;VY#;&%S<SYD969A=6QT/"]X;7!-33I296YD:71I;VY#;&%S<SX*(" @
M(" @(" @/'AM<$U-.D1E<FEV961&<F]M(')D9CIP87)S951Y<&4](E)E<V]U
M<F-E(CX*(" @(" @(" @(" @/'-T4F5F.FEN<W1A;F-E240^>&UP+FEI9#HT
M-3(W-V1B-"TT-#@P+3<S-#DM834X9"TY,#EF9#!C-CAC-V$\+W-T4F5F.FEN
M<W1A;F-E240^"B @(" @(" @(" @(#QS=%)E9CID;V-U;65N=$E$/GAM<"YD
M:60Z-#4R-S=D8C0M-#0X,"TW,S0Y+6$U.&0M.3 Y9F0P8S8X8S=A/"]S=%)E
M9CID;V-U;65N=$E$/@H@(" @(" @(" @(" \<W12968Z;W)I9VEN86Q$;V-U
M;65N=$E$/GAM<"YD:60Z1C@Q-#$P1$,T,D,W14$Q,3@Y-C X1D,Y-#1%,3$P
M040\+W-T4F5F.F]R:6=I;F%L1&]C=6UE;G1)1#X*(" @(" @(" @(" @/'-T
M4F5F.G)E;F1I=&EO;D-L87-S/F1E9F%U;'0\+W-T4F5F.G)E;F1I=&EO;D-L
M87-S/@H@(" @(" @(" \+WAM<$U-.D1E<FEV961&<F]M/@H@(" @(" @(" \
M>&UP34TZ2&ES=&]R>3X*(" @(" @(" @(" @/')D9CI397$^"B @(" @(" @
M(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @
M(" @(" @(" @(" @(" \<W1%=G0Z86-T:6]N/G-A=F5D/"]S=$5V=#IA8W1I
M;VX^"B @(" @(" @(" @(" @(" @(#QS=$5V=#II;G-T86YC94E$/GAM<"YI
M:60Z1C@Q-#$P1$,T,D,W14$Q,3@Y-C X1D,Y-#1%,3$P040\+W-T179T.FEN
M<W1A;F-E240^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IW:&5N/C(P,C M
M,#<M,394,30Z,SDZ-#$K,#4Z,S \+W-T179T.G=H96X^"B @(" @(" @(" @
M(" @(" @(#QS=$5V=#IS;V9T=V%R94%G96YT/D%D;V)E($EL;'5S=')A=&]R
M($-3-B H5VEN9&]W<RD\+W-T179T.G-O9G1W87)E06=E;G0^"B @(" @(" @
M(" @(" @(" @(#QS=$5V=#IC:&%N9V5D/B\\+W-T179T.F-H86YG960^"B @
M(" @(" @(" @(" @(#PO<F1F.FQI/@H@(" @(" @(" @(" @(" \<F1F.FQI
M(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @
M/'-T179T.F%C=&EO;CYS879E9#PO<W1%=G0Z86-T:6]N/@H@(" @(" @(" @
M(" @(" @(" \<W1%=G0Z:6YS=&%N8V5)1#YX;7 N:6ED.F(S9CEB,# W+3)D
M.&,M-C T82UA.#AC+3AA83 P8CEE,C(S,SPO<W1%=G0Z:6YS=&%N8V5)1#X*
M(" @(" @(" @(" @(" @(" @/'-T179T.G=H96X^,C R,"TP-RTQ-U0Q-3HR
M-CHQ-"LP-3HS,#PO<W1%=G0Z=VAE;CX*(" @(" @(" @(" @(" @(" @/'-T
M179T.G-O9G1W87)E06=E;G0^061O8F4@26QL=7-T<F%T;W(@0T,@,C Q-2 H
M5VEN9&]W<RD\+W-T179T.G-O9G1W87)E06=E;G0^"B @(" @(" @(" @(" @
M(" @(#QS=$5V=#IC:&%N9V5D/B\\+W-T179T.F-H86YG960^"B @(" @(" @
M(" @(" @(#PO<F1F.FQI/@H@(" @(" @(" @(" \+W)D9CI397$^"B @(" @
M(" @(#PO>&UP34TZ2&ES=&]R>3X*(" @(" @(" @/$5X=&5N<VES1F]N=%-E
M;G-E.G-L=6<^"B @(" @(" @(" @(#QR9&8Z0F%G/@H@(" @(" @(" @(" @
M(" \<F1F.FQI(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @
M(" @(" @(" @/$5X=&5N<VES1F]N=%-E;G-E.D9O;G1+:6YD/D]P96Y4>7!E
M("T@5%0\+T5X=&5N<VES1F]N=%-E;G-E.D9O;G1+:6YD/@H@(" @(" @(" @
M(" @(" @(" \17AT96YS:7-&;VYT4V5N<V4Z1F%M:6QY/D%R:6%L/"]%>'1E
M;G-I<T9O;G1396YS93I&86UI;'D^"B @(" @(" @(" @(" @(" @(#Q%>'1E
M;G-I<T9O;G1396YS93I/=71L:6YE1FEL95-I>F4^,#PO17AT96YS:7-&;VYT
M4V5N<V4Z3W5T;&EN949I;&53:7IE/@H@(" @(" @(" @(" @(" @(" \17AT
M96YS:7-&;VYT4V5N<V4Z1F]U;F1R>3Y-;VYO='EP92!4>7!O9W)A<&AY/"]%
M>'1E;G-I<T9O;G1396YS93I&;W5N9')Y/@H@(" @(" @(" @(" @(" @(" \
M17AT96YS:7-&;VYT4V5N<V4Z5F5R<VEO;CXW+C P/"]%>'1E;G-I<T9O;G13
M96YS93I697)S:6]N/@H@(" @(" @(" @(" @(" @(" \17AT96YS:7-&;VYT
M4V5N<V4Z2V5R;FEN9T-H96-K<W5M/C \+T5X=&5N<VES1F]N=%-E;G-E.DME
M<FYI;F=#:&5C:W-U;3X*(" @(" @(" @(" @(" @(" @/$5X=&5N<VES1F]N
M=%-E;G-E.D9O;G1396YS95\Q+C)?0VAE8VMS=6T^,S R-S(V,3$X,CPO17AT
M96YS:7-&;VYT4V5N<V4Z1F]N=%-E;G-E7S$N,E]#:&5C:W-U;3X*(" @(" @
M(" @(" @(" @(" @/$5X=&5N<VES1F]N=%-E;G-E.D-H96-K<W5M/C,P,C<R
M-C$Q.#(\+T5X=&5N<VES1F]N=%-E;G-E.D-H96-K<W5M/@H@(" @(" @(" @
M(" @(" @(" \17AT96YS:7-&;VYT4V5N<V4Z4&]S=%-C<FEP=$YA;64^07)I
M86Q-5#PO17AT96YS:7-&;VYT4V5N<V4Z4&]S=%-C<FEP=$YA;64^"B @(" @
M(" @(" @(" @(#PO<F1F.FQI/@H@(" @(" @(" @(" @(" \<F1F.FQI(')D
M9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @/$5X
M=&5N<VES1F]N=%-E;G-E.D9O;G1+:6YD/D]P96Y4>7!E("T@5%0\+T5X=&5N
M<VES1F]N=%-E;G-E.D9O;G1+:6YD/@H@(" @(" @(" @(" @(" @(" \17AT
M96YS:7-&;VYT4V5N<V4Z1F%M:6QY/D%R:6%L/"]%>'1E;G-I<T9O;G1396YS
M93I&86UI;'D^"B @(" @(" @(" @(" @(" @(#Q%>'1E;G-I<T9O;G1396YS
M93I/=71L:6YE1FEL95-I>F4^,#PO17AT96YS:7-&;VYT4V5N<V4Z3W5T;&EN
M949I;&53:7IE/@H@(" @(" @(" @(" @(" @(" \17AT96YS:7-&;VYT4V5N
M<V4Z1F]U;F1R>3Y-;VYO='EP92!4>7!O9W)A<&AY/"]%>'1E;G-I<T9O;G13
M96YS93I&;W5N9')Y/@H@(" @(" @(" @(" @(" @(" \17AT96YS:7-&;VYT
M4V5N<V4Z5F5R<VEO;CXW+C P/"]%>'1E;G-I<T9O;G1396YS93I697)S:6]N
M/@H@(" @(" @(" @(" @(" @(" \17AT96YS:7-&;VYT4V5N<V4Z2V5R;FEN
M9T-H96-K<W5M/C \+T5X=&5N<VES1F]N=%-E;G-E.DME<FYI;F=#:&5C:W-U
M;3X*(" @(" @(" @(" @(" @(" @/$5X=&5N<VES1F]N=%-E;G-E.D9O;G13
M96YS95\Q+C)?0VAE8VMS=6T^,C4R-3DV.3@Y,#PO17AT96YS:7-&;VYT4V5N
M<V4Z1F]N=%-E;G-E7S$N,E]#:&5C:W-U;3X*(" @(" @(" @(" @(" @(" @
M/$5X=&5N<VES1F]N=%-E;G-E.D-H96-K<W5M/C(U,C4Y-CDX.3 \+T5X=&5N
M<VES1F]N=%-E;G-E.D-H96-K<W5M/@H@(" @(" @(" @(" @(" @(" \17AT
M96YS:7-&;VYT4V5N<V4Z4&]S=%-C<FEP=$YA;64^07)I86PM0F]L9$U4/"]%
M>'1E;G-I<T9O;G1396YS93I0;W-T4V-R:7!T3F%M93X*(" @(" @(" @(" @
M(" @/"]R9&8Z;&D^"B @(" @(" @(" @(#PO<F1F.D)A9SX*(" @(" @(" @
M/"]%>'1E;G-I<T9O;G1396YS93IS;'5G/@H@(" @(" \+W)D9CI$97-C<FEP
M=&EO;CX*(" @/"]R9&8Z4D1&/@H\+W@Z>&UP;65T83X*(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @( H\/WAP86-K970@96YD/2)W(C\^_]L 0P ! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$!_]L 0P$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!_\  $0@!E0': P$1
M  (1 0,1 ?_$ !\  0 !! ,! 0$            )!08'" 0*"P," ?_$ ' 0
M   % P(#  80#P@-"@0' 0,$!08'  $""!$)(3$2(CE!47@*$Q05%ADR-CA2
M87&8M;:W%Q@T5VAU=G>1I[2XUMCG(S4W6&*!H;(:)RA45EES=).7L[G2)#-"
M5966L=35UR4F1YE#2%.&I-/A\?_$ !T! 0 #  ,! 0$            ! @,&
M!PD%! C_Q !8$0 " 0(# @<)"0D/! ,  P   0(#$00A,051!A)!<9&QP0<3
M,C5A<G2!T2(V=J&RM+7"\!05%C=2=8*2TB,S-$)55F)SE)6ST]3A\1=35)8(
M)=4DD\3_V@ , P$  A$#$0 _ ._Q0&H^O'&5 ]'NHM3AF3%*)'\W8@D)U);U
M06Z2<;F*!-AHK*Z93FL&H& RB,XEG A9,2W-F36!V\,9NIIZ294@"8@ E6NK
MZ75^8A/?.HO5FG:F=-:$W9)E45_*<7</0U$</7/*F;+G%G2.Q-01S68^GL@B
M%\R3X5V@.WF.;7W.LG S\:&D]I&"9E&&>@PB\)27%O;?GN:2MU^O7DRNSAQ3
MWKWD&*9%/PTLI.IYRE&GHQ67B/J_DU_,1$94^ON$WFMZSXY;[G;L7/I:2%6.
M9-(QF3^@^$@%&U'PCE<*83'1!"@*.9$R2OGEG+1)Y)Y977ESN[JWE9+QH*U(
MN_5GI@9LW/YF-Z/GFKO":F2Y6DTW H.EMIJM#LWR+#IL9&7U9(0%%2(JF;#N
MK@C'$9.&PL?\IR+8>5VWA._2UT.Q62LVM;>KVFXE20* 4 H!0"@% * 4 H!0
M"@% * 4 H".?BRJ4VMWA]ZFWG ,L.&'7ZP8K>SX#<K-0@%9Z*A!N--=.XM=I
M*@QD,1FJZRLV1O+7>G$51<3D@JJ$F\"DKJFG.= %HVXT;YJZ3Z2,#4YJ+UBM
M;79/36AQ]RFI24WLI$)13I^* G%2.E33HG<,9U2JVI= 96:<.C*JWGKL*I3*
M+OX7(14-.&Q6*+F!4\W=(&%DHV5\LLWN?'M:WFYVYGE?/*&A>5=>4D11+!G2
MU)D93JP&W*T>$V?*>M=PR\NGUHBL:48$=TO(#4=++3;+BZ&S]1"])B*< 6P\
MR+34\5EB)HX(+4P24L0[75U;+1*W\9VO=+DMR:6Y;DJ&@S4.X]6>CC3IJ2=R
M$BMAS3-&*"^5IOMS(]FA))]6Q%N,32\E,P;4,B@5P[>5W-F1QN=^R$RH5DK2
M:W-KHR-MZ$"@% * 4 H!0"@% * 4 H!0"@% * CRXK)^:D'A^ZI'C DKN"'7
M\P8=D5]EW.ST(!7>:@4:K'<:J&V6DI#F0\V>L+:P"D!YO!.)*BZEI8*D7;@*
M4X#Z8YD$6A;C1NKIM+6RS?81;:D-1>L-LZZI7:L0OR4E.2D3-6)1/I^ ".J,
M=.+3F%PSY"E+&7<V7FG"HZPM%]<B>A,P!_#BY*N;@!2XML9$(*N2.<$I1MGN
MNW;EXR5O5&[MES%_Z%=16M]7B>5U73PB)^MJ/45^Q:"W7_J<U"N>.%@F:5=*
M$'/*;$1OO7Z$,E*+R+MJ?%M_HQU!-$DPJP%VZZQR1P,NW,$%%!I75[JZODD[
MW;L[<9)96Y7OY;DO.BW42/JWTHP'J7,M()ACS7&Z _Q6< MYN0%N9K8.0UTH
M-=$2D/-5Q+=CV-CF20GW%WWN5#Z4(DN+)QO>SM<V>H5% * 4 H!0"@% * 4
MH!0"@% * 4 H!0"@(P>#Q[!)K>,)KE_/DU%U"T]<NMEI^$_5U(D^J2HH!0"@
M% * 4 H!0"@% * 4 H!0"@% * ^)CZG'_P B+_4RH",S@P=RKT(^+TS/ZAFA
M:?AR\Z76R3FA44 H!0"@% * 4 H!0"@% * 4 H!0"@% 4U9_>=5^UI[\E%H"
M-_@T=ROT(>+FP_R,2A>IX<N<DRH4% * 4 H!0"@% * 4 H!0"@% * 4 H!0"
M@(P>#Q[!)K>,)KE_/DU%U"T]<NMEI^$_5U(D^J2HH!0"@% * 4 H!0"@% *
M4 H!0"@% * ^)CZG'_R(O]3*@(S.#!W*O0CXO3,_J&:%I^'+SI=;).:%10"@
M% * 4 H!0"@% * 4 H!0"@% * 4!35G]YU7[6GOR46@(W^#1W*_0AXN;#_(Q
M*%ZGARYR3*A04 H!0"@% * 4 H!0"@% * 4 H!0"@% * C!X/'L$FMXPFN7\
M^3474+3URZV6GX3]74B3ZI*B@% * 4 H!0"@% * 4 H!0"@% * 4 H#XF/J<
M?_(B_P!3*@(S.#!W*O0CXO3,_J&:%I^'+SI=;).:%10"@% * 4 H!0"@% *
M4 H!0"@% * 4!35G]YU7[6GOR46@(W^#1W*_0AXN;#_(Q*%ZGARYR3*A04 H
M!0"@% * T6XBFMDIP_\ 38I:ASD;FY6P(O1E,P)GDW2 SA3!AY*OG6$=R7#*
M$X@P B&5KC" ^=8N0]NTQ$"OVU?5V'L?%\(-KX#8N!E1CC-I8B.&P\L1.5.B
MJDTVG4G"%248Y.[C"3\AAB<13PE"KB:W&[W1@ZD^)%2EQ5K9-QN_6B#IF^29
M7!(CI0F0Q.'D\'<[W.H I3?;;?GXDIK"NH&+W\J*DB)6&!!AL^QQS$$O;'L
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MY;WQZ\^5^G+ISZ]?Z* =ORWOCUY\K].73GUZ_P!% ?VV^W/;?O[=/Z=Z _M
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M0"@% * 4 H!0'Q,?4X_^1%_J94!&9P8.Y5Z$?%Z9G]0S0M/PY>=+K9)S0J*
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MT(^+TS/ZAFA:?AR\Z76R3FA44 H!0"@% * @H\D8=S0=/WZX)^7A.N>=R_\
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MP)"T]<NMD3\)^KJ7-U$JNV?ML>OM+]/!ZOK[O]%25&V?ML>OM+]/!ZOK[O\
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M-'9;J2@H!0$8/!X]@DUO&$UR_GR:BZA:>N76RT_"?JZD2?5)44 H!0"@% *
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MX9F<BP&65A1[%\! \A[A8YV"QSPR$[&V6-[@<8%0(*B<(=3#Q-1)"AFL S9
MR"<*B9@9"EQ\,#!?,0+/($<(4 7''.]PQ@Q \[8YX98V C8X,'<J]"/B],S^
MH9H6GX<O.EULDYH5(9V5[(_B!>-HW?S,](M:PT?/V(SJ:Q\WZTC-%7,Q0"@+
M2TZ=T">GB=-GYZW%64]5S=K-8:/G[$2NU0N04>2,.YH.G[]<$_+PG7/.Y?\
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M*47.,5:%:+<F\5:>=?;=T_*:^J)T#8KPBJ^8DG5/)XR3=#3$74A#@DE9MU\
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MV[/RNV/;WMV-K<]J @!A&>YQUKS?#,NM&67RH0A%+];3'=#J@9JR4A--ZGE
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M0XKF@ K  &50R7!#&4# (%K A#&\QA PK6#PRMA;L: JE * ^)CZG'_R(O\
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M/%S8?Y&)0O4\.7.294*$,$?^R%U_>-V0_-,TK5K#1\_8C.IK'S?K2,WU<S%
M* MC3?[/J0?% 8WSSOFLIZKF[6;0\#]*75$E7JA8@>\D;]S66OOZP;\K,JY[
MW+OQ@\$_SO0^3,^5MSQ1M#T:IV'0PKT3.G!0"@+<>/K1=/W.+GQ8:KC?#+WH
M<*O@WMSZ+Q1^[9?C+9WIV$^<4SUNV]^\"']ITS\B KS3.ZBL4 H!0"@,<JLP
MQ(A2&WHB7)2CE&EAW)IA9:D8*KW;*=(;G2"=C>1M5;S*-J8+D6DTKB0/7,'D
MU,,E0+$C=Q1<;%QNP"SUMEO.3'TJQ?+::J+,520PI-1T-=4&NM*T?/!O/--2
M',D^5>>C=5#S<45(JGKJ;Y>!YX)!L4%0)^7!>:"X?EF&X6:U5B/[@\>P2:WC
M":Y?SY-1=0M/7+K9:?A/U=2)/JDJ0\J'LXM9WVOTU_-FI5I3Y?5VE*ND.9];
M,K5H9"@% 8ZCCNC&GOQ.-;7SQZ!*SJ<GK[#6GI+GCU2)=:S+D2W'1[E3JR^U
M44_/O%U<BX(>^W@O\(MB?2>%/RX[^ XWT/%?X%0\[BO2XZ1% * XQWZC-_YL
M/_LLZ_/B_P""8KT>M_AR-*/[[2_K(?*1ZANA#V#VC7Q4]/'S1,^O+<[UEJ^=
M]9M90@4 H!0&-19GAX"1#,0CRQ&H,LDT#-UFXO%?;7#D0JUPPK#B.0RRLU6S
ME 0 P+V&S6!4S%.Q"O83(S;"_94!RV))\:R\TLGG$\AL:3V>8&4DX!UQX[4!
MZMH=03!,RRD1!76TH*:6(<3S..1<\5P-9#E!\;A#X!B6OC0EIK5-<^1H+P8.
MY5Z$?%Z9G]0S0F?AR\Z76R3FA4AG97LC^(%XVC=_,STBUK#1\_8C.IK'S?K2
M,T5<S% * M+3IW0)Z>)TV?GK<593U7-VLUAH^?L1*[5"Y!1Y(P[F@Z?OUP3\
MO"=<\[E_XP>"7YXP_5,^9MKQ1M+T2KV'0FKT4.FA0"@+>=WK4<_W/+7Q:9KC
MG#'WH\*?@YMSZ,Q1^[9?C+9WIV$^<4SULFIZUFU]H$?XN+5YI'=17Z 4 H!0
M&-AIFA\O(N</F)6C8"6PT$1TB1<,^FN%(H;8""N,*X\V3FJ8N;%!#!QR%$5\
MDRR?@%:XF1BV%KWH+/6V6\_#4E",Y>8BF\8FD1BR@T1 UQ+#=4=NU >K<S4T
MP,4NI)V"XVE!33,CZ>/^XGBF)JY@H-^YF P\^UH#1G@T=ROT(>+FP_R,2A>I
MX<N<DRH4(8(_]D+K^\;LA^:9I6K6&CY^Q&=36/F_6D9OJYF* 4!;&F_V?4@^
M* QOGG?-93U7-VLVAX'Z4NJ)*O5"Q ]Y(W[FLM??U@WY695SWN7?C!X)_G>A
M\F9\K;GBC:'HU3L.AA7HF=."@% 6X\?6BZ?N<7/BPU7&^&7O0X5?!O;GT7BC
M]VR_&6SO3L)\XIGK=M[]X$/[3IGY$!7FF=U%8H!0"@% 0P:N=,\\SSK08^:/
MIS;27I\04]NNA7GYHNN+6[*#MG-*;#W:<=.F1!CQD&23\7Z=DM]K:JV&2VPP
MUEVO!2'&,*H#73+(C@%E:V<L]ULM;Y<F=MUN?DQ=HHX<^H]OQB\VY(D@R5H@
M5Q6=HNC9-'TO/R)E=SNL;2AIY4H?>+R/*CCCJ1FH79TM+RX65DU.-(1*0;I[
M":AAQ#(8MS*(*)XROHI:^$M+V?(UIGTLV9X+"2.A\/2.T0PMK#A,(\VZTDL=
MP+N9$5<71D[6OJ%)BK"R*GD$X@(JJ@@.1Y2$(IY GF<'&R*DR@%\  X6GKEU
MLB?A/U=2)5>QO[?+KOTP_!ZCI_3[M25(>C]MM<6LWG>__P /TV<[[;_P9J?@
MM:W+IT]_G6E/E]7:4JZ0YGULRO6AD* 4!CF.+;\1C3USO;;1SK9ORVY_VX]
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MV=Z=A/G%,];)J>M9M?:!'^+BU>:1W45^@% * 4 H"FK/[SJOVM/?DHM 1O\
M!H[E?H0\7-A_D8E"]3PY<Y)E0H0P1_[(77]XW9#\TS2M6L-'S]B,ZFL?-^M(
MS?5S,4 H"V--_L^I!\4!C?/.^:RGJN;M9M#P/TI=425>J%B![R1OW-9:^_K!
MORLRKGO<N_&#P3_.]#Y,SY6W/%&T/1JG8=#"O1,Z<% * MQX^M%T_<XN?%AJ
MN-\,O>APJ^#>W/HO%'[ME^,MG>G83YQ3/6[;W[P(?VG3/R("O-,[J*Q0"@%
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M2TZ=T">GB=-GYZW%64]5S=K-8:/G[$2NU0N04>2,.YH.G[]<$_+PG7/.Y?\
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M#M_PRU:?Z\2?Z#URK_J+P\_G?PA_O7%_YI^#[T[*_DS _P!FI^P?V,GP[?\
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M*U[QMKHT[W3NM4N;UDL[7.2V[=/,W$%M5>:P[333?">Q")6/UIKR0D>;V4:
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MP(044-.1D\HED Q1Q+BCB8%"((!? 087+(07/$.V0@F5\\[Y97O>@*K0"@%
M* 4 H!0"@% * 4 H!0"@% * 4 H!UZT!_,<<<,;888XXXXVM;''&UL<<;6Y6
MM:UMK6M:W2UK;6H#^T H!0"@% * 4 H!0"@% * 4 H!0"@% * 4!:R.Q62W5
MM><S?9S50G(ZA<!W0X$=O)"8MN0<++/((9>521, ^L"AY"9Y8"*!@QGAEGG?
M&]KY7O<"Z: 4 H!0"@% * 4 H!0%K/E[M*,V4[I&?R^FM1C,)LKKR>+G6!_,
MR4W6NV4PTLKRVI#[9>4D4M+)FCIH2V.66((.=\<<LML;AKH6/",^11J,:!M\
MP^YQW,WTUPJ;36+*+;=;,7T!SHX1,RHH#D9[Z0VT[VVK@$E),4<2"ZA)QDPE
MJ:8JE@QDY1)&AQ+36IF&A H!0"@% * 4 H!0"@% * 4 H!0"@% * ^!DR6)%
MC!PX8 *$R@ IDT:,BA@%BQ8 /(4<P8'%RP"! !"PS$%%$RQ###QRSSRQQQO>
MP%FQW)\:2\W,'C$\AL:3VB*=.)H3JCMVH#U;@BBG"6"4"&"XVE!33,SI$7+$
M,X5Q-7'+"96P'#PRO:U 7S0"@% * 4 H!0"@% * 4 H!0"@% * 4 H"FK*RD
M-U(5' X%5-0D%#3SBNM+:R>*IB0CI2<7$.*"FJ*1T4 FGIY H"*:.'38P)8J
M7"$''%P"PRRL!0V)(##E%K);YC-[-&164MXF,T5X,1R(SN:RO@4,C$C626X&
M^=4$D_B6.%S!0QD4-BV!,@# "7Q%"SPQ NZ@% * 4 H!0"@% * 4 H!0"@%
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M?"%[EYH)\5J(/DDGT+3\.7G2ZV2,T*B@% * 4 H!0"@% * 4 H!0"@% * 4
MH!0$7?!8[EMHV^]F?^6SJH3+5\[ZR42A H!0"@% * 4 H!0"@% * 4 H!0"@
M% * Q+/O\!,U?>ED?Y'+- :Z<,/N;?#_ /$LTO?,HR:$RU?.^LWEH0* 4 H!
M0"@% * 4 H!0"@% * 4 H!0"@+:>?K/=GW-+OQ6:H#0OA"]R\T$^*U$'R23Z
M%I^'+SI=;)&:%10"@% * 4 H!0"@% * 4 H!0"@% * 4 H"+O@L=RVT;?>S/
M_+9U4)EJ^=]9*)0@4 H!0"@% * 4 H!0"@% * 4 H!0"@% 8EGW^ F:OO2R/
M\CEF@-=.&'W-OA_^)9I>^91DT)EJ^=]9O+0@^&1HKAE?#,R!AEC?;+'(8/'*
MU_!>U\K7M?W[4!^?-I/^^RW^G"_XZ >;2?\ ?9;_ $X7_'0#S:3_ +[+?Z<+
M_CH#Z!C C;^5#!"]CMV7E8F&?8[[[;]C>^V^U]M^NU]NE ?6@% * 4 H!0"@
M% * 4 H!0%M//UGNS[FEWXK-4!H7PA>Y>:"?%:B#Y))]"T_#EYTNMDC-"HH!
M0"@% * 4 H!0"@% * 4 H!0"@% * 4!%WP6.Y;:-OO9G_ELZJ$RU?.^LE$H0
M* 4 H!0"@% * 4 H!0"@% * 4 H!0"@,2S[_  $S5]Z61_D<LT!KIPP^YM\/
M_P 2S2]\RC)H3+5\[ZS>6A!UW6WI9TQ2S,&L-X2IIR@>2W:/J[EH@,Z9 B&/
MGDXQB)$HU@R1(5;<;>4E,0H3#RRP*E\S5P2^&5\0<,,;WM6D$FG=)Y[N8I4E
M)-)2DEQ8Y)M<AK7KRT\::83B1E&XBT5:4?1M)DZQ##))7QTV:?CHS;+2*Y<4
MTVKD@7D@)3/Q5!@P;(:,:=)O)#(JZR1.G2*OB7Q2#TR225DKMVT0IMR;XTY6
M46_"ER;[._1GUD=T^J,+M73!!$W1;IBT=+>5H2E]_24;^DPTWC.-U2M$YR.R
MZ3'[NCP!57LV$P',25GL([7PP5UR8$U3%D9MI53R3N;A!?JVK+)>7):WY=W/
MR[D:13<FI2FO=12?&E91DGG?E:?%R:RSORD[Y'0MH?-D29L713I6)BFBI<P*
M3'T[1#Y<4$&!P$S+#?\ R=;]U RRN$)RMV^%^5NE:)*R]REZD8.<[OW<G^D_
M:95T 1%%$,ZUM73:A^,(\BEN*&EO10N'T"-F4VV*B'EL>6==I =8.)3734LB
M95!B*<GDA5 8#,V(4($RV8V0)4###.:2>2MEVLUBVXYMOW3U=^2.\F3JA(H!
M0"@% * 4 H!0"@% 67)$B,R(H]?,JR,O%6NP(V:+B?;V<AW P*40FJU$DVN+
MZL."4!,&Q\""61,F;ER9<P;,7#L"5+CF! PLPUT,-Q_J"9D^PL[GXW420V21
M" =K<,(DO,%QQ<Z E!/0@CV0H*,ZRA+-32S1%4(&2BPCC**6((*83!38*TEK
M"8GB6K;O4[FOW"%[EYH)\5J(/DDGT)GX<O.EULD9H5% * 4 H!0"@% * 4 H
M!0"@% * 4 H#AJ*BGHZ>?5U<^32TI+)&E%34U$T 23TY/(@"&3I\\=,YA%BA
M,H6"%,&C1@0, N 'F*+G@'AEE8#$\(ZA82U(M=0>D$R8U)1:Z4M"-Q45VHHV
M/ )RW@F)BY@GG@LL C)08VA+:(OIUQP PU1 6DA<3A#24ID3@XEIK7[<G7ES
MY&C_  6.Y;:-OO9G_ELZJ"6KYWUDHE"!0"@% * 4 H!0"@% * 4 H!0"@% *
M H#K=398K8<3U>B^CM1H-%$5'*Z7.X5$JD(+>;R(2'4EA;650\*"33DM,3RQ
M@Z>.FA@BY4L"*,,)@'AEE8#7-<FR*)_TK3)(<,OM D-FC1Q+:)=;;YK(8(JM
M(K76BBLCJ)4<,N?2E9/'[&QI-4BI0Z$$*7,9 >9S)<442TUJ6+PP^YM\/_Q+
M-+WS*,F@EJ^=]9O+0@A5AOU_:OO'&F7\G:M:PT?/V(SJ^$O-CU&5'DRF;(K:
M567(+2;+Z9RZ"&67&F\D%*<[:62X0X1H(NJH2V4/):B"&9  ,!A'"HP> X(0
MV.-A \,K7LGJKE$VG=-I[T[,QZ-INT[F<47 Q D+CX-M;1G,W<1HM8PN*"Y&
MZA)#7;[@1<<T+*R6MH39;Z"W495(V /IB$B)"02, )Z:2+@Q9;ET(<:7Y3Y>
M5\N;Z7FS-%206_I)]GCJN\4?1%\\FOFLIZKF[6;0\#]*75$E0JA84 H!0"@%
M * 4 H!0"@,'ZF(,0=3FGB;M.SG5#Z$@3;%KWC%374H,(930B[R;Q]#LMIX
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M>O0F?AR\Y]9(SV6/ML>F_6W2V^]_>MM?\%Z%1V6/ML>F_6W2V^]_>MM?\%Z
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MF$LVGF&:(;P$*X*@)D$]ACED!F#>V56FG9EE9QXRO:]LU;DOR-F_M0!0"@%
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MC]O(;C5=0D3)Z$LKS8E?6TI.1$2E8V[0B"@K-]/=C6/+2<4'%-I9-R()D\"
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MH\ICZ).+CH>F I@HI,FF&HEX:=XRU,'U1^I=FZ12V/*[V4XZ;2 :&L;/7,R
M&]4\JW#C52L%$0TKK[=36^<73RGB7"!Q:Z7'7E6;^W29R.:_-%Z?DV<3NI2*
M2_HPCA<E]OYB.4"P)N,&P$\!7.^3 ]L;@I;=;(C >1%QJ"L(1#05=O'T56\Q
MJ^(9(019[G_S_P HSE%$Q1E.+7$><4O!,>;< 6%)O'#R=B;+C)B^CYAX*:(K
MIBD6)*J.KDK#%Q1TY4(E#F)<T4-6!N6-%Q10::U,ET(% * 4!8LHQPU)BC.1
M8B?9(128\IL5W1P\DX$QF4&/M5[H"@V7"2"-!?NA84TD*9P ,P'VX.8EA,.V
MQM0:&M.G?0O$,"-!W-Q9.KNH%<?KV3GZ\'_/:3';F=2RLH$<LB(6J'8JV6*S
MVBF$VU&L=-%L$,$AL$!S6) VJJA@^K*RB<,"7)OR65E;+*]_C;;ZLK(SK: 8
M(QM:V,*1)C:W2UHW9UK6]ZUD;:U!=[WTL_OT H)^LK$O^KAG?^C4%WO?2S4B
M))CT 3DL)J!&<?QZOK*L_G#'Q%-$@HHDFQ3;:CQ.E,\ZK@*[3)9X1Z89B\U3
MJ<^LL;-XXIO%J-S YBXUPHE9"7QEJWOU_P!S,N21I*PFP#3UE%<6VE,Q%IJ9
M0D/Z$B!<IE'Y-VDV085KK5F[YT8F,'&>+$[)=SEE'(+.YO$M<MAD+81>6]]+
M^W(77C'.E;)4<"'BP]/V2TTR(2HZ4?%KQS=4;28,!<T"HN!/L1N;1B(I:US
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MR*XA;*_EL6IG*/#+"<DI- 5?T>@N6$TAP+TKHXQ"+03;&2&D;*)SN/+EA2.
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MZ**>-I! RG'E4 F45$T8V(-4Y*G+1E&^L2-=$@NF1G.:6Y'9[7?H9Y(;FEI
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M@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% *
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M>T>B/5-]9N /A*R+^J?09;WT+VCT1ZIOK-P!\)61?U3Z#+>^A>T>B/5-]9N
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MQO0\ ,BX/!YO$)>D@LUUHXBR'(6!MX&"UG200V.FA89+ADFV"9IT*HEP;O\
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M=/[)J >G??8Q?CI_9-0#T[[[&+\=/[)J >G??8Q?CI_9-0#T[[[&+\=/[)J
M>G??8Q?CI_9-0#T[[[&+\=/[)J VBT$ZMOIOYNU(/7Z'_P!#ST,17IH:WG9Z
M*_1;YNV=NJ%6\W>;?0VV?,W[X>9_,OF0Q_S/EOFC]T\KP$\BYWU1)2J$"@%
+* 4 H!0"@% ?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>42
<FILENAME>g947560g70z93.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g947560g70z93.jpg
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M[V3SA2L[N:&";1QBSY76\5?)JT&,AVE+$:0_N#8>O,.CZK6E<>-4''&,*O\
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M*+34HR3:::::;35#';2DK&V:E)-65HTTVFGJ2Q33P.OW^U>,_P G6+_A#?\
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MA+@TO;(X)'5H=$"D&C$ZUN<D!QZ-<D/+WH9*E,<:2:#>A &(.];P0?4P!@#
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MW=_X^7<WTQ>DOULRG/>/P%_<WT1]+TM_$KR:KY6>.K;YF[?L8$6,V^=;& ,
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M MOFK3T)'7)Y]/31@P!@# / S^#,_F"_N[REIX.T[$O19:'/CVH\4=F7XO\
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M%P-=HIXX!JJ^*4&!T3+>O:<C%VFIB]Z%Z-5JSL4SK5$[FD["86SO-^M0B!F
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MVU]BR_Q+N_\ I[G/_)+=SP]]4#]O_P"1-&^G>C:?)+Q-#Z3>.,#;6S2!V48
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M[6=4J)Q=$ZU+9<R&$PKC[X@O8WT1.#_UO>0+,4\UU>MF>'@UVY^C9ELN4)&
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M#Z=W=_[3MB8+SSCV(<$6U8*$!?*A\.#MOZ-MJ?HPNP3'-=:XF$YR#C# & ,
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M#5D"*>);&#GM^B4CE4$D2!LNYU07:@2SK5;%1>2%09T86V)O"MUG#D\2%:I
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M+BR=&"HP!@%2/D/\H:;A2R:\KY1#JP5D2ZO9=82V4W%=B6EF5;\C%/#<PPZ
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M@.71.6/:).K"'2A H4%+D@RE2<DP#^\3EW^%_*+];7S_ +I*T3HO_IMQR?\
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M3ZZ^IHX+EW)$EG;4D9)7V!U"[-:&3PF9)4NT7+:/14EKF9L%A0QR]LW\QI%
M]LLPB[$\!2&&C0KQ(-(7-,M;5"M&>%>A>?;Y3)_N>[*^>EU%_P (Y-__ .6L
M"JW+S^TD:Q-RIG9&=I6OCK)EC8V(&]7(WT#06]OZE&E*3GO+P7'VEA80.;F:
M6):O RL;.U!5'&A;VM DT4E*$'U< 8 P!@# & >(P , (LP 3"QZV$8!AT,
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M>M;5!R<9J%6I2C*.&*GU\ 8 P"H^1_'7J?\ JJ;L_:OI/!9<R7:CPF6X8*C
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M_54W9^U?2>"RYDNU'A,MPP5& , 8 P!@# & , 8 P!@# & , 8 P!@# & ,
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MUZ1Z%Z0Z$T:@ZK_%'A,V!,%!@# & , 8 P!@# & , 8 P!@# & , 8 P!@#
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M&*0V&,#6SPR#1EE0MS+'DOKB1J7!<>K7+U!VQ#=:8)45%2N]O:WM;)3E$E$
MT604627K>]Z 4 )8-;WOT[WH(-:#K>]_AWOT?AW_ +<$'Z8 P!@# & , 8 P
M!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# &
M , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8
MP"GCL:=?N>+NK+==D5Q6.MK.0\>5U756Q+KSH/F2'G.E^SF(5?[9>X5#(MM3
M<$I_GZ60.STI@TD=E*1K^3R]A+$0).+)52__ &?D44_4R/ORMTW\T5[_ /\
M.EY ?^T>3JS^]7YW]"FM#[Y_F_U))T2Y4%9O,=0]$6(+K6MG"V7:0Q=OK:']
ML>0>\WX4OC;W.FUP8(LG@<_)E\V$!IKV22H]2W0)$)!'6QS='%*D;VI:L!!9
MIIT]_+L\^9SW#ZVY'GJ9]5Q6[[^<28PW,KQ(-G=V]J-1C0S2&%1.Q&=Y6D/%
M^-YY+,KATXBSS\K;+^3T^G4*!4I(<TB]$E"CW,RL= <UEB2!'<=Z $O2H5R
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M]R!4_P#*WJ+\^'M3_O\ X ^Y J?^5O47Y\/:G_?_  !]R!4_\K>HOSX>U/\
MO_@'[<@JW-320$SH^2.1&,%N]*0YO=9;)'Z82(<=@W25LPV*HG242AQ=Y&^G
M-$98FAH+<GQU<712G0DC6K5)_KG#$O/R)]Z3).8(& , 8 P"O7L%:G(LZ)*)
M ZVF*&P3D;LR['"&UI>5MT7]MDDJR0\OF1_3R_5)+(LY+1)6J22IJ;=N^GE
MU_;$O6E-9RC>O2)2JO*EWU*W(;/^B9S$(K-F;D*2EL\PC;'*6HM=YS>_B%H&
MV0-:5V0@6$E50H*)5!2JRM*"BSSRRSM#  XP.M#%.K-_X5^=_0JY03:UGA_[
M?ZDD^8GBN;:KSHN97NP]"T(Z\U7,;4,R:8KY)>[;P:'0PRI:<M=I=X\[)9=7
M<B=G%X37&T1M#$FZ$+GE:_H@HF@3JK=$B0,4:P>#ZZEL'1IU35<J;6O421@\
M$Y)L-W*CD<MKJ,J4&I1*_M2E78/?D!F!( .LC9QIE<2GERQN1HG("R)OY@VA
M8V$.H&U$!Z$CTS+F]>K$>HS7]P;F;W-,X_NT7A\GK3W%,C7??".N?<U:EG+4
M&NR=,J^Z-]@>>UE)%1CB44,9B$M,H&I"4$DS80/N&<O464F:5AMC=&%I'X]&
ME8U1G>79 $SRI<21J6].TGBZ%T4XGKDY9BA&2C$<8J) ,T@(RP[%H#!U=2<P
M(;*;ZB56?U&7/G4@DQ"U:[([R,;C%2AGD$B2LALI*NL<32RE9&XI)9,BB"I\
M(E*R,L3I(DS.:RHSEP0/TAU.<W3Q;-4D:G77QY5?/+M'Y*]NG5GD*C42T\1]
MY>X](D;!-)+;K1$9D*./L<>VB1G0Y[?D\?<4 TCP<B.-3@-$M4/ME4%S2>C6
MN!-RWF<@;24:AQ7%>0;KHQ&@3N*Y0UMYZU2#HS9*4E<YI%3<C-/&6!2N3*$A
M AJ"3"PB#WW#F[GUI)2*'6T^@FPA>C5.*$YP[Z["1$K6]"@-=%JY(8IZ(* I
M1HVP@]Q5*21#(3H"359HP)RQF: ^6LH;FY&ETKW:O12T)C1J0)TS-W7VD_N:
MYCW[CO3NV,['?[@ZNC=L+DWC][;D2HGV2U*;L?LSRQ" QU@K+DV41N.3%ANC
MH9PB<J:"WQID@>Y>VR&,M <B8W$C3VYJKX(1QA>H1R1C-3M$F.:'90)P*))0
MF'@.++ S3[G#GOY/^5OW5>@/DKV.E'RG]WYV#\G^[B(1J@G^^_=$^[>Q$F<6
M]3HWVGJ;(7HSM"]FJ($,#U <_P#-IA!"HNXKU&F5.Z&/IE /()UV(A2_.:0A
M>VLA!P>C-EG.[@A5)EJ%M+$)8K2*"%*<DPDTL8@/CL-.<N2>&.UAL=Q]!+H6
MP)'5<_R#7=W:*=$P)6-.<L>#7[2N_P A0R_)R(@Q:J YDI3"D6@+-@]V,+-&
M!]=+S]SDK3F*06KT.GTF2MRM>F<>\.S6ER:2G;9X6\#VU.G02-S8U2DU*K3Z
M0O"1$M+5HUB,U.6J2*22@,#F<*X^@+R&.2>ZND$\B-B#=/$L?:NU>ZY,^N$7
M>IM':WCZ]J9XQ=SPXNZB3SV61Z(Q-H;$RMZE;\Y ;HZWN9Y"H) &4P*E.:;.
M(5J(/9W3CUI F:5BY.+M3N=K<$:9[(/-;S538\WDW.*<(ST3JT*=&I0";I&P
MR6+.(4DCC+^U-H'(/W(%3_RMZB_/A[4_[_X ^Y J?^5O47Y\/:G_ '_P!]R!
M4_\ *WJ+\^'M3_O_ ( ^Y J?^5O47Y\/:G_?_ -3OR77-?M!=M754M2=,=41
M&O8G^YQ]K\>!U'T$]A;_ )=J6!R5U]#G([(>'E3[V]O+DNW[XXJ/8[4[3I_8
MI"B""AEBEJK!;=G2S=FP8A@%+_<T2FTTAW;[57L(E5C2=LMSQMS4N&PAK$]R
MMX9*XO:H+"ENV1H":2)P5ML2C#X[;3!-+$82A-UH6MX+QIA7#":[X47G9B?W
M1,T^9?W1^;RO_P#Y_,NNMS\WM./J/>O/[#FCE7F.93;QY\^UA84?;ZZET<D\
MXG+E KOJ9KL!M#MUL.U5S,U36#KGF.OC6X)&Z7-LK9':&SB'2I@DS6QJBGY0
MSA>6%ZQ&>3^4VNBC\B_X,Y5>.%@VS&EI;6?EDS4.42<G.P)7'R9'*)+]JU=\
MTU\-%*WY.^L<N<B7M/S6S.:UW:Y8Q3)K7R54YQB5,,H86&4)A#=?/Q;V4W]7
M0?):?%Y6B* OL.<I>8]NCRDLA$5,%T.:U;ZTI[ I9]IHDM"M=G-W=AAC*5^4
MR1K&K>5"@UUT,)ZC0E)ZH0:SX8;,*8T\A.!\H>LY'<<.OAV8=J;(@L4DD/C[
MM[T> @AJD[G&G568>D"+0#EJ(^,)RFT_U@ (3N3N XE2-0G,2"/?W[SB-KY6
M.:I5(WDBP@#8UZ:]VJ,,:J$-+BICS+T]92.W;N2NBUW<G)DERISG+6U&PLQT
MBJ=HC$>2GL+ZQ37WX]?@FOJ\RHCY<*XRBL:K5973BOBQS<Z7K6]Z+F2'UJRP
M:M&YUK0^L3&Z/0^LB7-[:XJRO9E6MC_(0DN:_:N=R&6RY*4B$[$-2$&Z]U.E
M]?OE@1/EGC8>XP@K6-THO@"IF0QV(U]-ETZ:DK<2RQ>--/*C"LDL/BK3&W1*
M?/7='S.@>2I -[:A-3@L^0M-[A\K(9O7@FM6VZXU>_.O3O=<NXD%T5P5';^*
ML[8IMN*.%K2W3](78J*^^.J9GW0"BA L36^,LDB,F3B;T*UPE36(Q^.CAKBY
MNC+*8E*HXYN#<I$5RZ,N^O'.FS PZ;>-&!S)H<VW<Z5M"E\;>DT+^X)(:P'B
M?E'1R7HY*X+GI.H/$6[#B)?1S\!I)<Q+ +B&1.F5B**=%V@!7%/=3S4]A^JK
MQ]+AO;O(DMG0@T^92.&2BPX:]TB)QJF2+()+[DFS&T-<,:K0CSQ&HH.0VT2]
M/,?*F3D"4/$3*-EJM_:)5+F-V"OKICBFZ>S+IS/P?O&W')DGE3?-['!(FES@
M#]6$30#KUI!J+Q)RB_4<8:U2\QQ>W<#_ "]K3=32<:I_3$1Y XE1MG3)X^U>
M^NAZ@2G2F&VK[T_)ETGQ++\8$9L-YD:@FTUD9CK^FM(HF/M4,**TR#M,SHK3
MFE0A02EJC+HRHT_1LA$G;Y5$9$M2.#*0JC[O'44CE[6]B$Z4\_2E2B\E"1;=
MS*Y1F-L06E]8'&5H>C(S?#JG;8[]H5?&;)2-<&D;+&X8A7234>2DUT4N>&M&
M8[.(72TB_MF<EZ(#PKTB"O72E-_4N^A@T'\=%#1B-QN,OI#I(T,1::X0L0&E
MQ>:](3N$ JZ!U>:]*T<(>FI.Z+9&@KUD<EP7,*L*8X.TA AD!V(P&WCT^].K
M'RGWX9P["X(ME!;3/9\YQB86[5UO/D9E;GJ2!5O%6+#I,VI37A:(+FI.?;&+
M9Y])7E<8K='IT9RR',U9[ZN5'!7U^?#A@J9$@JH@3G"AV:Z/2A(-TL>V)7/C
MD;<:::VM;:<F9XE%TJ;9Q*<85BJ(1&/O,C+"5LD$M=9 %*>L2^Q6J ;RZ%3U
M^LY:P0, 8 P"+O'O_@X[_2$[ _:XN_!+S\D>")18(& , 8 P"O3KQA>)39>X
MQ'6Y4\2"1^/3R%,+&THB_:K71X=W_D1O;&Y(5Z=>T5+5J@A,G+].O7-- 'TZ
M]."RP_.CZROBGKBLB%5'5D-?.+>X0/42KF$1AX EY^7J$P71AC+8U. 4ZC3\
M'1Y 5:0[1)V@AT:7H(]!UZWHUD4TDEC@EN]IA<&V\5F]_L)*\151.K*J_OLB
M=5[/:20]!=5CE$.:+IK)C.<G>&(N7.4X"I5R2M9<!X99#"Y!)Z\ED7>V5>(K
M;XQ$NR5&X,ZT]*Z(J2=6W[Y&1*BBJY+9VF^_'<<N-_CLCX6A] ZV)_\ 61U'
M6PV%RC\%;TT=JM-75Q?NME1ZGHO-'VPCX;"GE064T*X<X2&2LY6S7%1ZBAJ5
MD1U#!-<:YYK'S5>VGJV'QH+XRH)&S@K9/,4\Q6AF\0F99*N'J%34@%$I1R1)
M0LS0"<3*PI C;';?),=1KB%$F7D)@2QT+:TZ%J9F1F3B=;WKOKGAT]'K))E\
M@U(XUE1=9S-O-EK?S^)@/A2XS>VD?O$?;]-J8*A&A,$06@.3%IP&("!!"6%(
MF+3G%%@$$8ANK;WGZ2;G%:[7$"V6.> 8])WPJPDD=610+T6"VFZF9Y1++)E+
MIJ0-9BB)$P:=#-=H26B3+')_CS*XHI@RI#7EM=0KAY*>2M>)@2?B>.A2]2(S
M)$Q-A?34#GU?.XX36,7@1B=#8#Q9CZOE4X(CR@EMLZQ$:NSG)$5,G)O8E:UJ
M;ROE1,L?GB2R%Y"N5<4MCX'%EG\% ;W9GL6D$4"-G,>GMD3)%$9<S-C'7+N*
MT7E*J<"Y:V-<>>M2Q/$&L"U)%&E82V 2.JI#)R75*LCR5K= 3WUV9/=UUQ_J
MLF9@;PPE>:DHN'/<N:4DWIOF^!40ED::*$O#9[>,OE-2-_=&H6ET:DC.WR0Z
MHRV XV+/<.EC>S/AKI&9/%92U,KPWA7/IZ<<FL_+CO,*9O&7!FJ'HXV98+DI
M=DT]634R6?:RD&]GHU5=VA7Y43&O<WAV>3F-("SE;X3\H/;@H,<FE.-0,XY6
MH5!"N?3[5[#T&[QM',3$E2QNYT<?D+95$=I!N=6JJ$;:S**_CRM :8N?F)IF
M[:XK+-D: <B:Y'9S#)HN_B+<8^Z1PN-O\.;'8\3K;\56N?1TUPVT:?34RT7C
M[;7"2-*YXF\53PMHE59S1-6<.J1)&H@E=Z\*Y<;M,38B<9K)RF^ *F'E2'-;
M-%-D*E3#N2RDY6_R!-IA;V9[]1%>#6>^OGQ\IA,K\7<0>&I$QQJR3H<S@K-+
M6[B@;844B+4[2FO1P9BC4124P]<3(Q;=Q)3VUY5R&"O"$(MRB&R%U011VBH:
MSW\:=5,J'*<?X<*BM5]%0)MG#8H<KLIQ?3S0X(X2EBC<QM8'"Z9$RO$G1-KN
MYFRZ3&22[Y'N4/VC&@E^9&UE1[8T[D!Y=GP&Z][?E=*^3#_D^P/A6K)2X;?)
MZF4*CGT=SN\N9F):NCA[H]W-:D0MCT+IA%U3 _NY=?+(M]J\?/4[*"XLRT\X
M]*BUZ$6PKN\CV[>ZM<C'I#X\:Y.D1\EADVG$;/W"]Q5$R/KY(9A'D2YND//[
M[%'U,<*1L4V;%47!SM#D;:KC4WCLH;E0PR>,2R,2YK;GTL*[_?.O?5G*_.7-
MFJ$?),H3/(G1L65[6\!0FGG*U#@\+8M,KJM*63-R]\,4&MQTEG%]29(D81.#
MX8W-; @5'OZ]0YFDH@;KT>Z5.Y?T)7X(& , 8!HK^9#XD'1O_P H?U#U?@S0
MYJ\O%F]1@PC -<OS0R21Q/D?R7O43D4@BCV5,/'TC(?(N]ND=>TR5UMJLVMR
M)2/#,J1.20"]M6*T"KW945L](I/3F;$4:,.^P<D[I=[_ ,J>35QOEE&WNE]Y
M0:&NEZL).2C;7>\Z1NUC;V4G%QDHVEE.4&XRC))NC3HS!?)SLKC?+6S>K:65
MTOEI"5$]6<+O.<))---QDDU5-561I>?NJW#_ .MMY_VV6I];\]T_W1_!Q^"U
MR_\ GO\ _NS5/]H]-?YZ?_Q7?_M&]1R'T-+ZR\/G$5A&6E&FZQ); &6/LJVU
M4ZZ;OEG3):T3Q='8:TGN\[A96WMU>&=M<))*95*DK%&*X99M(7QR8T;:.3L?
M@&_V<+&_7VRLXJ-G97N\V=G%5:C"%M.,8IMMT44EBV\,6;=A648-XMP@W3#%
MQ3;P6_<NHFS/>G)FPV_"X8SO%8GH1IN<2'6-(]J)"[V8^77<LKJBRD==/Y+^
MU[2D\^M,:)L62^I&9&J/9'$)<C(BJ7V+@/B$I57?Y**OGQIU'QYYW/(()82Z
M-G4D6\0]#.UD-U(VRQ%!TL6DLUNT%3#ZO;X$77IQ"IQU*.C(2KCS&&8!V]M+
M/+QJW)D<4<>;I.)4<\=WG3?13(]-H[@=9]SY:%JQ9IK>-ND$LNDJ\5R!+/06
M[7,38[C14-(7:SI8YM"&O1!;*AA%W'2J?1]0O9$*4N#O CIDACRD$E3AJNM'
MN;IMPKQITG"DCZKZU=;&75%1.X7=KJPHN@366>PR%0I7'9^OK:,\CNT8(?0R
MWH6M8^SM+!*>@91!K+<X-*Y XG.#"V"9F)F=$LF9V<**B;JLO/7H>=,.LE=6
MUGV\W6K>+;:\G1RB(P.6P:&1V,UK3$K=7Q&Y6!"HA-R%SP\1YUE+@K98X)Z<
M6)4\J(NR-@D>DKV[*&D0!IC!%%14W5Q:WM=&XB K[UMU"MG321+J3D9<,C4X
MLR+S!GCHS(Y=26.PFCI!#J;A&F>VY*B:IE;CY8TZ(@Y*Q_<K*;XU%(ZO?:M.
M&\:<'033?AOZ,6JTW+#KRK7*8'//0DKM-3?#DA>X1=L4KM:A:XF=421GCKT_
M3!(NFB>:Q%G2R^R3V]QC32)JC+%#[#E+G!6R;28F>+4(0Q!O8G=2(:IL:Z_?
MK_J?(D/2UBJ:(YXL-QCB#F6076]M#9,%=X)F20,]0I%%-6!:(W)[31R?-K<8
MC>7^%M4$:0/TJC3PF/EB/;LRMTC 5'1@EGT;MN*]568,^]?S_3OR(Y)@P2-1
M^U8U5RZYH2<>S/UH-,RN&75'#6")1B-.,\B3VE0PYYGCAJPW73!)7!B:%"!W
M$U>\MP6:0!3/W3SQKUK#?C0RB;]K22'6X\5^733>Z15DF>HPKF'[IAZ1[.0M
MLJYBB,E=4<+*KMP).5I''JB&&Q]H'+"0OR6,S$3@YQLXF/$R$*85ZO/7V'HU
M]WANQ:GFMCL5=QI:Z1YSY\;&2,-%MI'Q*L5]'K(4DB+1,Y"BA6A0631D4X;=
M3M@ R2<3.<G4A;%KXF,1K%(EQRQP=7EC19X<,>XX]+\E"ATETW@$4J6,R:5Q
M-_6,Z?V5K2-ICJTACCW5+])5+@[/-*HW1&:A,Y3E#2T"8(]+6%]721H]$C;R
MF]X$E#5PK[_X=U?ONOHQ..'CR;R%HU9KV"*Q=;$FFJ9)+8HA'(TJ"UDT@:[+
M[GBR12FK\)#@FFL63LO,,:525:2_QLR+I#WY_%\OI KDK&&KET^R+?I<-N?-
M#UY'(O%T=M/K['J_4Q"O W&FC4HB]UH'A)/G^FH<\RAWCI"5XA,84L;B\N3(
MYPUB];3N4]2*/RXV/"?6)B2/#T(2JTO5DG3VU]=<#U7CR(N,7<I.JE=.,['
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M0TZ?7\MM-2E/KN!:&H]Z\_L/N%_9 O%Q)19!-7],%$E%@**)+A-4@*+* '0
M%EEAN?0 %@!K00 #K00AUH.M:UK6L#4>]>?V&,OGG3X%DB!6UO=)=$+D#@E:
MV]P3"@=4$!<&IG<"W- RKQ)KH),6L(%1>]*6)4,UG7I#UC<O1*F]<M2GAJ/>
MO?R&KMY)^^:>O7M6Z+4B,;LINCTI_<Z^3T<C9XND>2?D2IX)'%?OB=LF3NA+
;]HN:%)J?V#BH]=*,@9GL3A&$%#)%427OF?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>43
<FILENAME>g947560g91o61.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g947560g91o61.jpg
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MO5<]N1;]RRO?+9;>O^A:I% 4 * % "@!0 H 4 * % "@!0 H 4 * % "@!0
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M\@H%E;.4'B";ELI95!;'LDU+6RM;/'KO;KM;*V.5O5M>WJVM?U* .>@!0 H
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M5>N]N;PXY9;)B6\HKQ79:E(ZNTS+N+R+S>W(U>08.]5B77(C=\[%;7@468M
M!G'?48(Q2*O1A6V;4 _7<-TDWQ\?']UQ24D9D1F5C,CN9'D6_D16V?L[?2-D
MHOTP6OYJX-C(QQXWH],OMEQS5.H,7S*. XUMR52#;LNTQDDTFQ<LTC<12%22
M$F3SU(\\N06ARPQT/8O)2J2B D(-)E]]_18K_'I^HSQI,.EJE$ V%LAW,]=L
MA&M-=0\_L1U"!H^/2[9CD-"^!.P.7$QB3S8L5W43U:UDK.00=R!$GHXQFD<(
ML[6"KX,5G><N&A))O:VT\O1^T1%O7W_C8+C+NET!0TZ0SEFI9W!VNNWN]H[L
MG6Q$7#)7-C4F@NL>+.U-:H1.<@-LM(-'T92 Y20IH3Q,L) Q0,N";0D>B8N+
MJG9#&_;T']UO>(T=F=[VL>?"HCRM?(TGLWM[/++$EZ3</ MDZ3U1L'0<[CLP
MVEL*)ZUE@\/L+3&PE=4&]@[I?:)@):4M->3N3$6T2DLS8*+(R"0LHE@FPNL*
M;M'TZ%'88*D1:][&617W^ C/>WKV_NS&S_"/=LKY)<1^/.^ITPCXN8;9U9%I
MO(QT4:$6$;9EC;'%R[;A698J<)MAZ:E[V;HOBY%SAAZBCM7+^%02LB2HR+81
M[XV%BOL>%_U>_P#BJ4%(TRZ2'>FT>.O%8QLG3:MT=@J[=XU:\$*)1-C.2%F6
MX.1NK-42#$'$29B/#3\DSCTS*81L<_."F2YVX_%T^;(=L5Q"I)$9V/@4?!L(
MSVY\&8\Z!W2(<Y-#R *GR<TL&.1L9JG:FSY2.<^E[4&SL]7C.5&L-.:VV60B
MP$_N:.,I\[AT_N2)ZF:3!@(?8HY$7<LBI3%..J ,DYV/98N$KV.^RV5RR.WU
M'M%^DO3/(C9!MR.17C<5V Z@QZ-MH.1BTRGA<9.XH:VEM_59&4*,@6@SDR*J
M!"NG#;Y07H"'\CVSU%]=LB;3<1J:VC8-'T^N^6]?:=BV;;F7UC+_ !XZ5V&<
MD.1D.TC!]22EU%)> B2R&W&#N0DHXTE,KXRQ3E2V:YYJZ_&Q52%6@LM'QMG(
MU)XVFSZ;]K:J:K8Q=XTE:@#38CS_  V7MPWV^C9OC8;3>Z-XR7F]RXT5LIIK
MT?KO6&I.,NQM.LH:J8)G,Q&V)ER?C)DG/#A<<'Q5D1C'3@1]Z7PP[()%FRF
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MDYMGM# :;MW'+K)8JYM@NZ*>#^I>V?[6@:K[?PR^\78+TQ7(#602\FD(P=M
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MT3X#YC#=49?RB<MGTRRW\L^$S/ZQ2Q?##A<$>04B(XR\=QI'6*H]QKL@RU9
MF[^%.Q4T7V.+?QIXF'Q<B"0[8#M_-F)-FJD_:2HF5/(.4R94BY=-$^ ^8PW5
M'G$_;+WC/L/C4'U[%P4(@@2,0V&Q<:V#1N*Q=B,!1X )9X63:# X<:FV8#F#
M9.UL$&C1!)!+&W8X88V]2ECX#YC$&Z@\S<09\)K+WC[BCYEE'A5[.VU[7;W]
M7MZ7MJG_ .ZFBK@/F,-T;_UT?6HB_$QV3HJ)RABF,DHV/2(:B2#F41YUF-+,
M4C$=+,ST?+)M'Z;A# D".#AYD.^Q3LZ&%F#,BR50>-4%L%CX#YC#=&_.(^VG
MWB)/PS6\L<+NY3%(1)7;D/E'7#H^" F7#B/YE&)S,$NL1:N5%0^9H8-+Y#%,
MLF610>Q(70N[:-UDUCX#YC#=&_.(^VGWC&[WC1Q9)-Y8S(\?] /VD](*%IRU
M>ZJUTZ;S,HL3P-+$I8@N!42D1!4RFF64>&,7CG,FG@_R4NZQQ5LT3X#YC#=4
M><1]LO>+B,U7I@)+6,^#:XU@(G8N+M(.-FHR'Q1A+1T*88)),8@QD;0<D8:1
M=DDBBFTC[=XF);X))8(M,,4\+66/@/F,-U1YQ'#^V6WAVBW(#(JU.$I.V'Q]
MO)#(T2&,2%!H.1.%1 !P6=@A1(LFGB_?#0KH^=<B6+IPJU'.#199FDBH2>9+
M+'P'S&&Z-^<1]M/O$OW:S]UMO[=+_72Q\!\QANC?G$?:3[Q7XT^97'N^IVV]
M202JU_X]+U+VDQ:_5_O?\+VIHJX#YCWQ!.-_ZZ-I_P!9/"?I'2,0^ 2"50Z<
M&PD>*2_7OIAO!Y&]1:KEXMZ;!J8>2^@CS.]U6/HX+128$NTWQ[I;)XI*=>-K
M6I8^ ^8Q.Z-^<1]I/O&-)IQJXU;'7DSB?:AUA,59I(7DLEMY''A!;&220AI]
M]Q^?&C*;Q-5(@_=Z2)D-6N%G."EU84\< L[79J9)W6/@/F,3NJ"V.)^V7#?A
MX<_7F,>(<$N$39,,FEQQTQ;$#('LJ'74C M92Y\G>(*%R!%9;MBIK(TZ@$))
M'&YK,@T-F(J#-%4'A8<W>X-$^ ^8PW5&S=$V/+]LO?\ %SX1D6%<;N-VN'>R
MG\!U-K6'O-PI/&^S',=!BQ2TP:$'LA*/6!51IBEE<:Y+RZ5FE1K:[=AD;D\B
M,]S>BALD[<K'P'S&&ZH\XC+_ .]//MV[,_07 0PJTZ.#H^&,72A+3BCH-"(H
MJEU4H[A#0WH3A8^%0CIQMW'E:Z5V!8,T8,B(W+&X]W8:*76;9N10Y9LT3_U3
MY@W9.W=4\.:R/.][YGPC=Q%<>W1201<ML$D$\$4L.Z$[]@FGC;##'KRSOE?L
M<<;6Z\KWO?JZ[WO?U:6/@/F,1NC?G$?:3[Q!!7S*Y*76L[;=>,A;6O\ QZ7J
M7]*D8RZO][_A>U__ 'IHJX#S]!ANC?G$?:3[QTY+#X!,B4),2H)'CY76\IRF
M\"?E$6KMU$I?G&I%#LY&"54O?)@6RBLNDX"[Q&^*MQ9TDUZ^UN5+76/@/F,-
MU;\XC/;]-/O%,D^B]"S4X6DDOUMKZ3'3Q&"EC9,V&%DG)<CK+T=[W[LCDZP5
MQ>*Q&TGD.(/M^.>++ R1PPQ[%TK;)HGP'S&&ZH+8X@O_ ,R]XP?AT>W Q,$G
M&L>,.CO0--9)6[#**"L\'":4>2B.3%ZKGV3@@(=1%NRB9 (^6<!R<6&BHX18
MN@PD:R:M$^ ^8Q.[)+_I4_;+WC,\)X_<>];;!F.UH!J[7,.V/L!-TE,)E'08
MH6<.)D7[<L6P<.VN"=T,3AAHT,R"S/%MZ8#3-H7-=WDFJ#I-8^ ^8PW5!Y;H
MBQ?_ 'I]XP@(Z.S@( CA*(A>+NCA<:+2(/+GP=E%AB#-25QX9,@X&3)8896R
M:2 */V%-D!1EIF@18928JX:N4G+CMV+1/@/F,-V1MW5/VR]XVWB4?A<"BT<@
M\($1V)0V(!!<:BL6CK4>' 1V/!&2(X.$"BF."#(<+&,&Z#-BR:HI-VS9%-%)
M/'#"UK+'P'S&(W5L]KB/MI]X-GS+TUFL>ZVW7:/1B][=O2_)<E+K6O\ [W\]
M\;__ ,4T5<!\Q_&^&Z-^<1]I/O%A[M9^ZVW]NE_KI8^ ^8PW1OSB/M)]XJ&$
M*ULE&FD,3B4'3AX\DP,L(I@! X1ID8%2-"8"RK0%BTL+;$ALM:MI2P?(M<'3
M.1MT#;=5,FBFZQ6/@/F,-U;\XC[:?>*BYT5QY>GPTK>:<TP[E$<>/2,>DCG7
ML'7/@B!&7K[!(/@QA41F1%O'\]=.9N]<L7*"[J7N%Y*OFH964>Y+'P'S&&ZH
M\XC[9>KAX,A$8<:N+:<55@J>@=!)PA:5ISM:'8:KUWA%59PEAVI*9*Q[$#80
MI*TT_P"+3D63.Y?##^!B\MCZE+'P'S&)W5'G$\'[9;.#:+])X!JR;EH@?F<*
M@$N.Z^*Y'($:D\;CI\M"#>=D+9F(@1*LG;R-%<K-FULB 99D[RLW0M=:]DD^
MQ6/@/F,1NK?G$?;3[Q=N[6?NMM_;I?ZZ6/@/F,-T;\XC[2?>*\X?,O36'Q[K
M;==X])+]7;TOR6)16U[_ .]U?EO:FBK@/F/XW@W1OSB/M)]XL/=K/W6V_MTO
M]=+'P'S&&Z-^<1]I/O#NUG[K;?VZ7^NECX#YC#=&_.(^TGWAW:S]UMO[=+_7
M2Q\!\QANC?G$?:3[QU>H-V79]0SL[Y]LOGU->RNIV_%UV?9?E[/NG#!QV77V
M7;\<5NOMF-LK+'P'S&&Z-^<1]I/O'$HW +(Y-UD ZK?/N>^:"B;)1'.[17M[
M6^266-\,NYE_XYOUXW[2K_&)]CG_  J6/@/F,-T;\XC[2?>/ZH@!54>+*HB%
M%2+;%F054399J/VF&*F&#5YGEC?)TVQP55PQ07OFECBHIC;&UL\K76/@/F,-
MT;\XC[2?>/[BB"QS64Q2$XJ.4F[=QGC@SMFN@T[+N1%;*UK9*I->SS[G3SOE
M@AV>7:L<>ROUK'P'S&&Z-^<1]I/O'UFF$44064P%9JMG"CQLKGBTR4;NU4\T
ME72&>5KY).%4E%$E%T[XJYIJ9X997QRRM=8^ ^8PW1OSB/M)]X[?=K/W6V_M
MTO\ 72Q\!\QANC?G$?:3[P[M9^ZVW]NE_KI8^ ^8PW1OSB/M)]X=VL_=;;^W
M2_UTL? ?,8;HWYQ'VD^\5Z3OF5AK:]W;:UO3#$;?^.E^7*5A<;6_WOY[WM:F
MBK@/F/>#=&_.(^TGWBP]VL_=;;^W2_UTL? ?,8;HWYQ'VD^\.[6?NMM_;I?Z
MZ6/@/F,-T;\XC[2?>.IE@%RP1PRQ%Y8-[98H898M+X(8Y7QOEBCC>W4E;*^&
M%\K86QM>^&-[^KC;J6/@/F,-T;\XC[2?>,!:QXO\>]/SN6[,@4758S6:HNF9
M8N=G\\FR0T6]D[R:O0,*$3B6R,)K>,O)<_<R1W%]>#8O'G)FZ)!89FY:M5$5
MCX#YC#=6_P#71]I/O&=UV<<<VSQ<M0KC%1LX9J8KH,5;9M':N*[MKG93'*V3
M9ROA@LX0RZTEE<,5%,<L\;966/@/F,-T;\XC[2?>._@Z8)X8)IN&B::>..&&
M&"J..&&&-K8XX88XY6QQQQQM:V.-K6M:UK6M:UK4L? ?,8;HWYQ'VD^\=K'+
M'*ULL;VRQRM:^.6-[7M>U_5M>U[>I>U[>K:]O4O4"LC(RN1W(\R,MAEPC_-W
MAT+EFP9"SB<(CY24R8B@2<L 85HH^)O$ XMZ;**-FB-LE5K,1(Y\0<6PQRRP
M;-5E.J]L+U["D2&(C2GY+K;#*#02W75$A"3<6EM!&H\BTG%I05]JE$6^/QTI
M].GU:6W ID1^=->2\MJ+&;4Z\XF.P[)?-#:;J5N4=EUU5B,R0A1VR%S&Z&W.
M8:Z[>C-8S-ZSVTC*G.LW2 -[DA.&\'P65EZ\<5NG; DC&T4%EBZJ&5\&2">:
MRV6*5NSK&75*<VJ6E<V,E4 V"FI-U-XQR3(HY/%>Z#>,R)LCS49D19C9,X6Q
M'(12'&*+476Z^F<NBK3%<--313"4=05#5:SR8:4J5(4FY-I2:E&22N,<A 9J
M2EQT?CH@F>.F'B \2%#,'10L4?N<[)MV0\<R27=O':ZF5L$6[=%153.]L<,+
MWOU5F..MLMK=><0TTVDU...+2AM"2S-2UJ,DI219F:C(BWS&GC1I,V0S$AQW
MY4J0XEF/&C-+?D/NK/10TRRTE3CCBS,B2A"5*4>1$9CM1>+R.;2,)$(B$)22
M420FS#  (=HJ^*%BK];%NS8L6B&.:J[APMGCAAAAC?U;]=[VQM>]J7WV8S+L
MB0XAEAE"G'77%$E#;:",U*4H\B(B*YBN#!F5.9&I]/C/3)TQYN/%BQVU.OR'
MW5$EMIIM)&I:UJ,B(B+[AUSX$U%CIF,R06^!R&.E2 ,Z%)ME&9(08%.U6)(:
M_:+8XK-GK%X@LV<H*XXJ)+)9IYVMEC>U2TZV^TV\RM+K+S:'6G$&2D.-N))2
M%H461I4DR4DRR,C(Q3+BR8,J3"F,.Q9<-]Z+*C/H4V]'D,.*:>9=;41*0XTX
MA2%H41&E23(RN0B:N#'&7-4:#W1O5<VUT[K*8[)<1M%BX/(Q *Z,*"42>;I,
M>J^Q:X9W0P>9L7>#>^?593)NK;'U<+U@3ZI3J83:JA-CPR>-9-'(<2V3AH))
MK)&D9:1I)23,BV7(;^@X5Q)BA4E&'J+4:RN$EI<M-/C+D''2^;A,J=)!'HDX
M;3A(O^T:%6V"G3>"336DG*0K844D$)EP11)(M&Y0)>A30_)PW2=MKN1[]%!R
MFFZ:+H.VBUT^U.FBZ+EOFH@JFIED1I4:8PW)B/M28[I&;;S*TN-K(C-)Z*TF
M9&:5$:5%>Z5$:3(C(R&OJ=+J5&G/TVK09=-J$524R(4UAR-)9-:$N(TVG4I6
M1.-K0XVJVBXVM+B#4A23/B/0R5Q<?%RLBCY0,-FP3*21%Z0:J-VTB X$WX;,
MN*5SM;%VQQ*BR(^ZZ=[X6=,G"77V2>5JEJ0P^M]#+K;BXSNXR$H42C9=T$N;
MFX1?LKT%H7HGGHJ(]\4RJ=.A,P7Y<1^,S4HQS(#KS:D(EQ2?>C'(84>3C12&
M'FM-.6FVM.\(Y<$;;!A\B<ARC>/EWQ(8*.+L'20@F2#)#US \>242Q9O7HI$
ML*5)-6RRBS%,F/S=8)8O&]U*R=;4XMDG$&ZVE"UM$M)N(0X:R;6M!'I)2X;;
MA(49$2C0LDF9I5:RJ+)1'9F+COHB2'7F&)2FEICOO1DLKD-,O&DFW'&$R&%/
M(0I2FDOLFLDDXC2X10LB<*#0HAFX(EB[]F+%CVB>2SI^1(.$VC)FV2QZ\E7#
MIRLD@BGC:^6:F>.-O5O4N+0TA;CBB0VVA2UK4=DI0@C4I2CWB2DC,SWB(4L,
M/27V8T=M;S\AUMAAEM)J<=>=63;;:$EFI:UJ2E*2S-1D1#(\7T7N*:SZ0ZLB
M6MIA(MCQ/,^G)82("NWLC"*19_87(DR M'#)RWS#$;V9/\,L.R;N;V2RMV7J
M5AOU.GQHK,Y^9'9AODT;,EQQ*67"?1ILFA9GHF3B/I(S^D6P;B%A?$-2JLNA
M0*-4)E8@'+*;38\9QR9&."[N$PGF4D:T'&>_DW2,KH7]$\Q$$]5;(#:]CNV2
MT)D@[6DN+/@48G#L6Y0C9XP-4?HD!PLGGA9N\=,UA1))PFCEE=-1BZPRZLD<
M[6N(G0W);T!N2RN;';2Z_&2LC>:;62#0M:"S2E1.(,C/:2BMM%A^A5F-2(=>
MD4R8S1J@^[%A5-QA:8<J0PIU+S+#YD2'%MJ8>2M*3.RFG"/-)D5 K*&I"@"R
MS"&RK7\B(1&; "D7DXJS+(D",M5&1)E8BP:E6-W+96UE$[.QSYH]0[*W\8W<
MI*6_@YVJS'D,2V42(SJ'V7-+0=;42D*T%J;7919'HK2I)\"DF6\,VHTZ?29C
MU/J<1^#-8W,WHLELVGFB>:;?:-:%6,MT9=;=1?:A:5%D9"M5>&$,][*XL\C]
M.QY"7;2TALR"19PZ;L4Y'(XD7'@[/'>.631HL44;=Q-W#O'#.[1%PLDHY[!2
MR&*E\,[6U<.N4>H.FQ!J<*4^236;+,AM;NBG]I1-DK2,DY:1D1DFY7M<AU59
MP-C'#T1%0KF&:U2X*UI;*9,@2&HI..%=M"GS1N2%N9[FE:DFY8] E6.V!*V@
MY4* % "@!0!?26K=D!@1J3&8-*1 &.%(Z$/$RH1^.;B"TN#+2*+#R'=B*"C5
MS( +=8P(35PQ[O&X=VM[J-\L<\L5$Z&XZVRW)8<=>0\XTA#B5FXW'<)E]:-$
MS)2673)MPR/Z"ST56/(;1ZAUB-%DS9%+G1XL-^'&E/OQG641Y%0CKF06G=T2
MDT+EQ4*D1R41;JR1.(N@TF="K*&K$B'#E9"7%@ 0]X7-G"+$.'%#T%'3\F5)
MN4F0\>Q:HXY*N7CUVNBV;()8Y*++*X)X8WRRM:]#CB&FUNNK2VVTA3CCBS)*
M4(0DU+6I1Y$E*2,U&>1$1F8O1X[\N0Q%BLN2),EYJ/'890IQU]]Y:6V66FTD
M:EN.N*2A"$D:E*422(S,9?OQIW]Z.J1E/4<Y<'4H,4V;D-9@W+U?+7H0H["%
MIFEDTQ727CC$NQ=C5RJ*BC7%XADA92ZE\;7U_P LTK<B>.H12:.4B$2U.I27
MC;C9.HC'I6,GEMJ2M*#LHTF1VL.@/!F*O&E0BH%37*32WZV;+49;JSI$9]R,
M_44[EIDN&U(:<94^@U(W1!H(S58CQO(X3+8@UB[V41XJ!:36.H2Z)KE&BC3"
M0QAT^?C6IX7VVV-W0IR_%D6B#Q.UT5EF3G!/+*Z675F,R8\A3Z6'FW51GCCO
MDA1*-E]*4K4TY;]EQ*%H4:3S(E),RS(::939]/1"<FQ'XJ*E#14("GVU-E+@
MN.O,(EL:1$:V%O,/-H<+Z*E-+))GHF(U\!.#!X8L2#%1XJ1(.W4?)/A[MHP.
M-6#Q0>]<AW:Z2:!)NT((K,7*[-19)!XBLU4SQ7243QK2ZTM;C:'$+6R:4NH2
MM*E-*4DEI2XDC,T&I)DHB41&:3)1%8R,678LIAF/(>C/M,3$N+B/.LN-M2D-
M.*9=7'<6DD/(;=2II:FS4E#B5(49*29%9WNK=CC8G"YX0A,E9PO8I H)@DH<
MB7:0.6$@KZPPJQ!D<T[-W[E@0[)FX31SRRP<8*I>KDBK;"RF=#6_)BHDLJDP
MT(7*8)Q)NQT.(TVU.HO="5H^D1F69&1[Y#.=H=89@4ZJNTR:W3:N\^Q2YRX[
MB8T]Z,[N+[45TTZ#RVG;MK2@S,EDI.U*K7M[Q>Y$#I!.(H^TQL-I(]:16TXG
MX9>-$$WT0B&3*Y'&1G4<DK78"<F-LG6+Q6]DLD<%,K7OVI3L<5-:I"VHSZ:C
M#4S,?\6BN$^@T2)&EH;BT=_IN:7T=$L[F7"0VCN",7,RZG =PY5VYE%@?*E6
MCKANI=I]/W/=O')233_)1S:NLG%?1-)*,OV56YY?Q4Y)0&%MMCS/1^RXU 72
M(MRG,RT4*MHU@U-]HL(=.C.2%V#)H2R=-DV;IXN@W75<H(X*7563PRB/7*/*
MDG#C5.$]+2;B3C-R&U/&IJ^Z)2V2M)2D:*C4E)&HB2HS*Q&955# N,J5345F
MI89K,*DN)86FHOP'T0R1*T/%UKD&C<VD/&X@FUN*0E2EH21Z2B(\/RJ*R.#R
M,W$)<&(1V3QPBZ$' A1OFU?C2+-2Z3AJY1S]7'+#*W7CGC?))5.^"J.:B6>&
M>6P8?9DLMR([B'F7D)<:=09*0M"BN2DF7X;2.Y&1&1D.>G09E,F2:?4(ST.;
M#>7'DQGT&VZR\V>BM"TGL,CS(RNE1&2DF:3(S@*NC%"@!0 H 4 * % "@!0
MH 4 * % "@!0 H 4 * % "@!0 H 4 * % "@!0 H 4 * % "@!0 H 4 * %
M"@!0 H 4 * /] ;@PX5=<-.+BJV5\\\=$:Q;VO?\O:VD2%M4<?\ I@BBGA;_
M )8VKRAB+^D%<_XO4O[8\/UF\'7_ ,O\#?\ @_#7_HT(?ARXN[12TKR+TIM-
MTMVD7"MD14M(,NPSS[9%O15NUE;:^&&.>>>+N-N2K7+#'!2^6*U\>UJ6OV&7
MINMP3J5(J4%)7<DPWVV=A6?T#4PJYV(M%Y+:KW*UMI;1^86"*XG#>+\-UUQ1
MI8IM9@2)9D1J,X)/H1.18B,SW2&M]LR(CN2K6/8/8.8\R>- F&\AH!!Y<DN*
MX\:\8P7A 0P'E+.I-ELW29#3.X"3/)0<C<6X3+E5)ODH]LP3=7P54324SODG
M?Y_'P[67)-)ER6#)=6EJE8E1IMZ+/B5214:>A5EGNB=S;**1(-9IRS(AZ#J/
MA%P9'IV+J52Z@E3&$:2U2_!F\33^Z33K6&WL-XA>;-3*386E]\ZGI.&T3EC-
M*3S(YD3R;X703:O&F6:]SU1'HN!VMKYR&,M!(]>9ZSULKJ8G&-@C)B 8<<HR
M\13>2TFR=%RDGVOM*5^F8=G,8B2:C7CY5*VNB8CE0:S'E^///NP):7&U.K3&
MFS2GH?B+CNKK#R3-,="DMH9@PH^X+\6D(-:4I/(CXT\&]+KN#)](.@PX,2NT
ME<:0W'954J-1U4%^%5V:C$:P?"6E+D]]MR0_-KU<G^/-'4:>^VRXZ:?//BUL
M/5.H=U;XW=N&;M"4BAL>GP_6U].C!XQU+ME[**.X2I.=6L5HX"B((-$(\:DT
MU!)$0<<'BNUQ_ 8!05;HB4^MK<2=/IU+IM/C&AF0]$7,^4%K6F/"AH3*\6FK
M)YV0Z[(=:9C.FAQY:[O&MTR,W!\EP/5J%A_$F*<38AJ;;TRG1*JU1O)YEIA=
M0K59?<IAU2AM*AQ:?%C4^))FU**EZ+$98M$)F(E2$QRWM'%--<AI5OG<VB?0
MMYM'9>GM,'BA/:6D".Y[:QEX*<+PW<XZ51*,ZXV0+0D.Y8Z(CLC#R$7&'K D
M_,2(&F4CKLNE>_+J14:0Q2Z=5--,&%4*BRA$*I(IWCL=V*4BG+9?>F1'#:IS
MKCS+C+CQ+0AMETT/$@R'U!E_#N+IV*<1X8\7=KE9P]AR6\]7,,.XC*B3XM27
M3L2,SH$*C5EA$S$4./$EQI<>"XT^[)EQ2>AN2$J.R;@FG"O7<DY109U%=.L3
M8;;N^1TUAA=B(CBTA!.-> PVK1L <#N/^U3"&<8EZ!K$<+A4YU$XBDR1R/25
MV7$O<U&=FGQ\1S&:)))^H*:<I]+7&DH4X\3+I2W7)RY9+JL!"MWCFV:UR8U0
M)^.9-,I;<21+S,05'P;T>9CBEN0</-R8^(,5,U*G/MQX:Y<9=)C1Z$S25LX3
MKTA)PJ@F233-,JF'UT^HI.5-7(8=,V]+-([]XA:YT1OP+WIR\C=2T/QX;'=6
M[8V*9?--IF8O/GY&7D8>9UJ$@9.&MP8]RH7'M"Q8O9-QDRQ=7-MT73!UT=2I
M=?F5.E.>/MLE'<JRFIT"&VE4)M^*A$=$AN:[+1(-U9;FM2&V[EI:.YF:5I^<
M8:Q5X/Z/A7%<7Y"D3'*A&P@B50Z]6)+C=<DP:JZ]47J?)HL6E/TU$9E9R&4/
MOODE9M:?C*$N,N;HBN0W#4UL?9TK.2O44L2,O] .H$GL6/8A1P7C-%X._#'=
M"$,I)HSD(^QE46(MF(J9M(\U"2N?-<A9V-;'8J-5A:/.+I&(6X<%AIB>P;2*
MJF4<1[=%.5E^2EUJJH2S5*2C<'T&M<<WE.1XJM-IZ&HE$X?T9G%W@[DUFMSI
M,Z@3TR7<)N4HJO$*,S&P7"ICL>7A5XYF%\7.^/P7D-1ZDW$1%GU9LV94*LM&
MVIA&.M>;OXHNL=3E'L^@4?RUKQX0BXJ&S".,)$T8YO>3L\E1J-82V;Z6VRBR
M)!=:DA;M7 3K[.1S<60<@11N,D'#M5'+E4RNI*>A,64]XY5UOKD1WE,J6146
M*PT^<>+4X!K2Y,;6DMTF;C%<2EUQMY!)(]/2,38$65!?=JE+B'1L()A,4ZH0
MVIB&5.8VJLZ3#34*GANO$T_&HSS*S*/2#F51AY<5B3">6M:+^OR'X>D"$&C3
MN5Z74U%KSDOS*(Q&'*0$6S0"H[( JD^.LW;9.-12W%/7H<ZX+-#.+\1(6(DF
MO!E9%!)0'@HAE'<4J1B%"93Z6:D50ET;#R)$CQM:E.G#=)NKQE$50CF<IQI*
M%-&AQE3B"DDS*8<E.+>VZL7>#UUZEPG)^&SP_2,:>$5ZGTXZ2RVB*58BK?PA
M4T&K#\^U(CR5OM2"=CS&H[RZ6<JESHU+CMPJM']X<36$\E)>'GN.6M-@L)CQ
M@,3"=R:&I;)B$Z@D08%<MV,]>*,N.T/#@9\7,J1MV<4AFLX(UDA(<N6C!A#L
MLG(^^]3*ZN*RW(:J\R(N/6VX\5F0<.1&E2%M_)JI9*J\AQR*VV3R6BDS)2F4
MK)#[:MBL&)B; 355G2*=+P?1:LU4<$R*A5)M.*LTZJ4JGM/^4K5(4WA"G1XE
M5D23A.RE4VBTIN<\RJ1!?1FXS@'17*;7NH.>7,KD,TEK.P,ZAR</:L*8MR':
M9D7/[)2E,(&,DKL[KHWE#-MCVFQ-!FA@DKDF_P F_7EA6UJ=#EU#"V'J0J.K
M=6CHK4YNZ+QVVHFXR5J/2L>X*,[F@U'<KHOD.4PQCBDX?\*7A%Q:W/;\6E)Q
MK*H;Y(>T:C(E5E,ZF,M)W/23X\V@M'=DMI)*C)TT7,AN=L[DGPMEBNL-/P[:
MT3%ZGTWO X9@>1V'XF0+T24T++9/@6=CI?!9/'QC9]NR=$(EB>/PN38 "3%M
M(%HT2'L&ZM^=A4?$<<IM0D0'USZC3&FY1-2-R<2XBJ1V#;2N/*8=6:*;&3(W
M)J2P;J%*:)Y"U&0^C5O&7@XGKHF'J=78#% P[B>5(I9RJ>F3%<COX5GS2D.,
MU"ES8C#;N):H[ 3+ETR841]I$M4)YEE*SQD7VUQ&?RB6$-9SGC% ]D&XYQE=
M&Y[LG4+38.NB82.#Y0,Y QP6$0TF!$K3 R3QC9$NX#:[UJOL$6CAZ!K1Q=RL
MDQS6X%>1'81-BUN5#:>K26HL.H*B3$.NK8727ENG4G7$QVV]W0VER9-**X?\
MJEXB(U:217L O39[M%J>"J769,+!;DFJUG#[=6I#\:&S-9Q;#8C)PU$CKJ,F
M04-^0N/1Z,NKLI+Q4X:EJ2UA@=*>(#G4F$C4F.ET) *XE<K=56ARNNC0J8F]
MSR">3 YJJ5L!>45+"QV"L4?ATHU(24O6*QSJ91[![99DXR:[!;&($SS:\7J)
MM.5ZASO&"F-N1VJ<U%8:G,+7NZ'%V?2X;S*(Y(>^D]HV45^=8F^#U= \<54<
M-IEL8"QW0OD]5'DQZC)Q)+JE0DT&>TP<!]ADC@.QRA3'J@IZ'_)PR=);2]#:
M,+O/A/(-L[FFTUV9JF01V>S<>'+AY?!!:ZKR'->,\1BP0HQ+F-*SR8GV/?&2
M)CK!(]+=5IQ$F)REA$F8;.6S)WI7*9B1J!3HT:%.9>BQW'&W(\I:23(56I#[
MB%-MU&+':5XF:%[H\Q..0ASQ=#;9I4M/<1\3^#67B#$=3J5:H4N'5:DQ&D1Z
MA3&%*=I[>"Z=!C/M/R,-52HRVBK*7VO%HE0H94]^/\H//R&UH:=\JN7>V81,
MAVA8-JYOKY*&PO06F?3&M$8!'(X:=[?[WH<9LI>4R=K'QLFDI7 JR39O+D29
M$3=PTN]8VR<N7;QUW% @RHZJI)G*EG(D56H[B4B6\\VFG^-N+ADPPIY;#*-S
M6:DZ"$.65H+R2E*?A6/Z]3*BSA6ET1%)33J;A3#GCBJ?28<.2YB'Y(CLUI<Z
M:B(S-F/D^VEMW=GWF--K=&B-:W'%^@VV-V<8@6S^8&T"F\8?N77_ "APU7&1
M>F8"RV,J<P&A)KK0W)Y5-5)##XO%PCZ-@(@=;QST*.G";U^:22:J,<.ZUDN4
M@4VMNP</PD4R13I5$\>?7492X9-&MV-,:88C$S(??=2\[(:-[=&FD(0T9F2C
MT2/ZQ7\28*C5OP@UM_$U/Q%2<;HH4%G#M*;K!RB9BU*BR9L^I+ETZ%!BNPHM
M/E)A;A+DONNR4D@VB)Q2<M*2KBKM;<>(/3\5TY)IHE!>3Q73<SBFO[SX)KED
M\" ;Z:<[*U7%N+<%:W"0[%L97#L2H?=DO@KQ^[<28L99HLR66 3%<@4[=:@_
M46(YRJ*BHQGY917)BDN.E44PIS]<E*W23I-DX:%TV/*2A),-MJ-2"WZI^!J]
MB(HV'H&'IM132\;2,.U*#23JL:CM.1HAX;76J'!P-2T>*TXD251V7XV):C27
M'7%S9$ELFW3G3\@XH:=V!B"V6)T2'VF[TYQ!/2-T=UZ&UU!Y1'5(](RFY&#2
M,%.-^TUXD0EKP@"+G8ACKC7D_- '8X>*-QIX(S&8VFFJ]4(NZPUU1R"51Q T
MTEJ8Y,E,.[LRW3U*>;K$$I"(Z4.MM2/'9<1MU*UN-O)<)P\J3+P%AZK>*UF/
MA>-7',.^#Z5,<E4B/1Z7/B'$EO8C:;@O8.KBH#U0<=C/RJ>5&I%5DQ'&68\F
M$Y'-A.H+7>W$WO8-=?-0NHQ<8,\7N7&)<<MKL27FC';[K9$[-\=@_?*)P=":
MJ&Q ):.I1HK@]'L\$7&&1Q)JHG@U8] JEUWQU4M3D];[=:H.YK*8XW&53TPH
MC57<\31*.,33CI/;L@TK49D>Y&9'I*^?-XHP&5#12&XU 8A2<$^$ I#*J0Q(
MJ36(%UFJRL'Q_EI^EHJ2I4>*J&F$^3C+:4K2<I+9D3;6P,FWKT?N&S]-$PP7
M13K78>:2PO';.0#,DZC.M+\<)<#'0C8$&9<=8;CFV(;1=Q9?M$UV'M>5-9:/
M?'6)G(27=/6VI8IF*_$JBAQRIIEN1H[;VBZI!/S?EB.XN3$E+J\BQI@I>+2C
M0X+"HZD-+;);:4'UDW$_@G*M8=?C1L+KI$>I3Y$0G(K3ZX5%/!]1C,TRK4MK
M"%.NAVN.05:%3J]>G(GM.R6I)L2%NHPGKK>''<GQ<G179DMTF1W).-9;R+*Q
M573VMXN]C^[&)%!?4R8P)']"N?1'-V,"L"0B0I;,BL'$W>+1)U"2+MVZ>H[*
M73*NBN140F*DBG19M,;)\JA+?0[35(,IYK<>JB21HK=6VXR<)^4YHE(3*2E*
M4'S='Q-A!_ ]4?K4_#3V(JI1L42%058>H\%V)B5IY+E )B-$PLO=C<9C-/1Y
MB:U I<?=5TYRF/.+6Z6:MB<C.&$VW :F^VY/J?9,5DF\.+\I%6#:ZOF5&ZU!
M:DGH:4CYFU90H&0*MH]LAP#)S:/+.#+PS&<@X1/(FU'M0HK71*1B*-3VHT!F
M?#?8IM;9<W299"YKL^(XPN,I4EU"%/0TNHC/$3:&G]T</0-:G'.EK.,/!O4\
M0R:G7YM!K,";B?!$]CQ>CF;[-%BT"JQYS52;:ID9Z0B)6%1GJG#4J2[)A''B
MENR&VXS&(36\>.<8 '29L_QLV)R1&<8-RC7$^@VDX]CJP[L4GN76!71[ '%2
MNL8]$WT_B4"'S11Y(5X0T:)C7 X"3*%G#)RDIGMTRL/.M(::K$2C+K5.6425
M4G3G-0T4Z:W4ENOHFO/IB/REQR2R4E2C62W4(0E23+GI.)\'PHDI^5*P;5\9
M,8)Q$RNJTS#43Y#E5A_$=#D88:C0'Z+$I[M6I]*:J)N3%4MMM+*FHC[[ZV5I
M5CR$S;3$AZ5#5LSUVK#V<,DCC7/H.XCH9M%HJRW(=T2'$=ULQ& \6P$*M][.
M^ZE\FS!JR3+XKO&O\3DFM?+DQJBS@>=&EE(5)9*9NB773??53FJHXYHJ<TW%
M.7I:=$M)2E&W9*L[D-13*GAV7X<J)4J2JGMTV:NC^++AQFX,%O$4K"T:/NC<
M<F6&HZD8I<-:S0RAM,@E.-D:3(SS3QTYP:OT=QRTHG)R>6'(*#[68\?-A@2(
M\@H:1XP.=O7V_/7+U95AFWS;+*9NH/FP[K5(7O?-',?FA@JI?75C#4ZIU>I&
MRB]*DP55:(ZA:2;.MII_R?%2DDK)1*(B3))>B2-AZ5[$.DPAX2Z'AC!V&TS7
MC+%E+KK>$ZM$>9>5)1@E>(/*&JK<4;1I-"C-=,-G=#=VH-@T)-0R$,Y%<'5]
MB[#"-R6MCD9UACQPU=JP]M1BA@#F/&W6$!=LI]'F#X_H+>+U)R=G+\@1D08+
M&(3,Y8T?LW(&:L70QP@OB.4C$I0XCBD3&GIORQ.G-0%&;L>LS9251'EI:JU,
M2I+45*4,N./R8["D*)V,LG",MNSB_P &:ZQ6(R'J-)A40L'T2A2JZT@HU1P;
M1*4XU5H33LO"F)W"5*JCKKTN-%A4NHU!MYM<6I-+86E7G]RQVS!]OZ0X?Q^$
M2W7[ ? Q.P865@B09-C*8!VW:$G<15P=/I0@0^+QFT!=1K/(E<DZ<%RV!60%
M0MI.0-O7/54&!)I]3Q [)CRU+E.1)+<DW#4Q*M"9)\FFCDN(;?\ &DO?0T4D
MVV;;2'#80TE/R?'E>IF(,,>#V)39])::I4>KTU^EE'2W/I1'7)JX"Y4M%,8=
MD0ODI<(S>-];DF03\M^-X\[)=7N'M;DGPVGNK))QCC<YE;,%H8'J QH>92<:
MS1UT<E6E'N0^6JQ%J*89RMF<W6(ETS)D',G008.RC 6LHH/[G:MW'/P:-B&)
M.9K3T9A3U5<GMU2.PM1RVF*D@EQR?4M1,&U37(\=M!,F:DH6X1:=S,OH5=QE
MX.ZK0YF"X=4J#<7"L7#\C"U1FLMIH\F?AIW<:@JGM,,G/;E8ECSZB^ZN:E+3
MCS+"C4SH-MKV=VMS[XKR(=O0L#V.,4V!M^(\BM224MB..XM#.NX/&^0N>@$V
MME V"B2TS?;:B8O!53.U^N(L\"23%%FFI;2P<*UQE=,;=AK*+3Y%(GL-[HUI
M-RY+U)*JFJSAD91T0)#AD7_:%:!K-1D?:U[PJX&F,XH?BUAE56Q#3\84":_N
M$HFY%(ID'%IX4)N\8C2JHNU^ P2E**YT]LG4MI;)1:B;-W7H8*<Y#;G';]A$
MU9;CX21GCQ'-,1=CL-S,E]AJZNUY"<B\P2*PL1!Q0B$EXZ3D34DE*BCU51HT
M2'H)O7/:*Z"'3:HZW2:<NE28ZJ=B5^KNU%]<,HY1/'Y<G<XYMR7)2W)+;S;*
MD&PVDB4HUF:$W' 5K$F%HTG%N)&<54RI-XB\&D'",/#D)JKKJ*JLJATBF'(J
M*9%-CTR/'IDB&_,0\F<^ZHVVTLH2ZO0&BO/E=KEOD6P5['.7 -&\=8WLY?&_
M6HMLT%I*#CY?@[R_+D28/4<!1:V?\<F48/$7'_:$U:Z;"I*^2EK+)AVI5=Z$
MG>3"=J4I<?1MEH+29N-VR-M:33]$R'S#PJ*0>*6&E6.H1<,80AUM6^JM1<,T
MMFH$L[%_+-.))A^Y$I+[3B5D2TJ(:55T8^;A0 H 4 * % "@!0 H 4 * % "
M@!0 H 4 * % "@!0 H 4 * % "@!0 H 4 * % "@!0 H 4 * % "@!0 H 4
M* % '[_^"'_DPXN__P"CM<_LTPKRAB/^D%<_XO4O[8\/UF\'7_R^P-_X/PU_
MZ-"'Y=770T\FVSA5' I%'&*>>6-EDDS-L,^J_5V6-LV..5K7_+ZMNNOKNM2E
M<73OMQNT'D'YJ>*N4^'_ &51[N.OX&_D][NC'R"WU.FM2E<6SO:1NT#YJ>*N
M4^'_ &51[N'@;^3WNZ,?(+?4Z:U*5Q;.]I&[0/FIXJY3X?\ 95'NX>!OY/>[
MHQ\@M]3IK4I7%L[VD;M ^:GBKE/A_P!E4>[B:!=$GR_BSZY.,RQE'"5T%&UR
M (C)!#Z[9:^-UF]W8])NO=!6^&%U$KJ=KSOCCV6-^QMU6W?"=1'TZ#U(E/(N
M2M!WQ1Q.D5[*T5K,KE<[':Y7,9,7_!>QK!=W:%C&D0WC2I!O155:.[H*L:D;
MHTRA>BHR(U)O8[%<LB$2KT.G*)=51=<E'%EEE,U5EE?1A15553*^:BBBF;2^
M>:F>=[Y9YY7OEEE>^65[WO>]5EX4Z21$14V:1$1$1$N,1$19$1$3EB(BV$,=
M7^"IBM2C4K%% 4I1FI2E-U(U*49W,S,X]S,SS,SS,\S''X&_D][NC'R"WU.I
MUJ4KBV=[2-V@CYJ>*N4^'_95'NX>!OY/>[HQ\@M]3IK4I7%L[VD;M ^:GBKE
M/A_V51[N.F.Z'WDR28,R"+V-8HO6R+I*V6!7LK8+)XJ8VR[%I>W7:V5NOJO>
MU2?A4I1'_FV?]:XQ'_Y@?-3Q5RFP_P"RJ/=AW/ W\GO=T8^06^IU&M2E<6SO
M:1NT#YJ>*N4^'_95'NX>!OY/>[HQ\@M]3IK4I7%L[VD;M ^:GBKE/A_V51[N
M'@;^3WNZ,?(+?4Z:U*5Q;.]I&[0/FIXJY3X?]E4>[AX&_D][NC'R"WU.FM2E
M<6SO:1NT#YJ>*N4^'_95'NX>!OY/>[HQ\@M]3IK4I7%L[VD;M ^:GBKE/A_V
M51[N'@;^3WNZ,?(+?4Z:U*5Q;.]I&[0/FIXJY3X?]E4>[AX&_D][NC'R"WU.
MFM2E<6SO:1NT#YJ>*N4^'_95'NX>!OY/>[HQ\@M]3IK4I7%L[VD;M ^:GBKE
M/A_V51[N'@;^3WNZ,?(+?4Z:U*5Q;.]I&[0/FIXJY3X?]E4>[B0%=$-RS!$&
MI<'(1 8JQ4NJR)BG1\<0:*WPR3NHU>LVZ+ENI=///"^:2N&5\,LL;WZLKVO0
MYX4*,ZA3;M*EN-J*RD.'%6A17O925+-)E<B/,CS*XNL?X+6,8KR)$;%M$C/M
M'I-OL%5&7FU6,M)#C;"5H.QF5TJ([&9;#'\)]$'RQ-OW14R?#%RCY6Z[TD3<
M'G[]XOE:UKK.GCINJX<*WM:UKJ+*9YWM:UKWZK6J4>%&CMH2VW2YC:$E9*$*
MBH0DN!*4K(B+T$1$#W^"SC"2ZM^1BRB2'W5:3CSQ51UUQ6S26XXPI:U6(BNH
MS/+:([/H<N3N&&>=WL8ZL,<LK]6!;KZL;7O?JZV?5^2U5:U*5Q;.^W&[06OF
MIXJY38?]E4>[#KL>AZY-/V3-\D]C-DGK5N[2ME@6[*R;E'!;"V74SO;KMCG:
MU^J][=?Y/4IK4I7%L[[<;M ^:GBKE/A_V51[N.UX&_D][NC'R"WU.FM2E<6S
MO:1NT#YJ>*N4^'_95'NX>!OY/>[HQ\@M]3IK4I7%L[VD;M ^:GBKE/A_V51[
MN'@;^3WNZ,?(+?4Z:U*5Q;.]I&[0/FIXJY3X?]E4>[CD1Z'7E&W5270)1Q!=
M!3!9%9'T935153RMFFJDI@TQS343SQMGAGAE;+#*ULL;VO:UZ@_"G23(R.FS
M3(R,C(UQC(R/(R,C<L9&6TA*?\%3%B5)4G%% 2I)DI*DMU(E)41W)23*.1D9
M&1&1D=R/,AR.^AZY4/W3E\^+@'KUZX6=O'CO,VY=.W3E3)9PY<N%FN:R[A=;
M/-5997/-153/+//+++*][D^%.D)2E*:9-2E)$E*4KC$E*2*Q)21+(B(B(B(B
M*Q%D0J<_P5L6NN+==Q50G'7%J<<<<14UN.+69J6M:U1S4I:E&:E*49FHS,S,
MS,=?P-_)[W=&/D%OJ=3K4I7%L[VD;M!1\U/%7*?#_LJCW<=,?T/G)DBR;O47
MD:Q2<8=GA;+ KV5K=EECZO8M+VZ^O&_Y+U)^%2E$?^;9_P!:XQ'_ .8'S4\5
M<IL/^RJ/=AW/ W\GO=T8^06^IU&M2E<6SO:1NT#YJ>*N4^'_ &51[N'@;^3W
MNZ,?(+?4Z:U*5Q;.]I&[0/FIXJY3X?\ 95'NX^L>ARY0898YX$(UAGAE;+#/
M'$OCECEC>U\<L<K,[7QRQO:U[7M>U[7M:]K]=-:E*/;39WVXW: 7^"GBHCN6
M)\/D99D9-5*Y'P_Y..P^Z'[E64>O"1,T"(D2#E=Z_(/E3CMZ^>.E<EW+MXZ<
M-E%W+EPMGFLNNLIFJLKGDHIGEGE>]Z4^%*D(2E"*7,0A"22A"514I2E)62E*
M261)2DB(B(B(B(K$5A6[_@KXN?=<>>Q70GGGEK====34W'77%J-2W''%L&I:
MUJ,U+6HS4I1F9F9F9CJ^!OY/>[HQ\@M]3JK6I2N+9WM(W:"CYJ>*N4^'_95'
MNX>!OY/>[HQ\@M]3IK4I7%L[VD;M ^:GBKE/A_V51[N.FQZ'SDR_2552>1JV
M*+Q\RR[+ KUW58/%F2M[=32_\&ZJ&=\>OU>KJZ[6OUVIK4I7%L[[<;M ^:GB
MKE/A_P!E4>[CN>!OY/>[HQ\@M]3IK4I7%L[VD;M ^:GBKE/A_P!E4>[AX&_D
M][NC'R"WU.FM2E<6SO:1NT#YJ>*N4^'_ &51[N'@;^3WNZ,?(+?4Z:U*5Q;.
M]I&[0/FIXJY3X?\ 95'NX>!OY/>[HQ\@M]3IK4I7%L[VD;M ^:GBKE/A_P!E
M4>[AX&_D][NC'R"WU.FM2E<6SO:1NT#YJ>*N4^'_ &51[N'@;^3WNZ,?(+?4
MZ:U*5Q;.]I&[0/FIXJY3X?\ 95'NXZ;7H?.3+I<B@F]C5LQKS!DO>^!;JR54
M'L2-KX]3/_=[201QOU]5^RME_-U7NUJ4KBV=]N-V@?-3Q5RGP_[*H]W'<\#?
MR>]W1CY!;ZG36I2N+9WM(W:!\U/%7*?#_LJCW</ W\GO=T8^06^ITUJ4KBV=
M[2-V@?-3Q5RGP_[*H]W#P-_)[W=&/D%OJ=-:E*XMG>TC=H'S4\5<I\/^RJ/=
MP\#?R>]W1CY!;ZG36I2N+9WM(W:!\U/%7*?#_LJCW</ W\GO=T8^06^ITUJ4
MKBV=[2-V@?-3Q5RGP_[*H]W#P-_)[W=&/D%OJ=-:E*XMG>TC=H'S4\5<I\/^
MRJ/=QT\.A\Y,J$'0ZSV-=N:LV+U3*^!;L;I$%R*"-K?]CZ^RMF-7OEUVZNK+
M'JZ_5ZFM2E<6SOMQNT#YJ>*N4^'_ &51[N.YX&_D][NC'R"WU.FM2E<6SO:1
MNT#YJ>*N4^'_ &51[N'@;^3WNZ,?(+?4Z:U*5Q;.]I&[0/FIXJY3X?\ 95'N
MX>!OY/>[HQ\@M]3IK4I7%L[VD;M ^:GBKE/A_P!E4>[AX&_D][NC'R"WU.FM
M2E<6SO:1NT#YJ>*N4^'_ &51[N'@;^3WNZ,?(+?4Z:U*5Q;.]I&[0/FIXJY3
MX?\ 95'NX>!OY/>[HQ\@M]3IK4I7%L[VD;M ^:GBKE/A_P!E4>[CIY]#[R9P
M(-AMWL:[<Y9O7N%^P+=C9)BNP05M?_L?7V5\R*-\>JW5U8Y==[7O;KG6I2K7
M^39^W_7C6Y]TV^@/FIXJY38?]E4>[#N>!OY/>[HQ\@M]3J-:E*XMG>TC=H'S
M4\5<I\/^RJ/=P\#?R>]W1CY!;ZG36I2N+9WM(W:!\U/%7*?#_LJCW</ W\GO
M=T8^06^ITUJ4KBV=[2-V@?-3Q5RGP_[*H]W#P-_)[W=&/D%OJ=-:E*XMG>TC
M=H'S4\5<I\/^RJ/=P\#?R>]W1CY!;ZG36I2N+9WM(W:!\U/%7*?#_LJCW</
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M''?Y5*I/:?K/\1!;"]1"P5 D* % "@!0 H 4 * % "@!0!PN/Y.O_0J_W,J
M(R.>QX#^AA?^10H(3L+U%^ F:"0H 4 * % "@"OQ7V/"_P"KW_Q5* +!0 H
M4 * % "@" C?K>Z_3\I_:8O006SZU?B8GZ"0H 4 * % "@"OAO7&6_&!M^RL
M9H L% "@!0 H 4 * *^V]E1GXOQG]8RV@"P4 * % "@!0 H K[CV5!_B_(_U
MC%: +!0 H 4 * % "@!0 H 4 * % %?DWK<V^,$2_:H-0!8* % "@!0 H 4
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M"OAO7&6_&!M^RL9H L% "@!0 H 4 * *^V]E1GXOQG]8RV@"P4 * % "@!0
MH K[CV5!_B_(_P!8Q6@"P4 * % "@!0 H 4 * % "@!0!7Y-ZW-OC!$OVJ#4
M 6"@#6I'EYQ\>2"21\;/D"^<,D>40F)L,)-EXM%9/A_XP<[)1X]P(8*-+]DF
M1?*.KB12R3EL3(,W#-XDW[#R"Q646+*72G&2GQ"GP8[[T=B;-A'^S(C0W74/
MNI<R-EM*-W?2I"V&G$+0I7 K\)^"$S)T--<:>^3)OR;4Y<=B5(I].GE^U&FS
MV&7(T<V\R?=6X4>,I+B9#S2FG21L*N6%-<QZ;HF/;*%UK-Q6"[ULCF37R2NO
MB@/Q44QR>K70QR6LFVLKG=+&ZEL>PM>]<D3;AZ=FUGN9&;ED*/<R([&:[%]
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MK,<+;N'KC)9SFS$C1HAEVWN04.8#T&S-$(/,S/A%\H 4 * % "@#A<?R=?\
MH5?[F5 'X%9;[*I-\8#/ZQ<U[YI7^:Z;_N$/^SMC\&L3?TCQ!_QNJ_V^0*_6
M>-(% "@!0 H 4 * % "@!0 H 4 * % "@!0 H 4 * % "@!0 H 4 * -U.%G
M-.><0IY9^PNZD6LI$Z;X3Z YN.P0((8=BE8Z"NKEV@=*AR'\E=?P&Y)OA883
MO=O=NX8\3C7!4#&$#<W-"-5(R%'3Z@2;J;4=S\7D6+2<B.*_;1FII1[JU]+2
M2Y]H\#'AGKW@BKWC$?=:CAFHNME7Z ;ED2$%9!3H)K/0C56,C^:=^BW);3XK
M*NV;;C'Z^-4[6@>ZX& V1K<^UD44D36SAD];W[!=LOAU8NQA-IE?MXXN.7[)
ML1'.<<'#5QAECEC?&^&>?CZK4F?1)\BFU*.N-+C+T5H5FE23S0ZTLOHN,NIL
MMMQ!FE:3(R.]R+]=L*8KH.-:# Q)AN>U4:546MT9>;R<:663T64R?TXTN,N[
M4B.Z27&G$F1D9&E1V1M[*C/Q?C/ZQEM:X=$+!0 H 4 * % "@"ON/94'^+\C
M_6,5H T"YA\ AG)R5S*9@3L:U_))YP]WYQ6D\C3BZJTG,I;8GG'R8Q V2D8D
M@(,.1.NT=/REH+#7>65;/)ZZ(!G@I:Q'T1"2.UO09'S>\0R_!78T"TORJUMH
M'<3:/2O?G(8)NB#;#W#EL#>\JU:Q;ZUT5K\M?"6[0FLLFLCV,SOJ8R5@,\,R
M%ZI WIZ/K#!RJ<08LU@F^9&9;."Q7S/>(K6SS*PU@9]%#N2".S)726Y]-ZQ?
ML]=VC.JVZ>IY))FNJY%)8)P2UQ*B()S*9P;=/FT"CW!H 0T22+X/Y#%)/-&1
MR0O#[K78W*1@TK[;GG<\[7S4?XJ_&QE<;8ZUX!!=6'@$GAPG4,==M>-6@M"R
M$ %BTM:AC3W2,UCI89)'1RTOQG9O 7#8Z.C$2]-,F-%FJPH4K("1P=B_'/0B
M]]O"9\]O<+5O#AP]VELG8^R\M@LH^A(-7DP$;178D<<H5/F4:5&PW9^+UL88
MHY$H(4S4D(1Q9-!Z*>XXO1SYD]13=X WC^H8';='_/,;G7<;W1!W^,Q8#%9.
MY<Q1L66GJ[$?Q5CKO"3^CMIA&SS,8RXWDO0IS)HQ,6^'?(-A5A+;!-4F[!?;
M]WH+/+U9YCZA/1T;&A> 3-UM&$3G >VA;F:1J2Q>1-8EO*0 M!Z4T\:);:9M
M) Z<E,G4HU<^VL+<N<S;Q*2K1U EF^]#R+U^$W+/(_1GLV[/1GG\6S7J;AK)
M=21U\B\WP<>RHSJ/;NN9GMF^!-K,I'()H3A2FN-CDGA61D[9GM7,@<HL"2>/
MW7<Q&9E5A[UIW<4S(A!F7 6];ZM[TWWQV]1<+KPJ7G)G*'>OEU3<"V/KYG&(
MO$GV,?A\?G@320=T'C*\B*DB%@!0OJN4;"D8=:Z")"8;4DRKC-^\N2/GP7^.
M?;PGF-<1'1N;0&C8R.8<G,X_"P6NA,'&ZWC@R2-M>NL64%8XM4%$6\Q'.LPI
M+<!2<S%PW%*"G]HB?"0X8\9YQ]J54"35F9V+/A(C_AO9<WI'I/HC7!75.N&4
M-,$ACYRE(YV?;LP+9XTC46%S"<R*6AH)%6Q!PX=HQ>!BC3.( ,,NXFMA@9MZ
M&!(V)[AC@D*1D&3>MS;XP1+]J@U %@H TXW9S#CVEY<W N8>3DP5K)V<"D!L
M4322(H[&.::VEN2*:YBD>S8+9RR:R$? 8J";!\R@+MI7<&NT12YET[)L& 21
M7^/21?Q+[^ 8XU1TBFN=@QR/2F01(Y#PA*'Z,-2,RS>8RP#!Y)N5"-CU Q\T
MU'"FJD=CVPI@%U.TE0ZSM\<G8/:"#R*1H)JJ6FFX+<!WV_=_=GZM^^0_BO2)
M0==*1YA=6[/(+A)#IH#@->!5Q1E@EN][K9G"3TY$YM73V"ASF>UXCD!;/$B4
MG(VQDF1.. $8=*5Q(#(R^_[C,OX";3Z1OC66R8VB4A*2;M\T2@[ON6.R;#-(
MXZB927!1 Y%J#(K%)#,VX,\%U\(LFT0F<DCYP*.*8.F2/=8+'_'>V'O^GZA6
MT^DHU"J)V?AD .L9WKAEOI=;7I1Z.:FKDM#L-H$2D?DEV]WKB.DCC/4,Q(MR
M0X=*(B,%7C3IY)\W4WA3"0@M_#9GM^.?+>.WHQ:_7;K_ ./J^K:]K_\ O:_J
MV_Z7]6@@* % "@!0 H 4 * % %?BGL:!_HUK_A8T 6"@!0 H 4 * % "@!0
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M?Y"[4>3?( F9X>JR6%H29K!HI)5%V0'5'(T<E.<),,D$C5VHU?*XA2$GDCH
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M.=H:LV X>R<%)VQN<1E&>Q*=C6S]Z@R1=AA:8<-%0@S*Y&67U6W]XK\%M\=
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M0)J&01]&=K[6);[6C42W#%))(DIP<ADBU_Z6I@PA9I$P*9R-C(G&)".Z^$,
M7*V]<C,]^YD9%OEO;3_]QI>[TYTP!=K&=6.FIL?JAGK>'AI.R;S3C6@ )RL:
M<@<Q6D4?-QRT9VS%SS N.EL=- UG\DB)D-DT)#R^.)C*/1X)NF]_29G>_!P9
MEMSWAOGP^9]( S)2!IRZ?[%+LVVUI2K&I W5XI!X\9@"\!+8,D)3#($/D,J#
M0X?*<!^<.<Q[8+O9!J2.4'<U$Q:",GP!Z%)VWN N'(_X\WU#\I4M]E4F^,!G
M]8N:]\TK_-=-_P!PA_V=L?@SB;^D>(/^-U7^WR!7ZSQI H 4 * % "@!0 H
M4 * % "@!0 H 4 * % "@!0 H 4 * % "@!0 H W3X6\+9YR]GEAX^SJ.ZSC
MKIOG/I]FW[- >AGV*M@0*RN/:",I(H?R5K_#0&H9V)D[6;V;MWO$XUQK P?
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MVQ^#6)OZ1X@_XW5?[?(%?K/&D"@!0 H 4 * % "@!0 H 4 * % "@!0 H 4
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M@TTCZ3CKBK&]*E/&6G)F25W<D2'#-;BSWDDE*;(V]E1GXOQG]8RVM<.C%@H
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MC'E)5^F.^\-1G@?_ '=85ZK9#\!?A[^;EJGR69>:GEUC'E)5^F.^\-1G@?\
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M=]X:C/ _^[K"O5;(?@+\/?S<M4^2S+S4\NL8\I*OTQWWAJ,\#_[NL*]5LA^
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M * % "@!0!7PWKC+?C V_96,T 6"@!0 H 4 * % %?;>RHS\7XS^L9;0!8*
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M#ZO3YS-3@0:E&)91ZA#C3F"=227"9ELH?:)Q)*425DAQ.FDE*(E7(E&17/\
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M[ETSQSFL0V$(UW>+WAR,ZG4)AFSMD8'=-Q[<+K".P14BF1<V9AS"V&)-=J.
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M756J6AF1+IT3QIAE'B,N4O0D+(HZU.$TIM3[*TZ9)<0/&^OH0^7A0 H 4 *
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M@!0 H 4 * % "@!0 H 4 * % "@!0 H 4 * % "@!0 H 4 * % "@!0 H 4
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M!RO?TW[!QZUEVB2JM^QQE=L<>O//+^#C:V-OR6M:UJ:S,:<=*Z#2^X@7@FP
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MB&J; ')Y/6%6_40\ !PO^!:WEAL/][*:S,:\<JZ#2^XAJFP!R>3UA5OU$/
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M,QKQRKH-+[B&J; ')Y/6%6_40\ !PO\ @6MY8;#_ 'LIK,QKQRKH-+[B&J;
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MW$-4V .3R>L*M^HAX #A?\"UO+#8?[V4UF8UXY5T&E]Q#5-@#D\GK"K?J(>
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M 4 * % "@"OAO7&6_&!M^RL9H L% "@!0 H 4 * *^V]E1GXOQG]8RV@"P4
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M!0 H K[;V5&?B_&?UC+: +!0 H 4 * % "@"ON/94'^+\C_6,5H L% "@!0
MH 4 * % "@!0 H 4 5^3>MS;XP1+]J@U %@H 4 * % "@!0 H 4 * % "@!0
M H 4 * *_%O6-G_2/OU@ZH L% "@!0 H 4 * % "@!0 H 4 <+C^3K_T*O\
M<RH C(Y['@/Z&%_Y%"@A.PO47X"9H)"@!0 H 4 * *_%?8\+_J]_\52@"P4
M* % "@!0 H @(WZWNOT_*?VF+T$%L^M7XF)^@D* % "@!0 H KX;UQEOQ@;?
MLK&: +!0 H 4 * % "@"OMO949^+\9_6,MH L% "@!0 H 4 * *^X]E0?XOR
M/]8Q6@"P4 * % "@!0 H 4 * % "@!0!7Y-ZW-OC!$OVJ#4 6"@!0 H 4 *
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M)HV21 &70Q- V^3#!4PTN1P0Q3E<333)814YB\"8'3>+2Q%<*!D>@!0 H 4
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MPHT),0"K&/F[E2S]Z1.!B1FSE=J2;*YZ6HO1Y,M<F,E;:))$\XRLR4IF0O\
MRA!+0VTVI"G26ZUN;:4H:<0W8E(4193"7&VR;<,E&V9H2LK_ $VR_8,R,U*(
MR29(5I*,S4DU7,E$8UUF7(+96L-N;C&R_P!)<@UEK;7^D9J&"1*($A^S9$1W
M_LW:6JX=$6QB0[2PC9 L,/ZZ9972&QW(U-EY0W 1*-7D;88-D6"+]MGI.V?U
M7^K,8R9=)EKXK$9/-Q6E-V.@4/CDEDQ[)WCJT"];,H!JN'[<V2VQ8R/9@AQ<
MG"8_/X>/=#EL$'ALT4=(QY$D/!'R(T&B9&5[9[^]OVS]-A9HCSW8;(G$4B4
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MO\>FU_5Z11M?](MH:8Q2\X-*'H=$<(QKN3.I*Y!GY#'1;;8 9BHWS.2&-A"
M("/;3Q<UI]@^,D6*Q_9\'GT<8#\,HNY76!8[V])EP;/N^\?![I%=, ,)SFZ
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MK]GGCU8VSU9GE:W5C;\N5[]?7ZM/G 8NXJPYT:I_JH?-GP1QQBKI=(_11*>
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M 4 * % "@!0!7Y-ZW-OC!$OVJ#4 6"@!0 H 4 * % "@!0 H 4 * % "@!0
MH K\8]:,?T@;M_[V-D>NW_M0!8* % "@!0 H 4 * % "@!0 H X7'\G7_H5?
M[F5 $9'/8\!_0PO_ "*%!"=A>HOP$S02% "@!0 H 4 5^*^QX7_5[_XJE %@
MH 4 * % "@!0! 1OUO=?I^4_M,7H(+9]:OQ,3]!(4 * % "@!0!7PWKC+?C
MV_96,T 6"@!0 H 4 * % %?;>RHS\7XS^L9;0!8* % "@!0 H 4 5]Q[*@_Q
M?D?ZQBM %@H 4 * % "@!0 H 4 * % "@"OR;UN;?&")?M4&H L% "@!0 H
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M1'?HY@_V+35?@WB]_K";VX:XL=\91>K8/8AX7+G)XR([]','^Q::K\&\7O\
M6$WMPUQ8[XRB]6P>Q#PN7.3QD1WZ.8/]BTU7X-XO?ZPF]N&N+'?&47JV#V(Z
MK?I9N;K59\NCL:/XJ$76#QU>^O(5E;-?!DS'XY8XY!KV3QLU8-L+X86MC?+'
M)2]NSSSO=JOP;Q>_Z/\ 'YO;!KAQWQE%S_[M@]B.UX7+G)XR([]','^Q::K\
M&\7O]83>W#7%COC*+U;![$/"Y<Y/&1'?HY@_V+35?@WB]_K";VX:XL=\91>K
M8/8AX7+G)XR([]','^Q::K\&\7O]83>W#7%COC*+U;![$/"Y<Y/&1'?HY@_V
M+35?@WB]_K";VX:XL=\91>K8/8AX7+G)XR([]','^Q::K\&\7O\ 6$WMPUQ8
M[XRB]6P>Q#PN7.3QD1WZ.8/]BTU7X-XO?ZPF]N&N+'?&47JV#V(ZN'2S<W<'
MK@ACL:/V=.FK-FMG?7D*OCD@P6?+ML;)W#=ACEBH1=7RSQM;+.V>..=[V3PM
M9JOP;Q>_T^;VWJ#7#COC*+U;!['TCM>%RYR>,B._1S!_L6FJ_!O%[_6$WMPU
MQ8[XRB]6P>Q#PN7.3QD1WZ.8/]BTU7X-XO?ZPF]N&N+'?&47JV#V(>%RYR>,
MB._1S!_L6FJ_!O%[_6$WMPUQ8[XRB]6P>Q#PN7.3QD1WZ.8/]BTU7X-XO?ZP
MF]N&N+'?&47JV#V(>%RYR>,B._1S!_L6FJ_!O%[_ %A-[<-<6.^,HO5L'L0\
M+ESD\9$=^CF#_8M-5^#>+W^L)O;AKBQWQE%ZM@]B.KGTLW-W-Z@0RV/'[N6S
M5VS2R[WD*MCB@]59+N,;IV#=AEEDHP;7QSRM?+"V&6.-[6SSM=JOP;Q>_P!/
MF]M?[[!KAQWQE%ZM@]CZ!VO"Y<Y/&1'?HY@_V+35?@WB]_K";VX:XL=\91>K
M8/8AX7+G)XR([]','^Q::K\&\7O]83>W#7%COC*+U;![$/"Y<Y/&1'?HY@_V
M+35?@WB]_K";VX:XL=\91>K8/8AX7+G)XR([]','^Q::K\&\7O\ 6$WMPUQ8
M[XRB]6P>Q#PN7.3QD1WZ.8/]BTU7X-XO?ZPF]N&N+'?&47JV#V(>%RYR>,B.
M_1S!_L6FJ_!O%[_6$WMPUQ8[XRB]6P>Q#PN7.3QD1WZ.8/\ 8M-5^#>+W^L)
MO;AKBQWQE%ZM@]B'A<N<GC(COT<P?[%IJOP;Q>_UA-[<-<6.^,HO5L'L0\+E
MSD\9$=^CF#_8M-5^#>+W^L)O;AKBQWQE%ZM@]B'A<N<GC(COT<P?[%IJOP;Q
M>_UA-[<-<6.^,HO5L'L0\+ESD\9$=^CF#_8M-5^#>+W^L)O;AKBQWQE%ZM@]
MB.J\Z6;FZ_1P0<[&C^2>#IB\QMCKR%87LN.>MR#7*^6 :U[XX.FJ.>6%[]BI
MCC=/.U\,LK7:K\&\7O\ 3YOU_P#3!KAQWQE%ZM@[W_Z1VO"Y<Y/&1'?HY@_V
M+35?@WB]_K";VX:XL=\91>K8/8AX7+G)XR([]','^Q::K\&\7O\ 6$WMPUQ8
M[XRB]6P>Q#PN7.3QD1WZ.8/]BTU7X-XO?ZPF]N&N+'?&47JV#V(>%RYR>,B.
M_1S!_L6FJ_!O%[_6$WMPUQ8[XRB]6P>Q#PN7.3QD1WZ.8/\ 8M-5^#>+W^L)
MO;AKBQWQE%ZM@]B'A<N<GC(COT<P?[%IJOP;Q>_UA-[8-<6.^,HO5L'L1^J7
MC]+C<_T+I*>29PF\D<VU%K:72!VBW09HNC<DAH4R5<)-&V"39JFN_>KJX-VZ
M::"&.5DDL,$\<<;>;*W%9A5JKPHZ31'B52H16$FHU&EF/+>::2:E&:E&E"$D
M:E&9F97,S,[CUAAZ8_4*!0Y\I1+DSJ/3)DA:4I0E;\F$R\\HD)(DH)3BU&24
MD24D=B(B(A^*SBIKN)[:Y':9UO.G6;6(S">! YWM;J[%5ZS67NIZ#(/<,TU6
MJYY5-(*@X0SP<I+$,,VV5G&*=Z]<8FGRJ70*M4(225*B0GG6;I)9(616W8TG
M<E)8(S>4E1&DR;,E%HW'B'"5-AU?$M$ID]1IAS:@PS(LO<U+0H[[BE=R-"GU
M$3"5$9*)3A&GZ5AM,,U@XY.GH9%7?&R/\;&"6S-@1I[LN"B).CA<1"-?G)Z8
MU@Z@T@,N<I;L<8-C;S,8<Q+#'C]\Y1%E4;64NZ2YIRI)PXQ+DIQ _B!9TZ#(
M13ICL<SW69.9A-5%,UAI/BM/<=?23C)M.(;0DW&CN6B?6-4E>*9$*(YAB/AA
MLJI48SE4@,RDEN,&G/SWJ6J!(?5XW4FFHJS:D$ZTIQQ1-.I*YJ+%$YXJ"K@8
M9L#5^P0B$#G6M3VQA8_>$BA.JYVV3BTK/P\N%:#7DB7'2UV^? %"$<RC;A5R
M69/$T;#D5V^62^SA8F=W>7!J4%XYD.H,0''*.Q+J4)9R8K$IIY3B&"<C(2AX
MD/\ C"22TI)GIF1Y:B?A%HX\&HTJHL)@3Z7(J;3=>DP:3/2467(AO,(:7)4U
M+6XN.;D;Q91J=;61;F2DF:MRN0^E-/33D%'^+6K5-!0<F>V)$P;Q*,ZOV@VV
M?# N4+RD9=\4E!@BE!)7DXZKX-08!5-X4?D0[+!PTLB_<I<I0JO58E#D8DJ)
M5N8VQ!E/(5(J5.539;WCGB[2&XS*#FQB3M4\^1H;0VZLR49MI/M<24.BSL11
ML*4I6'H#LBI1([B8M)JB*K!8.%XR\X[+>=3 EFK8AB.9+=<<9;)2-%Q18*#\
M/M+&8W;;F&QMJC=/9:>VILR[$G!8TCM)(EJ#:&N=>' EA%I5:.+CY%C/T'((
MU8NABS(LWXT@U5S%.<W&Y=Q55VI'R7XA3'*K\JTVGZ;<R0=.-NJ4Z=.9>W7Q
M;=TN,>)*2\SN:C6VI#B%%NB2+0LX,H;T7Y8^4JNU1CHU6JFYNP(J:L3E&JE-
MITAC<?&_%E-R2J"5QWR>22'$.-N),VE:4MAPST*TBV$D,;2VNGFPUWQJV>='
MCH-$W/9".1RC(4*CXIVYES6V14"6(M"!$J\;X,KB;+M&H]V_P364MGBRMJDG
M':IM+/3GX@IS"W)DI/\ *4 EN.ONI3&59MYMM2&VD*->Z64I:$&9%=3@K#Z8
MI27ZK5R-NG88J<AMN##5=G$JD,M1V5*EIN['><0XX\M)(W'20EM;A$HXMUP*
M&L-@0^#*SPP\Q/;$YF08H6:1]O@FP1XM@+& Y1-#)ZM9/*8J7LD0:N'%\1>&
M5K-5WF=K997$8U<7!E3"A,H-F!A.8VTI]5UGB1_<G6S/0(S**5S;4E-W#+Z2
M4BTOP?--U&% .H/K*14<:P'7TQDD3985C[LPZ23<41'-49)<0I9[D7["EGF,
MG,^%VMMHSO7@Y94[K6.R'5/#\ V-1QM"40+O9^YM8M2Y)^35F,S!%3AQ\_:N
M"]XG"PQPP506(OE%0K1ACF[UJL75"FPIRR)FH/L5/%+ZFI"IAOIIU*J"FFVV
MBBQ'FF64(4EKQF6ZRTTHFT$3RG+)VR<#TNJU"FMF<BF1I%(P='2_&3!3'75*
MU3"==<=5-FL.OR''$&]XI"8?>>2;BS-A*"-<(0XV:=#Z]"Y1MHNYF7X&F\=E
M3(G+!%R(@A*H7MAW"$#<<R3E*.<?+-G(H@/$.+M5!S2/M1Q%Z+=FBI7!K?1B
M"JNSWBD+(HGE91Z?$;BNZ#R(TNF)F*9?(XQE(:4EQ"W4Z1.*?6MM#B6FFC5C
MNX8HK--8\60:II8+KU2FNRV=T9=EP:PJ F1&,I9''>2MIQME6@;:(R&W%M+?
M==)'\9]'E!RVP5-9BMH3/ _ MR:LTYMDB:A(P4 ($-I!31-F;U4ZQ/O'1EJ&
M<@G"2[ ZU8N"05XQD;99NV4[BN5CN8W!*H.4Z)N$VDU*K4MMJ8XZ^ANFNM-K
M9J:380EI3R72-*V%+2VZE;"B4HM(&_!Q >J)TMJJSBD4^LTJC5=U^"TU'<=J
ML=]Y#])64A:GD,J841MR$(4ZPM$A*DI/0/3_ '/I>'0Z+Z0FVM)/)I)']R#9
M@FV;3$&*CYH<;@\U=0LCEDB),FF%AIA=) D.3R>J.6""V39XX<*)W6OU5(J\
MN7(K$2HQH\=^DN134J*\X^TXS,AHF(S<::7NC25&VX9()*U%I((B.PXRN4.%
M"BT*;2Y4J3'K3<TDIFL-1WFGX$]<%PS)EY]O<GE)2XV6F:FTGHK4HRN-D&_#
MK5;6;1C6A61[(?2/9NYMI:1A4D!I1_TKQ0QJ=^)BA6431B[%J$#(TO*'CHTL
M!&/XX\BD#Q9DWA<X]6NG6@5BNI+AR*@TQ 1'I])IM8EL/&_XS*:J:')+<:&I
M#I(:<:C)2R3SB'T29IJ;2TR@KCI4X+I*)\6ENR:FY)JE;JU"@R6"CE%B/4AQ
MF(]*FH6T;C[;TM:WC8:<C+B0"0ZMY]9Z(C)9QHX\0,!J][))K*UY%,!F@R#N
M)!=AZQ?R.0(;DU@A+SC\7'&(0E(==C8(?*A$4G$\&/$I@%>8W"N$UG*#_&N+
MB&NSGZBB/$C)8BN5M")3U/J*([!TJHG%9;=D+?;8GNS6&WE&F$X@XCR#W9)D
ME2#MR\+8;@,4I<F=+5)FM8><5#9J5*<DR2K5+3+?<:C-QW9--:@2'F$DJH-+
M*:PN["B-27!C61: A8K<LY%LQ>S%='ZVV'+=82:26.0IY*<I'%<B[6Y)PM88
M/0CL3<+LV1,Y(%(L?1B,=R)/U43KME@Q7V,>N3':3"=6[3BK%0@1:C'C[C+1
M&*/))I6YI2;KAR)226MME@I+!RG]S02F$K-:=7)P[!:K<]EMJJ'0J94IE*E2
MC?@KEG*B&\C=5&33:8T-2D-NR)!Q))0XVZN&F0I!(/.TOX,ZXA;*6YD)5M(L
MYC\I)E&.$;CT=*OS>LQ^^-?Z49BPP"[UMD7V-)$YZUEL<53.LA#UBFP99"<%
M2F*[721<9SY:XNA&IK:'XS;2S??D-(9J*Z+.JZW'7]!1-0(YPE17RW%QU"S6
MO=;-Z*M_,P%3(*)ANRZJZJ-*=>04:-&><?I;=?I]#0TS'TT[M4I/CZ)<8RD(
M9<;)M&Y7>)2,)N>+4<D_*".\?('/6 #$PA#V\A7G4@BQ!_!)890%IRF!YE!C
MD"!GDLB91^H.4'1SN%=^_:O12*&+L:[4K<)Q*_&PY(KLV$M_<3E*83#8DMHF
MQFC<.--)MQ+[T*-);02R<D::4(4APU&EQ)#1*PG%E8JC8=@5!N.3R(9253Y$
M5UR!,?2T4JG[JTJ/'J$N(ZX;9MQM!3CB7&DITVEF('1W&'/=,EV3JP/(&;W;
M$:]*#Z')1HR&D,+DH=Q-@D5GBZ9D?=R@1O'A4G82YL\&$<&>(4!)<W.*UDTU
M&U^L8B*D1Z?4G6%HIDCQI$LY#3S$N.ZF&])A$;*]$V]W=CKBJ0XWIF\_')-K
MF2K%!PJ=<E5.DLR4.5>+XDY"**^S(@RF%SF(E043[9+2YXLS*;F)<;=)!,QY
M)J)5B-.=Y1Q/X]^EW7#B#[%-K%=Q24F(@C^63Z&#K8ALN0DFTT D:L';PK P
M?'+A02$G*JL)*+P:J*D$T\KH#K]NTL;$]=.14$S(#)-4J.V[-1&@RW+O?(<>
MJOQRF',-EAQ+SQQVR<CN:1$@SL;GT=_*PAASQ>F'!J;ZGJU)=9@.3*A":LR>
M(I5%CR504P=VD-J9CIE/&W):)!FX1'HMYSH'A7J*3$W1!DZVB#@\7>[YC\H+
MR:?:3:JNC^FXR7-M,2&+'-Y(M1N#*L>+N"(.?01^W&QU08>8RPLV>H67L/8N
MJL=M+:TTUZ9)119$9J/"JZR2Q5I#3*MSTR0Q5$M$^TEMZ%-;4Y()QE<5I2%&
M61'P-1I3BW4+JT>#$77X\IV5/H:%+D46*\^C="0:Y-'4^J,\IQBH0'$M1C:D
M(F/)6DE8<UAQ#6VGN%!B)929/1&#R8.WTKCDBB6PY,J!U^!<DSZ(!8"U8-C9
M8P3:)@(NZQC;0:\*F@[;J<7SRS5VU1Q25-I1K=7'^6C1%2B-(8E0(Y/3GTML
MJ?)Y:U,M--*-^2CQA3B&VG5'H["TE*P:JK5I+;*)/R 2YBW)<:3#J,HX]/CK
M=D)CG'0VE]UYU!1XJ_%4-+=>93]*]U=)AQ!<X;SY#Z.-F'K(OJ6,EC,2)WP3
M;-)!DM-X$ AI0NFHS=.$09Z-SAG(5<&:.#Y/!5M9._\ !414K<Q4GY&H599:
M0MJIR6V93=S4M@DPYS\MMHR6E*GF)$);!&M1H,R49[QE0U@Q7R_B.@R'G&WJ
M1$>?ANV)*)%YT!B$Z\1H6HF)$:<B0HFR)9721'D:3N(;@8JX1-,2FW8-@2<N
MXN#A9]@E-LHDXE9/=)?21J.'T%X%:48+-9.(SP8$F GT'4:.$B:I#-KBLDGB
M/8U)*FE-TN8;:427I;"U0RE)BMTEJKLR&%)F^+&2HSI&XVMW=24DVTHTK&><
MQX/]),A#U9@DXI<5B#);3..&J6[7'Z&_&D)53_&B-,IDR;=;:)DTJ)U3AH(R
M+O\ X!OHC HZ]830>#V1(G4-8AP)]^3(@9$2/P78<M>!6#X)![Y!2ZRT%60'
M9''>$?:HW4Q?2)=1PDJWH\M="<^A<-QZGL)EK>?90VV]';8FP8J'EH=F6>:(
MIA&YN*3?4JQH8(DF1W#\'VZ4^,MN<VQ4Y*H3;+$AQUV-(=D0*C,6PVXQ!NPZ
MI4!1-F^LHR$WW22HU)-/1EO!AJ,CHV0#-H  ]L%)R3F#:2HR8BUB4.@FM-/S
M<B>L1CT,N[//%G^U!@ZX<8#[>AZ,@$D%"*#&5%P]<7&:G9#C"Z:^[E#;BJCJ
MCMKDRYM0JD-#&YORM!E"44YQS=7'M%6Y/&HFS7&:=MS,!(:C-26JK'8L<]V:
MF4F4ZB'"@4RCSG)!.1H.G(6IRJM-[BTQI)W9@DFX3<IYFMO.$I:(EFL>GD^B
MN$BD[+;Z4(!Q?.0O'A![J^#G9DUD1!R2BC,.VB$@S&!Q**#@J-E3?TT-R#@*
MCZ!F&.&0C&#4II3\*#)\7C+I1S'I),)2VBI3&8BF&TMR5NJE,$XZZ9I;<C*\
M64VET]V:6,56!G8CR(U0J,4I4I%93 CQ/&%K<<I4"1-1)<6[$0P4.0;3#)(4
M\U,2<M+BF2W!YL9+XMZKU0^C/' ;L"+@I"[Y1[AW=KI0Z43R4=1-.+:Y!1+7
MC82MCG;-@]5V5M!K)'V:5K9/K!P"2F%\6J=\]=B2I5-$FON09+S"<.4JCSR9
M;.R9)R9[TJ>IU/\ 705/IRHZ+Y(W5\R.ZCML\)TJCKC8::J,6/)7BNLURFJ?
M>3I*AE$IK$.G(9.Y&VXJIU1$E9I_G-QCD?[&>S$OXQZ%BFL)+)DX7',9!Q1U
M#+=9;LN_=W682SD#.M<ZD3UU(7>%G/8=J![)V'-!:=NRLCV^$XWSS[7BW[;S
MT7$5;DU&-'.6_N&):K%J-(T$&2XU#A3ZF<]A!Z-[O0($1RV9VF7(LSMU$S"V
M'XE+DR2@QO&,)4:92ZX;J[MS,13Z91_DV2LB5D3%3J,YHMI$<',[$F]0CW1_
M:-@VY8K%)U/RT];C9%/8+-HHQ<1!-T3D\<TI)=G,I$*1BTZ>'@49:N(^];J@
MY:D'D:SCTKYNFV0B1.[,,M_'%9FTF3)AP6H2G(\*;#DK3+-#<9^KQZ<MAQ4B
M$EEZ0I+Z%$]%-U@D^,$E1.L)->''\'= @5J+$GU%ZH(:DU"!.B-JADMV5&H4
MJJHDM%$GK?CQD*CK2<>83,E2CBFM)LR%DC4;A-IJ.;-V_,I*8C"$VUCIV'2J
M=O(S+C0.',9H1OBH!UG"3TA*E64? .Y/*28G-YFY*69]RC2J**J_5ABIU&+Z
ML_3J5$CM23AU&JRXT)$B*T]*7$;R>J$QAAIM;[R(T9MW1T6M+2<:,R*YVX_
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M "@!0 H 4 * % "@!0 H 4 * % "@!0 H 4 * % "@!0 H 4 * % "@!0 H
M4 ?NMXD_^53C+_\ ;YIC_P#'$;KQGB?^DN(?^.5;^WR![WPC_13#'_AZB_\
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M\U+GPGSF&B7P2?RAWJ=?_!81\S2\U+GPGSF&B7P2?RCA<:JU_P!H7_[KB/\
MP5?_ /#2_P#HR_Y4TCX3YPT2^"3[A%QO5$ M'0%KQ@1E>P45:^5V:77>]F*%
MKWOZGY;_ )::1\)\YB"25B]1;R?<)KO4Z_\ @L(^9I>:ESX3YS$Z)?!)_*'>
MIU_\%A'S-+S4N?"?.8:)?!)_*'>IU_\ !81\S2\U+GPGSF&B7P2?RAWJ=?\
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M9^+\9_6,MH L% "@!0 H 4 * *^X]E0?XOR/]8Q6@"P4 * % "@!0 H 4 *
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M7V/"_P"KW_Q5* +!0 H 4 * % "@" C?K>Z_3\I_:8O006SZU?B8GZ"0H 4
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MO<<Z%6VJ9TT(;;%7)C+O):FW"3(MZVW+UW+,]ZQE<^ CN5ME]P-. ^:4;9Z
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M H 4 * % %?;>RHS\7XS^L9;0!8* % "@!0 H 4 5]Q[*@_Q?D?ZQBM %@H
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M9^+\9_6,MH L% "@!0 H 4 * *^X]E0?XOR/]8Q6@"P4 * % "@!0 H 4 *
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M4 .^',O?I3YH/^J4 .^',O?I3YH/^J4 .^',O?I3YH/^J4 .^',O?I3YH/\
MJE #OAS+WZ4^:#_JE #OAS+WZ4^:#_JE #OAS+WZ4^:#_JE '\RV#,,\<L,C
M2E\<L;XY6[D'VZ[96O:]NNS2U[==K_EM>U_^% '$VG<L:-T&K<PHFW;(I-T$
M^Y6.78(HX8II8=EFURSR['#'''LL\LLK]77EE>][WH&P<W?#F7OTI\T'_5*
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7CA;''&^6>6675CCCC;KZK6M;JM0!_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>44
<FILENAME>g947560g95s99.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g947560g95s99.jpg
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M & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & ,
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MTX*C & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@#
M& , U:_'5_K;=/(;A!_HK7:/E#\O7&\O5_\ Y8Y3.Y0@Z'K$:_\ AT :.0\W
M22/LI^]:]5=.ST.A>LY!"(9*M_-3;?532O\ _1M*8,8P!@# & , 8 P!@# &
M , 8 P!@# & , 8 P!@# & , C/VG^1QUG]6>^/NME6":=5TKM,7>+[YM;Q]
M_4JY>^Y.$X)K\.KRJNUDZ<%1@# & , 8 P!@# & , 8 P!@# & , 8 P!@#
M& , 8 P!@# & , 8 P!@# & :NE0)%39X]O(7<C4G./?>5O,7T_ULV"3EB./
M V<Z]31NRK!2EE%ZV88!\JAEGT:5EE^@9B%Z5 #Z=B]&VAD?A*<YHI770DL^
M9FT&D5I7!(E7H5!*M$M3D*T:I.8$U.I2J2@G)U!!H-[ 82<4,!A1@-[", @B
M#O>MZW@QGL8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & 1G[3_(XZ
MS^K/?'W6RK!-.JZ5VF+O%]\VMX^_J5<O?<G"<$U^'5Y57:R=."HP!@# & ,
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M!$7)*V)82S/(Y>^M1!LD4I.<\\X4<%/^F6>_22PK!48 P!@# & , 8 P!@#
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M,(6H* I."V/#$\2:)0B0%IWMKTC=#6=WCI"Q@5*SV0:][ @ ]. JXW:<YDC
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M47[6M\K/;E_O33%8]&:T> W8A#T3YFM6]'Z,FE"+#<$# & , 8 P!@# & ,
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MW]T5;_8#_34XE,A8.7&>I.>J;EE>.C:E;8#3M4V5+K@Z?3VE#UKT5.I?*F=
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MNQ(M8',<)C\L,6O"-U:HI,.K:BC\G9$PVYR1D^YO;+)W]L7:,)&:8D=%16C
MZ$'U1>AN4MS]A9/4U0UM1<&:ZUJ6)-T(@S*>Y*6N.-1BPQ$B/=W!2ZN1A0UZ
MI8IV)6X*U*HSUSQZT8<+0-!!Z Z%6VW+,D8(& , _(Q@+ ,PP82RRPB&88,6
M@   &MB$,8A;T$(0AUO8A;WK6M:WO>]:U@&J=&/.-SBZ>2A7<GQ L5)S;,*C
MA?+3/=J@V.Z3:5-UR2R0H+C70T+EM^1U"\J)<D+3N8AF2E&P%AE#A%$Z4TY$
MDYNKN=Y6IY,7*]6&C!NBF[M=\H[ZK-32IO.U.WWMRG,3LO;=*H^4:U1W8=S]
M?+=7<Y3CIY3INU671WFZK#Q-%+=>$6(=/>W?I5-5+IG9=Q.RJW=^0;6><(;*
M, 8 P!@# & , 8!K!]:4W ;[N'I?H^=W+4?&M9\EW2T5]8?2/$=)W6+LTY2L
M5Q<Q0*R^G6IOCT5;6^-(']I<K.(88!<T8J]M-<BIO+&\UI=R$(NLDE$SFE4U
ML[_T=9UARFYR6>>S>V!)"VMX4ZXQS("A2!(<CE!:LUP)T07HM<:J)"$E28K!
MH)XU!00EG",V8 .@BUK0H>[@%:EN^2Z!5!975\ ?JILTANY.Y,EG4[_-7YK.
MB#%8R6)KUS:JA=8%/Z(A7)P*'!(6S)YTG#N**I":>S-1[H8W+U! F)C/-N%Z
M,V]VOX\"/-N>2VA+'\;M[VC;TOJ6@#[2KOHRH*[C#M>U>3XV4S5MJM>7N,HW
MF+*"T),S&N>BD:B$J2BI AUM"K/3^Z.S>::+*E[22EPT\D])UZ.?0F1XOOFU
MO'W]2KE[[DX3@BOPZO*J[63IP5& , 8 P!@# & , 8 P!@%?[%\Z?:?\G_07
M]8OI/!.Y=+[*2P#! P!@# & , 8 P!@# & , 8 P!@&N)TY=O8U;=3=>P.F2
MIUSO$WJ=,MX2Z[8)Q\[7$4.I:OX[@S0V39KDKY')3#K@MCH.^54)YT(KQD0G
M22NX!0+BXHVA"L>54I,%TJ83;EQ"4I9NIY/@DLYT;>N1?%0<@L66T52TJN"/
M%Q&VI-4U<R"T8F4G-2%1BQ7F'LSC-H\4E.-/.3%LLE4N;:!.:<<:2%-HLPTP
M0=CV*O5QQ,LX(/35N+>@$F N7(T8UAP4R0"M40G$J4#WK0$Z8)PP;/.%L0=!
M**T(P6]ZUH.][U@%/QOEYC4GD]MQ"FJ1=['=(WT/0G-5%NKM.TL'B%_2^[&Z
MP'$Z9(Y 9$Y$=$:IC1%6SM0V39,U33X^M30D?8RU"9WMH6*WXEMG)-O5-Z:1
MDN&L^G76,F1_S!<():CHNS+MO.#\ZO-Z5@WV<R5S9[\4GDK8WF/#S%7I*8>W
MIU")R(99C&I+'-.B40$[@:SFJR"2BC0 ""HJ;<*8<-K3TF%O!I+XS8- ]<3V
M%/2&20Z;^2[MZ7Q*1-AFSFU^C,ELI.\L+TWG;"'9J%T:EJ5<D,V$.QD'EBV'
M7I]&@KR</)[-'JHNJP5*J+B_UL.Y+B+_ -R,G77COF:L&M_[E661QY*'=*J$
M'?X] >'FO>H6\(@Z]7:QIK_0O0+35O81;]'H?:O].WCG)SQ]_D%\1_5$YL^Y
MJ%Y%.BZ%V$5:OI?:2[R2"OKRB?D;2G]-/'W]<6A<%J/"7G[&6"X*C /66+$C
M<D5.#@J3(4"%.<K6K5AY25(C2)RQ'*%*I2>(!*=.04 9IQQHP%E%A$,8@A#O
M>@("/GD8J*0O#C#.5HA8W;L^;E9S6N2<WM+:\U7''8L6R1))QTC*G6,<^Q<Q
M(?HP#FT L1WF:0"=5[O$%ZDD*4P6V6M<NG7JU\\1SGQ3ZC[VZ+).!=]VP_D.
MMG0LPM74?)Y!%AVZX-:H._:M<NZ=MF*$LK2(TG84SBEJNC(\[(QF*PLUF'Z]
MV7:>_O[H9+13SO3J]KTU6>6LO=GAC6T)TK+:X@4S>[QYTHFK*QZV=:0+B0DE
MVS6@D=X.<:F]#L,Z3R-2TR"2L4#A3\XL#F7"VQZL LIO@A9;$^.7QPUL=?=3
MRI7R0N1F['Q96J</WU6ZOC#P]$*FRZMOO>RJ4J-I6U6Z%#JF6],M]P?(%ONA
MJ[IU3BOCM6)N8M8=WK?Q*G&W-JJK%*WWE7MMW*JKNR\0[5-VIUTVX5-"W6(!
M/8?:<&A]E5[(&Z602?1IDF$/DS0=[=L?HU(FY.ZLSLB-WH(A)UR!40H+T8 !
MH-#]F:66:$8 ZX;BU#:>JR9R[ & , 8 P!@# & :E?8UNLD6LSK^I:RD/D&)
MY>G<OZ0G'5]45I!>12ZZFL5J^*QA9W[*:<N2U'H%RQ!B8D4MC2&?1!*D2ODI
ME4X=S:84%$'N2QK&1+1O9G=.U.^-,N,;LL\M=AKIJQYS3_/PI]3+U2L"B<1C
MA3S()]<C/9<NCL#KYL9@C0+(]5%8DH)?:#^J%\'-33#4DTA2U48>6!"M=G0:
M5D6"BU]_=$<>$NFKPOR:6.S.EW<X=&0*LY._0N8RV 4/>O+LTC\B:W%]94+G
M&(U8LRN6(717+U)8K*XRW3V)S&+,FUT:??@]?)5;.M0A$U))*$U.:EJI1TI*
M'S:HDO9O)$8LJUIU<@;%M& S>;\SJ>8P/%>/C2PN42CQLW7SY)-XFXJ&-R5(
MIRV/:_>DA[@)SCIJ1.4F<(^M*,5 /$3VSUQ["+-K<95Q3'#O<8)8Y+K_ )]8
ML,Z0OZ=6?;\9KQ5(76TW:BR8>!_96:*0Z,0^&%-,3@$.8FI+%8^U[**92URI
M0L=%2Q<>)3;J6[10M$IF..N>;9F[Q??-K>/OZE7+WW)PG K\.KRJNUDZ<%1@
M# & , 8 P!@# & 8%Z?Z,KWDBA;)Z,M4N0&U]5;,E?).5%6PAYD(T2MX;6,D
M+6V*5S:0L4;7.J7UBS%R8.BO:&>OO8-!%>W;KO7+=JW2Z[EVNFW;H6M5==2I
MHI7/54TESL>=+)MMZ))2Y\Q2#_Z45XV?^;?4G_TDC?\ YD9N']7G=K_P[C^J
MS_U3!\:PWZ^CJK_*16;/W1-P0D[=F_09L>Z-^(4@Y6JRFT!8*Q8!/VI?#K<N
M*;.XSV[<^T06T;9IRR!2+0KAFG+-+2!)"@)P''/ZO.[7_AW']5G_ *I/QK#0
MEWZC5[J]\?\ +S$J?_2BO&S_ ,V^I/\ Z21O_P R,?U>=VO_  [C^JS_ -4C
MXUAOU]'57^4O2YWO:$=.4?5_0-:@>RX%;D0:YM% 21O*:GT#,[E[-2!=6XA8
MX$HUN@ZWHX@M:I  7XM'#U^/--JI=-3IJ454MTM/5-.&GT,SF9L@# & , 8
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MUHYSW&+OE\[<OW_,<X<T(.>H0K_$5>';PES9(#4HOWGPA#^3Z[>/E%<Q?O\
M1Q*2X;$H-R*V0+2ED/"8 &Q,):N>:GT_*TZ(3\Q[*/QV0RPU:9_[-M:S.V7X
MI02N#$;65H(OS>TK2# F$A8^7:_)8ZH=$J799>D2NUT%KRHCT#&9*CS#3!B#
M:X991S]>ONN!/QC8F2,-#='HTS-4>8&=(2@:&-C;TC2T-:%.'U"$3<VH"4Z)
M"D(!K024R8@HDL.O5  .OQ8*GU< KZ;?G59G_)]5E_6-MK!;]#_%^!PRG?\
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MU?')[I46.MG2SD5%+ 7%:E4.['4K/8%AV.UU)!55[&L<?@HI',RFJLY*RR.
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M<IKI=52V:G<=\(^4R>_ODD9X<YF;U7[TL;Y)+LZVE* D7[W9RIH967DZ,A<
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M@# & 5->='YIOM/]'4?^\F$YR')/TKR9]88+[S:(J\&OR*_49UBF>^#6!@#
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M:_(K]1G6*9[X-8& , [2/PW_ #6G"GU=H+_-#,_/W$?.+_[Z[Z]1M!9;F$#
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MF@4)UK<XHE!Z1:D/)4ICC230#%)->3AY/9H]5%SF"IC6Y_XGK7_1K.OZ+NN
M8.\??Y!?$?U1.;/N:A>13HNA=A-6KZ7VDN\D@@;W!R[T!U7%TM=USTA7])UT
M>NKZ0R-HD7.KA;\D=996EH1RTHTY-LF3WK5Z5E:!.T284#FR&QUW.5HRUXB7
M=(8M+TC%J6DY:;>Z&E^#)55,QVE'8,UM-S6%%;1L%.>Y#=YI#*X5U/'G).>X
M*3FLE'!UT]LM2UF-[8-*@5'CF#CIR4IS7 !* *G2$@0XG*4N=R^N%V&2,$#
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MK0WDIV]K:6MO3IT+<W(4Y"-"C()3)B2B2@ ")KU_PT>K27.X*F-;G_B>M?\
M1K.OZ+NN 8.\??Y!?$?U1.;/N:A>13HNA=A-6KZ7VDN\D@8 P!@# & , 8 P
M!@# *R+L_P!A5TPAZQ;O]!YPZ0=8;5W8B$O]XUU[9PMH8;175!P1>A.WM:D1
MC11MWN>QD%:CBJJYFY"+;:Z>U)PLLU&]9KHWK\5'/DYRLWP5*^/%/\WERQ^C
MP[^D\@P6K\)^;L18/@J, 8!K:]^U/,2NJKZN*8VE2MC&5'R&7<*^$S3QIU]T
M015_-;%:\RVQ-J&367UI!RG>PQ+!VM(5BJ)L$9#*8O!7$N1IMNS?732N%UI&
M:EQX49^9=&LQ/2;&$:5)%T<8%S>I3+$"QD:E2)6C1";4BI(H0D')E*5N'L0V
M],>2,!I"(8A"2E""0+>]E[W@H?:P!@$9^T_R..L_JSWQ]ULJP33JNE=IB[Q?
M?-K>/OZE7+WW)PG!-?AU>55VLG3@J, 8 P!@# ,/OU^5!&+?A%#/LY:&ZV+$
MC4SET1B1WO(E#DQP%?!&R2FG+RTXVIK6DK+*AI;8T.JY$[2 MT./8$3F0UNQ
MB$(RGS=<^PC9Q?Y :X[E46>?5$ G;/%JT>#V3<RDTEHUS;I4L)?I"Q!TVQRN
M;AGM@13WS4=/>&TBTH=7ZQT8ES>XMR946:>%.):B,TYX3ETREZ)T/J\S]IG]
M&6M;]/.7,?0U#2JD6B&.4V47 .CEK&2OGR90YQJ+)G2GKJM@K4L4QY.&4JV)
M>%"K:XVO8G9RTE3R6.[=0:A)RG/"?Q2]!-[!!4UYT?FF^T_T=1_[R83G(<D_
M2O)GUA@OO-HBKP:_(K]1G6*9[X-8& , [2/PW_-:<*?5V@O\T,S\_<1\XO\
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M:8J>R*OC-<U)9#1#XFV/--M4I=@H%-95_+E)R][4OZ Y6<8YRA?H/K)PZ+(
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M8*G^IN>[CY[L]?"JL9M&A,9V$P5)=4T*3/S&OU=#&YSAM>37!1_I"LD8]:]
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M9E5;J\(VN.KTS:0>W:3#B.&6<Z=?6LI+;2\7C.?&,EEDE$I.8XZDMX;XB.(
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M@# & 4\>&3^*_N'^51[Y^]T6"U6J\FCU*2X?!48 P!@# & , 8 P!@# & ,
M8 P!@%?'BG^;RY8_1X=_2>08+5^$_-V(L'P5& , 8 P!@# (S]I_D<=9_5GO
MC[K95@FG5=*[3%WB^^;6\??U*N7ON3A.":_#J\JKM9B'RU-"*24%3$3=MK3&
M"8=F<KQ62H43FYM G>.OEEHD3NT*5C0L0KPHG%(8-.J+)5%;,+%L.]Y]G)]N
MB[CL);N4JNBN_;IKI>E5+J2:?,T?)C*ZK>$Q-RANFNBQ=JIJ6M-5-%334[TU
M)%S\'YR)^:3_ /OMF_WTSL+^A^3/V*SU/VFD?TKRA^U7.JG\IZ1'CKXT3+%S
M@FI5$G7N?NWPDN(F=CE+'#W(K9"/WY27, G*_="!")3>\#,]@5O997J WO6/
MZ'Y,_8K/4_:/Z6Y1T^-W(6B^3E.OZ)C:^.%^6HS1URR1AK(YL?(_5-B/;,Y)
MY[9?O#>[-40>%[<N(]>8C![9(L3DGE>N 8?7+#ZP1:].MX<1R3R;3A[]5.#L
MJJFS=JI:3E-45--9ZIJ3-A^4\?5B+%-6)N.FJ]:IJ35,-.NE-/Y.C3@O#Y24
MJ%G+G-BQ8H.5*U5!4ZI5*E)IAZA2H/KN.&GJ%!YHAFG''&C$8::8(1AA@A#&
M+8M[WOK<WH@SYN/FZ['_ $U\8_UT>?\ .;[F?[Q]S_UWR5]_PYQ?+GT'RW]3
M\J?<,0:_6>Y3R6, ^8]?[S.W_5B_^:FYAQ'S>_\ N;OJ5&6Q_;V?WMOUZ3:A
M\:/S<G ?U*^6ON.@V>!3V)5J^E]I'3SH_--]I_HZC_WDPG.0Y)^E>3/K#!?>
M;16KP:_(K]1G6*9[X-8& , [2/PW_-:<*?5V@O\ -#,_/W$?.+_[Z[Z]1M!9
M;F$# & , Z\KR3_.3=X?IU8ON(IG.YO@]^A+_P!97_N^$/-OPP?WGP7U'A?O
M_*1#3-Z.J1@%X7[GB_+XMSZH+_\ ?/5N=3_"-\[Y,_A\1_,H/0/P,_1W+G\;
M@_Y%XW/LZW.YQ@# & , 8 P!@# & , IX\,G\5_</\JCWS][HL%JM5Y-'J4E
MP^"HP!@# & , 8 P!@# & , 8 P!@&*KCNRLZ!AH[ MF1&Q>)%N:%G&Z$L$E
MD@].+E[;W)/\&1-G?';>CO8&^D_2':<KU?\ /'%^L#U@_ KV\/-VUO.>-:<J
MB.O#J9853P!&38,8=X=-8PLCAKO))(8W%''R>/,Z!<8H+*&/8&I6N$2'0=J-
M%:&#UA:KPG[[BU[!48 P!@# & , C/VG^1QUG]6>^/NME6":=5TKM,7>+[YM
M;Q]_4JY>^Y.$X)K\.KRJNUF-/*9_%+SI]>SD+[U6_/OY+^D<%_$VO71\6/\
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M4>^?O=%@M5JO)H]2DN'P5& , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8
MP#%]UW' >>ZDL2[K2=C&.O:NB;Q,Y8Y)T2IS6$M#,E&I.);FQ$6:M='1:,):
M%J;$91BMQ<5*5$F (X\ =B4I:7%P0CMWJVI[\X'["EC*I>H$N8JLZ>J*5P2V
M$*.#SV(V;$:R?@O,*?&10Y+$@WD"-T9G9)IE<W=&O:7IK6I%9H57J@$I-5+?
MFGEFHG6?>-'F>WXRK.K5O\</ J!?8<&0KD7&7,B18B62Q@3*TBI/2\+*4)E2
M8YP <G4$&@&4<2: !A1@1 &$(@[UH36GM59/PGN?%F-O*!9=<N-4<\EM\_A*
MXPCN/DE8>6CE3$I&2D2VD@,4JC0$+QB+3)R];,//'K110-;$8((=>G/NY,:7
M*.";:26)M-MN$EM+-MZ'Q8^FIX+%Q2_FU[<_U=1]/Y3*W_.#"/UK8?\ Q^=G
M=^M?K;?VZ?:=>=[N?JZ_LU>P?*96_P"<&$?K6P_^/QWZU^MM_;I]H[W<_5U_
M9J]AACH^QZ\4<\7R01/(8>>?3%HDDDDRAC,-.-,@[X LHHL"X0S##!BT   !
MV(8MZ"'6][UK,&)NVGAL0E<MSWB[^G3^KJYS/A;=SXSA_D5_V]K]&K]93S$_
M^4+3K!-RUS6F4V/ TZA/0-.$*$Y\OCQ1Q!Q5=QPLTDXHQQ"84:48$0#"QA",
M P["+6MZWK.JCL>'P?4R$_FHLBNW;QZV*A:I["W-:9<_'!H$;?*6-:J&4E[)
MH14J- G3+C#1%IDI)RE0/0-A)3DFG&;"66,6N:[FVJ>Z+D"JII4KEKDIMMI)
M)8ZPVVWDDEFV\DCC.6Z:GR)RTE34V^2.4TDDVVW@<0DDDI;;R26;>10=\;(K
M_P YH_\ _.6[_P 3GMWX[@_VO#?Y]K\YY0^*XG]GO_Y-S\H^-D5_YS1__P"<
MMW_B<?'<'^UX;_/M?G'Q7$_L]_\ R;GY3YKU+(MMG=M:DL?WO;8OUK6GENWO
M>]I3?1K6O>?Q[WF'$8S".Q?C%8;^QN_^O:\2K_F,MC"XGOUG_P#'O_VMO_TK
MGCK_ )3:'\;EGUH@\=_!B%=8<&1+47&?,"18C5RU@3*DBI-2<()4)E*<YP <
M0H(. ,HXDT #"C " ,(1!WK7@X]?-.7D]7N?$CSYP+(KMW\5'9;:TSV%NCBK
MKQ@ E0-TI8UJU2,-C0LP0$Z5,N-/.$$L Q["66+>@!$+>O5#O>OOY*:7*G)K
M;22Q^#;;<))8BVVVWDDEJRM2>S7D_ KW/Q6=:%[PG_Y<G_M0?][/>'QW!_M>
M&_S[7YS6=BOQ:OLOV#WA/_RY/_:@_P"]CX[@_P!KPW^?:_.-BOQ:OLOV#WA/
M_P N3_VH/^]CX[@_VO#?Y]K\XV*_%J^R_8=GGX?;+KAK\8/#K<YV!"6YP1\]
MP<A6A7RIB1K$IX$AFADJ4JA>6>0:#?XA%F@",/\ PZUG@;$9XB_'ZZ[Z]1L\
M/@^HLB^5JJOSF5]^N<<_M+,(A\'U,?*U57YS*^_7..?VE@0^#ZF/E:JK\YE?
M?KG'/[2P(?!]3'RM55^<ROOUSCG]I8$/@^IG7X^1R1QY?Y&^YUZ%^95J%9>+
M&<D6I'1"I2*B=4;3I.S4R@D\9)Y>C2C2MC*&(.C"S ;WZP!:UW%W 7;5'(M^
MFN[;H?\ 2-]Q7732X^+X3.&TXR>9YQ^%W#W[G=+@ZK=F[72N1,*FZ+==23^/
M<I.&Z:6IAIQK#7$AY\,L_P#[5;?_ (Y+_P#=S>/C&'_7V?\ -H_,=6?%,7^S
M8C_)N?E'PRS_ /M5M_\ CDO_ -W'QC#_ *^S_FT?F'Q3%_LV(_R;GY2[']S[
M3"),?>%LK'J4QQH1F\D/R8M4Z/;8WIC%(KCK T*<!ZM424,_919AFB@BV9LL
ML8]!]4(MZZJ^$2Y;N8KDQVZZ*TL/?G8JIJB;E$3#<'?OP.6;MOD_EM7+5RVW
MC<(TJZ*J6TK%Z6E4E*6^#<@^5JJOSF5]^N<<_M+.NCN2'P?4SE+)(H_)DAB^
M-OK/($)*@:0U:R.:)U2%*RRRCC$IBA >H) H 2H(-&2(>C EG%&;#H)@-B$0
MUJH/L8 P!@# & , CG-NL*&K_H2G>5Y%/&\%\WFCE+M!:\0 ,<GD,?B$3E<Q
M<Y-)0)-&!BL>5ML*DR1@='P2,F1N[.YMK'[\>U.WN#\28<-[D1G8O+#QI*(G
M(Y9&Y18CZ%H?ZR88Q&FZG;*-FMN:NEZE,?J%_I:)CCA;O9L3L9S@LV#&Y)&T
MZEK&DB3ZY.)[>VI JS1+I:]/F:U3X-93TDW:@MJ 7Q5\#N6K'\N45W948:I?
M$'TM*M;Q.#*\)@*4PU+:YIT;HUKR/6$F<6IT1I'-K7D*6]P2IEB8\D JU&3*
MO_#)_%?W#_*H]\_>Z+!:K5>31ZE)</@J, 8 P!@# & , 8 P!@# & , 8 P!
M@# & , 8 P!@$<^N>>6[K#FFY^='.2*X<3;,'<XPDEJ) 4[*(N\B$2OC\ATT
M'*4)3P2S/J)N<530-<@TZI4YS?[^AVITJ)$IPT^!$2&>+2CIG7DR9.VHC5?5
M,WL?HFQ^FY.N.@;K%("P6!8;'%8><B@$4<IC+GIH9VN%0>+,GM'B5O2]R5I%
MSH<:FTM B2O?WX$[33E.(4>8_7X%+Q2?05H;]75O]IX)[Y7XS'X%+Q2?05H;
M]75O]IX'?*_&9@JZ_'?X'^< ,1E\\\\BU*"3HY"XQ[<ZV%@^&&^([9=RM>WZ
M6NY>U**,DR%G62!67K9#,W+0N;B8F;R5*HD3MW'I54S%[_R%X$4+U/H/"N2Z
M$N.X*_1R(Y=1U31DR1VF].$8,]@[,C$U.+^QL9B],?\ O%"MVD+0PMR<)SD[
MO+<TI52\@-NY$[3CC*,H\V>-'P[=14O$+P@WC_JMBC<P.E"-,T2V,-P'Q OA
MTO?X,_)SE<4F4KB+TA"_QISVS26'RF31&4,VT$AC#^\,;F@7G@ZZTXVG[^:>
MO/B9T_ I>*3Z"M#?JZM_M/!'?*_&8_ I>*3Z"M#?JZM_M/ [Y7XS,)73XX_!
M5SDWM#I>O-_)M4H)!IZVQ*)J4)E"\_%QO"[/^FP"AUT:NVRM0MNCH%, P2%M
M+/7J-%I$YYQ8;=QZ5-F+73D#P!DR*2P&)\Q<YVG;,>CTBD*.G*LC:Z8V7,?B
MY$UDT.9H2QI'0E%('IS840U+,26ZD(5OM2#!N!"48E(!.W<B=IQINZ,^'G.>
M<R>-_P //4U6EVI#_'E6<20ER^=P-UCLTCD?4.[5**XECK"Y0C+>Z_GT\KZ4
M-Q#XS+2D,C@TVE,;<2P;TF=A*B%B5*#KK3C:?OYB0?X%+Q2?05H;]75O]IX(
M[Y7XS'X%+Q2?05H;]75O]IX'?*_&9B&X_&?X.^>V1GD=W<Q<K5>R2%W41]A<
M9@E,:$[T_)6!ZE)S*T^W=-#<';XOQU\=2FY( U8H3-BK:<DT8- V)5=QZ5-F
M(3N0_P!SXFR8N"Q[G_EF=6$OBZ67QJOH"SN$NETW:'6"$V7'OB0W-"\\F4*9
M5"U2%[BY+8K-"]IG!!M&8/WHOTAM7-74TM'.[.,UKKS'*.6_'?X>^K()))O&
M/'#!:^/AMBRBK)9$;(BT;U(668Q ML.>4/PE7EC6%!7HA,%W2)E*J-S)Z*;'
MDEVC#U\&2A@?65M!UUK])\SXKSI/K1)3\"EXI/H*T-^KJW^T\$=\K\9C\"EX
MI/H*T-^KJW^T\#OE?C,?@4O%)]!6AOU=6_VG@=\K\9C\"EXI/H*T-^KJW^T\
M#OE?C,?@4O%)]!6AOU=6_P!IX'?*_&8_ I>*3Z"M#?JZM_M/ [Y7XS(::Y@_
M<X8V:02$BN.(UK-%38\5(5[<M"Y$M>Y4J?D$?&HT@=%)FT[DY1:2M1:HH!B8
MEX87=H4FDN3>J2E"=J[QJ[-.DQXPT1X$)?=T'IV%\+5S,62?R2+P%EO2/PYE
M/I8JT)Q Y]9D,K14XJI^CGYLBDD+K26.:-V:Z\<H,E5ID3$ZRYO?W!.V;#;N
M>,]_H<-\,G[="P[\"EXI/H*T-^KJW^T\$=\K\9C\"EXI/H*T-^KJW^T\#OE?
MC,F7SOR]S[R7"G2N>;JGB5.P9ZE*V;.L9AB(U"UKI6Y-+(Q+GT\DT]0(2]4S
MQMB;S3-#T':=K2AT'6P;V(5=3J<MR],S/6"!@# & , ^%*&/4GC4BC6W=]C^
MI"Q.['M^B[B)GDK)IV;U"#;O'78!9PFM];?>/?6AQ"2:)$X$IU.BQ[*T'8$)
M'SB8P^?<3R5'9DJER'E>5W*\RN1VV[JIK;-H--GTI;-7-J!UG):=O,5*HTX6
M<8L1GKTWLDS&A$W(RP'CT<.(TYG/H:_$F=>=?BG^!7)7GATO&O&VNI(FO>J7
MNU.82^1(=S&:M@<N00=SK/D5ZOI0RE74E228UY.F%A,70<D;GI7#C2VR-KXZ
MRN+:2[ 7+$J:2SJF<GFZF\]]43NT4>?T$D(YX2^(I-2?/%>=/UDCZ"GU$U*A
MK(NQ#95:-?DN0#9%(9Q(!M\;A-@-"%"U*II+Y,XM29>)U=$+<L3-RAV6!2%C
MT(VG+C)-S&7L)_\ ,W*M \=5KNH.;:\2UE7(I$\2T4:1OLID)8I$_!2!=W,3
ME,'R0O C5H4"3VA0G':<&R="))+$,S8Q#;;EYOW1(3! P!@# & , 8 P!@#
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ML3JWH3+$X(P1B&Q%B+TD2EHV./LB1/[<*MU<#7![='1R6 W,<RC?^,DE,$#
M(_W9SQ%KRDU%RB1O#VV*J%L*6V-'$K3\';2/+K+Z.MFB5B)["O1*S!($D>MU
MZ>D?N)B-2%\:VD1IYB$*M(I$IQ/.H?6G^!'^LO&SSI5D,KEDCAMF)IW6-+PN
MF(W;R*T9TURY(B@E2-E-,$Q2QM&^ZJU'+TD9:$:\D\J "9RY 4%W$T&J/6V,
M3M/3=,Q"XSVF6N5>7&OEY@LE&784OM&56_9RJV;!F4M;87'3'25GPV&0 LQK
MB==1F(0R/IQ1N Q\UTVV,9:V024U[D[TL6.3P=LH0W,9)0HRZ6_Q)38(& ,
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M(<(G-WH_V2<GG1"("KWR/H/4.V<((2?;E[+WLS0@!*X+T^TMWP0, 8 P!@#
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M4U- D5-2:P6^;UT<Z(Y^BK1]F2J$/ *,N$J=^4/:<:[IW<ST9GCS.?DO0/\
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M!"*$.)REKG4/JE]ID[! P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# &
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A# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8!__9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
